DRUG_NAME,TARGET_NAME,GENE,ACT_VALUE,ACT_TYPE,SMILES
cefamandole,Solute carrier family 15 member 1,SLC15A1,2.09,Ki,CN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)C1=CC=CC=C1)C2=O)C(O)=O
dichloroacetic acid,"[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial",PDK3,2.097,Ki,OC(=O)C(Cl)Cl
cefadroxil,Solute carrier family 15 member 1,SLC15A1,2.14,Ki,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=C(O)C=C1)C2=O)C(O)=O
adenosine phosphate,Ketopantoate reductase,panE,2.2,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
procaine,Ryanodine receptor 1,RYR1,2.222,IC50,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
metformin,Solute carrier family 22 member 3,SLC22A3,2.499,Km,CN(C)C(=N)NC(N)=N
pentobarbital,Potassium voltage-gated channel subfamily H member 2,KCNH2,2.553,IC50,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
proglumide,Histamine H2 receptor,Hrh2,2.6,IC50,CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1
metformin,Solute carrier family 22 member 1,SLC22A1,2.697,IC50,CN(C)C(=N)NC(N)=N
tyramine,Beta-secretase 1,BACE1,2.7,Kd,NCCC1=CC=C(O)C=C1
flecainide,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,2.77,IC50,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
aminosalicylic acid,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,2.92,Kd,NC1=CC(O)=C(C=C1)C(O)=O
nomifensine,Amine oxidase [flavin-containing] A,MAOA,2.947,Km,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
dichloroacetic acid,"[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial",PDK1,3,Ki,OC(=O)C(Cl)Cl
dopamine,Dopamine beta-hydroxylase,DBH,3,Km,NCCC1=CC(O)=C(O)C=C1
siponimod,Sphingosine 1-phosphate receptor 3,S1PR3,3,EC50,CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F
levofloxacin,Potassium voltage-gated channel subfamily H member 2,KCNH2,3.04,IC50,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
phenazone,Transient receptor potential cation channel subfamily A member 1,TRPA1,3.081,IC50,CN1N(C(=O)C=C1C)C1=CC=CC=C1
hydroxyamfetamine,Beta-secretase 1,BACE1,3.1,Kd,CC(N)CC1=CC=C(O)C=C1
levosimendan,"Troponin C, slow skeletal and cardiac muscles",TNNC1,3.155,Kd,C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1
adenosine phosphate,L-lactate dehydrogenase A chain,LDHA,3.19,Kd,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
troglitazone,Cytochrome P450 3A4,CYP3A4,3.208,Km,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
etoposide,Canalicular multispecific organic anion transporter 1,ABCC2,3.21,Km,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
bambuterol,Acetylcholinesterase,ACHE,3.25,Ki,CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C
etoposide,Multidrug resistance protein 1,ABCB1,3.282,Ki,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
lidocaine,5-hydroxytryptamine receptor 3A,HTR3A,3.296,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
dichloroacetic acid,"[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial",PDK4,3.301,Ki,OC(=O)C(Cl)Cl
nabumetone,Prostaglandin G/H synthase 1,PTGS1,3.34,IC50,COC1=CC=C2C=C(CCC(C)=O)C=CC2=C1
azithromycin,Potassium voltage-gated channel subfamily H member 2,KCNH2,3.39,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
metformin,Solute carrier family 22 member 2,SLC22A2,3.401,IC50,CN(C)C(=N)NC(N)=N
colchicine,Glycine receptor subunit alpha-1,GLRA1,3.49,IC50,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
benzocaine,Sodium channel protein type 5 subunit alpha,SCN5A,3.495,ED50,CCOC(=O)C1=CC=C(N)C=C1
losartan,Multidrug resistance protein 1,ABCB1,3.498,Km,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
mexiletine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,3.51,IC50,CC(N)COC1=C(C)C=CC=C1C
procaine,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,3.529,IC50,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
ibuprofen,Acid-sensing ion channel 1,ASIC1,3.53,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
lidocaine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,3.559,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
chlorpromazine,Ryanodine receptor 1,RYR1,3.569,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
disopyramide,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,3.604,IC50,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
diazoxide,Nicotinamide phosphoribosyltransferase,NAMPT,3.64,Kd,CC1=NC2=CC=C(Cl)C=C2S(=O)(=O)N1
dichloroacetic acid,"[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial",PDK2,3.699,Ki,OC(=O)C(Cl)Cl
azithromycin,Multidrug resistance protein 1,ABCB1,3.7,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
zolpidem,Multidrug resistance protein 1,ABCB1,3.703,Km,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
colchicine,Multidrug resistance protein 1,ABCB1,3.801,Kd,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
pregabalin,Large neutral amino acids transporter small subunit 1,SLC7A5,3.801,IC50,CC(C)C[C@H](CN)CC(O)=O
lamotrigine,Sigma non-opioid intracellular receptor 1,SIGMAR1,3.839,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
alprazolam,Cytochrome P450 3A4,CYP3A4,3.85,Ki,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
theophylline,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,3.85,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
parecoxib,Prostaglandin G/H synthase 1,PTGS1,3.854,IC50,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1
procainamide,Potassium voltage-gated channel subfamily H member 2,KCNH2,3.86,IC50,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
oxyquinoline,72 kDa type IV collagenase,MMP2,3.89,IC50,OC1=CC=CC2=C1N=CC=C2
cinchophen,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,3.9,Kd,OC(=O)C1=CC(=NC2=CC=CC=C12)C1=CC=CC=C1
methaqualone,GABA A receptor alpha-4/beta-3/delta,GABRA4|GABRB3|GABRD,3.91,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
alfentanil,Multidrug resistance protein 1,ABCB1,3.951,IC50,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O
nomifensine,Myeloperoxidase,MPO,3.963,Km,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
warfarin,Cytochrome P450 3A4,CYP3A4,3.98,Ki,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
acetylsalicylic acid,Acid-sensing ion channel 3,ASIC3,4,IC50,CC(=O)OC1=CC=CC=C1C(O)=O
adenosine,"Histone-lysine N-methyltransferase, H3 lysine-79 specific",DOT1L,4,IC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
aminoquinuride,Matrix metalloproteinase-9,MMP9,4,IC50,CC1=NC2=CC=C(NC(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=C2C(N)=C1
amiodarone,Lysine-specific demethylase 5A,KDM5A,4,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amitriptyline,G protein-activated inward rectifier potassium channel 2,Kcnj6,4,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
atomoxetine,Krueppel-like factor 10,KLF10,4,IC50,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
benoxaprofen,Bile salt export pump,Abcb11,4,IC50,CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1
bethanechol,Muscarinic acetylcholine receptor M1,CHRM1,4,Ki,CC(C[N+](C)(C)C)OC(N)=O
bethanechol,Muscarinic acetylcholine receptor M2,CHRM2,4,Ki,CC(C[N+](C)(C)C)OC(N)=O
bethanechol,Muscarinic acetylcholine receptor M4,CHRM4,4,Ki,CC(C[N+](C)(C)C)OC(N)=O
caffeine,Adenosine receptor A1,ADORA1,4,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
levocarnitine,"Carnitine O-palmitoyltransferase 1, muscle isoform",Cpt1b,4,Ki,C[N+](C)(C)C[C@H](O)CC([O-])=O
levocarnitine,Carnitine palmitoyltransferase 2,Cpt2,4,Ki,C[N+](C)(C)C[C@H](O)CC([O-])=O
chlordiazepoxide,Cholecystokinin receptor,CCKAR|CCKBR,4,IC50,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
chlordiazepoxide,Cholecystokinin receptor,Cckar|Cckbr,4,IC50,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
chlortetracycline,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,4,IC50,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)C1=C(C(Cl)=CC=C1O)[C@@]3(C)O
chlortetracycline,Protein-arginine deiminase type-4,PADI4,4,IC50,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)C1=C(C(Cl)=CC=C1O)[C@@]3(C)O
chlorzoxazone,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,4,EC50,ClC1=CC2=C(OC(=O)N2)C=C1
clavulanic acid,Beta-lactamase,,4,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clioquinol,Amyloid beta A4 protein,APP,4,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1I
cyclovalone,Integrase,pol,4,IC50,COC1=C(O)C=CC(C=C2CCCC(=CC3=CC(OC)=C(O)C=C3)C2=O)=C1
dichlorophen,78 kDa glucose-regulated protein,HSPA5,4,IC50,OC1=C(CC2=C(O)C=CC(Cl)=C2)C=C(Cl)C=C1
diclofenac,Acid-sensing ion channel 3,ASIC3,4,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
diltiazem,Potassium voltage-gated channel subfamily C member 1,Kcnc1,4,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
diltiazem,Voltage-dependent L-type calcium channel subunit alpha-1F,Cacna1f,4,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
epinastine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4,IC50,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
estriol succinate,Lanosterol 14-alpha demethylase,cyp51,4,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
flecainide,Potassium voltage-gated channel subfamily A member 5,KCNA5,4,Kd,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
flecainide,Potassium voltage-gated channel subfamily C member 1,Kcnc1,4,IC50,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
flufenamic acid,Aldose reductase,AKR1B1,4,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
flufenamic acid,Potassium channel subfamily K member 2,KCNK2,4,EC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
glutamic acid,Glutamate receptor 3,Gria3,4,EC50,N[C@@H](CCC(O)=O)C(O)=O
ibuprofen,Dehydrogenase/reductase SDR family member 9,Dhrs9,4,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
levodopa,Large neutral amino acids transporter small subunit 1,SLC7A5,4,IC50,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
lidocaine,Sodium channel protein type X alpha subunit,Scn10a,4,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
maprotiline,G protein-activated inward rectifier potassium channel 2,Kcnj6,4,IC50,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
menadione,Aldehyde oxidase,AOX1,4,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
menadione,Aldehyde oxidase,AOX1,4,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
methoxamine,Alpha-1B adrenergic receptor,ADRA1B,4,Ki,COC1=CC(C(O)C(C)N)=C(OC)C=C1
mezlocillin,Cannabinoid receptor 1,CNR1,4,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
miglitol,Beta-galactosidase,GLB1,4,Ki,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
framycetin,Extracellular calcium-sensing receptor,Casr,4,Kd,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
nifedipine,Potassium voltage-gated channel subfamily A member 1,Kcna1,4,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
phenylalanine,Intestinal-type alkaline phosphatase,ALPI,4,IC50,N[C@@H](CC1=CC=CC=C1)C(O)=O
pramipexole,Beta-2 adrenergic receptor,ADRB2,4,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
primaquine,Reverse transcriptase,reverse transcriptas,4,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
primaquine,Reverse transcriptase,reverse transcriptas,4,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
mepacrine,Phospholipase A2 group 1B,PLA2G1B,4,IC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
mepacrine,Phospholipase A2 group 1B,Pla2g1b,4,IC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
quinidine,Potassium channel subfamily T member 1,Kcnt1,4,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
rolitetracycline,Insulin-degrading enzyme,IDE,4,IC50,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(=O)NCN2CCCC2)=C1O)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
rolitetracycline,Insulin-degrading enzyme,IDE,4,IC50,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(=O)NCN2CCCC2)=C1O)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
salicylic acid,Polyphenol oxidase 2,PPO2,4,IC50,OC(=O)C1=CC=CC=C1O
sildenafil,"High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A",PDE8A,4,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sotalol,Potassium voltage-gated channel subfamily H member 2,KCNH2,4,Ki,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
sulfinpyrazone,Solute carrier family 22 member 12,SLC22A12,4,IC50,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1
tadalafil,Potassium voltage-gated channel subfamily H member 2,KCNH2,4,IC50,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
thiopental,Potassium voltage-gated channel subfamily C member 4,Kcnc4,4,IC50,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O
trientine,Carbonic anhydrase 1,CA1,4,Ki,NCCNCCNCCN
trifluoperazine,DNA-dependent protein kinase catalytic subunit,PRKDC,4,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
zidovudine,Sigma non-opioid intracellular receptor 1,SIGMAR1,4,Ki,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
suramin,P2Y purinoceptor 6,P2RY6,4,Kb,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
estriol,Lanosterol 14-alpha demethylase,cyp51,4,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
ornithine,G-protein coupled receptor family C group 6 member A,GPRC6A,4,EC50,NCCC[C@H](N)C(O)=O
quercetin,Chymotrypsinogen B,CTRB1,4,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Chymotrypsin C,CTRC,4,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
triclosan,78 kDa glucose-regulated protein,HSPA5,4,IC50,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
linagliptin,Dipeptidyl peptidase 9,DPP9,4,IC50,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1
arbutin,Polyphenol oxidase 2,PPO2,4,IC50,OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O
chenodiol,fMet-Leu-Phe receptor,FPR1,4,Ki,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
deoxycholic acid,fMet-Leu-Phe receptor,FPR1,4,Ki,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
migalastat,Non-lysosomal glucosylceramidase,GBA2,4,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
cytisine,Acetylcholine receptor subunit delta,chrnd,4,EC50,O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12
siponimod,Sphingosine 1-phosphate receptor 2,S1PR2,4,EC50,CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F
propofol,Carbonic anhydrase 2,CA2,4.005,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
amiloride,Sodium/hydrogen exchanger,NHE1,4.01,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
cianidanol,Dihydroorotate dehydrogenase,DHODH,4.01,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
doxorubicin,Multidrug resistance protein 1,ABCB1,4.01,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
fenoprofen,Cyclooxygenase,PTGS1|PTGS2,4.01,IC50,CC(C(O)=O)C1=CC=CC(OC2=CC=CC=C2)=C1
mexiletine,Potassium channel subfamily K member 3,KCNK3,4.01,IC50,CC(N)COC1=C(C)C=CC=C1C
mezlocillin,Arachidonate 5-lipoxygenase,ALOX5,4.01,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
norfloxacin,Multidrug resistance protein mdtK,mdtK,4.01,Kd,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
praziquantel,Bile salt export pump,ABCB11,4.01,IC50,O=C(C1CCCCC1)N1CC2N(CCC3=C2C=CC=C3)C(=O)C1
topiramate,Sodium channel protein type 2 subunit alpha,Scn2a,4.01,IC50,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
trifluridine,Thymidylate kinase,tmk,4.01,Ki,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F
diltiazem,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,4.017,Ki,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
phenylbutanoic acid,Aldose reductase,AKR1B1,4.02,IC50,OC(=O)CCCC1=CC=CC=C1
doxorubicin,Type-2 restriction enzyme HindIII,hindIIIR,4.02,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
lamotrigine,Sodium channel protein type 10 subunit alpha,SCN10A,4.02,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
metoclopramide,Solute carrier family 22 member 1,SLC22A1,4.02,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
nifedipine,Potassium voltage-gated channel subfamily A member 1,KCNA1,4.02,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
primaquine,Amine oxidase [flavin-containing] B,MAOB,4.02,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
probenecid,UDP-glucuronosyltransferase 1-7,UGT1A7,4.02,Ki,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
simvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,hmg1,4.02,IC50,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
valdecoxib,Cytochrome c oxidase subunit 1,MT-CO1,4.02,IC50,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
rutoside,Neuraminidase,,4.02,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
phenylacetic acid,Aldose reductase,AKR1B1,4.02,IC50,OC(=O)CC1=CC=CC=C1
phenylbutanoic acid,Histone deacetylase 8,HDAC8,4.03,IC50,OC(=O)CCCC1=CC=CC=C1
astemizole,Polycomb protein EED,EED,4.03,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
carvedilol,Multidrug and toxin extrusion protein 1,SLC47A1,4.03,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
cianidanol,Prostaglandin G/H synthase 2,PTGS2,4.03,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
enprofylline,Adenosine receptor A3,ADORA3,4.03,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
lactose,Galectin-3,LGALS3,4.03,Kd,OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
lansoprazole,"Indoleamine 2,3-dioxygenase 1",Ido1,4.03,IC50,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
terbinafine,Squalene monooxygenase,Sqle,4.03,IC50,CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
thioguanine,Xanthine dehydrogenase/oxidase,XDH,4.03,IC50,NC1=NC2=C(NC=N2)C(=S)N1
linoleic acid,Prostaglandin G/H synthase 2,PTGS2,4.03,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
linolenic acid,Prostaglandin G/H synthase 1,PTGS1,4.03,IC50,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
fenofibrate,Beta-3 adrenergic receptor,ADRB3,4.032,Ki,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
amoxapine,Sodium- and chloride-dependent glycine transporter 2,SLC6A5,4.036,IC50,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
disopyramide,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.036,IC50,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
acyclovir,Purine nucleoside phosphorylase,PNP,4.04,Ki,NC1=NC2=C(N=CN2COCCO)C(=O)N1
acyclovir,Purine nucleoside phosphorylase,PNP,4.04,Ki,NC1=NC2=C(N=CN2COCCO)C(=O)N1
bifemelane,Lethal(3)malignant brain tumor-like protein 1,L3MBTL1,4.04,IC50,CNCCCCOC1=C(CC2=CC=CC=C2)C=CC=C1
ciprofloxacin,Multidrug resistance protein mdtK,mdtK,4.04,Kd,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
enprofylline,Adenosine A2a receptor,ADORA2A,4.04,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
fendiline,Transcriptional activator protein luxR,luxR,4.04,IC50,CC(NCCC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1
hexamethonium,Neuronal acetylcholine receptor; alpha4/beta4,CHRNB4|CHRNA4,4.04,IC50,C[N+](C)(C)CCCCCC[N+](C)(C)C
hexamethonium,Neuronal acetylcholine receptor subunit alpha-6,CHRNA6,4.04,IC50,C[N+](C)(C)CCCCCC[N+](C)(C)C
nicotinamide,NAD-dependent deacetylase HST2,HST2,4.04,IC50,NC(=O)C1=CN=CC=C1
terfenadine,Transcriptional activator protein luxR,luxR,4.04,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
theophylline,Heart phosphodiesterase,PDE3B|PDE1A|PDE1B,4.04,IC50,CN1C2=C(N=CN2)C(=O)N(C)C1=O
phenol,Endolysin,E,4.04,Kd,OC1=CC=CC=C1
elvitegravir,Reverse transcriptase,reverse transcriptas,4.04,IC50,COC1=C(CC2=C(F)C(Cl)=CC=C2)C=C2C(=O)C(=CN([C@H](CO)C(C)C)C2=C1)C(O)=O
carfilzomib,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.04,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
carfilzomib,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.04,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
trenbolone hexahydrobenzylcarbonate,Polymerase acidic protein,PA,4.04,Kd,C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)OCC1CCCCC1
metamizole,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.041,IC50,CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1
adenosine triphosphate,Adenylate kinase 2,Ak2,4.05,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
benzyl benzoate,Beta-lactamase,ampC,4.05,IC50,O=C(OCC1=CC=CC=C1)C1=CC=CC=C1
cetirizine,Angiopoietin-1 receptor,TEK,4.05,Kd,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
dactinomycin,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,4.05,Kd,CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2=C3N=C4C(OC3=C(C)C=C2)=C(C)C(=O)C(N)=C4C(=O)N[C@H]2[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]3CCCN3C(=O)[C@H](NC2=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O
delavirdine,Beta-lactamase,ampC,4.05,IC50,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
flupentixol,Solute carrier family 22 member 1,SLC22A1,4.05,IC50,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
valproic acid,Alcohol dehydrogenase [NADP(+)],AKR1A1,4.05,IC50,CCCC(CCC)C(O)=O
quercetin,Amine oxidase [flavin-containing] B,MAOB,4.05,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
thiram,Bifunctional protein GlmU,glmU,4.05,IC50,CN(C)C(=S)SSC(=S)N(C)C
fampridine,Voltage-gated potassium channel,KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4,4.05,IC50,NC1=CC=NC=C1
hydrochloric acid,Carbonic anhydrase 4,CA4,4.05,Ki,Cl
migalastat,Beta-galactosidase,GLB1,4.05,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
omeprazole,Multidrug resistance protein 1,ABCB1,4.051,IC50,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
argatroban,Tissue-type plasminogen activator,PLAT,4.06,Ki,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2
gefitinib,Cruzipain,,4.06,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glycyrrhizic acid,High mobility group protein B1,HMGB1,4.06,Kd,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O
nitrofurazone,Snake venom metalloproteinase Bap1,,4.06,IC50,NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O
pentobarbital,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,4.06,IC50,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
sulindac,Bile salt export pump,Abcb11,4.06,IC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
theophylline,Transmembrane domain-containing protein TMIGD3,TMIGD3,4.06,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
tolmetin,Lactoylglutathione lyase,GLO1,4.06,Ki,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
enoxolone,High mobility group protein B1,HMGB1,4.06,Kd,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
resorcinol,Prostaglandin G/H synthase 1,PTGS1,4.06,Kd,OC1=CC(O)=CC=C1
quinidine,Solute carrier family 22 member 2,SLC22A2,4.061,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
tamoxifen,Solute carrier family 22 member 2,SLC22A2,4.061,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
methoxsalen,Amine oxidase [flavin-containing] A,MAOA,4.07,IC50,COC1=C2OC=CC2=CC2=C1OC(=O)C=C2
adenine,"Phosphatidylinositol 4-kinase, PI4K",PI4KA|PI4K2B|PI4K2A|PI4KB,4.07,Ki,NC1=NC=NC2=C1NC=N2
cefapirin,Cannabinoid receptor 1,CNR1,4.07,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
clotrimazole,Alpha-chymotrypsin,,4.07,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
delavirdine,Malate dehydrogenase cytoplasmic ,MDH1,4.07,IC50,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
diazepam,GABA-A receptor; anion channel,Gabre|Gabra6|Gabrg2|Gabrd|Gabra2|Gabra3|Gabrg3|Gabrb1|Gabra1|Gabrb3|Gabra5|Gabrp|Gabra4|Gabrq|Gabrg1,4.07,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
disulfiram,Bifunctional protein GlmU,glmU,4.07,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
leucine,Large neutral amino acids transporter small subunit 1,SLC7A5,4.07,IC50,CC(C)C[C@H](N)C(O)=O
minaprine,Acetylcholinesterase,ACHE,4.07,IC50,CC1=C(NCCN2CCOCC2)N=NC(=C1)C1=CC=CC=C1
minaprine,Acetylcholinesterase,Ache,4.07,IC50,CC1=C(NCCN2CCOCC2)N=NC(=C1)C1=CC=CC=C1
penciclovir,Thymidine kinase,UL23,4.07,IC50,NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2
procaterol,D(2) dopamine receptor,DRD2,4.07,Ki,CC[C@@H](NC(C)C)[C@@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
promethazine,Chloroquine resistance transporter,CRT,4.07,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
tetrabenazine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.07,IC50,COC1=CC2=C(C=C1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
theophylline,Adenosine receptor A3,Adora3,4.07,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
zafirlukast,Cytosolic phospholipase A2,PLA2G4A,4.07,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
quercetin,Beta-lactamase,ampC,4.07,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Beta-lactamase,ampC,4.07,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
proline,Angiotensin-converting enzyme,ACE,4.07,Ki,OC(=O)[C@@H]1CCCN1
filgotinib,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.07,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
filgotinib,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.07,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
leucovorin,Thymidylate synthase,TYMS,4.071,Ki,NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
verapamil,Solute carrier family 22 member 2,SLC22A2,4.071,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
acetazolamide,Carbonic anhydrase 3,CA3,4.08,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
amiodarone,Lysine-specific demethylase PHF2,PHF2,4.08,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
cinoxacin,Carbonic anhydrase 2,CA2,4.08,IC50,CCN1N=C(C(O)=O)C(=O)C2=C1C=C1OCOC1=C2
diazepam,Aldo-keto reductase family 1 member C3,AKR1C3,4.08,IC50,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
estradiol,Steryl-sulfatase,STS,4.08,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
miglitol,Glucosylceramidase,GBA,4.08,IC50,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
niclosamide,3-phosphoinositide-dependent protein kinase 1,PDPK1,4.08,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
sulindac,Retinoic acid receptor RXR-alpha,RXRA,4.08,IC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
mifepristone,Mitogen-activated protein kinase 14,MAPK14,4.081,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
solriamfetol,Sodium-dependent serotonin transporter,SLC6A4,4.088,Ki,N[C@@H](COC(N)=O)CC1=CC=CC=C1
ampicillin,Angiopoietin-1 receptor,TEK,4.09,Kd,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
amrinone,Dual specificity protein kinase TTK,TTK,4.09,Ki,NC1=CC(=CNC1=O)C1=CC=NC=C1
dexamethasone palmitate,Androgen receptor,Ar,4.09,IC50,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
dexamethasone valerate,Androgen receptor,Ar,4.09,IC50,CCCCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
disopyramide,Solute carrier family 22 member 1,SLC22A1,4.09,IC50,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
ditiocarb,Histone-lysine N-methyltransferase EHMT1,EHMT1,4.09,IC50,CCN(CC)C(S)=S
hymecromone,Amine oxidase [flavin-containing] B,MAOB,4.09,IC50,CC1=CC(=O)OC2=C1C=CC(O)=C2
menadione sodium bisulfite,Aldose reductase,Akr1b1,4.09,IC50,CC1(CC(=O)C2=CC=CC=C2C1=O)S(O)(=O)=O
pentamidine,Protein arginine N-methyltransferase 1,PRMT1,4.09,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pregnenolone succinate,Glucose-6-phosphate 1-dehydrogenase,G6PD,4.09,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)OC(=O)CCC(O)=O
salicylic acid,Carbonic anhydrase 7,CA7,4.09,Ki,OC(=O)C1=CC=CC=C1O
theophylline,"Alkaline phosphatase, tissue-nonspecific isozyme",ALPL,4.09,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
vidarabine,Adenylate cyclase type V,Adcy5,4.09,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
bufexamac,M1-family alanyl aminopeptidase,,4.09,IC50,CCCCOC1=CC=C(CC(=O)NO)C=C1
quercetin,Phosphodiesterase 2A,Pde2a,4.09,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
pefloxacin,Cytochrome P450 1A2,CYP1A2,4.097,Ki,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1
adenosine phosphate,Adenylate kinase 2,Ak2,4.1,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
amiodarone,Lysine-specific demethylase 7A,KDM7A,4.1,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
caffeine,Adenosine A2a receptor,ADORA2A,4.1,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
carprofen,Fatty-acid amide hydrolase 1,Faah,4.1,IC50,CC(C(O)=O)C1=CC2=C(C=C1)C1=CC(Cl)=CC=C1N2
chlorzoxazone,Small conductance calcium-activated potassium channel protein 2,Kcnn2,4.1,EC50,ClC1=CC2=C(OC(=O)N2)C=C1
cianidanol,Prostaglandin G/H synthase 1,PTGS1,4.1,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
diazepam,Alpha-1A adrenergic receptor,ADRA1A,4.1,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
flutamide,Bile salt export pump,Abcb11,4.1,IC50,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
haloperidol,G protein-activated inward rectifier potassium channel 2,Kcnj6,4.1,EC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hesperetin,Lysine-specific histone demethylase 1A,KDM1A,4.1,IC50,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
hesperetin,Lysine-specific histone demethylase 1A,KDM1A,4.1,IC50,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
histamine,Histamine H1 receptor,HRH1,4.1,Ki,NCCC1=CN=CN1
ibandronic acid,Geranylgeranyl pyrophosphate synthase,GGPS1,4.1,IC50,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
mercaptopurine,Purine nucleoside phosphorylase,punA,4.1,Kd,S=C1N=CNC2=C1NC=N2
moclobemide,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.1,IC50,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
perhexiline,Carnitine palmitoyltransferase 2,Cpt2,4.1,IC50,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
phenylalanine,Intestinal alkaline phosphatase,ALPI,4.1,IC50,N[C@@H](CC1=CC=CC=C1)C(O)=O
phenylalanine,E3 ubiquitin-protein ligase XIAP,XIAP,4.1,IC50,N[C@@H](CC1=CC=CC=C1)C(O)=O
pioglitazone,Enoyl-[acyl-carrier-protein] reductase [NADH],fabI,4.1,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
salicylic acid,Carbonic anhydrase 9,CA9,4.1,Ki,OC(=O)C1=CC=CC=C1O
sulindac,Prostaglandin E synthase,PTGES,4.1,IC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
tropisetron,Glycine receptor subunit alpha-1,GLRA1,4.1,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
tubocurarine,Solute carrier family 22 member 2,SLC22A2,4.1,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
furtrethonium,Muscarinic acetylcholine receptor M1,CHRM1,4.1,Ki,C[N+](C)(C)CC1=CC=CO1
furtrethonium,Muscarinic acetylcholine receptor M3,CHRM3,4.1,Ki,C[N+](C)(C)CC1=CC=CO1
oleic acid,Tissue factor,F3,4.1,IC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
phenol,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,4.1,Ki,OC1=CC=CC=C1
stearic acid,"Fatty acid-binding protein, adipocyte",FABP4,4.1,Kd,CCCCCCCCCCCCCCCCCC(O)=O
evogliptin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.1,IC50,CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F
nelfinavir,Tyrosine-protein kinase Lck,LCK,4.101,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
quinidine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,4.106,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
chlorprothixene,Solute carrier family 22 member 1,SLC22A1,4.11,IC50,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dicloxacillin,Sodium-dependent dopamine transporter,SLC6A3,4.11,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
mefenamic acid,Aldose reductase,AKR1B1,4.11,IC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
niclosamide,Glycogen synthase kinase-3 beta,GSK3B,4.11,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
perhexiline,Carnitine palmitoyltransferase 1A,Cpt1a,4.11,IC50,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
sulindac,Lactoylglutathione lyase,GLO1,4.11,Ki,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
theophylline,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,4.11,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
theophylline,Uncharacterized protein,PDE3B,4.11,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
valdecoxib,Carbonic anhydrase 3,CA3,4.11,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
vinblastine,Amine oxidase [flavin-containing] B,MAOB,4.11,Ki,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
eicosapentaenoic acid,Tissue factor,F3,4.11,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
quercetin,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,4.11,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
baicalin,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,4.11,Ki,O[C@@H]1[C@@H](O)[C@H](OC2=C(O)C(O)=C3C(=O)C=C(OC3=C2)C2=CC=CC=C2)O[C@@H]([C@H]1O)C(O)=O
vaniprevir,Cathepsin S,CTSS,4.11,IC50,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1[C@H]2CCN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
butenafine,Enoyl-[acyl-carrier-protein] reductase [NADH],fabI,4.12,IC50,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
caffeine,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,4.12,IC50,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
diethylstilbestrol,UDP-glucose 4-epimerase,GALE,4.12,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
flufenamic acid,Androgen receptor,AR,4.12,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
ifenprodil,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,4.12,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
ifenprodil,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,4.12,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
miglitol,Alpha-mannosidase,,4.12,IC50,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
oxycodone,Acetylcholinesterase,ache,4.12,IC50,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
pemetrexed,Thymidylate synthase (EC 2.1.1.45) (TS) (TSase),,4.12,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
primaquine,Amine oxidase [flavin-containing] A,MAOA,4.12,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
rifampicin,Glutathione S-transferase omega-1,GSTO1,4.12,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
theophylline,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,4.12,IC50,CN1C2=C(N=CN2)C(=O)N(C)C1=O
gentisic acid,Arachidonate 5-lipoxygenase,ALOX5,4.12,IC50,OC(=O)C1=C(O)C=CC(O)=C1
quercetin,Cyclin-dependent kinase 1/cyclin B,CCNB2|CDK1|CCNB1|CCNB3,4.12,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ribociclib,Cyclin-dependent kinase 2,CDK2,4.12,IC50,CN(C)C(=O)C1=CC2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N1C1CCCC1
carbamazepine,Histamine H1 receptor,HRH1,4.125,Ki,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
caffeine,"Glycogen phosphorylase, muscle form",PYGM,4.13,IC50,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
edetic acid,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",,4.13,IC50,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
foscarnet,DNA polymerase catalytic subunit,,4.13,IC50,OC(=O)P(O)(O)=O
glibenclamide,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.13,IC50,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
irinotecan,Solute carrier family 22 member 3,SLC22A3,4.13,IC50,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
methaqualone,GABA-A receptor alpha-6/beta-2,GABRA6|GABRB2,4.13,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
mitoxantrone,Solute carrier family 22 member 2,SLC22A2,4.13,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
nitrendipine,Platelet-activating factor receptor,PTAFR,4.13,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
tazobactam,Carbepenem-hydrolyzing beta-lactamase KPC,bla,4.13,Ki,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
ticlopidine,Bile salt export pump,ABCB11,4.13,IC50,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
hydroquinone,Carbonic anhydrase 13,Ca13,4.13,Ki,OC1=CC=C(O)C=C1
clorotepine,Potassium channel subfamily K member 9,KCNK9,4.13,IC50,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clorotepine,Potassium channel subfamily K member 9,KCNK9,4.13,IC50,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
digoxin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.136,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
clavulanic acid,Carbapenem-hydrolizing beta-lactamase SFC-1,,4.14,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
nordazepam,GABA-A receptor; anion channel,Gabre|Gabra6|Gabrg2|Gabrd|Gabra2|Gabra3|Gabrg3|Gabrb1|Gabra1|Gabrb3|Gabra5|Gabrp|Gabra4|Gabrq|Gabrg1,4.14,Ki,ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1
doxorubicin,Telomerase reverse transcriptase,TERT,4.14,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
doxycycline,Matrilysin,MMP7,4.14,Kd,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C(O)C=CC=C12
hydroxychloroquine,Alpha-2B adrenergic receptor,ADRA2B,4.14,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
mianserin,G-protein coupled receptor,tyr1,4.14,IC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
perhexiline,"Carnitine O-palmitoyltransferase 2, mitochondrial",CPT2,4.14,IC50,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
levomenol,Signal transducer and activator of transcription 3,STAT3,4.14,IC50,CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1
anagliptin,Prolyl endopeptidase FAP,FAP,4.14,IC50,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N
migalastat,Lactase-phlorizin hydrolase,Lct,4.14,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
paracetamol,Carbonic anhydrase 9,CA9,4.15,Ki,CC(=O)NC1=CC=C(O)C=C1
adenosine phosphate,Transient receptor potential cation channel subfamily M member 2,TRPM2,4.15,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
dichlorophen,"Indoleamine 2,3-dioxygenase 1",IDO1,4.15,IC50,OC1=C(CC2=C(O)C=CC(Cl)=C2)C=C(Cl)C=C1
ergotamine,Adenylate cyclase,cyaC,4.15,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
flufenamic acid,Transient receptor potential cation channel subfamily M member 2,TRPM2,4.15,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
flunarizine,CAAX prenyl protease 2,RCE1,4.15,AC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
fluostigmine,Acetylcholinesterase,ache,4.15,Kd,CC(C)OP(F)(=O)OC(C)C
menadione,Ubiquitin carboxyl-terminal hydrolase isozyme L3,UCHL3,4.15,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
miconazole,"Alkaline phosphatase, tissue-nonspecific isozyme",ALPL,4.15,EC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nicotine,Serotonin 3 (5-HT3) receptor,HTR3E|HTR3B|HTR3A|HTR3D|HTR3C,4.15,Ki,CN1CCC[C@H]1C1=CC=CN=C1
voglibose,Glycogen debranching enzyme,AGL,4.15,IC50,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
podophyllotoxin,Human papillomavirus regulatory protein E2,E2,4.15,Kd,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
disulfiram,Sodium-dependent noradrenaline transporter,SLC6A2,4.156,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
clotrimazole,Epidermal growth factor receptor,EGFR,4.159,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
azithromycin,Canalicular multispecific organic anion transporter 1,ABCC2,4.16,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
dicloxacillin,Bile salt export pump,ABCB11,4.16,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
loperamide,Menin,MEN1,4.16,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
nimesulide,Dipeptidyl peptidase 3,,4.16,Ki,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
phenylalanine,Large neutral amino acids transporter small subunit 1,SLC7A5,4.16,IC50,N[C@@H](CC1=CC=CC=C1)C(O)=O
sulfathiazole,Endothelin-1 receptor,Ednra,4.16,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1
enoxolone,Cocaine esterase,CES2,4.16,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
resorcinol,Carbonic anhydrase 9,CA9,4.16,Ki,OC1=CC(O)=CC=C1
rutoside,Polyphenol oxidase 2,PPO2,4.16,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
sulfathiazole,Endothelin-1 receptor,EDNRA,4.161,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1
atazanavir,Multidrug resistance protein 1,ABCB1,4.17,IC50,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
bromopride,Acetylcholinesterase,ACHE,4.17,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Br)=C1
epalrestat,Sorbitol dehydrogenase,SORD,4.17,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
granisetron,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,4.17,Ki,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
methaqualone,GABA A receptor alpha-4/beta-2/delta,GABRD|GABRB2|GABRA4,4.17,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
niclosamide,Angiopoietin-1 receptor,TEK,4.17,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
primaquine,Chloroquine resistance transporter,CRT,4.17,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
salicylic acid,Carbonic anhydrase 13,Ca13,4.17,Ki,OC(=O)C1=CC=CC=C1O
tyrosine,Large neutral amino acids transporter small subunit 1,SLC7A5,4.17,IC50,N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
gentisic acid,Carbonic anhydrase 7,CA7,4.17,Ki,OC(=O)C1=C(O)C=CC(O)=C1
gentisic acid,Carbonic anhydrase 14,CA14,4.17,Ki,OC(=O)C1=C(O)C=CC(O)=C1
quercetin,Cholinesterase,BCHE,4.17,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
valine,Large neutral amino acids transporter small subunit 1,SLC7A5,4.17,IC50,CC(C)[C@H](N)C(O)=O
bezafibrate,Peroxisome proliferator-activated receptor gamma,PPARG,4.178,EC50,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
clotrimazole,Receptor tyrosine-protein kinase erbB-2,ERBB2,4.178,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
carbachol,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,4.18,Ki,C[N+](C)(C)CCOC(N)=O
mezlocillin,Serum albumin,ALB,4.18,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
novobiocin,ATP-binding cassette sub-family G member 2,ABCG2,4.18,IC50,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
ribavirin,DNA topoisomerase 1,TOP1,4.18,IC50,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
sulbactam,Beta-lactamase,ampC,4.18,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
suramin,Ectonucleoside triphosphate diphosphohydrolase 2,Entpd2,4.18,Ki,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
enoxolone,"Glycogen phosphorylase, muscle form",PYGM,4.18,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
enoxolone,Protein-tyrosine phosphatase 1C,PTPN6,4.18,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
brexanolone,Glucose-6-phosphate 1-dehydrogenase,G6PD,4.18,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)C3CC[C@]12C
phenylbutanoic acid,Histone deacetylase 2,HDAC2,4.19,IC50,OC(=O)CCCC1=CC=CC=C1
phenylbutanoic acid,Histone deacetylase 1,HDAC1,4.19,IC50,OC(=O)CCCC1=CC=CC=C1
alprazolam,Cholecystokinin receptor type A,Cckar,4.19,IC50,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
colchicine,Cytochrome P450 3A4,CYP3A4,4.19,Ki,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
dopamine,Beta-2 adrenergic receptor,ADRB2,4.19,Kd,NCCC1=CC(O)=C(O)C=C1
edetic acid,Eyes absent homolog 2,EYA2,4.19,IC50,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
edetic acid,Eyes absent homolog 2,EYA2,4.19,IC50,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
enprofylline,Adenosine receptor A3,Adora3,4.19,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
floxacillin,Matrix metalloproteinase-9,MMP9,4.19,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1F
meclofenamic acid,Androgen receptor,AR,4.19,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
mepenzolate,Solute carrier family 22 member 1,SLC22A1,4.19,IC50,C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
methylphenidate,Sodium-dependent serotonin transporter,SLC6A4,4.19,Ki,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
miconazole,"Fatty acid hydroperoxide lyase, chloroplastic",HPL,4.19,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
modafinil,Transporter,NET,4.19,IC50,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
piroxicam,Cyclooxygenase,PTGS1|PTGS2,4.19,IC50,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=CC=CC=C2S1(=O)=O
trientine,Carbonic anhydrase 2,CA2,4.19,Ki,NCCNCCNCCN
linoleic acid,Adenosine receptor A1,Adora1,4.19,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
phenol,Beta-carbonic anhydrase 1,mtcA1,4.19,Ki,OC1=CC=CC=C1
colchicine,Glycine receptor subunit alpha-2,GLRA2,4.194,IC50,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
reboxetine,G protein-activated inward rectifier potassium channel 2,KCNJ6,4.194,IC50,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
benzbromarone,M1-family alanyl aminopeptidase,,4.2,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
bethanechol,Muscarinic acetylcholine receptor M3,CHRM3,4.2,Ki,CC(C[N+](C)(C)C)OC(N)=O
camphor,Transient receptor potential cation channel subfamily A member 1,Trpa1,4.2,IC50,CC1(C)C2CCC1(C)C(=O)C2
ciclosporin,ATP-binding cassette sub-family G member 2,ABCG2,4.2,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
diazoxide,ATP-sensitive inward rectifier potassium channel 11,Kcnj11,4.2,EC50,CC1=NC2=CC=C(Cl)C=C2S(=O)(=O)N1
diltiazem,Potassium voltage-gated channel subfamily A member 7,Kcna7,4.2,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
levomenthol,Transient receptor potential cation channel subfamily M member 8,Trpm8,4.2,EC50,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
levomenthol,Transient receptor potential cation channel subfamily A member 1,Trpa1,4.2,IC50,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
estramustine phosphate,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,4.2,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2OP(O)(O)=O
ibuprofen,Sodium-coupled monocarboxylate transporter 1,SLC5A8,4.2,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
lidocaine,Sodium channel protein type 5 subunit alpha,Scn5a,4.2,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
loratadine,Potassium channel subfamily K member 9,KCNK9,4.2,IC50,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
loratadine,Potassium channel subfamily K member 9,KCNK9,4.2,IC50,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
mezlocillin,Cannabinoid receptor 2,CNR2,4.2,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
nafamostat,Acid-sensing ion channel 2,ASIC2,4.2,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
nicardipine,Adenosine receptor A2a,Adora2a,4.2,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
pantoprazole,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",DDAH1,4.2,IC50,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
propranolol,Solute carrier family 22 member 1,SLC22A1,4.2,IC50,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
sildenafil,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,4.2,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
spiperone,5-hydroxytryptamine receptor 5A,HTR5A,4.2,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sulfasalazine,Proton-coupled folate transporter,SLC46A1,4.2,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
thioridazine,G protein-activated inward rectifier potassium channel 2,Kcnj6,4.2,EC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
vinburnine,Muscarinic acetylcholine receptor M2,CHRM2,4.2,Kd,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C1=CC=CC=C41)C(=O)C2
eburnamonine,Muscarinic acetylcholine receptor M2,CHRM2,4.2,Kd,CC[C@]12CCCN3CCC4=C([C@@H]13)N(C1=CC=CC=C41)C(=O)C2
quercetin,Cell division protein kinase 5,Cdk5,4.2,EC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
resorcinol,Carbonic anhydrase 13,Ca13,4.2,Ki,OC1=CC(O)=CC=C1
oxedrine,5-hydroxytryptamine receptor 1A,HTR1A,4.2,Ki,CNCC(O)C1=CC=C(O)C=C1
vincamine,Muscarinic acetylcholine receptor M4,CHRM4,4.2,Kd,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C1=CC=CC=C41)[C@](O)(C2)C(=O)OC
amikacin,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",mphB,4.201,Km,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
clozapine,UDP-glucuronosyltransferase 1-4,UGT1A4,4.208,app Km,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
nelfinavir,Muscarinic acetylcholine receptor M5,CHRM5,4.209,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
clozapine,Calmodulin,CALM,4.21,Kd,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cocaine,Muscarinic acetylcholine receptor M1,Chrm1,4.21,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
fenofibrate,Cruzipain,,4.21,IC50,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
glutamic acid,Excitatory amino acid transporter 2,SLC1A2,4.21,Ki,N[C@@H](CCC(O)=O)C(O)=O
hymecromone,Aldose reductase,Akr1b1,4.21,IC50,CC1=CC(=O)OC2=C1C=CC(O)=C2
lactose,Galectin-8,LGALS8,4.21,Kd,OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
lamotrigine,Sodium channel protein type 5 subunit alpha,SCN5A,4.21,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
topotecan,Solute carrier family 22 member 2,SLC22A2,4.21,IC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
troglitazone,"Indoleamine 2,3-dioxygenase 1",Ido1,4.21,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
valdecoxib,Carbonic anhydrase,,4.21,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
valproic acid,Histone deacetylase 2,HDAC2,4.21,IC50,CCCC(CCC)C(O)=O
vancomycin,D-alanyl-D-alanine dipeptidase,vanX,4.21,Ki,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(C=C(O)C=C3O)[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC=C(O4)C(Cl)=C1)C(O)=O)C(Cl)=C2
methionine,S-ribosylhomocysteine lyase,luxS,4.21,Ki,CSCC[C@H](N)C(O)=O
quercetin,Cyclin-dependent kinase 4/cyclin D1,CDK4|CCND1,4.21,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
kojic acid,Tyrosinase,Tyr,4.21,IC50,OCC1=CC(=O)C(O)=CO1
amiloride,Sodium/hydrogen exchanger 1,SLC9A1,4.22,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
amitriptyline,High affinity nerve growth factor receptor,NTRK1,4.22,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
caffeine,Adenosine receptor,Adora1|Adora3|Adora2b|Adora2a,4.22,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
chlorcyclizine,Apoptosis regulator Bcl-2,BCL2,4.22,Kd,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
colforsin daropate,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.22,IC50,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C
dicoumarol,ATP phosphoribosyltransferase,hisG,4.22,Ki,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
enprofylline,Adenosine receptor A1,ADORA1,4.22,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
guaiacol,Carbonic anhydrase 1,CA1,4.22,Ki,COC1=CC=CC=C1O
mitoxantrone,Solute carrier family 22 member 3,SLC22A3,4.22,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
promethazine,Calmodulin-1,CALM1,4.22,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
ademetionine,S-adenosylmethionine decarboxylase proenzyme,Amd1,4.22,Ki,C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N
sitagliptin,Dipeptidyl peptidase 2,DPP7,4.22,IC50,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
sulconazole,"Alkaline phosphatase, tissue-nonspecific isozyme",ALPL,4.22,EC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
thiabendazole,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,4.22,Kd,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
estrone sulphate,Steryl-sulfatase,STS,4.22,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
flurazepam,Solute carrier family 22 member 2,SLC22A2,4.222,IC50,CCN(CC)CCN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=C(F)C=CC=C1
dronedarone,Thyroid hormone receptor alpha,THRA,4.229,IC50,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
dronedarone,THAP domain-containing protein 1,THAP1,4.229,IC50,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
clarithromycin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.23,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC
cysteine,Cystine/glutamate transporter,SLC7A11,4.23,Ki,N[C@@H](CS)C(O)=O
cytarabine,Enoyl-[acyl-carrier-protein] reductase [NADH],fabI,4.23,IC50,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
gemfibrozil,Peroxisome proliferator-activated receptor alpha,PPARA,4.23,EC50,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1
niclosamide,RAC-alpha serine/threonine-protein kinase,AKT1,4.23,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
ofloxacin,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,4.23,IC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
promazine,Trypanothione reductase,TPR,4.23,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
tranylcypromine,D(2) dopamine receptor,Drd2,4.23,Ki,N[C@@H]1C[C@H]1C1=CC=CC=C1
trientine,Carbonic anhydrase 15,Ca15,4.23,Ki,NCCNCCNCCN
bupivacaine,5-hydroxytryptamine receptor 3A,HTR3A,4.233,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
amiloride,Solute carrier family 22 member 1,SLC22A1,4.24,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
cefixime,D(2) dopamine receptor,DRD2,4.24,IC50,NC1=NC(=CS1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
cefonicid,Somatostatin receptor type 4,SSTR4,4.24,IC50,O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
hexachlorophene,M1-family alanyl aminopeptidase,,4.24,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
miglitol,Alpha-glucosidase,aglA,4.24,IC50,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
sulfadiazine,High affinity choline transporter 1,SLC5A7,4.24,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
sulfanilamide,Carbonic anhydrase,,4.24,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
trientine,Carbonic anhydrase 12,CA12,4.24,Ki,NCCNCCNCCN
tubocurarine,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,4.24,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
valproic acid,Aldose reductase,AKR1B1,4.24,IC50,CCCC(CCC)C(O)=O
disufenton,Lipoxygenase,,4.24,IC50,CC(C)(C)[N+]([O-])=CC1=C(C=C(C=C1)S(O)(=O)=O)S(O)(=O)=O
disufenton,Lipoxygenase,,4.24,IC50,CC(C)(C)[N+]([O-])=CC1=C(C=C(C=C1)S(O)(=O)=O)S(O)(=O)=O
asparagine,Amino acid transporter,Slc1a5,4.24,IC50,N[C@@H](CC(N)=O)C(O)=O
serine,Amino acid transporter,Slc1a5,4.24,IC50,N[C@@H](CO)C(O)=O
estrone sulphate,Solute carrier family 22 member 20,Slc22a20,4.24,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
cenobamate,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,4.24,EC50,NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl
cenobamate,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,4.24,EC50,NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl
chloramphenicol,Cytochrome P450 3A4,CYP3A4,4.25,IC50,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
clofibrate,Peroxisome proliferator-activated receptor alpha,PPARA,4.25,IC50,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
deanol,High affinity choline transporter 1,Slc5a7,4.25,Ki,CN(C)CCO
desipramine,Solute carrier family 22 member 1,SLC22A1,4.25,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
diclofenac,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.25,EC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
diclofenac,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.25,EC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
ditiocarb,Carbonic anhydrase 13,Ca13,4.25,Ki,CCN(CC)C(S)=S
fulvestrant,Beta-lactamase TEM,bla; blaT-3; blaT-4;,4.25,IC50,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
fulvestrant,Beta-lactamase TEM,bla; blaT-3; blaT-4;,4.25,IC50,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
lidocaine,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,4.25,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
mexiletine,Sodium channel protein type 10 subunit alpha,SCN10A,4.25,IC50,CC(N)COC1=C(C)C=CC=C1C
pimethixene,Transcriptional activator protein luxR,luxR,4.25,IC50,CN1CCC(CC1)=C1C2=CC=CC=C2SC2=C1C=CC=C2
sulindac,Prostaglandin G/H synthase 2,PTGS2,4.25,IC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
trimethoprim,Solute carrier family 22 member 1,SLC22A1,4.25,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
valproic acid,Aldose reductase,Akr1b1,4.25,IC50,CCCC(CCC)C(O)=O
valproic acid,Aldose reductase-related protein 1,Akr1b7,4.25,IC50,CCCC(CCC)C(O)=O
capsaicin,Arachidonate 5-lipoxygenase,ALOX5,4.25,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
capsaicin,Arachidonate 5-lipoxygenase,ALOX5,4.25,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
peramivir,Sialidase 2,NEU2,4.25,Ki,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
nelfinavir,Epidermal growth factor receptor,EGFR,4.255,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
epinephrine,D(1A) dopamine receptor,DRD1,4.26,Kd,CNC[C@H](O)C1=CC=C(O)C(O)=C1
lysine,"Glutathione reductase, mitochondrial",GSR,4.26,Ki,NCCCC[C@H](N)C(O)=O
melphalan,L-type amino acid transporter 1,Slc7a5,4.26,Ki,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
menadione,Trypanothione reductase,TPR,4.26,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
methylthioninium chloride,Cruzipain,,4.26,IC50,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
mexiletine,Solute carrier family 22 member 2,SLC22A2,4.26,IC50,CC(N)COC1=C(C)C=CC=C1C
phenylalanine,L-type amino acid transporter 1,Slc7a5,4.26,Ki,N[C@@H](CC1=CC=CC=C1)C(O)=O
tolbutamide,Solute carrier family 22 member 6,Slc22a6,4.26,Ki,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1
troglitazone,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,4.26,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
tropisetron,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,4.26,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
tubocurarine,Multidrug and toxin extrusion protein 2,SLC47A2,4.26,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
butethamine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.26,IC50,CC(C)CNCCOC(=O)C1=CC=C(N)C=C1
benzbromarone,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,4.27,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
chlorphenamine,Chloroquine resistance transporter,CRT,4.27,IC50,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
flufenamic acid,Transcriptional enhancer factor TEF-3,TEAD4,4.27,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
flufenamic acid,Transcriptional enhancer factor TEF-3,TEAD4,4.27,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
indomethacin,Aldo-keto reductase family 1 member C4,AKR1C4,4.27,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
mequitazine,Trypanothione reductase,,4.27,IC50,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
niclosamide,Aurora kinase A,AURKA,4.27,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
pentamidine,Protein-tyrosine phosphatase 4A3,PTP4A3,4.27,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
phenazopyridine,Snake venom metalloproteinase Bap1,,4.27,IC50,NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
pindolol,5-hydroxytryptamine receptor 2C,HTR2C,4.27,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
prilocaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.27,IC50,CCCNC(C)C(=O)NC1=C(C)C=CC=C1
triazolam,Cytochrome P450 3A4,CYP3A4,4.27,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
valdecoxib,Carbonic anhydrase 1,CA1,4.27,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
eicosapentaenoic acid,Aromatase,CYP19A1,4.27,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
tonzonium,Insulin-degrading enzyme,IDE,4.27,EC50,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1
dabrafenib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,4.27,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
dabrafenib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,4.27,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
cannabidiol,Fatty-acid amide hydrolase 1,Faah,4.27,IC50,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
cannabidiol,Fatty-acid amide hydrolase 1,Faah,4.27,IC50,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
amodiaquine,Heparanase,HPSE,4.28,Kd,CCN(CC)CC1=C(O)C=CC(NC2=CC=NC3=CC(Cl)=CC=C23)=C1
argatroban,Coagulation factor X,F10,4.28,Ki,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2
carbamazepine,Sodium channel protein type 4 subunit alpha,SCN4A,4.28,Ki,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
codeine,Delta-type opioid receptor,OPRD1,4.28,Ki,COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C
diclofenac,UDP-glucuronosyltransferase 1-1,UGT1A1,4.28,Ki,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
doxorubicin,Reverse transcriptase,reverse transcriptas,4.28,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
estriol succinate,Olfactory receptor 51E2,OR51E2,4.28,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
levofloxacin,DNA gyrase subunit A,gyrA,4.28,IC50,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
mibefradil,Calcium release-activated calcium channel protein 1,ORAI1,4.28,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
norfloxacin,DNA gyrase subunit A,gyrA,4.28,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
pravastatin,Solute carrier family 22 member 6,Slc22a6,4.28,Ki,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12
rabeprazole,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",DDAH1,4.28,IC50,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
rabeprazole,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",DDAH1,4.28,IC50,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
ropivacaine,Potassium channel subfamily K member 3,KCNK3,4.28,IC50,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
ropivacaine,Potassium channel subfamily K member 3,KCNK3,4.28,IC50,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
ticlopidine,Prostaglandin G/H synthase 1,PTGS1,4.28,IC50,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
tramadol,Solute carrier family 22 member 1,SLC22A1,4.28,IC50,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
trientine,Carbonic anhydrase 13,Ca13,4.28,Ki,NCCNCCNCCN
zoledronic acid,Matrix metalloproteinase-9,MMP9,4.28,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
capsaicin,NADH-ubiquinone oxidoreductase chain 1 ,MT-ND1,4.28,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
estriol,Olfactory receptor 51E2,OR51E2,4.28,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
hexamidine,Protein arginine N-methyltransferase 1,PRMT1,4.28,IC50,NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
rutoside,Xanthine dehydrogenase/oxidase,XDH,4.28,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
vildagliptin,Prolyl endopeptidase FAP,Fap,4.28,IC50,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
kojic acid,Tyrosinase,,4.28,IC50,OCC1=CC(=O)C(O)=CO1
thymol,Transient receptor potential cation channel subfamily M member 8,Trpm8,4.28,EC50,CC(C)C1=C(O)C=C(C)C=C1
dexrabeprazole,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",DDAH1,4.28,IC50,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
dexrabeprazole,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",DDAH1,4.28,IC50,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
atomoxetine,G protein-activated inward rectifier potassium channel 2,KCNJ6,4.282,IC50,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
felbamate,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,4.284,IC50,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
propofol,Fatty-acid amide hydrolase 1,FAAH,4.284,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
warfarin,Vitamin K epoxide reductase complex subunit 1-like protein 1,VKORC1L1,4.284,Ki,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
pyrimethamine,Cytochrome P450 2C9,CYP2C9,4.288,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
clotrimazole,"Indoleamine 2,3-dioxygenase 1",Ido1,4.29,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
lansoprazole,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",DDAH1,4.29,IC50,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
masoprocol,Lipoxygenase,,4.29,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
rifampicin,Solute carrier organic anion transporter family member 1A2,SLCO1A2,4.29,Ki,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
articaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.29,IC50,CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC
estrone,Steryl-sulfatase,STS,4.29,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
quinine,Solute carrier family 22 member 1,SLC22A1,4.29,IC50,COC1=CC=C2N=CC=C([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
cannabidiol,N-arachidonyl glycine receptor,GPR18,4.29,EC50,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
propranolol,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,4.297,IC50,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
acetoxolone,Liver carboxylesterase 1,CES1,4.3,IC50,CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C
bezafibrate,Peroxisome proliferator-activated receptor alpha,PPARA,4.3,EC50,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
bupropion,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,4.3,IC50,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
camphor,Acetylcholinesterase,ache,4.3,Ki,CC1(C)C2CCC1(C)C(=O)C2
cefdinir,Cytoplasmic zinc-finger protein,pos-1,4.3,EC50,NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
celecoxib,Carbonic anhydrase 1,CA1,4.3,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cefradine,Somatostatin receptor type 4,SSTR4,4.3,IC50,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O
chlordiazepoxide,Acetylcholinesterase,ache,4.3,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
chlorzoxazone,"Nitric oxide synthase, brain",NOS1,4.3,IC50,ClC1=CC2=C(OC(=O)N2)C=C1
citalopram,5-hydroxytryptamine receptor 1A,Htr1a,4.3,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
desipramine,G protein-activated inward rectifier potassium channel 4,Kcnj5,4.3,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
dihydroergotamine,Solute carrier family 22 member 2,SLC22A2,4.3,IC50,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dipyridamole,"High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B",PDE8B,4.3,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
dopamine,Beta-2 adrenergic receptor,ADRB2,4.3,Ki,NCCC1=CC(O)=C(O)C=C1
enalapril,Angiotensin-converting enzyme,ACE,4.3,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
etomidate,Acetylcholine receptor subunit delta,chrnd,4.3,IC50,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
grepafloxacin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.3,IC50,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O
griseofulvin,Lanosterol 14-alpha demethylase,CYP51A1,4.3,IC50,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC
histamine,Histamine H2 receptor,HRH2,4.3,Ki,NCCC1=CN=CN1
ibuprofen,Cytochrome P450 2C9,CYP2C9,4.3,Ki,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
imipramine,G protein-activated inward rectifier potassium channel 2,Kcnj6,4.3,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
levosulpiride,D(1A) dopamine receptor,DRD1,4.3,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
masoprocol,Prostaglandin G/H synthase 1,PTGS1,4.3,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
masoprocol,"Fatty acid hydroperoxide lyase, chloroplastic",HPL,4.3,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
meclofenamic acid,Transthyretin,TTR,4.3,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
mezlocillin,Peroxisome proliferator-activated receptor gamma,PPARG,4.3,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
miglitol,Lactase-phlorizin hydrolase,LCT,4.3,IC50,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nicotinamide,NAD-dependent protein deacetylase sirtuin-1,SIRT1,4.3,IC50,NC(=O)C1=CN=CC=C1
nicardipine,Malate dehydrogenase cytoplasmic ,MDH1,4.3,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
nifedipine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.3,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
norepinephrine,D(1A) dopamine receptor,DRD1,4.3,Kd,NC[C@H](O)C1=CC(O)=C(O)C=C1
pamidronic acid,Hypoxanthine-guanine phosphoribosyltransferase,HGPRT,4.3,Ki,NCCC(O)(P(O)(O)=O)P(O)(O)=O
penicillamine,Succinyl-diaminopimelate desuccinylase,dapE,4.3,IC50,CC(C)(S)[C@@H](N)C(O)=O
pentobarbital,GABA A receptor alpha-2/beta-2/gamma-2,GABRG2|GABRA2|GABRB2,4.3,EC50,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
probenecid,Solute carrier family 22 member 12,SLC22A12,4.3,IC50,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
prochlorperazine,Solute carrier family 22 member 1,SLC22A1,4.3,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
promethazine,Calmodulin,CALM,4.3,Kd,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
riluzole,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.3,IC50,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
salicylic acid,Carbonic anhydrase 14,CA14,4.3,Ki,OC(=O)C1=CC=CC=C1O
spiperone,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,4.3,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
stiripentol,Sodium- and chloride-dependent GABA transporter 1,SLC6A1,4.3,IC50,CC(C)(C)C(O)C=CC1=CC=C2OCOC2=C1
testosterone,Lanosterol 14-alpha demethylase,CYP51A1,4.3,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
tolcapone,Krueppel-like factor 10,KLF10,4.3,IC50,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
ubenimex,Endoplasmic reticulum aminopeptidase 1,ERAP1,4.3,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
valproic acid,Alcohol dehydrogenase [NADP(+)],AKR1A1,4.3,IC50,CCCC(CCC)C(O)=O
valproic acid,Alcohol dehydrogenase [NADP(+)],Akr1a1,4.3,IC50,CCCC(CCC)C(O)=O
verapamil,Potassium voltage-gated channel subfamily A member 10,KCNA10,4.3,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
vinpocetine,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C",PDE1C,4.3,IC50,CCOC(=O)C1=C[C@]2(CC)CCCN3CCC4=C([C@H]23)N1C1=CC=CC=C41
suramin,P2Y purinoceptor 2,P2RY2,4.3,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
furtrethonium,Muscarinic acetylcholine receptor M4,CHRM4,4.3,Ki,C[N+](C)(C)CC1=CC=CO1
quercetin,Aldose reductase,AKR1B1,4.3,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
sulmazole,Phosphodiesterase 3,PDE3B|PDE3A,4.3,IC50,COC1=C(C=CC(=C1)S(C)=O)C1=NC2=C(N1)N=CC=C2
tolnaftate,Lanosterol 14-alpha demethylase,CYP51A1,4.3,IC50,CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC(C)=CC=C1
serine,Gamma-glutamyltranspeptidase 1,Ggt1,4.3,Ki,N[C@@H](CO)C(O)=O
vernakalant,Potassium voltage-gated channel subfamily D member 2,KCND2,4.3,IC50,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1
migalastat,Lactase-phlorizin hydrolase,LCT,4.3,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
aprindine,Sodium/calcium exchanger 1,SLC8A1,4.301,IC50,CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1
dobutamine,Catechol O-methyltransferase,COMT,4.301,Km,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
pentobarbital,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,4.301,EC50,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
ritonavir,Cytochrome P450 2D6,CYP2D6,4.301,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
trovafloxacin,Sodium-dependent dopamine transporter,SLC6A3,4.306,Ki,N[C@H]1[C@@H]2CN(C[C@H]12)C1=C(F)C=C2C(=O)C(=CN(C3=C(F)C=C(F)C=C3)C2=N1)C(O)=O
paracetamol,Prostaglandin G/H synthase 2,PTGS2,4.31,IC50,CC(=O)NC1=CC=C(O)C=C1
carbamazepine,Neuronal acetylcholine receptor; alpha2/beta4,CHRNB4|CHRNA2,4.31,IC50,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
cianidanol,Prothrombin,F2,4.31,Kd,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
cocaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.31,IC50,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
cycloserine,Cytochrome P450 3A4,CYP3A4,4.31,IC50,N[C@@H]1CONC1=O
methaqualone,GABA A receptor alpha-3/beta-2/gamma-2,GABRG2|GABRA3|GABRB2,4.31,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
omeprazole,Cytochrome P450 3A4,CYP3A4,4.31,Km,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
ticlopidine,Bile salt export pump,Abcb11,4.31,IC50,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
trientine,"Carbonic anhydrase 5B, mitochondrial",CA5B,4.31,Ki,NCCNCCNCCN
quercetin,Glutathione reductase,GLR1,4.31,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
aztreonam,Penicillin-binding protein 1B,mrcB,4.317,IC50,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
reboxetine,Kir3.1/Kir3.2,KCNJ6|KCNJ3,4.317,IC50,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
propranolol,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,4.319,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
benzbromarone,Polymerase acidic protein,PA,4.32,Kd,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
betamipron,Solute carrier family 22 member 8,SLC22A8,4.32,Ki,OC(=O)CCNC(=O)C1=CC=CC=C1
celecoxib,3-phosphoinositide-dependent protein kinase 1,PDPK1,4.32,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
ibuprofen,"Fatty acid-binding protein, liver",Fabp1,4.32,Ki,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
progesterone,Multidrug resistance protein 1,ABCB1,4.32,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
propranolol,Multidrug resistance protein 1,ABCB1,4.32,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
ademetionine,Protein-beta-aspartate methyltransferase,PCMT1,4.32,Ki,C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N
trientine,Carbonic anhydrase 3,CA3,4.32,Ki,NCCNCCNCCN
viloxazine,Sodium-dependent dopamine transporter,Slc6a3,4.32,Ki,CCOC1=CC=CC=C1OCC1CNCCO1
choline,Neuronal acetylcholine receptor; alpha3/beta4,Chrna3|Chrnb4,4.32,Ki,C[N+](C)(C)CCO
linoleic acid,Aromatase,CYP19A1,4.32,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
montelukast,Arachidonate 5-lipoxygenase,ALOX5,4.328,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
gemigliptin,Dipeptidyl peptidase 9,DPP9,4.328,IC50,N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(N=C(N=C2C1)C(F)(F)F)C(F)(F)F
acetohydroxamic acid,Carbonic anhydrase 2,CA2,4.33,IC50,CC(=O)NO
caffeine,Adenosine receptor A3,ADORA3,4.33,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
cibenzoline,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,4.33,IC50,C1C(C2=NCCN2)C1(C1=CC=CC=C1)C1=CC=CC=C1
denopamine,Solute carrier family 22 member 1,SLC22A1,4.33,IC50,COC1=CC=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1OC
dicoumarol,Enoyl-[acyl-carrier-protein] reductase [NADH],fabI,4.33,IC50,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
levamfetamine,Sigma non-opioid intracellular receptor 1,SIGMAR1,4.33,Ki,C[C@@H](N)CC1=CC=CC=C1
meclofenamic acid,Arachidonate 5-lipoxygenase,ALOX5,4.33,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
mezlocillin,Prostaglandin E2 receptor EP1 subtype,PTGER1,4.33,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
mezlocillin,Prostaglandin E2 receptor EP3 subtype,PTGER3,4.33,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
mezlocillin,Prostaglandin E2 receptor EP4 subtype,PTGER4,4.33,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
nicotinamide,"NAD-dependent protein deacylase sirtuin-5, mitochondrial",SIRT5,4.33,IC50,NC(=O)C1=CN=CC=C1
ticlopidine,Prostaglandin G/H synthase 2,PTGS2,4.33,IC50,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
tolcapone,Bile salt export pump,Abcb11,4.33,IC50,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
tolfenamic acid,Androgen receptor,AR,4.33,IC50,CC1=C(NC2=C(C=CC=C2)C(O)=O)C=CC=C1Cl
fenofibrate,D(3) dopamine receptor,DRD3,4.331,Ki,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
disulfiram,Membrane-associated progesterone receptor component 1,Pgrmc1,4.333,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
ambenonium,Acetylcholinesterase,Ache,4.34,Kd,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC1=C(Cl)C=CC=C1
buspirone,Multidrug and toxin extrusion protein 2,SLC47A2,4.34,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
dabigatran etexilate,Tissue-type plasminogen activator,PLAT,4.34,Ki,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
fentanyl,Solute carrier family 22 member 1,SLC22A1,4.34,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
fentanyl,Solute carrier family 22 member 1,SLC22A1,4.34,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
gossypol,Beta-lactamase,ampC,4.34,IC50,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
hexachlorophene,Cytoplasmic zinc-finger protein,pos-1,4.34,EC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
nifedipine,"Indoleamine 2,3-dioxygenase 1",Ido1,4.34,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nifedipine,Bile salt export pump,Abcb11,4.34,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
ondansetron,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,4.34,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
enoxolone,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,4.34,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
tirbanibulin,Proto-oncogene tyrosine-protein kinase Src,SRC,4.34,IC50,C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
tirbanibulin,Proto-oncogene tyrosine-protein kinase Src,SRC,4.34,IC50,C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
procaine,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,4.342,IC50,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
alcuronium,Neuronal acetylcholine receptor; alpha4/beta4,CHRNB4|CHRNA4,4.347,IC50,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
omeprazole,Cytochrome P450 2C9,CYP2C9,4.347,Ki,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
suprofen,Cytochrome P450 2C9,CYP2C9,4.347,Ki,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
verapamil,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,4.348,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
amfetamine,Sodium-dependent serotonin transporter,Slc6a4,4.35,IC50,CC(N)CC1=CC=CC=C1
bezafibrate,"Fatty acid-binding protein, liver",Fabp1,4.35,Ki,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
cinacalcet,Metabotropic glutamate receptor 5,Grm5,4.35,Ki,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=C1C=CC=C2
diltiazem,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.35,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
dipyridamole,Phosphodiesterase 1,PDE1A|PDE1B|PDE1C,4.35,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
incadronic acid,Vacuolar-type proton translocating pyrophosphatase 1,PPase1,4.35,IC50,OP(O)(=O)C(NC1CCCCCC1)P(O)(O)=O
lonazolac,Prostaglandin E synthase,PTGES,4.35,IC50,OC(=O)CC1=CN(N=C1C1=CC=C(Cl)C=C1)C1=CC=CC=C1
thiamazole,Dopamine beta-hydroxylase,DBH,4.35,Ki,CN1C=CNC1=S
methotrexate,Thymidylate synthase,Tyms,4.35,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
nimodipine,Adenosine receptor A2a,Adora2a,4.35,Ki,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
phenoxybenzamine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.35,IC50,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
thiabendazole,Methionine aminopeptidase 2,METAP2,4.35,IC50,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
tiliquinol,Catechol O-methyltransferase,Comt,4.35,IC50,CC1=CC=C(O)C2=C1C=CC=N2
trientine,Carbonic anhydrase 7,CA7,4.35,Ki,NCCNCCNCCN
cholic acid,Bile acid receptor,NR1H4,4.35,EC50,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
thiram,Fatty-acid amide hydrolase 1,FAAH,4.35,IC50,CN(C)C(=S)SSC(=S)N(C)C
ruxolitinib,Oxysterols receptor LXR-beta,NR1H2,4.35,Ki,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Oxysterols receptor LXR-beta,NR1H2,4.35,Ki,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
linolenic acid,Aromatase,CYP19A1,4.35,IC50,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
safinamide,Amine oxidase [flavin-containing] A,MAOA,4.35,IC50,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O
deoxycholic acid,Bile acid receptor,NR1H4,4.35,EC50,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
midazolam,Multidrug resistance protein 1,ABCB1,4.353,Km,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
nifedipine,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,4.355,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
aprindine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,4.359,IC50,CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1
paracetamol,Arachidonate 5-lipoxygenase-activating protein,ALOX5AP,4.36,IC50,CC(=O)NC1=CC=C(O)C=C1
benzatropine,Sodium-dependent neutral amino acid transporter B(0)AT1,SLC6A19,4.36,IC50,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
dipyridamole,Cyclic nucleotide phosphodiesterase PDE3A,,4.36,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
mitoxantrone,Solute carrier family 22 member 1,SLC22A1,4.36,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
nicotinamide,Sterile alpha and TIR motif-containing protein 1,SARM1,4.36,IC50,NC(=O)C1=CN=CC=C1
pantoprazole,Multidrug and toxin extrusion protein 2,SLC47A2,4.36,IC50,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
pentamidine,Protein S100-B,S100b,4.36,Kd,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pirlindole,Transcriptional enhancer factor TEF-5,TEAD3,4.36,IC50,CC1=CC2=C(C=C1)N1CCNC3CCCC2=C13
salicylic acid,Solute carrier family 22 member 20,Slc22a20,4.36,Ki,OC(=O)C1=CC=CC=C1O
tacrine,Glutamate NMDA receptor; GRIN1/GRIN2B,GRIN1|GRIN2B,4.36,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
levothyroxine,"Malate dehydrogenase, mitochondrial",MDH2,4.36,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
amfetamine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,4.37,Ki,CC(N)CC1=CC=CC=C1
cefuroxime,72 kDa type IV collagenase,MMP2,4.37,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C1=CC=CO1
desloratadine,Multidrug resistance protein 1,ABCB1,4.37,IC50,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
diltiazem,Multidrug resistance protein 1,ABCB1,4.37,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
dioxyline,Methionine aminopeptidase 1,METAP1,4.37,IC50,CCOC1=C(OC)C=C(CC2=NC(C)=CC3=CC(OC)=C(OC)C=C23)C=C1
diphenhydramine,Histamine H4 receptor,HRH4,4.37,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
dipyridamole,Phosphodiesterase 3,PDE3B|PDE3A,4.37,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
glutamic acid,"Glutathione reductase, mitochondrial",GSR,4.37,Ki,N[C@@H](CCC(O)=O)C(O)=O
ibuprofen,Aldo-keto reductase family 1 member C2,AKR1C2,4.37,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
sildenafil,Phosphodiesterase 2A,PDE2A,4.37,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
trientine,Carbonic anhydrase 6,CA6,4.37,Ki,NCCNCCNCCN
bithionol,M1-family alanyl aminopeptidase,,4.37,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
dexibuprofen,Aldo-keto reductase family 1 member C2,AKR1C2,4.37,IC50,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
pilsicainide,Sodium channel protein type 4 subunit alpha,SCN4A,4.377,IC50,CC1=CC=CC(C)=C1NC(=O)CC12CCCN1CCC2
clotrimazole,Prostaglandin G/H synthase 2,PTGS2,4.379,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
candesartan cilexetil,Cruzipain,,4.38,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
cefalexin,Solute carrier family 15 member 2,SLC15A2,4.38,IC50,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=CC=C1)C2=O)C(O)=O
chlorphenamine,Lethal(3)malignant brain tumor-like protein 3,L3MBTL3,4.38,IC50,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
dexniguldipine,Adenosine receptor A1,Adora1,4.38,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
enprofylline,Adenosine receptor A1,ADORA1,4.38,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
mexiletine,Sodium channel protein type 4 subunit alpha,SCN4A,4.38,IC50,CC(N)COC1=C(C)C=CC=C1C
ropinirole,D(1B) dopamine receptor,DRD5,4.38,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
trimethoprim,Dihydrofolate reductase,dhfR,4.38,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
vigabatrin,Gamma-amino-N-butyrate transaminase,Abat,4.38,IC50,NC(CCC(O)=O)C=C
capsaicin,"Tyrosine--tRNA ligase, cytoplasmic",YARS,4.38,Ki,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
choline,Acetylcholine receptor subunit delta,chrnd,4.38,Ki,C[N+](C)(C)CCO
choline,Creatine transporter,Slc6a8,4.38,Ki,C[N+](C)(C)CCO
hydroquinone,Carbonic anhydrase 14,CA14,4.38,Ki,OC1=CC=C(O)C=C1
rutoside,Serum albumin,ALB,4.38,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
prazosin,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,4.38,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
cenobamate,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,4.38,EC50,NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl
cenobamate,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,4.38,EC50,NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl
reboxetine,Kir3.1/Kir3.4,KCNJ5|KCNJ3,4.387,IC50,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
terconazole,5-hydroxytryptamine receptor 1B,Htr1b,4.389,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
acetoxolone,Cocaine esterase,CES2,4.39,IC50,CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C
amrinone,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,4.39,IC50,NC1=CC(=CNC1=O)C1=CC=NC=C1
bupivacaine,Potassium channel subfamily K member 3,KCNK3,4.39,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
bupivacaine,Potassium channel subfamily K member 3,KCNK3,4.39,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
chlorphenamine,Lethal(3)malignant brain tumor-like protein 1,L3MBTL1,4.39,IC50,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
cianidanol,Prostaglandin G/H synthase 1,PTGS1,4.39,Kd,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
coumarin,Amine oxidase [flavin-containing] A,Maoa,4.39,IC50,O=C1OC2=CC=CC=C2C=C1
estramustine phosphate,Protein-tyrosine phosphatase 1C,PTPN6,4.39,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2OP(O)(O)=O
indomethacin,Prostaglandin E synthase,PTGES,4.39,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
levofloxacin,CAAX prenyl protease 2,RCE1,4.39,AC50,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
lindane,Androgen receptor,Ar,4.39,IC50,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
meptazinol,Acetylcholinesterase,Ache,4.39,IC50,CCC1(CCCCN(C)C1)C1=CC(O)=CC=C1
mimosine,Ribonucleoside-diphosphate reductase large subunit,,4.39,IC50,N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O
linoleic acid,Tissue factor,F3,4.39,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
modafinil,Cytochrome P450 1A2,CYP1A2,4.396,Ki,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
fluphenazine,Epidermal growth factor receptor,EGFR,4.397,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
progabide,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,4.398,Ki,NC(=O)CCCN=C(C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1
regadenoson,Adenosine receptor A1,ADORA1,4.398,EC50,CNC(=O)C1=CN(N=C1)C1=NC(N)=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=N1
adenosine phosphate,2'-deoxynucleoside 5'-phosphate N-hydrolase 1,Dnph1,4.4,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
amidefrine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,4.4,IC50,CNCC(O)C1=CC(NS(C)(=O)=O)=CC=C1
aminocaproic acid,Plasminogen,PLG,4.4,IC50,NCCCCCC(O)=O
cefalotin,Somatostatin receptor type 4,SSTR4,4.4,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O
chlorpropamide,Solute carrier family 22 member 6,Slc22a6,4.4,Ki,CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
clofibric acid,Peroxisome proliferator-activated receptor alpha,PPARA,4.4,EC50,CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O
clomipramine,G protein-activated inward rectifier potassium channel 2,Kcnj6,4.4,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clonidine,Beta-1 adrenergic receptor,ADRB1,4.4,Kd,ClC1=CC=CC(Cl)=C1NC1=NCCN1
clonidine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1,Hcn1,4.4,IC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
coumarin,Carbonic anhydrase 15,Ca15,4.4,Ki,O=C1OC2=CC=CC=C2C=C1
desipramine,G protein-activated inward rectifier potassium channel 2,Kcnj6,4.4,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
diflunisal,Prostaglandin G/H synthase 1,PTGS1,4.4,IC50,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
disulfiram,"Aldehyde dehydrogenase, mitochondrial",Aldh2,4.4,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
doxycycline,Collagenase 3,MMP13,4.4,IC50,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C(O)C=CC=C12
erythromycin,Cytochrome P450 1B1,CYP1B1,4.4,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
fluconazole,Lanosterol 14-alpha demethylase,CYP51A1,4.4,Kd,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
fluvastatin,Sodium/bile acid cotransporter,SLC10A1,4.4,IC50,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C1=CC=C(F)C=C1
fluvastatin,Sodium/bile acid cotransporter,SLC10A1,4.4,IC50,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C1=CC=C(F)C=C1
folic acid,Thymidylate synthase,TYMS,4.4,Ki,NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=N1
ifenprodil,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,4.4,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
ifenprodil,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,4.4,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
ketoconazole,Cytochrome P450 2C9,CYP2C9,4.4,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
arginine hydrochloride,G-protein coupled receptor family C group 6 member A,GPRC6A,4.4,EC50,N[C@@H](CCCNC(N)=N)C(O)=O
methotrexate,Thymidylate synthase,thyA,4.4,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
miconazole,Beta-lactamase,ampC,4.4,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nicotinamide,Putative silent information regulator 2,SIR2RP1,4.4,IC50,NC(=O)C1=CN=CC=C1
niclosamide,Replicase polyprotein 1ab,rep,4.4,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
nilotinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,4.4,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nitroxoline,Cathepsin B,CTSB,4.4,Ki,OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O
phenytoin,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,4.4,IC50,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
progabide,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,4.4,Ki,NC(=O)CCCN=C(C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1
propafenone,Potassium voltage-gated channel subfamily A member 5,KCNA5,4.4,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
rebamipide,Cholecystokinin receptor type A,Cckar,4.4,IC50,OC(=O)C(CC1=CC(=O)NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1
rosiglitazone,Bile salt export pump,Abcb11,4.4,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
tamoxifen,Transcriptional activator protein luxR,luxR,4.4,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
telithromycin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.4,IC50,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCN3C=NC(=C3)C3=CN=CC=C3)C(=O)O[C@]12C)OC
tolfenamic acid,Transthyretin,TTR,4.4,IC50,CC1=C(NC2=C(C=CC=C2)C(O)=O)C=CC=C1Cl
tryptophan,Extracellular calcium-sensing receptor,CASR,4.4,Kd,N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
capsaicin,Potassium voltage-gated channel subfamily A member 2,Kcna2,4.4,Kd,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
quercetin,Cyclin-dependent kinase 2,CDK2,4.4,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
sulfur,Carbonic anhydrase 2,CA2,4.4,Ki,[S]
doconexent,Transient receptor potential cation channel subfamily A member 1,Trpa1,4.4,EC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
linopirdine,Potassium voltage-gated channel subfamily KQT member 1,Kcnq1,4.4,IC50,O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1
peramivir,Sialidase,nanH,4.4,IC50,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
amiodarone,5-hydroxytryptamine receptor 1B,Htr1b,4.407,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
celecoxib,Carbonic anhydrase,,4.41,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
eflornithine,Ornithine decarboxylase,Odc1,4.41,Ki,NCCCC(N)(C(F)F)C(O)=O
etidocaine,Potassium channel subfamily K member 3,KCNK3,4.41,IC50,CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
etidocaine,Potassium channel subfamily K member 3,KCNK3,4.41,IC50,CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
masoprocol,Androgen receptor,AR,4.41,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
methaqualone,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,4.41,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
ofloxacin,Muscarinic acetylcholine receptor M1,CHRM1,4.41,IC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
papaverine,Protein-arginine deiminase type-4,PADI4,4.41,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
triazolam,Cholecystokinin receptor type A,Cckar,4.41,IC50,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
trientine,Carbonic anhydrase 9,CA9,4.41,Ki,NCCNCCNCCN
fenticlor,Uracil-DNA glycosylase,UNG,4.41,IC50,OC1=C(SC2=C(O)C=CC(Cl)=C2)C=C(Cl)C=C1
armodafinil,D(3) dopamine receptor,DRD3,4.41,Ki,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
omarigliptin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.41,IC50,CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=C(F)C=CC(F)=C1
sparfloxacin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.413,Ki,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O
acarbose,"Oligo-1,6-glucosidase",IMA1,4.42,IC50,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
adenosine phosphate,Alcohol dehydrogenase,,4.42,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
amantadine,Multidrug and toxin extrusion protein 1,SLC47A1,4.42,IC50,NC12CC3CC(CC(C3)C1)C2
aminoacridine,Trypanothione reductase,TPR,4.42,Ki,NC1=C2C=CC=CC2=NC2=CC=CC=C12
bosentan,Bile salt export pump,ABCB11,4.42,IC50,COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1
dasatinib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,4.42,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diazepam,Cytochrome P450 3A4,CYP3A4,4.42,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
dicloxacillin,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,4.42,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
doxycycline,Zinc finger protein mex-5,mex-5,4.42,EC50,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C(O)C=CC=C12
granisetron,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,4.42,Ki,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
trientine,"Carbonic anhydrase 5A, mitochondrial",CA5A,4.42,Ki,NCCNCCNCCN
quercetin,Acetylcholinesterase,ACHE,4.42,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Alcohol dehydrogenase [NADP(+)],AKR1A1,4.42,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Lymphocyte differentiation antigen CD38,CD38,4.42,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
prazosin,Multidrug and toxin extrusion protein 2,SLC47A2,4.42,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
ethyl hydroxybenzoate,Estrogen receptor,ESR1,4.42,EC50,CCOC(=O)C1=CC=C(O)C=C1
dithranol,5-lipoxygenase,,4.43,IC50,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2
benserazide,Cytoplasmic zinc-finger protein,pos-1,4.43,EC50,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
cefapirin,Interstitial collagenase,MMP1,4.43,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
erythromycin,Motilin receptor,MLNR,4.43,Ki,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
felodipine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.43,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
gallamine,Acetylcholinesterase,ACHE,4.43,Ki,CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
milnacipran,Sodium-dependent dopamine transporter,Slc6a3,4.43,IC50,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
nifedipine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.43,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
physostigmine,Muscarinic acetylcholine receptor M1,Chrm1,4.43,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
verapamil,ATP-binding cassette sub-family G member 2,ABCG2,4.43,EC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
choline,Neuronal acetylcholine receptor; alpha3/beta2,Chrna3|Chrnb2,4.43,Ki,C[N+](C)(C)CCO
choline,Neuronal acetylcholine receptor; alpha4/beta2,Chrna4|Chrnb2,4.43,Ki,C[N+](C)(C)CCO
econazole,Melanocortin receptor 5,MC5R,4.431,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acetylsalicylic acid,Gamma-glutamyltranspeptidase 1,GGT1,4.44,IC50,CC(=O)OC1=CC=CC=C1C(O)=O
celecoxib,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,4.44,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cianidanol,Prostaglandin G/H synthase 1,PTGS1,4.44,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
famotidine,Solute carrier family 22 member 2,SLC22A2,4.44,IC50,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
famotidine,Multidrug and toxin extrusion protein 2,SLC47A2,4.44,IC50,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
fasudil,"Myosin light chain kinase, smooth muscle",MYLK,4.44,Ki,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
aminobutyric acid,Sodium- and chloride-dependent betaine transporter,SLC6A12,4.44,IC50,NCCCC(O)=O
indomethacin,Aldo-keto reductase family 1 member C2,AKR1C2,4.44,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
ketorolac,Serine/threonine-protein kinase PAK 1,PAK1,4.44,IC50,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1
methaqualone,GABA-A receptor alpha-6/beta-2/delta,GABRB2|GABRA6|GABRD,4.44,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
miglustat,Uncharacterized protein,TREH,4.44,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nitrendipine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.44,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
oxaprozin,Prostaglandin G/H synthase 2,PTGS2,4.44,IC50,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
phloroglucinol,Beta-secretase 1,BACE1,4.44,IC50,OC1=CC(O)=CC(O)=C1
pirlindole,Transcriptional enhancer factor TEF-3,TEAD4,4.44,IC50,CC1=CC2=C(C=C1)N1CCNC3CCCC2=C13
pirlindole,Transcriptional enhancer factor TEF-3,TEAD4,4.44,IC50,CC1=CC2=C(C=C1)N1CCNC3CCCC2=C13
oliceridine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,4.44,IC50,COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
oliceridine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,4.44,IC50,COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
acarbose,Pancreatic alpha-amylase,AMY2,4.45,IC50,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
bezafibrate,Peroxisome proliferator-activated receptor delta,PPARD,4.45,EC50,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
ketoconazole,Alpha-1A adrenergic receptor,Adra1a,4.45,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nandrolone,Solute carrier family 22 member 1,SLC22A1,4.45,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O
promethazine,Solute carrier family 22 member 1,SLC22A1,4.45,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
tolonium,Zinc finger protein mex-5,mex-5,4.45,EC50,CN(C)C1=CC2=[S+]C3=CC(N)=C(C)C=C3N=C2C=C1
quercetin,Sorbitol dehydrogenase,SORD,4.45,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
pioglitazone,Amine oxidase [flavin-containing] A,MAOA,4.455,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
adenosine,Glyceraldehyde-3-phosphate dehydrogenase liver,GAPDH,4.46,IC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
cefotiam,Matrix metalloproteinase-9,MMP9,4.46,IC50,CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
clotrimazole,Malate dehydrogenase cytoplasmic ,MDH1,4.46,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Serine/threonine-protein kinase mTOR,MTOR,4.46,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dioxyline,Methionine aminopeptidase 2,METAP2,4.46,IC50,CCOC1=C(OC)C=C(CC2=NC(C)=CC3=CC(OC)=C(OC)C=C23)C=C1
donepezil,Multidrug resistance protein 1,ABCB1,4.46,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
glutamic acid,Excitatory amino acid transporter 1,SLC1A3,4.46,Ki,N[C@@H](CCC(O)=O)C(O)=O
glutamic acid,Glutamate receptor 1,Gria1,4.46,EC50,N[C@@H](CCC(O)=O)C(O)=O
lamotrigine,Sodium channel protein type 2 subunit alpha,Scn2a,4.46,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
nandrolone decanoate,Solute carrier family 22 member 1,SLC22A1,4.46,IC50,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
noscapine,Multidrug and toxin extrusion protein 1,SLC47A1,4.46,IC50,COC1=CC=C2[C@H](OC(=O)C2=C1OC)[C@@H]1N(C)CCC2=C1C(OC)=C1OCOC1=C2
rifampicin,Bile salt export pump,Abcb11,4.46,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
spiperone,Dopamine receptor,Drd3|Drd4|Drd2|Drd1|Drd5,4.46,IC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
tamoxifen,Prostaglandin G/H synthase 2,PTGS2,4.46,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
testolactone,Aromatase,CYP19A1,4.46,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2
tranylcypromine,Lysine-specific histone demethylase 1B,KDM1B,4.46,IC50,N[C@@H]1C[C@H]1C1=CC=CC=C1
trientine,Carbonic anhydrase 4,CA4,4.46,Ki,NCCNCCNCCN
quercetin,Cytosol aminopeptidase,LAP3,4.46,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
tiratricol,Androgen receptor,AR,4.46,IC50,OC(=O)CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
clobetasol propionate,Bile salt export pump,Abcb11,4.46,IC50,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
choline fenofibrate,Peroxisome proliferator-activated receptor alpha,PPARA,4.46,Ki,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O
anagrelide,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,4.47,IC50,ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
cefotiam,Vasoactive intestinal polypeptide receptor 1,VIPR1,4.47,IC50,CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
chlorphenamine,MBT domain-containing protein 1,MBTD1,4.47,IC50,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
diflunisal,Dihydrofolate reductase,DHFR,4.47,Ki,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
diflunisal,Dihydrofolate reductase,DHFR,4.47,Ki,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
ergotamine,Cholecystokinin A receptor,Cckar,4.47,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
pimozide,Solute carrier family 22 member 2,SLC22A2,4.47,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
probucol,Trypsin,,4.47,IC50,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
ritonavir,Solute carrier family 22 member 1,SLC22A1,4.47,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
choline,Neuronal acetylcholine receptor; alpha4/beta4,Chrna4|Chrnb4,4.47,Ki,C[N+](C)(C)CCO
quercetin,Bifunctional epoxide hydrolase 2,EPHX2,4.47,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
rutoside,Neuraminidase,,4.47,Ki,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
edaravone,Polyunsaturated fatty acid lipoxygenase ALOX15,Alox15,4.47,IC50,CC1=NN(C(=O)C1)C1=CC=CC=C1
atomoxetine,Kir3.1/Kir3.2,KCNJ6|KCNJ3,4.478,IC50,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
bezafibrate,"Fatty acid-binding protein, intestinal",FABP2,4.48,Ki,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
cefdinir,Zinc finger protein mex-5,mex-5,4.48,EC50,NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
cefonicid,Prostaglandin G/H synthase 2,PTGS2,4.48,IC50,O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
cianidanol,Amyloid beta A4 protein,APP,4.48,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
cianidanol,Amyloid beta A4 protein,APP,4.48,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
clonidine,Multidrug and toxin extrusion protein 1,SLC47A1,4.48,IC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
cortisone acetate,Potassium voltage-gated channel subfamily A member 1,KCNA1,4.48,EC50,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
dextromethorphan,Cytochrome P450 2D6,CYP2D6,4.48,Ks,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
ibuprofen,Aldo-keto reductase family 1 member C3,AKR1C3,4.48,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
metoclopramide,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,4.48,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
pheniramine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.48,IC50,CN(C)CCC(C1=CC=CC=C1)C1=NC=CC=C1
pirlindole,Transcriptional enhancer factor TEF-4,TEAD2,4.48,IC50,CC1=CC2=C(C=C1)N1CCNC3CCCC2=C13
raloxifene,Cruzipain,,4.48,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
pyrithione,Protein-lysine 6-oxidase,LOX,4.48,IC50,[O-][N+]1=C(S)C=CC=C1
yohimbine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.48,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
doconexent,Aromatase,CYP19A1,4.48,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
safinamide,Sodium channel protein type 9 subunit alpha,SCN9A,4.48,IC50,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O
osimertinib,Dipeptidyl peptidase 1,CTSC,4.48,IC50,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
propyphenazone,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.481,IC50,CC(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1
diethylstilbestrol,Mitogen-activated protein kinase 14,MAPK14,4.483,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
verapamil,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,4.485,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
econazole,Epidermal growth factor receptor,EGFR,4.489,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
atorvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,4.49,IC50,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
atropine,Nicotinic acetylcholine receptor alpha 5 subunit,nAChRalpha5,4.49,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
brivudine,Thymidine kinase,UL23,4.49,IC50,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O
camostat,Hepatocyte growth factor activator,HGFAC,4.49,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
carvedilol,Toll-like receptor 4,TLR4,4.49,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
cefotetan,72 kDa type IV collagenase,MMP2,4.49,IC50,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
desipramine,Equilibrative nucleoside transporter 4,SLC29A4,4.49,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
doxorubicin,UDP-galactopyranose mutase,glf,4.49,AC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
enprofylline,Adenosine receptor A2a,ADORA2A,4.49,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
enprofylline,Adenosine receptor A1,Adora1,4.49,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
enprofylline,Adenosine receptor A2a,Adora2a,4.49,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
flurbiprofen,Aldo-keto reductase family 1 member C2,AKR1C2,4.49,IC50,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
glafenine,Bile salt export pump,Abcb11,4.49,IC50,OCC(O)COC(=O)C1=C(NC2=CC=NC3=CC(Cl)=CC=C23)C=CC=C1
indomethacin,Multidrug resistance protein 1,ABCB1,4.49,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
methazolamide,Carbonic anhydrase,,4.49,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
mepacrine,Cyclooxygenase,PTGS1|PTGS2,4.49,IC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
ropinirole,D(1A) dopamine receptor,DRD1,4.49,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
rosiglitazone,Amine oxidase [flavin-containing] A,Maoa,4.49,Ki,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sulfanilamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,4.49,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
tiludronic acid,Neutrophil collagenase,MMP8,4.49,IC50,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O
cetylpyridinium,High affinity choline transporter 1,Slc5a7,4.49,Ki,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1
hydroquinone,Carbonic anhydrase 9,CA9,4.49,Ki,OC1=CC=C(O)C=C1
oleic acid,Aromatase,CYP19A1,4.49,IC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
quercetin,Dipeptidyl peptidase 4,DPP4,4.49,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
dexibuprofen,Aldo-keto reductase family 1 member C3,AKR1C3,4.49,IC50,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
ascorbic acid,Tyrosinase,TYR,4.49,IC50,OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
rucaparib,Poly [ADP-ribose] polymerase 15,PARP15,4.49,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
carbamazepine,Sodium-dependent serotonin transporter,SLC6A4,4.495,Kd,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
doxorubicin,Tyrosine-protein kinase Lck,LCK,4.496,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
clotrimazole,Tyrosine-protein kinase Fyn,FYN,4.497,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
amiodarone,Beta-3 adrenergic receptor,ADRB3,4.498,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
levobupivacaine,Potassium voltage-gated channel subfamily D member 3,KCND3,4.5,IC50,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
adenosine triphosphate,"Heat shock protein 75 kDa, mitochondrial",TRAP1,4.5,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
bupivacaine,Potassium voltage-gated channel subfamily D member 3,KCND3,4.5,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
bupivacaine,Potassium voltage-gated channel subfamily D member 3,Kcnd3,4.5,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
camostat,Prothrombin,F2,4.5,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
chloroquine,Alpha-2B adrenergic receptor,ADRA2B,4.5,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
dinoprostone,Thromboxane A2 receptor,TBXA2R,4.5,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
levomenthol,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.5,EC50,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
glycine,Sodium- and chloride-dependent glycine transporter 1,SLC6A9,4.5,IC50,NCC(O)=O
imipramine,G protein-activated inward rectifier potassium channel 4,Kcnj5,4.5,EC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
aspartic acid,Excitatory amino acid transporter 2,SLC1A2,4.5,IC50,N[C@@H](CC(O)=O)C(O)=O
linezolid,Amine oxidase [flavin-containing] B,MAOB,4.5,Ki,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
methaqualone,GABA-A receptor alpha-6/beta-3/delta,GABRD|GABRB3|GABRA6,4.5,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
methoxamine,Alpha-1D adrenergic receptor,Adra1d,4.5,Ki,COC1=CC(C(O)C(C)N)=C(OC)C=C1
mibefradil,Cation channel sperm-associated protein 1,CATSPER1,4.5,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mibefradil,Cation channel sperm-associated protein 2,CATSPER2,4.5,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mibefradil,Cation channel sperm-associated protein 3,CATSPER3,4.5,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mibefradil,Cation channel sperm-associated protein 4,CATSPER4,4.5,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
naproxen,Aldo-keto reductase family 1 member C2,AKR1C2,4.5,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
nifedipine,Glycine receptor subunit alpha-3,GLRA3,4.5,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
probenecid,Transient receptor potential cation channel subfamily V member 2,Trpv2,4.5,EC50,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
salmeterol,D(2) dopamine receptor,DRD2,4.5,Ki,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
tolbutamide,ATP-sensitive inward rectifier potassium channel 11,Kcnj11,4.5,IC50,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1
tubocurarine,Small conductance calcium-activated potassium channel protein 3,KCNN3,4.5,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
tubocurarine,Serotonin 3 receptor (5HT3),HTR3B|HTR3A,4.5,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
capsaicin,Potassium voltage-gated channel subfamily A member 1,Kcna1,4.5,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
furtrethonium,Muscarinic acetylcholine receptor M2,CHRM2,4.5,Ki,C[N+](C)(C)CC1=CC=CO1
dexfosfoserine,Metabotropic glutamate receptor 7,GRM7,4.5,EC50,N[C@@H](COP(O)(O)=O)C(O)=O
fampridine,Potassium voltage-gated channel subfamily C member 1,Kcnc1,4.5,IC50,NC1=CC=NC=C1
cannabidiol,Transient receptor potential cation channel subfamily V member 2,TRPV2,4.5,EC50,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
econazole,Melanocortin receptor 3,MC3R,4.503,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
amlodipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,4.507,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
metoclopramide,Aldehyde oxidase,AOX1,4.509,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
aminoquinuride,Interstitial collagenase,MMP1,4.51,IC50,CC1=NC2=CC=C(NC(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=C2C(N)=C1
amrinone,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B",PDE3B,4.51,IC50,NC1=CC(=CNC1=O)C1=CC=NC=C1
bosentan,Bile salt export pump,Abcb11,4.51,IC50,COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1
dextromethorphan,Taste receptor type 2 member 46,TAS2R46,4.51,EC50,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
dextromethorphan,Taste receptor type 2 member 46,TAS2R46,4.51,EC50,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
dorzolamide,Carbonic anhydrase,,4.51,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
hydroxycarbamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,4.51,Ki,NC(=O)NO
imatinib,Proto-oncogene tyrosine-protein kinase Src,SRC,4.51,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
lamotrigine,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,4.51,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
mafenide,Carbonic anhydrase 2,mtcA2,4.51,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
naltrexone,Neuronal acetylcholine receptor subunit alpha-4,Chrna4,4.51,IC50,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
mexiletine,Sodium channel protein type X alpha subunit,Scn10a,4.51,IC50,CC(N)COC1=C(C)C=CC=C1C
nifedipine,Bile salt export pump,ABCB11,4.51,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
phenylalanine,Probable G-protein coupled receptor 139,GPR139,4.51,IC50,N[C@@H](CC1=CC=CC=C1)C(O)=O
rosiglitazone,Short transient receptor potential channel 5,TRPC5,4.51,EC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
verapamil,Muscarinic acetylcholine receptor M2,CHRM2,4.51,EC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
zonisamide,Amine oxidase [flavin-containing],mao,4.51,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
oleic acid,DNA topoisomerase 1,TOP1,4.51,IC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
quercetin,Polyphenol oxidase 2,PPO2,4.51,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
rutoside,Sialidase,nanH,4.51,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
tamoxifen,Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform,PPP3CA,4.515,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
paracetamol,Carbonic anhydrase 13,Ca13,4.52,Ki,CC(=O)NC1=CC=C(O)C=C1
amiloride,Acid-sensing ion channel 1,Asic1,4.52,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
carvedilol,Amyloid beta A4 protein,APP,4.52,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
cetirizine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.52,IC50,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
cianidanol,Beta-secretase 1,BACE1,4.52,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
dasatinib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,4.52,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diltiazem,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,4.52,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
gamolenic acid,Tissue factor,F3,4.52,IC50,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
methaqualone,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,4.52,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
methylthioninium chloride,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,4.52,IC50,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
paroxetine,5-hydroxytryptamine receptor 1A,HTR1A,4.52,Kd,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
rifampicin,Lanosterol 14-alpha demethylase,CYP51A1,4.52,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
sulfasalazine,Cystine/glutamate transporter,SLC7A11,4.52,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
testosterone,Constitutive androstane receptor,Nr1i3,4.52,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
tiludronic acid,Matrix metalloproteinase-14,MMP14,4.52,IC50,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O
triflupromazine,Trypanothione reductase,TPR,4.52,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
verapamil,Chloroquine resistance transporter,CRT,4.52,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
vidarabine,Adenosylhomocysteinase ,Ahcy,4.52,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
quercetin,Adenosine receptor A3,ADORA3,4.52,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
yohimbine,DNA topoisomerase 1,TOP1,4.52,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
docosanoic acid,Peroxisome proliferator-activated receptor alpha,PPARA,4.52,IC50,CCCCCCCCCCCCCCCCCCCCCC(O)=O
docosanoic acid,Peroxisome proliferator-activated receptor gamma,PPARG,4.52,IC50,CCCCCCCCCCCCCCCCCCCCCC(O)=O
docosanoic acid,Peroxisome proliferator-activated receptor delta,PPARD,4.52,IC50,CCCCCCCCCCCCCCCCCCCCCC(O)=O
pyridoxal,Aldehyde oxidase,AOX1,4.52,Ki,CC1=C(O)C(C=O)=C(CO)C=N1
arbutin,Tyrosinase,TYR,4.52,IC50,OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O
arbutin,Tyrosinase,Tyr,4.52,IC50,OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O
lacosamide,Sodium channel protein type 2 subunit alpha,Scn2a,4.52,IC50,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
stearic acid,Peroxisome proliferator-activated receptor gamma,PPARG,4.52,IC50,CCCCCCCCCCCCCCCCCC(O)=O
linolenic acid,Tissue factor,F3,4.52,IC50,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
dodecanoic acid,Peroxisome proliferator-activated receptor alpha,PPARA,4.52,IC50,CCCCCCCCCCCC(O)=O
dodecanoic acid,Peroxisome proliferator-activated receptor gamma,PPARG,4.52,IC50,CCCCCCCCCCCC(O)=O
dodecanoic acid,Peroxisome proliferator-activated receptor delta,PPARD,4.52,IC50,CCCCCCCCCCCC(O)=O
gluconolactone,Glucosylceramidase,GBA,4.52,Ki,OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O
clotrimazole,Carbonic anhydrase 2,CA2,4.521,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
chlorzoxazone,Calcium-activated potassium channel subunit alpha-1,KCNMA1,4.523,EC50,ClC1=CC2=C(OC(=O)N2)C=C1
gabapentin,Large neutral amino acids transporter small subunit 1,SLC7A5,4.523,IC50,NCC1(CC(O)=O)CCCCC1
gemfibrozil,Cytochrome P450 2C9,CYP2C9,4.523,Ki,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1
isotretinoin,Dehydrogenase/reductase SDR family member 9,DHRS9,4.523,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
betacarotene,Core protein,,4.53,IC50,C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C
epinastine,Multidrug and toxin extrusion protein 2,SLC47A2,4.53,IC50,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
mexiletine,Sodium channel protein type 5 subunit alpha,SCN5A,4.53,IC50,CC(N)COC1=C(C)C=CC=C1C
pindolol,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,4.53,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
rosiglitazone,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.53,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
rosiglitazone,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.53,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sulconazole,"Indoleamine 2,3-dioxygenase 1",Ido1,4.53,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
sulfanilamide,Carbonic anhydrase 2,mtcA2,4.53,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
thiopental,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,4.53,IC50,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O
dabrafenib,Dual serine/threonine and tyrosine protein kinase,DSTYK,4.53,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
dabrafenib,Dual serine/threonine and tyrosine protein kinase,DSTYK,4.53,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
daclatasvir,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.53,IC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C
sulfasalazine,Androgen receptor,Ar,4.533,Ki,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
tamoxifen,Melanocortin receptor 4,MC4R,4.533,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
miconazole,Epidermal growth factor receptor,EGFR,4.534,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
sibutramine,Solute carrier family 22 member 2,SLC22A2,4.538,IC50,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
aminoglutethimide,Cytochrome P450 11A1,CYP11A1,4.54,IC50,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1
brodimoprim,Dihydrofolate reductase,DHFR,4.54,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br
caffeine,Adenosine receptor A1,ADORA1,4.54,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
chlorpromazine,Epidermal growth factor receptor,EGFR,4.54,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
epinephrine,Adrenergic receptor beta,Adrb2|Adrb1|Adrb3,4.54,IC50,CNC[C@H](O)C1=CC=C(O)C(O)=C1
fluconazole,Cytochrome P450 2C9,CYP2C9,4.54,IC50,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
hexamethonium,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,4.54,IC50,C[N+](C)(C)CCCCCC[N+](C)(C)C
ifenprodil,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,4.54,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
ifenprodil,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,4.54,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
lidocaine,Sodium channel protein type 9 subunit alpha,SCN9A,4.54,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
metformin,Dipeptidyl peptidase 4,DPP4,4.54,IC50,CN(C)C(=N)NC(N)=N
ofloxacin,Sodium-dependent serotonin transporter,SLC6A4,4.54,IC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
oxprenolol,Solute carrier family 22 member 1,SLC22A1,4.54,IC50,CC(C)NCC(O)COC1=C(OCC=C)C=CC=C1
rolitetracycline,DNA repair protein RAD52 homolog,RAD52,4.54,IC50,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(=O)NCN2CCCC2)=C1O)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
sitosterol,Dipeptidyl peptidase 4,DPP4,4.54,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sulfasalazine,Caspase-1,CASP1,4.54,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
tretinoin,"Indoleamine 2,3-dioxygenase 2",Ido2,4.54,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
zonisamide,Beta-carbonic anhydrase 1,mtcA1,4.54,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
suramin,Protein kinase C (PKC),PRKD3|PRKCG|PRKCB|PRKCA|PRKCH|PRKCI|PRKCE|PRKCQ|PRKCZ|PRKCD|PRKD1,4.54,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
capsaicin,Potassium voltage-gated channel subfamily A member 1,KCNA1,4.54,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
quercetin,Prostaglandin G/H synthase 2,PTGS2,4.54,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
sulbentine,Delta-type opioid receptor,Oprd1,4.54,IC50,S=C1SCN(CC2=CC=CC=C2)CN1CC1=CC=CC=C1
thymol,Heat sensitive channel TRPV3,,4.54,EC50,CC(C)C1=C(O)C=C(C)C=C1
niraparib,Poly [ADP-ribose] polymerase 15,PARP15,4.54,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
roxadustat,Egl nine homolog 1,EGLN1,4.54,IC50,CC1=C2C=C(OC3=CC=CC=C3)C=CC2=C(O)C(=N1)C(=O)NCC(O)=O
vadadustat,Hypoxia-inducible factor 1-alpha inhibitor,HIF1AN,4.54,IC50,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
vadadustat,Hypoxia-inducible factor 1-alpha inhibitor,HIF1AN,4.54,IC50,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
econazole,Cannabinoid receptor 1,CNR1,4.543,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
paracetamol,Arachidonate 15-lipoxygenase,ALOX15,4.547,IC50,CC(=O)NC1=CC=C(O)C=C1
amiodarone,Androgen receptor,Ar,4.55,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
chloroxine,"Arachidonate 15-lipoxygenase, type II",ALOX15B,4.55,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1Cl
diclofenac,UDP-glucuronosyltransferase 1-10,UGT1A10,4.55,Ki,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dicycloverine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.55,IC50,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
dimetacrine,Apical membrane antigen 1,AMA1,4.55,IC50,CN(C)CCCN1C2=CC=CC=C2C(C)(C)C2=C1C=CC=C2
edetic acid,Beta-lactamase,blaIMP-1,4.55,IC50,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
glutamic acid,Glutamate racemase,murI,4.55,Ki,N[C@@H](CCC(O)=O)C(O)=O
hydroxycarbamide,Carbonic anhydrase 2,CA2,4.55,Ki,NC(=O)NO
mafenide,Carbonic anhydrase,,4.55,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
morphine,Solute carrier family 22 member 1,SLC22A1,4.55,IC50,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
nicotine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,4.55,IC50,CN1CCC[C@H]1C1=CC=CN=C1
niflumic acid,Transcriptional enhancer factor TEF-3,TEAD4,4.55,Kd,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
ofloxacin,Histamine H3 receptor,HRH3,4.55,IC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
risperidone,Transporter,NET,4.55,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
rolitetracycline,Integrase,,4.55,IC50,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(=O)NCN2CCCC2)=C1O)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
secnidazole,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,4.55,IC50,CC(O)CN1C(C)=NC=C1[N+]([O-])=O
sorivudine,Deoxynucleoside kinase,dnk,4.55,IC50,OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O
zidovudine,Thymidylate kinase,DTYMK,4.55,Ki,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
zidovudine,Thymidylate kinase,tmk,4.55,Ki,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
capsaicin,Transient receptor potential cation channel subfamily M member 8,Trpm8,4.55,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
oxiconazole,"Indoleamine 2,3-dioxygenase 1",IDO1,4.55,IC50,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
sulbentine,Mu-type opioid receptor,Oprm1,4.55,IC50,S=C1SCN(CC2=CC=CC=C2)CN1CC1=CC=CC=C1
diosmetin,Lysine-specific histone demethylase 1A,KDM1A,4.55,IC50,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O)C=C2O1
diosmetin,Lysine-specific histone demethylase 1A,KDM1A,4.55,IC50,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O)C=C2O1
saquinavir,Sodium-dependent dopamine transporter,SLC6A3,4.555,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
acefylline,Adenosine receptor A2b,ADORA2B,4.56,Ki,CN1C2=C(N(CC(O)=O)C=N2)C(=O)N(C)C1=O
aminobutyric acid,Sodium- and chloride-dependent GABA transporter 2,Slc6a13,4.56,IC50,NCCCC(O)=O
hexachlorophene,Heat shock cognate 71 kDa protein,HSPA8,4.56,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
mafenide,"Carbonic anhydrase 5A, mitochondrial",CA5A,4.56,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
methaqualone,GABA A receptor alpha-5/beta-2/gamma-2,GABRG2|GABRA5|GABRB2,4.56,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
niclosamide,Mast/stem cell growth factor receptor Kit,KIT,4.56,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
ropivacaine,Sodium channel protein type 5 subunit alpha,SCN5A,4.56,IC50,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
rosiglitazone,Amine oxidase [flavin-containing] A,MAOA,4.56,Ki,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
trimipramine,Solute carrier family 22 member 1,SLC22A1,4.56,IC50,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=C1C=CC=C2
dydrogesterone,Nuclear receptor subfamily 2 group E member 1,NR2E1,4.561,Kd,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C
medroxyprogesterone,Histamine H2 receptor,HRH2,4.561,Ki,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
miconazole,Receptor tyrosine-protein kinase erbB-2,ERBB2,4.562,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
atovaquone,Dihydroorotate dehydrogenase,dhod,4.57,Ki,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O
beclometasone dipropionate,Interleukin-5,IL5,4.57,IC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
caffeine,Adenosine A2 receptor,Adora2b|Adora2a,4.57,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
chlorpromazine,Solute carrier family 22 member 1,SLC22A1,4.57,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dapsone,Cytochrome P450 3A4,CYP3A4,4.57,Ki,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
fenoprofen,Sodium-coupled monocarboxylate transporter 1,SLC5A8,4.57,IC50,CC(C(O)=O)C1=CC=CC(OC2=CC=CC=C2)=C1
glutamine,Amino acid transporter,Slc1a5,4.57,IC50,N[C@@H](CCC(N)=O)C(O)=O
hesperetin,Glycogen synthase kinase-3 beta,GSK3B,4.57,IC50,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
levosulpiride,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,4.57,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
memantine,Solute carrier family 22 member 1,SLC22A1,4.57,IC50,CC12CC3CC(C)(C1)CC(N)(C3)C2
miconazole,Calcium release-activated calcium channel protein 1,ORAI1,4.57,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nimesulide,Aromatase,CYP19A1,4.57,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
sertraline,Transcriptional activator protein luxR,luxR,4.57,IC50,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
sulbactam,Beta-lactamase,ampC,4.57,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulfobromophthalein,Hematopoietic prostaglandin D synthase,HPGDS,4.57,IC50,OC1=C(C=C(C=C1)C1(OC(=O)C2=C1C(Br)=C(Br)C(Br)=C2Br)C1=CC(=C(O)C=C1)S(O)(=O)=O)S(O)(=O)=O
tropisetron,Acetylcholine receptor; alpha1/beta1/delta/gamma,CHRNA1|CHRNG|CHRNB1|CHRND,4.57,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
valdecoxib,Prostaglandin G/H synthase 1,PTGS1,4.57,IC50,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
gabexate,Membrane primary amine oxidase,Aoc3,4.57,Ki,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
quinine,Equilibrative nucleoside transporter 4,SLC29A4,4.57,Ki,COC1=CC=C2N=CC=C([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
diethylstilbestrol,5-hydroxytryptamine receptor 2C,HTR2C,4.575,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
ritonavir,Mu-type opioid receptor,OPRM1,4.575,Ki,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
astemizole,Multidrug and toxin extrusion protein 1,SLC47A1,4.58,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
beclometasone dipropionate,Interleukin-5,Il5,4.58,IC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
budesonide,Interleukin-5,Il5,4.58,IC50,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
clotrimazole,Alpha-1A adrenergic receptor,Adra1a,4.58,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
fenoprofen,Prostaglandin G/H synthase 2,PTGS2,4.58,IC50,CC(C(O)=O)C1=CC=CC(OC2=CC=CC=C2)=C1
aminobutyric acid,Sodium- and chloride-dependent GABA transporter 2,SLC6A13,4.58,IC50,NCCCC(O)=O
masoprocol,Cytoplasmic zinc-finger protein,pos-1,4.58,EC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
reserpine,ATP-binding cassette sub-family G member 2,ABCG2,4.58,IC50,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
sitosterol,DNA polymerase beta,POLB,4.58,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
tadalafil,Acetylcholinesterase,Ache,4.58,IC50,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
tadalafil,Acetylcholinesterase,Ache,4.58,IC50,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
zanamivir,Sialidase-4,NEU4,4.58,Ki,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
ascorbic acid,Pancreatic alpha-amylase,Amy2,4.58,IC50,OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
eugenol,Arachidonate 5-lipoxygenase,ALOX5,4.58,IC50,COC1=CC(CC=C)=CC=C1O
eugenol,Arachidonate 5-lipoxygenase,ALOX5,4.58,IC50,COC1=CC(CC=C)=CC=C1O
succinimide,Protein cereblon,CRBN,4.58,Ki,O=C1CCC(=O)N1
ketobemidone,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,4.585,Ki,CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1
miconazole,Prostaglandin G/H synthase 2,PTGS2,4.588,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
bufuralol,Cytochrome P450 2D6,CYP2D6,4.59,Ks,CCC1=CC=CC2=C1OC(=C2)C(O)CNC(C)(C)C
cefapirin,D(3) dopamine receptor,DRD3,4.59,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
clozapine,Beta-1 adrenergic receptor,Adrb1,4.59,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
codeine,Kappa-type opioid receptor,OPRK1,4.59,Ki,COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C
flurbiprofen,"Fatty acid-binding protein, intestinal",FABP2,4.59,Ki,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
imatinib,Vascular endothelial growth factor receptor 2,KDR,4.59,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Solute carrier family 22 member 3,SLC22A3,4.59,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
losartan,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,4.59,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
lovastatin,Histone deacetylase 2,HDAC2,4.59,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
menadione,Amine oxidase [flavin-containing] A,MAOA,4.59,Ki,CC1=CC(=O)C2=CC=CC=C2C1=O
nisoldipine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.59,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
pralidoxime,Acetylcholinesterase,ACHE,4.59,Kd,C[N+]1=CC=CC=C1C=NO
sitosterol,Acetylcholinesterase,ache,4.59,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sitosterol,Acetylcholinesterase,ache,4.59,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
tryptophan,Probable G-protein coupled receptor 139,GPR139,4.59,IC50,N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
tyramine,5-hydroxytryptamine receptor 3A,HTR3A,4.59,EC50,NCCC1=CC=C(O)C=C1
phenol,Carbonic anhydrase 2,CAN2,4.59,Ki,OC1=CC=CC=C1
nelfinavir,Beta-3 adrenergic receptor,ADRB3,4.592,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
diethylstilbestrol,Acetylcholinesterase,ACHE,4.593,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
terconazole,Sodium-dependent noradrenaline transporter,SLC6A2,4.599,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
amiloride,Acid-sensing ion channel 2,ASIC2,4.6,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
bisantrene,NAD(P)H dehydrogenase [quinone] 1,NQO1,4.6,IC50,C1CN=C(N\N=C\C2=C3C=CC=CC3=C(\C=N\NC3=NCCN3)C3=C2C=CC=C3)N1
clavulanic acid,Beta-lactamase SHV-5,bla,4.6,Ki,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
dabigatran etexilate,Multidrug and toxin extrusion protein 2,SLC47A2,4.6,IC50,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
darifenacin,D(2) dopamine receptor,DRD2,4.6,IC50,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
levomenthol,Transient receptor potential cation channel subfamily M member 8,TRPM8,4.6,EC50,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
doxorubicin,Ribonuclease pancreatic,RNASE1,4.6,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
doxorubicin,Type-2 restriction enzyme ScaI,scaIR,4.6,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
doxycycline,Stromelysin-1,MMP3,4.6,IC50,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C(O)C=CC=C12
doxycycline,Neutrophil collagenase,MMP8,4.6,IC50,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C(O)C=CC=C12
econazole,Beta-lactamase,ampC,4.6,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
econazole,Malate dehydrogenase cytoplasmic ,MDH1,4.6,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ethacrynic acid,Glutathione S-transferase omega-1,GSTO1,4.6,IC50,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
fasudil,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.6,Ki,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
aminobutyric acid,Gamma-aminobutyric acid type B receptor subunit 1,Gabbr1,4.6,IC50,NCCCC(O)=O
ketoconazole,"Indoleamine 2,3-dioxygenase 1",IDO1,4.6,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lamotrigine,Sodium channel protein type X alpha subunit,Scn10a,4.6,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
levorphanol,Acetylcholinesterase,ache,4.6,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
levorphanol,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.6,IC50,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
naltrexone,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,4.6,IC50,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
miconazole,Malate dehydrogenase cytoplasmic ,MDH1,4.6,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miltefosine,Dual specificity phosphatase Cdc25A,CDC25A,4.6,IC50,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
mitomycin,"Indoleamine 2,3-dioxygenase 1",IDO1,4.6,Ki,CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
omeprazole,Cytosolic endo-beta-N-acetylglucosaminidase,ENGASE,4.6,IC50,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
ondansetron,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,4.6,IC50,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
picrotin,Glycine receptor subunit beta,GLRB,4.6,IC50,CC(C)(O)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C
quinidine,Equilibrative nucleoside transporter 4,SLC29A4,4.6,Ki,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
sulbactam,Beta-lactamase 1,blaY,4.6,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tranylcypromine,Lysine-specific histone demethylase 1A,KDM1A,4.6,Ki,N[C@@H]1C[C@H]1C1=CC=CC=C1
tubocurarine,Small conductance calcium-activated potassium channel protein 1,KCNN1,4.6,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
vecuronium,Multidrug and toxin extrusion protein 2,SLC47A2,4.6,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
vinburnine,Muscarinic acetylcholine receptor M4,CHRM4,4.6,Kd,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C1=CC=CC=C41)C(=O)C2
capsaicin,Potassium voltage-gated channel subfamily A member 7,Kcna7,4.6,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
eburnamonine,Muscarinic acetylcholine receptor M4,CHRM4,4.6,Kd,CC[C@]12CCCN3CCC4=C([C@@H]13)N(C1=CC=CC=C41)C(=O)C2
quercetin,Cyclin-dependent kinase 6,CDK6,4.6,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
tiratricol,Proliferating cell nuclear antigen,PCNA,4.6,IC50,OC(=O)CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
rimonabant,Acetylcholinesterase,ACHE,4.6,IC50,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
dexlansoprazole,Cytosolic endo-beta-N-acetylglucosaminidase,ENGASE,4.6,IC50,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=C(N1)C=CC=C2
fampridine,Potassium voltage-gated channel subfamily C member 2,Kcnc2,4.6,IC50,NC1=CC=NC=C1
indacaterol,D(2) dopamine receptor,DRD2,4.6,IC50,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2
acetic acid,Free fatty acid receptor 2,FFAR2,4.6,EC50,CC(O)=O
dibutylphthalate,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.6,EC50,CCCCOC(=O)C1=C(C=CC=C1)C(=O)OCCCC
etelcalcetide,Extracellular calcium-sensing receptor,CASR,4.6,EC50,C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O
adenosine,Adenosine deaminase,ADA,4.602,Kd,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
carbutamide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,4.602,Kd,CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1
propafenone,Solute carrier family 22 member 2,SLC22A2,4.602,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
tamoxifen,Melanocortin receptor 5,MC5R,4.604,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
vindesine,Cytochrome P450 3A4,CYP3A4,4.607,Km,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O
aliskiren,Cytochrome P450 3A4,CYP3A4,4.61,Km,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
celecoxib,Cytochrome c oxidase subunit 1,MT-CO1,4.61,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
profenamine,Acetylcholinesterase,ACHE,4.61,Ki,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
hymecromone,Aldose reductase,AKR1B1,4.61,IC50,CC1=CC(=O)OC2=C1C=CC(O)=C2
lansoprazole,Cytosolic endo-beta-N-acetylglucosaminidase,ENGASE,4.61,IC50,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
methaqualone,GABA A receptor alpha-2/beta-2/gamma-2,GABRG2|GABRA2|GABRB2,4.61,EC50,CC1=C(C=CC=C1)N1C(C)=NC2=CC=CC=C2C1=O
mibefradil,Potassium channel subfamily K member 9,KCNK9,4.61,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mibefradil,Potassium channel subfamily K member 9,KCNK9,4.61,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
molsidomine,Estrogen receptor,ESR1,4.61,IC50,CCOC(=O)N=C1O[N-][N+](=C1)N1CCOCC1
papaverine,Acetylcholinesterase,ACHE,4.61,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
papaverine,Acetylcholinesterase,ache,4.61,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
ritonavir,Solute carrier family 22 member 2,SLC22A2,4.61,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
warfarin,Proprotein convertase subtilisin/kexin type 7,PCSK7,4.61,IC50,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
enoxolone,Arachidonate 5-lipoxygenase,ALOX5,4.61,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
enoxolone,Arachidonate 5-lipoxygenase,ALOX5,4.61,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
rutoside,Bifunctional epoxide hydrolase 2,EPHX2,4.61,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
beclabuvir,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.61,IC50,COC1=CC=C2C3=C(C4CCCCC4)C4=CC=C(C=C4N3C[C@]3(C[C@H]3C2=C1)C(=O)N1C2CCC1CN(C)C2)C(=O)NS(=O)(=O)N(C)C
nelfinavir,Androgen receptor,Ar,4.615,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
cefotaxime,Penicillin-binding protein 2,mrdA,4.617,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
adenosine,Adenosine receptor A2b,ADORA2B,4.62,EC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
allopurinol,Shiga toxin subunit A,stxA,4.62,IC50,OC1=NC=NC2=C1C=NN2
benzatropine,Sodium-dependent serotonin transporter,SLC6A4,4.62,IC50,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
betamipron,Solute carrier family 22 member 6,SLC22A6,4.62,Ki,OC(=O)CCNC(=O)C1=CC=CC=C1
doxycycline,72 kDa type IV collagenase,MMP2,4.62,IC50,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C(O)C=CC=C12
flufenamic acid,Transient receptor potential cation channel subfamily M member 5,TRPM5,4.62,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
ketoconazole,Sodium-dependent noradrenaline transporter,SLC6A2,4.62,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
meclofenamic acid,Arachidonate 5-lipoxygenase,Alox5,4.62,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
menadione,Dual specificity protein phosphatase 1,Dusp1,4.62,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
niclosamide,Tyrosine-protein kinase Lyn,LYN,4.62,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
phenytoin,Sodium channel protein type 4 subunit alpha,SCN4A,4.62,Ki,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
sulfafurazole,Endothelin B receptor,EDNRB,4.62,IC50,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
tretinoin,Nuclear receptor subfamily 2 group C member 2,NR2C2,4.62,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
trimethoprim,Dihydrofolate reductase,dfrA,4.62,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
propoxycaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.62,IC50,CCCOC1=C(C=CC(N)=C1)C(=O)OCCN(CC)CC
parethoxycaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.62,IC50,CCOC1=CC=C(C=C1)C(=O)OCCN(CC)CC
sulfisoxazole acetyl,Endothelin B receptor,EDNRB,4.62,IC50,CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1
migalastat,Beta-galactosidase,Glb1,4.62,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
paclitaxel,Tyrosine-protein kinase Fyn,FYN,4.621,IC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
sulfasalazine,Interstitial collagenase,MMP1,4.628,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
benserazide,SUMO-activating enzyme,SAE1|UBA2,4.63,IC50,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
dexamethasone palmitate,Progesterone receptor,PGR,4.63,IC50,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
dexamethasone valerate,Progesterone receptor,PGR,4.63,IC50,CCCCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
diazoxide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,4.63,EC50,CC1=NC2=CC=C(Cl)C=C2S(=O)(=O)N1
loperamide,Solute carrier family 22 member 1,SLC22A1,4.63,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
rofecoxib,Prostaglandin G/H synthase 1,PTGS1,4.63,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
topiramate,Carbonic anhydrase,,4.63,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
cloxiquine,Catechol O-methyltransferase,Comt,4.63,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1
quercetin,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,4.63,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
terazosin,Solute carrier family 22 member 1,SLC22A1,4.63,IC50,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
nelfinavir,Delta-type opioid receptor,OPRD1,4.632,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
nimesulide,Interstitial collagenase,MMP1,4.632,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
latamoxef,Penicillin-binding protein 1B,mrcB,4.637,IC50,CO[C@]1(NC(=O)C(C(O)=O)C2=CC=C(O)C=C2)[C@H]2OCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
estradiol benzoate,Tyrosine-protein kinase Fyn,FYN,4.638,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
nisoldipine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.638,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
acetohexamide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,4.639,Ki,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
alpidem,Bile salt export pump,Abcb11,4.64,IC50,CCCN(CCC)C(=O)CC1=C(N=C2C=CC(Cl)=CN12)C1=CC=C(Cl)C=C1
bifonazole,"Indoleamine 2,3-dioxygenase 1",IDO1,4.64,IC50,C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1
diclofenac,UDP-glucuronosyltransferase 1-6,UGT1A6,4.64,Ki,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dihydroergotamine,Gastrin/cholecystokinin type B receptor,Cckbr,4.64,IC50,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
fluoxetine,Equilibrative nucleoside transporter 4,SLC29A4,4.64,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
hydroxycarbamide,Carbonic anhydrase 9,CA9,4.64,Ki,NC(=O)NO
lactose,Galectin-9,LGALS9,4.64,Kd,OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
lapatinib,Tyrosine-protein kinase ABL1,ABL1,4.64,IC50,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
liothyronine,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,4.64,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
miglustat,Ceramide glucosyltransferase,Ugcg,4.64,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nicardipine,Quinolone resistance protein NorA,norA,4.64,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
niclosamide,Vascular endothelial growth factor receptor 2,KDR,4.64,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
nicotine,Acetylcholine receptor subunit alpha,CHRNA1,4.64,IC50,CN1CCC[C@H]1C1=CC=CN=C1
nimesulide,Sodium-dependent neutral amino acid transporter B(0)AT1,Slc6a19,4.64,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
nitrendipine,Adenosine receptor A2a,Adora2a,4.64,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
raltitrexed,Dihydrofolate reductase,dfrA17,4.64,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
sulbactam,Carbapenem-hydrolizing beta-lactamase SFC-1,,4.64,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
trifluoperazine,Trypanothione reductase,TPR,4.64,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
verapamil,Two pore calcium channel protein 1,TPCN1,4.64,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
enilconazole,"Indoleamine 2,3-dioxygenase 1",IDO1,4.64,IC50,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC=C
isoconazole,"Indoleamine 2,3-dioxygenase 1",IDO1,4.64,IC50,ClC1=CC=C([C@H](CN2C=CN=C2)OCC2=C(Cl)C=CC=C2Cl)C(Cl)=C1
quercetin,Cyclin-dependent kinase 5/CDK5 activator 1,CDK5|CDK5R1,4.64,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
clotrimazole,Platelet-activating factor receptor,PTAFR,4.645,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
mestranol,Cannabinoid receptor 1,CNR1,4.647,Ki,COC1=CC2=C(C=C1)[C@H]1CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@@H]1CC2
nelfinavir,Mitogen-activated protein kinase 3,MAPK3,4.648,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
atorvastatin,Histone deacetylase 2,HDAC2,4.65,IC50,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
clonidine,Solute carrier family 22 member 1,SLC22A1,4.65,IC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
econazole,Acetylcholinesterase,ache,4.65,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
glafenine,Bile salt export pump,ABCB11,4.65,IC50,OCC(O)COC(=O)C1=C(NC2=CC=NC3=CC(Cl)=CC=C23)C=CC=C1
masoprocol,Estrogen receptor,ESR1,4.65,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
pethidine,Solute carrier family 22 member 1,SLC22A1,4.65,IC50,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
pethidine,Solute carrier family 22 member 1,SLC22A1,4.65,IC50,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
methysergide,Bcl-2-like protein 1,BCL2L1,4.65,IC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nifedipine,Adenosine receptor A2a,ADORA2A,4.65,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
yohimbine,Dual specificity phosphatase Cdc25A,CDC25A,4.65,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
kojic acid,Polyphenol oxidase 2,PPO2,4.65,Ki,OCC1=CC(=O)C(O)=CO1
fluphenazine,Beta-3 adrenergic receptor,ADRB3,4.655,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
disulfiram,5-hydroxytryptamine receptor 2B,HTR2B,4.658,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
bepridil,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,4.66,IC50,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
bromocriptine,Vesicular glutamate transporter 3,Slc17a8,4.66,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bupivacaine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.66,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
carbamazepine,Sodium channel protein type 9 subunit alpha,SCN9A,4.66,IC50,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
cefalotin,Matrix metalloproteinase-9,MMP9,4.66,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O
cefapirin,D(2) dopamine receptor,DRD2,4.66,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
chloroquine,Muscarinic acetylcholine receptor M5,CHRM5,4.66,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
dexamethasone,"Fatty acid-binding protein, liver",Fabp1,4.66,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
dexamethasone palmitate,"Fatty acid-binding protein, liver",Fabp1,4.66,Ki,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
dexamethasone valerate,"Fatty acid-binding protein, liver",Fabp1,4.66,Ki,CCCCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
glibenclamide,Cystic fibrosis transmembrane conductance regulator,CFTR,4.66,Ki,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
hexamethonium,Neuronal acetylcholine receptor; alpha4/beta2,Chrna4|Chrnb2,4.66,Ki,C[N+](C)(C)CCCCCC[N+](C)(C)C
imipramine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,4.66,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
mequitazine,Trypanothione reductase,TPR,4.66,IC50,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
pentamidine,Solute carrier family 22 member 1,SLC22A1,4.66,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
phenytoin,Sodium channel protein type 2 subunit alpha,Scn2a,4.66,IC50,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
raloxifene,"HLA class I histocompatibility antigen, A-3 alpha chain",HLA-A,4.66,Kd,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
risperidone,Beta-1 adrenergic receptor,Adrb1,4.66,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sulbactam,Beta-lactamase OXA-1,bla,4.66,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulfacetamide,Dihydrofolate reductase,DHFR,4.66,IC50,CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1
tacrine,Solute carrier family 22 member 1,SLC22A1,4.66,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
tamoxifen,Alpha-1A adrenergic receptor,Adra1a,4.66,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tolrestat,Aldo-keto reductase family 1 member C21,Akr1c21,4.66,Ki,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
oleic acid,Seed linoleate 13S-lipoxygenase-1,LOX1.1,4.66,Ki,CCCCCCCC\C=C/CCCCCCCC(O)=O
picloxydine,Acetylcholinesterase,ache,4.66,Ki,ClC1=CC=C(NC(=N)NC(=N)N2CCN(CC2)C(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
dexamethasone phosphate,"Fatty acid-binding protein, liver",Fabp1,4.66,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
tapentadol,Solute carrier family 22 member 1,SLC22A1,4.66,IC50,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
tapentadol,Solute carrier family 22 member 1,SLC22A1,4.66,IC50,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
teriflunomide,Dihydroorotate dehydrogenase,dhod,4.66,Ki,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
plecanatide,Tumor necrosis factor receptor superfamily member 1A,TNFRSF1A,4.66,IC50,CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(O)=O
terconazole,Acetylcholinesterase,ACHE,4.666,IC50,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
ketoconazole,Histamine H2 receptor,HRH2,4.667,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
primaquine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.668,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
cortisone acetate,Multidrug and toxin extrusion protein 1,SLC47A1,4.67,IC50,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
econazole,Alpha-1A adrenergic receptor,Adra1a,4.67,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
fexofenadine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.67,IC50,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
fluphenazine,Trypanothione reductase,TPR,4.67,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
miconazole,Acetylcholinesterase,ache,4.67,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mifepristone,Tyrosine-protein kinase Fyn,FYN,4.67,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
oxyquinoline,Catechol O-methyltransferase,Comt,4.67,IC50,OC1=CC=CC2=C1N=CC=C2
oxyquinoline,Methionine aminopeptidase 1,METAP1,4.67,IC50,OC1=CC=CC2=C1N=CC=C2
pramocaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.67,IC50,CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1
quercetin,Alpha-amylase 1,AMY1A,4.67,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
vilazodone,Acetylcholinesterase,Ache,4.67,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
obidoxime,Acetylcholinesterase,ACHE,4.67,Kd,O\N=C\C1=CC=[N+](COC[N+]2=CC=C(\C=N\O)C=C2)C=C1
nifedipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,4.672,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
chlorpromazine,Melanocortin receptor 3,MC3R,4.673,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
fenofibrate,Sodium-dependent noradrenaline transporter,SLC6A2,4.673,Ki,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
miconazole,Melanocortin receptor 5,MC5R,4.674,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nelfinavir,Thromboxane-A synthase,TBXAS1,4.676,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
diphenhydramine,Solute carrier family 22 member 2,SLC22A2,4.678,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
nomifensine,Hemoglobin HbA,HBB|HBA1,4.678,Km,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
raltitrexed,Dihydrofolate reductase,DHFR,4.678,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
acetazolamide,Endochitinase,CTS1,4.68,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
amiloride,Sodium/hydrogen exchanger 5,SLC9A5,4.68,Ki,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
apomorphine,Solute carrier family 22 member 1,SLC22A1,4.68,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
cefsulodin,Protein-tyrosine phosphatase 1C,PTPN6,4.68,IC50,NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C2=CC=CC=C2)S(O)(=O)=O)C3=O)C([O-])=O)C=C1
cefapirin,Alpha-2C adrenergic receptor,ADRA2C,4.68,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
dabigatran etexilate,Vitamin K-dependent protein C,PROC,4.68,Ki,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
deanol,Creatine transporter,Slc6a8,4.68,Ki,CN(C)CCO
diltiazem,5-hydroxytryptamine receptor 3A,HTR3A,4.68,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
ethinylestradiol,Multidrug and toxin extrusion protein 1,SLC47A1,4.68,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
irinotecan,Solute carrier family 22 member 1,SLC22A1,4.68,IC50,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
ketotifen,Histamine H4 receptor,HRH4,4.68,IC50,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
mexiletine,Sodium channel protein type 1 subunit alpha,Scn1a,4.68,IC50,CC(N)COC1=C(C)C=CC=C1C
nafamostat,Coagulation factor X,F10,4.68,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
nicotine,Acetylcholine receptor subunit alpha,CHRNA1,4.68,IC50,CN1CCC[C@H]1C1=CC=CN=C1
piroxicam,Prostaglandin G/H synthase 1,PTGS1,4.68,IC50,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=CC=CC=C2S1(=O)=O
riluzole,Small conductance calcium-activated potassium channel protein 1,KCNN1,4.68,EC50,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
strychnine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.68,IC50,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
suxamethonium,Acetylcholinesterase,Ache,4.68,Ki,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
sulfadiazine,Aurora kinase A,AURKA,4.68,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
cetylpyridinium,Caspase-2,CASP2,4.68,EC50,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1
enoxolone,Liver carboxylesterase 1,CES1,4.68,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
sulmazole,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,4.68,IC50,COC1=C(C=CC(=C1)S(C)=O)C1=NC2=C(N1)N=CC=C2
kojic acid,D-amino-acid oxidase,DAO,4.68,Ki,OCC1=CC(=O)C(O)=CO1
cariprazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.68,IC50,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
leflunomide,Amine oxidase [flavin-containing] A,MAOA,4.684,IC50,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
probucol,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.686,IC50,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
cladribine,Adenosine receptor A2a,Adora2a,4.69,Ki,NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1
clioquinol,Botulinum neurotoxin type A,botA,4.69,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1I
ethinylestradiol,Multidrug and toxin extrusion protein 2,SLC47A2,4.69,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
profenamine,Solute carrier family 22 member 1,SLC22A1,4.69,IC50,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
imatinib,"Carbonic anhydrase 5A, mitochondrial",CA5A,4.69,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
levamisole,Intestinal-type alkaline phosphatase,ALPI,4.69,IC50,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1
menadione,Dual specificity protein phosphatase 6,Dusp6,4.69,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
methysergide,Induced myeloid leukemia cell differentiation protein Mcl-1,MCL1,4.69,IC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
norepinephrine,Alpha-1B adrenergic receptor,ADRA1B,4.69,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
ondansetron,Solute carrier family 22 member 1,SLC22A1,4.69,IC50,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
phenylbutazone,fMet-Leu-Phe receptor,FPR1,4.69,IC50,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
pilsicainide,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.69,IC50,CC1=CC=CC(C)=C1NC(=O)CC12CCCN1CCC2
practolol,Beta-2 adrenergic receptor,ADRB2,4.69,Kd,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
tirilazad,Epidermal growth factor receptor,EGFR,4.69,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
lovastatin,Androgen receptor,Ar,4.697,Ki,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
propranolol,Histamine H1 receptor,HRH1,4.699,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
saquinavir,Canalicular multispecific organic anion transporter 1,ABCC2,4.699,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
acediasulfone,Aldose reductase,AKR1B1,4.7,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCC(O)=O)C=C1
adenosine phosphate,Transient receptor potential cation channel subfamily M member 4,TRPM4,4.7,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
amiodarone,Beta-1 adrenergic receptor,ADRB1,4.7,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
carmofur,"Sulfide:quinone oxidoreductase, mitochondrial",SQRDL,4.7,IC50,CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O
cefalotin,Prostaglandin G/H synthase 2,PTGS2,4.7,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O
chlordiazepoxide,Thyrotropin-releasing hormone receptor,Trhr,4.7,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
clotrimazole,Beta-lactamase,ampC,4.7,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clozapine,Calmodulin-1,CALM1,4.7,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
colchicine,Bromodomain-containing protein 4,BRD4,4.7,Kd,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
cyproheptadine,Histone-lysine N-methyltransferase SETD7,SETD7,4.7,IC50,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
doxorubicin,DNA topoisomerase 1,TOP1,4.7,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
eplerenone,Progesterone receptor,PGR,4.7,Ki,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13
eplerenone,Progesterone receptor,PGR,4.7,Ki,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13
eplerenone,Progesterone receptor,PGR,4.7,Ki,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13
fentanyl,Histamine H1 receptor,Hrh1,4.7,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
gefitinib,Beta-secretase 1,BACE1,4.7,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gossypol,"Solute carrier family 2, facilitated glucose transporter member 1",SLC2A1,4.7,Ki,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
haloperidol,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,4.7,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
histidine,Large neutral amino acids transporter small subunit 1,SLC7A5,4.7,IC50,N[C@@H](CC1=CN=CN1)C(O)=O
hydroxychloroquine,Muscarinic acetylcholine receptor M5,CHRM5,4.7,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
indomethacin,"Nitric oxide synthase, inducible",Nos2,4.7,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
ketanserin,5-hydroxytryptamine receptor 5A,HTR5A,4.7,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketoconazole,Cytochrome P450 24A1,Cyp24a1,4.7,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
loxapine,Potassium channel subfamily K member 2,KCNK2,4.7,IC50,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
mesalazine,Tumor necrosis factor,TNF,4.7,IC50,NC1=CC(C(O)=O)=C(O)C=C1
mifepristone,P-glycoprotein 3,Abcb1a,4.7,Kd,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
mycophenolic acid,Inosine-5'-monophosphate dehydrogenase (IMPDH),IMPDH2|IMPDH1,4.7,IC50,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
nelfinavir,Multidrug resistance protein 1,ABCB1,4.7,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
nicardipine,Beta-lactamase,ampC,4.7,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
nifedipine,Potassium voltage-gated channel subfamily A member 2,KCNA2,4.7,Kd,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nifedipine,Potassium voltage-gated channel subfamily A member 2,Kcna2,4.7,Kd,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nimodipine,Adenosine receptor A1,Adora1,4.7,Ki,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nitroxoline,Catechol O-methyltransferase,Comt,4.7,IC50,OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O
omeprazole,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",DDAH1,4.7,IC50,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
ondansetron,5-hydroxytryptamine receptor 1D,Htr1d,4.7,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
pemetrexed,Thymidylate synthase,Tyms,4.7,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
benzylpenicillin,Beta-lactamase TEM,bla; blaT-3; blaT-4;,4.7,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
piroxicam,Prostaglandin G/H synthase 2,PTGS2,4.7,IC50,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=CC=CC=C2S1(=O)=O
progesterone,"Fatty acid-binding protein, intestinal",FABP2,4.7,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
mepacrine,Bacterial DNA-directed RNA polymerase,rpoA|rpoZ|rpoC|rpoB,4.7,IC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
sibutramine,Potassium voltage-gated channel subfamily D member 3,KCND3,4.7,IC50,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
sibutramine,Potassium voltage-gated channel subfamily D member 3,Kcnd3,4.7,IC50,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
sildenafil,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,4.7,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sitagliptin,Dipeptidyl peptidase 9,DPP9,4.7,IC50,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
strychnine,Glycine receptor subunit alpha-1,GLRA1,4.7,IC50,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
succinic acid,Succinate receptor 1,SUCNR1,4.7,EC50,OC(=O)CCC(O)=O
sulconazole,Malate dehydrogenase cytoplasmic ,MDH1,4.7,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
sulfinpyrazone,fMet-Leu-Phe receptor,FPR1,4.7,Ki,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1
tetrabenazine,Chromaffin granule amine transporter,SLC18A1,4.7,Ki,COC1=CC2=C(C=C1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
theophylline,Adenosine receptor,Adora1|Adora3|Adora2b|Adora2a,4.7,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
topotecan,DNA topoisomerase I,Top1,4.7,IC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
troglitazone,UDP-glucuronosyltransferase 1-6,UGT1A6,4.7,Ki,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
troglitazone,Polyunsaturated fatty acid lipoxygenase ALOX15,Alox15,4.7,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
xamoterol,Beta-3 adrenergic receptor,ADRB3,4.7,Kd,OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1
ximelagatran,Coagulation factor XI,F11,4.7,IC50,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
ethacridine,Reverse transcriptase,reverse transcriptas,4.7,IC50,CCOC1=CC2=C(N)C3=CC=C(N)C=C3N=C2C=C1
oleic acid,Free fatty acid receptor 4,FFAR4,4.7,EC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
podophyllotoxin,Regulatory protein E2,E2,4.7,Kd,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
quercetin,Tyrosine-protein kinase SYK,SYK,4.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Lysine--tRNA ligase,KARS,4.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Amine oxidase [flavin-containing] B,MAOB,4.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,4.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Cyclin-dependent kinase 1/cyclin B1,CDK1|CCNB1,4.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,D-alanylalanine synthetase,ddlB,4.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
androstanolone,Glucocorticoid receptor,Nr3c1,4.7,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
spaglumic acid,Metabotropic glutamate receptor 3,GRM3,4.7,Ki,CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O
tedisamil,Potassium voltage-gated channel subfamily A member 7,Kcna7,4.7,IC50,C(C1CC1)N1C[C@@H]2CN(CC3CC3)C[C@H](C1)C21CCCC1
astemizole,Tyrosine-protein kinase Lck,LCK,4.701,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
flavoxate,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.704,Ki,CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1
sulfasalazine,Thromboxane-A synthase,TBXAS1,4.707,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
fluphenazine,Receptor tyrosine-protein kinase erbB-2,ERBB2,4.708,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
acitretin,Bile salt export pump,Abcb11,4.71,IC50,COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
clomipramine,Solute carrier family 22 member 1,SLC22A1,4.71,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
diethylstilbestrol,Alpha-1A adrenergic receptor,Adra1a,4.71,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
aspartic acid,Excitatory amino acid transporter 3,SLC1A1,4.71,IC50,N[C@@H](CC(O)=O)C(O)=O
nicardipine,Adenosine receptor A1,Adora1,4.71,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
propofol,Carbonic anhydrase 1,CA1,4.71,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
pyridostigmine,Acetylcholinesterase,ACHE,4.71,Ki,CN(C)C(=O)OC1=C[N+](C)=CC=C1
sufentanil,Solute carrier family 22 member 1,SLC22A1,4.71,IC50,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
sufentanil,Solute carrier family 22 member 1,SLC22A1,4.71,IC50,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
ubenimex,Aminopeptidase N,Anpep,4.71,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
retinol,Nuclear receptor subfamily 2 group C member 2,NR2C2,4.71,EC50,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
octanoic acid,G-protein coupled receptor 84,GPR84,4.71,Ki,CCCCCCCC(O)=O
octanoic acid,G-protein coupled receptor 84,GPR84,4.71,Ki,CCCCCCCC(O)=O
clotrimazole,Acetylcholinesterase,ACHE,4.712,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
chlorpromazine,Receptor tyrosine-protein kinase erbB-2,ERBB2,4.713,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
miconazole,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,4.715,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
adenosine phosphate,2'-deoxynucleoside 5'-phosphate N-hydrolase 1,DNPH1,4.72,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
amidefrine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,4.72,IC50,CNCC(O)C1=CC(NS(C)(=O)=O)=CC=C1
ampicillin,Transient receptor potential cation channel subfamily M member 4,TRPM4,4.72,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
cefotetan,Matrix metalloproteinase-9,MMP9,4.72,IC50,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
diclofenac,UDP-glucuronosyltransferase 1-7,UGT1A7,4.72,Ki,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
ethambutol,Cytochrome P450 3A5,CYP3A5,4.72,IC50,CC[C@@H](CO)NCCN[C@@H](CC)CO
hexachlorophene,Zinc finger protein mex-5,mex-5,4.72,EC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
hexachlorophene,Heat shock 70 kDa protein 1A,HSPA1A,4.72,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
ketoconazole,Cytochrome P450 2C19,CYP2C19,4.72,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
levamisole,"Alkaline phosphatase, tissue-nonspecific isozyme",ALPL,4.72,IC50,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1
meptazinol,Solute carrier family 22 member 1,SLC22A1,4.72,IC50,CCC1(CCCCN(C)C1)C1=CC(O)=CC=C1
meptazinol,Solute carrier family 22 member 1,SLC22A1,4.72,IC50,CCC1(CCCCN(C)C1)C1=CC(O)=CC=C1
mezlocillin,Cytochrome P450 2C9,CYP2C9,4.72,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
phenylbutazone,Cytochrome P450 2C9,CYP2C9,4.72,Ki,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
mepacrine,Trypanothione reductase,TPR,4.72,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
vinpocetine,Phosphodiesterase 1,PDE1A|PDE1B,4.72,IC50,CCOC(=O)C1=C[C@]2(CC)CCCN3CCC4=C([C@H]23)N1C1=CC=CC=C41
fumaric acid,Egl nine homolog 1,EGLN1,4.72,IC50,OC(=O)\C=C\C(O)=O
alcuronium,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,4.721,Ki,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
estradiol,Glucocorticoid receptor,NR3C1,4.725,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
cyclobenzaprine,Multidrug resistance protein 1,ABCB1,4.728,IC50,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
ketoconazole,Sodium-dependent dopamine transporter,SLC6A3,4.729,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miconazole,Acetylcholinesterase,ACHE,4.729,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acetoxolone,Estradiol 17-beta-dehydrogenase 1,HSD17B1,4.73,IC50,CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C
aminoglutethimide,Thromboxane-A synthase,TBXAS1,4.73,IC50,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1
citalopram,Solute carrier family 22 member 1,SLC22A1,4.73,IC50,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
ethinylestradiol,Adenosine receptor A3,ADORA3,4.73,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
mafenide,Carbonic anhydrase 2,CAN2,4.73,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
menadione,Dual specificity phosphatase Cdc25C,CDC25C,4.73,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
spironolactone,Multidrug and toxin extrusion protein 1,SLC47A1,4.73,IC50,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
sulfanilamide,Carbonic anhydrase,NCE103,4.73,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
verapamil,Equilibrative nucleoside transporter 4,SLC29A4,4.73,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
vernakalant,Sodium channel protein type 5 subunit alpha,SCN5A,4.73,IC50,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1
nifedipine,Thromboxane-A synthase,TBXAS1,4.731,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
disulfiram,C-C chemokine receptor type 5,CCR5,4.738,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
nelfinavir,Mitogen-activated protein kinase 14,MAPK14,4.739,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
acitretin,Bile salt export pump,ABCB11,4.74,IC50,COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
carbachol,Muscarinic acetylcholine receptor,GPM3,4.74,Kd,C[N+](C)(C)CCOC(N)=O
cycloserine,"Glutamate receptor ionotropic, NMDA 2C",Grin2c,4.74,EC50,N[C@@H]1CONC1=O
cyproterone acetate,Androgen receptor,Ar,4.74,IC50,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
dinoprostone,Solute carrier family 22 member 20,Slc22a20,4.74,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
eplerenone,Glucocorticoid receptor,NR3C1,4.74,IC50,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13
indomethacin,Lactoylglutathione lyase,GLO1,4.74,Ki,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
lopinavir,CAAX prenyl protease 1 homolog,Zmpste24,4.74,IC50,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
menatetrenone,Cruzipain,,4.74,IC50,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)C2=CC=CC=C2C1=O
nifedipine,Adenosine receptor A2a,Adora2a,4.74,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
omeprazole,Cytochrome P450 1A2,CYP1A2,4.74,IC50,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
perospirone,5-hydroxytryptamine receptor 2A,Htr2a,4.74,Ki,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)C1=NSC2=CC=CC=C12
sulfacetamide,Dihydrofolate reductase,DHFR,4.74,IC50,CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1
zafirlukast,Prostaglandin E synthase,PTGES,4.74,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
zidovudine,Reverse transcriptase,reverse transcriptas,4.74,IC50,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
choline,Neuronal acetylcholine receptor; alpha2/beta2,Chrna2|Chrnb2,4.74,Ki,C[N+](C)(C)CCO
mesterolone,Androgen receptor,Ar,4.74,IC50,C[C@H]1CC(=O)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]12C
clofenotane,Androgen receptor,Ar,4.74,IC50,ClC1=CC=C(C=C1)C(C1=CC=C(Cl)C=C1)C(Cl)(Cl)Cl
eosin,RmtA,rmtA,4.74,IC50,OC1=C(Br)C2=C(C=C1Br)C1(OC(=O)C3=C1C=CC=C3)C1=CC(Br)=C(O)C(Br)=C1O2
lamotrigine,5-hydroxytryptamine receptor 3A,HTR3A,4.744,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
aprindine,Calmodulin,CALM1|CALM2|CALM3,4.745,ID50,CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1
bortezomib,Cytochrome P450 2C19,CYP2C19,4.745,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
flecainide,Sodium channel protein type 4 subunit alpha,SCN4A,4.745,Ki,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
estriol,Glucocorticoid receptor,NR3C1,4.748,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
aminopterin,Folylpoly-gamma-glutamate synthetase,Fpgs,4.75,Ki,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
acediasulfone,"Dihydropteroate synthetase, putative",,4.75,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCC(O)=O)C=C1
acediasulfone,"6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase",PPPK-DHPS,4.75,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCC(O)=O)C=C1
alexidine,Replicase polyprotein 1ab,rep,4.75,IC50,CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC
captopril,Beta-lactamase II,bla2,4.75,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
clotrimazole,5-hydroxytryptamine receptor 1A,Htr1a,4.75,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
deferoxamine,Hypoxia-inducible factor 1-alpha,HIF1A,4.75,EC50,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
estriol succinate,Glucocorticoid receptor,NR3C1,4.75,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
gossypol,Apoptosis regulator Bcl-W,BCL2L2,4.75,Ki,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
levofloxacin,Multidrug and toxin extrusion protein 1,SLC47A1,4.75,IC50,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
pethidine,Sodium-dependent dopamine transporter,Slc6a3,4.75,Ki,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
methylprednisolone,Androgen receptor,Ar,4.75,Ki,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
miconazole,"Indoleamine 2,3-dioxygenase 1",Ido1,4.75,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
norfloxacin,Multidrug and toxin extrusion protein 1,SLC47A1,4.75,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
phenelzine,Lysine-specific histone demethylase 1A,KDM1A,4.75,Ki,NNCCC1=CC=CC=C1
promethazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,4.75,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
sitagliptin,Dipeptidyl peptidase IV,DPP IV,4.75,IC50,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
telmisartan,Multidrug and toxin extrusion protein 1,SLC47A1,4.75,IC50,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O
thioguanine,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,4.75,Kd,NC1=NC2=C(NC=N2)C(=S)N1
zoledronic acid,Neutrophil collagenase,MMP8,4.75,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
pyrithione,Lysyl oxidase homolog 2,LOXL2,4.75,IC50,[O-][N+]1=C(S)C=CC=C1
terazosin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.75,IC50,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
olaparib,Poly [ADP-ribose] polymerase 15,PARP15,4.75,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
betrixaban,Prothrombin,F2,4.75,IC50,COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1
acetohydroxamic acid,Urease,,4.76,IC50,CC(=O)NO
acetohydroxamic acid,Urease subunit beta,ureB,4.76,IC50,CC(=O)NO
adenosine triphosphate,Heat shock cognate 71 kDa protein,HSPA8,4.76,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
cycloguanil,Dihydrofolate reductase,folA,4.76,Ki,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1
diltiazem,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.76,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
econazole,Cholinesterase,BCHE,4.76,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
efavirenz,Cytochrome P450 3A4,CYP3A4,4.76,IC50,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
efavirenz,Cytochrome P450 3A4,CYP3A4,4.76,IC50,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
etofylline,Adenosine receptor A2b,ADORA2B,4.76,Ki,CN1C2=C(N(CCO)C=N2)C(=O)N(C)C1=O
fusidic acid,Bile salt export pump,Abcb11,4.76,IC50,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O
maraviroc,Multidrug and toxin extrusion protein 1,SLC47A1,4.76,IC50,CC(C)C1=NN=C(C)N1[C@@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
nefazodone,Bile salt export pump,Abcb11,4.76,IC50,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nifedipine,"Glutathione reductase, mitochondrial",GSR,4.76,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
ondansetron,Solute carrier family 22 member 3,SLC22A3,4.76,IC50,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
promazine,Solute carrier family 22 member 1,SLC22A1,4.76,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
viloxazine,Sodium-dependent serotonin transporter,SLC6A4,4.76,Kd,CCOC1=CC=CC=C1OCC1CNCCO1
proline,"Glutamate receptor ionotropic, NMDA 1",Grin1,4.76,IC50,OC(=O)[C@@H]1CCCN1
phenol,Carbonic anhydrase,NCE103,4.76,Ki,OC1=CC=CC=C1
tamoxifen,Melanocortin receptor 3,MC3R,4.761,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
orphenadrine,Sodium channel protein type 9 subunit alpha,SCN9A,4.764,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
estradiol benzoate,Sodium-dependent noradrenaline transporter,SLC6A2,4.767,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
sulfasalazine,Aldose reductase,Akr1b1,4.768,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
adiphenine,Histamine H1 receptor,Hrh1,4.77,IC50,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
amitriptyline,Solute carrier family 22 member 1,SLC22A1,4.77,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
apomorphine,Cytoplasmic zinc-finger protein,pos-1,4.77,EC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
atomoxetine,Cytochrome P450 2D6,CYP2D6,4.77,Ki,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
benzarone,Eyes absent homolog 3,EYA3,4.77,IC50,CCC1=C(C(=O)C2=CC=C(O)C=C2)C2=C(O1)C=CC=C2
caffeine,Adenosine receptor A2b,ADORA2B,4.77,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
caffeine,Adenosine receptor A1,Adora1,4.77,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
captopril,Prostaglandin G/H synthase 1,PTGS1,4.77,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
carbamazepine,Frizzled-8,FZD8,4.77,Kd,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
cefsulodin,Tyrosine-protein phosphatase non-receptor type 11,PTPN11,4.77,IC50,NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C2=CC=CC=C2)S(O)(=O)=O)C3=O)C([O-])=O)C=C1
econazole,Calcium release-activated calcium channel protein 1,ORAI1,4.77,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ergotamine,Gastrin/cholecystokinin type B receptor,Cckbr,4.77,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
glutamic acid,Glutamate receptor 4,Gria4,4.77,EC50,N[C@@H](CCC(O)=O)C(O)=O
imatinib,"Carbonic anhydrase 5B, mitochondrial",CA5B,4.77,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imipramine,Solute carrier family 22 member 1,SLC22A1,4.77,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
lamotrigine,Sodium channel protein type 3 subunit alpha,SCN3A,4.77,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
lamotrigine,Sodium channel protein type 4 subunit alpha,SCN4A,4.77,Ki,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
lamotrigine,Sodium channel protein type 9 subunit alpha,SCN9A,4.77,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
lapatinib,Insulin receptor,INSR,4.77,IC50,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
linezolid,Amine oxidase [flavin-containing] B,Maob,4.77,IC50,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
lovastatin,Acyl-CoA:cholesterol acyltransferase,ACAT,4.77,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
minaprine,Muscarinic acetylcholine receptor M1,CHRM1,4.77,Ki,CC1=C(NCCN2CCOCC2)N=NC(=C1)C1=CC=CC=C1
minaprine,Muscarinic acetylcholine receptor M1,Chrm1,4.77,IC50,CC1=C(NCCN2CCOCC2)N=NC(=C1)C1=CC=CC=C1
niflumic acid,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,4.77,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
pemetrexed,"Serine hydroxymethyltransferase, cytosolic",SHMT1,4.77,Kd,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
pimobendan,Type-1 angiotensin II receptor,AGTR1,4.77,IC50,COC1=CC=C(C=C1)C1=NC2=C(N1)C=CC(=C2)C1=NNC(=O)CC1C
progesterone,Sterol O-acyltransferase 1,SOAT1,4.77,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
sunitinib,Bromodomain-containing protein 9,BRD9,4.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zanamivir,Sialidase 2,NEU2,4.77,Ki,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
zolpidem,CAAX prenyl protease 2,RCE1,4.77,AC50,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
thyropropic acid,Proliferating cell nuclear antigen,PCNA,4.77,IC50,OC(=O)CCC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
fingolimod,Sphingosine-1-phosphate lyase 1,SGPL1,4.77,IC50,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
boceprevir,Neutrophil elastase,ELANE,4.77,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
abiraterone acetate,Androgen receptor,AR,4.77,EC50,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C4=CC=CN=C4)[C@@H]3CC=C2C1
dicycloverine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.773,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
amrinone,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,4.78,IC50,NC1=CC(=CNC1=O)C1=CC=NC=C1
camostat,Solute carrier family 22 member 2,SLC22A2,4.78,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
citalopram,Sodium-dependent dopamine transporter,SLC6A3,4.78,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
clotrimazole,Cysteinyl leukotriene receptor 1,CYSLTR1,4.78,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,Cysteinyl leukotriene receptor 1,CYSLTR1,4.78,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
mefenamic acid,Prostaglandin G/H synthase 1,PTGS1,4.78,IC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
miconazole,Cannabinoid receptor 1,CNR1,4.78,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nicardipine,ATP-binding cassette sub-family G member 2,ABCG2,4.78,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
viloxazine,Sodium-dependent serotonin transporter,Slc6a4,4.78,Ki,CCOC1=CC=CC=C1OCC1CNCCO1
vemurafenib,GTPase KRas,KRAS,4.78,IC50,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F
dexchlorpheniramine,Alpha-1D adrenergic receptor,ADRA1D,4.781,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
astemizole,Adenosine receptor A3,ADORA3,4.784,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
phentolamine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.784,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
dexamethasone,Androgen receptor,Ar,4.786,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
mercaptopurine,Prostaglandin G/H synthase 1,PTGS1,4.789,IC50,S=C1N=CNC2=C1NC=N2
tirilazad,Mitogen-activated protein kinase 3,MAPK3,4.789,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
econazole,5-hydroxytryptamine receptor 1A,Htr1a,4.79,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
erlotinib,Solute carrier family 22 member 1,SLC22A1,4.79,IC50,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fleroxacin,DNA gyrase subunit A,gyrA,4.79,IC50,CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN(CCF)C2=C1F)C(O)=O
lovastatin,Histone deacetylase 6,HDAC6,4.79,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
quercetin,"Nitric oxide synthase, inducible",Nos2,4.79,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
dexamethasone phosphate,Androgen receptor,Ar,4.79,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
osimertinib,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.79,IC50,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
amiodarone,Endothelin-1 receptor,EDNRA,4.791,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
miconazole,Melanocortin receptor 3,MC3R,4.792,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
thioguanine,Arachidonate 15-lipoxygenase,ALOX15,4.792,IC50,NC1=NC2=C(NC=N2)C(=S)N1
disulfiram,Arachidonate 15-lipoxygenase,ALOX15,4.794,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
paclitaxel,Melanocortin receptor 5,MC5R,4.794,Ki,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
bupropion,Alpha-1A adrenergic receptor,ADRA1A,4.796,Ki,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
clonidine,Solute carrier family 22 member 2,SLC22A2,4.796,IC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
nortriptyline,ATP-sensitive inward rectifier potassium channel 10,KCNJ10,4.796,IC50,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
chlorpromazine,Arachidonate 15-lipoxygenase,ALOX15,4.797,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
amantadine,Matrix protein 2,M,4.8,IC50,NC12CC3CC(CC(C3)C1)C2
amantadine,Matrix protein 2,M2,4.8,IC50,NC12CC3CC(CC(C3)C1)C2
buspirone,Alpha-1A adrenergic receptor,ADRA1A,4.8,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
carvedilol,Ryanodine receptor 2,RYR2,4.8,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
celecoxib,Carbonic anhydrase 9,CA9,4.8,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cianidanol,Mast/stem cell growth factor receptor Kit,KIT,4.8,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
cianidanol,Mast/stem cell growth factor receptor Kit,KIT,4.8,IC50,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
cocaine,Serotonin 3 receptor (5HT3),HTR3B|HTR3A,4.8,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
desloratadine,Histamine H4 receptor,HRH4,4.8,IC50,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
dicloxacillin,Histamine H2 receptor,HRH2,4.8,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
doxazosin,"HLA class I histocompatibility antigen, A-3 alpha chain",HLA-A,4.8,Kd,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
epoprostenol,Prostaglandin E2 receptor EP1 subtype,PTGER1,4.8,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O
fluoxetine,G protein-activated inward rectifier potassium channel 2,Kcnj6,4.8,IC50,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
ganciclovir,Purine nucleoside phosphorylase,punA,4.8,Kd,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
glutamic acid,Metabotropic glutamate receptor 6,Grm6,4.8,EC50,N[C@@H](CCC(O)=O)C(O)=O
hydroxychloroquine,Alpha-2C adrenergic receptor,ADRA2C,4.8,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
levamisole,"Alkaline phosphatase, tissue-nonspecific isozyme",ALPL,4.8,Ki,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1
lidocaine,Sodium channel protein type 5 subunit alpha,SCN5A,4.8,Kd,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
mefenamic acid,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.8,EC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
mefenamic acid,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.8,EC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
methylthioninium chloride,"Glutathione reductase, mitochondrial",GSR,4.8,IC50,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
nicotine,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.8,EC50,CN1CCC[C@H]1C1=CC=CN=C1
oxycodone,Kappa-type opioid receptor,OPRK1,4.8,EC50,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
oxycodone,Kappa-type opioid receptor,Oprk1,4.8,EC50,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
quinidine,Potassium voltage-gated channel subfamily A member 7,KCNA7,4.8,Kd,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
sulindac,Prostaglandin G/H synthase 1,PTGS1,4.8,IC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
sumatriptan,5-hydroxytryptamine receptor 5A,Htr5a,4.8,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
levothyroxine,Macrophage migration inhibitory factor,MIF,4.8,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
toremifene,Envelope glycoprotein,GP,4.8,Kd,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
triflupromazine,Multidrug resistance protein 1,ABCB1,4.8,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
tropisetron,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,4.8,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
verapamil,Potassium voltage-gated channel subfamily A member 7,KCNA7,4.8,Kd,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
quercetin,"Solute carrier family 2, facilitated glucose transporter member 4",Slc2a4,4.8,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
vincamine,Muscarinic acetylcholine receptor M1,CHRM1,4.8,Kd,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C1=CC=CC=C41)[C@](O)(C2)C(=O)OC
meldonium,Gamma-butyrobetaine dioxygenase,BBOX1,4.8,Ki,C[N+](C)(C)NCCC([O-])=O
mozavaptan,Vasopressin V1b receptor,AVPR1B,4.8,Ki,CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C2=CC=CC=C12
lacosamide,Sodium channel protein type X alpha subunit,Scn10a,4.8,IC50,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
aceclidine,Muscarinic acetylcholine receptor M4,CHRM4,4.8,EC50,CC(=O)OC1CN2CCC1CC2
linopirdine,Potassium voltage-gated channel subfamily KQT member 5,KCNQ5,4.8,Kd,O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1
linolenic acid,Peroxisome proliferator-activated receptor delta,PPARD,4.8,IC50,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
deoxycholic acid,Steroid Delta-isomerase,ksi,4.8,Kd,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
abametapir,C-C chemokine receptor type 1,CCR1,4.8,EC50,CC1=CN=C(C=C1)C2=NC=C(C=C2)C
abametapir,C-C chemokine receptor type 1,CCR1,4.8,EC50,CC1=CN=C(C=C1)C2=NC=C(C=C2)C
tirilazad,Tyrosine-protein kinase Lck,LCK,4.802,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
doxorubicin,5-hydroxytryptamine receptor 1B,Htr1b,4.805,Ki,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
lovastatin,Adenosine receptor A1,ADORA1,4.807,Ki,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
tamoxifen,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,4.807,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tirilazad,Beta-2 adrenergic receptor,ADRB2,4.807,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
fenofibrate,Acetylcholinesterase,ACHE,4.808,IC50,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
hydroxychloroquine,Muscarinic acetylcholine receptor M1,CHRM1,4.81,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
ketoconazole,Bile salt export pump,Abcb11,4.81,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
framycetin,Menin,MEN1,4.81,Kd,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
gabexate,Tissue-type plasminogen activator,PLAT,4.81,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
quercetin,G-protein coupled receptor 35,GPR35,4.81,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
adenosine,cAMP-dependent protein kinase A,PRKAR2A|PRKACA|PRKACB|PRKAR2B,4.82,Ki,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
amprenavir,Cathepsin D,CTSD,4.82,IC50,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
cefapirin,5-hydroxytryptamine receptor 2B,HTR2B,4.82,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
chlordiazepoxide,Thyrotropin-releasing hormone receptor,Trhr,4.82,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
dicoumarol,Urease,,4.82,IC50,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
donepezil,Amine oxidase [flavin-containing] B,MAOB,4.82,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
donepezil,Amine oxidase [flavin-containing] B,Maob,4.82,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
gallamine,Acetylcholinesterase,ache,4.82,Ki,CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
labetalol,CAAX prenyl protease 2,RCE1,4.82,AC50,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
lamotrigine,Dihydrofolate reductase,dfrA17,4.82,Ki,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
levosulpiride,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,4.82,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
meptazinol,Cholinesterase,Bche,4.82,IC50,CCC1(CCCCN(C)C1)C1=CC(O)=CC=C1
ofloxacin,Gag-Pro-Pol polyprotein,gag-pro-pol,4.82,IC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
pemetrexed,Thymidylate synthase,thyA,4.82,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
phenindione,Arachidonate 5-lipoxygenase,Alox5,4.82,IC50,O=C1C(C(=O)C2=C1C=CC=C2)C1=CC=CC=C1
phenoxybenzamine,Solute carrier family 22 member 1,SLC22A1,4.82,IC50,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
phenylbutazone,Cyclooxygenase,Ptgs2|Ptgs1,4.82,IC50,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
pranlukast,Bile acid receptor,NR1H4,4.82,EC50,O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
pranlukast,Bile acid receptor,NR1H4,4.82,EC50,O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
rosiglitazone,Retinoic acid receptor RXR-alpha,RXRA,4.82,Kd,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
theophylline,Adenosine A2b receptor,Adora2b,4.82,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
toloxatone,Amine oxidase [flavin-containing] B,MAOB,4.82,Ki,CC1=CC=CC(=C1)N1CC(CO)OC1=O
toloxatone,Amine oxidase [flavin-containing] B,MAOB,4.82,Ki,CC1=CC=CC(=C1)N1CC(CO)OC1=O
triclabendazole,Cruzipain,,4.82,IC50,CSC1=NC2=C(N1)C=C(Cl)C(OC1=C(Cl)C(Cl)=CC=C1)=C2
voriconazole,Cytochrome P450 2C19,CYP2C19,4.82,IC50,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
zomepirac,Cyclooxygenase,PTGS1|PTGS2,4.82,IC50,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
oxycinchophen,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,4.82,Kd,OC(=O)C1=C(O)C(=NC2=CC=CC=C12)C1=CC=CC=C1
pyrithione,Lysyl oxidase homolog 4,LOXL4,4.82,IC50,[O-][N+]1=C(S)C=CC=C1
tipranavir,Cathepsin D,CTSD,4.82,Ki,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC(NS(=O)(=O)C3=CC=C(C=N3)C(F)(F)F)=CC=C2)C(=O)O1
kojic acid,Polyphenol oxidase 1,PPO1,4.82,IC50,OCC1=CC(=O)C(O)=CO1
doconexent,Prostaglandin G/H synthase 1,PTGS1,4.82,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
nifedipine,Arachidonate 15-lipoxygenase,ALOX15,4.821,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
tamoxifen,Androgen receptor,Ar,4.821,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
erythromycin,Aldehyde oxidase,AOX1,4.824,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
ipratropium,Solute carrier family 22 member 2,SLC22A2,4.824,IC50,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
fendosal,Plasminogen activator inhibitor 1,SERPINE1,4.824,IC50,OC(=O)C1=C(O)C=CC(=C1)N1C2=C(C=C1C1=CC=CC=C1)C1=CC=CC=C1CC2
methoxsalen,Polyphenol oxidase 2,PPO2,4.83,EC50,COC1=C2OC=CC2=CC2=C1OC(=O)C=C2
methoxsalen,Polyphenol oxidase 2,PPO2,4.83,EC50,COC1=C2OC=CC2=CC2=C1OC(=O)C=C2
alfuzosin,Solute carrier family 22 member 1,SLC22A1,4.83,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
cloperastine,Solute carrier family 22 member 1,SLC22A1,4.83,IC50,ClC1=CC=C(C=C1)C(OCCN1CCCCC1)C1=CC=CC=C1
diacerein,Caspase-7,CASP7,4.83,EC50,CC(=O)OC1=C2C(=O)C3=C(OC(C)=O)C=C(C=C3C(=O)C2=CC=C1)C(O)=O
domperidone,Multidrug and toxin extrusion protein 2,SLC47A2,4.83,IC50,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
framycetin,Lecithin retinol acyltransferase,LRAT,4.83,IC50,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
nilotinib,"Carbonic anhydrase 5B, mitochondrial",CA5B,4.83,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
chlorpromazine,Melanocortin receptor 4,MC4R,4.835,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
apomorphine,Mannose-6-phosphate isomerase,MPI,4.84,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
atorvastatin,Histone deacetylase 6,HDAC6,4.84,IC50,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
cefapirin,Cytochrome P450 2D6,CYP2D6,4.84,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
dexamfetamine,Amine oxidase [flavin-containing] A,MAOA,4.84,Ki,C[C@H](N)CC1=CC=CC=C1
diethylstilbestrol,Nuclear receptor subfamily 1 group I member 2,NR1I2,4.84,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
ketoconazole,Alpha-1D adrenergic receptor,ADRA1D,4.84,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
sorafenib,Receptor-interacting serine/threonine-protein kinase 3,RIPK3,4.84,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Receptor-interacting serine/threonine-protein kinase 3,RIPK3,4.84,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
thiabendazole,Reverse transcriptase/RNaseH,pol,4.84,IC50,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
trimethoprim,Dihydrofolate reductase,Dhfr,4.84,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
hexamidine,Urokinase-type plasminogen activator,PLAU,4.84,Ki,NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
baicalin,Cyclin-dependent kinase 1,CDK1,4.84,IC50,O[C@@H]1[C@@H](O)[C@H](OC2=C(O)C(O)=C3C(=O)C=C(OC3=C2)C2=CC=CC=C2)O[C@@H]([C@H]1O)C(O)=O
nelfinavir,Kappa-type opioid receptor,OPRK1,4.842,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
atomoxetine,Kir3.1/Kir3.4,KCNJ5|KCNJ3,4.845,IC50,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
propafenone,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,4.845,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
diethylstilbestrol,Tyrosine-protein kinase Fyn,FYN,4.847,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
solriamfetol,Sodium-dependent dopamine transporter,SLC6A3,4.848,Ki,N[C@@H](COC(N)=O)CC1=CC=CC=C1
atropine,Alpha-2A adrenergic receptor,ADRA2A,4.85,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
captopril,Beta-lactamase NDM-1,blaNDM-1,4.85,Kd,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
cefotetan,Catechol O-methyltransferase,COMT,4.85,IC50,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
celecoxib,Prostaglandin G/H synthase 1,Ptgs1,4.85,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cefapirin,Nischarin,NISCH,4.85,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
cefapirin,Substance-K receptor,TACR2,4.85,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
chlorzoxazone,"Nitric oxide synthase, inducible",NOS2,4.85,IC50,ClC1=CC2=C(OC(=O)N2)C=C1
cortisone acetate,Protein farnesyltransferase,FNTA|FNTB,4.85,IC50,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
diethylstilbestrol,Androgen receptor,Ar,4.85,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
dopamine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,4.85,Ki,NCCC1=CC(O)=C(O)C=C1
edetic acid,Angiotensin-converting enzyme,ACE,4.85,IC50,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
ethacrynic acid,UDP-glucose 4-epimerase,GALE,4.85,IC50,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
flufenamic acid,Prostaglandin G/H synthase 1,PTGS1,4.85,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
fluoxetine,Potassium channel subfamily K member 2,KCNK2,4.85,IC50,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
gamolenic acid,3-oxo-5-alpha-steroid 4-dehydrogenase 2,SRD5A2,4.85,IC50,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
imipramine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,4.85,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
indomethacin,Dehydrogenase/reductase SDR family member 9,DHRS9,4.85,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
masoprocol,Cyclooxygenase,PTGS1|PTGS2,4.85,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
melatonin,Cytochrome P450 1B1,CYP1B1,4.85,Ki,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
nicotinamide,NAD-dependent deacetylase sirtuin 3,SIRT3,4.85,IC50,NC(=O)C1=CN=CC=C1
norepinephrine,Mu-type opioid receptor,Oprm1,4.85,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
phenelzine,"Indoleamine 2,3-dioxygenase 1",IDO1,4.85,IC50,NNCCC1=CC=CC=C1
probucol,Arachidonate 15-lipoxygenase,ALOX15,4.85,IC50,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
progabide,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,4.85,Ki,NC(=O)CCCN=C(C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1
propofol,Fatty-acid amide hydrolase 1,Faah,4.85,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
sulconazole,Beta-lactamase,ampC,4.85,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
voriconazole,Cytochrome P450 2C9,CYP2C9,4.85,IC50,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
suramin,"NAD-dependent protein deacylase sirtuin-5, mitochondrial",SIRT5,4.85,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
hydroquinone,"Carbonic anhydrase 5A, mitochondrial",CA5A,4.85,Ki,OC1=CC=C(O)C=C1
quercetin,Beta-secretase 1,BACE1,4.85,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
azacyclonol,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.85,IC50,OC(C1CCNCC1)(C1=CC=CC=C1)C1=CC=CC=C1
alitretinoin,Nuclear receptor ROR-gamma,RORC,4.85,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
dronabinol,G-protein coupled receptor 55,GPR55,4.85,IC50,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
dronabinol,Transient receptor potential cation channel subfamily V member 2,Trpv2,4.85,EC50,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
vorinostat,Lysine-specific demethylase 4E,KDM4E,4.85,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
amitriptyline,Solute carrier family 22 member 2,SLC22A2,4.854,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
celecoxib,D(1A) dopamine receptor,DRD1,4.854,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorpromazine,Solute carrier family 22 member 2,SLC22A2,4.854,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
rizatriptan,Cytochrome P450 2D6,CYP2D6,4.854,Ki,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
cyproheptadine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.855,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
celecoxib,Adenosine receptor A3,ADORA3,4.856,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
digitoxin,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.857,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
econazole,Receptor tyrosine-protein kinase erbB-2,ERBB2,4.857,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
tirilazad,Histamine H2 receptor,HRH2,4.857,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
tamoxifen,Adenosine receptor A1,ADORA1,4.858,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
exisulind,Mitogen-activated protein kinase 1,MAPK1,4.859,IC50,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)(=O)=O
cyclothiazide,Glutamate receptor 3,GRIA3,4.86,EC50,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C2CC3CC2C=C3)C=C1Cl
flutrimazole,Bile acid receptor,NR1H4,4.86,IC50,FC1=CC=C(C=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=C(F)C=CC=C1
imatinib,Mitogen-activated protein kinase 14,MAPK14,4.86,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
nelfinavir,Arachidonate 15-lipoxygenase,ALOX15,4.86,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
bergapten,Amine oxidase [flavin-containing] A,MAOA,4.86,IC50,COC1=C2C=COC2=CC2=C1C=CC(=O)O2
quercetin,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,4.86,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
phenol,Carbonic anhydrase,ca,4.86,Ki,OC1=CC=CC=C1
benzoic acid,Solute carrier family 22 member 20,Slc22a20,4.86,Ki,OC(=O)C1=CC=CC=C1
metizoline,Amine oxidase [flavin-containing] A,Maoa,4.86,Ki,CC1=C(CC2=NCCN2)C2=CC=CC=C2S1
disulfiram,Amine oxidase [flavin-containing] A,MAOA,4.862,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
econazole,Acetylcholinesterase,ACHE,4.864,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
doxorubicin,Arachidonate 15-lipoxygenase,ALOX15,4.867,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
warfarin,Cytochrome P450 2C9,CYP2C9,4.867,Ki,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
astemizole,Melanocortin receptor 3,MC3R,4.868,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
astemizole,Melanocortin receptor 4,MC4R,4.87,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
bexarotene,Cytochrome P450 26A1,CYP26A1,4.87,IC50,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
clomifene,Androgen receptor,Ar,4.87,IC50,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
ciclosporin,Canalicular multispecific organic anion transporter 1,ABCC2,4.87,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
furaltadone,Mitogen-activated protein kinase 9,MAPK9,4.87,IC50,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(CN2CCOCC2)OC1=O
isepamicin,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",mphB,4.87,Km,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O
mafenide,Carbonic anhydrase,,4.87,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
pyrimethamine,Solute carrier family 22 member 1,SLC22A1,4.87,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
pyrimethamine,Pteridine reductase 1,PTR1,4.87,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
pyrimethamine,Pteridine reductase 1,PTR1,4.87,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
practolol,Beta-2 adrenergic receptor,Adrb2,4.87,Ki,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
prazosin,Solute carrier family 22 member 2,SLC22A2,4.87,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
zafirlukast,Cytochrome P450 3A4,CYP3A4,4.873,Ki,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
vernakalant,Potassium voltage-gated channel subfamily A member 5,KCNA5,4.875,IC50,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1
amiodarone,Melanocortin receptor 4,MC4R,4.879,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
pioglitazone,Aldose reductase,Akr1b1,4.879,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
carprofen,Prostaglandin G/H synthase 1,PTGS1,4.88,IC50,CC(C(O)=O)C1=CC2=C(C=C1)C1=CC(Cl)=CC=C1N2
chloramphenicol,Probable HTH-type transcriptional regulator TtgR,ttgR,4.88,Kd,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
clotrimazole,Putative cytochrome P450 130,cyp130,4.88,Kd,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
dienestrol,Estrogen receptor,ESR1,4.88,EC50,C\C=C(\C(=C\C)\C1=CC=C(O)C=C1)/C1=CC=C(O)C=C1
fluoxetine,Potassium voltage-gated channel subfamily C member 1,Kcnc1,4.88,IC50,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
metoclopramide,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,4.88,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
niclosamide,Fibroblast growth factor receptor 1,FGFR1,4.88,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
pitavastatin,Retinoic acid receptor RXR-alpha,RXRA,4.88,Kd,O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=C(C=CC=C2)N=C1C1CC1)CC(O)=O
terconazole,Alpha-1A adrenergic receptor,Adra1a,4.88,IC50,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
tranylcypromine,Cationic trypsin,,4.88,Ki,N[C@@H]1C[C@H]1C1=CC=CC=C1
verapamil,Multidrug resistance-associated protein 1,ABCC1,4.88,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
vesnarinone,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B",PDE3B,4.88,IC50,COC1=C(OC)C=C(C=C1)C(=O)N1CCN(CC1)C1=CC=C2NC(=O)CCC2=C1
nicotinic acid,Amyloid beta A4 protein,APP,4.88,IC50,OC(=O)C1=CN=CC=C1
astemizole,Receptor tyrosine-protein kinase erbB-2,ERBB2,4.883,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
doxepin,Solute carrier family 22 member 2,SLC22A2,4.886,IC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
orphenadrine,Sodium channel protein type 5 subunit alpha,SCN5A,4.886,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
orphenadrine,Sodium channel protein type 1 subunit alpha,SCN1A,4.889,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
levobupivacaine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.89,IC50,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
fluorouracil,Uracil phosphoribosyltransferase,upp,4.89,Ki,FC1=CNC(=O)NC1=O
acemetacin,Lactoylglutathione lyase,GLO1,4.89,Ki,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O
benzbromarone,Envelope glycoprotein gp160,env,4.89,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
bortezomib,Prothrombin,F2,4.89,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
caffeine,Adenosine receptor A2b,Adora2b,4.89,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
carprofen,Prostaglandin G/H synthase 1,PTGS1,4.89,IC50,CC(C(O)=O)C1=CC2=C(C=C1)C1=CC(Cl)=CC=C1N2
cefotetan,Interstitial collagenase,MMP1,4.89,IC50,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
cefapirin,Substance-P receptor,TACR1,4.89,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
chloramphenicol,Chloramphenicol acetyltransferase,cat,4.89,Kd,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
clonixin,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,4.89,IC50,CC1=C(NC2=C(C=CC=N2)C(O)=O)C=CC=C1Cl
cloxacillin,Beta-lactamase TEM,bla; blaT-3; blaT-4;,4.89,Ki,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1
cloxacillin,Beta-lactamase TEM,bla,4.89,Ki,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1
diazepam,Acetylcholinesterase,ache,4.89,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
eflornithine,Ornithine decarboxylase,ODC1,4.89,Kd,NCCCC(N)(C(F)F)C(O)=O
formoterol,D(2) dopamine receptor,DRD2,4.89,Ki,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
glutamic acid,Excitatory amino acid transporter 4,Slc1a6,4.89,IC50,N[C@@H](CCC(O)=O)C(O)=O
ibuprofen,Prostaglandin-H2 D-isomerase,Ptgds,4.89,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
lorazepam,"Fatty acid-binding protein, liver",Fabp1,4.89,Ki,OC1N=C(C2=CC(Cl)=CC=C2NC1=O)C1=C(Cl)C=CC=C1
losartan,Phosphodiesterase 3,PDE3B|PDE3A,4.89,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
lovastatin,Leukocyte adhesion glycoprotein LFA-1 alpha,ITGAL,4.89,Kd,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
mexiletine,Sodium channel protein type 9 subunit alpha,SCN9A,4.89,Ki,CC(N)COC1=C(C)C=CC=C1C
mezlocillin,Adenosine receptor A3,ADORA3,4.89,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
miglustat,Trehalase,Treh,4.89,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
milrinone,Cyclic AMP-specific phosphodiesterase SSPDE4A1A,PDE4A,4.89,IC50,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
naproxen,Prostaglandin-H2 D-isomerase,Ptgds,4.89,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
pentamidine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.89,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
phenylephrine,Beta-1 adrenergic receptor,Adrb1,4.89,Ki,CNC[C@H](O)C1=CC(O)=CC=C1
propranolol,D(2) dopamine receptor,Drd2,4.89,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
pyrazinamide,Cytochrome P450 3A5,CYP3A5,4.89,IC50,NC(=O)C1=NC=CN=C1
riluzole,Small conductance calcium-activated potassium channel protein 2,Kcnn2,4.89,EC50,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
saquinavir,Chloroquine resistance transporter,CRT,4.89,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
sunitinib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,4.89,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
theophylline,Adenosine A2a receptor,ADORA2A,4.89,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
tranylcypromine,D(3) dopamine receptor,Drd3,4.89,Ki,N[C@@H]1C[C@H]1C1=CC=CC=C1
valdecoxib,Beta-carbonic anhydrase 1,mtcA1,4.89,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
voriconazole,Cytochrome P450 3A4,CYP3A4,4.89,IC50,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
cloxiquine,Methionine aminopeptidase 1,METAP1,4.89,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1
eicosapentaenoic acid,Prostaglandin G/H synthase 1,PTGS1,4.89,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
linoleic acid,Prostaglandin G/H synthase 1,PTGS1,4.89,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
quercetin,Calmodulin,CALM1|CALM2|CALM3,4.89,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Tyrosine-protein kinase Lck,LCK,4.89,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Prolyl endopeptidase,PREP,4.89,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
rutoside,Aldose reductase,Akr1b1,4.89,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
migalastat,Beta-galactosidase,lacZ,4.89,Ki,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
danazol,Beta-3 adrenergic receptor,ADRB3,4.894,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
diethylstilbestrol,Beta-1 adrenergic receptor,ADRB1,4.894,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
terconazole,D(1A) dopamine receptor,DRD1,4.895,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
ketoconazole,Alpha-1B adrenergic receptor,Adra1b,4.897,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acyclovir,Purine nucleoside phosphorylase,punA,4.9,Kd,NC1=NC2=C(N=CN2COCCO)C(=O)N1
bethanechol,Muscarinic acetylcholine receptor,GPM3,4.9,Kd,CC(C[N+](C)(C)C)OC(N)=O
camostat,Multidrug and toxin extrusion protein 2,SLC47A2,4.9,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
dihydroergotamine,Multidrug and toxin extrusion protein 2,SLC47A2,4.9,IC50,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
donepezil,Cholinesterase,BCHE,4.9,Ki,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
fructose,Glycine receptor subunit alpha-1,GLRA1,4.9,EC50,OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O
furosemide,Holo-[acyl-carrieir-protein] synthase,acpS,4.9,IC50,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
methoxamine,Alpha-1D adrenergic receptor,ADRA1D,4.9,EC50,COC1=CC(C(O)C(C)N)=C(OC)C=C1
mibefradil,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,4.9,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
nafamostat,Acid-sensing ion channel 1,ASIC1,4.9,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
nifedipine,Potassium voltage-gated channel subfamily A member 7,Kcna7,4.9,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
orphenadrine,Solute carrier family 22 member 1,SLC22A1,4.9,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
pantoprazole,"Indoleamine 2,3-dioxygenase 2",Ido2,4.9,IC50,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
phendimetrazine,5-hydroxytryptamine receptor 1A,HTR1A,4.9,Kd,C[C@H]1[C@@H](OCCN1C)C1=CC=CC=C1
phentolamine,Histamine H1 receptor,Hrh1,4.9,IC50,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
phenytoin,Sodium channel protein type 2 subunit alpha,SCN2A,4.9,IC50,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
picrotin,Glycine receptor subunit alpha-2,GLRA2,4.9,IC50,CC(C)(O)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C
probenecid,Solute carrier family 22 member 6,SLC22A6,4.9,IC50,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
riluzole,Small conductance calcium-activated potassium channel protein 3,KCNN3,4.9,EC50,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
tropisetron,Glycine receptor subunit alpha-2,GLRA2,4.9,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
verapamil,Potassium voltage-gated channel subfamily C member 2,KCNC2,4.9,EC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
verapamil,Potassium voltage-gated channel subfamily C member 2,Kcnc2,4.9,EC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
thiamine,Heat shock protein HSP 90-alpha,HSP90AA1,4.9,IC50,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
zidovudine,Thymidine kinase,tdk,4.9,IC50,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
zoledronic acid,Matrix metalloproteinase-14,MMP14,4.9,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
suramin,Nucleoside triphosphate diphosphohydrolase 3,Entpd3,4.9,Ki,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
hydroquinone,"Carbonic anhydrase 5B, mitochondrial",CA5B,4.9,Ki,OC1=CC=C(O)C=C1
dronabinol,Transient receptor potential cation channel subfamily A member 1,TRPA1,4.9,EC50,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
quinine,Potassium voltage-gated channel subfamily B member 2,KCNB2,4.9,IC50,COC1=CC=C2N=CC=C([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
linopirdine,Potassium voltage-gated channel subfamily KQT member 4,KCNQ4,4.9,IC50,O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1
migalastat,Beta-galactosidase,lacZ,4.9,Ki,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
voxelotor,Cytochrome P450 3A4,CYP3A4,4.9,IC50,CC(C)N1N=CC=C1C1=C(COC2=C(C=O)C(O)=CC=C2)C=CC=N1
clotrimazole,5-hydroxytryptamine receptor 1B,Htr1b,4.906,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
nelfinavir,Sodium-dependent dopamine transporter,SLC6A3,4.909,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
amfetamine,Amine oxidase [flavin-containing] A,Maoa,4.91,Ki,CC(N)CC1=CC=CC=C1
atropine,Solute carrier family 22 member 1,SLC22A1,4.91,IC50,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
dapsone,"Dihydropteroate synthetase, putative",,4.91,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
dapsone,"6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase",PPPK-DHPS,4.91,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
dexamfetamine,Amine oxidase [flavin-containing] A,Maoa,4.91,Ki,C[C@H](N)CC1=CC=CC=C1
diltiazem,Solute carrier family 22 member 1,SLC22A1,4.91,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
estradiol benzoate,Adenosine receptor A3,ADORA3,4.91,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
mafenide,"Carbonic anhydrase 5B, mitochondrial",CA5B,4.91,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
methysergide,Zinc finger protein mex-5,mex-5,4.91,EC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
propofol,Cytochrome P450 2C9,CYP2C9,4.91,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
bufexamac,Histone deacetylase 10,HDAC10,4.91,Kd,CCCCOC1=CC=C(CC(=O)NO)C=C1
kainic acid,Glutamate receptor 2,GRIA2,4.91,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
kojic acid,Polymerase acidic protein,PA,4.91,IC50,OCC1=CC(=O)C(O)=CO1
kojic acid,Polymerase acidic protein,PA,4.91,IC50,OCC1=CC(=O)C(O)=CO1
thioguanine,Adenosine receptor A3,ADORA3,4.912,Ki,NC1=NC2=C(NC=N2)C(=S)N1
doxorubicin,Caspase-1,CASP1,4.914,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
econazole,Tyrosine-protein kinase Fyn,FYN,4.916,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
celecoxib,Beta-3 adrenergic receptor,ADRB3,4.917,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
mifepristone,Alpha-2B adrenergic receptor,ADRA2B,4.918,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
tamoxifen,B2 bradykinin receptor,BDKRB2,4.919,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
acetazolamide,Carbonic anhydrase,,4.92,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
amiodarone,Squalene monooxygenase,SQLE,4.92,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
buspirone,Solute carrier family 22 member 2,SLC22A2,4.92,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
captopril,Prostaglandin G/H synthase 2,PTGS2,4.92,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
clotrimazole,Solute carrier family 22 member 1,SLC22A1,4.92,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
coumarin,Amine oxidase [flavin-containing] B,Maob,4.92,IC50,O=C1OC2=CC=CC=C2C=C1
dobutamine,Carbonic anhydrase 14,CA14,4.92,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
etoricoxib,Prostaglandin G/H synthase 1,PTGS1,4.92,IC50,CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
fluconazole,14-alpha sterol demethylase Cyp51A,,4.92,Kd,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
glutamic acid,Metabotropic glutamate receptor 4,Grm4,4.92,EC50,N[C@@H](CCC(O)=O)C(O)=O
glibenclamide,"NACHT, LRR and PYD domains-containing protein 3",NLRP3,4.92,IC50,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
indomethacin,Multidrug resistance-associated protein 1,ABCC1,4.92,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
indoramin,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,4.92,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
irbesartan,Sodium/bile acid cotransporter,SLC10A1,4.92,Ki,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
isoprenaline,D(2) dopamine receptor,DRD2,4.92,Ki,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
levallorphan,Acetylcholinesterase,ache,4.92,Ki,OC1=CC2=C(C[C@@H]3[C@@H]4CCCC[C@]24CCN3CC=C)C=C1
lovastatin,Histone deacetylase 1,HDAC1,4.92,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
mefloquine,Protein kinase Pfmrk,Pfmrk,4.92,IC50,O[C@H]([C@H]1CCCCN1)C1=CC(=NC2=C(C=CC=C12)C(F)(F)F)C(F)(F)F
menadione,"Glutathione reductase, mitochondrial",GSR,4.92,Ki,CC1=CC(=O)C2=CC=CC=C2C1=O
meropenem,Beta-lactamase class B VIM-2,blaVIM-2,4.92,Kd,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
methylprednisolone,Short transient receptor potential channel 5,TRPC5,4.92,EC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
mezlocillin,Multidrug resistance-associated protein 1,ABCC1,4.92,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
mezlocillin,Prostaglandin D2 receptor,PTGDR,4.92,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
papaverine,Phosphodiesterase 1,Pde1b|Pde1c|Pde1a,4.92,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
pirlindole,Transcriptional enhancer factor TEF-1,TEAD1,4.92,Kd,CC1=CC2=C(C=C1)N1CCNC3CCCC2=C13
ademetionine,Protein arginine N-methyltransferase 1,PRMT1,4.92,IC50,C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N
salicylic acid,Carbonic anhydrase 6,CA6,4.92,Ki,OC(=O)C1=CC=CC=C1O
sulbactam,Class D beta-lactamase,oxa-63,4.92,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sunitinib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,4.92,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamoxifen,5-hydroxytryptamine receptor 1A,Htr1a,4.92,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
trientine,Carbonic anhydrase 14,CA14,4.92,Ki,NCCNCCNCCN
trimethoprim,Dihydrofolate reductase,DFR1,4.92,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
oxycinchophen,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,4.92,IC50,OC(=O)C1=C(O)C(=NC2=CC=CC=C12)C1=CC=CC=C1
pyrithione,Lysyl oxidase homolog 3,LOXL3,4.92,IC50,[O-][N+]1=C(S)C=CC=C1
quercetin,Urokinase-type plasminogen activator,PLAU,4.92,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,"Carbonic anhydrase 5B, mitochondrial",CA5B,4.92,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Neutrophil elastase,ELANE,4.92,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,"Solute carrier family 2, facilitated glucose transporter member 2",SLC2A2,4.92,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
baicalin,Prolyl endopeptidase,PREP,4.92,IC50,O[C@@H]1[C@@H](O)[C@H](OC2=C(O)C(O)=C3C(=O)C=C(OC3=C2)C2=CC=CC=C2)O[C@@H]([C@H]1O)C(O)=O
acetic acid,Free fatty acid receptor 3,FFAR3,4.92,EC50,CC(O)=O
quinine,Multidrug resistance protein 1,ABCB1,4.92,Ki,COC1=CC=C2N=CC=C([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
linolenic acid,Prostaglandin G/H synthase 2,PTGS2,4.92,IC50,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
atazanavir,Cytochrome P450 2C9,CYP2C9,4.921,Ki,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
atazanavir,Cytochrome P450 1A2,CYP1A2,4.921,Ki,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
disopyramide,G protein-activated inward rectifier potassium channel 4,KCNJ5,4.921,IC50,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
fendiline,Extracellular calcium-sensing receptor,CASR,4.921,EC50,CC(NCCC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1
ranolazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.921,IC50,COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1
saquinavir,Multidrug resistance protein 1,ABCB1,4.921,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
miconazole,Melanocortin receptor 4,MC4R,4.922,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
estradiol,Sodium-dependent dopamine transporter,SLC6A3,4.926,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
nimesulide,Sodium-dependent dopamine transporter,SLC6A3,4.927,Ki,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
tirilazad,5-hydroxytryptamine receptor 2B,HTR2B,4.929,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
aminopterin,Dihydrofolate reductase,DHFR,4.93,IC50,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
atorvastatin,Histone deacetylase 1,HDAC1,4.93,IC50,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
budipine,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,4.93,Ki,CC(C)(C)N1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
ethinylestradiol,Adenosine receptor A2a,ADORA2A,4.93,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
thiamazole,Lactoperoxidase,LPO,4.93,IC50,CN1C=CNC1=S
raloxifene,Nuclear receptor subfamily 1 group I member 2,NR1I2,4.93,EC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sulbactam,ADC-18 protein,adc-18,4.93,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
dexchlorpheniramine,Membrane-associated progesterone receptor component 1,Pgrmc1,4.931,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
diphenhydramine,Cytochrome P450 2D6,CYP2D6,4.932,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
paracetamol,Carbonic anhydrase 4,CA4,4.94,Ki,CC(=O)NC1=CC=C(O)C=C1
acetylcholine,Nicotinic acetylcholine receptor alpha8 subunit,,4.94,EC50,CC(=O)OCC[N+](C)(C)C
chloroxine,Botulinum neurotoxin type A,botA,4.94,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1Cl
cianidanol,Carbonic anhydrase 14,CA14,4.94,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
dasatinib,Quinolone resistance protein NorA,norA,4.94,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
erythromycin propionate,Bile salt export pump,Abcb11,4.94,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
fusidic acid,Bile salt export pump,ABCB11,4.94,IC50,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O
ketorolac,"Fatty acid-binding protein, liver",Fabp1,4.94,Ki,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1
loratadine,Multidrug resistance protein 1,ABCB1,4.94,Ki,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
miconazole,5-hydroxytryptamine receptor 1A,Htr1a,4.94,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
moclobemide,Amine oxidase [flavin-containing] A,MAOA,4.94,Ki,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
raloxifene,Bile acid receptor,NR1H4,4.94,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
rofecoxib,Prostaglandin G/H synthase 1,Ptgs1,4.94,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
tranilast,Hematopoietic prostaglandin D synthase,HPGDS,4.94,IC50,COC1=C(OC)C=C(\C=C\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1
phenol,Carbonic anhydrase 14,CA14,4.94,Ki,OC1=CC=CC=C1
amiodarone,C-C chemokine receptor type 4,CCR4,4.943,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
estradiol,Arachidonate 15-lipoxygenase,ALOX15,4.947,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
candesartan cilexetil,DNULL polymerase eta,POLH,4.95,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
doxepin,Solute carrier family 22 member 1,SLC22A1,4.95,IC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
econazole,"Indoleamine 2,3-dioxygenase 1",Ido1,4.95,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
promazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,4.95,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
propafenone,Solute carrier family 22 member 1,SLC22A1,4.95,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
propofol,GABA A receptor alpha-2/beta-2/gamma-2,GABRG2|GABRA2|GABRB2,4.95,EC50,CC(C)C1=CC=CC(C(C)C)=C1O
quinidine,Multidrug and toxin extrusion protein 1,SLC47A1,4.95,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
rifampicin,Bile salt export pump,ABCB11,4.95,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
salicylic acid,Carbonic anhydrase 4,CA4,4.95,Ki,OC(=O)C1=CC=CC=C1O
paclitaxel,Receptor tyrosine-protein kinase erbB-2,ERBB2,4.954,IC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
lidocaine,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,4.955,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
mifepristone,Sigma non-opioid intracellular receptor 1,SIGMAR1,4.957,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
mestranol,Progesterone receptor,PGR,4.958,Ki,COC1=CC2=C(C=C1)[C@H]1CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@@H]1CC2
econazole,Neuropeptide Y receptor type 2,NPY2R,4.959,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
carbon tetrachloride,Cytochrome P450 2E1,CYP2E1,4.959,IC50,ClC(Cl)(Cl)Cl
empagliflozin,Sodium/glucose cotransporter 4,SLC5A9,4.959,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1
azaribine,Orotidine 5'-phosphate decarboxylase,pyrF,4.96,Ki,CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1N=CC(=O)NC1=O
adenine,Xanthine dehydrogenase/oxidase,XDH,4.96,IC50,NC1=NC=NC2=C1NC=N2
amsacrine,DNA topoisomerase 2-beta,TOP2B,4.96,EC50,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
brompheniramine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,4.96,IC50,CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1
ceftazidime,Penicillin-binding protein 1B,mrcB,4.96,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1)C(O)=O
cefuroxime,Matrix metalloproteinase-9,MMP9,4.96,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C1=CC=CO1
chlorpromazine,Sphingomyelin phosphodiesterase,SMPD1,4.96,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlortalidone,Carbonic anhydrase 3,CA3,4.96,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
clavulanic acid,Carbepenem-hydrolyzing beta-lactamase KPC,bla,4.96,Ki,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
dabigatran etexilate,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,4.96,IC50,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
diclofenac,UDP-glucuronosyltransferase 1-9,UGT1A9,4.96,Ki,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
etomidate,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,4.96,EC50,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
finasteride,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1,HSD3B1,4.96,Ki,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
fluvastatin,Retinoic acid receptor RXR-alpha,RXRA,4.96,Kd,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C1=CC=C(F)C=C1
isoniazid,Cytochrome P450 3A5,CYP3A5,4.96,IC50,NNC(=O)C1=CC=NC=C1
lapatinib,Cyclin-dependent kinase 2,CDK2,4.96,IC50,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
aspartic acid,Excitatory amino acid transporter 4,Slc1a6,4.96,IC50,N[C@@H](CC(O)=O)C(O)=O
masoprocol,"Arachidonate 15-lipoxygenase, type II",ALOX15B,4.96,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
mecamylamine,Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3,CHRNB2|CHRNA3|CHRNB3|CHRNA6,4.96,IC50,CNC1(C)C2CCC(C2)C1(C)C
mecamylamine,Neuronal acetylcholine receptor subunit alpha-6,CHRNA6,4.96,IC50,CNC1(C)C2CCC(C2)C1(C)C
meropenem,Beta-lactamase NDM-1,blaNDM-1,4.96,Kd,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
mexiletine,Sodium channel protein type 1 subunit alpha,SCN1A,4.96,IC50,CC(N)COC1=C(C)C=CC=C1C
mexiletine,Sodium channel protein type 9 subunit alpha,Scn9a,4.96,IC50,CC(N)COC1=C(C)C=CC=C1C
naproxen,Prostaglandin G/H synthase 1,PTGS1,4.96,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
nicardipine,Adenosine receptor A3,Adora3,4.96,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
ofloxacin,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,4.96,IC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
paroxetine,Cytochrome P450 1A2,CYP1A2,4.96,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
penciclovir,Thymidine kinase,TK,4.96,IC50,NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2
perhexiline,"Carnitine O-palmitoyltransferase 1, muscle isoform",Cpt1b,4.96,IC50,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
rabeprazole,Insulin-degrading enzyme,IDE,4.96,IC50,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
rabeprazole,Insulin-degrading enzyme,IDE,4.96,IC50,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
ramatroban,Prostaglandin D2 receptor,PTGDR,4.96,Ki,OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C2=CC=C(F)C=C2)C2=CC=CC=C12
rimantadine,Polymerase acidic protein,PA,4.96,IC50,CC(N)C12CC3CC(CC(C3)C1)C2
rimantadine,Polymerase acidic protein,PA,4.96,IC50,CC(N)C12CC3CC(CC(C3)C1)C2
risperidone,Solute carrier family 22 member 2,SLC22A2,4.96,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sitagliptin,Angiotensin-converting enzyme,ACE,4.96,IC50,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
sitagliptin,Dipeptidyl peptidase 8,DPP8,4.96,IC50,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
sulfadiazine,5-hydroxytryptamine receptor 2B,HTR2B,4.96,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
sunitinib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,4.96,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
troglitazone,Amine oxidase [flavin-containing] B,Maob,4.96,Ki,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
zonisamide,Carbonic anhydrase 12,CA12,4.96,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
quercetin,Aldo-keto reductase family 1 member C21,Akr1c21,4.96,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
prazosin,D(2) dopamine receptor,Drd2,4.96,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
dequalinium,Protein kinase C alpha type,PRKCA,4.96,IC50,CC1=[N+](CCCCCCCCCC[N+]2=C(C)C=C(N)C3=CC=CC=C23)C2=CC=CC=C2C(N)=C1
carfilzomib,Cathepsin B,CTSB,4.96,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
choline fenofibrate,Solute carrier family 22 member 12,SLC22A12,4.96,IC50,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O
eugenol,Prostaglandin G/H synthase 1,PTGS1,4.96,IC50,COC1=CC(CC=C)=CC=C1O
rifamycin,Solute carrier organic anion transporter family member 1A2,SLCO1A2,4.96,Ki,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O
dexrabeprazole,Insulin-degrading enzyme,IDE,4.96,IC50,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
dexrabeprazole,Insulin-degrading enzyme,IDE,4.96,IC50,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
pitolisant,Histamine H2 receptor,HRH2,4.96,Ki,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
abemaciclib,Potassium voltage-gated channel subfamily H member 2,KCNH2,4.96,IC50,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
terconazole,Tyrosine-protein kinase Fyn,FYN,4.963,IC50,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
ethinylestradiol,Mu-type opioid receptor,OPRM1,4.964,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
amiodarone,Melanocortin receptor 3,MC3R,4.967,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
chlorphenamine,Cytochrome P450 2D6,CYP2D6,4.967,Ki,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
paracetamol,Carbonic anhydrase 14,CA14,4.97,Ki,CC(=O)NC1=CC=C(O)C=C1
caffeine,Adenosine receptor A1,ADORA1,4.97,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
famotidine,Solute carrier family 22 member 3,SLC22A3,4.97,IC50,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
gossypol,Kinesin-like protein 1,KIF11,4.97,IC50,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
imiquimod,Toll-like receptor 7,TLR7,4.97,EC50,CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12
sulpiride,Carbonic anhydrase 3,CA3,4.97,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
troglitazone,Bile salt export pump,Abcb11,4.97,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
vesnarinone,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,4.97,IC50,COC1=C(OC)C=C(C=C1)C(=O)N1CCN(CC1)C1=CC=C2NC(=O)CCC2=C1
bithionol,N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D,NAPEPLD,4.97,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
bufexamac,Histone deacetylase 6,HDAC6,4.97,Kd,CCCCOC1=CC=C(CC(=O)NO)C=C1
gabexate,Multidrug and toxin extrusion protein 2,SLC47A2,4.97,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
hydroquinone,Carbonic anhydrase 1,CA1,4.97,Ki,OC1=CC=C(O)C=C1
hydroquinone,Carbonic anhydrase 4,CA4,4.97,Ki,OC1=CC=C(O)C=C1
hydroquinone,Carbonic anhydrase 15,Ca15,4.97,Ki,OC1=CC=C(O)C=C1
resorcinol,Carbonic anhydrase 14,CA14,4.97,Ki,OC1=CC(O)=CC=C1
danazol,Alpha-2B adrenergic receptor,ADRA2B,4.976,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
amantadine,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,4.98,Ki,NC12CC3CC(CC(C3)C1)C2
carbimazole,Lactoperoxidase,LPO,4.98,IC50,CCOC(=O)N1C=CN(C)C1=S
cianidanol,Carbonic anhydrase 13,CA13,4.98,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
dextromethorphan,Solute carrier family 22 member 1,SLC22A1,4.98,IC50,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
escitalopram,Transporter,NET,4.98,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
fludarabine phosphate,Adenosine receptor A3,Adora3,4.98,Ki,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
fosfomycin,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,4.98,IC50,C[C@@H]1O[C@@H]1P(O)(O)=O
lidocaine,Sodium channel protein type 3 subunit alpha,SCN3A,4.98,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
losartan,Platelet glycoprotein VI,GP6,4.98,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
metiazinic acid,Prostaglandin G/H synthase 2,PTGS2,4.98,IC50,CN1C2=CC=CC=C2SC2=C1C=C(CC(O)=O)C=C2
niclosamide,Epidermal growth factor receptor,EGFR,4.98,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
nitazoxanide,Pyruvate-flavodoxin oxidoreductase,,4.98,Ki,CC(=O)OC1=C(C=CC=C1)C(=O)NC1=NC=C(S1)[N+]([O-])=O
pentamidine,Coagulation factor X,F10,4.98,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pentamidine,Coagulation factor X,F10,4.98,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pitavastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,4.98,IC50,O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=C(C=CC=C2)N=C1C1CC1)CC(O)=O
selegiline,Amine oxidase [flavin-containing] A,Maoa,4.98,Ki,C[C@H](CC1=CC=CC=C1)N(C)CC#C
sorivudine,"Thymidine kinase, mitochondrial",TK2,4.98,Ki,OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O
levothyroxine,Transthyretin,TTR,4.98,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
troglitazone,Amine oxidase [flavin-containing] A,MAOA,4.98,Ki,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
suramin,P2X purinoceptor 2,P2rx2,4.98,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
suramin,Signal transducer and activator of transcription 5B,STAT5B,4.98,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
phenol,Carbonic anhydrase 15,Ca15,4.98,Ki,OC1=CC=CC=C1
diethylstilbestrol,Vasopressin V1a receptor,AVPR1A,4.983,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
amiodarone,Histamine H2 receptor,HRH2,4.984,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
ethinylestradiol,Kappa-type opioid receptor,OPRK1,4.985,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
tinoridine,Adenosine receptor A1,ADORA1,4.987,EC50,CCOC(=O)C1=C(N)SC2=C1CCN(CC1=CC=CC=C1)C2
benzbromarone,Eyes absent homolog 2,EYA2,4.99,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
caffeine,Guanine deaminase,GDA,4.99,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
celecoxib,Beta-carbonic anhydrase 1,mtcA1,4.99,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
danazol,D(1A) dopamine receptor,DRD1,4.99,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
diethazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,4.99,IC50,CCN(CC)CCN1C2=CC=CC=C2SC2=C1C=CC=C2
lopinavir,Multidrug resistance protein 1,ABCB1,4.99,IC50,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
methysergide,Cytoplasmic zinc-finger protein,pos-1,4.99,EC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nateglinide,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,4.99,Ki,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O
nifekalant,Solute carrier family 22 member 2,SLC22A2,4.99,IC50,CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N+]([O-])=O)N(C)C1=O
pamabrom,Adenosine receptor A1,Adora1,4.99,Ki,CN1C2=C(N=C(Br)N2)C(=O)N(C)C1=O
diosmin,Lysine-specific histone demethylase 1A,KDM1A,4.99,IC50,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1
diosmin,Lysine-specific histone demethylase 1A,KDM1A,4.99,IC50,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1
quercetin,Macrophage metalloelastase,MMP12,4.99,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Hypoxia-inducible factor 1-alpha inhibitor,HIF1AN,4.99,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
clotrimazole,5-hydroxytryptamine receptor 1A,HTR1A,4.995,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
astemizole,Beta-1 adrenergic receptor,ADRB1,4.998,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
econazole,5-hydroxytryptamine receptor 1B,Htr1b,4.999,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acebutolol,5-hydroxytryptamine receptor 1A,Htr1a,5,Ki,CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1
paracetamol,Carbonic anhydrase 1,CA1,5,Ki,CC(=O)NC1=CC=C(O)C=C1
aclarubicin,72 kDa type IV collagenase,MMP2,5,IC50,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C2=C(O)C3=C(C=C2[C@H]1C(=O)OC)C(=O)C1=CC=CC(O)=C1C3=O
adenosine,Phosphatidylinositol 4-kinase type 2-alpha,PI4K2A,5,IC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
adenosine,Phosphatidylinositol 4-kinase type 2-beta,PI4K2B,5,IC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
alcuronium,Muscarinic acetylcholine receptor M1,CHRM1,5,Kd,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
amiloride,Acid-sensing ion channel 1,ASIC1,5,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
amiloride,Membrane primary amine oxidase,Aoc3,5,Ki,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
amiodarone,Potassium voltage-gated channel subfamily H member 2,KCNH2,5,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amitriptyline,Potassium voltage-gated channel subfamily H member 2,KCNH2,5,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amitriptylinoxide,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5,IC50,C[N+](C)([O-])CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amoxapine,Cytochrome P450 2D6,CYP2D6,5,IC50,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
amsacrine,DNA topoisomerase 2-alpha,TOP2A,5,IC50,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
androstenediol,Corticosteroid-binding globulin,SERPINA6,5,Ki,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O
atenolol,5-hydroxytryptamine receptor 1A,Htr1a,5,Ki,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
bepridil,Potassium voltage-gated channel subfamily KQT member 4,KCNQ4,5,IC50,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
bisacodyl,Cytochrome P450 2C9,CYP2C9,5,IC50,CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1
buspirone,Alpha-2A adrenergic receptor,ADRA2A,5,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
buspirone,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
carbenicillin,Muscarinic acetylcholine receptor M3,CHRM3,5,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
ceftriaxone,D-amino-acid oxidase,DAO,5,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(=O)NN3C)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
chlorhexidine,Synaptojanin-2,SYNJ2,5,IC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
chloroquine,Alpha-2C adrenergic receptor,ADRA2C,5,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
chlorphenamine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5,IC50,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
cilostazol,Cytochrome P450 2C9,CYP2C9,5,IC50,O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1
clomifene,Cytochrome P450 2D6,CYP2D6,5,IC50,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
clonidine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,Hcn4,5,IC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
prasterone,Corticosteroid-binding globulin,SERPINA6,5,Ki,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O
disulfiram,Lysine-specific demethylase 5A,KDM5A,5,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
dopamine,Beta-1 adrenergic receptor,ADRB1,5,Ki,NCCC1=CC(O)=C(O)C=C1
dopamine,Beta-1 adrenergic receptor,Adrb1,5,Ki,NCCC1=CC(O)=C(O)C=C1
doxazosin,Multidrug resistance protein 1,ABCB1,5,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
enoxacin,"V-type proton ATPase subunit B, brain isoform",ATP6V1B2,5,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
estradiol,Corticosteroid-binding globulin,SERPINA6,5,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
estriol succinate,Corticosteroid-binding globulin,SERPINA6,5,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
flecainide,Potassium voltage-gated channel subfamily D member 2,Kcnd2,5,IC50,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
flupirtine,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,5,EC50,CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1
aminobutyric acid,Gamma-aminobutyric acid receptor subunit alpha-1,Gabra1,5,EC50,NCCCC(O)=O
glutamic acid,Metabotropic glutamate receptor 1,Grm1,5,EC50,N[C@@H](CCC(O)=O)C(O)=O
haloperidol,Muscarinic acetylcholine receptor M3,CHRM3,5,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ibuproxam,Cyclooxygenase,Ptgs2|Ptgs1,5,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO
imatinib,Insulin receptor,INSR,5,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Tyrosine-protein kinase JAK2,JAK2,5,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,5,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Fibroblast growth factor receptor 1,FGFR1,5,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Fibroblast growth factor receptor 2,FGFR2,5,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Ephrin type-B receptor 1,EPHB1,5,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Ephrin type-B receptor 4,EPHB4,5,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imidapril,Angiotensin-converting enzyme,ACE,5,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O
imipramine,Major prion protein,PRNP,5,EC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
indapamide,Carbonic anhydrase 1,CA1,5,Kd,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
irbesartan,Endothelin-1 receptor,EDNRA,5,Ki,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
fluostigmine,Lysosomal protective protein,CTSA,5,IC50,CC(C)OP(F)(=O)OC(C)C
ketanserin,5-hydroxytryptamine receptor 1A,HTR1A,5,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
lamotrigine,Sodium channel protein type 2 subunit alpha,SCN2A,5,IC50,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
leflunomide,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,5,IC50,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
loperamide,Aldehyde oxidase,AOX1,5,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
losartan,Type-2 angiotensin II receptor,AGTR2,5,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
loxoprofen,Prostaglandin G/H synthase 2,PTGS2,5,IC50,CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1
megestrol acetate,Cytochrome P450 2C9,CYP2C9,5,IC50,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
methamphetamine,5-hydroxytryptamine receptor 2B,HTR2B,5,Ki,CN[C@@H](C)CC1=CC=CC=C1
metoprolol,5-hydroxytryptamine receptor 1A,Htr1a,5,Ki,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
mexiletine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5,IC50,CC(N)COC1=C(C)C=CC=C1C
mezlocillin,Carbonic anhydrase 2,CA2,5,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
mifepristone,Nuclear receptor subfamily 1 group I member 2,NR1I2,5,EC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
miglustat,Glycogen debranching enzyme,AGL,5,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
molindone,5-hydroxytryptamine receptor 2C,HTR2C,5,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
molindone,Muscarinic acetylcholine receptor M3,CHRM3,5,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
niclosamide,Proto-oncogene tyrosine-protein kinase Src,SRC,5,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
niclosamide,Tyrosine-protein kinase JAK2,JAK2,5,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
nicotine,Transient receptor potential cation channel subfamily A member 1,Trpa1,5,EC50,CN1CCC[C@H]1C1=CC=CN=C1
nicotine,Transient receptor potential cation channel subfamily A member 1,Trpa1,5,EC50,CN1CCC[C@H]1C1=CC=CN=C1
nifekalant,Potassium voltage-gated channel subfamily H member 2,KCNH2,5,IC50,CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N+]([O-])=O)N(C)C1=O
niflumic acid,Chloride channel protein ClC-Ka,CLCNKA,5,EC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
niflumic acid,Chloride channel protein ClC-Kb,CLCNKB,5,EC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
nitrendipine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
ondansetron,Muscarinic acetylcholine receptor M1,Chrm1,5,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
ondansetron,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,5,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
paroxetine,Beta-1 adrenergic receptor,ADRB1,5,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
phentolamine,Cytochrome P450 2D6,CYP2D6,5,IC50,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
oxagrelate,Phosphodiesterase 1,PDE1A|PDE1B|PDE1C,5,Ki,CCOC(=O)C1=C(C)C2=C(C=C1C)C(CO)=NNC2=O
pindolol,5-hydroxytryptamine receptor 2A,HTR2A,5,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
quinidine,Sodium channel protein type 5 subunit alpha,Scn5a,5,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
regadenoson,Adenosine receptor A2b,ADORA2B,5,EC50,CNC(=O)C1=CN(N=C1)C1=NC(N)=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=N1
regadenoson,Adenosine receptor A3,ADORA3,5,Ki,CNC(=O)C1=CN(N=C1)C1=NC(N)=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=N1
risperidone,Muscarinic acetylcholine receptor M3,CHRM3,5,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
rosiglitazone,Retinoic acid receptor gamma,RARG,5,Ki,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
salicylic acid,Carbonic anhydrase 1,CA1,5,Ki,OC(=O)C1=CC=CC=C1O
strychnine,Muscarinic acetylcholine receptor M1,CHRM1,5,Kd,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
strychnine,Muscarinic acetylcholine receptor M2,CHRM2,5,Kd,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
strychnine,Muscarinic acetylcholine receptor M4,CHRM4,5,Kd,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
sulconazole,"Indoleamine 2,3-dioxygenase 2",Ido2,5,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
sunitinib,Mitogen-activated protein kinase 7,MAPK7,5,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tretoquinol,Adrenergic receptor alpha,Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a,5,Ki,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
triamterene,Cytochrome P450 2D6,CYP2D6,5,IC50,NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1
vancomycin,UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase,murG,5,IC50,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(C=C(O)C=C3O)[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC=C(O4)C(Cl)=C1)C(O)=O)C(Cl)=C2
verapamil,Two pore calcium channel protein 2,TPCN2,5,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
ziprasidone,Muscarinic acetylcholine receptor M3,CHRM3,5,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
chlorquinaldol,Botulinum neurotoxin type A,botA,5,IC50,CC1=NC2=C(O)C(Cl)=CC(Cl)=C2C=C1
cholic acid,G-protein coupled bile acid receptor 1,GPBAR1,5,EC50,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
estriol,Corticosteroid-binding globulin,SERPINA6,5,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
estrone,Corticosteroid-binding globulin,SERPINA6,5,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
linoleic acid,Peroxisome proliferator-activated receptor delta,PPARD,5,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
protoporphyrin,Cytoplasmic zinc-finger protein,pos-1,5,EC50,CC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O
pyridoxal phosphate,P2X purinoceptor 1,P2RX1,5,IC50,CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O
quercetin,C-C chemokine receptor type 4,CCR4,5,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
paliperidone,Prostaglandin E2 receptor EP3 subtype,PTGER3,5,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
rimonabant,N-arachidonyl glycine receptor,GPR18,5,IC50,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
linagliptin,Dipeptidyl peptidase IV,DPP IV,5,IC50,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1
retigabine,Potassium voltage-gated channel subfamily KQT member 5,KCNQ5,5,EC50,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
prazosin,Solute carrier family 22 member 1,SLC22A1,5,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
prazosin,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
axitinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,5,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Serine/threonine-protein kinase ULK2,ULK2,5,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
phenol,Carbonic anhydrase 1,CA1,5,Ki,OC1=CC=CC=C1
aceclidine,Muscarinic acetylcholine receptor M1,CHRM1,5,EC50,CC(=O)OC1CN2CCC1CC2
laropiprant,Prostaglandin F2-alpha receptor,PTGFR,5,Ki,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
racepinefrine,Alpha-1A adrenergic receptor,ADRA1A,5,Ki,CNCC(O)C1=CC(O)=C(O)C=C1
esatenolol,Beta-2 adrenergic receptor,ADRB2,5,Ki,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
esatenolol,5-hydroxytryptamine receptor 1A,Htr1a,5,Ki,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
olaparib,Poly [ADP-ribose] polymerase 12,PARP12,5,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
migalastat,Glycogen debranching enzyme,AGL,5,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
fedratinib,Dual specificity mitogen-activated protein kinase kinase 4,MAP2K4,5,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ozanimod,Sphingosine 1-phosphate receptor 3,S1PR3,5,EC50,CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1
umbralisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,5,Kd,C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
umbralisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",PIK3CB,5,Kd,C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
tamoxifen,Beta-1 adrenergic receptor,ADRB1,5.001,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
saquinavir,Delta-type opioid receptor,OPRD1,5.003,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
amiodarone,Adenosine receptor A3,ADORA3,5.004,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
salmeterol,Aldehyde oxidase,AOX1,5.004,IC50,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
fluphenazine,Kappa-type opioid receptor,OPRK1,5.005,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
econazole,Adenosine receptor A1,ADORA1,5.006,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
danazol,D(3) dopamine receptor,DRD3,5.009,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
ketoconazole,Membrane-associated progesterone receptor component 1,Pgrmc1,5.009,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nelfinavir,Substance-K receptor,TACR2,5.009,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
ouabain,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.009,IC50,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O
cefapirin,D(4) dopamine receptor,DRD4,5.01,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
dobutamine,Carbonic anhydrase 9,CA9,5.01,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
gefitinib,Quinolone resistance protein NorA,norA,5.01,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
hexachlorophene,N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D,NAPEPLD,5.01,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
methadone,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.01,IC50,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
phenylpropanolamine,Alpha-1A adrenergic receptor,Adra1a,5.01,Ki,CC(N)C(O)C1=CC=CC=C1
pilocarpine,Muscarinic acetylcholine receptor M2,Chrm2,5.01,Ki,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
sorafenib,Tyrosine-protein kinase Srms,SRMS,5.01,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulbactam,"Serine beta-lactamase-like protein LACTB, mitochondrial",LACTB,5.01,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
theophylline,Adenosine receptor A1,ADORA1,5.01,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
tubocurarine,Neuronal acetylcholine receptor; alpha4/beta2,Chrna4|Chrnb2,5.01,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
zafirlukast,Solute carrier family 22 member 2,SLC22A2,5.01,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
hydroquinone,Polyphenol oxidase 2,PPO2,5.01,IC50,OC1=CC=C(O)C=C1
rasagiline,Amine oxidase [flavin-containing] A,MAOA,5.01,Ki,C#CCN[C@@H]1CCC2=C1C=CC=C2
ruboxistaurin,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,5.01,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
sitaxentan,Endothelin B receptor,EDNRB,5.01,IC50,CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl
tioxolone,Amine oxidase [flavin-containing] A,MAOA,5.01,IC50,OC1=CC2=C(SC(=O)O2)C=C1
doconexent,Prostaglandin G/H synthase 2,PTGS2,5.01,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
ceritinib,Tyrosine-protein kinase ZAP-70,ZAP70,5.01,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
fedratinib,Receptor-interacting serine/threonine-protein kinase 4,RIPK4,5.01,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Myosin light chain kinase 3,MYLK3,5.01,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
roxadustat,Alpha-ketoglutarate-dependent dioxygenase FTO,FTO,5.01,IC50,CC1=C2C=C(OC3=CC=CC=C3)C=CC2=C(O)C(=N1)C(=O)NCC(O)=O
nifedipine,5-hydroxytryptamine receptor 2C,HTR2C,5.019,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
racecadotril,Thermolysin,npr,5.02,IC50,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1
dobutamine,Carbonic anhydrase 6,CA6,5.02,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
dobutamine,Carbonic anhydrase 13,CA13,5.02,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
erlotinib,Tyrosine-protein kinase CSK,CSK,5.02,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethoxzolamide,Carbonic anhydrase 3,CA3,5.02,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
fluindione,Arachidonate 5-lipoxygenase,Alox5,5.02,IC50,FC1=CC=C(C=C1)C1C(=O)C2=C(C=CC=C2)C1=O
flunarizine,Kappa-type opioid receptor,OPRK1,5.02,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
memantine,"Glutamate receptor ionotropic, NMDA 1",GRIN1,5.02,IC50,CC12CC3CC(C)(C1)CC(N)(C3)C2
levomepromazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.02,IC50,COC1=CC2=C(SC3=CC=CC=C3N2C[C@H](C)CN(C)C)C=C1
miltefosine,RAC-alpha serine/threonine-protein kinase,AKT1,5.02,IC50,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
mitoxantrone,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Dyrk1a,5.02,AC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
pentamidine,Solute carrier family 22 member 3,SLC22A3,5.02,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
phenylpropanolamine,Alpha-1B adrenergic receptor,ADRA1B,5.02,Ki,CC(N)C(O)C1=CC=CC=C1
sorafenib,LIM domain kinase 2,LIMK2,5.02,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Myosin light chain kinase 3,MYLK3,5.02,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfanilamide,Carbonic anhydrase 15,Ca15,5.02,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulfasalazine,Sodium/bile acid cotransporter,SLC10A1,5.02,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
sulfasalazine,Sodium/bile acid cotransporter,SLC10A1,5.02,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
troglitazone,Amine oxidase [flavin-containing] B,MAOB,5.02,Ki,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
enoxolone,Tyrosine-protein phosphatase non-receptor type 11,PTPN11,5.02,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
rutoside,Alpha-2C adrenergic receptor,ADRA2C,5.02,Ki,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
tioxolone,Amine oxidase [flavin-containing] B,MAOB,5.02,IC50,OC1=CC2=C(SC(=O)O2)C=C1
serine,Asc-type amino acid transporter 1,Slc7a10,5.02,IC50,N[C@@H](CO)C(O)=O
phenol,Carbonic anhydrase 4,CA4,5.02,Ki,OC1=CC=CC=C1
fedratinib,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,DYRK1B,5.02,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase D3,PRKD3,5.02,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ozanimod,Sphingosine 1-phosphate receptor 2,S1PR2,5.02,EC50,CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1
chlorambucil,Aldose reductase,Akr1b1,5.026,IC50,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
lovastatin,Substance-K receptor,TACR2,5.027,Ki,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
mianserin,Sodium-dependent dopamine transporter,SLC6A3,5.027,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
zimeldine,Sodium-dependent noradrenaline transporter,SLC6A2,5.027,Ki,CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CN=CC=C1
ketoconazole,Muscarinic acetylcholine receptor M2,CHRM2,5.028,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
misoprostol,Prostaglandin F2-alpha receptor,PTGFR,5.028,Ki,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
miconazole,5-hydroxytryptamine receptor 1B,Htr1b,5.029,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
paracetamol,Carbonic anhydrase 15,Ca15,5.03,Ki,CC(=O)NC1=CC=C(O)C=C1
aminohippuric acid,Solute carrier family 22 member 6,Slc22a6,5.03,Ki,NC1=CC=C(C=C1)C(=O)NCC(O)=O
atovaquone,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,5.03,IC50,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O
caffeine,Adenosine receptor A2a,Adora2a,5.03,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
citalopram,Sodium-dependent dopamine transporter,Slc6a3,5.03,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
coumarin,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.03,Ki,O=C1OC2=CC=CC=C2C=C1
dasatinib,Aurora kinase A,AURKA,5.03,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desipramine,Sodium-dependent serotonin transporter,Slc6a4,5.03,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
diflunisal,Carbonic anhydrase 2,CA2,5.03,Ki,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
edetic acid,Beta-lactamase VIM-1; Class B carbapenemase VIM-1; Metallo-beta-lactamase; Metallo-beta-lactamase VIM-1; Metallobeta-lactamase; VIM-1; VIM-1 metallo-beta lactamase; VIM-1 metallo-beta-lactamase; VIM-1,blaVIM,5.03,IC50,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
erlotinib,Serine/threonine-protein kinase 17B,STK17B,5.03,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
galantamine,Cholinesterase,BCHE,5.03,Ki,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
gatifloxacin,DNA gyrase subunit A,gyrA,5.03,IC50,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1
kanamycin,Gap junction beta-2 protein,GJB2,5.03,IC50,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
aspartic acid,Excitatory amino acid transporter 1,SLC1A3,5.03,IC50,N[C@@H](CC(O)=O)C(O)=O
ofloxacin,Trypsin,,5.03,AC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
pemetrexed,Trifunctional purine biosynthetic protein adenosine-3,Gart,5.03,Ki,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
sulfanilamide,Beta-carbonic anhydrase 1,mtcA1,5.03,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
thioridazine,Cytochrome P450 1A2,CYP1A2,5.03,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tubocurarine,Multidrug and toxin extrusion protein 1,SLC47A1,5.03,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
suramin,Reverse transcriptase/RNaseH,pol,5.03,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
suramin,Signal transducer and activator of transcription 5A,STAT5A,5.03,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
iloperidone,Gastrin/cholecystokinin type B receptor,CCKBR,5.03,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
quercetin,Carbonic anhydrase 12,CA12,5.03,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
rutoside,Alpha-2A adrenergic receptor,ADRA2A,5.03,Ki,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
tonzonium,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Dyrk1a,5.03,AC50,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1
fedratinib,Serine/threonine-protein kinase B-raf,BRAF,5.03,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
propofol,Sodium-dependent noradrenaline transporter,SLC6A2,5.031,Ki,CC(C)C1=CC=CC(C(C)C)=C1O
celecoxib,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,5.033,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
stanozolol,Cytochrome P450 2D6,CYP2D6,5.033,IC50,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=NN5
econazole,5-hydroxytryptamine receptor 1A,HTR1A,5.034,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
tamoxifen,Histamine H2 receptor,HRH2,5.034,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
amiodarone,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.039,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
paracetamol,Carbonic anhydrase 7,CA7,5.04,Ki,CC(=O)NC1=CC=C(O)C=C1
alpidem,Bile salt export pump,ABCB11,5.04,IC50,CCCN(CCC)C(=O)CC1=C(N=C2C=CC(Cl)=CN12)C1=CC=C(Cl)C=C1
anisindione,Arachidonate 5-lipoxygenase,Alox5,5.04,IC50,COC1=CC=C(C=C1)C1C(=O)C2=C(C=CC=C2)C1=O
bisoprolol,Beta-3 adrenergic receptor,ADRB3,5.04,Ki,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
bortezomib,Lysosomal protective protein,CTSA,5.04,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
bupropion,Sodium-dependent serotonin transporter,SLC6A4,5.04,Kd,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
camylofin,Solute carrier family 22 member 1,SLC22A1,5.04,IC50,CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1
cefonicid,Matrix metalloproteinase-9,MMP9,5.04,IC50,O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
chloroquine,Muscarinic acetylcholine receptor M1,CHRM1,5.04,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
clemizole,Short transient receptor potential channel 3,TRPC3,5.04,IC50,ClC1=CC=C(CN2C(CN3CCCC3)=NC3=C2C=CC=C3)C=C1
coumarin,Carbonic anhydrase 2,CA2,5.04,Ki,O=C1OC2=CC=CC=C2C=C1
coumarin,Carbonic anhydrase 9,CA9,5.04,Ki,O=C1OC2=CC=CC=C2C=C1
coumarin,Carbonic anhydrase 13,Ca13,5.04,Ki,O=C1OC2=CC=CC=C2C=C1
ditiocarb,Histone-lysine N-methyltransferase EHMT2,EHMT2,5.04,IC50,CCN(CC)C(S)=S
dopamine,Melatonin receptor type 1B,MTNR1B,5.04,Ki,NCCC1=CC(O)=C(O)C=C1
doxycycline,"Tetracycline resistance protein, class B",tetA,5.04,IC50,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C(O)C=CC=C12
hexachlorophene,78 kDa glucose-regulated protein,HSPA5,5.04,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
orciprenaline,Beta-2 adrenergic receptor,ADRB2,5.04,Kd,CC(C)NCC(O)C1=CC(O)=CC(O)=C1
moxifloxacin,DNA gyrase subunit A,gyrA,5.04,IC50,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1C[C@@H]2CCCN[C@@H]2C1)C1CC1
nateglinide,Solute carrier family 22 member 6,Slc22a6,5.04,Ki,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O
oxacillin,"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A",PDE11A,5.04,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=CC=CC=C1
phencyclidine,Muscarinic acetylcholine receptor,Chrm1|Chrm4|Chrm5|Chrm3|Chrm2,5.04,Kd,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
repaglinide,Solute carrier family 22 member 1,SLC22A1,5.04,IC50,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N2CCCCC2)=C1)C(O)=O
riluzole,Short transient receptor potential channel 5,TRPC5,5.04,EC50,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
selegiline,Amine oxidase [flavin-containing] A,MAOA,5.04,Ki,C[C@H](CC1=CC=CC=C1)N(C)CC#C
sildenafil,Uncharacterized protein,PDE3B,5.04,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
tubocurarine,Small conductance calcium-activated potassium channel protein 3,Kcnn3,5.04,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
suramin,Signal transducer and activator of transcription 1-alpha/beta,STAT1,5.04,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
quercetin,Carbonic anhydrase 13,Ca13,5.04,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
phenol,Carbonic anhydrase 12,CA12,5.04,Ki,OC1=CC=CC=C1
quizartinib,Ephrin type-A receptor 6,EPHA6,5.04,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
dexfenfluramine,5-hydroxytryptamine receptor 6,HTR6,5.042,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
fenfluramine,5-hydroxytryptamine receptor 6,HTR6,5.042,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
chlorpromazine,Substance-K receptor,TACR2,5.043,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
amiodarone,5-hydroxytryptamine receptor 6,HTR6,5.045,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
chlorpropamide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,5.046,Kd,CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
donepezil,Sodium-dependent serotonin transporter,SLC6A4,5.046,Ki,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
tolbutamide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,5.046,Kd,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1
fluphenazine,Melanocortin receptor 5,MC5R,5.049,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
flutamide,Androgen receptor,Ar,5.049,Ki,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
adenosine,Adenosine kinase,AK,5.05,Ki,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
amiodarone,Melanocortin receptor 5,MC5R,5.05,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
candesartan cilexetil,Cytochrome P450 3A4,CYP3A4,5.05,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
cefotetan,Prostaglandin G/H synthase 2,PTGS2,5.05,IC50,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
celiprolol,5-hydroxytryptamine receptor 1A,Htr1a,5.05,Ki,CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1
cocaine,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.05,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
coumarin,Carbonic anhydrase 12,CA12,5.05,Ki,O=C1OC2=CC=CC=C2C=C1
dactinomycin,Discoidin domain-containing receptor 2,DDR2,5.05,IC50,CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2=C3N=C4C(OC3=C(C)C=C2)=C(C)C(=O)C(N)=C4C(=O)N[C@H]2[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]3CCCN3C(=O)[C@H](NC2=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O
diethylstilbestrol,Cysteinyl leukotriene receptor 1,CYSLTR1,5.05,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
dipyridamole,ORF 73,,5.05,AC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
dobutamine,Carbonic anhydrase 4,CA4,5.05,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
ibuprofen,Prostaglandin G/H synthase 1,PTGS1,5.05,Ki,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
ibuprofen,Prostaglandin G/H synthase 2,PTGS2,5.05,Ki,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
ketoconazole,Cytochrome P450 21,CYP21A2,5.05,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
meclofenamic acid,"Fatty acid-binding protein, intestinal",FABP2,5.05,Ki,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
miglustat,Lysosomal alpha-glucosidase,Gaa,5.05,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nimodipine,Bile acid receptor,NR1H4,5.05,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nitrendipine,Adenosine receptor A1,Adora1,5.05,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
papaverine,Phosphodiesterase 1,PDE1A|PDE1B|PDE1C,5.05,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
rilmenidine,Alpha-1A adrenergic receptor,ADRA1A,5.05,Ki,C1CC1C(NC1=NCCO1)C1CC1
sitosterol,Amine oxidase [flavin-containing] A,Maoa,5.05,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sitosterol,Amine oxidase [flavin-containing] A,Maoa,5.05,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sulfathiazole,Transcriptional activator protein LasR,lasR,5.05,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1
sunitinib,Tankyrase-2,TNKS2,5.05,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
trifluoperazine,Lysozyme C-1,Lyz1,5.05,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
protoporphyrin,Zinc finger protein mex-5,mex-5,5.05,EC50,CC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O
quercetin,Death-associated protein kinase 1,DAPK1,5.05,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
tipranavir,Cathepsin E,CTSE,5.05,Ki,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC(NS(=O)(=O)C3=CC=C(C=N3)C(F)(F)F)=CC=C2)C(=O)O1
dodecanoic acid,G-protein coupled receptor 84,GPR84,5.05,EC50,CCCCCCCCCCCC(O)=O
tenidap,Arachidonate 5-lipoxygenase,Alox5,5.05,IC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
rucaparib,Poly [ADP-ribose] polymerase 14,PARP14,5.05,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
fedratinib,Misshapen-like kinase 1,MINK1,5.05,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
diethylstilbestrol,Cysteinyl leukotriene receptor 1,CYSLTR1,5.052,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
econazole,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.052,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
danazol,Substance-K receptor,TACR2,5.053,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
nitrendipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.056,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
nelfinavir,Sodium-dependent noradrenaline transporter,SLC6A2,5.057,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
clotrimazole,Substance-P receptor,TACR1,5.058,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
cefapirin,Delta-type opioid receptor,OPRD1,5.06,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
chlorzoxazone,"Nitric oxide synthase, endothelial",NOS3,5.06,IC50,ClC1=CC2=C(OC(=O)N2)C=C1
cibenzoline,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.06,IC50,C1C(C2=NCCN2)C1(C1=CC=CC=C1)C1=CC=CC=C1
dilazep,Equilibrative nucleoside transporter 2,Slc29a2,5.06,IC50,COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN1CCCN(CCCOC(=O)C2=CC(OC)=C(OC)C(OC)=C2)CC1
domperidone,Retinoic acid receptor RXR-alpha,RXRA,5.06,Kd,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
estriol succinate,Arachidonate 15-lipoxygenase,ALOX15,5.06,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
galantamine,Acetylcholinesterase,ACHE,5.06,IC50,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
imatinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,5.06,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
mafenide,Beta-carbonic anhydrase 1,mtcA1,5.06,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
masoprocol,Zinc finger protein mex-5,mex-5,5.06,EC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
meclofenamic acid,Aldo-keto reductase family 1 member C2,AKR1C2,5.06,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
nilotinib,Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma,PIP4K2C,5.06,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
papaverine,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,5.06,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
papaverine,Phosphodiesterase 1,PDE1A|PDE1B,5.06,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
propylthiouracil,Thyroid peroxidase,TPO,5.06,IC50,CCCC1=CC(=O)NC(=S)N1
salicylic acid,Carbonic anhydrase 12,CA12,5.06,Ki,OC(=O)C1=CC=CC=C1O
sorafenib,Cyclin-dependent kinase 2,CDK2,5.06,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfasalazine,Carbonic anhydrase 2,CA2,5.06,Ki,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
suprofen,Prostaglandin G/H synthase 2,PTGS2,5.06,IC50,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
thioridazine,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,5.06,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
quercetin,Cytochrome P450 1A1,CYP1A1,5.06,EC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
resorcinol,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.06,Ki,OC1=CC(O)=CC=C1
ruboxistaurin,RAC-beta serine/threonine-protein kinase,AKT2,5.06,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,BMP-2-inducible protein kinase,BMP2K,5.06,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
telaprevir,Plasminogen,PLG,5.06,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
ruxolitinib,Aurora kinase C,AURKC,5.06,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
phenol,Carbonic anhydrase 9,CA9,5.06,Ki,OC1=CC=CC=C1
ethyl hydroxybenzoate,Carbonic anhydrase 7,CA7,5.06,Ki,CCOC(=O)C1=CC=C(O)C=C1
tedizolid phosphate,Amine oxidase [flavin-containing] A,MAOA,5.06,IC50,CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O
midostaurin,Tyrosine-protein kinase CSK,CSK,5.06,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Cyclin-dependent kinase 9,CDK9,5.06,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
chlorpromazine,Tyrosine-protein kinase Fyn,FYN,5.061,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
lovastatin,Sodium-dependent noradrenaline transporter,SLC6A2,5.061,Ki,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
paliperidone,Histamine H4 receptor,HRH4,5.061,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
estrone,5-hydroxytryptamine receptor 2B,HTR2B,5.062,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
estriol,Arachidonate 15-lipoxygenase,ALOX15,5.064,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
astemizole,Substance-P receptor,TACR1,5.065,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
dexchlorpheniramine,Alpha-1B adrenergic receptor,Adra1b,5.065,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
diiodohydroxyquinoline,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.067,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
paroxetine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.068,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
nilotinib,Tyrosine-protein kinase JAK2,JAK2,5.069,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
tamoxifen,Substance-P receptor,TACR1,5.069,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
amitriptyline,Sodium-dependent serotonin transporter,Slc6a4,5.07,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
bortezomib,Carbonic anhydrase 13,CA13,5.07,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
cianidanol,Polyphenol oxidase 2,PPO2,5.07,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
cianidanol,Polyphenol oxidase 2,PPO2,5.07,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
clavulanic acid,Beta-lactamase,blaTEM-125,5.07,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
diflunisal,Carbonic anhydrase 1,CA1,5.07,Ki,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
etravirine,Multidrug resistance-associated protein 1,ABCC1,5.07,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
fluvoxamine,Cytochrome P450 1A2,CYP1A2,5.07,Ki,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F
gallamine,Muscarinic acetylcholine receptor M1,CHRM1,5.07,Ki,CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
lapatinib,Platelet-derived growth factor receptor beta,PDGFRB,5.07,IC50,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
lopinavir,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.07,IC50,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
pargyline,Amine oxidase [flavin-containing] A,Maoa,5.07,Ki,CN(CC#C)CC1=CC=CC=C1
phenylpropanolamine,Alpha-1D adrenergic receptor,Adra1d,5.07,Ki,CC(N)C(O)C1=CC=CC=C1
sorafenib,Tyrosine-protein kinase HCK,HCK,5.07,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
topotecan,Multidrug and toxin extrusion protein 2,SLC47A2,5.07,IC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
trazodone,Sodium-dependent noradrenaline transporter,SLC6A2,5.07,Kd,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
tyramine,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,5.07,Kd,NCCC1=CC=C(O)C=C1
zonisamide,Carbonic anhydrase 4,CA4,5.07,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
zonisamide,Carbonic anhydrase 3,CA3,5.07,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
oleic acid,Telomerase reverse transcriptase,TERT,5.07,IC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
quercetin,Collagenase 3,MMP13,5.07,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
chlorthenoxazine,Poly [ADP-ribose] polymerase 1,PARP1,5.07,IC50,ClCCC1NC(=O)C2=CC=CC=C2O1
clobetasol propionate,Bile salt export pump,ABCB11,5.07,IC50,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
ethyl hydroxybenzoate,Carbonic anhydrase 12,CA12,5.07,Ki,CCOC(=O)C1=CC=C(O)C=C1
nintedanib,Ephrin type-A receptor 3,EPHA3,5.07,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
quizartinib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,5.07,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Cyclin-dependent kinase 15,CDK15,5.07,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,NT-3 growth factor receptor,NTRK3,5.07,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
voxelotor,Cytochrome P450 2C9,CYP2C9,5.07,IC50,CC(C)N1N=CC=C1C1=C(COC2=C(C=O)C(O)=CC=C2)C=CC=N1
imipramine,Sodium-dependent dopamine transporter,SLC6A3,5.071,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
norepinephrine,Sodium-dependent dopamine transporter,SLC6A3,5.071,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
fluphenazine,Delta-type opioid receptor,OPRD1,5.072,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
nimodipine,Adenosine receptor A3,ADORA3,5.072,Ki,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
tofogliflozin,Sodium/glucose cotransporter 1,SLC5A1,5.073,IC50,CCC1=CC=C(CC2=CC3=C(CO[C@]33O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C2)C=C1
fluphenazine,Mu-type opioid receptor,OPRM1,5.075,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
phenelzine,Sodium-dependent dopamine transporter,SLC6A3,5.076,Ki,NNCCC1=CC=CC=C1
nelfinavir,Adenosine receptor A3,ADORA3,5.078,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
benzbromarone,Eyes absent homolog 3,EYA3,5.08,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
dichlorophen,Solute carrier family 22 member 1,SLC22A1,5.08,IC50,OC1=C(CC2=C(O)C=CC(Cl)=C2)C=C(Cl)C=C1
dorzolamide,Carbonic anhydrase 2,CAN2,5.08,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
erlotinib,SRSF protein kinase 3,SRPK3,5.08,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
estramustine phosphate,Tyrosine-protein phosphatase non-receptor type 11,PTPN11,5.08,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2OP(O)(O)=O
hesperetin,Replicase polyprotein 1ab,rep,5.08,IC50,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
isoniazid,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,5.08,IC50,NNC(=O)C1=CC=NC=C1
methamphetamine,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.08,Ki,CN[C@@H](C)CC1=CC=CC=C1
thiamazole,Lactoperoxidase,LPO,5.08,IC50,CN1C=CNC1=S
nifedipine,Adenosine receptor A3,ADORA3,5.08,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
aminobenzoic acid,Carbonic anhydrase 1,CA1,5.08,Ki,NC1=CC=C(C=C1)C(O)=O
phentolamine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.08,IC50,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
probenecid,Solute carrier family 22 member 20,Slc22a20,5.08,Ki,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
ranitidine,Multidrug and toxin extrusion protein 1,SLC47A1,5.08,IC50,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O
rifampicin,Caspase-1,CASP1,5.08,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
sertaconazole,"Indoleamine 2,3-dioxygenase 1",IDO1,5.08,IC50,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl
sorafenib,Tyrosine-protein kinase Fyn,FYN,5.08,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
iloperidone,Muscarinic acetylcholine receptor M4,CHRM4,5.08,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
ruboxistaurin,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,5.08,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,5.08,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
prazosin,D(4) dopamine receptor,DRD4,5.08,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
aceclidine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,5.08,Ki,CC(=O)OC1CN2CCC1CC2
tenidap,Prostaglandin G/H synthase 2,PTGS2,5.08,IC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
pitolisant,Cholinesterase,BCHE,5.08,IC50,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
pitolisant,Cholinesterase,BCHE,5.08,IC50,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
neratinib,Macrophage-stimulating protein receptor,MST1R,5.08,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
amisulpride,5-hydroxytryptamine receptor 2A,HTR2A,5.081,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
nitrendipine,Adenosine receptor A3,ADORA3,5.081,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
empagliflozin,Sodium/glucose cotransporter 1,SLC5A1,5.081,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1
flutamide,5-hydroxytryptamine receptor 6,HTR6,5.082,Ki,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
dopamine,5-hydroxytryptamine receptor 1A,HTR1A,5.084,Ki,NCCC1=CC(O)=C(O)C=C1
ketoconazole,Alpha-2B adrenergic receptor,ADRA2B,5.084,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
dexchlorpheniramine,Histamine H2 receptor,HRH2,5.085,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
econazole,Adenosine receptor A2a,ADORA2A,5.086,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
danazol,Sodium-dependent serotonin transporter,SLC6A4,5.087,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
noscapine,Cytochrome P450 2C9,CYP2C9,5.087,IC50,COC1=CC=C2[C@H](OC(=O)C2=C1OC)[C@@H]1N(C)CCC2=C1C(OC)=C1OCOC1=C2
nifedipine,Sodium/nucleoside cotransporter 1,SLC28A1,5.089,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
carmustine,"Glutathione reductase, mitochondrial",GSR,5.09,IC50,ClCCNC(=O)N(CCCl)N=O
dabigatran etexilate,Multidrug and toxin extrusion protein 1,SLC47A1,5.09,IC50,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
diflunisal,Prostaglandin G/H synthase 2,PTGS2,5.09,IC50,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
econazole,"Indoleamine 2,3-dioxygenase 1",IDO1,5.09,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
escitalopram,Sodium-dependent dopamine transporter,Slc6a3,5.09,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
ethinylestradiol,Androgen receptor,Ar,5.09,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
fenbufen,Prostaglandin G/H synthase 2,PTGS2,5.09,IC50,OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
fluconazole,Cytochrome P450 2C19,CYP2C19,5.09,IC50,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
aminobutyric acid,Sodium- and chloride-dependent GABA transporter 3,Slc6a11,5.09,IC50,NCCCC(O)=O
hymecromone,Carbonic anhydrase 12,CA12,5.09,Ki,CC1=CC(=O)OC2=C1C=CC(O)=C2
lansoprazole,"Indoleamine 2,3-dioxygenase 2",Ido2,5.09,IC50,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
linezolid,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",SDHA,5.09,IC50,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
lumefantrine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.09,IC50,CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\C2=C\C1=CC=C(Cl)C=C1
nifedipine,Potassium channel subfamily K member 2,Kcnk2,5.09,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nitazoxanide,Aldose reductase,AKR1B1,5.09,IC50,CC(=O)OC1=C(C=CC=C1)C(=O)NC1=NC=C(S1)[N+]([O-])=O
aminobenzoic acid,Carbonic anhydrase 2,CA2,5.09,Ki,NC1=CC=C(C=C1)C(O)=O
sorafenib,Carbonic anhydrase 7,CA7,5.09,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Carbonic anhydrase 7,CA7,5.09,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
terfenadine,Cytochrome P450 2J2,CYP2J2,5.09,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
varenicline,Acetylcholine receptor; alpha1/beta1/delta/gamma,CHRNA1|CHRNG|CHRNB1|CHRND,5.09,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
bithionol,Estrogen receptor beta,ESR2,5.09,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
ethacridine,Telomerase reverse transcriptase,TERT,5.09,IC50,CCOC1=CC2=C(N)C3=CC=C(N)C=C3N=C2C=C1
hydroquinone,Carbonic anhydrase 3,CA3,5.09,Ki,OC1=CC=C(O)C=C1
quercetin,Carbonic anhydrase 3,CA3,5.09,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Replicase polyprotein 1ab,rep,5.09,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
silodosin,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.09,IC50,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
crizotinib,SRSF protein kinase 3,SRPK3,5.09,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ethyl hydroxybenzoate,Carbonic anhydrase 9,CA9,5.09,Ki,CCOC(=O)C1=CC=C(O)C=C1
ibrutinib,Tyrosine-protein kinase Fer,FER,5.09,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
safinamide,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,5.09,IC50,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O
fedratinib,Ribosomal protein S6 kinase alpha-3,RPS6KA3,5.09,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Protein kinase C epsilon type,PRKCE,5.09,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
voxelotor,hemoglobin subunit alpha,HBA1,5.09,EC50,CC(C)N1N=CC=C1C1=C(COC2=C(C=O)C(O)=CC=C2)C=CC=N1
flupentixol,5-hydroxytryptamine receptor 1A,HTR1A,5.095,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
lovastatin,Sodium-dependent dopamine transporter,SLC6A3,5.095,Ki,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
mifepristone,Kappa-type opioid receptor,OPRK1,5.095,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
tamoxifen,Tyrosine-protein kinase Lck,LCK,5.095,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
nilotinib,Fibroblast growth factor receptor 1,FGFR1,5.096,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
aripiprazole,5-hydroxytryptamine receptor 1E,HTR1E,5.097,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
domperidone,Cytochrome P450 2D6,CYP2D6,5.097,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
fluphenazine,Tyrosine-protein kinase Fyn,FYN,5.097,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
miconazole,Adenosine receptor A2a,ADORA2A,5.097,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
palbociclib,Ribosomal protein S6 kinase alpha-1,RPS6KA1,5.097,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
nelfinavir,Tyrosine-protein kinase Fyn,FYN,5.098,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
acetylcholine,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,5.1,Ki,CC(=O)OCC[N+](C)(C)C
amiodarone,Squalene synthase,FDFT1,5.1,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amlodipine,Alpha-1B adrenergic receptor,ADRA1B,5.1,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
apomorphine,Transient receptor potential cation channel subfamily A member 1,TRPA1,5.1,EC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
astemizole,Histamine H4 receptor,HRH4,5.1,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
benziodarone,Baculoviral IAP repeat-containing protein 5,BIRC5,5.1,Kd,CCC1=C(C(=O)C2=CC(I)=C(O)C(I)=C2)C2=C(O1)C=CC=C2
buprenorphine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.1,IC50,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
cimetidine,Multidrug and toxin extrusion protein 2,SLC47A2,5.1,Ki,CNC(NCCSCC1=C(C)NC=N1)=NC#N
clonidine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2,Hcn2,5.1,IC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
cocaine,Kappa-type opioid receptor,OPRK1,5.1,IC50,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
diacerein,Caspase-3,CASP3,5.1,EC50,CC(=O)OC1=C2C(=O)C3=C(OC(C)=O)C=C(C=C3C(=O)C2=CC=C1)C(O)=O
dinoprost,Thromboxane A2 receptor,TBXA2R,5.1,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dipyridamole,"High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A",PDE8A,5.1,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
domperidone,Solute carrier family 22 member 2,SLC22A2,5.1,IC50,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
dorzolamide,Carbonic anhydrase 3,CA3,5.1,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
epoprostenol,Prostaglandin E2 receptor EP4 subtype,PTGER4,5.1,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O
flecainide,Potassium voltage-gated channel subfamily A member 7,KCNA7,5.1,Kd,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
fluconazole,Cytochrome P450 3A4,CYP3A4,5.1,IC50,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
flucytosine,5-hydroxytryptamine receptor 2A,HTR2A,5.1,IC50,NC1=NC(=O)NC=C1F
galantamine,Butyrylcholinesterase,BCHE,5.1,Ki,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
indomethacin,Prostaglandin G/H synthase 1,PTGS1,5.1,Ki,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
irinotecan,Multidrug and toxin extrusion protein 2,SLC47A2,5.1,IC50,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
isoxicam,Prostaglandin G/H synthase 1,PTGS1,5.1,IC50,CN1C(C(=O)NC2=NOC(C)=C2)=C(O)C2=CC=CC=C2S1(=O)=O
levorphanol,Solute carrier family 22 member 1,SLC22A1,5.1,IC50,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
levorphanol,Solute carrier family 22 member 1,SLC22A1,5.1,IC50,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
linezolid,Amine oxidase [flavin-containing] A,MAOA,5.1,Ki,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
methoxamine,Alpha-1A adrenergic receptor,ADRA1A,5.1,EC50,COC1=CC(C(O)C(C)N)=C(OC)C=C1
nalidixic acid,5-hydroxytryptamine receptor 2B,HTR2B,5.1,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC=C(C)N=C12
paclitaxel,Nucleotide-binding oligomerization domain-containing protein 2,NOD2,5.1,IC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
promethazine,Major prion protein,PRNP,5.1,EC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
raltitrexed,Thymidylate synthase,thyA,5.1,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
rizatriptan,5-hydroxytryptamine receptor 2A,HTR2A,5.1,IC50,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
rizatriptan,5-hydroxytryptamine receptor 2C,HTR2C,5.1,IC50,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
sorafenib,TRAF2 and NCK-interacting protein kinase,TNIK,5.1,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfanilamide,Carbonic anhydrase,,5.1,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
levothyroxine,Bile acid receptor,NR1H4,5.1,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
tilidine,Mu-type opioid receptor,OPRM1,5.1,EC50,CCOC(=O)C1(CCC=CC1N(C)C)C1=CC=CC=C1
verapamil,Potassium voltage-gated channel subfamily A member 3,KCNA3,5.1,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
vinburnine,Muscarinic acetylcholine receptor M1,CHRM1,5.1,Kd,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C1=CC=CC=C41)C(=O)C2
vinpocetine,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",PDE1A,5.1,IC50,CCOC(=O)C1=C[C@]2(CC)CCCN3CCC4=C([C@H]23)N1C1=CC=CC=C41
eburnamonine,Muscarinic acetylcholine receptor M1,CHRM1,5.1,Kd,CC[C@]12CCCN3CCC4=C([C@@H]13)N(C1=CC=CC=C41)C(=O)C2
quercetin,Carbonic anhydrase 4,CA4,5.1,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Amyloid beta A4 protein,APP,5.1,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
vincamine,Muscarinic acetylcholine receptor M2,CHRM2,5.1,Kd,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C1=CC=CC=C41)[C@](O)(C2)C(=O)OC
vandetanib,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,5.1,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
aceclidine,Muscarinic acetylcholine receptor M3,CHRM3,5.1,EC50,CC(=O)OC1CN2CCC1CC2
aceclidine,Muscarinic acetylcholine receptor M5,CHRM5,5.1,EC50,CC(=O)OC1CN2CCC1CC2
racepinefrine,Alpha-1B adrenergic receptor,ADRA1B,5.1,Ki,CNCC(O)C1=CC(O)=C(O)C=C1
methylnaltrexone,Cytochrome P450 2D6,CYP2D6,5.1,Ki,C[N+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
ethyl hydroxybenzoate,Carbonic anhydrase 1,CA1,5.1,Ki,CCOC(=O)C1=CC=C(O)C=C1
ceritinib,Tyrosine-protein kinase JAK3,JAK3,5.1,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
cariprazine,D(1B) dopamine receptor,DRD5,5.1,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
neratinib,Protein-tyrosine kinase 2-beta,PTK2B,5.1,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,LIM domain kinase 2,LIMK2,5.1,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase LATS2,LATS2,5.1,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
voxelotor,Cytochrome P450 2C8,CYP2C8,5.1,IC50,CC(C)N1N=CC=C1C1=C(COC2=C(C=O)C(O)=CC=C2)C=CC=N1
terconazole,Alpha-1B adrenergic receptor,Adra1b,5.102,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
clotrimazole,Sodium-dependent noradrenaline transporter,SLC6A2,5.104,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,Adenosine receptor A1,ADORA1,5.106,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
isoflurane,5-hydroxytryptamine receptor 2B,HTR2B,5.109,Ki,FC(F)OC(Cl)C(F)(F)F
miconazole,Type-2 angiotensin II receptor,AGTR2,5.109,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
aminoglutethimide,Aromatase,CYP19A1,5.11,IC50,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1
apomorphine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.11,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
celecoxib,Prostaglandin G/H synthase 1,PTGS1,5.11,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
celecoxib,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,5.11,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cefapirin,Cytochrome P450 3A5,CYP3A5,5.11,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
cianidanol,Carbonic anhydrase 15,Ca15,5.11,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
edetic acid,Amyloid beta A4 protein,APP,5.11,IC50,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
emetine,Putative hydrolase RBBP9,RBBP9,5.11,IC50,CC[C@H]1CN2CCC3=CC(OC)=C(OC)C=C3[C@@H]2C[C@@H]1C[C@H]1NCCC2=CC(OC)=C(OC)C=C12
etravirine,Canalicular multispecific organic anion transporter 1,ABCC2,5.11,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
imatinib,Serine/threonine-protein kinase PLK4,PLK4,5.11,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indinavir,Multidrug and toxin extrusion protein 2,SLC47A2,5.11,IC50,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
labetalol,CAAX prenyl protease 1,STE24,5.11,AC50,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
mesalazine,Prostaglandin G/H synthase 1,PTGS1,5.11,IC50,NC1=CC(C(O)=O)=C(O)C=C1
mesalazine,Prostaglandin G/H synthase 1,PTGS1,5.11,IC50,NC1=CC(C(O)=O)=C(O)C=C1
mesalazine,Hydroxyacid oxidase 1,Hao1,5.11,IC50,NC1=CC(C(O)=O)=C(O)C=C1
metoclopramide,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,5.11,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
metoclopramide,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.11,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
perhexiline,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.11,IC50,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
sildenafil,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,5.11,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,Tyrosine-protein kinase Fgr,FGR,5.11,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulbactam,Beta-lactamase,adc-16,5.11,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulfaethidole,RAC-alpha serine/threonine-protein kinase,AKT1,5.11,Kd,CCC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1
sulfanilamide,Astrosclerin-3,,5.11,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Megakaryocyte-associated tyrosine-protein kinase,MATK,5.11,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
testosterone,C-8 sterol isomerase,ERG2,5.11,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
tranylcypromine,7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,CYP8B1,5.11,IC50,N[C@@H]1C[C@H]1C1=CC=CC=C1
trifluoperazine,Beta-glucuronidase,Gusb,5.11,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
valdecoxib,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,5.11,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
hydroquinone,Carbonic anhydrase 12,CA12,5.11,Ki,OC1=CC=C(O)C=C1
pyrithione,Carbonic anhydrase 7,CA7,5.11,Ki,[O-][N+]1=C(S)C=CC=C1
quercetin,D(4) dopamine receptor,DRD4,5.11,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
resorcinol,Carbonic anhydrase 2,CA2,5.11,Ki,OC1=CC(O)=CC=C1
ruboxistaurin,Calcium/calmodulin-dependent protein kinase type II subunit gamma,CAMK2G,5.11,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
crizotinib,Tyrosine-protein kinase BTK,BTK,5.11,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ethyl hydroxybenzoate,Carbonic anhydrase 14,CA14,5.11,Ki,CCOC(=O)C1=CC=C(O)C=C1
midostaurin,Rho-associated protein kinase 1,ROCK1,5.11,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Casein kinase I isoform gamma-3,CSNK1G3,5.11,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Ephrin type-A receptor 8,EPHA8,5.11,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fenfluramine,Beta-2 adrenergic receptor,ADRB2,5.111,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
sulprostone,Prostaglandin E2 receptor EP4 subtype,PTGER4,5.111,Ki,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
estrone,Androgen receptor,Ar,5.111,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
amiodarone,Mu-type opioid receptor,OPRM1,5.112,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
clotrimazole,Androgen receptor,Ar,5.112,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
amiodarone,B2 bradykinin receptor,BDKRB2,5.115,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
disulfiram,D(2) dopamine receptor,DRD2,5.115,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
dexchlorpheniramine,Alpha-2A adrenergic receptor,ADRA2A,5.118,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
bromperidol,Muscarinic acetylcholine receptor M1,CHRM1,5.119,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
propofol,Arachidonate 15-lipoxygenase,ALOX15,5.119,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
rabeprazole,5-hydroxytryptamine receptor 1D,HTR1D,5.119,Ki,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
acetylsalicylic acid,Prostaglandin G/H synthase 2,PTGS2,5.12,IC50,CC(=O)OC1=CC=CC=C1C(O)=O
amfetamine,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,5.12,Ki,CC(N)CC1=CC=CC=C1
amsacrine,Cytochrome P450 2D6,CYP2D6,5.12,Ki,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
carbachol,Acetylcholine receptor subunit alpha,CHRNA1,5.12,IC50,C[N+](C)(C)CCOC(N)=O
carvedilol,Potassium channel subfamily K member 10,KCNK10,5.12,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
carvedilol,Solute carrier family 22 member 2,SLC22A2,5.12,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
chlorhexidine,72 kDa type IV collagenase,MMP2,5.12,IC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
chlorhexidine,Matrix metalloproteinase-9,MMP9,5.12,IC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
clotrimazole,5-hydroxytryptamine receptor 2C,HTR2C,5.12,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
econazole,"Indoleamine 2,3-dioxygenase 2",Ido2,5.12,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
etravirine,Multidrug resistance protein 1,ABCB1,5.12,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
gefitinib,Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma,PIP4K2C,5.12,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
halofantrine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.12,Ki,CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F
ibuprofen,Prostaglandin G/H synthase 1,PTGS1,5.12,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
imatinib,Epidermal growth factor receptor,EGFR,5.12,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
iproniazid,Amine oxidase [flavin-containing] B,Maob,5.12,IC50,CC(C)NNC(=O)C1=CC=NC=C1
iproniazid,Amine oxidase [flavin-containing] B,MAOB,5.12,IC50,CC(C)NNC(=O)C1=CC=NC=C1
lapatinib,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma,PIK3C2G,5.12,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
levosulpiride,Myeloperoxidase,MPO,5.12,IC50,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
mesalazine,Prostaglandin G/H synthase 2,PTGS2,5.12,IC50,NC1=CC(C(O)=O)=C(O)C=C1
oxametacin,Arachidonate 5-lipoxygenase,Alox5,5.12,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)NO
phenelzine,FAD-linked sulfhydryl oxidase ALR,GFER,5.12,AC50,NNCCC1=CC=CC=C1
primaquine,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,5.12,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
promethazine,Sodium-dependent serotonin transporter,SLC6A4,5.12,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
propafenone,Potassium channel subfamily K member 2,KCNK2,5.12,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
sorafenib,Mitogen-activated protein kinase 12,MAPK12,5.12,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Dual specificity protein kinase CLK1,CLK1,5.12,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,5.12,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
thiamphenicol,Cytochrome P450 2C19,CYP2C19,5.12,IC50,CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl
zafirlukast,Multidrug and toxin extrusion protein 2,SLC47A2,5.12,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
eicosapentaenoic acid,Retinoic acid receptor RXR-alpha,RXRA,5.12,Ki,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
eicosapentaenoic acid,Retinoic acid receptor RXR-alpha,RXRA,5.12,Ki,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
quercetin,Serine/threonine-protein kinase B-raf,BRAF,5.12,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
resorcinol,Carbonic anhydrase 12,CA12,5.12,Ki,OC1=CC(O)=CC=C1
meprylcaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.12,IC50,CCCNC(C)(C)COC(=O)C1=CC=CC=C1
vorinostat,Leukotriene A-4 hydrolase,LTA4H,5.12,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
nintedanib,Casein kinase II subunit alpha,CSNK2A1,5.12,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
fedratinib,Serine/threonine-protein kinase 26,STK26,5.12,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,5.12,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cepharanthine,Trypanothione reductase,TPR,5.12,Ki,COC1=C2OC3=CC=C(C[C@@H]4N(C)CCC5=CC6=C(OCO6)C(OC6=C(OC)C=C7CCN(C)[C@H](CC(C=C1)=C2)C7=C6)=C45)C=C3
abametapir,C-C chemokine receptor type 8,CCR8,5.12,EC50,CC1=CN=C(C=C1)C2=NC=C(C=C2)C
vadadustat,Vascular endothelial growth factor A,VEGFA,5.12,EC50,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
vadadustat,Vascular endothelial growth factor A,VEGFA,5.12,EC50,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
fluphenazine,Substance-K receptor,TACR2,5.125,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
ebastine,Acetylcholinesterase,ACHE,5.126,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
disulfiram,5-hydroxytryptamine receptor 6,HTR6,5.129,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
buspirone,Cytochrome P450 3A4,CYP3A4,5.13,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
celecoxib,Carbonic anhydrase 3,CA3,5.13,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cycloserine,"Glutamate receptor ionotropic, NMDA 1",Grin1,5.13,IC50,N[C@@H]1CONC1=O
dobutamine,Carbonic anhydrase 3,CA3,5.13,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
erlotinib,Focal adhesion kinase 1,PTK2,5.13,IC50,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
furosemide,Solute carrier family 12 member 2,SLC12A2,5.13,IC50,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
gliclazide,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,5.13,Ki,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1
haloperidol,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,5.13,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ibandronic acid,Farnesyl pyrophosphate synthase,Fdps,5.13,IC50,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
imatinib,Carbonic anhydrase 13,Ca13,5.13,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
ketoconazole,Alpha-2A adrenergic receptor,ADRA2A,5.13,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
losartan,Type-2 angiotensin II receptor,Agtr2,5.13,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
mafenide,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,5.13,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mezlocillin,"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A",PDE11A,5.13,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
miglustat,Ceramide glucosyltransferase,UGCG,5.13,Ki,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
quinidine,Cholinesterase,BCHE,5.13,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
ribavirin,Adenosine receptor A1,ADORA1,5.13,Ki,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
ribavirin,Adenosine receptor A1,ADORA1,5.13,Ki,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
tolcapone,G-protein coupled receptor 35,GPR35,5.13,EC50,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
trazodone,Sodium-dependent dopamine transporter,SLC6A3,5.13,Kd,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
triamterene,Cathepsin G,CTSG,5.13,IC50,NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1
triflupromazine,Cholinesterase,BCHE,5.13,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
kainic acid,Glutamate receptor 1,GRIA1,5.13,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
kojic acid,Tyrosinase,TYR,5.13,IC50,OCC1=CC(=O)C(O)=CO1
tirilazad,Mitogen-activated protein kinase 14,MAPK14,5.13,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
axitinib,"Interferon-induced, double-stranded RNA-activated protein kinase",EIF2AK2,5.13,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
trypan blue,Tyrosine-protein phosphatase 1,PTP1,5.13,IC50,CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O
neratinib,Serine/threonine-protein kinase PAK 6,PAK6,5.13,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Ribosomal protein S6 kinase alpha-1,RPS6KA1,5.13,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
econazole,Beta-1 adrenergic receptor,ADRB1,5.131,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
clotrimazole,5-hydroxytryptamine receptor 2B,HTR2B,5.132,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,Alpha-1D adrenergic receptor,ADRA1D,5.132,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
chlorpromazine,Delta-type opioid receptor,OPRD1,5.133,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
estradiol benzoate,5-hydroxytryptamine receptor 2B,HTR2B,5.133,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
miconazole,Adenosine receptor A1,ADORA1,5.136,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miconazole,Beta-1 adrenergic receptor,ADRB1,5.137,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lesinurad,Solute carrier family 22 member 12,SLC22A12,5.137,IC50,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1
aminoquinuride,Botulinum neurotoxin type A,botA,5.14,IC50,CC1=NC2=CC=C(NC(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=C2C(N)=C1
beraprost,Prostaglandin E2 receptor EP4 subtype,PTGER4,5.14,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12
bicalutamide,Progesterone receptor,Pgr,5.14,Ki,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
bortezomib,Beta-carbonic anhydrase 1,mtcA1,5.14,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
caffeine,Acetylcholinesterase,ACHE,5.14,IC50,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
celecoxib,Sodium-dependent noradrenaline transporter,SLC6A2,5.14,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
citric acid,3-dehydroquinate dehydratase,aroQ,5.14,Kd,OC(=O)CC(O)(CC(O)=O)C(O)=O
cladribine,Adenosine receptor A1,Adora1,5.14,Ki,NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1
cocaine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.14,IC50,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
cyclovalone,Transcription factor AP-1,JUN,5.14,IC50,COC1=C(O)C=CC(C=C2CCCC(=CC3=CC(OC)=C(O)C=C3)C2=O)=C1
diacerein,Female germline-specific tumor suppressor gld-1,gld-1,5.14,IC50,CC(=O)OC1=C2C(=O)C3=C(OC(C)=O)C=C(C=C3C(=O)C2=CC=C1)C(O)=O
erlotinib,G protein-coupled receptor kinase 4,GRK4,5.14,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fluoxetine,Histamine H3 receptor,HRH3,5.14,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
aminobutyric acid,Sodium- and chloride-dependent GABA transporter 1,Slc6a1,5.14,IC50,NCCCC(O)=O
gemfibrozil,CDGSH iron-sulfur domain-containing protein 1,CISD1,5.14,Ki,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1
griseofulvin,Solute carrier family 22 member 1,SLC22A1,5.14,IC50,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC
hexachlorophene,Envelope glycoprotein gp160,env,5.14,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
ibuprofen,Prostaglandin G/H synthase 2,PTGS2,5.14,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
imatinib,Multidrug resistance protein 1,ABCB1,5.14,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
masoprocol,Transthyretin,TTR,5.14,EC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
papaverine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.14,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
phenelzine,Cytochrome P450 2C8,CYP2C8,5.14,Ki,NNCCC1=CC=CC=C1
rimantadine,Multidrug and toxin extrusion protein 1,SLC47A1,5.14,IC50,CC(N)C12CC3CC(CC(C3)C1)C2
salicylic acid,Carbonic anhydrase 15,Ca15,5.14,Ki,OC(=O)C1=CC=CC=C1O
sorafenib,Tyrosine-protein kinase JAK3,JAK3,5.14,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
tiludronic acid,72 kDa type IV collagenase,MMP2,5.14,IC50,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O
gentisic acid,Carbonic anhydrase 12,CA12,5.14,Ki,OC(=O)C1=C(O)C=CC(O)=C1
androstanolone,Progesterone receptor,PGR,5.14,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
androstanolone,Progesterone receptor,PGR,5.14,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
pazopanib,Serine/threonine-protein kinase SIK2,SIK2,5.14,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Serine/threonine-protein kinase Nek5,NEK5,5.14,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
diosmetin,Inositol polyphosphate multikinase,IPMK,5.14,IC50,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O)C=C2O1
benzoin,Liver carboxylesterase 1,CES1,5.14,Ki,OC(C(=O)C1=CC=CC=C1)C1=CC=CC=C1
midostaurin,Epithelial discoidin domain-containing receptor 1,DDR1,5.14,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Cyclin-dependent kinase 19,CDK19,5.14,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Serine/threonine-protein kinase 25,STK25,5.14,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,MAP kinase-interacting serine/threonine-protein kinase 1,MKNK1,5.14,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Cyclin-dependent kinase-like 5,CDKL5,5.14,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
nilotinib,Fibroblast growth factor receptor 2,FGFR2,5.141,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
fluphenazine enanthate,Muscarinic acetylcholine receptor M2,CHRM2,5.145,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
bromperidol,Muscarinic acetylcholine receptor M3,CHRM3,5.146,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
chlorpromazine,Melanocortin receptor 5,MC5R,5.146,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
tamoxifen,Mu-type opioid receptor,OPRM1,5.146,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
clotrimazole,Adenosine receptor A2a,ADORA2A,5.147,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
mestranol,Androgen receptor,Ar,5.147,Ki,COC1=CC2=C(C=C1)[C@H]1CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@@H]1CC2
zafirlukast,Leukotriene B4 receptor 1,LTB4R,5.147,Ki,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
bepridil,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.149,Ki,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
paracetamol,Carbonic anhydrase 3,CA3,5.15,Ki,CC(=O)NC1=CC=C(O)C=C1
allopurinol,Xanthine dehydrogenase/oxidase,XDH,5.15,Ki,OC1=NC=NC2=C1C=NN2
buflomedil,C-8 sterol isomerase,ERG2,5.15,Ki,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
dasatinib,Wee1-like protein kinase,WEE1,5.15,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Bone morphogenetic protein receptor type-1A,BMPR1A,5.15,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diazepam,Thyrotropin-releasing hormone receptor,Trhr,5.15,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
donepezil,Cholinesterase,Bche,5.15,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
dopamine,Melatonin receptor type 1A,MTNR1A,5.15,Ki,NCCC1=CC(O)=C(O)C=C1
erlotinib,Ribosomal protein S6 kinase alpha-4,RPS6KA4,5.15,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethambutol,5-hydroxytryptamine receptor 2B,HTR2B,5.15,IC50,CC[C@@H](CO)NCCN[C@@H](CC)CO
aminobutyric acid,Sodium- and chloride-dependent GABA transporter 3,SLC6A11,5.15,IC50,NCCCC(O)=O
hexylcaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.15,IC50,CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1
hydralazine,Acetylcholinesterase,ache,5.15,Ki,NNC1=NN=CC2=CC=CC=C12
ketobemidone,Opioid receptor,Sigmar1|Oprd1|Oprk1|Oprm1,5.15,IC50,CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1
arginine hydrochloride,"Nitric oxide synthase, inducible",NOS2,5.15,Kd,N[C@@H](CCCNC(N)=N)C(O)=O
liothyronine,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,5.15,EC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
lomefloxacin,DNA gyrase subunit A,gyrA,5.15,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12
nilotinib,Dual specificity protein kinase CLK4,CLK4,5.15,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
paroxetine,Quinolone resistance protein NorA,norA,5.15,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
periciazine,Acetylcholinesterase,ACHE,5.15,IC50,OC1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C#N)CC1
pranlukast,Cruzipain,,5.15,IC50,O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
reserpine,Quinolone resistance protein NorA,norA,5.15,IC50,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
salicylic acid,Carbonic anhydrase 2,CA2,5.15,Ki,OC(=O)C1=CC=CC=C1O
sildenafil,Phosphodiesterase 3,PDE3B|PDE3A,5.15,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,5-hydroxytryptamine receptor 7,HTR7,5.15,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Myosin-IIIb,MYO3B,5.15,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
trimetaphan,Acetylcholine receptor subunit alpha,CHRNA1,5.15,IC50,O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
zafirlukast,Cysteinyl leukotriene receptor 2,CYSLTR2,5.15,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
zoledronic acid,72 kDa type IV collagenase,MMP2,5.15,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
eicosapentaenoic acid,Prostaglandin G/H synthase 2,PTGS2,5.15,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
quercetin,Multidrug resistance protein 1,ABCB1,5.15,Kd,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Carbonic anhydrase 9,CA9,5.15,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Cationic trypsin,,5.15,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
resorcinol,"Carbonic anhydrase 5B, mitochondrial",CA5B,5.15,Ki,OC1=CC(O)=CC=C1
ruboxistaurin,Platelet-derived growth factor receptor beta,PDGFRB,5.15,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,MAP kinase-interacting serine/threonine-protein kinase 1,MKNK1,5.15,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Aurora kinase A,AURKA,5.15,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
tofacitinib,BMP-2-inducible protein kinase,BMP2K,5.15,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
cridanimod,Trypsin,,5.15,AC50,OC(=O)CN1C2=CC=CC=C2C(=O)C2=CC=CC=C12
fedratinib,Ephrin type-A receptor 3,EPHA3,5.15,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
saquinavir,Vasopressin V1a receptor,AVPR1A,5.153,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
atropine,5-hydroxytryptamine receptor 2A,HTR2A,5.155,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
chlorpromazine,Cytochrome P450 2D6,CYP2D6,5.155,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cimetidine,5-hydroxytryptamine receptor 2A,HTR2A,5.155,Ki,CNC(NCCSCC1=C(C)NC=N1)=NC#N
econazole,Matrix metalloproteinase-9,MMP9,5.155,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
idebenone,Cytochrome P450 3A4,CYP3A4,5.155,IC50,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
mitoxantrone,ATP-binding cassette sub-family G member 2,ABCG2,5.155,Kact,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
phenylpropanolamine,5-hydroxytryptamine receptor 7,HTR7,5.155,Ki,CC(N)C(O)C1=CC=CC=C1
clotrimazole,D(4) dopamine receptor,DRD4,5.156,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
dexfenfluramine,Muscarinic acetylcholine receptor M4,CHRM4,5.156,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
prazosin,Matrix metalloproteinase-9,MMP9,5.157,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
dipyridamole,Arachidonate 15-lipoxygenase,ALOX15,5.158,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
tamoxifen,5-hydroxytryptamine receptor 1A,HTR1A,5.158,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
amiloride,Urokinase-type plasminogen activator,PLAU,5.16,Ki,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
bortezomib,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.16,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
bortezomib,Carbonic anhydrase 7,CA7,5.16,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
bupropion,Sodium-dependent noradrenaline transporter,SLC6A2,5.16,Ki,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
cefmetazole,Insulin-degrading enzyme,IDE,5.16,IC50,CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
cefmetazole,Insulin-degrading enzyme,IDE,5.16,IC50,CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
chloroquine,Beta-secretase 1,BACE1,5.16,IC50,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
chloroquine,Amyloid beta A4 protein,APP,5.16,IC50,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
duloxetine,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,5.16,IC50,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
ethambutol,5-hydroxytryptamine receptor 2C,HTR2C,5.16,IC50,CC[C@@H](CO)NCCN[C@@H](CC)CO
fasudil,C-C motif chemokine 2,CCL2,5.16,IC50,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
flufenamic acid,Transient receptor potential cation channel subfamily A member 1,TRPA1,5.16,EC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
flufenamic acid,Transient receptor potential cation channel subfamily A member 1,TRPA1,5.16,EC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
gefitinib,TRAF2 and NCK-interacting protein kinase,TNIK,5.16,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Myotonin-protein kinase,DMPK,5.16,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
levamfetamine,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,5.16,Kd,C[C@@H](N)CC1=CC=CC=C1
menadione,Dual specificity phosphatase Cdc25A,CDC25A,5.16,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
menadione,M-phase inducer phosphatase 1,CDC25A,5.16,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
naproxen,Prostaglandin G/H synthase 1,PTGS1,5.16,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
pilocarpine,Muscarinic acetylcholine receptor M1,Chrm1,5.16,EC50,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
promethazine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.16,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
quinidine,Sodium channel protein type 5 subunit alpha,SCN5A,5.16,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
ranolazine,Voltage-gated sodium channel Nav1.5 cardiac isoform,SCN5A,5.16,IC50,COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1
sorafenib,TGF-beta receptor type-2,TGFBR2,5.16,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulconazole,Bile acid receptor,NR1H4,5.16,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
sulfasalazine,Carbonic anhydrase 1,CA1,5.16,Ki,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
sunitinib,Cyclin-dependent-like kinase 5,CDK5,5.16,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tazobactam,Carbapenem-hydrolizing beta-lactamase SFC-1,,5.16,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
thioridazine,Serine/threonine-protein kinase pim-1,PIM1,5.16,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
topotecan,UDP-galactopyranose mutase,glf,5.16,AC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
tranylcypromine,Cytochrome P450 2B6,CYP2B6,5.16,IC50,N[C@@H]1C[C@H]1C1=CC=CC=C1
quercetin,ATP-binding cassette sub-family G member 2,ABCG2,5.16,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Adenosine receptor A2a,Adora2a,5.16,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
tiratricol,Sodium/bile acid cotransporter,SLC10A1,5.16,IC50,OC(=O)CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
tiratricol,Sodium/bile acid cotransporter,SLC10A1,5.16,IC50,OC(=O)CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
pazopanib,Tyrosine-protein kinase JAK3,JAK3,5.16,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vernakalant,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.16,IC50,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1
midostaurin,"Interferon-induced, double-stranded RNA-activated protein kinase",EIF2AK2,5.16,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,"Chaperone activity of bc1 complex-like, mitochondrial",COQ8A,5.16,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase PAK 6,PAK6,5.16,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 10,MAP3K10,5.16,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
butenafine,Acetylcholinesterase,ACHE,5.161,IC50,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
mecamylamine,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,5.161,Ki,CNC1(C)C2CCC(C2)C1(C)C
danazol,Alpha-2A adrenergic receptor,ADRA2A,5.163,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
fenofibrate,Sodium-dependent dopamine transporter,SLC6A3,5.164,Ki,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
orphenadrine,Histamine H2 receptor,HRH2,5.165,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
chlorphenamine,5-hydroxytryptamine receptor 2B,HTR2B,5.167,Ki,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
fenfluramine,Muscarinic acetylcholine receptor M4,CHRM4,5.167,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
sertraline,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.167,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
carbidopa,Tyrosine-protein kinase Lck,LCK,5.168,IC50,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
felodipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.168,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
aripiprazole,Muscarinic acetylcholine receptor M1,CHRM1,5.169,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
adenosine triphosphate,P2Y purinoceptor 11,P2RY11,5.17,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
bortezomib,"Carbonic anhydrase 5B, mitochondrial",CA5B,5.17,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
cefapirin,Somatostatin receptor type 4,SSTR4,5.17,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
coumarin,Carbonic anhydrase 4,CA4,5.17,Ki,O=C1OC2=CC=CC=C2C=C1
glibornuride,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,5.17,Ki,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H]1[C@H](O)[C@]2(C)CC[C@H]1C2(C)C
hexamethonium,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,5.17,IC50,C[N+](C)(C)CCCCCC[N+](C)(C)C
kanamycin,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,5.17,IC50,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
mezlocillin,Cytochrome P450 3A4,CYP3A4,5.17,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
miconazole,Cholinesterase,BCHE,5.17,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miconazole,"Indoleamine 2,3-dioxygenase 2",Ido2,5.17,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nilotinib,Serine/threonine-protein kinase 10,STK10,5.17,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
procyclidine,Histamine H1 receptor,Hrh1,5.17,IC50,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
ranolazine,Sodium channel protein type 5 subunit alpha,SCN5A,5.17,IC50,COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1
ropinirole,D(2) dopamine receptor,DRD2,5.17,IC50,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sumatriptan,Multidrug and toxin extrusion protein 1,SLC47A1,5.17,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
tetracaine,cGMP-gated cation channel alpha-1,CNGA1,5.17,Kd,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
theophylline,Adenosine receptor A2a,Adora2a,5.17,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
verapamil,Solute carrier family 22 member 1,SLC22A1,5.17,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
zanamivir,Sialidase 3,NEU3,5.17,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
quercetin,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.17,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
pazopanib,Leukocyte tyrosine kinase receptor,LTK,5.17,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Serine/threonine-protein kinase ULK3,ULK3,5.17,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Receptor-interacting serine/threonine-protein kinase 3,RIPK3,5.17,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Receptor-interacting serine/threonine-protein kinase 3,RIPK3,5.17,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
tofacitinib,Serine/threonine-protein kinase DCLK1,DCLK1,5.17,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
idelalisib,DNA-dependent protein kinase catalytic subunit,PRKDC,5.17,IC50,CC[C@H](NC1=NC=NC2=C1NC=N2)C1=NC2=C(C(F)=CC=C2)C(=O)N1C1=CC=CC=C1
iguratimod,Macrophage migration inhibitory factor,MIF,5.17,IC50,CS(=O)(=O)NC1=CC2=C(C=C1OC1=CC=CC=C1)C(=O)C(NC=O)=CO2
fedratinib,Calcium/calmodulin-dependent protein kinase type II subunit beta,CAMK2B,5.17,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Activin receptor type-1B,ACVR1B,5.17,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
econazole,Androgen receptor,Ar,5.171,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
fluphenazine,Adenosine receptor A3,ADORA3,5.171,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
phenylpropanolamine,Muscarinic acetylcholine receptor M1,CHRM1,5.171,Ki,CC(N)C(O)C1=CC=CC=C1
amprenavir,Thromboxane-A synthase,TBXAS1,5.172,IC50,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
clotrimazole,Multidrug resistance protein 1,ABCB1,5.174,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
orphenadrine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.174,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
progesterone,Sodium/nucleoside cotransporter 1,SLC28A1,5.174,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
amiodarone,Kappa-type opioid receptor,OPRK1,5.176,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amiodarone,D(2) dopamine receptor,DRD2,5.177,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
diethylstilbestrol,Sodium-dependent serotonin transporter,SLC6A4,5.178,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
miconazole,Histamine H2 receptor,HRH2,5.178,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
dexamfetamine,5-hydroxytryptamine receptor 1A,HTR1A,5.18,Ki,C[C@H](N)CC1=CC=CC=C1
dorzolamide,Carbonic anhydrase,,5.18,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
famprofazone,Nuclear receptor subfamily 2 group E member 1,NR2E1,5.18,Kd,CC(C)C1=C(CCN(C)C(C)CC2=CC=CC=C2)N(C)N(C1=O)C1=CC=CC=C1
iproniazid,Amine oxidase [flavin-containing] A,MAOA,5.18,IC50,CC(C)NNC(=O)C1=CC=NC=C1
montelukast,Uracil nucleotide/cysteinyl leukotriene receptor,GPR17,5.18,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
pentoxifylline,Acetylcholinesterase,ACHE,5.18,IC50,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
pioglitazone,Peroxisome proliferator-activated receptor alpha,PPARA,5.18,EC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
piroxicam,Prostaglandin G/H synthase 1,PTGS1,5.18,IC50,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=CC=CC=C2S1(=O)=O
sorafenib,Mitogen-activated protein kinase 13,MAPK13,5.18,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiclomazine,Beta-secretase 1,BACE1,5.18,IC50,ClC1=CC=C2SC3=CC=CC=C3N(CCCN3CCC4(CC3)NC(=O)CS4)C2=C1
bithionol,Multidrug and toxin extrusion protein 2,SLC47A2,5.18,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
gentisic acid,Carbonic anhydrase 9,CA9,5.18,Ki,OC(=O)C1=C(O)C=CC(O)=C1
quercetin,72 kDa type IV collagenase,MMP2,5.18,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
oxedrine,Neuromedin-U receptor 2,NMUR2,5.18,EC50,CNCC(O)C1=CC=C(O)C=C1
darunavir,Multidrug resistance protein 1,ABCB1,5.18,IC50,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1
darunavir,Multidrug resistance protein 1,ABCB1,5.18,IC50,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1
laropiprant,Prostacyclin receptor,PTGIR,5.18,Ki,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
rucaparib,Poly [ADP-ribose] polymerase 12,PARP12,5.18,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
neratinib,Casein kinase I isoform gamma-2,CSNK1G2,5.18,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
roxadustat,Egl nine homolog 3,EGLN3,5.18,IC50,CC1=C2C=C(OC3=CC=CC=C3)C=CC2=C(O)C(=N1)C(=O)NCC(O)=O
pemetrexed,Dihydrofolate reductase,DHFR,5.181,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
estrone,Arachidonate 15-lipoxygenase,ALOX15,5.181,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
miconazole,5-hydroxytryptamine receptor 1A,HTR1A,5.183,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
iprindole,Sodium-dependent dopamine transporter,SLC6A3,5.185,Ki,CN(C)CCCN1C2=C(CCCCCC2)C2=CC=CC=C12
clotrimazole,Beta-1 adrenergic receptor,ADRB1,5.186,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
escitalopram,Sodium-dependent noradrenaline transporter,SLC6A2,5.186,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
clomifene,Histamine H1 receptor,HRH1,5.187,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
ergotamine,Tyrosine-protein kinase Lck,LCK,5.187,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ethylestrenol,Acetylcholinesterase,ACHE,5.187,IC50,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
latanoprost,Prostaglandin E2 receptor EP3 subtype,PTGER3,5.187,Ki,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
lenvatinib,Epidermal growth factor receptor,EGFR,5.187,IC50,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
econazole,Substance-P receptor,TACR1,5.189,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nelfinavir,D(1A) dopamine receptor,DRD1,5.189,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
bortezomib,Carbonic anhydrase 4,CA4,5.19,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
clemizole,Short transient receptor potential channel 4,TRPC4,5.19,IC50,ClC1=CC=C(CN2C(CN3CCCC3)=NC3=C2C=CC=C3)C=C1
clomipramine,Trypanothione reductase,TPR,5.19,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
dasatinib,Serine/threonine-protein kinase Nek2,NEK2,5.19,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Aurora kinase B,AURKB,5.19,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desipramine,Sodium-dependent dopamine transporter,Slc6a3,5.19,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
ditiocarb,Carbonic anhydrase 4,CA4,5.19,Ki,CCN(CC)C(S)=S
dopamine,Sodium-dependent dopamine transporter,SLC6A3,5.19,Ki,NCCC1=CC(O)=C(O)C=C1
emetine,Alpha-1A adrenergic receptor,Adra1a,5.19,IC50,CC[C@H]1CN2CCC3=CC(OC)=C(OC)C=C3[C@@H]2C[C@@H]1C[C@H]1NCCC2=CC(OC)=C(OC)C=C12
erlotinib,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,5.19,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
flecainide,Sodium channel protein type 5 subunit alpha,SCN5A,5.19,IC50,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
hydroxychloroquine,Alpha-2A adrenergic receptor,ADRA2A,5.19,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
ketanserin,5-hydroxytryptamine receptor 1B,HTR1B,5.19,IC50,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
loxoprofen,Prostaglandin G/H synthase 1,PTGS1,5.19,IC50,CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1
methylthioninium chloride,Glutathione reductase,GR3,5.19,IC50,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
propentofylline,Acetylcholinesterase,ACHE,5.19,IC50,CCCN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
rosiglitazone,Bile salt export pump,ABCB11,5.19,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sertindole,Multidrug resistance protein 1,ABCB1,5.19,IC50,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sulbactam,Beta-lactamase,blaZ,5.19,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulconazole,"Indoleamine 2,3-dioxygenase 1",IDO1,5.19,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
thioridazine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.19,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
trifluoperazine,Multidrug resistance protein 1,ABCB1,5.19,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
zafirlukast,Sodium/bile acid cotransporter,SLC10A1,5.19,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
zafirlukast,Sodium/bile acid cotransporter,SLC10A1,5.19,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
quercetin,Short transient receptor potential channel 5,TRPC5,5.19,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Short transient receptor potential channel 5,TRPC5,5.19,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
resorcinol,Carbonic anhydrase,ca,5.19,Ki,OC1=CC(O)=CC=C1
vandetanib,Serine/threonine-protein kinase ULK3,ULK3,5.19,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
tofacitinib,Serine/threonine-protein kinase ULK3,ULK3,5.19,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
midostaurin,Dual specificity mitogen-activated protein kinase kinase 6,MAP2K6,5.19,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase Fyn,FYN,5.19,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Dual serine/threonine and tyrosine protein kinase,DSTYK,5.19,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Serine/threonine-protein kinase 32B,STK32B,5.19,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
quizartinib,Ephrin type-A receptor 3,EPHA3,5.19,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Ephrin type-A receptor 7,EPHA7,5.19,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
amiodarone,Substance-K receptor,TACR2,5.191,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
citalopram,5-hydroxytryptamine receptor 2A,HTR2A,5.191,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
desipramine,5-hydroxytryptamine receptor 1A,HTR1A,5.194,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
thioridazine,Cytochrome P450 2C19,CYP2C19,5.195,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
sulfasalazine,Mitogen-activated protein kinase 1,MAPK1,5.198,IC50,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
acetylsalicylic acid,Acidic phospholipase A2 3,,5.2,Kd,CC(=O)OC1=CC=CC=C1C(O)=O
azelastine,Muscarinic acetylcholine receptor M1,CHRM1,5.2,IC50,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
clozapine,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.2,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
danazol,Adenosine receptor A3,ADORA3,5.2,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
deptropine,Soluble acetylcholine receptor,,5.2,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1C2=CC=CC=C2CCC2=CC=CC=C12
diclofenac,Transient receptor potential cation channel subfamily M member 3,TRPM3,5.2,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
erlotinib,Serine/threonine-protein kinase 17A,STK17A,5.2,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
esmolol,Beta-2 adrenergic receptor,Adrb2,5.2,Kd,COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1
hydroxyzine,Envelope glycoprotein gp160,env,5.2,IC50,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
iloprost,Thromboxane A2 receptor,TBXA2R,5.2,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
imatinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,5.2,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
isoxicam,Prostaglandin G/H synthase 2,PTGS2,5.2,IC50,CN1C(C(=O)NC2=NOC(C)=C2)=C(O)C2=CC=CC=C2S1(=O)=O
bekanamycin,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,5.2,IC50,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
melatonin,5-hydroxytryptamine receptor 2B,HTR2B,5.2,Ki,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
milnacipran,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,5.2,IC50,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
nicotine,Acetylcholine receptor,CHRNA1|CHRNB1|CHRNG|chrnd,5.2,Ki,CN1CCC[C@H]1C1=CC=CN=C1
paroxetine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.2,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
probenecid,Solute carrier family 22 member 6,Slc22a6,5.2,Ki,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
propofol,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1,Hcn1,5.2,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
quinidine,Potassium voltage-gated channel subfamily A member 5,KCNA5,5.2,Kd,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
rizatriptan,5-hydroxytryptamine receptor 2A,Htr2a,5.2,IC50,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
sulfanilamide,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,5.2,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sumatriptan,5-hydroxytryptamine receptor 6,Htr6,5.2,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Testis-specific serine/threonine-protein kinase 1,TSSK1B,5.2,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Muscarinic acetylcholine receptor M2,CHRM2,5.2,EC50,NC1=C2CCCCC2=NC2=CC=CC=C12
tubocurarine,Zinc-activated ligand-gated ion channel,ZACN,5.2,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
vinburnine,Muscarinic acetylcholine receptor M3,CHRM3,5.2,Kd,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C1=CC=CC=C41)C(=O)C2
ximelagatran,Urokinase-type plasminogen activator,PLAU,5.2,Ki,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
ximelagatran,Urokinase-type plasminogen activator,PLAU,5.2,Ki,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
eburnamonine,Muscarinic acetylcholine receptor M3,CHRM3,5.2,Kd,CC[C@]12CCCN3CCC4=C([C@@H]13)N(C1=CC=CC=C41)C(=O)C2
quercetin,Vasopressin V2 receptor,AVPR2,5.2,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
uridine triphosphate,P2Y purinoceptor 6,P2RY6,5.2,EC50,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O
uridine triphosphate,P2Y purinoceptor 11,P2RY11,5.2,EC50,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O
retigabine,Potassium voltage-gated channel subfamily KQT member 4,KCNQ4,5.2,EC50,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
ruxolitinib,Mast/stem cell growth factor receptor Kit,KIT,5.2,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase 25,STK25,5.2,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
doconexent,Retinoic acid receptor RXR-alpha,RXRA,5.2,Ki,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
doconexent,Retinoic acid receptor RXR-alpha,RXRA,5.2,Ki,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
bosutinib,Macrophage-stimulating protein receptor,MST1R,5.2,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
rifamycin,Bile salt export pump,ABCB11,5.2,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O
levomilnacipran,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,5.2,IC50,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1
midostaurin,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,5.2,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase D2,PRKD2,5.2,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Leukocyte tyrosine kinase receptor,LTK,5.2,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 12,MAP3K12,5.2,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
orphenadrine,Sodium channel protein type 10 subunit alpha,SCN10A,5.201,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
ticlopidine,Cytochrome P450 2D6,CYP2D6,5.201,IC50,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
econazole,5-hydroxytryptamine receptor 2C,HTR2C,5.202,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
tamoxifen,Kappa-type opioid receptor,OPRK1,5.204,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
cyclizine,Cytochrome P450 2D6,CYP2D6,5.206,IC50,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
amiodarone,D(4) dopamine receptor,DRD4,5.207,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
danazol,Kappa-type opioid receptor,OPRK1,5.207,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
pindolol,5-hydroxytryptamine receptor 1D,HTR1D,5.209,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
paracetamol,Carbonic anhydrase 2,CA2,5.21,Ki,CC(=O)NC1=CC=C(O)C=C1
acrivastine,Histamine H1 receptor,HRH1,5.21,IC50,CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC(\C=C\C(O)=O)=N1
alexidine,Toll-like receptor 9,TLR9,5.21,IC50,CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC
amitriptyline,Sodium-dependent dopamine transporter,SLC6A3,5.21,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
buspirone,D(1A) dopamine receptor,DRD1,5.21,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
candesartan cilexetil,DNULL polymerase iota,POLI,5.21,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
citalopram,Sodium-dependent noradrenaline transporter,SLC6A2,5.21,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
citalopram,Transporter,Slc6a2,5.21,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
cyclothiazide,"Glutamate receptor ionotropic, AMPA",Gria1|Gria2|Gria3|Gria4,5.21,IC50,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C2CC3CC2C=C3)C=C1Cl
prasterone,Glucose-6-phosphate 1-dehydrogenase,G6PD,5.21,Ki,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O
didanosine,Reverse transcriptase/RNaseH,pol,5.21,IC50,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1N=CNC2=O
flutrimazole,Nuclear receptor subfamily 1 group I member 2,NR1I2,5.21,EC50,FC1=CC=C(C=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=C(F)C=CC=C1
loperamide,Alpha-1A adrenergic receptor,Adra1a,5.21,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
mefenamic acid,Acetylcholinesterase,ache,5.21,IC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
milnacipran,Sodium-dependent dopamine transporter,SLC6A3,5.21,IC50,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
nifedipine,Potassium voltage-gated channel subfamily A member 5,KCNA5,5.21,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nimesulide,Prostaglandin G/H synthase 1,PTGS1,5.21,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
phenylephrine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.21,Ki,CNC[C@H](O)C1=CC(O)=CC=C1
piribedil,Alpha-1B adrenergic receptor,ADRA1B,5.21,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
propafenone,Alpha-1A adrenergic receptor,Adra1a,5.21,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
sorafenib,5-hydroxytryptamine receptor 6,HTR6,5.21,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Cyclin-dependent-like kinase 5,CDK5,5.21,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Citron Rho-interacting kinase,CIT,5.21,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulbactam,Beta-lactamase,blaSCO-1,5.21,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sunitinib,Solute carrier family 22 member 1,SLC22A1,5.21,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
vesnarinone,Phosphodiesterase 3,PDE3B|PDE3A,5.21,IC50,COC1=C(OC)C=C(C=C1)C(=O)N1CCN(CC1)C1=CC=C2NC(=O)CCC2=C1
bithionol,Envelope glycoprotein gp160,env,5.21,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
carbaryl,Acetylcholinesterase,ACHE,5.21,IC50,CNC(=O)OC1=CC=CC2=C1C=CC=C2
linoleic acid,Peroxisome proliferator-activated receptor gamma,PPARG,5.21,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
pyrithione,Carbonic anhydrase 4,CA4,5.21,Ki,[O-][N+]1=C(S)C=CC=C1
quercetin,Carbonic anhydrase 6,CA6,5.21,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Lactoperoxidase,LPO,5.21,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Ribosomal protein S6 kinase alpha-4,RPS6KA4,5.21,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,CaM kinase II,CAMK2B|CAMK2G|CAMK2D|CAMK2A,5.21,IC50,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vorinostat,Leukotriene A-4 hydrolase,Lta4h,5.21,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
boceprevir,Cathepsin B,CTSB,5.21,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
crizotinib,Serine/threonine-protein kinase RIO1,RIOK1,5.21,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase 17A,STK17A,5.21,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Ephrin type-A receptor 3,EPHA3,5.21,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,G protein-coupled receptor kinase 4,GRK4,5.21,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Myosin-IIIa,MYO3A,5.21,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Testis-specific serine/threonine-protein kinase 1,TSSK1B,5.21,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
crisaborole,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",PDE1A,5.21,IC50,OB1OCC2=CC(OC3=CC=C(C=C3)C#N)=CC=C12
fedratinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,5.21,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
lemborexant,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.21,IC50,CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=CC=C(F)C=N2)C2=CC=CC(F)=C2)C(C)=N1
oliceridine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.21,IC50,COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
oliceridine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.21,IC50,COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
ketoconazole,5-hydroxytryptamine receptor 1B,Htr1b,5.211,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
hexachlorophene,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,5.212,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
carmofur,Mitogen-activated protein kinase 3,MAPK3,5.213,IC50,CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O
methysergide,Muscarinic acetylcholine receptor M2,CHRM2,5.213,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
terfenadine,Tyrosine-protein kinase Fyn,FYN,5.213,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
ketorolac,Aldose reductase,Akr1b1,5.214,IC50,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1
terconazole,Sodium-dependent serotonin transporter,SLC6A4,5.216,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
exisulind,Endothelin-1 receptor,EDNRA,5.217,Ki,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)(=O)=O
astemizole,Epidermal growth factor receptor,EGFR,5.218,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
irinotecan,Interstitial collagenase,MMP1,5.218,IC50,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
propofol,5-hydroxytryptamine receptor 2C,HTR2C,5.218,Ki,CC(C)C1=CC=CC(C(C)C)=C1O
astemizole,Beta-3 adrenergic receptor,ADRB3,5.219,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
aminohippuric acid,Solute carrier family 22 member 6,SLC22A6,5.22,Ki,NC1=CC=C(C=C1)C(=O)NCC(O)=O
clebopride,D(1A) dopamine receptor,DRD1,5.22,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
clofazimine,Cruzipain,,5.22,IC50,CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C3=CC=CC=C3N=C2C=C1NC1=CC=C(Cl)C=C1
clofibrate,"Fatty acid-binding protein, liver",Fabp1,5.22,Kd,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
clotrimazole,Potassium voltage-gated channel subfamily A member 3,KCNA3,5.22,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
diphenhydramine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.22,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
erlotinib,Death-associated protein kinase 3,DAPK3,5.22,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
etravirine,ATP-binding cassette sub-family G member 2,ABCG2,5.22,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
fluconazole,Mycocyclosin synthase,cyp121,5.22,Kd,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
flufenamic acid,Aldo-keto reductase family 1 member C1,AKR1C1,5.22,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
gefitinib,Tyrosine-protein kinase TXK,TXK,5.22,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
haloperidol,5-hydroxytryptamine receptor 6,HTR6,5.22,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
indomethacin,Aldose reductase,AKR1B1,5.22,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
fluostigmine,Acetylcholinesterase,ACHE,5.22,Ki,CC(C)OP(F)(=O)OC(C)C
manidipine,Cruzipain,,5.22,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
milrinone,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,5.22,IC50,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
norepinephrine,Beta-2 adrenergic receptor,ADRB2,5.22,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
orphenadrine,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,5.22,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
picrotin,Glycine receptor subunit alpha-3,GLRA3,5.22,IC50,CC(C)(O)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C
quinagolide,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.22,IC50,CCCN1C[C@H](C[C@@H]2CC3=C(C[C@@H]12)C=CC=C3O)NS(=O)(=O)N(CC)CC
sunitinib,Protein kinase C alpha type,PRKCA,5.22,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
telmisartan,Angiotensin-converting enzyme,ACE,5.22,Ki,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O
tetracaine,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,5.22,IC50,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
tubocurarine,Acetylcholine receptor subunit alpha,CHRNA1,5.22,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
ubenimex,Aminopeptidase B,Rnpep,5.22,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
zonisamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,5.22,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
oleic acid,Fatty-acid amide hydrolase 1,FAAH,5.22,Ki,CCCCCCCC\C=C/CCCCCCCC(O)=O
quercetin,Malate dehydrogenase,mdh,5.22,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
vilazodone,Adrenergic receptor alpha-2,ADRA2A|ADRA2B|ADRA2C,5.22,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
axitinib,Activated CDC42 kinase 1,TNK2,5.22,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
thymol,Transient receptor potential cation channel subfamily A member 1,TRPA1,5.22,EC50,CC(C)C1=C(O)C=C(C)C=C1
stearic acid,Peroxisome proliferator-activated receptor delta,PPARD,5.22,IC50,CCCCCCCCCCCCCCCCCC(O)=O
migalastat,Lysosomal alpha-glucosidase,GAA,5.22,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
neratinib,Tyrosine-protein kinase ABL1,ABL1,5.22,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Serine/threonine-protein kinase PAK 2,PAK2,5.22,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Wee1-like protein kinase 2,WEE2,5.22,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
alpha-Ergocryptine,Cytochrome P450 2C9,CYP2C9,5.222,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
imipramine,Solute carrier family 22 member 2,SLC22A2,5.222,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
olanzapine,Aldehyde oxidase,AOX1,5.222,IC50,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
pimozide,Calmodulin,CALM1|CALM2|CALM3,5.222,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
fenbendazole,Beta-lactamase 1,penPC,5.222,IC50,COC(=O)NC1=NC2=C(N1)C=CC(SC1=CC=CC=C1)=C2
diethylstilbestrol,5-hydroxytryptamine receptor 6,HTR6,5.223,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
fluphenazine enanthate,Sodium-dependent serotonin transporter,SLC6A4,5.225,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
tranylcypromine,5-hydroxytryptamine receptor 1A,HTR1A,5.225,Ki,N[C@@H]1C[C@H]1C1=CC=CC=C1
dolasetron,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.226,IC50,O=C(O[C@H]1C[C@H]2CC3C[C@@H](C1)N2CC3=O)C1=CNC2=C1C=CC=C2
aceclofenac,Mitogen-activated protein kinase 1,MAPK1,5.227,IC50,OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
prochlorperazine,5-hydroxytryptamine receptor 1A,HTR1A,5.229,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
tranylcypromine,Sodium-dependent noradrenaline transporter,SLC6A2,5.229,Ki,N[C@@H]1C[C@H]1C1=CC=CC=C1
amiodarone,Alpha-2B adrenergic receptor,ADRA2B,5.23,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
atracurium,Small conductance calcium-activated potassium channel protein 3,Kcnn3,5.23,Ki,COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1
bexarotene,Cytochrome P450 26B1,CYP26B1,5.23,IC50,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
bortezomib,Carbonic anhydrase 12,CA12,5.23,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
candesartan cilexetil,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.23,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
citalopram,Transporter,NET,5.23,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
clotrimazole,"Indoleamine 2,3-dioxygenase 2",Ido2,5.23,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
decamethonium,Acetylcholinesterase,ACHE,5.23,IC50,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
fenoprofen,Prostaglandin G/H synthase 2,PTGS2,5.23,IC50,CC(C(O)=O)C1=CC=CC(OC2=CC=CC=C2)=C1
galantamine,Butyrylcholinesterase; Protein Bche,Bche,5.23,IC50,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
loperamide,Angiopoietin-1 receptor,TEK,5.23,Kd,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
pregnenolone succinate,Corticosteroid-binding globulin,SERPINA6,5.23,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)OC(=O)CCC(O)=O
rabeprazole,Fatty acid synthase,FASN,5.23,Ki,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
sitagliptin,Prolyl endopeptidase FAP,FAP,5.23,IC50,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
sunitinib,Acetylcholinesterase,ACHE,5.23,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,5.23,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
suramin,RmtA,rmtA,5.23,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
hydroquinone,Carbonic anhydrase,ca,5.23,Ki,OC1=CC=C(O)C=C1
ruboxistaurin,Serine/threonine-protein kinase STK11,STK11,5.23,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Interleukin-1 receptor-associated kinase 1,IRAK1,5.23,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
bosutinib,NUAK family SNF1-like kinase 1,NUAK1,5.23,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dabrafenib,GTPase KRas,KRAS,5.23,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
dexrabeprazole,Fatty acid synthase,FASN,5.23,Ki,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
nintedanib,Calcium/calmodulin-dependent protein kinase type 1,CAMK1,5.23,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Serine/threonine-protein kinase ICK,ICK,5.23,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Tyrosine-protein kinase CSK,CSK,5.23,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
carbetocin,Vasopressin V2 receptor,AVPR2,5.232,Ki,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
nelfinavir,Mu-type opioid receptor,OPRM1,5.232,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
chlorpromazine,Mu-type opioid receptor,OPRM1,5.233,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
gentian violet,Acetylcholinesterase,ACHE,5.233,IC50,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
clotrimazole,5-hydroxytryptamine receptor 6,HTR6,5.235,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
nelfinavir,Progesterone receptor,PGR,5.236,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
disulfiram,Sodium/nucleoside cotransporter 1,SLC28A1,5.237,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
imipramine,5-hydroxytryptamine receptor 1A,HTR1A,5.237,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
maprotiline,Sodium-dependent serotonin transporter,SLC6A4,5.237,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
tamoxifen,Beta-3 adrenergic receptor,ADRB3,5.238,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
acetazolamide,Carbonic anhydrase,ca,5.24,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
cefapirin,Histamine H2 receptor,HRH2,5.24,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
cerulenin,Fatty acid synthase,FASN,5.24,IC50,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O
chlorhexidine,CAAX prenyl protease 2,RCE1,5.24,AC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
chloroquine,Muscarinic acetylcholine receptor M4,CHRM4,5.24,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
colchicine,Tubulin beta chain,TUBB,5.24,Ki,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
colchicine,Tubulin beta-4B chain,TUBB4B,5.24,Ki,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
colchicine,Tubulin,TUBA1A,5.24,Ki,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
decamethonium,Neuronal acetylcholine receptor; alpha4/beta2,Chrna4|Chrnb2,5.24,Ki,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
dexamfetamine,Sodium-dependent serotonin transporter,SLC6A4,5.24,Ki,C[C@H](N)CC1=CC=CC=C1
doxazosin,Interstitial collagenase,MMP1,5.24,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
erlotinib,Vascular endothelial growth factor receptor 2,KDR,5.24,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
gefitinib,Death-associated protein kinase 3,DAPK3,5.24,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Serine/threonine-protein kinase 36,STK36,5.24,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Serine/threonine-protein kinase pim-3,PIM3,5.24,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,Glutamate racemase,murI,5.24,Ki,N[C@@H](CCC(O)=O)C(O)=O
gossypol,"Malate dehydrogenase, cytoplasmic",MDH1,5.24,IC50,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
ketoconazole,Substance-K receptor,TACR2,5.24,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mirtazapine,D(3) dopamine receptor,DRD3,5.24,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
nilotinib,Mitogen-activated protein kinase 9,MAPK9,5.24,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norepinephrine,Alpha-2A adrenergic receptor,Adra2a,5.24,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
quetiapine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.24,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
rosiglitazone,Amine oxidase [flavin-containing] B,Maob,5.24,Ki,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sorafenib,Hepatocyte growth factor receptor,MET,5.24,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Hepatocyte growth factor receptor,MET,5.24,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,5.24,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
valdecoxib,Carbonic anhydrase,CA2,5.24,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
zafirlukast,Epidermal growth factor receptor,EGFR,5.24,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
quercetin,Serine/threonine-protein kinase PLK1,PLK1,5.24,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Serine/threonine-protein kinase Nek2,NEK2,5.24,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Serine/threonine-protein kinase N1,PKN1,5.24,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,TRAF2 and NCK-interacting protein kinase,TNIK,5.24,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Proto-oncogene tyrosine-protein kinase ROS,ROS1,5.24,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
thiram,Gamma-butyrobetaine dioxygenase,BBOX1,5.24,IC50,CN(C)C(=S)SSC(=S)N(C)C
xanomeline,Muscarinic acetylcholine receptor M1,Chrm1,5.24,EC50,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
pazopanib,Tyrosine-protein kinase HCK,HCK,5.24,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Serine/threonine-protein kinase Nek7,NEK7,5.24,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,5.24,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Uncharacterized serine/threonine-protein kinase SBK3,SBK3,5.24,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Serine/threonine-protein kinase PAK 3,PAK3,5.24,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Megakaryocyte-associated tyrosine-protein kinase,MATK,5.24,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tedizolid phosphate,Amine oxidase [flavin-containing] B,MAOB,5.24,IC50,CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O
selexipag,Prostaglandin E2 receptor EP2 subtype,PTGER2,5.24,Ki,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1
selexipag,Prostaglandin E2 receptor EP2 subtype,PTGER2,5.24,Ki,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase Chk1,CHEK1,5.24,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Mitogen-activated protein kinase kinase kinase 11,MAP3K11,5.24,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
quizartinib,Tyrosine-protein kinase Lyn,LYN,5.24,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Serine/threonine-protein kinase 38,STK38,5.24,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
roxadustat,Egl nine homolog 2,EGLN2,5.24,IC50,CC1=C2C=C(OC3=CC=CC=C3)C=CC2=C(O)C(=N1)C(=O)NCC(O)=O
dotinurad,Cytochrome P450 2C9,CYP2C9,5.24,IC50,C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
danazol,Mu-type opioid receptor,OPRM1,5.243,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
estradiol,Sodium-dependent serotonin transporter,SLC6A4,5.243,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
loxapine,Sodium-dependent noradrenaline transporter,SLC6A2,5.244,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
raltitrexed,Thymidylate synthase,thyA,5.244,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
lacidipine,Sodium-dependent noradrenaline transporter,SLC6A2,5.245,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
prochlorperazine,Tyrosine-protein kinase Fyn,FYN,5.245,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
ethinylestradiol,Arachidonate 15-lipoxygenase,ALOX15,5.246,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
danazol,Sodium-dependent noradrenaline transporter,SLC6A2,5.248,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
betamethasone phosphate,Muscarinic acetylcholine receptor M5,CHRM5,5.248,Ki,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
bicalutamide,Progesterone receptor,PGR,5.25,IC50,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
candesartan cilexetil,DNULL polymerase kappa,POLK,5.25,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
celecoxib,Prostaglandin G/H synthase 1,PTGS1,5.25,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
coumarin,Carbonic anhydrase 3,CA3,5.25,Ki,O=C1OC2=CC=CC=C2C=C1
diazepam,Aldo-keto reductase family 1 member C1,AKR1C1,5.25,IC50,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
entacapone,G-protein coupled receptor 35,GPR35,5.25,EC50,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N
diiodohydroxyquinoline,Catechol O-methyltransferase,Comt,5.25,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
bekanamycin,3-oxoacyl-[acyl-carrier-protein] synthase 3,fabH,5.25,IC50,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
mefloquine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.25,IC50,O[C@H]([C@H]1CCCCN1)C1=CC(=NC2=C(C=CC=C12)C(F)(F)F)C(F)(F)F
mezlocillin,Thromboxane-A synthase,TBXAS1,5.25,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
aminobenzoic acid,Dihydropteroate synthase,folP,5.25,Kd,NC1=CC=C(C=C1)C(O)=O
pargyline,"Aldehyde dehydrogenase, mitochondrial",Aldh2,5.25,IC50,CN(CC#C)CC1=CC=CC=C1
quinagolide,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.25,IC50,CCCN1C[C@H](C[C@@H]2CC3=C(C[C@@H]12)C=CC=C3O)NS(=O)(=O)N(CC)CC
theophylline,Adenosine receptor A2b,Adora2b,5.25,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
oxiconazole,5-hydroxytryptamine receptor 1A,Htr1a,5.25,IC50,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
quercetin,Stromelysin-1,MMP3,5.25,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
axitinib,Mitogen-activated protein kinase kinase kinase 4,MAP3K4,5.25,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
neratinib,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,5.25,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
nizatidine,Acetylcholinesterase,ACHE,5.251,IC50,CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O
diethylstilbestrol,Prostaglandin G/H synthase 1,PTGS1,5.252,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
methylphenidate,Alpha-2A adrenergic receptor,ADRA2A,5.252,Ki,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
nimodipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.252,Ki,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
dobutamine,Epidermal growth factor receptor,EGFR,5.256,IC50,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
dexfenfluramine,5-hydroxytryptamine receptor 7,HTR7,5.257,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
dobutamine,Tyrosine-protein kinase Lck,LCK,5.258,IC50,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
thioguanine,Mitogen-activated protein kinase 3,MAPK3,5.258,IC50,NC1=NC2=C(NC=N2)C(=S)N1
amlodipine,Aldehyde oxidase,AOX1,5.26,IC50,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
benserazide,Hexokinase-2,HK2,5.26,IC50,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
cycloserine,"Glutamate receptor ionotropic, NMDA 1",GRIN1,5.26,IC50,N[C@@H]1CONC1=O
diltiazem,5-hydroxytryptamine receptor 3A,Htr3a,5.26,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
estriol succinate,Sodium-dependent serotonin transporter,SLC6A4,5.26,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
fentanyl,Monoamine oxidase,MAOA|MAOB,5.26,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
gefitinib,Ephrin type-A receptor 3,EPHA3,5.26,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Leukocyte tyrosine kinase receptor,LTK,5.26,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
haloperidol,Potassium channel subfamily K member 2,KCNK2,5.26,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,Transporter,NET,5.26,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hexachlorophene,Transitional endoplasmic reticulum ATPase,VCP,5.26,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
hexachlorophene,Macrophage migration inhibitory factor,MIF,5.26,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
hydroxychloroquine,Muscarinic acetylcholine receptor M4,CHRM4,5.26,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
imatinib,Cyclin-dependent kinase 19,CDK19,5.26,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
lapatinib,Receptor tyrosine-protein kinase erbB-3,ERBB3,5.26,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
loxapine,Muscarinic acetylcholine receptor M1,CHRM1,5.26,IC50,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
masoprocol,Estradiol 17-beta-dehydrogenase 1,HSD17B1,5.26,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
memantine,Glutamate NMDA receptor; GRIN1/GRIN2B,GRIN1|GRIN2B,5.26,IC50,CC12CC3CC(C)(C1)CC(N)(C3)C2
methylparaben,Carbonic anhydrase 9,CA9,5.26,Ki,COC(=O)C1=CC=C(O)C=C1
mianserin,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.26,IC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nifedipine,Cytochrome P450 3A4,CYP3A4,5.26,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nilotinib,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.26,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
sumatriptan,5-hydroxytryptamine receptor 1E,HTR1E,5.26,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
bithionol,5-hydroxytryptamine receptor 1A,Htr1a,5.26,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
bithionol,Solute carrier family 22 member 3,SLC22A3,5.26,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
estriol,Sodium-dependent serotonin transporter,SLC6A4,5.26,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
ibufenac,Prostaglandin G/H synthase 2,Ptgs2,5.26,IC50,CC(C)CC1=CC=C(CC(O)=O)C=C1
vandetanib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,5.26,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,5.26,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2",INPPL1,5.26,IC50,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
phenol,Carbonic anhydrase 2,CA2,5.26,Ki,OC1=CC=CC=C1
bosutinib,Serine/threonine-protein kinase PknB,pknB,5.26,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
olodaterol,Beta-3 adrenergic receptor,ADRB3,5.26,Ki,COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1
nintedanib,Protein kinase C theta type,PRKCQ,5.26,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Microtubule-associated serine/threonine-protein kinase 1,MAST1,5.26,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
hydroxyprogesterone caproate,Sodium-dependent dopamine transporter,SLC6A3,5.261,Ki,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
bopindolol,Cytochrome P450 2D6,CYP2D6,5.262,IC50,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
desipramine,D(1A) dopamine receptor,DRD1,5.263,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
methysergide,Muscarinic acetylcholine receptor M1,CHRM1,5.263,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
mirtazapine,D(2) dopamine receptor,DRD2,5.263,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
ritonavir,Kappa-type opioid receptor,OPRK1,5.263,Ki,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
sibutramine,Sodium-dependent noradrenaline transporter,SLC6A2,5.263,Ki,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
danazol,Sodium-dependent dopamine transporter,SLC6A3,5.265,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
ketoconazole,Arachidonate 15-lipoxygenase,ALOX15,5.266,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
clotrimazole,Beta-3 adrenergic receptor,ADRB3,5.267,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
mitoxantrone,Epidermal growth factor receptor,EGFR,5.269,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
amlodipine,Alpha-1D adrenergic receptor,ADRA1D,5.27,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
amfetamine,5-hydroxytryptamine receptor 2B,Htr2b,5.27,Kd,CC(N)CC1=CC=CC=C1
amfetamine,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,5.27,Kd,CC(N)CC1=CC=CC=C1
brimonidine,Alpha-1B adrenergic receptor,ADRA1B,5.27,Ki,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
clonidine,5-hydroxytryptamine receptor 1A,Htr1a,5.27,IC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
dasatinib,Serine/threonine-protein kinase TAO2,TAOK2,5.27,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dopamine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,5.27,IC50,NCCC1=CC(O)=C(O)C=C1
ethoxzolamide,Carbonic anhydrase,,5.27,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
famotidine,"Carbonic anhydrase 5B, mitochondrial",CA5B,5.27,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
nicardipine,Equilibrative nucleoside transporter 1,Slc29a1,5.27,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
paroxetine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.27,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
proguanil,Trace amine-associated receptor 1,Taar1,5.27,EC50,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1
promazine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.27,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
sulfanilamide,Carbonic anhydrase 14,CA14,5.27,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha,PIP5K1A,5.27,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terconazole,Alpha-1D adrenergic receptor,ADRA1D,5.27,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
zoledronic acid,Carbonic anhydrase 9,CA9,5.27,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
suramin,Protein arginine N-methyltransferase 1,PRMT1,5.27,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
pyrithione,Carbonic anhydrase 12,CA12,5.27,Ki,[O-][N+]1=C(S)C=CC=C1
quercetin,Carbonic anhydrase 14,CA14,5.27,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,RAC-alpha serine/threonine-protein kinase,AKT1,5.27,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,3-oxoacyl-acyl-carrier protein reductase,fabG,5.27,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,DYRK1B,5.27,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,5.27,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
bosutinib,Serine/threonine-protein kinase DCLK3,DCLK3,5.27,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
neratinib,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,5.27,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
brilliant Blue G,Alpha-synuclein,SNCA,5.27,IC50,CCOC1=CC=C(NC2=CC=C(C=C2)C(=C2\C=C/C(/C=C2C)=[N+](/CC)CC2=CC=CC(=C2)S([O-])(=O)=O)\C2=C(C)C=C(C=C2)N(CC)CC2=CC=CC(=C2)S([O-])(=O)=O)C=C1
infigratinib,Tyrosine-protein kinase SYK,SYK,5.27,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Tyrosine-protein kinase SYK,SYK,5.27,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
miconazole,D(4) dopamine receptor,DRD4,5.271,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
diethylstilbestrol,Alpha-2B adrenergic receptor,ADRA2B,5.272,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
diethylstilbestrol,Alpha-1D adrenergic receptor,ADRA1D,5.274,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
fluphenazine enanthate,Muscarinic acetylcholine receptor M4,CHRM4,5.274,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
dosulepin,Sodium-dependent dopamine transporter,SLC6A3,5.275,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
lansoprazole,Cytochrome P450 2D6,CYP2D6,5.275,IC50,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
abacavir,Gag-Pol polyprotein,gag-pol,5.276,EC50,NC1=NC(NC2CC2)=C2N=CN([C@@H]3C[C@H](CO)C=C3)C2=N1
delavirdine,Histamine H4 receptor,HRH4,5.276,Ki,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
diethylstilbestrol,Alpha-2A adrenergic receptor,ADRA2A,5.276,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
risperidone,Cytochrome P450 2D6,CYP2D6,5.278,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
diiodohydroxyquinoline,Mitogen-activated protein kinase 3,MAPK3,5.279,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
abacavir,Reverse transcriptase/RNaseH,pol,5.28,EC50,NC1=NC(NC2CC2)=C2N=CN([C@@H]3C[C@H](CO)C=C3)C2=N1
alexidine,Beta-lactamase,bla(tem-2),5.28,IC50,CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC
coumarin,"Carbonic anhydrase 5B, mitochondrial",CA5B,5.28,Ki,O=C1OC2=CC=CC=C2C=C1
dasatinib,Mitogen-activated protein kinase kinase kinase 13,MAP3K13,5.28,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dipyridamole,Cyclic AMP-specific phosphodiesterase SSPDE4A1A,PDE4A,5.28,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
glibenclamide,Bile salt export pump,ABCB11,5.28,IC50,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
imatinib,Mitogen-activated protein kinase 9,MAPK9,5.28,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
lansoprazole,Fatty acid synthase,FASN,5.28,Ki,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
methamphetamine,Trace amine-associated receptor 1,TAAR1,5.28,EC50,CN[C@@H](C)CC1=CC=CC=C1
norgestimate,Short transient receptor potential channel 6,TRPC6,5.28,IC50,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C
ofloxacin,DNA gyrase subunit A,gyrA,5.28,IC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
paclitaxel,Botulinum neurotoxin type A,botA,5.28,IC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
picrotin,Glycine receptor subunit alpha-1,GLRA1,5.28,IC50,CC(C)(O)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C
raltitrexed,Thymidylate synthase,thyA,5.28,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
sorafenib,Insulin receptor,INSR,5.28,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Dual specificity mitogen-activated protein kinase kinase 6,MAP2K6,5.28,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
ubenimex,Cytosol aminopeptidase,LAP3,5.28,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
ubenimex,Cytosol aminopeptidase,LAP3,5.28,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
zonisamide,Carbonic anhydrase 14,CA14,5.28,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
bithionol,Multidrug and toxin extrusion protein 1,SLC47A1,5.28,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
oleic acid,Peroxisome proliferator-activated receptor delta,PPARD,5.28,IC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
axitinib,Cyclin-dependent kinase 16,CDK16,5.28,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Activin receptor type-2B,ACVR2B,5.28,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Discoidin domain-containing receptor 2,DDR2,5.28,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Tyrosine-protein kinase receptor UFO,AXL,5.28,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Dual specificity mitogen-activated protein kinase kinase 7,MAP2K7,5.28,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Tyrosine-protein kinase HCK,HCK,5.28,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Interleukin-1 receptor-associated kinase 3,IRAK3,5.28,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Dual specificity mitogen-activated protein kinase kinase 3,MAP2K3,5.28,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase 36,STK36,5.28,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Vascular endothelial growth factor receptor 2,KDR,5.28,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,5.28,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
methyldopa,Epidermal growth factor receptor,EGFR,5.282,IC50,C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O
saquinavir,D(3) dopamine receptor,DRD3,5.282,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
busulfan,Matrix metalloproteinase-9,MMP9,5.283,IC50,CS(=O)(=O)OCCCCOS(C)(=O)=O
amiodarone,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.284,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
epirubicin,Tyrosine-protein kinase Fyn,FYN,5.286,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
methyldopa,Tyrosine-protein kinase Fyn,FYN,5.286,IC50,C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O
clotrimazole,Muscarinic acetylcholine receptor M2,CHRM2,5.287,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
leflunomide,Sodium/nucleoside cotransporter 1,SLC28A1,5.287,Ki,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
doxorubicin,Tyrosine-protein kinase Fyn,FYN,5.288,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
atorvastatin,Cytochrome P450 3A4,CYP3A4,5.29,IC50,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
benzatropine,Sodium-dependent serotonin transporter,Slc6a4,5.29,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
caramiphen,Sodium-dependent dopamine transporter,Slc6a3,5.29,Ki,CCN(CC)CCOC(=O)C1(CCCC1)C1=CC=CC=C1
cefapirin,Kappa-type opioid receptor,OPRK1,5.29,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
chlorprothixene,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.29,IC50,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dextromethorphan,Sigma non-opioid intracellular receptor 1,Sigmar1,5.29,Ki,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
etravirine,Canalicular multispecific organic anion transporter 2,ABCC3,5.29,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
norfloxacin,DNA topoisomerase 4 subunit A,parC,5.29,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
pentoxifylline,Adenosine receptor A2b,ADORA2B,5.29,Ki,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
promazine,5-hydroxytryptamine receptor 1A,Htr1a,5.29,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
propafenone,Potassium channel subfamily K member 3,KCNK3,5.29,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
rosiglitazone,Sodium/bile acid cotransporter,SLC10A1,5.29,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
rosiglitazone,Sodium/bile acid cotransporter,SLC10A1,5.29,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sultiame,Beta-carbonic anhydrase 1,mtcA1,5.29,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
sunitinib,NT-3 growth factor receptor,NTRK3,5.29,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tadalafil,Phosphodiesterase 6,PDE6G|PDE6A|PDE6C|PDE6H|PDE6B|PDE6D,5.29,IC50,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
pyrithione,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.29,Ki,[O-][N+]1=C(S)C=CC=C1
quercetin,NUAK family SNF1-like kinase 1,NUAK1,5.29,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Epidermal growth factor receptor,EGFR,5.29,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Fibroblast growth factor receptor 1,FGFR1,5.29,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vandetanib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,5.29,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
bosutinib,Platelet-derived growth factor receptor alpha,PDGFRA,5.29,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
olaparib,Mono [ADP-ribose] polymerase PARP16,PARP16,5.29,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
niraparib,Tankyrase-2,TNKS2,5.29,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
neratinib,Tyrosine-protein kinase SYK,SYK,5.29,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Cyclin-dependent kinase 7,CDK7,5.29,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,5.29,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
alprenolol,5-hydroxytryptamine receptor 2A,HTR2A,5.292,Ki,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
butriptyline,Sodium-dependent noradrenaline transporter,SLC6A2,5.292,Ki,CC(CC1C2=CC=CC=C2CCC2=C1C=CC=C2)CN(C)C
tolazamide,Arachidonate 15-lipoxygenase,ALOX15,5.292,IC50,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1
tranylcypromine,Sodium-dependent dopamine transporter,SLC6A3,5.292,Ki,N[C@@H]1C[C@H]1C1=CC=CC=C1
trifluoperazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.292,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
bupivacaine,Sodium channel protein type 1 subunit alpha,SCN1A,5.293,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
clotrimazole,Histamine H2 receptor,HRH2,5.294,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
danazol,Estrogen receptor,ESR1,5.294,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
diethylstilbestrol,Adenosine receptor A2a,ADORA2A,5.296,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
econazole,5-hydroxytryptamine receptor 6,HTR6,5.296,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miconazole,5-hydroxytryptamine receptor 6,HTR6,5.296,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
loxapine,Histamine H4 receptor,HRH4,5.297,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
spiperone,5-hydroxytryptamine receptor 1E,HTR1E,5.297,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
thioridazine,Tyrosine-protein kinase Fyn,FYN,5.297,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
vinblastine,Arachidonate 15-lipoxygenase,ALOX15,5.298,IC50,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
bithionol,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,5.299,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
acarbose,Lysosomal alpha-glucosidase,GAA,5.3,IC50,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
acepromazine,Major prion protein,PRNP,5.3,EC50,CN(C)CCCN1C2=CC=CC=C2SC2=CC=C(C=C12)C(C)=O
adenosine triphosphate,P2X purinoceptor 4,P2rx4,5.3,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adenosine triphosphate,P2X purinoceptor 4,P2rx4,5.3,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
amiodarone,Multidrug resistance protein 1,ABCB1,5.3,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amsacrine,Solute carrier family 22 member 1,SLC22A1,5.3,IC50,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
azimilide,Potassium voltage-gated channel subfamily KQT member 1,Kcnq1,5.3,IC50,CN1CCN(CCCCN2C(=O)CN(N=CC3=CC=C(O3)C3=CC=C(Cl)C=C3)C2=O)CC1
bimatoprost,Aldo-keto reductase family 1 member C3,AKR1C3,5.3,IC50,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
bimatoprost,Prostaglandin F2-alpha receptor,PTGFR,5.3,Ki,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
chlorpromazine,5-hydroxytryptamine receptor 7,Htr7,5.3,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cianidanol,Carbonic anhydrase 9,CA9,5.3,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
ciclopirox,Deoxyhypusine hydroxylase,DOHH,5.3,IC50,CC1=CC(=O)N(O)C(=C1)C1CCCCC1
clomipramine,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,5.3,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clozapine,5-hydroxytryptamine receptor 5A,Htr5a,5.3,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
colforsin daropate,"Solute carrier family 2, facilitated glucose transporter member 1",SLC2A1,5.3,Kd,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C
dactinomycin,Growth factor receptor-bound protein 2,GRB2,5.3,IC50,CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2=C3N=C4C(OC3=C(C)C=C2)=C(C)C(=O)C(N)=C4C(=O)N[C@H]2[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]3CCCN3C(=O)[C@H](NC2=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O
dactinomycin,Growth factor receptor-bound protein 2,Grb2,5.3,IC50,CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2=C3N=C4C(OC3=C(C)C=C2)=C(C)C(=O)C(N)=C4C(=O)N[C@H]2[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]3CCCN3C(=O)[C@H](NC2=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O
dasatinib,Vascular endothelial growth factor receptor 1,FLT1,5.3,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
deferoxamine,Deoxyhypusine hydroxylase,DOHH,5.3,IC50,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
diethylstilbestrol,Estrogen-related receptor gamma,ESRRG,5.3,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
diethylstilbestrol,Steroid hormone receptor ERR2,ESRRB,5.3,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
diethylstilbestrol,Steroid hormone receptor ERR1,Esrra,5.3,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
dinoprostone,Prostaglandin D2 receptor 2,PTGDR2,5.3,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
diphenoxylate,Potassium voltage-gated channel subfamily A member 3,KCNA3,5.3,IC50,CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1
docetaxel,Nucleotide-binding oligomerization domain-containing protein 2,NOD2,5.3,IC50,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
ethacrynic acid,Glutathione S-transferase A1,GSTA1,5.3,IC50,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
ethoxzolamide,Carbonic anhydrase 3,CA3,5.3,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
fasudil,Ribosomal protein S6 kinase alpha-5,RPS6KA5,5.3,IC50,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
felodipine,Bile acid receptor,NR1H4,5.3,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
fenoldopam,Adrenergic receptor alpha-1,ADRA1D|ADRA1A|ADRA1B,5.3,Kd,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
fentanyl,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.3,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
fentanyl,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.3,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
fluoxetine,5-hydroxytryptamine receptor 2B,HTR2B,5.3,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
aminobutyric acid,Sodium- and chloride-dependent GABA transporter 1,SLC6A1,5.3,IC50,NCCCC(O)=O
aminobutyric acid,Sodium- and chloride-dependent GABA transporter 2,Slc6a13,5.3,IC50,NCCCC(O)=O
granisetron,Multidrug and toxin extrusion protein 1,SLC47A1,5.3,IC50,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
imatinib,Tyrosine-protein kinase SYK,SYK,5.3,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Lysine--tRNA ligase,KARS,5.3,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imipramine,Sphingomyelin phosphodiesterase,SMPD1,5.3,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
indomethacin,Aldose reductase,AKR1B1,5.3,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
iproniazid,Amine oxidase [flavin-containing] A,Maoa,5.3,IC50,CC(C)NNC(=O)C1=CC=NC=C1
isoprenaline,Beta-3 adrenergic receptor,Adrb3,5.3,Ki,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Beta-3 adrenergic receptor,Adrb3,5.3,Ki,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
lucanthone,DNA-(apurinic or apyrimidinic site) lyase,APEX1,5.3,IC50,CCN(CC)CCNC1=CC=C(C)C2=C1C(=O)C1=CC=CC=C1S2
mifepristone,Estrogen receptor,ESR1,5.3,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
milrinone,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,5.3,IC50,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
mimosine,Deoxyhypusine hydroxylase,DOHH,5.3,IC50,N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O
mirtazapine,5-hydroxytryptamine receptor 1A,HTR1A,5.3,Kd,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
moclobemide,5-hydroxytryptamine receptor 1A,HTR1A,5.3,Kd,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
norepinephrine,Beta-2 adrenergic receptor,ADRB2,5.3,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
ondansetron,5-hydroxytryptamine receptor 2C,Htr2c,5.3,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
oxaprozin,Bifunctional epoxide hydrolase 2,EPHX2,5.3,IC50,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
paclitaxel,Nuclear receptor subfamily 1 group I member 2,NR1I2,5.3,EC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
palmidrol,Fatty-acid amide hydrolase 1,Faah,5.3,IC50,CCCCCCCCCCCCCCCC(=O)NCCO
phenylephrine,Alpha-1A adrenergic receptor,ADRA1A,5.3,Ki,CNC[C@H](O)C1=CC(O)=CC=C1
physostigmine,Cholinesterase,BCHE,5.3,Ki,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
progesterone,Short transient receptor potential channel 5,TRPC5,5.3,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
promazine,Major prion protein,PRNP,5.3,EC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
pyrimethamine,Dihydrofolate reductase,DFR1,5.3,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
sotalol,Beta-2 adrenergic receptor,ADRB2,5.3,IC50,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
spiperone,D(1B) dopamine receptor,DRD5,5.3,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
strychnine,Taste receptor type 2 member 10,TAS2R10,5.3,EC50,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
sunitinib,Serine/threonine-protein kinase pim-2,PIM2,5.3,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terconazole,Heme oxygenase 2,Hmox2,5.3,IC50,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
terconazole,Heme oxygenase 2,Hmox2,5.3,IC50,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
tranylcypromine,Cytochrome P450 2C19,CYP2C19,5.3,IC50,N[C@@H]1C[C@H]1C1=CC=CC=C1
tretoquinol,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,5.3,Ki,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
triamterene,"Amiloride-sensitive sodium channel, ENaC",SCNN1A|SCNN1B|SCNN1G,5.3,IC50,NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1
trifluoperazine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.3,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
tropisetron,Glycine receptor subunit beta,GLRB,5.3,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
suramin,P2Y purinoceptor 1,P2RY1,5.3,Ki,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
broxuridine,"Thymidine kinase, cytosolic",TK1,5.3,Ki,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(Br)C(=O)NC1=O
broxuridine,Thymidylate kinase,tmk,5.3,Ki,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(Br)C(=O)NC1=O
clorindione,Arachidonate 5-lipoxygenase,Alox5,5.3,IC50,ClC1=CC=C(C=C1)C1C(=O)C2=C(C=CC=C2)C1=O
homonicotinic acid,Hydroxycarboxylic acid receptor 2,HCAR2,5.3,EC50,OC(=O)CC1=CN=CC=C1
yohimbine,5-hydroxytryptamine receptor 5A,HTR5A,5.3,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
mozavaptan,Vasopressin V1 receptor,Avpr1a|Avpr1b,5.3,IC50,CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C2=CC=CC=C12
dronabinol,Glycine receptor subunit alpha-3,GLRA3,5.3,EC50,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
pazopanib,Tyrosine-protein kinase Yes,YES1,5.3,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Serine/threonine-protein kinase 32A,STK32A,5.3,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vemurafenib,"Ferrochelatase, mitochondrial",FECH,5.3,EC50,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F
deferiprone,Deoxyhypusine hydroxylase,DOHH,5.3,IC50,CN1C=CC(=O)C(O)=C1C
vilazodone,5-hydroxytryptamine receptor 1B,Htr1b,5.3,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
bosutinib,Hormonally up-regulated neu tumor-associated kinase,HUNK,5.3,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
linopirdine,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,5.3,IC50,O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase 9,MAPK9,5.3,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
enasidenib,Isocitrate dehydrogenase [NADP] cytoplasmic,IDH1,5.3,IC50,CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=CC=CC(=N1)C(F)(F)F
enasidenib,Isocitrate dehydrogenase [NADP] cytoplasmic,IDH1,5.3,IC50,CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=CC=CC(=N1)C(F)(F)F
fedratinib,Tyrosine-protein kinase Srms,SRMS,5.3,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cadralazine,Myeloperoxidase,MPO,5.301,IC50,CCOC(=O)NNC1=CC=C(N=N1)N(CC)CC(C)O
carmofur,Cytochrome P450 2D6,CYP2D6,5.301,IC50,CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O
clozapine,Beta-1 adrenergic receptor,ADRB1,5.301,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dextropropoxyphene,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,5.301,IC50,CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1
dihydroergotamine,Cytochrome P450 3A4,CYP3A4,5.301,IC50,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
duloxetine,5-hydroxytryptamine receptor 1A,HTR1A,5.301,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
haloperidol,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,5-hydroxytryptamine receptor 1F,HTR1F,5.301,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,5-hydroxytryptamine receptor 1E,HTR1E,5.301,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
idebenone,Cytochrome P450 2C9,CYP2C9,5.301,IC50,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
mefenamic acid,Cytochrome P450 2C9,CYP2C9,5.301,EC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
montelukast,Cysteinyl leukotriene receptor 2,CYSLTR2,5.301,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
nabumetone,Cytochrome P450 1A2,CYP1A2,5.301,IC50,COC1=CC=C2C=C(CCC(C)=O)C=CC2=C1
olanzapine,Beta-1 adrenergic receptor,ADRB1,5.301,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
olanzapine,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
omeprazole,Cytochrome P450 2C19,CYP2C19,5.301,Ki,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
palmidrol,Cannabinoid receptor 1,CNR1,5.301,Ki,CCCCCCCCCCCCCCCC(=O)NCCO
palmidrol,Cannabinoid receptor 2,CNR2,5.301,Ki,CCCCCCCCCCCCCCCC(=O)NCCO
pipamperone,Beta-1 adrenergic receptor,ADRB1,5.301,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
pipamperone,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
pipamperone,5-hydroxytryptamine receptor 1F,HTR1F,5.301,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
pipamperone,5-hydroxytryptamine receptor 1E,HTR1E,5.301,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
quetiapine,Beta-1 adrenergic receptor,ADRB1,5.301,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
quetiapine,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
risperidone,Beta-1 adrenergic receptor,ADRB1,5.301,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
risperidone,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sertindole,Beta-1 adrenergic receptor,ADRB1,5.301,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sertindole,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
tacrine,Aldehyde oxidase,AOX1,5.301,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
ziprasidone,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
podophyllotoxin,Cytochrome P450 2C19,CYP2C19,5.301,IC50,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
asenapine,Beta-1 adrenergic receptor,ADRB1,5.301,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
asenapine,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
paliperidone,Beta-1 adrenergic receptor,ADRB1,5.301,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
paliperidone,Beta-2 adrenergic receptor,ADRB2,5.301,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
ritonavir,Vasopressin V1a receptor,AVPR1A,5.303,Ki,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
famotidine,Heat shock protein HSP 90-alpha,HSP90AA1,5.304,IC50,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
mitoxantrone,Sodium-dependent noradrenaline transporter,SLC6A2,5.306,Ki,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
dexchlorpheniramine,Sodium-dependent noradrenaline transporter,SLC6A2,5.308,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
bepridil,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,5.31,IC50,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
caffeine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.31,IC50,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
cefapirin,Cytochrome P450 3A4,CYP3A4,5.31,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
cianidanol,Carbonic anhydrase 4,CA4,5.31,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
cianidanol,Carbonic anhydrase 6,CA6,5.31,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
clemastine,Solute carrier family 22 member 1,SLC22A1,5.31,IC50,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
ciclosporin,Cytochrome P450 3A4,CYP3A4,5.31,Ki,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dexamfetamine,Sodium-dependent dopamine transporter,Slc6a3,5.31,IC50,C[C@H](N)CC1=CC=CC=C1
eperisone,Cytochrome P450 2D6,CYP2D6,5.31,IC50,CCC1=CC=C(C=C1)C(=O)C(C)CN1CCCCC1
erlotinib,Receptor-interacting serine/threonine-protein kinase 4,RIPK4,5.31,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
glutamic acid,Metabotropic glutamate receptor 6,GRM6,5.31,EC50,N[C@@H](CCC(O)=O)C(O)=O
indapamide,Carbonic anhydrase 14,CA14,5.31,Ki,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
isoniazid,Cytochrome P450 3A4,CYP3A4,5.31,IC50,NNC(=O)C1=CC=NC=C1
ketamine,Acetylcholine receptor subunit alpha,CHRNA1,5.31,IC50,CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1
masoprocol,Transient receptor potential cation channel subfamily A member 1,TRPA1,5.31,EC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
masoprocol,Transient receptor potential cation channel subfamily A member 1,TRPA1,5.31,EC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
paclitaxel,Tyrosine-protein kinase Mer,MERTK,5.31,IC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
tacrine,Glutamate NMDA receptor; GRIN1/GRIN2A,GRIN1|GRIN2A,5.31,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
tiamenidine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.31,IC50,CC1=CSC(Cl)=C1N=C1NCCN1
topiramate,Carbonic anhydrase 4,CA4,5.31,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
triflupromazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.31,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
enoxolone,Aldo-keto reductase family 1 member B10,AKR1B10,5.31,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
iloperidone,Muscarinic acetylcholine receptor M1,CHRM1,5.31,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
benidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,5.31,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1
guanabenz,Solute carrier family 22 member 1,SLC22A1,5.31,IC50,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
ruxolitinib,Serine/threonine-protein kinase Nek7,NEK7,5.31,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,G protein-coupled receptor kinase 4,GRK4,5.31,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Activin receptor type-1B,ACVR1B,5.31,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Tyrosine-protein kinase receptor TYRO3,TYRO3,5.31,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
selexipag,Prostaglandin E2 receptor EP4 subtype,PTGER4,5.31,Ki,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1
selexipag,Prostaglandin E2 receptor EP4 subtype,PTGER4,5.31,Ki,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1
monobenzone,Arachidonate 15-lipoxygenase,ALOX15,5.311,IC50,OC1=CC=C(OCC2=CC=CC=C2)C=C1
astemizole,Sodium/nucleoside cotransporter 1,SLC28A1,5.312,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
diethylstilbestrol,Sodium/nucleoside cotransporter 1,SLC28A1,5.316,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
myrtecaine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.316,Ki,CCN(CC)CCOCCC1=CC[C@H]2C[C@@H]1C2(C)C
aztreonam,Penicillin-binding protein 1A,mrcA,5.317,IC50,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
diethylstilbestrol,Glucocorticoid receptor,NR3C1,5.317,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
nilotinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,5.318,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
thiothixene,Muscarinic acetylcholine receptor M5,CHRM5,5.318,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
bromperidol,Muscarinic acetylcholine receptor M5,CHRM5,5.319,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
disulfiram,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,5.319,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
aldosterone,Sex hormone-binding globulin,SHBG,5.32,Kd,C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3CC[C@H](C(=O)CO)[C@]3(C[C@H](O)[C@H]21)C=O
bepridil,Lethal factor,lef,5.32,IC50,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
carbachol,Neuronal acetylcholine receptor; alpha3/beta4,Chrna3|Chrnb4,5.32,Ki,C[N+](C)(C)CCOC(N)=O
clioquinol,Catechol O-methyltransferase,Comt,5.32,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1I
clotrimazole,14-alpha sterol demethylase Cyp51A,,5.32,Kd,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
cromoglicic acid,G-protein coupled receptor 35,Gpr35,5.32,EC50,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O
hydroxychloroquine,Muscarinic acetylcholine receptor M3,CHRM3,5.32,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
ibuproxam,Arachidonate 5-lipoxygenase,Alox5,5.32,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO
mafenide,Carbonic anhydrase 6,CA6,5.32,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mosapride,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.32,IC50,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
nicardipine,Multidrug resistance protein 1,ABCB1,5.32,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
nicotine,Lycopene cyclase,crtY,5.32,IC50,CN1CCC[C@H]1C1=CC=CN=C1
perlapine,Histamine H4 receptor,HRH4,5.32,Ki,CN1CCN(CC1)C1=NC2=C(CC3=CC=CC=C13)C=CC=C2
pioglitazone,CDGSH iron-sulfur domain-containing protein 2,CISD2,5.32,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
ademetionine,Phenylethanolamine N-methyltransferase,PNMT,5.32,Kd,C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N
sorafenib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,5.32,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,5.32,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiperone,5-hydroxytryptamine receptor 1B,Htr1b,5.32,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
thiotepa,Cytochrome P450 2B6,CYP2B6,5.32,Ki,S=P(N1CC1)(N1CC1)N1CC1
troglitazone,Amine oxidase [flavin-containing] A,Maoa,5.32,Ki,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
tubocurarine,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,5.32,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
voriconazole,Cytochrome P450 11A1,CYP11A1,5.32,Kd,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
voriconazole,"Cholesterol side-chain cleavage enzyme, mitochondrial",CYP11A1,5.32,Kd,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
quercetin,Carbonic anhydrase 7,CA7,5.32,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,"Glycogen phosphorylase, liver form",PYGL,5.32,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
rasagiline,Cholinesterase,BCHE,5.32,IC50,C#CCN[C@@H]1CCC2=C1C=CC=C2
ruxolitinib,Mitogen-activated protein kinase 8,MAPK8,5.32,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Serine/threonine-protein kinase MRCK beta,CDC42BPB,5.32,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Serine/threonine-protein kinase SBK1,SBK1,5.32,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
tofacitinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,5.32,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
thioctic acid,SUMO-activating enzyme,SAE1|UBA2,5.32,IC50,OC(=O)CCCCC1CCSS1
ethyl hydroxybenzoate,Carbonic anhydrase 2,CA2,5.32,Ki,CCOC(=O)C1=CC=C(O)C=C1
midostaurin,Testis-specific serine/threonine-protein kinase 1,TSSK1B,5.32,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Dual specificity mitogen-activated protein kinase kinase 4,MAP2K4,5.32,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase TXK,TXK,5.32,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
dexfenfluramine,Muscarinic acetylcholine receptor M3,CHRM3,5.326,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
miconazole,Androgen receptor,Ar,5.326,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
stanozolol,Adenosine receptor A3,ADORA3,5.327,Ki,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=NN5
cefsulodin,Penicillin-binding protein 1B,mrcB,5.328,IC50,NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C2=CC=CC=C2)S(O)(=O)=O)C3=O)C([O-])=O)C=C1
montelukast,Tyrosine-protein kinase Fyn,FYN,5.328,IC50,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
primaquine,Aryl hydrocarbon receptor,AHR,5.328,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
tamoxifen,Delta-type opioid receptor,OPRD1,5.328,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
aripiprazole,Muscarinic acetylcholine receptor M3,CHRM3,5.33,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
chloroquine,Muscarinic acetylcholine receptor M2,CHRM2,5.33,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
cianidanol,Carbonic anhydrase 12,CA12,5.33,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
dabigatran etexilate,Solute carrier family 22 member 2,SLC22A2,5.33,IC50,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
enprofylline,Adenosine receptor A2b,ADORA2B,5.33,Ki,CCCN1C2=C(N=CN2)C(=O)NC1=O
fluphenazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.33,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine,Potassium channel subfamily K member 2,KCNK2,5.33,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
gamolenic acid,Free fatty acid receptor 1,FFAR1,5.33,EC50,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
haloperidol,5-hydroxytryptamine receptor 2C,HTR2C,5.33,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ibuprofen,Solute carrier family 22 member 6,Slc22a6,5.33,Ki,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
isoniazid,Myeloperoxidase,MPO,5.33,IC50,NNC(=O)C1=CC=NC=C1
isoprenaline,D(3) dopamine receptor,DRD3,5.33,Ki,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
itraconazole,7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,CYP8B1,5.33,IC50,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mianserin,5-hydroxytryptamine receptor 1B,Htr1b,5.33,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
milrinone,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,5.33,Ki,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
nilotinib,Carbonic anhydrase 13,Ca13,5.33,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Serine/threonine-protein kinase TAO1,TAOK1,5.33,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
orlistat,Fatty acid synthase,FASN,5.33,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
paroxetine,P2X purinoceptor 4,P2RX4,5.33,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
phenolphthalein,Thymidylate synthase,thyA,5.33,Ki,OC1=CC=C(C=C1)C1(OC(=O)C2=C1C=CC=C2)C1=CC=C(O)C=C1
phenolphthalein,Thymidylate synthase,thyA,5.33,Ki,OC1=CC=C(C=C1)C1(OC(=O)C2=C1C=CC=C2)C1=CC=C(O)C=C1
sildenafil,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",PDE7A,5.33,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sulfamethoxazole,Dihydropteroate synthase,folP,5.33,IC50,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
sunitinib,Serine/threonine-protein kinase PLK2,PLK2,5.33,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
valsartan,Type-1 angiotensin II receptor,AGTR1,5.33,Ki,CCCCC(=O)N(CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)[C@@H](C(C)C)C(O)=O
zolpidem,Translocator protein,Tspo,5.33,IC50,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
pazopanib,Tyrosine-protein kinase SYK,SYK,5.33,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
ceritinib,Cyclin-dependent kinase 4,CDK4,5.33,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
midostaurin,Serine/threonine-protein kinase 17B,STK17B,5.33,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Death-associated protein kinase 1,DAPK1,5.33,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Dual serine/threonine and tyrosine protein kinase,DSTYK,5.33,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
upadacitinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,5.33,IC50,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F
fedratinib,5'-AMP-activated protein kinase catalytic subunit alpha-2,PRKAA2,5.33,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
oliceridine,Sodium channel protein type 5 subunit alpha,SCN5A,5.33,IC50,COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
oliceridine,Sodium channel protein type 5 subunit alpha,SCN5A,5.33,IC50,COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
trilaciclib,Cyclin-dependent kinase 7,CDK7,5.33,IC50,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
oxiconazole,Acetylcholinesterase,ACHE,5.333,IC50,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
methysergide,Muscarinic acetylcholine receptor M3,CHRM3,5.334,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
tamoxifen,D(2) dopamine receptor,DRD2,5.335,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
econazole,D(1A) dopamine receptor,DRD1,5.336,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
econazole,Beta-3 adrenergic receptor,ADRB3,5.336,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lofepramine,5-hydroxytryptamine receptor 1A,HTR1A,5.337,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
mirtazapine,Sodium-dependent noradrenaline transporter,SLC6A2,5.337,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
nisoldipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.337,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
propafenone,Cytochrome P450 2D6,CYP2D6,5.337,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
bithionol,5-hydroxytryptamine receptor 2C,HTR2C,5.337,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
leflunomide,Sodium-dependent noradrenaline transporter,SLC6A2,5.338,Ki,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
terconazole,Muscarinic acetylcholine receptor M2,CHRM2,5.338,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
felodipine,Cytochrome P450 2C9,CYP2C9,5.339,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
amiodarone,D(1A) dopamine receptor,DRD1,5.34,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
astemizole,Delta-type opioid receptor,OPRD1,5.34,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
bortezomib,Carbonic anhydrase 3,CA3,5.34,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
cefapirin,Mu-type opioid receptor,OPRM1,5.34,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
chlormadinone,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,5.34,IC50,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
cycloserine,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,5.34,IC50,N[C@@H]1CONC1=O
dasatinib,Serine/threonine-protein kinase ULK3,ULK3,5.34,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
gefitinib,NUAK family SNF1-like kinase 2,NUAK2,5.34,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
imatinib,Carbonic anhydrase 4,CA4,5.34,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
mebendazole,Tyrosine-protein kinase ABL1,ABL1,5.34,Ki,COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1=CC=CC=C1
metyrapone,"Cytochrome P450 11B1, mitochondrial",Cyp11b1,5.34,IC50,CC(C)(C(=O)C1=CN=CC=C1)C1=CN=CC=C1
mezlocillin,Aldose reductase,AKR1B1,5.34,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
omeprazole,Glutathione S-transferase omega-1,GSTO1,5.34,IC50,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
remoxipride,D(3) dopamine receptor,DRD3,5.34,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
sildenafil,Phosphodiesterase 4,Pde4d|Pde4c|Pde4b|Pde4a,5.34,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sunitinib,Protein-tyrosine kinase 6,PTK6,5.34,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
gabexate,Coagulation factor X,F10,5.34,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
ivabradine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2,Hcn2,5.34,EC50,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
ruboxistaurin,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,5.34,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
crizotinib,Serine/threonine-protein kinase NIM1,NIM1K,5.34,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
lacosamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.34,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
bosutinib,Testis-specific serine/threonine-protein kinase 1,TSSK1B,5.34,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase D3,PRKD3,5.34,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dolutegravir,Vesicular acetylcholine transporter,Slc18a3,5.34,Ki,C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12
nintedanib,Microtubule-associated serine/threonine-protein kinase 1,MAST1,5.34,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Wee1-like protein kinase,WEE1,5.34,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Insulin receptor-related protein,INSRR,5.34,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Mitogen-activated protein kinase kinase kinase 10,MAP3K10,5.34,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
quizartinib,STE20-like serine/threonine-protein kinase,SLK,5.34,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
enoximone,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,5.345,IC50,CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1
loperamide,Somatostatin receptor type 5,SSTR5,5.345,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,D(1A) dopamine receptor,DRD1,5.346,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
ketoconazole,Delta-type opioid receptor,OPRD1,5.346,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
propranolol,5-hydroxytryptamine receptor 1D,HTR1D,5.346,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
amiodarone,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,5.347,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
nifedipine,Adenosine receptor A1,ADORA1,5.348,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
apomorphine,Zinc finger protein mex-5,mex-5,5.35,EC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
apomorphine,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,5.35,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
chlorpromazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.35,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cisapride,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,5.35,IC50,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cisapride,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.35,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
dexamfetamine,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,5.35,Kd,C[C@H](N)CC1=CC=CC=C1
dinoprost,Prostaglandin D2 receptor,PTGDR,5.35,IC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
erlotinib,TRAF2 and NCK-interacting protein kinase,TNIK,5.35,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
histamine,Histamine H1 receptor,Hrh1,5.35,EC50,NCCC1=CN=CN1
imatinib,Dual specificity protein kinase CLK1,CLK1,5.35,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
progesterone,C-8 sterol isomerase,ERG2,5.35,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
protionamide,Polyphenol oxidase 2,PPO2,5.35,IC50,CCCC1=CC(=CC=N1)C(N)=S
pyrimethamine,Beta-hexosaminidase subunit beta,HEXB,5.35,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
mepacrine,Cholinesterase,BCHE,5.35,IC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
rabeprazole,Cytosolic endo-beta-N-acetylglucosaminidase,ENGASE,5.35,IC50,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
sildenafil,"Indoleamine 2,3-dioxygenase 2",Ido2,5.35,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,Tyrosine-protein kinase receptor UFO,AXL,5.35,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Myosin-IIIb,MYO3B,5.35,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
troglitazone,"Indoleamine 2,3-dioxygenase 2",Ido2,5.35,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
vardenafil,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,5.35,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
ivabradine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1,Hcn1,5.35,EC50,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
quercetin,C-X-C chemokine receptor type 1,CXCR1,5.35,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,5.35,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vandetanib,"Chaperone activity of bc1 complex-like, mitochondrial",COQ8A,5.35,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
axitinib,Serine/threonine-protein kinase PAK 4,PAK4,5.35,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,Carbonic anhydrase 7,CA7,5.35,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
afatinib,Receptor tyrosine-protein kinase erbB-3,ERBB3,5.35,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,5.35,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,5.35,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dexrabeprazole,Cytosolic endo-beta-N-acetylglucosaminidase,ENGASE,5.35,IC50,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
istradefylline,Adenosine receptor A3,ADORA3,5.35,Ki,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
nintedanib,Inhibitor of nuclear factor kappa-B kinase subunit alpha,CHUK,5.35,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Serine/threonine-protein kinase 35,STK35,5.35,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
clotrimazole,Alpha-2A adrenergic receptor,ADRA2A,5.351,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
duloxetine,5-hydroxytryptamine receptor 1F,HTR1F,5.352,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
chlorpromazine,Kappa-type opioid receptor,OPRK1,5.353,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clotrimazole,Sodium-dependent dopamine transporter,SLC6A3,5.353,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
diethylstilbestrol,D(2) dopamine receptor,DRD2,5.353,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
dicoumarol,Mitogen-activated protein kinase 1,MAPK1,5.354,IC50,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
clozapine,Aldehyde oxidase,AOX1,5.356,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
fluoxetine,Beta-1 adrenergic receptor,ADRB1,5.356,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
flutamide,Cytochrome P450 1A2,CYP1A2,5.356,Ki,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
nicotine,Cytochrome P450 2A6,CYP2A6,5.356,IC50,CN1CCC[C@H]1C1=CC=CN=C1
perhexiline,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.356,Ki,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
disulfiram,C-C chemokine receptor type 4,CCR4,5.357,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
melperone,Muscarinic acetylcholine receptor M4,CHRM4,5.357,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
tamoxifen,Prostaglandin G/H synthase 1,PTGS1,5.357,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
amlodipine,Sodium-dependent dopamine transporter,SLC6A3,5.358,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
econazole,Alpha-1D adrenergic receptor,ADRA1D,5.359,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
zafirlukast,Mitogen-activated protein kinase 3,MAPK3,5.359,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
adenosine,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,5.36,Kd,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
amiloride,Acid-sensing ion channel 3,ASIC3,5.36,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
bortezomib,Carbonic anhydrase 6,CA6,5.36,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
brinzolamide,Carbonic anhydrase,,5.36,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
chloroquine,Alpha-2A adrenergic receptor,ADRA2A,5.36,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
dobutamine,Carbonic anhydrase 12,CA12,5.36,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
erlotinib,Vascular endothelial growth factor receptor 1,FLT1,5.36,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Serine/threonine-protein kinase 36,STK36,5.36,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Eukaryotic translation initiation factor 2-alpha kinase 4,EIF2AK4,5.36,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fenoprofen,Prostaglandin G/H synthase 1,PTGS1,5.36,IC50,CC(C(O)=O)C1=CC=CC(OC2=CC=CC=C2)=C1
gefitinib,Tyrosine-protein kinase HCK,HCK,5.36,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,Metabotropic glutamate receptor 5,Grm5,5.36,EC50,N[C@@H](CCC(O)=O)C(O)=O
lapatinib,Dual specificity mitogen-activated protein kinase kinase 7,MAP2K7,5.36,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
loxapine,Potassium channel subfamily T member 1,KCNT1,5.36,EC50,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
methylthioninium chloride,Amine oxidase [flavin-containing] B,MAOB,5.36,IC50,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
rimantadine,Solute carrier family 22 member 2,SLC22A2,5.36,IC50,CC(N)C12CC3CC(CC(C3)C1)C2
ritonavir,Multidrug and toxin extrusion protein 2,SLC47A2,5.36,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
thalidomide,Cereblon isoform 4,,5.36,Ki,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2
cetrimonium,Dynamin-1,DNM1,5.36,IC50,CCCCCCCCCCCCCCCC[N+](C)(C)C
pazopanib,Serine/threonine-protein kinase NLK,NLK,5.36,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Misshapen-like kinase 1,MINK1,5.36,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Mitogen-activated protein kinase kinase kinase 1,MAP3K1,5.36,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
quinine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.36,IC50,COC1=CC=C2N=CC=C([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
idelalisib,Phosphatidylinositol 3-kinase catalytic subunit type 3,PIK3C3,5.36,IC50,CC[C@H](NC1=NC=NC2=C1NC=N2)C1=NC2=C(C(F)=CC=C2)C(=O)N1C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase 8,MAPK8,5.36,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,RAC-gamma serine/threonine-protein kinase,AKT3,5.36,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
elagolix,Gonadotropin-releasing hormone receptor,Gnrhr,5.36,Ki,COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(F)C=CC=C2C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O
fedratinib,Ephrin type-A receptor 2,EPHA2,5.36,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Hepatocyte growth factor receptor,MET,5.36,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Aurora kinase A,AURKA,5.36,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase NIM1,NIM1K,5.36,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
diethylstilbestrol,Thromboxane-A synthase,TBXAS1,5.361,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
econazole,5-hydroxytryptamine receptor 2B,HTR2B,5.362,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
terconazole,Sodium-dependent dopamine transporter,SLC6A3,5.362,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
maprotiline,Cytochrome P450 3A4,CYP3A4,5.364,IC50,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
amoxapine,Sodium-dependent dopamine transporter,SLC6A3,5.365,Kd,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
sertraline,Melanocortin receptor 5,MC5R,5.365,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
bithionol,5-hydroxytryptamine receptor 2B,HTR2B,5.365,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
norepinephrine,Beta-3 adrenergic receptor,ADRB3,5.367,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
amiodarone,C-C chemokine receptor type 2,CCR2,5.368,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
etynodiol,Amine oxidase [flavin-containing] A,MAOA,5.368,IC50,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1
carbenicillin,Muscarinic acetylcholine receptor M1,CHRM1,5.37,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
chlorpromazine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.37,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
colchicine,Serine/threonine-protein kinase pim-1,PIM1,5.37,IC50,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
dobutamine,Carbonic anhydrase 7,CA7,5.37,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
dorzolamide,Carbonic anhydrase,cynT,5.37,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
econazole,D(2) dopamine receptor,DRD2,5.37,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
epinastine,Solute carrier family 22 member 2,SLC22A2,5.37,IC50,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
erlotinib,Mitogen-activated protein kinase 10,MAPK10,5.37,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
flunarizine,5-hydroxytryptamine receptor 1A,Htr1a,5.37,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
granisetron,Solute carrier family 22 member 2,SLC22A2,5.37,IC50,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
hydrochlorothiazide,Delta carbonic anhydrase,ca1,5.37,Ki,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
imatinib,Serine/threonine-protein kinase TNNI3K,TNNI3K,5.37,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
pimethixene,Histone-lysine N-methyltransferase SETD7,SETD7,5.37,IC50,CN1CCC(CC1)=C1C2=CC=CC=C2SC2=C1C=CC=C2
risperidone,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.37,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
saquinavir,5-hydroxytryptamine receptor 1A,Htr1a,5.37,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
sunitinib,Mitogen-activated protein kinase 10,MAPK10,5.37,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Protein kinase C theta type,PRKCQ,5.37,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
ivabradine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,5.37,EC50,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
quercetin,D-alanine--D-alanine ligase,ddl,5.37,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Serine/threonine-protein kinase Nek6,NEK6,5.37,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
crizotinib,Aurora kinase C,AURKC,5.37,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
vilazodone,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,5.37,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
axitinib,Dual specificity testis-specific protein kinase 1,TESK1,5.37,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Serine/threonine-protein kinase 10,STK10,5.37,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
tofacitinib,Serine/threonine-protein kinase 3,STK3,5.37,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
tofacitinib,G protein-coupled receptor kinase 7,GRK7,5.37,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
succinimide,Cereblon isoform 4,,5.37,Ki,O=C1CCC(=O)N1
fedratinib,Vascular endothelial growth factor receptor 1,FLT1,5.37,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ankyrin repeat and protein kinase domain-containing protein 1,ANKK1,5.37,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
clomifene,Beta-3 adrenergic receptor,ADRB3,5.371,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
estradiol,Progesterone receptor,PGR,5.372,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
tamoxifen,D(1A) dopamine receptor,DRD1,5.372,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
terconazole,Sodium/nucleoside cotransporter 1,SLC28A1,5.373,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
disulfiram,C-X-C chemokine receptor type 2,CXCR2,5.376,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
mitotane,Adenosine receptor A3,ADORA3,5.376,Ki,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
promethazine,Sodium-dependent noradrenaline transporter,SLC6A2,5.376,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
femoxetine,Histamine H1 receptor,HRH1,5.377,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
fenfluramine,5-hydroxytryptamine receptor 7,HTR7,5.378,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
pheniramine,Histamine H4 receptor,HRH4,5.378,Ki,CN(C)CCC(C1=CC=CC=C1)C1=NC=CC=C1
propranolol,5-hydroxytryptamine receptor 2A,HTR2A,5.378,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
alprenolol,Squalene synthase,Fdft1,5.38,IC50,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
astemizole,Glycine receptor subunit alpha-1,GLRA1,5.38,EC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
chlortalidone,Carbonic anhydrase 14,CA14,5.38,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
cianidanol,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.38,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
cyclovalone,Nuclear factor NF-kappa-B p105 subunit,NFKB1,5.38,IC50,COC1=C(O)C=CC(C=C2CCCC(=CC3=CC(OC)=C(O)C=C3)C2=O)=C1
dinoprost,Prostaglandin E2 receptor EP4 subtype,PTGER4,5.38,IC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dobutamine,Solute carrier family 22 member 1,SLC22A1,5.38,IC50,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
gefitinib,Serine/threonine-protein kinase NLK,NLK,5.38,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
imatinib,Solute carrier family 22 member 2,SLC22A2,5.38,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
miconazole,D(2) dopamine receptor,DRD2,5.38,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mirtazapine,D(1A) dopamine receptor,DRD1,5.38,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
mirtazapine,D(1A) dopamine receptor,Drd1,5.38,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
nefazodone,Bile salt export pump,ABCB11,5.38,IC50,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
norepinephrine,Beta-2 adrenergic receptor,Adrb2,5.38,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
rivastigmine,Acetylcholinesterase,ache,5.38,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
rosiglitazone,Amine oxidase [flavin-containing] B,MAOB,5.38,Ki,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sorafenib,Fibroblast growth factor receptor 3,FGFR3,5.38,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
toremifene,5-hydroxytryptamine receptor 6,HTR6,5.38,Ki,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
gentisic acid,Carbonic anhydrase 1,CA1,5.38,Ki,OC(=O)C1=C(O)C=CC(O)=C1
pyrithione,Carbonic anhydrase 13,CA13,5.38,Ki,[O-][N+]1=C(S)C=CC=C1
ticagrelor,P2Y purinoceptor 12,P2ry12,5.38,IC50,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1
crizotinib,Tyrosine-protein kinase ZAP-70,ZAP70,5.38,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,G protein-coupled receptor kinase 4,GRK4,5.38,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Casein kinase II subunit alpha,CSNK2A1,5.38,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Mitogen-activated protein kinase kinase kinase 1,MAP3K1,5.38,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase PknB,pknB,5.38,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ceritinib,Vascular endothelial growth factor receptor 2,KDR,5.38,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Serine/threonine-protein kinase receptor R3,ACVRL1,5.38,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,TGF-beta receptor type-1,TGFBR1,5.38,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Tyrosine-protein kinase Lyn,LYN,5.38,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase TAO3,TAOK3,5.38,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
ozanimod,Sphingosine 1-phosphate receptor 4,S1PR4,5.38,EC50,CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1
dotinurad,ATP-binding cassette sub-family G member 2,ABCG2,5.38,IC50,C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
infigratinib,Serine/threonine-protein kinase B-raf,BRAF,5.38,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Serine/threonine-protein kinase B-raf,BRAF,5.38,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
miconazole,Tyrosine-protein kinase Fyn,FYN,5.381,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
amisulpride,5-hydroxytryptamine receptor 6,HTR6,5.382,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
methamphetamine,Alpha-2A adrenergic receptor,ADRA2A,5.383,Ki,CN[C@@H](C)CC1=CC=CC=C1
dexfenfluramine,5-hydroxytryptamine receptor 2B,HTR2B,5.384,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
miconazole,Beta-3 adrenergic receptor,ADRB3,5.386,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nilotinib,Insulin receptor,INSR,5.387,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
dicoumarol,Aldose reductase,Akr1b1,5.388,IC50,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
terbinafine,Sodium-dependent noradrenaline transporter,SLC6A2,5.388,Ki,CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
paracetamol,Carbonic anhydrase 12,CA12,5.39,Ki,CC(=O)NC1=CC=C(O)C=C1
ambroxol,Glucosylceramidase,GBA,5.39,IC50,NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br
astemizole,Somatostatin receptor type 5,SSTR5,5.39,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
broxyquinoline,Catechol O-methyltransferase,Comt,5.39,IC50,OC1=C2N=CC=CC2=C(Br)C=C1Br
cyproheptadine,Sodium-dependent serotonin transporter,SLC6A4,5.39,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cyproheptadine,Sodium-dependent serotonin transporter,Slc6a4,5.39,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
erythromycin,Bile salt export pump,ABCB11,5.39,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
erythromycin propionate,Bile salt export pump,ABCB11,5.39,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
fluconazole,14-alpha sterol demethylase,cyp51B,5.39,Kd,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
loperamide,Cocaine esterase,CES2,5.39,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
medroxyprogesterone,Aldo-keto reductase family 1 member C2,AKR1C2,5.39,IC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
methylparaben,Carbonic anhydrase 14,CA14,5.39,Ki,COC(=O)C1=CC=C(O)C=C1
nicotine,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,5.39,Ki,CN1CCC[C@H]1C1=CC=CN=C1
pantoprazole,Fatty acid synthase,FASN,5.39,Ki,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
pranlukast,Uracil nucleotide/cysteinyl leukotriene receptor,GPR17,5.39,Ki,O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
propofol,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,5.39,EC50,CC(C)C1=CC=CC(C(C)C)=C1O
sunitinib,Serine/threonine-protein kinase Nek7,NEK7,5.39,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tiracizine,Nuclear receptor subfamily 1 group I member 3,NR1I3,5.39,IC50,CCOC(=O)NC1=CC=C2CCC3=C(C=CC=C3)N(C(=O)CN(C)C)C2=C1
gentisic acid,Carbonic anhydrase 2,CA2,5.39,Ki,OC(=O)C1=C(O)C=CC(O)=C1
oleic acid,Peroxisome proliferator-activated receptor gamma,PPARG,5.39,IC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
ruboxistaurin,Cyclin-dependent kinase-like 5,CDKL5,5.39,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Dual specificity mitogen-activated protein kinase kinase 6,MAP2K6,5.39,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Hepatocyte growth factor receptor,MET,5.39,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Cyclin-dependent kinase 7,CDK7,5.39,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Hormonally up-regulated neu tumor-associated kinase,HUNK,5.39,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
prazosin,Alpha-2A adrenergic receptor,ADRA2A,5.39,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
neratinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.39,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Ribosomal protein S6 kinase alpha-2,RPS6KA2,5.39,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Wee1-like protein kinase,WEE1,5.39,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 4,MAP3K4,5.39,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma,PIP4K2C,5.39,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
dotinurad,Solute carrier family 22 member 6,SLC22A6,5.39,IC50,C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
clotrimazole,D(2) dopamine receptor,DRD2,5.391,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
ketotifen,Histamine H2 receptor,HRH2,5.391,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
perhexiline,Tyrosine-protein kinase Fyn,FYN,5.391,IC50,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
rosiglitazone,Carbonic anhydrase 2,CA2,5.391,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
zotepine,Beta-1 adrenergic receptor,ADRB1,5.394,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
prazosin,Interstitial collagenase,MMP1,5.394,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
nisoldipine,Adenosine receptor A3,ADORA3,5.395,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
trovafloxacin,Thromboxane-A synthase,TBXAS1,5.395,IC50,N[C@H]1[C@@H]2CN(C[C@H]12)C1=C(F)C=C2C(=O)C(=CN(C3=C(F)C=C(F)C=C3)C2=N1)C(O)=O
quinapril,Angiotensin-converting enzyme,ACE,5.397,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O
altretamine,Cytochrome P450 1A2,CYP1A2,5.398,IC50,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
aprindine,Proteasome subunit alpha type-1,PSMA1,5.398,IC50,CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1
disulfiram,Cytochrome P450 1A2,CYP1A2,5.398,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
isotretinoin,17-beta-hydroxysteroid dehydrogenase type 6,HSD17B6,5.398,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
mianserin,Sodium-dependent serotonin transporter,SLC6A4,5.398,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nimodipine,Cytochrome P450 2C19,CYP2C19,5.398,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
phenelzine,Cytochrome P450 2C9,CYP2C9,5.398,IC50,NNCCC1=CC=CC=C1
phentolamine,Histamine H1 receptor,HRH1,5.398,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
propranolol,Cytochrome P450 1A2,CYP1A2,5.398,IC50,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
sirolimus,Cytochrome P450 2C19,CYP2C19,5.398,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
thiothixene,Muscarinic acetylcholine receptor M3,CHRM3,5.398,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
troglitazone,Cytochrome P450 2C9,CYP2C9,5.398,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
podophyllotoxin,Cytochrome P450 2C9,CYP2C9,5.398,IC50,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
luseogliflozin,Sodium/glucose cotransporter 1,SLC5A1,5.399,IC50,CCOC1=CC=C(CC2=C(C)C=C(OC)C(=C2)[C@@H]2S[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
adenosine triphosphate,P2Y purinoceptor 13,P2RY13,5.4,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
agomelatine,5-hydroxytryptamine receptor 2A,HTR2A,5.4,Ki,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
amiodarone,Cruzipain,,5.4,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amlexanox,G-protein coupled receptor 35,GPR35,5.4,EC50,CC(C)C1=CC=C2OC3=C(C=C(C(O)=O)C(N)=N3)C(=O)C2=C1
amodiaquine,Amyloid beta A4 protein,APP,5.4,IC50,CCN(CC)CC1=C(O)C=CC(NC2=CC=NC3=CC(Cl)=CC=C23)=C1
benzquinamide,D(2) dopamine receptor,DRD2,5.4,Ki,CCN(CC)C(=O)C1CN2CCC3=C(C=C(OC)C(OC)=C3)C2CC1OC(C)=O
brinzolamide,Carbonic anhydrase 4,CA4,5.4,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
bupivacaine,Potassium voltage-gated channel subfamily A member 5,KCNA5,5.4,Kd,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
buspirone,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.4,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
cefradine,Matrix metalloproteinase-9,MMP9,5.4,IC50,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O
cerulenin,Coagulation factor XIII A chain,F13A1,5.4,IC50,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O
chloroquine,Major prion protein,PRNP,5.4,EC50,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
cianidanol,"Carbonic anhydrase 5B, mitochondrial",CA5B,5.4,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
citalopram,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.4,IC50,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
levomenthol,Transient receptor potential cation channel subfamily M member 8,Trpm8,5.4,EC50,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
epinephrine,Mu-type opioid receptor,Oprm1,5.4,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
erlotinib,Tyrosine-protein kinase receptor UFO,AXL,5.4,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethionamide,Polyphenol oxidase 2,PPO2,5.4,IC50,CCC1=CC(=CC=N1)C(N)=S
etravirine,Cruzipain,,5.4,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
gefitinib,Ephrin type-A receptor 1,EPHA1,5.4,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,Metabotropic glutamate receptor 2,Grm2,5.4,EC50,N[C@@H](CCC(O)=O)C(O)=O
loratadine,Sodium-dependent neutral amino acid transporter B(0)AT2,SLC6A15,5.4,IC50,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
montelukast,5-hydroxytryptamine receptor 2B,HTR2B,5.4,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
nevirapine,Reverse transcriptase protein,reverse transcriptase,5.4,Ki,CC1=CC=NC2=C1NC(=O)C1=CC=CN=C1N2C1CC1
nifedipine,Acetylcholinesterase,ache,5.4,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
norepinephrine,Beta-2 adrenergic receptor,ADRB2,5.4,Kd,NC[C@H](O)C1=CC(O)=C(O)C=C1
oxycodone,Delta-type opioid receptor,OPRD1,5.4,EC50,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
propofol,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,5.4,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
raloxifene,Phospholipase D1,PLD1,5.4,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
remoxipride,5-hydroxytryptamine receptor 1A,HTR1A,5.4,Kd,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
riluzole,Pteridine reductase 1,PTR1,5.4,Ki,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
rizatriptan,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,5.4,IC50,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
sulbactam,Beta-lactamase,blaPER-6,5.4,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulfamethoxazole,Endothelin-1 receptor,Ednra,5.4,IC50,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
tamoxifen,Adenosine receptor A2a,ADORA2A,5.4,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
terbutaline,Beta-2 adrenergic receptor,ADRB2,5.4,Kd,CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1
sapropterin,Phenylalanine-4-hydroxylase,PAH,5.4,Ki,C[C@H](O)[C@H](O)[C@H]1CNC2=C(N1)C(=O)NC(N)=N2
trimethoprim,Bifunctional dihydrofolate reductase-thymidylate synthase,DHFR-TS,5.4,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
suramin,P2X purinoceptor 5,P2rx5,5.4,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
bithionol,Estrogen receptor,ESR1,5.4,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
eicosapentaenoic acid,Peroxisome proliferator-activated receptor delta,PPARD,5.4,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
prucalopride,5-hydroxytryptamine receptor 3A,HTR3A,5.4,Ki,COCCCN1CCC(CC1)NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2
quercetin,Beta-lactamase,ampC,5.4,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Arginase,,5.4,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
pazopanib,MAP/microtubule affinity-regulating kinase 3,MARK3,5.4,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
dexfosfoserine,Metabotropic glutamate receptor 4,Grm4,5.4,EC50,N[C@@H](COP(O)(O)=O)C(O)=O
crizotinib,Serine/threonine-protein kinase RIO3,RIOK3,5.4,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Dual specificity tyrosine-phosphorylation-regulated kinase 2,DYRK2,5.4,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,5.4,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase VRK2,VRK2,5.4,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
vilazodone,5-hydroxytryptamine receptor 1D,Htr1d,5.4,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
chenodiol,G-protein coupled bile acid receptor 1,GPBAR1,5.4,EC50,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
linopirdine,Potassium voltage-gated channel subfamily KQT member 3,Kcnq3,5.4,IC50,O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1
linolenic acid,Prostaglandin G/H synthase 1,PTGS1,5.4,Ki,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
vortioxetine,5-hydroxytryptamine receptor 1D,Htr1d,5.4,IC50,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
ceritinib,Cyclin-dependent kinase 2,CDK2,5.4,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,5.4,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Hepatocyte growth factor receptor,MET,5.4,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Ephrin type-A receptor 4,EPHA4,5.4,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Calcium/calmodulin-dependent protein kinase kinase 2,CAMKK2,5.4,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
dobutamine,Tyrosine-protein kinase Fyn,FYN,5.401,IC50,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
epinephrine,Beta-1 adrenergic receptor,ADRB1,5.401,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
duloxetine,5-hydroxytryptamine receptor 1B,HTR1B,5.402,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
chlorphentermine,Sodium-dependent dopamine transporter,SLC6A3,5.404,Ki,CC(C)(N)CC1=CC=C(Cl)C=C1
butriptyline,Sodium-dependent dopamine transporter,SLC6A3,5.405,Ki,CC(CC1C2=CC=CC=C2CCC2=C1C=CC=C2)CN(C)C
tamoxifen,D(4) dopamine receptor,DRD4,5.407,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
amiloride,Amine oxidase [flavin-containing] A,MAOA,5.408,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
diethylstilbestrol,Muscarinic acetylcholine receptor M3,CHRM3,5.408,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
saquinavir,Mu-type opioid receptor,OPRM1,5.408,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
hydroxyzine,Cytochrome P450 2D6,CYP2D6,5.409,Ki,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clozapine,Sodium-dependent serotonin transporter,SLC6A4,5.41,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyclothiazide,Glutamate receptor 4,GRIA4,5.41,EC50,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C2CC3CC2C=C3)C=C1Cl
dasatinib,Fibroblast growth factor receptor 3,FGFR3,5.41,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
erlotinib,Tyrosine-protein kinase receptor TYRO3,TYRO3,5.41,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fenbufen,Prostaglandin G/H synthase 1,PTGS1,5.41,IC50,OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
flecainide,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.41,IC50,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
ganciclovir,Metabotropic glutamate receptor 5,GRM5,5.41,Ki,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
hydralazine,Aldehyde oxidase,AOX1,5.41,IC50,NNC1=NN=CC2=CC=CC=C12
itraconazole,Tyrosine-protein kinase Fyn,FYN,5.41,IC50,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
methotrexate,Dihydrofolate reductase,Dhfr,5.41,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
nilotinib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,5.41,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
remoxipride,D(4) dopamine receptor,DRD4,5.41,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
sulbactam,Beta-lactamase SHV-1,bla,5.41,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sunitinib,Tyrosine-protein kinase receptor Tie-1,TIE1,5.41,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,MAP kinase-interacting serine/threonine-protein kinase 1,MKNK1,5.41,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Citron Rho-interacting kinase,CIT,5.41,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
talipexole,Alpha-1B adrenergic receptor,ADRA1B,5.41,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
valdecoxib,Carbonic anhydrase 7,CA7,5.41,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
bithionol,Solute carrier family 22 member 1,SLC22A1,5.41,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
ruboxistaurin,Dual specificity mitogen-activated protein kinase kinase 6,MAP2K6,5.41,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase TAO2,TAOK2,5.41,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vandetanib,Serine/threonine-protein kinase SIK3,SIK3,5.41,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vilazodone,5-hydroxytryptamine receptor 7,HTR7,5.41,Ki,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
vilazodone,5-hydroxytryptamine receptor 7,HTR7,5.41,Ki,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
axitinib,Mitogen-activated protein kinase 8,MAPK8,5.41,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Dual specificity protein kinase TTK,TTK,5.41,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Angiopoietin-1 receptor,TEK,5.41,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,5.41,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,SRSF protein kinase 3,SRPK3,5.41,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
trypan blue,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,5.41,IC50,CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O
thioctic acid,Bifunctional protein GlmU,glmU,5.41,IC50,OC(=O)CCCCC1CCSS1
fedratinib,Ephrin type-A receptor 6,EPHA6,5.41,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ephrin type-B receptor 2,EPHB2,5.41,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,5.41,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
butenafine,Sodium-dependent noradrenaline transporter,SLC6A2,5.411,Ki,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
diethylstilbestrol,D(1A) dopamine receptor,DRD1,5.411,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
thiothixene,Sodium-dependent serotonin transporter,SLC6A4,5.411,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
escitalopram,Alpha-1A adrenergic receptor,ADRA1A,5.412,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
monobenzone,Sodium-dependent noradrenaline transporter,SLC6A2,5.414,Ki,OC1=CC=C(OCC2=CC=CC=C2)C=C1
reserpine,D(1A) dopamine receptor,DRD1,5.415,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
propofol,Prostaglandin G/H synthase 1,PTGS1,5.417,IC50,CC(C)C1=CC=CC(C(C)C)=C1O
zafirlukast,Thromboxane-A synthase,TBXAS1,5.419,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
acetoxolone,Estradiol 17-beta-dehydrogenase 2,HSD17B2,5.42,IC50,CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C
dabigatran etexilate,Coagulation factor X,F10,5.42,Ki,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
dasatinib,Serine/threonine-protein kinase 4,STK4,5.42,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diphenhydramine,Sodium-dependent serotonin transporter,SLC6A4,5.42,Kd,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
erlotinib,Tyrosine-protein kinase TXK,TXK,5.42,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
furosemide,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,5.42,IC50,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
furosemide,Corticosteroid 11-beta-dehydrogenase isozyme 1,Hsd11b1,5.42,IC50,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
gefitinib,Serine/threonine-protein kinase 17B,STK17B,5.42,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.42,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
levosalbutamol,Beta-2 adrenergic receptor,ADRB2,5.42,Ki,CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1
miconazole,"Indoleamine 2,3-dioxygenase 1",IDO1,5.42,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mitoxantrone,Integrase,pol,5.42,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
nimesulide,Prostaglandin G/H synthase 1,PTGS1,5.42,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
omeprazole,Potassium-transporting ATPase,ATP4B|ATP4A,5.42,IC50,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
aminobenzoic acid,Polyphenol oxidase 2,PPO2,5.42,IC50,NC1=CC=C(C=C1)C(O)=O
aminobenzoic acid,Polyphenol oxidase 2,PPO2,5.42,IC50,NC1=CC=C(C=C1)C(O)=O
paroxetine,D(3) dopamine receptor,DRD3,5.42,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
phenylbutazone,Cyclooxygenase 2; Prostaglandin G/H synthase-2; Uncharacterized protein,PTGS2,5.42,IC50,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
pimozide,Delta-type opioid receptor,OPRD1,5.42,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
promethazine,Cytochrome P450 2D6,CYP2D6,5.42,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
ropinirole,5-hydroxytryptamine receptor 2B,HTR2B,5.42,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
selegiline,Amine oxidase [flavin-containing] A,MAOA,5.42,Ki,C[C@H](CC1=CC=CC=C1)N(C)CC#C
sorafenib,Aurora kinase A,AURKA,5.42,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Serine/threonine-protein kinase 36,STK36,5.42,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Cyclin-dependent kinase 3,CDK3,5.42,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Serine/threonine-protein kinase RIO3,RIOK3,5.42,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
theophylline,Adenosine receptor A1,ADORA1,5.42,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
capsaicin,Prostaglandin G/H synthase 1,PTGS1,5.42,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
khellin,Cytochrome P450 1A1,CYP1A1,5.42,Ki,COC1=C2OC=CC2=C(OC)C2=C1OC(C)=CC2=O
posaconazole,7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,CYP8B1,5.42,IC50,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=CC=C(F)C=C2F)C=C1
pyrovalerone,Sodium-dependent serotonin transporter,SLC6A4,5.42,Ki,CCCC(N1CCCC1)C(=O)C1=CC=C(C)C=C1
quercetin,Phosphatidylinositol 3-kinase regulatory subunit alpha,PIK3R1,5.42,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
bosutinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5.42,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
midostaurin,Myotonin-protein kinase,DMPK,5.42,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Inhibitor of nuclear factor kappa-B kinase subunit alpha,CHUK,5.42,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Tyrosine-protein kinase ZAP-70,ZAP70,5.42,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Chk1,CHEK1,5.42,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase PAK 4,PAK4,5.42,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,cGMP-dependent protein kinase 1,PRKG1,5.42,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
molindone,5-hydroxytryptamine receptor 1A,HTR1A,5.421,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
trimipramine,Sodium-dependent dopamine transporter,SLC6A3,5.423,Ki,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=C1C=CC=C2
danazol,Muscarinic acetylcholine receptor M3,CHRM3,5.425,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
suloctidil,Beta-3 adrenergic receptor,ADRB3,5.426,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
carbidopa,Tyrosine-protein kinase Fyn,FYN,5.428,IC50,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
duloxetine,5-hydroxytryptamine receptor 1E,HTR1E,5.428,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
granisetron,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.428,IC50,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
levodopa,Tyrosine-protein kinase Lck,LCK,5.428,IC50,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
trazodone,D(1A) dopamine receptor,DRD1,5.428,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
clotrimazole,Alpha-2B adrenergic receptor,ADRA2B,5.429,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
monobenzone,Prostaglandin G/H synthase 2,PTGS2,5.429,IC50,OC1=CC=C(OCC2=CC=CC=C2)C=C1
chlorothiazide,Solute carrier family 12 member 3,SLC12A3,5.43,A2,NS(=O)(=O)C1=C(Cl)C=C2N=CNS(=O)(=O)C2=C1
dasatinib,Fibroblast growth factor receptor 1,FGFR1,5.43,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,5.43,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
erlotinib,Tyrosine-protein kinase JAK2,JAK2,5.43,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Dual specificity protein kinase TTK,TTK,5.43,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fluphenazine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.43,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
gefitinib,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,5.43,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
miconazole,Substance-P receptor,TACR1,5.43,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mimosine,Tyrosinase,TYR,5.43,IC50,N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O
mimosine,Polyphenol oxidase 2,PPO2,5.43,IC50,N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O
ondansetron,5-hydroxytryptamine receptor 1B,Htr1b,5.43,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
rupatadine,Platelet-activating factor receptor,PTAFR,5.43,IC50,CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1
tolazoline,Alpha-2C adrenergic receptor,ADRA2C,5.43,Ki,C(C1=NCCN1)C1=CC=CC=C1
ximelagatran,Coagulation factor X,F10,5.43,Ki,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
kainic acid,Glutamate receptor 2,Gria2,5.43,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
ruboxistaurin,Serine/threonine-protein kinase Chk2,CHEK2,5.43,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vildagliptin,Prolyl endopeptidase FAP,FAP,5.43,IC50,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
pazopanib,Calcium/calmodulin-dependent protein kinase type 1G,CAMK1G,5.43,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
paliperidone,Sodium-dependent serotonin transporter,SLC6A4,5.43,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
gentian violet,Androgen receptor,Ar,5.43,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
vandetanib,Tyrosine-protein kinase TXK,TXK,5.43,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Dual specificity testis-specific protein kinase 1,TESK1,5.43,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Rho-associated protein kinase 1,ROCK1,5.43,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Dual specificity tyrosine-phosphorylation-regulated kinase 2,DYRK2,5.43,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
lacosamide,Carbonic anhydrase 12,CA12,5.43,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
afatinib,STE20-like serine/threonine-protein kinase,SLK,5.43,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,5.43,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,STE20/SPS1-related proline-alanine-rich protein kinase,STK39,5.43,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dabrafenib,TGF-beta receptor type-1,TGFBR1,5.43,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
ceritinib,Tyrosine-protein kinase JAK1,JAK1,5.43,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Dual specificity mitogen-activated protein kinase kinase 4,MAP2K4,5.43,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Calcium/calmodulin-dependent protein kinase type IV,CAMK4,5.43,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,5.43,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
cannabidiol,Transient receptor potential cation channel subfamily V member 2,Trpv2,5.43,EC50,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
quizartinib,Ephrin type-A receptor 7,EPHA7,5.43,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
sulconazole,Tyrosine-protein kinase Fyn,FYN,5.431,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
risperidone,Muscarinic acetylcholine receptor M2,CHRM2,5.432,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
lesinurad,Solute carrier family 22 member 11,SLC22A11,5.432,IC50,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1
solriamfetol,Sodium-dependent noradrenaline transporter,SLC6A2,5.432,Ki,N[C@@H](COC(N)=O)CC1=CC=CC=C1
doxorubicin,Muscarinic acetylcholine receptor M1,CHRM1,5.433,Ki,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
disulfiram,Sodium-dependent dopamine transporter,SLC6A3,5.434,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
epinephrine,Sodium-dependent noradrenaline transporter,SLC6A2,5.434,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
raloxifene,Tyrosine-protein kinase Fyn,FYN,5.436,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
triamterene,Caspase-1,CASP1,5.436,IC50,NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1
diethylstilbestrol,Muscarinic acetylcholine receptor M1,CHRM1,5.437,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
hydralazine,Arachidonate 15-lipoxygenase,ALOX15,5.438,IC50,NNC1=NN=CC2=CC=CC=C12
terconazole,5-hydroxytryptamine receptor 2C,HTR2C,5.438,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
diethylstilbestrol,Sodium-dependent noradrenaline transporter,SLC6A2,5.439,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
chloroxine,Arachidonate 5-lipoxygenase,ALOX5,5.44,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1Cl
flunarizine,Delta-type opioid receptor,OPRD1,5.44,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
flunarizine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.44,Kd,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
gallopamil,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.44,IC50,COC1=CC(=CC(OC)=C1OC)C(CCCN(C)CCC1=CC(OC)=C(OC)C=C1)(C#N)C(C)C
imipramine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.44,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
indomethacin,Aldose reductase,Akr1b1,5.44,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
itraconazole,Lanosterol 14-alpha demethylase,CYP51A1,5.44,IC50,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lapatinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,5.44,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
liothyronine,Proliferating cell nuclear antigen,PCNA,5.44,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
mebendazole,Vascular endothelial growth factor receptor 2,KDR,5.44,IC50,COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1=CC=CC=C1
methoxamine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.44,IC50,COC1=CC(C(O)C(C)N)=C(OC)C=C1
nicardipine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.44,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
niflumic acid,G-protein coupled receptor 35,GPR35,5.44,Ki,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
benzylpenicillin,Beta-lactamase,ampC,5.44,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
benzylpenicillin,Beta-lactamase,ampC,5.44,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
pentamidine,Plasminogen,PLG,5.44,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pentamidine,Plasminogen,PLG,5.44,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pranlukast,Cysteinyl leukotriene receptor 2,CYSLTR2,5.44,IC50,O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
pyrimethamine,Solute carrier family 22 member 1,Slc22a1,5.44,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
quetiapine,Alpha-2A adrenergic receptor,ADRA2A,5.44,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
rosiglitazone,Peroxisome proliferator-activated receptor delta,PPARD,5.44,EC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sorafenib,High affinity nerve growth factor receptor,NTRK1,5.44,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Mitogen-activated protein kinase 9,MAPK9,5.44,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Tyrosine-protein kinase Mer,MERTK,5.44,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorivudine,Thymidine kinase,TK,5.44,IC50,OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O
sulfanilamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,5.44,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,MAP/microtubule affinity-regulating kinase 4,MARK4,5.44,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
venlafaxine,Sodium-dependent dopamine transporter,SLC6A3,5.44,Ki,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
voriconazole,14-alpha sterol demethylase Cyp51A,,5.44,Kd,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
zidovudine,Reverse transcriptase protein,reverse transcriptase,5.44,IC50,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
benzethonium,KiSS-1 receptor,KISS1R,5.44,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
ruboxistaurin,Casein kinase II subunit alpha,CSNK2A1,5.44,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
gentian violet,Cytochrome P450 3A4,CYP3A4,5.44,IC50,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
vandetanib,Rho-associated protein kinase 2,ROCK2,5.44,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,5.44,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Interleukin-1 receptor-associated kinase 4,IRAK4,5.44,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Homeodomain-interacting protein kinase 4,HIPK4,5.44,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,5.44,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Ankyrin repeat and protein kinase domain-containing protein 1,ANKK1,5.44,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Calcium/calmodulin-dependent protein kinase type II subunit gamma,CAMK2G,5.44,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
corbadrine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.44,Ki,C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1
gepirone,5-hydroxytryptamine receptor 2A,HTR2A,5.44,Ki,CC1(C)CC(=O)N(CCCCN2CCN(CC2)C2=NC=CC=N2)C(=O)C1
stearic acid,Acetylcholinesterase,ache,5.44,Ki,CCCCCCCCCCCCCCCCCC(O)=O
nintedanib,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,5.44,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Mitogen-activated protein kinase 10,MAPK10,5.44,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Dual specificity protein kinase CLK3,CLK3,5.44,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
cefiderocol,Penicillin-binding protein 4,pbpD_1,5.44,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
cladribine,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,5.441,IC50,NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1
hexachlorophene,5-hydroxytryptamine receptor 2B,HTR2B,5.441,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
zotepine,Sodium-dependent dopamine transporter,SLC6A3,5.441,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
fluoxetine,Sodium-dependent dopamine transporter,SLC6A3,5.444,Kd,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
benzquinamide,D(3) dopamine receptor,DRD3,5.445,Ki,CCN(CC)C(=O)C1CN2CCC3=C(C=C(OC)C(OC)=C3)C2CC1OC(C)=O
estradiol benzoate,Alpha-2C adrenergic receptor,ADRA2C,5.446,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
terfenadine,Epidermal growth factor receptor,EGFR,5.448,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
rosiglitazone,Thromboxane-A synthase,TBXAS1,5.449,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
tamoxifen,Epidermal growth factor receptor,EGFR,5.449,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
oxiconazole,Beta-3 adrenergic receptor,ADRB3,5.449,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acetylcholine,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,5.45,Ki,CC(=O)OCC[N+](C)(C)C
cianidanol,Carbonic anhydrase 3,CA3,5.45,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
penfluridol,5-hydroxytryptamine receptor 1D,HTR1D,5.45,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
pinacidil,ATP-binding cassette sub-family C member 9,ABCC9,5.45,EC50,CC(NC(NC1=CC=NC=C1)=NC#N)C(C)(C)C
varenicline,Acetylcholine receptor,CHRNA1|CHRNB1|CHRNG|chrnd,5.45,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
kainic acid,Glutamate receptor 4,Gria4,5.45,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
pyrithione,"Carbonic anhydrase 5B, mitochondrial",CA5B,5.45,Ki,[O-][N+]1=C(S)C=CC=C1
terazosin,5-hydroxytryptamine receptor 2A,HTR2A,5.45,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
baicalin,Lysine-specific histone demethylase 1A,KDM1A,5.45,IC50,O[C@@H]1[C@@H](O)[C@H](OC2=C(O)C(O)=C3C(=O)C=C(OC3=C2)C2=CC=CC=C2)O[C@@H]([C@H]1O)C(O)=O
baicalin,Lysine-specific histone demethylase 1A,KDM1A,5.45,IC50,O[C@@H]1[C@@H](O)[C@H](OC2=C(O)C(O)=C3C(=O)C=C(OC3=C2)C2=CC=CC=C2)O[C@@H]([C@H]1O)C(O)=O
cytisine,Acetylcholine receptor subunit alpha,CHRNA1,5.45,IC50,O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12
dacomitinib,Tyrosine-protein kinase JAK3,JAK3,5.45,IC50,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1
miconazole,5-hydroxytryptamine receptor 2B,HTR2B,5.452,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
aripiprazole,Muscarinic acetylcholine receptor M2,CHRM2,5.455,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
pramipexole,5-hydroxytryptamine receptor 1B,HTR1B,5.455,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
etomidate,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,5.456,EC50,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
ketoconazole,Aldehyde oxidase,AOX1,5.456,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
propofol,5-hydroxytryptamine receptor 2B,HTR2B,5.456,Ki,CC(C)C1=CC=CC(C(C)C)=C1O
travoprost,Prostaglandin E2 receptor EP3 subtype,PTGER3,5.456,Ki,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC(=CC=C1)C(F)(F)F
trazodone,D(2) dopamine receptor,DRD2,5.456,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
verapamil,Aldehyde oxidase,AOX1,5.456,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
ziprasidone,Histamine H2 receptor,HRH2,5.456,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
ixazomib,Proteasome subunit beta type-2,PSMB2,5.456,IC50,CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O
alprazolam,Platelet-activating factor receptor,PTAFR,5.457,Ki,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
hexachlorophene,Tyrosine-protein kinase Fyn,FYN,5.459,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
mepacrine,Histamine H2 receptor,HRH2,5.459,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
acarbose,Lysosomal alpha-glucosidase,Gaa,5.46,Ki,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
amiodarone,Lethal factor,lef,5.46,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
dasatinib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,5.46,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
decamethonium,Acetylcholinesterase,Ache,5.46,Ki,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
dopamine,Adenylate cyclase,Adcy1|Adcy3|Adcy2|Adcy4|Adcy8|Adcy6|Adcy5,5.46,EC50,NCCC1=CC(O)=C(O)C=C1
doxorubicin,DNA topoisomerase 2-beta,TOP2B,5.46,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
doxorubicin,CDGSH iron-sulfur domain-containing protein 1,CISD1,5.46,Ki,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
erlotinib,Casein kinase I isoform delta,CSNK1D,5.46,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
etomidate,GABA A receptor alpha-2/beta-2/gamma-2,GABRG2|GABRA2|GABRB2,5.46,EC50,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
flunarizine,CAAX prenyl protease 2,RCE1,5.46,AC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
gefitinib,Hepatocyte growth factor receptor,MET,5.46,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Serine/threonine-protein kinase D1,PRKD1,5.46,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
loperamide,Calmodulin,CALM,5.46,Kd,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
loxapine,5-hydroxytryptamine receptor 1D,HTR1D,5.46,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
methotrexate,Folate transporter 1,SLC19A1,5.46,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
norfloxacin,DNA topoisomerase 4 subunit A,parC,5.46,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
pyridostigmine,Cholinesterase,BCHE,5.46,Ki,CN(C)C(=O)OC1=C[N+](C)=CC=C1
sorafenib,Dual specificity protein kinase TTK,TTK,5.46,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,3-phosphoinositide-dependent protein kinase 1,PDPK1,5.46,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase BRSK1,BRSK1,5.46,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
talipexole,D(1B) dopamine receptor,DRD5,5.46,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
terfenadine,Heat shock protein HSP 90-alpha,HSP90AA1,5.46,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
trichlormethiazide,Carbonic anhydrase 14,CA14,5.46,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
ubenimex,Puromycin-sensitive aminopeptidase,NPEPPS,5.46,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
vecuronium,Solute carrier family 22 member 2,SLC22A2,5.46,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
propamidine,Acrosin,ACR,5.46,Ki,NC(=N)C1=CC=C(OCCCOC2=CC=C(C=C2)C(N)=N)C=C1
quercetin,Cytochrome P450 2C8,CYP2C8,5.46,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
telaprevir,Cathepsin L1,CTSL,5.46,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
ruxolitinib,Serine/threonine-protein kinase 17B,STK17B,5.46,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Myotonin-protein kinase,DMPK,5.46,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
tofacitinib,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,5.46,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Tyrosine-protein kinase ZAP-70,ZAP70,5.46,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
palbociclib,Receptor-type tyrosine-protein kinase FLT3,FLT3,5.46,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
fedratinib,Dual specificity mitogen-activated protein kinase kinase 3,MAP2K3,5.46,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cefiderocol,Penicillin-binding protein 1B,mrcB,5.46,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
danazol,Alpha-2C adrenergic receptor,ADRA2C,5.462,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
perphenazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.462,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
econazole,Kappa-type opioid receptor,OPRK1,5.463,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
clotrimazole,Histamine H1 receptor,HRH1,5.466,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
melperone,5-hydroxytryptamine receptor 1D,HTR1D,5.469,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
adenosine triphosphate,Heat shock 70 kDa protein 1A,HSPA1A,5.47,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
diphenidol,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.47,IC50,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
benziodarone,Eyes absent homolog 3,EYA3,5.47,IC50,CCC1=C(C(=O)C2=CC(I)=C(O)C(I)=C2)C2=C(O1)C=CC=C2
bortezomib,Carbonic anhydrase 9,CA9,5.47,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
carvedilol,Solute carrier family 22 member 1,SLC22A1,5.47,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
clemizole,Heme oxygenase 2,Hmox2,5.47,IC50,ClC1=CC=C(CN2C(CN3CCCC3)=NC3=C2C=CC=C3)C=C1
clomipramine,Trypanothione reductase,TPR,5.47,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
cocaine,5-hydroxytryptamine receptor 1B,HTR1B,5.47,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
dasatinib,Serine/threonine-protein kinase 25,STK25,5.47,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexfenfluramine,5-hydroxytryptamine receptor 1A,Htr1a,5.47,IC50,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
dinoprostone,Solute carrier family 22 member 6,Slc22a6,5.47,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
erlotinib,Serine/threonine-protein kinase MRCK gamma,CDC42BPG,5.47,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethacrynic acid,Glutathione S-transferase P,GSTP1,5.47,IC50,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
glutamic acid,Metabotropic glutamate receptor 8,Grm8,5.47,Ki,N[C@@H](CCC(O)=O)C(O)=O
imatinib,ATP-binding cassette sub-family G member 2,ABCG2,5.47,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
ketoprofen,Cyclooxygenase,PTGS1|PTGS2,5.47,IC50,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
methylparaben,Carbonic anhydrase 2,CA2,5.47,Ki,COC(=O)C1=CC=C(O)C=C1
naproxen,Prostaglandin G/H synthase 2,PTGS2,5.47,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
omeprazole,Fatty acid synthase,FASN,5.47,Ki,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
pargyline,Amine oxidase [flavin-containing] A,MAOA,5.47,IC50,CN(CC#C)CC1=CC=CC=C1
pargyline,Amine oxidase [flavin-containing] B,Maob,5.47,Ki,CN(CC#C)CC1=CC=CC=C1
raloxifene,Phospholipase D2,PLD2,5.47,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sildenafil,"High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A",PDE9A,5.47,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,Serine/threonine-protein kinase PLK4,PLK4,5.47,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,5.47,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tazobactam,Beta-lactamase,,5.47,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tetracaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.47,IC50,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
thiabendazole,Methionine aminopeptidase 1,METAP1,5.47,EC50,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
triamterene,Pteridine reductase 1,PTR1,5.47,Ki,NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1
trifluoperazine,Calmodulin,CALM,5.47,Kd,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
ubenimex,72 kDa type IV collagenase,MMP2,5.47,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
quinisocaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.47,IC50,CCCCC1=CC2=CC=CC=C2C(OCCN(C)C)=N1
ruboxistaurin,Casein kinase II subunit alpha',CSNK2A2,5.47,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Non-receptor tyrosine-protein kinase TYK2,TYK2,5.47,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Macrophage-stimulating protein receptor,MST1R,5.47,IC50,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Misshapen-like kinase 1,MINK1,5.47,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
rivaroxaban,Suppressor of tumorigenicity 14 protein,ST14,5.47,Ki,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
ruxolitinib,Phosphatidylinositol 4-kinase beta,PI4KB,5.47,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
vilazodone,D(4) dopamine receptor,Drd4,5.47,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
bosutinib,NT-3 growth factor receptor,NTRK3,5.47,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
chenodiol,Bile acid receptor,NR1H4,5.47,EC50,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
cabozantinib,Aurora kinase A,AURKA,5.47,Kd,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
ceritinib,Tyrosine-protein kinase BTK,BTK,5.47,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
fedratinib,Serine/threonine-protein kinase Nek1,NEK1,5.47,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cefiderocol,Penicillin-binding protein 1B,mrcB,5.47,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
infigratinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5.47,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Insulin receptor,INSR,5.47,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,5.47,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5.47,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Insulin receptor,INSR,5.47,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5.47,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,5.47,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
buspirone,Membrane-associated progesterone receptor component 1,Pgrmc1,5.471,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
clotrimazole,Substance-K receptor,TACR2,5.471,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
cisapride,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,5.472,IC50,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
tolperisone,BetaB2-crystallin,Crybb2,5.474,IC50,CC(CN1CCCCC1)C(=O)C1=CC=C(C)C=C1
celecoxib,Sodium-dependent serotonin transporter,SLC6A4,5.477,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
labetalol,Sodium-dependent noradrenaline transporter,SLC6A2,5.478,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
hexachlorophene,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.479,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
hexachlorophene,Androgen receptor,Ar,5.479,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
amiloride,Adenosine receptor A2a,ADORA2A,5.48,Ki,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
aztreonam,Penicillin-binding protein 1A,mrcA,5.48,IC50,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
bortezomib,Carbonic anhydrase 14,CA14,5.48,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
candesartan cilexetil,Epidermal growth factor receptor,EGFR,5.48,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
cefoxitin,Streptokinase A,ska,5.48,EC50,CO[C@]1(NC(=O)CC2=CC=CS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O
cefapirin,5-hydroxytryptamine receptor 1A,HTR1A,5.48,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
chloroquine,Muscarinic acetylcholine receptor M3,CHRM3,5.48,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
coumarin,Carbonic anhydrase 7,CA7,5.48,Ki,O=C1OC2=CC=CC=C2C=C1
ethambutol,5-hydroxytryptamine receptor 2A,HTR2A,5.48,IC50,CC[C@@H](CO)NCCN[C@@H](CC)CO
gefitinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,5.48,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,"Glutamate receptor ionotropic, kainate 2",Grik2,5.48,Ki,N[C@@H](CCC(O)=O)C(O)=O
imatinib,Serine/threonine-protein kinase B-raf,BRAF,5.48,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
lapatinib,STE20-like serine/threonine-protein kinase,SLK,5.48,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
metronidazole,Thioredoxin reductase,,5.48,Ki,CC1=NC=C(N1CCO)[N+]([O-])=O
mianserin,D(4) dopamine receptor,DRD4,5.48,IC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nicotinamide,Fatty-acid amide hydrolase 1,Faah,5.48,IC50,NC(=O)C1=CN=CC=C1
nifedipine,Glycine receptor subunit alpha-1,GLRA1,5.48,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
propafenone,Sodium channel protein type 5 subunit alpha,SCN5A,5.48,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
mepacrine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.48,IC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
sildenafil,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.48,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,5-hydroxytryptamine receptor 5A,HTR5A,5.48,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spironolactone,Estrogen receptor beta,ESR2,5.48,EC50,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
sunitinib,Mitogen-activated protein kinase kinase kinase 4,MAP3K4,5.48,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
verapamil,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.48,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
ximelagatran,Coagulation factor VII,F7,5.48,IC50,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
iloperidone,Muscarinic acetylcholine receptor M2,CHRM2,5.48,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
propamidine,Trypsin-1,PRSS1,5.48,Ki,NC(=N)C1=CC=C(OCCCOC2=CC=C(C=C2)C(N)=N)C=C1
quercetin,ALK tyrosine kinase receptor,ALK,5.48,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
pazopanib,Angiopoietin-1 receptor,TEK,5.48,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Tyrosine-protein kinase Mer,MERTK,5.48,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
dexlansoprazole,Sterile alpha and TIR motif-containing protein 1,SARM1,5.48,IC50,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=C(N1)C=CC=C2
crizotinib,Rho-associated protein kinase 2,ROCK2,5.48,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Dual specificity mitogen-activated protein kinase kinase 3,MAP2K3,5.48,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Cyclin-dependent kinase 7,CDK7,5.48,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Casein kinase II subunit alpha',CSNK2A2,5.48,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,SRSF protein kinase 3,SRPK3,5.48,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Tyrosine-protein kinase JAK2,JAK2,5.48,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha,PIP5K1A,5.48,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
levmetamfetamine,Trace amine-associated receptor 1,TAAR1,5.48,EC50,CN[C@H](C)CC1=CC=CC=C1
tofacitinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5.48,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
cridanimod,Stimulator of interferon genes protein,Tmem173,5.48,Kd,OC(=O)CN1C2=CC=CC=C2C(=O)C2=CC=CC=C12
nintedanib,Serine/threonine-protein kinase PAK 2,PAK2,5.48,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Mitogen-activated protein kinase 8,MAPK8,5.48,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Serine/threonine-protein kinase SIK2,SIK2,5.48,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
cefiderocol,Penicillin-binding protein 1A,mrcA,5.48,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
infigratinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,5.48,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,5.48,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
astemizole,Cytochrome P450 3A4,CYP3A4,5.481,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
mepacrine,Aldehyde oxidase,AOX1,5.481,IC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
propafenone,Cytochrome P450 1A2,CYP1A2,5.483,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
trazodone,Histamine H2 receptor,HRH2,5.483,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
epinephrine,Arachidonate 15-lipoxygenase,ALOX15,5.484,IC50,CNC[C@H](O)C1=CC=C(O)C(O)=C1
econazole,D(4) dopamine receptor,DRD4,5.485,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
perhexiline,Sodium-dependent noradrenaline transporter,SLC6A2,5.486,Ki,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
fenfluramine,Muscarinic acetylcholine receptor M3,CHRM3,5.489,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
adenosine triphosphate,Endoplasmin,HSP90B1,5.49,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
candesartan cilexetil,Beta-3 adrenergic receptor,ADRB3,5.49,Ki,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
chlorpromazine,Trypanothione reductase,TPR,5.49,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clavulanic acid,Beta-lactamase OXA-1,bla,5.49,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clonidine,5-hydroxytryptamine receptor 1A,HTR1A,5.49,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
clotrimazole,Bile acid receptor,NR1H4,5.49,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,5.49,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Serine/threonine-protein kinase VRK2,VRK2,5.49,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diclofenac,"Fatty acid-binding protein, liver",Fabp1,5.49,Ki,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dipyridamole,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,5.49,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
donepezil,Beta-secretase 1,BACE1,5.49,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
fendiline,5-hydroxytryptamine receptor 2B,HTR2B,5.49,Ki,CC(NCCC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1
furosemide,G-protein coupled receptor 35,GPR35,5.49,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
gefitinib,Casein kinase I isoform delta,CSNK1D,5.49,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Ephrin type-B receptor 6,EPHB6,5.49,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
imatinib,Mitogen-activated protein kinase 8,MAPK8,5.49,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
mafenide,Carbonic anhydrase 14,CA14,5.49,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
methotrexate,"Folylpolyglutamate synthase, mitochondrial",FPGS,5.49,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
midazolam,Thyrotropin-releasing hormone receptor,Trhr,5.49,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
nicardipine,Adenosine receptor A3,ADORA3,5.49,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
quinidine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.49,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
sorivudine,Thymidine kinase,,5.49,IC50,OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O
sunitinib,Serine/threonine-protein kinase SIK1,SIK1,5.49,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
telmisartan,Glycine receptor subunit alpha-1,GLRA1,5.49,EC50,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O
oxybenzone,Hormone-sensitive lipase,Lipe,5.49,IC50,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1
quercetin,Lactoylglutathione lyase,GLO1,5.49,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,cAMP-dependent protein kinase catalytic subunit beta,PRKACB,5.49,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
kinetin,Endochitinase,CTS1,5.49,Ki,C(NC1=C2N=CN=C2N=CN1)C1=CC=CO1
gentian violet,Sodium-dependent dopamine transporter,SLC6A3,5.49,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
crizotinib,Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha,PIP5K1A,5.49,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Tyrosine-protein kinase Mer,MERTK,5.49,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,5.49,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Ribosomal protein S6 kinase alpha-2,RPS6KA2,5.49,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Dual specificity protein kinase CLK4,CLK4,5.49,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Tyrosine-protein kinase Tec,TEC,5.49,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase N2,PKN2,5.49,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Homeodomain-interacting protein kinase 3,HIPK3,5.49,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ceftobiprole medocaril,MecA,mecA,5.49,IC50,CC1=C(COC(=O)N2CC[C@H](C2)N2CC\C(=C/C3=C(N4[C@H](SC3)[C@H](NC(=O)C(=N/O)\C3=NSC(N)=N3)C4=O)C(O)=O)C2=O)OC(=O)O1
armodafinil,Sodium-dependent dopamine transporter,Slc6a3,5.49,Ki,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
levomilnacipran,Sodium-dependent dopamine transporter,SLC6A3,5.49,IC50,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1
ceritinib,Transcription factor ETV6,ETV6,5.49,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Death-associated protein kinase 2,DAPK2,5.49,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
infigratinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,5.49,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,5.49,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,5.49,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,5.49,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
asenapine,Muscarinic acetylcholine receptor M3,CHRM3,5.491,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
aripiprazole,Sodium-dependent dopamine transporter,SLC6A3,5.492,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
fenofibrate,Adenosine receptor A3,ADORA3,5.492,Ki,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
suloctidil,Muscarinic acetylcholine receptor M5,CHRM5,5.492,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
tienilic acid,Aldose reductase,Akr1b1,5.494,IC50,OC(=O)COC1=C(Cl)C(Cl)=C(C=C1)C(=O)C1=CC=CS1
montelukast,Beta-3 adrenergic receptor,ADRB3,5.495,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
montelukast,Epidermal growth factor receptor,EGFR,5.495,IC50,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
fenbendazole,Mitogen-activated protein kinase 14,MAPK14,5.496,IC50,COC(=O)NC1=NC2=C(N1)C=CC(SC1=CC=CC=C1)=C2
clotrimazole,5-hydroxytryptamine receptor 2A,HTR2A,5.497,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
diethylstilbestrol,Substance-K receptor,TACR2,5.497,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
etoposide,Arachidonate 15-lipoxygenase,ALOX15,5.497,IC50,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
oxiconazole,5-hydroxytryptamine receptor 1A,HTR1A,5.497,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
armodafinil,Sodium-dependent dopamine transporter,SLC6A3,5.497,IC50,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
econazole,Membrane-associated progesterone receptor component 1,Pgrmc1,5.498,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acetylcholine,Acetylcholine-binding protein,,5.5,Ki,CC(=O)OCC[N+](C)(C)C
azithromycin,Motilin receptor,MLNR,5.5,EC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
clozapine,Histamine H4 receptor,Hrh4,5.5,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cocaine,Sodium- and chloride-dependent GABA transporter 1,SLC6A1,5.5,IC50,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
cocaine,Transporter,NET,5.5,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
dinoprostone,Prostaglandin D2 receptor 2,Ptgdr2,5.5,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
dobutamine,Beta-1 adrenergic receptor,ADRB1,5.5,EC50,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
ergotamine,Tyrosine-protein kinase Fyn,FYN,5.5,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
hydroxystilbamidine,Trypsin,,5.5,AC50,NC(=N)C1=CC=C(C=CC2=CC=C(C=C2O)C(N)=N)C=C1
meclofenamic acid,Aldo-keto reductase family 1 member C1,AKR1C1,5.5,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
meticillin,NH(3)-dependent NAD(+) synthetase,nadE,5.5,IC50,COC1=CC=CC(OC)=C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O
mirtazapine,Alpha-1A adrenergic receptor,ADRA1A,5.5,IC50,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
pimozide,G protein-activated inward rectifier potassium channel 2,Kcnj6,5.5,EC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
rabeprazole,Sterile alpha and TIR motif-containing protein 1,SARM1,5.5,IC50,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
tolazoline,Alpha-1A adrenergic receptor,ADRA1A,5.5,Ki,C(C1=NCCN1)C1=CC=CC=C1
tolazoline,Alpha-2B adrenergic receptor,ADRA2B,5.5,Ki,C(C1=NCCN1)C1=CC=CC=C1
roflumilast,Phosphodiesterase,PDEB1,5.5,Ki,FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl
dexrabeprazole,Sterile alpha and TIR motif-containing protein 1,SARM1,5.5,IC50,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
midostaurin,Serine/threonine-protein kinase D3,PRKD3,5.5,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
quizartinib,Tyrosine-protein kinase receptor Tie-1,TIE1,5.5,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Calcium/calmodulin-dependent protein kinase type 1G,CAMK1G,5.5,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,5.5,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Dual specificity testis-specific protein kinase 1,TESK1,5.5,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,BDNF/NT-3 growth factors receptor,NTRK2,5.5,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,BDNF/NT-3 growth factors receptor,NTRK2,5.5,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
bithionol,5-hydroxytryptamine receptor 1A,HTR1A,5.501,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
hydroxyprogesterone caproate,Mitogen-activated protein kinase 3,MAPK3,5.501,IC50,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
meclofenamic acid,Mitogen-activated protein kinase 1,MAPK1,5.503,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
terconazole,Muscarinic acetylcholine receptor M5,CHRM5,5.504,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
asenapine,Sodium-dependent dopamine transporter,SLC6A3,5.504,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
miconazole,D(1A) dopamine receptor,DRD1,5.505,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
quetiapine,5-hydroxytryptamine receptor 5A,HTR5A,5.506,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
histamine,Trace amine-associated receptor 1,TAAR1,5.508,Ki,NCCC1=CN=CN1
cyclobenzaprine,Aldehyde oxidase,AOX1,5.509,IC50,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dicoumarol,Vitamin K epoxide reductase complex subunit 1,VKORC1,5.509,IC50,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
etoperidone,Histamine H1 receptor,HRH1,5.509,Ki,CCN1C(=O)N(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)N=C1CC
isradipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.509,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
pimozide,5-hydroxytryptamine receptor 1D,HTR1D,5.509,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
remoxipride,5-hydroxytryptamine receptor 2A,HTR2A,5.509,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
sunitinib,Ephrin type-B receptor 4,EPHB4,5.509,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
amitriptyline,Sodium channel protein type 2 subunit alpha,SCN2A,5.51,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
candesartan cilexetil,Thromboxane-A synthase,TBXAS1,5.51,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
pentoxyverine,Sodium-dependent dopamine transporter,Slc6a3,5.51,Ki,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1
celecoxib,Carbonic anhydrase 2,CAN2,5.51,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
clofarabine,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,5.51,IC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1
coumarin,Carbonic anhydrase 1,CA1,5.51,Ki,O=C1OC2=CC=CC=C2C=C1
dasatinib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,5.51,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
ditiocarb,Carbonic anhydrase 2,CA2,5.51,Ki,CCN(CC)C(S)=S
erlotinib,Serine/threonine-protein kinase TBK1,TBK1,5.51,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethoxzolamide,Carbonic anhydrase,,5.51,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
gefitinib,Mitogen-activated protein kinase 4,MAPK4,5.51,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
hexachlorophene,Thromboxane-A synthase,TBXAS1,5.51,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
imatinib,Tyrosine-protein kinase Fyn,FYN,5.51,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Mitogen-activated protein kinase 10,MAPK10,5.51,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
loratadine,Bile acid receptor,NR1H4,5.51,IC50,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
mecamylamine,Neuronal acetylcholine receptor; alpha2/beta4,CHRNB4|CHRNA2,5.51,IC50,CNC1(C)C2CCC(C2)C1(C)C
pilocarpine,Muscarinic acetylcholine receptor M1,Chrm1,5.51,Ki,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
pranoprofen,Prostaglandin G/H synthase 1,PTGS1,5.51,IC50,CC(C(O)=O)C1=CC2=C(OC3=NC=CC=C3C2)C=C1
pyrimethamine,Beta-hexosaminidase subunit alpha,HEXA,5.51,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
sildenafil,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,5.51,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,Ephrin type-A receptor 1,EPHA1,5.51,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Myosin-IIIa,MYO3A,5.51,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tubocurarine,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,5.51,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
vardenafil,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,5.51,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
zidovudine,5-hydroxytryptamine receptor 2A,HTR2A,5.51,IC50,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
zonisamide,Amine oxidase [flavin-containing] B,MAOB,5.51,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
carbaryl,Acetylcholinesterase,ache,5.51,IC50,CNC(=O)OC1=CC=CC2=C1C=CC=C2
lenalidomide,Cereblon isoform 4,,5.51,Ki,NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
lenalidomide,Cereblon isoform 4,,5.51,Ki,NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
ruboxistaurin,cGMP-dependent protein kinase 2,PRKG2,5.51,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruxolitinib,Serine/threonine-protein kinase 26,STK26,5.51,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Ephrin type-B receptor 6,EPHB6,5.51,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Tyrosine-protein kinase JAK3,JAK3,5.51,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Tyrosine-protein kinase Blk,BLK,5.51,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Interleukin-1 receptor-associated kinase 1,IRAK1,5.51,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
apixaban,Prothrombin,F2,5.51,Ki,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
afatinib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,5.51,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Tyrosine-protein kinase TXK,TXK,5.51,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Ephrin type-B receptor 6,EPHB6,5.51,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,High affinity nerve growth factor receptor,NTRK1,5.51,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
levomenol,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,5.51,IC50,CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1
levomenol,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,5.51,IC50,CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1
rifamycin,Bile salt export pump,Abcb11,5.51,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O
laninamivir octanoate hydrate,Neuraminidase,,5.51,IC50,CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O
midostaurin,Receptor tyrosine-protein kinase erbB-4,ERBB4,5.51,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase pim-2,PIM2,5.51,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Tubulin alpha-1A chain,Tuba1a,5.51,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Ephrin type-B receptor 6,EPHB6,5.51,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Homeodomain-interacting protein kinase 2,HIPK2,5.51,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,5.51,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Serine/threonine-protein kinase MARK2,MARK2,5.51,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Cyclin-dependent kinase 16,CDK16,5.51,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,5.51,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,BDNF/NT-3 growth factors receptor,NTRK2,5.51,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 11,MAP3K11,5.51,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase PAK 1,PAK1,5.51,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,5.51,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,ALK tyrosine kinase receptor,ALK,5.51,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,ALK tyrosine kinase receptor,ALK,5.51,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
desloratadine,Sodium-dependent dopamine transporter,SLC6A3,5.511,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
terconazole,Muscarinic acetylcholine receptor M3,CHRM3,5.511,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
mitotane,5-hydroxytryptamine receptor 2B,HTR2B,5.512,Ki,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
bupivacaine,Prostaglandin E2 receptor EP1 subtype,PTGER1,5.514,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
clemastine,Sodium-dependent noradrenaline transporter,SLC6A2,5.514,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clotrimazole,Sodium-dependent serotonin transporter,SLC6A4,5.514,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
ergotamine,Thromboxane-A synthase,TBXAS1,5.514,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dexamethasone,Progesterone receptor,PGR,5.517,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
clomifene,Adenosine receptor A3,ADORA3,5.519,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
loperamide,Histamine H2 receptor,HRH2,5.519,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
aztreonam,Beta-lactamase,ampC,5.52,Ki,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
benserazide,Estrogen receptor beta,ESR2,5.52,IC50,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
bexarotene,Peroxisome proliferator-activated receptor gamma,PPARG,5.52,IC50,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
candesartan cilexetil,Sodium-dependent noradrenaline transporter,SLC6A2,5.52,Ki,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
candesartan cilexetil,Cytochrome P450 2C9,CYP2C9,5.52,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
clotrimazole,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.52,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
dopamine,Lysine-specific demethylase 4E,KDM4E,5.52,IC50,NCCC1=CC(O)=C(O)C=C1
dopamine,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,5.52,IC50,NCCC1=CC(O)=C(O)C=C1
entacapone,Alpha-ketoglutarate-dependent dioxygenase FTO,FTO,5.52,IC50,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N
entacapone,Alpha-ketoglutarate-dependent dioxygenase FTO,FTO,5.52,IC50,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N
epinephrine,Beta-1 adrenergic receptor,ADRB1,5.52,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
epinephrine,M18 aspartyl aminopeptidase,,5.52,IC50,CNC[C@H](O)C1=CC=C(O)C(O)=C1
estradiol mustard,Estrogen receptor,Esr1,5.52,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)CC3=CC=C(C=C3)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2OC(=O)CC1=CC=C(C=C1)N(CCCl)CCCl
ethinylestradiol,Nuclear receptor subfamily 1 group I member 3,NR1I3,5.52,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
fasudil,Protein kinase C epsilon type,PRKCE,5.52,IC50,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
flufenamic acid,Prostaglandin G/H synthase 1,PTGS1,5.52,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
glutamic acid,Metabotropic glutamate receptor 3,Grm3,5.52,EC50,N[C@@H](CCC(O)=O)C(O)=O
gossypol,DNA-3-methyladenine glycosylase,MPG,5.52,IC50,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
ibuprofen,Serum albumin,ALB,5.52,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
isotretinoin,Alpha-2B adrenergic receptor,ADRA2B,5.52,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
itraconazole,Cruzipain,,5.52,IC50,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
loratadine,Nuclear receptor subfamily 1 group I member 2,NR1I2,5.52,EC50,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
melatonin,Myeloperoxidase,MPO,5.52,IC50,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
melatonin,Myeloperoxidase,MPO,5.52,IC50,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
methyldopa,Lysine-specific demethylase 4E,KDM4E,5.52,IC50,C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O
mitoxantrone,Proto-oncogene tyrosine-protein kinase ROS,ROS1,5.52,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
nifuroxazide,Signal transducer and activator of transcription 3,STAT3,5.52,EC50,OC1=CC=C(C=C1)C(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O
norgestimate,Short transient receptor potential channel 3,TRPC3,5.52,Ki,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C
periciazine,Androgen receptor,Ar,5.52,Ki,OC1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C#N)CC1
phenylbutazone,Prostaglandin G/H synthase 1,PTGS1,5.52,IC50,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
rofecoxib,Cytochrome c oxidase subunit 2,MT-CO2,5.52,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
sorafenib,Tyrosine-protein kinase Lyn,LYN,5.52,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
succinic acid,Egl nine homolog 1,EGLN1,5.52,IC50,OC(=O)CCC(O)=O
sulbactam,Beta-lactamase,,5.52,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulbactam,Beta-lactamase,bla(BEL1),5.52,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulfanilamide,Carbonic anhydrase 4,CA4,5.52,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulfanilamide,Carbonic anhydrase 4,CA4,5.52,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
tadalafil,"Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha",PDE6A,5.52,IC50,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
terconazole,Lanosterol 14-alpha demethylase,CYP51A1,5.52,IC50,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
topiramate,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,5.52,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
ubenimex,Aminopeptidase N,Anpep,5.52,Ki,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
verapamil,5-hydroxytryptamine receptor 1A,Htr1a,5.52,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
suramin,ATP-dependent 6-phosphofructokinase,pfk,5.52,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
suramin,P2X purinoceptor 3,P2rx3,5.52,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
quercetin,Calcium/calmodulin-dependent protein kinase type II subunit beta,CAMK2B,5.52,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Aurora kinase C,AURKC,5.52,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
dexamethasone phosphate,Progesterone receptor,PGR,5.52,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
pazopanib,Abelson tyrosine-protein kinase 2,ABL2,5.52,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,5.52,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,TGF-beta receptor type-2,TGFBR2,5.52,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,5.52,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Mitogen-activated protein kinase kinase kinase 4,MAP3K4,5.52,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vilazodone,5-hydroxytryptamine receptor 7,Htr7,5.52,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
vilazodone,5-hydroxytryptamine receptor 6,Htr6,5.52,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
axitinib,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,5.52,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
piperonyl butoxide,Cytochrome P450 3A4,CYP3A4,5.52,IC50,CCCCOCCOCCOCC1=CC2=C(OCO2)C=C1CCC
bosutinib,Serine/threonine-protein kinase Chk1,CHEK1,5.52,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Leukocyte tyrosine kinase receptor,LTK,5.52,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Ephrin type-B receptor 6,EPHB6,5.52,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
diosmetin,Multidrug resistance-associated protein 1,ABCC1,5.52,IC50,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O)C=C2O1
linolenic acid,Free fatty acid receptor 1,FFAR1,5.52,EC50,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
ceritinib,Tyrosine-protein kinase SYK,SYK,5.52,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Serine/threonine-protein kinase PAK 4,PAK4,5.52,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Leukocyte tyrosine kinase receptor,LTK,5.52,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Insulin receptor,INSR,5.52,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Angiopoietin-1 receptor,TEK,5.52,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,5.52,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,Hepatocyte growth factor receptor,MET,5.52,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Ephrin type-B receptor 1,EPHB1,5.52,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Hepatocyte growth factor receptor,MET,5.52,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Ephrin type-B receptor 1,EPHB1,5.52,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
hexachlorophene,Acetylcholinesterase,ACHE,5.521,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
chlormadinone,Cytochrome P450 2C19,CYP2C19,5.523,IC50,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
dihydroergocristine,Cytochrome P450 3A4,CYP3A4,5.523,IC50,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergocristine,Cytochrome P450 2C9,CYP2C9,5.523,IC50,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergocristine,Cytochrome P450 2C19,CYP2C19,5.523,IC50,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
domperidone,Aldehyde oxidase,AOX1,5.523,IC50,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
duloxetine,5-hydroxytryptamine receptor 1D,HTR1D,5.523,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
idebenone,Cytochrome P450 2D6,CYP2D6,5.523,IC50,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
isotretinoin,Alcohol dehydrogenase 4,ADH4,5.523,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
methysergide,Histamine H1 receptor,HRH1,5.523,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nitrendipine,Cytochrome P450 2C19,CYP2C19,5.523,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
nortriptyline,Cytochrome P450 2C19,CYP2C19,5.523,IC50,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
spironolactone,Cytochrome P450 2C19,CYP2C19,5.523,IC50,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
tibolone,Cytochrome P450 2C19,CYP2C19,5.523,IC50,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
ziprasidone,Muscarinic acetylcholine receptor M2,CHRM2,5.523,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
capsaicin,Cytochrome P450 1A2,CYP1A2,5.523,IC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
oxiconazole,Cytochrome P450 2C9,CYP2C9,5.523,IC50,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
tolnaftate,Cytochrome P450 2C19,CYP2C19,5.523,IC50,CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC(C)=CC=C1
acotiamide,Acetylcholinesterase,ACHE,5.523,IC50,COC1=CC(O)=C(C=C1OC)C(=O)NC1=NC(=CS1)C(=O)NCCN(C(C)C)C(C)C
propafenone,Sodium-dependent noradrenaline transporter,SLC6A2,5.524,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
quetiapine,Muscarinic acetylcholine receptor M5,CHRM5,5.524,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
diethylstilbestrol,D(3) dopamine receptor,DRD3,5.525,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
imiquimod,Adenosine receptor A2a,ADORA2A,5.525,Ki,CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12
tretinoin,Adenosine receptor A3,ADORA3,5.525,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
diethylstilbestrol,Arachidonate 15-lipoxygenase,ALOX15,5.528,IC50,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
troglitazone,Thromboxane-A synthase,TBXAS1,5.528,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
hydroxyamfetamine,Trace amine-associated receptor 1,TAAR1,5.529,EC50,CC(N)CC1=CC=C(O)C=C1
promazine,5-hydroxytryptamine receptor 1A,HTR1A,5.529,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
apomorphine,5-hydroxytryptamine receptor 1B,HTR1B,5.53,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
benzbromarone,Adenosine receptor A3,ADORA3,5.53,Ki,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
ergometrine,D(1A) dopamine receptor,DRD1,5.53,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
guaiacol,Carbonic anhydrase 2,CA2,5.53,Ki,COC1=CC=CC=C1O
rifampicin,Arachidonate 15-lipoxygenase,ALOX15,5.53,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
tamoxifen,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.53,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
iloperidone,Sodium-dependent dopamine transporter,SLC6A3,5.53,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
casopitant,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.53,Ki,C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=C(C)C=C(F)C=C1)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
chromic chloride,Epidermal growth factor receptor,EGFR,5.53,IC50,Cl[Cr](Cl)Cl
trilaciclib,Cyclin-dependent kinase 1,CDK1,5.53,IC50,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
infigratinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.53,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.53,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.53,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
cyamemazine,5-hydroxytryptamine receptor 3A,HTR3A,5.531,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
ipriflavone,Prostaglandin G/H synthase 1,PTGS1,5.531,IC50,CC(C)OC1=CC=C2C(=O)C(=COC2=C1)C1=CC=CC=C1
thioridazine,Epidermal growth factor receptor,EGFR,5.531,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
troglitazone,Adenosine receptor A3,ADORA3,5.531,Ki,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
flunarizine,Adenosine receptor A3,ADORA3,5.532,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
mitoxantrone,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.532,Ki,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
oxiconazole,5-hydroxytryptamine receptor 2B,HTR2B,5.533,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
indapamide,Arachidonate 15-lipoxygenase,ALOX15,5.535,IC50,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
miconazole,Sodium-dependent noradrenaline transporter,SLC6A2,5.535,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
valdecoxib,Sodium-dependent noradrenaline transporter,SLC6A2,5.537,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
fluoxetine,Muscarinic acetylcholine receptor M4,CHRM4,5.538,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
pimozide,Multidrug resistance protein 1,ABCB1,5.538,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
risperidone,Muscarinic acetylcholine receptor M4,CHRM4,5.538,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
tafamidis,Solute carrier family 22 member 6,SLC22A6,5.538,IC50,OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1
riociguat,"cAMP-specific 3',5'-cyclic phosphodiesterase 7B",PDE7B,5.538,IC50,COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=NC=CC=C12
argatroban,Cationic trypsin,,5.54,Ki,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2
bumetanide,G-protein coupled receptor 35,GPR35,5.54,EC50,CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
levobunolol,5-hydroxytryptamine receptor 1A,Htr1a,5.54,IC50,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
camostat,Multidrug and toxin extrusion protein 1,SLC47A1,5.54,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
dasatinib,Vascular endothelial growth factor receptor 2,KDR,5.54,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Tyrosine-protein kinase SYK,SYK,5.54,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,TGF-beta receptor type-2,TGFBR2,5.54,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
enoximone,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,5.54,IC50,CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1
erlotinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.54,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Myotonin-protein kinase,DMPK,5.54,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,5.54,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
gefitinib,Serine/threonine-protein kinase DCLK3,DCLK3,5.54,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,"Glutamate receptor ionotropic, NMDA 1",Grin1,5.54,EC50,N[C@@H](CCC(O)=O)C(O)=O
ibuprofen,Prostaglandin G/H synthase 1,PTGS1,5.54,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
isoprenaline,D(4) dopamine receptor,DRD4,5.54,Ki,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
ketoconazole,Bile salt export pump,ABCB11,5.54,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
losartan,Cytochrome P450 2C9,CYP2C9,5.54,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
mexiletine,Sodium channel protein type 2 subunit alpha,SCN2A,5.54,IC50,CC(N)COC1=C(C)C=CC=C1C
mianserin,Sodium-dependent serotonin transporter,Slc6a4,5.54,IC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
mifepristone,Estrogen receptor beta,ESR2,5.54,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
mirtazapine,5-hydroxytryptamine receptor 3A,HTR3A,5.54,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
niclosamide,Potassium channel subfamily T member 1,KCNT1,5.54,EC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
nifedipine,Adenosine receptor A1,Adora1,5.54,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
olanzapine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.54,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
ondansetron,Mu-type opioid receptor,Oprm1,5.54,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
sorafenib,Tyrosine-protein kinase CSK,CSK,5.54,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Cyclin-dependent kinase 15,CDK15,5.54,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Cyclin-dependent kinase 14,CDK14,5.54,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Discoidin domain-containing receptor 2,DDR2,5.54,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terfenadine,Muscarinic acetylcholine receptor M1,CHRM1,5.54,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
trazodone,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.54,IC50,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
zidovudine,"Thymidine kinase, cytosolic",TK1,5.54,Ki,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
zonisamide,Amine oxidase [flavin-containing] B,Maob,5.54,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
oxybuprocaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.54,IC50,CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC
lubeluzole,Calmodulin,CALM,5.54,Kd,CN(C1CCN(C[C@H](O)COC2=CC(F)=C(F)C=C2)CC1)C1=NC2=C(S1)C=CC=C2
pyrithione,Carbonic anhydrase 14,CA14,5.54,Ki,[O-][N+]1=C(S)C=CC=C1
pazopanib,AP2-associated protein kinase 1,AAK1,5.54,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase 1,MAP3K1,5.54,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Tyrosine-protein kinase FRK,FRK,5.54,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase PAK 6,PAK6,5.54,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Bone morphogenetic protein receptor type-1B,BMPR1B,5.54,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Citron Rho-interacting kinase,CIT,5.54,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Serine/threonine-protein kinase N1,PKN1,5.54,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Tyrosine-protein kinase receptor Tie-1,TIE1,5.54,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Ephrin type-A receptor 2,EPHA2,5.54,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Wee1-like protein kinase,WEE1,5.54,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Tyrosine-protein kinase Mer,MERTK,5.54,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
cannabidiol,Cannabinoid receptor 2,CNR2,5.54,Ki,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
fedratinib,Serine/threonine-protein kinase 10,STK10,5.54,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Bone morphogenetic protein receptor type-2,BMPR2,5.54,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Uncharacterized serine/threonine-protein kinase SBK3,SBK3,5.54,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,Macrophage-stimulating protein receptor,MST1R,5.54,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Tyrosine-protein kinase JAK2,JAK2,5.54,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Tyrosine-protein kinase JAK2,JAK2,5.54,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Macrophage-stimulating protein receptor,MST1R,5.54,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
levodopa,Epidermal growth factor receptor,EGFR,5.541,IC50,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
mepacrine,Sodium-dependent noradrenaline transporter,SLC6A2,5.542,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
ebastine,Histamine H2 receptor,HRH2,5.543,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
astemizole,Tyrosine-protein kinase Fyn,FYN,5.546,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
amiodarone,Delta-type opioid receptor,OPRD1,5.549,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
adenosine triphosphate,P2Y purinoceptor 1,P2RY1,5.55,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adenosine triphosphate,MAP kinase-activated protein kinase 2,MAPKAPK2,5.55,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adenosine triphosphate,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,5.55,Kd,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
benzarone,Solute carrier family 22 member 12,SLC22A12,5.55,IC50,CCC1=C(C(=O)C2=CC=C(O)C=C2)C2=C(O1)C=CC=C2
brimonidine,Alpha-1A adrenergic receptor,ADRA1A,5.55,Ki,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
chlorambucil,Delta-type opioid receptor,OPRD1,5.55,IC50,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
dihydroergotamine,Multidrug and toxin extrusion protein 1,SLC47A1,5.55,IC50,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
flufenamic acid,Transient receptor potential cation channel subfamily M member 4,TRPM4,5.55,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
glibenclamide,Bile salt export pump,Abcb11,5.55,IC50,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
gossypol,"Malate dehydrogenase, mitochondrial",MDH2,5.55,IC50,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
haloperidol,5-hydroxytryptamine receptor 1A,HTR1A,5.55,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hexylresorcinol,Arachidonate 5-lipoxygenase,ALOX5,5.55,IC50,CCCCCCC1=C(O)C=C(O)C=C1
imatinib,Serine/threonine-protein kinase 17A,STK17A,5.55,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
ketanserin,5-hydroxytryptamine receptor 6,HTR6,5.55,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
mafenide,Carbonic anhydrase 4,CA4,5.55,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mafenide,Carbonic anhydrase 4,CA4,5.55,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mianserin,D(3) dopamine receptor,DRD3,5.55,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
oxametacin,Prostaglandin G/H synthase 1,PTGS1,5.55,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)NO
pantoprazole,Multidrug and toxin extrusion protein 1,SLC47A1,5.55,IC50,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
pilocarpine,Muscarinic acetylcholine receptor DM1,mAChR-A,5.55,Ki,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
propylthiouracil,Myeloperoxidase,MPO,5.55,IC50,CCCC1=CC(=O)NC(=S)N1
risperidone,Muscarinic acetylcholine receptor M1,CHRM1,5.55,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sulfafurazole,Histamine H4 receptor,HRH4,5.55,IC50,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
talinolol,Bifunctional epoxide hydrolase 2,EPHX2,5.55,IC50,CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1
talinolol,Bifunctional epoxide hydrolase 2,EPHX2,5.55,IC50,CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1
estrone,Sodium-dependent serotonin transporter,SLC6A4,5.55,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
quercetin,Amine oxidase [flavin-containing] A,MAOA,5.55,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Aldose reductase,AKR1B1,5.55,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Tyrosine-protein kinase HCK,HCK,5.55,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.55,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Fibroblast growth factor receptor 4,FGFR4,5.55,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
rimonabant,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.55,IC50,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
vandetanib,Serine/threonine-protein kinase TNNI3K,TNNI3K,5.55,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Serine/threonine-protein kinase 26,STK26,5.55,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Mitogen-activated protein kinase kinase kinase 15,MAP3K15,5.55,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Casein kinase II subunit alpha',CSNK2A2,5.55,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,5.55,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.55,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,DYRK1B,5.55,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
nintedanib,3-phosphoinositide-dependent protein kinase 1,PDPK1,5.55,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Mitogen-activated protein kinase kinase kinase 13,MAP3K13,5.55,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Ephrin type-B receptor 6,EPHB6,5.55,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
quizartinib,TRAF2 and NCK-interacting protein kinase,TNIK,5.55,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Peripheral plasma membrane protein CASK,CASK,5.55,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
promazine,Histamine H2 receptor,HRH2,5.551,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
cinnarizine,Sodium-dependent noradrenaline transporter,SLC6A2,5.552,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
domperidone,Kappa-type opioid receptor,OPRK1,5.553,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
nicardipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.553,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
chlorzoxazone,"Nitric oxide synthase, brain",Nos1,5.554,IC50,ClC1=CC2=C(OC(=O)N2)C=C1
venlafaxine,5-hydroxytryptamine receptor 6,HTR6,5.554,Ki,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
miconazole,5-hydroxytryptamine receptor 2C,HTR2C,5.555,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
saquinavir,Kappa-type opioid receptor,OPRK1,5.556,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
tamoxifen,Muscarinic acetylcholine receptor M2,CHRM2,5.557,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
olanzapine,Arachidonate 15-lipoxygenase,ALOX15,5.558,IC50,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
chlortalidone,Carbonic anhydrase 2,CA2,5.56,Kd,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
clomipramine,Sodium-dependent dopamine transporter,SLC6A3,5.56,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
donepezil,Butyrylcholinesterase; Protein Bche,Bche,5.56,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
hydroxychloroquine,Toll-like receptor 7,TLR7,5.56,IC50,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
imatinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.56,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
methapyrilene,Cytochrome P450 2D6,CYP2D6,5.56,IC50,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
mitotane,Alpha-2A adrenergic receptor,ADRA2A,5.56,Ki,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
phenyltoloxamine,D(2) dopamine receptor,DRD2,5.56,Ki,CN(C)CCOC1=C(CC2=CC=CC=C2)C=CC=C1
phenyltoloxamine,D(4) dopamine receptor,DRD4,5.56,Ki,CN(C)CCOC1=C(CC2=CC=CC=C2)C=CC=C1
sitosterol,Amine oxidase [flavin-containing] B,MAOB,5.56,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sitosterol,Amine oxidase [flavin-containing] B,MAOB,5.56,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
tacrine,Alpha-1A adrenergic receptor,Adra1a,5.56,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
trimetaphan,Nicotinic acetylcholine receptor alpha 5 subunit,nAChRalpha5,5.56,Ki,O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
ceritinib,High affinity nerve growth factor receptor,NTRK1,5.56,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
haloprogin,Sodium-dependent noradrenaline transporter,SLC6A2,5.561,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
levamisole,Membrane-associated progesterone receptor component 1,Pgrmc1,5.568,Ki,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1
disopyramide,Histamine H1 receptor,HRH1,5.569,Ki,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
fluoxetine,Muscarinic acetylcholine receptor M2,CHRM2,5.569,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
fluoxetine,Muscarinic acetylcholine receptor M5,CHRM5,5.569,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
procaine,5-hydroxytryptamine receptor 3A,HTR3A,5.569,IC50,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
bortezomib,Carbonic anhydrase 15,Ca15,5.57,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
chlorpromazine,Potassium channel subfamily K member 2,KCNK2,5.57,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cocaine,Sodium-dependent noradrenaline transporter,SLC6A2,5.57,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
ciclosporin,Multidrug resistance-associated protein 1,ABCC1,5.57,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
gefitinib,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,5.57,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
haloperidol,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.57,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
irinotecan,Solute carrier family 22 member 2,SLC22A2,5.57,IC50,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
lovastatin,Acetylcholinesterase,ache,5.57,Ki,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
thiamazole,Thyroid peroxidase,TPO,5.57,IC50,CN1C=CNC1=S
nicotine,Acetylcholine receptor subunit beta-like 2,nAChRbeta2,5.57,Ki,CN1CCC[C@H]1C1=CC=CN=C1
nifekalant,Multidrug and toxin extrusion protein 2,SLC47A2,5.57,IC50,CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N+]([O-])=O)N(C)C1=O
nomifensine,Histamine H1 receptor,HRH1,5.57,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
papaverine,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,5.57,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
pentamidine,Multidrug and toxin extrusion protein 2,SLC47A2,5.57,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
perlapine,D(2) dopamine receptor,Drd2,5.57,IC50,CN1CCN(CC1)C1=NC2=C(CC3=CC=CC=C13)C=CC=C2
ropinirole,D(2) dopamine receptor,Drd2,5.57,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sertindole,Muscarinic acetylcholine receptor M3,CHRM3,5.57,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sorafenib,Tyrosine-protein kinase Lck,LCK,5.57,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Fibroblast growth factor receptor 2,FGFR2,5.57,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Serine/threonine-protein kinase TAO3,TAOK3,5.57,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,RAC-beta serine/threonine-protein kinase,AKT2,5.57,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase DCLK2,DCLK2,5.57,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
theophylline,Adenosine receptor A2b,ADORA2B,5.57,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
trimethoprim,Dihydrofolate reductase,folA,5.57,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
troglitazone,Bile salt export pump,ABCB11,5.57,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
zoledronic acid,Geranylgeranyl pyrophosphate synthase,GGPS1,5.57,Ki,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
butacaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.57,IC50,CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1
hexamidine,Trypsin-1,PRSS1,5.57,Ki,NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
posaconazole,14-alpha sterol demethylase Cyp51A,,5.57,Kd,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=CC=C(F)C=C2F)C=C1
quercetin,Carbonic anhydrase 1,CA1,5.57,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,5.57,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
stallimycin,DNA topoisomerase 1,TOP1,5.57,IC50,CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC=O)=CN3C)=CN2C)C=C1C(=O)NCCC(N)=N
pazopanib,Tyrosine-protein kinase Fyn,FYN,5.57,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Tyrosine-protein kinase Fer,FER,5.57,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,5.57,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
dexfosfoserine,Metabotropic glutamate receptor 6,Grm6,5.57,EC50,N[C@@H](COP(O)(O)=O)C(O)=O
abiraterone acetate,Cytochrome P450 3A4,CYP3A4,5.57,IC50,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C4=CC=CN=C4)[C@@H]3CC=C2C1
crizotinib,Epidermal growth factor receptor,EGFR,5.57,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Fibroblast growth factor receptor 3,FGFR3,5.57,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase OSR1,OXSR1,5.57,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Tyrosine-protein kinase Lck,LCK,5.57,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Tyrosine-protein kinase Yes,YES1,5.57,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Cyclin-G-associated kinase,GAK,5.57,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,5.57,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Serine/threonine-protein kinase N2,PKN2,5.57,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
phenol,Carbonic anhydrase 3,CA3,5.57,Ki,OC1=CC=CC=C1
afatinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,5.57,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,5.57,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,5.57,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Mitogen-activated protein kinase kinase kinase 11,MAP3K11,5.57,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tofacitinib,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,5.57,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Tyrosine-protein kinase FRK,FRK,5.57,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Myosin-IIIb,MYO3B,5.57,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
quizartinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,5.57,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Platelet-derived growth factor receptor alpha,PDGFRA,5.57,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Tyrosine-protein kinase SYK,SYK,5.57,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Cyclin-dependent kinase 18,CDK18,5.57,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,Platelet-derived growth factor receptor alpha,PDGFRA,5.57,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Platelet-derived growth factor receptor alpha,PDGFRA,5.57,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
clotrimazole,Adenosine receptor A3,ADORA3,5.571,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
pramipexole,Histamine H2 receptor,HRH2,5.571,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
mepacrine,Muscarinic acetylcholine receptor M5,CHRM5,5.571,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
econazole,Alpha-2B adrenergic receptor,ADRA2B,5.572,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
hydroxyprogesterone caproate,Adenosine receptor A3,ADORA3,5.573,Ki,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
montelukast,Sodium-dependent noradrenaline transporter,SLC6A2,5.574,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
mepacrine,Acetylcholinesterase,ACHE,5.574,IC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
fluphenazine,Muscarinic acetylcholine receptor M2,CHRM2,5.575,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
astemizole,Kappa-type opioid receptor,OPRK1,5.577,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
dexfenfluramine,Muscarinic acetylcholine receptor M2,CHRM2,5.577,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
etodolac,Prostaglandin G/H synthase 1,PTGS1,5.577,IC50,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
emetine,Alpha-1D adrenergic receptor,ADRA1D,5.578,Ki,CC[C@H]1CN2CCC3=CC(OC)=C(OC)C=C3[C@@H]2C[C@@H]1C[C@H]1NCCC2=CC(OC)=C(OC)C=C12
orphenadrine,Sodium-dependent noradrenaline transporter,SLC6A2,5.578,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
secobarbital,Matrix metalloproteinase-9,MMP9,5.578,IC50,CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
diphenidol,Alpha-1B adrenergic receptor,Adra1b,5.579,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
miconazole,Kappa-type opioid receptor,OPRK1,5.579,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
tubocurarine,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,5.579,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
camostat,Plasminogen,Plg,5.58,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
clenbuterol,5-hydroxytryptamine receptor 1A,Htr1a,5.58,IC50,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
ebastine,Alpha-1A adrenergic receptor,Adra1a,5.58,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ethisterone,Polyphenol oxidase 2,PPO2,5.58,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C
gossypol,Lactate dehydrogenase,LDH,5.58,IC50,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
ketoconazole,Solute carrier family 22 member 1,SLC22A1,5.58,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
letrozole,"Cytochrome P450 11B1, mitochondrial",CYP11B1,5.58,IC50,N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
montelukast,D(3) dopamine receptor,DRD3,5.58,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
oxycodone,Kappa-type opioid receptor,Oprk1,5.58,Ki,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
prednisolone,"Fatty acid-binding protein, liver",Fabp1,5.58,Ki,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,"Fatty acid-binding protein, liver",Fabp1,5.58,Ki,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
kainic acid,Glutamate receptor 3,GRIA3,5.58,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
quercetin,Xanthine dehydrogenase/oxidase,XDH,5.58,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
lorcaserin,Sodium-dependent serotonin transporter,SLC6A4,5.58,Ki,C[C@H]1CNCCC2=CC=C(Cl)C=C12
quizartinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,5.58,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Cyclin-dependent kinase 14,CDK14,5.58,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Maternal embryonic leucine zipper kinase,MELK,5.58,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,G protein-coupled receptor kinase 7,GRK7,5.58,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase RIO2,RIOK2,5.58,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
prazosin,5-hydroxytryptamine receptor 2B,HTR2B,5.582,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
lacidipine,Androgen receptor,Ar,5.583,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
loperamide,5-hydroxytryptamine receptor 2B,HTR2B,5.583,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
molindone,Alpha-1A adrenergic receptor,ADRA1A,5.583,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
uridine triphosphate,P2X purinoceptor 3,P2RX3,5.583,Ki,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O
levobunolol,Sodium-dependent serotonin transporter,SLC6A4,5.585,Ki,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
thiothixene,Muscarinic acetylcholine receptor M1,CHRM1,5.585,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
domperidone,Sodium-dependent noradrenaline transporter,SLC6A2,5.586,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
tamoxifen,Progesterone receptor,PGR,5.587,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
oxybutynin,Sodium-dependent noradrenaline transporter,SLC6A2,5.589,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
brimonidine,5-hydroxytryptamine receptor 1A,Htr1a,5.59,IC50,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
carbachol,Muscarinic acetylcholine receptor M4,Chrm4,5.59,Ki,C[N+](C)(C)CCOC(N)=O
diclofenac,Aldo-keto reductase family 1 member C3,AKR1C3,5.59,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
diphenhydramine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.59,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
epalrestat,Alcohol dehydrogenase [NADP(+)],AKR1A1,5.59,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
erlotinib,Serine/threonine-protein kinase SIK2,SIK2,5.59,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
aminobutyric acid,Sodium- and chloride-dependent GABA transporter 1,Slc6a1,5.59,IC50,NCCCC(O)=O
gefitinib,Tyrosine-protein kinase Fgr,FGR,5.59,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gossypol,Estrogen receptor,ESR1,5.59,IC50,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
imatinib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,5.59,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
lapatinib,Serine/threonine-protein kinase 10,STK10,5.59,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
methylparaben,Carbonic anhydrase 1,CA1,5.59,Ki,COC(=O)C1=CC=C(O)C=C1
nortriptyline,D(2) dopamine receptor,DRD2,5.59,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
noscapine,Solute carrier family 22 member 2,SLC22A2,5.59,IC50,COC1=CC=C2[C@H](OC(=O)C2=C1OC)[C@@H]1N(C)CCC2=C1C(OC)=C1OCOC1=C2
paclitaxel,Multidrug resistance protein 1,ABCB1,5.59,IC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
promethazine,5-hydroxytryptamine receptor 1A,Htr1a,5.59,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
pyrvinium,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,5.59,IC50,CN(C)C1=CC=C2C(C=CC(\C=C\C3=C(C)N(C(C)=C3)C3=CC=CC=C3)=[N+]2C)=C1
quinidine,Multidrug resistance protein 1,ABCB1,5.59,Ki,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
sorafenib,Vascular endothelial growth factor receptor 2,kdr,5.59,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Insulin-like growth factor 1 receptor,IGF1R,5.59,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
ursodiol,M1-family alanyl aminopeptidase,,5.59,IC50,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
ziprasidone,Beta-1 adrenergic receptor,ADRB1,5.59,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
ruboxistaurin,Death-associated protein kinase 2,DAPK2,5.59,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Glycogen synthase kinase-3 beta,GSK3B,5.59,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,5.59,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Cyclin-dependent kinase 16,CDK16,5.59,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase 33,STK33,5.59,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase LATS1,LATS1,5.59,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,5.59,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Tyrosine-protein kinase TXK,TXK,5.59,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Tyrosine-protein kinase Blk,BLK,5.59,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.59,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Serine/threonine-protein kinase MRCK alpha,CDC42BPA,5.59,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ruxolitinib,Activated CDC42 kinase 1,TNK2,5.59,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,5.59,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,5.59,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Casein kinase I isoform alpha-like,CSNK1A1L,5.59,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Dual specificity mitogen-activated protein kinase kinase 3,MAP2K3,5.59,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Dual specificity mitogen-activated protein kinase kinase 4,MAP2K4,5.59,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tenidap,Prostaglandin G/H synthase 1,PTGS1,5.59,IC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
midostaurin,Tyrosine-protein kinase ZAP-70,ZAP70,5.59,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
verapamil,Histamine H2 receptor,HRH2,5.594,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
clomifene,Alpha-1B adrenergic receptor,Adra1b,5.597,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
danazol,5-hydroxytryptamine receptor 2A,HTR2A,5.597,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
escitalopram,5-hydroxytryptamine receptor 2C,HTR2C,5.597,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
isotretinoin,Mitogen-activated protein kinase 14,MAPK14,5.597,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
clotrimazole,Kappa-type opioid receptor,OPRK1,5.598,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
loperamide,Alpha-1D adrenergic receptor,ADRA1D,5.599,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clobetasol propionate,Androgen receptor,Ar,5.599,Ki,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
acetylcholine,Muscarinic acetylcholine receptor M4,CHRM4,5.6,Ki,CC(=O)OCC[N+](C)(C)C
acipimox,Hydroxycarboxylic acid receptor 2,HCAR2,5.6,EC50,CC1=CN=C(C=[N+]1[O-])C(O)=O
alcuronium,Muscarinic acetylcholine receptor M4,CHRM4,5.6,Ki,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
amitriptyline,Transporter,Slc6a2,5.6,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
astemizole,"HLA class I histocompatibility antigen, A-3 alpha chain",HLA-A,5.6,Kd,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
biotin,Insulin-degrading enzyme,IDE,5.6,EC50,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12
bumetanide,Solute carrier family 12 member 2,SLC12A2,5.6,IC50,CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
cefotaxime,Beta-lactamase,ampC,5.6,Ki,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
cerulenin,Pol polyprotein,pol,5.6,IC50,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O
chloroquine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.6,IC50,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
chlorpromazine,Calmodulin,CALM,5.6,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
citric acid,3-dehydroquinate dehydratase,aroQ,5.6,Kd,OC(=O)CC(O)(CC(O)=O)C(O)=O
citric acid,Transient receptor potential cation channel subfamily V member 4,Trpv4,5.6,EC50,OC(=O)CC(O)(CC(O)=O)C(O)=O
clomifene,Tyrosine-protein kinase Fyn,FYN,5.6,IC50,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,Vasopressin V2 receptor,AVPR2,5.6,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clozapine,5-hydroxytryptamine receptor 1B,Htr1b,5.6,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
colchicine,Tubulin alpha-1A chain,TUBA1A,5.6,Ki,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
dicloxacillin,Muscarinic acetylcholine receptor M3,CHRM3,5.6,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
dihydroergotamine,5-hydroxytryptamine receptor 1E,HTR1E,5.6,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dinoprost,Prostaglandin E2 receptor EP2 subtype,Ptger2,5.6,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
ephedrine,Beta-2 adrenergic receptor,ADRB2,5.6,Ki,CN[C@@H](C)[C@H](O)C1=CC=CC=C1
erlotinib,AarF domain-containing protein kinase 4,COQ8B,5.6,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Mitogen-activated protein kinase 4,MAPK4,5.6,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,5.6,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
estradiol,Calcium-activated potassium channel subunit alpha-1,KCNMA1,5.6,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
flufenamic acid,Transient receptor potential cation channel subfamily M member 4,Trpm4,5.6,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
flunarizine,Potassium channel subfamily K member 2,Kcnk2,5.6,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
fluspirilene,5-hydroxytryptamine receptor 1E,HTR1E,5.6,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
foscarnet,DNA polymerase catalytic subunit,UL54,5.6,IC50,OC(=O)P(O)(O)=O
foscarnet,Reverse transcriptase,reverse transcriptas,5.6,IC50,OC(=O)P(O)(O)=O
galantamine,Acetylcholinesterase,Ache,5.6,IC50,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
gallamine,Muscarinic acetylcholine receptor M2,Chrm2,5.6,Ki,CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
gefitinib,Ephrin type-B receptor 4,EPHB4,5.6,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
iloprost,Prostaglandin E2 receptor EP4 subtype,Ptger4,5.6,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
ketanserin,D(1B) dopamine receptor,DRD5,5.6,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketotifen,5-hydroxytryptamine receptor 1A,Htr1a,5.6,IC50,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
levorphanol,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,5.6,IC50,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
mefloquine,Glycine receptor subunit alpha-1,GLRA1,5.6,EC50,O[C@H]([C@H]1CCCCN1)C1=CC(=NC2=C(C=CC=C12)C(F)(F)F)C(F)(F)F
mitoxantrone,DNA-3-methyladenine glycosylase,MPG,5.6,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
modafinil,Sodium-dependent dopamine transporter,Slc6a3,5.6,Ki,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
nafamostat,Acid-sensing ion channel 3,ASIC3,5.6,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
naproxen,Prostaglandin G/H synthase 2,PTGS2,5.6,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
orlistat,Cannabinoid receptor 1,CNR1,5.6,Ki,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
pentamidine,Sodium-dependent dopamine transporter,SLC6A3,5.6,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
phenobarbital,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,5.6,IC50,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1
pipamperone,5-hydroxytryptamine receptor 1A,HTR1A,5.6,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
pipamperone,Histamine H1 receptor,HRH1,5.6,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
prednisolone,Androgen receptor,AR,5.6,Ki,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,Androgen receptor,AR,5.6,Ki,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
quetiapine,5-hydroxytryptamine receptor 1F,HTR1F,5.6,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
rosiglitazone,Free fatty acid receptor 1,FFAR1,5.6,EC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
rotigotine,D(1A) dopamine receptor,DRD1,5.6,Ki,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
sitosterol,Nuclear factor NF-kappa-B p105 subunit,NFKB1,5.6,IC50,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sorafenib,Fibroblast growth factor receptor 1,FGFR1,5.6,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiperone,"HLA class I histocompatibility antigen, A-3 alpha chain",HLA-A,5.6,Kd,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sulfathiazole,Dihydropteroate synthase,folP,5.6,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1
sumatriptan,5-hydroxytryptamine receptor 6,HTR6,5.6,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
tegaserod,5-hydroxytryptamine receptor 3A,HTR3A,5.6,Ki,CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2
terbutaline,Beta-2 adrenergic receptor,ADRB2,5.6,Ki,CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1
thioridazine,D(1B) dopamine receptor,DRD5,5.6,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
trazodone,"HLA class I histocompatibility antigen, A-3 alpha chain",HLA-A,5.6,Kd,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
treprostinil,Prostaglandin E2 receptor EP3 subtype,PTGER3,5.6,Ki,CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2CC3=C(OCC(O)=O)C=CC=C3C[C@H]12
tubocurarine,Small conductance calcium-activated potassium channel protein 2,Kcnn2,5.6,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
suramin,P2Y purinoceptor 13,P2RY13,5.6,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
estrone,Aromatase,CYP19A1,5.6,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
linoleic acid,Potassium voltage-gated channel subfamily B member 1,KCNB1,5.6,EC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
quercetin,Carbonic anhydrase 2,CA2,5.6,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
uridine triphosphate,P2Y purinoceptor 4,P2ry4,5.6,EC50,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O
xanomeline,5-hydroxytryptamine receptor 1E,HTR1E,5.6,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
yohimbine,5-hydroxytryptamine receptor 7,HTR7,5.6,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
pazopanib,Tyrosine-protein kinase Srms,SRMS,5.6,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Tyrosine-protein kinase CSK,CSK,5.6,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Serine/threonine-protein kinase MRCK beta,CDC42BPB,5.6,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
retigabine,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,5.6,EC50,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
crizotinib,Tyrosine-protein kinase SYK,SYK,5.6,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase RIO1,RIOK1,5.6,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase/endoribonuclease IRE1,ERN1,5.6,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,5.6,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.6,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dequalinium,Cyclic nucleotide-gated olfactory channel,CNGA2,5.6,IC50,CC1=[N+](CCCCCCCCCC[N+]2=C(C)C=C(N)C3=CC=CC=C23)C2=CC=CC=C2C(N)=C1
corbadrine,Alpha-1D adrenergic receptor,ADRA1D,5.6,Ki,C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1
levmetamfetamine,Trace amine-associated receptor 1,TAAR1,5.6,EC50,CN[C@H](C)CC1=CC=CC=C1
nintedanib,Mitogen-activated protein kinase 7,MAPK7,5.6,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Glycogen synthase kinase-3 alpha,GSK3A,5.6,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,5.6,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase 10,MAPK10,5.6,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
quizartinib,Tyrosine-protein kinase Lck,LCK,5.6,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
quizartinib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,5.6,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Dual specificity protein kinase CLK1,CLK1,5.6,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Sgk3,SGK3,5.6,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,Tyrosine-protein kinase Lck,LCK,5.6,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Tyrosine-protein kinase Lck,LCK,5.6,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
ciprofloxacin,DNA topoisomerase 4 subunit A,parC,5.602,IC50,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
dichlorphenamide,Cytochrome P450 2C9,CYP2C9,5.602,EC50,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
mecamylamine,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,5.602,Ki,CNC1(C)C2CCC(C2)C1(C)C
propafenone,Aldehyde oxidase,AOX1,5.602,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
ipriflavone,Sodium-dependent noradrenaline transporter,SLC6A2,5.604,Ki,CC(C)OC1=CC=C2C(=O)C(=COC2=C1)C1=CC=CC=C1
propafenone,Alpha-1D adrenergic receptor,ADRA1D,5.604,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
yohimbine,D(3) dopamine receptor,DRD3,5.604,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
dexchlorpheniramine,Muscarinic acetylcholine receptor M2,CHRM2,5.604,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
dihydroergocristine,Beta-3 adrenergic receptor,ADRB3,5.605,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
doxorubicin,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.605,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
hexachlorophene,Mitogen-activated protein kinase 3,MAPK3,5.605,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
suloctidil,Histamine H1 receptor,HRH1,5.606,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
tropisetron,Muscarinic acetylcholine receptor M5,CHRM5,5.606,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
dexfenfluramine,5-hydroxytryptamine receptor 2A,HTR2A,5.607,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
diiodohydroxyquinoline,Tyrosine-protein kinase Lck,LCK,5.609,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
miconazole,Mu-type opioid receptor,OPRM1,5.609,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
phentolamine,5-hydroxytryptamine receptor 2A,HTR2A,5.609,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
terconazole,5-hydroxytryptamine receptor 4,HTR4,5.609,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
alprazolam,Bromodomain-containing protein 4,BRD4,5.61,Kd,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
caffeine,Adenosine receptor A2a,ADORA2A,5.61,Ki,CN1C=NC2=C1C(=O)N(C)C(=O)N2C
lomerizine,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,5.61,IC50,COC1=C(OC)C(OC)=C(CN2CCN(CC2)C(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)C=C1
loxapine,5-hydroxytryptamine receptor 1A,HTR1A,5.61,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
methamphetamine,Synaptic vesicular amine transporter,Slc18a2,5.61,Ki,CN[C@@H](C)CC1=CC=CC=C1
nicotine,Nicotinic acetylcholine receptor alpha 5 subunit,nAChRalpha5,5.61,Ki,CN1CCC[C@H]1C1=CC=CN=C1
paroxetine,P2X purinoceptor 4,P2rx4,5.61,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
paroxetine,P2X purinoceptor 4,P2rx4,5.61,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
paroxetine,P2X purinoceptor 4,P2rx4,5.61,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
trichlormethiazide,Carbonic anhydrase 6,CA6,5.61,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
trimipramine,Sodium-dependent noradrenaline transporter,SLC6A2,5.61,Ki,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=C1C=CC=C2
zafirlukast,Peroxisome proliferator-activated receptor gamma,PPARG,5.61,EC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
quercetin,Adenosine receptor A1,Adora1,5.61,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
yohimbine,D(3) dopamine receptor,Drd3,5.61,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
tamoxifen,Alpha-1D adrenergic receptor,ADRA1D,5.611,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
trihexyphenidyl,Cytochrome P450 2D6,CYP2D6,5.611,IC50,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
disulfiram,Kappa-type opioid receptor,OPRK1,5.612,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
flunarizine,5-hydroxytryptamine receptor 1A,HTR1A,5.612,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
saquinavir,5-hydroxytryptamine receptor 1A,HTR1A,5.612,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
terconazole,Arachidonate 15-lipoxygenase,ALOX15,5.612,IC50,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
salbutamol,Beta-1 adrenergic receptor,ADRB1,5.613,Ki,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
hexachlorophene,Tyrosine-protein kinase Lck,LCK,5.614,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
methylphenidate,Alpha-2B adrenergic receptor,ADRA2B,5.615,Ki,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
phentolamine,5-hydroxytryptamine receptor 2B,HTR2B,5.616,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
econazole,Sodium-dependent noradrenaline transporter,SLC6A2,5.617,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
paliperidone,5-hydroxytryptamine receptor 6,HTR6,5.617,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
hexachlorophene,5-hydroxytryptamine receptor 2C,HTR2C,5.618,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
norethisterone,Sodium-dependent serotonin transporter,SLC6A4,5.618,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
acetylsalicylic acid,Prostaglandin G/H synthase 2,PTGS2,5.62,IC50,CC(=O)OC1=CC=CC=C1C(O)=O
amodiaquine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.62,IC50,CCN(CC)CC1=C(O)C=CC(NC2=CC=NC3=CC(Cl)=CC=C23)=C1
benserazide,Genome polyprotein [Cleaved into: P1; Capsid protein VP0,,5.62,IC50,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
bortezomib,Alpha-chymotrypsin,,5.62,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
captopril,Beta-lactamase,blaIMP-1,5.62,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
chloroxine,Arachidonate 15-lipoxygenase,ALOX15,5.62,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1Cl
cianidanol,Carbonic anhydrase 1,CA1,5.62,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
desipramine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.62,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
diazepam,Aldo-keto reductase family 1 member C2,AKR1C2,5.62,IC50,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
diltiazem,5-hydroxytryptamine receptor 2A,HTR2A,5.62,Ki,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
erlotinib,Ephrin type-A receptor 3,EPHA3,5.62,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,5.62,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
flunarizine,Mu-type opioid receptor,OPRM1,5.62,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
imatinib,Tyrosine-protein kinase Fgr,FGR,5.62,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
melperone,Muscarinic acetylcholine receptor M2,CHRM2,5.62,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
molindone,D(4) dopamine receptor,DRD4,5.62,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
montelukast,Beta-2 adrenergic receptor,ADRB2,5.62,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
nefazodone,Sodium-dependent dopamine transporter,Slc6a3,5.62,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nilotinib,Tyrosine-protein kinase CSK,CSK,5.62,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norethindrone acetate,Sodium-dependent serotonin transporter,SLC6A4,5.62,Ki,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
piretanide,Solute carrier family 12 member 2,SLC12A2,5.62,IC50,NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O
sorafenib,Serine/threonine-protein kinase 33,STK33,5.62,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulbactam,Beta-lactamase,SHV-11,5.62,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sunitinib,Mitogen-activated protein kinase 9,MAPK9,5.62,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,5.62,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase PAK 6,PAK6,5.62,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase pim-3,PIM3,5.62,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Bone morphogenetic protein receptor type-1B,BMPR1B,5.62,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ephrin type-A receptor 7,EPHA7,5.62,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
thioridazine,Histamine H4 receptor,HRH4,5.62,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tolmetin,Aldose reductase,AKR1B1,5.62,IC50,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
tramadol,Mu-type opioid receptor,Oprm1,5.62,Ki,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
ubenimex,Aminopeptidase N,ANPEP,5.62,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
ursodiol,G-protein coupled bile acid receptor 1,GPBAR1,5.62,EC50,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
pyrithione,Carbonic anhydrase 6,CA6,5.62,Ki,[O-][N+]1=C(S)C=CC=C1
quercetin,Multidrug resistance-associated protein 1,ABCC1,5.62,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
pazopanib,Activin receptor type-2B,ACVR2B,5.62,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Ephrin type-A receptor 7,EPHA7,5.62,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,5.62,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase ULK3,ULK3,5.62,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Tyrosine-protein kinase TXK,TXK,5.62,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Protein kinase C epsilon type,PRKCE,5.62,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Cyclin-dependent kinase 16,CDK16,5.62,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Citron Rho-interacting kinase,CIT,5.62,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
carfilzomib,Proteasome subunit beta type-9,PSMB9,5.62,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
gepirone,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.62,Ki,CC1(C)CC(=O)N(CCCCN2CCN(CC2)C2=NC=CC=N2)C(=O)C1
iclaprim,Dihydrofolate reductase,,5.62,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=C2C=CC(OC2=C1OC)C1CC1
midostaurin,Fibroblast growth factor receptor 2,FGFR2,5.62,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Tyrosine-protein kinase FRK,FRK,5.62,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase 32A,STK32A,5.62,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase D3,PRKD3,5.62,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Serine/threonine-protein kinase Nek3,NEK3,5.62,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
cannabidiol,Cannabinoid receptor 1,CNR1,5.62,Ki,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
fedratinib,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,5.62,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase receptor R3,ACVRL1,5.62,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase PLK2,PLK2,5.62,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ergotamine,Beta-1 adrenergic receptor,ADRB1,5.621,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
flunarizine,Cannabinoid receptor 1,CNR1,5.621,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
amisulpride,D(4) dopamine receptor,DRD4,5.625,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
pethidine,Kappa-type opioid receptor,OPRK1,5.625,Ki,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
celecoxib,Progesterone receptor,PGR,5.627,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
tafamidis,Solute carrier family 22 member 8,SLC22A8,5.627,IC50,OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1
isotretinoin,Adenosine receptor A3,ADORA3,5.628,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
gentian violet,Adenosine receptor A3,ADORA3,5.628,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
atazanavir,Cytochrome P450 3A4,CYP3A4,5.629,Ki,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
prucalopride,D(4) dopamine receptor,DRD4,5.629,Ki,COCCCN1CCC(CC1)NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2
amlodipine,Alpha-1A adrenergic receptor,ADRA1A,5.63,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
clioquinol,Carbonic anhydrase 15,Ca15,5.63,Ki,OC1=C2N=CC=CC2=C(Cl)C=C1I
cromoglicic acid,G-protein coupled receptor 35,GPR35,5.63,Ki,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O
daunorubicin,ORF 73,,5.63,AC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1
diethylstilbestrol,Mu-type opioid receptor,OPRM1,5.63,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
ditiocarb,Carbonic anhydrase 1; GH09688p,CAH1,5.63,Ki,CCN(CC)C(S)=S
leucovorin,Dihydrofolate reductase,DHFR,5.63,Ki,NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
hydroxychloroquine,Alpha-1D adrenergic receptor,ADRA1D,5.63,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
methapyrilene,Muscarinic acetylcholine receptor M5,CHRM5,5.63,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
raloxifene,Delta-type opioid receptor,OPRD1,5.63,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
terfenadine,Adrenergic receptor alpha-1,ADRA1D|ADRA1A|ADRA1B,5.63,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
quercetin,Alcohol dehydrogenase [NADP(+)],Akr1a1,5.63,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
dronedarone,Potassium voltage-gated channel subfamily A member 5,KCNA5,5.63,IC50,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
prazosin,5-hydroxytryptamine receptor 1A,Htr1a,5.63,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
upadacitinib,Tyrosine-protein kinase JAK3,JAK3,5.63,IC50,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F
desipramine,D(2) dopamine receptor,DRD2,5.631,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
terconazole,5-hydroxytryptamine receptor 2A,HTR2A,5.632,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
aripiprazole,Muscarinic acetylcholine receptor M5,CHRM5,5.633,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
econazole,Mu-type opioid receptor,OPRM1,5.636,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
hexachlorophene,Sodium-dependent serotonin transporter,SLC6A4,5.636,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
estradiol benzoate,Glucocorticoid receptor,NR3C1,5.637,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
duloxetine,Histamine H1 receptor,HRH1,5.638,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
etoperidone,D(2) dopamine receptor,DRD2,5.638,Ki,CCN1C(=O)N(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)N=C1CC
minocycline,"Tetracycline resistance protein, class B",tetA,5.638,IC50,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(O)=CC=C4N(C)C)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
zotepine,Beta-2 adrenergic receptor,ADRB2,5.638,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
nortriptyline,Histamine H2 receptor,HRH2,5.639,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
paracetamol,Myoglobin,MB,5.64,IC50,CC(=O)NC1=CC=C(O)C=C1
alosetron,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.64,IC50,CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC1=C(C)N=CN1)CC2
amiloride,Urokinase-type plasminogen activator,Plau,5.64,Ki,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
amiodarone,Thyroid hormone receptor alpha,THRA,5.64,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
bortezomib,Neutrophil elastase,ELANE,5.64,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
cycloserine,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,5.64,IC50,N[C@@H]1CONC1=O
cycloserine,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,5.64,IC50,N[C@@H]1CONC1=O
cycloserine,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,5.64,IC50,N[C@@H]1CONC1=O
cycloserine,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,5.64,IC50,N[C@@H]1CONC1=O
cycloserine,"Glutamate receptor ionotropic, NMDA 3B",GRIN3B,5.64,IC50,N[C@@H]1CONC1=O
cycloserine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,5.64,IC50,N[C@@H]1CONC1=O
dasatinib,Serine/threonine-protein kinase TAO3,TAOK3,5.64,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
domperidone,Multidrug and toxin extrusion protein 1,SLC47A1,5.64,IC50,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
erlotinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,5.64,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fluspirilene,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.64,IC50,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
furosemide,CDGSH iron-sulfur domain-containing protein 1,CISD1,5.64,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
gefitinib,Mitogen-activated protein kinase 10,MAPK10,5.64,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Activated CDC42 kinase 1,TNK2,5.64,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
haloperidol,Adenylate cyclase,Adcy1|Adcy3|Adcy2|Adcy4|Adcy8|Adcy6|Adcy5,5.64,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
leflunomide,Sodium-dependent dopamine transporter,SLC6A3,5.64,Ki,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
papaverine,"cGMP-dependent 3',5'-cyclic phosphodiesterase",PDE2A,5.64,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
pemetrexed,Dihydrofolate reductase,folA,5.64,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
pemetrexed,Dihydrofolate reductase,dfrA17,5.64,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
pentamidine,Trypsin-1,PRSS1,5.64,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pentamidine,Acrosin,ACR,5.64,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
quinagolide,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,5.64,IC50,CCCN1C[C@H](C[C@@H]2CC3=C(C[C@@H]12)C=CC=C3O)NS(=O)(=O)N(CC)CC
rifampicin,Nuclear receptor subfamily 1 group I member 2,NR1I2,5.64,EC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
rosiglitazone,CDGSH iron-sulfur domain-containing protein 2,CISD2,5.64,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sildenafil,"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A",PDE11A,5.64,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,Non-receptor tyrosine-protein kinase TNK1,TNK1,5.64,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulpiride,Beta-carbonic anhydrase 1,mtcA1,5.64,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sunitinib,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,DYRK1B,5.64,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase PAK 4,PAK4,5.64,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
thiethylperazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.64,IC50,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
oxetacaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.64,IC50,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1)C(C)(C)CC1=CC=CC=C1
quercetin,Inositol polyphosphate multikinase,IPMK,5.64,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Serine/threonine-protein kinase MARK2,MARK2,5.64,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Ribosomal protein S6 kinase alpha-6,RPS6KA6,5.64,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Protein-tyrosine kinase 6,PTK6,5.64,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,TRAF2 and NCK-interacting protein kinase,TNIK,5.64,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Fibroblast growth factor receptor 4,FGFR4,5.64,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Vascular endothelial growth factor receptor 1,FLT1,5.64,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,AP2-associated protein kinase 1,AAK1,5.64,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,5.64,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Epidermal growth factor receptor,EGFR,5.64,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,G protein-coupled receptor kinase 4,GRK4,5.64,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,SRSF protein kinase 3,SRPK3,5.64,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Serine/threonine-protein kinase 17A,STK17A,5.64,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,AP2-associated protein kinase 1,AAK1,5.64,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Myosin-IIIb,MYO3B,5.64,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase PAK 1,PAK1,5.64,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Ephrin type-A receptor 1,EPHA1,5.64,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Mitogen-activated protein kinase 7,MAPK7,5.64,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Mitogen-activated protein kinase kinase kinase 10,MAP3K10,5.64,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Rho-associated protein kinase 2,ROCK2,5.64,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase/endoribonuclease IRE1,ERN1,5.64,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Homeodomain-interacting protein kinase 3,HIPK3,5.64,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Myosin light chain kinase 3,MYLK3,5.64,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Cyclin-dependent kinase 16,CDK16,5.64,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Interleukin-1 receptor-associated kinase 1,IRAK1,5.64,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
quizartinib,High affinity nerve growth factor receptor,NTRK1,5.64,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Ribosomal protein S6 kinase alpha-2,RPS6KA2,5.64,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Dual specificity protein kinase CLK2,CLK2,5.64,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
abametapir,C-C chemokine receptor type 5,CCR5,5.64,EC50,CC1=CN=C(C=C1)C2=NC=C(C=C2)C
abametapir,C-C chemokine receptor type 5,CCR5,5.64,EC50,CC1=CN=C(C=C1)C2=NC=C(C=C2)C
infigratinib,Tyrosine-protein kinase ABL1,ABL1,5.64,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Tyrosine-protein kinase ABL1,ABL1,5.64,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
femoxetine,5-hydroxytryptamine receptor 1A,HTR1A,5.641,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
lacidipine,Adenosine receptor A3,ADORA3,5.642,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
nisoldipine,Adenosine receptor A2a,ADORA2A,5.642,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
paclitaxel,Cholecystokinin receptor type A,CCKAR,5.643,Ki,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
suloctidil,Substance-K receptor,TACR2,5.645,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
duloxetine,5-hydroxytryptamine receptor 7,HTR7,5.646,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
flutamide,5-hydroxytryptamine receptor 4,HTR4,5.646,Ki,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
levodopa,Arachidonate 15-lipoxygenase,ALOX15,5.646,IC50,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
pipamazine,Muscarinic acetylcholine receptor M5,CHRM5,5.646,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
zafirlukast,Cytochrome P450 2C9,CYP2C9,5.646,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
amiodarone,Sodium-dependent noradrenaline transporter,SLC6A2,5.647,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
paroxetine,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.647,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
bithionol,Tyrosine-protein kinase Lck,LCK,5.647,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
haloperidol,5-hydroxytryptamine receptor 5A,HTR5A,5.648,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
benzethonium,Acetylcholinesterase,ACHE,5.649,IC50,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
cyclothiazide,Glutamate receptor 2,GRIA2,5.65,EC50,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C2CC3CC2C=C3)C=C1Cl
dextromethorphan,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,5.65,Ki,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
indoramin,Alpha-2A adrenergic receptor,ADRA2A,5.65,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
tryptophan,Myeloperoxidase,MPO,5.65,IC50,N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
tryptophan,Myeloperoxidase,MPO,5.65,IC50,N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
benzoin,Cocaine esterase,CES2,5.65,Ki,OC(C(=O)C1=CC=CC=C1)C1=CC=CC=C1
ceritinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,5.65,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
bithionol,Mu-type opioid receptor,OPRM1,5.651,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
venlafaxine,5-hydroxytryptamine receptor 2A,HTR2A,5.652,Ki,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
diethylstilbestrol,Alpha-2C adrenergic receptor,ADRA2C,5.657,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
ciprofloxacin,DNA topoisomerase 4 subunit A,parC,5.658,IC50,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
clomipramine,Cytochrome P450 2D6,CYP2D6,5.658,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
diphenhydramine,Sodium-dependent dopamine transporter,SLC6A3,5.658,Kd,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
melperone,5-hydroxytryptamine receptor 1A,HTR1A,5.658,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
nifedipine,Transthyretin,TTR,5.658,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
orphenadrine,Sodium channel protein type 4 subunit alpha,SCN4A,5.658,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
pentamidine,Sodium-dependent noradrenaline transporter,SLC6A2,5.658,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
tamoxifen,Aldehyde oxidase,AOX1,5.658,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
cefotaxime,Penicillin-binding protein 1B,mrcB,5.659,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
bupivacaine,Sodium channel protein type 5 subunit alpha,SCN5A,5.66,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
celecoxib,Carbonic anhydrase 7,CA7,5.66,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
dicloxacillin,Muscarinic acetylcholine receptor M2,CHRM2,5.66,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
erlotinib,Tyrosine-protein kinase Yes,YES1,5.66,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Aurora kinase A,AURKA,5.66,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Ephrin type-B receptor 4,EPHB4,5.66,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethinylestradiol,Solute carrier family 22 member 2,SLC22A2,5.66,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
gamolenic acid,Peroxisome proliferator-activated receptor gamma,PPARG,5.66,IC50,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
levomethadyl acetate,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.66,IC50,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
menadione,M-phase inducer phosphatase 2,CDC25B,5.66,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
acetylmethadol,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.66,IC50,CCC(OC(C)=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
methapyrilene,Sodium-dependent dopamine transporter,SLC6A3,5.66,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
mianserin,D(2) dopamine receptor,DRD2,5.66,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nebivolol,Beta-3 adrenergic receptor,ADRB3,5.66,Ki,OC(CNCC(O)C1CCC2=CC(F)=CC=C2O1)C1CCC2=CC(F)=CC=C2O1
nebivolol,Beta-3 adrenergic receptor,ADRB3,5.66,Ki,OC(CNCC(O)C1CCC2=CC(F)=CC=C2O1)C1CCC2=CC(F)=CC=C2O1
propafenone,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,5.66,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
quinidine,Potassium voltage-gated channel subfamily D member 2,Kcnd2,5.66,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
raloxifene,Alpha-1A adrenergic receptor,Adra1a,5.66,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
rifaximin,Nuclear receptor subfamily 1 group I member 2,NR1I2,5.66,EC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C2N=C2C=C(C)C=CN12
sunitinib,Activated CDC42 kinase 1,TNK2,5.66,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zileuton,Arachidonate 5-lipoxygenase-activating protein,ALOX5AP,5.66,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
podophyllotoxin,Tubulin,TUBA1A,5.66,Ki,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
quercetin,Arachidonate 15-lipoxygenase,ALOX15,5.66,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Neuraminidase,,5.66,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Ribosomal protein S6 kinase alpha-3,RPS6KA3,5.66,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,ALK tyrosine kinase receptor,ALK,5.66,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,5.66,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Serine/threonine-protein kinase SIK1,SIK1,5.66,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Serine/threonine-protein kinase MRCK gamma,CDC42BPG,5.66,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ruxolitinib,Serine/threonine-protein kinase B-raf,BRAF,5.66,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Calcium/calmodulin-dependent protein kinase type 1G,CAMK1G,5.66,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Maternal embryonic leucine zipper kinase,MELK,5.66,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Serine/threonine-protein kinase 3,STK3,5.66,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Tyrosine-protein kinase HCK,HCK,5.66,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Hepatocyte growth factor receptor,MET,5.66,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Hepatocyte growth factor receptor,MET,5.66,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase RIO1,RIOK1,5.66,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase NLK,NLK,5.66,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tofacitinib,Tyrosine-protein kinase ABL1,ABL1,5.66,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,5.66,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Tyrosine-protein kinase receptor Tie-1,TIE1,5.66,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Serine/threonine-protein kinase LATS2,LATS2,5.66,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
encorafenib,Mitogen-activated protein kinase 14,MAPK14,5.66,IC50,COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C
alpelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Pik3cb,5.66,IC50,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F
fedratinib,Insulin-like growth factor 1 receptor,IGF1R,5.66,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Rho-associated protein kinase 2,ROCK2,5.66,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ribosomal protein S6 kinase alpha-5,RPS6KA5,5.66,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cefiderocol,"Peptidoglycan D,D-transpeptidase MrdA",mrdA,5.66,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
selumetinib,Epidermal growth factor receptor,EGFR,5.66,Kd,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C=C12)C(=O)NOCCO
saquinavir,Thromboxane-A synthase,TBXAS1,5.661,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
methysergide,Alpha-2B adrenergic receptor,ADRA2B,5.663,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
ketoconazole,Thromboxane-A synthase,TBXAS1,5.665,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
orphenadrine,5-hydroxytryptamine receptor 2B,HTR2B,5.666,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
sertraline,5-hydroxytryptamine receptor 2B,HTR2B,5.666,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
phentolamine,5-hydroxytryptamine receptor 1A,HTR1A,5.667,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
tolmetin,Aldose reductase,Akr1b1,5.667,IC50,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
levodopa,Tyrosine-protein kinase Fyn,FYN,5.668,IC50,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
bithionol,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.668,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
gentian violet,Tyrosine-protein kinase Fyn,FYN,5.668,IC50,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
disulfiram,5-hydroxytryptamine receptor 1B,Htr1b,5.669,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
cocaine,Histamine H1 receptor,HRH1,5.67,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
hexachlorophene,Estrogen receptor,ESR1,5.67,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
terbinafine,Alpha-2A adrenergic receptor,ADRA2A,5.67,Ki,CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
topotecan,ORF 73,,5.67,AC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
rutoside,Lysine-specific histone demethylase 1A,KDM1A,5.67,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
rutoside,Lysine-specific histone demethylase 1A,KDM1A,5.67,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
astemizole,D(4) dopamine receptor,DRD4,5.671,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
propranolol,Membrane-associated progesterone receptor component 1,Pgrmc1,5.671,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
methyldopa,Arachidonate 15-lipoxygenase,ALOX15,5.672,IC50,C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O
astemizole,Melanocortin receptor 5,MC5R,5.673,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
oxiconazole,Sodium-dependent dopamine transporter,SLC6A3,5.676,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
clotrimazole,Muscarinic acetylcholine receptor M3,CHRM3,5.677,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
dexchlorpheniramine,Alpha-2B adrenergic receptor,ADRA2B,5.677,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
aliskiren,Multidrug resistance protein 1,ABCB1,5.678,Km,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
chlorpromazine,Sodium-dependent dopamine transporter,SLC6A3,5.678,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
duloxetine,5-hydroxytryptamine receptor 2B,HTR2B,5.678,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
kanamycin,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",mphB,5.678,Km,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
melperone,5-hydroxytryptamine receptor 2C,HTR2C,5.678,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
ondansetron,Aldehyde oxidase,AOX1,5.678,IC50,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
protriptyline,Sodium-dependent dopamine transporter,SLC6A3,5.678,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
sertraline,Muscarinic acetylcholine receptor M2,CHRM2,5.678,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
tetrabenazine,D(2) dopamine receptor,DRD2,5.678,Ki,COC1=CC2=C(C=C1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
thiothixene,Muscarinic acetylcholine receptor M2,CHRM2,5.678,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
estrone,Progesterone receptor,PGR,5.678,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
lacidipine,D(3) dopamine receptor,DRD3,5.679,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
suloctidil,Adenosine receptor A3,ADORA3,5.679,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
tamoxifen,Adenosine receptor A3,ADORA3,5.679,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
aripiprazole,Sodium-dependent noradrenaline transporter,SLC6A2,5.68,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
atomoxetine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.68,IC50,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
chloroquine,Riboflavin-binding protein,,5.68,Kd,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
cocaine,Alpha-1A adrenergic receptor,ADRA1A,5.68,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
cyclophosphamide,Cytochrome P450 3A4,CYP3A4,5.68,IC50,ClCCN(CCCl)P1(=O)NCCCO1
dantrolene,CDGSH iron-sulfur domain-containing protein 1,CISD1,5.68,Ki,[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
dasatinib,Ephrin type-A receptor 6,EPHA6,5.68,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Serine/threonine-protein kinase MRCK beta,CDC42BPB,5.68,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
erlotinib,Vascular endothelial growth factor receptor 3,FLT4,5.68,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
gefitinib,Serine/threonine-protein kinase SIK2,SIK2,5.68,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,5.68,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
guanfacine,Alpha-2C adrenergic receptor,ADRA2C,5.68,EC50,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
imatinib,Dual specificity protein kinase CLK4,CLK4,5.68,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
irinotecan,Multidrug and toxin extrusion protein 1,SLC47A1,5.68,IC50,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
levosulpiride,D(4) dopamine receptor,DRD4,5.68,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
mifepristone,Mineralocorticoid receptor,NR3C2,5.68,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
miglustat,"Maltase-glucoamylase, intestinal",MGAM,5.68,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
miglustat,Lysosomal alpha-glucosidase,Gaa,5.68,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nilotinib,Dual specificity protein kinase CLK1,CLK1,5.68,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nimesulide,Myeloperoxidase,MPO,5.68,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
pioglitazone,Amine oxidase [flavin-containing] B,Maob,5.68,Ki,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
prednisolone,Progesterone receptor,PGR,5.68,IC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone,Progesterone receptor,PGR,5.68,IC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,Progesterone receptor,PGR,5.68,IC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
prednisolone tebutate,Progesterone receptor,PGR,5.68,IC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
sorafenib,Angiopoietin-1 receptor,TEK,5.68,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,BDNF/NT-3 growth factors receptor,NTRK2,5.68,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sufentanil,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.68,IC50,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
sufentanil,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.68,IC50,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
sulpiride,D(4) dopamine receptor,DRD4,5.68,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sunitinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.68,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ephrin type-A receptor 3,EPHA3,5.68,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Tyrosine-protein kinase BTK,BTK,5.68,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Fibroblast growth factor receptor 4,FGFR4,5.68,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Receptor-interacting serine/threonine-protein kinase 4,RIPK4,5.68,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Muscarinic acetylcholine receptor M2,Chrm2,5.68,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
tolazoline,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.68,IC50,C(C1=NCCN1)C1=CC=CC=C1
vardenafil,Phosphodiesterase 3,PDE3B|PDE3A,5.68,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
verapamil,Alpha-1A adrenergic receptor,Adra1a,5.68,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
quercetin,Glycogen synthase kinase-3,GSK3A|GSK3B,5.68,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Serine/threonine-protein kinase tousled-like 1,TLK1,5.68,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
androstanolone,Mineralocorticoid receptor,Nr3c2,5.68,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
guanabenz,5-hydroxytryptamine receptor 1A,Htr1a,5.68,IC50,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
pazopanib,Calcium/calmodulin-dependent protein kinase type 1,CAMK1,5.68,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Cyclin-dependent kinase 11B,CDK11B,5.68,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase 10,MAP3K10,5.68,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,ALK tyrosine kinase receptor,ALK,5.68,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Cyclin-dependent kinase-like 2,CDKL2,5.68,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Receptor-interacting serine/threonine-protein kinase 4,RIPK4,5.68,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,SRSF protein kinase 1,SRPK1,5.68,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Receptor-interacting serine/threonine-protein kinase 4,RIPK4,5.68,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Serine/threonine-protein kinase SIK1,SIK1,5.68,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Mitogen-activated protein kinase 9,MAPK9,5.68,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Serine/threonine-protein kinase tousled-like 2,TLK2,5.68,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Ankyrin repeat and protein kinase domain-containing protein 1,ANKK1,5.68,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Death-associated protein kinase 3,DAPK3,5.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Dual specificity mitogen-activated protein kinase kinase 3,MAP2K3,5.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
ripasudil,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,5.68,IC50,C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=C1C(F)=CN=C2
chidamide,Nicotinamide phosphoribosyltransferase,NAMPT,5.68,IC50,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1
chidamide,Nicotinamide phosphoribosyltransferase,NAMPT,5.68,IC50,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1
cariprazine,D(1A) dopamine receptor,DRD1,5.68,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
selexipag,Prostacyclin receptor,Ptgir,5.68,Ki,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1
midostaurin,Tyrosine-protein kinase Fyn,FYN,5.68,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,5.68,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase PAK 2,PAK2,5.68,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
quizartinib,Serine/threonine-protein kinase 10,STK10,5.68,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Rho-associated protein kinase 1,ROCK1,5.68,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Tyrosine-protein kinase HCK,HCK,5.68,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ephrin type-B receptor 4,EPHB4,5.68,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,5.68,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,Vascular endothelial growth factor receptor 3,FLT4,5.68,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Vascular endothelial growth factor receptor 3,FLT4,5.68,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
aripiprazole,D(1B) dopamine receptor,DRD5,5.681,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
benzethonium,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.681,IC50,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
doxorubicin,5-hydroxytryptamine receptor 4,HTR4,5.682,Ki,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
ethylestrenol,Sodium-dependent noradrenaline transporter,SLC6A2,5.682,Ki,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
penfluridol,5-hydroxytryptamine receptor 2C,HTR2C,5.682,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
pentamidine,Muscarinic acetylcholine receptor M5,CHRM5,5.683,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
saquinavir,Substance-K receptor,TACR2,5.684,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
oxiconazole,D(1A) dopamine receptor,DRD1,5.684,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
etynodiol,Androgen receptor,Ar,5.685,Ki,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1
loperamide,Beta-2 adrenergic receptor,ADRB2,5.685,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
montelukast,Sodium-dependent dopamine transporter,SLC6A3,5.685,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
tolperisone,SMR1-alpha3,VCS-alpha3,5.685,Ki,CC(CN1CCCCC1)C(=O)C1=CC=C(C)C=C1
hexachlorophene,Alpha-2A adrenergic receptor,ADRA2A,5.686,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
terfenadine,D(2) dopamine receptor,DRD2,5.687,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
femoxetine,Sodium-dependent dopamine transporter,SLC6A3,5.688,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
betahistine,Histamine H3 receptor,Hrh3,5.69,Ki,CNCCC1=CC=CC=N1
dapiprazole,5-hydroxytryptamine receptor 1A,Htr1a,5.69,IC50,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
foscarnet,Reverse transcriptase/RNaseH,pol,5.69,IC50,OC(=O)P(O)(O)=O
gossypol,Malate dehydrogenase,,5.69,IC50,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
nifedipine,"Myosin light chain kinase, smooth muscle",MYLK,5.69,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
novobiocin,ParE,parE,5.69,IC50,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
paclitaxel,Substance-K receptor,TACR2,5.69,Ki,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
suloctidil,Sodium-dependent dopamine transporter,SLC6A3,5.69,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
oxyquinoline,Methionine aminopeptidase 2,METAP2,5.69,IC50,OC1=CC=CC2=C1N=CC=C2
tofacitinib,Tyrosine-protein kinase JAK2,Jak2,5.69,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
bempedoic acid,ATP-citrate synthase,ACLY,5.69,Ki,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
infigratinib,Angiopoietin-1 receptor,TEK,5.69,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Angiopoietin-1 receptor,TEK,5.69,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
mitoxantrone,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.691,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
troglitazone,Aldose reductase,Akr1b1,5.691,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
exemestane,Aromatase,CYP19A1,5.692,IC50,C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O
miconazole,Membrane-associated progesterone receptor component 1,Pgrmc1,5.692,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
yohimbine,Cytochrome P450 2D6,CYP2D6,5.692,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
mosapride,Sodium-dependent serotonin transporter,SLC6A4,5.694,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
droperidol,Membrane-associated progesterone receptor component 1,Pgrmc1,5.695,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
clomipramine,Histamine H2 receptor,HRH2,5.696,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
acarbose,"Maltase-glucoamylase, intestinal",MGAM,5.697,IC50,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
econazole,Substance-K receptor,TACR2,5.697,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
sulconazole,Sodium-dependent noradrenaline transporter,SLC6A2,5.697,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
ticlopidine,Membrane-associated progesterone receptor component 1,Pgrmc1,5.697,Ki,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
astemizole,D(1A) dopamine receptor,DRD1,5.698,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
desloratadine,Alpha-1B adrenergic receptor,Adra1b,5.698,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
venlafaxine,5-hydroxytryptamine receptor 2C,HTR2C,5.698,Ki,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
alfaxalone,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,5.699,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
bambuterol,Cytochrome P450 2D6,CYP2D6,5.699,IC50,CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C
bromocriptine,Cytochrome P450 3A4,CYP3A4,5.699,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bupropion,Cytochrome P450 2C19,CYP2C19,5.699,IC50,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
clemastine,Cytochrome P450 2D6,CYP2D6,5.699,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
dextromethorphan,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,5.699,IC50,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
diethylstilbestrol,5-hydroxytryptamine receptor 2B,HTR2B,5.699,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
docetaxel,Cytochrome P450 3A4,CYP3A4,5.699,IC50,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
fexofenadine,Multidrug resistance protein 1,ABCB1,5.699,Km,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
fexofenadine,Solute carrier organic anion transporter family member 1A2,SLCO1A2,5.699,Km,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
finasteride,Cytochrome P450 2C9,CYP2C9,5.699,IC50,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
fluoxetine,Alpha-1A adrenergic receptor,ADRA1A,5.699,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
fluoxetine,D(3) dopamine receptor,DRD3,5.699,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
lacidipine,Cytochrome P450 2C9,CYP2C9,5.699,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
lacidipine,Cytochrome P450 2C19,CYP2C19,5.699,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
lofepramine,D(2) dopamine receptor,DRD2,5.699,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
loperamide,Histamine H1 receptor,HRH1,5.699,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
loperamide,Cytochrome P450 2D6,CYP2D6,5.699,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
medroxyprogesterone,Cytochrome P450 2C19,CYP2C19,5.699,IC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
naloxone,Cytochrome P450 2D6,CYP2D6,5.699,IC50,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
nelfinavir,Cytochrome P450 3A4,CYP3A4,5.699,IC50,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
phenelzine,Cytochrome P450 3A4,CYP3A4,5.699,IC50,NNCCC1=CC=CC=C1
prochlorperazine,Cytochrome P450 1A2,CYP1A2,5.699,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
propranolol,Cytochrome P450 2D6,CYP2D6,5.699,IC50,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
raloxifene,Cytochrome P450 2C9,CYP2C9,5.699,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sirolimus,Cytochrome P450 3A4,CYP3A4,5.699,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
sirolimus,Cytochrome P450 2C9,CYP2C9,5.699,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
artemisinin,Cytochrome P450 1A2,CYP1A2,5.699,IC50,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4
empagliflozin,Sodium/myo-inositol cotransporter 2,SLC5A11,5.699,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1
palbociclib,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,DYRK1A,5.699,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
alfaxalone,GABA A receptor alpha-2/beta-2/gamma-2,GABRG2|GABRA2|GABRB2,5.7,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
amiodarone,Sodium channel protein type 5 subunit alpha,Scn5a,5.7,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amitriptyline,5-hydroxytryptamine receptor 1A,Htr1a,5.7,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
apomorphine,Alpha-1A adrenergic receptor,ADRA1A,5.7,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
aztreonam,Beta-lactamase,blaPER-2,5.7,Ki,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
beclometasone dipropionate,Matrix metalloproteinase-9,MMP9,5.7,IC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
carbidopa,Lysine-specific demethylase 4E,KDM4E,5.7,Ki,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
chlorhexidine,Trypanothione reductase,TPR,5.7,Ki,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
chlorpromazine,Major prion protein,PRNP,5.7,EC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlorpromazine,Major prion protein,Prnp,5.7,EC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cisapride,5-hydroxytryptamine receptor 7,HTR7,5.7,EC50,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
clavulanic acid,Class D beta-lactamase,oxa-63,5.7,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clotrimazole,C-X-C chemokine receptor type 1,CXCR1,5.7,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clozapine,5-hydroxytryptamine receptor 1A,Htr1a,5.7,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,Histamine H4 receptor,Hrh4,5.7,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
coumarin,Carbonic anhydrase 6,CA6,5.7,Ki,O=C1OC2=CC=CC=C2C=C1
cyclothiazide,Glutamate receptor 1,GRIA1,5.7,EC50,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C2CC3CC2C=C3)C=C1Cl
dasatinib,TRAF2 and NCK-interacting protein kinase,TNIK,5.7,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Serine/threonine-protein kinase MRCK alpha,CDC42BPA,5.7,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
deptropine,Acetylcholine-binding protein,,5.7,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1C2=CC=CC=C2CCC2=CC=CC=C12
dichlorphenamide,Carbonic anhydrase 2,mtcA2,5.7,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
digoxin,Nuclear receptor ROR-gamma,RORC,5.7,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
digoxin,Nuclear receptor ROR-gamma,Rorc,5.7,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
donepezil,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.7,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
dopamine,M18 aspartyl aminopeptidase,,5.7,IC50,NCCC1=CC(O)=C(O)C=C1
epinephrine,Alpha-1A adrenergic receptor,ADRA1A,5.7,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
erlotinib,Tyrosine-protein kinase FRK,FRK,5.7,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Mitogen-activated protein kinase 9,MAPK9,5.7,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
etodolac,Prostaglandin G/H synthase 2,PTGS2,5.7,IC50,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
flupentixol,Potassium channel subfamily K member 2,KCNK2,5.7,IC50,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
gefitinib,Serine/threonine-protein kinase B-raf,BRAF,5.7,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Serine/threonine-protein kinase 17A,STK17A,5.7,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Tyrosine-protein kinase FRK,FRK,5.7,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,Metabotropic glutamate receptor 8,GRM8,5.7,IC50,N[C@@H](CCC(O)=O)C(O)=O
glibenclamide,ATP-sensitive inward rectifier potassium channel 11,Kcnj11,5.7,IC50,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
ibuprofen,Cyclooxygenase,Ptgs2|Ptgs1,5.7,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
iloprost,Prostaglandin E2 receptor EP2 subtype,PTGER2,5.7,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
imipramine,Potassium voltage-gated channel subfamily H member 1,KCNH1,5.7,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
lidocaine,Sodium channel protein type 4 subunit alpha,SCN4A,5.7,IC50,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
meclozine,Serine protease hepsin,HPN,5.7,IC50,CC1=CC=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=C1
metacycline,DNA repair protein RAD52 homolog,RAD52,5.7,IC50,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)C4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
mitoxantrone,DNA-(apurinic or apyrimidinic site) lyase,APEX1,5.7,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
molindone,Histamine H1 receptor,HRH1,5.7,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
mosapride,5-hydroxytryptamine receptor 3A,HTR3A,5.7,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
moxonidine,Alpha-2C adrenergic receptor,ADRA2C,5.7,Ki,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1
nilotinib,Mitogen-activated protein kinase 10,MAPK10,5.7,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nimesulide,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,5.7,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
olanzapine,5-hydroxytryptamine receptor 1E,HTR1E,5.7,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
olanzapine,Transporter,NET,5.7,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
omeprazole,Potassium-transporting ATPase,ATP4A|ATP4B,5.7,IC50,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
pentamidine,Spermidine/spermine N(1)-acetyltransferase 1,SAT1,5.7,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pimozide,Histamine H4 receptor,HRH4,5.7,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pimozide,Ubiquitin carboxyl-terminal hydrolase 1,USP1,5.7,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pindolol,5-hydroxytryptamine receptor 2B,HTR2B,5.7,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
pioglitazone,Bile salt export pump,Abcb11,5.7,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
propofol,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,5.7,EC50,CC(C)C1=CC=CC(C(C)C)=C1O
propylthiouracil,Taste receptor type 2 member 38,TAS2R38,5.7,EC50,CCCC1=CC(=O)NC(=S)N1
mepyramine,5-hydroxytryptamine receptor 2A,HTR2A,5.7,Ki,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
quetiapine,5-hydroxytryptamine receptor 1D,HTR1D,5.7,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
riluzole,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,5.7,IC50,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
sorafenib,Ephrin type-A receptor 2,EPHA2,5.7,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
strychnine,Muscarinic acetylcholine receptor M3,CHRM3,5.7,Kd,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
sunitinib,Epithelial discoidin domain-containing receptor 1,DDR1,5.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Cyclin-dependent kinase 4,CDK4,5.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Muscarinic acetylcholine receptor M1,Chrm1,5.7,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
tazobactam,Beta-lactamase,,5.7,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tazobactam,Beta-lactamase,bla(BEL1),5.7,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
trifluridine,Thymidine kinase,UL23,5.7,IC50,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F
tubocurarine,Small conductance calcium-activated potassium channel protein 2,KCNN2,5.7,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
tubocurarine,Neuronal acetylcholine receptor; alpha3/beta4,CHRNB4|CHRNA3,5.7,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
zafirlukast,Bifunctional epoxide hydrolase 2,EPHX2,5.7,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
somatostatin,Delta-type opioid receptor,Oprd1,5.7,IC50,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
cyclomethycaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.7,IC50,CC1CCCCN1CCCOC(=O)C1=CC=C(OC2CCCCC2)C=C1
eicosapentaenoic acid,Peroxisome proliferator-activated receptor gamma,PPARG,5.7,Kd,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
eicosapentaenoic acid,Oxoeicosanoid receptor 1,OXER1,5.7,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
kainic acid,Glutamate receptor 3,Gria3,5.7,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
ivabradine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1,HCN1,5.7,IC50,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
ivabradine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3,HCN3,5.7,IC50,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
linoleic acid,Free fatty acid receptor 1,FFAR1,5.7,EC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
oleic acid,Free fatty acid receptor 1,FFAR1,5.7,EC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
quercetin,Phospholipase A2,PLA2G1B,5.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Glycogen synthase kinase-3 beta,GSK3B,5.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Proteasome subunit beta type-5,PSMB5,5.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Proteasome subunit beta type-5,PSMB5,5.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
tipranavir,Pepsin A-5,PGA5,5.7,Ki,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC(NS(=O)(=O)C3=CC=C(C=N3)C(F)(F)F)=CC=C2)C(=O)O1
vincamine,Muscarinic acetylcholine receptor M3,CHRM3,5.7,Kd,CC[C@@]12CCCN3CCC4=C([C@H]13)N(C1=CC=CC=C41)[C@](O)(C2)C(=O)OC
yohimbine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,5.7,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
kojic acid,D-amino-acid oxidase,DAO,5.7,IC50,OCC1=CC(=O)C(O)=CO1
pazopanib,Mitogen-activated protein kinase 8,MAPK8,5.7,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,5.7,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Hepatocyte growth factor receptor,MET,5.7,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
rimonabant,G-protein coupled receptor 55,GPR55,5.7,EC50,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
crizotinib,Tyrosine-protein kinase ITK/TSK,ITK,5.7,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase RIO3,RIOK3,5.7,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,5.7,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
vilazodone,5-hydroxytryptamine receptor 2C,Htr2c,5.7,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
vilazodone,Adrenergic receptor alpha-1,ADRA1D|ADRA1A|ADRA1B,5.7,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
doconexent,Oxoeicosanoid receptor 1,OXER1,5.7,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
aceclidine,Muscarinic acetylcholine receptor M2,CHRM2,5.7,EC50,CC(=O)OC1CN2CCC1CC2
afatinib,Mitogen-activated protein kinase 10,MAPK10,5.7,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
N-Acetylglucosamine,Killer cell lectin-like receptor subfamily B member 1A,Klrb1a,5.7,IC50,CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O
linolenic acid,Peroxisome proliferator-activated receptor gamma,PPARG,5.7,Kd,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
benzoic acid,D-amino-acid oxidase,DAO,5.7,Ki,OC(=O)C1=CC=CC=C1
tofacitinib,Protein kinase C delta type,PRKCD,5.7,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
tofacitinib,Serine/threonine-protein kinase PknB,pknB,5.7,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
rifamycin,Solute carrier organic anion transporter family member 1B1,SLCO1B1,5.7,Ki,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O
tavaborole,Carbonic anhydrase 1,CA1,5.7,Ki,OB1OCC2=C1C=CC(F)=C2
nintedanib,Abelson tyrosine-protein kinase 2,ABL2,5.7,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Eukaryotic translation initiation factor 2-alpha kinase 4,EIF2AK4,5.7,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,MAP/microtubule affinity-regulating kinase 4,MARK4,5.7,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase/endoribonuclease IRE1,ERN1,5.7,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Uncharacterized serine/threonine-protein kinase SBK3,SBK3,5.7,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
alectinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,5.7,Ki,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O
midostaurin,Calcium/calmodulin-dependent protein kinase type 1,CAMK1,5.7,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase PAK 1,PAK1,5.7,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase JAK3,JAK3,5.7,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
quizartinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,5.7,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Vascular endothelial growth factor receptor 3,FLT4,5.7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,5.7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Dual specificity protein kinase CLK4,CLK4,5.7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ribosomal protein S6 kinase beta-1,RPS6KB1,5.7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase tousled-like 2,TLK2,5.7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Fibroblast growth factor receptor 4,FGFR4,5.7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
amiodarone,Sodium-dependent dopamine transporter,SLC6A3,5.701,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
budesonide,Matrix metalloproteinase-9,MMP9,5.701,IC50,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
gentian violet,Alpha-1B adrenergic receptor,Adra1b,5.701,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
zotepine,Histamine H4 receptor,HRH4,5.704,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
escitalopram,Histamine H1 receptor,HRH1,5.706,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
danazol,Glucocorticoid receptor,NR3C1,5.708,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
ertugliflozin,Sodium/glucose cotransporter 1,SLC5A1,5.708,IC50,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1
pimozide,Muscarinic acetylcholine receptor M3,CHRM3,5.709,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
clomifene,5-hydroxytryptamine receptor 6,HTR6,5.71,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
cocaine,5-hydroxytryptamine receptor 3A,HTR3A,5.71,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
estradiol benzoate,Sodium-dependent serotonin transporter,SLC6A4,5.71,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
fulvestrant,Nuclear receptor subfamily 1 group I member 2,NR1I2,5.71,EC50,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
ofloxacin,CAAX prenyl protease 1,STE24,5.71,AC50,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
oxaprozin,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,5.71,IC50,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
pergolide,Alpha-1A adrenergic receptor,Adra1a,5.71,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
sorafenib,5-hydroxytryptamine receptor 2A,HTR2A,5.71,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
ceritinib,Tyrosine-protein kinase Fgr,FGR,5.71,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
benzbromarone,Mitogen-activated protein kinase 1,MAPK1,5.711,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
fluphenazine,Sodium-dependent noradrenaline transporter,SLC6A2,5.711,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
miconazole,Progesterone receptor,PGR,5.711,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
flunarizine,D(1A) dopamine receptor,DRD1,5.713,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
montelukast,Muscarinic acetylcholine receptor M1,CHRM1,5.713,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
imatinib,Histamine H2 receptor,HRH2,5.714,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
labetalol,5-hydroxytryptamine receptor 2B,HTR2B,5.714,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
raloxifene,D(1A) dopamine receptor,DRD1,5.714,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sulconazole,5-hydroxytryptamine receptor 2B,HTR2B,5.716,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
terconazole,Muscarinic acetylcholine receptor M4,CHRM4,5.718,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
ebastine,Beta-3 adrenergic receptor,ADRB3,5.719,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
terfenadine,Sodium-dependent noradrenaline transporter,SLC6A2,5.719,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
chloroxine,"Arachidonate 12-lipoxygenase, 12S-type",ALOX12,5.72,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1Cl
cinnarizine,Alpha-1A adrenergic receptor,Adra1a,5.72,IC50,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Serine/threonine-protein kinase 26,STK26,5.72,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
daunorubicin,72 kDa type IV collagenase,MMP2,5.72,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1
dexfenfluramine,5-hydroxytryptamine receptor 1B,HTR1B,5.72,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
dexniguldipine,Adenosine receptor A3,ADORA3,5.72,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
diclofenac,Aldo-keto reductase family 1 member B10,AKR1B10,5.72,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dobutamine,Carbonic anhydrase 1,CA1,5.72,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
erlotinib,Serine/threonine-protein kinase PLK4,PLK4,5.72,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Fibroblast growth factor receptor 2,FGFR2,5.72,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,"Chaperone activity of bc1 complex-like, mitochondrial",COQ8A,5.72,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
estradiol,Cytochrome P450 1B1,CYP1B1,5.72,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
fasudil,Rho-associated protein kinase 2,Rock2,5.72,IC50,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
fenoldopam,Lysine-specific demethylase 4E,KDM4E,5.72,Ki,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
fluoxetine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.72,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
gefitinib,Vascular endothelial growth factor receptor 2,KDR,5.72,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,5.72,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gossypol,L-lactate dehydrogenase A chain,LDHA,5.72,Ki,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
hydralazine,Cholinesterase,BCHE,5.72,Ki,NNC1=NN=CC2=CC=CC=C12
imatinib,Maternal embryonic leucine zipper kinase,MELK,5.72,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
ketanserin,5-hydroxytryptamine receptor 1B,Htr1b,5.72,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketoconazole,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.72,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
methylthioninium chloride,Microtubule-associated protein tau,MAPT,5.72,IC50,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
metochalcone,ATP-binding cassette sub-family G member 2,ABCG2,5.72,IC50,COC1=CC=C(C=CC(=O)C2=C(OC)C=C(OC)C=C2)C=C1
mianserin,Muscarinic acetylcholine receptor M5,Chrm5,5.72,IC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nilotinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.72,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Ephrin type-A receptor 5,EPHA5,5.72,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
proparacaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.72,IC50,CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC
sorafenib,Ephrin type-A receptor 3,EPHA3,5.72,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Ephrin type-B receptor 2,EPHB2,5.72,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Uncharacterized serine/threonine-protein kinase SBK3,SBK3,5.72,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
testosterone,Steroid 5-alpha-reductase,Srd5a1|Srd5a2,5.72,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
tiopronin,Angiotensin-converting enzyme,ACE,5.72,IC50,CC(S)C(=O)NCC(O)=O
vecuronium,Multidrug and toxin extrusion protein 1,SLC47A1,5.72,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
bithionol,Solute carrier family 22 member 2,SLC22A2,5.72,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
ruboxistaurin,Dual specificity protein kinase CLK4,CLK4,5.72,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Mitogen-activated protein kinase 10,MAPK10,5.72,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,"Interferon-induced, double-stranded RNA-activated protein kinase",EIF2AK2,5.72,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma,PIP5K1C,5.72,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
testosterone propionate,Androgen receptor,Ar,5.72,IC50,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
vandetanib,Serine/threonine-protein kinase SIK1,SIK1,5.72,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Tyrosine-protein kinase Srms,SRMS,5.72,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ruxolitinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,5.72,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,STE20/SPS1-related proline-alanine-rich protein kinase,STK39,5.72,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Myosin-IIIa,MYO3A,5.72,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Serine/threonine-protein kinase PAK 2,PAK2,5.72,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Homeodomain-interacting protein kinase 2,HIPK2,5.72,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase TAO2,TAOK2,5.72,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
thiocolchicoside,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,5.72,IC50,COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC
canagliflozin,Sodium/glucose cotransporter 1,SLC5A1,5.72,IC50,CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
niraparib,Poly [ADP-ribose] polymerase 10,PARP10,5.72,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
midostaurin,Angiopoietin-1 receptor,TEK,5.72,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase 17A,STK17A,5.72,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Focal adhesion kinase 1,PTK2,5.72,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Tyrosine-protein kinase Fgr,FGR,5.72,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Angiopoietin-1 receptor,TEK,5.72,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Epithelial discoidin domain-containing receptor 1,DDR1,5.72,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase ICK,ICK,5.72,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase TAO3,TAOK3,5.72,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase SIK3,SIK3,5.72,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
trilaciclib,Cyclin-dependent kinase 2,CDK2,5.72,IC50,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
infigratinib,Tyrosine-protein kinase Fyn,FYN,5.72,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Tyrosine-protein kinase Fyn,FYN,5.72,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
atazanavir,UDP-glucuronosyltransferase 1-1,UGT1A1,5.721,Ki,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
raloxifene,Sodium-dependent serotonin transporter,SLC6A4,5.721,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sertraline,Muscarinic acetylcholine receptor M5,CHRM5,5.721,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
ergotamine,Beta-2 adrenergic receptor,ADRB2,5.722,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
oxiconazole,Sodium-dependent noradrenaline transporter,SLC6A2,5.723,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
doxazosin,Beta-2 adrenergic receptor,ADRB2,5.724,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
diiodohydroxyquinoline,Epidermal growth factor receptor,EGFR,5.724,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
mepacrine,Alpha-1B adrenergic receptor,Adra1b,5.724,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
gentian violet,Adenosine receptor A2a,ADORA2A,5.724,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
fenfluramine,Muscarinic acetylcholine receptor M2,CHRM2,5.726,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
sulconazole,Muscarinic acetylcholine receptor M5,CHRM5,5.727,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
zimeldine,D(2) dopamine receptor,DRD2,5.727,Ki,CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CN=CC=C1
ipragliflozin,Sodium/glucose cotransporter 1,SLC5A1,5.727,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC3=C(S2)C=CC=C3)=C(F)C=C1
alpha-Ergocryptine,Beta-3 adrenergic receptor,ADRB3,5.728,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
vinblastine,Thromboxane-A synthase,TBXAS1,5.728,IC50,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
oxiconazole,Delta-type opioid receptor,OPRD1,5.728,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mitoxantrone,5-hydroxytryptamine receptor 2C,HTR2C,5.729,Ki,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
digoxin,Signal transducer and activator of transcription 3,STAT3,5.73,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
gemfibrozil,"Fatty acid-binding protein, liver",Fabp1,5.73,Ki,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1
haloprogin,5-hydroxytryptamine receptor 6,HTR6,5.73,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
levamfetamine,Trace amine-associated receptor 1,TAAR1,5.73,EC50,C[C@@H](N)CC1=CC=CC=C1
pecazine,Sodium-dependent noradrenaline transporter,SLC6A2,5.73,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
nortriptyline,5-hydroxytryptamine receptor 1A,Htr1a,5.73,IC50,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
ropinirole,Alpha-2A adrenergic receptor,ADRA2A,5.73,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
thiothixene,5-hydroxytryptamine receptor 3A,HTR3A,5.73,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
tubocurarine,Nicotinic acetylcholine receptor alpha 5 subunit,nAChRalpha5,5.73,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
fluticasone furoate,Androgen receptor,Ar,5.73,IC50,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)SCF
ethyl hydroxybenzoate,Estrogen receptor beta,ESR2,5.73,EC50,CCOC(=O)C1=CC=C(O)C=C1
tavaborole,"Leucine--tRNA ligase, cytoplasmic",CDC60,5.73,Ki,OB1OCC2=C1C=CC(F)=C2
tamoxifen,Muscarinic acetylcholine receptor M5,CHRM5,5.731,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
nabumetone,Sodium-dependent noradrenaline transporter,SLC6A2,5.732,Ki,COC1=CC=C2C=C(CCC(C)=O)C=CC2=C1
dexfenfluramine,Muscarinic acetylcholine receptor M1,CHRM1,5.733,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
indinavir,Thromboxane-A synthase,TBXAS1,5.733,IC50,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
perphenazine,Muscarinic acetylcholine receptor M3,CHRM3,5.733,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
terfenadine,Alpha-1B adrenergic receptor,Adra1b,5.734,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
disulfiram,Alpha-2A adrenergic receptor,ADRA2A,5.735,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
bithionol,Thromboxane-A synthase,TBXAS1,5.735,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
aztreonam,Peptidoglycan synthase FtsI,ftsI,5.736,IC50,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
chlorpromazine,5-hydroxytryptamine receptor 1B,Htr1b,5.736,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
diltiazem,Cytochrome P450 3A4,CYP3A4,5.736,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
doxepin,Histamine H2 receptor,HRH2,5.736,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
econazole,Adenosine receptor A3,ADORA3,5.736,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
fenfluramine,5-hydroxytryptamine receptor 1B,HTR1B,5.736,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
valdecoxib,5-hydroxytryptamine receptor 2B,HTR2B,5.736,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
ketotifen,Alpha-1D adrenergic receptor,ADRA1D,5.737,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
reserpine,5-hydroxytryptamine receptor 1A,HTR1A,5.737,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
chloroxylenol,Amine oxidase [flavin-containing] A,MAOA,5.738,IC50,CC1=CC(O)=CC(C)=C1Cl
diethylstilbestrol,Kappa-type opioid receptor,OPRK1,5.739,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
bupropion,Neuronal acetylcholine receptor; alpha3/beta4,CHRNB4|CHRNA3,5.74,IC50,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
captopril,Succinyl-diaminopimelate desuccinylase,dapE,5.74,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
cianidanol,Carbonic anhydrase 2,CA2,5.74,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
citalopram,Alpha-1B adrenergic receptor,Adra1b,5.74,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
epalrestat,Cytochrome P450 4A11,CYP4A11,5.74,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
erlotinib,Platelet-derived growth factor receptor alpha,PDGFRA,5.74,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Tyrosine-protein kinase HCK,HCK,5.74,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fentanyl,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.74,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
flufenamic acid,Myeloperoxidase,MPO,5.74,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
gefitinib,Mast/stem cell growth factor receptor Kit,KIT,5.74,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Ephrin type-A receptor 8,EPHA8,5.74,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Tyrosine-protein kinase receptor UFO,AXL,5.74,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Misshapen-like kinase 1,MINK1,5.74,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gemfibrozil,Cytochrome P450 2C8,CYP2C8,5.74,Ki,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1
haloperidol,Sodium-dependent serotonin transporter,SLC6A4,5.74,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,Sodium-dependent noradrenaline transporter,SLC6A2,5.74,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,Muscarinic acetylcholine receptor M1,Chrm1,5.74,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hexamethonium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRNG|chrnd,5.74,Kd,C[N+](C)(C)CCCCCC[N+](C)(C)C
ketanserin,5-hydroxytryptamine receptor 1A,Htr1a,5.74,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
medroxyprogesterone,Aldo-keto reductase family 1 member C1,AKR1C1,5.74,IC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
methotrexate,Thymidylate synthase,thyA,5.74,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
pargyline,Amine oxidase [flavin-containing] B,MAOB,5.74,Ki,CN(CC#C)CC1=CC=CC=C1
rabeprazole,Adenosine receptor A3,ADORA3,5.74,Ki,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
raltegravir,Integrase,,5.74,IC50,CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
rivastigmine,Acetylcholinesterase,Ache,5.74,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
simvastatin,Acetylcholinesterase,ache,5.74,Ki,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
sorafenib,Ephrin type-B receptor 4,EPHB4,5.74,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Leukocyte tyrosine kinase receptor,LTK,5.74,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tretinoin,Nuclear receptor subfamily 2 group E member 1,NR2E1,5.74,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
tretinoin,Nuclear receptor subfamily 2 group E member 1,NR2E1,5.74,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
vincristine,Tubulin,TUBB2B,5.74,IC50,CC[C@]1(O)C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
ximelagatran,Plasminogen,PLG,5.74,Ki,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
ruboxistaurin,Protein kinase C eta type,PRKCH,5.74,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,NUAK family SNF1-like kinase 1,NUAK1,5.74,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase TAO1,TAOK1,5.74,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
minodronic acid,Geranylgeranyl pyrophosphate synthase,GGPS1,5.74,Ki,OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O
pazopanib,Serine/threonine-protein kinase TAO2,TAOK2,5.74,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Ephrin type-A receptor 3,EPHA3,5.74,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,5.74,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Citron Rho-interacting kinase,CIT,5.74,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,SRSF protein kinase 1,SRPK1,5.74,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,5.74,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Dual specificity mitogen-activated protein kinase kinase 4,MAP2K4,5.74,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Casein kinase I isoform alpha,CSNK1A1,5.74,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Bone morphogenetic protein receptor type-1B,BMPR1B,5.74,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,High affinity nerve growth factor receptor,NTRK1,5.74,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Tyrosine-protein kinase Fgr,FGR,5.74,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,SRSF protein kinase 1,SRPK1,5.74,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,MAP kinase-interacting serine/threonine-protein kinase 1,MKNK1,5.74,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Dual specificity tyrosine-phosphorylation-regulated kinase 2,DYRK2,5.74,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Serine/threonine-protein kinase PLK1,PLK1,5.74,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase 32A,STK32A,5.74,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
regorafenib,Glycine receptor subunit alpha-1,GLRA1,5.74,EC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
ceritinib,BDNF/NT-3 growth factors receptor,NTRK2,5.74,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
dexrabeprazole,Adenosine receptor A3,ADORA3,5.74,Ki,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
nintedanib,Fibroblast growth factor receptor 4,FGFR4,5.74,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
migalastat,Alpha-galactosidase C,aglC,5.74,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
astemizole,Alpha-2A adrenergic receptor,ADRA2A,5.741,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
amiodarone,Muscarinic acetylcholine receptor M2,CHRM2,5.743,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
ebastine,Adenosine receptor A3,ADORA3,5.743,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ambroxol,Sodium-dependent serotonin transporter,SLC6A4,5.744,Ki,NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br
ceftriaxone,Penicillin-binding protein 1B,mrcB,5.744,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(=O)NN3C)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
semustine,Alpha-2A adrenergic receptor,ADRA2A,5.744,Ki,C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O
bromperidol,Muscarinic acetylcholine receptor M2,CHRM2,5.745,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
phenprocoumon,Vitamin K epoxide reductase complex subunit 1,VKORC1,5.745,IC50,CCC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
mitoxantrone,Arachidonate 15-lipoxygenase,ALOX15,5.748,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
guanabenz,Amine oxidase [flavin-containing] A,MAOA,5.748,IC50,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
trazodone,5-hydroxytryptamine receptor 7,HTR7,5.749,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
ciprofloxacin,DNA gyrase subunit A,gyrA,5.75,IC50,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
dexamfetamine,Sodium-dependent serotonin transporter,Slc6a4,5.75,EC50,C[C@H](N)CC1=CC=CC=C1
pimozide,Potassium channel subfamily K member 2,KCNK2,5.75,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pipamazine,5-hydroxytryptamine receptor 1A,Htr1a,5.75,IC50,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
proparacaine,Amine oxidase [flavin-containing] A,MAOA,5.75,IC50,CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC
quercetin,ELAV-like protein 3,ELAVL3,5.75,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
tioxolone,Carbonic anhydrase 2,CA2,5.75,IC50,OC1=CC2=C(SC(=O)O2)C=C1
temsirolimus,Serine/threonine-protein kinase mTOR,MTOR,5.75,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO
istradefylline,Adenosine receptor A2b,ADORA2B,5.75,Ki,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
olaparib,Poly [ADP-ribose] polymerase 6,PARP6,5.75,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
midostaurin,Death-associated protein kinase 3,DAPK3,5.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Glycogen synthase kinase-3 beta,GSK3B,5.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Calcium/calmodulin-dependent protein kinase type 1G,CAMK1G,5.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase 25,STK25,5.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
betrixaban,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.75,Ki,COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1
quizartinib,Tyrosine-protein kinase FRK,FRK,5.75,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Calcium/calmodulin-dependent protein kinase kinase 1,CAMKK1,5.75,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase TNNI3K,TNNI3K,5.75,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,5.75,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
mepyramine,5-hydroxytryptamine receptor 2B,HTR2B,5.751,Ki,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
thioridazine,Cytochrome P450 2D6,CYP2D6,5.751,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
isoprenaline,Arachidonate 15-lipoxygenase,ALOX15,5.752,IC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
amfetamine,Sodium-dependent serotonin transporter,SLC6A4,5.753,Ki,CC(N)CC1=CC=CC=C1
astemizole,Alpha-2B adrenergic receptor,ADRA2B,5.756,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
bisacodyl,Sodium-dependent dopamine transporter,SLC6A3,5.756,Ki,CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1
clotrimazole,Delta-type opioid receptor,OPRD1,5.756,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
minocycline,30S ribosomal protein S9,rpsI,5.756,Ka,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(O)=CC=C4N(C)C)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
latanoprost,Prostaglandin E2 receptor EP1 subtype,PTGER1,5.757,Ki,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
amisulpride,5-hydroxytryptamine receptor 1B,HTR1B,5.758,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
androstenedione,Corticosteroid-binding globulin,SERPINA6,5.76,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
candesartan cilexetil,Alpha-2B adrenergic receptor,ADRA2B,5.76,Ki,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
citalopram,Alpha-1A adrenergic receptor,Adra1a,5.76,IC50,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
clavulanic acid,Beta-lactamase,blaSHV-72,5.76,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
verapamil,Membrane-associated progesterone receptor component 1,Pgrmc1,5.76,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
eseridine,Acetylcholinesterase,ache,5.76,IC50,CNC(=O)OC1=CC2=C(C=C1)N(C)[C@H]1ON(C)CC[C@@]21C
pyrithione,Carbonic anhydrase 9,CA9,5.76,Ki,[O-][N+]1=C(S)C=CC=C1
alitretinoin,Oxysterols receptor LXR-beta,NR1H2,5.76,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
abiraterone acetate,"Cytochrome P450 11B2, mitochondrial",CYP11B2,5.76,IC50,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C4=CC=CN=C4)[C@@H]3CC=C2C1
chromic chloride,Tyrosine-protein kinase Fyn,FYN,5.76,IC50,Cl[Cr](Cl)Cl
niraparib,Poly [ADP-ribose] polymerase 14,PARP14,5.76,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
bithionol,Sodium-dependent dopamine transporter,SLC6A3,5.761,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
verapamil,5-hydroxytryptamine receptor 1A,HTR1A,5.763,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
pentamidine,5-hydroxytryptamine receptor 2C,HTR2C,5.765,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
riluzole,Sodium-dependent noradrenaline transporter,SLC6A2,5.765,Ki,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
domperidone,Mu-type opioid receptor,OPRM1,5.766,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
tetracaine,5-hydroxytryptamine receptor 2C,HTR2C,5.766,Ki,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
acetylsalicylic acid,Prostaglandin G/H synthase 1,PTGS1,5.77,IC50,CC(=O)OC1=CC=CC=C1C(O)=O
alendronic acid,Farnesyl pyrophosphate synthase,Fdps,5.77,IC50,NCCCC(O)(P(O)(O)=O)P(O)(O)=O
alendronic acid,Farnesyl pyrophosphate synthase,Fdps,5.77,IC50,NCCCC(O)(P(O)(O)=O)P(O)(O)=O
bromperidol,Muscarinic acetylcholine receptor M4,CHRM4,5.77,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
buspirone,Multidrug and toxin extrusion protein 1,SLC47A1,5.77,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
cefsulodin,tRNA 2'-phosphotransferase,TPT1,5.77,IC50,NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C2=CC=CC=C2)S(O)(=O)=O)C3=O)C([O-])=O)C=C1
cisapride,D(1A) dopamine receptor,DRD1,5.77,IC50,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cisapride,D(1A) dopamine receptor,Drd1,5.77,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
dabigatran etexilate,Plasminogen,PLG,5.77,Ki,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
dasatinib,Dual specificity mitogen-activated protein kinase kinase; MEK1/2,MAP2K2|MAP2K1,5.77,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
erlotinib,Ephrin type-B receptor 6,EPHB6,5.77,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fasudil,Serine/threonine-protein kinase N1,PKN1,5.77,IC50,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
fluphenazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.77,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
gefitinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5.77,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
imatinib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,5.77,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indinavir,Substance-K receptor,TACR2,5.77,Ki,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
indinavir,Multidrug and toxin extrusion protein 1,SLC47A1,5.77,IC50,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
nilotinib,Serine/threonine-protein kinase TAO3,TAOK3,5.77,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
ondansetron,Solute carrier family 22 member 2,SLC22A2,5.77,IC50,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
papaverine,Cyclic AMP-specific phosphodiesterase SSPDE4A1A,PDE4A,5.77,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
penfluridol,Delta-type opioid receptor,OPRD1,5.77,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
pentobarbital,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,5.77,IC50,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
pimozide,Glycine receptor subunit alpha-1,GLRA1,5.77,EC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
prochlorperazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.77,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
procyclidine,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,5.77,Ki,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
pyrazinamide,Carbonic anhydrase 2,CA2,5.77,IC50,NC(=O)C1=NC=CN=C1
ritonavir,UDP-glucuronosyltransferase 1-1,UGT1A1,5.77,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
rofecoxib,Prostaglandin G/H synthase 1,PTGS1,5.77,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
sorafenib,Ephrin type-B receptor 1,EPHB1,5.77,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Homeodomain-interacting protein kinase 2,HIPK2,5.77,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Aurora kinase A,AURKA,5.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Cyclin-dependent kinase 18,CDK18,5.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Dual specificity mitogen-activated protein kinase kinase 3,MAP2K3,5.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
talipexole,5-hydroxytryptamine receptor 1A,HTR1A,5.77,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
thiamphenicol,Streptokinase A,ska,5.77,EC50,CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl
suramin,DNA-dependent protein kinase catalytic subunit,PRKDC,5.77,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
capsaicin,Transient receptor potential cation channel subfamily V member 1,Trpv1,5.77,Ki,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
dibrompropamidine,Acrosin,ACR,5.77,Ki,NC(=N)C1=CC(Br)=C(OCCCOC2=C(Br)C=C(C=C2)C(N)=N)C=C1
kainic acid,Glutamate receptor 4,GRIA4,5.77,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
evans blue,Luciferin 4-monooxygenase,,5.77,IC50,CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O
phenacaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.77,IC50,CCOC1=CC=C(NC(C)=NC2=CC=C(OCC)C=C2)C=C1
quercetin,Sialidase,nanH,5.77,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Cyclin-dependent kinase 7,CDK7,5.77,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Tyrosine-protein kinase JAK2,JAK2,5.77,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,5.77,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Tyrosine-protein kinase BTK,BTK,5.77,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,AarF domain-containing protein kinase 4,COQ8B,5.77,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ruxolitinib,Dual specificity protein kinase CLK4,CLK4,5.77,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase TBK1,TBK1,5.77,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Mitogen-activated protein kinase kinase kinase 12,MAP3K12,5.77,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Myosin light chain kinase 3,MYLK3,5.77,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Dual specificity protein kinase CLK2,CLK2,5.77,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Tyrosine-protein kinase ITK/TSK,ITK,5.77,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,G protein-coupled receptor kinase 7,GRK7,5.77,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ceritinib,Proto-oncogene tyrosine-protein kinase Src,SRC,5.77,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Serine/threonine-protein kinase ICK,ICK,5.77,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
pitolisant,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.77,IC50,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
pitolisant,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.77,IC50,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
midostaurin,Fibroblast growth factor receptor 3,FGFR3,5.77,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,NT-3 growth factor receptor,NTRK3,5.77,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Serine/threonine-protein kinase Nek2,NEK2,5.77,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ephrin type-B receptor 1,EPHB1,5.77,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Megakaryocyte-associated tyrosine-protein kinase,MATK,5.77,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Phosphatidylinositol 4-kinase beta,PI4KB,5.77,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Dual serine/threonine and tyrosine protein kinase,DSTYK,5.77,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
amitriptyline,5-hydroxytryptamine receptor 1B,Htr1b,5.771,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
dobutamine,D(3) dopamine receptor,DRD3,5.771,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
lacidipine,Thromboxane-A synthase,TBXAS1,5.771,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
montelukast,Delta-type opioid receptor,OPRD1,5.772,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
prednisone,Sodium/nucleoside cotransporter 1,SLC28A1,5.772,Ki,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
nefopam,5-hydroxytryptamine receptor 2A,HTR2A,5.773,Ki,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1
raloxifene,Alpha-2B adrenergic receptor,ADRA2B,5.773,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
reserpine,Mu-type opioid receptor,OPRM1,5.773,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
thioridazine,Sodium-dependent dopamine transporter,SLC6A3,5.774,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
betamethasone phosphate,Muscarinic acetylcholine receptor M1,CHRM1,5.776,Ki,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
chlorpromazine,Membrane-associated progesterone receptor component 1,Pgrmc1,5.777,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clomifene,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.778,IC50,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
diethylstilbestrol,Adenosine receptor A1,ADORA1,5.778,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
oxiconazole,Alpha-2B adrenergic receptor,ADRA2B,5.778,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
butenafine,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.779,Ki,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
betamethasone phosphate,Muscarinic acetylcholine receptor M4,CHRM4,5.779,Ki,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
levobunolol,5-hydroxytryptamine receptor 1A,HTR1A,5.78,Ki,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
flunarizine,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,5.78,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
fluphenazine,5-hydroxytryptamine receptor 1A,Htr1a,5.78,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
glibenclamide,CDGSH iron-sulfur domain-containing protein 1,CISD1,5.78,Ki,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
pramipexole,5-hydroxytryptamine receptor 1D,HTR1D,5.78,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
teicoplanin aglycone,Cathepsin L1,CTSL,5.78,IC50,N[C@@H]1C2=CC(OC3=CC(=CC(O)=C3)[C@@H]3NC(=O)[C@@H](CC4=CC=C(OC5=C(O)C6=CC(=C5)[C@@H](NC3=O)C(=O)N[C@@H]3C5=CC(=C(O)C=C5)C5=C(O)C=C(O)C=C5[C@H](NC(=O)[C@@H](NC3=O)[C@H](O)C3=CC(Cl)=C(O6)C=C3)C(O)=O)C(Cl)=C4)NC1=O)=C(O)C=C2
prazosin,Alpha-2A adrenergic receptor,Adra2a,5.78,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
astemizole,Histamine H2 receptor,HRH2,5.781,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
clotrimazole,Muscarinic acetylcholine receptor M1,CHRM1,5.781,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
domperidone,5-hydroxytryptamine receptor 2B,HTR2B,5.781,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
droperidol,Muscarinic acetylcholine receptor M5,CHRM5,5.782,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
sulconazole,Substance-K receptor,TACR2,5.782,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
clozapine,Beta-2 adrenergic receptor,ADRB2,5.783,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
digoxin,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,5.783,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
clotrimazole,Muscarinic acetylcholine receptor M4,CHRM4,5.785,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
miconazole,Alpha-2B adrenergic receptor,ADRA2B,5.785,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
sulconazole,Alpha-2B adrenergic receptor,ADRA2B,5.786,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
fluphenazine,Sodium-dependent dopamine transporter,SLC6A3,5.788,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
zaleplon,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,5.789,EC50,CCN(C(C)=O)C1=CC(=CC=C1)C1=CC=NC2=C(C=NN12)C#N
levobupivacaine,Sodium channel protein type 1 subunit alpha,SCN1A,5.79,IC50,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
dexfenfluramine,5-hydroxytryptamine receptor 2C,HTR2C,5.79,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
domperidone,Sodium-dependent serotonin transporter,SLC6A4,5.79,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
econazole,Alpha-2A adrenergic receptor,ADRA2A,5.79,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
fenfluramine,5-hydroxytryptamine receptor 2C,HTR2C,5.79,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
formoterol,D(3) dopamine receptor,DRD3,5.79,Ki,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
iprindole,Sodium-dependent serotonin transporter,SLC6A4,5.79,Ki,CN(C)CCCN1C2=C(CCCCCC2)C2=CC=CC=C12
aspartic acid,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,5.79,IC50,N[C@@H](CC(O)=O)C(O)=O
mirtazapine,Transporter,Slc6a2,5.79,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
propafenone,5-hydroxytryptamine receptor 1A,Htr1a,5.79,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
quetiapine,D(1B) dopamine receptor,DRD5,5.79,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
sibutramine,Cytochrome P450 2B6,CYP2B6,5.79,IC50,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
tolazoline,Trace amine-associated receptor 1,TAAR1,5.79,Ki,C(C1=NCCN1)C1=CC=CC=C1
pyrithione,Carbonic anhydrase 3,CA3,5.79,Ki,[O-][N+]1=C(S)C=CC=C1
quercetin,Matrix metalloproteinase-9,MMP9,5.79,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
yohimbine,5-hydroxytryptamine receptor 2A,Htr2a,5.79,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
abiraterone acetate,"Cytochrome P450 11B1, mitochondrial",CYP11B1,5.79,IC50,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C4=CC=CN=C4)[C@@H]3CC=C2C1
econazole,D(3) dopamine receptor,DRD3,5.792,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miconazole,Substance-K receptor,TACR2,5.792,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
tamoxifen,Alpha-2B adrenergic receptor,ADRA2B,5.794,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
glibenclamide,Cytochrome P450 2C9,CYP2C9,5.795,IC50,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
quetiapine,Muscarinic acetylcholine receptor M3,CHRM3,5.795,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
adenosine,Adenosylhomocysteinase,AHCY,5.796,Km,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
amperozide,5-hydroxytryptamine receptor 6,HTR6,5.796,Ki,CCNC(=O)N1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1
dicycloverine,Histamine H2 receptor,HRH2,5.796,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
dobutamine,Membrane-associated progesterone receptor component 1,Pgrmc1,5.796,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
mitotane,Sodium-dependent serotonin transporter,SLC6A4,5.796,Ki,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
promazine,Aldehyde oxidase,AOX1,5.796,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
terconazole,D(3) dopamine receptor,DRD3,5.796,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
ziprasidone,Muscarinic acetylcholine receptor M4,CHRM4,5.796,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
ziprasidone,Muscarinic acetylcholine receptor M5,CHRM5,5.796,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
pimozide,Alpha-2A adrenergic receptor,ADRA2A,5.798,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
miconazole,Adenosine receptor A3,ADORA3,5.799,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acetylcholine,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,5.8,EC50,CC(=O)OCC[N+](C)(C)C
adenosine triphosphate,Transient receptor potential cation channel subfamily M member 4,TRPM4,5.8,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
alcuronium,Muscarinic acetylcholine receptor M3,CHRM3,5.8,Kd,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
amitriptyline,Sodium channel protein type 5 subunit alpha,SCN5A,5.8,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amoxicillin,5-hydroxytryptamine receptor 2C,HTR2C,5.8,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O
atenolol,Beta-2 adrenergic receptor,ADRB2,5.8,Kd,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
carvedilol,Potassium channel subfamily K member 2,KCNK2,5.8,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
cisapride,5-hydroxytryptamine receptor 7,Htr7,5.8,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
clotrimazole,C-C chemokine receptor type 4,CCR4,5.8,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clozapine,Histamine H3 receptor,Hrh3,5.8,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Eukaryotic translation initiation factor 2-alpha kinase 4,EIF2AK4,5.8,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
denopamine,Beta-1 adrenergic receptor,ADRB1,5.8,Ki,COC1=CC=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1OC
desipramine,Sodium-dependent noradrenaline transporter,Slc6a2,5.8,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
disulfiram,Histone-lysine N-methyltransferase EHMT1,EHMT1,5.8,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
fluoxetine,5-hydroxytryptamine receptor 6,Htr6,5.8,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
gefitinib,Abelson tyrosine-protein kinase 2,ABL2,5.8,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Mitogen-activated protein kinase 6,MAPK6,5.8,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
haloperidol,Muscarinic acetylcholine receptor M1,CHRM1,5.8,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
iloprost,Prostaglandin E2 receptor EP2 subtype,Ptger2,5.8,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
ketanserin,Chromaffin granule amine transporter,SLC18A1,5.8,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
maprotiline,Transient receptor potential cation channel subfamily M member 3,TRPM3,5.8,IC50,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
mefenamic acid,Aldo-keto reductase family 1 member B10,AKR1B10,5.8,IC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
methacholine,Muscarinic acetylcholine receptor M4,CHRM4,5.8,Ki,CC(C[N+](C)(C)C)OC(C)=O
methacholine,Muscarinic acetylcholine receptor M4,Chrm4,5.8,Ki,CC(C[N+](C)(C)C)OC(C)=O
metixene,Cholinesterase,BCHE,5.8,IC50,CN1CCCC(CC2C3=CC=CC=C3SC3=C2C=CC=C3)C1
mibefradil,Multidrug resistance protein 1,ABCB1,5.8,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
molindone,D(1A) dopamine receptor,Drd1,5.8,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
naftopidil,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.8,Ki,COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1
nilotinib,Tyrosine-protein kinase Fyn,FYN,5.8,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
progesterone,Steroid 5-alpha-reductase,Srd5a1|Srd5a2,5.8,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
progesterone,P2X purinoceptor 3,P2RX3,5.8,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
quetiapine,D(4) dopamine receptor,DRD4,5.8,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
quinidine,Potassium voltage-gated channel subfamily H member 1,KCNH1,5.8,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
remoxipride,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,5.8,IC50,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
reserpine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.8,IC50,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
rifampicin,Solute carrier organic anion transporter family member 1B3,SLCO1B3,5.8,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
risperidone,Multidrug and toxin extrusion protein 1,SLC47A1,5.8,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
rivastigmine,Cholinesterase,Bche,5.8,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
sorafenib,LIM domain kinase 1,LIMK1,5.8,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,5.8,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Cyclin-dependent kinase 17,CDK17,5.8,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiperone,5-hydroxytryptamine receptor 6,HTR6,5.8,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
spiperone,5-hydroxytryptamine receptor 6,Htr6,5.8,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sulpiride,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,5.8,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tamoxifen,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.8,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tramadol,Mu-type opioid receptor,OPRM1,5.8,Ki,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
choline,High affinity choline transporter 1,Slc5a7,5.8,IC50,C[N+](C)(C)CCO
cynarine,Integrase,pol,5.8,IC50,O[C@@H]1C[C@](C[C@@H](OC(=O)\C=C\C2=CC(O)=C(O)C=C2)[C@H]1O)(OC(=O)\C=C\C1=CC(O)=C(O)C=C1)C(O)=O
dibrompropamidine,Urokinase-type plasminogen activator,PLAU,5.8,Ki,NC(=N)C1=CC(Br)=C(OCCCOC2=C(Br)C=C(C=C2)C(N)=N)C=C1
oxyquinoline,Catechol O-methyltransferase,COMT,5.8,IC50,OC1=CC=CC2=C1N=CC=C2
octopamine,Trace amine-associated receptor 1,TAAR1,5.8,EC50,NCC(O)C1=CC=C(O)C=C1
octopamine,Trace amine-associated receptor 1,Taar1,5.8,EC50,NCC(O)C1=CC=C(O)C=C1
practolol,Beta-2 adrenergic receptor,Adrb2,5.8,Kd,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
ruboxistaurin,SRSF protein kinase 3,SRPK3,5.8,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase PRP4 homolog,PRPF4B,5.8,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
tetryzoline,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.8,IC50,C1CN=C(N1)C1CCCC2=CC=CC=C12
xanomeline,Alpha-1B adrenergic receptor,ADRA1B,5.8,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
pazopanib,Tyrosine-protein kinase Fgr,FGR,5.8,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,5.8,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Ephrin type-A receptor 4,EPHA4,5.8,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Ribosomal protein S6 kinase beta-1,RPS6KB1,5.8,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,5.8,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,5.8,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase ULK2,ULK2,5.8,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase PAK 4,PAK4,5.8,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
prazosin,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.8,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
prazosin,Multidrug and toxin extrusion protein 1,SLC47A1,5.8,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
afatinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,5.8,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Protein kinase C delta type,PRKCD,5.8,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase Nek2,NEK2,5.8,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Cyclin-dependent kinase 15,CDK15,5.8,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Tyrosine-protein kinase ZAP-70,ZAP70,5.8,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase RIO3,RIOK3,5.8,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tofacitinib,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,5.8,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
tofacitinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,5.8,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Activated CDC42 kinase 1,TNK2,5.8,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,DYRK1B,5.8,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Fibroblast growth factor receptor 1,FGFR1,5.8,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,TRAF2 and NCK-interacting protein kinase,TNIK,5.8,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Maternal embryonic leucine zipper kinase,MELK,5.8,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
duvelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,5.8,IC50,C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=C(C(Cl)=CC=C2)C(=O)N1C1=CC=CC=C1
fedratinib,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,5.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Calcium/calmodulin-dependent protein kinase type 1,CAMK1,5.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Insulin receptor-related protein,INSRR,5.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase PLK3,PLK3,5.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,cGMP-dependent protein kinase 2,PRKG2,5.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,STE20/SPS1-related proline-alanine-rich protein kinase,STK39,5.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Nek4,NEK4,5.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
phentermine,Sodium-dependent dopamine transporter,SLC6A3,5.801,Ki,CC(C)(N)CC1=CC=CC=C1
pemafibrate,Peroxisome proliferator-activated receptor delta,PPARD,5.801,EC50,CC[C@@H](OC1=CC=CC(CN(CCCOC2=CC=C(OC)C=C2)C2=NC3=C(O2)C=CC=C3)=C1)C(O)=O
dipyridamole,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,5.802,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
diiodohydroxyquinoline,Tyrosine-protein kinase Fyn,FYN,5.804,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
econazole,Histamine H2 receptor,HRH2,5.805,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
haloprogin,Sodium-dependent dopamine transporter,SLC6A3,5.805,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
promazine,Membrane-associated progesterone receptor component 1,Pgrmc1,5.806,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
bithionol,Substance-K receptor,TACR2,5.809,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
gentian violet,D(1A) dopamine receptor,DRD1,5.809,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
pentoxyverine,Solute carrier family 22 member 1,SLC22A1,5.81,IC50,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1
fasudil,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,5.81,AC50,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
flurbiprofen,Aldo-keto reductase family 1 member C3,AKR1C3,5.81,IC50,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
lysergide,Histamine H1 receptor,HRH1,5.81,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
norethynodrel,Androgen receptor,Ar,5.81,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C
progesterone,Androgen receptor,Ar,5.81,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
gabexate,Plasminogen,PLG,5.81,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
quercetin,Estradiol 17-beta-dehydrogenase 2,HSD17B2,5.81,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
timolol,5-hydroxytryptamine receptor 1A,HTR1A,5.81,Ki,CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1
amisulpride,Alpha-2C adrenergic receptor,ADRA2C,5.812,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
miconazole,Muscarinic acetylcholine receptor M2,CHRM2,5.812,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
thiothixene,Muscarinic acetylcholine receptor M4,CHRM4,5.812,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
thioridazine,Sodium-dependent noradrenaline transporter,SLC6A2,5.813,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
oxiconazole,Alpha-2A adrenergic receptor,ADRA2A,5.815,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
montelukast,Thromboxane-A synthase,TBXAS1,5.817,IC50,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
aripiprazole,Muscarinic acetylcholine receptor M4,CHRM4,5.818,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
bromocriptine,Androgen receptor,Ar,5.818,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
topotecan,Cytochrome P450 3A4,CYP3A4,5.818,IC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
astemizole,5-hydroxytryptamine receptor 6,HTR6,5.819,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
sulconazole,Alpha-2A adrenergic receptor,ADRA2A,5.819,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
chloroquine,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,5.82,IC50,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
clenbuterol,5-hydroxytryptamine receptor 1A,HTR1A,5.82,Ki,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
cloxazolam,Aldo-keto reductase family 1 member C3,AKR1C3,5.82,Ki,ClC1=CC=C2NC(=O)CN3CCOC3(C2=C1)C1=C(Cl)C=CC=C1
dapsone,Dihydrofolate reductase,,5.82,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
dasatinib,Casein kinase I isoform epsilon,CSNK1E,5.82,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
ebastine,Multidrug resistance protein 1,ABCB1,5.82,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
epalrestat,Alcohol dehydrogenase [NADP(+)],AKR1A1,5.82,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
epalrestat,Alcohol dehydrogenase [NADP(+)],Akr1a1,5.82,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
gefitinib,Ephrin type-A receptor 5,EPHA5,5.82,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Interleukin-1 receptor-associated kinase 3,IRAK3,5.82,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
idoxuridine,Thymidine kinase,UL23,5.82,IC50,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O
imatinib,Tyrosine-protein kinase FRK,FRK,5.82,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
intoplicine,DNA topoisomerase 2-alpha,TOP2A,5.82,IC50,CN(C)CCCNC1=NC=C(C)C2=C1C1=C3C=CC(O)=CC3=CC=C1N2
mecamylamine,Acetylcholine receptor subunit alpha,CHRNA1,5.82,IC50,CNC1(C)C2CCC(C2)C1(C)C
methapyrilene,Alpha-2B adrenergic receptor,ADRA2B,5.82,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
mianserin,D(3) dopamine receptor,Drd3,5.82,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
miconazole,7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,CYP8B1,5.82,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
naftifine,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,5.82,Ki,CN(C\C=C\C1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12
nifedipine,"Indoleamine 2,3-dioxygenase 2",Ido2,5.82,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
norepinephrine,Alpha-1A adrenergic receptor,ADRA1A,5.82,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
nortriptyline,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5.82,IC50,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
pantoprazole,Solute carrier family 22 member 2,SLC22A2,5.82,IC50,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
prochlorperazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.82,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
ropinirole,5-hydroxytryptamine receptor 7,HTR7,5.82,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sorafenib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,5.82,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,5.82,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Calcium/calmodulin-dependent protein kinase kinase 2,CAMKK2,5.82,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamoxifen,C-8 sterol isomerase,ERG2,5.82,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
telmisartan,Peroxisome proliferator-activated receptor gamma,PPARG,5.82,EC50,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O
toloxatone,Amine oxidase [flavin-containing] A,MAOA,5.82,Ki,CC1=CC=CC(=C1)N1CC(CO)OC1=O
ximelagatran,Tissue-type plasminogen activator,PLAT,5.82,Ki,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
mitoguazone,Amiloride-sensitive amine oxidase [copper-containing],Aoc1,5.82,IC50,C\C(\C=N\NC(N)=N)=N/NC(N)=N
quercetin,Beta-hydroxyacyl-ACP dehydratase; Fatty acid synthesis protein,fabZ,5.82,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Calcium/calmodulin-dependent protein kinase kinase 1,CAMKK1,5.82,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase N2,PKN2,5.82,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
dexibuprofen,Prostaglandin G/H synthase 2,PTGS2,5.82,IC50,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
vandetanib,Aurora kinase C,AURKC,5.82,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Casein kinase I isoform epsilon,CSNK1E,5.82,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Tyrosine-protein kinase receptor Tie-1,TIE1,5.82,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,5.82,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Mitogen-activated protein kinase 6,MAPK6,5.82,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Calcium/calmodulin-dependent protein kinase kinase 2,CAMKK2,5.82,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,High affinity nerve growth factor receptor,NTRK1,5.82,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,ALK tyrosine kinase receptor,ALK,5.82,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase PLK2,PLK2,5.82,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Peripheral plasma membrane protein CASK,CASK,5.82,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
prazosin,5-hydroxytryptamine receptor 2A,Htr2a,5.82,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
vilazodone,5-hydroxytryptamine receptor 2A,Htr2a,5.82,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
axitinib,Calcium/calmodulin-dependent protein kinase kinase 2,CAMKK2,5.82,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Hormonally up-regulated neu tumor-associated kinase,HUNK,5.82,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Serine/threonine-protein kinase NIM1,NIM1K,5.82,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
migalastat,"Maltase-glucoamylase, intestinal",MGAM,5.82,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
midostaurin,Ribosomal protein S6 kinase alpha-6,RPS6KA6,5.82,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,5.82,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,NUAK family SNF1-like kinase 1,NUAK1,5.82,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Homeodomain-interacting protein kinase 4,HIPK4,5.82,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
abemaciclib,Cyclin-dependent kinase 1,CDK1,5.82,IC50,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
fedratinib,Tyrosine-protein kinase TXK,TXK,5.82,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,Vascular endothelial growth factor receptor 1,FLT1,5.82,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Vascular endothelial growth factor receptor 1,FLT1,5.82,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
disulfiram,Mitogen-activated protein kinase 3,MAPK3,5.821,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
ketoconazole,Sodium/nucleoside cotransporter 1,SLC28A1,5.821,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
astemizole,D(2) dopamine receptor,DRD2,5.822,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
clomifene,Substance-K receptor,TACR2,5.822,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
quetiapine,5-hydroxytryptamine receptor 1B,HTR1B,5.822,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
arsenic trioxide,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.824,IC50,O=[As]O[As]=O
dexniguldipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,5.824,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
saquinavir,Cytochrome P450 3A4,CYP3A4,5.824,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
tobramycin,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",mphB,5.824,Km,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
zileuton,Cysteinyl leukotriene receptor 2,CYSLTR2,5.824,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
olaparib,Tankyrase-1,TNKS,5.824,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
clorprenaline,Beta-1 adrenergic receptor,ADRB1,5.825,Ki,CC(C)NCC(O)C1=C(Cl)C=CC=C1
miconazole,Alpha-1D adrenergic receptor,ADRA1D,5.825,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
chlorpromazine,5-hydroxytryptamine receptor 1B,HTR1B,5.827,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
raloxifene,Alpha-1B adrenergic receptor,Adra1b,5.827,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
miconazole,Alpha-2A adrenergic receptor,ADRA2A,5.828,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
perhexiline,Epidermal growth factor receptor,EGFR,5.828,IC50,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
raloxifene,Sodium-dependent dopamine transporter,SLC6A3,5.828,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sulconazole,Adenosine receptor A3,ADORA3,5.828,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
clotrimazole,Glucocorticoid receptor,NR3C1,5.829,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
imiquimod,Histamine H2 receptor,HRH2,5.829,Ki,CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12
paclitaxel,Delta-type opioid receptor,OPRD1,5.829,Ki,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
promethazine,5-hydroxytryptamine receptor 1A,HTR1A,5.829,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
propafenone,Sodium-dependent dopamine transporter,SLC6A3,5.829,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
camostat,Kallikrein-1,KLK1,5.83,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
chlorpromazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.83,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clozapine,Sodium-dependent noradrenaline transporter,SLC6A2,5.83,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
nicotine,Acetylcholine receptor; alpha1/beta1/delta/gamma,CHRNA1|CHRNG|CHRNB1|CHRND,5.83,Ki,CN1CCC[C@H]1C1=CC=CN=C1
ritonavir,Multidrug resistance protein 1,ABCB1,5.83,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
tramadol,Sodium-dependent serotonin transporter,SLC6A4,5.83,IC50,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
bergapten,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Dyrk1a,5.83,AC50,COC1=C2C=COC2=CC2=C1C=CC(=O)O2
iloperidone,Sodium-dependent noradrenaline transporter,SLC6A2,5.83,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
dexibuprofen,Prostaglandin G/H synthase 1,PTGS1,5.83,IC50,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
metizoline,Amine oxidase [flavin-containing] B,Maob,5.83,Ki,CC1=C(CC2=NCCN2)C2=CC=CC=C2S1
lumateperone,5-hydroxytryptamine receptor 1A,HTR1A,5.83,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
trilaciclib,Cyclin-dependent-like kinase 5,CDK5,5.83,IC50,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
disulfiram,Alpha-2B adrenergic receptor,ADRA2B,5.833,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
montelukast,Alpha-2A adrenergic receptor,ADRA2A,5.833,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
tamoxifen,Sodium-dependent dopamine transporter,SLC6A3,5.835,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
brimonidine,5-hydroxytryptamine receptor 1A,HTR1A,5.836,Ki,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
reserpine,Sodium-dependent serotonin transporter,SLC6A4,5.836,Kd,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
sulconazole,5-hydroxytryptamine receptor 2C,HTR2C,5.836,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
tamoxifen,Sodium-dependent noradrenaline transporter,SLC6A2,5.836,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
modafinil,Sodium-dependent dopamine transporter,SLC6A3,5.837,Ki,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
nortriptyline,5-hydroxytryptamine receptor 1B,Htr1b,5.837,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
testosterone,Glucocorticoid receptor,NR3C1,5.837,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
pergolide,Alpha-1B adrenergic receptor,Adra1b,5.838,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
ketotifen,5-hydroxytryptamine receptor 1A,HTR1A,5.839,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
doxorubicin,ORF 73,,5.84,AC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
famotidine,"Carbonic anhydrase 5A, mitochondrial",CA5A,5.84,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
mirtazapine,D(2) dopamine receptor,Drd2,5.84,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
topiramate,Carbonic anhydrase 14,CA14,5.84,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
carfilzomib,Proteasome subunit beta type-1,PSMB1,5.84,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
carfilzomib,Proteasome subunit beta type-1,PSMB1,5.84,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
fluphenazine enanthate,Muscarinic acetylcholine receptor M3,CHRM3,5.841,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
mitoxantrone,Multidrug resistance protein 1,ABCB1,5.841,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
chlorphenamine,Sodium-dependent noradrenaline transporter,SLC6A2,5.842,Kd,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
methapyrilene,5-hydroxytryptamine receptor 6,HTR6,5.843,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
bithionol,Alpha-2A adrenergic receptor,ADRA2A,5.843,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
voriconazole,Lanosterol 14-alpha demethylase,cyp51,5.844,MIC,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
bithionol,D(3) dopamine receptor,DRD3,5.844,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
doxazosin,Sodium-dependent serotonin transporter,SLC6A4,5.845,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
fenfluramine,5-hydroxytryptamine receptor 2A,HTR2A,5.845,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
bupropion,Membrane-associated progesterone receptor component 1,Pgrmc1,5.846,Ki,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
disulfiram,Mu-type opioid receptor,OPRM1,5.846,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
dicycloverine,5-hydroxytryptamine receptor 6,HTR6,5.847,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
propranolol,5-hydroxytryptamine receptor 6,HTR6,5.847,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
ebastine,5-hydroxytryptamine receptor 1B,Htr1b,5.849,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
propafenone,Alpha-1B adrenergic receptor,Adra1b,5.849,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
adenosine triphosphate,P2X purinoceptor 2,P2rx2,5.85,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
atomoxetine,Sodium-dependent dopamine transporter,Slc6a3,5.85,Ki,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
clotrimazole,Transitional endoplasmic reticulum ATPase,VCP,5.85,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,Transitional endoplasmic reticulum ATPase,VCP,5.85,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.85,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Fibroblast growth factor receptor 2,FGFR2,5.85,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,5.85,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexamethasone,Androgen receptor,AR,5.85,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
dexamethasone palmitate,Androgen receptor,AR,5.85,Ki,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
dexamethasone valerate,Androgen receptor,AR,5.85,Ki,CCCCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
cinchocaine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.85,IC50,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
ditiocarb,Carbonic anhydrase 9,CA9,5.85,Ki,CCN(CC)C(S)=S
dopamine,FAD-linked sulfhydryl oxidase ALR,GFER,5.85,AC50,NCCC1=CC(O)=C(O)C=C1
erlotinib,Platelet-derived growth factor receptor beta,PDGFRB,5.85,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Ephrin type-A receptor 7,EPHA7,5.85,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Aurora kinase B,AURKB,5.85,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
gefitinib,Mitogen-activated protein kinase 9,MAPK9,5.85,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Serine/threonine-protein kinase ULK3,Ulk3,5.85,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,Metabotropic glutamate receptor 4,GRM4,5.85,Ki,N[C@@H](CCC(O)=O)C(O)=O
gossypol,L-lactate dehydrogenase B chain,LDHB,5.85,Ki,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
hexobendine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.85,IC50,COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN(C)CCN(C)CCCOC(=O)C1=CC(OC)=C(OC)C(OC)=C1
imatinib,Ephrin type-A receptor 8,EPHA8,5.85,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
letrozole,"Cytochrome P450 11B2, mitochondrial",CYP11B2,5.85,IC50,N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
meloxicam,Prostaglandin G/H synthase 1,PTGS1,5.85,IC50,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
mianserin,D(1A) dopamine receptor,Drd1,5.85,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
molindone,5-hydroxytryptamine receptor 2A,Htr2a,5.85,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
morphine,"Opioid receptor, delta 1b",oprd1b,5.85,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
nicardipine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.85,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
nomifensine,Sodium-dependent serotonin transporter,SLC6A4,5.85,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
oxacillin,Prostaglandin G/H synthase 2,PTGS2,5.85,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=CC=CC=C1
papaverine,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,5.85,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
papaverine,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,5.85,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
perphenazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.85,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
phenolphthalein,Thymidylate synthase,thyA,5.85,Ki,OC1=CC=C(C=C1)C1(OC(=O)C2=C1C=CC=C2)C1=CC=C(O)C=C1
oxagrelate,Phosphodiesterase 3,PDE3B|PDE3A,5.85,Ki,CCOC(=O)C1=C(C)C2=C(C=C1C)C(CO)=NNC2=O
pyrimethamine,Dihydrofolate reductase,Dhfr,5.85,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
quetiapine,5-hydroxytryptamine receptor 6,HTR6,5.85,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
remoxipride,D(2) dopamine receptor,Drd2,5.85,IC50,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
risperidone,Sodium-dependent serotonin transporter,SLC6A4,5.85,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sunitinib,Calcium/calmodulin-dependent protein kinase type II subunit beta,CAMK2B,5.85,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Carbonic anhydrase 2,Ca2,5.85,IC50,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
trifluoperazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.85,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
zanamivir,Neuraminidase,,5.85,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
quercetin,ELAV-like protein 1,ELAVL1,5.85,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,RAC-gamma serine/threonine-protein kinase,AKT3,5.85,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,5.85,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Citron Rho-interacting kinase,CIT,5.85,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Protein kinase C iota type,PRKCI,5.85,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase Sgk3,SGK3,5.85,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
dexamethasone phosphate,Androgen receptor,AR,5.85,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
mozavaptan,Vasopressin V1a receptor,Avpr1a,5.85,IC50,CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C2=CC=CC=C12
pazopanib,Tyrosine-protein kinase Fes/Fps,FES,5.85,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Serine/threonine-protein kinase 33,STK33,5.85,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,5.85,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Tyrosine-protein kinase Mer,MERTK,5.85,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Myotonin-protein kinase,DMPK,5.85,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Serine/threonine-protein kinase 4,STK4,5.85,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Calcium/calmodulin-dependent protein kinase kinase 1,CAMKK1,5.85,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Receptor-interacting serine/threonine-protein kinase 4,RIPK4,5.85,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,5.85,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Tyrosine-protein kinase FRK,FRK,5.85,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Cyclin-dependent kinase 14,CDK14,5.85,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tofacitinib,Ribosomal protein S6 kinase alpha-1,RPS6KA1,5.85,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Cyclin-dependent kinase 2,CDK2,5.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Angiopoietin-1 receptor,TEK,5.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase MARK2,MARK2,5.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase N2,PKN2,5.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase MARK1,MARK1,5.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Mitogen-activated protein kinase kinase kinase 15,MAP3K15,5.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
alectinib,Vascular endothelial growth factor receptor 2,KDR,5.85,IC50,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O
cytisine,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,5.85,Ki,O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12
midostaurin,Tyrosine-protein kinase receptor Tie-1,TIE1,5.85,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta,PIK3C2B,5.85,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase Sgk3,SGK3,5.85,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
vadadustat,Prolyl 3-hydroxylase OGFOD1,OGFOD1,5.85,IC50,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
umbralisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,5.85,Kd,C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
montelukast,Muscarinic acetylcholine receptor M3,CHRM3,5.853,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
loxapine,5-hydroxytryptamine receptor 1E,HTR1E,5.854,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
maprotiline,Aldehyde oxidase,AOX1,5.854,IC50,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
quetiapine,Aldehyde oxidase,AOX1,5.854,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
sertraline,Muscarinic acetylcholine receptor M4,CHRM4,5.854,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
terfenadine,Multidrug resistance protein 1,ABCB1,5.854,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
suloctidil,Sodium-dependent noradrenaline transporter,SLC6A2,5.857,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
bromocriptine,Beta-1 adrenergic receptor,ADRB1,5.858,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
eperisone,Alpha-2B adrenergic receptor,ADRA2B,5.859,Ki,CCC1=CC=C(C=C1)C(=O)C(C)CN1CCCCC1
androstenediol,Androgen receptor,Ar,5.86,IC50,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O
benzatropine,Sodium-dependent noradrenaline transporter,SLC6A2,5.86,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
cyclizine,Alpha-1B adrenergic receptor,Adra1b,5.86,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
ciclosporin,Substance-K receptor,TACR2,5.86,Ki,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
desipramine,Alpha-2A adrenergic receptor,ADRA2A,5.86,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
desipramine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.86,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
fenoldopam,FAD-linked sulfhydryl oxidase ALR,GFER,5.86,AC50,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
hexachlorophene,Substance-K receptor,TACR2,5.86,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
meloxicam,Prostaglandin G/H synthase 2,PTGS2,5.86,IC50,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
methapyrilene,Sodium-dependent noradrenaline transporter,SLC6A2,5.86,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
mosapride,Alpha-2A adrenergic receptor,ADRA2A,5.86,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
paroxetine,Beta-adrenergic receptor kinase 1,GRK2,5.86,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
prochlorperazine,Sodium-dependent dopamine transporter,SLC6A3,5.86,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
ropinirole,5-hydroxytryptamine receptor 1D,HTR1D,5.86,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
ipragliflozin,Sodium/glucose cotransporter 1,Slc5a1,5.86,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC3=C(S2)C=CC=C3)=C(F)C=C1
remimazolam,GABA A receptor alpha-5/beta-2/gamma-2,Gabra5|Gabrb2|Gabrg2,5.86,EC50,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
terconazole,Muscarinic acetylcholine receptor M1,CHRM1,5.862,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
clorprenaline,Beta-2 adrenergic receptor,ADRB2,5.863,Ki,CC(C)NCC(O)C1=C(Cl)C=CC=C1
mestranol,Sodium-dependent noradrenaline transporter,SLC6A2,5.863,Ki,COC1=CC2=C(C=C1)[C@H]1CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@@H]1CC2
nimodipine,Cannabinoid receptor 1,CNR1,5.863,Ki,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
promethazine,D(1A) dopamine receptor,DRD1,5.863,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
sulconazole,Sodium-dependent dopamine transporter,SLC6A3,5.863,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
tamoxifen,5-hydroxytryptamine receptor 2A,HTR2A,5.863,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
butenafine,Alpha-2A adrenergic receptor,ADRA2A,5.864,Ki,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
diethylstilbestrol,5-hydroxytryptamine receptor 2A,HTR2A,5.864,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
pipamazine,5-hydroxytryptamine receptor 1B,Htr1b,5.864,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
astemizole,Sodium-dependent noradrenaline transporter,SLC6A2,5.865,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
benzquinamide,Alpha-2A adrenergic receptor,ADRA2A,5.865,Ki,CCN(CC)C(=O)C1CN2CCC3=C(C=C(OC)C(OC)=C3)C2CC1OC(C)=O
butriptyline,Sodium-dependent serotonin transporter,SLC6A4,5.866,Ki,CC(CC1C2=CC=CC=C2CCC2=C1C=CC=C2)CN(C)C
haloprogin,5-hydroxytryptamine receptor 2C,HTR2C,5.866,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
betamethasone phosphate,Muscarinic acetylcholine receptor M3,CHRM3,5.866,Ki,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
tivozanib,Hepatocyte growth factor receptor,MET,5.866,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
metergoline,Substance-K receptor,TACR2,5.867,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
pentamidine,D(3) dopamine receptor,DRD3,5.867,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
dobutamine,Alpha-2B adrenergic receptor,ADRA2B,5.868,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
thiothixene,5-hydroxytryptamine receptor 2C,HTR2C,5.868,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
miconazole,Sodium-dependent dopamine transporter,SLC6A3,5.869,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
chlortalidone,Carbonic anhydrase 6,CA6,5.87,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
glutamic acid,Glutamate receptor 1,GRIA1,5.87,Ki,N[C@@H](CCC(O)=O)C(O)=O
guanfacine,Alpha-1A adrenergic receptor,Adra1a,5.87,IC50,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
mibefradil,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,5.87,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
selegiline,Amine oxidase [flavin-containing] B,Maob,5.87,Ki,C[C@H](CC1=CC=CC=C1)N(C)CC#C
sulfaguanidine,Trypsin,PRSS1|PRSS2|PRSS3,5.87,Ki,NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1
valdecoxib,Carbonic anhydrase 4,CA4,5.87,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
gabexate,Plasma kallikrein,KLKB1,5.87,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
telaprevir,Cathepsin L2,CTSV,5.87,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
ceritinib,Hepatocyte growth factor receptor,MET,5.87,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
amlodipine,5-hydroxytryptamine receptor 6,HTR6,5.871,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
ebastine,Membrane-associated progesterone receptor component 1,Pgrmc1,5.871,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
metergoline,Acetylcholinesterase,ACHE,5.872,IC50,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
amisulpride,5-hydroxytryptamine receptor 1D,HTR1D,5.873,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
cicaprost,Prostaglandin D2 receptor,PTGDR,5.873,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
cicaprost,Prostaglandin F2-alpha receptor,PTGFR,5.873,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
terfenadine,D(1A) dopamine receptor,DRD1,5.874,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
citalopram,Muscarinic acetylcholine receptor M1,CHRM1,5.875,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
econazole,Progesterone receptor,PGR,5.875,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
guanfacine,5-hydroxytryptamine receptor 2B,HTR2B,5.875,Ki,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
raloxifene,Substance-K receptor,TACR2,5.876,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
ethinylestradiol,5-hydroxytryptamine receptor 4,HTR4,5.877,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
flunarizine,Sodium-dependent noradrenaline transporter,SLC6A2,5.877,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
tamoxifen,5-hydroxytryptamine receptor 2B,HTR2B,5.877,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
epirubicin,5-hydroxytryptamine receptor 4,HTR4,5.878,Ki,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
triazolam,Platelet-activating factor receptor,PTAFR,5.879,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
pentamidine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,5.88,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
promegestone,Androgen receptor,Ar,5.88,IC50,CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C
theophylline,Adenosine A2 receptor,Adora2b|Adora2a,5.88,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
nifenalol,Beta-2 adrenergic receptor,ADRB2,5.88,Kd,CC(C)NCC(O)C1=CC=C(C=C1)[N+]([O-])=O
dotinurad,Solute carrier family 22 member 8,SLC22A8,5.88,IC50,C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
hexachlorophene,Cytochrome P450 1A2,CYP1A2,5.882,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
cevimeline,Muscarinic acetylcholine receptor M4,CHRM4,5.883,EC50,CC1OC2(CS1)CN1CCC2CC1
cinnarizine,Sodium-dependent dopamine transporter,SLC6A3,5.885,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
sertraline,Membrane-associated progesterone receptor component 1,Pgrmc1,5.885,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
cyproheptadine,5-hydroxytryptamine receptor 1D,HTR1D,5.886,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
nicorandil,ATP-sensitive inward rectifier potassium channel 11,KCNJ11,5.886,IC50,[O-][N+](=O)OCCNC(=O)C1=CN=CC=C1
regadenoson,Adenosine receptor A2a,ADORA2A,5.886,EC50,CNC(=O)C1=CN(N=C1)C1=NC(N)=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=N1
sertraline,Muscarinic acetylcholine receptor M3,CHRM3,5.886,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
tetrabenazine,Alpha-2C adrenergic receptor,ADRA2C,5.886,Ki,COC1=CC2=C(C=C1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
telbivudine,Protein P,P,5.886,EC50,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O
benzatropine,5-hydroxytryptamine receptor 6,HTR6,5.888,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
benzethonium,Sodium-dependent serotonin transporter,SLC6A4,5.888,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
clomifene,Muscarinic acetylcholine receptor M2,CHRM2,5.889,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
ethylestrenol,Cytochrome P450 2C19,CYP2C19,5.889,IC50,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
aceclofenac,Aldose reductase,Akr1b1,5.89,IC50,OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
adapalene,Glycine receptor subunit alpha-1,GLRA1,5.89,EC50,COC1=CC=C(C=C1C12CC3CC(CC(C3)C1)C2)C1=CC=C2C=C(C=CC2=C1)C(O)=O
adenosine triphosphate,Tyrosine-protein kinase JAK2,JAK2,5.89,Kd,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adenosine triphosphate,Tyrosine-protein kinase JAK2,JAK2,5.89,Kd,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adenosine phosphate,"Fructose-1,6-bisphosphatase 1",FBP1,5.89,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
androstenedione,Androgen receptor,Ar,5.89,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
azapetine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.89,IC50,C=CCN1CC2=CC=CC=C2C2=C(C1)C=CC=C2
bortezomib,Carbonic anhydrase 1,CA1,5.89,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
buflomedil,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.89,Ki,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
carbachol,Neuronal acetylcholine receptor; alpha4/beta4,Chrna4|Chrnb4,5.89,Ki,C[N+](C)(C)CCOC(N)=O
chlorpromazine,Transient receptor potential cation channel subfamily V member 1,Trpv1,5.89,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlorpromazine,Acetylcholine receptor subunit alpha,CHRNA1,5.89,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlorpromazine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,5.89,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clemizole,Short transient receptor potential channel 6,TRPC6,5.89,IC50,ClC1=CC=C(CN2C(CN3CCCC3)=NC3=C2C=CC=C3)C=C1
dasatinib,Myotonin-protein kinase,DMPK,5.89,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,5.89,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dextromethorphan,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,5.89,IC50,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
dicoumarol,Proprotein convertase subtilisin/kexin type 7,PCSK7,5.89,IC50,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
erlotinib,Mast/stem cell growth factor receptor Kit,KIT,5.89,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,"Interferon-induced, double-stranded RNA-activated protein kinase",EIF2AK2,5.89,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Misshapen-like kinase 1,MINK1,5.89,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Dual specificity tyrosine-phosphorylation-regulated kinase 2,DYRK2,5.89,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fenoldopam,D(2) dopamine receptor,Drd2,5.89,Kd,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
flutamide,Androgen receptor,AR,5.89,Ki,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
gefitinib,Ephrin type-B receptor 1,EPHB1,5.89,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Citron Rho-interacting kinase,CIT,5.89,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
hexafluronium,Acetylcholinesterase,ache,5.89,Ki,C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C2=C1C=CC=C2)C1C2=CC=CC=C2C2=C1C=CC=C2
imiquimod,Alpha-1D adrenergic receptor,ADRA1D,5.89,Ki,CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12
methamphetamine,Trace amine-associated receptor 1,TAAR1,5.89,EC50,CN[C@@H](C)CC1=CC=CC=C1
nilotinib,Ephrin type-B receptor 1,EPHB1,5.89,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norepinephrine,D(2) dopamine receptor,DRD2,5.89,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
paroxetine,Beta-adrenergic receptor kinase 1,GRK2,5.89,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
promazine,FAD-linked sulfhydryl oxidase ALR,GFER,5.89,AC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
sorafenib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,5.89,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Abelson tyrosine-protein kinase 2,ABL2,5.89,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Ephrin type-A receptor 4,EPHA4,5.89,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,5.89,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Serine/threonine-protein kinase N2,PKN2,5.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase 11,MAP3K11,5.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase 15,MAP3K15,5.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 35,STK35,5.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Dual serine/threonine and tyrosine protein kinase,DSTYK,5.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Calcium-dependent protein kinase 1,CPK1,5.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
thioridazine,Pleiotropic ABC efflux transporter of multiple drugs,PDR5,5.89,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
thioridazine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,5.89,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
topotecan,Multidrug and toxin extrusion protein 1,SLC47A1,5.89,IC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
trimetazidine,"Carnitine O-palmitoyltransferase 1, muscle isoform",Cpt1b,5.89,IC50,COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1
voglibose,"Maltase-glucoamylase, intestinal",MGAM,5.89,IC50,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
ximelagatran,Vitamin K-dependent protein C,PROC,5.89,IC50,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
zafirlukast,Multidrug and toxin extrusion protein 1,SLC47A1,5.89,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
somatostatin,Somatostatin receptor,Sstr5|Sstr1|Sstr2|Sstr3|Sstr4,5.89,IC50,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
evans blue,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,5.89,IC50,CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O
linoleic acid,Free fatty acid receptor 4,FFAR4,5.89,EC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
ruboxistaurin,Tyrosine-protein kinase Lck,LCK,5.89,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Death-associated protein kinase 3,DAPK3,5.89,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Ribosomal protein S6 kinase alpha-5,RPS6KA5,5.89,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
triclosan,Enoyl-[acyl-carrier-protein] reductase [NADH],fabI,5.89,IC50,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
diperodon,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.89,IC50,O=C(NC1=CC=CC=C1)OCC(CN1CCCCC1)OC(=O)NC1=CC=CC=C1
dronabinol,Glycine receptor subunit alpha-1,GLRA1,5.89,EC50,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
pazopanib,Cyclin-dependent kinase 11A,CDK11A,5.89,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
paliperidone,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.89,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
retigabine,Potassium voltage-gated channel subfamily KQT member 2,Kcnq2,5.89,EC50,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
crizotinib,Tyrosine-protein kinase Fyn,FYN,5.89,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,5.89,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase SBK1,SBK1,5.89,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase PAK 7,PAK5,5.89,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase TAO1,TAOK1,5.89,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase SIK3,SIK3,5.89,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase SBK1,SBK1,5.89,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,5.89,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,NUAK family SNF1-like kinase 2,NUAK2,5.89,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,5.89,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
afatinib,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,5.89,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Casein kinase I isoform epsilon,CSNK1E,5.89,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Mitogen-activated protein kinase 14,MAPK14,5.89,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
afatinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,5.89,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,5.89,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Dual specificity mitogen-activated protein kinase kinase 6,MAP2K6,5.89,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase TAO1,TAOK1,5.89,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dequalinium,Small conductance calcium-activated potassium channel protein 3,KCNN3,5.89,IC50,CC1=[N+](CCCCCCCCCC[N+]2=C(C)C=C(N)C3=CC=CC=C23)C2=CC=CC=C2C(N)=C1
paliperidone palmitate,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.89,IC50,CCCCCCCCCCCCCCCC(=O)OC1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=C3C=CC(F)=C4)=C(C)N=C12
ceritinib,Mast/stem cell growth factor receptor Kit,KIT,5.89,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Casein kinase I isoform delta,CSNK1D,5.89,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase PAK 7,PAK5,5.89,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Cyclin-dependent kinase-like 2,CDKL2,5.89,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase OSR1,OXSR1,5.89,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Homeodomain-interacting protein kinase 1,HIPK1,5.89,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
niraparib,Poly [ADP-ribose] polymerase 3,PARP3,5.89,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
midostaurin,Ribosomal protein S6 kinase beta-1,RPS6KB1,5.89,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase Chk1,CHEK1,5.89,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase ULK3,ULK3,5.89,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Wee1-like protein kinase 2,WEE2,5.89,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Testis-specific serine/threonine-protein kinase 1,TSSK1B,5.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase tousled-like 1,TLK1,5.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,5.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Cyclin-dependent kinase-like 2,CDKL2,5.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Homeodomain-interacting protein kinase 3,HIPK3,5.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,5.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase TAO1,TAOK1,5.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
labetalol,Sodium-dependent dopamine transporter,SLC6A3,5.894,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
tolnaftate,5-hydroxytryptamine receptor 2B,HTR2B,5.894,Ki,CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC(C)=CC=C1
montelukast,Substance-K receptor,TACR2,5.895,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
clomifene,Muscarinic acetylcholine receptor M5,CHRM5,5.896,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
trazodone,D(3) dopamine receptor,DRD3,5.896,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
dexfenfluramine,5-hydroxytryptamine receptor 1D,HTR1D,5.898,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
cyproheptadine,5-hydroxytryptamine receptor 1B,Htr1b,5.899,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
iprindole,Sodium-dependent noradrenaline transporter,SLC6A2,5.899,Ki,CN(C)CCCN1C2=C(CCCCCC2)C2=CC=CC=C12
dithranol,Trypsin,,5.9,IC50,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2
cicaprost,Prostaglandin E2 receptor EP1 subtype,PTGER1,5.9,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
cicaprost,Prostaglandin E2 receptor EP2 subtype,Ptger2,5.9,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
cimetidine,Histamine H2 receptor,Hrh2,5.9,Ki,CNC(NCCSCC1=C(C)NC=N1)=NC#N
dapsone,Dihydropteroate synthase 1,folP1,5.9,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
dinoprost,Prostaglandin E2 receptor EP1 subtype,Ptger1,5.9,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dipyridamole,Equilibrative nucleoside transporter 4,SLC29A4,5.9,Ki,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
disulfiram,Monoglyceride lipase,MGLL,5.9,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
hydrochlorothiazide,Carbonic anhydrase 2,CA2,5.9,Ki,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
iloprost,Prostaglandin E2 receptor EP2 subtype,Ptger2,5.9,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
imipramine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.9,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
indoprofen,"Fatty acid-binding protein, liver",Fabp1,5.9,Ki,CC(C(O)=O)C1=CC=C(C=C1)N1CC2=C(C=CC=C2)C1=O
mitoxantrone,Tyrosine-protein kinase Fyn,FYN,5.9,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
nifedipine,Glycine receptor subunit beta,GLRB,5.9,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
olanzapine,5-hydroxytryptamine receptor 1A,HTR1A,5.9,Kd,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
phencyclidine,Glutamate NMDA receptor; GRIN1/GRIN2B,GRIN1|GRIN2B,5.9,IC50,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
phenylephrine,Alpha-1D adrenergic receptor,ADRA1D,5.9,IC50,CNC[C@H](O)C1=CC(O)=CC=C1
phenylephrine,Alpha-1B adrenergic receptor,ADRA1B,5.9,Ki,CNC[C@H](O)C1=CC(O)=CC=C1
piribedil,5-hydroxytryptamine receptor 2B,HTR2B,5.9,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
probenecid,Carbonic anhydrase 12,CA12,5.9,Ki,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
promazine,Histamine H1 receptor,Hrh1,5.9,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
pyrvinium,Synaptojanin-2,SYNJ2,5.9,IC50,CN(C)C1=CC=C2C(C=CC(\C=C\C3=C(C)N(C(C)=C3)C3=CC=CC=C3)=[N+]2C)=C1
quetiapine,5-hydroxytryptamine receptor 1E,HTR1E,5.9,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
risperidone,5-hydroxytryptamine receptor 1F,HTR1F,5.9,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
risperidone,5-hydroxytryptamine receptor 1E,HTR1E,5.9,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
rosuvastatin,Phosphodiesterase 6D,PDE6D,5.9,Kd,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
talipexole,Alpha-1D adrenergic receptor,ADRA1D,5.9,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
thioridazine,Sodium-dependent serotonin transporter,SLC6A4,5.9,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tiaprofenic acid,Prostaglandin G/H synthase 1,PTGS1,5.9,IC50,CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1
alimemazine,FAD-linked sulfhydryl oxidase ALR,GFER,5.9,AC50,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
cloxiquine,Methionine aminopeptidase 2,METAP2,5.9,IC50,OC1=C2N=CC=CC2=C(Cl)C=C1
octopamine,Trace amine-associated receptor 1,Taar1,5.9,EC50,NCC(O)C1=CC=C(O)C=C1
quercetin,Myeloperoxidase,MPO,5.9,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Lysine-specific histone demethylase 1A,KDM1A,5.9,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Lysine-specific histone demethylase 1A,KDM1A,5.9,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
xanomeline,5-hydroxytryptamine receptor 6,HTR6,5.9,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
yohimbine,5-hydroxytryptamine receptor 1E,HTR1E,5.9,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
romidepsin,Histone deacetylase 7,HDAC7,5.9,Ki,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
ceritinib,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.9,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
ceritinib,Tyrosine-protein kinase ABL1,ABL1,5.9,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
ceritinib,Rho-associated protein kinase 2,ROCK2,5.9,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
olaparib,Poly [ADP-ribose] polymerase 10,PARP10,5.9,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
cannabidiol,Cannabinoid receptor 1,Cnr1,5.9,Ki,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
estradiol benzoate,Progesterone receptor,PGR,5.902,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
diethylstilbestrol,Adenosine receptor A3,ADORA3,5.904,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
metoclopramide,5-hydroxytryptamine receptor 2C,HTR2C,5.904,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
terconazole,Alpha-2B adrenergic receptor,ADRA2B,5.904,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
aripiprazole,5-hydroxytryptamine receptor 5A,HTR5A,5.906,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
escitalopram,Muscarinic acetylcholine receptor M1,CHRM1,5.906,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
fenofibrate,5-hydroxytryptamine receptor 2C,HTR2C,5.906,Ki,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
atropine,Histamine H1 receptor,HRH1,5.907,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
tamoxifen,Sodium-dependent serotonin transporter,SLC6A4,5.907,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
troglitazone,Mitogen-activated protein kinase 1,MAPK1,5.907,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
benzbromarone,Mitogen-activated protein kinase 14,MAPK14,5.908,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
promazine,D(1A) dopamine receptor,DRD1,5.909,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
trioxsalen,5-hydroxytryptamine receptor 2C,HTR2C,5.909,Ki,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1
apomorphine,5-hydroxytryptamine receptor 1D,HTR1D,5.91,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
bupropion,Sodium-dependent dopamine transporter,Slc6a3,5.91,IC50,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
chlorpromazine,Calmodulin,CALM1|CALM2|CALM3,5.91,Kd,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
ketoconazole,Cytochrome P450 11A1,Cyp11a1,5.91,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mefloquine,Adenosine receptor A1,ADORA1,5.91,Ki,O[C@H]([C@H]1CCCCN1)C1=CC(=NC2=C(C=CC=C12)C(F)(F)F)C(F)(F)F
nimesulide,Prostaglandin G/H synthase 2,PTGS2,5.91,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
quinidine,Cholinesterase,BCHE,5.91,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
tamoxifen,Estrogen receptor beta,ESR2,5.91,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tizanidine,Alpha-2C adrenergic receptor,ADRA2C,5.91,EC50,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
yohimbine,Alpha-1A adrenergic receptor,Adra1a,5.91,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
cytisine,Nicotinic acetylcholine receptor alpha 5 subunit,nAChRalpha5,5.91,Ki,O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12
hexachlorophene,Cytochrome P450 2C19,CYP2C19,5.911,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
amiodarone,Sodium-dependent serotonin transporter,SLC6A4,5.912,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
bithionol,Sodium-dependent noradrenaline transporter,SLC6A2,5.912,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
tamoxifen,Substance-K receptor,TACR2,5.913,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
dexchlorpheniramine,5-hydroxytryptamine receptor 2C,HTR2C,5.915,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
olanzapine,5-hydroxytryptamine receptor 5A,HTR5A,5.916,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
prochlorperazine,5-hydroxytryptamine receptor 1B,Htr1b,5.919,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
propranolol,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.919,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
aceclofenac,Transthyretin,TTR,5.92,Kd,OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
bortezomib,Chymase,CMA1,5.92,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
cefixime,"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1",PLCG1,5.92,IC50,NC1=NC(=CS1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
cefuroxime,Carbonic anhydrase 2,CA2,5.92,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C1=CC=CO1
cimetidine,Multidrug and toxin extrusion protein 1,SLC47A1,5.92,IC50,CNC(NCCSCC1=C(C)NC=N1)=NC#N
dasatinib,Serine/threonine-protein kinase 10,STK10,5.92,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Serine/threonine-protein kinase MRCK gamma,CDC42BPG,5.92,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Serine/threonine-protein kinase SBK1,SBK1,5.92,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
delavirdine,Reverse transcriptase,reverse transcriptas,5.92,IC50,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
dichlorphenamide,Carbonic anhydrase 2,CAN2,5.92,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
erlotinib,AP2-associated protein kinase 1,AAK1,5.92,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,ALK tyrosine kinase receptor,ALK,5.92,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,BMP-2-inducible protein kinase,BMP2K,5.92,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Serine/threonine-protein kinase SBK1,SBK1,5.92,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fluspirilene,Glycine receptor subunit alpha-1,GLRA1,5.92,EC50,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
gatifloxacin,DNA topoisomerase 4 subunit A,parC,5.92,IC50,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1
gefitinib,Tyrosine-protein kinase Blk,BLK,5.92,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Ribosomal protein S6 kinase alpha-4,RPS6KA4,5.92,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
haloperidol,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,5.92,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,5.92,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hydralazine,Lactoperoxidase,LPO,5.92,IC50,NNC1=NN=CC2=CC=CC=C12
imatinib,Interleukin-1 receptor-associated kinase 1,IRAK1,5.92,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
levorphanol,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,5.92,IC50,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
medroxyprogesterone,Mineralocorticoid receptor,NR3C2,5.92,IC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
mosapride,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,5.92,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
naproxen,Hormone-sensitive lipase,Lipe,5.92,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
nicotinamide,NAD-dependent protein deacetylase sirtuin-2,SIRT2,5.92,IC50,NC(=O)C1=CN=CC=C1
nifedipine,Cholinesterase,BCHE,5.92,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
ondansetron,5-hydroxytryptamine receptor 4,Htr4,5.92,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
pentamidine,Alpha-1A adrenergic receptor,Adra1a,5.92,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pentamidine,Solute carrier family 22 member 2,SLC22A2,5.92,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
phenolphthalein,Thymidylate synthase,TYMS,5.92,Ki,OC1=CC=C(C=C1)C1(OC(=O)C2=C1C=CC=C2)C1=CC=C(O)C=C1
propranolol,5-hydroxytryptamine receptor 2C,HTR2C,5.92,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
ropinirole,Alpha-2C adrenergic receptor,ADRA2C,5.92,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sildenafil,Multidrug resistance-associated protein 5,ABCC5,5.92,Ki,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sulindac,Prostaglandin G/H synthase 1,PTGS1,5.92,IC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
sulpiride,Carbonic anhydrase 1,CA1,5.92,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sunitinib,Tyrosine-protein kinase JAK3,JAK3,5.92,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Hepatocyte growth factor receptor,MET,5.92,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ephrin type-A receptor 5,EPHA5,5.92,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Cyclin-dependent kinase 17,CDK17,5.92,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase MARK1,MARK1,5.92,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
testosterone,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.92,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
tolrestat,Alcohol dehydrogenase [NADP(+)],Akr1a1,5.92,IC50,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
evans blue,Tyrosine-protein phosphatase 1,PTP1,5.92,IC50,CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O
quercetin,Focal adhesion kinase 1,PTK2,5.92,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
quercetin,Xanthine dehydrogenase/oxidase,XDH,5.92,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,SRSF protein kinase 1,SRPK1,5.92,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
rutoside,Neuromedin-U receptor 2,NMUR2,5.92,EC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
tipranavir,CAAX prenyl protease 1 homolog,Zmpste24,5.92,IC50,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC(NS(=O)(=O)C3=CC=C(C=N3)C(F)(F)F)=CC=C2)C(=O)O1
androstanolone,Corticosteroid-binding globulin,SERPINA6,5.92,Ki,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
pazopanib,Tyrosine-protein kinase Lck,LCK,5.92,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Cyclin-dependent kinase 16,CDK16,5.92,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Macrophage colony-stimulating factor 1 receptor,CSF1R,5.92,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Interleukin-1 receptor-associated kinase 1,IRAK1,5.92,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Serine/threonine-protein kinase TAO1,TAOK1,5.92,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,5.92,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Homeodomain-interacting protein kinase 3,HIPK3,5.92,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase RIO2,RIOK2,5.92,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Homeodomain-interacting protein kinase 1,HIPK1,5.92,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,AP2-associated protein kinase 1,AAK1,5.92,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Serine/threonine-protein kinase 10,STK10,5.92,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Tyrosine-protein kinase ITK/TSK,ITK,5.92,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Serine/threonine-protein kinase RIO1,RIOK1,5.92,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,5.92,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,Carbonic anhydrase 13,CA13,5.92,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
bosutinib,Tyrosine-protein kinase JAK3,JAK3,5.92,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Ribosomal protein S6 kinase alpha-3,RPS6KA3,5.92,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,BDNF/NT-3 growth factors receptor,NTRK2,5.92,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Cyclin-dependent kinase 7,CDK7,5.92,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase ULK1,ULK1,5.92,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
paraoxon,Cannabinoid receptor 1,Cnr1,5.92,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
paraoxon,Monoglyceride lipase,Mgll,5.92,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
tofacitinib,Calcium/calmodulin-dependent protein kinase type 1,CAMK1,5.92,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
tofacitinib,Serine/threonine-protein kinase N2,PKN2,5.92,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
tofacitinib,Myotonin-protein kinase,DMPK,5.92,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
tofacitinib,Tyrosine-protein kinase JAK3,Jak3,5.92,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Ephrin type-A receptor 1,EPHA1,5.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Tyrosine-protein kinase Fes/Fps,FES,5.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,G protein-coupled receptor kinase 7,GRK7,5.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Homeodomain-interacting protein kinase 4,HIPK4,5.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Calcium-dependent protein kinase 1,CPK1,5.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Proto-oncogene tyrosine-protein kinase Src,SRC,5.92,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Tyrosine-protein kinase Fer,FER,5.92,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase RIO1,RIOK1,5.92,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase BRSK1,BRSK1,5.92,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
alpelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",PIK3CB,5.92,IC50,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F
quizartinib,Ephrin type-B receptor 6,EPHB6,5.92,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,5.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Protein-tyrosine kinase 6,PTK6,5.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase PAK 7,PAK5,5.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase 6,MAPK6,5.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Interleukin-1 receptor-associated kinase 4,IRAK4,5.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase/endoribonuclease IRE1,ERN1,5.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Nek11,NEK11,5.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Calcium-dependent protein kinase 1,CPK1,5.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
dibekacin,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",mphB,5.921,Km,NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1
nitrendipine,Transthyretin,TTR,5.921,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
nortriptyline,Sodium-dependent dopamine transporter,SLC6A3,5.921,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
dihydroergotamine,D(1A) dopamine receptor,DRD1,5.922,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
miconazole,Delta-type opioid receptor,OPRD1,5.923,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
tamoxifen,Tyrosine-protein kinase Fyn,FYN,5.923,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
pramipexole,5-hydroxytryptamine receptor 7,HTR7,5.925,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
oxiconazole,5-hydroxytryptamine receptor 2A,HTR2A,5.925,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
benzatropine,Histamine H2 receptor,HRH2,5.926,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
guanfacine,Alpha-2B adrenergic receptor,ADRA2B,5.926,EC50,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
raloxifene,Adenosine receptor A2a,ADORA2A,5.926,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
protriptyline,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.928,IC50,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
chloroxylenol,5-hydroxytryptamine receptor 2B,HTR2B,5.928,Ki,CC1=CC(O)=CC(C)=C1Cl
guanabenz,5-hydroxytryptamine receptor 1A,HTR1A,5.928,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
dapiprazole,5-hydroxytryptamine receptor 1A,HTR1A,5.929,Ki,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
atenolol,Beta-2 adrenergic receptor,Adrb2,5.93,Kd,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
celecoxib,Histone deacetylase 1,HDAC1,5.93,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
flurbiprofen,"Fatty acid-binding protein, liver",Fabp1,5.93,Ki,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
fluspirilene,5-hydroxytryptamine receptor 6,HTR6,5.93,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
glutamic acid,Metabotropic glutamate receptor 7,GRM7,5.93,EC50,N[C@@H](CCC(O)=O)C(O)=O
medetomidine,Adrenergic receptor alpha-1,ADRA1D|ADRA1A|ADRA1B,5.93,EC50,CC(C1=CNC=N1)C1=C(C)C(C)=CC=C1
nomifensine,5-hydroxytryptamine receptor 1A,HTR1A,5.93,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
pramipexole,5-hydroxytryptamine receptor 2A,HTR2A,5.93,EC50,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
sorafenib,5-hydroxytryptamine receptor 1A,HTR1A,5.93,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
quercetin,Casein kinase II subunit alpha,CSNK2A1,5.93,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
esatenolol,Beta-2 adrenergic receptor,Adrb2,5.93,Kd,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
ipragliflozin,Sodium/glucose cotransporter 1,Slc5a1,5.93,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC3=C(S2)C=CC=C3)=C(F)C=C1
citalopram,5-hydroxytryptamine receptor 2B,HTR2B,5.931,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
loperamide,Sodium-dependent serotonin transporter,SLC6A4,5.932,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
betamethasone phosphate,Histamine H1 receptor,HRH1,5.932,Ki,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
benzethonium,Alpha-2A adrenergic receptor,ADRA2A,5.934,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
econazole,Muscarinic acetylcholine receptor M2,CHRM2,5.936,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
quetiapine,Membrane-associated progesterone receptor component 1,Pgrmc1,5.936,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
tafamidis,ATP-binding cassette sub-family G member 2,ABCG2,5.936,IC50,OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1
clomipramine,Membrane-associated progesterone receptor component 1,Pgrmc1,5.937,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
latamoxef,Peptidoglycan synthase FtsI,ftsI,5.938,IC50,CO[C@]1(NC(=O)C(C(O)=O)C2=CC=C(O)C=C2)[C@H]2OCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
econazole,5-hydroxytryptamine receptor 2A,HTR2A,5.939,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ethacrynic acid,Aldose reductase,Akr1b1,5.939,IC50,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
methapyrilene,Muscarinic acetylcholine receptor M1,CHRM1,5.939,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
salbutamol,Beta-2 adrenergic receptor,Adrb2,5.94,Kd,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
benperidol,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.94,EC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2
benzbromarone,5-hydroxytryptamine receptor 2B,HTR2B,5.94,Ki,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
bisoprolol,Beta-2 adrenergic receptor,ADRB2,5.94,Ki,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
bortezomib,Carbonic anhydrase 2,CA2,5.94,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
estradiol benzoate,Sex hormone-binding globulin,SHBG,5.94,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
ouabain,Signal transducer and activator of transcription 3,STAT3,5.94,IC50,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O
pentamidine,Suppressor of tumorigenicity 14 protein,ST14,5.94,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pioglitazone,Peroxisome proliferator-activated receptor alpha,Ppara,5.94,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
pioglitazone,Peroxisome proliferator-activated receptor alpha,Ppara,5.94,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
spiperone,5-hydroxytryptamine receptor 2C,HTR2C,5.94,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
tirilazad,Alpha-2C adrenergic receptor,ADRA2C,5.94,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
crizotinib,Tyrosine-protein kinase ABL1,Abl1,5.94,IC50,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
laropiprant,Prostaglandin E2 receptor EP1 subtype,PTGER1,5.94,Ki,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
ceritinib,Platelet-derived growth factor receptor alpha,PDGFRA,5.94,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
pitolisant,Histamine H1 receptor,HRH1,5.94,Ki,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
promethazine,Histamine H2 receptor,HRH2,5.941,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
clotrimazole,Progesterone receptor,PGR,5.942,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
tenoxicam,Prostaglandin G/H synthase 1,PTGS1,5.943,IC50,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
oxiconazole,Muscarinic acetylcholine receptor M1,CHRM1,5.943,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
gentian violet,Histamine H2 receptor,HRH2,5.945,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
haloperidol,Alpha-2A adrenergic receptor,ADRA2A,5.947,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
promethazine,5-hydroxytryptamine receptor 6,HTR6,5.948,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
stanozolol,Cytochrome P450 2C9,CYP2C9,5.948,IC50,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=NN5
salbutamol,Beta-2 adrenergic receptor,ADRB2,5.95,Ki,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
brimonidine,Alpha-1A adrenergic receptor,ADRA1A,5.95,EC50,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
nicorandil,ATP-sensitive inward rectifier potassium channel 1,KCNJ1,5.95,IC50,[O-][N+](=O)OCCNC(=O)C1=CN=CC=C1
nicotine,Neuronal acetylcholine receptor; alpha3/beta4,CHRNB4|CHRNA3,5.95,Ki,CN1CCC[C@H]1C1=CC=CN=C1
rivastigmine,Acetylcholinesterase,Ache,5.95,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
sulbactam,Beta-lactamase,adc-14,5.95,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulconazole,5-hydroxytryptamine receptor 2A,HTR2A,5.95,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
sapropterin,"Nitric oxide synthase, brain",NOS1,5.95,Kd,C[C@H](O)[C@H](O)[C@H]1CNC2=C(N1)C(=O)NC(N)=N2
ursodiol,CDGSH iron-sulfur domain-containing protein 1,CISD1,5.95,Ki,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
yohimbine,D(2) dopamine receptor,Drd2,5.95,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
fluspirilene,5-hydroxytryptamine receptor 1B,HTR1B,5.951,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
fluvoxamine,Sodium-dependent noradrenaline transporter,SLC6A2,5.951,Ki,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F
miconazole,5-hydroxytryptamine receptor 2A,HTR2A,5.952,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mepyramine,Alpha-2A adrenergic receptor,ADRA2A,5.952,Ki,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
tirilazad,Tyrosine-protein kinase Fyn,FYN,5.952,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
amisulpride,Alpha-2A adrenergic receptor,ADRA2A,5.953,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
bromhexine,Sodium-dependent serotonin transporter,SLC6A4,5.954,Ki,CN(CC1=C(N)C(Br)=CC(Br)=C1)C1CCCCC1
droperidol,Alpha-2A adrenergic receptor,ADRA2A,5.954,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
tacrine,Alpha-1D adrenergic receptor,ADRA1D,5.954,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
desloratadine,Sodium-dependent noradrenaline transporter,SLC6A2,5.956,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
prochlorperazine,Muscarinic acetylcholine receptor M2,CHRM2,5.956,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
disulfiram,D(4) dopamine receptor,DRD4,5.957,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
montelukast,Cytochrome P450 2C8,CYP2C8,5.958,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
alcuronium,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,5.959,Ki,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
floctafenine,Prostaglandin G/H synthase 2,PTGS2,5.959,IC50,OCC(O)COC(=O)C1=C(NC2=CC=NC3=C(C=CC=C23)C(F)(F)F)C=CC=C1
fluoxetine,Histamine H1 receptor,HRH1,5.959,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
mitoxantrone,DNA topoisomerase 2-alpha,TOP2A,5.959,IC90,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
empagliflozin,Sodium/glucose cotransporter 5,SLC5A10,5.959,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1
pemafibrate,Peroxisome proliferator-activated receptor gamma,PPARG,5.959,EC50,CC[C@@H](OC1=CC=CC(CN(CCCOC2=CC=C(OC)C=C2)C2=NC3=C(O2)C=CC=C3)=C1)C(O)=O
adapalene,Retinoic acid receptor alpha,RARA,5.96,Ki,COC1=CC=C(C=C1C12CC3CC(CC(C3)C1)C2)C1=CC=C2C=C(C=CC2=C1)C(O)=O
amoxicillin,5-hydroxytryptamine receptor 2B,HTR2B,5.96,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O
beclometasone dipropionate,Androgen receptor,Ar,5.96,Ki,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
diphenidol,D(2) dopamine receptor,DRD2,5.96,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
benzyl benzoate,Hormone-sensitive lipase,Lipe,5.96,IC50,O=C(OCC1=CC=CC=C1)C1=CC=CC=C1
carbachol,Neuronal acetylcholine receptor; alpha3/beta2,Chrna3|Chrnb2,5.96,Ki,C[N+](C)(C)CCOC(N)=O
celecoxib,Prostaglandin G/H synthase 2,Ptgs2,5.96,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorphenamine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.96,IC50,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
clemizole,Short transient receptor potential channel 5,TRPC5,5.96,IC50,ClC1=CC=C(CN2C(CN3CCCC3)=NC3=C2C=CC=C3)C=C1
prasterone,Glucose-6-phosphate 1-dehydrogenase,g6pd,5.96,Ki,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O
dicloxacillin,Muscarinic acetylcholine receptor M1,CHRM1,5.96,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
ditiocarb,Carbonic anhydrase 12,CA12,5.96,Ki,CCN(CC)C(S)=S
doxorubicin,72 kDa type IV collagenase,MMP2,5.96,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
ebastine,Muscarinic acetylcholine receptor M1,CHRM1,5.96,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
epinastine,Multidrug and toxin extrusion protein 1,SLC47A1,5.96,IC50,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
epinephrine,Beta-1 adrenergic receptor,Adrb1,5.96,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
erlotinib,Hepatocyte growth factor receptor,MET,5.96,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Tyrosine-protein kinase Fgr,FGR,5.96,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Ephrin type-B receptor 1,EPHB1,5.96,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Receptor tyrosine-protein kinase erbB-3,ERBB3,5.96,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
flunarizine,Alpha-1A adrenergic receptor,Adra1a,5.96,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
gefitinib,ATP-binding cassette sub-family G member 2,ABCG2,5.96,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.96,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,"Glutamate receptor ionotropic, kainate 2",GRIK2,5.96,Ki,N[C@@H](CCC(O)=O)C(O)=O
ibuprofen,Prostaglandin G/H synthase 2,PTGS2,5.96,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
ibuprofen,Solute carrier family 22 member 20,Slc22a20,5.96,Ki,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
lapatinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,5.96,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
lovastatin,Cholinesterase,BCHE,5.96,Ki,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
medetomidine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.96,Ki,CC(C1=CNC=N1)C1=C(C)C(C)=CC=C1
methadone,Delta-type opioid receptor,OPRD1,5.96,IC50,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
molindone,Alpha-2A adrenergic receptor,ADRA2A,5.96,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
nilotinib,Tyrosine-protein kinase Yes,YES1,5.96,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
oxametacin,Cyclooxygenase,Ptgs2|Ptgs1,5.96,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)NO
oxycodone,Delta-type opioid receptor,Oprd1,5.96,Ki,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
pemetrexed,Thymidylate synthase,thyA,5.96,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
phencyclidine,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.96,Ki,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
propafenone,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.96,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
mepyramine,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.96,IC50,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
rifampicin,Solute carrier organic anion transporter family member 1B1,SLCO1B1,5.96,Ki,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
rosiglitazone,CDGSH iron-sulfur domain-containing protein 1,Cisd1,5.96,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sorafenib,Homeodomain-interacting protein kinase 1,HIPK1,5.96,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Tyrosine-protein kinase Fer,FER,5.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Wee1-like protein kinase,WEE1,5.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase BRSK2,BRSK2,5.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Cyclin-dependent kinase-like 2,CDKL2,5.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
suprofen,Prostaglandin G/H synthase 1,PTGS1,5.96,IC50,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
tetracaine,Sodium channel protein type 2 subunit alpha,SCN2A,5.96,IC50,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
thiethylperazine,FAD-linked sulfhydryl oxidase ALR,GFER,5.96,AC50,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
tranexamic acid,Plasminogen,PLG,5.96,Kd,NC[C@H]1CC[C@@H](CC1)C(O)=O
valdecoxib,Cytochrome c oxidase subunit 2,MT-CO2,5.96,IC50,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
vesnarinone,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.96,IC50,COC1=C(OC)C=C(C=C1)C(=O)N1CCN(CC1)C1=CC=C2NC(=O)CCC2=C1
zoledronic acid,Farnesyl diphosphate synthase,ispA,5.96,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
suramin,NAD-dependent protein deacetylase sirtuin-2,SIRT2,5.96,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
eicosapentaenoic acid,Peroxisome proliferator-activated receptor alpha,PPARA,5.96,IC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
ruboxistaurin,Cyclin-G-associated kinase,GAK,5.96,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Calcium/calmodulin-dependent protein kinase kinase 2,CAMKK2,5.96,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,SRSF protein kinase 2,SRPK2,5.96,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,5.96,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
thiram,Histone-lysine N-methyltransferase EHMT1,EHMT1,5.96,IC50,CN(C)C(=S)SSC(=S)N(C)C
tramazoline,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,5.96,IC50,C1CN=C(NC2=C3CCCCC3=CC=C2)N1
alitretinoin,Oxysterols receptor LXR-alpha,NR1H3,5.96,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
minodronic acid,Farnesyl diphosphate synthase,ispA,5.96,IC50,OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O
romidepsin,Histone deacetylase 9,HDAC9,5.96,Ki,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
romidepsin,Histone deacetylase,HDAC3|HDAC4|HDAC1|HDAC7|HDAC2|HDAC10|HDAC11|HDAC8|HDAC6|HDAC9|HDAC5,5.96,Ki,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
boceprevir,Cathepsin F,CTSF,5.96,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
vandetanib,Ephrin type-A receptor 2,EPHA2,5.96,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,5.96,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Fibroblast growth factor receptor 2,FGFR2,5.96,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,5.96,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,AarF domain-containing protein kinase 4,COQ8B,5.96,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,"Interferon-induced, double-stranded RNA-activated protein kinase",EIF2AK2,5.96,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Mitogen-activated protein kinase kinase kinase 1,MAP3K1,5.96,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Tyrosine-protein kinase ABL1,ABL1,5.96,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Mitogen-activated protein kinase kinase kinase 15,MAP3K15,5.96,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase Nek3,NEK3,5.96,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Mitogen-activated protein kinase 10,MAPK10,5.96,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Tyrosine-protein kinase CSK,CSK,5.96,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Tyrosine-protein kinase JAK2,JAK2,5.96,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Ephrin type-A receptor 6,EPHA6,5.96,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
stearic acid,Peroxisome proliferator-activated receptor alpha,PPARA,5.96,IC50,CCCCCCCCCCCCCCCCCC(O)=O
tofacitinib,Tyrosine-protein kinase Fyn,FYN,5.96,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
ibrutinib,Potassium voltage-gated channel subfamily H member 2,KCNH2,5.96,Ki,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
nintedanib,Ephrin type-B receptor 4,EPHB4,5.96,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase 33,STK33,5.96,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,5.96,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,5.96,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase LATS1,LATS1,5.96,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase 17B,STK17B,5.96,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Serine/threonine-protein kinase D2,PRKD2,5.96,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Tyrosine-protein kinase Fer,FER,5.96,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase N1,PKN1,5.96,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,TGF-beta receptor type-2,TGFBR2,5.96,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,"Interferon-induced, double-stranded RNA-activated protein kinase",EIF2AK2,5.96,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ponesimod,Sphingosine 1-phosphate receptor 4,S1PR4,5.96,EC50,CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
infigratinib,Tyrosine-protein kinase Yes,YES1,5.96,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Tyrosine-protein kinase Yes,YES1,5.96,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
fluphenazine enanthate,Muscarinic acetylcholine receptor M1,CHRM1,5.961,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
perhexiline,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.962,Ki,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
sibutramine,Alpha-2B adrenergic receptor,ADRA2B,5.962,Ki,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
budesonide,Androgen receptor,Ar,5.963,Ki,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
suramin,P2X purinoceptor 3,P2RX3,5.963,Ki,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
miconazole,D(3) dopamine receptor,DRD3,5.964,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
suloctidil,Muscarinic acetylcholine receptor M1,CHRM1,5.965,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
benzethonium,Sodium-dependent dopamine transporter,SLC6A3,5.965,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
desloratadine,Histamine H2 receptor,HRH2,5.967,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
disulfiram,D(1A) dopamine receptor,DRD1,5.967,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
amiodarone,Muscarinic acetylcholine receptor M5,CHRM5,5.968,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
oxiconazole,Substance-K receptor,TACR2,5.969,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
aripiprazole,Sodium-dependent serotonin transporter,Slc6a4,5.97,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
atomoxetine,Sodium-dependent dopamine transporter,SLC6A3,5.97,Kd,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
cinnarizine,5-hydroxytryptamine receptor 1A,Htr1a,5.97,IC50,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
emetine,Alpha-1B adrenergic receptor,Adra1b,5.97,Ki,CC[C@H]1CN2CCC3=CC(OC)=C(OC)C=C3[C@@H]2C[C@@H]1C[C@H]1NCCC2=CC(OC)=C(OC)C=C12
moclobemide,Amine oxidase [flavin-containing] B,MAOB,5.97,Ki,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
moclobemide,Amine oxidase [flavin-containing] B,Maob,5.97,Ki,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
prenalterol,Beta-2 adrenergic receptor,ADRB2,5.97,Kd,CC(C)NC[C@H](O)COC1=CC=C(O)C=C1
dicoumarol,Cytochrome P450 2C9,CYP2C9,5.971,Ki,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
niflumic acid,Prostaglandin G/H synthase 1,PTGS1,5.973,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
chlorphenamine,Sodium-dependent dopamine transporter,SLC6A3,5.975,Kd,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
venlafaxine,Sodium-dependent noradrenaline transporter,SLC6A2,5.975,Kd,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
gentian violet,D(2) dopamine receptor,DRD2,5.975,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
benzbromarone,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,5.976,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
dobutamine,Sigma non-opioid intracellular receptor 1,SIGMAR1,5.976,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
ebastine,Receptor tyrosine-protein kinase erbB-2,ERBB2,5.976,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
sulconazole,D(3) dopamine receptor,DRD3,5.977,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
dexchlorpheniramine,5-hydroxytryptamine receptor 2A,HTR2A,5.977,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
clomifene,Epidermal growth factor receptor,EGFR,5.979,IC50,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
hydroxychloroquine,Muscarinic acetylcholine receptor M2,CHRM2,5.979,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
metoclopramide,5-hydroxytryptamine receptor 2A,HTR2A,5.979,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
fesoterodine,Muscarinic acetylcholine receptor M5,CHRM5,5.979,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
nefazodone,Acetylcholinesterase,ACHE,5.98,IC50,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
pergolide,Alpha-1A adrenergic receptor,ADRA1A,5.98,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
promazine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,5.98,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
salmeterol,D(3) dopamine receptor,DRD3,5.98,Ki,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
tamoxifen,5-hydroxytryptamine receptor 6,HTR6,5.98,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
podophyllotoxin,Regulatory protein E2,E2,5.98,Kd,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
thiram,Protein-lysine 6-oxidase,LOX,5.98,IC50,CN(C)C(=S)SSC(=S)N(C)C
xylometazoline,Alpha-2B adrenergic receptor,ADRA2B,5.98,Ki,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
indacaterol,D(3) dopamine receptor,DRD3,5.98,Ki,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2
cefiderocol,Penicillin-binding protein 1A,ponA,5.98,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
cevimeline,Muscarinic acetylcholine receptor M2,CHRM2,5.983,EC50,CC1OC2(CS1)CN1CCC2CC1
domperidone,Alpha-2A adrenergic receptor,ADRA2A,5.988,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
amiodarone,5-hydroxytryptamine receptor 2A,HTR2A,5.989,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
chlorpromazine,FAD-linked sulfhydryl oxidase ALR,GFER,5.99,AC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cinnarizine,Alpha-2B adrenergic receptor,ADRA2B,5.99,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
clonidine,Alpha-1B adrenergic receptor,Adra1b,5.99,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
cycloguanil,Dihydrofolate reductase,dfrA17,5.99,Ki,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1
ethoxzolamide,Beta-carbonic anhydrase 1,mtcA1,5.99,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
spiperone,Vesicular acetylcholine transporter,Slc18a3,5.99,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sultiame,Carbonic anhydrase,NCE103,5.99,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
bietamiverine,Muscarinic acetylcholine receptor M2,CHRM2,5.99,Ki,CCN(CC)CCOC(=O)C(N1CCCCC1)C1=CC=CC=C1
benzydamine,Soluble guanylate cyclase,GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3,5.99,EC50,CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=C1C=CC=C2
paraoxon,Carbonic anhydrase 13,Ca13,5.99,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
fedratinib,Tyrosine-protein kinase JAK3,JAK3,5.99,IC50,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ebastine,5-hydroxytryptamine receptor 6,HTR6,5.991,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
lisuride,Histamine H2 receptor,HRH2,5.991,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
metoclopramide,Alpha-2A adrenergic receptor,ADRA2A,5.991,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
paliperidone,5-hydroxytryptamine receptor 1E,HTR1E,5.991,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
monobenzone,Prostaglandin G/H synthase 1,PTGS1,5.992,IC50,OC1=CC=C(OCC2=CC=CC=C2)C=C1
pipamazine,5-hydroxytryptamine receptor 1A,HTR1A,5.992,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
cyclizine,D(3) dopamine receptor,DRD3,5.993,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
hexachlorophene,Alpha-2C adrenergic receptor,ADRA2C,5.994,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
mepacrine,Alpha-1D adrenergic receptor,ADRA1D,5.994,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
desloratadine,5-hydroxytryptamine receptor 6,HTR6,5.997,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
dobutamine,Sodium-dependent serotonin transporter,SLC6A4,5.997,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
molindone,5-hydroxytryptamine receptor 6,HTR6,5.997,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
fluphenazine,Muscarinic acetylcholine receptor M3,CHRM3,5.999,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
haloperidol,Histamine H2 receptor,HRH2,5.999,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
(S)-nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,6,IC50,CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
(S)-nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,6,IC50,CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
(S)-nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1S,Cacna1s,6,IC50,CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
acarbose,Alpha-amylase 1,AMY1A,6,IC50,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
adenosine,Adenosine kinase,ADK,6,IC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
adenosine triphosphate,P2X purinoceptor 4,P2rx4,6,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adenosine triphosphate,P2X purinoceptor 6,P2rx6,6,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adenosine triphosphate,P2X purinoceptor 5,P2rx5,6,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
ajmaline,Cytochrome P450 2D6,CYP2D6,6,IC50,CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H]([C@H]2[C@H]4O)N3[C@@H]1O
allopurinol,Xanthine dehydrogenase/oxidase,XDH,6,Ki,OC1=NC=NC2=C1C=NN2
alfacalcidol,Sodium-dependent noradrenaline transporter,SLC6A2,6,Ki,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
amiloride,Sodium/hydrogen exchanger 1,Slc9a1,6,Ki,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
amiloride,Sodium/hydrogen exchanger 2,SLC9A2,6,Ki,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
amineptine,Sodium-dependent dopamine transporter,Slc6a3,6,IC50,OC(=O)CCCCCCNC1C2=CC=CC=C2CCC2=CC=CC=C12
amiodarone,Potassium voltage-gated channel subfamily A member 7,KCNA7,6,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amitriptyline,Sodium channel protein type 9 subunit alpha,SCN9A,6,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amitriptyline,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amlexanox,Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,6,IC50,CC(C)C1=CC=C2OC3=C(C=C(C(O)=O)C(N)=N3)C(=O)C2=C1
amlexanox,Serine/threonine-protein kinase TBK1,TBK1,6,IC50,CC(C)C1=CC=C2OC3=C(C=C(C(O)=O)C(N)=N3)C(=O)C2=C1
amfetamine,Sodium-dependent noradrenaline transporter,Slc6a2,6,IC50,CC(N)CC1=CC=CC=C1
amprenavir,Cytochrome P450 3A4,CYP3A4,6,IC50,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
astemizole,Calmodulin,CALM1|CALM2|CALM3,6,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
bepridil,Potassium channel subfamily T member 1,Kcnt1,6,IC50,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
bethanechol,Muscarinic receptor 2,GPM2,6,EC50,CC(C[N+](C)(C)C)OC(N)=O
bicalutamide,Cytochrome P450 2C19,CYP2C19,6,IC50,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
bupivacaine,Sodium channel protein type 4 subunit alpha,SCN4A,6,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
bupropion,Neuronal acetylcholine receptor; alpha3/beta2,CHRNB2|CHRNA3,6,IC50,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
buspirone,5-hydroxytryptamine receptor 2C,Htr2c,6,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
camostat,Transmembrane protease serine 2,TMPRSS2,6,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
celecoxib,Cytochrome P450 2D6,CYP2D6,6,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
ciprofloxacin,DNA topoisomerase 4 subunit A,parC,6,IC50,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
clozapine,5-hydroxytryptamine receptor 5A,HTR5A,6,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
ciclosporin,Sodium/bile acid cotransporter,SLC10A1,6,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
cyproheptadine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,6,IC50,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dasatinib,Tyrosine-protein kinase JAK2,JAK2,6,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,6,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexamfetamine,Trace amine-associated receptor 1,TAAR1,6,EC50,C[C@H](N)CC1=CC=CC=C1
diclofenac,Transthyretin,TTR,6,Kd,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dinoprost,Prostaglandin E2 receptor EP2 subtype,PTGER2,6,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dipyridamole,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,6,Ki,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
dipyridamole,"cAMP-specific 3',5'-cyclic phosphodiesterase 7B",PDE7B,6,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
doxorubicin,DNA topoisomerase 2-alpha,TOP2A,6,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
duloxetine,5-hydroxytryptamine receptor 2C,HTR2C,6,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
edatrexate,Dihydrofolate reductase,Dhfr,6,Ki,CCC(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
ergotamine,Cytochrome P450 3A4,CYP3A4,6,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
erlotinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,6,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Proto-oncogene tyrosine-protein kinase Src,SRC,6,IC50,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma,PIP4K2C,6,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
etidocaine,Sodium channel protein type 2 subunit alpha,Scn2a,6,IC50,CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
fendiline,Extracellular calcium-sensing receptor,CASR,6,EC50,CC(NCCC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1
fenofibrate,Peroxisome proliferator-activated receptor alpha,PPARA,6,IC50,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
finasteride,Cytochrome P450 2C19,CYP2C19,6,IC50,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
fludarabine phosphate,Ribonucleoside-diphosphate reductase large subunit,RRM1,6,IC50,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
fludarabine phosphate,Ribonucleoside-diphosphate reductase subunit M2,RRM2,6,IC50,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
flufenamic acid,Aldo-keto reductase family 1 member C2,AKR1C2,6,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
fluoxetine,Muscarinic acetylcholine receptor M3,CHRM3,6,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
fluphenazine,Muscarinic acetylcholine receptor M1,CHRM1,6,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
flurbiprofen,Prostaglandin G/H synthase 1,PTGS1,6,Ki,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
fluspirilene,5-hydroxytryptamine receptor 1D,HTR1D,6,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
gallamine,Acetylcholine receptor subunit alpha,CHRNA1,6,IC50,CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
gefitinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Tyrosine-protein kinase Lyn,LYN,6,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
histamine,Histamine H2 receptor,HRH2,6,EC50,NCCC1=CN=CN1
hydroxychloroquine,Transmembrane protein 97,TMEM97,6,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
hymecromone,Testosterone 17-beta-dehydrogenase 3,HSD17B3,6,IC50,CC1=CC(=O)OC2=C1C=CC(O)=C2
ifenprodil,Histamine H1 receptor,HRH1,6,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
imatinib,Cyclin-G-associated kinase,GAK,6,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indomethacin,Prostaglandin D2 receptor 2,Ptgdr2,6,Ki,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
isoetarine,Beta-2 adrenergic receptor,ADRB2,6,Kd,CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1
isoprenaline,Beta-2 adrenergic receptor,ADRB2,6,IC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
itraconazole,14-alpha sterol demethylase Cyp51A,,6,Kd,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ketoconazole,Multidrug resistance protein 1,ABCB1,6,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lovastatin,Nuclear receptor subfamily 1 group I member 2,NR1I2,6,EC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
loxapine,5-hydroxytryptamine receptor 2C,Htr2c,6,IC50,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
loxapine,Histamine H1 receptor,Hrh1,6,IC50,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
maprotiline,Sodium-dependent dopamine transporter,SLC6A3,6,Kd,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
meloxicam,Prostaglandin G/H synthase 1,PTGS1,6,IC50,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
menadione,"Indoleamine 2,3-dioxygenase 1",IDO1,6,IC50,CC1=CC(=O)C2=CC=CC=C2C1=O
naltrexone,Cytochrome P450 2D6,CYP2D6,6,IC50,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
metoclopramide,5-hydroxytryptamine receptor 4,HTR4,6,EC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
metoclopramide,5-hydroxytryptamine receptor 4,Htr4,6,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
mianserin,D(1A) dopamine receptor,DRD1,6,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
miconazole,Cytochrome P450 2D6,CYP2D6,6,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
midazolam,Cytochrome P450 3A4,CYP3A4,6,Km,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
miglitol,"Maltase-glucoamylase, intestinal",MGAM,6,Ki,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
milrinone,Uncharacterized protein,PDE3B,6,IC50,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
minocycline,30S ribosomal protein S4,rpsD,6,Ka,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(O)=CC=C4N(C)C)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
mitoxantrone,Tyrosine-protein kinase BTK,BTK,6,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
mosapride,Cytochrome P450 2C9,CYP2C9,6,IC50,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
mosapride,Cytochrome P450 2C19,CYP2C19,6,IC50,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
moxonidine,Alpha-2B adrenergic receptor,Adra2b,6,Ki,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1
nafamostat,Complement C1r subcomponent,C1R,6,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
naftopidil,Beta-2 adrenergic receptor,ADRB2,6,Ki,COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1
nalbuphine,Delta-type opioid receptor,OPRD1,6,Ki,O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5
nefazodone,Cytochrome P450 3A4,CYP3A4,6,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
neostigmine,Acetylcholinesterase,ache,6,Ki,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
nifedipine,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,6,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nilotinib,Angiopoietin-1 receptor,TEK,6,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Tyrosine-protein kinase receptor Tie-1,TIE1,6,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Ephrin type-B receptor 3,EPHB3,6,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nimodipine,Cytochrome P450 2C9,CYP2C9,6,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nimodipine,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,6,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nimodipine,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,6,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nisoldipine,Cytochrome P450 1A2,CYP1A2,6,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1F,CACNA1F,6,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,6,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1S,Cacna1s,6,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
nitroxoline,Prostaglandin G/H synthase 2,PTGS2,6,Ki,OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O
norepinephrine,Beta-1 adrenergic receptor,ADRB1,6,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
norepinephrine,Adrenergic receptor beta,Adrb2|Adrb1|Adrb3,6,IC50,NC[C@H](O)C1=CC(O)=C(O)C=C1
pantoprazole,Potassium-transporting ATPase,ATP4B|ATP4A,6,IC50,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
paroxetine,Cytochrome P450 2D6,CYP2D6,6,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
penfluridol,5-hydroxytryptamine receptor 6,HTR6,6,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
penfluridol,Histamine H1 receptor,HRH1,6,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
penfluridol,Histamine H2 receptor,HRH2,6,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
penfluridol,D(4) dopamine receptor,DRD4,6,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
penfluridol,Kappa-type opioid receptor,OPRK1,6,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
penfluridol,5-hydroxytryptamine receptor 5A,HTR5A,6,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
pentamidine,Protein S100-B,S100B,6,Kd,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
phenelzine,Cytochrome P450 2D6,CYP2D6,6,IC50,NNCCC1=CC=CC=C1
pimozide,Kappa-type opioid receptor,OPRK1,6,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pimozide,Multidrug resistance-associated protein 1,ABCC1,6,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pioglitazone,CDGSH iron-sulfur domain-containing protein 1,Cisd1,6,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
procainamide,Acetylcholinesterase,ACHE,6,Ki,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
procainamide,Acetylcholinesterase,ACHE,6,Ki,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
pyrvinium,Synaptojanin-1,SYNJ1,6,IC50,CN(C)C1=CC=C2C(C=CC(\C=C\C3=C(C)N(C(C)=C3)C3=CC=CC=C3)=[N+]2C)=C1
ribavirin,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,6,IC50,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
ribavirin,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,6,IC50,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
rotigotine,D(1B) dopamine receptor,DRD5,6,Ki,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
salicylic acid,High mobility group protein B1,HMGB1,6,Kd,OC(=O)C1=CC=CC=C1O
salmeterol,Beta-3 adrenergic receptor,ADRB3,6,EC50,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
sertraline,Cytochrome P450 2C19,CYP2C19,6,IC50,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
sorafenib,STE20-like serine/threonine-protein kinase,SLK,6,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiperone,5-hydroxytryptamine receptor 1D,HTR1D,6,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
spiperone,5-hydroxytryptamine receptor 2C,Htr2c,6,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sulbactam,Beta-lactamase,ampC,6,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sumatriptan,5-hydroxytryptamine receptor 7,HTR7,6,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Abelson tyrosine-protein kinase 2,ABL2,6,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrolimus,Potassium voltage-gated channel subfamily H member 2,KCNH2,6,IC50,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
tacrolimus,Cytochrome P450 3A4,CYP3A4,6,IC50,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
tretinoin,Retinoic acid receptor RXR-alpha,Rxra,6,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
trifluoperazine,Muscarinic acetylcholine receptor M3,CHRM3,6,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
trifluoperazine,Calmodulin,CALM1|CALM2|CALM3,6,Kd,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
trimethoprim,Bifunctional dihydrofolate reductase-thymidylate synthase,,6,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
tropicamide,Cytochrome P450 2C9,CYP2C9,6,IC50,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1
tropicamide,Cytochrome P450 2C19,CYP2C19,6,IC50,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1
verapamil,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,6,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
verapamil,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,6,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
vinorelbine,Cytochrome P450 3A4,CYP3A4,6,IC50,CCC1=C[C@@H]2C[N@](C1)CC1=C(NC3=C1C=CC=C3)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC
suramin,P2Y purinoceptor 11,P2RY11,6,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
suramin,P2X purinoceptor 1,P2rx1,6,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
bithionol,Potassium channel subfamily T member 1,Kcnt1,6,EC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
linoleic acid,"Fatty acid-binding protein, adipocyte",FABP4,6,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
linoleic acid,Seed linoleate 13S-lipoxygenase-1,LOX1.1,6,IC50,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
mitoguazone,S-adenosylmethionine decarboxylase proenzyme,Amd1,6,IC50,C\C(\C=N\NC(N)=N)=N/NC(N)=N
oxiconazole,Cytochrome P450 2D6,CYP2D6,6,IC50,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
podophyllotoxin,Tubulin,TUBB4A|TUBB|TUBA1B|TUBA4A|TUBB4B|TUBB3|TUBA3C|TUBB2A|TUBB8|TUBA3E|TUBA1A|TUBA1C|TUBB6|TUBB2B|TUBB1,6,IC50,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
quercetin,Aldose reductase,Akr1b1,6,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
xanomeline,D(2) dopamine receptor,DRD2,6,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
yohimbine,5-hydroxytryptamine receptor 5A,Htr5a,6,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
bropirimine,Xanthine dehydrogenase/oxidase,XDH,6,IC50,NC1=NC(=C(Br)C(=O)N1)C1=CC=CC=C1
velnacrine,Acetylcholinesterase,Ache,6,IC50,NC1=C2C(O)CCCC2=NC2=CC=CC=C12
dronabinol,Glycine receptor subunit alpha-2,GLRA2,6,EC50,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
pazopanib,Fibroblast growth factor receptor 1,FGFR1,6,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Bone morphogenetic protein receptor type-1B,BMPR1B,6,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
dexfosfoserine,Metabotropic glutamate receptor 4,GRM4,6,EC50,N[C@@H](COP(O)(O)=O)C(O)=O
boceprevir,Lysosomal protective protein,CTSA,6,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
vandetanib,Angiopoietin-1 receptor,TEK,6,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Ephrin type-A receptor 5,EPHA5,6,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase D1,PRKD1,6,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase 3,STK3,6,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,TGF-beta receptor type-1,TGFBR1,6,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase ULK1,ULK1,6,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,6,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Homeodomain-interacting protein kinase 2,HIPK2,6,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,BMP-2-inducible protein kinase,BMP2K,6,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,STE20-like serine/threonine-protein kinase,SLK,6,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
axitinib,Serine/threonine-protein kinase RIO3,RIOK3,6,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
doconexent,Free fatty acid receptor 1,FFAR1,6,EC50,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
bosutinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
eosin,Protein arginine N-methyltransferase 1,PRMT1,6,IC50,OC1=C(Br)C2=C(C=C1Br)C1(OC(=O)C3=C1C=CC=C3)C1=CC(Br)=C(O)C(Br)=C1O2
choline fenofibrate,"Fatty acid-binding protein, intestinal",FABP2,6,Ki,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O
racepinefrine,Alpha-1D adrenergic receptor,ADRA1D,6,Ki,CNCC(O)C1=CC(O)=C(O)C=C1
tenidap,Cytochrome P450 1A2,CYP1A2,6,IC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
nintedanib,Serine/threonine-protein kinase D1,PRKD1,6,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Rhodopsin kinase,GRK1,6,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase Sgk3,SGK3,6,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
acalabrutinib,Tyrosine-protein kinase Lyn,LYN,6,EC50,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
quizartinib,"Muscle, skeletal receptor tyrosine-protein kinase",MUSK,6,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Myotonin-protein kinase,DMPK,6,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Homeodomain-interacting protein kinase 2,HIPK2,6,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Eukaryotic translation initiation factor 2-alpha kinase 1,EIF2AK1,6,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
vericiguat,Guanylate cyclase soluble subunit beta-1,Gucy1b1,6,EC50,COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
mifepristone,Mu-type opioid receptor,OPRM1,6.001,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
nabumetone,Amine oxidase [flavin-containing] A,MAOA,6.001,IC50,COC1=CC=C2C=C(CCC(C)=O)C=CC2=C1
astemizole,Substance-K receptor,TACR2,6.002,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
dexfenfluramine,Beta-1 adrenergic receptor,ADRB1,6.002,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
thioridazine,Kappa-type opioid receptor,OPRK1,6.002,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
haloperidol,Mu-type opioid receptor,OPRM1,6.003,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
mianserin,Histamine H2 receptor,HRH2,6.003,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
fenfluramine,Beta-1 adrenergic receptor,ADRB1,6.004,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
alpha-Ergocryptine,Mu-type opioid receptor,OPRM1,6.007,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
desloratadine,Alpha-2B adrenergic receptor,ADRA2B,6.009,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
suloctidil,Muscarinic acetylcholine receptor M3,CHRM3,6.009,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
celecoxib,"Carbonic anhydrase, alpha family",,6.01,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chloramphenicol,Streptokinase A,ska,6.01,EC50,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
chlorpromazine,5-hydroxytryptamine receptor 3A,HTR3A,6.01,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cromoglicic acid,G protein-coupled receptor GPR35,Gpr35,6.01,EC50,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O
dasatinib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,6.01,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dopamine,Adenosine A2b receptor,Adora2b,6.01,Ki,NCCC1=CC(O)=C(O)C=C1
epinephrine,Alpha-1B adrenergic receptor,Adra1b,6.01,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
erlotinib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,6.01,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Tyrosine-protein kinase Mer,MERTK,6.01,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
gefitinib,Protein-tyrosine kinase 6,PTK6,6.01,IC50,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
hexylresorcinol,Polyphenol oxidase 2,PPO2,6.01,IC50,CCCCCCC1=C(O)C=C(O)C=C1
imatinib,Carbonic anhydrase 12,CA12,6.01,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
mafenide,Carbonic anhydrase 15,Ca15,6.01,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mafenide,Astrosclerin-3,,6.01,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mefenamic acid,Myeloperoxidase,MPO,6.01,IC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
nitroxoline,Bromodomain-containing protein 4,BRD4,6.01,IC50,OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O
nitroxoline,Bromodomain-containing protein 4,BRD4,6.01,IC50,OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O
phenylalanine,Voltage-dependent calcium channel subunit alpha-2/delta-1,Cacna2d1,6.01,Ki,N[C@@H](CC1=CC=CC=C1)C(O)=O
selegiline,Amine oxidase [flavin-containing] B,MAOB,6.01,Ki,C[C@H](CC1=CC=CC=C1)N(C)CC#C
sulfanilamide,Carbonic anhydrase 3,CA3,6.01,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Calcium/calmodulin-dependent protein kinase type 1,CAMK1,6.01,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 38-like,STK38L,6.01,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tadalafil,Phosphodiesterase 6,PDE6D|PDE6A|PDE6G|PDE6B|PDE6C|PDE6H,6.01,IC50,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
zolpidem,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,6.01,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
zolpidem,GABA A receptor alpha-6/beta-2/gamma-2,Gabrg2|Gabra6|Gabrb2,6.01,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
zonisamide,Carbonic anhydrase 2,CAN2,6.01,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
octopamine,TyR1,,6.01,EC50,NCC(O)C1=CC=C(O)C=C1
ruboxistaurin,Death-associated protein kinase 1,DAPK1,6.01,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase TBK1,TBK1,6.01,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
thiram,Monoglyceride lipase,MGLL,6.01,IC50,CN(C)C(=S)SSC(=S)N(C)C
pazopanib,Serine/threonine-protein kinase Nek2,NEK2,6.01,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Non-receptor tyrosine-protein kinase TNK1,TNK1,6.01,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,6.01,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,6.01,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
afatinib,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,DYRK1A,6.01,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
fedratinib,MAP/microtubule affinity-regulating kinase 4,MARK4,6.01,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
bisacodyl,Kappa-type opioid receptor,OPRK1,6.011,Ki,CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1
tetracaine,5-hydroxytryptamine receptor 2A,HTR2A,6.011,Ki,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
gentian violet,Alpha-1D adrenergic receptor,ADRA1D,6.012,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
domperidone,Alpha-2B adrenergic receptor,ADRA2B,6.013,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
nedocromil,G-protein coupled receptor 35,GPR35,6.013,EC50,CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O
troglitazone,Carbonic anhydrase 2,CA2,6.013,IC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
bopindolol,5-hydroxytryptamine receptor 2B,HTR2B,6.014,Ki,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
fenfluramine,Muscarinic acetylcholine receptor M1,CHRM1,6.016,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
quetiapine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.016,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
diphenhydramine,Sodium-dependent noradrenaline transporter,SLC6A2,6.018,Kd,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
metergoline,Histamine H2 receptor,HRH2,6.018,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
tetrabenazine,Alpha-2A adrenergic receptor,ADRA2A,6.018,Ki,COC1=CC2=C(C=C1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
oxiconazole,Muscarinic acetylcholine receptor M3,CHRM3,6.018,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
diethylstilbestrol,Delta-type opioid receptor,OPRD1,6.019,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
oxymetazoline,Muscarinic acetylcholine receptor M5,CHRM5,6.019,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
acetazolamide,Carbonic anhydrase 2,CA2,6.02,IC50,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
amfetamine,Sodium-dependent dopamine transporter,Slc6a3,6.02,IC50,CC(N)CC1=CC=CC=C1
cortisone acetate,Glucocorticoid receptor,NR3C1,6.02,Kd,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
disulfiram,C-C chemokine receptor type 2,CCR2,6.02,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
erlotinib,Homeodomain-interacting protein kinase 4,HIPK4,6.02,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
imatinib,Homeodomain-interacting protein kinase 4,HIPK4,6.02,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
miconazole,Muscarinic acetylcholine receptor M1,CHRM1,6.02,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
olanzapine,Transporter,Slc6a2,6.02,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
prochlorperazine,5-hydroxytryptamine receptor 1A,Htr1a,6.02,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
sorafenib,Ephrin type-A receptor 8,EPHA8,6.02,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiperone,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.02,IC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Ephrin type-A receptor 6,EPHA6,6.02,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Tyrosine-protein kinase Fes/Fps,FES,6.02,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
dibrompropamidine,Prothrombin,F2,6.02,Ki,NC(=N)C1=CC(Br)=C(OCCCOC2=C(Br)C=C(C=C2)C(N)=N)C=C1
quercetin,Tyrosine-protein kinase receptor UFO,AXL,6.02,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Serine/threonine-protein kinase 3,STK3,6.02,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
dronabinol,N-arachidonyl glycine receptor,GPR18,6.02,EC50,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
pazopanib,Phosphatidylinositol 4-kinase beta,PI4KB,6.02,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vemurafenib,Serine/threonine-protein kinase A-Raf,ARAF,6.02,IC50,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F
bosutinib,Serine/threonine-protein kinase PLK2,PLK2,6.02,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ceritinib,Fibroblast growth factor receptor 4,FGFR4,6.02,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
midostaurin,Tyrosine-protein kinase Yes,YES1,6.02,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,RAC-alpha serine/threonine-protein kinase,AKT1,6.02,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,6.02,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Homeodomain-interacting protein kinase 4,HIPK4,6.02,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Calcium-dependent protein kinase 1,CPK1,6.02,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,cAMP-dependent protein kinase catalytic subunit PRKX,PRKX,6.02,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Discoidin domain-containing receptor 2,DDR2,6.02,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ethinylestradiol,Sodium-dependent noradrenaline transporter,SLC6A2,6.022,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
trifluoperazine,5-hydroxytryptamine receptor 1A,HTR1A,6.022,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
astemizole,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.025,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
clomifene,5-hydroxytryptamine receptor 2A,HTR2A,6.025,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
brexpiprazole,Sodium-dependent dopamine transporter,SLC6A3,6.025,IC50,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
sibutramine,Sodium-dependent dopamine transporter,SLC6A3,6.026,Ki,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
perhexiline,Cytochrome P450 2D6,CYP2D6,6.027,IC50,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
verapamil,Alpha-1B adrenergic receptor,Adra1b,6.027,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
cobicistat,Cytochrome P450 3A,CYP3A4|CYP3A5|CYP3A7|CYP3A43,6.027,Ki,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
propafenone,5-hydroxytryptamine receptor 1A,HTR1A,6.029,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
spironolactone,Progesterone receptor,PGR,6.029,EC50,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
amoxapine,Muscarinic acetylcholine receptor M2,CHRM2,6.03,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
bortezomib,Proteasome subunit beta type-10,PSMB10,6.03,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
brimonidine,Alpha-1B adrenergic receptor,,6.03,EC50,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
erlotinib,Ephrin type-A receptor 8,EPHA8,6.03,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
famotidine,Carbonic anhydrase 4,CA4,6.03,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
flupirtine,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,6.03,IC50,CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1
glutamic acid,Glutamate receptor 2,GRIA2,6.03,Ki,N[C@@H](CCC(O)=O)C(O)=O
lapatinib,Phosphatidylinositol 4-kinase beta,PI4KB,6.03,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
medroxyprogesterone,Estrogen receptor,ESR1|ESR2,6.03,IC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
phenylephrine,Alpha-1A adrenergic receptor,ADRA1A,6.03,Ki,CNC[C@H](O)C1=CC(O)=CC=C1
quetiapine,Sodium-dependent noradrenaline transporter,SLC6A2,6.03,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
sulfadiazine,5-hydroxytryptamine receptor 2A,HTR2A,6.03,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
sulfanilamide,Carbonic anhydrase 6,CA6,6.03,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Interleukin-1 receptor-associated kinase 3,IRAK3,6.03,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Casein kinase I isoform gamma-1,CSNK1G1,6.03,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamsulosin,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,6.03,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
tazobactam,Beta-lactamase,ampC,6.03,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
hexamidine,Suppressor of tumorigenicity 14 protein,ST14,6.03,Ki,NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
ruboxistaurin,Dual specificity mitogen-activated protein kinase kinase 4,MAP2K4,6.03,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Acetylcholinesterase,ACHE,6.03,IC50,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,6.03,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Tyrosine-protein kinase Lyn,LYN,6.03,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Bone morphogenetic protein receptor type-2,BMPR2,6.03,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
nintedanib,Tyrosine-protein kinase Lyn,LYN,6.03,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Ephrin type-A receptor 6,EPHA6,6.03,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Serine/threonine-protein kinase 33,STK33,6.03,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,LIM domain kinase 1,LIMK1,6.03,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
trazodone,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.033,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
cinnarizine,Mu-type opioid receptor,OPRM1,6.035,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
niflumic acid,Prostaglandin G/H synthase 2,PTGS2,6.037,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
quetiapine,Muscarinic acetylcholine receptor M2,CHRM2,6.037,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
gentian violet,Muscarinic acetylcholine receptor M3,CHRM3,6.037,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
tamoxifen,Thromboxane-A synthase,TBXAS1,6.038,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
asenapine,Muscarinic acetylcholine receptor M2,CHRM2,6.039,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
buspirone,5-hydroxytryptamine receptor 2C,HTR2C,6.04,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
cefalotin,Tyrosine-protein phosphatase non-receptor type 7,PTPN7,6.04,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O
chlortalidone,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.04,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
epinephrine,D(2) dopamine receptor,DRD2,6.04,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
ergotamine,Muscarinic acetylcholine receptor M2,CHRM2,6.04,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
erlotinib,Serine/threonine-protein kinase ULK3,ULK3,6.04,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
famotidine,Carbonic anhydrase 1,CA1,6.04,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
gefitinib,STE20-like serine/threonine-protein kinase,SLK,6.04,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
pethidine,Mu-type opioid receptor,OPRM1,6.04,Ki,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
methysergide,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.04,IC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nilotinib,Serine/threonine-protein kinase MRCK beta,CDC42BPB,6.04,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
valdecoxib,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.04,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
quercetin,Aurora kinase B,AURKB,6.04,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Dual specificity protein kinase CLK1,CLK1,6.04,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,6.04,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
ruxolitinib,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,DYRK1A,6.04,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,6.04,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Protein kinase C theta type,PRKCQ,6.04,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Calcium/calmodulin-dependent protein kinase kinase 2,CAMKK2,6.04,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
esflurbiprofen,Prostaglandin G/H synthase 2,PTGS2,6.04,IC50,C[C@H](C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
osimertinib,Insulin receptor,INSR,6.04,IC50,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
midostaurin,Protein kinase C theta type,PRKCQ,6.04,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
relebactam,Beta-lactamase,blaKPC-4,6.04,IC50,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O
fedratinib,Casein kinase II subunit alpha,CSNK2A1,6.04,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
remimazolam,GABA A receptor alpha-3/beta-2/gamma-2,Gabrg2|Gabra3|Gabrb2,6.04,EC50,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
hexachlorophene,Adenosine receptor A2a,ADORA2A,6.043,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
diiodohydroxyquinoline,Angiotensin-converting enzyme,ACE,6.043,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
clotrimazole,D(3) dopamine receptor,DRD3,6.046,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
itraconazole,Cytochrome P450 3A4,CYP3A4,6.046,IC50,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lacidipine,Cytochrome P450 3A4,CYP3A4,6.046,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
benzethonium,Sodium-dependent noradrenaline transporter,SLC6A2,6.046,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
fluoxetine,Muscarinic acetylcholine receptor M1,CHRM1,6.047,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
fluphenazine enanthate,5-hydroxytryptamine receptor 2C,HTR2C,6.048,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
felbinac,Prostaglandin G/H synthase 1,PTGS1,6.049,IC50,OC(=O)CC1=CC=C(C=C1)C1=CC=CC=C1
astemizole,Multidrug resistance protein 1,ABCB1,6.05,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
brompheniramine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.05,IC50,CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1
celecoxib,Cyclooxygenase 2; Prostaglandin G/H synthase-2; Uncharacterized protein,PTGS2,6.05,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
ciprofibrate,Peroxisome proliferator-activated receptor alpha,PPARA,6.05,EC50,CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O
clebopride,Acetylcholinesterase,ACHE,6.05,IC50,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
clomipramine,Sodium-dependent noradrenaline transporter,Slc6a2,6.05,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
dexniguldipine,Alpha-2A adrenergic receptor,ADRA2A,6.05,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
dobutamine,"Carbonic anhydrase 5B, mitochondrial",CA5B,6.05,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
doxorubicin,Integrase,pol,6.05,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
erlotinib,Leukocyte tyrosine kinase receptor,LTK,6.05,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ganciclovir,Metabotropic glutamate receptor 1,GRM1,6.05,Ki,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
hydralazine,Myeloperoxidase,MPO,6.05,IC50,NNC1=NN=CC2=CC=CC=C12
imatinib,Tyrosine-protein kinase Lyn,LYN,6.05,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indapamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.05,Ki,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
isotretinoin,Cellular retinoic acid-binding protein 1,CRABP1,6.05,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
masoprocol,Insulin-like growth factor 1 receptor,IGF1R,6.05,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
metoclopramide,5-hydroxytryptamine receptor 4,Htr4,6.05,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
nilotinib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,6.05,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norfloxacin,DNA gyrase subunit A,gyrA,6.05,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
paroxetine,Substance-P receptor,TACR1,6.05,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
raltitrexed,Thymidylate synthase,Tyms,6.05,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
sunitinib,Calcium/calmodulin-dependent protein kinase type IV,CAMK4,6.05,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase TAO1,TAOK1,6.05,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
talinolol,Beta-2 adrenergic receptor,ADRB2,6.05,Ki,CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1
talinolol,Beta-2 adrenergic receptor,ADRB2,6.05,Ki,CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1
terfenadine,Substance-K receptor,TACR2,6.05,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
tofisopam,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,6.05,IC50,CCC1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC(OC)=C(OC)C=C1
tofisopam,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,6.05,IC50,CCC1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC(OC)=C(OC)C=C1
gabexate,Solute carrier family 22 member 2,SLC22A2,6.05,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
quercetin,Epidermal growth factor receptor,EGFR,6.05,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,AP2-associated protein kinase 1,AAK1,6.05,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase D2,PRKD2,6.05,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,6.05,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Tyrosine-protein kinase Lyn,LYN,6.05,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,6.05,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase TAO2,TAOK2,6.05,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
acetic acid,Tyrosine-protein kinase Fyn,FYN,6.05,Kd,CC(O)=O
laropiprant,Prostaglandin E2 receptor EP3 subtype,PTGER3,6.05,Ki,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
bosutinib,Serine/threonine-protein kinase 25,STK25,6.05,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
plerixafor,C-X-C chemokine receptor type 4,CXCR4,6.05,Ki,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
diosmetin,Inositol hexakisphosphate kinase 2,IP6K2,6.05,IC50,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O)C=C2O1
methylnaltrexone,Delta-type opioid receptor,OPRD1,6.05,Ki,C[N+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
vortioxetine,Sodium-dependent dopamine transporter,Slc6a3,6.05,IC50,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
ibrutinib,Redox-regulatory protein FAM213A,FAM213A,6.05,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
ceritinib,Epidermal growth factor receptor,EGFR,6.05,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Casein kinase II subunit alpha',CSNK2A2,6.05,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
rucaparib,Tankyrase-2,TNKS2,6.05,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
midostaurin,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,6.05,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Death-associated protein kinase 2,DAPK2,6.05,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
quizartinib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,6.05,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
pexidartinib,NT-3 growth factor receptor,NTRK3,6.05,IC50,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
etoperidone,Sodium-dependent serotonin transporter,SLC6A4,6.051,Ki,CCN1C(=O)N(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)N=C1CC
cyproterone acetate,Mu-type opioid receptor,OPRM1,6.053,Ki,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
sulconazole,Muscarinic acetylcholine receptor M1,CHRM1,6.053,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
pimozide,5-hydroxytryptamine receptor 2C,HTR2C,6.058,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
ritonavir,Substance-K receptor,TACR2,6.058,Ki,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
aripiprazole,D(1A) dopamine receptor,DRD1,6.06,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
celecoxib,Carbonic anhydrase 4,CA4,6.06,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
dichlorphenamide,Beta-carbonic anhydrase 1,mtcA1,6.06,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
ebastine,Alpha-1D adrenergic receptor,ADRA1D,6.06,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
fluconazole,Sterol 14-alpha demethylase,CYP51,6.06,IC50,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
glutamic acid,Glutamate receptor 4,GRIA4,6.06,Ki,N[C@@H](CCC(O)=O)C(O)=O
mafenide,Carbonic anhydrase,,6.06,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mosapride,Alpha-2B adrenergic receptor,ADRA2B,6.06,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
naftifine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.06,Ki,CN(C\C=C\C1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12
nilotinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6.06,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nomifensine,Sodium-dependent serotonin transporter,Slc6a4,6.06,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
penfluridol,Mu-type opioid receptor,OPRM1,6.06,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
remoxipride,D(2) dopamine receptor,DRD2,6.06,IC50,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
remoxipride,D(2) dopamine receptor,DRD2,6.06,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
sildenafil,Adenosine receptor A1,ADORA1,6.06,Ki,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sulfanilamide,Carbonic anhydrase,,6.06,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulpiride,"Carbonic anhydrase, alpha family",,6.06,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sunitinib,Tyrosine-protein kinase HCK,HCK,6.06,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zonisamide,Carbonic anhydrase 2,mtcA2,6.06,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
gentian violet,Mu-type opioid receptor,OPRM1,6.06,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
bosutinib,Rho-associated protein kinase 1,ROCK1,6.06,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
pexidartinib,Vascular endothelial growth factor receptor 1,FLT1,6.06,IC50,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
fedratinib,Serine/threonine-protein kinase 36,STK36,6.06,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase DCLK2,DCLK2,6.06,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Cyclin-dependent kinase 4,CDK4,6.06,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,6.06,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fluphenazine,5-hydroxytryptamine receptor 1B,Htr1b,6.061,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
clomifene,5-hydroxytryptamine receptor 2B,HTR2B,6.062,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
ergotamine,D(1A) dopamine receptor,DRD1,6.063,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
flunarizine,Alpha-2B adrenergic receptor,ADRA2B,6.063,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
orphenadrine,Alpha-2B adrenergic receptor,ADRA2B,6.063,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
propafenone,5-hydroxytryptamine receptor 6,HTR6,6.063,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
ergotamine,Muscarinic acetylcholine receptor M1,CHRM1,6.064,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
guanfacine,5-hydroxytryptamine receptor 2A,HTR2A,6.065,Ki,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
pipamperone,Alpha-2A adrenergic receptor,ADRA2A,6.066,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
tubocurarine,Neuronal acetylcholine receptor; alpha4/beta4,CHRNB4|CHRNA4,6.066,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
fluorometholone,Androgen receptor,Ar,6.067,Ki,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12
diphenidol,Muscarinic acetylcholine receptor M5,CHRM5,6.068,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
clomifene,Sodium-dependent noradrenaline transporter,SLC6A2,6.068,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
methylphenidate,Alpha-2C adrenergic receptor,ADRA2C,6.068,Ki,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
montelukast,Mitogen-activated protein kinase 14,MAPK14,6.068,IC50,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
oxaprozin,Prostaglandin G/H synthase 1,PTGS1,6.068,IC50,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
mepacrine,Alpha-2A adrenergic receptor,ADRA2A,6.068,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
droperidol,5-hydroxytryptamine receptor 2B,HTR2B,6.069,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
pecazine,5-hydroxytryptamine receptor 6,HTR6,6.069,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
adenosine triphosphate,P2Y purinoceptor 1,P2RY1,6.07,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
budipine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.07,IC50,CC(C)(C)N1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
diethylstilbestrol,Sodium-dependent dopamine transporter,SLC6A3,6.07,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
ditiocarb,Cytochrome P450 2E1,CYP2E1,6.07,IC50,CCN(CC)C(S)=S
erlotinib,Tyrosine-protein kinase receptor Tie-1,TIE1,6.07,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fluoxetine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.07,IC50,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
ganciclovir,Capsid scaffolding protein,UL26,6.07,EC50,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
ibuprofen,Prostaglandin G/H synthase 2,Ptgs2,6.07,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
meropenem,Beta-lactamase,bla OXA-48,6.07,Kd,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
milrinone,Cyclic nucleotide phosphodiesterase PDE3A,,6.07,IC50,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
perphenazine,5-hydroxytryptamine receptor 1A,HTR1A,6.07,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
ropinirole,D(4) dopamine receptor,DRD4,6.07,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sulfanilamide,Carbonic anhydrase 2,CA2,6.07,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Epidermal growth factor receptor,EGFR,6.07,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ephrin type-B receptor 6,EPHB6,6.07,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase NIM1,NIM1K,6.07,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terfenadine,C-C chemokine receptor type 5,CCR5,6.07,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
crizotinib,Activin receptor type-1B,ACVR1B,6.07,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Tyrosine-protein kinase TXK,TXK,6.07,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
levmetamfetamine,Trace amine-associated receptor 1,Taar1,6.07,EC50,CN[C@H](C)CC1=CC=CC=C1
nintedanib,Tyrosine-protein kinase TXK,TXK,6.07,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Homeodomain-interacting protein kinase 3,HIPK3,6.07,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Dual specificity protein kinase CLK2,CLK2,6.07,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Vascular endothelial growth factor receptor 2,KDR,6.07,IC50,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Serine/threonine-protein kinase Chk2,CHEK2,6.07,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
pexidartinib,Tyrosine-protein kinase Lck,LCK,6.07,IC50,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
fedratinib,Insulin receptor,INSR,6.07,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Tyrosine-protein kinase BTK,BTK,6.07,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Homeodomain-interacting protein kinase 1,HIPK1,6.07,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cefiderocol,Penicillin-binding protein 1A,mrcA,6.07,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
osilodrostat,Aromatase,CYP19A1,6.07,IC50,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12
nortriptyline,Aldehyde oxidase,AOX1,6.071,IC50,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
zileuton,Leukotriene A-4 hydrolase,LTA4H,6.071,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
loperamide,Membrane-associated progesterone receptor component 1,Pgrmc1,6.072,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
nifedipine,C-C chemokine receptor type 2,CCR2,6.072,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
verapamil,Alpha-1D adrenergic receptor,ADRA1D,6.072,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
brimonidine,Alpha-1D adrenergic receptor,ADRA1D,6.073,Ki,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
raloxifene,5-hydroxytryptamine receptor 1B,Htr1b,6.073,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
methyltestosterone,Glucocorticoid receptor,NR3C1,6.077,Ki,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
troglitazone,5-hydroxytryptamine receptor 2B,HTR2B,6.078,Ki,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
mepacrine,Alpha-2B adrenergic receptor,ADRA2B,6.079,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
bepridil,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,6.08,IC50,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
brinzolamide,Beta-carbonic anhydrase 1,mtcA1,6.08,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
dabigatran etexilate,Serine protease hepsin,HPN,6.08,Ki,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
dexfenfluramine,5-hydroxytryptamine receptor 1A,HTR1A,6.08,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
donepezil,Cholinesterase,BCHE,6.08,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
eperisone,Muscarinic acetylcholine receptor M2,CHRM2,6.08,Ki,CCC1=CC=C(C=C1)C(=O)C(C)CN1CCCCC1
flunarizine,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,6.08,Kd,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
mafenide,Carbonic anhydrase,cynT,6.08,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
medroxalol,Alpha-1A adrenergic receptor,ADRA1A,6.08,pA2,CC(CCC1=CC2=C(OCO2)C=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
mianserin,D(2) dopamine receptor,Drd2,6.08,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
rivastigmine,Cholinesterase,BCHE,6.08,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
trioxsalen,Amine oxidase [flavin-containing] A,MAOA,6.08,IC50,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1
evans blue,Ectonucleotide pyrophosphatase/phosphodiesterase family member 2,ENPP2,6.08,Ki,CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O
ruboxistaurin,Phosphatidylinositol 5-phosphate 4-kinase type-2 beta,PIP4K2B,6.08,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
crizotinib,LIM domain kinase 1,LIMK1,6.08,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Peripheral plasma membrane protein CASK,CASK,6.08,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ceritinib,Tyrosine-protein kinase Lyn,LYN,6.08,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
istradefylline,Adenosine receptor A1,ADORA1,6.08,Ki,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
rucaparib,Poly [ADP-ribose] polymerase 4,PARP4,6.08,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
fedratinib,High affinity nerve growth factor receptor,NTRK1,6.08,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Inhibitor of nuclear factor kappa-B kinase subunit alpha,CHUK,6.08,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
trazodone,5-hydroxytryptamine receptor 1B,Htr1b,6.081,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
polmacoxib,Prostaglandin G/H synthase 1,PTGS1,6.081,IC50,CC1(C)OC(=C(C1=O)C1=CC=CC(F)=C1)C1=CC=C(C=C1)S(N)(=O)=O
dicycloverine,5-hydroxytryptamine receptor 2B,HTR2B,6.082,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
ospemifene,Estrogen receptor,ESR1,6.082,IC50,OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
trazodone,Membrane-associated progesterone receptor component 1,Pgrmc1,6.083,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
gentian violet,Cytochrome P450 2D6,CYP2D6,6.084,IC50,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
ketotifen,Alpha-2A adrenergic receptor,ADRA2A,6.086,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
oxybutynin,Membrane-associated progesterone receptor component 1,Pgrmc1,6.086,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
pimozide,Alpha-2B adrenergic receptor,ADRA2B,6.086,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
idelalisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,6.086,IC50,CC[C@H](NC1=NC=NC2=C1NC=N2)C1=NC2=C(C(F)=CC=C2)C(=O)N1C1=CC=CC=C1
dihydroergocristine,5-hydroxytryptamine receptor 4,HTR4,6.087,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
loxapine,Muscarinic acetylcholine receptor M4,CHRM4,6.087,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
amiodarone,Tyrosine-protein kinase Fyn,FYN,6.088,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
papaverine,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,6.088,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
celecoxib,Mitogen-activated protein kinase 14,MAPK14,6.09,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
decamethonium,Histamine H3 receptor,HRH3,6.09,IC50,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
fenoldopam,D(2) dopamine receptor,DRD2,6.09,Ki,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
folic acid,Dihydrofolate reductase,dfrA17,6.09,Kd,NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=N1
mefenamic acid,Aldo-keto reductase family 1 member C1,AKR1C1,6.09,Ki,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
methamphetamine,Alpha-2C adrenergic receptor,ADRA2C,6.09,Ki,CN[C@@H](C)CC1=CC=CC=C1
methylparaben,Carbonic anhydrase 12,CA12,6.09,Ki,COC(=O)C1=CC=C(O)C=C1
mitotane,Sodium-dependent noradrenaline transporter,SLC6A2,6.09,Ki,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
nitrofurantoin,CDGSH iron-sulfur domain-containing protein 1,CISD1,6.09,Ki,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
sulpiride,Carbonic anhydrase 2,CAN2,6.09,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tazobactam,Beta-lactamase,ampC,6.09,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tretinoin,Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,PIN1,6.09,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
ruboxistaurin,Serine/threonine-protein kinase RIO1,RIOK1,6.09,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vildagliptin,Dipeptidyl peptidase 8,DPP8,6.09,Ki,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
alitretinoin,Nuclear receptor subfamily 4 group A member 1,NR4A1,6.09,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
ruxolitinib,JAK2/TYK2,JAK2|TYK2,6.09,IC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
telbivudine,Capsid protein,HBcAg,6.09,EC50,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O
axitinib,Hepatocyte growth factor receptor,MET,6.09,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
nintedanib,Interleukin-1 receptor-associated kinase 4,IRAK4,6.09,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase 35,STK35,6.09,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Tyrosine-protein kinase Lyn,LYN,6.09,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Serine/threonine-protein kinase D1,PRKD1,6.09,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Tyrosine-protein kinase Mer,MERTK,6.09,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
filgotinib,Tyrosine-protein kinase JAK3,JAK3,6.09,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
ebastine,Tyrosine-protein kinase Fyn,FYN,6.091,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ondansetron,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.091,IC50,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
orphenadrine,Alpha-2A adrenergic receptor,ADRA2A,6.092,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
flibanserin,5-hydroxytryptamine receptor 5A,HTR5A,6.093,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
sildenafil,Alpha-1B adrenergic receptor,Adra1b,6.094,Ki,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
idebenone,Cytochrome P450 2C19,CYP2C19,6.097,IC50,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
labetalol,Cytochrome P450 2D6,CYP2D6,6.097,IC50,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
metoclopramide,Cytochrome P450 2D6,CYP2D6,6.097,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
metyrapone,Cytochrome P450 3A4,CYP3A4,6.097,IC50,CC(C)(C(=O)C1=CN=CC=C1)C1=CN=CC=C1
norethindrone acetate,Cytochrome P450 2C19,CYP2C19,6.097,IC50,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
phenelzine,Cytochrome P450 2C19,CYP2C19,6.097,IC50,NNCCC1=CC=CC=C1
propafenone,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.097,IC50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
sulconazole,Cytochrome P450 2D6,CYP2D6,6.097,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
thiabendazole,Cytochrome P450 1A2,CYP1A2,6.097,IC50,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
acetophenazine,Androgen receptor,Ar,6.1,Ki,CC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(CCO)CC3)C2=C1
acetoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,6.1,IC50,CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C
acetylcholine,Muscarinic acetylcholine receptor M5,CHRM5,6.1,EC50,CC(=O)OCC[N+](C)(C)C
adenosine triphosphate,Transient receptor potential cation channel subfamily M member 4,Trpm4,6.1,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
aripiprazole,5-hydroxytryptamine receptor 1B,HTR1B,6.1,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
bifonazole,Cytochrome P450 3A4,CYP3A4,6.1,IC50,C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1
bromocriptine,5-hydroxytryptamine receptor 2C,HTR2C,6.1,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
celecoxib,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.1,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlordiazepoxide,GABA-A receptor; anion channel,GABRA1|GABRB1|GABRA2|GABRA3|GABRA4|GABRG2,6.1,IC50,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
cisapride,5-hydroxytryptamine receptor 1A,HTR1A,6.1,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
clavulanic acid,Beta-lactamase,ampC,6.1,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clotrimazole,7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,CYP8B1,6.1,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
colchicine,Tubulin,TUBB2B,6.1,IC50,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
ciclosporin,Solute carrier organic anion transporter family member 1B3,SLCO1B3,6.1,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dexamethasone,Nuclear receptor subfamily 1 group I member 2,Nr1i2,6.1,EC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
diltiazem,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,6.1,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
dimetindene,Muscarinic acetylcholine receptor M5,CHRM5,6.1,Ki,CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C1=CC=CC=N1
ditiocarb,Carbonic anhydrase 1,CA1,6.1,Ki,CCN(CC)C(S)=S
enalapril,Angiotensin-converting enzyme,ACE,6.1,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
erlotinib,Epithelial discoidin domain-containing receptor 1,DDR1,6.1,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
etoricoxib,Prostaglandin G/H synthase 2,PTGS2,6.1,IC50,CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
fenoldopam,D(2) dopamine receptor,DRD2,6.1,Ki,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
flufenamic acid,Aldo-keto reductase family 1 member C3,AKR1C3,6.1,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
flunarizine,Muscarinic acetylcholine receptor M5,CHRM5,6.1,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
fluphenazine,Androgen receptor,Ar,6.1,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fulvestrant,Bile acid receptor,NR1H4,6.1,IC50,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
gefitinib,Serine/threonine-protein kinase Chk2,CHEK2,6.1,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Receptor tyrosine-protein kinase erbB-3,ERBB3,6.1,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,"Glutamate receptor ionotropic, kainate 3",GRIK3,6.1,Ki,N[C@@H](CCC(O)=O)C(O)=O
haloperidol,5-hydroxytryptamine receptor 2B,HTR2B,6.1,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
itraconazole,Vasopressin V2 receptor,AVPR2,6.1,IC50,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ketoprofen,Prostaglandin G/H synthase 1,PTGS1,6.1,IC50,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
levetiracetam,Synaptic vesicle glycoprotein 2A,Sv2a,6.1,IC50,CC[C@H](N1CCCC1=O)C(N)=O
levetiracetam,Synaptic vesicle glycoprotein 2A,SV2A,6.1,Ki,CC[C@H](N1CCCC1=O)C(N)=O
metergoline,5-hydroxytryptamine receptor 1E,HTR1E,6.1,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
mitotane,Sodium-dependent dopamine transporter,SLC6A3,6.1,Ki,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
moxifloxacin,DNA topoisomerase 4 subunit A,parC,6.1,IC50,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1C[C@@H]2CCCN[C@@H]2C1)C1CC1
nicardipine,Potassium voltage-gated channel subfamily A member 4,Kcna4,6.1,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
nilotinib,Calcium-dependent protein kinase 1,CPK1,6.1,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
oseltamivir,Neuraminidase,,6.1,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
oxytocin,Vasopressin V2 receptor,AVPR2,6.1,EC50,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
oxytocin,Vasopressin V1a receptor,Avpr1a,6.1,Ki,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
phenprocoumon,Pol polyprotein,pol,6.1,Ki,CCC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
piribedil,Alpha-1A adrenergic receptor,ADRA1A,6.1,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
salmeterol,Beta-1 adrenergic receptor,ADRB1,6.1,Ki,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
sildenafil,Solute carrier organic anion transporter family member 1B3,SLCO1B3,6.1,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sotalol,Beta-1 adrenergic receptor,ADRB1,6.1,Ki,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
sulbactam,Beta-lactamase TEM,bla; blaT-3; blaT-4;,6.1,Ki,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulbactam,Beta-lactamase TEM,bla,6.1,Ki,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
suloctidil,Epidermal growth factor receptor,EGFR,6.1,IC50,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
tramadol,Sodium-dependent noradrenaline transporter,SLC6A2,6.1,IC50,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
vardenafil,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,6.1,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
quercetin,Arachidonate 5-lipoxygenase,ALOX5,6.1,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Rhodopsin kinase,GRK1,6.1,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Interleukin-1 receptor-associated kinase 3,IRAK3,6.1,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Mast/stem cell growth factor receptor Kit,KIT,6.1,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Tyrosine-protein kinase receptor TYRO3,TYRO3,6.1,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase Nek9,NEK9,6.1,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
pomalidomide,Cereblon isoform 4,,6.1,Ki,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
pomalidomide,Cereblon isoform 4,,6.1,Ki,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
vilanterol,Beta-3 adrenergic receptor,ADRB3,6.1,EC50,OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl
simeprevir,Cathepsin S,CTSS,6.1,IC50,COC1=C(C)C2=C(C=C1)C(O[C@@H]1C[C@@H]3[C@@H](C1)C(=O)N(C)CCCC\C=C/[C@@H]1C[C@]1(NC3=O)C(=O)NS(=O)(=O)C1CC1)=CC(=N2)C1=NC(=CS1)C(C)C
dexrabeprazole,Alpha-2B adrenergic receptor,ADRA2B,6.1,Ki,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
dexrabeprazole,D(3) dopamine receptor,DRD3,6.1,Ki,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
nintedanib,Homeodomain-interacting protein kinase 2,HIPK2,6.1,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
palbociclib,Cyclin-dependent kinase 9,CDK9,6.1,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
aripiprazole lauroxil,5-hydroxytryptamine receptor 1B,HTR1B,6.1,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
baricitinib,Tyrosine-protein kinase JAK3,JAK3,6.1,IC50,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
midostaurin,Tyrosine-protein kinase ABL1,ABL1,6.1,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase 10,MAP3K10,6.1,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,"Muscle, skeletal receptor tyrosine-protein kinase",MUSK,6.1,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase SBK1,SBK1,6.1,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
astemizole,Sodium-dependent dopamine transporter,SLC6A3,6.101,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
fluphenazine,Sodium-dependent serotonin transporter,SLC6A4,6.101,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
pentamidine,Amine oxidase [flavin-containing] A,MAOA,6.101,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
rabeprazole,Alpha-2B adrenergic receptor,ADRA2B,6.101,Ki,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
rabeprazole,D(3) dopamine receptor,DRD3,6.102,Ki,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
flunarizine,Muscarinic acetylcholine receptor M4,CHRM4,6.103,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
diphenidol,D(3) dopamine receptor,DRD3,6.105,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
perhexiline,Muscarinic acetylcholine receptor M5,CHRM5,6.105,Ki,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
sertraline,5-hydroxytryptamine receptor 2A,HTR2A,6.106,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
yohimbine,5-hydroxytryptamine receptor 6,HTR6,6.106,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
asenapine,Muscarinic acetylcholine receptor M1,CHRM1,6.107,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
tiapride,Alpha-2A adrenergic receptor,ADRA2A,6.108,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O
acenocoumarol,Vitamin K epoxide reductase complex subunit 1,Vkorc1,6.11,IC50,CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=C(OC1=O)C=CC=C2
acetylcholine,Muscarinic acetylcholine receptor M1,CHRM1,6.11,EC50,CC(=O)OCC[N+](C)(C)C
amiloride,Amiloride-sensitive sodium channel subunit alpha,SCNN1A,6.11,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
aripiprazole,Multidrug resistance protein 1,ABCB1,6.11,IC50,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
colchicine,Tubulin beta-2B chain,TUBB2B,6.11,Ki,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
dasatinib,Serine/threonine-protein kinase 35,STK35,6.11,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dipyridamole,Protein prune homolog,PRUNE,6.11,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
ethinylestradiol,Glucocorticoid receptor,NR3C1,6.11,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
fasudil,Serine/threonine-protein kinase N2,PKN2,6.11,IC50,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
fluoxetine,5-hydroxytryptamine receptor 6,HTR6,6.11,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
fluoxetine,Sodium-dependent dopamine transporter,Slc6a3,6.11,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
haloperidol,Histone H1.0,H1F0,6.11,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
loxapine,5-hydroxytryptamine receptor 5A,HTR5A,6.11,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
methazolamide,Beta-carbonic anhydrase 1,mtcA1,6.11,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methylparaben,Carbonic anhydrase 7,CA7,6.11,Ki,COC(=O)C1=CC=C(O)C=C1
sulfanilamide,Carbonic anhydrase 2,CAN2,6.11,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulfafurazole,Endothelin-1 receptor,EDNRA,6.11,IC50,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
sulfafurazole,Endothelin-1 receptor,Ednra,6.11,IC50,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
topiramate,"Carbonic anhydrase, alpha family",,6.11,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
zidovudine,Reverse transcriptase/RNaseH,pol,6.11,IC50,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
crizotinib,Tyrosine-protein kinase Yes,YES1,6.11,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Insulin-like growth factor 1 receptor,IGF1R,6.11,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Ankyrin repeat and protein kinase domain-containing protein 1,ANKK1,6.11,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Calcium/calmodulin-dependent protein kinase kinase 2,CAMKK2,6.11,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
sulfisoxazole acetyl,Endothelin-1 receptor,EDNRA,6.11,IC50,CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1
sulfisoxazole acetyl,Endothelin-1 receptor,Ednra,6.11,IC50,CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1
iclaprim,Dihydrofolate reductase,DHFR,6.11,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=C2C=CC(OC2=C1OC)C1CC1
nintedanib,MAP/microtubule affinity-regulating kinase 3,MARK3,6.11,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase DCLK3,DCLK3,6.11,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,RAC-beta serine/threonine-protein kinase,AKT2,6.11,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
oxymetazoline,5-hydroxytryptamine receptor 6,HTR6,6.111,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
acenocoumarol,Vitamin K epoxide reductase complex subunit 1,VKORC1,6.114,IC50,CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=C(OC1=O)C=CC=C2
zafirlukast,Adenosine receptor A3,ADORA3,6.114,Ki,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
clemastine,D(1A) dopamine receptor,DRD1,6.115,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
montelukast,Alpha-2C adrenergic receptor,ADRA2C,6.115,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
benzethonium,Tyrosine-protein kinase Fyn,FYN,6.115,IC50,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
labetalol,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.117,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
papaverine,Cytochrome P450 2C19,CYP2C19,6.118,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
guanfacine,5-hydroxytryptamine receptor 2C,HTR2C,6.119,Ki,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
mepacrine,5-hydroxytryptamine receptor 2A,HTR2A,6.119,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
femoxetine,Sodium-dependent noradrenaline transporter,SLC6A2,6.119,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
methoxsalen,Acetylcholinesterase,ACHE,6.12,IC50,COC1=C2OC=CC2=CC2=C1OC(=O)C=C2
allopurinol,Xanthine dehydrogenase/oxidase,Xdh,6.12,IC50,OC1=NC=NC2=C1C=NN2
astemizole,5-hydroxytryptamine receptor 1A,Htr1a,6.12,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
carbachol,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,6.12,Ki,C[N+](C)(C)CCOC(N)=O
colchicine,Tubulin polymerization-promoting protein,TPPP,6.12,EC50,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
epirubicin,NS3,NS3,6.12,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
famotidine,Multidrug and toxin extrusion protein 1,SLC47A1,6.12,IC50,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
flufenamic acid,Aldo-keto reductase family 1 member B10,AKR1B10,6.12,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
gamolenic acid,Peroxisome proliferator-activated receptor delta,PPARD,6.12,IC50,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
mezlocillin,Aldo-keto reductase family 1 member C3,AKR1C3,6.12,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
nimodipine,Cytochrome P450 3A4,CYP3A4,6.12,Ki,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
pirenzepine,Muscarinic acetylcholine receptor,Chrm1|Chrm4|Chrm5|Chrm3|Chrm2,6.12,IC50,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
rofecoxib,Prostaglandin G/H synthase 2,Ptgs2,6.12,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
ropinirole,Alpha-2B adrenergic receptor,ADRA2B,6.12,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
simvastatin,Cholinesterase,BCHE,6.12,Ki,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
suloctidil,Alpha-2A adrenergic receptor,ADRA2A,6.12,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
trichlormethiazide,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.12,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
zolpidem,Gamma-aminobutyric acid receptor subunit alpha-2,Gabra2,6.12,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
iloperidone,D(1A) dopamine receptor,Drd1,6.12,IC50,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
pazopanib,Aurora kinase C,AURKC,6.12,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Tyrosine-protein kinase FRK,FRK,6.12,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,6.12,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
boceprevir,Cathepsin L1,CTSL,6.12,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
crizotinib,Activated CDC42 kinase 1,TNK2,6.12,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Cyclin-dependent kinase 11B,CDK11B,6.12,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase DCLK2,DCLK2,6.12,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
dodecanoic acid,Free fatty acid receptor 1,FFAR1,6.12,EC50,CCCCCCCCCCCC(O)=O
nintedanib,Dual specificity protein kinase CLK2,CLK2,6.12,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
fedratinib,Serine/threonine-protein kinase TAO2,TAOK2,6.12,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
infigratinib,Mast/stem cell growth factor receptor Kit,KIT,6.12,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Mast/stem cell growth factor receptor Kit,KIT,6.12,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
olanzapine,5-hydroxytryptamine receptor 1D,HTR1D,6.121,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
sulpiride,Alpha-2A adrenergic receptor,ADRA2A,6.121,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
guanabenz,Alpha-1B adrenergic receptor,Adra1b,6.122,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
gentian violet,5-hydroxytryptamine receptor 2A,HTR2A,6.124,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
butenafine,Sodium-dependent serotonin transporter,SLC6A4,6.125,Ki,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
mianserin,Histamine H4 receptor,HRH4,6.125,EC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
siponimod,Sphingosine 1-phosphate receptor 4,S1PR4,6.125,EC50,CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F
carvedilol,D(1A) dopamine receptor,DRD1,6.126,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
hexachlorophene,Epidermal growth factor receptor,EGFR,6.126,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
dexchlorpheniramine,Muscarinic acetylcholine receptor M5,CHRM5,6.126,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
quetiapine,Alpha-2B adrenergic receptor,ADRA2B,6.127,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
imatinib,Sodium-dependent serotonin transporter,SLC6A4,6.128,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
methamphetamine,Alpha-2B adrenergic receptor,ADRA2B,6.128,Ki,CN[C@@H](C)CC1=CC=CC=C1
pergolide,Alpha-1D adrenergic receptor,ADRA1D,6.128,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
sertraline,Muscarinic acetylcholine receptor M1,CHRM1,6.128,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
brimonidine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.13,Ki,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
bromocriptine,Beta-2 adrenergic receptor,ADRB2,6.13,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
dorzolamide,Beta-carbonic anhydrase 1,mtcA1,6.13,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
droperidol,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,6.13,IC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
lysergide,Beta-2 adrenergic receptor,ADRB2,6.13,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
mianserin,5-hydroxytryptamine receptor 1A,HTR1A,6.13,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
milrinone,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,6.13,IC50,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
mometasone furoate,Multidrug resistance protein 1,ABCB1,6.13,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)CCl
oxatomide,Muscarinic acetylcholine receptor M1,CHRM1,6.13,Ki,O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
sunitinib,Serine/threonine-protein kinase tousled-like 1,TLK1,6.13,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
pazopanib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.13,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase 11,MAP3K11,6.13,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,BMP-2-inducible protein kinase,BMP2K,6.13,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
laropiprant,Prostaglandin D2 receptor 2,PTGDR2,6.13,Ki,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
nintedanib,Serine/threonine-protein kinase N1,PKN1,6.13,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Ribosomal protein S6 kinase alpha-3,RPS6KA3,6.13,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase 13,MAP3K13,6.13,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
diphenidol,5-hydroxytryptamine receptor 2A,HTR2A,6.131,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
dexchlorpheniramine,Sodium-dependent dopamine transporter,SLC6A3,6.131,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
methamphetamine,Sodium-dependent serotonin transporter,SLC6A4,6.133,Ki,CN[C@@H](C)CC1=CC=CC=C1
trioxsalen,Adenosine receptor A2a,ADORA2A,6.133,Ki,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1
chidamide,Histone deacetylase 8,HDAC8,6.135,IC50,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1
clotrimazole,Mu-type opioid receptor,OPRM1,6.136,Ki,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
tamoxifen,Alpha-2A adrenergic receptor,ADRA2A,6.139,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
amsacrine,DNA topoisomerase II,TOP2A|TOP2B,6.14,EC50,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
celecoxib,Astrosclerin-3,,6.14,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cimetidine,Histamine H2 receptor,HRH2,6.14,Kd,CNC(NCCSCC1=C(C)NC=N1)=NC#N
codeine,Mu-type opioid receptor,OPRM1,6.14,Ki,COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C
dasatinib,STE20-like serine/threonine-protein kinase,SLK,6.14,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dobutamine,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.14,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
doxazosin,Alpha-2A adrenergic receptor,ADRA2A,6.14,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
epinephrine,Beta-2 adrenergic receptor,Adrb2,6.14,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
profenamine,Cholinesterase,BCHE,6.14,IC50,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
imipramine,D(2) dopamine receptor,Drd2,6.14,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
mexiletine,5-hydroxytryptamine receptor 2B,HTR2B,6.14,Ki,CC(N)COC1=C(C)C=CC=C1C
nandrolone,Corticosteroid-binding globulin,SERPINA6,6.14,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O
nandrolone decanoate,Corticosteroid-binding globulin,SERPINA6,6.14,Ki,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
nilotinib,Ephrin type-B receptor 4,EPHB4,6.14,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
pentamidine,Glutamate NMDA receptor; GRIN1/GRIN2A,GRIN1|GRIN2A,6.14,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
tolrestat,Alcohol dehydrogenase [NADP(+)],AKR1A1,6.14,IC50,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
dexibuprofen,Prostaglandin G/H synthase 2,PTGS2,6.14,IC50,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
pazopanib,LIM domain kinase 1,LIMK1,6.14,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
fingolimod,Transient receptor potential cation channel subfamily M member 7,Trpm7,6.14,IC50,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
ruxolitinib,Rhodopsin kinase,GRK1,6.14,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,6.14,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
nintedanib,Serine/threonine-protein kinase D2,PRKD2,6.14,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
crisaborole,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",PDE7A,6.14,IC50,OB1OCC2=CC(OC3=CC=C(C=C3)C#N)=CC=C12
midostaurin,Tyrosine-protein kinase HCK,HCK,6.14,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Protein kinase C alpha type,PRKCA,6.14,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Tyrosine-protein kinase Fgr,FGR,6.14,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,cAMP-dependent protein kinase catalytic subunit alpha,PRKACA,6.14,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Ephrin type-A receptor 1,EPHA1,6.14,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
suloctidil,Tyrosine-protein kinase Fyn,FYN,6.141,IC50,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
ceftriaxone,Peptidoglycan synthase FtsI,ftsI,6.142,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(=O)NN3C)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
clomifene,Alpha-2B adrenergic receptor,ADRA2B,6.142,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
sulconazole,Muscarinic acetylcholine receptor M3,CHRM3,6.142,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
sulconazole,Alpha-2C adrenergic receptor,ADRA2C,6.144,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
suloctidil,D(3) dopamine receptor,DRD3,6.146,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
citalopram,Alpha-1D adrenergic receptor,ADRA1D,6.148,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
diphenhydramine,5-hydroxytryptamine receptor 2B,HTR2B,6.148,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
gallamine,Muscarinic acetylcholine receptor M2,CHRM2,6.148,Ki,CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
atovaquone,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Dhodh,6.15,IC50,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O
celecoxib,Carbonic anhydrase 2,mtcA2,6.15,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorhexidine,Multidrug and toxin extrusion protein 1,SLC47A1,6.15,IC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
digitoxin,Signal transducer and activator of transcription 3,STAT3,6.15,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
elliptinium,Platelet-derived growth factor receptor alpha,PDGFRA,6.15,IC50,CC1=C2C=C[N+](C)=CC2=C(C)C2=C1NC1=CC=C(O)C=C21
erlotinib,Tyrosine-protein kinase JAK3,JAK3,6.15,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Proto-oncogene tyrosine-protein kinase Src,SRC,6.15,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Ephrin type-A receptor 5,EPHA5,6.15,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
flucytosine,ATP-dependent molecular chaperone HSP82,HSP82,6.15,EC50,NC1=NC(=O)NC=C1F
glutamic acid,"Glutamate receptor ionotropic, kainate 1",GRIK1,6.15,Ki,N[C@@H](CCC(O)=O)C(O)=O
glutamic acid,"Glutamate receptor ionotropic, kainate 5",GRIK5,6.15,Ki,N[C@@H](CCC(O)=O)C(O)=O
memantine,"Glutamate receptor ionotropic, NMDA 2C",Grin2c,6.15,Ki,CC12CC3CC(C)(C1)CC(N)(C3)C2
pethidine,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,6.15,EC50,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
moxonidine,5-hydroxytryptamine receptor 1A,Htr1a,6.15,IC50,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1
pioglitazone,Peroxisome proliferator-activated receptor gamma,Pparg,6.15,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
pioglitazone,Peroxisome proliferator-activated receptor gamma,Pparg,6.15,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
raloxifene,Complement C5,C5,6.15,Kd,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
raloxifene,Complement C5,C5,6.15,Kd,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sunitinib,Serine/threonine-protein kinase N1,PKN1,6.15,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Dual specificity mitogen-activated protein kinase kinase 4,MAP2K4,6.15,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
theophylline,Adenosine receptor A1,Adora1,6.15,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
trifluoperazine,NS3,NS3,6.15,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
valdecoxib,Carbonic anhydrase 2,CAN2,6.15,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
rasagiline,Amine oxidase [flavin-containing] B,MAOB,6.15,Ki,C#CCN[C@@H]1CCC2=C1C=CC=C2
ruboxistaurin,3-phosphoinositide-dependent protein kinase 1,PDPK1,6.15,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,6.15,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Tyrosine-protein kinase receptor Tie-1,TIE1,6.15,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Ephrin type-A receptor 3,EPHA3,6.15,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,6.15,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase PLK3,PLK3,6.15,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Serine/threonine-protein kinase VRK2,VRK2,6.15,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Mitogen-activated protein kinase kinase kinase 11,MAP3K11,6.15,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
flunarizine,Muscarinic acetylcholine receptor M1,CHRM1,6.151,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
aclarubicin,5-hydroxytryptamine receptor 2B,HTR2B,6.152,Ki,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C2=C(O)C3=C(C=C2[C@H]1C(=O)OC)C(=O)C1=CC=CC(O)=C1C3=O
carvedilol,5-hydroxytryptamine receptor 6,HTR6,6.152,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
tetracaine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.153,Ki,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
trazodone,D(4) dopamine receptor,DRD4,6.153,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
adenosine,Adenosine receptor A2a,ADORA2A,6.155,EC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
astemizole,Sodium-dependent serotonin transporter,SLC6A4,6.155,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
bromperidol,Histamine H1 receptor,HRH1,6.155,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
fluoxetine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.155,IC50,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
fluoxetine,Cytochrome P450 2D6,CYP2D6,6.155,IC50,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
ketanserin,Synaptic vesicular amine transporter,SLC18A2,6.155,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
mosapride,Cytochrome P450 3A4,CYP3A4,6.155,IC50,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
omeprazole,Potassium-transporting ATPase,ATP4B|ATP4A,6.155,IC50,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
thiethylperazine,5-hydroxytryptamine receptor 1A,HTR1A,6.155,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
tenidap,Cytochrome P450 2C9,CYP2C9,6.155,IC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
domperidone,5-hydroxytryptamine receptor 2C,HTR2C,6.156,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
fluoxetine,Alpha-2B adrenergic receptor,ADRA2B,6.156,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
mepyramine,Sodium-dependent dopamine transporter,SLC6A3,6.156,Ki,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
molindone,D(2) dopamine receptor,DRD2,6.157,IC50,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
dexchlorpheniramine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.157,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
candesartan cilexetil,Adenosine receptor A3,ADORA3,6.16,Ki,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
celecoxib,Alpha-2B adrenergic receptor,ADRA2B,6.16,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
celecoxib,Carbonic anhydrase 14,CA14,6.16,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
celecoxib,Carbonic anhydrase,CA2,6.16,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
clotrimazole,Nuclear receptor subfamily 1 group I member 3,NR1I3,6.16,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clozapine,Transporter,Slc6a2,6.16,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,D(2) dopamine receptor,DRD2,6.16,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
diacerein,N-acylethanolamine-hydrolyzing acid amidase,NAAA,6.16,IC50,CC(=O)OC1=C2C(=O)C3=C(OC(C)=O)C=C(C=C3C(=O)C2=CC=C1)C(O)=O
erlotinib,MAP kinase-interacting serine/threonine-protein kinase 1,MKNK1,6.16,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
flunarizine,5-hydroxytryptamine receptor 2B,HTR2B,6.16,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
haloprogin,5-hydroxytryptamine receptor 2A,HTR2A,6.16,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
pergolide,Alpha-1B adrenergic receptor,ADRA1B,6.16,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pramipexole,5-hydroxytryptamine receptor 1A,HTR1A,6.16,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
sorafenib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,6.16,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
gabexate,Prothrombin,F2,6.16,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
quercetin,Inositol hexakisphosphate kinase 2,IP6K2,6.16,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha,PIP5K1A,6.16,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
crizotinib,LIM domain kinase 2,LIMK2,6.16,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase TBK1,TBK1,6.16,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,cGMP-dependent protein kinase 2,PRKG2,6.16,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,ALK tyrosine kinase receptor,ALK,6.16,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
eltrombopag,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.16,IC50,CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC(=CC=C2)C(O)=O)=C1O)C1=CC(C)=C(C)C=C1
corticotropin,Melanocortin receptor 4,MC4R,6.16,Ki,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
quizartinib,Discoidin domain-containing receptor 2,DDR2,6.16,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Tyrosine-protein kinase receptor Tie-1,TIE1,6.16,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase MARK1,MARK1,6.16,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
benzquinamide,Alpha-2B adrenergic receptor,ADRA2B,6.161,Ki,CCN(CC)C(=O)C1CN2CCC3=C(C=C(OC)C(OC)=C3)C2CC1OC(C)=O
esketamine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,6.161,Ki,CN[C@@]1(CCCCC1=O)C1=C(Cl)C=CC=C1
oxymetazoline,Alpha-1B adrenergic receptor,Adra1b,6.162,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
yohimbine,D(2) dopamine receptor,DRD2,6.163,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
maprotiline,Muscarinic acetylcholine receptor M2,CHRM2,6.164,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
zolpidem,GABA A receptor alpha-3/beta-2/gamma-2,GABRG2|GABRA3|GABRB2,6.164,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
maprotiline,Alpha-2A adrenergic receptor,ADRA2A,6.165,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
pecazine,D(3) dopamine receptor,DRD3,6.167,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
tamoxifen,Muscarinic acetylcholine receptor M1,CHRM1,6.167,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
amiodarone,Muscarinic acetylcholine receptor M3,CHRM3,6.168,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
ouabain,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,6.169,IC50,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O
oxiconazole,D(3) dopamine receptor,DRD3,6.169,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
apomorphine,Alpha-1B adrenergic receptor,ADRA1B,6.17,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
beraprost,Prostaglandin E2 receptor EP3 subtype,PTGER3,6.17,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12
bicalutamide,Androgen receptor,Ar,6.17,IC50,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
chlorpromazine,5-hydroxytryptamine receptor 1A,HTR1A,6.17,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
erlotinib,Citron Rho-interacting kinase,CIT,6.17,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
famotidine,Carbonic anhydrase 14,CA14,6.17,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
fentanyl,Delta-type opioid receptor,OPRD1,6.17,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
lapatinib,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta,PIK3C2B,6.17,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
mebendazole,Calmodulin-domain protein kinase 1,CDPK1,6.17,IC50,COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1=CC=CC=C1
ondansetron,Gastrin/cholecystokinin type B receptor,Cckbr,6.17,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
ondansetron,Sigma non-opioid intracellular receptor 1,Sigmar1,6.17,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
quetiapine,Transporter,NET,6.17,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
ripazepam,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,6.17,IC50,CCN1N=C(C)C2=C1C(=NCC(=O)N2)C1=CC=CC=C1
sorafenib,Ephrin type-A receptor 7,EPHA7,6.17,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spironolactone,Androgen receptor,Ar,6.17,IC50,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
sunitinib,Non-receptor tyrosine-protein kinase TNK1,TNK1,6.17,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,"Interferon-induced, double-stranded RNA-activated protein kinase",EIF2AK2,6.17,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Dual specificity tyrosine-phosphorylation-regulated kinase 2,DYRK2,6.17,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
valdecoxib,Carbonic anhydrase 2,mtcA2,6.17,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
quercetin,NADPH oxidase 4,NOX4,6.17,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
vildagliptin,Dipeptidyl peptidase 9,DPP9,6.17,IC50,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
telaprevir,Neutrophil elastase,ELANE,6.17,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
crizotinib,Tyrosine-protein kinase Fgr,FGR,6.17,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Serine/threonine-protein kinase ULK3,ULK3,6.17,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Mitogen-activated protein kinase kinase kinase 12,MAP3K12,6.17,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
gepirone,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,6.17,IC50,CC1(C)CC(=O)N(CCCCN2CCN(CC2)C2=NC=CC=N2)C(=O)C1
Choline C-11,High affinity choline transporter 1,Slc5a7,6.17,Ki,C[N+](C)([11CH3])CCO
nintedanib,Serine/threonine-protein kinase 17B,STK17B,6.17,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase SIK1,SIK1,6.17,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Vascular endothelial growth factor receptor 3,FLT4,6.17,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Tyrosine-protein kinase JAK1,JAK1,6.17,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,6.17,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,6.17,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Activated CDC42 kinase 1,TNK2,6.17,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,STE20-like serine/threonine-protein kinase,SLK,6.17,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cefiderocol,"Peptidoglycan D,D-transpeptidase FtsI",ftsI,6.17,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
selegiline,Alpha-2A adrenergic receptor,ADRA2A,6.171,Ki,C[C@H](CC1=CC=CC=C1)N(C)CC#C
fenfluramine,5-hydroxytryptamine receptor 1A,HTR1A,6.172,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
carvedilol,Sodium-dependent dopamine transporter,SLC6A3,6.173,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
dapiprazole,5-hydroxytryptamine receptor 2B,HTR2B,6.173,Ki,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
imipramine,D(2) dopamine receptor,DRD2,6.173,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
tamoxifen,Muscarinic acetylcholine receptor M4,CHRM4,6.173,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
miconazole,Muscarinic acetylcholine receptor M3,CHRM3,6.175,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ticlopidine,Cytochrome P450 2C19,CYP2C19,6.175,IC50,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
dexfenfluramine,Sodium-dependent serotonin transporter,SLC6A4,6.176,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
fenfluramine,Sodium-dependent serotonin transporter,SLC6A4,6.176,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
ketotifen,D(3) dopamine receptor,DRD3,6.176,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
atropine,Alpha-1D adrenergic receptor,ADRA1D,6.177,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
cisapride,Alpha-2A adrenergic receptor,ADRA2A,6.177,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
clomifene,5-hydroxytryptamine receptor 2C,HTR2C,6.177,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
maprotiline,D(2) dopamine receptor,DRD2,6.177,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
suloctidil,Sodium-dependent serotonin transporter,SLC6A4,6.177,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
econazole,Sodium-dependent dopamine transporter,SLC6A3,6.178,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
amantadine,Matrix protein 2,M,6.18,EC50,NC12CC3CC(CC(C3)C1)C2
betaxolol,Beta-2 adrenergic receptor,ADRB2,6.18,IC50,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
buspirone,D(3) dopamine receptor,DRD3,6.18,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
celecoxib,Sodium-dependent dopamine transporter,SLC6A3,6.18,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
dexniguldipine,Alpha-2B adrenergic receptor,ADRA2B,6.18,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
ditiocarb,"Carbonic anhydrase 2, isoform A; LD26647p",CAH2,6.18,Ki,CCN(CC)C(S)=S
epinephrine,Beta-2 adrenergic receptor,ADRB2,6.18,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
etilamfetamine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.18,Ki,CCNC(C)CC1=CC=CC=C1
glibenclamide,Peroxisome proliferator-activated receptor gamma,PPARG,6.18,Ki,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
glibenclamide,Peroxisome proliferator-activated receptor gamma,PPARG,6.18,Ki,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
lofexidine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.18,IC50,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
methazolamide,Carbonic anhydrase 2,mtcA2,6.18,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methylphenidate,Sodium-dependent noradrenaline transporter,SLC6A2,6.18,Ki,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
perhexiline,Muscarinic acetylcholine receptor M3,CHRM3,6.18,Ki,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
progesterone,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.18,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
sultiame,Carbonic anhydrase 2,mtcA2,6.18,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
terguride,Beta-1 adrenergic receptor,ADRB1,6.18,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
valdecoxib,Carbonic anhydrase,NCE103,6.18,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
xamoterol,Beta-2 adrenergic receptor,ADRB2,6.18,Kd,OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1
azacyclonol,Histamine H1 receptor,HRH1,6.18,Ki,OC(C1CCNCC1)(C1=CC=CC=C1)C1=CC=CC=C1
mozavaptan,Oxytocin receptor,OXTR,6.18,Ki,CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C2=CC=CC=C12
ruxolitinib,Serine/threonine-protein kinase MARK2,MARK2,6.18,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
vilazodone,D(2) dopamine receptor,DRD2,6.18,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
vilazodone,D(2) dopamine receptor,Drd2,6.18,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
bosutinib,Ribosomal protein S6 kinase beta-1,RPS6KB1,6.18,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ipidacrine,Acetylcholinesterase,ACHE,6.18,IC50,NC1=C2CCCC2=NC2=C1CCCC2
avibactam,Beta-lactamase,ampC,6.18,Kd,NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O
midostaurin,Protein-tyrosine kinase 2-beta,PTK2B,6.18,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
remimazolam,GABA A receptor alpha-2/beta-2/gamma-2,Gabrg2|Gabra2|Gabrb2,6.18,EC50,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
thiothixene,5-hydroxytryptamine receptor 1D,HTR1D,6.181,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
haloperidol,Muscarinic acetylcholine receptor M5,CHRM5,6.182,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
yohimbine,Alpha-1B adrenergic receptor,Adra1b,6.182,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
amifostine,D(3) dopamine receptor,DRD3,6.184,Ki,NCCCNCCSP(O)(O)=O
mepyramine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.184,Ki,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
bithionol,Adenosine receptor A2a,ADORA2A,6.184,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
ebastine,Sodium-dependent serotonin transporter,SLC6A4,6.185,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
perhexiline,Muscarinic acetylcholine receptor M1,CHRM1,6.185,Ki,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
trifluoperazine,Alpha-2A adrenergic receptor,ADRA2A,6.185,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
mitotane,5-hydroxytryptamine receptor 6,HTR6,6.186,Ki,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
sertraline,Alpha-2C adrenergic receptor,ADRA2C,6.187,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
fesoterodine,Muscarinic acetylcholine receptor M4,CHRM4,6.187,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
desloratadine,D(3) dopamine receptor,DRD3,6.189,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
amiodarone,THAP domain-containing protein 1,THAP1,6.19,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
celecoxib,Histone deacetylase 6,HDAC6,6.19,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
dasatinib,Tyrosine-protein kinase JAK3,JAK3,6.19,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,6.19,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Calcium-dependent protein kinase 1,CPK1,6.19,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
donepezil,Butyrylcholinesterase,BCHE,6.19,Ki,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
etryptamine,Transporter,Slc6a2,6.19,EC50,CCC(N)CC1=CNC2=C1C=CC=C2
ibandronic acid,Squalene synthase,Fdft1,6.19,IC50,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
imipramine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,6.19,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
nafamostat,Kallikrein-1,KLK1,6.19,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
nifekalant,Multidrug and toxin extrusion protein 1,SLC47A1,6.19,IC50,CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N+]([O-])=O)N(C)C1=O
nilotinib,Ephrin type-A receptor 6,EPHA6,6.19,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Ephrin type-B receptor 2,EPHB2,6.19,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norepinephrine,Alpha-2C adrenergic receptor,Adra2c,6.19,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
oxaprozin,Complement C5,C5,6.19,Kd,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
oxaprozin,Complement C5,C5,6.19,Kd,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
perphenazine,Alpha-2A adrenergic receptor,ADRA2A,6.19,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
ranitidine,Acetylcholinesterase,ACHE,6.19,IC50,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O
sorafenib,Serine/threonine-protein kinase NLK,NLK,6.19,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfanilamide,Carbonate dehydratase,,6.19,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sumatriptan,5-hydroxytryptamine receptor 1A,Htr1a,6.19,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Serine/threonine-protein kinase PAK 7,PAK5,6.19,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,SNF-related serine/threonine-protein kinase,SNRK,6.19,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terfenadine,5-hydroxytryptamine receptor 2C,HTR2C,6.19,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
trichlormethiazide,Carbonic anhydrase 13,Ca13,6.19,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
venlafaxine,Transporter,NET,6.19,IC50,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
zonisamide,Carbonic anhydrase,CA2,6.19,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
ruboxistaurin,Serine/threonine-protein kinase RIO3,RIOK3,6.19,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase LATS2,LATS2,6.19,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
crizotinib,Ribosomal protein S6 kinase beta-1,RPS6KB1,6.19,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
acetic acid,Tyrosine-protein kinase Lck,LCK,6.19,Kd,CC(O)=O
bosutinib,Serine/threonine-protein kinase Nek11,NEK11,6.19,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
plerixafor,C-C chemokine receptor type 4,CCR4,6.19,IC50,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
nintedanib,Serine/threonine-protein kinase D3,PRKD3,6.19,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Myosin light chain kinase family member 4,MYLK4,6.19,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,6.19,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase BRSK2,BRSK2,6.19,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,ALK tyrosine kinase receptor,ALK,6.19,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,6.19,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Tyrosine-protein kinase Blk,BLK,6.19,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Nek3,NEK3,6.19,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ebastine,Substance-K receptor,TACR2,6.191,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
hexachlorophene,Prostaglandin G/H synthase 2,PTGS2,6.191,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
benzethonium,Substance-K receptor,TACR2,6.192,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
raloxifene,Kappa-type opioid receptor,OPRK1,6.193,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sertindole,Alpha-2A adrenergic receptor,ADRA2A,6.194,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
fenfluramine,5-hydroxytryptamine receptor 1D,HTR1D,6.195,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
bithionol,Alpha-2C adrenergic receptor,ADRA2C,6.195,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
suloctidil,Muscarinic acetylcholine receptor M4,CHRM4,6.196,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
econazole,Muscarinic acetylcholine receptor M1,CHRM1,6.197,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
propranolol,5-hydroxytryptamine receptor 1B,HTR1B,6.197,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
ingenol mebutate,Protein kinase C alpha type,PRKCA,6.197,EC50,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C
droperidol,5-hydroxytryptamine receptor 4,HTR4,6.199,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
pramocaine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.199,Ki,CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1
adenosine triphosphate,P2Y purinoceptor 4,P2RY4,6.2,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
agomelatine,5-hydroxytryptamine receptor 2C,HTR2C,6.2,Ki,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
bortezomib,Cathepsin G,CTSG,6.2,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
bromocriptine,D(1A) dopamine receptor,DRD1,6.2,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
cabergoline,5-hydroxytryptamine receptor 2C,HTR2C,6.2,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
chlorpromazine,Alpha-2A adrenergic receptor,ADRA2A,6.2,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cicloprolol,Beta-2 adrenergic receptor,ADRB2,6.2,Ki,CC(C)NCC(O)COC1=CC=C(OCCOCC2CC2)C=C1
ciprofloxacin,DNA gyrase subunit A,gyrA,6.2,IC50,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
clozapine,5-hydroxytryptamine receptor 1B,HTR1B,6.2,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dichlorphenamide,Carbonic anhydrase,,6.2,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
diclofenac,Peroxisome proliferator-activated receptor gamma,PPARG,6.2,Ki,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dinoprost,Prostaglandin E2 receptor EP4 subtype,Ptger4,6.2,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dinoprost,Prostaglandin D2 receptor 2,Ptgdr2,6.2,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dobutamine,Beta-2 adrenergic receptor,ADRB2,6.2,EC50,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
epinephrine,Beta-2 adrenergic receptor,ADRB2,6.2,Kd,CNC[C@H](O)C1=CC=C(O)C(O)=C1
epinephrine,Alpha-1A adrenergic receptor,Adra1a,6.2,IC50,CNC[C@H](O)C1=CC=C(O)C(O)=C1
erlotinib,Serine/threonine-protein kinase ULK3,Ulk3,6.2,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Non-receptor tyrosine-protein kinase TNK1,TNK1,6.2,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
flunarizine,Sodium channel protein type 1 subunit alpha,SCN1A,6.2,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
furosemide,Solute carrier family 12 member 1,SLC12A1,6.2,IC50,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
gefitinib,Tyrosine-protein kinase Lck,LCK,6.2,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
haloperidol,Potassium voltage-gated channel subfamily H member 1,KCNH1,6.2,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hydrocortisone,Sex hormone-binding globulin,SHBG,6.2,Kd,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
iloprost,Prostaglandin F2-alpha receptor,PTGFR,6.2,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
medroxyprogesterone,Sex hormone-binding globulin,SHBG,6.2,Kd,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
metergoline,5-hydroxytryptamine receptor 5A,HTR5A,6.2,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
oxymetazoline,Alpha-2B adrenergic receptor,ADRA2B,6.2,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
pipamperone,5-hydroxytryptamine receptor 1B,HTR1B,6.2,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
pramipexole,Alpha-2B adrenergic receptor,ADRA2B,6.2,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
primidone,Transient receptor potential cation channel subfamily M member 3,TRPM3,6.2,IC50,CCC1(C(=O)NCNC1=O)C1=CC=CC=C1
ranitidine,Histamine H2 receptor,Hrh2,6.2,Ki,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O
roxithromycin,Motilin receptor,MLNR,6.2,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
sirolimus,Multidrug resistance protein 1,ABCB1,6.2,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
sulfanilamide,"Carbonic anhydrase, alpha family",,6.2,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Serine/threonine-protein kinase LATS1,LATS1,6.2,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zonisamide,Carbonic anhydrase 15,Ca15,6.2,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
yohimbine,5-hydroxytryptamine receptor 1F,Htr1f,6.2,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
telaprevir,Cathepsin K,CTSK,6.2,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
retigabine,Potassium voltage-gated channel subfamily KQT member 3,KCNQ3,6.2,EC50,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
bosutinib,Eukaryotic translation initiation factor 2-alpha kinase 1,EIF2AK1,6.2,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
canagliflozin,Protease,protease,6.2,Ki,CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
nintedanib,Tyrosine-protein kinase Fyn,FYN,6.2,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Mitogen-activated protein kinase 8,MAPK8,6.2,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Calcium/calmodulin-dependent protein kinase kinase 1,CAMKK1,6.2,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
deoxycholic acid,G-protein coupled bile acid receptor 1,GPBAR1,6.2,EC50,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
amiodarone,Muscarinic acetylcholine receptor M1,CHRM1,6.201,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
astemizole,5-hydroxytryptamine receptor 1B,Htr1b,6.201,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
dichlorphenamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.201,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
ergometrine,Alpha-2A adrenergic receptor,ADRA2A,6.201,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
tamoxifen,Muscarinic acetylcholine receptor M3,CHRM3,6.201,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
avanafil,"Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'",PDE6C,6.201,IC50,COC1=C(Cl)C=C(CNC2=NC(=NC=C2C(=O)NCC2=NC=CC=N2)N2CCC[C@H]2CO)C=C1
aripiprazole,5-hydroxytryptamine receptor 3A,HTR3A,6.202,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
raloxifene,Alpha-2A adrenergic receptor,ADRA2A,6.205,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
clomifene,Sodium-dependent dopamine transporter,SLC6A3,6.206,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
sulfadimethoxine,5-hydroxytryptamine receptor 6,HTR6,6.206,Ki,COC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(OC)=N1
prochlorperazine,Sodium-dependent serotonin transporter,SLC6A4,6.207,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
cinnarizine,5-hydroxytryptamine receptor 1A,HTR1A,6.208,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
oxiconazole,Thromboxane-A synthase,TBXAS1,6.209,IC50,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acetylcholine,Neuronal acetylcholine receptor; alpha3/beta4,Chrna3|Chrnb4,6.21,Ki,CC(=O)OCC[N+](C)(C)C
cefapirin,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.21,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
citalopram,5-hydroxytryptamine receptor 2C,HTR2C,6.21,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
dasatinib,Activin receptor type-1,ACVR1,6.21,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
gefitinib,Cyclin-dependent kinase 7,CDK7,6.21,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,Adenosine receptor A3,ADORA3,6.21,IC50,N[C@@H](CCC(O)=O)C(O)=O
ifenprodil,5-hydroxytryptamine receptor 2A,HTR2A,6.21,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
indomethacin,Cytochrome c oxidase subunit 2,MT-CO2,6.21,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
indoramin,Alpha-1D adrenergic receptor,Adra1d,6.21,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
ketamine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,6.21,IC50,CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1
mianserin,5-hydroxytryptamine receptor 3A,HTR3A,6.21,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
buphenine,Adrenergic receptor alpha-1,ADRA1D|ADRA1A|ADRA1B,6.21,Kd,CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1
olanzapine,5-hydroxytryptamine receptor 1A,Htr1a,6.21,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
oxymorphone,Delta-type opioid receptor,Oprd1,6.21,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
papaverine,Cyclic nucleotide phosphodiesterase PDE3A,,6.21,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
raloxifene,5-hydroxytryptamine receptor 2C,HTR2C,6.21,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
rivastigmine,Acetylcholinesterase,ACHE,6.21,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
sunitinib,Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,6.21,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Beta-carbonic anhydrase 1,mtcA1,6.21,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
trazodone,Histamine H1 receptor,HRH1,6.21,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
isoconazole,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,6.21,Ki,ClC1=CC=C([C@H](CN2C=CN=C2)OCC2=C(Cl)C=CC=C2Cl)C(Cl)=C1
picloxydine,Cholinesterase,BCHE,6.21,Ki,ClC1=CC=C(NC(=N)NC(=N)N2CCN(CC2)C(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
timolol,5-hydroxytryptamine receptor 1A,Htr1a,6.21,Ki,CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1
pazopanib,Fibroblast growth factor receptor 3,FGFR3,6.21,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Serine/threonine-protein kinase RIO2,RIOK2,6.21,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
gentian violet,Kappa-type opioid receptor,OPRK1,6.21,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
vandetanib,Serine/threonine-protein kinase PLK4,PLK4,6.21,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Receptor-interacting serine/threonine-protein kinase 4,RIPK4,6.21,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Serine/threonine-protein kinase 35,STK35,6.21,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
carfilzomib,Proteasome subunit beta type-10,PSMB10,6.21,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
ceritinib,Tyrosine-protein kinase JAK2,JAK2,6.21,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Ribosomal protein S6 kinase alpha-4,RPS6KA4,6.21,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Tyrosine-protein kinase receptor UFO,AXL,6.21,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
quizartinib,BDNF/NT-3 growth factors receptor,NTRK2,6.21,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,6.21,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase 17A,STK17A,6.21,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tirabrutinib hydrochloride,Receptor tyrosine-protein kinase erbB-2,ERBB2,6.21,Kd,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
tirabrutinib hydrochloride,Receptor tyrosine-protein kinase erbB-2,ERBB2,6.21,Kd,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
tepotinib,Interleukin-1 receptor-associated kinase 4,IRAK4,6.21,IC50,CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N
amoxapine,Muscarinic acetylcholine receptor M5,CHRM5,6.211,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
bithionol,Epidermal growth factor receptor,EGFR,6.212,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
ceftriaxone,Penicillin-binding protein 2,mrdA,6.213,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(=O)NN3C)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
diethylstilbestrol,Progesterone receptor,PGR,6.214,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
methysergide,Alpha-2A adrenergic receptor,ADRA2A,6.214,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
alosetron,Cytochrome P450 1A2,CYP1A2,6.218,IC50,CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC1=C(C)N=CN1)CC2
astemizole,Mu-type opioid receptor,OPRM1,6.218,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
cinnarizine,Muscarinic acetylcholine receptor M1,CHRM1,6.218,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
cyclizine,Sodium-dependent dopamine transporter,SLC6A3,6.218,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
fenofibrate,5-hydroxytryptamine receptor 2A,HTR2A,6.218,Ki,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
flunarizine,Alpha-1B adrenergic receptor,Adra1b,6.218,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
terfenadine,5-hydroxytryptamine receptor 6,HTR6,6.218,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
oxiconazole,Alpha-2C adrenergic receptor,ADRA2C,6.218,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
paliperidone,5-hydroxytryptamine receptor 1A,HTR1A,6.218,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
amiodarone,Thyroid hormone receptor beta,THRB,6.22,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amiodarone,Cytochrome P450 3A4,CYP3A4,6.22,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amoxicillin,5-hydroxytryptamine receptor 2A,HTR2A,6.22,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O
aripiprazole,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.22,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
captopril,Beta-lactamase class B VIM-2,blaVIM-2,6.22,Kd,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
chlorpromazine,Multidrug resistance protein 1,ABCB1,6.22,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlorpromazine,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,6.22,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cianidanol,Arginase,,6.22,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
clebopride,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.22,IC50,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
clebopride,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,6.22,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
clonidine,Alpha-1D adrenergic receptor,ADRA1D,6.22,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
ciclosporin,Bile salt export pump,Abcb11,6.22,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dilazep,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,6.22,IC50,COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN1CCCN(CCCOC(=O)C2=CC(OC)=C(OC)C(OC)=C2)CC1
dipyridamole,Phosphodiesterase 7,PDE7A|PDE7B,6.22,Ki,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
disulfiram,Histone-lysine N-methyltransferase EHMT2,EHMT2,6.22,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
erlotinib,Aurora kinase C,AURKC,6.22,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fluoxetine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.22,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
gefitinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,6.22,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
isoprenaline,Beta-1 adrenergic receptor,Adrb1,6.22,IC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
mecamylamine,Acetylcholine receptor subunit alpha,CHRNA1,6.22,IC50,CNC1(C)C2CCC(C2)C1(C)C
methotrexate,Thymidylate synthase,TYMS,6.22,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mezlocillin,Prostaglandin G/H synthase 2,PTGS2,6.22,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
mibefradil,Cytochrome P450 3A4,CYP3A4,6.22,Ki,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
miconazole,Aromatase,CYP19A1,6.22,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miglustat,Sucrase-isomaltase,Sis,6.22,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
mirtazapine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.22,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
nilotinib,NT-3 growth factor receptor,NTRK3,6.22,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norfloxacin,DNA topoisomerase 2-beta,TOP2B,6.22,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
penfluridol,Alpha-1D adrenergic receptor,ADRA1D,6.22,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
pentagastrin,Cholecystokinin receptor type A,Cckar,6.22,IC50,CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
propranolol,Beta-3 adrenergic receptor,ADRB3,6.22,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
sorafenib,NT-3 growth factor receptor,NTRK3,6.22,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiperone,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,6.22,IC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Serine/threonine-protein kinase/endoribonuclease IRE1,ERN1,6.22,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
testosterone,Aromatase,CYP19A1,6.22,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
verapamil,Cytochrome P450 3A4,CYP3A4,6.22,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
zileuton,Prostaglandin E synthase,PTGES,6.22,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
oleic acid,Peroxisome proliferator-activated receptor alpha,PPARA,6.22,IC50,CCCCCCCC\C=C/CCCCCCCC(O)=O
quercetin,Integrase,pol,6.22,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
crizotinib,Insulin receptor-related protein,INSRR,6.22,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
sulfur,Carbonic anhydrase 1,CA1,6.22,Ki,[S]
bosutinib,Dual specificity protein kinase CLK1,CLK1,6.22,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Interleukin-1 receptor-associated kinase 1,IRAK1,6.22,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tofacitinib,Ribosomal protein S6 kinase alpha-2,RPS6KA2,6.22,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Activin receptor type-1,ACVR1,6.22,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
fedratinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,6.22,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
thioguanine,Prostaglandin G/H synthase 1,PTGS1,6.221,IC50,NC1=NC2=C(NC=N2)C(=S)N1
amfetamine,Trace amine-associated receptor 1,TAAR1,6.222,EC50,CC(N)CC1=CC=CC=C1
anastrozole,Aromatase,CYP19A1,6.222,IC50,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
clemastine,Cytochrome P450 2C19,CYP2C19,6.222,IC50,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
alpha-Ergocryptine,Cytochrome P450 3A4,CYP3A4,6.222,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
gliclazide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,6.222,Kd,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1
mazindol,Histamine H1 receptor,HRH1,6.222,Ki,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
mecamylamine,Neuronal acetylcholine receptor; alpha3/beta4,CHRNB4|CHRNA3,6.222,Ki,CNC1(C)C2CCC(C2)C1(C)C
oxybutynin,Cytochrome P450 2C19,CYP2C19,6.222,IC50,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
sulconazole,Cytochrome P450 1A2,CYP1A2,6.222,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
podophyllotoxin,Cytochrome P450 3A4,CYP3A4,6.222,IC50,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
dobutamine,Arachidonate 15-lipoxygenase,ALOX15,6.223,IC50,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
ketobemidone,Kappa-type opioid receptor,OPRK1,6.223,Ki,CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1
reserpine,D(3) dopamine receptor,DRD3,6.223,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
cyclizine,Alpha-1D adrenergic receptor,ADRA1D,6.224,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
ebastine,D(1A) dopamine receptor,DRD1,6.224,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
felodipine,Adenosine receptor A3,ADORA3,6.224,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
suloctidil,5-hydroxytryptamine receptor 2B,HTR2B,6.224,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
levonorgestrel,Sodium-dependent serotonin transporter,SLC6A4,6.225,Ki,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
methylergometrine,Alpha-2A adrenergic receptor,ADRA2A,6.225,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
nortriptyline,Cytochrome P450 2D6,CYP2D6,6.225,Km,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
spironolactone,Glucocorticoid receptor,NR3C1,6.227,IC50,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
methapyrilene,Muscarinic acetylcholine receptor M2,CHRM2,6.228,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
mepyramine,5-hydroxytryptamine receptor 2C,HTR2C,6.228,Ki,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
fluspirilene,Beta-1 adrenergic receptor,ADRB1,6.229,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
femoxetine,D(2) dopamine receptor,DRD2,6.229,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
halcinonide,Androgen receptor,Ar,6.229,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl
bortezomib,Proteasome subunit beta type-2,PSMB2,6.23,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
carbachol,Neuronal acetylcholine receptor; alpha4/beta2,Chrna4|Chrnb2,6.23,Ki,C[N+](C)(C)CCOC(N)=O
carvedilol,5-hydroxytryptamine receptor 1B,Htr1b,6.23,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
dihydroergocristine,D(1A) dopamine receptor,DRD1,6.23,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
doxazosin,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.23,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
gefitinib,Ephrin type-A receptor 6,EPHA6,6.23,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
nilotinib,Ephrin type-A receptor 1,EPHA1,6.23,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
pioglitazone,Peroxisome proliferator-activated receptor gamma,PPARG,6.23,EC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
sunitinib,BDNF/NT-3 growth factors receptor,NTRK2,6.23,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zileuton,Bifunctional epoxide hydrolase 2,EPHX2,6.23,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
quercetin,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.23,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,G protein-coupled receptor kinase 4,GRK4,6.23,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
tamibarotene,Retinoic acid receptor gamma,RARG,6.23,EC50,CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12
pazopanib,Dual specificity mitogen-activated protein kinase kinase 4,MAP2K4,6.23,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vorinostat,Histone deacetylase 8,HDAC8,6.23,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
ruxolitinib,Serine/threonine-protein kinase TAO3,TAOK3,6.23,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
nintedanib,"Muscle, skeletal receptor tyrosine-protein kinase",MUSK,6.23,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
avibactam,Penicillin-binding protein 2,mrdA,6.23,IC50,NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O
avibactam,Penicillin-binding protein 2,mrdA,6.23,IC50,NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O
midostaurin,Serine/threonine-protein kinase 10,STK10,6.23,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase Fes/Fps,FES,6.23,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,6.23,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 13,MAP3K13,6.23,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
amiodarone,5-hydroxytryptamine receptor 2B,HTR2B,6.231,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
haloprogin,Alpha-2C adrenergic receptor,ADRA2C,6.231,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
reserpine,D(2) dopamine receptor,DRD2,6.232,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
olanzapine,5-hydroxytryptamine receptor 1B,HTR1B,6.233,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
cyclizine,Alpha-2A adrenergic receptor,ADRA2A,6.235,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
cinnarizine,Sodium-dependent serotonin transporter,SLC6A4,6.237,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
melperone,Histamine H1 receptor,HRH1,6.237,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
thioridazine,5-hydroxytryptamine receptor 1D,HTR1D,6.237,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
carprofen,Complement C5,C5,6.24,Kd,CC(C(O)=O)C1=CC2=C(C=C1)C1=CC(Cl)=CC=C1N2
carprofen,Complement C5,C5,6.24,Kd,CC(C(O)=O)C1=CC2=C(C=C1)C1=CC(Cl)=CC=C1N2
chloropyramine,Focal adhesion kinase 1,PTK2,6.24,Kd,CN(C)CCN(CC1=CC=C(Cl)C=C1)C1=CC=CC=N1
ciclosporin,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Pik3cg,6.24,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dasatinib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,6.24,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,LIM domain kinase 1,LIMK1,6.24,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Activin receptor type-2B,ACVR2B,6.24,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
erlotinib,Serine/threonine-protein kinase TNNI3K,TNNI3K,6.24,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fenofibrate,Peroxisome proliferator-activated receptor gamma,PPARG,6.24,EC50,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
metyrapone,Cytochrome P450 11B1,CYP11B1,6.24,Ki,CC(C)(C(=O)C1=CN=CC=C1)C1=CN=CC=C1
mianserin,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,6.24,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
miglustat,"Sucrase-isomaltase, intestinal",Si,6.24,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nefazodone,Transporter,Slc6a2,6.24,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nilotinib,Serine/threonine-protein kinase B-raf,BRAF,6.24,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
solifenacin,Muscarinic acetylcholine receptor M2,CHRM2,6.24,IC50,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
sotalol,Beta-2 adrenergic receptor,ADRB2,6.24,Kd,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
sulindac,Complement C5,C5,6.24,Kd,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
sulindac,Complement C5,C5,6.24,Kd,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
sunitinib,Serine/threonine-protein kinase SIK2,SIK2,6.24,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Bone morphogenetic protein receptor type-2,BMPR2,6.24,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tolfenamic acid,Prostaglandin G/H synthase 1,PTGS1,6.24,IC50,CC1=C(NC2=C(C=CC=C2)C(O)=O)C=CC=C1Cl
tretinoin,Mitogen-activated protein kinase 1,MAPK1,6.24,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
valdecoxib,Carbonic anhydrase 6,CA6,6.24,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
quercetin,Hepatocyte growth factor receptor,MET,6.24,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
xylometazoline,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.24,IC50,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
pazopanib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,6.24,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Serine/threonine-protein kinase 4,STK4,6.24,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Ephrin type-B receptor 4,EPHB4,6.24,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
afatinib,Tyrosine-protein kinase Lck,LCK,6.24,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Focal adhesion kinase 1,PTK2,6.24,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase 36,STK36,6.24,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase tousled-like 1,TLK1,6.24,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Bone morphogenetic protein receptor type-2,BMPR2,6.24,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Proto-oncogene tyrosine-protein kinase Src,SRC,6.24,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
niraparib,Tankyrase-1,TNKS,6.24,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
midostaurin,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma,PIK3C2G,6.24,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Epidermal growth factor receptor,EGFR,6.24,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Abelson tyrosine-protein kinase 2,ABL2,6.24,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Nek5,NEK5,6.24,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,6.24,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
benzquinamide,D(4) dopamine receptor,DRD4,6.241,Ki,CCN(CC)C(=O)C1CN2CCC3=C(C=C(OC)C(OC)=C3)C2CC1OC(C)=O
quetiapine,Alpha-2C adrenergic receptor,ADRA2C,6.241,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
gentian violet,Alpha-2B adrenergic receptor,ADRA2B,6.241,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
cinnarizine,Alpha-1D adrenergic receptor,ADRA1D,6.242,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
clomipramine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.243,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
tirilazad,5-hydroxytryptamine receptor 2A,HTR2A,6.243,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
cefotaxime,Peptidoglycan synthase FtsI,ftsI,6.244,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
chlorpromazine,Aldehyde oxidase,AOX1,6.244,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
eptifibatide,Integrin alpha-IIb/beta-3,ITGB3|ITGA2B,6.244,IC50,NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O
ethinylestradiol,Aldehyde oxidase,AOX1,6.244,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
fluspirilene,Alpha-2A adrenergic receptor,ADRA2A,6.244,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
sertraline,5-hydroxytryptamine receptor 2C,HTR2C,6.246,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
idelalisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",PIK3CB,6.248,IC50,CC[C@H](NC1=NC=NC2=C1NC=N2)C1=NC2=C(C(F)=CC=C2)C(=O)N1C1=CC=CC=C1
amitriptyline,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.25,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
chlordiazepoxide,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,6.25,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
dexamethasone,Progesterone receptor,PGR,6.25,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
dexamethasone palmitate,Progesterone receptor,PGR,6.25,Ki,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
dexamethasone valerate,Progesterone receptor,PGR,6.25,Ki,CCCCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
ethambutol,Cytochrome P450 3A4,CYP3A4,6.25,IC50,CC[C@@H](CO)NCCN[C@@H](CC)CO
floxacillin,Androgen receptor,AR,6.25,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1F
furosemide,Carbonic anhydrase 4,CA4,6.25,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
gefitinib,Serine/threonine-protein kinase SBK1,SBK1,6.25,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
hexylresorcinol,Tyrosinase,TYR,6.25,IC50,CCCCCCC1=C(O)C=C(O)C=C1
hymecromone,Carbonic anhydrase 9,CA9,6.25,Ki,CC1=CC(=O)OC2=C1C=CC(O)=C2
maprotiline,Alpha-1A adrenergic receptor,Adra1a,6.25,IC50,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
methazolamide,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,6.25,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
pemetrexed,Dihydrofolate reductase,Dhfr,6.25,Ki,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
dexamethasone phosphate,Progesterone receptor,PGR,6.25,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
vandetanib,Fibroblast growth factor receptor 1,FGFR1,6.25,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Proto-oncogene tyrosine-protein kinase Src,SRC,6.25,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Misshapen-like kinase 1,MINK1,6.25,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
vortioxetine,Beta-2 adrenergic receptor,ADRB2,6.25,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
ceritinib,Tyrosine-protein kinase Lck,LCK,6.25,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
rucaparib,Poly [ADP-ribose] polymerase 10,PARP10,6.25,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
midostaurin,Serine/threonine-protein kinase pim-1,PIM1,6.25,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Hepatocyte growth factor receptor,MET,6.25,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase SIK2,SIK2,6.25,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase pim-3,PIM3,6.25,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
chlordiazepoxide,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,6.252,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
fluphenazine,Histamine H2 receptor,HRH2,6.252,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,Histamine H2 receptor,HRH2,6.252,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
mepacrine,Alpha-2C adrenergic receptor,ADRA2C,6.252,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
bithionol,Alpha-2B adrenergic receptor,ADRA2B,6.252,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
gentian violet,Substance-K receptor,TACR2,6.252,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
ebastine,Epidermal growth factor receptor,EGFR,6.253,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ambroxol,Cytochrome P450 2D6,CYP2D6,6.254,IC50,NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br
molindone,Alpha-2B adrenergic receptor,ADRA2B,6.254,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
dacarbazine,Matrix metalloproteinase-9,MMP9,6.255,IC50,CN(C)\N=N\C1=C(NC=N1)C(N)=O
mifepristone,Arachidonate 15-lipoxygenase,ALOX15,6.256,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
sulconazole,Muscarinic acetylcholine receptor M4,CHRM4,6.258,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
bepridil,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.26,IC50,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
dabigatran etexilate,Thrombin,thrombin,6.26,IC50,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
dipyridamole,Replicase polyprotein 1ab,REP,6.26,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
fentiazac,Prostaglandin D2 receptor 2,PTGDR2,6.26,IC50,OC(=O)CC1=C(N=C(S1)C1=CC=CC=C1)C1=CC=C(Cl)C=C1
furosemide,Carbonic anhydrase 13,Ca13,6.26,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
haloperidol,Alpha-2C adrenergic receptor,ADRA2C,6.26,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
methylthioninium chloride,Amyloid beta A4 protein,APP,6.26,IC50,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
metoclopramide,5-hydroxytryptamine receptor 4,HTR4,6.26,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
mezlocillin,Prostaglandin D2 receptor 2,PTGDR2,6.26,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
olanzapine,Sodium-dependent serotonin transporter,SLC6A4,6.26,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
pemetrexed,Thymidylate synthase,thyA,6.26,Ki,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
phentolamine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.26,IC50,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
salmeterol,Beta-1 adrenergic receptor,Adrb1,6.26,Ki,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
salmeterol,Beta-1 adrenergic receptor,Adrb1,6.26,Ki,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
suloctidil,5-hydroxytryptamine receptor 1A,Htr1a,6.26,IC50,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
sunitinib,Proto-oncogene tyrosine-protein kinase Src,SRC,6.26,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Casein kinase I isoform alpha-like,CSNK1A1L,6.26,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tetroxoprim,Dihydrofolate reductase,folA,6.26,Ki,COCCOC1=C(OC)C=C(CC2=CN=C(N)N=C2N)C=C1OC
zotepine,Muscarinic acetylcholine receptor M4,CHRM4,6.26,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
terazosin,Alpha-2A adrenergic receptor,ADRA2A,6.26,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
thiram,Histone-lysine N-methyltransferase EHMT2,EHMT2,6.26,IC50,CN(C)C(=S)SSC(=S)N(C)C
romidepsin,Histone deacetylase 5,HDAC5,6.26,Ki,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
vandetanib,Leukocyte tyrosine kinase receptor,LTK,6.26,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
axitinib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,6.26,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,6.26,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tofacitinib,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,6.26,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Ephrin type-B receptor 1,EPHB1,6.26,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Tyrosine-protein kinase CSK,CSK,6.26,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
quizartinib,NT-3 growth factor receptor,NTRK3,6.26,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
ceftazidime,Peptidoglycan synthase FtsI,ftsI,6.261,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1)C(O)=O
roxithromycin,Alpha-1B adrenergic receptor,Adra1b,6.261,Ki,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
dexchlorpheniramine,Muscarinic acetylcholine receptor M3,CHRM3,6.262,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
droperidol,D(1A) dopamine receptor,DRD1,6.263,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
guanfacine,Alpha-1D adrenergic receptor,ADRA1D,6.263,Ki,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
pecazine,Alpha-2A adrenergic receptor,ADRA2A,6.263,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
benzquinamide,Alpha-2C adrenergic receptor,ADRA2C,6.264,Ki,CCN(CC)C(=O)C1CN2CCC3=C(C=C(OC)C(OC)=C3)C2CC1OC(C)=O
cinnarizine,Muscarinic acetylcholine receptor M5,CHRM5,6.264,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
terfenadine,Alpha-2C adrenergic receptor,ADRA2C,6.264,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
quetiapine,Muscarinic acetylcholine receptor M4,CHRM4,6.266,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
floctafenine,Prostaglandin G/H synthase 1,PTGS1,6.268,IC50,OCC(O)COC(=O)C1=C(NC2=CC=NC3=C(C=CC=C23)C(F)(F)F)C=CC=C1
fluphenazine,5-hydroxytryptamine receptor 1E,HTR1E,6.268,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,5-hydroxytryptamine receptor 1E,HTR1E,6.268,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
imatinib,5-hydroxytryptamine receptor 2A,HTR2A,6.268,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
isotretinoin,5-hydroxytryptamine receptor 2B,HTR2B,6.268,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
methylergometrine,D(1A) dopamine receptor,DRD1,6.268,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
teneligliptin,Dipeptidyl peptidase 9,DPP9,6.268,IC50,CC1=NN(C(=C1)N1CCN(CC1)[C@@H]1CN[C@@H](C1)C(=O)N1CCSC1)C1=CC=CC=C1
clemastine,Sodium-dependent dopamine transporter,SLC6A3,6.269,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
zafirlukast,Mitogen-activated protein kinase 1,MAPK1,6.269,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
benzethonium,5-hydroxytryptamine receptor 2C,HTR2C,6.269,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
celecoxib,Cytochrome c oxidase subunit 2,MT-CO2,6.27,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
desipramine,Muscarinic acetylcholine receptor M2,CHRM2,6.27,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
diazepam,"Fatty acid-binding protein, liver",Fabp1,6.27,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
droperidol,Muscarinic acetylcholine receptor M4,CHRM4,6.27,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
galantamine,Acetylcholinesterase,Ache,6.27,IC50,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
gefitinib,Interleukin-1 receptor-associated kinase 4,IRAK4,6.27,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
meclofenamic acid,Aldo-keto reductase family 1 member C3,AKR1C3,6.27,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
methapyrilene,5-hydroxytryptamine receptor 2B,HTR2B,6.27,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
nemonapride,Alpha-1A adrenergic receptor,Adra1a,6.27,IC50,CNC1=CC(OC)=C(C=C1Cl)C(=O)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C
sorafenib,Serine/threonine-protein kinase TAO1,TAOK1,6.27,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Serine/threonine-protein kinase TAO2,TAOK2,6.27,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
tolmetin,Prostaglandin G/H synthase 1,PTGS1,6.27,IC50,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
tolrestat,Alcohol dehydrogenase [NADP(+)],AKR1A1,6.27,IC50,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
troglitazone,Peroxisome proliferator-activated receptor gamma,PPARG,6.27,EC50,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
dibrompropamidine,Suppressor of tumorigenicity 14 protein,ST14,6.27,Ki,NC(=N)C1=CC(Br)=C(OCCCOC2=C(Br)C=C(C=C2)C(N)=N)C=C1
ruboxistaurin,Serine/threonine-protein kinase Chk1,CHEK1,6.27,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
androstanolone,Glucocorticoid receptor,NR3C1,6.27,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
ruxolitinib,G protein-coupled receptor kinase 7,GRK7,6.27,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
paraoxon,Fatty-acid amide hydrolase 1,Faah,6.27,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
tofacitinib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,6.27,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Serine/threonine-protein kinase DCLK1,DCLK1,6.27,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Protein kinase C epsilon type,PRKCE,6.27,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Calcium/calmodulin-dependent protein kinase type II subunit gamma,CAMK2G,6.27,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
vinorelbine,Substance-K receptor,TACR2,6.271,Ki,CCC1=C[C@@H]2C[N@](C1)CC1=C(NC3=C1C=CC=C3)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC
fesoterodine,Muscarinic acetylcholine receptor M3,CHRM3,6.271,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
cyclizine,5-hydroxytryptamine receptor 2C,HTR2C,6.272,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
loperamide,Alpha-1B adrenergic receptor,Adra1b,6.272,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
pentamidine,Alpha-1B adrenergic receptor,Adra1b,6.272,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
carvedilol,Sodium-dependent noradrenaline transporter,SLC6A2,6.273,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
dexfenfluramine,Alpha-2A adrenergic receptor,ADRA2A,6.275,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
nefopam,Sodium-dependent dopamine transporter,SLC6A3,6.275,Ki,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1
raloxifene,D(3) dopamine receptor,DRD3,6.275,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
desvenlafaxine,Sodium-dependent noradrenaline transporter,SLC6A2,6.275,Ki,CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
atropine,5-hydroxytryptamine receptor 2C,HTR2C,6.276,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
domperidone,Alpha-1B adrenergic receptor,ADRA1B,6.276,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
ketotifen,5-hydroxytryptamine receptor 6,HTR6,6.276,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
apatinib,Proto-oncogene tyrosine-protein kinase Src,SRC,6.276,IC50,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1
buspirone,Alpha-1D adrenergic receptor,ADRA1D,6.277,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
diiodohydroxyquinoline,Adenosine receptor A3,ADORA3,6.278,Ki,OC1=C2N=CC=CC2=C(I)C=C1I
dapiprazole,Alpha-2B adrenergic receptor,ADRA2B,6.279,Ki,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
salbutamol,Beta-2 adrenergic receptor,ADRB2,6.28,Kd,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
aldosterone,Corticosteroid-binding globulin,SERPINA6,6.28,Ki,C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3CC[C@H](C(=O)CO)[C@]3(C[C@H](O)[C@H]21)C=O
bupropion,Sodium-dependent dopamine transporter,SLC6A3,6.28,Kd,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
clomipramine,Alpha-2A adrenergic receptor,ADRA2A,6.28,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
dipyridamole,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,6.28,IC50,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
droperidol,Histamine H1 receptor,HRH1,6.28,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
erlotinib,Tyrosine-protein kinase Lyn,LYN,6.28,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Solute carrier organic anion transporter family member 2B1,SLCO2B1,6.28,Ki,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
etoricoxib,Mitogen-activated protein kinase 14,MAPK14,6.28,IC50,CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
flunarizine,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,6.28,Kd,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
gefitinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,6.28,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
imatinib,Carbonic anhydrase 3,CA3,6.28,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Tyrosine-protein kinase Blk,BLK,6.28,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indoramin,Alpha-2B adrenergic receptor,ADRA2B,6.28,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
medazepam,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,6.28,Ki,CN1CCN=C(C2=CC=CC=C2)C2=C1C=CC(Cl)=C2
mitoxantrone,Multidrug and toxin extrusion protein 2,SLC47A2,6.28,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
phencyclidine,Sigma non-opioid intracellular receptor 1,Sigmar1,6.28,IC50,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
phencyclidine,Cholinesterase,Bche,6.28,Ki,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
phenoxybenzamine,Alpha-2A adrenergic receptor,ADRA2A,6.28,IC50,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
sunitinib,Tyrosine-protein kinase Fyn,FYN,6.28,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Fibroblast growth factor receptor 1,FGFR1,6.28,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Fibroblast growth factor receptor 2,FGFR2,6.28,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Tyrosine-protein kinase FRK,FRK,6.28,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Inhibitor of nuclear factor kappa-B kinase subunit alpha,CHUK,6.28,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase OSR1,OXSR1,6.28,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tetracaine,Sodium channel protein type 5 subunit alpha,SCN5A,6.28,IC50,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
tetracaine,Sodium channel protein type 8 subunit alpha,SCN8A,6.28,IC50,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
valdecoxib,"Carbonic anhydrase, alpha family",,6.28,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
vandetanib,Ephrin type-B receptor 4,EPHB4,6.28,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ruxolitinib,Protein kinase C epsilon type,PRKCE,6.28,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Microtubule-associated serine/threonine-protein kinase 1,MAST1,6.28,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Cyclin-dependent kinase-like 2,CDKL2,6.28,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,Carbonic anhydrase 4,CA4,6.28,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
bosutinib,Homeodomain-interacting protein kinase 1,HIPK1,6.28,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,STE20/SPS1-related proline-alanine-rich protein kinase,STK39,6.28,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
apatinib,Tyrosine-protein kinase CSK,CSK,6.28,IC50,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1
neratinib,Dual specificity mitogen-activated protein kinase kinase 7,MAP2K7,6.28,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,"Myosin light chain kinase, smooth muscle",MYLK,6.28,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Tyrosine-protein kinase Fes/Fps,FES,6.28,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cisapride,Alpha-2B adrenergic receptor,ADRA2B,6.281,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
docetaxel,Substance-K receptor,TACR2,6.283,Ki,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
orphenadrine,5-hydroxytryptamine receptor 6,HTR6,6.283,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
nordazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,6.284,IC50,ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1
imipramine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.284,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
thioridazine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.284,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
mitoxantrone,Multidrug resistance-associated protein 1,ABCC1,6.287,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
pentamidine,Alpha-2A adrenergic receptor,ADRA2A,6.287,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
bromocriptine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,6.29,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bromocriptine,Cerebral cortex alpha adrenergic receptor,ADRA1A|ADRA2A,6.29,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
diphenhydramine,5-hydroxytryptamine receptor 2C,HTR2C,6.29,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
furosemide,Carbonic anhydrase 7,CA7,6.29,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
hesperetin,Cytochrome P450 1B1,CYP1B1,6.29,IC50,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
mafenide,Carbonic anhydrase,CA2,6.29,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
methadone,Kappa-type opioid receptor,OPRK1,6.29,IC50,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
norfloxacin,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,6.29,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
norfloxacin,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,6.29,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
norfloxacin,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,6.29,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
norfloxacin,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,6.29,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
norfloxacin,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,6.29,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
norfloxacin,Gamma-aminobutyric acid receptor subunit alpha-6,GABRA6,6.29,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
penfluridol,Beta-3 adrenergic receptor,ADRB3,6.29,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
rimantadine,Matrix protein 2,M,6.29,Kd,CC(N)C12CC3CC(CC(C3)C1)C2
sunitinib,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,6.29,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Sodium-dependent noradrenaline transporter,SLC6A2,6.29,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
tazobactam,Beta-lactamase,penP,6.29,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
valdecoxib,Astrosclerin-3,,6.29,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
ruboxistaurin,Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma,PIP5K1C,6.29,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
rivaroxaban,Coagulation factor X,F10,6.29,IC50,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
crizotinib,Epithelial discoidin domain-containing receptor 1,DDR1,6.29,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Mitogen-activated protein kinase 7,MAPK7,6.29,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase D3,PRKD3,6.29,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Wee1-like protein kinase,WEE1,6.29,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Cyclin-dependent kinase 18,CDK18,6.29,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Tyrosine-protein kinase Fer,FER,6.29,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Mitogen-activated protein kinase 15,MAPK15,6.29,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cinnarizine,Muscarinic acetylcholine receptor M4,CHRM4,6.292,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
fluspirilene,Beta-2 adrenergic receptor,ADRB2,6.292,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
promethazine,Aldehyde oxidase,AOX1,6.292,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
terfenadine,D(3) dopamine receptor,DRD3,6.292,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
romidepsin,Histone deacetylase 4,HDAC4,6.292,IC50,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
econazole,Delta-type opioid receptor,OPRD1,6.294,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
gentian violet,Muscarinic acetylcholine receptor M2,CHRM2,6.294,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
pentamidine,Muscarinic acetylcholine receptor M2,CHRM2,6.295,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
amiodarone,Muscarinic acetylcholine receptor M4,CHRM4,6.296,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
astemizole,Muscarinic acetylcholine receptor M5,CHRM5,6.297,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
maprotiline,D(3) dopamine receptor,DRD3,6.298,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
oxybutynin,5-hydroxytryptamine receptor 2B,HTR2B,6.298,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
cinnarizine,Alpha-1B adrenergic receptor,Adra1b,6.299,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
adenosine triphosphate,P2X purinoceptor 4,P2RX4,6.3,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adenosine triphosphate,P2Y purinoceptor 4,P2ry4,6.3,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
alprostadil,Cation channel sperm-associated protein 1,CATSPER1,6.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
alprostadil,Cation channel sperm-associated protein 2,CATSPER2,6.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
alprostadil,Cation channel sperm-associated protein 3,CATSPER3,6.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
alprostadil,Cation channel sperm-associated protein 4,CATSPER4,6.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
aminoquinuride,Lethal factor,lef,6.3,Ki,CC1=NC2=CC=C(NC(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=C2C(N)=C1
amiodarone,Alpha-2A adrenergic receptor,ADRA2A,6.3,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amoxapine,5-hydroxytryptamine receptor 7,HTR7,6.3,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
astemizole,Muscarinic acetylcholine receptor M2,CHRM2,6.3,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
azelastine,5-hydroxytryptamine receptor 2C,HTR2C,6.3,Ki,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
bromocriptine,D(1B) dopamine receptor,DRD5,6.3,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
levobunolol,Beta-3 adrenergic receptor,Adrb3,6.3,Ki,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
cabergoline,5-hydroxytryptamine receptor 1B,HTR1B,6.3,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
cefotaxime,Beta-lactamase,,6.3,Ki,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
cefoxitin,Beta-lactamase,ampC,6.3,Ki,CO[C@]1(NC(=O)CC2=CC=CS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O
chlorhexidine,Multidrug and toxin extrusion protein 2,SLC47A2,6.3,IC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
chloroquine,Transmembrane protein 97,TMEM97,6.3,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
clopidogrel,Cytochrome P450 2B6,CYP2B6,6.3,Ki,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=C(Cl)C=CC=C1
cyamemazine,5-hydroxytryptamine receptor 1A,HTR1A,6.3,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
ciclosporin,fMet-Leu-Phe receptor,FPR1,6.3,EC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
ciclosporin,Bile salt export pump,ABCB11,6.3,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dasatinib,Serine/threonine-protein kinase B-raf,BRAF,6.3,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
digoxin,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,6.3,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
dinoprostone,Cation channel sperm-associated protein 1,CATSPER1,6.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
dinoprostone,Cation channel sperm-associated protein 2,CATSPER2,6.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
dinoprostone,Cation channel sperm-associated protein 3,CATSPER3,6.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
dinoprostone,Cation channel sperm-associated protein 4,CATSPER4,6.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
dorzolamide,Carbonic anhydrase 1,CA1,6.3,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
doxepin,Alpha-2A adrenergic receptor,ADRA2A,6.3,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
duloxetine,5-hydroxytryptamine receptor 2A,HTR2A,6.3,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
elliptinium,Fibroblast growth factor receptor 3,FGFR3,6.3,IC50,CC1=C2C=C[N+](C)=CC2=C(C)C2=C1NC1=CC=C(O)C=C21
epinephrine,Alpha-1D adrenergic receptor,Adra1d,6.3,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
ergotamine,5-hydroxytryptamine receptor 1E,HTR1E,6.3,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
erlotinib,Casein kinase I isoform epsilon,CSNK1E,6.3,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fendiline,Calmodulin,CALM,6.3,Kd,CC(NCCC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1
flurbiprofen,Prostaglandin G/H synthase 2,Ptgs2,6.3,IC50,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
fluspirilene,Nociceptin receptor,OPRL1,6.3,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
furosemide,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.3,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
gatifloxacin,DNA gyrase,gyrA|gyrB,6.3,IC50,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1
gossypol,Aldose reductase,AKR1B1,6.3,Ki,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
haloperidol,Calmodulin,CALM1|CALM2|CALM3,6.3,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,5-hydroxytryptamine receptor 7,Htr7,6.3,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloprogin,UDP-glucose 4-epimerase,GALE,6.3,IC50,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
indomethacin,Prostaglandin-H2 D-isomerase,Ptgds,6.3,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
itraconazole,Beta-2 adrenergic receptor,ADRB2,6.3,Ki,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ketoconazole,Potassium voltage-gated channel subfamily A member 10,KCNA10,6.3,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
latanoprost,Prostaglandin F2-alpha receptor,PTGFR,6.3,Ki,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
pethidine,Opioid receptor,Sigmar1|Oprd1|Oprk1|Oprm1,6.3,IC50,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
orciprenaline,Beta-2 adrenergic receptor,ADRB2,6.3,Kd,CC(C)NCC(O)C1=CC(O)=CC(O)=C1
metoprolol,Beta-2 adrenergic receptor,ADRB2,6.3,Ki,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
metoprolol,Adrenergic receptor beta,Adrb2|Adrb1|Adrb3,6.3,IC50,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
mezlocillin,Prostaglandin-H2 D-isomerase,PTGDS,6.3,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
mibefradil,Sodium channel protein type 5 subunit alpha,SCN5A,6.3,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mibefradil,Sodium channel protein type 9 subunit alpha,SCN9A,6.3,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mibefradil,Sodium channel protein type 2 subunit alpha,Scn2a,6.3,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mibefradil,Sodium channel protein type 4 subunit alpha,Scn4a,6.3,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
miglitol,"Sucrase-isomaltase, intestinal",SI,6.3,IC50,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
miglustat,"Sucrase-isomaltase, intestinal",SI,6.3,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nadolol,Beta-3 adrenergic receptor,ADRB3,6.3,Ki,CC(C)(C)NCC(O)COC1=CC=CC2=C1CC(O)C(O)C2
nandrolone,Sex hormone-binding globulin,SHBG,6.3,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O
nandrolone decanoate,Sex hormone-binding globulin,SHBG,6.3,Kd,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
framycetin,Lethal factor,lef,6.3,Ki,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
nevirapine,Reverse transcriptase,reverse transcriptas,6.3,IC50,CC1=CC=NC2=C1NC(=O)C1=CC=CN=C1N2C1CC1
nifedipine,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,6.3,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nilotinib,Tyrosine-protein kinase Blk,BLK,6.3,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Ephrin type-B receptor 6,EPHB6,6.3,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
perhexiline,Muscarinic acetylcholine receptor M4,CHRM4,6.3,Ki,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
pioglitazone,Amine oxidase [flavin-containing] B,MAOB,6.3,Ki,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
prenylamine,Calmodulin,CALM,6.3,Kd,CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1
pyrimethamine,Multidrug and toxin extrusion protein 2,Slc47a2,6.3,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
pyrvinium,Fumarate reductase,,6.3,IC50,CN(C)C1=CC=C2C(C=CC(\C=C\C3=C(C)N(C(C)=C3)C3=CC=CC=C3)=[N+]2C)=C1
raloxifene,5-hydroxytryptamine receptor 6,HTR6,6.3,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
reboxetine,Sodium-dependent serotonin transporter,Slc6a4,6.3,Ki,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
rotigotine,D(1A) dopamine receptor,DRD1,6.3,Ki,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
suloctidil,Alpha-2C adrenergic receptor,ADRA2C,6.3,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
sumatriptan,5-hydroxytryptamine receptor 5A,HTR5A,6.3,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.3,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase Nek2,NEK2,6.3,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Hormonally up-regulated neu tumor-associated kinase,HUNK,6.3,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tazobactam,Beta-lactamase,penB1,6.3,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
terodiline,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.3,IC50,CC(CC(C1=CC=CC=C1)C1=CC=CC=C1)NC(C)(C)C
tetracaine,Sodium channel protein type 9 subunit alpha,SCN9A,6.3,Ki,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
thalidomide,Prostaglandin G/H synthase 2,PTGS2,6.3,IC50,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2
tioconazole,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,6.3,Ki,ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1
trifluoperazine,C-8 sterol isomerase,ERG2,6.3,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
trimethoprim,Dihydrofolate reductase,Dhfr,6.3,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
trimethoprim,Dihydrofolate reductase type 1,dhfrI,6.3,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
ubenimex,Leukotriene A-4 hydrolase,LTA4H,6.3,IC50,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
ubenimex,Cytosol aminopeptidase,LAP3,6.3,Ki,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
ziprasidone,Alpha-2A adrenergic receptor,ADRA2A,6.3,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
zoledronic acid,Farnesyl pyrophosphate synthase,Fdps,6.3,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
ziconotide,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,Cacna1a,6.3,IC50,CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)[C@@H](C)O
gabexate,Multidrug and toxin extrusion protein 1,SLC47A1,6.3,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
triclosan,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,6.3,IC50,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
uridine triphosphate,P2Y purinoceptor 4,P2RY4,6.3,EC50,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O
rilpivirine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.3,IC50,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=NC(NC2=CC=C(C=C2)C#N)=NC=C1
rilpivirine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.3,IC50,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=NC(NC2=CC=C(C=C2)C#N)=NC=C1
bosutinib,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,6.3,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
teriparatide,Parathyroid hormone 2 receptor,Pth2r,6.3,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
bedaquiline,ATP synthase subunit c,atpE,6.3,Kd,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2
midostaurin,Tyrosine-protein kinase Blk,BLK,6.3,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Tyrosine-protein kinase Lyn,LYN,6.3,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
trifarotene,Retinoic acid receptor alpha,RARA,6.3,EC50,CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=C(OCCO)C=CC(=C1)C1=CC=C(C=C1)C(O)=O
osilodrostat,"Cytochrome P450 11B1, mitochondrial",Cyp11b1,6.3,IC50,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12
ciclosporin,Multidrug resistance protein 1,ABCB1,6.301,EC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
lanreotide,Somatostatin receptor type 1,SSTR1,6.301,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
leflunomide,Cytochrome P450 1A2,CYP1A2,6.301,IC50,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
liothyronine,Cytochrome P450 2C9,CYP2C9,6.301,EC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
thalidomide,Prostaglandin G/H synthase 2,PTGS2,6.301,IC50,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2
thiethylperazine,D(1A) dopamine receptor,DRD1,6.301,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
zotepine,Histamine H2 receptor,HRH2,6.301,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
flunarizine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.304,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
amoxapine,Alpha-2A adrenergic receptor,ADRA2A,6.307,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
clorotepine,Trace amine-associated receptor 1,TAAR1,6.307,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
hydroxyprogesterone caproate,Androgen receptor,Ar,6.307,Ki,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
maprotiline,D(1A) dopamine receptor,DRD1,6.308,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
haloprogin,Substance-K receptor,TACR2,6.309,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
pentamidine,Alpha-1D adrenergic receptor,ADRA1D,6.309,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
talipexole,D(2) dopamine receptor,DRD2,6.309,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
androstenedione,Testosterone 17-beta-dehydrogenase 3,HSD17B3,6.31,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
flunarizine,Sodium channel protein type 2 subunit alpha,Scn2a,6.31,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
glutamic acid,"Glutamate receptor ionotropic, kainate 3",Grik3,6.31,Ki,N[C@@H](CCC(O)=O)C(O)=O
nilotinib,BDNF/NT-3 growth factors receptor,NTRK2,6.31,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
paroxetine,Sodium-dependent dopamine transporter,SLC6A3,6.31,Kd,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
sorafenib,Cyclin-dependent kinase-like 3,CDKL3,6.31,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,"Muscle, skeletal receptor tyrosine-protein kinase",MUSK,6.31,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zoledronic acid,Butyrophilin subfamily 3 member A1,BTN3A1,6.31,EC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
crizotinib,Serine/threonine-protein kinase TAO3,TAOK3,6.31,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase 16,STK16,6.31,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,"Myosin light chain kinase, smooth muscle",MYLK,6.31,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
crisaborole,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,6.31,IC50,OB1OCC2=CC(OC3=CC=C(C=C3)C#N)=CC=C12
neratinib,Tyrosine-protein kinase HCK,HCK,6.31,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Tyrosine-protein kinase ITK/TSK,ITK,6.31,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Aurora kinase B,AURKB,6.31,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
filgotinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,6.31,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
filgotinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,6.31,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
fluphenazine,Muscarinic acetylcholine receptor M4,CHRM4,6.315,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
stanozolol,Progesterone receptor,PGR,6.316,Ki,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=NN5
clomipramine,Aldehyde oxidase,AOX1,6.319,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
haloperidol,Alpha-2B adrenergic receptor,ADRA2B,6.319,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
metergoline,Histamine H1 receptor,HRH1,6.319,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
tapentadol,Sodium-dependent noradrenaline transporter,SLC6A2,6.319,Ki,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
buspirone,5-hydroxytryptamine receptor 2A,Htr2a,6.32,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
dobutamine,Carbonic anhydrase 2,CA2,6.32,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
gossypol,Bcl-2-like protein 1,BCL2L1,6.32,Ki,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
indoramin,Alpha-2C adrenergic receptor,ADRA2C,6.32,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
fluostigmine,Acetylcholinesterase,ache,6.32,IC50,CC(C)OP(F)(=O)OC(C)C
naproxen,Aldo-keto reductase family 1 member C3,AKR1C3,6.32,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
oseltamivir,Neuraminidase,,6.32,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
raltitrexed,Bifunctional dihydrofolate reductase-thymidylate synthase,,6.32,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
sunitinib,Ephrin type-B receptor 1,EPHB1,6.32,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Carbonic anhydrase 2,mtcA2,6.32,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
kainic acid,Glutamate receptor 1,Gria1,6.32,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
pazopanib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,6.32,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Receptor tyrosine-protein kinase erbB-4,ERBB4,6.32,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Tubulin alpha-1A chain,Tuba1a,6.32,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ruxolitinib,Dual specificity protein kinase TTK,TTK,6.32,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Mitogen-activated protein kinase kinase kinase 13,MAP3K13,6.32,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
raloxifene,Mu-type opioid receptor,OPRM1,6.321,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
raloxifene,Alpha-1D adrenergic receptor,ADRA1D,6.321,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
spiperone,Histamine H1 receptor,HRH1,6.322,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
doxepin,D(3) dopamine receptor,DRD3,6.325,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
gentian violet,Epidermal growth factor receptor,EGFR,6.325,IC50,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
methysergide,D(1A) dopamine receptor,DRD1,6.326,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
zotepine,5-hydroxytryptamine receptor 3A,HTR3A,6.326,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
dicycloverine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.327,IC50,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
femoxetine,Muscarinic acetylcholine receptor M4,CHRM4,6.328,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
cefaclor,Streptokinase A,ska,6.33,EC50,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
clozapine,D(3) dopamine receptor,DRD3,6.33,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Serine/threonine-protein kinase Nek11,NEK11,6.33,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dextromethorphan,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,6.33,IC50,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
gefitinib,Serine/threonine-protein kinase 10,STK10,6.33,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
imatinib,Carbonic anhydrase 14,CA14,6.33,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indomethacin,Prostaglandin G/H synthase 2,PTGS2,6.33,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
pentamidine,5-hydroxytryptamine receptor 2A,HTR2A,6.33,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
sunitinib,Serine/threonine-protein kinase ICK,ICK,6.33,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
thiabendazole,Methionine aminopeptidase,map,6.33,IC50,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
bithionol,Adenosine receptor A3,ADORA3,6.33,Ki,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
pazopanib,Serine/threonine-protein kinase 36,STK36,6.33,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Vascular endothelial growth factor receptor 2,KDR,6.33,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Serine/threonine-protein kinase receptor R3,ACVRL1,6.33,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Ephrin type-A receptor 7,EPHA7,6.33,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Calcium/calmodulin-dependent protein kinase type 1,CAMK1,6.33,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Dual specificity mitogen-activated protein kinase kinase 3,MAP2K3,6.33,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
lacosamide,Carbonic anhydrase 14,CA14,6.33,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
afatinib,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,6.33,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
tofacitinib,Rho-associated protein kinase 1,ROCK1,6.33,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
tavaborole,Carbonic anhydrase 2,CA2,6.33,Ki,OB1OCC2=C1C=CC(F)=C2
nintedanib,Cyclin-dependent kinase 14,CDK14,6.33,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
relebactam,Beta-lactamase,ampC,6.33,IC50,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O
relebactam,Beta-lactamase,L2camp,6.33,IC50,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O
fedratinib,Fibroblast growth factor receptor 2,FGFR2,6.33,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cinnarizine,5-hydroxytryptamine receptor 2B,HTR2B,6.333,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
flunarizine,Sodium-dependent dopamine transporter,SLC6A3,6.333,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
isotretinoin,Mitogen-activated protein kinase 1,MAPK1,6.335,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
amoxapine,Alpha-2C adrenergic receptor,ADRA2C,6.336,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
irinotecan,Alpha-2C adrenergic receptor,ADRA2C,6.336,Ki,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
chlordiazepoxide,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,6.337,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
lofepramine,Muscarinic acetylcholine receptor M5,CHRM5,6.337,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
haloprogin,Kappa-type opioid receptor,OPRK1,6.338,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
haloprogin,Alpha-2A adrenergic receptor,ADRA2A,6.339,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
amperozide,Fatty-acid amide hydrolase 1,FAAH,6.34,IC50,CCNC(=O)N1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1
aprepitant,Neuromedin-K receptor,TACR3,6.34,Ki,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
ciclosporin,Reverse transcriptase/RNaseH,pol,6.34,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dasatinib,Serine/threonine-protein kinase receptor R3,ACVRL1,6.34,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dichlorphenamide,Delta carbonic anhydrase,ca1,6.34,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
ftivazide,Myeloperoxidase,MPO,6.34,IC50,COC1=C(O)C=CC(C=NNC(=O)C2=CC=NC=C2)=C1
hesperetin,Carbonic anhydrase 12,CA12,6.34,Ki,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
miglitol,Lysosomal alpha-glucosidase,Gaa,6.34,Ki,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nilotinib,Carbonic anhydrase 6,CA6,6.34,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Mitogen-activated protein kinase 14,MAPK14,6.34,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
reboxetine,5-hydroxytryptamine receptor 2C,HTR2C,6.34,Ki,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
reboxetine,5-hydroxytryptamine receptor 6,HTR6,6.34,Ki,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
sitosterol,Amine oxidase [flavin-containing] A,MAOA,6.34,Ki,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sitosterol,Amine oxidase [flavin-containing] A,MAOA,6.34,Ki,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sunitinib,Rho-associated protein kinase 1,ROCK1,6.34,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase LATS2,LATS2,6.34,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
vardenafil,"High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A",PDE9A,6.34,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
podophyllotoxin,Tubulin alpha-1A chain,TUBA1A,6.34,IC50,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
podophyllotoxin,Tubulin,TUBB2B,6.34,IC50,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
crizotinib,Abelson tyrosine-protein kinase 2,ABL2,6.34,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Dual specificity protein kinase CLK2,CLK2,6.34,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
lacosamide,Carbonic anhydrase 15,Ca15,6.34,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
bosutinib,Serine/threonine-protein kinase ULK3,ULK3,6.34,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tofacitinib,Tyrosine-protein kinase Lck,LCK,6.34,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
midostaurin,5'-AMP-activated protein kinase catalytic subunit alpha-2,PRKAA2,6.34,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,6.34,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ebastine,Sodium-dependent noradrenaline transporter,SLC6A2,6.341,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ebastine,D(4) dopamine receptor,DRD4,6.341,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ondansetron,5-hydroxytryptamine receptor 2B,HTR2B,6.341,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
tolperisone,Alpha-2B adrenergic receptor,ADRA2B,6.341,Ki,CC(CN1CCCCC1)C(=O)C1=CC=C(C)C=C1
cyclizine,Muscarinic acetylcholine receptor M5,CHRM5,6.342,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
oxymetazoline,Muscarinic acetylcholine receptor M4,CHRM4,6.342,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
loperamide,D(3) dopamine receptor,DRD3,6.343,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
bopindolol,5-hydroxytryptamine receptor 2A,HTR2A,6.345,Ki,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
chlorpromazine,5-hydroxytryptamine receptor 1D,HTR1D,6.345,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
sertindole,Alpha-2B adrenergic receptor,ADRA2B,6.347,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sertindole,Alpha-2C adrenergic receptor,ADRA2C,6.347,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
safinamide,Amine oxidase [flavin-containing] B,MAOB,6.347,Ki,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O
clemastine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.349,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clomifene,D(3) dopamine receptor,DRD3,6.349,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
mepacrine,D(3) dopamine receptor,DRD3,6.349,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
asenapine,5-hydroxytryptamine receptor 3A,HTR3A,6.349,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
carbachol,Acetylcholine receptor subunit delta,chrnd,6.35,Ki,C[N+](C)(C)CCOC(N)=O
cianidanol,Carbonic anhydrase 7,CA7,6.35,Ki,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
dexniguldipine,Alpha-2C adrenergic receptor,ADRA2C,6.35,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
pethidine,Mu-type opioid receptor,OPRM1,6.35,Ki,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
nilotinib,Carbonic anhydrase 4,CA4,6.35,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Mitogen-activated protein kinase 8,MAPK8,6.35,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Carbonic anhydrase 3,CA3,6.35,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norepinephrine,Alpha-1A adrenergic receptor,ADRA1A,6.35,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
oxytocin,Vasopressin V1b receptor,AVPR1B,6.35,EC50,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
penfluridol,Alpha-2C adrenergic receptor,ADRA2C,6.35,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
sumatriptan,5-hydroxytryptamine receptor 1A,Htr1a,6.35,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
tretoquinol,Thromboxane A2 receptor,TBXA2R,6.35,IC50,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
trichlormethiazide,Carbonic anhydrase 4,CA4,6.35,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
trimethoprim,Dihydrofolate reductase,folA,6.35,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
trimethoprim,Dihydrofolate reductase,folA,6.35,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
quercetin,Cyclin-dependent kinase 1,CDK1,6.35,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
vandetanib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,6.35,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Tyrosine-protein kinase Fes/Fps,FES,6.35,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Angiopoietin-1 receptor,Tek,6.35,IC50,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Dual serine/threonine and tyrosine protein kinase,DSTYK,6.35,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Serine/threonine-protein kinase ULK2,ULK2,6.35,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
panobinostat,Histone deacetylase 8,HDAC8,6.35,IC50,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
midostaurin,Vascular endothelial growth factor receptor 1,FLT1,6.35,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,6.35,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
cannabidiol,G-protein coupled receptor 55,GPR55,6.35,EC50,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
fedratinib,Dual specificity protein kinase TTK,TTK,6.35,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tucatinib,Epidermal growth factor receptor,EGFR,6.35,IC50,CC1=CC(NC2=NC=NC3=C2C=C(NC2=NC(C)(C)CO2)C=C3)=CC=C1OC1=CC2=NC=NN2C=C1
miconazole,Muscarinic acetylcholine receptor M4,CHRM4,6.351,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
pipamazine,Sodium-dependent noradrenaline transporter,SLC6A2,6.351,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
ethinylestradiol,Sodium-dependent dopamine transporter,SLC6A3,6.353,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
maprotiline,Alpha-2C adrenergic receptor,ADRA2C,6.355,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
flunarizine,Alpha-1D adrenergic receptor,ADRA1D,6.357,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
clomifene,Muscarinic acetylcholine receptor M3,CHRM3,6.358,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
astemizole,5-hydroxytryptamine receptor 1A,HTR1A,6.359,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
ketotifen,Muscarinic acetylcholine receptor M2,CHRM2,6.359,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
aminoacridine,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,6.36,IC50,NC1=C2C=CC=CC2=NC2=CC=CC=C12
aminoacridine,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,6.36,IC50,NC1=C2C=CC=CC2=NC2=CC=CC=C12
bexarotene,Oxysterols receptor LXR-beta,NR1H2,6.36,EC50,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
chlordiazepoxide,Translocator protein,Tspo,6.36,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
cinnarizine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,6.36,IC50,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
erlotinib,Ephrin type-A receptor 6,EPHA6,6.36,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
haloperidol,Histamine H1 receptor,HRH1,6.36,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
lansoprazole,Phosphoethanolamine/phosphocholine phosphatase,PHOSPHO1,6.36,IC50,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
mafenide,Carbonic anhydrase,NCE103,6.36,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
methapyrilene,Alpha-2A adrenergic receptor,ADRA2A,6.36,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
milrinone,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,6.36,IC50,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
mofezolac,Prostaglandin G/H synthase 2,PTGS2,6.36,IC50,COC1=CC=C(C=C1)C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1
mofezolac,Prostaglandin G/H synthase 2,PTGS2,6.36,IC50,COC1=CC=C(C=C1)C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1
primaquine,"Serine hydroxymethyltransferase, mitochondrial",SHMT2,6.36,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
sorafenib,Tyrosine-protein kinase FRK,FRK,6.36,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Aurora kinase B,AURKB,6.36,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Focal adhesion kinase 1,PTK2,6.36,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Calcium/calmodulin-dependent protein kinase type II subunit gamma,CAMK2G,6.36,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Calcium/calmodulin-dependent protein kinase type 1G,CAMK1G,6.36,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
pyrithione,FAD-linked sulfhydryl oxidase ALR,GFER,6.36,AC50,[O-][N+]1=C(S)C=CC=C1
quercetin,"Arachidonate 12-lipoxygenase, 12S-type",ALOX12,6.36,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
androstanolone,Progesterone receptor,PGR,6.36,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
vandetanib,Ephrin type-B receptor 2,EPHB2,6.36,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Activin receptor type-1,ACVR1,6.36,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Leukocyte tyrosine kinase receptor,LTK,6.36,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
nintedanib,Myosin light chain kinase family member 4,MYLK4,6.36,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Receptor-interacting serine/threonine-protein kinase 4,RIPK4,6.36,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
quizartinib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,6.36,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
pexidartinib,Vascular endothelial growth factor receptor 2,KDR,6.36,IC50,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
ketotifen,D(1A) dopamine receptor,DRD1,6.361,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
sulindac,Aldose reductase,Akr1b1,6.362,IC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
nimodipine,Sodium/nucleoside cotransporter 1,SLC28A1,6.364,Ki,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
olanzapine,5-hydroxytryptamine receptor 1B,Htr1b,6.364,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
chidamide,Histone deacetylase 11,HDAC11,6.365,IC50,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1
haloprogin,Sodium-dependent serotonin transporter,SLC6A4,6.366,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
ergometrine,Alpha-1B adrenergic receptor,ADRA1B,6.367,Kd,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
maprotiline,D(1B) dopamine receptor,DRD5,6.367,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
strychnine,Taste receptor type 2 member 46,TAS2R46,6.367,EC50,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
zomepirac,Prostaglandin G/H synthase 1,PTGS1,6.367,Ki,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
apatinib,Mast/stem cell growth factor receptor Kit,KIT,6.368,IC50,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1
amlodipine,Potassium channel subfamily K member 2,Kcnk2,6.37,IC50,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
celecoxib,Prostaglandin E synthase,PTGES,6.37,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
dasatinib,Misshapen-like kinase 1,MINK1,6.37,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dichlorphenamide,Alpha carbonic anhydrase,CA,6.37,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
galantamine,Acetylcholinesterase,ache,6.37,Ki,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
gefitinib,Casein kinase I isoform epsilon,CSNK1E,6.37,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
indomethacin,Cyclooxygenase,PTGS1|PTGS2,6.37,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
mafenide,Delta carbonic anhydrase,ca1,6.37,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
pemetrexed,Bifunctional dihydrofolate reductase-thymidylate synthase,,6.37,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
probenecid,Carbonic anhydrase 2,CA2,6.37,Ki,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
probucol,Serine protease hepsin,HPN,6.37,IC50,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
risperidone,5-hydroxytryptamine receptor 1A,Htr1a,6.37,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
rofecoxib,Prostaglandin G/H synthase 2,PTGS2,6.37,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
sulfanilamide,Carbonic anhydrase,cynT,6.37,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulpiride,Alpha carbonic anhydrase,CA,6.37,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sultiame,"Carbonic anhydrase, alpha family",,6.37,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
sunitinib,Insulin receptor-related protein,INSRR,6.37,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
valdecoxib,Carbonic anhydrase 13,Ca13,6.37,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
valdecoxib,Carbonic anhydrase 13,CA13,6.37,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
voriconazole,14-alpha sterol demethylase,cyp51B,6.37,Kd,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
zonisamide,Carbonic anhydrase 13,CA13,6.37,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
gabexate,Urokinase-type plasminogen activator,PLAU,6.37,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
quercetin,Arachidonate 15-lipoxygenase,ALOX15,6.37,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,BMP-2-inducible protein kinase,BMP2K,6.37,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
triclosan,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,6.37,IC50,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
biriperone,D(1A) dopamine receptor,Drd1,6.37,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCN2CC3=C(CC2C1)C1=CC=CC=C1N3
pazopanib,Serine/threonine-protein kinase B-raf,BRAF,6.37,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Serine/threonine-protein kinase SIK2,SIK2,6.37,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ceritinib,Fibroblast growth factor receptor 3,FGFR3,6.37,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Glycogen synthase kinase-3 alpha,GSK3A,6.37,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Proto-oncogene tyrosine-protein kinase ROS,ROS1,6.37,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
setmelanotide,Melanocortin receptor 5,MC5R,6.37,Ki,C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
setmelanotide,Melanocortin receptor 5,MC5R,6.37,Ki,C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
oxiconazole,Sodium-dependent serotonin transporter,SLC6A4,6.372,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
dopamine,Trace amine-associated receptor 1,TAAR1,6.375,Ki,NCCC1=CC(O)=C(O)C=C1
tivozanib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.375,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
loxapine,Muscarinic acetylcholine receptor M2,CHRM2,6.376,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
diphenylpyraline,Sodium-dependent dopamine transporter,SLC6A3,6.377,IC50,CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
nicardipine,Cytochrome P450 3A4,CYP3A4,6.377,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
dosulepin,Alpha-1A adrenergic receptor,ADRA1A,6.378,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
cisapride,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.379,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
oxymetazoline,5-hydroxytryptamine receptor 1E,HTR1E,6.379,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
racecadotril,Angiotensin-converting enzyme,ACE,6.38,IC50,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1
clozapine,D(1A) dopamine receptor,DRD1,6.38,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,D(1A) dopamine receptor,DRD1,6.38,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dapsone,Myeloperoxidase,MPO,6.38,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
dapsone,Myeloperoxidase,MPO,6.38,IC50,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
diphenylpyraline,Sodium-dependent dopamine transporter,Slc6a3,6.38,IC50,CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
furosemide,Carbonic anhydrase 9,CA9,6.38,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
ketamine,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,6.38,Ki,CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1
pecazine,Mucosa-associated lymphoid tissue lymphoma translocation protein 1,MALT1,6.38,IC50,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
miglustat,Putative alpha-glucosidase,P0504H10.9,6.38,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
papaverine,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B",PDE3B,6.38,Ki,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
phenyltoloxamine,D(1B) dopamine receptor,DRD5,6.38,Ki,CN(C)CCOC1=C(CC2=CC=CC=C2)C=CC=C1
raltitrexed,Thymidylate synthase,Tyms,6.38,Ki,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
sertraline,Sodium-dependent noradrenaline transporter,SLC6A2,6.38,Kd,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
sorafenib,5-hydroxytryptamine receptor 2C,HTR2C,6.38,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulpiride,Carbonic anhydrase,CA2,6.38,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sunitinib,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,6.38,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Calcium/calmodulin-dependent protein kinase kinase 1,CAMKK1,6.38,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zileuton,Leukotriene B4 receptor 1,LTB4R,6.38,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
ruboxistaurin,Tyrosine-protein kinase JAK3,JAK3,6.38,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Dual specificity protein kinase CLK2,CLK2,6.38,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
crizotinib,Cyclin-dependent kinase 11A,CDK11A,6.38,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Tyrosine-protein kinase receptor UFO,AXL,6.38,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,Sodium channel protein type 3 subunit alpha,Scn3a,6.38,IC50,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
azilsartan medoxomil,Type-1 angiotensin II receptor,AGTR1,6.38,IC50,CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NOC(=O)N1
tofacitinib,Rho-associated protein kinase 2,ROCK2,6.38,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Serine/threonine-protein kinase LATS1,LATS1,6.38,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Aurora kinase B,AURKB,6.38,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Serine/threonine-protein kinase RIO3,RIOK3,6.38,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Ribosomal protein S6 kinase alpha-1,RPS6KA1,6.38,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
prochlorperazine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.381,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
maprotiline,5-hydroxytryptamine receptor 6,HTR6,6.383,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
miconazole,Sodium-dependent serotonin transporter,SLC6A4,6.383,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
pemoline,Sodium-dependent dopamine transporter,SLC6A3,6.383,Ki,NC1=NC(=O)C(O1)C1=CC=CC=C1
raloxifene,5-hydroxytryptamine receptor 2A,HTR2A,6.383,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
cyclizine,Muscarinic acetylcholine receptor M2,CHRM2,6.385,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
dicycloverine,D(3) dopamine receptor,DRD3,6.386,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
thiothixene,Histamine H2 receptor,HRH2,6.386,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
amiodarone,D(3) dopamine receptor,DRD3,6.387,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
melperone,D(4) dopamine receptor,DRD4,6.387,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
thiothixene,5-hydroxytryptamine receptor 1A,HTR1A,6.387,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
chlorhexidine,Solute carrier family 22 member 3,SLC22A3,6.39,IC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
ciprofloxacin,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,6.39,IC50,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
dasatinib,Mitogen-activated protein kinase 11,MAPK11,6.39,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dimetindene,Muscarinic acetylcholine receptor M4,CHRM4,6.39,Ki,CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C1=CC=CC=N1
dorzolamide,Carbonic anhydrase,,6.39,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
erlotinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,6.39,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
estradiol,Androgen receptor,Ar,6.39,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
gefitinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,6.39,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
gefitinib,Tubulin alpha-1A chain,Tuba1a,6.39,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
pethidine,Sodium-dependent serotonin transporter,Slc6a4,6.39,Ki,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
mianserin,Alpha-1A adrenergic receptor,ADRA1A,6.39,IC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
pentamidine,Multidrug and toxin extrusion protein 1,SLC47A1,6.39,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pimobendan,Phosphodiesterase 3,PDE3B|PDE3A,6.39,IC50,COC1=CC=C(C=C1)C1=NC2=C(N1)C=CC(=C2)C1=NNC(=O)CC1C
sunitinib,Tyrosine-protein kinase JAK2,JAK2,6.39,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,MAP/microtubule affinity-regulating kinase 3,MARK3,6.39,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 38,STK38,6.39,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
trifluoperazine,5-hydroxytryptamine receptor 1A,Htr1a,6.39,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
zolpidem,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,6.39,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
zonisamide,Delta carbonic anhydrase,ca1,6.39,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
zonisamide,"Carbonic anhydrase, alpha family",,6.39,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
naphazoline,Alpha-2B adrenergic receptor,ADRA2B,6.39,Ki,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
naphazoline,Alpha-2C adrenergic receptor,ADRA2C,6.39,Ki,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
adipic acid,Solute carrier family 22 member 6,Slc22a6,6.39,Ki,OC(=O)CCCCC(O)=O
rasagiline,Amine oxidase [flavin-containing] A,Maoa,6.39,IC50,C#CCN[C@@H]1CCC2=C1C=CC=C2
lacosamide,Carbonic anhydrase 6,CA6,6.39,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
olaparib,Poly [ADP-ribose] polymerase 4,PARP4,6.39,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
rucaparib,Poly [ADP-ribose] polymerase 3,PARP3,6.39,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
midostaurin,Dual specificity protein kinase CLK4,CLK4,6.39,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
quizartinib,"Myosin light chain kinase, smooth muscle",MYLK,6.39,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
quizartinib,Myosin light chain kinase 3,MYLK3,6.39,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Bone morphogenetic protein receptor type-1B,BMPR1B,6.39,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,6.39,IC50,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
inqovi,Cytidine deaminase,CDA,6.39,IC50,C1CN(C(=O)N[C@@H]1O)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
tofacitinib,JAK2/JAK1,JAK2|JAK1,6.391,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
thalidomide,Protein cereblon,CRBN,6.393,EC50,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2
fesoterodine,Muscarinic acetylcholine receptor M1,CHRM1,6.393,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
cisapride,5-hydroxytryptamine receptor 2C,HTR2C,6.396,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
clemizole,Histamine H4 receptor,HRH4,6.396,Ki,ClC1=CC=C(CN2C(CN3CCCC3)=NC3=C2C=CC=C3)C=C1
metoclopramide,5-hydroxytryptamine receptor 2B,HTR2B,6.397,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
moxonidine,5-hydroxytryptamine receptor 1A,HTR1A,6.397,Ki,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1
bupivacaine,Cytochrome P450 2D6,CYP2D6,6.398,IC50,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
econazole,Cytochrome P450 2D6,CYP2D6,6.398,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
fenfluramine,5-hydroxytryptamine receptor 2B,HTR2B,6.398,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
fluvastatin,Cytochrome P450 2C9,CYP2C9,6.398,IC50,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C1=CC=C(F)C=C1
indinavir,Cytochrome P450 3A4,CYP3A4,6.398,IC50,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
mosapride,Cytochrome P450 1A2,CYP1A2,6.398,IC50,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
noscapine,Cytochrome P450 2C19,CYP2C19,6.398,IC50,COC1=CC=C2[C@H](OC(=O)C2=C1OC)[C@@H]1N(C)CCC2=C1C(OC)=C1OCOC1=C2
orphenadrine,Cytochrome P450 2D6,CYP2D6,6.398,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
phenylpropanolamine,Alpha-2B adrenergic receptor,ADRA2B,6.398,Ki,CC(N)C(O)C1=CC=CC=C1
raloxifene,Acetylcholinesterase,ACHE,6.398,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
femoxetine,Muscarinic acetylcholine receptor M5,CHRM5,6.398,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
acarbose,"Sucrase-isomaltase, intestinal",Si,6.4,IC50,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
acebutolol,Beta-2 adrenergic receptor,ADRB2,6.4,Ki,CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1
amitriptyline,5-hydroxytryptamine receptor 7,HTR7,6.4,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amitriptyline,5-hydroxytryptamine receptor 7,Htr7,6.4,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amlodipine,Potassium channel subfamily K member 2,KCNK2,6.4,IC50,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
azimilide,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.4,IC50,CN1CCN(CCCCN2C(=O)CN(N=CC3=CC=C(O3)C3=CC=C(Cl)C=C3)C2=O)CC1
bromocriptine,D(4) dopamine receptor,DRD4,6.4,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
levobunolol,Beta-3 adrenergic receptor,Adrb3,6.4,Ki,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
buspirone,5-hydroxytryptamine receptor 7,Htr7,6.4,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
buspirone,5-hydroxytryptamine receptor 7,Htr7,6.4,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
chlorhexidine,Solute carrier family 22 member 2,SLC22A2,6.4,IC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
chloroquine,Histidine-rich protein PFHRP-II,,6.4,IC50,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
clavulanic acid,Beta-lactamase,ampC,6.4,Kd,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clozapine,5-hydroxytryptamine receptor 1D,HTR1D,6.4,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,5-hydroxytryptamine receptor 1E,HTR1E,6.4,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
digoxin,Sodium/potassium-transporting ATPase,ATP1A1|ATP1B1|ATP1A3|ATP1B2|ATP1A2|ATP1B3|FXYD2|ATP1A4,6.4,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
dinoprost,Prostaglandin D2 receptor 2,PTGDR2,6.4,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dinoprost,Prostaglandin E2 receptor EP1 subtype,Ptger1,6.4,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dipyridamole,"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A",PDE11A,6.4,Ki,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
disulfiram,Gasdermin-D,GSDMD,6.4,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
ditiocarb,Gasdermin-D,GSDMD,6.4,IC50,CCN(CC)C(S)=S
duloxetine,5-hydroxytryptamine receptor 6,HTR6,6.4,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
elliptinium,Mast/stem cell growth factor receptor Kit,KIT,6.4,IC50,CC1=C2C=C[N+](C)=CC2=C(C)C2=C1NC1=CC=C(O)C=C21
fentanyl,Delta-type opioid receptor,Oprd1,6.4,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
fluoxetine,5-hydroxytryptamine receptor 2C,HTR2C,6.4,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
haloperidol,Histamine H1 receptor,HRH1,6.4,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,5-hydroxytryptamine receptor 1A,Htr1a,6.4,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hydrochlorothiazide,Astrosclerin-3,,6.4,Ki,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
imatinib,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,6.4,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
ketanserin,5-hydroxytryptamine receptor 7,Htr7,6.4,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketoconazole,Aromatase,CYP19A1,6.4,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
masoprocol,5-lipoxygenase,,6.4,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
masoprocol,Arachidonate 5-lipoxygenase,Alox5,6.4,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
menadione,Amine oxidase [flavin-containing] B,MAOB,6.4,Ki,CC1=CC(=O)C2=CC=CC=C2C1=O
methacholine,Muscarinic acetylcholine receptor M1,Chrm1,6.4,EC50,CC(C[N+](C)(C)C)OC(C)=O
mibefradil,Voltage-dependent R-type calcium channel subunit alpha-1E,Cacna1e,6.4,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
miconazole,Aromatase,Cyp19a1,6.4,EC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
framycetin,Transient receptor potential cation channel subfamily V member 1,TRPV1,6.4,IC50,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
nevirapine,Reverse transcriptase/RNaseH,pol,6.4,Ki,CC1=CC=NC2=C1NC(=O)C1=CC=CN=C1N2C1CC1
nimesulide,Prostaglandin G/H synthase 2,PTGS2,6.4,IC50,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
norepinephrine,Beta-1 adrenergic receptor,ADRB1,6.4,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
octreotide,Somatostatin receptor type 4,SSTR4,6.4,Ki,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
oxymetazoline,Alpha-1D adrenergic receptor,ADRA1D,6.4,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
penfluridol,Alpha-2B adrenergic receptor,ADRA2B,6.4,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
phencyclidine,Glutamate NMDA receptor; GRIN1/GRIN2A,GRIN1|GRIN2A,6.4,IC50,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
piribedil,5-hydroxytryptamine receptor 1A,HTR1A,6.4,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
risperidone,5-hydroxytryptamine receptor 6,Htr6,6.4,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sertindole,5-hydroxytryptamine receptor 1F,HTR1F,6.4,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sertindole,5-hydroxytryptamine receptor 1E,HTR1E,6.4,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sildenafil,Phosphodiesterase 1,PDE1A|PDE1B,6.4,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
torsemide,Solute carrier family 12 member 1,SLC12A1,6.4,IC50,CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC(C)=CC=C1
trifluoperazine,5-hydroxytryptamine receptor 2C,HTR2C,6.4,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
valproic acid,Histone deacetylase 1,HDAC1,6.4,IC50,CCCC(CCC)C(O)=O
colecalciferol,Glycine receptor subunit alpha-1,GLRA1,6.4,EC50,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
zileuton,Arachidonate 15-lipoxygenase,ALOX15,6.4,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
ziprasidone,5-hydroxytryptamine receptor 3A,HTR3A,6.4,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
cinromide,Sodium-dependent neutral amino acid transporter B(0)AT1,SLC6A19,6.4,IC50,CCNC(=O)\C=C\C1=CC(Br)=CC=C1
ruboxistaurin,STE20-like serine/threonine-protein kinase,SLK,6.4,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Ribosomal protein S6 kinase alpha-1,RPS6KA1,6.4,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
xanomeline,D(3) dopamine receptor,DRD3,6.4,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
yohimbine,Alpha-1A adrenergic receptor,ADRA1A,6.4,Kd,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
dexfosfoserine,Metabotropic glutamate receptor 6,GRM6,6.4,EC50,N[C@@H](COP(O)(O)=O)C(O)=O
vandetanib,Ribosomal protein S6 kinase alpha-1,RPS6KA1,6.4,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
icatibant,B1 bradykinin receptor,Bdkrb1,6.4,Ki,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CS1)C(=O)N[C@@H](CO)C(=O)N1CC2=C(C[C@@H]1C(=O)N1[C@H]3CCCC[C@H]3C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C2
dequalinium,Small conductance calcium-activated potassium channel protein 1,KCNN1,6.4,IC50,CC1=[N+](CCCCCCCCCC[N+]2=C(C)C=C(N)C3=CC=CC=C23)C2=CC=CC=C2C(N)=C1
tenidap,Inward rectifier potassium channel 4,KCNJ4,6.4,EC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
vilanterol,Beta-1 adrenergic receptor,ADRB1,6.4,EC50,OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl
ceritinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6.4,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
diquafosol,P2Y purinoceptor 4,P2RY4,6.4,EC50,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O)N1C=CC(=O)NC1=O
neratinib,Tyrosine-protein kinase Mer,MERTK,6.4,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
relebactam,Beta-lactamase,blaCTX-M-15,6.4,IC50,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O
epinephrine,Alpha-2B adrenergic receptor,ADRA2B,6.401,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
fesoterodine,Muscarinic acetylcholine receptor M2,CHRM2,6.401,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
prochlorperazine,Sodium-dependent noradrenaline transporter,SLC6A2,6.402,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
maprotiline,Histamine H2 receptor,HRH2,6.406,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
clomifene,Muscarinic acetylcholine receptor M1,CHRM1,6.407,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
trifluoperazine,Alpha-2C adrenergic receptor,ADRA2C,6.407,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
raloxifene,D(2) dopamine receptor,DRD2,6.408,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
macitentan,Endothelin B receptor,EDNRB,6.408,IC50,CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1
methapyrilene,5-hydroxytryptamine receptor 2C,HTR2C,6.409,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
pyrimethamine,Bifunctional dihydrofolate reductase-thymidylate synthase,,6.409,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
buspirone,5-hydroxytryptamine receptor 2B,HTR2B,6.41,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
clozapine,Transporter,NET,6.41,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6.41,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dobutamine,Carbonic anhydrase 15,Ca15,6.41,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
ethoxzolamide,Astrosclerin-3,,6.41,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
glutamic acid,Metabotropic glutamate receptor 5,GRM5,6.41,Ki,N[C@@H](CCC(O)=O)C(O)=O
haloperidol,Vesicular acetylcholine transporter,Slc18a3,6.41,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
imatinib,Carbonic anhydrase 6,CA6,6.41,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
labetalol,5-hydroxytryptamine receptor 1A,Htr1a,6.41,IC50,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
mecamylamine,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,6.41,IC50,CNC1(C)C2CCC(C2)C1(C)C
mezlocillin,Prostaglandin G/H synthase 1,PTGS1,6.41,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
miglitol,Glycogen debranching enzyme,AGL,6.41,IC50,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nilotinib,Tyrosine-protein kinase HCK,HCK,6.41,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nimodipine,Nuclear receptor subfamily 1 group I member 2,NR1I2,6.41,EC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
norepinephrine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.41,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
phenylephrine,Adrenergic receptor alpha-2,ADRA2A|ADRA2B|ADRA2C,6.41,Ki,CNC[C@H](O)C1=CC(O)=CC=C1
pirenzepine,Muscarinic acetylcholine receptor DM1,mAChR-A,6.41,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
pranoprofen,Prostaglandin G/H synthase 1,Ptgs1,6.41,IC50,CC(C(O)=O)C1=CC2=C(OC3=NC=CC=C3C2)C=C1
quetiapine,D(1A) dopamine receptor,DRD1,6.41,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
sorafenib,Proto-oncogene tyrosine-protein kinase Src,SRC,6.41,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Homeodomain-interacting protein kinase 3,HIPK3,6.41,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,U4/U6 small nuclear ribonucleoprotein Prp4,PRPF4,6.41,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase PRP4 homolog,PRPF4B,6.41,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Delta carbonic anhydrase,ca1,6.41,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
guanabenz,Alpha-1A adrenergic receptor,Adra1a,6.41,IC50,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
pazopanib,LIM domain kinase 2,LIMK2,6.41,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
romidepsin,Histone deacetylase 6,Hdac6,6.41,IC50,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
ruxolitinib,Ankyrin repeat and protein kinase domain-containing protein 1,ANKK1,6.41,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Protein-tyrosine kinase 2-beta,PTK2B,6.41,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
teriflunomide,Dihydrofolate reductase,DHFR,6.41,IC50,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
nintedanib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,6.41,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Tyrosine-protein kinase receptor Tie-1,TIE1,6.41,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
entrectinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6.41,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
fedratinib,Wee1-like protein kinase,WEE1,6.41,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase PRP4 homolog,PRPF4B,6.41,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tazemetostat,Histone-lysine N-methyltransferase EZH1,EZH1,6.41,IC50,CCN(C1CCOCC1)C1=CC(=CC(C(=O)NCC2=C(C)C=C(C)NC2=O)=C1C)C1=CC=C(CN2CCOCC2)C=C1
loxapine,5-hydroxytryptamine receptor 1B,HTR1B,6.411,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
pecazine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.411,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
imipramine,D(3) dopamine receptor,DRD3,6.412,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
promazine,Muscarinic acetylcholine receptor M2,CHRM2,6.412,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
bithionol,Mitogen-activated protein kinase 1,MAPK1,6.415,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
gentian violet,Muscarinic acetylcholine receptor M5,CHRM5,6.416,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
mianserin,Muscarinic acetylcholine receptor M2,CHRM2,6.417,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
tianeptine,Mu-type opioid receptor,OPRM1,6.417,Ki,CN1C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C2S1(=O)=O
zolpidem,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,6.417,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
tamoxifen,Membrane-associated progesterone receptor component 1,Pgrmc1,6.419,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
cilostazol,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B",PDE3B,6.42,IC50,O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1
dexmedetomidine,Alpha-1A adrenergic receptor,ADRA1A,6.42,EC50,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
dexniguldipine,Alpha-1B adrenergic receptor,Adra1b,6.42,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
dichlorphenamide,Carbonic anhydrase 4,CA4,6.42,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
diltiazem,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,6.42,Ki,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
dobutamine,Sodium-dependent noradrenaline transporter,SLC6A2,6.42,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
haloperidol,Histamine H1 receptor,Hrh1,6.42,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hydroxyzine,D(2) dopamine receptor,DRD2,6.42,Ki,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
imatinib,Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma,PIP4K2C,6.42,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
masoprocol,Estradiol 17-beta-dehydrogenase 2,HSD17B2,6.42,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
mesoridazine,5-hydroxytryptamine receptor 6,HTR6,6.42,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
nilotinib,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,6.42,IC50,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
pemetrexed,Trifunctional purine biosynthetic protein adenosine-3,GART,6.42,Ki,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
sulindac,Glycine receptor subunit alpha-1,GLRA1,6.42,EC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
sulpiride,Astrosclerin-3,,6.42,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sumatriptan,5-hydroxytryptamine receptor 2A,HTR2A,6.42,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Aurora kinase B,AURKB,6.42,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase D2,PRKD2,6.42,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tenofovir,Reverse transcriptase,reverse transcriptas,6.42,IC50,C[C@H](CN1C=NC2=C(N)N=CN=C12)OCP(O)(O)=O
toloxatone,Amine oxidase [flavin-containing] A,Maoa,6.42,Ki,CC1=CC=CC(=C1)N1CC(CO)OC1=O
toloxatone,Amine oxidase [flavin-containing] A,MAOA,6.42,Ki,CC1=CC=CC(=C1)N1CC(CO)OC1=O
valdecoxib,Delta carbonic anhydrase,ca1,6.42,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
zolpidem,GABA A receptor alpha-3/beta-2/gamma-2,Gabrg2|Gabra3|Gabrb2,6.42,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
gabexate,Serine protease hepsin,HPN,6.42,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
ruboxistaurin,Mast/stem cell growth factor receptor Kit,KIT,6.42,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Tyrosine-protein kinase ABL1,ABL1,6.42,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Dual specificity testis-specific protein kinase 1,TESK1,6.42,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Fibroblast growth factor receptor 1,FGFR1,6.42,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
dapagliflozin,Sodium/myo-inositol cotransporter 2,SLC5A11,6.42,IC50,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
bosutinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,6.42,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase 24,STK24,6.42,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Dual serine/threonine and tyrosine protein kinase,DSTYK,6.42,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Serine/threonine-protein kinase LATS2,LATS2,6.42,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Tyrosine-protein kinase Blk,BLK,6.42,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase ULK2,ULK2,6.42,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,High affinity nerve growth factor receptor,NTRK1,6.42,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Cyclin-G-associated kinase,GAK,6.42,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,6.42,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
econazole,Muscarinic acetylcholine receptor M3,CHRM3,6.421,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
amoxapine,Muscarinic acetylcholine receptor M3,CHRM3,6.423,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
dichlorphenamide,Carbonic anhydrase,cynT,6.423,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
pimozide,Alpha-2C adrenergic receptor,ADRA2C,6.424,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
tirilazad,5-hydroxytryptamine receptor 2C,HTR2C,6.425,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=NC(=NC(=C1)N1CCCC1)N1CCCC1
fenfluramine,Alpha-2A adrenergic receptor,ADRA2A,6.428,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
pipamazine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.429,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
cortisone acetate,Sex hormone-binding globulin,SHBG,6.43,Kd,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
duloxetine,Sodium-dependent dopamine transporter,Slc6a3,6.43,IC50,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
olanzapine,FAD-linked sulfhydryl oxidase ALR,GFER,6.43,AC50,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
pimozide,Mu-type opioid receptor,OPRM1,6.43,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pioglitazone,CDGSH iron-sulfur domain-containing protein 1,CISD1,6.43,Ki,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
sulbactam,Beta-lactamase GES-13,blaGES-13,6.43,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sulindac,Aldose reductase,AKR1B1,6.43,IC50,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
sultiame,Carbonic anhydrase 1,CA1,6.43,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
sunitinib,Serine/threonine-protein kinase DCLK1,DCLK1,6.43,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,6.43,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
thalidomide,Prostaglandin G/H synthase 1,PTGS1,6.43,IC50,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2
topiramate,Carbonic anhydrase 2,CAN2,6.43,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
tretinoin,Cellular retinoic acid-binding protein 1,CRABP1,6.43,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
tyramine,TyR1,,6.43,EC50,NCCC1=CC=C(O)C=C1
ruboxistaurin,Serine/threonine-protein kinase PLK4,PLK4,6.43,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Calcium-dependent protein kinase 1,CPK1,6.43,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
rimonabant,Cannabinoid receptor 2,Cnr2,6.43,Ki,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
linagliptin,Prolyl endopeptidase FAP,Fap,6.43,IC50,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1
crizotinib,Serine/threonine-protein kinase DCLK2,DCLK2,6.43,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Serine/threonine-protein kinase 16,STK16,6.43,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,Carbonic anhydrase 3,CA3,6.43,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
bosutinib,Serine/threonine-protein kinase 3,STK3,6.43,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bedaquiline,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.43,IC50,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2
midostaurin,MAP/microtubule affinity-regulating kinase 4,MARK4,6.43,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase 12,MAP3K12,6.43,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
tirabrutinib hydrochloride,Tyrosine-protein kinase Lck,LCK,6.43,IC50,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
tirabrutinib hydrochloride,Tyrosine-protein kinase Lck,LCK,6.43,IC50,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
sirolimus,Sodium/nucleoside cotransporter 1,SLC28A1,6.431,Ki,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
diphenhydramine,5-hydroxytryptamine receptor 2A,HTR2A,6.432,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
nefazodone,Histamine H1 receptor,HRH1,6.432,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
thalidomide,Prostaglandin G/H synthase 1,PTGS1,6.432,IC50,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2
ximelagatran,Prothrombin,F2,6.432,Ki,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
terconazole,Alpha-2A adrenergic receptor,ADRA2A,6.433,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
disulfiram,D(3) dopamine receptor,DRD3,6.434,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
acalabrutinib,Tyrosine-protein kinase TXK,TXK,6.434,IC50,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
buspirone,Alpha-1A adrenergic receptor,ADRA1A,6.435,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
clemastine,Histamine H2 receptor,HRH2,6.439,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
diiodohydroxyquinoline,Mitogen-activated protein kinase 14,MAPK14,6.439,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
tamoxifen,D(3) dopamine receptor,DRD3,6.439,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
thioridazine,5-hydroxytryptamine receptor 5A,HTR5A,6.439,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
flibanserin,D(3) dopamine receptor,DRD3,6.439,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
dexmedetomidine,Alpha-1B adrenergic receptor,,6.44,EC50,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
galantamine,Acetylcholinesterase,ache,6.44,IC50,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
gefitinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,6.44,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
ketanserin,D(2) dopamine receptor,Drd2,6.44,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketoconazole,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial",Cyp27b1,6.44,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
metergoline,Sodium-dependent noradrenaline transporter,SLC6A2,6.44,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
nilotinib,Serine/threonine-protein kinase TNNI3K,TNNI3K,6.44,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
penfluridol,5-hydroxytryptamine receptor 2A,HTR2A,6.44,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
probenecid,Carbonic anhydrase 9,CA9,6.44,Ki,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
promethazine,FAD-linked sulfhydryl oxidase ALR,GFER,6.44,AC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
pyridostigmine,Acetylcholinesterase,ACHE,6.44,IC50,CN(C)C(=O)OC1=C[N+](C)=CC=C1
sorafenib,Ephrin type-A receptor 5,EPHA5,6.44,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfanilamide,Alpha carbonic anhydrase,CA,6.44,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,6.44,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Carbonic anhydrase,CA2,6.44,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
venlafaxine,Sodium-dependent dopamine transporter,Slc6a3,6.44,Ki,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
ziprasidone,5-hydroxytryptamine receptor 1E,HTR1E,6.44,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
enoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 2,Hsd11b2,6.44,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
ruboxistaurin,Protein kinase C alpha type,PRKCA,6.44,IC50,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
triclocarban,Epoxide hydrolase 1,Ephx1,6.44,IC50,ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1
velnacrine,Acetylcholinesterase,Ache,6.44,IC50,NC1=C2C(O)CCCC2=NC2=CC=CC=C12
androstanolone,Mineralocorticoid receptor,NR3C2,6.44,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
pazopanib,Serine/threonine-protein kinase 16,STK16,6.44,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Tyrosine-protein kinase Fyn,FYN,6.44,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Tyrosine-protein kinase HCK,HCK,6.44,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,MAP kinase-interacting serine/threonine-protein kinase 1,MKNK1,6.44,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vemurafenib,Vascular endothelial growth factor receptor 2,KDR,6.44,IC50,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F
crizotinib,Ephrin type-A receptor 4,EPHA4,6.44,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,"Myosin light chain kinase, smooth muscle",MYLK,6.44,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,BDNF/NT-3 growth factors receptor,NTRK2,6.44,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Ephrin type-B receptor 6,EPHB6,6.44,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,Carbonic anhydrase 1,CA1,6.44,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
afatinib,Homeodomain-interacting protein kinase 4,HIPK4,6.44,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Rho-associated protein kinase 2,ROCK2,6.44,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Tyrosine-protein kinase Fer,FER,6.44,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Interleukin-1 receptor-associated kinase 4,IRAK4,6.44,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
fedratinib,Fibroblast growth factor receptor 3,FGFR3,6.44,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Inhibitor of nuclear factor kappa-B kinase subunit beta,IKBKB,6.44,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,6.44,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Non-receptor tyrosine-protein kinase TNK1,TNK1,6.44,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,6.44,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,6.44,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
remimazolam,GABA-A receptor; alpha-1/beta-2/gamma-2,Gabrg2|Gabra1|Gabrb2,6.44,EC50,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
hexachlorophene,Adenosine receptor A3,ADORA3,6.442,Ki,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
thiothixene,5-hydroxytryptamine receptor 5A,HTR5A,6.442,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
risperidone,5-hydroxytryptamine receptor 1A,HTR1A,6.443,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
lofepramine,Histamine H1 receptor,HRH1,6.444,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
nefazodone,Sodium-dependent noradrenaline transporter,SLC6A2,6.444,Kd,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nefazodone,Sodium-dependent dopamine transporter,SLC6A3,6.444,Kd,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
mepacrine,Muscarinic acetylcholine receptor M1,CHRM1,6.445,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
oxiconazole,Adenosine receptor A3,ADORA3,6.445,Ki,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
fluphenazine,Muscarinic acetylcholine receptor M5,CHRM5,6.447,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,Muscarinic acetylcholine receptor M5,CHRM5,6.447,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
epinephrine,Alpha-2C adrenergic receptor,ADRA2C,6.449,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
amoxapine,Alpha-1A adrenergic receptor,Adra1a,6.45,IC50,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
fentanyl,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.45,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
fentanyl,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.45,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
haloperidol,5-hydroxytryptamine receptor 7,HTR7,6.45,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
penfluridol,5-hydroxytryptamine receptor 1A,HTR1A,6.45,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
lacosamide,Carbonic anhydrase 9,CA9,6.45,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
promethazine,Alpha-2C adrenergic receptor,ADRA2C,6.452,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
zafirlukast,Mitogen-activated protein kinase 14,MAPK14,6.452,IC50,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
clomifene,Alpha-2A adrenergic receptor,ADRA2A,6.455,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
flunarizine,5-hydroxytryptamine receptor 2C,HTR2C,6.455,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
citalopram,Histamine H1 receptor,HRH1,6.456,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
mizolastine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.456,IC50,CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1
lumacaftor,Cystic fibrosis transmembrane conductance regulator,CFTR,6.456,EC50,CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC=CC(=C1)C(O)=O
dextromethorphan,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.458,D2,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
acetylsalicylic acid,Prostaglandin G/H synthase 1,PTGS1,6.46,IC50,CC(=O)OC1=CC=CC=C1C(O)=O
carvedilol,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.46,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
chlortalidone,Carbonic anhydrase 1,CA1,6.46,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
desipramine,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,6.46,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
dichlorphenamide,Carbonic anhydrase 14,CA14,6.46,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
donepezil,Histamine H3 receptor,HRH3,6.46,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
imatinib,Multidrug and toxin extrusion protein 2,SLC47A2,6.46,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
loratadine,Histamine H1 receptor,Hrh1,6.46,Ki,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
mafenide,Carbonic anhydrase,,6.46,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mafenide,Carbonate dehydratase,,6.46,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
metoclopramide,Myeloperoxidase,MPO,6.46,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
miglitol,Lysosomal alpha-glucosidase,GAA,6.46,IC50,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nateglinide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,6.46,Ki,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O
phenyltoloxamine,D(1A) dopamine receptor,DRD1,6.46,Ki,CN(C)CCOC1=C(CC2=CC=CC=C2)C=CC=C1
rivastigmine,Butyrylcholinesterase; Protein Bche,Bche,6.46,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
sunitinib,Maternal embryonic leucine zipper kinase,MELK,6.46,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tretinoin,Retinoic acid receptor RXR-gamma,Rxrg,6.46,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
trichlormethiazide,Carbonic anhydrase 1,CA1,6.46,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
ruboxistaurin,Serine/threonine-protein kinase N1,PKN1,6.46,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
rufinamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.46,Ki,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1
rufinamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.46,Ki,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1
axitinib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,6.46,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,BMP-2-inducible protein kinase,BMP2K,6.46,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase,PKMYT1,6.46,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Microtubule-associated serine/threonine-protein kinase 1,MAST1,6.46,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Fibroblast growth factor receptor 2,FGFR2,6.46,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Dual specificity protein kinase TTK,TTK,6.46,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Dual specificity protein kinase CLK1,CLK1,6.46,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase STK11,STK11,6.46,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
entrectinib,Tyrosine-protein kinase JAK3,JAK3,6.46,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
fedratinib,Aurora kinase C,AURKC,6.46,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Cyclin-dependent kinase 17,CDK17,6.46,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
clomifene,Prostaglandin G/H synthase 1,PTGS1,6.461,IC50,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
pipamazine,Sodium-dependent serotonin transporter,SLC6A4,6.461,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
dihydroergocristine,Mu-type opioid receptor,OPRM1,6.462,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
bopindolol,Beta-3 adrenergic receptor,ADRB3,6.463,Ki,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
chlorpromazine,5-hydroxytryptamine receptor 1E,HTR1E,6.463,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
mianserin,Muscarinic acetylcholine receptor M1,CHRM1,6.465,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
mepacrine,Muscarinic acetylcholine receptor M2,CHRM2,6.465,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
thioridazine,Alpha-2B adrenergic receptor,ADRA2B,6.466,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
lofepramine,Muscarinic acetylcholine receptor M4,CHRM4,6.468,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
pemetrexed,Thymidylate synthase,TYMS,6.468,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
acarbose,Alpha-amylase,,6.47,Ki,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
bifonazole,Lanosterol 14-alpha demethylase,CYP51A1,6.47,IC50,C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1
clomifene,Sodium-dependent serotonin transporter,SLC6A4,6.47,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
hexafluronium,Butyrylcholinesterase,BCHE,6.47,Ki,C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C2=C1C=CC=C2)C1C2=CC=CC=C2C2=C1C=CC=C2
indomethacin,Prostaglandin G/H synthase 2,PTGS2,6.47,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
ketoconazole,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial",CYP27B1,6.47,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lysergide,D(1B) dopamine receptor,DRD5,6.47,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
pemetrexed,Thymidylate synthase,Tyms,6.47,Ki,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
pergolide,D(1A) dopamine receptor,DRD1,6.47,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pimozide,Sodium channel protein type 2 subunit alpha,Scn2a,6.47,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
risperidone,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,6.47,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sivelestat,Myeloblastin,PRTN3,6.47,IC50,CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=C(C=CC=C1)C(=O)NCC(O)=O
sunitinib,Serine/threonine-protein kinase 26,STK26,6.47,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
valdecoxib,Carbonic anhydrase 4,CA4,6.47,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
practolol,Beta-1 adrenergic receptor,Adrb1,6.47,Kd,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
timolol,Beta-3 adrenergic receptor,ADRB3,6.47,Ki,CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1
crizotinib,Insulin receptor,INSR,6.47,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Ribosomal protein S6 kinase alpha-4,RPS6KA4,6.47,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Epithelial discoidin domain-containing receptor 1,DDR1,6.47,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,6.47,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
afatinib,Ephrin type-A receptor 6,EPHA6,6.47,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,6.47,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase TAO3,TAOK3,6.47,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
paraoxon,Carbonic anhydrase 1,CA1,6.47,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
nintedanib,Serine/threonine-protein kinase ULK1,ULK1,6.47,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Serine/threonine-protein kinase 17A,STK17A,6.47,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
entrectinib,Aurora kinase B,AURKB,6.47,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
fedratinib,Bromodomain testis-specific protein,BRDT,6.47,IC50,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
filgotinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.47,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
filgotinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.47,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
chlorphentermine,Sodium-dependent serotonin transporter,SLC6A4,6.471,Ki,CC(C)(N)CC1=CC=C(Cl)C=C1
ebastine,Alpha-2B adrenergic receptor,ADRA2B,6.472,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
lansoprazole,Cytochrome P450 2C19,CYP2C19,6.473,IC50,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
sertraline,Alpha-1B adrenergic receptor,Adra1b,6.475,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
fluphenazine,5-hydroxytryptamine receptor 1B,HTR1B,6.476,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine,5-hydroxytryptamine receptor 1D,HTR1D,6.476,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,5-hydroxytryptamine receptor 1B,HTR1B,6.476,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
fluphenazine enanthate,5-hydroxytryptamine receptor 1D,HTR1D,6.476,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
dexchlorpheniramine,Muscarinic acetylcholine receptor M1,CHRM1,6.478,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
dasatinib,Activin receptor type-1B,ACVR1B,6.48,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dextrothyroxine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,6.48,IC50,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
dutasteride,Glycine receptor subunit alpha-1,GLRA1,6.48,EC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=C(C=CC(=C1)C(F)(F)F)C(F)(F)F
epalrestat,Aldo-keto reductase family 1 member B10,AKR1B10,6.48,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
erlotinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6.48,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
hydrochlorothiazide,Carbonic anhydrase 1,CA1,6.48,Ki,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
isoprenaline,Beta-2 adrenergic receptor,ADRB2,6.48,Kd,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
mecamylamine,Neuronal acetylcholine receptor; alpha4/beta4,CHRNB4|CHRNA4,6.48,IC50,CNC1(C)C2CCC(C2)C1(C)C
mecamylamine,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,6.48,IC50,CNC1(C)C2CCC(C2)C1(C)C
nilotinib,Ephrin type-A receptor 4,EPHA4,6.48,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norepinephrine,Alpha-2B adrenergic receptor,ADRA2B,6.48,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
oxymetazoline,Alpha-1D adrenergic receptor,Adra1d,6.48,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
pirenzepine,Muscarinic acetylcholine receptor M4,Chrm4,6.48,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
sunitinib,Cyclin-dependent kinase 7,CDK7,6.48,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase tousled-like 2,TLK2,6.48,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
talipexole,D(4) dopamine receptor,DRD4,6.48,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
zotepine,5-hydroxytryptamine receptor 1A,HTR1A,6.48,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
atosiban,Vasopressin V2 receptor,AVPR2,6.48,Ki,CCOC1=CC=C(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)C=C1
crizotinib,Tyrosine-protein kinase JAK1,JAK1,6.48,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Cyclin-dependent kinase 7,CDK7,6.48,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase DCLK1,DCLK1,6.48,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,NT-3 growth factor receptor,NTRK3,6.48,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,6.48,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,Carbonic anhydrase 2,CA2,6.48,Ki,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
bosutinib,Tyrosine-protein kinase Fes/Fps,FES,6.48,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
vortioxetine,5-hydroxytryptamine receptor 6,HTR6,6.48,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
niraparib,Poly [ADP-ribose] polymerase 4,PARP4,6.48,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
midostaurin,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,DYRK1B,6.48,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,SRSF protein kinase 2,SRPK2,6.48,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,6.48,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,6.48,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
lofepramine,Muscarinic acetylcholine receptor M2,CHRM2,6.481,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
nefopam,5-hydroxytryptamine receptor 2B,HTR2B,6.481,Ki,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1
quetiapine,D(2) dopamine receptor,DRD2,6.483,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
dapiprazole,5-hydroxytryptamine receptor 2C,HTR2C,6.485,Ki,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
pecazine,5-hydroxytryptamine receptor 2B,HTR2B,6.485,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
diphenidol,Cytochrome P450 2D6,CYP2D6,6.486,IC50,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
levobunolol,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.488,Ki,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
zopiclone,GABA A receptor alpha-3/beta-2/gamma-3,GABRA3|GABRB2|GABRG3,6.488,Ki,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
ketotifen,Alpha-2B adrenergic receptor,ADRA2B,6.489,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
bortezomib,Chymotrypsinogen B,CTRB1,6.49,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
cinacalcet,Glycine receptor subunit alpha-1,GLRA1,6.49,EC50,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=C1C=CC=C2
clozapine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,6.49,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
econazole,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,6.49,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
furosemide,"Carbonic anhydrase 5B, mitochondrial",CA5B,6.49,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
lumiracoxib,Prostaglandin G/H synthase 2,PTGS2,6.49,Ki,CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1
pethidine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.49,IC50,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
methazolamide,Astrosclerin-3,,6.49,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
nilotinib,Tyrosine-protein kinase Fgr,FGR,6.49,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
oxycodone,Kappa-type opioid receptor,OPRK1,6.49,Ki,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
oxycodone,Kappa-type opioid receptor,OPRK1,6.49,Ki,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
pinacidil,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,6.49,Ki,CC(NC(NC1=CC=NC=C1)=NC#N)C(C)(C)C
quetiapine,D(3) dopamine receptor,DRD3,6.49,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
quinidine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.49,IC50,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
risperidone,Glycine receptor subunit alpha-1,GLRA1,6.49,EC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
spiperone,D(1A) dopamine receptor,DRD1,6.49,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
tizanidine,Alpha-1B adrenergic receptor,,6.49,EC50,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
ruboxistaurin,NUAK family SNF1-like kinase 2,NUAK2,6.49,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Protein kinase C (PKC),Prkca|Prkcd|Prkce|Prkcz|Prkcg|Prkcb|Prkch|Prkcq,6.49,IC50,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vandetanib,Discoidin domain-containing receptor 2,DDR2,6.49,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Non-receptor tyrosine-protein kinase TNK1,TNK1,6.49,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,NUAK family SNF1-like kinase 2,NUAK2,6.49,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
labetalol,Alpha-1B adrenergic receptor,Adra1b,6.491,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
lisuride,Beta-1 adrenergic receptor,ADRB1,6.491,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
olanzapine,Alpha-2A adrenergic receptor,ADRA2A,6.492,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
prochlorperazine,Muscarinic acetylcholine receptor M3,CHRM3,6.493,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
chlordiazepoxide,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,6.495,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
ethylestrenol,Estrogen receptor,ESR1,6.495,Ki,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
nifedipine,5-hydroxytryptamine receptor 2A,HTR2A,6.495,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
iloperidone,D(1B) dopamine receptor,DRD5,6.496,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
propafenone,Beta-3 adrenergic receptor,ADRB3,6.498,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
bithionol,Mitogen-activated protein kinase 14,MAPK14,6.498,IC50,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
tetracaine,Amine oxidase [flavin-containing] A,MAOA,6.499,IC50,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
racecadotril,Angiotensin-converting enzyme,ACE,6.5,IC50,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1
acetylcholine,Muscarinic acetylcholine receptor M2,CHRM2,6.5,Ki,CC(=O)OCC[N+](C)(C)C
amantadine,Matrix protein 2,M,6.5,Kd,NC12CC3CC(CC(C3)C1)C2
bromocriptine,5-hydroxytryptamine receptor 1B,HTR1B,6.5,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
cabergoline,Alpha-1A adrenergic receptor,ADRA1A,6.5,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
clonidine,Alpha-1A adrenergic receptor,ADRA1A,6.5,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
clonidine,Alpha-1B adrenergic receptor,ADRA1B,6.5,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
darifenacin,Beta-1 adrenergic receptor,ADRB1,6.5,IC50,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
delavirdine,Gag-Pol polyprotein,gag-pol,6.5,IC50,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
desipramine,5-hydroxytryptamine receptor 2B,HTR2B,6.5,EC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
desipramine,5-hydroxytryptamine receptor 2C,HTR2C,6.5,EC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
dexmedetomidine,Alpha-1B adrenergic receptor,ADRA1B,6.5,Ki,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
disulfiram,Protein-lysine 6-oxidase,LOX,6.5,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
doxepin,D(1A) dopamine receptor,DRD1,6.5,EC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
doxepin,D(2) dopamine receptor,DRD2,6.5,EC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
epinephrine,Alpha-1B adrenergic receptor,ADRA1B,6.5,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
fenoldopam,D(4) dopamine receptor,DRD4,6.5,Ki,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
fluoxetine,5-hydroxytryptamine receptor 2A,Htr2a,6.5,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
formoterol,Beta-1 adrenergic receptor,ADRB1,6.5,Ki,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
ketanserin,5-hydroxytryptamine receptor 7,HTR7,6.5,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
loxiglumide,Cholecystokinin receptor type A,Cckar,6.5,IC50,CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1
mesoridazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.5,IC50,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
metergoline,5-hydroxytryptamine receptor 1F,HTR1F,6.5,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
mibefradil,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,Cacna1a,6.5,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
molindone,5-hydroxytryptamine receptor 2A,HTR2A,6.5,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
oxymetazoline,Alpha-1B adrenergic receptor,ADRA1B,6.5,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
pergolide,5-hydroxytryptamine receptor 2C,HTR2C,6.5,EC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pimozide,Potassium voltage-gated channel subfamily A member 10,KCNA10,6.5,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
piribedil,D(4) dopamine receptor,DRD4,6.5,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
promazine,Alpha-2B adrenergic receptor,ADRA2B,6.5,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
protriptyline,5-hydroxytryptamine receptor 2C,HTR2C,6.5,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
raloxifene,G-protein coupled estrogen receptor 1,GPER1,6.5,EC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
spiperone,5-hydroxytryptamine receptor 2B,HTR2B,6.5,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
taltirelin,Thyrotropin-releasing hormone receptor,TRHR,6.5,Ki,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCCC1C(N)=O
zoledronic acid,Carbonic anhydrase 12,CA12,6.5,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
zotepine,5-hydroxytryptamine receptor 1E,HTR1E,6.5,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
xanomeline,5-hydroxytryptamine receptor 1F,HTR1F,6.5,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
alitretinoin,Retinoic acid receptor RXR-alpha,RXRA,6.5,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
tolvaptan,Vasopressin V1a receptor,Avpr1a,6.5,Ki,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=CC(Cl)=CC=C12
dronedarone,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.5,IC50,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
vilazodone,Histamine H1 receptor,HRH1,6.5,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
dihydroergocryptine,5-hydroxytryptamine receptor 7,Htr7,6.5,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@@H]3C[C@H]4[C@@H](CC5=CNC6=CC=CC4=C56)N(C)C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
midostaurin,Protein kinase C delta type,PRKCD,6.5,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
quizartinib,Tyrosine-protein kinase ABL1,ABL1,6.5,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
quizartinib,Homeodomain-interacting protein kinase 4,HIPK4,6.5,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
tucatinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,6.5,IC50,CC1=CC(NC2=NC=NC3=C2C=C(NC2=NC(C)(C)CO2)C=C3)=CC=C1OC1=CC2=NC=NN2C=C1
fluphenazine,Alpha-2A adrenergic receptor,ADRA2A,6.503,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,Alpha-2A adrenergic receptor,ADRA2A,6.503,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
flunarizine,Muscarinic acetylcholine receptor M3,CHRM3,6.504,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
metergoline,Sodium-dependent serotonin transporter,SLC6A4,6.504,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
ebastine,Alpha-2A adrenergic receptor,ADRA2A,6.506,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ketoconazole,"1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial",CYP24A1,6.506,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
suloctidil,5-hydroxytryptamine receptor 1A,HTR1A,6.508,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
adenosine,Adenosine receptor A1,ADORA1,6.509,EC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
nortriptyline,5-hydroxytryptamine receptor 1A,HTR1A,6.509,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
olanzapine,5-hydroxytryptamine receptor 1F,HTR1F,6.509,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
aripiprazole,5-hydroxytryptamine receptor 6,HTR6,6.51,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
benazepril,Angiotensin-converting enzyme,ACE,6.51,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
dasatinib,Mitogen-activated protein kinase kinase kinase 4,MAP3K4,6.51,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
econazole,7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,CYP8B1,6.51,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
gefitinib,Homeodomain-interacting protein kinase 4,HIPK4,6.51,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
naftifine,C-8 sterol isomerase,ERG2,6.51,Ki,CN(C\C=C\C1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12
rofecoxib,Prostaglandin G/H synthase 2,PTGS2,6.51,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
sorafenib,Cyclin-dependent kinase 8,CDK8,6.51,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Serine/threonine-protein kinase MARK2,MARK2,6.51,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase D1,PRKD1,6.51,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ankyrin repeat and protein kinase domain-containing protein 1,ANKK1,6.51,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tretinoin,Retinoic acid receptor RXR-beta,Rxrb,6.51,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
trichlormethiazide,Carbonic anhydrase 12,CA12,6.51,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
ruboxistaurin,Misshapen-like kinase 1,MINK1,6.51,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,G protein-coupled receptor kinase 7,GRK7,6.51,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,TRAF2 and NCK-interacting protein kinase,TNIK,6.51,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Focal adhesion kinase 1,PTK2,6.51,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Calcium/calmodulin-dependent protein kinase type II subunit beta,CAMK2B,6.51,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase TAO2,TAOK2,6.51,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Angiopoietin-1 receptor,TEK,6.51,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
nintedanib,Tyrosine-protein kinase BTK,BTK,6.51,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,BDNF/NT-3 growth factors receptor,NTRK2,6.51,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha,PIP5K1A,6.51,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Serine/threonine-protein kinase STK11,STK11,6.51,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cefotaxime,Penicillin-binding protein 1A,mrcA,6.512,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
quetiapine,5-hydroxytryptamine receptor 7,HTR7,6.512,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
ceftriaxone,Penicillin-binding protein 1A,mrcA,6.513,IC50,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(=O)NN3C)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
flibanserin,D(2) dopamine receptor,DRD2,6.516,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
azacitidine,DNA (cytosine-5)-methyltransferase 1,DNMT1,6.52,IC50,NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
acetylsalicylic acid,Prostaglandin G/H synthase 1,PTGS1,6.52,IC50,CC(=O)OC1=CC=CC=C1C(O)=O
alfaxalone,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,6.52,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
amitriptyline,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,6.52,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
apomorphine,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,6.52,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
brivudine,Thymidine kinase,TK,6.52,IC50,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O
brotizolam,Platelet-activating factor receptor,PTAFR,6.52,IC50,CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C1=C(Cl)C=CC=C1
chlordiazepoxide,Cholinesterase,BCHE,6.52,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
cyclobenzaprine,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6.52,IC50,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
gemifloxacin,DNA topoisomerase 4 subunit A,parC,6.52,IC50,CO\N=C1/CN(CC1CN)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=N1)C(O)=O
imipramine,Muscarinic acetylcholine receptor M5,Chrm5,6.52,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
intoplicine,"DNA topoisomerase I, mitochondrial",TOP1MT,6.52,IC50,CN(C)CCCNC1=NC=C(C)C2=C1C1=C3C=CC(O)=CC3=CC=C1N2
intoplicine,DNA topoisomerase 1,TOP1,6.52,IC50,CN(C)CCCNC1=NC=C(C)C2=C1C1=C3C=CC(O)=CC3=CC=C1N2
medroxyprogesterone,Aldo-keto reductase family 1 member C3,AKR1C3,6.52,IC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
mefenamic acid,Aldo-keto reductase family 1 member C3,AKR1C3,6.52,Ki,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
mezlocillin,Interleukin-1 receptor type 1,IL1R1,6.52,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
morphine,Kappa-type opioid receptor,Oprk1,6.52,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
moxifloxacin,DNA gyrase,gyrA|gyrB,6.52,IC50,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1C[C@@H]2CCCN[C@@H]2C1)C1CC1
nilotinib,Carbonic anhydrase 12,CA12,6.52,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
pentamidine,Protein tyrosine phosphatase type IVA 2,PTP4A2,6.52,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pentamidine,Protein tyrosine phosphatase type IVA 1,PTP4A1,6.52,IC50,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
pioglitazone,Bile salt export pump,ABCB11,6.52,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
prenylamine,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,6.52,IC50,CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1
mepacrine,Major prion protein,PRNP,6.52,EC50,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
rofecoxib,Prostaglandin G/H synthase 2,PTGS2,6.52,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
sulfanilamide,Carbonic anhydrase 1,CA1,6.52,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulfanilamide,Carbonic anhydrase,CA2,6.52,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Serine/threonine-protein kinase Chk1,CHEK1,6.52,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
verapamil,Multidrug resistance protein 1,ABCB1,6.52,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
nicotinic acid,Hydroxycarboxylic acid receptor 3,HCAR3,6.52,EC50,OC(=O)C1=CN=CC=C1
zileuton,Arachidonate 5-lipoxygenase,ALOX5,6.52,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
suramin,NAD-dependent protein deacetylase sirtuin-1,SIRT1,6.52,IC50,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
quercetin,Insulin-like growth factor 1 receptor,IGF1R,6.52,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Protein kinase C gamma type,PRKCG,6.52,IC50,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
alitretinoin,Retinoic acid receptor alpha,RARA,6.52,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
vorinostat,Histone deacetylase-like amidohydrolase,hdaH,6.52,Kd,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
telaprevir,Cathepsin S,CTSS,6.52,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
vandetanib,Vascular endothelial growth factor receptor 3,FLT4,6.52,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ruxolitinib,Serine/threonine-protein kinase ULK1,ULK1,6.52,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Dual specificity protein kinase CLK3,CLK3,6.52,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Tyrosine-protein kinase Fgr,FGR,6.52,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Cyclin-dependent kinase 7,CDK7,6.52,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
abemaciclib,Cyclin-dependent kinase 7,CDK7,6.52,IC50,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
abemaciclib,Cyclin-dependent kinase 7,CDK7,6.52,IC50,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
fedratinib,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,6.52,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,MAP/microtubule affinity-regulating kinase 3,MARK3,6.52,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,AarF domain-containing protein kinase 4,COQ8B,6.52,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ephrin type-B receptor 6,EPHB6,6.52,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tirabrutinib hydrochloride,Tyrosine-protein kinase Blk,BLK,6.52,IC50,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
infigratinib,Tyrosine-protein kinase Lyn,LYN,6.52,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Tyrosine-protein kinase Lyn,LYN,6.52,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
cefsulodin,Penicillin-binding protein 1A,mrcA,6.522,IC50,NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C2=CC=CC=C2)S(O)(=O)=O)C3=O)C([O-])=O)C=C1
butenafine,Cytochrome P450 2D6,CYP2D6,6.523,IC50,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
canrenone,Mineralocorticoid receptor,NR3C2,6.523,IC50,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1
cisapride,Cytochrome P450 3A4,CYP3A4,6.523,IC50,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
danazol,Cytochrome P450 2C9,CYP2C9,6.523,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
econazole,Cytochrome P450 1A2,CYP1A2,6.523,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
felodipine,Aldehyde oxidase,AOX1,6.523,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
nifedipine,Cytochrome P450 1A2,CYP1A2,6.523,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
nitrendipine,Cytochrome P450 2C9,CYP2C9,6.523,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
prochlorperazine,Cytochrome P450 2D6,CYP2D6,6.523,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
promazine,Cytochrome P450 2D6,CYP2D6,6.523,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
mepyramine,Cytochrome P450 2D6,CYP2D6,6.523,IC50,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
quetiapine,5-hydroxytryptamine receptor 2B,HTR2B,6.523,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
raloxifene,5-hydroxytryptamine receptor 1D,HTR1D,6.523,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
tacrine,Cytochrome P450 2D6,CYP2D6,6.523,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
romidepsin,Histone deacetylase 6,HDAC6,6.523,Ki,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
clopidogrel,Sodium-dependent serotonin transporter,SLC6A4,6.524,Ki,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=C(Cl)C=CC=C1
tazobactam,Beta-lactamase 1,penPC,6.524,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tivozanib,Fibroblast growth factor receptor 1,FGFR1,6.524,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
mianserin,Muscarinic acetylcholine receptor M3,CHRM3,6.526,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
sibutramine,Sodium-dependent serotonin transporter,SLC6A4,6.526,Ki,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
tazobactam,Beta-lactamase,blaZ,6.527,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
lenalidomide,Protein cereblon,CRBN,6.527,EC50,NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
econazole,Muscarinic acetylcholine receptor M4,CHRM4,6.529,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
apomorphine,5-hydroxytryptamine receptor 1A,HTR1A,6.53,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
apomorphine,5-hydroxytryptamine receptor 1A,Htr1a,6.53,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
dexniguldipine,D(2) dopamine receptor,Drd2,6.53,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
dilevalol,5-hydroxytryptamine receptor 1A,Htr1a,6.53,Ki,C[C@H](CCC1=CC=CC=C1)NC[C@H](O)C1=CC(C(N)=O)=C(O)C=C1
hydrochlorothiazide,"Carbonic anhydrase, alpha family",,6.53,Ki,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
indomethacin,Prostaglandin D2 receptor 2,PTGDR2,6.53,Ki,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
lovastatin,Hydroxycarboxylic acid receptor 3,HCAR3,6.53,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
naftifine,Dehydrosqualene desaturase,crtN,6.53,IC50,CN(C\C=C\C1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12
zaleplon,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,6.53,EC50,CCN(C(C)=O)C1=CC(=CC=C1)C1=CC=NC2=C(C=NN12)C#N
linagliptin,Muscarinic acetylcholine receptor M1,CHRM1,6.53,IC50,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1
ruxolitinib,JAK1/JAK2/TYK2,JAK2|JAK1|TYK2,6.53,IC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
enzalutamide,Androgen receptor,Ar,6.53,IC50,CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC(=C(C=C1)C#N)C(F)(F)F
diiodohydroxyquinoline,Mitogen-activated protein kinase 1,MAPK1,6.532,IC50,OC1=C2N=CC=CC2=C(I)C=C1I
benzethonium,Alpha-2B adrenergic receptor,ADRA2B,6.532,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
norethindrone acetate,Glucocorticoid receptor,NR3C1,6.533,Ki,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
ceftazidime,Penicillin-binding protein 1A,mrcA,6.534,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1)C(O)=O
trifluoperazine,5-hydroxytryptamine receptor 7,HTR7,6.536,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
ziprasidone,5-hydroxytryptamine receptor 5A,HTR5A,6.536,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
chlordiazepoxide,Thyrotropin-releasing hormone receptor,TRHR,6.538,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
dicycloverine,SMR1-alpha2,Vcsa2,6.538,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
doxepin,5-hydroxytryptamine receptor 1A,HTR1A,6.538,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
estradiol,Aldehyde oxidase,AOX1,6.538,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
pipamperone,Alpha-2C adrenergic receptor,ADRA2C,6.538,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
adenosine,Adenosine receptor A3,ADORA3,6.54,Ki,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
blonanserin,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.54,Ki,CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1
celecoxib,Carbonic anhydrase 4,CA4,6.54,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
clozapine,D(2) dopamine receptor,Drd2,6.54,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproheptadine,Sodium-dependent noradrenaline transporter,SLC6A2,6.54,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cyproheptadine,Sodium-dependent noradrenaline transporter,Slc6a2,6.54,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
gefitinib,MAP kinase-interacting serine/threonine-protein kinase 1,MKNK1,6.54,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glutamic acid,Metabotropic glutamate receptor 2,GRM2,6.54,EC50,N[C@@H](CCC(O)=O)C(O)=O
nafamostat,Prothrombin,F2,6.54,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
pentamidine,Amiloride-sensitive amine oxidase [copper-containing],AOC1,6.54,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
piribedil,Alpha-2B adrenergic receptor,ADRA2B,6.54,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
regadenoson,Adenosine receptor A2a,Adora2a,6.54,Ki,CNC(=O)C1=CN(N=C1)C1=NC(N)=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=N1
ropinirole,5-hydroxytryptamine receptor 1A,HTR1A,6.54,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sunitinib,Fibroblast growth factor receptor 3,FGFR3,6.54,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 25,STK25,6.54,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Rhodopsin kinase,GRK1,6.54,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tranylcypromine,Amine oxidase [flavin-containing] A,Maoa,6.54,IC50,N[C@@H]1C[C@H]1C1=CC=CC=C1
enoxolone,Lactoylglutathione lyase,Glo1,6.54,Ki,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
ruboxistaurin,"Myosin light chain kinase, smooth muscle",MYLK,6.54,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,6.54,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Serine/threonine-protein kinase PLK4,PLK4,6.54,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,6.54,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,6.54,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Ephrin type-B receptor 1,EPHB1,6.54,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Tyrosine-protein kinase JAK2,JAK2,6.54,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Interleukin-1 receptor-associated kinase 1,IRAK1,6.54,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Tyrosine-protein kinase SYK,SYK,6.54,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,"Myosin light chain kinase, smooth muscle",MYLK,6.54,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase Chk1,CHEK1,6.54,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,6.54,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,6.54,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Protein kinase C eta type,PRKCH,6.54,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Casein kinase I isoform epsilon,CSNK1E,6.54,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
alpelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,6.54,IC50,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F
fedratinib,Serine/threonine-protein kinase ULK3,ULK3,6.54,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
mianserin,Muscarinic acetylcholine receptor M4,CHRM4,6.541,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
amoxapine,Muscarinic acetylcholine receptor M1,CHRM1,6.542,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
astemizole,Alpha-2C adrenergic receptor,ADRA2C,6.545,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
doxazosin,5-hydroxytryptamine receptor 2C,HTR2C,6.545,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
benzethonium,Alpha-2C adrenergic receptor,ADRA2C,6.545,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
dasatinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,6.55,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
domperidone,Alpha-1A adrenergic receptor,Adra1a,6.55,IC50,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
dorzolamide,Astrosclerin-3,,6.55,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
doxazosin,Alpha-2C adrenergic receptor,ADRA2C,6.55,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
ebastine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.55,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
glutamic acid,Glutamate receptor 2,Gria2,6.55,Ki,N[C@@H](CCC(O)=O)C(O)=O
haloprogin,D(1A) dopamine receptor,DRD1,6.55,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
hesperetin,Dipeptidyl peptidase 4,DPP4,6.55,IC50,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
ketoconazole,Sodium-dependent serotonin transporter,SLC6A4,6.55,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lidoflazine,Equilibrative nucleoside transporter 1,SLC29A1,6.55,Ki,CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1
mecamylamine,Neuronal acetylcholine receptor; alpha3/beta2,CHRNB2|CHRNA3,6.55,IC50,CNC1(C)C2CCC(C2)C1(C)C
milrinone,"cGMP-inhibited 3',5'-cyclic phosphodiesterase B",PDE3B,6.55,IC50,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
papaverine,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,6.55,Ki,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
physostigmine,Cholinesterase,Bche,6.55,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
piperacillin,Streptokinase A,ska,6.55,EC50,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C2=CC=CC=C2)C(=O)C1=O
pirenzepine,Muscarinic acetylcholine receptor M5,CHRM5,6.55,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
sorafenib,Serine/threonine-protein kinase TNNI3K,TNNI3K,6.55,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Serine/threonine-protein kinase D3,PRKD3,6.55,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
ziprasidone,Muscarinic acetylcholine receptor M1,CHRM1,6.55,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
quercetin,Vascular endothelial growth factor receptor 2,KDR,6.55,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Ribosomal protein S6 kinase alpha-2,RPS6KA2,6.55,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase 10,STK10,6.55,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Myotonin-protein kinase,DMPK,6.55,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Cyclin-dependent kinase 4,CDK4,6.55,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma,PIP4K2C,6.55,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
gentian violet,D(3) dopamine receptor,DRD3,6.55,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
crizotinib,Ephrin type-A receptor 8,EPHA8,6.55,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Casein kinase I isoform alpha,CSNK1A1,6.55,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ibrutinib,Fibroblast growth factor receptor 2,FGFR2,6.55,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
nintedanib,Serine/threonine-protein kinase SIK2,SIK2,6.55,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Tyrosine-protein kinase Lck,LCK,6.55,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase 16,STK16,6.55,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Maternal embryonic leucine zipper kinase,MELK,6.55,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Serine/threonine-protein kinase PLK1,PLK1,6.55,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Fibroblast growth factor receptor 1,FGFR1,6.55,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
nicardipine,Cytochrome P450 2C9,CYP2C9,6.553,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
orphenadrine,5-hydroxytryptamine receptor 2C,HTR2C,6.553,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
raloxifene,Sodium-dependent noradrenaline transporter,SLC6A2,6.553,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
ebastine,Muscarinic acetylcholine receptor M2,CHRM2,6.554,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
paliperidone,5-hydroxytryptamine receptor 5A,HTR5A,6.556,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
mepacrine,Muscarinic acetylcholine receptor M4,CHRM4,6.558,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
epinephrine,Alpha-2A adrenergic receptor,ADRA2A,6.559,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
methylergometrine,D(2) dopamine receptor,DRD2,6.559,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
dexchlorpheniramine,Muscarinic acetylcholine receptor M4,CHRM4,6.559,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
brinzolamide,Astrosclerin-3,,6.56,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
dorzolamide,Carbonic anhydrase,,6.56,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
indapamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,6.56,Ki,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
phenylpropanolamine,Alpha-2A adrenergic receptor,ADRA2A,6.56,Ki,CC(N)C(O)C1=CC=CC=C1
sultiame,Astrosclerin-3,,6.56,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
tramazoline,Alpha-2C adrenergic receptor,ADRA2C,6.56,Ki,C1CN=C(NC2=C3CCCCC3=CC=C2)N1
nintedanib,Multidrug resistance protein 1,ABCB1,6.56,EC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Multidrug resistance protein 1,ABCB1,6.56,EC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
filgotinib,Vascular endothelial growth factor receptor 3,FLT4,6.56,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
filgotinib,Vascular endothelial growth factor receptor 3,FLT4,6.56,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
belotecan,DNA topoisomerase 1,TOP1,6.561,IC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C(CCNC(C)C)C4=CC=CC=C4N=C13)C2=O
chlordiazepoxide,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,6.561,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
nortriptyline,Alpha-2A adrenergic receptor,ADRA2A,6.561,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
diphenidol,Muscarinic acetylcholine receptor M2,CHRM2,6.562,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
metergoline,5-hydroxytryptamine receptor 4,HTR4,6.562,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
gentian violet,Alpha-2C adrenergic receptor,ADRA2C,6.562,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
asenapine,Muscarinic acetylcholine receptor M5,CHRM5,6.565,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
haloperidol,5-hydroxytryptamine receptor 1B,HTR1B,6.569,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ipidacrine,Acetylcholinesterase,Ache,6.569,IC50,NC1=C2CCCC2=NC2=C1CCCC2
amoxapine,5-hydroxytryptamine receptor 3A,HTR3A,6.57,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
bopindolol,5-hydroxytryptamine receptor 1A,Htr1a,6.57,IC50,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
dexfenfluramine,Alpha-1A adrenergic receptor,ADRA1A,6.57,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
dexmethylphenidate,Transporter,Slc6a2,6.57,Ki,COC(=O)[C@@H]([C@H]1CCCCN1)C1=CC=CC=C1
fenfluramine,Alpha-1A adrenergic receptor,ADRA1A,6.57,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
aminobutyric acid,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,6.57,EC50,NCCCC(O)=O
gamolenic acid,Peroxisome proliferator-activated receptor alpha,PPARA,6.57,IC50,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
loperamide,"Sodium channel alpha subunits; brain (Types I, II, III)",SCN1A|SCN2A|SCN3A,6.57,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
methysergide,D(2) dopamine receptor,DRD2,6.57,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nortriptyline,D(1A) dopamine receptor,DRD1,6.57,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
phenylephrine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,6.57,Ki,CNC[C@H](O)C1=CC(O)=CC=C1
sildenafil,Phosphodiesterase 1,PDE1A|PDE1B|PDE1C,6.57,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sitosterol,Prothrombin,F2,6.57,Ki,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
sunitinib,Tyrosine-protein kinase Lyn,LYN,6.57,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Tyrosine-protein kinase Fgr,FGR,6.57,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Cyclin-dependent kinase 14,CDK14,6.57,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
bietamiverine,Muscarinic acetylcholine receptor M1,CHRM1,6.57,Ki,CCN(CC)CCOC(=O)C(N1CCCCC1)C1=CC=CC=C1
exisulind,Aldose reductase,Akr1b1,6.57,IC50,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)(=O)=O
pazopanib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6.57,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Tyrosine-protein kinase Fgr,FGR,6.57,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Angiopoietin-1 receptor,TEK,6.57,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Tyrosine-protein kinase Fer,FER,6.57,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,6.57,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,6.57,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Eukaryotic translation initiation factor 2-alpha kinase 4,EIF2AK4,6.57,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Mitogen-activated protein kinase 10,MAPK10,6.57,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,ALK tyrosine kinase receptor,ALK,6.57,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Phosphatidylinositol 5-phosphate 4-kinase type-2 beta,PIP4K2B,6.57,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase 4,STK4,6.57,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
tezacaftor,Cystic fibrosis transmembrane conductance regulator,CFTR,6.57,EC50,CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C2)N1C[C@@H](O)CO
quizartinib,Mitogen-activated protein kinase 15,MAPK15,6.57,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Serine/threonine-protein kinase ULK1,ULK1,6.57,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tenidap,Prostaglandin G/H synthase 2,PTGS2,6.573,IC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
mepacrine,Muscarinic acetylcholine receptor M3,CHRM3,6.575,Ki,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
doxepin,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.577,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
flunarizine,Sodium-dependent serotonin transporter,SLC6A4,6.577,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
ketotifen,Muscarinic acetylcholine receptor M3,CHRM3,6.577,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
phenylpropanolamine,Alpha-2C adrenergic receptor,ADRA2C,6.577,Ki,CC(N)C(O)C1=CC=CC=C1
pomalidomide,Protein cereblon,CRBN,6.577,EC50,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
ergotamine,5-hydroxytryptamine receptor 4,HTR4,6.578,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
loperamide,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.578,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
gentian violet,Muscarinic acetylcholine receptor M1,CHRM1,6.578,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
celecoxib,Delta carbonic anhydrase,ca1,6.58,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cimetidine,Histamine H2 receptor,HRH2,6.58,Kd,CNC(NCCSCC1=C(C)NC=N1)=NC#N
dimetindene,Muscarinic acetylcholine receptor M1,CHRM1,6.58,Ki,CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C1=CC=CC=N1
furosemide,Carbonic anhydrase 12,CA12,6.58,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
haloperidol,5-hydroxytryptamine receptor 7,Htr7,6.58,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
miconazole,Thromboxane-A synthase,TBXAS1,6.58,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mirtazapine,5-hydroxytryptamine receptor 7,HTR7,6.58,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
molindone,5-hydroxytryptamine receptor 7,HTR7,6.58,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
norepinephrine,Alpha-1B adrenergic receptor,ADRA1B,6.58,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
phenylpropanolamine,Alpha-2B adrenergic receptor,Adra2b,6.58,Ki,CC(N)C(O)C1=CC=CC=C1
mepacrine,Riboflavin-binding protein,,6.58,Kd,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12
sulpiride,Carbonic anhydrase 2,mtcA2,6.58,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sultiame,Carbonic anhydrase,,6.58,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
tizanidine,Alpha-1A adrenergic receptor,ADRA1A,6.58,EC50,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
trazodone,Alpha-2A adrenergic receptor,ADRA2A,6.58,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
zonisamide,Carbonic anhydrase,,6.58,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
fedratinib,Mitogen-activated protein kinase 8,MAPK8,6.58,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
delgocitinib,Rho-associated protein kinase 2,ROCK2,6.58,IC50,C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N
olanzapine,Alpha-1B adrenergic receptor,ADRA1B,6.582,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
zopiclone,GABA A receptor alpha-3/beta-2/gamma-2,GABRG2|GABRA3|GABRB2,6.582,Ki,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
amlodipine,Alpha-2C adrenergic receptor,ADRA2C,6.583,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
thiothixene,D(1B) dopamine receptor,DRD5,6.583,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
amitriptyline,Aldehyde oxidase,AOX1,6.585,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
diphenhydramine,Muscarinic acetylcholine receptor M5,CHRM5,6.585,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
zotepine,Muscarinic acetylcholine receptor M5,CHRM5,6.585,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
teneligliptin,Dipeptidyl peptidase 8,DPP8,6.585,IC50,CC1=NN(C(=C1)N1CCN(CC1)[C@@H]1CN[C@@H](C1)C(=O)N1CCSC1)C1=CC=CC=C1
astemizole,Muscarinic acetylcholine receptor M4,CHRM4,6.587,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
cinnarizine,D(2) dopamine receptor,DRD2,6.587,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
pecazine,5-hydroxytryptamine receptor 2C,HTR2C,6.587,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
tropisetron,Sodium-dependent serotonin transporter,SLC6A4,6.587,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
dosulepin,5-hydroxytryptamine receptor 2A,HTR2A,6.588,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
aminoglutethimide,Aromatase,Cyp19a1,6.59,EC50,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1
astemizole,Muscarinic acetylcholine receptor M1,CHRM1,6.59,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
clonidine,Alpha-1A adrenergic receptor,Adra1a,6.59,Kd,ClC1=CC=CC(Cl)=C1NC1=NCCN1
clozapine,D(3) dopamine receptor,DRD3,6.59,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Serine/threonine-protein kinase NLK,NLK,6.59,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dinoprostone,Prostacyclin receptor,PTGIR,6.59,IC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
hydrocodone,Kappa-type opioid receptor,OPRK1,6.59,Ki,COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C
imipramine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,6.59,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
ketanserin,5-hydroxytryptamine receptor 1D,HTR1D,6.59,IC50,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
meclofenamic acid,"Fatty acid-binding protein, liver",Fabp1,6.59,Ki,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
niflumic acid,Transthyretin,TTR,6.59,Kd,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
oxymetazoline,5-hydroxytryptamine receptor 2A,HTR2A,6.59,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
progesterone,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.59,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
raltitrexed,Thymidylate synthase,TYMS,6.59,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
sildenafil,Phosphodiesterase 1,Pde1b|Pde1c|Pde1a,6.59,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,Mitogen-activated protein kinase 14,MAPK14,6.59,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulpiride,Delta carbonic anhydrase,ca1,6.59,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
zoledronic acid,Geranylgeranyl pyrophosphate synthase,BTS1,6.59,Ki,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
zonisamide,Alpha carbonic anhydrase,CA,6.59,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
lubeluzole,Sodium channel protein type 2 subunit alpha,Scn2a,6.59,IC50,CN(C1CCN(C[C@H](O)COC2=CC(F)=C(F)C=C2)CC1)C1=NC2=C(S1)C=CC=C2
pazopanib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,6.59,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Vascular endothelial growth factor receptor 1,FLT1,6.59,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Aurora kinase A,AURKA,6.59,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase DCLK3,DCLK3,6.59,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ceritinib,Fibroblast growth factor receptor 2,FGFR2,6.59,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,6.59,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Calcium/calmodulin-dependent protein kinase type 1G,CAMK1G,6.59,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
migalastat,"Sucrase-isomaltase, intestinal",SI,6.59,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
midostaurin,Ribosomal protein S6 kinase alpha-1,RPS6KA1,6.59,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Ribosomal protein S6 kinase alpha-4,RPS6KA4,6.59,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
relebactam,Beta-lactamase,bla,6.59,IC50,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O
droperidol,Alpha-2C adrenergic receptor,ADRA2C,6.592,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
promethazine,Alpha-2A adrenergic receptor,ADRA2A,6.592,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
amoxapine,Alpha-2B adrenergic receptor,ADRA2B,6.593,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
levobunolol,Beta-3 adrenergic receptor,ADRB3,6.593,Ki,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
clozapine,D(1B) dopamine receptor,DRD5,6.594,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
glutamic acid,Glutamate receptor 3,GRIA3,6.595,Ki,N[C@@H](CCC(O)=O)C(O)=O
testosterone,Progesterone receptor,PGR,6.599,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
acetazolamide,Beta-carbonic anhydrase 1,mtcA1,6.6,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
agomelatine,5-hydroxytryptamine receptor 2B,HTR2B,6.6,Ki,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
bepridil,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CACNA1A,6.6,Ki,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
buspirone,5-hydroxytryptamine receptor 2A,HTR2A,6.6,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
cicaprost,Prostaglandin E2 receptor EP3 subtype,PTGER3,6.6,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
clozapine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.6,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,D(2) dopamine receptor,DRD2,6.6,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
desogestrel,Sex hormone-binding globulin,SHBG,6.6,Kd,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
dicycloverine,Muscarinic acetylcholine receptor M2,CHRM2,6.6,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
erlotinib,Tyrosine-protein kinase Lck,LCK,6.6,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
glutamic acid,Metabotropic glutamate receptor 1,GRM1,6.6,Ki,N[C@@H](CCC(O)=O)C(O)=O
glycine,"Glutamate receptor ionotropic, NMDA 1",Grin1,6.6,IC50,NCC(O)=O
haloperidol,5-hydroxytryptamine receptor 1D,HTR1D,6.6,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloprogin,Alpha-2B adrenergic receptor,ADRA2B,6.6,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
iloprost,Prostaglandin D2 receptor,PTGDR,6.6,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
indapamide,Carbonic anhydrase 6,CA6,6.6,Kd,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
levamfetamine,Trace amine-associated receptor 1,TAAR1,6.6,EC50,C[C@@H](N)CC1=CC=CC=C1
methysergide,5-hydroxytryptamine receptor 6,Htr6,6.6,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
mianserin,Serotonin 3 receptor (5HT3),Htr3a|Htr3b,6.6,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nepafenac,Prostaglandin G/H synthase 1,PTGS1,6.6,IC50,NC(=O)CC1=C(N)C(=CC=C1)C(=O)C1=CC=CC=C1
niclosamide,Signal transducer and activator of transcription 3,STAT3,6.6,IC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
nimodipine,Voltage-dependent L-type calcium channel subunit alpha-1D,Cacna1d,6.6,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
pergolide,5-hydroxytryptamine receptor 1B,HTR1B,6.6,EC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
piribedil,D(3) dopamine receptor,DRD3,6.6,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
pramipexole,D(2) dopamine receptor,DRD2,6.6,EC50,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
prednisolone,G-protein coupled bile acid receptor 1,GPBAR1,6.6,IC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,G-protein coupled bile acid receptor 1,GPBAR1,6.6,IC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
prenalterol,Beta-1 adrenergic receptor,ADRB1,6.6,Ki,CC(C)NC[C@H](O)COC1=CC=C(O)C=C1
propranolol,Beta-3 adrenergic receptor,Adrb3,6.6,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
ramipril,Angiotensin-converting enzyme,ACE,6.6,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O
sarpogrelate,5-hydroxytryptamine receptor 2B,HTR2B,6.6,Ki,COC1=CC=CC(CCC2=C(OCC(CN(C)C)OC(=O)CCC(O)=O)C=CC=C2)=C1
sorafenib,Cyclin-dependent kinase 19,CDK19,6.6,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Casein kinase I isoform alpha,CSNK1A1,6.6,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfanilamide,Carbonic anhydrase,,6.6,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sumatriptan,5-hydroxytryptamine receptor 7,Htr7,6.6,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Serine/threonine-protein kinase 16,STK16,6.6,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,SRSF protein kinase 1,SRPK1,6.6,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terguride,5-hydroxytryptamine receptor 1B,HTR1B,6.6,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
topiramate,Carbonic anhydrase 1,CA1,6.6,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
valethamate,Cytochrome P450 2D6,CYP2D6,6.6,IC50,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1
zolmitriptan,5-hydroxytryptamine receptor 1A,HTR1A,6.6,Ki,CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2
enoxolone,Protein kinase C eta type,PRKCH,6.6,Kd,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
ruboxistaurin,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,DYRK1A,6.6,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vandetanib,Tyrosine-protein kinase receptor UFO,AXL,6.6,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vilazodone,5-hydroxytryptamine receptor 4,HTR4,6.6,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
vilazodone,5-hydroxytryptamine receptor 4,Htr4,6.6,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
bosutinib,Serine/threonine-protein kinase TBK1,TBK1,6.6,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nalfurafine,Orexin receptor type 1,HCRTR1,6.6,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
pleconaril,Nuclear receptor subfamily 1 group I member 2,NR1I2,6.6,EC50,CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C2=NOC(=N2)C(F)(F)F)=C1
midostaurin,Vascular endothelial growth factor receptor 2,KDR,6.6,IC50,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Non-receptor tyrosine-protein kinase TYK2,TYK2,6.6,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Casein kinase II subunit alpha,CSNK2A1,6.6,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,cGMP-dependent protein kinase 1,PRKG1,6.6,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase Nek2,NEK2,6.6,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Cyclin-G-associated kinase,GAK,6.6,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
alpelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,6.6,IC50,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F
mibefradil,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,6.602,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
pipamperone,D(3) dopamine receptor,DRD3,6.602,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
pyrimethamine,Bifunctional dihydrofolate reductase-thymidylate synthase,,6.602,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
tazobactam,Beta-lactamase TEM,bla; blaT-3; blaT-4;,6.602,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
zotepine,D(1B) dopamine receptor,DRD5,6.606,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
acarbose,"Sucrase-isomaltase, intestinal",SI,6.609,Ki,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
promethazine,D(2) dopamine receptor,DRD2,6.609,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
fluoxetine,5-hydroxytryptamine receptor 2A,HTR2A,6.61,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
furosemide,Carbonic anhydrase 6,CA6,6.61,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
mazindol,Sodium-dependent serotonin transporter,Slc6a4,6.61,Ki,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
miconazole,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,6.61,Ki,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nicotine,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,6.61,Ki,CN1CCC[C@H]1C1=CC=CN=C1
pirenzepine,Muscarinic acetylcholine receptor M3,CHRM3,6.61,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
naphazoline,Nischarin,Nisch,6.61,Ki,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
oleic acid,"Fatty acid-binding protein, epidermal",FABP5,6.61,Ki,CCCCCCCC\C=C/CCCCCCCC(O)=O
perampanel,Glutamate receptor ionotropic AMPA,GRIA1|GRIA2|GRIA3|GRIA4,6.61,IC50,O=C1N(C=C(C=C1C1=C(C=CC=C1)C#N)C1=CC=CC=N1)C1=CC=CC=C1
trametinib,Multidrug resistance protein 1,ABCB1,6.61,EC50,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=C(F)C=C(I)C=C1)C1=CC(NC(C)=O)=CC=C1
trametinib,Multidrug resistance protein 1,ABCB1,6.61,EC50,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=C(F)C=C(I)C=C1)C1=CC(NC(C)=O)=CC=C1
dicycloverine,5-hydroxytryptamine receptor 2C,HTR2C,6.611,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
montelukast,Adenosine receptor A3,ADORA3,6.611,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
venetoclax,Apoptosis regulator Bcl-W,BCL2L2,6.611,Ki,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CC4=C(NC=C4)N=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC(=C(NCC3CCOCC3)C=C2)[N+]([O-])=O)=C(C1)C1=CC=C(Cl)C=C1
prochlorperazine,Muscarinic acetylcholine receptor M1,CHRM1,6.613,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
orphenadrine,Sodium-dependent serotonin transporter,SLC6A4,6.614,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
ebastine,Muscarinic acetylcholine receptor M5,CHRM5,6.615,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
amoxapine,Muscarinic acetylcholine receptor M4,CHRM4,6.616,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
tamoxifen,5-hydroxytryptamine receptor 2C,HTR2C,6.618,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
azimilide,Potassium voltage-gated channel subfamily KQT member 1,KCNQ1,6.62,IC50,CN1CCN(CCCCN2C(=O)CN(N=CC3=CC=C(O3)C3=CC=C(Cl)C=C3)C2=O)CC1
brivudine,Thymidine kinase,TK,6.62,Ki,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O
cyproheptadine,Alpha-1A adrenergic receptor,Adra1a,6.62,IC50,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dexfenfluramine,Alpha-2B adrenergic receptor,ADRA2B,6.62,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
droperidol,5-hydroxytryptamine receptor 1A,Htr1a,6.62,IC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
duloxetine,Sodium-dependent dopamine transporter,SLC6A3,6.62,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
fluoxetine,Sodium-dependent noradrenaline transporter,SLC6A2,6.62,Kd,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
gefitinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,6.62,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
haloperidol,Muscarinic acetylcholine receptor M2,Chrm2,6.62,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ibudilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,6.62,IC50,CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C
ifenprodil,5-hydroxytryptamine receptor 1A,Htr1a,6.62,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
ketanserin,D(2) dopamine receptor,DRD2,6.62,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketoprofen,Prostaglandin G/H synthase 2,PTGS2,6.62,IC50,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
liothyronine,Adenosine receptor A1,ADORA1,6.62,Ki,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
loperamide,Sodium channel protein type 5 subunit alpha,SCN5A,6.62,IC50,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
methazolamide,Carbonic anhydrase 4,CA4,6.62,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
modafinil,D(2) dopamine receptor,DRD2,6.62,EC50,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
morphine,Delta-type opioid receptor,OPRD1,6.62,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
nafamostat,Plasminogen,PLG,6.62,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
progesterone,Sigma non-opioid intracellular receptor 1,Sigmar1,6.62,Kd,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
sorafenib,Ephrin type-A receptor 6,EPHA6,6.62,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Ephrin type-B receptor 6,EPHB6,6.62,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfanilamide,Carbonic anhydrase 2,CA2,6.62,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulfanilamide,Carbonic anhydrase 9,CA9,6.62,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulfanilamide,Carbonic anhydrase,NCE103,6.62,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Casein kinase I isoform gamma-3,CSNK1G3,6.62,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
talinolol,Beta-1 adrenergic receptor,ADRB1,6.62,Ki,CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1
tazobactam,Beta-lactamase,blaTEM-125,6.62,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tenofovir,Capsid protein,HBcAg,6.62,EC50,C[C@H](CN1C=NC2=C(N)N=CN=C12)OCP(O)(O)=O
tranylcypromine,Amine oxidase [flavin-containing] A,MAOA,6.62,IC50,N[C@@H]1C[C@H]1C1=CC=CC=C1
ruboxistaurin,Serine/threonine-protein kinase ICK,ICK,6.62,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,STE20-like serine/threonine-protein kinase,SLK,6.62,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Serine/threonine-protein kinase TAO1,TAOK1,6.62,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Fibroblast growth factor receptor 3,FGFR3,6.62,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Ephrin type-A receptor 5,EPHA5,6.62,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,6.62,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Bone morphogenetic protein receptor type-1B,BMPR1B,6.62,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Uncharacterized serine/threonine-protein kinase SBK3,SBK3,6.62,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
afatinib,Interleukin-1 receptor-associated kinase 1,IRAK1,6.62,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Casein kinase I isoform delta,CSNK1D,6.62,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
diamorphine,D(1A) dopamine receptor,Drd1,6.62,Ki,CN1CC[C@]23[C@H]4OC5=C(OC(C)=O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4OC(C)=O)=C35
tofacitinib,NUAK family SNF1-like kinase 2,NUAK2,6.62,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,6.62,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,cAMP-dependent protein kinase catalytic subunit beta,PRKACB,6.62,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Ribosomal protein S6 kinase alpha-2,RPS6KA2,6.62,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Ribosomal protein S6 kinase alpha-5,RPS6KA5,6.62,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Hormonally up-regulated neu tumor-associated kinase,HUNK,6.62,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase Yes,YES1,6.62,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Mitogen-activated protein kinase 9,MAPK9,6.62,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
efonidipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,6.621,IC50,CC1=C(C(C2=CC(=CC=C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1=CC=CC=C1)C1=CC=CC=C1
cyclizine,5-hydroxytryptamine receptor 2B,HTR2B,6.623,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
droperidol,5-hydroxytryptamine receptor 2C,HTR2C,6.623,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
raloxifene,Membrane-associated progesterone receptor component 1,Pgrmc1,6.625,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
quazepam,GABA A receptor alpha-3/beta-1/gamma-2,GABRB1|GABRG2|GABRA3,6.627,Ki,FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12
terbinafine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.628,Ki,CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
estriol succinate,Sex hormone-binding globulin,SHBG,6.63,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
etryptamine,Sodium-dependent dopamine transporter,Slc6a3,6.63,EC50,CCC(N)CC1=CNC2=C1C=CC=C2
mazindol,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.63,IC50,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
pimozide,5-hydroxytryptamine receptor 1A,HTR1A,6.63,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
estriol,Sex hormone-binding globulin,SHBG,6.63,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
tamibarotene,Retinoic acid receptor beta,RARB,6.63,EC50,CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12
levmetamfetamine,Trace amine-associated receptor 1,Taar1,6.63,EC50,CN[C@H](C)CC1=CC=CC=C1
doxazosin,5-hydroxytryptamine receptor 2B,HTR2B,6.631,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
ebastine,Alpha-1B adrenergic receptor,Adra1b,6.633,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
nefazodone,Alpha-2B adrenergic receptor,ADRA2B,6.635,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
norethisterone,Estrogen receptor,ESR1,6.636,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
clomifene,Muscarinic acetylcholine receptor M4,CHRM4,6.638,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
gimeracil,Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,6.638,Ki,OC1=CC(=O)NC=C1Cl
mianserin,Muscarinic acetylcholine receptor M5,CHRM5,6.638,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
androstenediol,Androgen receptor,AR,6.64,IC50,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O
dithranol,Serine protease hepsin,HPN,6.64,IC50,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2
cisapride,D(2) dopamine receptor,DRD2,6.64,IC50,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cisapride,D(2) dopamine receptor,Drd2,6.64,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
dasatinib,Tyrosine-protein kinase ITK/TSK,ITK,6.64,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,TGF-beta receptor type-1,TGFBR1,6.64,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diphenhydramine,Muscarinic acetylcholine receptor M3,CHRM3,6.64,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
erlotinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,6.64,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
erlotinib,Tubulin alpha-1A chain,Tuba1a,6.64,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
etoricoxib,Prostaglandin G/H synthase 2,PTGS2,6.64,IC50,CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
etoricoxib,Prostaglandin G/H synthase 2,PTGS2,6.64,IC50,CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
flunarizine,D(2) dopamine receptor,Drd2,6.64,IC50,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
gefitinib,Tyrosine-protein kinase ABL1,ABL1,6.64,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
ketorolac,Prostaglandin-H2 D-isomerase,Ptgds,6.64,IC50,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1
mifepristone,Cytochrome P450 3A4,CYP3A4,6.64,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
miglustat,Non-lysosomal glucosylceramidase,GBA2,6.64,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nilotinib,Ephrin type-A receptor 2,EPHA2,6.64,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norethindrone acetate,Estrogen receptor,ESR1,6.64,Ki,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
periciazine,Cholinesterase,BCHE,6.64,IC50,OC1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C#N)CC1
quetiapine,5-hydroxytryptamine receptor 1A,Htr1a,6.64,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
sorafenib,MAP kinase-interacting serine/threonine-protein kinase 1,MKNK1,6.64,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sumatriptan,5-hydroxytryptamine receptor 1A,HTR1A,6.64,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Tyrosine-protein kinase Lck,LCK,6.64,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tolazoline,Alpha-2A adrenergic receptor,ADRA2A,6.64,Ki,C(C1=NCCN1)C1=CC=CC=C1
ruboxistaurin,Homeodomain-interacting protein kinase 1,HIPK1,6.64,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vandetanib,Platelet-derived growth factor receptor alpha,PDGFRA,6.64,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Ephrin type-A receptor 1,EPHA1,6.64,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,"Muscle, skeletal receptor tyrosine-protein kinase",MUSK,6.64,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Mitogen-activated protein kinase kinase kinase 13,MAP3K13,6.64,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Bone morphogenetic protein receptor type-1B,BMPR1B,6.64,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
afatinib,Tyrosine-protein kinase ABL1,ABL1,6.64,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
tofacitinib,JAK2/TYK2,JAK2|TYK2,6.64,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
vortioxetine,5-hydroxytryptamine receptor 3A,Htr3a,6.64,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
nintedanib,Casein kinase I isoform epsilon,CSNK1E,6.64,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,6.64,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
palbociclib,CDK2/Cyclin A,CCNA2|CDK2,6.64,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
cannabidiol,Cannabinoid receptor 2,Cnr2,6.64,Ki,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
relebactam,Beta-lactamase,KPC-2,6.64,IC50,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O
fedratinib,SNF-related serine/threonine-protein kinase,SNRK,6.64,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tretinoin,5-hydroxytryptamine receptor 2B,HTR2B,6.642,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
pipamperone,5-hydroxytryptamine receptor 2C,HTR2C,6.644,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
amlodipine,Alpha-2A adrenergic receptor,ADRA2A,6.646,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
digitoxin,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,6.648,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
econazole,Sodium-dependent serotonin transporter,SLC6A4,6.648,Ki,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
labetalol,5-hydroxytryptamine receptor 1A,HTR1A,6.648,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
aripiprazole,D(4) dopamine receptor,DRD4,6.65,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
domperidone,Alpha-1A adrenergic receptor,ADRA1A,6.65,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
mirtazapine,Alpha-2B adrenergic receptor,ADRA2B,6.65,IC50,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
morphine,Opioid receptor homologue,oprd1a,6.65,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
nilotinib,Carbonic anhydrase 14,CA14,6.65,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
octreotide,Somatostatin receptor type 1,SSTR1,6.65,Ki,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
risperidone,5-hydroxytryptamine receptor 6,HTR6,6.65,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sorafenib,Tyrosine-protein kinase ABL1,Abl1,6.65,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
tazobactam,Beta-lactamase SHV-1,bla,6.65,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
trazodone,5-hydroxytryptamine receptor 2C,HTR2C,6.65,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
trazodone,5-hydroxytryptamine receptor 1A,Htr1a,6.65,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
hexamidine,Prothrombin,F2,6.65,Ki,NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
methylnaltrexone,Kappa-type opioid receptor,OPRK1,6.65,Ki,C[N+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
cabozantinib,Epidermal growth factor receptor,EGFR,6.65,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
benzatropine,D(3) dopamine receptor,DRD3,6.654,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
promazine,5-hydroxytryptamine receptor 2B,HTR2B,6.656,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
clemastine,5-hydroxytryptamine receptor 1B,Htr1b,6.658,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
pentamidine,Muscarinic acetylcholine receptor M4,CHRM4,6.658,Ki,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
femoxetine,Muscarinic acetylcholine receptor M3,CHRM3,6.658,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
ipidacrine,Butyrylcholinesterase; Protein Bche,Bche,6.658,IC50,NC1=C2CCCC2=NC2=C1CCCC2
acetylcholine,Muscarinic acetylcholine receptor M3,CHRM3,6.66,EC50,CC(=O)OCC[N+](C)(C)C
amoxapine,5-hydroxytryptamine receptor 1A,HTR1A,6.66,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
clomipramine,D(1A) dopamine receptor,DRD1,6.66,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
dinoprost,Prostaglandin E2 receptor EP1 subtype,PTGER1,6.66,IC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
epinephrine,Alpha-1D adrenergic receptor,ADRA1D,6.66,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
ezetimibe,Niemann-Pick C1-like protein 1,NPC1L1,6.66,Kd,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
isoprenaline,Beta-1 adrenergic receptor,Adrb1,6.66,Ki,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isradipine,Voltage-dependent L-type calcium channel subunit alpha-1D,Cacna1d,6.66,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
meclofenamic acid,Prostaglandin G/H synthase 1,PTGS1,6.66,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
mefenamic acid,Aldo-keto reductase family 1 member C2,AKR1C2,6.66,Ki,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
orlistat,Pancreatic triacylglycerol lipase,PNLIP,6.66,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
phencyclidine,Acetylcholine receptor subunit alpha,CHRNA1,6.66,IC50,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
phentolamine,Alpha-1B adrenergic receptor,ADRA1B,6.66,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
piribedil,Alpha-1D adrenergic receptor,ADRA1D,6.66,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
quetiapine,5-hydroxytryptamine receptor 2A,Htr2a,6.66,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
levisoprenaline,Beta-1 adrenergic receptor,Adrb1,6.66,Ki,CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1
levisoprenaline,Beta-1 adrenergic receptor,Adrb1,6.66,Ki,CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1
sorafenib,Calcium-dependent protein kinase 1,CPK1,6.66,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Aurora kinase C,AURKC,6.66,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,6.66,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase Sgk3,SGK3,6.66,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Muscarinic acetylcholine receptor M2,Chrm2,6.66,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
zonisamide,Carbonic anhydrase,cynT,6.66,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
ruboxistaurin,Serine/threonine-protein kinase 4,STK4,6.66,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
triclocarban,Epoxide hydrolase; Epoxide hydrolase EphB,,6.66,IC50,ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1
alitretinoin,Retinoic acid receptor RXR-gamma,RXRG,6.66,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
androstanolone,Aromatase,CYP19A1,6.66,Ki,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
crizotinib,Mixed lineage kinase domain-like protein,MLKL,6.66,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
afatinib,Tyrosine-protein kinase Blk,BLK,6.66,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,NUAK family SNF1-like kinase 2,NUAK2,6.66,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dolutegravir,Sigma non-opioid intracellular receptor 1,Sigmar1,6.66,Ki,C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12
vortioxetine,5-hydroxytryptamine receptor 5A,HTR5A,6.66,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
nintedanib,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,6.66,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,"Myosin light chain kinase, smooth muscle",MYLK,6.66,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,BMP-2-inducible protein kinase,BMP2K,6.66,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,STE20-like serine/threonine-protein kinase,SLK,6.66,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase SIK1,SIK1,6.66,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,6.66,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Protein-tyrosine kinase 2-beta,PTK2B,6.66,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase 33,STK33,6.66,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Homeodomain-interacting protein kinase 4,HIPK4,6.66,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Interleukin-1 receptor-associated kinase 1,IRAK1,6.66,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
flunarizine,Alpha-2A adrenergic receptor,ADRA2A,6.662,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
propranolol,5-hydroxytryptamine receptor 2B,HTR2B,6.662,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
spironolactone,Progesterone receptor,PGR,6.663,Ki,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
dexfenfluramine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.664,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
irinotecan,Muscarinic acetylcholine receptor M4,CHRM4,6.664,Ki,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
verapamil,Alpha-2A adrenergic receptor,ADRA2A,6.664,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
diazepam,GABA A receptor alpha-3/beta-2/gamma-3,GABRA3|GABRB2|GABRG3,6.665,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
clomifene,Alpha-2C adrenergic receptor,ADRA2C,6.668,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
chlorphenamine,Histamine H4 receptor,HRH4,6.67,Ki,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
diazepam,Translocator protein,Tspo,6.67,Kd,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
indapamide,Carbonic anhydrase 4,CA4,6.67,Ki,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
maprotiline,5-hydroxytryptamine receptor 2B,HTR2B,6.67,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
nortriptyline,5-hydroxytryptamine receptor 6,HTR6,6.67,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
terconazole,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.67,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
iloperidone,D(1A) dopamine receptor,DRD1,6.67,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
belinostat,Histone deacetylase,HDAC1,6.67,IC50,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
entrectinib,Aurora kinase A,AURKA,6.67,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
amiodarone,5-hydroxytryptamine receptor 2C,HTR2C,6.674,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
methylergometrine,Alpha-2B adrenergic receptor,ADRA2B,6.678,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
amsacrine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.68,IC50,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
brinzolamide,Carbonic anhydrase,cynT,6.68,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
carbachol,Neuronal acetylcholine receptor; alpha2/beta2,Chrna2|Chrnb2,6.68,Ki,C[N+](C)(C)CCOC(N)=O
chlorhexidine,Solute carrier family 22 member 1,SLC22A1,6.68,IC50,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
clozapine,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,6.68,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Serine/threonine-protein kinase 36,STK36,6.68,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Activin receptor type-2A,ACVR2A,6.68,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desipramine,Muscarinic acetylcholine receptor M3,CHRM3,6.68,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
dexamfetamine,Sodium-dependent dopamine transporter,SLC6A3,6.68,Ki,C[C@H](N)CC1=CC=CC=C1
iloprost,Prostaglandin E2 receptor EP4 subtype,PTGER4,6.68,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
levosulpiride,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,6.68,IC50,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
metoclopramide,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,6.68,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
mezlocillin,Prostaglandin E2 receptor EP2 subtype,PTGER2,6.68,Ki,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
prenylamine,Voltage-gated L-type calcium channel,Cacna1c|Cacna1d|Cacna1s,6.68,Kd,CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1
sertindole,D(1A) dopamine receptor,DRD1,6.68,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sorafenib,Aurora kinase C,AURKC,6.68,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Serine/threonine-protein kinase TAO3,TAOK3,6.68,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zonisamide,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,6.68,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
iloperidone,5-hydroxytryptamine receptor 1A,Htr1a,6.68,IC50,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
ruboxistaurin,Ribosomal protein S6 kinase beta-1,RPS6KB1,6.68,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
pazopanib,Fibroblast growth factor receptor 2,FGFR2,6.68,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
telaprevir,Cathepsin B,CTSB,6.68,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
crizotinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.68,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,6.68,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,6.68,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,BMP-2-inducible protein kinase,BMP2K,6.68,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
prazosin,Alpha-2A adrenergic receptor,ADRA2A,6.68,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
axitinib,Fibroblast growth factor receptor 3,FGFR3,6.68,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Ephrin type-B receptor 3,EPHB3,6.68,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
trabectedin,Proto-oncogene tyrosine-protein kinase Src,SRC,6.68,IC50,COC1=CC2=C(CCN[C@]22CS[C@H]3[C@H]4[C@@H]5N(C)[C@@H](CC6=C5C(O)=C(OC)C(C)=C6)[C@H](O)N4[C@@H](COC2=O)C2=C3C(OC(C)=O)=C(C)C3=C2OCO3)C=C1O
nintedanib,Focal adhesion kinase 1,PTK2,6.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Tyrosine-protein kinase ITK/TSK,ITK,6.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Non-receptor tyrosine-protein kinase TNK1,TNK1,6.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase PAK 3,PAK3,6.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
cariprazine,Alpha-1D adrenergic receptor,ADRA1D,6.68,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
midostaurin,Calcium/calmodulin-dependent protein kinase type II subunit beta,CAMK2B,6.68,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,6.68,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase PAK 1,PAK1,6.68,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
entrectinib,Insulin receptor,INSR,6.68,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
osilodrostat,"Cytochrome P450 11B2, mitochondrial",Cyp11b2,6.68,IC50,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12
thiothixene,5-hydroxytryptamine receptor 6,HTR6,6.681,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
chlordiazepoxide,Histamine H1 receptor,HRH1,6.682,Ki,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
loxapine,Histamine H2 receptor,HRH2,6.682,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
mosapride,5-hydroxytryptamine receptor 2C,HTR2C,6.683,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
phentolamine,5-hydroxytryptamine receptor 2C,HTR2C,6.684,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
amitriptyline,D(3) dopamine receptor,DRD3,6.686,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
zotepine,Alpha-2A adrenergic receptor,ADRA2A,6.686,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
risperidone,5-hydroxytryptamine receptor 5A,HTR5A,6.687,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
clomipramine,Alpha-2C adrenergic receptor,ADRA2C,6.688,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
propafenone,Beta-1 adrenergic receptor,ADRB1,6.688,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
quazepam,GABA A receptor alpha-2/beta-1/gamma-2,GABRB1|GABRG2|GABRA2,6.688,Ki,FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12
azapetine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.69,IC50,C=CCN1CC2=CC=CC=C2C2=C(C1)C=CC=C2
benzatropine,Alpha-2A adrenergic receptor,ADRA2A,6.69,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
cisapride,Sodium-dependent serotonin transporter,SLC6A4,6.69,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
ketoconazole,Cytochrome P450 17A1,Cyp17a1,6.69,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
oxymetazoline,Alpha-1B adrenergic receptor,ADRA1B,6.69,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
talipexole,Alpha-2B adrenergic receptor,ADRA2B,6.69,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
benzethonium,Muscarinic acetylcholine receptor M2,CHRM2,6.69,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
corbadrine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,6.69,Ki,C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1
carfilzomib,Proteasome subunit beta type-2,PSMB2,6.69,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
terfenadine,Sodium-dependent dopamine transporter,SLC6A3,6.693,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
thiothixene,D(4) dopamine receptor,DRD4,6.693,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
alpha-Ergocryptine,D(1A) dopamine receptor,DRD1,6.695,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
olanzapine,5-hydroxytryptamine receptor 3A,HTR3A,6.695,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
propranolol,Sodium-dependent serotonin transporter,SLC6A4,6.695,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
talipexole,Alpha-2C adrenergic receptor,ADRA2C,6.695,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
disulfiram,Adenosine receptor A3,ADORA3,6.697,Ki,CCN(CC)C(=S)SSC(=S)N(CC)CC
pecazine,Muscarinic acetylcholine receptor M2,CHRM2,6.697,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
propafenone,5-hydroxytryptamine receptor 2C,HTR2C,6.697,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
gentian violet,Alpha-2A adrenergic receptor,ADRA2A,6.697,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
ciclosporin,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,6.699,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
docetaxel,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,6.699,ID50,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
econazole,Cytochrome P450 2C9,CYP2C9,6.699,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
fluconazole,Lanosterol 14-alpha demethylase,ERG11,6.699,IC50,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
metergoline,Cytochrome P450 2D6,CYP2D6,6.699,IC50,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
methylergometrine,Cytochrome P450 2D6,CYP2D6,6.699,IC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
metoclopramide,5-hydroxytryptamine receptor 3A,HTR3A,6.699,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
miconazole,Cytochrome P450 2C9,CYP2C9,6.699,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nefazodone,Sodium-dependent serotonin transporter,SLC6A4,6.699,Kd,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
oxymetazoline,Cytochrome P450 2D6,CYP2D6,6.699,IC50,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
pergolide,Cytochrome P450 2D6,CYP2D6,6.699,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
physostigmine,Cytochrome P450 2D6,CYP2D6,6.699,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
sulconazole,Cytochrome P450 2C9,CYP2C9,6.699,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
sulfaphenazole,Cytochrome P450 2C9,CYP2C9,6.699,IC50,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1
terbinafine,Cytochrome P450 2D6,CYP2D6,6.699,IC50,CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
dronedarone,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,6.699,IC50,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
thiocolchicoside,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,6.699,IC50,COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC
vortioxetine,5-hydroxytryptamine receptor 7,Htr7,6.699,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
acetoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 2,HSD11B2,6.7,IC50,CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C
alizapride,D(2) dopamine receptor,Drd2,6.7,IC50,COC1=CC2=C(C=C1C(=O)NCC1CCCN1CC=C)N=NN2
amiloride,"Amiloride-sensitive sodium channel, ENaC",SCNN1A|SCNN1B|SCNN1G,6.7,IC50,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
amfetamine,Transporter,NET,6.7,IC50,CC(N)CC1=CC=CC=C1
apomorphine,D(2) dopamine receptor,DRD2,6.7,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
astemizole,Potassium voltage-gated channel subfamily H member 1,KCNH1,6.7,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
brinzolamide,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,6.7,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
cabergoline,D(1A) dopamine receptor,DRD1,6.7,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
cefalotin,Solute carrier family 22 member 11,SLC22A11,6.7,Ki,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O
chlordiazepoxide,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,6.7,IC50,CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1
cilnidipine,Voltage-dependent N-type calcium channel subunit alpha-1B,Cacna1b,6.7,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1
cilostazol,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,6.7,IC50,O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1
clometacin,Prostaglandin-H2 D-isomerase,Ptgds,6.7,IC50,COC1=CC2=C(C=C1)C(C(=O)C1=CC=C(Cl)C=C1)=C(C)N2CC(O)=O
clonidine,Alpha-2C adrenergic receptor,ADRA2C,6.7,EC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
clotrimazole,Lanosterol 14-alpha demethylase,cyp51,6.7,Kd,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
cocaine,Sodium-dependent dopamine transporter,Slc6a3,6.7,IC50,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
dasatinib,Wee1-like protein kinase 2,WEE2,6.7,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexmedetomidine,Alpha-1A adrenergic receptor,ADRA1A,6.7,Ki,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
dopamine,Sodium-dependent dopamine transporter,Slc6a3,6.7,IC50,NCCC1=CC(O)=C(O)C=C1
doxepin,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,6.7,IC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
econazole,Lanosterol 14-alpha demethylase,cyp51,6.7,Kd,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
edrophonium,Acetylcholinesterase,ACHE,6.7,Ki,CC[N+](C)(C)C1=CC=CC(O)=C1
enprostil,Prostaglandin E2 receptor EP1 subtype,Ptger1,6.7,Ki,COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O
erlotinib,Abelson tyrosine-protein kinase 2,ABL2,6.7,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethoxzolamide,Carbonic anhydrase,,6.7,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
ezetimibe,Niemann-Pick C1-like protein 1,Npc1l1,6.7,Ki,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
fluconazole,Lanosterol 14-alpha demethylase,cyp51,6.7,Kd,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
haloperidol,Multidrug resistance protein 1,ABCB1,6.7,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
histamine,Histamine H1 receptor,HRH1,6.7,EC50,NCCC1=CN=CN1
indapamide,Carbonic anhydrase 2,CA2,6.7,Kd,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
indoprofen,Luciferin 4-monooxygenase,,6.7,IC50,CC(C(O)=O)C1=CC=C(C=C1)N1CC2=C(C=CC=C2)C1=O
isradipine,Voltage-dependent L-type calcium channel subunit alpha-1F,Cacna1f,6.7,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
itraconazole,C-C chemokine receptor type 4,CCR4,6.7,IC50,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ketanserin,D(1A) dopamine receptor,DRD1,6.7,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketanserin,5-hydroxytryptamine receptor 2B,HTR2B,6.7,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketanserin,5-hydroxytryptamine receptor 7,Htr7,6.7,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
lofepramine,5-hydroxytryptamine receptor 2C,HTR2C,6.7,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
mafenide,"Carbonic anhydrase, alpha family",,6.7,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
meclofenamic acid,Prostaglandin G/H synthase 2,PTGS2,6.7,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
meclofenamic acid,Prostaglandin G/H synthase 2,Ptgs2,6.7,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
methysergide,5-hydroxytryptamine receptor 5A,Htr5a,6.7,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
metoclopramide,Serotonin 3 receptor (5HT3),Htr3a|Htr3b,6.7,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
mibefradil,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,6.7,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
miconazole,Lanosterol 14-alpha demethylase,CYP51A1,6.7,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miconazole,Lanosterol 14-alpha demethylase,cyp51,6.7,Kd,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nandrolone phenpropionate,Estrogen receptor,ESR1,6.7,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2OC(=O)CCC1=CC=CC=C1
nepafenac,Cyclooxygenase,PTGS1|PTGS2,6.7,IC50,NC(=O)CC1=C(N)C(=CC=C1)C(=O)C1=CC=CC=C1
nicotine,Neuronal acetylcholine receptor; alpha3/beta4,Chrna3|Chrnb4,6.7,Ki,CN1CCC[C@H]1C1=CC=CN=C1
novobiocin,DNA gyrase subunit B,gyrB,6.7,IC50,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
omapatrilat,Amyloid beta A4 protein,APP,6.7,IC50,OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12
omapatrilat,Amyloid beta A4 protein,APP,6.7,IC50,OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12
ozagrel,Thromboxane-A synthase,Tbxas1,6.7,IC50,OC(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1
perhexiline,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.7,Kd,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
phenprocoumon,Vitamin K epoxide reductase complex subunit 1,Vkorc1,6.7,Ki,CCC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
phenprocoumon,Vitamin K epoxide reductase complex subunit 1,Vkorc1,6.7,Ki,CCC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
piperacillin,Beta-lactamase,blaPER-2,6.7,Ki,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C2=CC=CC=C2)C(=O)C1=O
sildenafil,Adenosine receptor A2a,ADORA2A,6.7,Ki,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sivelestat,Neutrophil elastase,ELANE,6.7,Ki,CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=C(C=CC=C1)C(=O)NCC(O)=O
sorafenib,Mitogen-activated protein kinase 11,MAPK11,6.7,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sufentanil,Kappa-type opioid receptor,OPRK1,6.7,EC50,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
sulpiride,D(2) dopamine receptor,DRD2,6.7,IC50,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sulprostone,Prostaglandin F2-alpha receptor,PTGFR,6.7,Ki,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
sunitinib,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,DYRK1A,6.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Microtubule-associated serine/threonine-protein kinase 1,MAST1,6.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase SBK1,SBK1,6.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamoxifen,Steroid hormone receptor ERR1,ESRRA,6.7,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
ticlopidine,Cytochrome P450 2A6,CYP2A6,6.7,Ki,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
ticlopidine,Cytochrome P450 2B6,CYP2B6,6.7,IC50,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
trazodone,5-hydroxytryptamine receptor 2C,Htr2c,6.7,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
treprostinil,Prostaglandin E2 receptor EP1 subtype,PTGER1,6.7,Ki,CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2CC3=C(OCC(O)=O)C=CC=C3C[C@H]12
treprostinil,Prostaglandin E2 receptor EP4 subtype,PTGER4,6.7,EC50,CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2CC3=C(OCC(O)=O)C=CC=C3C[C@H]12
tretinoin,Retinoic acid receptor alpha,RARA,6.7,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
tretinoin,Nuclear receptor ROR-alpha,RORA,6.7,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
tretinoin,Retinoic acid receptor beta,RARB,6.7,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
tretinoin,Retinoic acid receptor gamma,RARG,6.7,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
tretinoin,Nuclear receptor ROR-gamma,RORC,6.7,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
valethamate,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.7,Ki,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1
viloxazine,Sodium-dependent noradrenaline transporter,SLC6A2,6.7,IC50,CCOC1=CC=CC=C1OCC1CNCCO1
carbaryl,Acetylcholinesterase,Ache,6.7,IC50,CNC(=O)OC1=CC=CC2=C1C=CC=C2
oleic acid,"Fatty acid-binding protein, liver",FABP1,6.7,Kd,CCCCCCCC\C=C/CCCCCCCC(O)=O
quercetin,Arachidonate 5-lipoxygenase,Alox5,6.7,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
stallimycin,GTPase HRas,HRAS,6.7,IC50,CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC=O)=CN3C)=CN2C)C=C1C(=O)NCCC(N)=N
triclosan,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,6.7,Ki,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
triclosan,Enoyl-ACP reductase,FabI,6.7,IC50,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
triclosan,Enoyl-[acyl-carrier-protein] reductase [NULLDH],inhA,6.7,Ki,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
alitretinoin,Retinoic acid receptor RXR-beta,RXRB,6.7,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
pazopanib,Cyclin-G-associated kinase,GAK,6.7,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
crizotinib,Tyrosine-protein kinase JAK3,JAK3,6.7,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase SIK2,SIK2,6.7,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Serine/threonine-protein kinase PLK4,PLK4,6.7,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,6.7,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Platelet-derived growth factor receptor beta,PDGFRB,6.7,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,6.7,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dequalinium,cGMP-gated cation channel alpha-1,CNGA1,6.7,IC50,CC1=[N+](CCCCCCCCCC[N+]2=C(C)C=C(N)C3=CC=CC=C23)C2=CC=CC=C2C(N)=C1
nintedanib,Hepatocyte growth factor receptor,MET,6.7,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Ribosomal protein S6 kinase alpha-5,RPS6KA5,6.7,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
cobimetinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,6.7,IC50,OC1(CN(C1)C(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1)[C@@H]1CCCCN1
fedratinib,Mitogen-activated protein kinase 10,MAPK10,6.7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Tyrosine-protein kinase FRK,FRK,6.7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
ebastine,5-hydroxytryptamine receptor 2B,HTR2B,6.701,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ketanserin,Alpha-2B adrenergic receptor,ADRA2B,6.701,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
clemastine,Muscarinic acetylcholine receptor M2,CHRM2,6.703,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
imatinib,Thromboxane-A synthase,TBXAS1,6.703,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
zolpidem,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,6.703,EC50,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
pimozide,Alpha-1A adrenergic receptor,ADRA1A,6.704,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
promazine,D(2) dopamine receptor,DRD2,6.704,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
diazepam,GABA-A receptor alpha-1/beta-2/gamma-3,GABRA1|GABRB2|GABRG3,6.705,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
dexfenfluramine,Alpha-2C adrenergic receptor,ADRA2C,6.706,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
norethisterone,Glucocorticoid receptor,NR3C1,6.706,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
levobupivacaine,Cytochrome P450 2D6,CYP2D6,6.707,IC50,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
amitriptyline,D(2) dopamine receptor,DRD2,6.708,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amoxapine,D(1A) dopamine receptor,DRD1,6.708,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
bromhexine,Cytochrome P450 2D6,CYP2D6,6.708,IC50,CN(CC1=C(N)C(Br)=CC(Br)=C1)C1CCCCC1
carvedilol,D(3) dopamine receptor,DRD3,6.708,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
hexachlorophene,Mitogen-activated protein kinase 1,MAPK1,6.708,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
apomorphine,E3 ubiquitin-protein ligase Mdm2,MDM2,6.71,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
bexarotene,Oxysterols receptor LXR-alpha,NR1H3,6.71,EC50,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
chlortalidone,Carbonic anhydrase 4,CA4,6.71,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
cyproheptadine,Histamine H2 receptor,HRH2,6.71,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
fentanyl,Kappa-type opioid receptor,OPRK1,6.71,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
fentanyl,Kappa-type opioid receptor,OPRK1,6.71,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
ketoconazole,Cytochrome P450 7A1,Cyp7a1,6.71,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
loxiglumide,Cholecystokinin receptor type A,CCKAR,6.71,IC50,CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1
maprotiline,Alpha-1D adrenergic receptor,ADRA1D,6.71,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
pimozide,Histamine H1 receptor,HRH1,6.71,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
terconazole,Membrane-associated progesterone receptor component 1,Pgrmc1,6.71,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
pyrovalerone,Sodium-dependent noradrenaline transporter,SLC6A2,6.71,Ki,CCCC(N1CCCC1)C(=O)C1=CC=C(C)C=C1
mozavaptan,Vasopressin V1a receptor,AVPR1A,6.71,Ki,CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C2=CC=CC=C12
ruxolitinib,JAK1/TYK2,JAK1|TYK2,6.71,IC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
alectinib,SRSF protein kinase 1,SRPK1,6.71,IC50,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O
alectinib,SRSF protein kinase 1,SRPK1,6.71,IC50,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O
entrectinib,Protein-tyrosine kinase 6,PTK6,6.71,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
prochlorperazine,5-hydroxytryptamine receptor 4,HTR4,6.712,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
thioridazine,5-hydroxytryptamine receptor 1E,HTR1E,6.712,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
ergometrine,D(3) dopamine receptor,DRD3,6.714,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
latamoxef,Penicillin-binding protein 1A,mrcA,6.716,IC50,CO[C@]1(NC(=O)C(C(O)=O)C2=CC=C(O)C=C2)[C@H]2OCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
fenfluramine,Alpha-2B adrenergic receptor,ADRA2B,6.717,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
melperone,5-hydroxytryptamine receptor 2A,HTR2A,6.717,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
benzbromarone,Multidrug resistance-associated protein 1,ABCC1,6.72,Ki,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
dasatinib,"Chaperone activity of bc1 complex-like, mitochondrial",COQ8A,6.72,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dimetindene,Muscarinic acetylcholine receptor M3,CHRM3,6.72,Ki,CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C1=CC=CC=N1
erlotinib,Tyrosine-protein kinase Blk,BLK,6.72,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fadrozole,"Cytochrome P450 11B2, mitochondrial",Cyp11b2,6.72,IC50,N#CC1=CC=C(C=C1)C1CCCC2=CN=CN12
galantamine,Cholinesterase,BCHE,6.72,Ki,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
haloperidol,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,6.72,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
mibefradil,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.72,Ki,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mitoxantrone,Multidrug and toxin extrusion protein 1,SLC47A1,6.72,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
nilotinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,6.72,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
pamidronic acid,Farnesyl pyrophosphate synthase,,6.72,Ki,NCCC(O)(P(O)(O)=O)P(O)(O)=O
ritodrine,Beta-3 adrenergic receptor,ADRB3,6.72,EC50,C[C@@H](NCCC1=CC=C(O)C=C1)[C@@H](O)C1=CC=C(O)C=C1
sorafenib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,6.72,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Serine/threonine-protein kinase PLK4,PLK4,6.72,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,SRSF protein kinase 2,SRPK2,6.72,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tazobactam,Beta-lactamase,ampC,6.72,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
testosterone,Corticosteroid-binding globulin,SERPINA6,6.72,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
trimethoprim,Dihydrofolate reductase,folA,6.72,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
ubenimex,M1 family aminopeptidase,,6.72,Ki,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
zileuton,Arachidonate 5-lipoxygenase,Alox5,6.72,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
vandetanib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.72,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Protein-tyrosine kinase 2-beta,PTK2B,6.72,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,6.72,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Serine/threonine-protein kinase ULK2,ULK2,6.72,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Serine/threonine-protein kinase 4,STK4,6.72,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
hydrocortisone succinate,Glucocorticoid receptor,Nr3c1,6.72,Kd,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O
nintedanib,Aurora kinase C,AURKC,6.72,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Ribosomal protein S6 kinase beta-1,RPS6KB1,6.72,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
beclabuvir,RNA-directed RNA polymerase,NS5b,6.72,IC50,COC1=CC=C2C3=C(C4CCCCC4)C4=CC=C(C=C4N3C[C@]3(C[C@H]3C2=C1)C(=O)N1C2CCC1CN(C)C2)C(=O)NS(=O)(=O)N(C)C
midostaurin,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,6.72,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase 33,STK33,6.72,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Microtubule-associated serine/threonine-protein kinase 1,MAST1,6.72,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase receptor UFO,AXL,6.72,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Serine/threonine-protein kinase DCLK1,DCLK1,6.72,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
amitriptyline,5-hydroxytryptamine receptor 1A,HTR1A,6.721,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
loxapine,5-hydroxytryptamine receptor 3A,HTR3A,6.721,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
prochlorperazine,Muscarinic acetylcholine receptor M4,CHRM4,6.721,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
promethazine,D(3) dopamine receptor,DRD3,6.721,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
plecanatide,Heat-stable enterotoxin receptor,GUCY2C,6.721,EC50,CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(O)=O
chlorpromazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.724,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
paroxetine,Muscarinic acetylcholine receptor M2,CHRM2,6.724,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
mosapride,5-hydroxytryptamine receptor 2B,HTR2B,6.725,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
propafenone,5-hydroxytryptamine receptor 2A,HTR2A,6.728,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
apomorphine,5-hydroxytryptamine receptor 7,Htr7,6.73,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
dobutamine,Alpha-1B adrenergic receptor,Adra1b,6.73,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
ethoxzolamide,Carbonic anhydrase,,6.73,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
morphine,Mu opioid receptor-like OR2,oprm1,6.73,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
bietamiverine,Muscarinic acetylcholine receptor M3,CHRM3,6.73,Ki,CCN(CC)CCOC(=O)C(N1CCCCC1)C1=CC=CC=C1
oleic acid,"Fatty acid-binding protein, adipocyte",FABP4,6.73,Ki,CCCCCCCC\C=C/CCCCCCCC(O)=O
ruxolitinib,Tyrosine-protein kinase JAK2,Jak2,6.73,EC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Tyrosine-protein kinase JAK2,Jak2,6.73,EC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
valbenazine,Synaptic vesicular amine transporter,Slc18a2,6.73,Ki,COC1=CC2=C(C=C1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2
astemizole,Membrane-associated progesterone receptor component 1,Pgrmc1,6.733,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
cyproheptadine,Alpha-2C adrenergic receptor,ADRA2C,6.733,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
fenfluramine,Alpha-2C adrenergic receptor,ADRA2C,6.735,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
sulconazole,Thromboxane-A synthase,TBXAS1,6.738,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
primaquine,Cytochrome P450 1A2,CYP1A2,6.739,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
androstenediol,Estrogen receptor,ESR1,6.74,IC50,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O
apraclonidine,Adrenergic receptor alpha-1,ADRA1D|ADRA1A|ADRA1B,6.74,Ki,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1
azimilide,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.74,IC50,CN1CCN(CCCCN2C(=O)CN(N=CC3=CC=C(O3)C3=CC=C(Cl)C=C3)C2=O)CC1
bexarotene,Retinoic acid receptor alpha,RARA,6.74,Ki,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
clozapine,Dopamine receptor,DRD2|DRD1,6.74,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dapsone,5-hydroxytryptamine receptor 6,HTR6,6.74,Ki,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
dyclonine,Acetylcholinesterase,ACHE,6.74,IC50,CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1
gossypol,Induced myeloid leukemia cell differentiation protein Mcl-1,MCL1,6.74,Ki,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
lysergide,D(1A) dopamine receptor,Drd1,6.74,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
masoprocol,Seed linoleate 13S-lipoxygenase-1,LOX1.1,6.74,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
melperone,Alpha-1A adrenergic receptor,ADRA1A,6.74,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
methazolamide,Carbonic anhydrase,,6.74,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
mezlocillin,Cytochrome P450 2C8,CYP2C8,6.74,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
naproxen,Prostaglandin G/H synthase 1,PTGS1,6.74,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
olanzapine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.74,IC50,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
penfluridol,5-hydroxytryptamine receptor 2B,HTR2B,6.74,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
quetiapine,D(2) dopamine receptor,Drd2,6.74,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
retinol acetate,Retinol-binding protein 4,RBP4,6.74,Kd,CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
sulfanilamide,Delta carbonic anhydrase,ca1,6.74,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sunitinib,Insulin receptor,INSR,6.74,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Eukaryotic translation initiation factor 2-alpha kinase 4,EIF2AK4,6.74,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,6.74,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,G protein-coupled receptor kinase 7,GRK7,6.74,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tiagabine,Sodium- and chloride-dependent betaine transporter,Slc6a12,6.74,IC50,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1
tolazoline,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,6.74,Ki,C(C1=NCCN1)C1=CC=CC=C1
vardenafil,Phosphodiesterase 1,PDE1A|PDE1B,6.74,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
retinol,Retinol-binding protein 4,RBP4,6.74,Kd,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
oleic acid,"Fatty acid-binding protein, liver",Fabp1,6.74,Ki,CCCCCCCC\C=C/CCCCCCCC(O)=O
sabcomeline,Muscarinic acetylcholine receptor M2,CHRM2,6.74,IC50,CO\N=C(/C#N)[C@H]1CN2CCC1CC2
vitamin A palmitate,Retinol-binding protein 4,RBP4,6.74,Kd,CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
axitinib,TRAF2 and NCK-interacting protein kinase,TNIK,6.74,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lacosamide,Sodium channel protein type 9 subunit alpha,SCN9A,6.74,IC50,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
dimethyl fumarate,Hydroxycarboxylic acid receptor 2,HCAR2,6.74,Ki,COC(=O)\C=C\C(=O)OC
vortioxetine,5-hydroxytryptamine receptor 2A,HTR2A,6.74,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
vortioxetine,5-hydroxytryptamine receptor 2C,HTR2C,6.74,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
vortioxetine,Histamine H1 receptor,HRH1,6.74,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
vortioxetine,Histamine H2 receptor,HRH2,6.74,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
nintedanib,Ribosomal protein S6 kinase alpha-1,RPS6KA1,6.74,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
umbralisib,Casein kinase I isoform epsilon,CSNK1E,6.74,Kd,C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
infigratinib,Vascular endothelial growth factor receptor 2,KDR,6.74,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Vascular endothelial growth factor receptor 2,KDR,6.74,IC50,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
carvedilol,5-hydroxytryptamine receptor 4,HTR4,6.742,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
pecazine,Alpha-2B adrenergic receptor,ADRA2B,6.742,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
mitoxantrone,Muscarinic acetylcholine receptor M1,CHRM1,6.744,Ki,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
clomifene,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.745,IC50,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
mebhydrolin,Muscarinic acetylcholine receptor M1,CHRM1,6.745,Ki,CN1CCC2=C(C1)C1=C(C=CC=C1)N2CC1=CC=CC=C1
methapyrilene,5-hydroxytryptamine receptor 2A,HTR2A,6.745,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
nefazodone,D(2) dopamine receptor,DRD2,6.745,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
chlorpromazine,Muscarinic acetylcholine receptor M2,CHRM2,6.746,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
ticlopidine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.747,Ki,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
suramin,P2X purinoceptor 4,P2RX4,6.749,Ki,CC1=CC=C(C=C1NC(=O)C1=CC=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=CC=C(C3=CC(=CC(=C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)=C1)C(=O)NC1=CC=C(C2=CC(=CC(=C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
astemizole,Muscarinic acetylcholine receptor M3,CHRM3,6.75,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
buspirone,5-hydroxytryptamine receptor 2A,HTR2A,6.75,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
chlorpromazine,5-hydroxytryptamine receptor 1A,Htr1a,6.75,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
ketoprofen,Prostaglandin G/H synthase 2,PTGS2,6.75,IC50,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
sulpiride,Carbonic anhydrase,cynT,6.75,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
trazodone,Alpha-2B adrenergic receptor,ADRA2B,6.75,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
zopiclone,GABA A receptor alpha-5/beta-3/gamma-3,GABRB3|GABRA5|GABRG3,6.75,Ki,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
zopiclone,GABA A receptor alpha-5/beta-2/gamma-3,GABRA5|GABRB2|GABRG3,6.75,Ki,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
kainic acid,"Glutamate receptor ionotropic, kainate 1",GRIK1,6.75,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
thiram,Lysyl oxidase homolog 4,LOXL4,6.75,IC50,CN(C)C(=S)SSC(=S)N(C)C
cabozantinib,Proto-oncogene tyrosine-protein kinase Src,SRC,6.75,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
osimertinib,ALK tyrosine kinase receptor,ALK,6.75,IC50,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
osimertinib,ALK tyrosine kinase receptor,ALK,6.75,IC50,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
midostaurin,Platelet-derived growth factor receptor alpha,PDGFRA,6.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,6.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase PAK 3,PAK3,6.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Interleukin-1 receptor-associated kinase 3,IRAK3,6.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,6.75,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
tiapride,D(3) dopamine receptor,DRD3,6.756,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O
dantrolene,Ryanodine receptor 1,RYR1,6.757,Ki,[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
chlorpromazine,Histamine H2 receptor,HRH2,6.759,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
buspirone,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,6.76,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
celecoxib,Carbonic anhydrase,,6.76,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
desipramine,Muscarinic acetylcholine receptor M1,CHRM1,6.76,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
pergolide,D(1B) dopamine receptor,DRD5,6.76,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pirenzepine,Muscarinic acetylcholine receptor M2,CHRM2,6.76,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
sulpiride,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.76,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
topiramate,Carbonic anhydrase,cynT,6.76,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
tretoquinol,Beta-1 adrenergic receptor,ADRB1,6.76,EC50,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
vorinostat,Histone deacetylase 8,HDAC8,6.76,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
lumateperone,5-hydroxytryptamine receptor 2C,HTR2C,6.76,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
dapiprazole,5-hydroxytryptamine receptor 2A,HTR2A,6.762,Ki,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
molindone,Alpha-2C adrenergic receptor,ADRA2C,6.763,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
selegiline,Alpha-2B adrenergic receptor,ADRA2B,6.764,Ki,C[C@H](CC1=CC=CC=C1)N(C)CC#C
ticlopidine,Alpha-2C adrenergic receptor,ADRA2C,6.767,Ki,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
amitriptyline,D(1B) dopamine receptor,DRD5,6.77,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
androstenedione,Testosterone 17-beta-dehydrogenase 3,Hsd17b3,6.77,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
brinzolamide,Carbonic anhydrase,CA2,6.77,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
cicaprost,Prostaglandin E2 receptor EP3 subtype,Ptger3,6.77,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
clavulanic acid,Beta-lactamase SHV-1,bla,6.77,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
dexniguldipine,Alpha-1D adrenergic receptor,ADRA1D,6.77,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
epalrestat,Aldose reductase,AKR1B1,6.77,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
ergotamine,D(1B) dopamine receptor,DRD5,6.77,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
famotidine,Carbonic anhydrase 13,CA13,6.77,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
flurbiprofen,Prostaglandin G/H synthase 1,Ptgs1,6.77,IC50,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
glycine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,6.77,Ki,NCC(O)=O
gossypol,Apoptosis regulator Bcl-2,BCL2,6.77,Ki,CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C
fluostigmine,Prostaglandin G/H synthase 2,PTGS2,6.77,Ki,CC(C)OP(F)(=O)OC(C)C
loratadine,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.77,IC50,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
mafenide,Carbonic anhydrase 2,CA2,6.77,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mafenide,Carbonic anhydrase 1,CA1,6.77,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mafenide,Carbonic anhydrase,NCE103,6.77,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
methazolamide,Carbonic anhydrase,cynT,6.77,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methazolamide,Delta carbonic anhydrase,ca1,6.77,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
promethazine,5-hydroxytryptamine receptor 2A,HTR2A,6.77,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
sultiame,Delta carbonic anhydrase,ca1,6.77,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
sunitinib,ALK tyrosine kinase receptor,ALK,6.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
viloxazine,Transporter,Slc6a2,6.77,Ki,CCOC1=CC=CC=C1OCC1CNCCO1
zuclopenthixol,5-hydroxytryptamine receptor 6,HTR6,6.77,Ki,OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
ruboxistaurin,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,6.77,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
sabcomeline,Muscarinic acetylcholine receptor M1,CHRM1,6.77,IC50,CO\N=C(/C#N)[C@H]1CN2CCC1CC2
thiram,Lysyl oxidase homolog 2,LOXL2,6.77,IC50,CN(C)C(=S)SSC(=S)N(C)C
vandetanib,Tyrosine-protein kinase FRK,FRK,6.77,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Mitogen-activated protein kinase kinase kinase 12,MAP3K12,6.77,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Vascular endothelial growth factor receptor 3,FLT4,6.77,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Serine/threonine-protein kinase TNNI3K,TNNI3K,6.77,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
clopenthixol,5-hydroxytryptamine receptor 6,HTR6,6.77,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
tofacitinib,Serine/threonine-protein kinase N1,PKN1,6.77,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
ipidacrine,Acetylcholinesterase,ache,6.77,IC50,NC1=C2CCCC2=NC2=C1CCCC2
nintedanib,Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,6.77,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Aurora kinase C,AURKC,6.77,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase MARK1,MARK1,6.77,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Misshapen-like kinase 1,MINK1,6.77,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,G protein-coupled receptor kinase 4,GRK4,6.77,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,SRSF protein kinase 3,SRPK3,6.77,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cinnarizine,Alpha-2A adrenergic receptor,ADRA2A,6.777,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
citalopram,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.777,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
cabergoline,Alpha-1D adrenergic receptor,ADRA1D,6.78,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
pentoxyverine,Muscarinic acetylcholine receptor M2,CHRM2,6.78,Ki,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1
haloprogin,D(3) dopamine receptor,DRD3,6.78,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
ibudilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,6.78,IC50,CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C
pindolol,Beta-3 adrenergic receptor,ADRB3,6.78,Kd,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
trifluperidol,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,6.78,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC(=CC=C1)C(F)(F)F
zonisamide,Astrosclerin-3,,6.78,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
pralatrexate,Folate receptor alpha,FOLR1,6.78,IC50,NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
vorinostat,Histone deacetylase,Hdac2|Hdac1|Hdac5|Hdac3|Hdac7|Hdac6|Hdac4,6.78,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
pefloxacin,DNA gyrase subunit A,gyrA,6.785,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1
pefloxacin,DNA gyrase subunit B,gyrB,6.785,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1
trifluoperazine,Alpha-2B adrenergic receptor,ADRA2B,6.786,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
aripiprazole,Beta-2 adrenergic receptor,ADRB2,6.788,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
cyclizine,Muscarinic acetylcholine receptor M1,CHRM1,6.788,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
risperidone,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.788,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
androstanolone,Progesterone receptor,PGR,6.788,Ki,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
cinnarizine,Muscarinic acetylcholine receptor M3,CHRM3,6.79,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
clozapine,D(3) dopamine receptor,Drd3,6.79,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
desipramine,Sodium-dependent serotonin transporter,Slc6a4,6.79,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
domperidone,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.79,IC50,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
doxepin,Histamine H4 receptor,HRH4,6.79,EC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
eszopiclone,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,6.79,Ki,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
imatinib,Platelet-derived growth factor receptor beta,Pdgfrb,6.79,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
metoprolol,Beta-2 adrenergic receptor,Adrb2,6.79,Kd,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
orphenadrine,Histamine H1 receptor,Hrh1,6.79,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
valdecoxib,Carbonic anhydrase,,6.79,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
iloperidone,Alpha-2A adrenergic receptor,ADRA2A,6.79,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
iloperidone,Alpha-2B adrenergic receptor,ADRA2B,6.79,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
velnacrine,Acetylcholinesterase,ACHE,6.79,IC50,NC1=C2C(O)CCCC2=NC2=CC=CC=C12
pexidartinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.79,IC50,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
entrectinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.79,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
fedratinib,Bromodomain-containing protein 4,BRD4,6.79,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cinnarizine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.793,IC50,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
guanabenz,Alpha-2C adrenergic receptor,ADRA2C,6.793,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
desipramine,5-hydroxytryptamine receptor 2A,HTR2A,6.796,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
doxepin,Muscarinic acetylcholine receptor M2,CHRM2,6.796,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
imipramine,5-hydroxytryptamine receptor 2C,HTR2C,6.796,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
thioridazine,Aldehyde oxidase,AOX1,6.796,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
chidamide,Histone deacetylase 2,HDAC2,6.796,IC50,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1
brexpiprazole,D(1A) dopamine receptor,DRD1,6.796,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
brigatinib,Insulin receptor,INSR,6.796,IC50,COC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3P(C)(C)=O)=N2)C=CC(=C1)N1CCC(CC1)N1CCN(C)CC1
cyclizine,Muscarinic acetylcholine receptor M3,CHRM3,6.799,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
promazine,D(3) dopamine receptor,DRD3,6.799,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
alprostadil,Prostaglandin E2 receptor EP1 subtype,PTGER1,6.8,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
amitriptyline,Histamine H2 receptor,HRH2,6.8,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
aripiprazole,5-hydroxytryptamine receptor 6,Htr6,6.8,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
celiprolol,Beta-2 adrenergic receptor,ADRB2,6.8,Ki,CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1
ciclopirox,Poly [ADP-ribose] polymerase 1,PARP1,6.8,IC50,CC1=CC(=O)N(O)C(=C1)C1CCCCC1
ciclopirox,Poly [ADP-ribose] polymerase 1,PARP1,6.8,IC50,CC1=CC(=O)N(O)C(=C1)C1CCCCC1
clomifene,C-8 sterol isomerase,ERG2,6.8,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
clozapine,Alpha-1A adrenergic receptor,ADRA1A,6.8,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproheptadine,5-hydroxytryptamine receptor 6,HTR6,6.8,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
desipramine,Muscarinic acetylcholine receptor M4,CHRM4,6.8,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
dihydroergotamine,5-hydroxytryptamine receptor 7,Htr7,6.8,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ergotamine,5-hydroxytryptamine receptor 1F,HTR1F,6.8,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
fluoxetine,Transporter,NET,6.8,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
imipramine,5-hydroxytryptamine receptor 2C,Htr2c,6.8,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
incadronic acid,Farnesyl pyrophosphate synthase,,6.8,IC50,OP(O)(=O)C(NC1CCCCCC1)P(O)(O)=O
isotretinoin,Olfactory receptor 51E2,OR51E2,6.8,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
levocabastine,Neurotensin receptor type 2,NTSR2,6.8,Ki,C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1
meloxicam,Prostaglandin G/H synthase 2,PTGS2,6.8,IC50,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
methysergide,5-hydroxytryptamine receptor 6,HTR6,6.8,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
methysergide,5-hydroxytryptamine receptor 1E,HTR1E,6.8,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nimodipine,Mineralocorticoid receptor,NR3C2,6.8,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nimodipine,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,6.8,IC50,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
ondansetron,Multidrug and toxin extrusion protein 2,SLC47A2,6.8,IC50,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
oxycodone,Mu-type opioid receptor,Oprm1,6.8,EC50,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
oxymetazoline,5-hydroxytryptamine receptor 2C,HTR2C,6.8,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
penfluridol,D(2) dopamine receptor,DRD2,6.8,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
pipamperone,5-hydroxytryptamine receptor 1D,HTR1D,6.8,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
pronetalol,Beta-2 adrenergic receptor,ADRB2,6.8,Kd,CC(C)NCC(O)C1=CC2=CC=CC=C2C=C1
rivastigmine,Butyrylcholinesterase,BCHE,6.8,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
rizatriptan,5-hydroxytryptamine receptor 1F,HTR1F,6.8,Ki,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
rizatriptan,5-hydroxytryptamine receptor 1E,HTR1E,6.8,Ki,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
sertraline,Transporter,Slc6a2,6.8,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
solifenacin,Muscarinic acetylcholine receptor M4,CHRM4,6.8,Ki,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
spiperone,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,6.8,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Serine/threonine-protein kinase 3,Stk3,6.8,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Casein kinase II subunit alpha',CSNK2A2,6.8,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Homeodomain-interacting protein kinase 4,HIPK4,6.8,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tazobactam,Class D beta-lactamase,oxa-63,6.8,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
trazodone,Sodium-dependent serotonin transporter,SLC6A4,6.8,Kd,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
flusalan,Kappa-type opioid receptor,OPRK1,6.8,IC50,OC1=C(C=C(Br)C=C1Br)C(=O)NC1=CC(=CC=C1)C(F)(F)F
oxyquinoline,Bacterial leucyl aminopeptidase,,6.8,Ki,OC1=CC=CC2=C1N=CC=C2
iloperidone,5-hydroxytryptamine receptor 1A,Htr1a,6.8,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
practolol,Beta-1 adrenergic receptor,ADRB1,6.8,Ki,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
vandetanib,Receptor tyrosine-protein kinase erbB-3,ERBB3,6.8,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
axitinib,Non-receptor tyrosine-protein kinase TNK1,TNK1,6.8,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
dequalinium,Small conductance calcium-activated potassium channel protein 2,Kcnn2,6.8,IC50,CC1=[N+](CCCCCCCCCC[N+]2=C(C)C=C(N)C3=CC=CC=C23)C2=CC=CC=C2C(N)=C1
nintedanib,NUAK family SNF1-like kinase 1,NUAK1,6.8,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Cyclin-dependent kinase 4,CDK4,6.8,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
aripiprazole lauroxil,5-hydroxytryptamine receptor 6,Htr6,6.8,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
midostaurin,Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,6.8,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase SIK1,SIK1,6.8,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase BTK,BTK,6.8,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Tyrosine-protein kinase receptor UFO,AXL,6.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Phosphatidylinositol 5-phosphate 4-kinase type-2 beta,PIP4K2B,6.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Nek7,NEK7,6.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,SRSF protein kinase 1,SRPK1,6.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
prochlorperazine,Muscarinic acetylcholine receptor M5,CHRM5,6.801,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
guanabenz,Alpha-1D adrenergic receptor,ADRA1D,6.801,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
dihydroergotamine,5-hydroxytryptamine receptor 4,HTR4,6.804,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
mesoridazine,5-hydroxytryptamine receptor 2C,HTR2C,6.804,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
butenafine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.805,Ki,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
domperidone,Histamine H1 receptor,HRH1,6.807,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
loratadine,5-hydroxytryptamine receptor 2B,HTR2B,6.807,Ki,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
zolpidem,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,6.807,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
clozapine,Adenosine receptor A3,ADORA3,6.81,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
ethinylestradiol,Sex hormone-binding globulin,SHBG,6.81,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
ethoxzolamide,Carbonic anhydrase,cynT,6.81,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
loperamide,Kappa-type opioid receptor,OPRK1,6.81,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
novobiocin,DNA gyrase subunit B,gyrB,6.81,IC50,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
trazodone,Alpha-2C adrenergic receptor,ADRA2C,6.81,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
verapamil,5-hydroxytryptamine receptor 2C,HTR2C,6.81,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
viloxazine,Sodium-dependent dopamine transporter,SLC6A3,6.81,Kd,CCOC1=CC=CC=C1OCC1CNCCO1
zolpidem,GABA A receptor alpha-2/beta-2/gamma-2,Gabrg2|Gabra2|Gabrb2,6.81,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
brexanolone,GABA-A receptor alpha-6/beta-3/delta,GABRA6|GABRB3|GABRD,6.81,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)C3CC[C@]12C
cyclobenzaprine,5-hydroxytryptamine receptor 2B,HTR2B,6.812,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
tafamidis,Transthyretin,TTR,6.812,Kd,OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1
bopindolol,5-hydroxytryptamine receptor 1A,HTR1A,6.815,Ki,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
clozapine,Histamine H2 receptor,HRH2,6.815,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
thioridazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.815,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
clomipramine,5-hydroxytryptamine receptor 2B,HTR2B,6.818,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
zimeldine,Sodium-dependent serotonin transporter,SLC6A4,6.818,Ki,CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CN=CC=C1
ziprasidone,D(1B) dopamine receptor,DRD5,6.818,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
cisapride,Serotonin 3 (5-HT3) receptor,HTR3E|HTR3B|HTR3A|HTR3D|HTR3C,6.82,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
dichlorphenamide,Carbonic anhydrase,,6.82,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dimemorfan,Sigma non-opioid intracellular receptor 1,Sigmar1,6.82,Ki,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC1=CC=C(C)C=C31
disulfiram,Lysyl oxidase homolog 2,LOXL2,6.82,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
dopamine,D(1A) dopamine receptor,Drd1,6.82,Ki,NCCC1=CC(O)=C(O)C=C1
fluspirilene,5-hydroxytryptamine receptor 2B,HTR2B,6.82,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
imipenem,Beta-lactamase GES-13,blaGES-13,6.82,IC50,C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O
indomethacin,Prostaglandin G/H synthase (cyclooxygenase),PTGS1|PTGS2,6.82,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
ketoconazole,Cytochrome P450 11B1,CYP11B1,6.82,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
meloxicam,Prostaglandin G/H synthase 2,Ptgs2,6.82,IC50,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
melperone,Alpha-2A adrenergic receptor,ADRA2A,6.82,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
milrinone,Phosphodiesterase 3,PDE3B|PDE3A,6.82,Ki,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
moxonidine,Alpha-2A adrenergic receptor,ADRA2A,6.82,Ki,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1
naftidrofuryl,5-hydroxytryptamine receptor 2A,HTR2A,6.82,Ki,CCN(CC)CCOC(=O)C(CC1CCCO1)CC1=CC=CC2=CC=CC=C12
nepafenac,Prostaglandin G/H synthase 2,PTGS2,6.82,IC50,NC(=O)CC1=C(N)C(=CC=C1)C(=O)C1=CC=CC=C1
sunitinib,Death-associated protein kinase 2,DAPK2,6.82,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,NUAK family SNF1-like kinase 2,NUAK2,6.82,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
trimethoprim,Dihydrofolate reductase,,6.82,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
ziprasidone,Histamine H1 receptor,Hrh1,6.82,IC50,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
edoxudine,Thymidine kinase,UL23,6.82,IC50,CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O
eseridine,Acetylcholinesterase,ACHE,6.82,IC50,CNC(=O)OC1=CC2=C(C=C1)N(C)[C@H]1ON(C)CC[C@@]21C
pazopanib,Dual specificity protein kinase TTK,TTK,6.82,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vandetanib,Activin receptor type-1,ACVR1,6.82,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ruxolitinib,Ribosomal protein S6 kinase alpha-2,RPS6KA2,6.82,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Ribosomal protein S6 kinase alpha-6,RPS6KA6,6.82,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,6.82,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor),NPM1|ALK,6.82,IC50,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
carfilzomib,Glutathione S-transferase omega-1,GSTO1,6.82,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
esatenolol,Beta-1 adrenergic receptor,ADRB1,6.82,Ki,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
dabrafenib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,6.82,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
istradefylline,Adenosine receptor A1,Adora1,6.82,Ki,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
nintedanib,Leukocyte tyrosine kinase receptor,LTK,6.82,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,6.82,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase TBK1,TBK1,6.82,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
fedratinib,Activin receptor type-1,ACVR1,6.82,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Nek9,NEK9,6.82,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cyclobenzaprine,5-hydroxytryptamine receptor 7,HTR7,6.821,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
loxapine,Alpha-2A adrenergic receptor,ADRA2A,6.821,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
meprobamate,Multidrug resistance protein 1,ABCB1,6.821,IC50,CCCC(C)(COC(N)=O)COC(N)=O
thiothixene,5-hydroxytryptamine receptor 1B,HTR1B,6.821,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
zotepine,Sodium-dependent serotonin transporter,SLC6A4,6.821,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
promethazine,Histamine H4 receptor,HRH4,6.823,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
perlapine,5-hydroxytryptamine receptor 6,HTR6,6.824,Ki,CN1CCN(CC1)C1=NC2=C(CC3=CC=CC=C13)C=CC=C2
femoxetine,Muscarinic acetylcholine receptor M2,CHRM2,6.824,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
thiocolchicoside,GABA A receptor alpha-1/beta-1/gamma-2,GABRA1|GABRB1|GABRG2,6.824,IC50,COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC
imipramine,5-hydroxytryptamine receptor 2A,HTR2A,6.825,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
promazine,Muscarinic acetylcholine receptor M1,CHRM1,6.825,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
doxazosin,Sodium-dependent dopamine transporter,SLC6A3,6.827,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
trimipramine,Sodium-dependent serotonin transporter,SLC6A4,6.827,Ki,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=C1C=CC=C2
eliglustat,Ceramide glucosyltransferase,UGCG,6.827,IC50,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1
loxapine,Muscarinic acetylcholine receptor M5,CHRM5,6.829,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
aripiprazole,Sodium-dependent serotonin transporter,SLC6A4,6.83,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
astemizole,D(3) dopamine receptor,DRD3,6.83,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
azelastine,Histamine H3 receptor,HRH3,6.83,Ki,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
flumazenil,GABA-A receptor alpha-6/beta-3/gamma-2,GABRG2|GABRB3|GABRA6,6.83,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
fluticasone propionate,Mineralocorticoid receptor,NR3C2,6.83,EC50,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF
mefenamic acid,Prostaglandin G/H synthase 2,PTGS2,6.83,IC50,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
oxymetazoline,5-hydroxytryptamine receptor 2B,HTR2B,6.83,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
oxymorphone,Kappa-type opioid receptor,OPRK1,6.83,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
penfluridol,D(1A) dopamine receptor,DRD1,6.83,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
quetiapine,5-hydroxytryptamine receptor 1A,HTR1A,6.83,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
fluticasone furoate,Mineralocorticoid receptor,NR3C2,6.83,IC50,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)SCF
domperidone,Alpha-2C adrenergic receptor,ADRA2C,6.833,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
lorcaserin,5-hydroxytryptamine receptor 2B,HTR2B,6.833,Ki,C[C@H]1CNCCC2=CC=C(Cl)C=C12
nalfurafine,Nociceptin receptor,OPRL1,6.833,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
phenelzine,Amine oxidase [flavin-containing] A,MAOA,6.836,IC50,NNCCC1=CC=CC=C1
ingenol mebutate,Protein kinase C beta type,PRKCB,6.836,EC50,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C
fluphenazine enanthate,5-hydroxytryptamine receptor 1A,HTR1A,6.837,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
oxybutynin,D(3) dopamine receptor,DRD3,6.837,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
fluphenazine,5-hydroxytryptamine receptor 1A,HTR1A,6.838,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
cyclobenzaprine,5-hydroxytryptamine receptor 6,HTR6,6.839,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
fluphenazine,5-hydroxytryptamine receptor 5A,HTR5A,6.839,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,5-hydroxytryptamine receptor 5A,HTR5A,6.839,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
metergoline,Alpha-1B adrenergic receptor,Adra1b,6.839,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
desipramine,Muscarinic acetylcholine receptor M5,CHRM5,6.84,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
fluoxetine,Transporter,Slc6a2,6.84,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
pecazine,Alpha-1A adrenergic receptor,Adra1a,6.84,IC50,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
pyrimethamine,Multidrug and toxin extrusion protein 1,Slc47a1,6.84,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
sivelestat,Neutrophil elastase,Elane,6.84,IC50,CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=C(C=CC=C1)C(=O)NCC(O)=O
tolmetin,Prostaglandin G/H synthase 2,PTGS2,6.84,IC50,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
rucaparib,Tankyrase-1,TNKS,6.84,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
amoxapine,Alpha-1D adrenergic receptor,ADRA1D,6.842,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
pimozide,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.842,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
benidipine,Voltage-dependent T-type calcium channel subunit alpha-1H,CACNA1H,6.843,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1
ketobemidone,Delta-type opioid receptor,OPRD1,6.845,Ki,CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1
maprotiline,Muscarinic acetylcholine receptor M1,CHRM1,6.845,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
ticlopidine,Alpha-2A adrenergic receptor,ADRA2A,6.845,Ki,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
clemastine,Alpha-2B adrenergic receptor,ADRA2B,6.848,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
dexfenfluramine,Alpha-1B adrenergic receptor,ADRA1B,6.848,Ki,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
fenfluramine,Alpha-1B adrenergic receptor,ADRA1B,6.848,Ki,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
cinnarizine,Histamine H4 receptor,HRH4,6.849,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
trifluoperazine,5-hydroxytryptamine receptor 6,HTR6,6.849,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
adenosine phosphate,"Fructose-1,6-bisphosphatase 1",FBP1,6.85,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
benzatropine,Alpha-1A adrenergic receptor,Adra1a,6.85,IC50,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
cefoxitin,Beta-lactamase,blaPER-2,6.85,Ki,CO[C@]1(NC(=O)CC2=CC=CS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O
celecoxib,Carbonic anhydrase,,6.85,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
clozapine,Adenylate cyclase,Adcy1|Adcy3|Adcy2|Adcy4|Adcy8|Adcy6|Adcy5,6.85,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproheptadine,D(2) dopamine receptor,Drd2,6.85,IC50,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dasatinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,6.85,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
enalapril,Angiotensin-converting enzyme,Ace,6.85,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
glutamic acid,"Glutamate receptor ionotropic, kainate 1",Grik1,6.85,Ki,N[C@@H](CCC(O)=O)C(O)=O
lysergide,Beta-1 adrenergic receptor,ADRB1,6.85,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
methazolamide,Carbonic anhydrase,,6.85,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
miglustat,Non-lysosomal glucosylceramidase,Gba2,6.85,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nafamostat,Complement C1s subcomponent,C1S,6.85,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
rizatriptan,5-hydroxytryptamine receptor 1A,HTR1A,6.85,Ki,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
ropinirole,5-hydroxytryptamine receptor 2A,HTR2A,6.85,EC50,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sildenafil,"Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha",PDE6A,6.85,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,Serine/threonine-protein kinase 10,STK10,6.85,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Cyclin-dependent kinase 7,CDK7,6.85,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Rho-associated protein kinase 2,ROCK2,6.85,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,6.85,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,G protein-coupled receptor kinase 4,GRK4,6.85,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,STE20/SPS1-related proline-alanine-rich protein kinase,STK39,6.85,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tropisetron,5-hydroxytryptamine receptor 4,HTR4,6.85,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
nicotinic acid,Hydroxycarboxylic acid receptor 2,Hcar2,6.85,IC50,OC(=O)C1=CN=CC=C1
zileuton,Arachidonate 5-lipoxygenase,Alox5,6.85,IC50,CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2
zonisamide,Carbonate dehydratase,,6.85,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
ruboxistaurin,Homeodomain-interacting protein kinase 2,HIPK2,6.85,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
crizotinib,Ephrin type-A receptor 1,EPHA1,6.85,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Peripheral plasma membrane protein CASK,CASK,6.85,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Ribosomal protein S6 kinase alpha-5,RPS6KA5,6.85,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,6.85,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Discoidin domain-containing receptor 2,DDR2,6.85,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dequalinium,Small conductance calcium-activated potassium channel protein 3,Kcnn3,6.85,Ki,CC1=[N+](CCCCCCCCCC[N+]2=C(C)C=C(N)C3=CC=CC=C23)C2=CC=CC=C2C(N)=C1
plerixafor,Atypical chemokine receptor 3,ACKR3,6.85,EC50,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
haloperidol decanoate,D(1A) dopamine receptor,DRD1,6.85,Ki,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ceritinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,6.85,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,6.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Ephrin type-B receptor 6,EPHB6,6.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Mitogen-activated protein kinase kinase kinase 13,MAP3K13,6.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Mitogen-activated protein kinase kinase kinase 12,MAP3K12,6.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Macrophage colony-stimulating factor 1 receptor,CSF1R,6.85,IC50,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Calcium/calmodulin-dependent protein kinase type II subunit gamma,CAMK2G,6.85,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,6.85,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,TRAF2 and NCK-interacting protein kinase,TNIK,6.85,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,NUAK family SNF1-like kinase 2,NUAK2,6.85,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
pexidartinib,Cyclin-dependent kinase 19,CDK19,6.85,IC50,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
entrectinib,Focal adhesion kinase 1,PTK2,6.85,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
fedratinib,Citron Rho-interacting kinase,CIT,6.85,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Ribosomal protein S6 kinase alpha-4,RPS6KA4,6.85,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
aripiprazole,Beta-1 adrenergic receptor,ADRB1,6.851,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
verapamil,5-hydroxytryptamine receptor 2A,HTR2A,6.854,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
zotepine,Muscarinic acetylcholine receptor M2,CHRM2,6.854,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
gentian violet,Muscarinic acetylcholine receptor M4,CHRM4,6.854,Ki,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
brexpiprazole,5-hydroxytryptamine receptor 5A,HTR5A,6.854,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
ethinylestradiol,Progesterone receptor,PGR,6.857,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
ticlopidine,Alpha-2B adrenergic receptor,ADRA2B,6.857,Ki,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
brexpiprazole,Sodium-dependent noradrenaline transporter,SLC6A2,6.857,IC50,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
alprenolol,Beta-3 adrenergic receptor,ADRB3,6.86,Kd,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
buspirone,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,6.86,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
clozapine,D(2) dopamine receptor,DRD2,6.86,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dorzolamide,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,6.86,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
droperidol,5-hydroxytryptamine receptor 1A,HTR1A,6.86,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
nefazodone,Sodium-dependent serotonin transporter,Slc6a4,6.86,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
pemetrexed,Folate transporter 1,SLC19A1,6.86,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
protriptyline,Muscarinic acetylcholine receptor M5,CHRM5,6.86,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
ranitidine,Histamine H2 receptor,HRH2,6.86,Kd,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O
venlafaxine,Transporter,Slc6a2,6.86,Ki,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
tramazoline,Alpha-2B adrenergic receptor,ADRA2B,6.86,Ki,C1CN=C(NC2=C3CCCCC3=CC=C2)N1
ebastine,Muscarinic acetylcholine receptor M3,CHRM3,6.863,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
flufenamic acid,Taste receptor type 2 member 14,TAS2R14,6.863,EC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
oxymetholone,Androgen receptor,Ar,6.863,Ki,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)\C(C[C@]4(C)[C@H]3CC[C@]12C)=C/O
sertraline,Alpha-1A adrenergic receptor,ADRA1A,6.863,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
thioridazine,Histamine H2 receptor,HRH2,6.866,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
chlorpromazine,Histamine H4 receptor,HRH4,6.87,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clotiapine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,6.87,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dexamfetamine,Trace amine-associated receptor 1,TAAR1,6.87,EC50,C[C@H](N)CC1=CC=CC=C1
isoprenaline,Beta-2 adrenergic receptor,ADRB2,6.87,Ki,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
penfluridol,D(3) dopamine receptor,DRD3,6.87,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
levisoprenaline,Beta-2 adrenergic receptor,ADRB2,6.87,Ki,CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1
sultiame,Carbonic anhydrase 6,CA6,6.87,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
trichlormethiazide,"Carbonic anhydrase 5B, mitochondrial",CA5B,6.87,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
laropiprant,Prostaglandin E2 receptor EP2 subtype,PTGER2,6.87,Ki,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
cariprazine,5-hydroxytryptamine receptor 2C,HTR2C,6.87,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
baricitinib,Cyclin-G-associated kinase,GAK,6.87,Kd,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
thioridazine,Alpha-2A adrenergic receptor,ADRA2A,6.872,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
orphenadrine,Muscarinic acetylcholine receptor M2,CHRM2,6.873,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
maprotiline,Alpha-2B adrenergic receptor,ADRA2B,6.876,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
amitriptyline,Alpha-2A adrenergic receptor,ADRA2A,6.879,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
ergometrine,Alpha-2B adrenergic receptor,ADRA2B,6.879,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
perphenazine,5-hydroxytryptamine receptor 2C,HTR2C,6.879,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
fludarabine phosphate,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.88,Ki,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
fludarabine phosphate,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.88,Ki,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
methamphetamine,Trace amine-associated receptor 1,Taar1,6.88,EC50,CN[C@@H](C)CC1=CC=CC=C1
methazolamide,Carbonic anhydrase,CA2,6.88,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
solifenacin,Muscarinic acetylcholine receptor M3,CHRM3,6.88,IC50,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
trimethoprim,Dihydrofolate reductase,folA,6.88,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
terazosin,Alpha-2C adrenergic receptor,ADRA2C,6.88,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
lenvatinib,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.88,Ki,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
lenvatinib,"Carbonic anhydrase 5A, mitochondrial",CA5A,6.88,Ki,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
phenmetrazine,Sodium-dependent dopamine transporter,SLC6A3,6.883,EC50,CC1NCCOC1C1=CC=CC=C1
dexamethasone,Prostaglandin G/H synthase 2,PTGS2,6.886,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
dexloxiglumide,Cholecystokinin receptor type A,CCKAR,6.886,IC50,CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1
lofepramine,Muscarinic acetylcholine receptor M3,CHRM3,6.886,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
thiocolchicoside,GABA A receptor alpha-2/beta-2/gamma-2,GABRG2|GABRA2|GABRB2,6.886,IC50,COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC
abacavir,Reverse transcriptase,reverse transcriptas,6.89,IC50,NC1=NC(NC2CC2)=C2N=CN([C@@H]3C[C@H](CO)C=C3)C2=N1
adapalene,Retinoic acid receptor gamma,RARG,6.89,Ki,COC1=CC=C(C=C1C12CC3CC(CC(C3)C1)C2)C1=CC=C2C=C(C=CC2=C1)C(O)=O
bexarotene,Retinoic acid receptor gamma,RARG,6.89,Ki,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
clotrimazole,Lanosterol 14-alpha demethylase,CYP51A1,6.89,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clozapine,D(1A) dopamine receptor,DRD1,6.89,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cortisone acetate,Corticosteroid-binding globulin,SERPINA6,6.89,Ki,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
dasatinib,Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase,PKMYT1,6.89,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dinoprost,Prostaglandin F2-alpha receptor,PTGFR,6.89,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
erlotinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.89,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fluoxetine,Acetylcholinesterase,ACHE,6.89,IC50,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
gallamine,Muscarinic acetylcholine receptor M2,CHRM2,6.89,EC50,CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
nicotine,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,6.89,Ki,CN1CCC[C@H]1C1=CC=CN=C1
promazine,Dopamine receptor,DRD2|DRD1,6.89,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
pyrazinamide,Cytochrome P450 3A4,CYP3A4,6.89,IC50,NC(=O)C1=NC=CN=C1
risperidone,5-hydroxytryptamine receptor 1A,Htr1a,6.89,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sorafenib,Tyrosine-protein kinase ABL1,ABL1,6.89,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,6.89,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,"Muscle, skeletal receptor tyrosine-protein kinase",MUSK,6.89,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Cyclin-dependent kinase-like 2,CDKL2,6.89,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Serine/threonine-protein kinase B-raf,Braf,6.89,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Cyclin-dependent kinase 16,CDK16,6.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,6.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamoxifen,Progesterone receptor,PGR,6.89,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tulobuterol,Beta-2 adrenergic receptor,ADRB2,6.89,Kd,CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1
valdecoxib,Carbonic anhydrase,,6.89,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
vardenafil,"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A",PDE11A,6.89,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
bufexamac,Arachidonate 5-lipoxygenase,Alox5,6.89,IC50,CCCCOC1=CC=C(CC(=O)NO)C=C1
ruboxistaurin,Receptor-type tyrosine-protein kinase FLT3,FLT3,6.89,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
ruboxistaurin,Serine/threonine-protein kinase pim-2,PIM2,6.89,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
xylometazoline,Alpha-2C adrenergic receptor,ADRA2C,6.89,Ki,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
oxitriptan,5-hydroxytryptamine receptor 2A,HTR2A,6.89,EC50,N[C@@H](CC1=CNC2=CC=C(O)C=C12)C(O)=O
minodronic acid,Geranylgeranyl pyrophosphate synthase,BTS1,6.89,Ki,OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O
saxagliptin,Dipeptidyl peptidase 8,DPP8,6.89,Ki,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2
vorinostat,Histone deacetylase 7,HDAC7,6.89,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
telaprevir,NS3 protease,,6.89,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
ruxolitinib,Serine/threonine-protein kinase PLK1,PLK1,6.89,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Homeodomain-interacting protein kinase 4,HIPK4,6.89,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
midostaurin,Calcium/calmodulin-dependent protein kinase kinase 1,CAMKK1,6.89,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,6.89,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,6.89,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Myosin light chain kinase family member 4,MYLK4,6.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
mosapride,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.891,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
benzatropine,5-hydroxytryptamine receptor 2B,HTR2B,6.896,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
doxazosin,5-hydroxytryptamine receptor 4,HTR4,6.896,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
ketoconazole,"Cytochrome P450 11B1, mitochondrial",CYP11B1,6.896,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
promazine,5-hydroxytryptamine receptor 6,HTR6,6.896,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
verapamil,Sodium-dependent serotonin transporter,SLC6A4,6.896,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
alcuronium,Muscarinic acetylcholine receptor M2,CHRM2,6.9,Kd,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
apomorphine,Alpha-2A adrenergic receptor,ADRA2A,6.9,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
apomorphine,5-hydroxytryptamine receptor 2A,HTR2A,6.9,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
apomorphine,5-hydroxytryptamine receptor 2B,HTR2B,6.9,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
brinzolamide,Carbonic anhydrase 2,mtcA2,6.9,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
clonidine,Alpha-1D adrenergic receptor,Adra1d,6.9,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
clopidogrel,P2Y purinoceptor 12,P2RY12,6.9,Ki,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=C(Cl)C=CC=C1
clozapine,5-hydroxytryptamine receptor 1F,HTR1F,6.9,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproheptadine,5-hydroxytryptamine receptor 7,HTR7,6.9,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cyproheptadine,Alpha-1D adrenergic receptor,ADRA1D,6.9,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cyproheptadine,5-hydroxytryptamine receptor 6,Htr6,6.9,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dinoprostone,Prostaglandin F2-alpha receptor,PTGFR,6.9,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
dipyridamole,Phosphodiesterase 6,PDE6D|PDE6A|PDE6G|PDE6B|PDE6C|PDE6H,6.9,Ki,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
dydrogesterone,Progesterone receptor,PGR,6.9,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C
esmolol,Beta-1 adrenergic receptor,ADRB1,6.9,Ki,COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1
famotidine,Carbonic anhydrase 9,CA9,6.9,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
fenoterol,Beta-2 adrenergic receptor,ADRB2,6.9,EC50,CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1
haloprogin,Adenosine receptor A3,ADORA3,6.9,Ki,ClC1=CC(Cl)=C(OCC#CI)C=C1Cl
hydroxychloroquine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.9,Ki,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
ketorolac,Prostaglandin G/H synthase 2,PTGS2,6.9,IC50,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1
lanreotide,Somatostatin receptor type 3,Sstr3,6.9,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
lofexidine,5-hydroxytryptamine receptor 1A,HTR1A,6.9,Ki,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
lysergide,D(3) dopamine receptor,DRD3,6.9,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
meropenem,Streptokinase A,ska,6.9,EC50,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
mibefradil,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,6.9,IC50,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C
mosapride,5-hydroxytryptamine receptor 4,HTR4,6.9,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
nadolol,Beta-1 adrenergic receptor,ADRB1,6.9,Ki,CC(C)(C)NCC(O)COC1=CC=CC2=C1CC(O)C(O)C2
norepinephrine,Beta-1 adrenergic receptor,Adrb1,6.9,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
novobiocin,DNA gyrase subunit B,gyrB,6.9,IC50,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
penfluridol,D(1B) dopamine receptor,DRD5,6.9,Ki,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
phenylephrine,Alpha-1B adrenergic receptor,ADRA1B,6.9,Ki,CNC[C@H](O)C1=CC(O)=CC=C1
piribedil,D(2) dopamine receptor,DRD2,6.9,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
promazine,Alpha-2A adrenergic receptor,ADRA2A,6.9,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
protriptyline,Muscarinic acetylcholine receptor M2,CHRM2,6.9,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
rizatriptan,5-hydroxytryptamine receptor 1B,HTR1B,6.9,Ki,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
sotalol,Beta-2 adrenergic receptor,ADRB2,6.9,Ki,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
tropisetron,5-hydroxytryptamine receptor 4,HTR4,6.9,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
varenicline,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,6.9,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
xanomeline,5-hydroxytryptamine receptor 2A,HTR2A,6.9,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
xanomeline,5-hydroxytryptamine receptor 7,HTR7,6.9,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
yohimbine,5-hydroxytryptamine receptor 1A,Htr1a,6.9,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
trifarotene,Retinoic acid receptor beta,RARB,6.9,EC50,CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=C(OCCO)C=CC(=C1)C1=CC=C(C=C1)C(O)=O
dihydroergocristine,5-hydroxytryptamine receptor 2C,HTR2C,6.903,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
orphenadrine,5-hydroxytryptamine receptor 2A,HTR2A,6.903,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
ebastine,5-hydroxytryptamine receptor 2C,HTR2C,6.905,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
molindone,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.907,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
prochlorperazine,5-hydroxytryptamine receptor 6,HTR6,6.907,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
tibolone,Estrogen receptor,ESR1,6.907,Ki,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
cabozantinib,Macrophage-stimulating protein receptor,MST1R,6.907,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
cyproheptadine,5-hydroxytryptamine receptor 1A,Htr1a,6.91,IC50,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dobutamine,Sodium-dependent dopamine transporter,SLC6A3,6.91,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
loperamide,Delta-type opioid receptor,OPRD1,6.91,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
mefloquine,Adenosine receptor A2a,ADORA2A,6.91,Ki,O[C@H]([C@H]1CCCCN1)C1=CC(=NC2=C(C=CC=C12)C(F)(F)F)C(F)(F)F
nortriptyline,Alpha-1D adrenergic receptor,ADRA1D,6.91,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
oxytocin,Vasopressin V1a receptor,AVPR1A,6.91,EC50,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
sulpiride,Carbonic anhydrase,NCE103,6.91,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sultiame,Carbonic anhydrase,CA2,6.91,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
entrectinib,Insulin-like growth factor 1 receptor,IGF1R,6.91,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
ripretinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,6.91,IC50,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
propranolol,5-hydroxytryptamine receptor 1A,HTR1A,6.913,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
desloratadine,Sodium-dependent serotonin transporter,SLC6A4,6.914,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
loxapine,Muscarinic acetylcholine receptor M3,CHRM3,6.914,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
prochlorperazine,5-hydroxytryptamine receptor 2C,HTR2C,6.914,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
talipexole,Alpha-2A adrenergic receptor,ADRA2A,6.915,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
paliperidone,Histamine H2 receptor,HRH2,6.916,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
bambuterol,Cholinesterase,BCHE,6.92,IC50,CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C
buspirone,D(2) dopamine receptor,Drd2,6.92,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
buspirone,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,6.92,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
chlorpromazine,Sodium-dependent serotonin transporter,SLC6A4,6.92,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cocaine,Sodium-dependent serotonin transporter,SLC6A4,6.92,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
gabapentin,Voltage-dependent calcium channel subunit alpha-2/delta-1,Cacna2d1,6.92,Ki,NCC1(CC(O)=O)CCCCC1
ketoconazole,Cytochrome P450 3A5,CYP3A5,6.92,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
methacholine,Muscarinic acetylcholine receptor M3,Chrm3,6.92,EC50,CC(C[N+](C)(C)C)OC(C)=O
methazolamide,Carbonic anhydrase,NCE103,6.92,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methotrexate,Proton-coupled folate transporter,SLC46A1,6.92,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mycophenolic acid,Inosine-5'-monophosphate dehydrogenase,,6.92,IC50,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
nalorphine,Delta-type opioid receptor,OPRD1,6.92,Ki,O[C@H]1C=C[C@H]2[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
nizatidine,Histamine H2 receptor,HRH2,6.92,Kd,CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O
norethisterone,Androgen receptor,Ar,6.92,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
pergolide,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.92,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
phenoxybenzamine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,6.92,Ki,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
pirenzepine,Muscarinic acetylcholine receptor M2,Chrm2,6.92,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
ritonavir,Cytochrome P450 3A5,CYP3A5,6.92,Ki,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
solifenacin,Muscarinic acetylcholine receptor M2,Chrm2,6.92,Ki,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
sunitinib,Tyrosine-protein kinase Yes,YES1,6.92,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Death-associated protein kinase 1,DAPK1,6.92,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase TBK1,TBK1,6.92,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Carbonic anhydrase,,6.92,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
trimethoprim,Bifunctional dihydrofolate reductase-thymidylate synthase,,6.92,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
ziprasidone,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.92,IC50,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
femoxetine,Sodium-dependent noradrenaline transporter,Slc6a2,6.92,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
naphazoline,Nischarin,NISCH,6.92,Ki,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
oleandrin,Neurogenic locus notch homolog protein 1,Notch1,6.92,IC50,CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O
quercetin,Proto-oncogene tyrosine-protein kinase Src,SRC,6.92,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
triclocarban,Epoxide hydrolase 1,EPHX1,6.92,IC50,ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1
xanomeline,Muscarinic acetylcholine receptor M2,CHRM2,6.92,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
boceprevir,Cathepsin S,CTSS,6.92,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
vandetanib,Tyrosine-protein kinase Yes,YES1,6.92,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Ephrin type-B receptor 1,EPHB1,6.92,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,NUAK family SNF1-like kinase 2,NUAK2,6.92,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,AP2-associated protein kinase 1,AAK1,6.92,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Calcium/calmodulin-dependent protein kinase type 1D,CAMK1D,6.92,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Ribosomal protein S6 kinase alpha-1,RPS6KA1,6.92,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
aceclidine,Muscarinic acetylcholine receptor M1,Chrm1,6.92,IC50,CC(=O)OC1CN2CCC1CC2
bosutinib,Epithelial discoidin domain-containing receptor 1,DDR1,6.92,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase Chk2,CHEK2,6.92,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tofacitinib,Non-receptor tyrosine-protein kinase TNK1,TNK1,6.92,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Interleukin-1 receptor-associated kinase 1,IRAK1,6.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Activated CDC42 kinase 1,TNK2,6.92,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,6.92,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Tankyrase-2,TNKS2,6.92,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase Lck,LCK,6.92,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
upadacitinib,Tyrosine-protein kinase JAK2,JAK2,6.92,IC50,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F
fedratinib,Tyrosine-protein kinase Yes,YES1,6.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Cyclin-dependent kinase 7,CDK7,6.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Casein kinase II subunit alpha',CSNK2A2,6.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Interleukin-1 receptor-associated kinase 3,IRAK3,6.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase Nek6,NEK6,6.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
delapril,Angiotensin-converting enzyme,ACE,6.921,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=C(C1)C=CC=C2
diphenhydramine,Muscarinic acetylcholine receptor M2,CHRM2,6.921,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
iprindole,Histamine H1 receptor,HRH1,6.921,Ki,CN(C)CCCN1C2=C(CCCCCC2)C2=CC=CC=C12
maprotiline,5-hydroxytryptamine receptor 2A,HTR2A,6.921,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
mebhydrolin,5-hydroxytryptamine receptor 5A,HTR5A,6.921,Ki,CN1CCC2=C(C1)C1=C(C=CC=C1)N2CC1=CC=CC=C1
promethazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.921,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
risperidone,Histamine H2 receptor,HRH2,6.921,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
trimethoprim,Bifunctional dihydrofolate reductase-thymidylate synthase,,6.921,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
armodafinil,D(2) dopamine receptor,DRD2,6.921,EC50,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
cyclizine,Muscarinic acetylcholine receptor M4,CHRM4,6.924,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
carvedilol,Sodium-dependent serotonin transporter,SLC6A4,6.928,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
chlorpromazine,5-hydroxytryptamine receptor 5A,HTR5A,6.928,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
gabapentin,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,6.928,IC50,NCC1(CC(O)=O)CCCCC1
alprenolol,5-hydroxytryptamine receptor 1A,Htr1a,6.93,Ki,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
benzatropine,Sodium-dependent dopamine transporter,Slc6a3,6.93,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
brinzolamide,Delta carbonic anhydrase,ca1,6.93,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
chlorpromazine,D(1B) dopamine receptor,DRD5,6.93,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlorpromazine,Adenylate cyclase,Adcy1|Adcy3|Adcy2|Adcy4|Adcy8|Adcy6|Adcy5,6.93,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
flufenamic acid,Prostaglandin G/H synthase 2,PTGS2,6.93,IC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
methazolamide,Carbonic anhydrase,,6.93,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
trazodone,Alpha-1A adrenergic receptor,Adra1a,6.93,IC50,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
zonisamide,Carbonic anhydrase 7,CA7,6.93,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
terazosin,Alpha-2B adrenergic receptor,ADRA2B,6.93,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
benzylsulfamide,Carbonic anhydrase 1,CA1,6.93,Ki,NS(=O)(=O)C1=CC=C(NCC2=CC=CC=C2)C=C1
apremilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",PDE4C,6.93,IC50,CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O
amiodarone,Membrane-associated progesterone receptor component 1,Pgrmc1,6.932,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
carvedilol,5-hydroxytryptamine receptor 2A,HTR2A,6.932,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
cyproheptadine,D(1A) dopamine receptor,DRD1,6.932,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
flunarizine,D(2) dopamine receptor,DRD2,6.932,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
amfetamine,Sodium-dependent dopamine transporter,SLC6A3,6.936,Ki,CC(N)CC1=CC=CC=C1
domperidone,Alpha-1D adrenergic receptor,ADRA1D,6.936,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
flunarizine,5-hydroxytryptamine receptor 2A,HTR2A,6.936,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
ebastine,Muscarinic acetylcholine receptor M4,CHRM4,6.937,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
maprotiline,Muscarinic acetylcholine receptor M5,CHRM5,6.939,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
brinzolamide,Carbonic anhydrase,NCE103,6.94,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
celecoxib,Carbonic anhydrase,,6.94,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
eszopiclone,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,6.94,Ki,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
methotrexate,Folate receptor alpha,FOLR1,6.94,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
pipamperone,D(2) dopamine receptor,DRD2,6.94,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
progesterone,Sex hormone-binding globulin,SHBG,6.94,Kd,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
protriptyline,Muscarinic acetylcholine receptor M4,CHRM4,6.94,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
zonisamide,Carbonic anhydrase,,6.94,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
imrecoxib,Prostaglandin G/H synthase 1,Ptgs1,6.94,IC50,CCCN1CC(=C(C1=O)C1=CC=C(C)C=C1)C1=CC=C(C=C1)S(C)(=O)=O
filgotinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,6.94,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
ponesimod,Sphingosine 1-phosphate receptor 3,S1PR3,6.94,EC50,CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
nortriptyline,Alpha-1B adrenergic receptor,Adra1b,6.943,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
pioglitazone,Carbonic anhydrase 2,CA2,6.943,IC50,CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1
promazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.943,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
cisapride,Alpha-2C adrenergic receptor,ADRA2C,6.947,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
arformoterol,Beta-1 adrenergic receptor,ADRB1,6.947,Kd,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1
benserazide,Zinc finger protein mex-5,mex-5,6.95,EC50,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
clomipramine,D(2) dopamine receptor,DRD2,6.95,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clomipramine,5-hydroxytryptamine receptor 6,HTR6,6.95,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clonidine,Nischarin,Nisch,6.95,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
cyclobenzaprine,Muscarinic acetylcholine receptor M1,CHRM1,6.95,IC50,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cycloguanil,Dihydrofolate reductase,DHFR,6.95,Ki,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1
cyproheptadine,D(2) dopamine receptor,Drd2,6.95,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dichlorphenamide,Carbonic anhydrase,,6.95,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dorzolamide,Carbonic anhydrase,CA2,6.95,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
pilocarpine,Muscarinic acetylcholine receptor M2,CHRM2,6.95,EC50,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
sulpiride,Carbonic anhydrase,,6.95,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
vorinostat,Histone deacetylase 1,Hdac1,6.95,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
cariprazine,5-hydroxytryptamine receptor 7,HTR7,6.95,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
entrectinib,Tyrosine-protein kinase JAK1,JAK1,6.95,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
benzatropine,Membrane-associated progesterone receptor component 1,Pgrmc1,6.951,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
cyproheptadine,D(2) dopamine receptor,DRD2,6.951,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
diphenhydramine,Muscarinic acetylcholine receptor M4,CHRM4,6.951,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
imipramine,Muscarinic acetylcholine receptor M4,CHRM4,6.951,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
guanabenz,5-hydroxytryptamine receptor 2A,HTR2A,6.951,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
cilastatin,Dipeptidase 1,DPEP1,6.959,Ki,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O
pecazine,5-hydroxytryptamine receptor 2A,HTR2A,6.959,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
nortriptyline,Muscarinic acetylcholine receptor M2,CHRM2,6.959,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
sunitinib,Platelet-derived growth factor receptor alpha,PDGFRA,6.959,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sofosbuvir,Genome polyprotein,,6.959,EC90,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
candesartan cilexetil,Type-1 angiotensin II receptor,AGTR1,6.96,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
cilastatin,Dipeptidase 1,DPEP1,6.96,Ki,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O
cycloguanil,Dihydrofolate reductase,Dhfr,6.96,IC50,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1
dasatinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,6.96,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dinoprost,Prostaglandin E2 receptor EP3 subtype,PTGER3,6.96,IC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
dobutamine,Alpha-1A adrenergic receptor,Adra1a,6.96,IC50,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
dorzolamide,Carbonic anhydrase,NCE103,6.96,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
fenoldopam,D(1B) dopamine receptor,DRD5,6.96,Ki,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
fluoxetine,5-hydroxytryptamine receptor 2C,Htr2c,6.96,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
ifenprodil,Alpha-2A adrenergic receptor,Adra2a,6.96,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
imatinib,Carbonic anhydrase 7,CA7,6.96,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indoramin,Alpha-1D adrenergic receptor,ADRA1D,6.96,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
masoprocol,Arachidonate 15-lipoxygenase,ALOX15,6.96,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
masoprocol,"Arachidonate 12-lipoxygenase, 12S-type",ALOX12,6.96,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
masoprocol,Arachidonate 15-lipoxygenase,ALOX15,6.96,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
methylphenidate,Sodium-dependent dopamine transporter,SLC6A3,6.96,Ki,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
miglitol,"Sucrase-isomaltase, intestinal",Si,6.96,IC50,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
nilotinib,Ephrin type-A receptor 3,EPHA3,6.96,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
pirenzepine,Muscarinic acetylcholine receptor,GPM3,6.96,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
sorafenib,Mitogen-activated protein kinase 1,MAPK1,6.96,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiperone,5-hydroxytryptamine receptor 7,HTR7,6.96,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Serine/threonine-protein kinase 17B,STK17B,6.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,6.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase ULK3,Ulk3,6.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase DCLK3,DCLK3,6.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Casein kinase I isoform gamma-2,CSNK1G2,6.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Histamine N-methyltransferase,Hnmt,6.96,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
tazobactam,Beta-lactamase SHV-1,bla,6.96,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
topiramate,Carbonic anhydrase,NCE103,6.96,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topiramate,Carbonic anhydrase,,6.96,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
varenicline,Neuronal acetylcholine receptor; alpha4/beta4,CHRNB4|CHRNA4,6.96,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
voglibose,Lysosomal alpha-glucosidase,Gaa,6.96,IC50,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
iloperidone,D(2) dopamine receptor,Drd2,6.96,IC50,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
thiram,Lysyl oxidase homolog 3,LOXL3,6.96,IC50,CN(C)C(=S)SSC(=S)N(C)C
alitretinoin,Retinoic acid receptor RXR-alpha,Rxra,6.96,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
vorinostat,Histone deacetylase 1/3/5/8,HDAC3|HDAC1|HDAC8|HDAC5,6.96,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
vandetanib,Tyrosine-protein kinase Lyn,LYN,6.96,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Tyrosine-protein kinase receptor Tie-1,TIE1,6.96,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Serine/threonine-protein kinase TNNI3K,TNNI3K,6.96,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Tyrosine-protein kinase Blk,BLK,6.96,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,6.96,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
axitinib,Fibroblast growth factor receptor 2,FGFR2,6.96,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Casein kinase I isoform epsilon,CSNK1E,6.96,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Mitogen-activated protein kinase kinase kinase 4,MAP3K4,6.96,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Tyrosine-protein kinase Mer,MERTK,6.96,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Serine/threonine-protein kinase 17A,STK17A,6.96,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase 24,STK24,6.96,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase SBK1,SBK1,6.96,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Myosin light chain kinase 3,MYLK3,6.96,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
cariprazine,D(4) dopamine receptor,DRD4,6.96,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
midostaurin,Platelet-derived growth factor receptor beta,PDGFRB,6.96,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,3-phosphoinositide-dependent protein kinase 1,PDPK1,6.96,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,G protein-coupled receptor kinase 4,GRK4,6.96,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
dacomitinib,Proto-oncogene tyrosine-protein kinase Src,SRC,6.96,IC50,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1
osilodrostat,"Cytochrome P450 11B2, mitochondrial",Cyp11b2,6.96,IC50,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12
cisapride,Membrane-associated progesterone receptor component 1,Pgrmc1,6.963,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
dosulepin,Muscarinic acetylcholine receptor M2,CHRM2,6.963,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
thioridazine,5-hydroxytryptamine receptor 1B,HTR1B,6.963,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
sertraline,Alpha-2A adrenergic receptor,ADRA2A,6.965,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
diphenidol,Sigma non-opioid intracellular receptor 1,SIGMAR1,6.967,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
cyclobenzaprine,Sodium-dependent serotonin transporter,SLC6A4,6.967,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
loxapine,Alpha-2B adrenergic receptor,ADRA2B,6.967,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
methysergide,5-hydroxytryptamine receptor 1B,Htr1b,6.967,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
acetazolamide,Carbonic anhydrase 1; GH09688p,CAH1,6.97,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
bendamustine,Histone deacetylase 8,HDAC8,6.97,IC50,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
carbenoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 1,Hsd11b1,6.97,IC50,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O
celecoxib,Carbonic anhydrase,NCE103,6.97,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cocaine,Transporter,Slc6a2,6.97,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
fenfluramine,Sodium-dependent serotonin transporter,Slc6a4,6.97,EC50,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
isradipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,6.97,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
ketanserin,Potassium voltage-gated channel subfamily H member 2,KCNH2,6.97,IC50,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
loratadine,Histamine H1 receptor,HRH1,6.97,Ki,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
methotrexate,Folate receptor beta,FOLR2,6.97,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
minoxidil,ATP-sensitive inward rectifier potassium channel 1,KCNJ1,6.97,IC50,NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1
morphine,Kappa-type opioid receptor,OPRK1,6.97,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
pilocarpine,Muscarinic acetylcholine receptor M3,CHRM3,6.97,EC50,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
valdecoxib,Carbonic anhydrase 14,CA14,6.97,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
zonisamide,Carbonic anhydrase,NCE103,6.97,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
etoxadrol,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,6.97,Ki,CC[C@@]1(OC[C@@H](O1)[C@@H]1CCCCN1)C1=CC=CC=C1
prazosin,Alpha-2A adrenergic receptor,ADRA2A,6.97,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
plerixafor,C-X-C chemokine receptor type 4,Cxcr4,6.97,IC50,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
fedratinib,Tyrosine-protein kinase JAK1,JAK1,6.97,IC50,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
lumateperone,D(4) dopamine receptor,DRD4,6.97,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
raloxifene,Alpha-2C adrenergic receptor,ADRA2C,6.971,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
guanabenz,5-hydroxytryptamine receptor 2C,HTR2C,6.971,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
cyproheptadine,Alpha-2A adrenergic receptor,ADRA2A,6.975,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
desipramine,5-hydroxytryptamine receptor 1B,HTR1B,6.975,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
fluorometholone,Progesterone receptor,PGR,6.975,Ki,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12
methapyrilene,Sodium-dependent serotonin transporter,SLC6A4,6.975,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
trazodone,5-hydroxytryptamine receptor 1D,HTR1D,6.975,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
lysergide,D(2) dopamine receptor,DRD2,6.979,EC50,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
melperone,D(2) dopamine receptor,DRD2,6.979,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
olanzapine,5-hydroxytryptamine receptor 7,HTR7,6.979,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
perphenazine,Alpha-2B adrenergic receptor,ADRA2B,6.979,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
verapamil,5-hydroxytryptamine receptor 2B,HTR2B,6.979,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
betaxolol,Beta-2 adrenergic receptor,Adrb2,6.98,Kd,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
clebopride,5-hydroxytryptamine receptor 4,HTR4,6.98,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
clebopride,5-hydroxytryptamine receptor 4,Htr4,6.98,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
doxepin,5-hydroxytryptamine receptor 6,HTR6,6.98,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
ethoxzolamide,Carbonic anhydrase,CA2,6.98,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
mesoridazine,5-hydroxytryptamine receptor 1A,HTR1A,6.98,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
metoclopramide,D(2) dopamine receptor,Drd2,6.98,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
practolol,Beta-1 adrenergic receptor,ADRB1,6.98,Kd,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
ambrisentan,Endothelin B receptor,EDNRB,6.98,Ki,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
ethylestrenol,Muscarinic acetylcholine receptor M2,CHRM2,6.983,Ki,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
nintedanib,Vascular endothelial growth factor receptor 1,FLT1,6.983,IC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
cinnarizine,5-hydroxytryptamine receptor 2A,HTR2A,6.987,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,14-alpha sterol demethylase,cyp51B,6.99,Kd,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
dichlorphenamide,Carbonic anhydrase,NCE103,6.99,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
eszopiclone,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,6.99,Ki,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
hesperetin,Carbonic anhydrase 4,CA4,6.99,Ki,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
mafenide,Carbonic anhydrase 9,CA9,6.99,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
mesoridazine,D(1A) dopamine receptor,DRD1,6.99,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
mianserin,5-hydroxytryptamine receptor 1D,HTR1D,6.99,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
zonisamide,Carbonic anhydrase 2,CA2,6.99,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
aripiprazole,Alpha-2B adrenergic receptor,ADRA2B,6.991,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
droperidol,Alpha-2B adrenergic receptor,ADRA2B,6.996,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
adenosine,Adenosine receptor A3,Adora3,7,Ki,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
adenosine phosphate,Proto-oncogene tyrosine-protein kinase Src,SRC,7,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
alizapride,Alpha-2C adrenergic receptor,ADRA2C,7,Ki,COC1=CC2=C(C=C1C(=O)NCC1CCCN1CC=C)N=NN2
alprostadil,Prostaglandin E2 receptor EP1 subtype,Ptger1,7,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
alvimopan,Kappa-type opioid receptor,OPRK1,7,Ki,C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1
amiodarone,Sigma non-opioid intracellular receptor 1,SIGMAR1,7,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
amitriptyline,5-hydroxytryptamine receptor 7,Htr7,7,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amlodipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,7,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
dithranol,"NAD-dependent protein deacylase sirtuin-5, mitochondrial",SIRT5,7,IC50,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2
apomorphine,5-hydroxytryptamine receptor 2C,HTR2C,7,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
apomorphine,D(1A) dopamine receptor,Drd1,7,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
aripiprazole,Histamine H1 receptor,HRH1,7,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
azelastine,Potassium voltage-gated channel subfamily H member 2,KCNH2,7,IC50,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
brivudine,"Thymidine kinase, cytosolic",TK1,7,Ki,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O
bromocriptine,5-hydroxytryptamine receptor 2A,HTR2A,7,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bromperidol,D(1A) dopamine receptor,DRD1,7,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
buspirone,D(4) dopamine receptor,DRD4,7,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
carprofen,Prostaglandin G/H synthase 2,PTGS2,7,IC50,CC(C(O)=O)C1=CC2=C(C=C1)C1=CC(Cl)=CC=C1N2
cefoxitin,Beta-lactamase,,7,Ki,CO[C@]1(NC(=O)CC2=CC=CS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O
clavulanic acid,Beta-lactamase GES-13,blaGES-13,7,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clavulanic acid,Beta-lactamase,,7,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clavulanic acid,Beta-lactamase,bla(BEL1),7,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
cytarabine,Prostatic acid phosphatase,ACPP,7,GI50,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
dasatinib,MAP kinase p38,MAPK13|MAPK12|MAPK11|MAPK14,7,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desipramine,Alpha-1A adrenergic receptor,ADRA1A,7,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
dexamfetamine,Sodium-dependent noradrenaline transporter,SLC6A2,7,Ki,C[C@H](N)CC1=CC=CC=C1
dinoprostone,Prostaglandin D2 receptor,PTGDR,7,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
dinoprostone,Prostaglandin F2-alpha receptor,Ptgfr,7,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
diphenhydramine,Muscarinic acetylcholine receptor M1,CHRM1,7,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
dorzolamide,Carbonic anhydrase 2,mtcA2,7,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
doxapram,Cytochrome P450 2D6,CYP2D6,7,IC50,CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
doxepin,5-hydroxytryptamine receptor 2C,HTR2C,7,EC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
doxepin,Alpha-2C adrenergic receptor,ADRA2C,7,IC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
efonidipine,Voltage-dependent T-type calcium channel subunit alpha-1G,Cacna1g,7,IC50,CC1=C(C(C2=CC(=CC=C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1=CC=CC=C1)C1=CC=CC=C1
eplerenone,Mineralocorticoid receptor,NR3C2,7,IC50,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13
esmolol,Beta-1 adrenergic receptor,ADRB1,7,Kd,COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1
famotidine,Histamine H2 receptor,HRH2,7,Kd,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
fasudil,Rho-associated protein kinase 1,ROCK1,7,Ki,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
fosfomycin,UDP-N-acetylglucosamine 1-carboxyvinyltransferase,murA,7,IC50,C[C@@H]1O[C@@H]1P(O)(O)=O
fulvestrant,G-protein coupled estrogen receptor 1,GPER1,7,EC50,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
gemfibrozil,Transthyretin,TTR,7,Kd,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1
haloperidol,5-hydroxytryptamine receptor 2A,HTR2A,7,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,Pol polyprotein,pol,7,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,Protease,protease,7,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ifenprodil,Potassium voltage-gated channel subfamily H member 2,KCNH2,7,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
ifenprodil,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
imipenem,Penicillin-binding protein 1,ponA,7,IC50,C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O
indapamide,Carbonic anhydrase 13,CA13,7,Kd,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
indomethacin,Aldo-keto reductase family 1 member C3,AKR1C3,7,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
indomethacin,Cyclooxygenase,Ptgs2|Ptgs1,7,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
isotretinoin,11-cis retinol dehydrogenase,RDH5,7,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
itraconazole,C-X-C chemokine receptor type 1,CXCR1,7,IC50,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ketanserin,Synaptic vesicular amine transporter,Slc18a2,7,IC50,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketoconazole,Cytochrome P450 3A4,CYP3A4,7,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ketoconazole,Lanosterol 14-alpha demethylase,ERG11,7,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lofepramine,Alpha-1A adrenergic receptor,ADRA1A,7,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
maprotiline,Muscarinic acetylcholine receptor M3,CHRM3,7,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
meclofenamic acid,Cyclooxygenase,Ptgs2|Ptgs1,7,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
methysergide,5-hydroxytryptamine receptor 5A,HTR5A,7,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
mianserin,5-hydroxytryptamine receptor 7,Htr7,7,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
miconazole,Cytochrome P450 3A4,CYP3A4,7,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miglustat,Lysosomal alpha-glucosidase,GAA,7,IC50,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
mitiglinide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,7,IC50,OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)CC1=CC=CC=C1
morphine,Delta-type opioid receptor,Oprd1,7,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
nafamostat,Transmembrane protease serine 2,TMPRSS2,7,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
nepafenac,Cyclooxygenase,Ptgs2|Ptgs1,7,IC50,NC(=O)CC1=C(N)C(=CC=C1)C(=O)C1=CC=CC=C1
nevirapine,Pol polyprotein,pol,7,IC50,CC1=CC=NC2=C1NC(=O)C1=CC=CN=C1N2C1CC1
nilotinib,Carbonic anhydrase 7,CA7,7,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nilotinib,Tyrosine-protein kinase Lyn,LYN,7,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nisoldipine,Voltage-dependent L-type calcium channel subunit alpha-1D,Cacna1d,7,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
nortriptyline,Alpha-2B adrenergic receptor,ADRA2B,7,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
novobiocin,DNA gyrase,gyrA|gyrB,7,IC50,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
olanzapine,5-hydroxytryptamine receptor 7,Htr7,7,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
perlapine,D(3) dopamine receptor,DRD3,7,Ki,CN1CCN(CC1)C1=NC2=C(CC3=CC=CC=C13)C=CC=C2
pilocarpine,Muscarinic acetylcholine receptor M5,CHRM5,7,EC50,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
pindolol,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,7,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
pipamazine,Cytochrome P450 2D6,CYP2D6,7,IC50,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
piroxicam,Cyclooxygenase,Ptgs2|Ptgs1,7,IC50,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=CC=CC=C2S1(=O)=O
proparacaine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7,Ki,CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC
protriptyline,5-hydroxytryptamine receptor 2B,HTR2B,7,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
protriptyline,Muscarinic acetylcholine receptor M3,CHRM3,7,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
pyrimethamine,Dihydrofolate reductase,DHFR,7,IC50,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
quetiapine,5-hydroxytryptamine receptor 2C,HTR2C,7,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
raltitrexed,Proton-coupled folate transporter,SLC46A1,7,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
reserpine,Multidrug resistance protein 1,ABCB1,7,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
sorafenib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfamethoxazole,Dihydrofolate reductase,,7,IC50,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
sulprostone,Prostaglandin E2 receptor EP1 subtype,PTGER1,7,Ki,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
sulprostone,Prostaglandin E2 receptor EP1 subtype,Ptger1,7,Ki,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
sunitinib,High affinity nerve growth factor receptor,NTRK1,7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Casein kinase I isoform alpha,CSNK1A1,7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Protein delta homolog 1,DLK1,7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase 12,MAP3K12,7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamoxifen,Multidrug resistance protein 1,ABCB1,7,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tazobactam,Beta-lactamase,ampC,7,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tertatolol,Beta-3 adrenergic receptor,Adrb3,7,Ki,CC(C)(C)NCC(O)COC1=C2SCCCC2=CC=C1
tertatolol,Beta-3 adrenergic receptor,Adrb3,7,Ki,CC(C)(C)NCC(O)COC1=C2SCCCC2=CC=C1
tetrabenazine,Synaptic vesicular amine transporter,SLC18A2,7,Ki,COC1=CC2=C(C=C1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
thiethylperazine,5-hydroxytryptamine receptor 2A,HTR2A,7,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thiethylperazine,5-hydroxytryptamine receptor 2B,HTR2B,7,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thiethylperazine,5-hydroxytryptamine receptor 2C,HTR2C,7,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thioridazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,7,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
thioridazine,Histamine H1 receptor,Hrh1,7,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tretinoin,11-cis retinol dehydrogenase,RDH5,7,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
tretoquinol,Adrenergic receptor beta,Adrb2|Adrb1|Adrb3,7,Ki,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
trichlormethiazide,Solute carrier family 12 member 3,SLC12A3,7,A2,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
vinblastine,Multidrug resistance protein 1,ABCB1,7,Ki,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
warfarin,Vitamin K epoxide reductase complex subunit 1,VKORC1,7,IC50,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
ziprasidone,Sodium-dependent serotonin transporter,SLC6A4,7,IC50,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
glucagon,Glucagon-like peptide 1 receptor,GLP1R,7,Ki,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
yohimbine,5-hydroxytryptamine receptor 1F,HTR1F,7,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
romidepsin,Histone deacetylase 1,HDAC1,7,IC50,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
vorinostat,Histone deacetylase,PfHDAC1,7,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
telaprevir,Lysosomal protective protein,CTSA,7,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
icatibant,B1 bradykinin receptor,BDKRB1,7,Ki,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CS1)C(=O)N[C@@H](CO)C(=O)N1CC2=C(C[C@@H]1C(=O)N1[C@H]3CCCC[C@H]3C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C2
crizotinib,Ephrin type-A receptor 2,EPHA2,7,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
hydroxyprogesterone caproate,Sex hormone-binding globulin,SHBG,7,Kd,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
ruxolitinib,Calcium/calmodulin-dependent protein kinase type II subunit gamma,CAMK2G,7,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Cyclin-G-associated kinase,GAK,7,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,7,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Tyrosine-protein kinase Srms,SRMS,7,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,7,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dihydroergocryptine,5-hydroxytryptamine receptor 7,Htr7,7,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@@H]3C[C@H]4[C@@H](CC5=CNC6=CC=CC4=C56)N(C)C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
lenvatinib,Mast/stem cell growth factor receptor Kit,KIT,7,IC50,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
climbazole,Cytochrome P450 3A4,CYP3A4,7,IC50,CC(C)(C)C(=O)C(OC1=CC=C(Cl)C=C1)N1C=CN=C1
brivaracetam,Synaptic vesicle glycoprotein 2A,Sv2a,7,IC50,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
selexipag,Prostaglandin D2 receptor,PTGDR,7,EC50,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1
obeticholic acid,G-protein coupled bile acid receptor 1,GPBAR1,7,EC50,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
midostaurin,Serine/threonine-protein kinase MARK2,MARK2,7,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,DYRK1A,7,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
enasidenib,"Isocitrate dehydrogenase [NADP], mitochondrial",IDH2,7,IC50,CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=CC=CC(=N1)C(F)(F)F
fedratinib,Serine/threonine-protein kinase RIO1,RIOK1,7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Eukaryotic translation initiation factor 2-alpha kinase 4,EIF2AK4,7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,SRSF protein kinase 2,SRPK2,7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase PknB,pknB,7,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
pralsetinib,Platelet-derived growth factor receptor beta,PDGFRB,7,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
enarodustat,Egl nine homolog 3,EGLN3,7,Ki,OC(=O)CNC(=O)C1=C2N=CNN2C(CCC2=CC=CC=C2)C=C1O
tirbanibulin,Tyrosine-protein kinase Lyn,LYN,7,IC50,C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
tirbanibulin,Tyrosine-protein kinase Lyn,LYN,7,IC50,C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
benzethonium,Muscarinic acetylcholine receptor M1,CHRM1,7.004,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
obeticholic acid,Bile acid receptor,NR1H4,7.004,EC50,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
pyrimethamine,Bifunctional dihydrofolate reductase-thymidylate synthase,,7.009,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
cefsulodin,Lethal(3)malignant brain tumor-like protein 1,L3MBTL1,7.01,IC50,NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C2=CC=CC=C2)S(O)(=O)=O)C3=O)C([O-])=O)C=C1
celecoxib,Carbonic anhydrase 13,CA13,7.01,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
ethoxzolamide,Carbonic anhydrase,NCE103,7.01,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
famotidine,Carbonic anhydrase 6,CA6,7.01,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
hexachlorophene,Estrogen receptor beta,ESR2,7.01,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
hydrochlorothiazide,Solute carrier family 12 member 3,SLC12A3,7.01,A2,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
ifenprodil,Sigma intracellular receptor 2,Tmem97,7.01,Ki,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
latanoprost,Prostaglandin F2-alpha receptor,PTGFR,7.01,Ki,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
pecazine,FAD-linked sulfhydryl oxidase ALR,GFER,7.01,AC50,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
paroxetine,Sodium-dependent dopamine transporter,Slc6a3,7.01,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
valdecoxib,Carbonic anhydrase,,7.01,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
ruboxistaurin,Serine/threonine-protein kinase TAO3,TAOK3,7.01,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
dexibuprofen,Prostaglandin G/H synthase 1,PTGS1,7.01,IC50,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
pazopanib,Discoidin domain-containing receptor 2,DDR2,7.01,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
ruxolitinib,Death-associated protein kinase 2,DAPK2,7.01,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Tyrosine-protein kinase receptor Tie-1,TIE1,7.01,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
midostaurin,Serine/threonine-protein kinase RIO2,RIOK2,7.01,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase SIK3,SIK3,7.01,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
latanoprostene bunod,Prostaglandin F2-alpha receptor,PTGFR,7.01,Ki,O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1
fedratinib,Serine/threonine-protein kinase SIK2,SIK2,7.01,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fluphenazine,Membrane-associated progesterone receptor component 1,Pgrmc1,7.013,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
nortriptyline,Muscarinic acetylcholine receptor M5,CHRM5,7.013,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
tubocurarine,Muscarinic acetylcholine receptor M2,CHRM2,7.013,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
ketotifen,Muscarinic acetylcholine receptor M1,CHRM1,7.016,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
zotepine,Alpha-2C adrenergic receptor,ADRA2C,7.016,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
astemizole,5-hydroxytryptamine receptor 3A,HTR3A,7.018,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
trazodone,5-hydroxytryptamine receptor 1A,HTR1A,7.018,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
zomepirac,Prostaglandin G/H synthase 2,PTGS2,7.018,Ki,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
benzethonium,Muscarinic acetylcholine receptor M5,CHRM5,7.018,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
tapentadol,Mu-type opioid receptor,OPRM1,7.018,Ki,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
alendronic acid,Farnesyl pyrophosphate synthase,,7.02,Ki,NCCCC(O)(P(O)(O)=O)P(O)(O)=O
astemizole,Transmembrane protein 97,TMEM97,7.02,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
bosentan,Endothelin B receptor,Ednrb,7.02,IC50,COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1
buspirone,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,7.02,IC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
cisapride,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,7.02,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cocaine,Dopamine transporter,SLC6A3,7.02,IC50,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
dapiprazole,Alpha-1A adrenergic receptor,Adra1a,7.02,IC50,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
dichlorphenamide,Carbonic anhydrase 4,CA4,7.02,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dichlorphenamide,Carbonic anhydrase 15,Ca15,7.02,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
erlotinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,7.02,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
losartan,Type-1 angiotensin II receptor,AGTR1,7.02,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
metergoline,Alpha-1A adrenergic receptor,Adra1a,7.02,IC50,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
oxacillin,Prostaglandin G/H synthase 1,PTGS1,7.02,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=CC=CC=C1
oxymorphone,Kappa-type opioid receptor,Oprk1,7.02,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
pilocarpine,Muscarinic acetylcholine receptor M1,CHRM1,7.02,EC50,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
sulfaguanidine,Prothrombin,F2,7.02,Ki,NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1
sunitinib,Ribosomal protein S6 kinase alpha-1,RPS6KA1,7.02,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ribosomal protein S6 kinase alpha-4,RPS6KA4,7.02,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase 13,MAP3K13,7.02,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tazobactam,Beta-lactamase,blaPER-2,7.02,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
yohimbine,Adenosine receptor A3,ADORA3,7.02,IC50,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
vandetanib,STE20-like serine/threonine-protein kinase,SLK,7.02,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,High affinity nerve growth factor receptor,NTRK1,7.02,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
neratinib,Eukaryotic translation initiation factor 2-alpha kinase 4,EIF2AK4,7.02,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Serine/threonine-protein kinase PLK4,PLK4,7.02,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
astemizole,Alpha-1B adrenergic receptor,Adra1b,7.022,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
cinnarizine,Alpha-2C adrenergic receptor,ADRA2C,7.022,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
ethisterone,Glucocorticoid receptor,NR3C1,7.022,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C
chidamide,Histone deacetylase 1,HDAC1,7.022,IC50,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1
risperidone,D(1B) dopamine receptor,DRD5,7.023,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
astemizole,5-hydroxytryptamine receptor 2C,HTR2C,7.027,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
quetiapine,Alpha-1A adrenergic receptor,ADRA1A,7.027,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
celecoxib,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.03,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
celecoxib,Carbonic anhydrase 6,CA6,7.03,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
disulfiram,Lysyl oxidase homolog 3,LOXL3,7.03,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
ethoxzolamide,Carbonic anhydrase 4,CA4,7.03,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
haloperidol,D(1A) dopamine receptor,DRD1,7.03,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
lysergide,5-hydroxytryptamine receptor 1E,HTR1E,7.03,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
oxprenolol,5-hydroxytryptamine receptor 1A,Htr1a,7.03,Ki,CC(C)NCC(O)COC1=C(OCC=C)C=CC=C1
pemetrexed,Proton-coupled folate transporter,SLC46A1,7.03,Ki,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
sunitinib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,7.03,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
vandetanib,Tyrosine-protein kinase receptor TYRO3,TYRO3,7.03,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
bosutinib,Wee1-like protein kinase 2,WEE2,7.03,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
choline fenofibrate,"Fatty acid-binding protein, liver",Fabp1,7.03,Kd,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O
peramivir,Neuraminidase,,7.03,IC50,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
nintedanib,Fibroblast growth factor receptor 3,FGFR3,7.03,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Cyclin-dependent kinase 17,CDK17,7.03,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Tyrosine-protein kinase JAK2,JAK2,7.03,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,7.03,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
apalutamide,Androgen receptor,Ar,7.03,Ki,CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F
dacomitinib,Tyrosine-protein kinase Lck,LCK,7.03,IC50,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1
sotorasib,GTPase KRas,KRAS,7.03,IC50,C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
medroxyprogesterone,Progesterone receptor,PGR,7.032,Ki,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
acalabrutinib,Tyrosine-protein kinase Tec,TEC,7.032,IC50,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
evocalcet,Extracellular calcium-sensing receptor,CASR,7.032,EC50,C[C@@H](N[C@H]1CCN(C1)C1=CC=C(CC(O)=O)C=C1)C1=CC=CC2=CC=CC=C12
mecillinam,Penicillin-binding protein 2,mrdA,7.035,IC50,CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O
levomilnacipran,Sodium-dependent noradrenaline transporter,SLC6A2,7.035,Ki,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1
dosulepin,Muscarinic acetylcholine receptor M5,CHRM5,7.036,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
femoxetine,Muscarinic acetylcholine receptor M1,CHRM1,7.036,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
lorcaserin,5-hydroxytryptamine receptor 2A,HTR2A,7.036,Ki,C[C@H]1CNCCC2=CC=C(Cl)C=C12
neratinib,Epidermal growth factor receptor,EGFR,7.036,IC50,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
lindane,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,7.04,IC50,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
phencyclidine,Lysosomal Pro-X carboxypeptidase,PRCP,7.04,IC50,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
rosiglitazone,Peroxisome proliferator-activated receptor gamma,PPARG,7.04,EC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
trichlormethiazide,Carbonic anhydrase 2,CA2,7.04,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
trimethoprim,Dihydrofolate reductase,DHFR,7.04,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
zoledronic acid,Carbonic anhydrase 14,CA14,7.04,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
xylometazoline,Alpha-1A adrenergic receptor,ADRA1A,7.04,Ki,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
vandetanib,Ephrin type-A receptor 8,EPHA8,7.04,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
indacaterol,Beta-1 adrenergic receptor,ADRB1,7.04,Ki,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2
bosutinib,Myotonin-protein kinase,DMPK,7.04,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
fedratinib,Serine/threonine-protein kinase RIO3,RIOK3,7.04,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase TBK1,TBK1,7.04,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tirabrutinib hydrochloride,Tyrosine-protein kinase TXK,TXK,7.04,IC50,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
vardenafil,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",PDE1A,7.041,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
glibornuride,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,7.046,Kd,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H]1[C@H](O)[C@]2(C)CC[C@H]1C2(C)C
maprotiline,Alpha-1B adrenergic receptor,Adra1b,7.046,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
mesoridazine,Muscarinic acetylcholine receptor M3,CHRM3,7.046,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
niclosamide,Cytochrome P450 2C9,CYP2C9,7.046,EC50,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
olanzapine,D(1B) dopamine receptor,DRD5,7.046,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
oxiconazole,Cytochrome P450 3A4,CYP3A4,7.046,IC50,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
mitoxantrone,Muscarinic acetylcholine receptor M4,CHRM4,7.047,Ki,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
flibanserin,5-hydroxytryptamine receptor 2B,HTR2B,7.049,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
amitriptyline,5-hydroxytryptamine receptor 6,HTR6,7.05,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
clebopride,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,7.05,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
clonidine,Alpha-1A adrenergic receptor,ADRA1A,7.05,EC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
idoxuridine,"Thymidine kinase, cytosolic",TK1,7.05,Ki,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O
propranolol,5-hydroxytryptamine receptor 1A,Htr1a,7.05,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
sunitinib,5'-AMP-activated protein kinase catalytic subunit alpha-2,PRKAA2,7.05,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tolmetin,Interleukin-8,CXCL8,7.05,IC50,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
venlafaxine,Alpha-1A adrenergic receptor,Adra1a,7.05,IC50,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
zonisamide,Carbonic anhydrase 6,CA6,7.05,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
enoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 1,Hsd11b1,7.05,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
hydroquinone,Carbonic anhydrase 2,CA2,7.05,Ki,OC1=CC=C(O)C=C1
iloperidone,5-hydroxytryptamine receptor 1B,HTR1B,7.05,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
ruboxistaurin,Serine/threonine-protein kinase 3,Stk3,7.05,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
guanabenz,Trace amine-associated receptor 1,TAAR1,7.05,EC50,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
linagliptin,Prolyl endopeptidase FAP,FAP,7.05,IC50,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1
ruxolitinib,Death-associated protein kinase 3,DAPK3,7.05,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,7.05,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,7.05,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ceritinib,Multidrug resistance protein 1,ABCB1,7.05,EC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
ceritinib,Multidrug resistance protein 1,ABCB1,7.05,EC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
tavaborole,Carbonic anhydrase 2,CAN2,7.05,Ki,OB1OCC2=C1C=CC(F)=C2
amitriptyline,D(1A) dopamine receptor,DRD1,7.051,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
paroxetine,Muscarinic acetylcholine receptor M5,CHRM5,7.051,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
benzethonium,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.051,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
idelalisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,7.051,IC50,CC[C@H](NC1=NC=NC2=C1NC=N2)C1=NC2=C(C(F)=CC=C2)C(=O)N1C1=CC=CC=C1
suloctidil,Histamine H2 receptor,HRH2,7.053,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
methysergide,Alpha-2C adrenergic receptor,ADRA2C,7.054,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
flibanserin,5-hydroxytryptamine receptor 2C,HTR2C,7.054,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
promazine,Muscarinic acetylcholine receptor M3,CHRM3,7.056,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
propafenone,Multidrug resistance protein 1,ABCB1,7.056,ED50,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
proscillaridin,Sodium/potassium-transporting ATPase subunit alpha-2,ATP1A2,7.056,IC50,C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)C2=COC(=O)C=C2)[C@H](O)[C@H](O)[C@H]1O
hexachlorophene,Mitogen-activated protein kinase 14,MAPK14,7.057,IC50,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
flupentixol,5-hydroxytryptamine receptor 2A,HTR2A,7.058,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
brinzolamide,Carbonic anhydrase 2,CAN2,7.06,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
domperidone,Alpha-1B adrenergic receptor,Adra1b,7.06,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
ethoxzolamide,Carbonic anhydrase 2,CAN2,7.06,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
levosulpiride,D(3) dopamine receptor,DRD3,7.06,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
mianserin,5-hydroxytryptamine receptor 7,HTR7,7.06,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
quetiapine,Alpha-1A adrenergic receptor,Adra1a,7.06,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
sunitinib,Serine/threonine-protein kinase PknB,pknB,7.06,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
trichlormethiazide,Carbonic anhydrase 9,CA9,7.06,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
tubocurarine,5-hydroxytryptamine receptor 3A,HTR3A,7.06,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
valdecoxib,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.06,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
ruboxistaurin,Mitogen-activated protein kinase 15,MAPK15,7.06,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vandetanib,Platelet-derived growth factor receptor beta,PDGFRB,7.06,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
nintedanib,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,7.06,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase 10,STK10,7.06,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
corticotropin,Melanocortin receptor 3,MC3R,7.06,Ki,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
midostaurin,Tyrosine-protein kinase SYK,SYK,7.06,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Tyrosine-protein kinase receptor TYRO3,TYRO3,7.06,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Tyrosine-protein kinase receptor TYRO3,TYRO3,7.06,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
quizartinib,Vascular endothelial growth factor receptor 2,KDR,7.06,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
melperone,D(3) dopamine receptor,DRD3,7.063,Ki,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
cinnarizine,D(3) dopamine receptor,DRD3,7.066,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
clomipramine,Muscarinic acetylcholine receptor M2,CHRM2,7.066,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
nortriptyline,5-hydroxytryptamine receptor 2B,HTR2B,7.066,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
varenicline,Neuronal acetylcholine receptor; alpha3/beta4,CHRNB4|CHRNA3,7.066,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
clavulanic acid,Beta-lactamase,bcl1,7.07,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
dasatinib,LIM domain kinase 2,LIMK2,7.07,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
ethoxzolamide,Delta carbonic anhydrase,ca1,7.07,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
fluoxetine,Sodium-dependent noradrenaline transporter,Slc6a2,7.07,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
masoprocol,Leukotriene B4 receptor 1,LTB4R,7.07,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
nicotine,Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3,CHRNB2|CHRNA3|CHRNB3|CHRNA6,7.07,IC50,CN1CCC[C@H]1C1=CC=CN=C1
nilotinib,Tyrosine-protein kinase FRK,FRK,7.07,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
perphenazine,Alpha-2C adrenergic receptor,ADRA2C,7.07,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
thioridazine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,7.07,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tizanidine,Alpha-2A adrenergic receptor,ADRA2A,7.07,EC50,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
varenicline,Neuronal acetylcholine receptor; alpha3/beta4,Chrna3|Chrnb4,7.07,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
vandetanib,Cyclin-G-associated kinase,GAK,7.07,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ibrutinib,Tyrosine-protein kinase ABL1,ABL1,7.07,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
midostaurin,Rhodopsin kinase,GRK1,7.07,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Tyrosine-protein kinase Blk,BLK,7.07,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
duvelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",PIK3CB,7.07,IC50,C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=C(C(Cl)=CC=C2)C(=O)N1C1=CC=CC=C1
vibegron,Beta-3 adrenergic receptor,Adrb3,7.07,EC50,O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C1=CC=CC=C1
etoperidone,5-hydroxytryptamine receptor 1A,HTR1A,7.071,Ki,CCN1C(=O)N(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)N=C1CC
ketotifen,Muscarinic acetylcholine receptor M4,CHRM4,7.075,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
ketotifen,5-hydroxytryptamine receptor 2C,HTR2C,7.076,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
nortriptyline,Muscarinic acetylcholine receptor M4,CHRM4,7.076,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
lusutrombopag,Thrombopoietin receptor,MPL,7.076,EC50,CCCCCCO[C@@H](C)C1=CC=CC(C2=CSC(NC(=O)C3=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C3)=N2)=C1OC
tiapride,D(2) dopamine receptor,DRD2,7.077,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O
acetazolamide,Delta carbonic anhydrase,ca1,7.08,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
adefovir dipivoxil,Capsid protein,HBcAg,7.08,EC50,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
carbenoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,7.08,IC50,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O
clonidine,Alpha-1B adrenergic receptor,,7.08,EC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
dexmethylphenidate,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,7.08,IC50,COC(=O)[C@@H]([C@H]1CCCCN1)C1=CC=CC=C1
dexniguldipine,Alpha-1D adrenergic receptor,Adra1d,7.08,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
mafenide,Alpha carbonic anhydrase,CA,7.08,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
methotrexate,Bifunctional dihydrofolate reductase-thymidylate synthase,,7.08,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methylphenidate,Sodium-dependent dopamine transporter,Slc6a3,7.08,IC50,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
pilocarpine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,7.08,Ki,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
tamsulosin,5-hydroxytryptamine receptor 7,HTR7,7.08,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
trazodone,5-hydroxytryptamine receptor 2B,HTR2B,7.08,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
pazopanib,Serine/threonine-protein kinase 10,STK10,7.08,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
nintedanib,Glycogen synthase kinase-3 beta,GSK3B,7.08,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,5'-AMP-activated protein kinase catalytic subunit alpha-2,PRKAA2,7.08,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Non-receptor tyrosine-protein kinase TNK1,TNK1,7.08,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
imipramine,Muscarinic acetylcholine receptor M5,CHRM5,7.081,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
sertraline,Alpha-2B adrenergic receptor,ADRA2B,7.082,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
doxepin,Muscarinic acetylcholine receptor M4,CHRM4,7.086,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
olanzapine,Alpha-2B adrenergic receptor,ADRA2B,7.086,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
thioridazine,5-hydroxytryptamine receptor 2B,HTR2B,7.086,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
fluphenazine,Alpha-2B adrenergic receptor,ADRA2B,7.087,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,Alpha-2B adrenergic receptor,ADRA2B,7.087,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
clotrimazole,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,7.089,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
acetazolamide,Carbonic anhydrase,NCE103,7.09,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
carbenoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 2,Hsd11b2,7.09,IC50,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O
oxymorphone,Delta-type opioid receptor,Oprd1,7.09,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
pancuronium,Acetylcholine receptor; alpha1/beta1/delta/gamma,CHRNA1|CHRNG|CHRNB1|CHRND,7.09,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1
pyridostigmine,Acetylcholinesterase,ache,7.09,IC50,CN(C)C(=O)OC1=C[N+](C)=CC=C1
rocuronium,Acetylcholine receptor; alpha1/beta1/delta/gamma,CHRNA1|CHRNG|CHRNB1|CHRND,7.09,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1
sunitinib,Protein-tyrosine kinase 2-beta,PTK2B,7.09,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Casein kinase II subunit alpha,CSNK2A1,7.09,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tubocurarine,Acetylcholine receptor; alpha1/beta1/delta/gamma,CHRNA1|CHRNG|CHRNB1|CHRND,7.09,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
vecuronium,Acetylcholine receptor; alpha1/beta1/delta/gamma,CHRNA1|CHRNG|CHRNB1|CHRND,7.09,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
pazopanib,Ephrin type-B receptor 6,EPHB6,7.09,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
telaprevir,NS3 protease,NS3,7.09,Ki,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
vandetanib,Serine/threonine-protein kinase 10,STK10,7.09,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,NT-3 growth factor receptor,NTRK3,7.09,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
regorafenib,Receptor-type tyrosine-protein kinase FLT3,FLT3,7.09,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Receptor-type tyrosine-protein kinase FLT3,FLT3,7.09,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
nintedanib,Protein-tyrosine kinase 2-beta,PTK2B,7.09,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Misshapen-like kinase 1,MINK1,7.09,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
quizartinib,Epithelial discoidin domain-containing receptor 1,DDR1,7.09,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fedratinib,Tyrosine-protein kinase Fgr,FGR,7.09,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
benzethonium,Muscarinic acetylcholine receptor M3,CHRM3,7.092,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
fostamatinib,Adenosine receptor A3,ADORA3,7.092,IC50,COC1=CC(NC2=NC(NC3=CC=C4OC(C)(C)C(=O)N(COP(O)(O)=O)C4=N3)=C(F)C=N2)=CC(OC)=C1OC
loxapine,Alpha-2C adrenergic receptor,ADRA2C,7.097,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
nefazodone,5-hydroxytryptamine receptor 1A,HTR1A,7.097,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nevirapine,Gag-Pol polyprotein,gag-pol,7.097,IC50,CC1=CC=NC2=C1NC(=O)C1=CC=CN=C1N2C1CC1
pregabalin,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,7.097,IC50,CC(C)C[C@H](CN)CC(O)=O
thiothixene,Alpha-2A adrenergic receptor,ADRA2A,7.097,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
brexanolone,GABA A receptor alpha-4/beta-3/delta,GABRA4|GABRB3|GABRD,7.097,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)C3CC[C@]12C
adenosine triphosphate,P2Y purinoceptor 2,P2RY2,7.1,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
adinazolam,Translocator protein,TSPO,7.1,IC50,CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
aliskiren,Renin,Ren1,7.1,IC50,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
amiodarone,Sodium channel protein type 5 subunit alpha,SCN5A,7.1,IC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
bosentan,Endothelin B receptor,EDNRB,7.1,Ki,COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1
bromfenac,Cyclooxygenase,PTGS1|PTGS2,7.1,IC50,NC1=C(C=CC=C1CC(O)=O)C(=O)C1=CC=C(Br)C=C1
bromperidol,Alpha-1A adrenergic receptor,ADRA1A,7.1,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
cabergoline,Alpha-2B adrenergic receptor,ADRA2B,7.1,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
chloroquine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.1,Ki,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
chlorpromazine,Alpha-2C adrenergic receptor,ADRA2C,7.1,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlorpromazine,D(2) dopamine receptor,DRD2,7.1,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dasatinib,Epidermal growth factor receptor,EGFR,7.1,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7.1,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dichlorphenamide,Carbonic anhydrase 6,CA6,7.1,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dichlorphenamide,Carbonic anhydrase,CA2,7.1,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dihydroergotamine,5-hydroxytryptamine receptor 1F,HTR1F,7.1,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
droxidopa,Muscarinic acetylcholine receptor M1,CHRM1,7.1,Ki,N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O
droxidopa,Muscarinic acetylcholine receptor M1,CHRM1,7.1,Ki,N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O
enprostil,Prostaglandin F2-alpha receptor,PTGFR,7.1,Ki,COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O
fluphenazine,Adenylate cyclase,Adcy1|Adcy3|Adcy2|Adcy4|Adcy8|Adcy6|Adcy5,7.1,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
histamine,Histamine H4 receptor,Hrh4,7.1,Ki,NCCC1=CN=CN1
hydroxychloroquine,Toll-like receptor 9,TLR9,7.1,IC50,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
imipramine,Alpha-2B adrenergic receptor,ADRA2B,7.1,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
metoclopramide,D(2) dopamine receptor,DRD2,7.1,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
nilotinib,Carbonic anhydrase 15,Ca15,7.1,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nisoldipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,7.1,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
orlistat,Monoacylglycerol lipase ABHD12,ABHD12,7.1,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
pindolol,5-hydroxytryptamine receptor 1B,HTR1B,7.1,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
pindolol,5-hydroxytryptamine receptor 1B,Htr1b,7.1,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
piribedil,Alpha-2A adrenergic receptor,ADRA2A,7.1,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
promethazine,Cholinesterase,BCHE,7.1,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
promethazine,Alpha-1A adrenergic receptor,Adra1a,7.1,IC50,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
pyrimethamine,Multidrug and toxin extrusion protein 1,SLC47A1,7.1,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
risperidone,Histamine H1 receptor,Hrh1,7.1,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
ritonavir,Multidrug and toxin extrusion protein 1,SLC47A1,7.1,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
rosiglitazone,Peroxisome proliferator-activated receptor alpha,Ppara,7.1,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
rosiglitazone,Peroxisome proliferator-activated receptor alpha,Ppara,7.1,IC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sunitinib,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,7.1,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrolimus,Peptidyl-prolyl cis-trans isomerase FKBP5,FKBP5,7.1,Ki,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
tamoxifen,Estrogen-related receptor gamma,ESRRG,7.1,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tazobactam,Beta-lactamase,blaSHV-72,7.1,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
thioridazine,D(1A) dopamine receptor,DRD1,7.1,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
thioridazine,5-hydroxytryptamine receptor 1A,HTR1A,7.1,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tiaprofenic acid,Prostaglandin G/H synthase 2,PTGS2,7.1,IC50,CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1
tropisetron,5-hydroxytryptamine receptor 4,Htr4,7.1,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
tubocurarine,5-hydroxytryptamine receptor 3A,Htr3a,7.1,Ki,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
tyramine,Trace amine-associated receptor 1,Taar1,7.1,EC50,NCCC1=CC=C(O)C=C1
urapidil,Alpha-1B adrenergic receptor,ADRA1B,7.1,Ki,COC1=C(C=CC=C1)N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1
sabcomeline,Muscarinic acetylcholine receptor M5,CHRM5,7.1,Ki,CO\N=C(/C#N)[C@H]1CN2CCC1CC2
xanomeline,Muscarinic acetylcholine receptor M5,CHRM5,7.1,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
crizotinib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,7.1,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,7.1,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Macrophage-stimulating protein receptor,Mst1r,7.1,IC50,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
afatinib,Cyclin-G-associated kinase,GAK,7.1,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,7.1,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Tyrosine-protein kinase Yes,YES1,7.1,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
brivaracetam,Synaptic vesicle glycoprotein 2A,SV2A,7.1,Ki,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
niraparib,Poly [ADP-ribose] polymerase 12,PARP12,7.1,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
midostaurin,Aurora kinase A,AURKA,7.1,IC50,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,SRSF protein kinase 3,SRPK3,7.1,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase PAK 2,PAK2,7.1,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Serine/threonine-protein kinase ULK2,ULK2,7.1,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
selpercatinib,Aurora kinase B,AURKB,7.1,IC50,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O
etoricoxib,Prostaglandin E2 receptor EP2 subtype,PTGER2,7.102,Ki,CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
olanzapine,Muscarinic acetylcholine receptor M2,CHRM2,7.102,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
ebastine,Sodium-dependent dopamine transporter,SLC6A3,7.106,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
diphenidol,Muscarinic acetylcholine receptor M1,CHRM1,7.108,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
mitoxantrone,Muscarinic acetylcholine receptor M2,CHRM2,7.108,Ki,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
prochlorperazine,D(1A) dopamine receptor,DRD1,7.108,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
chidamide,Histone deacetylase 10,HDAC10,7.108,IC50,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1
acetazolamide,"Carbonic anhydrase 2, isoform A; LD26647p",CAH2,7.11,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
buprenorphine,Nociceptin receptor,OPRL1,7.11,Ki,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
fasudil,Rho-associated protein kinase 2,ROCK2,7.11,Kd,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
imatinib,Carbonic anhydrase 15,Ca15,7.11,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
lidoflazine,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,7.11,Ki,CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1
lisuride,D(1A) dopamine receptor,DRD1,7.11,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
moxonidine,Nischarin,Nisch,7.11,Ki,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1
norepinephrine,Alpha-2B adrenergic receptor,Adra2b,7.11,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
sertraline,Sodium-dependent dopamine transporter,Slc6a3,7.11,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
topiramate,Carbonic anhydrase 15,Ca15,7.11,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
tranylcypromine,Amine oxidase [flavin-containing] B,Maob,7.11,IC50,N[C@@H]1C[C@H]1C1=CC=CC=C1
kainic acid,Adenosine receptor A3,ADORA3,7.11,IC50,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
quercetin,Cytochrome P450 1B1,CYP1B1,7.11,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Homeodomain-interacting protein kinase 3,HIPK3,7.11,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
tamibarotene,Retinoic acid receptor alpha,RARA,7.11,IC50,CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12
dabrafenib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,7.11,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
dabrafenib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,7.11,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
tirabrutinib hydrochloride,Receptor tyrosine-protein kinase erbB-4,ERBB4,7.11,IC50,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
alpha-Ergocryptine,5-hydroxytryptamine receptor 2C,HTR2C,7.114,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
ziprasidone,Alpha-2C adrenergic receptor,ADRA2C,7.114,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
mebhydrolin,Histamine H1 receptor,HRH1,7.119,Ki,CN1CCC2=C(C1)C1=C(C=CC=C1)N2CC1=CC=CC=C1
pecazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.119,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
ritonavir,Thromboxane-A synthase,TBXAS1,7.119,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
acetazolamide,Carbonic anhydrase,,7.12,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
aliskiren,Protease,protease,7.12,Ki,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
pentoxyverine,Muscarinic acetylcholine receptor M1,CHRM1,7.12,Ki,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1
desipramine,Histamine H1 receptor,HRH1,7.12,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
dinoprost,Prostaglandin E2 receptor EP3 subtype,Ptger3,7.12,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
imatinib,Carbonic anhydrase 9,CA9,7.12,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
mafenide,Carbonic anhydrase 7,CA7,7.12,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
norethisterone,Androgen receptor,AR,7.12,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
norethindrone acetate,Androgen receptor,AR,7.12,IC50,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
phenelzine,Amine oxidase [flavin-containing] B,Maob,7.12,IC50,NNCCC1=CC=CC=C1
pirenzepine,Muscarinic acetylcholine receptor M4,CHRM4,7.12,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
sulbactam,Beta-lactamase,bcl1,7.12,IC50,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
sunitinib,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,7.12,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
pentazocine,Kappa-type opioid receptor,OPRK1,7.12,Ki,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
boceprevir,Cathepsin L2,CTSV,7.12,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
vandetanib,Interleukin-1 receptor-associated kinase 4,IRAK4,7.12,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vandetanib,Ephrin type-B receptor 6,EPHB6,7.12,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,7.12,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
crizotinib,Aurora kinase B,AURKB,7.12,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
tofacitinib,JAK1/JAK2/TYK2,JAK2|JAK1|TYK2,7.12,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
fedratinib,Proto-oncogene tyrosine-protein kinase Src,SRC,7.12,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
pramipexole,Alpha-2A adrenergic receptor,ADRA2A,7.121,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
tibolone,Androgen receptor,Ar,7.123,Ki,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
diflunisal,Transthyretin,TTR,7.125,Kd1,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
doxepin,Muscarinic acetylcholine receptor M5,CHRM5,7.125,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
homatropine,Muscarinic acetylcholine receptor M2,CHRM2,7.125,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)C1=CC=CC=C1
loxapine,D(1B) dopamine receptor,DRD5,7.125,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
sulconazole,Sodium-dependent serotonin transporter,SLC6A4,7.125,Ki,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
thioridazine,Alpha-2C adrenergic receptor,ADRA2C,7.126,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
acetazolamide,Carbonic anhydrase,CA2,7.13,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
dexmethylphenidate,Sodium-dependent dopamine transporter,Slc6a3,7.13,Ki,COC(=O)[C@@H]([C@H]1CCCCN1)C1=CC=CC=C1
enprostil,Prostaglandin E2 receptor EP3 subtype,Ptger3,7.13,Ki,COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O
nilotinib,Platelet-derived growth factor receptor alpha,PDGFRA,7.13,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
risedronic acid,Farnesyl diphosphate synthase,FPPS,7.13,IC50,OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
alitretinoin,Retinoic acid receptor gamma,RARG,7.13,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
nalfurafine,Delta-type opioid receptor,OPRD1,7.13,EC50,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
midostaurin,cGMP-dependent protein kinase 2,PRKG2,7.13,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
aripiprazole,Alpha-2A adrenergic receptor,ADRA2A,7.131,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
quetiapine,5-hydroxytryptamine receptor 2A,HTR2A,7.131,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
apremilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,7.131,IC50,CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O
dacomitinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,7.133,IC50,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1
olanzapine,Muscarinic acetylcholine receptor M3,CHRM3,7.136,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
clomipramine,Alpha-1B adrenergic receptor,Adra1b,7.137,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
terfenadine,5-hydroxytryptamine receptor 2A,HTR2A,7.137,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
zotepine,Muscarinic acetylcholine receptor M3,CHRM3,7.137,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
brigatinib,Insulin-like growth factor 1 receptor,IGF1R,7.137,IC50,COC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3P(C)(C)=O)=N2)C=CC(=C1)N1CCC(CC1)N1CCN(C)CC1
acetazolamide,Carbonic anhydrase 15,Ca15,7.14,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
antazoline,Histamine H1 receptor,HRH1,7.14,Kd,C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1
bendamustine,Histone deacetylase 10,HDAC10,7.14,IC50,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
clotrimazole,Mycocyclosin synthase,cyp121,7.14,Kd,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
econazole,Mycocyclosin synthase,cyp121,7.14,Kd,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ifenprodil,"Glutamate receptor ionotropic, NMDA 1",Grin1,7.14,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
loratadine,Histamine H1 receptor,HRH1,7.14,Kd,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
miconazole,Mycocyclosin synthase,cyp121,7.14,Kd,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nicotine,Neuronal acetylcholine receptor subunit beta-4,Chrnb4,7.14,Ki,CN1CCC[C@H]1C1=CC=CN=C1
pregabalin,Uncharacterized protein; Voltage-dependent calcium channel alpha-2 delta subunit,CACNA2D1,7.14,IC50,CC(C)C[C@H](CN)CC(O)=O
sulfadoxine,"6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase",PF3D7_0810800,7.14,IC50,COC1=C(OC)C(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=N1
sulpiride,Carbonic anhydrase 15,Ca15,7.14,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tacrine,Acetylcholinesterase,ACHE,7.14,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
posaconazole,14-alpha sterol demethylase,cyp51B,7.14,Kd,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=CC=C(F)C=C2F)C=C1
xanomeline,Muscarinic acetylcholine receptor M4,CHRM4,7.14,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
crizotinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,7.14,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Death-associated protein kinase 1,DAPK1,7.14,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Aurora kinase A,AURKA,7.14,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Mast/stem cell growth factor receptor Kit,KIT,7.14,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Tyrosine-protein kinase TXK,TXK,7.14,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
tavaborole,Carbonic anhydrase,,7.14,Ki,OB1OCC2=C1C=CC(F)=C2
nintedanib,Tyrosine-protein kinase Fer,FER,7.14,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Calcium/calmodulin-dependent protein kinase kinase 2,CAMKK2,7.14,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Tyrosine-protein kinase Lck,LCK,7.14,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
lumateperone,Alpha-1A adrenergic receptor,ADRA1A,7.14,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
diazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,7.143,EC50,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
nefazodone,5-hydroxytryptamine receptor 2C,HTR2C,7.143,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
mianserin,Sodium-dependent noradrenaline transporter,SLC6A2,7.149,Kd,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
norethindrone acetate,Androgen receptor,Ar,7.149,Ki,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
pimozide,5-hydroxytryptamine receptor 6,HTR6,7.149,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
ivosidenib,Isocitrate dehydrogenase [NADP] cytoplasmic,IDH1,7.149,IC50,FC1=CN=CC(=C1)N([C@H](C(=O)NC1CC(F)(F)C1)C1=CC=CC=C1Cl)C(=O)[C@@H]1CCC(=O)N1C1=NC=CC(=C1)C#N
acetazolamide,Carbonic anhydrase 4,CA4,7.15,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
alizapride,D(2) dopamine receptor,DRD2,7.15,Ki,COC1=CC2=C(C=C1C(=O)NCC1CCCN1CC=C)N=NN2
captopril,Leukotriene A-4 hydrolase,LTA4H,7.15,IC50,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
cefsulodin,Beta-adrenergic receptor kinase 1,GRK2,7.15,EC50,NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C2=CC=CC=C2)S(O)(=O)=O)C3=O)C([O-])=O)C=C1
cisapride,5-hydroxytryptamine receptor 2B,HTR2B,7.15,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
clavulanic acid,Beta-lactamase,blaSCO-1,7.15,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clomipramine,Sodium-dependent serotonin transporter,Slc6a4,7.15,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clotrimazole,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,7.15,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
gabapentin,Uncharacterized protein; Voltage-dependent calcium channel alpha-2 delta subunit,CACNA2D1,7.15,IC50,NCC1(CC(O)=O)CCCCC1
methamphetamine,Trace amine-associated receptor 1,Taar1,7.15,EC50,CN[C@@H](C)CC1=CC=CC=C1
methylthioninium chloride,Amine oxidase [flavin-containing] A,MAOA,7.15,IC50,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
mianserin,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,7.15,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
neostigmine,Cholinesterase,BCHE,7.15,IC50,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
nicotine,Neuronal acetylcholine receptor; alpha2/beta4,CHRNB4|CHRNA2,7.15,Ki,CN1CCC[C@H]1C1=CC=CN=C1
nicotine,Neuronal acetylcholine receptor; alpha2/beta4,Chrna2|Chrnb4,7.15,Ki,CN1CCC[C@H]1C1=CC=CN=C1
pilocarpine,Muscarinic acetylcholine receptor M4,CHRM4,7.15,EC50,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
pregnenolone succinate,Sex hormone-binding globulin,SHBG,7.15,Kd,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)OC(=O)CCC(O)=O
proquazone,Cyclooxygenase,PTGS1|PTGS2,7.15,IC50,CC(C)N1C(=O)N=C(C2=CC=CC=C2)C2=CC=C(C)C=C12
sulfanilamide,Carbonic anhydrase 7,CA7,7.15,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
thioridazine,5-hydroxytryptamine receptor 7,HTR7,7.15,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
varenicline,Neuronal acetylcholine receptor; alpha2/beta4,Chrna2|Chrnb4,7.15,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
voglibose,"Sucrase-isomaltase, intestinal",Si,7.15,IC50,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
voglibose,Lysosomal alpha-glucosidase,GAA,7.15,IC50,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
zotepine,Sodium-dependent noradrenaline transporter,SLC6A2,7.15,IC50,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
kainic acid,"Glutamate receptor ionotropic, kainate 1",Grik1,7.15,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
triclosan,Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI,fabI,7.15,IC50,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
saxagliptin,Dipeptidyl peptidase 9,DPP9,7.15,Ki,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2
vandetanib,Proto-oncogene tyrosine-protein kinase Src,SRC,7.15,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
vilazodone,D(3) dopamine receptor,DRD3,7.15,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
vilazodone,D(3) dopamine receptor,Drd3,7.15,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
axitinib,Abelson tyrosine-protein kinase 2,ABL2,7.15,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
dolutegravir,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.15,Ki,C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12
ipidacrine,Cholinesterase,BCHE,7.15,IC50,NC1=C2CCCC2=NC2=C1CCCC2
migalastat,Alpha-galactosidase A,GLA,7.15,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
entrectinib,Activated CDC42 kinase 1,TNK2,7.15,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
elexacaftor,Cystic fibrosis transmembrane conductance regulator,CFTR,7.15,EC50,C[C@@H]1CN(C2=C(C=CC(=N2)N2C=CC(OCC(C)(C)C(F)(F)F)=N2)C(=O)NS(=O)(=O)C2=CN(C)N=C2C)C(C)(C)C1
hydralazine,Ryanodine receptor 2,Ryr2,7.152,IC50,NNC1=NN=CC2=CC=CC=C12
clozapine,Alpha-2A adrenergic receptor,ADRA2A,7.154,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cisapride,Cytochrome P450 2D6,CYP2D6,7.155,IC50,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
lofepramine,Sodium-dependent serotonin transporter,SLC6A4,7.155,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
remoxipride,D(3) dopamine receptor,DRD3,7.155,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
sulconazole,Cytochrome P450 3A4,CYP3A4,7.155,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
thiethylperazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.155,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
zopiclone,GABA-A receptor alpha-1/beta-2/gamma-3,GABRA1|GABRB2|GABRG3,7.155,Ki,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
benzethonium,Membrane-associated progesterone receptor component 1,Pgrmc1,7.155,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
acrivastine,Histamine H1 receptor,HRH1,7.16,IC50,CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC(\C=C\C(O)=O)=N1
etoposide,DNA topoisomerase 2-beta,TOP2B,7.16,IC50,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
gefitinib,Interleukin-1 receptor-associated kinase 1,IRAK1,7.16,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
lofexidine,Alpha-2C adrenergic receptor,ADRA2C,7.16,Ki,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
meclozine,Nuclear receptor subfamily 1 group I member 3,NR1I3,7.16,IC50,CC1=CC=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=C1
mirtazapine,5-hydroxytryptamine receptor 2A,HTR2A,7.16,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
mosapride,5-hydroxytryptamine receptor 4,HTR4,7.16,Ki,CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
raloxifene,5-hydroxytryptamine receptor 2B,HTR2B,7.16,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sitagliptin,Dipeptidyl peptidase 4,Dpp4,7.16,IC50,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
terguride,D(1A) dopamine receptor,Drd1,7.16,IC50,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
tolonium,Microtubule-associated protein tau,MAPT,7.16,Ki,CN(C)C1=CC2=[S+]C3=CC(N)=C(C)C=C3N=C2C=C1
tyramine,Trace amine-associated receptor 1,TAAR1,7.16,EC50,NCCC1=CC=C(O)C=C1
vandetanib,Abelson tyrosine-protein kinase 2,ABL2,7.16,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
teriflunomide,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Dhodh,7.16,IC50,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
fostamatinib,Vascular endothelial growth factor receptor 2,KDR,7.16,Kd,COC1=CC(NC2=NC(NC3=CC=C4OC(C)(C)C(=O)N(COP(O)(O)=O)C4=N3)=C(F)C=N2)=CC(OC)=C1OC
alprazolam,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,7.161,EC50,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
clemastine,Alpha-2A adrenergic receptor,ADRA2A,7.161,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clenbuterol,Beta-1 adrenergic receptor,ADRB1,7.161,Ki,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
dicycloverine,5-hydroxytryptamine receptor 2A,HTR2A,7.161,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
guanfacine,Alpha-2A adrenergic receptor,ADRA2A,7.164,EC50,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
phenylpropanolamine,Sodium-dependent dopamine transporter,SLC6A3,7.166,Ki,CC(N)C(O)C1=CC=CC=C1
diphenoxylate,Mu-type opioid receptor,OPRM1,7.167,IC50,CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1
levonorgestrel,Glucocorticoid receptor,NR3C1,7.167,Ki,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
tropicamide,Muscarinic acetylcholine receptor M1,CHRM1,7.167,Ki,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1
guanabenz,Alpha-2B adrenergic receptor,ADRA2B,7.167,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
anagliptin,Dipeptidyl peptidase 8,DPP8,7.167,IC50,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N
oxybutynin,Sodium-dependent dopamine transporter,SLC6A3,7.168,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
clavulanic acid,Beta-lactamase,blaPER-2,7.17,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
diclofenac,Prostaglandin G/H synthase 1,PTGS1,7.17,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
doxepin,Sodium-dependent serotonin transporter,SLC6A4,7.17,Kd,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
histamine,Histamine H3 receptor,Hrh3,7.17,Ki,NCCC1=CN=CN1
lindane,GABA A receptor alpha-1/beta-1/gamma-2,GABRA1|GABRB1|GABRG2,7.17,IC50,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
lofexidine,Alpha-2B adrenergic receptor,ADRA2B,7.17,Ki,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
prochlorperazine,D(4) dopamine receptor,DRD4,7.17,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
sorafenib,Tyrosine-protein kinase receptor Tie-1,TIE1,7.17,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spirapril,Angiotensin-converting enzyme,Ace,7.17,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2
sulpiride,Carbonate dehydratase,,7.17,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tiagabine,Sodium- and chloride-dependent GABA transporter 1,Slc6a1,7.17,Ki,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1
vildagliptin,Dipeptidyl peptidase 9,DPP9,7.17,Ki,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
ruxolitinib,Serine/threonine-protein kinase DCLK1,DCLK1,7.17,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ketoconazole,"Cytochrome P450 11B2, mitochondrial",CYP11B2,7.174,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
lisuride,Alpha-1B adrenergic receptor,Adra1b,7.174,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
lofepramine,Muscarinic acetylcholine receptor M1,CHRM1,7.174,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
chidamide,Histone deacetylase 3,HDAC3,7.174,IC50,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1
brexpiprazole,Beta-2 adrenergic receptor,ADRB2,7.174,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
brigatinib,Epidermal growth factor receptor,EGFR,7.174,IC50,COC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3P(C)(C)=O)=N2)C=CC(=C1)N1CCC(CC1)N1CCN(C)CC1
mianserin,5-hydroxytryptamine receptor 6,HTR6,7.175,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
zopiclone,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,7.176,Ki,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
lanreotide,Somatostatin receptor type 4,SSTR4,7.18,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
mianserin,Alpha-1B adrenergic receptor,Adra1b,7.18,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
norepinephrine,Alpha-2A adrenergic receptor,ADRA2A,7.18,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
orlistat,Lipoprotein lipase,LPL,7.18,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
orlistat,Lipoprotein lipase,LPL,7.18,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
raloxifene,C-8 sterol isomerase,ERG2,7.18,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sunitinib,Interleukin-1 receptor-associated kinase 4,IRAK4,7.18,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
valdecoxib,Carbonic anhydrase 15,Ca15,7.18,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
vandetanib,Tyrosine-protein kinase Blk,BLK,7.18,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
midostaurin,Serine/threonine-protein kinase PLK4,PLK4,7.18,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,STE20-like serine/threonine-protein kinase,SLK,7.18,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha,PIP5K1A,7.18,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Mitogen-activated protein kinase 7,MAPK7,7.18,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
iloperidone,5-hydroxytryptamine receptor 1A,HTR1A,7.181,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
apomorphine,Alpha-1D adrenergic receptor,ADRA1D,7.187,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
prochlorperazine,5-hydroxytryptamine receptor 2B,HTR2B,7.187,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
tranylcypromine,Cytochrome P450 2A6,CYP2A6,7.187,Ki,N[C@@H]1C[C@H]1C1=CC=CC=C1
darolutamide,Androgen receptor,AR,7.187,IC50,C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)[C@@H](C)O
azaribine,Orotidine 5'-phosphate decarboxylase,URA3,7.19,Ki,CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1N=CC(=O)NC1=O
chlorpromazine,D(1A) dopamine receptor,DRD1,7.19,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clomipramine,5-hydroxytryptamine receptor 2C,HTR2C,7.19,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
cocaine,Dopamine transporter,SLC6A3,7.19,IC50,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
furosemide,Carbonic anhydrase 2,CA2,7.19,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
ibudilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,7.19,IC50,CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C
imipramine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,7.19,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
ketoconazole,Cytochrome P450 51,Cyp51a1,7.19,Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
levamfetamine,Trace amine-associated receptor 1,Taar1,7.19,EC50,C[C@@H](N)CC1=CC=CC=C1
methazolamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,7.19,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methazolamide,Carbonic anhydrase 15,Ca15,7.19,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
olanzapine,Alpha-1A adrenergic receptor,Adra1a,7.19,IC50,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
ranitidine,Histamine H2 receptor,HRH2,7.19,Kd,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O
sultiame,Carbonic anhydrase 15,Ca15,7.19,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
sunitinib,Tyrosine-protein kinase Blk,BLK,7.19,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
iloperidone,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.19,IC50,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
crizotinib,Ephrin type-A receptor 6,EPHA6,7.19,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Serine/threonine-protein kinase SIK3,SIK3,7.19,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
sofosbuvir,NS5B protein,NS5B,7.19,EC50,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
nintedanib,Ribosomal protein S6 kinase alpha-3,RPS6KA3,7.19,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
fedratinib,Activated CDC42 kinase 1,TNK2,7.19,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
alosetron,5-hydroxytryptamine receptor 2B,HTR2B,7.194,Ki,CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC1=C(C)N=CN1)CC2
cyclizine,5-hydroxytryptamine receptor 2A,HTR2A,7.194,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
metoclopramide,D(2) dopamine receptor,DRD2,7.194,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
tropicamide,Muscarinic acetylcholine receptor M5,CHRM5,7.194,Ki,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1
bilastine,Histamine H1 receptor,HRH1,7.194,Ki,CCOCCN1C(=NC2=C1C=CC=C2)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1
ketoconazole,Lanosterol 14-alpha demethylase,CYP51A1,7.197,app Ki,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
almotriptan,5-hydroxytryptamine receptor 1F,HTR1F,7.2,Ki,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
amitriptyline,5-hydroxytryptamine receptor 6,Htr6,7.2,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amlodipine,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,7.2,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
amlodipine,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,7.2,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
apomorphine,Alpha-2B adrenergic receptor,ADRA2B,7.2,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
apomorphine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.2,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
aripiprazole,5-hydroxytryptamine receptor 1D,HTR1D,7.2,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
betaxolol,Beta-2 adrenergic receptor,ADRB2,7.2,Kd,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
cyamemazine,5-hydroxytryptamine receptor 7,HTR7,7.2,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
cyproheptadine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,7.2,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
darifenacin,Muscarinic acetylcholine receptor M2,Chrm2,7.2,Ki,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Myelin transcription factor 1,MYT1,7.2,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desoxycortone,Glucocorticoid receptor,NR3C1,7.2,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO
dihydroergocristine,5-hydroxytryptamine receptor 6,Htr6,7.2,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
doxepin,5-hydroxytryptamine receptor 2B,HTR2B,7.2,EC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
eletriptan,5-hydroxytryptamine receptor 1E,HTR1E,7.2,Ki,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
fluspirilene,5-hydroxytryptamine receptor 1A,HTR1A,7.2,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
histamine,Histamine H4 receptor,Hrh4,7.2,Ki,NCCC1=CN=CN1
metergoline,5-hydroxytryptamine receptor 1B,HTR1B,7.2,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
methazolamide,Carbonic anhydrase 2,CAN2,7.2,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methylergometrine,5-hydroxytryptamine receptor 1E,HTR1E,7.2,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
methysergide,5-hydroxytryptamine receptor 5A,Htr5a,7.2,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
mianserin,5-hydroxytryptamine receptor 7,Htr7,7.2,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nicorandil,Atrial natriuretic peptide receptor 1,NPR1,7.2,EC50,[O-][N+](=O)OCCNC(=O)C1=CN=CC=C1
nicotine,Acetylcholine-binding protein,,7.2,Ki,CN1CCC[C@H]1C1=CC=CN=C1
norepinephrine,Alpha-2C adrenergic receptor,ADRA2C,7.2,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
pergolide,Alpha-2C adrenergic receptor,ADRA2C,7.2,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pimozide,5-hydroxytryptamine receptor 6,Htr6,7.2,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
piribedil,Alpha-2C adrenergic receptor,ADRA2C,7.2,Ki,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
protriptyline,5-hydroxytryptamine receptor 2A,HTR2A,7.2,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
sertindole,5-hydroxytryptamine receptor 1D,HTR1D,7.2,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
solifenacin,Muscarinic acetylcholine receptor M1,CHRM1,7.2,IC50,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
solifenacin,Muscarinic acetylcholine receptor M5,CHRM5,7.2,Ki,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
spiperone,5-hydroxytryptamine receptor 7,Htr7,7.2,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Dual specificity protein kinase TTK,TTK,7.2,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 24,STK24,7.2,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Cholinesterase,Bche,7.2,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
tazarotene,Retinoic acid receptor alpha,RARA,7.2,EC50,CCOC(=O)C1=CN=C(C=C1)C#CC1=CC=C2SCCC(C)(C)C2=C1
thioridazine,5-hydroxytryptamine receptor 6,HTR6,7.2,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
thioridazine,5-hydroxytryptamine receptor 7,Htr7,7.2,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
trifluoperazine,Histamine H1 receptor,HRH1,7.2,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
tropisetron,5-hydroxytryptamine receptor 4,Htr4,7.2,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
tyramine,Trace amine-associated receptor 1,Taar1,7.2,EC50,NCCC1=CC=C(O)C=C1
zotepine,5-hydroxytryptamine receptor 1B,HTR1B,7.2,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
neridronic acid,Farnesyl pyrophosphate synthase,FDPS,7.2,Ki,NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O
xanomeline,5-hydroxytryptamine receptor 1A,HTR1A,7.2,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
dexfosfoserine,Metabotropic glutamate receptor 8,GRM8,7.2,IC50,N[C@@H](COP(O)(O)=O)C(O)=O
nintedanib,AP2-associated protein kinase 1,AAK1,7.2,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
palbociclib,Tyrosine-protein kinase JAK3,JAK3,7.2,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
aripiprazole lauroxil,5-hydroxytryptamine receptor 1D,HTR1D,7.2,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
midostaurin,NUAK family SNF1-like kinase 2,NUAK2,7.2,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,7.2,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
cefiderocol,"Peptidoglycan D,D-transpeptidase MrdA",mrdA,7.2,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
cevimeline,Muscarinic acetylcholine receptor M5,CHRM5,7.201,EC50,CC1OC2(CS1)CN1CCC2CC1
prochlorperazine,Alpha-2A adrenergic receptor,ADRA2A,7.201,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
verapamil,D(3) dopamine receptor,DRD3,7.201,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
diazepam,GABA A receptor alpha-5/beta-2/gamma-3,GABRA5|GABRB2|GABRG3,7.203,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
diazepam,GABA A receptor alpha-5/beta-3/gamma-3,GABRB3|GABRA5|GABRG3,7.203,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
oxatomide,D(3) dopamine receptor,DRD3,7.203,Ki,O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
fluspirilene,Alpha-2C adrenergic receptor,ADRA2C,7.208,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
guanabenz,5-hydroxytryptamine receptor 2B,HTR2B,7.208,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
paliperidone,5-hydroxytryptamine receptor 2B,HTR2B,7.209,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
amiodarone,C-8 sterol isomerase,ERG2,7.21,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
brinzolamide,Carbonic anhydrase 15,Ca15,7.21,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
darifenacin,Beta-2 adrenergic receptor,ADRB2,7.21,Ki,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
demeclocycline,Estrogen receptor beta,ESR2,7.21,IC50,CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(Cl)C=CC(O)=C4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
dichlorphenamide,Astrosclerin-3,,7.21,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dorzolamide,Carbonic anhydrase 15,Ca15,7.21,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
doxepin,Alpha-2B adrenergic receptor,ADRA2B,7.21,IC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
ebastine,D(2) dopamine receptor,DRD2,7.21,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
frovatriptan,5-hydroxytryptamine receptor 1A,HTR1A,7.21,Ki,CN[C@@H]1CCC2=C(C1)C1=CC(=CC=C1N2)C(N)=O
furosemide,Carbonic anhydrase 1,CA1,7.21,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
galantamine,Acetylcholinesterase,ACHE,7.21,Ki,COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1=C24
indomethacin,Prostaglandin G/H synthase 1,PTGS1,7.21,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
methazolamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.21,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
metoclopramide,D(3) dopamine receptor,Drd3,7.21,IC50,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
mianserin,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.21,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
montelukast,Uracil nucleotide/cysteinyl leukotriene receptor,Gpr17,7.21,IC50,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
oxytocin,Vasopressin V2 receptor,Avpr2,7.21,Ki,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
penfluridol,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,7.21,IC50,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F
sorafenib,Platelet-derived growth factor receptor alpha,PDGFRA,7.21,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sumatriptan,5-hydroxytryptamine receptor 1D,Htr1d,7.21,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
vidarabine,Dipeptidyl peptidase 4,DPP4,7.21,IC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
zoledronic acid,Carbonic anhydrase 2,CA2,7.21,IC50,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
bosutinib,Tyrosine-protein kinase receptor TYRO3,TYRO3,7.21,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Insulin-like growth factor 1 receptor,IGF1R,7.21,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Aurora kinase B,AURKB,7.21,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
cefiderocol,"Peptidoglycan D,D-transpeptidase FtsI",ftsI,7.21,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
enarodustat,Egl nine homolog 2,EGLN2,7.21,Ki,OC(=O)CNC(=O)C1=C2N=CNN2C(CCC2=CC=CC=C2)C=C1O
infigratinib,Fibroblast growth factor receptor 4,FGFR4,7.21,,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
aripiprazole,Histamine H1 receptor,HRH1,7.215,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
dosulepin,Muscarinic acetylcholine receptor M4,CHRM4,7.215,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
nortriptyline,D(3) dopamine receptor,DRD3,7.215,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
terconazole,Alpha-2C adrenergic receptor,ADRA2C,7.215,Ki,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
trazodone,Alpha-1B adrenergic receptor,Adra1b,7.215,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
aripiprazole lauroxil,Histamine H1 receptor,HRH1,7.215,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
acetazolamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,7.22,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Carbonic anhydrase,,7.22,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
aztreonam,AmpC,ampC,7.22,IC50,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
buflomedil,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,7.22,Ki,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
cabergoline,Alpha-1B adrenergic receptor,ADRA1B,7.22,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
cefixime,Streptokinase A,ska,7.22,EC50,NC1=NC(=CS1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
celecoxib,Cytochrome c oxidase subunit 2,MT-CO2,7.22,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorpromazine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,7.22,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dexniguldipine,Voltage-gated L-type calcium channel,Cacna1c|Cacna1d|Cacna1s,7.22,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
diclofenac,Prostaglandin G/H synthase 2,PTGS2,7.22,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dicloxacillin,Streptokinase A,ska,7.22,EC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
erlotinib,Serine/threonine-protein kinase B-raf,BRAF,7.22,IC50,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fenoterol,Beta-2 adrenergic receptor,Adrb2,7.22,IC50,CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1
imipenem,Beta-lactamase,blaPER-2,7.22,Ki,C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O
mupirocin,Isoleucine--tRNA ligase,ileS,7.22,Ki,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O
naproxen,Cyclooxygenase,Ptgs2|Ptgs1,7.22,IC50,COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O
neostigmine,Cholinesterase,BCHE,7.22,IC50,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
orlistat,Sn1-specific diacylglycerol lipase beta,DAGLB,7.22,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
pemetrexed,Folate receptor beta,FOLR2,7.22,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
phencyclidine,"Glutamate receptor ionotropic, NMDA 2C",Grin2c,7.22,Ki,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
pirenzepine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,7.22,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
protriptyline,Histamine H1 receptor,HRH1,7.22,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
reboxetine,Sodium-dependent dopamine transporter,SLC6A3,7.22,Ki,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
stavudine,Reverse transcriptase,reverse transcriptas,7.22,IC50,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
tazobactam,Beta-lactamase,blaTEM-1,7.22,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tazobactam,Beta-lactamase GES-13,blaGES-13,7.22,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
topotecan,Hypoxia-inducible factor 1-alpha,HIF1A,7.22,IC50,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
ziprasidone,5-hydroxytryptamine receptor 6,HTR6,7.22,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
bergapten,Cytochrome P450 1A1,CYP1A1,7.22,Ki,COC1=C2C=COC2=CC2=C1C=CC(=O)O2
sabcomeline,Muscarinic acetylcholine receptor M3,CHRM3,7.22,IC50,CO\N=C(/C#N)[C@H]1CN2CCC1CC2
triclosan,Carbonyl reductase [NADPH] 1,CBR1,7.22,Ki,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
velnacrine,Acetylcholinesterase,ache,7.22,IC50,NC1=C2C(O)CCCC2=NC2=CC=CC=C12
crizotinib,Serine/threonine-protein kinase PLK4,PLK4,7.22,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,Rho-associated protein kinase 1,ROCK1,7.22,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
desvenlafaxine,Alpha-1A adrenergic receptor,Adra1a,7.22,IC50,CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
ceritinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,7.22,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
nintedanib,Serine/threonine-protein kinase ULK3,ULK3,7.22,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
cefiderocol,"Peptidoglycan D,D-transpeptidase FtsI",ftsI,7.22,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
amoxapine,Alpha-1B adrenergic receptor,Adra1b,7.222,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
carvedilol,5-hydroxytryptamine receptor 2C,HTR2C,7.222,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
clozapine,Muscarinic acetylcholine receptor M4,CHRM4,7.222,EC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyclobenzaprine,Muscarinic acetylcholine receptor M2,CHRM2,7.222,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
imipramine,Muscarinic acetylcholine receptor M3,CHRM3,7.222,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
mesoridazine,Muscarinic acetylcholine receptor M5,CHRM5,7.222,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
perlapine,D(2) dopamine receptor,DRD2,7.222,Ki,CN1CCN(CC1)C1=NC2=C(CC3=CC=CC=C13)C=CC=C2
anagliptin,Dipeptidyl peptidase 9,DPP9,7.222,IC50,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N
butylphthalide,Potassium channel subfamily K member 2,KCNK2,7.222,IC50,CCCCC1OC(=O)C2=C1C=CC=C2
brexanolone,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,7.222,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)C3CC[C@]12C
iloperidone,5-hydroxytryptamine receptor 2C,HTR2C,7.227,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
benzatropine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.229,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
cyproheptadine,5-hydroxytryptamine receptor 1A,HTR1A,7.229,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
methysergide,D(3) dopamine receptor,DRD3,7.229,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
sunitinib,Vascular endothelial growth factor receptor 1,FLT1,7.229,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
brexpiprazole,Beta-1 adrenergic receptor,ADRB1,7.229,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
neratinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,7.229,IC50,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
disulfiram,Lysyl oxidase homolog 4,LOXL4,7.23,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
methacholine,Muscarinic acetylcholine receptor M2,CHRM2,7.23,Ki,CC(C[N+](C)(C)C)OC(C)=O
methacholine,Muscarinic acetylcholine receptor M2,Chrm2,7.23,Ki,CC(C[N+](C)(C)C)OC(C)=O
nalorphine,Opioid receptor,Sigmar1|Oprd1|Oprk1|Oprm1,7.23,IC50,O[C@H]1C=C[C@H]2[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
paroxetine,Transporter,NET,7.23,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
rilmenidine,Nischarin,NISCH,7.23,Ki,C1CC1C(NC1=NCCO1)C1CC1
sumatriptan,5-hydroxytryptamine 1D receptor,5htr1d,7.23,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,SRSF protein kinase 3,SRPK3,7.23,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
triclosan,Enoyl-[acyl-carrier-protein] reductase [NADPH],fabI,7.23,IC50,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
vorinostat,Histone deacetylase,HDAC1,7.23,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
paraoxon,Carbonic anhydrase 2,CA2,7.23,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
belinostat,Histone deacetylase 10,HDAC10,7.23,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
ponesimod,Sphingosine 1-phosphate receptor 5,S1PR5,7.23,EC50,CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
maprotiline,Muscarinic acetylcholine receptor M4,CHRM4,7.237,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
pecazine,Alpha-1D adrenergic receptor,ADRA1D,7.237,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
propafenone,5-hydroxytryptamine receptor 2B,HTR2B,7.237,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
brexpiprazole,5-hydroxytryptamine receptor 6,HTR6,7.237,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
acetylcholine,Neuronal acetylcholine receptor; alpha4/beta4,Chrna4|Chrnb4,7.24,Ki,CC(=O)OCC[N+](C)(C)C
celecoxib,Prostaglandin G/H synthase 2,PTGS2,7.24,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
celecoxib,Prostaglandin G/H synthase 2,PTGS2,7.24,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
clozapine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.24,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dopamine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.24,Ki,NCCC1=CC(O)=C(O)C=C1
erlotinib,Tyrosine-protein kinase ABL1,ABL1,7.24,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethoxzolamide,Carbonic anhydrase 15,Ca15,7.24,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
famotidine,Carbonic anhydrase 2,CA2,7.24,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
glycine,Olfactory receptor 51E2,OR51E2,7.24,EC50,NCC(O)=O
labetalol,Alpha-1A adrenergic receptor,Adra1a,7.24,IC50,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
oxymorphone,Kappa-type opioid receptor,OPRK1,7.24,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
sertraline,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.24,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
sorafenib,Platelet-derived growth factor receptor beta,Pdgfrb,7.24,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,7.24,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Carbonic anhydrase 9,CA9,7.24,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
verapamil,Voltage-dependent L-type calcium channel subunit alpha-1S,Cacna1s,7.24,Ki,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
pralatrexate,Proton-coupled folate transporter,SLC46A1,7.24,IC50,NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
pazopanib,Epithelial discoidin domain-containing receptor 1,DDR1,7.24,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
gepirone,D(2) dopamine receptor,DRD2,7.24,Ki,CC1(C)CC(=O)N(CCCCN2CCN(CC2)C2=NC=CC=N2)C(=O)C1
pleconaril,Protease,protease,7.24,EC50,CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C2=NOC(=N2)C(F)(F)F)=C1
nintedanib,Ribosomal protein S6 kinase alpha-2,RPS6KA2,7.24,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Serine/threonine-protein kinase 3,STK3,7.24,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
abemaciclib,Cyclin-dependent kinase 9,CDK9,7.24,IC50,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
abemaciclib,Cyclin-dependent kinase 9,CDK9,7.24,IC50,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
pralsetinib,High affinity nerve growth factor receptor,NTRK1,7.24,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
delgocitinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,7.24,IC50,C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N
aripiprazole,Alpha-1A adrenergic receptor,ADRA1A,7.244,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
benzatropine,Alpha-2C adrenergic receptor,ADRA2C,7.244,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
cyclobenzaprine,5-hydroxytryptamine receptor 2C,HTR2C,7.244,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
methylergometrine,D(3) dopamine receptor,DRD3,7.244,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
empagliflozin,Sodium/glucose cotransporter 2,SLC5A2,7.244,Kd,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1
adenosine triphosphate,P2X purinoceptor 1,P2RX1,7.25,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
bifonazole,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,7.25,Ki,C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1
blonanserin,Alpha-1A adrenergic receptor,ADRA1A,7.25,Ki,CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1
buspirone,5-hydroxytryptamine receptor 1A,HTR1A,7.25,EC50,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
chlorambucil,Disintegrin and metalloproteinase domain-containing protein 9,ADAM9,7.25,IC50,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
clomipramine,D(2) dopamine receptor,Drd2,7.25,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
cycloguanil,Dihydrofolate reductase,DHFR,7.25,Ki,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1
dexniguldipine,Alpha-1B adrenergic receptor,ADRA1B,7.25,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
dexamfetamine,Trace amine-associated receptor 1,Taar1,7.25,EC50,C[C@H](N)CC1=CC=CC=C1
donepezil,Acetylcholinesterase,ache,7.25,Ki,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
flufenamic acid,Transthyretin,TTR,7.25,Kd,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
lysergide,D(4) dopamine receptor,DRD4,7.25,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
pamidronic acid,Farnesyl pyrophosphate synthase,FDPS,7.25,Ki,NCCC(O)(P(O)(O)=O)P(O)(O)=O
pergolide,D(4) dopamine receptor,DRD4,7.25,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
quetiapine,Muscarinic acetylcholine receptor M1,CHRM1,7.25,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
sertindole,5-hydroxytryptamine receptor 1B,HTR1B,7.25,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sorafenib,5-hydroxytryptamine receptor 2B,HTR2B,7.25,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,STE20-like serine/threonine-protein kinase,SLK,7.25,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 3,STK3,7.25,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
testosterone propionate,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,7.25,IC50,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
vandetanib,Serine/threonine-protein kinase 35,STK35,7.25,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
nintedanib,Bone morphogenetic protein receptor type-2,BMPR2,7.25,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
chlorpromazine,Muscarinic acetylcholine receptor M3,CHRM3,7.251,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
nefopam,5-hydroxytryptamine receptor 2C,HTR2C,7.252,Ki,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1
terfenadine,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.252,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
zonisamide,Carbonic anhydrase 1,CA1,7.252,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
tofacitinib,JAK3/JAK1,JAK1|JAK3,7.252,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
benzatropine,Sodium-dependent dopamine transporter,SLC6A3,7.253,Kd,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
brimonidine,Alpha-2B adrenergic receptor,ADRA2B,7.26,EC50,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
dasatinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,7.26,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Tubulin alpha-1A chain,Tuba1a,7.26,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
finasteride,Steroid 5-alpha-reductase,Srd5a1|Srd5a2,7.26,Ki,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
gabapentin,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,7.26,IC50,NCC1(CC(O)=O)CCCCC1
nitroxoline,Methionine aminopeptidase 2,METAP2,7.26,IC50,OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O
nortriptyline,Alpha-1A adrenergic receptor,ADRA1A,7.26,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
pregabalin,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,7.26,IC50,CC(C)C[C@H](CN)CC(O)=O
remoxipride,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.26,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC
rotigotine,D(4) dopamine receptor,DRD4,7.26,Ki,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
selegiline,Amine oxidase [flavin-containing] B,MAOB,7.26,Ki,C[C@H](CC1=CC=CC=C1)N(C)CC#C
sunitinib,Tyrosine-protein kinase ABL1,ABL1,7.26,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ribosomal protein S6 kinase alpha-3,RPS6KA3,7.26,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Homeodomain-interacting protein kinase 1,HIPK1,7.26,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tenidap,Prostaglandin G/H synthase 1,PTGS1,7.26,IC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
eluxadoline,Kappa-type opioid receptor,OPRK1,7.26,Ki,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O
eluxadoline,Kappa-type opioid receptor,OPRK1,7.26,Ki,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O
midostaurin,U4/U6 small nuclear ribonucleoprotein Prp4,PRPF4,7.26,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase PRP4 homolog,PRPF4B,7.26,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
paliperidone,D(4) dopamine receptor,DRD4,7.265,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
loxapine,D(1A) dopamine receptor,DRD1,7.268,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
vortioxetine,5-hydroxytryptamine receptor 1D,HTR1D,7.268,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
acetazolamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.27,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
anagrelide,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,7.27,IC50,ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
diltiazem,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,7.27,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
ibudilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,7.27,IC50,CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C
lapatinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,7.27,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
lapatinib,Tubulin alpha-1A chain,Tuba1a,7.27,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
methysergide,5-hydroxytryptamine receptor 1A,Htr1a,7.27,IC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
naloxone,Delta-type opioid receptor,OPRD1,7.27,Ki,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
phenoxybenzamine,Alpha-1A adrenergic receptor,ADRA1A,7.27,IC50,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
topiramate,Carbonic anhydrase 4,CA4,7.27,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
velnacrine,Butyrylcholinesterase,BCHE,7.27,IC50,NC1=C2C(O)CCCC2=NC2=CC=CC=C12
bosutinib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,7.27,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
loxapine,Alpha-1B adrenergic receptor,ADRA1B,7.276,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
baricitinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,7.276,IC50,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
zopiclone,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,7.278,Ki,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
zopiclone,GABA A receptor alpha-5/beta-2/gamma-2,GABRG2|GABRA5|GABRB2,7.278,Ki,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
levocabastine,Histamine H1 receptor,HRH1,7.279,Ki,C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1
apomorphine,D(1A) dopamine receptor,Drd1,7.28,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
bortezomib,Proteasome subunit beta type-1,PSMB1,7.28,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
brimonidine,Alpha-2B adrenergic receptor,Adra2b,7.28,Ki,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
chlorpromazine,5-hydroxytryptamine receptor 2B,HTR2B,7.28,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clemastine,Alpha-1A adrenergic receptor,Adra1a,7.28,IC50,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clozapine,5-hydroxytryptamine receptor 3A,HTR3A,7.28,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,7.28,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Bone morphogenetic protein receptor type-1B,BMPR1B,7.28,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dorzolamide,Carbonic anhydrase 9,CA9,7.28,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
flunarizine,"Sodium channel alpha subunits; brain (Types I, II, III)",Scn1a|Scn2a|Scn3a,7.28,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
furosemide,Carbonic anhydrase 14,CA14,7.28,Ki,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
ketoconazole,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,7.28,IC50,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
nefazodone,5-hydroxytryptamine receptor 1A,Htr1a,7.28,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nefazodone,5-hydroxytryptamine receptor 1A,Htr1a,7.28,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
phencyclidine,"Glutamate receptor ionotropic, NMDA 1",Grin1,7.28,Ki,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
prednisolone,Glucocorticoid receptor,Nr3c1,7.28,IC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,Glucocorticoid receptor,Nr3c1,7.28,IC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
yohimbine,Alpha-1D adrenergic receptor,Adra1d,7.28,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
ruxolitinib,Rho-associated protein kinase 2,ROCK2,7.28,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Tyrosine-protein kinase receptor UFO,AXL,7.28,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,7.28,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Serine/threonine-protein kinase PLK4,PLK4,7.28,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,TRAF2 and NCK-interacting protein kinase,TNIK,7.28,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
lorlatinib,Tyrosine-protein kinase FRK,FRK,7.28,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
pramipexole,Alpha-2C adrenergic receptor,ADRA2C,7.282,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
diphenidol,Muscarinic acetylcholine receptor M3,CHRM3,7.284,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
clemastine,5-hydroxytryptamine receptor 2C,HTR2C,7.284,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
doxepin,Muscarinic acetylcholine receptor M3,CHRM3,7.284,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
pipamazine,5-hydroxytryptamine receptor 6,HTR6,7.284,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
promazine,5-hydroxytryptamine receptor 2C,HTR2C,7.284,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
thiothixene,Alpha-2C adrenergic receptor,ADRA2C,7.284,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
travoprost,Prostaglandin F2-alpha receptor,PTGFR,7.284,Ki,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC(=CC=C1)C(F)(F)F
acetazolamide,Astrosclerin-3,,7.29,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
clomipramine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.29,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
ciclosporin,Solute carrier organic anion transporter family member 1B1,SLCO1B1,7.29,Ki,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
glutamic acid,Excitatory amino acid transporter 3,SLC1A1,7.29,Ki,N[C@@H](CCC(O)=O)C(O)=O
levosulpiride,D(2) dopamine receptor,DRD2,7.29,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
lisinopril,Angiotensin-converting enzyme,ACE,7.29,Ki,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
methadone,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,7.29,IC50,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
milnacipran,Sodium-dependent serotonin transporter,SLC6A4,7.29,Ki,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
mitoxantrone,Serine/threonine-protein kinase pim-1,PIM1,7.29,IC50,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
zalcitabine,Reverse transcriptase/RNaseH,pol,7.29,Ki,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1
crizotinib,NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor),NPM1|ALK,7.29,IC50,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
nalfurafine,Delta-type opioid receptor,Oprd1,7.29,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
belinostat,Histone deacetylase 7,HDAC7,7.29,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
nintedanib,STE20-like serine/threonine-protein kinase,SLK,7.29,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
thiothixene,D(1A) dopamine receptor,DRD1,7.292,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
pramocaine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.292,Ki,CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1
ripasudil,Rho-associated protein kinase 1,ROCK1,7.292,IC50,C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=C1C(F)=CN=C2
lenvatinib,Platelet-derived growth factor receptor alpha,PDGFRA,7.292,IC50,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
phenmetrazine,Sodium-dependent noradrenaline transporter,SLC6A2,7.298,EC50,CC1NCCOC1C1=CC=CC=C1
acebutolol,Beta-1 adrenergic receptor,ADRB1,7.3,Ki,CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1
alprostadil,Prostaglandin D2 receptor,PTGDR,7.3,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
amoxapine,5-hydroxytryptamine receptor 6,HTR6,7.3,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
aripiprazole,D(4) dopamine receptor,Drd4,7.3,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
atenolol,Beta-1 adrenergic receptor,ADRB1,7.3,Ki,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
azelastine,Alpha-1A adrenergic receptor,ADRA1A,7.3,Ki,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
azelastine,Alpha-1B adrenergic receptor,ADRA1B,7.3,Ki,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
azelastine,Alpha-1A adrenergic receptor,Adra1a,7.3,Ki,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
baclofen,Adenosine receptor A3,ADORA3,7.3,IC50,NCC(CC(O)=O)C1=CC=C(Cl)C=C1
bexarotene,Retinoic acid receptor beta,RARB,7.3,Ki,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
brinzolamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,7.3,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
bromocriptine,5-hydroxytryptamine receptor 2B,HTR2B,7.3,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bupranolol,Beta-3 adrenergic receptor,ADRB3,7.3,Ki,CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1
cabergoline,D(4) dopamine receptor,DRD4,7.3,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
camostat,Trypsin-1,PRSS1,7.3,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
celecoxib,Prostaglandin G/H synthase 1,PTGS1,7.3,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorpromazine,Histamine H1 receptor,HRH1,7.3,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cinacalcet,Cytochrome P450 2D6,CYP2D6,7.3,IC50,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=C1C=CC=C2
clozapine,Muscarinic acetylcholine receptor M2,CHRM2,7.3,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproheptadine,5-hydroxytryptamine receptor 7,Htr7,7.3,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dabigatran etexilate,Trypsin,PRSS1|PRSS2|PRSS3,7.3,Ki,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
desloratadine,Muscarinic acetylcholine receptor M5,CHRM5,7.3,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
dorzolamide,Delta carbonic anhydrase,ca1,7.3,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
econazole,Lanosterol 14-alpha demethylase,CYP51A1,7.3,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ergotamine,5-hydroxytryptamine receptor 7,Htr7,7.3,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ergotamine,5-hydroxytryptamine receptor 1F,Htr1f,7.3,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
eszopiclone,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,7.3,Ki,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
ethinylestradiol,Androgen receptor,AR,7.3,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
ethoxzolamide,Carbonic anhydrase 13,Ca13,7.3,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
etoposide,DNA topoisomerase 2-alpha,TOP2A,7.3,IC50,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
hydroxyamfetamine,Trace amine-associated receptor 1,Taar1,7.3,EC50,CC(N)CC1=CC=C(O)C=C1
hydroxyzine,5-hydroxytryptamine receptor 2A,HTR2A,7.3,Ki,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
ibuprofen,Interleukin-8,CXCL8,7.3,IC50,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
iloprost,Prostaglandin E2 receptor EP3 subtype,PTGER3,7.3,EC50,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
imatinib,Platelet-derived growth factor receptor,PDGFRB|PDGFRA,7.3,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imipenem,Penicillin-binding protein 4,,7.3,IC50,C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O
indomethacin,Interleukin-8,CXCL8,7.3,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
irinotecan,Acetylcholinesterase,ACHE,7.3,Ki,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
fluostigmine,Liver carboxylesterase,,7.3,IC50,CC(C)OP(F)(=O)OC(C)C
ketanserin,5-hydroxytryptamine receptor 2C,Htr2c,7.3,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
loperamide,Delta-type opioid receptor,Oprd1,7.3,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
lovastatin,Hydroxycarboxylic acid receptor 2,HCAR2,7.3,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
mazindol,Sodium-dependent serotonin transporter,SLC6A4,7.3,Ki,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
meclofenamic acid,Prostaglandin G/H synthase 1,PTGS1,7.3,IC50,CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl
metoclopramide,Serotonin 3 (5-HT3) receptor,HTR3E|HTR3B|HTR3A|HTR3D|HTR3C,7.3,Kd,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
mezlocillin,Interleukin-8,CXCL8,7.3,IC50,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
naloxone,Delta-type opioid receptor,Oprd1,7.3,Kd,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
olanzapine,D(4) dopamine receptor,Drd4,7.3,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
orlistat,Platelet-activating factor acetylhydrolase,PLA2G7,7.3,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
oxymorphone,Delta-type opioid receptor,OPRD1,7.3,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
pergolide,Alpha-2A adrenergic receptor,ADRA2A,7.3,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pimozide,Voltage-dependent T-type calcium channel subunit alpha-1H,Cacna1h,7.3,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
propranolol,5-hydroxytryptamine receptor 1B,Htr1b,7.3,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
ramatroban,Prostaglandin D2 receptor 2,Ptgdr2,7.3,IC50,OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C2=CC=C(F)C=C2)C2=CC=CC=C12
ramatroban,Prostaglandin D2 receptor 2,Ptgdr2,7.3,Ki,OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C2=CC=C(F)C=C2)C2=CC=CC=C12
repaglinide,ATP-binding cassette sub-family C member 8,ABCC8,7.3,Kd,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N2CCCCC2)=C1)C(O)=O
rizatriptan,5-hydroxytryptamine receptor 1D,HTR1D,7.3,IC50,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
sirolimus,Programmed cell death protein 4,PDCD4,7.3,EC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
stavudine,Reverse transcriptase/RNaseH,pol,7.3,EC50,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
terguride,5-hydroxytryptamine receptor 2C,HTR2C,7.3,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
thioridazine,5-hydroxytryptamine receptor 2C,HTR2C,7.3,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
thioridazine,D(3) dopamine receptor,DRD3,7.3,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
thiothixene,5-hydroxytryptamine receptor 2A,HTR2A,7.3,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
thiothixene,Alpha-2B adrenergic receptor,ADRA2B,7.3,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
tolrestat,Aldo-keto reductase family 1 member B10,AKR1B10,7.3,Ki,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
vancomycin,Alpha-2A adrenergic receptor,ADRA2A,7.3,Ki,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(C=C(O)C=C3O)[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC=C(O4)C(Cl)=C1)C(O)=O)C(Cl)=C2
nicotinic acid,Hydroxycarboxylic acid receptor 2,HCAR2,7.3,Ki,OC(=O)C1=CN=CC=C1
ziprasidone,D(4) dopamine receptor,DRD4,7.3,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
zolpidem,Gamma-aminobutyric acid receptor subunit alpha-1,Gabra1,7.3,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
ruboxistaurin,Serine/threonine-protein kinase pim-1,PIM1,7.3,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
xanomeline,5-hydroxytryptamine receptor 1B,HTR1B,7.3,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
yohimbine,5-hydroxytryptamine receptor 1A,HTR1A,7.3,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
yohimbine,5-hydroxytryptamine receptor 2B,Htr2b,7.3,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
alitretinoin,Retinoic acid receptor beta,RARB,7.3,EC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
vorinostat,Histone deacetylase 10,HDAC10,7.3,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
vorinostat,HD2 type histone deacetylase HDA106; Histone deacetylase 2b; Uncharacterized protein,hda106,7.3,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
vandetanib,Ephrin type-A receptor 6,EPHA6,7.3,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ticagrelor,Equilibrative nucleoside transporter 1,SLC29A1,7.3,Ki,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1
aripiprazole lauroxil,D(4) dopamine receptor,Drd4,7.3,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
clascoterone,Androgen receptor,AR,7.3,IC50,CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO
trilaciclib,Cyclin-dependent kinase 9,CDK9,7.3,IC50,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
alendronic acid,Protein farnesyltransferase subunit beta,FNTB,7.301,IC50,NCCCC(O)(P(O)(O)=O)P(O)(O)=O
dichlorphenamide,Carbonic anhydrase 9,CA9,7.301,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dichlorphenamide,Carbonic anhydrase 12,CA12,7.301,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
econazole,Cytochrome P450 3A4,CYP3A4,7.301,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
eltanolone,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,7.301,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
metergoline,Sodium-dependent dopamine transporter,SLC6A3,7.301,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
nortriptyline,Muscarinic acetylcholine receptor M3,CHRM3,7.301,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
sufentanil,Delta-type opioid receptor,OPRD1,7.301,Ki,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
tacrine,Cholinesterase,BCHE,7.301,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
suloctidil,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.307,Ki,CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1
pentazocine,Delta-type opioid receptor,OPRD1,7.307,EC50,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
carvedilol,D(2) dopamine receptor,DRD2,7.31,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
cisapride,D(3) dopamine receptor,DRD3,7.31,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cisapride,Alpha-1D adrenergic receptor,ADRA1D,7.31,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
metoprolol,Beta-1 adrenergic receptor,Adrb1,7.31,Ki,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
metoprolol,Beta-1 adrenergic receptor,Adrb1,7.31,Ki,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
nemonapride,5-hydroxytryptamine receptor 2A,Htr2a,7.31,IC50,CNC1=CC(OC)=C(C=C1Cl)C(=O)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C
nomifensine,Sodium-dependent dopamine transporter,SLC6A3,7.31,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
prochlorperazine,Alpha-1B adrenergic receptor,Adra1b,7.31,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
sunitinib,"Myosin light chain kinase 2, skeletal/cardiac muscle",MYLK2,7.31,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Tyrosine-protein kinase receptor TYRO3,TYRO3,7.31,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase RIO2,RIOK2,7.31,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
yohimbine,Alpha-2A adrenergic receptor,ADRA2A,7.31,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
vorinostat,Histone deacetylase 9,HDAC9,7.31,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
vandetanib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,7.31,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
crizotinib,Interleukin-1 receptor-associated kinase 1,IRAK1,7.31,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
enzalutamide,Androgen receptor,AR,7.31,EC50,CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC(=C(C=C1)C#N)C(F)(F)F
nintedanib,Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha,PIP5K1A,7.31,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase 26,STK26,7.31,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
flibanserin,5-hydroxytryptamine receptor 2A,HTR2A,7.31,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
fedratinib,NUAK family SNF1-like kinase 2,NUAK2,7.31,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tibolone,Sodium-dependent serotonin transporter,SLC6A4,7.317,Ki,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
buspirone,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.319,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
cevimeline,Muscarinic acetylcholine receptor M3,CHRM3,7.319,EC50,CC1OC2(CS1)CN1CCC2CC1
diltiazem,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,7.319,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
fluspirilene,Alpha-2B adrenergic receptor,ADRA2B,7.319,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
pipamazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.319,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
stanozolol,Cytochrome P450 2C19,CYP2C19,7.319,IC50,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=NN5
ziprasidone,Alpha-2B adrenergic receptor,ADRA2B,7.319,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
paliperidone,5-hydroxytryptamine receptor 2C,HTR2C,7.319,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
venetoclax,Bcl-2-like protein 1,BCL2L1,7.319,Ki,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CC4=C(NC=C4)N=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC(=C(NCC3CCOCC3)C=C2)[N+]([O-])=O)=C(C1)C1=CC=C(Cl)C=C1
benzbromarone,Aldo-keto reductase family 1 member C1,AKR1C1,7.32,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
brinzolamide,Alpha carbonic anhydrase,CA,7.32,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
buspirone,Sigma non-opioid intracellular receptor 1,Sigmar1,7.32,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
captopril,Prothrombin,F2,7.32,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
coumarin,Carbonic anhydrase 14,CA14,7.32,Ki,O=C1OC2=CC=CC=C2C=C1
glibenclamide,Sur1-Trpm4; Sulfonylurea receptor 1 - Transient receptor potential melastatin 4,Abcc8|Trpm4,7.32,EC50,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
nalorphine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.32,IC50,O[C@H]1C=C[C@H]2[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
orlistat,Monoacylglycerol lipase ABHD6,ABHD6,7.32,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
pergolide,D(2) dopamine receptor,DRD2,7.32,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
phentolamine,Alpha-1B adrenergic receptor,ADRA1B,7.32,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
sunitinib,Ribosomal protein S6 kinase beta-1,RPS6KB1,7.32,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,NUAK family SNF1-like kinase 1,NUAK1,7.32,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
ziprasidone,Transporter,NET,7.32,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
carbaryl,Acetylcholinesterase,ace2,7.32,IC50,CNC(=O)OC1=CC=CC2=C1C=CC=C2
posaconazole,Sterol 14-alpha demethylase,CYP51,7.32,IC50,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=CC=C(F)C=C2F)C=C1
ruboxistaurin,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7.32,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
vemurafenib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,7.32,IC50,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F
tofacitinib,Tyrosine-protein kinase JAK3,Jak3,7.32,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Macrophage colony-stimulating factor 1 receptor,CSF1R,7.32,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,AP2-associated protein kinase 1,AAK1,7.32,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,G protein-coupled receptor kinase 7,GRK7,7.32,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,7.32,IC50,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
tirabrutinib hydrochloride,Tyrosine-protein kinase Tec,TEC,7.32,IC50,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
pipamperone,5-hydroxytryptamine receptor 2B,HTR2B,7.324,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
desvenlafaxine,Sodium-dependent serotonin transporter,SLC6A4,7.325,Ki,CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
bromocriptine,5-hydroxytryptamine receptor 1B,Htr1b,7.328,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
dihydroergotamine,5-hydroxytryptamine receptor 2C,HTR2C,7.328,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
flunisolide,Progesterone receptor,PGR,7.328,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
trazodone,Alpha-1D adrenergic receptor,ADRA1D,7.328,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
romidepsin,Histone deacetylase 2,HDAC2,7.328,IC50,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
dicycloverine,Muscarinic acetylcholine receptor M2,Chrm2,7.33,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
ebastine,5-hydroxytryptamine receptor 1A,HTR1A,7.33,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
ketoprofen,Prostaglandin G/H synthase 1,PTGS1,7.33,IC50,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
milnacipran,Sodium-dependent serotonin transporter,Slc6a4,7.33,IC50,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
nicotine,Neuronal acetylcholine receptor subunit alpha-3,Chrna3,7.33,Ki,CN1CCC[C@H]1C1=CC=CN=C1
nilotinib,Tyrosine-protein kinase Lck,LCK,7.33,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
topiramate,Carbonic anhydrase 13,Ca13,7.33,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topiramate,Carbonic anhydrase 13,CA13,7.33,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
ziprasidone,Histamine H1 receptor,HRH1,7.33,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
olodaterol,Beta-1 adrenergic receptor,ADRB1,7.33,Ki,COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1
upadacitinib,Tyrosine-protein kinase JAK1,JAK1,7.33,IC50,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F
infigratinib,Smoothened homolog,SMO,7.33,Ki,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
infigratinib,Smoothened homolog,SMO,7.33,Ki,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
clomipramine,Alpha-2B adrenergic receptor,ADRA2B,7.337,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
dosulepin,Sodium-dependent noradrenaline transporter,SLC6A2,7.337,Kd,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
promazine,Sodium-dependent serotonin transporter,SLC6A4,7.337,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
promazine,Muscarinic acetylcholine receptor M5,CHRM5,7.337,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
lenvatinib,Fibroblast growth factor receptor 1,FGFR1,7.337,IC50,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
acalabrutinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,7.337,IC50,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
lorlatinib,NT-3 growth factor receptor,NTRK3,7.337,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
clozapine,Muscarinic acetylcholine receptor M2,Chrm2,7.34,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
diltiazem,Voltage-dependent L-type calcium channel subunit alpha-1D,Cacna1d,7.34,IC50,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
famotidine,Carbonic anhydrase 12,CA12,7.34,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
imipramine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7.34,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
nortriptyline,Sodium-dependent serotonin transporter,SLC6A4,7.34,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
novobiocin,DNULL gyrase subunit B,gyrB,7.34,IC50,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
protriptyline,Sodium-dependent serotonin transporter,SLC6A4,7.34,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
sorafenib,Mitogen-activated protein kinase 15,MAPK15,7.34,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sultiame,Alpha carbonic anhydrase,CA,7.34,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
sunitinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,7.34,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Acetylcholinesterase,Ache,7.34,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
quercetin,5'-nucleotidase,Nt5e,7.34,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
dronabinol,Cannabinoid receptor,Cnr1|Cnr2,7.34,Ki,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
ruxolitinib,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,7.34,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
vortioxetine,Beta-1 adrenergic receptor,ADRB1,7.34,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
olaparib,Poly [ADP-ribose] polymerase 3,PARP3,7.34,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
dacomitinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,7.34,IC50,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1
fedratinib,Mast/stem cell growth factor receptor Kit,KIT,7.34,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
butenafine,Squalene monooxygenase,ERG1,7.347,IC50,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
clemastine,D(2) dopamine receptor,DRD2,7.347,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
dobutamine,Alpha-1D adrenergic receptor,ADRA1D,7.347,Ki,CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
phentolamine,Alpha-1B adrenergic receptor,Adra1b,7.347,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
trihexyphenidyl,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.347,Ki,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
alendronic acid,Farnesyl pyrophosphate synthase,FDPS,7.35,Ki,NCCCC(O)(P(O)(O)=O)P(O)(O)=O
brinzolamide,Carbonic anhydrase 4,CA4,7.35,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
celecoxib,Carbonic anhydrase 15,Ca15,7.35,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
cocaine,Sodium-dependent serotonin transporter,Slc6a4,7.35,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
conivaptan,Oxytocin receptor,Oxtr,7.35,Ki,CC1=NC2=C(N1)C1=C(C=CC=C1)N(CC2)C(=O)C1=CC=C(NC(=O)C2=C(C=CC=C2)C2=CC=CC=C2)C=C1
dasatinib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,7.35,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,7.35,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dimetindene,Muscarinic acetylcholine receptor M2,CHRM2,7.35,Ki,CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C1=CC=CC=N1
ebastine,Histamine H1 receptor,HRH1,7.35,IC50,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
haloperidol,5-hydroxytryptamine receptor 2A,Htr2a,7.35,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
naratriptan,5-hydroxytryptamine receptor 1A,HTR1A,7.35,Ki,CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1
nicotine,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,7.35,IC50,CN1CCC[C@H]1C1=CC=CN=C1
nilotinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,7.35,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
phentolamine,Alpha-1D adrenergic receptor,Adra1d,7.35,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
topiramate,Carbonic anhydrase 6,CA6,7.35,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
trazodone,5-hydroxytryptamine receptor 2A,HTR2A,7.35,Ki,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
yohimbine,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,7.35,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
pralatrexate,Dihydrofolate reductase,DHFR,7.35,Ki,NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
pazopanib,Serine/threonine-protein kinase TAO3,TAOK3,7.35,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
copanlisib,Serine/threonine-protein kinase mTOR,MTOR,7.35,IC50,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
fedratinib,Platelet-derived growth factor receptor beta,PDGFRB,7.35,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
fedratinib,Serine/threonine-protein kinase 17B,STK17B,7.35,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
nortriptyline,5-hydroxytryptamine receptor 2A,HTR2A,7.356,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
olanzapine,Histamine H2 receptor,HRH2,7.356,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
cyproheptadine,Alpha-1B adrenergic receptor,Adra1b,7.357,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
ethisterone,Androgen receptor,Ar,7.357,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C
ziprasidone,Sodium-dependent noradrenaline transporter,SLC6A2,7.357,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
aripiprazole lauroxil,D(4) dopamine receptor,DRD4,7.357,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
aripiprazole,5-hydroxytryptamine receptor 2C,HTR2C,7.36,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
buspirone,D(2) dopamine receptor,DRD2,7.36,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
eltanolone,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,7.36,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
haloperidol,Sigma intracellular receptor 2,Tmem97,7.36,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
imipramine,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,7.36,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
oxycodone,Mu-type opioid receptor,Oprm1,7.36,Ki,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
tacrine,Acetylcholine receptor subunit epsilon,CHRNE,7.36,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
atosiban,Vasopressin V1b receptor,AVPR1B,7.36,Ki,CCOC1=CC=C(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)C=C1
toliprolol,Beta-2 adrenergic receptor,ADRB2,7.36,Kd,CC(C)NCC(O)COC1=CC(C)=CC=C1
crizotinib,Serine/threonine-protein kinase 10,STK10,7.36,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
omarigliptin,Dipeptidyl peptidase 4,Dpp4,7.36,IC50,CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=C(F)C=CC(F)=C1
carvedilol,Alpha-2B adrenergic receptor,ADRA2B,7.367,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
doxepin,Alpha-1D adrenergic receptor,ADRA1D,7.367,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
ethylestrenol,Sodium-dependent serotonin transporter,SLC6A4,7.367,Ki,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
promethazine,5-hydroxytryptamine receptor 2B,HTR2B,7.367,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
acetylcholine,Acetylcholine receptor subunit delta,chrnd,7.37,Ki,CC(=O)OCC[N+](C)(C)C
aldosterone,Mineralocorticoid receptor,Nr3c2,7.37,IC50,C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3CC[C@H](C(=O)CO)[C@]3(C[C@H](O)[C@H]21)C=O
atomoxetine,Sodium-dependent serotonin transporter,Slc6a4,7.37,Ki,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
clozapine,D(1A) dopamine receptor,Drd1,7.37,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
diazepam,Cholinesterase,BCHE,7.37,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
dorzolamide,Carbonic anhydrase 4,CA4,7.37,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
dorzolamide,Carbonic anhydrase 4,CA4,7.37,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
hydrocortisone,Glucocorticoid receptor,Nr3c1,7.37,Kd,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
hydroflumethiazide,Solute carrier family 12 member 3,SLC12A3,7.37,A2,NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F
loxapine,5-hydroxytryptamine receptor 7,Htr7,7.37,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
methazolamide,Carbonic anhydrase 14,CA14,7.37,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
mianserin,Alpha-1A adrenergic receptor,ADRA1A,7.37,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
rilmenidine,Alpha-2B adrenergic receptor,ADRA2B,7.37,Ki,C1CC1C(NC1=NCCO1)C1CC1
sultiame,Carbonic anhydrase 9,CA9,7.37,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
valdecoxib,Carbonic anhydrase 2,CA2,7.37,IC50,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
valdecoxib,Carbonic anhydrase,NCE103,7.37,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
iloperidone,5-hydroxytryptamine receptor 6,HTR6,7.37,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
amitriptyline,Alpha-1B adrenergic receptor,Adra1b,7.377,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
chlorpromazine,Muscarinic acetylcholine receptor M5,CHRM5,7.377,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cyamemazine,Muscarinic acetylcholine receptor M2,CHRM2,7.377,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
imipramine,Muscarinic acetylcholine receptor M1,CHRM1,7.377,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
promazine,Muscarinic acetylcholine receptor M4,CHRM4,7.377,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
trifluoperazine,D(4) dopamine receptor,DRD4,7.377,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
clofibric acid,Peroxisome proliferator-activated receptor alpha,Ppara,7.38,EC50,CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O
desoxycortone,Sex hormone-binding globulin,SHBG,7.38,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO
dorzolamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,7.38,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
imipramine,Sodium-dependent serotonin transporter,Slc6a4,7.38,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
imipramine,Sodium-dependent dopamine transporter,Slc6a3,7.38,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
indomethacin,Peroxisome proliferator-activated receptor gamma,PPARG,7.38,Kd,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
lamivudine,Reverse transcriptase/RNaseH,pol,7.38,EC50,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
metyrapone,"Cytochrome P450 11B2, mitochondrial",CYP11B2,7.38,IC50,CC(C)(C(=O)C1=CN=CC=C1)C1=CN=CC=C1
nilotinib,Carbonic anhydrase 9,CA9,7.38,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
pemetrexed,Folate receptor alpha,FOLR1,7.38,IC50,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
progesterone,Corticosteroid-binding globulin,SERPINA6,7.38,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
sunitinib,Serine/threonine-protein kinase ULK3,ULK3,7.38,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
trimetrexate,Dihydrofolate reductase,DFR1,7.38,IC50,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
tubocurarine,Neuronal acetylcholine receptor; alpha2/beta2,CHRNB2|CHRNA2,7.38,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
xanomeline,Muscarinic acetylcholine receptor M1,CHRM1,7.38,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
nintedanib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,7.38,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Discoidin domain-containing receptor 2,DDR2,7.38,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,SRSF protein kinase 1,SRPK1,7.38,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Focal adhesion kinase 1,PTK2,7.38,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
lumateperone,D(1A) dopamine receptor,DRD1,7.38,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
tecovirimat,Envelope protein F13,C17L,7.382,EC50,FC(F)(F)C1=CC=C(C=C1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O
ebastine,D(3) dopamine receptor,DRD3,7.384,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
benzatropine,Alpha-1B adrenergic receptor,Adra1b,7.387,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
clemastine,Alpha-1B adrenergic receptor,Adra1b,7.387,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
maprotiline,5-hydroxytryptamine receptor 2C,HTR2C,7.387,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
paliperidone,D(1A) dopamine receptor,DRD1,7.387,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
fostamatinib,Tyrosine-protein kinase SYK,SYK,7.387,IC50,COC1=CC(NC2=NC(NC3=CC=C4OC(C)(C)C(=O)N(COP(O)(O)=O)C4=N3)=C(F)C=N2)=CC(OC)=C1OC
acetazolamide,Carbonic anhydrase 14,CA14,7.39,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetylcholine,Neuronal acetylcholine receptor; alpha3/beta2,Chrna3|Chrnb2,7.39,Ki,CC(=O)OCC[N+](C)(C)C
carbetocin,Vasopressin V1a receptor,AVPR1A,7.39,EC50,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
colforsin daropate,Adenylate cyclase type 1,ADCY1,7.39,IC50,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C
mafenide,Carbonic anhydrase 13,Ca13,7.39,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
orphenadrine,Muscarinic acetylcholine receptor M1,CHRM1,7.39,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
pergolide,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.39,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pergolide,Cerebral cortex alpha adrenergic receptor,ADRA1A|ADRA2A,7.39,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
physostigmine,Cholinesterase,BCHE,7.39,Ki,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
sunitinib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,7.39,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Homeodomain-interacting protein kinase 3,HIPK3,7.39,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
dronabinol,Cannabinoid receptor,CNR1|CNR2,7.39,Ki,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
lurasidone,Alpha-2A adrenergic receptor,ADRA2A,7.39,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
ruxolitinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,7.39,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
midostaurin,NUAK family SNF1-like kinase 1,NUAK1,7.39,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
quizartinib,Vascular endothelial growth factor receptor 1,FLT1,7.39,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
quizartinib,Vascular endothelial growth factor receptor 3,FLT4,7.39,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
ebastine,Alpha-2C adrenergic receptor,ADRA2C,7.397,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
methoxsalen,Cytochrome P450 1A2,CYP1A2,7.398,IC50,COC1=C2OC=CC2=CC2=C1OC(=O)C=C2
amiodarone,Cytochrome P450 2C9,CYP2C9,7.398,EC50,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
argatroban,Prothrombin,F2,7.398,Ki,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2
carvedilol,Alpha-2A adrenergic receptor,ADRA2A,7.398,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
chlorpromazine,Muscarinic acetylcholine receptor M4,CHRM4,7.398,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clomipramine,Alpha-1D adrenergic receptor,ADRA1D,7.398,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
econazole,Cytochrome P450 2C19,CYP2C19,7.398,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
pecazine,Muscarinic acetylcholine receptor M3,CHRM3,7.398,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
nitisinone,4-hydroxyphenylpyruvate dioxygenase,HPD,7.398,IC50,[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O
nortriptyline,Muscarinic acetylcholine receptor M1,CHRM1,7.398,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
olanzapine,D(1A) dopamine receptor,DRD1,7.398,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
paroxetine,Sodium-dependent noradrenaline transporter,SLC6A2,7.398,Kd,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
pergolide,5-hydroxytryptamine receptor 1B,Htr1b,7.398,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
sulpiride,Carbonic anhydrase 2,CA2,7.398,IC50,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
oxiconazole,Cytochrome P450 2C19,CYP2C19,7.398,IC50,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
acetazolamide,Carbonic anhydrase,NCE103,7.4,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
aminopicoline,"Nitric oxide synthase, inducible",NOS2,7.4,IC50,CC1=CC=NC(N)=C1
amisulpride,D(3) dopamine receptor,Drd3,7.4,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
amitriptyline,5-hydroxytryptamine receptor 2B,HTR2B,7.4,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amoxapine,5-hydroxytryptamine receptor 7,Htr7,7.4,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
apomorphine,Alpha-2C adrenergic receptor,ADRA2C,7.4,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
bexarotene,Retinoic acid receptor RXR-alpha,Rxra,7.4,EC50,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
bexarotene,Retinoic acid receptor RXR-alpha,Rxra,7.4,EC50,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
celecoxib,Prostaglandin G/H synthase 2,PTGS2,7.4,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorpromazine,5-hydroxytryptamine receptor 2C,HTR2C,7.4,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cicaprost,Prostaglandin E2 receptor EP4 subtype,PTGER4,7.4,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
clozapine,5-hydroxytryptamine receptor 7,Htr7,7.4,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproheptadine,Alpha-1A adrenergic receptor,ADRA1A,7.4,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
doxorubicin,Aurora kinase A,AURKA,7.4,IC50,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
eletriptan,5-hydroxytryptamine receptor 1A,HTR1A,7.4,Ki,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
enprostil,Prostaglandin E2 receptor EP4 subtype,PTGER4,7.4,Ki,COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O
eplerenone,Mineralocorticoid receptor,Nr3c2,7.4,IC50,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13
eplerenone,Mineralocorticoid receptor,Nr3c2,7.4,IC50,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13
erlotinib,Serine/threonine-protein kinase B-raf,Braf,7.4,IC50,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethoxzolamide,Alpha carbonic anhydrase,CA,7.4,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
glutamic acid,Metabotropic glutamate receptor 3,GRM3,7.4,Ki,N[C@@H](CCC(O)=O)C(O)=O
imatinib,Tyrosine-protein kinase Lck,LCK,7.4,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Multidrug and toxin extrusion protein 1,SLC47A1,7.4,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Tyrosine-protein kinase ABL,ABL1|ABL2,7.4,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
lumiracoxib,Prostaglandin G/H synthase 2,Ptgs2,7.4,IC50,CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1
metergoline,5-hydroxytryptamine receptor 6,HTR6,7.4,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
mianserin,Alpha-1B adrenergic receptor,ADRA1B,7.4,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
mianserin,5-hydroxytryptamine receptor 6,Htr6,7.4,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nalbuphine,Kappa-type opioid receptor,Oprk1,7.4,IC50,O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5
nicotine,Potassium voltage-gated channel subfamily D member 3,KCND3,7.4,IC50,CN1CCC[C@H]1C1=CC=CN=C1
nicotine,Potassium voltage-gated channel subfamily D member 3,Kcnd3,7.4,IC50,CN1CCC[C@H]1C1=CC=CN=C1
nitisinone,4-hydroxyphenylpyruvate dioxygenase,HPD,7.4,IC50,[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O
nitisinone,4-hydroxyphenylpyruvate dioxygenase,Hpd,7.4,IC50,[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O
norepinephrine,Alpha-1D adrenergic receptor,ADRA1D,7.4,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
pimozide,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,7.4,Kd,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pizotifen,5-hydroxytryptamine receptor 1A,HTR1A,7.4,Ki,CN1CCC(CC1)=C1C2=C(CCC3=C1C=CC=C3)SC=C2
quetiapine,Histamine H1 receptor,HRH1,7.4,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
quetiapine,Histamine H1 receptor,Hrh1,7.4,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
levisoprenaline,Beta-3 adrenergic receptor,ADRB3,7.4,EC50,CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1
risperidone,Alpha-1D adrenergic receptor,ADRA1D,7.4,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sarpogrelate,5-hydroxytryptamine receptor 2C,HTR2C,7.4,Ki,COC1=CC=CC(CCC2=C(OCC(CN(C)C)OC(=O)CCC(O)=O)C=CC=C2)=C1
spiperone,5-hydroxytryptamine receptor 1A,HTR1A,7.4,Kd,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
spironolactone,Androgen receptor,AR,7.4,Ki,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
sulpiride,Carbonic anhydrase,NCE103,7.4,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tacrine,Acetylcholinesterase,ache,7.4,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
tacrine,Acetylcholinesterase,ACHE,7.4,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
tacrine,Amine oxidase [flavin-containing] A,Maoa,7.4,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
tazarotene,Retinoic acid receptor gamma,RARG,7.4,EC50,CCOC(=O)C1=CN=C(C=C1)C#CC1=CC=C2SCCC(C)(C)C2=C1
tazobactam,Beta-lactamase,BlaGIL-1,7.4,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tazobactam,Beta-lactamase,,7.4,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
thioridazine,D(2) dopamine receptor,DRD2,7.4,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tripelennamine,Histamine H1 receptor,HRH1,7.4,IC50,CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1
atosiban,Oxytocin receptor,Oxtr,7.4,Ki,CCOC1=CC=C(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)C=C1
evans blue,Vesicular glutamate transporter 3,Slc17a8,7.4,Ki,CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O
iloperidone,5-hydroxytryptamine receptor 6,Htr6,7.4,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
xanomeline,5-hydroxytryptamine receptor 2C,HTR2C,7.4,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
dronabinol,Cannabinoid receptor 1,Cnr1,7.4,Ki,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
boceprevir,Cathepsin K,CTSK,7.4,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
teriparatide,Parathyroid hormone/parathyroid hormone-related peptide receptor,PTH1R,7.4,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
corticorelin,Corticotropin-releasing factor receptor 2,CRHR2,7.4,Kd,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)CC)C(N)=O
baricitinib,BMP-2-inducible protein kinase,BMP2K,7.4,Kd,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
midostaurin,Serine/threonine-protein kinase 3,STK3,7.4,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
entrectinib,Tyrosine-protein kinase JAK2,JAK2,7.4,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
fedratinib,Tyrosine-protein kinase ABL1,ABL1,7.4,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cefiderocol,Peptidoglycan synthase FtsI,ftsI,7.4,IC50,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
oliceridine,Nociceptin receptor,OPRL1,7.4,EC50,COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
homatropine,Muscarinic acetylcholine receptor M5,CHRM5,7.409,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)C1=CC=CC=C1
pirlindole,Amine oxidase [flavin-containing] A,MAOA,7.409,Ki,CC1=CC2=C(C=C1)N1CCNC3CCCC2=C13
quetiapine,Alpha-1B adrenergic receptor,ADRA1B,7.409,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
lenvatinib,Platelet-derived growth factor receptor beta,PDGFRB,7.409,IC50,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
aripiprazole lauroxil,5-hydroxytryptamine receptor 7,HTR7,7.409,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
ribociclib,Cyclin-dependent kinase 6,CDK6,7.409,IC50,CN(C)C(=O)C1=CC2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N1C1CCCC1
chlorpromazine,5-hydroxytryptamine receptor 7,HTR7,7.41,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clozapine,5-hydroxytryptamine receptor 1A,Htr1a,7.41,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dicoumarol,G-protein coupled receptor 35,GPR35,7.41,Ki,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
erythromycin,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.41,IC50,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
methotrexate,Pteridine reductase 1,PTR1,7.41,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mirtazapine,5-hydroxytryptamine receptor 2C,HTR2C,7.41,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
naftopidil,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7.41,Ki,COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1
olanzapine,D(3) dopamine receptor,Drd3,7.41,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
rosiglitazone,Peroxisome proliferator-activated receptor alpha,PPARA,7.41,EC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sildenafil,"Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'",PDE6C,7.41,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sunitinib,Phosphatidylinositol 5-phosphate 4-kinase type-2 beta,PIP4K2B,7.41,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tiagabine,Sodium- and chloride-dependent GABA transporter 1,Slc6a1,7.41,Ki,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1
verapamil,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,7.41,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
vinpocetine,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.41,IC50,CCOC(=O)C1=C[C@]2(CC)CCCN3CCC4=C([C@H]23)N1C1=CC=CC=C41
zotepine,D(4) dopamine receptor,DRD4,7.41,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
quercetin,Prothrombin,F2,7.41,Kd,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
crizotinib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,7.41,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
midostaurin,Eukaryotic translation initiation factor 2-alpha kinase 4,EIF2AK4,7.41,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase 4,MAP3K4,7.41,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Serine/threonine-protein kinase SIK1,SIK1,7.41,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
clomipramine,D(3) dopamine receptor,DRD3,7.412,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
aripiprazole,D(3) dopamine receptor,Drd3,7.42,IC50,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
diphenidol,Muscarinic acetylcholine receptor M4,CHRM4,7.42,Ki,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
clomipramine,Sodium-dependent noradrenaline transporter,SLC6A2,7.42,Kd,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clomipramine,Muscarinic acetylcholine receptor M5,CHRM5,7.42,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clozapine,Alpha-2B adrenergic receptor,ADRA2B,7.42,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dezocine,Mu-type opioid receptor,OPRM1,7.42,EC50,C[C@@]12CCCCC[C@@H](CC3=CC=C(O)C=C13)[C@@H]2N
dichlorphenamide,Carbonic anhydrase 2,CA2,7.42,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dichlorphenamide,Carbonic anhydrase,NCE103,7.42,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dosulepin,Muscarinic acetylcholine receptor M3,CHRM3,7.42,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
doxepin,Muscarinic acetylcholine receptor M1,CHRM1,7.42,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
flunarizine,Membrane-associated progesterone receptor component 1,Pgrmc1,7.42,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
fluphenazine enanthate,5-hydroxytryptamine receptor 6,HTR6,7.42,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
hydromorphone,Delta-type opioid receptor,OPRD1,7.42,Ki,CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CCC4=O)=CC=C5O
metergoline,Alpha-1D adrenergic receptor,ADRA1D,7.42,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
molindone,D(3) dopamine receptor,DRD3,7.42,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
nitrazepam,GABA-A receptor; anion channel,GABRA1|GABRB1|GABRA2|GABRA3|GABRA4|GABRG2,7.42,IC50,[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1
paroxetine,Muscarinic acetylcholine receptor M3,CHRM3,7.42,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
phencyclidine,Glutamate NMDA receptor,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,7.42,Ki,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
raloxifene,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.42,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
risperidone,5-hydroxytryptamine receptor 2B,HTR2B,7.42,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sunitinib,Serine/threonine-protein kinase STK11,STK11,7.42,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Astrosclerin-3,,7.42,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
eltrombopag,Thrombopoietin receptor,MPL,7.42,EC50,CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC(=CC=C2)C(O)=O)=C1O)C1=CC(C)=C(C)C=C1
nintedanib,Serine/threonine-protein kinase 3,STK3,7.42,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Fibroblast growth factor receptor 1,FGFR1,7.42,IC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
fedratinib,Tyrosine-protein kinase Fyn,FYN,7.42,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
aripiprazole,Alpha-2C adrenergic receptor,ADRA2C,7.421,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
adenosine triphosphate,Uracil nucleotide/cysteinyl leukotriene receptor,GPR17,7.43,EC50,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
amsacrine,"DNA topoisomerase I, mitochondrial",TOP1MT,7.43,IC50,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
amsacrine,DNA topoisomerase 1,TOP1,7.43,IC50,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
ciclesonide,Glucocorticoid receptor,NR3C1,7.43,Ki,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1
nilotinib,Ephrin type-A receptor 8,EPHA8,7.43,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
novobiocin,DNA gyrase subunit B,gyrB,7.43,IC50,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
progesterone,Androgen receptor,Ar,7.43,IC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
rivastigmine,Acetylcholinesterase,ACHE,7.43,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
ropinirole,D(3) dopamine receptor,DRD3,7.43,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sorafenib,Platelet-derived growth factor receptor beta,PDGFRB,7.43,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulfanilamide,Carbonic anhydrase 12,CA12,7.43,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
dronabinol,Cannabinoid receptor 1,Cnr1,7.43,Ki,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
crizotinib,BDNF/NT-3 growth factors receptor,NTRK2,7.43,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Serine/threonine-protein kinase 26,STK26,7.43,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase 33,STK33,7.43,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ibrutinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,7.43,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
nintedanib,Non-receptor tyrosine-protein kinase TYK2,TYK2,7.43,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,SRSF protein kinase 1,SRPK1,7.43,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,7.43,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
dotinurad,Solute carrier family 22 member 12,SLC22A12,7.43,IC50,C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
alprazolam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,7.432,EC50,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
cyproterone acetate,Androgen receptor,AR,7.432,IC50,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
dexniguldipine,Multidrug resistance protein 1,ABCB1,7.432,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
imipramine,Sodium-dependent noradrenaline transporter,SLC6A2,7.432,Kd,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
metergoline,D(1A) dopamine receptor,DRD1,7.432,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
orphenadrine,Muscarinic acetylcholine receptor M3,CHRM3,7.432,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
promazine,Alpha-2C adrenergic receptor,ADRA2C,7.432,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
tropicamide,Muscarinic acetylcholine receptor M2,CHRM2,7.432,Ki,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1
benzethonium,5-hydroxytryptamine receptor 2A,HTR2A,7.432,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
erdafitinib,Vascular endothelial growth factor receptor 2,KDR,7.434,IC50,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1
apomorphine,D(3) dopamine receptor,Drd3,7.44,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
brinzolamide,Carbonic anhydrase 9,CA9,7.44,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
chlorpromazine,5-hydroxytryptamine receptor 6,HTR6,7.44,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clavulanic acid,Beta-lactamase,,7.44,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clenbuterol,Beta-2 adrenergic receptor,ADRB2,7.44,Kd,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
febuxostat,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.44,EC50,CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
fluvoxamine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.44,Ki,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F
fluvoxamine,Sigma non-opioid intracellular receptor 1,Sigmar1,7.44,Ki,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F
indapamide,Carbonic anhydrase 9,CA9,7.44,Ki,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
methazolamide,Carbonic anhydrase 4,CA4,7.44,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
nilotinib,Mitogen-activated protein kinase 11,MAPK11,7.44,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
papaverine,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Pde10a,7.44,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
retinol acetate,Beta-lactoglobulin,LGB,7.44,Kd,CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
rilmenidine,Alpha-2A adrenergic receptor,ADRA2A,7.44,Ki,C1CC1C(NC1=NCCO1)C1CC1
retinol,Beta-lactoglobulin,LGB,7.44,Kd,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
iloperidone,Alpha-1A adrenergic receptor,ADRA1A,7.44,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
romidepsin,Bromodomain-containing protein 4,BRD4,7.44,IC50,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
vitamin A palmitate,Beta-lactoglobulin,LGB,7.44,Kd,CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
diamorphine,D(3) dopamine receptor,Drd3,7.44,Ki,CN1CC[C@]23[C@H]4OC5=C(OC(C)=O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4OC(C)=O)=C35
nintedanib,Serine/threonine-protein kinase RIO3,RIOK3,7.44,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,SRSF protein kinase 2,SRPK2,7.44,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Calcium/calmodulin-dependent protein kinase type II subunit delta,CAMK2D,7.44,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
bromhexine,Membrane-associated progesterone receptor component 1,Pgrmc1,7.444,Ki,CN(CC1=C(N)C(Br)=CC(Br)=C1)C1CCCCC1
clemastine,5-hydroxytryptamine receptor 6,HTR6,7.444,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clomipramine,Muscarinic acetylcholine receptor M3,CHRM3,7.444,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
cyclobenzaprine,Sodium-dependent noradrenaline transporter,SLC6A2,7.444,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
fluphenazine enanthate,D(4) dopamine receptor,DRD4,7.444,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
haloperidol,Membrane-associated progesterone receptor component 1,Pgrmc1,7.444,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
propafenone,Beta-2 adrenergic receptor,ADRB2,7.444,Ki,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
benzethonium,Muscarinic acetylcholine receptor M4,CHRM4,7.444,Ki,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
sotagliflozin,Sodium/glucose cotransporter 1,SLC5A1,7.444,IC50,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1
adiphenine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,7.45,Kd,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
clomipramine,5-hydroxytryptamine receptor 2A,HTR2A,7.45,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
doxepin,5-hydroxytryptamine receptor 2A,HTR2A,7.45,EC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
fenoldopam,Adenosine A2b receptor,Adora2b,7.45,Ki,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
medroxyprogesterone,Androgen receptor,Ar,7.45,IC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
aminobenzoic acid,Acetylcholinesterase,Ache,7.45,IC50,NC1=CC=C(C=C1)C(O)=O
reserpine,Chromaffin granule amine transporter,SLC18A1,7.45,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
terfenadine,Histamine H1 receptor,HRH1,7.45,Kd,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
zolmitriptan,5-hydroxytryptamine receptor 1F,HTR1F,7.45,Ki,CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2
rutoside,Muscarinic acetylcholine receptor M5,CHRM5,7.454,Ki,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
amitriptyline,Sodium-dependent noradrenaline transporter,SLC6A2,7.456,Kd,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
cyamemazine,Muscarinic acetylcholine receptor M5,CHRM5,7.456,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
fluphenazine,5-hydroxytryptamine receptor 2C,HTR2C,7.456,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
paroxetine,Muscarinic acetylcholine receptor M1,CHRM1,7.456,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
pipamperone,Alpha-2B adrenergic receptor,ADRA2B,7.456,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
tacrolimus,Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform,PPP3CC,7.456,Ki,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
tamoxifen,Nuclear receptor subfamily 1 group I member 2,NR1I2,7.456,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
thiothixene,Alpha-1B adrenergic receptor,ADRA1B,7.456,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
flunitrazepam,GABA-A receptor alpha-1/beta-2/gamma-3,GABRA1|GABRB2|GABRG3,7.457,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
quetiapine,Alpha-1D adrenergic receptor,ADRA1D,7.457,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
androstenedione,Sex hormone-binding globulin,SHBG,7.46,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
baclofen,GABA-B receptor,GABBR2|GABBR1,7.46,IC50,NCC(CC(O)=O)C1=CC=C(Cl)C=C1
chlorpromazine,D(1A) dopamine receptor,Drd1,7.46,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dextrothyroxine,Thyroid hormone receptor beta,Thrb,7.46,IC50,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
neostigmine,Acetylcholinesterase,Ache,7.46,IC50,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
sunitinib,Serine/threonine-protein kinase RIO1,RIOK1,7.46,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terguride,Alpha-1B adrenergic receptor,ADRA1B,7.46,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
levothyroxine,Thyroid hormone receptor beta,Thrb,7.46,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
zolpidem,Gamma-aminobutyric acid receptor subunit alpha-5,Gabra5,7.46,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
zonisamide,Carbonic anhydrase,NCE103,7.46,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
dioxadrol,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.46,Ki,C1OC(OC1C1CCCCN1)(C1=CC=CC=C1)C1=CC=CC=C1
guanabenz,Nischarin,NISCH,7.46,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
tofacitinib,JAK1/TYK2,JAK1|TYK2,7.46,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,7.46,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
fedratinib,AP2-associated protein kinase 1,AAK1,7.46,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
pralsetinib,Vascular endothelial growth factor receptor 2,KDR,7.46,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
aripiprazole,Alpha-1B adrenergic receptor,ADRA1B,7.463,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
fluphenazine,5-hydroxytryptamine receptor 6,HTR6,7.464,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
vardenafil,"Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha",PDE6A,7.465,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
rofecoxib,Prostaglandin E2 receptor EP2 subtype,PTGER2,7.466,Ki,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
amoxapine,Sodium-dependent serotonin transporter,SLC6A4,7.469,IC50,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
danazol,Progesterone receptor,PGR,7.469,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
pecazine,Alpha-1B adrenergic receptor,Adra1b,7.469,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
paroxetine,Muscarinic acetylcholine receptor M4,CHRM4,7.469,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
diquafosol,P2Y purinoceptor 2,P2RY2,7.469,EC50,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O)N1C=CC(=O)NC1=O
brexpiprazole,5-hydroxytryptamine receptor 2C,HTR2C,7.469,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
adapalene,Retinoic acid receptor beta,RARB,7.47,Ki,COC1=CC=C(C=C1C12CC3CC(CC(C3)C1)C2)C1=CC=C2C=C(C=CC2=C1)C(O)=O
amoxapine,D(4) dopamine receptor,DRD4,7.47,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
celecoxib,Alpha carbonic anhydrase,CA,7.47,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
clorazepate,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,7.47,EC50,OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O
clozapine,D(2) dopamine receptor,Drd2,7.47,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
ethoxzolamide,Carbonic anhydrase 9,CA9,7.47,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
levamfetamine,Trace amine-associated receptor 1,Taar1,7.47,EC50,C[C@@H](N)CC1=CC=CC=C1
physostigmine,Acetylcholinesterase,ache,7.47,Ki,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
vandetanib,Mast/stem cell growth factor receptor Kit,KIT,7.47,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
nintedanib,Mitogen-activated protein kinase kinase kinase 3,MAP3K3,7.47,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
fedratinib,NUAK family SNF1-like kinase 1,NUAK1,7.47,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
dasatinib,Dual specificity testis-specific protein kinase 1,TESK1,7.48,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexamethasone palmitate,Mineralocorticoid receptor,NR3C2,7.48,IC50,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
dexamethasone valerate,Mineralocorticoid receptor,NR3C2,7.48,IC50,CCCCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
dorzolamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.48,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
ethoxzolamide,Carbonic anhydrase 6,CA6,7.48,Kd,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
aminobutyric acid,Gamma-aminobutyric acid receptor subunit gamma-1,Gabrg1,7.48,IC50,NCCCC(O)=O
levocabastine,Neurotensin receptor 2,Ntsr2,7.48,Ki,C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1
molindone,D(2) dopamine receptor,Drd2,7.48,Ki,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
mycophenolic acid,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,7.48,Ki,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
oxymetazoline,Alpha-2 adrenergic receptor,Adra2b|Adra2c|Adra2a,7.48,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
paroxetine,Transporter,Slc6a2,7.48,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
sertindole,5-hydroxytryptamine receptor 1A,HTR1A,7.48,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sildenafil,"Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'",PDE6C,7.48,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sitagliptin,Dipeptidyl peptidase 4,Dpp4,7.48,IC50,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
sunitinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,7.48,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tadalafil,"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A",PDE11A,7.48,IC50,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
tolrestat,Aldose reductase,AKR1B1,7.48,IC50,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
tranylcypromine,Amine oxidase [flavin-containing] B,MAOB,7.48,IC50,N[C@@H]1C[C@H]1C1=CC=CC=C1
nicotinic acid,Hydroxycarboxylic acid receptor 2,Hcar2,7.48,Ki,OC(=O)C1=CN=CC=C1
vorinostat,Histone deacetylase 5,HDAC5,7.48,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
vandetanib,Protein-tyrosine kinase 6,PTK6,7.48,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
bosutinib,Ephrin type-B receptor 1,EPHB1,7.48,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
dihydroergocryptine,5-hydroxytryptamine receptor 2B,HTR2B,7.48,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@@H]3C[C@H]4[C@@H](CC5=CNC6=CC=CC4=C56)N(C)C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
lumateperone,Sodium-dependent serotonin transporter,SLC6A4,7.48,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
doxepin,Alpha-1B adrenergic receptor,Adra1b,7.481,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
flunarizine,D(3) dopamine receptor,DRD3,7.481,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
mycophenolate mofetil,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,7.481,Ki,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
nefopam,Sodium-dependent noradrenaline transporter,SLC6A2,7.481,Ki,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1
perphenazine,Aldehyde oxidase,AOX1,7.481,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
risperidone,Histamine H1 receptor,HRH1,7.481,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
talipexole,D(3) dopamine receptor,DRD3,7.481,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
methyltestosterone,Progesterone receptor,PGR,7.481,Ki,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
vortioxetine,5-hydroxytryptamine receptor 1B,HTR1B,7.481,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
aztreonam,Beta-lactamase,blaACC-4,7.49,IC50,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
pentoxyverine,Lysosomal Pro-X carboxypeptidase,PRCP,7.49,IC50,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1
clozapine,5-hydroxytryptamine receptor 3A,Htr3a,7.49,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cocaine,Sodium-dependent dopamine transporter,Slc6a3,7.49,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
desloratadine,Muscarinic acetylcholine receptor M3,CHRM3,7.49,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
droperidol,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.49,IC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
fondaparinux,Antithrombin-III,SERPINC1,7.49,Kd,CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
prednisolone,Glutamine synthetase,GLUL,7.49,EC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prochlorperazine,Alpha-1A adrenergic receptor,Adra1a,7.49,IC50,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
risperidone,5-hydroxytryptamine receptor 1B,HTR1B,7.49,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sulfanilamide,Carbonic anhydrase 13,Ca13,7.49,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
sulfanilamide,Carbonic anhydrase 13,CA13,7.49,Ki,NC1=CC=C(C=C1)S(N)(=O)=O
tandospirone,5-hydroxytryptamine receptor 1A,HTR1A,7.49,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
varenicline,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,7.49,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
kainic acid,"Glutamate receptor ionotropic, kainate 2",GRIK2,7.49,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
tasosartan,Type-1 angiotensin II receptor,AGTR1,7.49,IC50,CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=C(C=CC=C3)C3=NN=NN3)C2=N1
alitretinoin,Retinoic acid receptor RXR-alpha,Rxra,7.49,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
boceprevir,Chymase,CMA1,7.49,IC50,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
bosutinib,Tyrosine-protein kinase CSK,CSK,7.49,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
levobetaxolol,Beta-2 adrenergic receptor,ADRB2,7.49,Ki,CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1
nintedanib,NT-3 growth factor receptor,NTRK3,7.49,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
netarsudil,Rho-associated protein kinase 1,ROCK1,7.49,IC50,CC1=CC=C(C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC2=CC3=C(C=C2)C=NC=C3)C(C)=C1
lumateperone,D(2) dopamine receptor,DRD2,7.49,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
benzatropine,5-hydroxytryptamine receptor 2C,HTR2C,7.495,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
cyamemazine,Muscarinic acetylcholine receptor M3,CHRM3,7.495,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
flunarizine,Alpha-2C adrenergic receptor,ADRA2C,7.495,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
homatropine,Muscarinic acetylcholine receptor M1,CHRM1,7.495,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)C1=CC=CC=C1
imipramine,Alpha-1A adrenergic receptor,ADRA1A,7.495,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
promethazine,Alpha-1D adrenergic receptor,ADRA1D,7.495,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
stanozolol,Estrogen receptor,ESR1,7.495,Ki,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=NN5
ibrutinib,Tyrosine-protein kinase JAK3,JAK3,7.495,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
brexpiprazole,5-hydroxytryptamine receptor 1B,HTR1B,7.495,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
desoxycortone,5-hydroxytryptamine receptor 2B,HTR2B,7.498,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO
almotriptan,5-hydroxytryptamine receptor 1D,HTR1D,7.5,Ki,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
alprostadil,Prostacyclin receptor,PTGIR,7.5,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
alprostadil,Prostacyclin receptor,Ptgir,7.5,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
brinzolamide,Carbonic anhydrase,,7.5,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
bromocriptine,5-hydroxytryptamine receptor 6,HTR6,7.5,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bromocriptine,Alpha-2B adrenergic receptor,ADRA2B,7.5,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bromocriptine,D(3) dopamine receptor,DRD3,7.5,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bromocriptine,5-hydroxytryptamine receptor 6,Htr6,7.5,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bromperidol,D(3) dopamine receptor,DRD3,7.5,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
caramiphen,Muscarinic acetylcholine receptor M2,Chrm2,7.5,Ki,CCN(CC)CCOC(=O)C1(CCCC1)C1=CC=CC=C1
cisapride,5-hydroxytryptamine receptor 4,Htr4,7.5,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
clonidine,Alpha-2B adrenergic receptor,ADRA2B,7.5,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
cocaine,Sodium-dependent dopamine transporter,SLC6A3,7.5,Ki,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
dofetilide,Potassium voltage-gated channel subfamily H member 1,KCNH1,7.5,IC50,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
enalaprilat,Angiotensin-converting enzyme,ACE,7.5,IC50,C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
enprostil,Prostaglandin E2 receptor EP1 subtype,PTGER1,7.5,EC50,COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O
flunitrazepam,GABA A receptor alpha-3/beta-2/gamma-3,GABRA3|GABRB2|GABRG3,7.5,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
haloperidol,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.5,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hydrochlorothiazide,Carbonic anhydrase,,7.5,Ki,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
imatinib,Carbonic anhydrase 1,CA1,7.5,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indomethacin,Potassium voltage-gated channel subfamily A member 7,KCNA7,7.5,Ki,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
isradipine,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,7.5,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
ketanserin,5-hydroxytryptamine receptor 2C,HTR2C,7.5,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
metergoline,5-hydroxytryptamine receptor 7,Htr7,7.5,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
metergoline,5-hydroxytryptamine receptor 6,Htr6,7.5,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
methylergometrine,5-hydroxytryptamine receptor 1F,HTR1F,7.5,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
mianserin,Alpha-1D adrenergic receptor,ADRA1D,7.5,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
misoprostol,Prostaglandin E2 receptor EP2 subtype,PTGER2,7.5,Ki,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
nebivolol,Beta-2 adrenergic receptor,ADRB2,7.5,Ki,OC(CNCC(O)C1CCC2=CC(F)=CC=C2O1)C1CCC2=CC(F)=CC=C2O1
pergolide,Alpha-2B adrenergic receptor,ADRA2B,7.5,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pergolide,5-hydroxytryptamine receptor 6,Htr6,7.5,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pimozide,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,7.5,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pimozide,Voltage-dependent T-type calcium channel subunit alpha-1G,Cacna1g,7.5,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
prednisolone tebutate,Glutamine synthetase,GLUL,7.5,EC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
salmeterol,Beta-2 adrenergic receptor,Adrb2,7.5,EC50,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
tamoxifen,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.5,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tamoxifen,G-protein coupled estrogen receptor 1,GPER1,7.5,IC50,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tramazoline,Alpha-2A adrenergic receptor,ADRA2A,7.5,Ki,C1CN=C(NC2=C3CCCCC3=CC=C2)N1
gepirone,5-hydroxytryptamine receptor 1A,Htr1a,7.5,Ki,CC1(C)CC(=O)N(CCCCN2CCN(CC2)C2=NC=CC=N2)C(=O)C1
dolutegravir,Sigma intracellular receptor 2,Tmem97,7.5,Ki,C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12
fedratinib,BMP-2-inducible protein kinase,BMP2K,7.5,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
lumateperone,D(2) dopamine receptor,Drd2,7.5,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
olanzapine,Muscarinic acetylcholine receptor M1,CHRM1,7.506,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
loxapine,Alpha-1A adrenergic receptor,ADRA1A,7.509,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
methysergide,5-hydroxytryptamine receptor 1A,HTR1A,7.509,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
pipamazine,5-hydroxytryptamine receptor 2B,HTR2B,7.509,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
ixazomib,Proteasome subunit beta type-1,PSMB1,7.509,IC50,CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O
bortezomib,Proteasome subunit beta,PF3D7_1011400,7.51,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
brodimoprim,Dihydrofolate reductase,,7.51,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br
carbachol,Muscarinic acetylcholine receptor M1,Chrm1,7.51,Ki,C[N+](C)(C)CCOC(N)=O
dasatinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,7.51,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
imatinib,Platelet-derived growth factor receptor alpha,PDGFRA,7.51,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
itraconazole,14-alpha sterol demethylase,cyp51B,7.51,Kd,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
prednisolone,Corticosteroid-binding globulin,SERPINA6,7.51,Ki,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,Corticosteroid-binding globulin,SERPINA6,7.51,Ki,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
rosiglitazone,CDGSH iron-sulfur domain-containing protein 1,CISD1,7.51,Ki,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
sorafenib,Vascular endothelial growth factor receptor 1,FLT1,7.51,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulpiride,Carbonic anhydrase 9,CA9,7.51,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
sunitinib,Homeodomain-interacting protein kinase 2,HIPK2,7.51,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamoxifen,Estrogen receptor,ESR1,7.51,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
tretoquinol,Adrenergic receptor beta,ADRB2|ADRB1|ADRB3,7.51,EC50,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
crizotinib,Interleukin-1 receptor-associated kinase 3,IRAK3,7.51,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
ruxolitinib,JAK2/JAK1,JAK2|JAK1,7.51,IC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
axitinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,7.51,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,TRAF2 and NCK-interacting protein kinase,TNIK,7.51,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
panobinostat,Histone deacetylase 10,HDAC10,7.51,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
nintedanib,ALK tyrosine kinase receptor,ALK,7.51,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
lumateperone,Alpha-1B adrenergic receptor,ADRA1B,7.51,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
radotinib,Tyrosine-protein kinase ABL1,ABL1,7.514,IC50,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=N3)=C2)=CC(=C1)C(F)(F)F
adenosine,Adenosine receptor A2a,Adora2a,7.52,Ki,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
apraclonidine,Alpha-2C adrenergic receptor,ADRA2C,7.52,Ki,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1
baclofen,GABA B receptor,Gabbr2|Gabbr1,7.52,IC50,NCC(CC(O)=O)C1=CC=C(Cl)C=C1
baclofen,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,7.52,IC50,NCC(CC(O)=O)C1=CC=C(Cl)C=C1
brimonidine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.52,Ki,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
brinzolamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.52,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
bumetanide,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,7.52,Kd,CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
chloroquine,Dihydrofolate reductase,DHFR,7.52,IC50,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
ciprofloxacin,DNA topoisomerase II,TOP2A|TOP2B,7.52,EC50,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
cisapride,Alpha-1A adrenergic receptor,Adra1a,7.52,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cisapride,Alpha-2A adrenergic receptor,Adra2a,7.52,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
clozapine,D(4) dopamine receptor,DRD4,7.52,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
decitabine,DNA (cytosine-5)-methyltransferase 1,DNMT1,7.52,IC50,NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
diclofenac,Prostaglandin G/H synthase 1,PTGS1,7.52,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
haloperidol,D(1B) dopamine receptor,DRD5,7.52,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,5-hydroxytryptamine receptor 2A,HTR2A,7.52,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,5-hydroxytryptamine receptor 2A,HTR2A,7.52,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
imatinib,Carbonic anhydrase 2,CA2,7.52,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
leflunomide,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Dhodh,7.52,IC50,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
lysergide,5-hydroxytryptamine receptor 2B,HTR2B,7.52,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
milnacipran,Transporter,NET,7.52,IC50,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
nicotine,Soluble acetylcholine receptor,,7.52,Ki,CN1CCC[C@H]1C1=CC=CN=C1
ondansetron,Multidrug and toxin extrusion protein 1,SLC47A1,7.52,IC50,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
orlistat,Abhydrolase domain-containing protein 16A,ABHD16A,7.52,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
phenelzine,Amine oxidase [flavin-containing] A,Maoa,7.52,IC50,NNCCC1=CC=CC=C1
physostigmine,Acetylcholinesterase,ACHE,7.52,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
pravastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,7.52,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12
progesterone,Glucocorticoid receptor,NR3C1,7.52,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
rifampicin,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,7.52,IC50,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
rivastigmine,Cholinesterase,BCHE,7.52,IC50,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
rosiglitazone,Peroxisome proliferator-activated receptor gamma,Pparg,7.52,EC50,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
spiperone,5-hydroxytryptamine receptor 1A,Htr1a,7.52,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
tazobactam,IMI-1; IMI-1 carbapenemase,imiA,7.52,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
terbinafine,Squalene monooxygenase,SQLE,7.52,Ki,CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
topiramate,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.52,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
tropisetron,5-hydroxytryptamine receptor 3A,HTR3A,7.52,Kd,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
tetryzoline,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.52,IC50,C1CN=C(N1)C1CCCC2=CC=CC=C12
tipranavir,Pol polyprotein,pol,7.52,IC50,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC(NS(=O)(=O)C3=CC=C(C=N3)C(F)(F)F)=CC=C2)C(=O)O1
clobenztropine,Sodium-dependent dopamine transporter,Slc6a3,7.52,Ki,CN1[C@H]2CC[C@@H]1CC(C2)OC(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
telaprevir,Chymotrypsin-like elastase family member 1,CELA1,7.52,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
vemurafenib,Serine/threonine-protein kinase B-raf,Braf,7.52,IC50,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F
crizotinib,Tyrosine-protein kinase Lck,LCK,7.52,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
bosutinib,Serine/threonine-protein kinase SIK1,SIK1,7.52,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,7.52,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
teriflunomide,"Dihydroorotate dehydrogenase (quinone), mitochondrial",DHODH,7.52,Ki,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
esflurbiprofen,Prostaglandin G/H synthase 1,Ptgs1,7.52,IC50,C[C@H](C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
pemigatinib,Fibroblast growth factor receptor 4,FGFR4,7.52,IC50,CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F
benzatropine,Alpha-2B adrenergic receptor,ADRA2B,7.523,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
clomifene,Membrane-associated progesterone receptor component 1,Pgrmc1,7.523,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
dapiprazole,Alpha-1B adrenergic receptor,Adra1b,7.523,Ki,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
incadronic acid,Farnesyl pyrophosphate synthase,FDPS,7.523,IC50,OP(O)(=O)C(NC1CCCCCC1)P(O)(O)=O
nepinalone,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.523,Ki,CC1(CCN2CCCCC2)C(=O)CCC2=CC=CC=C12
nortriptyline,Alpha-2C adrenergic receptor,ADRA2C,7.523,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
perlapine,D(4) dopamine receptor,DRD4,7.523,Ki,CN1CCN(CC1)C1=NC2=C(CC3=CC=CC=C13)C=CC=C2
raltegravir,Gag-Pol polyprotein,gag-pol,7.523,IC50,CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
terfenadine,5-hydroxytryptamine receptor 2B,HTR2B,7.523,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
tropicamide,Muscarinic acetylcholine receptor M3,CHRM3,7.523,Ki,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1
ingenol mebutate,Serine/threonine-protein kinase D1,PRKD1,7.523,EC50,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C
riociguat,Guanylate cyclase soluble subunit beta-1,GUCY1B3,7.523,MEC,COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=NC=CC=C12
doxepin,Sodium-dependent noradrenaline transporter,SLC6A2,7.53,Kd,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
mianserin,5-hydroxytryptamine receptor 1B,HTR1B,7.53,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nilotinib,Carbonic anhydrase 1,CA1,7.53,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
ropinirole,D(3) dopamine receptor,Drd3,7.53,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
sulpiride,Carbonic anhydrase,,7.53,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
trifluoperazine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7.53,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
kainic acid,"Glutamate receptor ionotropic, AMPA",Gria1|Gria2|Gria3|Gria4,7.53,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
calcitonin human,Amylin receptor AMY1,CALCR|RAMP1,7.53,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O
remimazolam,GABA-A receptor; benzodiazepine binding site,GABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3,7.53,Ki,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
fluphenazine,D(4) dopamine receptor,DRD4,7.535,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
dipyridamole,Sodium/nucleoside cotransporter 1,SLC28A1,7.538,Ki,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
econazole,Thromboxane-A synthase,TBXAS1,7.538,IC50,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ethinylestradiol,Sodium-dependent serotonin transporter,SLC6A4,7.538,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
ketotifen,5-hydroxytryptamine receptor 2B,HTR2B,7.538,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
lisuride,Beta-2 adrenergic receptor,ADRB2,7.538,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
nefopam,Sodium-dependent serotonin transporter,SLC6A4,7.538,Ki,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1
olanzapine,Alpha-2C adrenergic receptor,ADRA2C,7.538,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
zotepine,5-hydroxytryptamine receptor 5A,HTR5A,7.538,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
paliperidone,D(1B) dopamine receptor,DRD5,7.538,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
ibrutinib,Tyrosine-protein kinase Fyn,FYN,7.538,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
ibrutinib,Tyrosine-protein kinase HCK,HCK,7.538,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
brexpiprazole,Sodium-dependent serotonin transporter,SLC6A4,7.538,IC50,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
fluphenazine,Alpha-2C adrenergic receptor,ADRA2C,7.539,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,Alpha-2C adrenergic receptor,ADRA2C,7.539,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
bexarotene,Retinoic acid receptor RXR-gamma,Rxrg,7.54,Kd,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
camostat,Serine protease hepsin,HPN,7.54,IC50,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1
carmofur,Acid ceramidase,Asah1,7.54,IC50,CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O
cisapride,5-hydroxytryptamine receptor 4,HTR4,7.54,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
colforsin daropate,Adenylate cyclase type 1,ADCY1,7.54,Kd,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C
indapamide,Solute carrier family 12 member 3,SLC12A3,7.54,A2,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
isoprenaline,Beta-2 adrenergic receptor,Adrb2,7.54,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
metoclopramide,D(2) dopamine receptor,Drd2,7.54,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
sunitinib,Dual specificity protein kinase CLK4,CLK4,7.54,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Misshapen-like kinase 1,MINK1,7.54,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
topiramate,Alpha carbonic anhydrase,CA,7.54,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
valdecoxib,Alpha carbonic anhydrase,CA,7.54,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
zopiclone,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,7.54,IC50,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1
zotepine,D(1A) dopamine receptor,DRD1,7.54,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
carbaryl,Ace-orthologous acetylcholinesterase; Acetylcholinesterase,AO-AChE,7.54,IC50,CNC(=O)OC1=CC=CC2=C1C=CC=C2
bosutinib,Activated CDC42 kinase 1,TNK2,7.54,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Serine/threonine-protein kinase SIK2,SIK2,7.54,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
diosmetin,Cytochrome P450 1B1,CYP1B1,7.54,IC50,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O)C=C2O1
neratinib,Misshapen-like kinase 1,MINK1,7.54,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Death-associated protein kinase 2,DAPK2,7.54,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
cyclobenzaprine,5-hydroxytryptamine receptor 2A,HTR2A,7.541,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
tibolone,Progesterone receptor,PGR,7.542,Ki,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
aripiprazole,Histone H1.0,H1F0,7.55,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
beclometasone dipropionate,Progesterone receptor,PGR,7.55,IC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
beclometasone dipropionate,Progesterone receptor,PGR,7.55,IC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
bromocriptine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,7.55,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
budesonide,Progesterone receptor,PGR,7.55,EC50,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
clavulanic acid,Beta-lactamase SHV-1,bla,7.55,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clozapine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,7.55,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Serine/threonine-protein kinase SIK3,SIK3,7.55,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
fenoldopam,D(1A) dopamine receptor,DRD1,7.55,Kd,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
fludarabine phosphate,Adenosine receptor A2a,Adora2a,7.55,Ki,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
fluvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,7.55,IC50,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C1=CC=C(F)C=C1
novobiocin,DNA gyrase subunit B,gyrB,7.55,Kd,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
perphenazine,5-hydroxytryptamine receptor 6,HTR6,7.55,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
pirenzepine,Muscarinic acetylcholine receptor M3,Chrm3,7.55,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
ritonavir,Cytochrome P450 3A4,CYP3A4,7.55,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
sorafenib,Macrophage colony-stimulating factor 1 receptor,CSF1R,7.55,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
tandospirone,D(2) dopamine receptor,DRD2,7.55,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
terguride,D(1A) dopamine receptor,DRD1,7.55,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
tizanidine,Nischarin,NISCH,7.55,Ki,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
vorinostat,Histone deacetylase,hd1b,7.55,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
hydrocortisone acetate,Corticosteroid-binding globulin,SERPINA6,7.55,Ki,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
methylnaltrexone,Mu-type opioid receptor,OPRM1,7.55,Ki,C[N+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
regorafenib,Serine/threonine-protein kinase B-raf,BRAF,7.55,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
rucaparib,Poly [ADP-ribose] polymerase 2,PARP2,7.55,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
filgotinib,Tyrosine-protein kinase JAK2,JAK2,7.55,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
chlorprothixene,Muscarinic acetylcholine receptor M2,CHRM2,7.553,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
desloratadine,5-hydroxytryptamine receptor 2B,HTR2B,7.553,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
haloperidol,Alpha-1D adrenergic receptor,ADRA1D,7.553,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
pecazine,Muscarinic acetylcholine receptor M5,CHRM5,7.553,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
sertindole,5-hydroxytryptamine receptor 7,HTR7,7.553,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
pimozide,5-hydroxytryptamine receptor 2A,HTR2A,7.559,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
acetazolamide,Carbonic anhydrase,,7.56,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
melatonin,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,7.56,Ki,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
pexidartinib,Mast/stem cell growth factor receptor Kit,KIT,7.56,IC50,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
ziprasidone,5-hydroxytryptamine receptor 2B,HTR2B,7.565,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
budesonide,Progesterone receptor,PGR,7.569,Ki,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
formestane,Aromatase,CYP19A1,7.569,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@]34C)[C@@H]1CCC2=O
metergoline,Alpha-2C adrenergic receptor,ADRA2C,7.569,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
mianserin,Alpha-2B adrenergic receptor,ADRA2B,7.569,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
belinostat,Histone deacetylase 4,HDAC4,7.569,IC50,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
acetazolamide,Carbonic anhydrase,,7.57,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
beclometasone dipropionate,Progesterone receptor,PGR,7.57,Ki,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
dasatinib,Mitogen-activated protein kinase 14,MAPK14,7.57,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexketoprofen,Prostaglandin G/H synthase 2,PTGS2,7.57,IC50,C[C@H](C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
dorzolamide,Carbonic anhydrase 14,CA14,7.57,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
ethoxzolamide,Carbonic anhydrase 2,mtcA2,7.57,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
lovastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,7.57,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
methazolamide,Carbonic anhydrase 9,CA9,7.57,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
morphine,Kappa-type opioid receptor,Oprk1,7.57,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
morphine,Opioid receptor,Sigmar1|Oprd1|Oprk1|Oprm1,7.57,IC50,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
progesterone,"Fatty acid-binding protein, liver",Fabp1,7.57,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
risedronic acid,Farnesyl diphosphate synthase,,7.57,IC50,OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
trimetrexate,Dihydrofolate reductase,folA,7.57,IC50,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
valdecoxib,Carbonic anhydrase 9,CA9,7.57,IC50,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
pazopanib,Vascular endothelial growth factor receptor 3,FLT4,7.57,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
bosutinib,Ephrin type-A receptor 5,EPHA5,7.57,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
apremilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,7.57,IC50,CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O
belinostat,Histone deacetylase 11,HDAC11,7.57,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
belinostat,Bromodomain-containing protein 4,BRD4,7.57,IC50,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
istradefylline,Amine oxidase [flavin-containing] B,MAOB,7.57,Ki,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
istradefylline,Amine oxidase [flavin-containing] B,MAOB,7.57,Ki,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
gallium (68Ga) gozetotide,Prostate-specific antigen,KLK3,7.57,Kd,[H+].C1=CC(=C(C=C1CCC(=O)NCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN(CCN(CC2=C(C=CC(=C2)CCC(=O)O)[O-])CC(=O)[O-])CC(=O)[O-])[O-].[68Ga+3]
zolpidem,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,7.574,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
carbachol,Muscarinic acetylcholine receptor M4,CHRM4,7.577,EC50,C[N+](C)(C)CCOC(N)=O
dichlorphenamide,Carbonic anhydrase 7,CA7,7.577,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
ajmaline,Potassium voltage-gated channel subfamily D member 3,KCND3,7.58,IC50,CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H]([C@H]2[C@H]4O)N3[C@@H]1O
cyclofenil,Estrogen receptor,ESR1,7.58,EC50,CC(=O)OC1=CC=C(C=C1)C(=C1CCCCC1)C1=CC=C(OC(C)=O)C=C1
cyclofenil,Estrogen receptor,ESR1,7.58,EC50,CC(=O)OC1=CC=C(C=C1)C(=C1CCCCC1)C1=CC=C(OC(C)=O)C=C1
finasteride,3-oxo-5-alpha-steroid 4-dehydrogenase 1,SRD5A1,7.58,IC50,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
haloperidol,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,7.58,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
irinotecan,Acetylcholinesterase,ache,7.58,Ki,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
methazolamide,"Carbonic anhydrase, alpha family",,7.58,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
topotecan,DNA topoisomerase 1,TOP1,7.58,Kd,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
tretoquinol,Beta-2 adrenergic receptor,Adrb2,7.58,EC50,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
trihexyphenidyl,Muscarinic acetylcholine receptor M3,CHRM3,7.58,IC50,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
prucalopride,5-hydroxytryptamine receptor 4,Htr4,7.58,EC50,COCCCN1CCC(CC1)NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2
benzatropine,Alpha-1D adrenergic receptor,ADRA1D,7.585,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
emetine,Alpha-2C adrenergic receptor,ADRA2C,7.585,Ki,CC[C@H]1CN2CCC3=CC(OC)=C(OC)C=C3[C@@H]2C[C@@H]1C[C@H]1NCCC2=CC(OC)=C(OC)C=C12
ethylestrenol,Progesterone receptor,PGR,7.585,Ki,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
olanzapine,Alpha-1D adrenergic receptor,ADRA1D,7.585,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
triamcinolone,Glucocorticoid receptor,NR3C1,7.585,Ki,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
ebastine,5-hydroxytryptamine receptor 2A,HTR2A,7.588,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
perphenazine,D(4) dopamine receptor,DRD4,7.588,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
alpidem,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,7.59,IC50,CCCN(CCC)C(=O)CC1=C(N=C2C=CC(Cl)=CN12)C1=CC=C(Cl)C=C1
aripiprazole,5-hydroxytryptamine receptor 2C,Htr2c,7.59,IC50,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
atazanavir,Reverse transcriptase/RNaseH,pol,7.59,IC50,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
benzbromarone,Solute carrier family 22 member 12,SLC22A12,7.59,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
caramiphen,Lysosomal Pro-X carboxypeptidase,PRCP,7.59,Ki,CCN(CC)CCOC(=O)C1(CCCC1)C1=CC=CC=C1
cefalotin,Solute carrier family 22 member 8,SLC22A8,7.59,IC50,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O
cloxacillin,Beta-lactamase,blaACC-4,7.59,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1
erlotinib,STE20-like serine/threonine-protein kinase,SLK,7.59,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
fulvestrant,Bifunctional epoxide hydrolase 2,EPHX2,7.59,Ki,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
mianserin,Transporter,Slc6a2,7.59,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
neostigmine,Acetylcholinesterase,ACHE,7.59,IC50,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
nilotinib,Abelson tyrosine-protein kinase 2,ABL2,7.59,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
nomifensine,Sodium-dependent dopamine transporter,Slc6a3,7.59,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
sumatriptan,5-hydroxytryptamine receptor 1F,HTR1F,7.59,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Tyrosine-protein kinase Mer,MERTK,7.59,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terazosin,Alpha-1A adrenergic receptor,ADRA1A,7.59,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
telaprevir,Chymase,CMA1,7.59,IC50,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
bosutinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,7.59,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ponatinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,7.59,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
dabrafenib,Serine/threonine-protein kinase A-Raf,ARAF,7.59,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
safinamide,Amine oxidase [flavin-containing] B,Maob,7.59,IC50,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O
neratinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,7.59,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
clozapine,Muscarinic acetylcholine receptor M3,CHRM3,7.591,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
thioridazine,Muscarinic acetylcholine receptor M3,CHRM3,7.595,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
(S)-nitrendipine,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,7.6,IC50,CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
amiodarone,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,7.6,Ki,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
bendamustine,Histone deacetylase 3,HDAC3,7.6,IC50,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
bromocriptine,Alpha-2C adrenergic receptor,ADRA2C,7.6,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bumetanide,Solute carrier family 12 member 1,SLC12A1,7.6,Ki,CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
chlorpromazine,Alpha-2B adrenergic receptor,ADRA2B,7.6,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlorpromazine,Dopamine receptor,DRD2|DRD1,7.6,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clemastine,Transmembrane protein 97,TMEM97,7.6,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clozapine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,7.6,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproheptadine,Alpha-1B adrenergic receptor,ADRA1B,7.6,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
darifenacin,Muscarinic acetylcholine receptor M2,CHRM2,7.6,Ki,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
desloratadine,Muscarinic acetylcholine receptor M2,CHRM2,7.6,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
desmopressin,Oxytocin receptor,OXTR,7.6,Ki,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
erlotinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7.6,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
ethoxzolamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,7.6,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
formoterol,Beta-3 adrenergic receptor,ADRB3,7.6,EC50,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
hexocyclium,Muscarinic acetylcholine receptor M2,CHRM2,7.6,Ki,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
indoramin,Alpha-1B adrenergic receptor,ADRA1B,7.6,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
lanreotide,Somatostatin receptor type 5,Sstr5,7.6,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
lopinavir,Protease,protease,7.6,IC50,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
maraviroc,C-C chemokine receptor type 5,CCR5,7.6,Kd,CC(C)C1=NN=C(C)N1[C@@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
masoprocol,Arachidonate 5-lipoxygenase,ALOX5,7.6,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
meclozine,Constitutive androstane receptor,Nr1i3,7.6,EC50,CC1=CC=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=C1
metergoline,5-hydroxytryptamine receptor 1B,Htr1b,7.6,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
methocarbamol,Carbonic anhydrase 1,CA1,7.6,Ki,COC1=C(OCC(O)COC(N)=O)C=CC=C1
methysergide,5-hydroxytryptamine receptor 1B,HTR1B,7.6,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
metoprolol,Beta-1 adrenergic receptor,ADRB1,7.6,Ki,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
milnacipran,Sodium-dependent noradrenaline transporter,SLC6A2,7.6,Ki,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
misoprostol,Prostaglandin E2 receptor EP4 subtype,PTGER4,7.6,Ki,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
nafamostat,Hepatocyte growth factor activator,HGFAC,7.6,Ki,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
nitrendipine,Intermediate conductance calcium-activated potassium channel protein 4,KCNN4,7.6,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
perphenazine,5-hydroxytryptamine receptor 7,Htr7,7.6,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
pizotifen,5-hydroxytryptamine receptor 7,HTR7,7.6,Ki,CN1CCC(CC1)=C1C2=C(CCC3=C1C=CC=C3)SC=C2
risperidone,5-hydroxytryptamine receptor 1D,HTR1D,7.6,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
risperidone,Alpha-2A adrenergic receptor,Adra2a,7.6,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
roxatidine acetate,Histamine H2 receptor,HRH2,7.6,Kd,CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1
sertraline,Sodium-dependent dopamine transporter,SLC6A3,7.6,Kd,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
sunitinib,TRAF2 and NCK-interacting protein kinase,TNIK,7.6,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
talipexole,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.6,IC50,NC1=NC2=C(CCN(CC=C)CC2)S1
terguride,5-hydroxytryptamine receptor 1A,Htr1a,7.6,IC50,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
topiramate,"Carbonic anhydrase 5A, mitochondrial",CA5A,7.6,Kd,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topiramate,Carbonic anhydrase V,CA5A|CA5B,7.6,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
venlafaxine,Sodium-dependent serotonin transporter,Slc6a4,7.6,Ki,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
zolpidem,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,7.6,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
iloperidone,D(4) dopamine receptor,DRD4,7.6,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
quercetin,Serine/threonine-protein kinase pim-1,PIM1,7.6,Kd,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
yohimbine,5-hydroxytryptamine receptor 1B,HTR1B,7.6,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
crizotinib,Macrophage-stimulating protein receptor,MST1R,7.6,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
belinostat,Histone deacetylase 5,HDAC5,7.6,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
arformoterol,Beta-3 adrenergic receptor,ADRB3,7.6,EC50,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1
bromhexine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.602,Ki,CN(CC1=C(N)C(Br)=CC(Br)=C1)C1CCCCC1
chlorpromazine,Muscarinic acetylcholine receptor M1,CHRM1,7.602,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlorprothixene,Muscarinic acetylcholine receptor M5,CHRM5,7.602,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
decamethonium,Muscarinic acetylcholine receptor M2,CHRM2,7.602,Ki,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
fluphenazine,5-hydroxytryptamine receptor 2B,HTR2B,7.602,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
pipamazine,Alpha-2A adrenergic receptor,ADRA2A,7.602,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
procyclidine,Muscarinic acetylcholine receptor M2,CHRM2,7.602,Ki,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
mepyramine,Sodium-dependent serotonin transporter,SLC6A4,7.602,Ki,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
thiethylperazine,Histamine H1 receptor,HRH1,7.602,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
romidepsin,Histone deacetylase 3,HDAC3,7.604,Ki,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
dichlorphenamide,"Carbonic anhydrase, alpha family",,7.61,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
indoramin,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7.61,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
methamphetamine,Sodium-dependent dopamine transporter,SLC6A3,7.611,Ki,CN[C@@H](C)CC1=CC=CC=C1
midazolam,GABA A receptor alpha-3/beta-2/gamma-3,GABRA3|GABRB2|GABRG3,7.613,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
imipramine,Histamine H1 receptor,HRH1,7.614,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
astemizole,Alpha-1A adrenergic receptor,Adra1a,7.62,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
atenolol,Beta-1 adrenergic receptor,ADRB1,7.62,Kd,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
brinzolamide,Carbonic anhydrase 14,CA14,7.62,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
calcitriol,Vitamin D-binding protein,GC,7.62,Kd,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
fluphenazine,Alpha-1A adrenergic receptor,Adra1a,7.62,IC50,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
haloperidol,AP-2 complex subunit sigma,Ap2s1,7.62,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
methotrexate,High mobility group protein B1,HMGB1,7.62,Kd,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
morphine,Kappa-type opioid receptor,OPRK1,7.62,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
procyclidine,Muscarinic acetylcholine receptor M5,CHRM5,7.62,Ki,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
promethazine,Alpha-2B adrenergic receptor,ADRA2B,7.62,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
ritodrine,Beta-2 adrenergic receptor,ADRB2,7.62,EC50,C[C@@H](NCCC1=CC=C(O)C=C1)[C@@H](O)C1=CC=C(O)C=C1
trifluoperazine,Alpha-1A adrenergic receptor,ADRA1A,7.62,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
tubocurarine,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,7.62,IC50,COC1=CC2=C3C=C1OC1=CC(C[C@@H]4C5=C(OC6=CC=C(C[C@@H]3N(C)CC2)C=C6)C(O)=C(OC)C=C5CC[N+]4(C)C)=CC=C1O
valethamate,Muscarinic acetylcholine receptor M5,CHRM5,7.62,Ki,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1
octopamine,5-hydroxytryptamine receptor 3A,HTR3A,7.62,EC50,NCC(O)C1=CC=C(O)C=C1
biriperone,5-hydroxytryptamine receptor 2A,Htr2a,7.62,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCN2CC3=C(CC2C1)C1=CC=CC=C1N3
prazosin,Alpha-2C adrenergic receptor,ADRA2C,7.62,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
esatenolol,Beta-1 adrenergic receptor,ADRB1,7.62,Kd,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
belinostat,Histone deacetylase 9,HDAC9,7.62,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
nintedanib,Insulin receptor,INSR,7.62,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
lorlatinib,High affinity nerve growth factor receptor,NTRK1,7.62,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
prochlorperazine,Alpha-1A adrenergic receptor,ADRA1A,7.622,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
doxepin,Alpha-1A adrenergic receptor,ADRA1A,7.629,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
cycloguanil,Dihydrofolate reductase,,7.63,Ki,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1
etryptamine,Sodium-dependent serotonin transporter,Slc6a4,7.63,EC50,CCC(N)CC1=CNC2=C1C=CC=C2
meglutol,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,7.63,Ki,CC(O)(CC(O)=O)CC(O)=O
terguride,D(1B) dopamine receptor,DRD5,7.63,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
cariprazine,Histamine H1 receptor,HRH1,7.63,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
paliperidone,Alpha-2B adrenergic receptor,ADRA2B,7.635,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
cevimeline,Muscarinic acetylcholine receptor M1,CHRM1,7.638,EC50,CC1OC2(CS1)CN1CCC2CC1
chlorproethazine,D(4) dopamine receptor,DRD4,7.638,Ki,CCN(CC)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clemastine,5-hydroxytryptamine receptor 2B,HTR2B,7.638,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
labetalol,Alpha-1D adrenergic receptor,ADRA1D,7.638,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
methacholine,Muscarinic acetylcholine receptor M1,CHRM1,7.638,Ki,CC(C[N+](C)(C)C)OC(C)=O
perphenazine,5-hydroxytryptamine receptor 7,HTR7,7.638,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
prochlorperazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.638,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
triamcinolone acetonide,Progesterone receptor,PGR,7.638,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
paliperidone,5-hydroxytryptamine receptor 1B,HTR1B,7.638,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
hydroxyprogesterone caproate,Glucocorticoid receptor,NR3C1,7.638,Ki,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
ceritinib,Testis-specific serine/threonine-protein kinase 1,TSSK1B,7.638,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
lorlatinib,BDNF/NT-3 growth factors receptor,NTRK2,7.638,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
alfuzosin,Alpha-1A adrenergic receptor,ADRA1A,7.64,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
chlortalidone,Carbonic anhydrase 9,CA9,7.64,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
diazepam,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,7.64,Kd,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
dichlorphenamide,Carbonic anhydrase 13,Ca13,7.64,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
dichlorphenamide,Carbonic anhydrase 13,CA13,7.64,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
imipramine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,7.64,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
lisuride,Alpha-1A adrenergic receptor,Adra1a,7.64,IC50,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
nicotine,Neuronal acetylcholine receptor; alpha4/beta4,CHRNB4|CHRNA4,7.64,Ki,CN1CCC[C@H]1C1=CC=CN=C1
risperidone,D(2) dopamine receptor,Drd2,7.64,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sumatriptan,5-hydroxytryptamine receptor 1B,Htr1b,7.64,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,"Myosin light chain kinase, smooth muscle",MYLK,7.64,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,"Myosin light chain kinase, smooth muscle",Mylk,7.64,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase ULK1,ULK1,7.64,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Myosin light chain kinase 3,MYLK3,7.64,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
zanamivir,Neuraminidase,,7.64,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
zanamivir,Neuraminidase,,7.64,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
xylometazoline,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.64,IC50,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
vemurafenib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,7.64,IC50,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F
ruxolitinib,JAK3/JAK1,JAK1|JAK3,7.64,IC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
carbamide,Olfactory receptor 51E2,OR51E2,7.64,EC50,NC(N)=O
nintedanib,Serine/threonine-protein kinase RIO1,RIOK1,7.64,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
asenapine,D(1B) dopamine receptor,DRD5,7.644,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
fluphenazine,D(1A) dopamine receptor,DRD1,7.649,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
bisoprolol,Beta-1 adrenergic receptor,ADRB1,7.65,Ki,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
desoxycortone,Corticosteroid-binding globulin,SERPINA6,7.65,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO
diazepam,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,7.65,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
nandrolone,Progesterone receptor,PGR,7.65,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O
nandrolone decanoate,Progesterone receptor,PGR,7.65,Ki,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
mirabegron,Beta-3 adrenergic receptor,ADRB3,7.65,EC50,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1
chlorprothixene,Muscarinic acetylcholine receptor M3,CHRM3,7.658,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clomipramine,Muscarinic acetylcholine receptor M1,CHRM1,7.658,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
fludroxycortide,Progesterone receptor,PGR,7.658,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
mestranol,Sodium-dependent serotonin transporter,SLC6A4,7.658,Ki,COC1=CC2=C(C=C1)[C@H]1CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@@H]1CC2
metergoline,Alpha-2A adrenergic receptor,ADRA2A,7.658,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
lenvatinib,Vascular endothelial growth factor receptor 1,FLT1,7.658,IC50,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
alprostadil,Prostaglandin E2 receptor EP2 subtype,Ptger2,7.66,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
clozapine,Alpha-1A adrenergic receptor,Adra1a,7.66,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dexamethasone,Glucocorticoid receptor,Nr3c1,7.66,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
dexamethasone palmitate,Glucocorticoid receptor,Nr3c1,7.66,IC50,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
dexamethasone valerate,Glucocorticoid receptor,Nr3c1,7.66,IC50,CCCCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
diclofenac,Prostaglandin G/H synthase 2,Ptgs2,7.66,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dinoprostone,Prostaglandin E2 receptor EP2 subtype,Ptger2,7.66,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
ethoxzolamide,Carbonic anhydrase 12,CA12,7.66,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
aminobutyric acid,Gamma-aminobutyric acid receptor subunit alpha-2,Gabra2,7.66,IC50,NCCCC(O)=O
glutamic acid,Metabotropic glutamate receptor 8,Grm8,7.66,EC50,N[C@@H](CCC(O)=O)C(O)=O
iloprost,Prostaglandin E2 receptor EP3 subtype,Ptger3,7.66,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
loxapine,D(3) dopamine receptor,DRD3,7.66,IC50,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
metoclopramide,D(3) dopamine receptor,DRD3,7.66,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
olanzapine,Muscarinic acetylcholine receptor M1,Chrm1,7.66,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
pirenzepine,Adenosine receptor A3,ADORA3,7.66,IC50,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
raltitrexed,Folate receptor beta,FOLR2,7.66,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
risperidone,Histamine H1 receptor,HRH1,7.66,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
risperidone,D(1A) dopamine receptor,Drd1,7.66,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sorafenib,Serine/threonine-protein kinase B-raf,BRAF,7.66,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
spiperone,Alpha-1D adrenergic receptor,Adra1d,7.66,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Death-associated protein kinase 3,DAPK3,7.66,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Dual specificity protein kinase CLK1,CLK1,7.66,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tiocarlide,"Epoxide hydrolase EphE; Hydrolase, alpha/beta hydrolase fold family",,7.66,IC50,CC(C)CCOC1=CC=C(NC(=S)NC2=CC=C(OCCC(C)C)C=C2)C=C1
iloperidone,5-hydroxytryptamine receptor 7,HTR7,7.66,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
quercetin,Enoyl-acyl-carrier protein reductase,fabI,7.66,Ki,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
dexamethasone phosphate,Glucocorticoid receptor,Nr3c1,7.66,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
panobinostat,Histone deacetylase 8,HDAC8,7.66,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
belinostat,Histone deacetylase 8,HDAC8,7.66,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
nintedanib,Dual specificity protein kinase TTK,TTK,7.66,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
vaniprevir,Genome polyprotein,,7.66,Ki,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1[C@H]2CCN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
avapritinib,Mast/stem cell growth factor receptor Kit,Kit,7.66,IC50,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1
terbinafine,Membrane-associated progesterone receptor component 1,Pgrmc1,7.662,Ki,CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
hydroxyprogesterone caproate,Progesterone receptor,PGR,7.664,IC50,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
alprenolol,5-hydroxytryptamine receptor 1A,HTR1A,7.67,Ki,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
alprenolol,5-hydroxytryptamine receptor 1A,HTR1A,7.67,Ki,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
lovastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,7.67,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
methazolamide,Alpha carbonic anhydrase,CA,7.67,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
nomifensine,Sodium-dependent noradrenaline transporter,SLC6A2,7.67,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
tretoquinol,Beta-2 adrenergic receptor,ADRB2,7.67,Ki,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
benzylsulfamide,Carbonic anhydrase 2,CA2,7.67,Ki,NS(=O)(=O)C1=CC=C(NCC2=CC=CC=C2)C=C1
dichlorphenamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.678,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
epalrestat,Aldose reductase,AKR1B1,7.678,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
etynodiol,Progesterone receptor,PGR,7.678,Ki,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1
fluphenazine enanthate,D(1A) dopamine receptor,DRD1,7.678,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
metergoline,D(2) dopamine receptor,DRD2,7.678,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
olanzapine,Alpha-1B adrenergic receptor,Adra1b,7.678,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
promethazine,Alpha-1B adrenergic receptor,Adra1b,7.678,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
bexarotene,Retinoic acid receptor RXR-beta,Rxrb,7.68,Kd,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
buspirone,D(2) dopamine receptor,DRD2,7.68,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
carmofur,Acid ceramidase,ASAH1,7.68,IC50,CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O
celecoxib,Carbonic anhydrase 2,CA2,7.68,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
celecoxib,Carbonic anhydrase,NCE103,7.68,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlormadinone,Androgen receptor,Ar,7.68,Ki,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
chlorpromazine,5-hydroxytryptamine receptor 7,Htr7,7.68,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
fluphenazine enanthate,Histamine H1 receptor,HRH1,7.68,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
lindane,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,7.68,IC50,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
loxapine,D(2) dopamine receptor,DRD2,7.68,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
loxapine,D(2) dopamine receptor,Drd2,7.68,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
oxymetazoline,Alpha-2A adrenergic receptor,ADRA2A,7.68,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
pirenzepine,Muscarinic acetylcholine receptor M1,CHRM1,7.68,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
risperidone,D(1A) dopamine receptor,DRD1,7.68,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
zolpidem,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,7.68,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
naphazoline,Alpha-2A adrenergic receptor,ADRA2A,7.68,Ki,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
vemurafenib,Serine/threonine-protein kinase B-raf,BRAF,7.68,IC50,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F
axitinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,7.68,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
clobetasol propionate,Cytochrome P450 3A5,CYP3A5,7.68,IC50,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
clobetasol propionate,Cytochrome P450 3A5,CYP3A5,7.68,IC50,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
fluticasone furoate,Progesterone receptor,PGR,7.68,IC50,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)SCF
fluticasone furoate,Progesterone receptor,PGR,7.68,IC50,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)SCF
nintedanib,Cyclin-dependent kinase 16,CDK16,7.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,NUAK family SNF1-like kinase 2,NUAK2,7.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Insulin receptor-related protein,INSRR,7.68,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,MAP/microtubule affinity-regulating kinase 3,MARK3,7.68,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
olanzapine,Muscarinic acetylcholine receptor M4,CHRM4,7.682,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
amantadine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.69,Ki,NC12CC3CC(CC(C3)C1)C2
aripiprazole,5-hydroxytryptamine receptor 7,HTR7,7.69,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
chlorpromazine,D(4) dopamine receptor,DRD4,7.69,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
tolcapone,Transthyretin,TTR,7.69,Kd,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
zonisamide,Carbonic anhydrase V,CA5A|CA5B,7.69,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
copper dotatate Cu-64,Somatostatin receptor type 2,SSTR2,7.69,Kd,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[64Cu+2]
indomethacin,Prostaglandin E2 receptor EP2 subtype,PTGER2,7.691,Ki,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
dolasetron,5-hydroxytryptamine receptor 3A,HTR3A,7.698,Ki,O=C(O[C@H]1C[C@H]2CC3C[C@@H](C1)N2CC3=O)C1=CNC2=C1C=CC=C2
clotrimazole,Cytochrome P450 3A4,CYP3A4,7.699,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
diazepam,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,7.699,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
diphenylpyraline,Muscarinic acetylcholine receptor M1,CHRM1,7.699,Ki,CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
megestrol acetate,Androgen receptor,Ar,7.699,Ki,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
midodrine,Heat shock protein HSP 90-alpha,HSP90AA1,7.699,IC50,COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1
naftopidil,Alpha-1B adrenergic receptor,ADRA1B,7.699,Ki,COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1
orphenadrine,Muscarinic acetylcholine receptor M5,CHRM5,7.699,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
oxatomide,Histamine H1 receptor,HRH1,7.699,Ki,O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
tipiracil,Thymidine phosphorylase,TYMP,7.699,IC50,ClC1=C(CN2CCCC2=N)NC(=O)NC1=O
selexipag,Prostacyclin receptor,PTGIR,7.699,Ki,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1
lobeglitazone,Peroxisome proliferator-activated receptor alpha,PPARA,7.699,EC50,COC1=CC=C(OC2=CC(=NC=N2)N(C)CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
fluorouracil,Thymidylate synthase,Tyms,7.7,IC50,FC1=CNC(=O)NC1=O
acetazolamide,Carbonic anhydrase,cynT,7.7,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
androstenedione,Aromatase,CYP19A1,7.7,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
azelastine,5-hydroxytryptamine receptor 2B,HTR2B,7.7,Ki,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
cabergoline,5-hydroxytryptamine receptor 1A,HTR1A,7.7,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
cabergoline,D(1B) dopamine receptor,DRD5,7.7,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
cabergoline,Alpha-2C adrenergic receptor,ADRA2C,7.7,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
carazolol,Beta-3 adrenergic receptor,Adrb3,7.7,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
carazolol,Beta-3 adrenergic receptor,Adrb3,7.7,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
carbachol,Muscarinic acetylcholine receptor M1,Chrm1,7.7,Ki,C[N+](C)(C)CCOC(N)=O
chloroquine,Cysteine proteinase falcipain 2a,,7.7,IC50,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
cinacalcet,Extracellular calcium-sensing receptor,CASR,7.7,EC50,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=C1C=CC=C2
clavulanic acid,Beta-lactamase,blaSHV-55,7.7,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clozapine,Alpha-1D adrenergic receptor,ADRA1D,7.7,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cytarabine,E3 ubiquitin-protein ligase Mdm2,MDM2,7.7,IC50,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
desloratadine,Muscarinic acetylcholine receptor M4,CHRM4,7.7,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
diazepam,GABA A receptor alpha-2/beta-2/gamma-2,Gabrg2|Gabra2|Gabrb2,7.7,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
diclofenac,Prostaglandin G/H synthase 2,PTGS2,7.7,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
dinoprostone,Prostaglandin E2 receptor EP1 subtype,Ptger1,7.7,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
ergometrine,5-hydroxytryptamine receptor 1E,HTR1E,7.7,EC50,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
profenamine,Cholinesterase,BCHE,7.7,Ki,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
profenamine,Butyrylcholinesterase,BCHE,7.7,Ki,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
glutathione,Glutathione S-transferase kappa 1,GSTK1,7.7,IC50,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O
haloperidol,D(1A) dopamine receptor,Drd1,7.7,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,Alpha-1A adrenergic receptor,ADRA1A,7.7,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ifenprodil,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,7.7,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
iloprost,Prostaglandin E2 receptor EP1 subtype,PTGER1,7.7,EC50,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
iloprost,Prostaglandin E2 receptor EP1 subtype,Ptger1,7.7,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
lisuride,5-hydroxytryptamine receptor 1B,HTR1B,7.7,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
metergoline,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,7.7,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
methazolamide,Carbonic anhydrase,CA12|CA1|CA2|CA3|CA4|CA6|CA5A|CA7|CA9|CA13|CA14|CA5B,7.7,IC50,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
mifepristone,Glucocorticoid receptor,NR3C1,7.7,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
mirtazapine,Alpha-2A adrenergic receptor,ADRA2A,7.7,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
naratriptan,5-hydroxytryptamine receptor 1E,HTR1E,7.7,Ki,CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1
nifedipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,7.7,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
norfloxacin,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,7.7,IC50,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
olanzapine,D(1A) dopamine receptor,Drd1,7.7,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
orlistat,Sn1-specific diacylglycerol lipase alpha,Dagla,7.7,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
paroxetine,Myeloperoxidase,MPO,7.7,IC50,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
paroxetine,Sodium-dependent noradrenaline transporter,Slc6a2,7.7,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
phenelzine,Membrane primary amine oxidase,AOC3,7.7,IC50,NNCCC1=CC=CC=C1
physostigmine,Acetylcholinesterase,ACHE,7.7,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
pindolol,5-hydroxytryptamine receptor 1A,Htr1a,7.7,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
protirelin,Thyrotropin-releasing hormone receptor,TRHR,7.7,Ki,NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
protirelin,Thyrotropin-releasing hormone receptor,Trhr,7.7,Ki,NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
protriptyline,Muscarinic acetylcholine receptor M1,CHRM1,7.7,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
risperidone,5-hydroxytryptamine receptor 2C,HTR2C,7.7,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sildenafil,Phosphodiesterase 6,PDE6G|PDE6A|PDE6C|PDE6H|PDE6B|PDE6D,7.7,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,Vascular endothelial growth factor receptor 3,Flt4,7.7,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulprostone,Prostaglandin E2 receptor EP1 subtype,Ptger1,7.7,Ki,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
sumatriptan,5-hydroxytryptamine receptor 1D,HTR1D,7.7,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,Dual specificity protein kinase CLK2,CLK2,7.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Cyclin-G-associated kinase,GAK,7.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrolimus,Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform,PPP3CA,7.7,Kd,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
terguride,Beta-2 adrenergic receptor,ADRB2,7.7,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
thioridazine,Histamine H1 receptor,HRH1,7.7,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
ubenimex,Leucyl-cystinyl aminopeptidase,Lnpep,7.7,Ki,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
zolmitriptan,5-hydroxytryptamine receptor 1B,HTR1B,7.7,Ki,CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2
zolmitriptan,5-hydroxytryptamine receptor 1E,HTR1E,7.7,Ki,CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2
zonisamide,"Carbonic anhydrase 5A, mitochondrial",CA5A,7.7,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
iloperidone,5-hydroxytryptamine receptor 7,Htr7,7.7,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
stallimycin,Estrogen receptor,ESR1|ESR2,7.7,IC50,CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC=O)=CN3C)=CN2C)C=C1C(=O)NCCC(N)=N
xanomeline,5-hydroxytryptamine receptor 2B,HTR2B,7.7,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
yohimbine,5-hydroxytryptamine receptor 1D,HTR1D,7.7,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
benzylsulfamide,Carbonic anhydrase 12,CA12,7.7,Ki,NS(=O)(=O)C1=CC=C(NCC2=CC=CC=C2)C=C1
silodosin,Alpha-1B adrenergic receptor,ADRA1B,7.7,Ki,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
bosutinib,Bcr/Abl fusion protein,ABL1|BCR,7.7,IC50,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
methylnaltrexone,Kappa-type opioid receptor,OPRK1,7.7,Ki,C[N+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
tipiracil,Thymidine phosphorylase,deoA,7.7,IC50,ClC1=C(CN2CCCC2=N)NC(=O)NC1=O
albiglutide,Glucagon-like peptide 1 receptor,Glp1r,7.7,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O
aripiprazole lauroxil,5-hydroxytryptamine receptor 2A,Htr2a,7.7,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
midostaurin,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,7.7,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Calcium/calmodulin-dependent protein kinase type II subunit alpha,CAMK2A,7.7,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
selinexor,Exportin-1,XPO1,7.7,IC50,FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F
perlapine,5-hydroxytryptamine receptor 2A,HTR2A,7.704,Ki,CN1CCN(CC1)C1=NC2=C(CC3=CC=CC=C13)C=CC=C2
calcitonin human,Amylin receptor AMY3,CALCR|RAMP3,7.706,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O
quazepam,GABA A receptor alpha-1/beta-1/gamma-2,GABRA1|GABRB1|GABRG2,7.708,Ki,FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12
pentoxyverine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.71,Ki,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1
phentolamine,Alpha-1D adrenergic receptor,ADRA1D,7.71,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
zucapsaicin,Transient receptor potential cation channel subfamily V member 1,TRPV1,7.71,EC50,COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O
safinamide,Sigma non-opioid intracellular receptor 1,Sigmar1,7.71,IC50,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O
amodiaquine,Histamine N-methyltransferase,HNMT,7.72,Ki,CCN(CC)CC1=C(O)C=CC(NC2=CC=NC3=CC(Cl)=CC=C23)=C1
beraprost,Prostacyclin receptor,Ptgir,7.72,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12
bicalutamide,Androgen receptor,AR,7.72,Ki,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
clozapine,Alpha-2A adrenergic receptor,Adra2a,7.72,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dihydroergocristine,5-hydroxytryptamine receptor 6,HTR6,7.72,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
erlotinib,Serine/threonine-protein kinase 10,STK10,7.72,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
estradiol,Androgen receptor,AR,7.72,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
ethoxzolamide,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.72,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
guanfacine,Nischarin,NISCH,7.72,Ki,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
losartan,Angiotensin-converting enzyme,ACE,7.72,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
medetomidine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.72,Ki,CC(C1=CNC=N1)C1=C(C)C(C)=CC=C1
methazolamide,Carbonic anhydrase 13,Ca13,7.72,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methazolamide,Carbonic anhydrase 13,CA13,7.72,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methotrexate,Dihydrofolate reductase,DHFR,7.72,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
quinagolide,Dopamine receptor,DRD2|DRD1,7.72,IC50,CCCN1C[C@H](C[C@@H]2CC3=C(C[C@@H]12)C=CC=C3O)NS(=O)(=O)N(CC)CC
sunitinib,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,7.72,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 10,STK10,7.72,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 4,STK4,7.72,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
valethamate,Muscarinic acetylcholine receptor M2,CHRM2,7.72,Ki,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1
zolpidem,GABA-A receptor; alpha-1/beta-2/gamma-2,Gabrg2|Gabra1|Gabrb2,7.72,Ki,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
rasagiline,Acetylcholinesterase,ACHE,7.72,IC50,C#CCN[C@@H]1CCC2=C1C=CC=C2
bosutinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,7.72,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,BDNF/NT-3 growth factors receptor,NTRK2,7.72,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
doravirine,Reverse transcriptase,reverse transcriptas,7.72,IC50,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F
doravirine,Reverse transcriptase,reverse transcriptas,7.72,IC50,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F
fedratinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7.72,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
pralsetinib,Tyrosine-protein kinase JAK2,JAK2,7.72,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
estetrol,Estrogen receptor beta,ESR2,7.72,Ki,C[C@]12CC[C@H]3[C@H]([C@@H]1[C@H]([C@H]([C@@H]2O)O)O)CCC4=C3C=CC(=C4)O
chlorpromazine,Sodium-dependent noradrenaline transporter,SLC6A2,7.721,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
fluphenazine,Alpha-1B adrenergic receptor,Adra1b,7.721,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
lisuride,Histamine H1 receptor,HRH1,7.721,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
pecazine,Muscarinic acetylcholine receptor M1,CHRM1,7.721,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
pecazine,Muscarinic acetylcholine receptor M4,CHRM4,7.721,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
mesoridazine,Muscarinic acetylcholine receptor M4,CHRM4,7.721,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
olanzapine,Alpha-1A adrenergic receptor,ADRA1A,7.721,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
paliperidone,5-hydroxytryptamine receptor 1D,HTR1D,7.721,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
vortioxetine,5-hydroxytryptamine receptor 7,HTR7,7.721,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
ibrutinib,Proto-oncogene tyrosine-protein kinase Src,SRC,7.721,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
ripasudil,Rho-associated protein kinase 2,ROCK2,7.721,IC50,C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=C1C(F)=CN=C2
brexpiprazole,Histamine H1 receptor,HRH1,7.721,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
prochlorperazine,Histamine H1 receptor,HRH1,7.723,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
mesoridazine,D(2) dopamine receptor,DRD2,7.724,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
ketotifen,Muscarinic acetylcholine receptor M5,CHRM5,7.73,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
trihexyphenidyl,Muscarinic acetylcholine receptor M2,CHRM2,7.73,IC50,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
prazosin,5-hydroxytryptamine receptor 2A,HTR2A,7.73,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
cariprazine,5-hydroxytryptamine receptor 2A,HTR2A,7.73,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
amoxapine,D(3) dopamine receptor,DRD3,7.734,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
glutamic acid,"Glutamate receptor ionotropic, kainate 4",GRIK4,7.738,Ki,N[C@@H](CCC(O)=O)C(O)=O
celecoxib,Carbonic anhydrase 12,CA12,7.74,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorprothixene,D(1A) dopamine receptor,DRD1,7.74,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dasatinib,Receptor tyrosine-protein kinase erbB-3,ERBB3,7.74,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desloratadine,Muscarinic acetylcholine receptor M1,CHRM1,7.74,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
dorzolamide,Carbonic anhydrase 13,Ca13,7.74,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
dorzolamide,Carbonic anhydrase 13,CA13,7.74,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
dorzolamide,Alpha carbonic anhydrase,CA,7.74,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
fenofibrate,"Fatty acid-binding protein, liver",Fabp1,7.74,Kd,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
losartan,Type-1 angiotensin II receptor,AGTR1,7.74,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
loxapine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7.74,IC50,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
mirtazapine,Alpha-2C adrenergic receptor,ADRA2C,7.74,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
naloxone,Delta-type opioid receptor,Oprd1,7.74,Kd,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
pergolide,Dopamine receptor,DRD2|DRD1,7.74,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
sorafenib,Mitogen-activated protein kinase 3,MAPK3,7.74,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulpiride,"Carbonic anhydrase 5B, mitochondrial",CA5B,7.74,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tacrine,Acetylcholinesterase,Ache,7.74,Kd,NC1=C2CCCCC2=NC2=CC=CC=C12
tetroxoprim,Dihydrofolate reductase,dfrA17,7.74,IC50,COCCOC1=C(OC)C=C(CC2=CN=C(N)N=C2N)C=C1OC
thioridazine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,7.74,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tretinoin,Retinoic acid receptor gamma,Rarg,7.74,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
romidepsin,Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2),HDAC3|NCOR2,7.74,IC50,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
crizotinib,STE20-like serine/threonine-protein kinase,SLK,7.74,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
hydroxyprogesterone caproate,Corticosteroid-binding globulin,SERPINA6,7.74,Ki,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
bosutinib,Epidermal growth factor receptor,EGFR,7.74,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Ephrin type-A receptor 2,EPHA2,7.74,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Ephrin type-A receptor 4,EPHA4,7.74,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Serine/threonine-protein kinase 16,STK16,7.74,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Dual specificity protein kinase CLK4,CLK4,7.74,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Serine/threonine-protein kinase STK11,STK11,7.74,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
dosulepin,Muscarinic acetylcholine receptor M1,CHRM1,7.744,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
bortezomib,26S proteasome non-ATPase regulatory subunit 1,PSMD1,7.745,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
bortezomib,PH and SEC7 domain-containing protein 1,PSD,7.745,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
chlorprothixene,Muscarinic acetylcholine receptor M4,CHRM4,7.745,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dimethyltubocurarinium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,7.745,IC50,COC1=CC=C2C[C@@H]3C4=C(OC5=CC=C(C[C@H]6C7=C(CC[N+]6(C)C)C=C(OC)C(OC1=C2)=C7)C=C5)C(OC)=C(OC)C=C4CC[N+]3(C)C
estradiol benzoate,Estrogen receptor,ESR1,7.745,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
ethylestrenol,Androgen receptor,Ar,7.745,Ki,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
flunarizine,Histamine H1 receptor,HRH1,7.745,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
indoramin,D(4) dopamine receptor,DRD4,7.745,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
oxazepam,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,7.745,IC50,OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O
pimozide,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.745,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
zotepine,Muscarinic acetylcholine receptor M1,CHRM1,7.745,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
nintedanib,Platelet-derived growth factor receptor alpha,PDGFRA,7.745,IC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
lobeglitazone,Peroxisome proliferator-activated receptor gamma,PPARG,7.745,EC50,COC1=CC=C(OC2=CC(=NC=N2)N(C)CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
alfuzosin,Acetylcholinesterase,ACHE,7.75,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
flupentixol,D(1A) dopamine receptor,DRD1,7.75,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
iloprost,Prostacyclin receptor,PTGIR,7.75,EC50,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
midazolam,GABA-A receptor alpha-1/beta-2/gamma-3,GABRA1|GABRB2|GABRG3,7.75,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
pergolide,5-hydroxytryptamine receptor 6,HTR6,7.75,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
sarpogrelate,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,7.75,Ki,COC1=CC=CC(CCC2=C(OCC(CN(C)C)OC(=O)CCC(O)=O)C=CC=C2)=C1
scopolamine,Muscarinic acetylcholine receptor M5,CHRM5,7.75,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
xamoterol,Beta-1 adrenergic receptor,ADRB1,7.75,Kd,OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1
anidulafungin,"Beta-1,3-glucan synthase catalytic subunit 1",GSC1,7.75,IC50,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O
imrecoxib,Prostaglandin G/H synthase 2,Ptgs2,7.75,IC50,CCCN1CC(=C(C1=O)C1=CC=C(C)C=C1)C1=CC=C(C=C1)S(C)(=O)=O
desipramine,Sodium-dependent serotonin transporter,SLC6A4,7.755,Kd,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
aprindine,Cytochrome P450 2D6,CYP2D6,7.757,Ki,CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1
haloperidol,Alpha-1A adrenergic receptor,Adra1a,7.76,Kd,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
thioridazine,D(1A) dopamine receptor,Drd1,7.76,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tivozanib,Ephrin type-B receptor 2,EPHB2,7.76,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
selpercatinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,7.76,IC50,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O
chlormadinone,Glucocorticoid receptor,NR3C1,7.764,Ki,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
acetazolamide,Carbonic anhydrase 13,Ca13,7.77,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
ajmaline,Potassium voltage-gated channel subfamily A member 5,KCNA5,7.77,IC50,CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H]([C@H]2[C@H]4O)N3[C@@H]1O
atracurium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,7.77,IC50,COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1
bendamustine,Histone deacetylase 1,HDAC1,7.77,IC50,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
brodimoprim,Bifunctional dihydrofolate reductase-thymidylate synthase,,7.77,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br
buspirone,5-hydroxytryptamine receptor 1B,Htr1b,7.77,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
cinnarizine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.77,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
cyproheptadine,Alpha-2B adrenergic receptor,ADRA2B,7.77,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
mianserin,Alpha-2A adrenergic receptor,ADRA2A,7.77,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nafamostat,Trypsin-1,PRSS1,7.77,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
nafamostat,Cationic trypsin,,7.77,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
nilotinib,Mast/stem cell growth factor receptor Kit,KIT,7.77,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
opipramol,C-8 sterol isomerase,ERG2,7.77,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3C=CC3=C2C=CC=C3)CC1
orphenadrine,Muscarinic acetylcholine receptor M4,CHRM4,7.77,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
papaverine,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",PDE10A,7.77,IC50,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
propranolol,Beta-2 adrenergic receptor,ADRB2,7.77,IC50,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
risedronic acid,Farnesyl pyrophosphate synthase,,7.77,Ki,OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
risperidone,Alpha-2B adrenergic receptor,ADRA2B,7.77,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
rocuronium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,7.77,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1
simvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,7.77,IC50,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
sunitinib,Vascular endothelial growth factor receptor 3,FLT4,7.77,Ki,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ribosomal protein S6 kinase alpha-2,RPS6KA2,7.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Ribosomal protein S6 kinase alpha-5,RPS6KA5,7.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase 33,STK33,7.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7.77,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tiagabine,Sodium- and chloride-dependent GABA transporter 1,SLC6A1,7.77,Ki,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1
tolterodine,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.77,IC50,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
trazodone,5-hydroxytryptamine receptor 2A,Htr2a,7.77,IC50,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
vildagliptin,Dipeptidyl peptidase IV,DPP IV,7.77,Ki,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
alitretinoin,Retinoic acid receptor gamma,Rarg,7.77,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
vandetanib,Tyrosine-protein kinase Lck,LCK,7.77,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
nintedanib,Phosphatidylinositol 5-phosphate 4-kinase type-2 beta,PIP4K2B,7.77,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,G protein-coupled receptor kinase 4,GRK4,7.77,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
brexpiprazole,Alpha-2B adrenergic receptor,ADRA2B,7.77,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
pitolisant,Histamine H3 receptor,Hrh3,7.77,Ki,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
baricitinib,AP2-associated protein kinase 1,AAK1,7.77,Kd,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
midostaurin,Serine/threonine-protein kinase 4,STK4,7.77,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase 11,MAP3K11,7.77,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
lorlatinib,Focal adhesion kinase 1,PTK2,7.77,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
lorlatinib,Activated CDC42 kinase 1,TNK2,7.77,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
bremelanotide,Melanocortin receptor 5,MC5R,7.77,Ki,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O
sitagliptin,Dipeptidyl peptidase 4,DPP4,7.774,Ki,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1
bortezomib,Proteasome subunit beta type-8,Psmb8,7.78,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
clozapine,5-hydroxytryptamine receptor 7,HTR7,7.78,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
lisuride,Alpha-1B adrenergic receptor,ADRA1B,7.78,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
nefazodone,Alpha-1A adrenergic receptor,ADRA1A,7.789,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
iloperidone,Alpha-2C adrenergic receptor,ADRA2C,7.79,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
vismodegib,Smoothened homolog,SMO,7.79,Ki,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1
clozapine,Muscarinic acetylcholine receptor M5,CHRM5,7.792,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
fluphenazine,Histamine H1 receptor,HRH1,7.793,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
amoxapine,D(2) dopamine receptor,DRD2,7.796,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
benzbromarone,Cytochrome P450 2C9,CYP2C9,7.796,IC50,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2
clemastine,Muscarinic acetylcholine receptor M1,CHRM1,7.796,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clotrimazole,Cytochrome P450 2C9,CYP2C9,7.796,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,Cytochrome P450 2C19,CYP2C19,7.796,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
ciclosporin,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,7.796,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
cyproterone acetate,Glucocorticoid receptor,NR3C1,7.796,IC50,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
desloratadine,5-hydroxytryptamine receptor 2C,HTR2C,7.796,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
homatropine,Muscarinic acetylcholine receptor M3,CHRM3,7.796,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)C1=CC=CC=C1
lisuride,Cytochrome P450 2D6,CYP2D6,7.796,IC50,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
loratadine,Cytochrome P450 2C19,CYP2C19,7.796,IC50,CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2
miconazole,Cytochrome P450 2C19,CYP2C19,7.796,IC50,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
oxycodone,Mu-type opioid receptor,OPRM1,7.796,Ki,COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
pipamazine,D(1A) dopamine receptor,DRD1,7.796,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
promazine,5-hydroxytryptamine receptor 2A,HTR2A,7.796,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
ritonavir,Cytochrome P450 2C9,CYP2C9,7.796,IC50,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
sulconazole,Cytochrome P450 2C19,CYP2C19,7.796,IC50,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
gemigliptin,Dipeptidyl peptidase 4,DPP4,7.796,IC50,N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(N=C(N=C2C1)C(F)(F)F)C(F)(F)F
telotristat ethyl,Tryptophan 5-hydroxylase 1,TPH1,7.796,IC50,CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=C(C=C(Cl)C=C2)N2C=CC(C)=N2)C(F)(F)F)=C1
acalabrutinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,7.796,IC50,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
apalutamide,Androgen receptor,AR,7.796,IC50,CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F
pridinol,Muscarinic acetylcholine receptor M5,CHRM5,7.799,Ki,OC(CCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
acetazolamide,Carbonic anhydrase 7,Ca7,7.8,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Alpha carbonic anhydrase,CA,7.8,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Carbonic anhydrase,CA2|CA6|CA3|CA4,7.8,IC50,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
amitriptyline,Muscarinic acetylcholine receptor M5,CHRM5,7.8,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
apomorphine,D(1B) dopamine receptor,DRD5,7.8,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
aripiprazole,5-hydroxytryptamine receptor 7,Htr7,7.8,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
beraprost,Prostacyclin receptor,Ptgir,7.8,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12
bromperidol,D(4) dopamine receptor,DRD4,7.8,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
cicaprost,Prostacyclin receptor,PTGIR,7.8,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
clenbuterol,Beta-2 adrenergic receptor,ADRB2,7.8,Kd,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
ciclosporin,Peptidyl-prolyl cis-trans isomerase FKBP4,FKBP4,7.8,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dexmethylphenidate,Sodium-dependent dopamine transporter,SLC6A3,7.8,Ki,COC(=O)[C@@H]([C@H]1CCCCN1)C1=CC=CC=C1
diltiazem,Voltage-gated L-type calcium channel,Cacna1c|Cacna1d|Cacna1s,7.8,Ki,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
donepezil,Acetylcholinesterase,ACHE,7.8,Ki,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
epoprostenol,Prostacyclin receptor,PTGIR,7.8,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O
flunitrazepam,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,7.8,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
fluphenazine,5-hydroxytryptamine receptor 6,Htr6,7.8,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
haloperidol,Transmembrane protein 97,TMEM97,7.8,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ketanserin,Alpha-1D adrenergic receptor,ADRA1D,7.8,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
lidoflazine,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.8,IC50,CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1
loxapine,5-hydroxytryptamine receptor 6,Htr6,7.8,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
methysergide,5-hydroxytryptamine receptor 7,HTR7,7.8,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
methysergide,5-hydroxytryptamine receptor 1F,Htr1f,7.8,IC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nilotinib,Platelet-derived growth factor receptor beta,PDGFRB,7.8,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
norepinephrine,Adrenergic receptor alpha,Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a,7.8,IC50,NC[C@H](O)C1=CC(O)=C(O)C=C1
octreotide,Somatostatin receptor type 3,Sstr3,7.8,Ki,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
olopatadine,Histamine H1 receptor,HRH1,7.8,Ki,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
ondansetron,5-hydroxytryptamine receptor 3A,HTR3A,7.8,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
perphenazine,5-hydroxytryptamine receptor 6,Htr6,7.8,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
physostigmine,Butyrylcholinesterase,BCHE,7.8,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
prednisolone,Glucocorticoid receptor,NR3C1,7.8,EC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
rimantadine,Matrix protein 2,M,7.8,Kd,CC(N)C12CC3CC(CC(C3)C1)C2
sorafenib,Mast/stem cell growth factor receptor Kit,KIT,7.8,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sorafenib,Vascular endothelial growth factor receptor 3,FLT4,7.8,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Serine/threonine-protein kinase PAK 3,PAK3,7.8,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,7.8,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
terfenadine,Potassium voltage-gated channel subfamily H member 1,KCNH1,7.8,IC50,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
terguride,5-hydroxytryptamine receptor 1D,HTR1D,7.8,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
tretinoin,Peroxisome proliferator-activated receptor delta,PPARD,7.8,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
troleandomycin,Cytochrome P450 3A4,CYP3A4,7.8,Ki,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
ziprasidone,Histamine H1 receptor,HRH1,7.8,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
methyltestosterone,Androgen receptor,Ar,7.8,IC50,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
xanomeline,Muscarinic acetylcholine receptor M2,Chrm2,7.8,IC50,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
vorinostat,Histone deacetylase 4,HDAC4,7.8,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
serine,Cholinesterase,BCHE,7.8,IC50,N[C@@H](CO)C(O)=O
indacaterol,Beta-2 adrenergic receptor,ADRB2,7.8,Ki,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2
bosutinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7.8,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
teriparatide,Parathyroid hormone 2 receptor,PTH2R,7.8,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
afamelanotide,Adenosine deaminase,ADA,7.8,Ki,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
corticorelin,Corticotropin-releasing factor receptor 2,Crhr2,7.8,Ki,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)CC)C(N)=O
cariprazine,D(2) dopamine receptor,Drd2,7.8,IC50,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
aripiprazole lauroxil,5-hydroxytryptamine receptor 7,Htr7,7.8,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
neratinib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7.8,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Death-associated protein kinase 1,DAPK1,7.8,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
pralsetinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,7.8,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
enarodustat,Egl nine homolog 1,EGLN1,7.8,Ki,OC(=O)CNC(=O)C1=C2N=CNN2C(CCC2=CC=CC=C2)C=C1O
berotralstat,Plasma kallikrein,KLKB1,7.8,IC50,C1CC1CN[C@@H](C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N
caramiphen,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.81,Ki,CCN(CC)CCOC(=O)C1(CCCC1)C1=CC=CC=C1
clodronic acid,Solute carrier family 17 member 9,SLC17A9,7.81,IC50,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O
diphenhydramine,Histamine H1 receptor,HRH1,7.81,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
calcitonin human,Calcitonin receptor,CALCR,7.81,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O
macimorelin,Growth hormone secretagogue receptor type 1,GHSR,7.81,IC50,CC(C)(N)C(=O)N[C@H](CC1=CC2=C(N1)C=CC=C2)C(=O)N[C@H](CC1=CNC2=C1C=CC=C2)NC=O
vadadustat,Egl nine homolog 1,EGLN1,7.81,IC50,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
procainamide,Muscarinic acetylcholine receptor M2,CHRM2,7.812,Ki,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
thiothixene,5-hydroxytryptamine receptor 7,HTR7,7.817,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
chlorphenamine,Sodium-dependent serotonin transporter,SLC6A4,7.818,Kd,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
alfentanil,Mu-type opioid receptor,OPRM1,7.82,IC50,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O
brodimoprim,Dihydrofolate reductase,Dhfr,7.82,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br
chlortalidone,Carbonic anhydrase 13,Ca13,7.82,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
clavulanic acid,Beta-lactamase,ampC,7.82,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
dextromethorphan,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.82,IC50,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
diazepam,Gamma-aminobutyric acid receptor subunit alpha-2,Gabra2,7.82,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
flumazenil,GABA A receptor alpha-6/beta-2/gamma-2,Gabrg2|Gabra6|Gabrb2,7.82,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
fluoxetine,Serotonin 1 (5-HT1) receptor,Htr1a|Htr1b|Htr1d|Htr1f,7.82,IC50,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
haloperidol,D(1A) dopamine receptor,DRD1,7.82,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
imatinib,Discoidin domain-containing receptor 2,DDR2,7.82,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
ketanserin,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7.82,IC50,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
loxapine,5-hydroxytryptamine receptor 6,HTR6,7.82,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
medroxalol,Beta-1 adrenergic receptor,ADRB1,7.82,pA2,CC(CCC1=CC2=C(OCO2)C=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
nalorphine,Kappa-type opioid receptor,OPRK1,7.82,Ki,O[C@H]1C=C[C@H]2[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
oseltamivir,Neuraminidase,,7.82,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
pergolide,5-hydroxytryptamine receptor 1A,Htr1a,7.82,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
phencyclidine,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,7.82,Ki,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1
phenelzine,Amine oxidase [flavin-containing] B,MAOB,7.82,Ki,NNCCC1=CC=CC=C1
raltitrexed,Folate receptor alpha,FOLR1,7.82,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
rotigotine,D(2) dopamine receptor,DRD2,7.82,Ki,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
sorafenib,Vascular endothelial growth factor receptor 2,Kdr,7.82,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Myosin light chain kinase family member 4,MYLK4,7.82,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Casein kinase I isoform delta,CSNK1D,7.82,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tolrestat,Aldose reductase,AKR1B1,7.82,IC50,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
tretinoin,Retinoic acid receptor alpha,Rara,7.82,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
trifluoperazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.82,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
varenicline,Neuronal acetylcholine receptor; alpha4/beta4,Chrna4|Chrnb4,7.82,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
ziprasidone,Histone H1.0,H1F0,7.82,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
kainic acid,"Glutamate receptor ionotropic, kainate 5",Grik5,7.82,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
triclosan,Enoyl-acyl carrier reductase; Enoyl-acyl carrier reductase ENR,ENR,7.82,IC50,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
xylometazoline,Alpha-2A adrenergic receptor,ADRA2A,7.82,Ki,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
serine,Acetylcholinesterase,ache,7.82,IC50,N[C@@H](CO)C(O)=O
rilpivirine,Reverse transcriptase,reverse transcriptas,7.82,IC50,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=NC(NC2=CC=C(C=C2)C#N)=NC=C1
ruxolitinib,Histone deacetylase 6,HDAC6,7.82,IC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
ruxolitinib,Histone deacetylase 6,HDAC6,7.82,IC50,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
vismodegib,Sonic hedgehog protein,SHH,7.82,IC50,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1
bosutinib,Mitogen-activated protein kinase kinase kinase kinase 1,MAP4K1,7.82,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
voclosporin,Peptidyl-prolyl cis-trans isomerase A,PPIA,7.82,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
voclosporin,Peptidyl-prolyl cis-trans isomerase A,PPIA,7.82,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
nintedanib,Platelet-derived growth factor receptor beta,PDGFRB,7.82,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Serine/threonine-protein kinase N2,PKN2,7.82,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase 9,MAP3K9,7.82,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,7.82,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
fedratinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,7.82,IC50,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
carpipramine,D(3) dopamine receptor,DRD3,7.824,Ki,NC(=O)C1(CCN(CCCN2C3=CC=CC=C3CCC3=C2C=CC=C3)CC1)N1CCCCC1
carvedilol,5-hydroxytryptamine receptor 2B,HTR2B,7.824,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
clemastine,Alpha-1D adrenergic receptor,ADRA1D,7.824,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
mesoridazine,Muscarinic acetylcholine receptor M2,CHRM2,7.824,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
phenylpropanolamine,Sodium-dependent noradrenaline transporter,SLC6A2,7.824,Ki,CC(N)C(O)C1=CC=CC=C1
prochlorperazine,5-hydroxytryptamine receptor 2A,HTR2A,7.824,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
stanozolol,Androgen receptor,Ar,7.824,Ki,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=NN5
tazobactam,Beta-lactamase,ampC,7.824,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
vecuronium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,7.824,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
iloperidone,5-hydroxytryptamine receptor 1D,HTR1D,7.824,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
guanabenz,Alpha-2A adrenergic receptor,ADRA2A,7.824,Ki,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
diflorasone diacetate,Progesterone receptor,PGR,7.824,Ki,C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O
vortioxetine,5-hydroxytryptamine receptor 1A,HTR1A,7.824,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
palbociclib,Cyclin-dependent kinase 6,CDK6,7.824,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
brexpiprazole,Alpha-2A adrenergic receptor,ADRA2A,7.824,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
aripiprazole lauroxil,5-hydroxytryptamine receptor 2C,HTR2C,7.824,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
osimertinib,Epidermal growth factor receptor,EGFR,7.824,IC50,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
imrecoxib,Prostaglandin G/H synthase 2,PTGS2,7.824,IC50,CCCN1CC(=C(C1=O)C1=CC=C(C)C=C1)C1=CC=C(C=C1)S(C)(=O)=O
amitriptyline,Muscarinic acetylcholine receptor M1,CHRM1,7.83,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
metoprolol,Beta-1 adrenergic receptor,ADRB1,7.83,Kd,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
prednisolone,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,7.83,IC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,Disintegrin and metalloproteinase domain-containing protein 17,ADAM17,7.83,IC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
quercetin,Aldose reductase,AKR1B1,7.83,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ibrexafungerp,"1,3-Beta-D-glucan-UDP glucosyltransferase",FKS1,7.83,IC50,C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
adenosine triphosphate,P2X purinoceptor 3,P2RX3,7.836,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
cisapride,5-hydroxytryptamine receptor 4,HTR4,7.84,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
prasterone,Sex hormone-binding globulin,SHBG,7.84,Kd,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O
donepezil,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.84,Ki,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
donepezil,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.84,Ki,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
losartan,Type-1A angiotensin II receptor,Agtr1,7.84,Ki,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
metyrapone,"Cytochrome P450 11B1, mitochondrial",CYP11B1,7.84,IC50,CC(C)(C(=O)C1=CN=CC=C1)C1=CN=CC=C1
pentagastrin,Gastrin/cholecystokinin type B receptor,CCKBR,7.84,Ki,CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
risperidone,5-hydroxytryptamine receptor 2C,Htr2c,7.84,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
cabozantinib,Angiopoietin-1 receptor,TEK,7.845,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
bexarotene,Retinoic acid receptor RXR-alpha,RXRA,7.85,Kd,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
bicalutamide,Androgen receptor,Ar,7.85,Ki,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
bromopride,D(2) dopamine receptor,DRD2,7.85,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Br)=C1
budesonide,Mineralocorticoid receptor,NR3C2,7.85,EC50,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
chlorpromazine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,7.85,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clotiapine,D(1A) dopamine receptor,Drd1,7.85,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
ergotamine,5-hydroxytryptamine receptor 5A,HTR5A,7.85,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ethoxzolamide,Carbonic anhydrase 1,CA1,7.85,Kd,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
imatinib,Platelet-derived growth factor receptor beta,PDGFRB,7.85,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imatinib,Bcr/Abl fusion protein,ABL1|BCR,7.85,Ki,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
methazolamide,Carbonic anhydrase 1,CA1,7.85,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
methazolamide,Carbonic anhydrase,NCE103,7.85,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
oxybutynin,Muscarinic acetylcholine receptor M5,CHRM5,7.85,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
risperidone,Histone H1.0,H1F0,7.85,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sunitinib,Interleukin-1 receptor-associated kinase 1,IRAK1,7.85,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
theophylline,Adenosine receptor A3,ADORA3,7.85,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
tramadol,Kappa-type opioid receptor,OPRK1,7.85,Ki,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
ubenimex,Aminopeptidase B,Rnpep,7.85,Ki,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
podophyllotoxin,Glucocorticoid receptor,NR3C1,7.85,IC50,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12
sabcomeline,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,7.85,IC50,CO\N=C(/C#N)[C@H]1CN2CCC1CC2
pazopanib,Vascular endothelial growth factor receptor 1,FLT1,7.85,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
pazopanib,Vascular endothelial growth factor receptor 2,KDR,7.85,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
boceprevir,Nonstructural protein NS3-4A,,7.85,Ki,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
vandetanib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,7.85,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ticagrelor,P2Y purinoceptor 12,P2RY12,7.85,Ki,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1
carfilzomib,Proteasome subunit beta type-8,PSMB8,7.85,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
apremilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,7.85,IC50,CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O
nintedanib,Tyrosine-protein kinase JAK2,JAK2,7.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,cGMP-dependent protein kinase 1,PRKG1,7.85,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
pitolisant,Histamine H3 receptor,Hrh3,7.85,Ki,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
neratinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,7.85,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
selumetinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,7.85,IC50,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C=C12)C(=O)NOCCO
selumetinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,7.85,IC50,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C=C12)C(=O)NOCCO
clemastine,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.854,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clemastine,Alpha-2C adrenergic receptor,ADRA2C,7.854,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clotrimazole,Thromboxane-A synthase,TBXAS1,7.854,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
diazepam,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,7.854,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
alpha-Ergocryptine,5-hydroxytryptamine receptor 2A,HTR2A,7.854,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
emetine,Alpha-2A adrenergic receptor,ADRA2A,7.854,Ki,CC[C@H]1CN2CCC3=CC(OC)=C(OC)C=C3[C@@H]2C[C@@H]1C[C@H]1NCCC2=CC(OC)=C(OC)C=C12
homatropine,Muscarinic acetylcholine receptor M4,CHRM4,7.854,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)C1=CC=CC=C1
mequitazine,Muscarinic acetylcholine receptor M2,CHRM2,7.854,Ki,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
nicotine,Neuronal acetylcholine receptor; alpha3/beta2,CHRNB2|CHRNA3,7.854,Ki,CN1CCC[C@H]1C1=CC=CN=C1
thioridazine,Muscarinic acetylcholine receptor M2,CHRM2,7.854,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tiapride,D(4) dopamine receptor,DRD4,7.854,Ki,CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O
ibrutinib,Tyrosine-protein kinase Lyn,LYN,7.854,Ki,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
lorlatinib,Protein-tyrosine kinase 2-beta,PTK2B,7.854,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
diazepam,GABA A receptor alpha-3/beta-2/gamma-2,Gabrg2|Gabra3|Gabrb2,7.86,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
morphine,Mu-type opioid receptor,OPRM1,7.86,EC50,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
morphine,Nociceptin receptor,OPRL1,7.86,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
reboxetine,Transporter,Slc6a2,7.86,Ki,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
quetiapine,Alpha-1B adrenergic receptor,Adra1b,7.866,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
spiperone,Alpha-1A adrenergic receptor,ADRA1A,7.87,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
tamsulosin,Alpha-2A adrenergic receptor,ADRA2A,7.87,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
medroxyprogesterone,Glucocorticoid receptor,NR3C1,7.88,Ki,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
oxymetazoline,Alpha-1A adrenergic receptor,ADRA1A,7.88,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
biriperone,D(2) dopamine receptor,Drd2,7.88,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCN2CC3=C(CC2C1)C1=CC=CC=C1N3
pexidartinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,7.88,IC50,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
hydrocortisone,Corticosteroid-binding globulin,SERPINA6,7.881,Ki,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
amisulpride,5-hydroxytryptamine receptor 2B,HTR2B,7.886,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
amoxapine,Sodium-dependent noradrenaline transporter,SLC6A2,7.886,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
carvedilol,Alpha-2C adrenergic receptor,ADRA2C,7.886,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
clomipramine,Muscarinic acetylcholine receptor M4,CHRM4,7.886,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
cyamemazine,Muscarinic acetylcholine receptor M1,CHRM1,7.886,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
fluphenazine,Alpha-1B adrenergic receptor,ADRA1B,7.886,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,Alpha-1B adrenergic receptor,ADRA1B,7.886,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
prochlorperazine,Alpha-1D adrenergic receptor,ADRA1D,7.886,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
promazine,Sodium-dependent noradrenaline transporter,SLC6A2,7.886,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
thioridazine,Muscarinic acetylcholine receptor M5,CHRM5,7.886,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
lenalidomide,Tumor necrosis factor,TNF,7.886,IC50,NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
asenapine,Alpha-2C adrenergic receptor,ADRA2C,7.886,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
lorcaserin,5-hydroxytryptamine receptor 2C,HTR2C,7.886,Ki,C[C@H]1CNCCC2=CC=C(Cl)C=C12
dexchlorpheniramine,Sodium-dependent serotonin transporter,SLC6A4,7.886,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
apatinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,7.886,IC50,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1
fluphenazine,D(1B) dopamine receptor,DRD5,7.887,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,D(1B) dopamine receptor,DRD5,7.887,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
amitriptyline,Muscarinic acetylcholine receptor M3,CHRM3,7.89,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
dasatinib,Tyrosine-protein kinase Tec,TEC,7.89,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Tyrosine-protein kinase Srms,SRMS,7.89,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
entacapone,Catechol O-methyltransferase,Comt,7.89,IC50,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N
epinephrine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,7.89,Ki,CNC[C@H](O)C1=CC=C(O)C(O)=C1
ethoxzolamide,Carbonic anhydrase 4,CA4,7.89,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
ethoxzolamide,Carbonic anhydrase 13,CA13,7.89,Kd,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
fomepizole,Alcohol dehydrogenase,,7.89,Kd,CC1=CNN=C1
imatinib,Mast/stem cell growth factor receptor Kit,KIT,7.89,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indapamide,Carbonic anhydrase 13,Ca13,7.89,Ki,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
mazindol,Sodium-dependent dopamine transporter,Slc6a3,7.89,IC50,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
opipramol,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,7.89,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3C=CC3=C2C=CC=C3)CC1
risperidone,Alpha-1A adrenergic receptor,Adra1a,7.89,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
selegiline,Monoamine oxidase,Maob|Maoa,7.89,IC50,C[C@H](CC1=CC=CC=C1)N(C)CC#C
sunitinib,Casein kinase I isoform epsilon,CSNK1E,7.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Tyrosine-protein kinase ITK/TSK,ITK,7.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Serine/threonine-protein kinase ULK2,ULK2,7.89,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamsulosin,D(2) dopamine receptor,DRD2,7.89,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
tretinoin,Retinoic acid receptor beta,Rarb,7.89,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
valdecoxib,Carbonic anhydrase 12,CA12,7.89,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
triclocarban,Bifunctional epoxide hydrolase 2,EPHX2,7.89,IC50,ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1
xanomeline,Muscarinic acetylcholine receptor M3,CHRM3,7.89,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
xylometazoline,5-hydroxytryptamine receptor 1B,HTR1B,7.89,Ki,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
vorinostat,Histone deacetylase 11,HDAC11,7.89,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
prazosin,Alpha-2B adrenergic receptor,ADRA2B,7.89,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
prazosin,Alpha-2 adrenergic receptor,Adra2b|Adra2c|Adra2a,7.89,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
gepirone,5-hydroxytryptamine receptor 1A,HTR1A,7.89,Ki,CC1(C)CC(=O)N(CCCCN2CCN(CC2)C2=NC=CC=N2)C(=O)C1
paraoxon,Acetylcholinesterase,Ache,7.89,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
nintedanib,Vascular endothelial growth factor receptor 2,Kdr,7.89,IC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
neratinib,Serine/threonine-protein kinase 10,STK10,7.89,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fedratinib,Serine/threonine-protein kinase DCLK3,DCLK3,7.89,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
delgocitinib,Tyrosine-protein kinase JAK3,JAK3,7.89,IC50,C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N
amitriptyline,Alpha-1A adrenergic receptor,ADRA1A,7.9,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
aripiprazole,5-hydroxytryptamine receptor 2A,HTR2A,7.9,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
bromocriptine,5-hydroxytryptamine receptor 1A,HTR1A,7.9,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
cabergoline,Alpha-2A adrenergic receptor,ADRA2A,7.9,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
cyamemazine,5-hydroxytryptamine receptor 2C,HTR2C,7.9,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
dinoprost,Prostaglandin F2-alpha receptor,Ptgfr,7.9,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
enprostil,Prostaglandin E2 receptor EP3 subtype,PTGER3,7.9,EC50,COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O
ergotamine,5-hydroxytryptamine receptor 2C,Htr2c,7.9,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
fluspirilene,Histamine H1 receptor,HRH1,7.9,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
haloperidol,Alpha-1A adrenergic receptor,ADRA1A,7.9,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
iloprost,Prostaglandin E2 receptor EP1 subtype,Ptger1,7.9,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
methylergometrine,5-hydroxytryptamine receptor 2A,Htr2a,7.9,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
methylergometrine,5-hydroxytryptamine receptor 2C,Htr2c,7.9,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
methysergide,5-hydroxytryptamine receptor 7,Htr7,7.9,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
methysergide,5-hydroxytryptamine receptor 7,Htr7,7.9,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
olanzapine,D(2) dopamine receptor,Drd2,7.9,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
pergolide,5-hydroxytryptamine receptor 1D,HTR1D,7.9,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
reserpine,Synaptic vesicular amine transporter,SLC18A2,7.9,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
rilmenidine,Alpha-2C adrenergic receptor,ADRA2C,7.9,Ki,C1CC1C(NC1=NCCO1)C1CC1
rizatriptan,5-hydroxytryptamine receptor 1D,HTR1D,7.9,Ki,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
sorafenib,Purine nucleoside phosphorylase,PNP,7.9,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
tegaserod,5-hydroxytryptamine receptor 4,HTR4,7.9,EC50,CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2
thioridazine,Alpha-1A adrenergic receptor,ADRA1A,7.9,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
trifluoperazine,5-hydroxytryptamine receptor 2A,HTR2A,7.9,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
urapidil,Alpha-1D adrenergic receptor,ADRA1D,7.9,Ki,COC1=C(C=CC=C1)N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1
pentazocine,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,7.9,IC50,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
yohimbine,5-hydroxytryptamine receptor 2B,HTR2B,7.9,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
tolvaptan,Vasopressin V1a receptor,AVPR1A,7.9,Ki,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=CC(Cl)=CC=C12
abiraterone acetate,Cytochrome P450 17A1,Cyp17a1,7.9,IC50,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C4=CC=CN=C4)[C@@H]3CC=C2C1
regorafenib,Vascular endothelial growth factor receptor 2,KDR,7.9,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
corticorelin,Corticotropin-releasing factor receptor 2,Crhr2,7.9,Kd,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)CC)C(N)=O
binimetinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,7.9,IC50,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO
binimetinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,7.9,IC50,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO
ponatinib,Mast/stem cell growth factor receptor Kit,KIT,7.903,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
procyclidine,Muscarinic acetylcholine receptor M3,CHRM3,7.907,Ki,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
brinzolamide,Carbonate dehydratase,,7.91,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
cetirizine,Histamine H1 receptor,HRH1,7.91,Ki,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
methamphetamine,Sodium-dependent noradrenaline transporter,SLC6A2,7.91,Ki,CN[C@@H](C)CC1=CC=CC=C1
methotrexate,Dihydrofolate reductase,dfrA,7.91,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
naltrexone,Delta-type opioid receptor,Oprd1,7.91,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
tacrine,Amyloid beta A4 protein,APP,7.91,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
iloperidone,Histamine H1 receptor,HRH1,7.91,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
acetazolamide,Carbonic anhydrase 1,CA1,7.92,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase,,7.92,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetylcholine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,7.92,IC50,CC(=O)OCC[N+](C)(C)C
alvimopan,Delta-type opioid receptor,OPRD1,7.92,Ki,C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1
butorphanol,Delta-type opioid receptor,OPRD1,7.92,Ki,OC1=CC2=C(C[C@H]3N(CC4CCC4)CC[C@@]22CCCC[C@@]32O)C=C1
clebopride,D(2) dopamine receptor,DRD2,7.92,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
diazepam,Adenosine receptor A3,ADORA3,7.92,IC50,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
diazepam,GABA-A receptor; alpha-1/beta-2/gamma-2,Gabrg2|Gabra1|Gabrb2,7.92,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
diclofenac,C-X-C chemokine receptor type 1,CXCR1,7.92,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
imipramine,Transporter,Slc6a2,7.92,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
imipramine,Sodium-dependent noradrenaline transporter,Slc6a2,7.92,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
indoramin,Alpha-1A adrenergic receptor,ADRA1A,7.92,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
nicotine,Neuronal acetylcholine receptor subunit alpha-2,Chrna2,7.92,Ki,CN1CCC[C@H]1C1=CC=CN=C1
olanzapine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,7.92,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
ondansetron,Serotonin 3 receptor (5HT3),Htr3a|Htr3b,7.92,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
penbutolol,5-hydroxytryptamine receptor 1A,HTR1A,7.92,Ki,CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C1CCCC1
rofecoxib,Prostaglandin G/H synthase 2,Ptgs2,7.92,IC50,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
sertindole,D(1A) dopamine receptor,Drd1,7.92,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sorafenib,Bifunctional epoxide hydrolase 2,EPHX2,7.92,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
strychnine,Glycine receptor subunit alpha-1,Glra1,7.92,Ki,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1C1=CC=CC=C61
eseridine,Cholinesterase,BCHE,7.92,IC50,CNC(=O)OC1=CC2=C(C=C1)N(C)[C@H]1ON(C)CC[C@@]21C
flusalan,Mu-type opioid receptor,OPRM1,7.92,IC50,OC1=C(C=C(Br)C=C1Br)C(=O)NC1=CC(=CC=C1)C(F)(F)F
naphazoline,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7.92,EC50,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
pentazocine,Sigma non-opioid intracellular receptor 1,Sigmar1,7.92,Ki,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
quercetin,Aromatase,CYP19A1,7.92,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
ruboxistaurin,Serine/threonine-protein kinase pim-3,PIM3,7.92,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
rutoside,Acetylcholinesterase,ACHE,7.92,IC50,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
alitretinoin,Retinoic acid receptor RXR-beta,Rxrb,7.92,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
mozavaptan,Vasopressin V2 receptor,Avpr2,7.92,IC50,CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C2=CC=CC=C12
vorinostat,Histone deacetylase 3/NCoR1,HDAC3|NCOR1,7.92,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
crizotinib,Leukocyte tyrosine kinase receptor,LTK,7.92,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
cabozantinib,Vascular endothelial growth factor receptor 1,FLT1,7.92,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
ponatinib,Cyclin-dependent kinase 19,CDK19,7.92,Kd,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
ponatinib,Receptor-interacting serine/threonine-protein kinase 1,RIPK1,7.92,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
nintedanib,Epithelial discoidin domain-containing receptor 1,DDR1,7.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Tyrosine-protein kinase receptor UFO,AXL,7.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,SRSF protein kinase 3,SRPK3,7.92,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Tyrosine-protein kinase JAK3,JAK3,7.92,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Serine/threonine-protein kinase 25,STK25,7.92,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
entrectinib,ALK tyrosine kinase receptor,ALK,7.92,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
alprazolam,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,7.921,EC50,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
carbachol,Muscarinic acetylcholine receptor M2,CHRM2,7.921,EC50,C[N+](C)(C)CCOC(N)=O
clemastine,Potassium voltage-gated channel subfamily H member 2,KCNH2,7.921,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
cyamemazine,Muscarinic acetylcholine receptor M4,CHRM4,7.921,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
alpha-Ergocryptine,Alpha-2B adrenergic receptor,ADRA2B,7.921,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
dosulepin,Alpha-2B adrenergic receptor,ADRA2B,7.921,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
octreotide,Mu-type opioid receptor,OPRM1,7.921,Ki,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
olanzapine,5-hydroxytryptamine receptor 2B,HTR2B,7.921,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
prochlorperazine,Alpha-2C adrenergic receptor,ADRA2C,7.921,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
promethazine,Muscarinic acetylcholine receptor M2,CHRM2,7.921,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
quinidine,Cytochrome P450 2D6,CYP2D6,7.921,Ki,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
doravirine,Reverse transcriptase/RNaseH,pol,7.921,EC50,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F
paliperidone,Alpha-2A adrenergic receptor,ADRA2A,7.925,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
domperidone,D(3) dopamine receptor,Drd3,7.93,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
famotidine,Histamine H2 receptor,HRH2,7.93,Kd,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
flibanserin,5-hydroxytryptamine receptor 1A,Htr1a,7.93,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
vadadustat,Egl nine homolog 2,EGLN2,7.93,IC50,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
apraclonidine,Alpha-2B adrenergic receptor,ADRA2B,7.938,Ki,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1
amisulpride,5-hydroxytryptamine receptor 7,HTR7,7.939,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
diazepam,GABA A receptor alpha-3/beta-2/gamma-2,GABRG2|GABRA3|GABRB2,7.939,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
enalaprilat,Angiotensin-converting enzyme,Ace,7.94,IC50,C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
phentolamine,Nischarin,NISCH,7.94,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
thiothixene,Alpha-1A adrenergic receptor,ADRA1A,7.94,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
cabozantinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,7.947,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
brodimoprim,Dihydrofolate reductase,folA,7.95,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br
clozapine,5-hydroxytryptamine receptor 6,HTR6,7.95,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
levocetirizine,Histamine H1 receptor,HRH1,7.95,Ki,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
rilmenidine,Nischarin,Nisch,7.95,Ki,C1CC1C(NC1=NCCO1)C1CC1
ximelagatran,Cationic trypsin,,7.95,IC50,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO
lasofoxifene,Estrogen receptor,Esr1|Esr2,7.95,IC50,OC1=CC=C2C(C(CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
cabozantinib,Fibroblast growth factor receptor 1,FGFR1,7.95,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
levomilnacipran,Sodium-dependent serotonin transporter,SLC6A4,7.951,Ki,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1
mequitazine,Muscarinic acetylcholine receptor M4,CHRM4,7.955,Ki,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
amoxapine,Histamine H1 receptor,HRH1,7.959,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
chlorprothixene,Muscarinic acetylcholine receptor M1,CHRM1,7.959,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
desoximetasone,Progesterone receptor,PGR,7.959,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
diazepam,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,7.959,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
dihydroergocristine,5-hydroxytryptamine receptor 1B,Htr1b,7.959,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
domperidone,5-hydroxytryptamine receptor 2A,HTR2A,7.959,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
ergometrine,5-hydroxytryptamine receptor 2C,HTR2C,7.959,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
glisoxepide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,7.959,Kd,CC1=CC(=NO1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1
labetalol,Beta-2 adrenergic receptor,ADRB2,7.959,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
mequitazine,Muscarinic acetylcholine receptor M5,CHRM5,7.959,Ki,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
olanzapine,5-hydroxytryptamine receptor 2C,HTR2C,7.959,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
orphenadrine,Histamine H1 receptor,HRH1,7.959,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1
pipamazine,5-hydroxytryptamine receptor 2C,HTR2C,7.959,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
pyrimethamine,Bifunctional dihydrofolate reductase-thymidylate synthase,,7.959,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
tirofiban,Integrin alpha-IIb/beta-3,ITGB3|ITGA2B,7.959,IC50,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O
femoxetine,Sodium-dependent serotonin transporter,SLC6A4,7.959,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
palbociclib,Cyclin-dependent kinase 4,CDK4,7.959,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
aminopterin,Dihydrofolate reductase,dfrA17,7.96,IC50,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
acetazolamide,Carbonic anhydrase 4,CA4,7.96,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Carbonic anhydrase 6,CA6,7.96,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Carbonic anhydrase,,7.96,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetylcholine,Neuronal acetylcholine receptor; alpha2/beta2,Chrna2|Chrnb2,7.96,Ki,CC(=O)OCC[N+](C)(C)C
aliskiren,Renin,,7.96,IC50,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
amitriptyline,5-hydroxytryptamine receptor 2A,HTR2A,7.96,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
brinzolamide,Carbonic anhydrase 13,CA13,7.96,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
pentoxyverine,Sigma non-opioid intracellular receptor 1,Sigmar1,7.96,Ki,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1
cyproheptadine,5-hydroxytryptamine receptor 2C,Htr2c,7.96,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dasatinib,Proto-oncogene tyrosine-protein kinase Src,SRC,7.96,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Serine/threonine-protein kinase TNNI3K,TNNI3K,7.96,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diazepam,Gamma-aminobutyric acid receptor subunit alpha-1,Gabra1,7.96,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
diazepam,GABA A receptor alpha-5/beta-3/gamma-2,Gabrg2|Gabra5|Gabrb3,7.96,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
alpha-Ergocryptine,Alpha-1A adrenergic receptor,Adra1a,7.96,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
dopamine,D(3) dopamine receptor,Drd3,7.96,Ki,NCCC1=CC(O)=C(O)C=C1
ifenprodil,Glutamate [NMDA] receptor subunit epsilon 2,Grin2b,7.96,Ki,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
imatinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,7.96,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
lindane,Gamma-aminobutyric acid receptor subunit beta,Rdl,7.96,IC50,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
masoprocol,Aromatase,CYP19A1,7.96,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
mifepristone,Glucocorticoid receptor,NR3C1,7.96,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
nilotinib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,7.96,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
ozagrel,Thromboxane-A synthase,TBXAS1,7.96,IC50,OC(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1
phentolamine,Alpha-1A adrenergic receptor,Adra1a,7.96,IC50,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
physostigmine,Acetylcholinesterase,ache,7.96,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
sertindole,D(4) dopamine receptor,DRD4,7.96,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sunitinib,AP2-associated protein kinase 1,AAK1,7.96,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrolimus,Splicing factor 3B subunit 3,SF3B3,7.96,IC50,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
triparanol,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,7.96,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(O)(CC1=CC=C(Cl)C=C1)C1=CC=C(C)C=C1
voriconazole,Cholesterol 24-hydroxylase,CYP46A1,7.96,Ki,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
ziprasidone,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,7.96,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
zoledronic acid,Farnesyl pyrophosphate synthase,,7.96,Ki,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
zotepine,D(2) dopamine receptor,DRD2,7.96,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
atosiban,Oxytocin receptor,OXTR,7.96,Ki,CCOC1=CC=C(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)C=C1
ruboxistaurin,Protein kinase C epsilon type,PRKCE,7.96,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
tetryzoline,Adrenergic receptor alpha,Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a,7.96,Ki,C1CN=C(N1)C1CCCC2=CC=CC=C12
biriperone,D(3) dopamine receptor,DRD3,7.96,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCN2CC3=C(CC2C1)C1=CC=CC=C1N3
vandetanib,Epithelial discoidin domain-containing receptor 1,DDR1,7.96,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
axitinib,Aurora kinase B,AURKB,7.96,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Tyrosine-protein kinase Fyn,FYN,7.96,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
diamorphine,D(2) dopamine receptor,Drd2,7.96,Ki,CN1CC[C@]23[C@H]4OC5=C(OC(C)=O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4OC(C)=O)=C35
midostaurin,Receptor-type tyrosine-protein kinase FLT3,FLT3,7.96,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
vibegron,Beta-3 adrenergic receptor,ADRB3,7.96,EC50,O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C1=CC=CC=C1
darolutamide,Androgen receptor,Ar,7.96,Ki,C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)[C@@H](C)O
tazemetostat,Histone-lysine N-methyltransferase EZH2,EZH2,7.96,IC50,CCN(C1CCOCC1)C1=CC(=CC(C(=O)NCC2=C(C)C=C(C)NC2=O)=C1C)C1=CC=C(CN2CCOCC2)C=C1
ozanimod,Sphingosine 1-phosphate receptor 5,S1PR5,7.96,EC50,CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1
pralsetinib,Fibroblast growth factor receptor 1,FGFR1,7.96,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
lurasidone,Alpha-2C adrenergic receptor,ADRA2C,7.967,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
alexidine,Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1,PTPMT1,7.97,IC50,CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC
desmopressin,Vasopressin V1a receptor,Avpr1a,7.97,Ki,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
fluoxetine,Sodium-dependent dopamine transporter,Slc6a3,7.97,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
imatinib,Tyrosine-protein kinase ABL1,Abl1,7.97,IC50,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
norethisterone,Sex hormone-binding globulin,SHBG,7.97,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
norethindrone acetate,Sex hormone-binding globulin,SHBG,7.97,Kd,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
asenapine,5-hydroxytryptamine receptor 1A,HTR1A,7.97,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
larotrectinib,NT-3 growth factor receptor,NTRK3,7.975,IC50,O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=CC(F)=CC=C1F
chlorproethazine,D(2) dopamine receptor,DRD2,7.979,Ki,CCN(CC)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
fluphenazine enanthate,5-hydroxytryptamine receptor 2A,HTR2A,7.979,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
thioridazine,D(4) dopamine receptor,DRD4,7.979,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
clebopride,D(3) dopamine receptor,DRD3,7.98,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
clozapine,Alpha-1B adrenergic receptor,ADRA1B,7.98,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
glimepiride,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,7.98,Ki,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O
naloxone,C-C chemokine receptor type 5,Ccr5,7.98,Kd,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
progesterone,Progesterone receptor,PGR,7.98,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
chlorproethazine,D(3) dopamine receptor,DRD3,7.987,Ki,CCN(CC)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
frovatriptan,5-hydroxytryptamine receptor 1B,HTR1B,7.99,Ki,CN[C@@H]1CCC2=C(C1)C1=CC(=CC=C1N2)C(N)=O
naltrexone,Delta-type opioid receptor,OPRD1,7.99,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
trihexyphenidyl,Muscarinic acetylcholine receptor M5,CHRM5,7.99,IC50,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
trimethoprim,Bifunctional dihydrofolate reductase-thymidylate synthase,,7.99,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
dronabinol,D(3) dopamine receptor,DRD3,7.99,EC50,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
oxybutynin,Sigma non-opioid intracellular receptor 1,SIGMAR1,7.991,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
acetazolamide,Carbonic anhydrase 2,CAN2,8,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
almotriptan,5-hydroxytryptamine receptor 1B,HTR1B,8,Ki,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
alprazolam,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,8,EC50,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
alprostadil,Prostaglandin E2 receptor EP2 subtype,PTGER2,8,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
alprostadil,Prostaglandin E2 receptor EP2 subtype,Ptger2,8,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
amitriptyline,Alpha-2B adrenergic receptor,ADRA2B,8,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
androstenediol,Estrogen receptor beta,ESR2,8,IC50,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O
atorvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,8,IC50,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
brinzolamide,Carbonic anhydrase 13,Ca13,8,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
bromocriptine,Alpha-2A adrenergic receptor,ADRA2A,8,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bromocriptine,5-hydroxytryptamine receptor 1D,HTR1D,8,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
bromocriptine,5-hydroxytryptamine receptor 7,Htr7,8,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
cerivastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,8,IC50,COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(N=C1C(C)C)C(C)C
cicaprost,Prostacyclin receptor,Ptgir,8,Ki,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/COCC(O)=O
cicloprolol,Beta-1 adrenergic receptor,ADRB1,8,Ki,CC(C)NCC(O)COC1=CC=C(OCCOCC2CC2)C=C1
cisapride,5-hydroxytryptamine receptor 4,Htr4,8,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cisatracurium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,8,IC50,COC1=C(OC)C=C(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C=C2)C=C1
clavulanic acid,Beta-lactamase,blaCTX-M-53,8,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
codeine,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,8,IC50,COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C
cyproheptadine,Muscarinic acetylcholine receptor M1,CHRM1,8,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cyproheptadine,Muscarinic acetylcholine receptor M2,CHRM2,8,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cyproheptadine,Muscarinic acetylcholine receptor M3,CHRM3,8,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
diazepam,GABA-A receptor; anion channel,GABRA1|GABRB1|GABRA2|GABRA3|GABRA4|GABRG2,8,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
dicoumarol,NAD(P)H dehydrogenase [quinone] 1,NQO1,8,Ki,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
dihydroergotamine,5-hydroxytryptamine receptor 7,HTR7,8,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dorzolamide,Carbonic anhydrase 6,CA6,8,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
ebastine,Histamine H1 receptor,HRH1,8,Ki,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
eletriptan,5-hydroxytryptamine receptor 1F,HTR1F,8,Ki,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
enfuvirtide,GP41,HIV1 ENV,8,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
epalrestat,Aldose reductase,Akr1b1,8,IC50,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1
ergometrine,D(2) dopamine receptor,DRD2,8,EC50,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
ergotamine,5-hydroxytryptamine receptor 2A,Htr2a,8,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
etravirine,Reverse transcriptase,reverse transcriptas,8,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
fexofenadine,Histamine H1 receptor,HRH1,8,Ki,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
flunarizine,Sigma non-opioid intracellular receptor 1,SIGMAR1,8,Ki,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
fluspirilene,5-hydroxytryptamine receptor 2A,HTR2A,8,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
hycanthone,DNA-(apurinic or apyrimidinic site) lyase,APEX1,8,Kd,CCN(CC)CCNC1=CC=C(CO)C2=C1C(=O)C1=CC=CC=C1S2
hydrocortisone,"Nitric oxide synthase, inducible",NOS2,8,IC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
ibutilide,Potassium voltage-gated channel subfamily H member 2,KCNH2,8,IC50,CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
ifenprodil,Glutamate NMDA receptor; GRIN1/GRIN2B,GRIN1|GRIN2B,8,Ki,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
iloprost,Prostacyclin receptor,Ptgir,8,Ki,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
indapamide,Carbonic anhydrase 12,CA12,8,Ki,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
indomethacin,Prostaglandin G/H synthase 2,Ptgs2,8,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
lanreotide,Somatostatin receptor type 3,SSTR3,8,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
levorphanol,Kappa-type opioid receptor,Oprk1,8,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
loxapine,5-hydroxytryptamine receptor 2C,HTR2C,8,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
masoprocol,Arachidonate 5-lipoxygenase,Alox5,8,IC50,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
mazindol,Sodium-dependent dopamine transporter,SLC6A3,8,Ki,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
mequitazine,Histamine H1 receptor,HRH1,8,Ki,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
mesoridazine,Muscarinic acetylcholine receptor M1,CHRM1,8,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
methazolamide,Carbonic anhydrase 6,CA6,8,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
nalbuphine,Kappa-type opioid receptor,OPRK1,8,Ki,O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5
nebivolol,5-hydroxytryptamine receptor 1A,HTR1A,8,Ki,OC(CNCC(O)C1CCC2=CC(F)=CC=C2O1)C1CCC2=CC(F)=CC=C2O1
nefazodone,5-hydroxytryptamine receptor 2A,HTR2A,8,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nisoldipine,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,8,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
nitrazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,8,EC50,[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1
nortriptyline,5-hydroxytryptamine receptor 2C,HTR2C,8,Ki,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
orlistat,Sn1-specific diacylglycerol lipase alpha,DAGLA,8,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
orlistat,Fatty-acid amide hydrolase 1,Faah,8,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
oxprenolol,Beta-2 adrenergic receptor,ADRB2,8,Ki,CC(C)NCC(O)COC1=C(OCC=C)C=CC=C1
periciazine,D(1A) dopamine receptor,DRD1,8,Ki,OC1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C#N)CC1
perphenazine,Alpha-1A adrenergic receptor,ADRA1A,8,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
phenylephrine,Alpha-1B adrenergic receptor,,8,EC50,CNC[C@H](O)C1=CC(O)=CC=C1
prednisone,Glucocorticoid receptor,NR3C1,8,EC50,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
protirelin,Protein Trhr2; Thyrotropin releasing hormone receptor 2; Thyrotropin-releasing hormone receptor 2,Trhr2,8,Ki,NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
protirelin,Thyrotropin-releasing hormone receptor,Trhr,8,Ki,NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
quetiapine,Histone H1.0,H1F0,8,Ki,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
raloxifene,Estrogen receptor beta,ESR2,8,EC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
raltegravir,Integrase,pol,8,IC50,CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
rifabutin,DNA-directed RNA polymerase subunit beta,rpoB,8,Ki,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC(C)C)CC3)N=C21
risperidone,Alpha-2A adrenergic receptor,ADRA2A,8,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
risperidone,D(4) dopamine receptor,DRD4,8,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
solifenacin,Muscarinic acetylcholine receptor M1,Chrm1,8,Ki,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
solifenacin,Muscarinic acetylcholine receptor M3,Chrm3,8,Ki,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
spiperone,5-hydroxytryptamine receptor 7,Htr7,8,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sulfamethoxazole,Pol polyprotein,pol,8,Ki,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
tacrine,Acetylcholinesterase,ache,8,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
tadalafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,8,Ki,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
tazobactam,Beta-lactamase,blaSCO-1,8,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
thalidomide,Tumor necrosis factor,TNF,8,IC50,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2
thioridazine,5-hydroxytryptamine receptor 2A,HTR2A,8,EC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
topiramate,Carbonic anhydrase,NCE103,8,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
trimethoprim,Dihydrofolate reductase,DHFR,8,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
trimethoprim,Bifunctional dihydrofolate reductase-thymidylate synthase,,8,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
trimetrexate,Dihydrofolate reductase,folA,8,IC50,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
tropisetron,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,8,EC50,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
verapamil,Potassium voltage-gated channel subfamily H member 2,KCNH2,8,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
ziprasidone,Alpha-1A adrenergic receptor,ADRA1A,8,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
gonadorelin,Gonadotropin-releasing hormone receptor,GNRHR,8,IC50,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
capsaicin,Transient receptor potential cation channel subfamily V member 1,Trpv1,8,EC50,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
kainic acid,"Glutamate receptor ionotropic, kainate 3",GRIK3,8,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
quercetin,Amine oxidase [flavin-containing] A,MAOA,8,IC50,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C=C2)=C1
dronedarone,Potassium voltage-gated channel subfamily KQT member 2,KCNQ2,8,IC50,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
asenapine,5-hydroxytryptamine receptor 1E,HTR1E,8,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
vorinostat,Bromodomain-containing protein 4,BRD4,8,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
vorinostat,Histone deacetylase,HDAC3|HDAC4|HDAC1|HDAC7|HDAC2|HDAC10|HDAC11|HDAC8|HDAC6|HDAC9|HDAC5,8,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
vorinostat,Histone deacetylase (HDAC1 and HDAC2),HDAC1|HDAC2,8,IC50,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
crizotinib,Tyrosine-protein kinase ABL1,ABL1,8,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
elvitegravir,Gag-Pol polyprotein,gag-pol,8,IC50,COC1=C(CC2=C(F)C(Cl)=CC=C2)C=C2C(=O)C(=CN([C@H](CO)C(C)C)C2=C1)C(O)=O
pasireotide,Somatostatin receptor type 1,SSTR1,8,IC50,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
bosutinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,8,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
paraoxon,Acetylcholinesterase,ACHE,8,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
tenidap,Cyclooxygenase,Ptgs2|Ptgs1,8,IC50,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=C1C=CC(Cl)=C2
nintedanib,Tyrosine-protein kinase ABL1,ABL1,8,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,8,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
vonoprazan,Potassium-transporting ATPase,ATP4A|ATP4B,8,Ki,CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1
eldecalcitol,Vitamin D3 receptor,Vdr,8,Kd,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C
ribociclib,Cyclin-dependent kinase 4,CDK4,8,IC50,CN(C)C(=O)C1=CC2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N1C1CCCC1
bremelanotide,Melanocortin receptor 4,MC4R,8,Kd,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O
brilliant Blue G,P2X purinoceptor 7,P2RX7,8,IC50,CCOC1=CC=C(NC2=CC=C(C=C2)C(=C2\C=C/C(/C=C2C)=[N+](/CC)CC2=CC=CC(=C2)S([O-])(=O)=O)\C2=C(C)C=C(C=C2)N(CC)CC2=CC=CC(=C2)S([O-])(=O)=O)C=C1
setmelanotide,Melanocortin receptor 3,MC3R,8,Ki,C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
setmelanotide,Melanocortin receptor 3,MC3R,8,Ki,C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
filgotinib,Tyrosine-protein kinase JAK1,JAK1,8,IC50,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
astemizole,Alpha-1D adrenergic receptor,ADRA1D,8.004,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
diazepam,GABA A receptor alpha-5/beta-2/gamma-2,GABRG2|GABRA5|GABRB2,8.004,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
clomipramine,Histamine H1 receptor,HRH1,8.007,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
seractide,Adrenocorticotropic hormone receptor,MC2R,8.009,Ki,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
bortezomib,Nuclear factor NF-kappa-B complex,NFKB1|NFKB2|RELA,8.01,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
ciclosporin,Peptidyl-prolyl cis-trans isomerase B,PPIB,8.01,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
diazepam,Gamma-aminobutyric acid receptor subunit alpha-5,Gabra5,8.01,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
droperidol,Alpha-1B adrenergic receptor,Adra1b,8.01,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
phenazocine,Mu-type opioid receptor,OPRM1,8.01,IC50,CC1C2CC3=C(C=C(O)C=C3)C1(C)CCN2CCC1=CC=CC=C1
pyrimethamine,Dihydrofolate reductase,,8.01,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
risperidone,D(3) dopamine receptor,Drd3,8.01,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
xanomeline,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,8.01,IC50,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
fluphenazine,Alpha-1D adrenergic receptor,ADRA1D,8.019,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
argatroban,Prothrombin,F2,8.02,Ki,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2
hydrocodone,Mu-type opioid receptor,OPRM1,8.02,Ki,COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C
ziprasidone,D(1A) dopamine receptor,DRD1,8.02,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
nintedanib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.02,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
desloratadine,5-hydroxytryptamine receptor 2A,HTR2A,8.025,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
nordazepam,Gamma-aminobutyric acid type B receptor subunit 2,GABBR2,8.027,IC50,ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1
ethoxzolamide,Carbonate dehydratase,,8.03,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
fentanyl,Delta-type opioid receptor,Oprd1,8.03,IC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
promazine,Alpha-1A adrenergic receptor,Adra1a,8.03,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
sumatriptan,5-hydroxytryptamine receptor 3A,HTR3A,8.03,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
tramadol,Delta-type opioid receptor,OPRD1,8.03,Ki,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
mozavaptan,Vasopressin V2 receptor,AVPR2,8.03,Ki,CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C2=CC=CC=C12
ponatinib,Fibroblast growth factor receptor 3,FGFR3,8.03,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
nintedanib,Mitogen-activated protein kinase kinase kinase 2,MAP3K2,8.03,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Serine/threonine-protein kinase N1,PKN1,8.03,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
midostaurin,Serine/threonine-protein kinase TBK1,TBK1,8.03,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
methylergometrine,5-hydroxytryptamine receptor 1B,Htr1b,8.033,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
nortriptyline,Histamine H1 receptor,HRH1,8.033,Kd,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
clemastine,5-hydroxytryptamine receptor 2A,HTR2A,8.036,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
olmutinib,Epidermal growth factor receptor,EGFR,8.036,IC50,CN1CCN(CC1)C1=CC=C(NC2=NC3=C(SC=C3)C(OC3=CC=CC(NC(=O)C=C)=C3)=N2)C=C1
lisuride,Alpha-1D adrenergic receptor,ADRA1D,8.037,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
dinoprostone,Prostaglandin E2 receptor EP1 subtype,PTGER1,8.04,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
tiamenidine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.04,IC50,CC1=CSC(Cl)=C1N=C1NCCN1
femoxetine,Sodium-dependent dopamine transporter,Slc6a3,8.04,Ki,COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C2=CC=CC=C2)C=C1
dronabinol,Cannabinoid receptor 2,Cnr2,8.04,Ki,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
bosutinib,Ephrin type-B receptor 4,EPHB4,8.04,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
mesoridazine,D(4) dopamine receptor,DRD4,8.041,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
fluphenazine,5-hydroxytryptamine receptor 2A,HTR2A,8.044,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
ciclosporin,Peptidyl-prolyl cis-trans isomerase A,PPIA,8.046,IC50,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
olanzapine,Muscarinic acetylcholine receptor M5,CHRM5,8.046,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
thioridazine,Muscarinic acetylcholine receptor M4,CHRM4,8.046,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
ziprasidone,Alpha-1B adrenergic receptor,ADRA1B,8.046,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
lifitegrast,Integrin alpha-L/beta-2,ITGAL|ITGB2,8.046,IC50,CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C=C3CN(CCC3=C2Cl)C(=O)C2=CC=C3C=COC3=C2)C(O)=O)=C1
ketotifen,5-hydroxytryptamine receptor 2A,HTR2A,8.047,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
acetazolamide,Carbonic anhydrase 9,CA9,8.05,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Carbonic anhydrase 2,mtcA2,8.05,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
apomorphine,D(4) dopamine receptor,DRD4,8.05,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
atomoxetine,Sodium-dependent serotonin transporter,SLC6A4,8.05,Kd,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
bendamustine,Histone deacetylase 2,HDAC2,8.05,IC50,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
chlorprothixene,D(1B) dopamine receptor,DRD5,8.05,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
chlortalidone,"Carbonic anhydrase 5B, mitochondrial",CA5B,8.05,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
clavulanic acid,Beta-lactamase,BlaGIL-1,8.05,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clavulanic acid,Beta-lactamase,blaUOE-1,8.05,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
clonidine,Nischarin,NISCH,8.05,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
clozapine,5-hydroxytryptamine receptor 2C,HTR2C,8.05,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,D(4) dopamine receptor,Drd4,8.05,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dorzolamide,Carbonic anhydrase,NCE103,8.05,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
leflunomide,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Dhodh,8.05,IC50,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
lysergide,5-hydroxytryptamine receptor 5A,HTR5A,8.05,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
methazolamide,Carbonic anhydrase 2,CA2,8.05,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
nilutamide,Androgen receptor,AR,8.05,IC50,CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
omapatrilat,Neprilysin,MME,8.05,Ki,OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12
oseltamivir,Neuraminidase,,8.05,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
oxatomide,Histamine H1 receptor,HRH1,8.05,IC50,O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
paclitaxel,Tubulin beta chain,TUBB,8.05,EC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
paclitaxel,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,8.05,EC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
raloxifene,Interleukin-6,IL6,8.05,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
reboxetine,Sodium-dependent serotonin transporter,SLC6A4,8.05,Ki,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
sultiame,Carbonic anhydrase 2,CA2,8.05,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
sultiame,Carbonic anhydrase,NCE103,8.05,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
sunitinib,Tyrosine-protein kinase JAK1,JAK1,8.05,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,Tyrosine-protein kinase receptor UFO,AXL,8.05,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Butyrylcholinesterase; Protein Bche,Bche,8.05,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
zanamivir,Neuraminidase,,8.05,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
iloperidone,5-hydroxytryptamine receptor 2A,HTR2A,8.05,IC50,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
iloperidone,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.05,IC50,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
vandetanib,Tyrosine-protein kinase ABL1,ABL1,8.05,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
bosutinib,Ephrin type-A receptor 8,EPHA8,8.05,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
teriflunomide,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Dhodh,8.05,IC50,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
nintedanib,Serine/threonine-protein kinase 4,STK4,8.05,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
ripretinib,Platelet-derived growth factor receptor beta,PDGFRB,8.05,IC50,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
pralsetinib,NT-3 growth factor receptor,NTRK3,8.05,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
venlafaxine,Sodium-dependent serotonin transporter,SLC6A4,8.051,Kd,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
fluspirilene,D(4) dopamine receptor,DRD4,8.056,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
oxatomide,5-hydroxytryptamine receptor 2A,HTR2A,8.056,Ki,O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
megestrol acetate,Glucocorticoid receptor,NR3C1,8.057,Ki,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
carpipramine,D(2) dopamine receptor,DRD2,8.06,Ki,NC(=O)C1(CCN(CCCN2C3=CC=CC=C3CCC3=C2C=CC=C3)CC1)N1CCCCC1
chlorphenamine,Histamine H1 receptor,HRH1,8.06,IC50,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
mazindol,Sodium-dependent dopamine transporter,Slc6a3,8.06,Kd,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
meptazinol,Mu-type opioid receptor,OPRM1,8.06,EC50,CCC1(CCCCN(C)C1)C1=CC(O)=CC=C1
mianserin,5-hydroxytryptamine receptor 1F,HTR1F,8.06,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
suvorexant,Orexin receptor type 2,Hcrtr2,8.06,Ki,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2
nintedanib,Dual specificity protein kinase CLK1,CLK1,8.06,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
midostaurin,Epidermal growth factor receptor,EGFR,8.06,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
cisapride,Alpha-1B adrenergic receptor,Adra1b,8.063,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cinnarizine,Histamine H1 receptor,HRH1,8.064,Ki,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
amitriptyline,Alpha-2C adrenergic receptor,ADRA2C,8.066,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
dosulepin,Sodium-dependent serotonin transporter,SLC6A4,8.066,Kd,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
fluphenazine,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.067,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
betamethasone,Glucocorticoid receptor,NR3C1,8.07,IC50,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
buprenorphine,Delta-type opioid receptor,OPRD1,8.07,Ki,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
chlorpromazine,Alpha-1A adrenergic receptor,Adra1a,8.07,IC50,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dichlorphenamide,Carbonate dehydratase,,8.07,Ki,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
efavirenz,Reverse transcriptase protein,reverse transcriptase,8.07,Ki,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
fentanyl,Mu-type opioid receptor,OPRM1,8.07,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
progesterone,Androgen receptor,AR,8.07,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
risperidone,D(3) dopamine receptor,DRD3,8.07,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
enoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,8.07,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
flusalan,Mu-type opioid receptor,Oprm1,8.07,IC50,OC1=C(C=C(Br)C=C1Br)C(=O)NC1=CC(=CC=C1)C(F)(F)F
levomilnacipran,Sodium-dependent serotonin transporter,Slc6a4,8.07,Ki,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1
nintedanib,Tyrosine-protein kinase Mer,MERTK,8.07,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
clonazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,8.071,Ki,[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1
primaquine,Sodium-dependent serotonin transporter,SLC6A4,8.075,Ki,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
diphenylpyraline,Histamine H1 receptor,HRH1,8.076,Ki,CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
bexarotene,Retinoic acid receptor RXR-gamma,RXRG,8.08,Ki,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
clomipramine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.08,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clonidine,Alpha-2B adrenergic receptor,Adra2b,8.08,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
imipramine,Muscarinic acetylcholine receptor M2,CHRM2,8.08,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
methotrexate,Dihydrofolate reductase,folA,8.08,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
metopimazine,Histamine H1 receptor,HRH1,8.08,Ki,CS(=O)(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCC(CC3)C(N)=O)C2=C1
phentolamine,Alpha-2C adrenergic receptor,ADRA2C,8.08,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
quinapril,Angiotensin-converting enzyme,ACE,8.08,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O
trimethoprim,Dihydrofolate reductase,folA,8.08,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
bosutinib,Ephrin type-B receptor 2,EPHB2,8.08,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Serine/threonine-protein kinase PRP4 homolog,PRPF4B,8.08,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
polmacoxib,Prostaglandin G/H synthase 2,PTGS2,8.081,IC50,CC1(C)OC(=C(C1=O)C1=CC=CC(F)=C1)C1=CC=C(C=C1)S(N)(=O)=O
omidenepag isopropyl,Prostaglandin E2 receptor EP2 subtype,PTGER2,8.081,EC50,CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1
calcitonin human,Amylin receptor AMY2,CALCR|RAMP2,8.082,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O
clemastine,Muscarinic acetylcholine receptor M3,CHRM3,8.084,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
udenafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,8.084,IC50,CCCOC1=CC=C(C=C1C1=NC(=O)C2=C(N1)C(CCC)=NN2C)S(=O)(=O)NCCC1CCCN1C
alpha-Ergocryptine,5-hydroxytryptamine receptor 2B,HTR2B,8.085,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
tertatolol,5-hydroxytryptamine receptor 1A,HTR1A,8.087,Ki,CC(C)(C)NCC(O)COC1=C2SCCCC2=CC=C1
perphenazine,Histamine H1 receptor,HRH1,8.088,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
alfentanil,Mu-type opioid receptor,Oprm1,8.09,Ki,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O
alfentanil,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,8.09,Ki,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O
alfuzosin,Alpha-1A adrenergic receptor,ADRA1A,8.09,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
bortezomib,Proteasome subunit beta type-8,PSMB8,8.09,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
ergometrine,5-hydroxytryptamine receptor 1A,Htr1a,8.09,IC50,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
ergotamine,Alpha-1A adrenergic receptor,Adra1a,8.09,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ethinylestradiol,Estrogen receptor beta,ESR2,8.09,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
flumazenil,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,8.09,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
methazolamide,Carbonate dehydratase,,8.09,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
olmesartan medoxomil,Type-1 angiotensin II receptor,AGTR1,8.09,IC50,CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=O)OCC1=C(C)OC(=O)O1)C(C)(C)O
oxybutynin,Muscarinic acetylcholine receptor M2,CHRM2,8.09,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
bosutinib,Mitogen-activated protein kinase kinase kinase kinase 4,MAP4K4,8.09,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bosutinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,8.09,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
nintedanib,Tyrosine-protein kinase JAK3,JAK3,8.09,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
vorapaxar,Proteinase-activated receptor 1,F2R,8.092,Ki,CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\C2=CC=C(C=N2)C2=CC(F)=CC=C2)C1
larotrectinib,BDNF/NT-3 growth factors receptor,NTRK2,8.092,IC50,O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=CC(F)=CC=C1F
carbachol,Muscarinic acetylcholine receptor M5,CHRM5,8.097,EC50,C[N+](C)(C)CCOC(N)=O
cyproheptadine,D(3) dopamine receptor,DRD3,8.097,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
danazol,Androgen receptor,Ar,8.097,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
fluphenazine,5-hydroxytryptamine receptor 7,HTR7,8.097,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine enanthate,5-hydroxytryptamine receptor 7,HTR7,8.097,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
haloperidol,Alpha-1B adrenergic receptor,ADRA1B,8.097,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
olanzapine,5-hydroxytryptamine receptor 6,HTR6,8.097,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
olanzapine,D(3) dopamine receptor,DRD3,8.097,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
lomitapide,Microsomal triglyceride transfer protein large subunit,MTTP,8.097,IC50,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=C1C=CC=C2
ceritinib,Insulin-like growth factor 1 receptor,IGF1R,8.097,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
racecadotril,Endothelin-converting enzyme 1,ECE1,8.1,IC50,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1
aliskiren,Renin,REN,8.1,IC50,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
amitriptyline,5-hydroxytryptamine receptor 2C,HTR2C,8.1,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amitriptyline,Muscarinic acetylcholine receptor M2,CHRM2,8.1,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amitriptyline,5-hydroxytryptamine receptor 2C,Htr2c,8.1,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
atracurium,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,8.1,IC50,COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1
cabergoline,5-hydroxytryptamine receptor 1D,HTR1D,8.1,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
carbachol,Acetylcholinesterase,Ache,8.1,Ki,C[N+](C)(C)CCOC(N)=O
carbachol,Muscarinic acetylcholine receptor M2,Chrm2,8.1,Ki,C[N+](C)(C)CCOC(N)=O
celiprolol,Beta-1 adrenergic receptor,ADRB1,8.1,Ki,CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1
chlorpromazine,5-hydroxytryptamine receptor 2A,HTR2A,8.1,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clomifene,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.1,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
clozapine,Alpha-1A adrenergic receptor,ADRA1A,8.1,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,5-hydroxytryptamine receptor 2C,Htr2c,8.1,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
darifenacin,Muscarinic acetylcholine receptor M4,CHRM4,8.1,Ki,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Tyrosine-protein kinase Blk,Blk,8.1,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
delavirdine,Reverse transcriptase/RNaseH,pol,8.1,IC50,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
diclofenac,Interleukin-8,CXCL8,8.1,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
digitoxin,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,8.1,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
digitoxin,Sodium/potassium-transporting ATPase,ATP1A1|ATP1B1|ATP1A3|ATP1B2|ATP1A2|ATP1B3|FXYD2|ATP1A4,8.1,IC50,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
alpha-Ergocryptine,Alpha-1B adrenergic receptor,Adra1b,8.1,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
dorzolamide,Carbonate dehydratase,,8.1,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
ethoxzolamide,Carbonic anhydrase,NCE103,8.1,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
etizolam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,8.1,EC50,CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=C(Cl)C=CC=C1
flupentixol,D(1B) dopamine receptor,DRD5,8.1,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine,5-hydroxytryptamine receptor 7,Htr7,8.1,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
flurazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,8.1,IC50,CCN(CC)CCN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=C(F)C=CC=C1
histamine,Histamine H4 receptor,HRH4,8.1,Ki,NCCC1=CN=CN1
misoprostol,Prostaglandin E2 receptor EP3 subtype,PTGER3,8.1,Ki,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
olmesartan medoxomil,Type-1 angiotensin II receptor,AGTR1,8.1,IC50,CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=O)OCC1=C(C)OC(=O)O1)C(C)(C)O
omapatrilat,Neprilysin,Mme,8.1,IC50,OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12
oseltamivir,Neuraminidase,,8.1,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
oseltamivir,Neuraminidase,,8.1,Ki,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
pergolide,5-hydroxytryptamine receptor 2A,HTR2A,8.1,EC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
phenazocine,Mu-type opioid receptor,Oprm1,8.1,IC50,CC1C2CC3=C(C=C(O)C=C3)C1(C)CCN2CCC1=CC=CC=C1
pindolol,5-hydroxytryptamine receptor 1A,HTR1A,8.1,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
pyrimethamine,Dihydrofolate reductase,DHFR,8.1,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
levisoprenaline,Beta-1 adrenergic receptor,ADRB1,8.1,EC50,CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1
spiperone,Alpha-1A adrenergic receptor,ADRA1A,8.1,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
spiperone,Alpha-1D adrenergic receptor,ADRA1D,8.1,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sulpiride,D(3) dopamine receptor,DRD3,8.1,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tamsulosin,Alpha-2C adrenergic receptor,ADRA2C,8.1,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
terguride,D(4) dopamine receptor,DRD4,8.1,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
tolfenamic acid,Aldo-keto reductase family 1 member C3,AKR1C3,8.1,Ki,CC1=C(NC2=C(C=CC=C2)C(O)=O)C=CC=C1Cl
trichlormethiazide,Carbonic anhydrase 7,CA7,8.1,Ki,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl
trifluoperazine,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,8.1,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
triparanol,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.1,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(O)(CC1=CC=C(Cl)C=C1)C1=CC=C(C)C=C1
zofenopril,Angiotensin-converting enzyme,Ace,8.1,IC50,C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1
kainic acid,"Glutamate receptor ionotropic, kainate 5",GRIK5,8.1,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
pyrovalerone,Sodium-dependent dopamine transporter,SLC6A3,8.1,Ki,CCCC(N1CCCC1)C(=O)C1=CC=C(C)C=C1
uridine triphosphate,P2Y purinoceptor 2,P2RY2,8.1,EC50,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O
pazopanib,Macrophage colony-stimulating factor 1 receptor,CSF1R,8.1,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
indacaterol,Beta-2 adrenergic receptor,Adrb2,8.1,IC50,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2
linolenic acid,Peroxisome proliferator-activated receptor alpha,PPARA,8.1,Kd,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
triazolam,GABA A receptor alpha-3/beta-2/gamma-3,GABRA3|GABRB2|GABRG3,8.108,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
carvedilol,Alpha-1A adrenergic receptor,Adra1a,8.11,IC50,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
dasatinib,Protein-tyrosine kinase 6,PTK6,8.11,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
gestrinone,Sex hormone-binding globulin,SHBG,8.11,Kd,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C
oxprenolol,Beta-1 adrenergic receptor,ADRB1,8.11,Ki,CC(C)NCC(O)COC1=C(OCC=C)C=CC=C1
paclitaxel,Tubulin beta-3 chain,TUBB3,8.11,IC50,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
progesterone,Cation channel sperm-associated protein 1,CATSPER1,8.11,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
progesterone,Cation channel sperm-associated protein 2,CATSPER2,8.11,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
progesterone,Cation channel sperm-associated protein 3,CATSPER3,8.11,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
progesterone,Cation channel sperm-associated protein 4,CATSPER4,8.11,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
sultiame,Carbonate dehydratase,,8.11,Ki,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
tertatolol,5-hydroxytryptamine receptor 1A,Htr1a,8.11,Ki,CC(C)(C)NCC(O)COC1=C2SCCCC2=CC=C1
nordefrin,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.11,Ki,CC(N)C(O)C1=CC(O)=C(O)C=C1
terazosin,Alpha-2B adrenergic receptor,Adra2b,8.11,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
crizotinib,Tyrosine-protein kinase receptor UFO,AXL,8.11,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
prazosin,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,8.11,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
midostaurin,Mast/stem cell growth factor receptor Kit,KIT,8.11,Kd,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1
neratinib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,8.11,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
neratinib,Receptor tyrosine-protein kinase erbB-3,ERBB3,8.11,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
trifarotene,Retinoic acid receptor gamma,RARG,8.11,EC50,CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=C(OCCO)C=CC(=C1)C1=CC=C(C=C1)C(O)=O
ethisterone,Progesterone receptor,PGR,8.111,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C
acetylcholine,Neuronal acetylcholine receptor; alpha4/beta2,Chrna4|Chrnb2,8.12,Ki,CC(=O)OCC[N+](C)(C)C
bosentan,Endothelin-1 receptor,EDNRA,8.12,IC50,COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1
mianserin,5-hydroxytryptamine receptor 2B,HTR2B,8.12,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
phentolamine,Alpha-2B adrenergic receptor,ADRA2B,8.12,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
physostigmine,Butyrylcholinesterase; Protein Bche,Bche,8.12,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
pizotifen,5-hydroxytryptamine receptor 2A,HTR2A,8.12,Ki,CN1CCC(CC1)=C1C2=C(CCC3=C1C=CC=C3)SC=C2
sulpiride,D(2) dopamine receptor,DRD2,8.12,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tetrabenazine,Synaptic vesicular amine transporter,Slc18a2,8.12,Ki,COC1=CC2=C(C=C1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
trandolapril,Angiotensin-converting enzyme,ACE,8.12,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O
bictegravir,Integrase,,8.12,IC50,OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O
bictegravir,Integrase,,8.12,IC50,OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O
vadadustat,Egl nine homolog 3,EGLN3,8.12,IC50,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
alpha-Ergocryptine,5-hydroxytryptamine receptor 6,HTR6,8.121,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
metergoline,Alpha-2B adrenergic receptor,ADRA2B,8.124,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
mesoridazine,5-hydroxytryptamine receptor 2A,HTR2A,8.125,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
quinidine,Muscarinic acetylcholine receptor M2,CHRM2,8.125,Ki,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
bictegravir,Integrase,pol,8.125,IC50,OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O
astemizole,5-hydroxytryptamine receptor 2B,HTR2B,8.126,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
seratrodast,Thromboxane A2 receptor,TBXA2R,8.13,IC50,CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O
sorafenib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.13,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sufentanil,Mu-type opioid receptor,OPRM1,8.13,EC50,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
zanamivir,Neuraminidase,,8.13,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
azilsartan medoxomil,Type-1 angiotensin II receptor,AGTR1,8.13,IC50,CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NOC(=O)N1
neratinib,Serine/threonine-protein kinase 26,STK26,8.13,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
acalabrutinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,8.13,Kd,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
acalabrutinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,8.13,Kd,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
ponesimod,Sphingosine 1-phosphate receptor 1,S1PR1,8.13,EC50,CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
dolutegravir,Integrase,pol,8.131,IC50,C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12
ipragliflozin,Sodium/glucose cotransporter 2,SLC5A2,8.132,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC3=C(S2)C=CC=C3)=C(F)C=C1
moperone,D(4) dopamine receptor,DRD4,8.134,Ki,CC1=CC=C(C=C1)C1(O)CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
amitriptyline,Histamine H4 receptor,HRH4,8.14,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amitriptyline,Muscarinic acetylcholine receptor M4,CHRM4,8.14,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
cisapride,5-hydroxytryptamine receptor 2A,HTR2A,8.14,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
profenamine,Muscarinic acetylcholine receptor M2,Chrm2,8.14,Ki,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
hydrochlorothiazide,Carbonate dehydratase,,8.14,Ki,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
ropinirole,D(2) dopamine receptor,DRD2,8.14,Ki,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
spiperone,Alpha-1A adrenergic receptor,Adra1a,8.14,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sumatriptan,5-hydroxytryptamine receptor 2C,HTR2C,8.14,IC50,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
tandospirone,D(4) dopamine receptor,DRD4,8.14,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
trimethoprim,Bifunctional dihydrofolate reductase-thymidylate synthase,,8.14,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
ziprasidone,D(3) dopamine receptor,DRD3,8.14,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
elvitegravir,Integrase,pol,8.14,IC50,COC1=C(CC2=C(F)C(Cl)=CC=C2)C=C2C(=O)C(=CN([C@H](CO)C(C)C)C2=C1)C(O)=O
bosutinib,Tyrosine-protein kinase Blk,Blk,8.14,IC50,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
daprodustat,Egl nine homolog 2,EGLN2,8.14,IC50,C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O
oxatomide,5-hydroxytryptamine receptor 2B,HTR2B,8.148,Ki,O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
carbetocin,Oxytocin receptor,OXTR,8.149,Ki,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
aripiprazole,5-hydroxytryptamine receptor 2A,Htr2a,8.15,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
aripiprazole,5-hydroxytryptamine receptor 1A,HTR1A,8.15,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
aztreonam,Beta-lactamase,,8.15,Ki,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
chlorphenamine,Histamine H1 receptor,HRH1,8.15,Ki,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
chlorpromazine,D(2) dopamine receptor,DRD2,8.15,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
ciclosporin,Peptidyl-prolyl cis-trans isomerase D,PPID,8.15,Ki,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dopamine,D(1A) dopamine receptor,DRD1,8.15,Ki,NCCC1=CC(O)=C(O)C=C1
dorzolamide,"Carbonic anhydrase, alpha family",,8.15,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
gefitinib,Cyclin-G-associated kinase,GAK,8.15,Kd,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
lapatinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,8.15,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
lumiracoxib,Prostaglandin G/H synthase 1,PTGS1,8.15,IC50,CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1
nefazodone,5-hydroxytryptamine receptor 2A,Htr2a,8.15,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nefazodone,5-hydroxytryptamine receptor 2A,Htr2a,8.15,Ki,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
nicotine,Neuronal acetylcholine receptor subunit alpha-4,Chrna4,8.15,IC50,CN1CCC[C@H]1C1=CC=CN=C1
novobiocin,DNULL gyrase subunit B,gyrB,8.15,Ki,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
oseltamivir,Neuraminidase,,8.15,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
pridinol,Muscarinic acetylcholine receptor M2,CHRM2,8.15,Ki,OC(CCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
protirelin,Thyrotropin-releasing hormone receptor 2,TRH-R2,8.15,IC50,NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
sorafenib,Serine/threonine-protein kinase A-Raf,ARAF,8.15,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sunitinib,Serine/threonine-protein kinase Chk2,CHEK2,8.15,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tacrine,Butyrylcholinesterase,BCHE,8.15,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
tolterodine,Muscarinic acetylcholine receptor M3,Chrm3,8.15,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
trimetrexate,Dihydrofolate reductase,dfrA17,8.15,IC50,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
zolmitriptan,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.15,Kd,CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2
iloperidone,D(3) dopamine receptor,DRD3,8.15,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
alitretinoin,Retinoic acid receptor alpha,Rara,8.15,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
alitretinoin,Retinoic acid receptor beta,Rarb,8.15,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
bosutinib,Serine/threonine-protein kinase 10,STK10,8.15,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
iclaprim,Dihydrofolate reductase,dfrA17,8.15,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=C2C=CC(OC2=C1OC)C1CC1
paraoxon,Cholinesterase,BCHE,8.15,IC50,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O
ponatinib,Fibroblast growth factor receptor 4,FGFR4,8.15,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
entrectinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,8.15,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
mycophenolate mofetil,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,8.155,Ki,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
olanzapine,Histamine H1 receptor,HRH1,8.155,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
procyclidine,Muscarinic acetylcholine receptor M4,CHRM4,8.155,Ki,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
zotepine,Alpha-1A adrenergic receptor,ADRA1A,8.155,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
ibrutinib,Tyrosine-protein kinase Tec,TEC,8.155,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
ceritinib,Insulin receptor,INSR,8.155,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
avibactam,Beta-lactamase,ampC,8.155,Kd,NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O
estradiol benzoate,Androgen receptor,Ar,8.156,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)C3=CC=CC=C3)=C4)[C@@H]1CC[C@@H]2O
benzatropine,5-hydroxytryptamine receptor 2A,HTR2A,8.157,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
bromocriptine,Alpha-1A adrenergic receptor,Adra1a,8.16,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
celecoxib,Carbonate dehydratase,,8.16,Ki,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
dasatinib,Ephrin type-B receptor 3,EPHB3,8.16,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
levosulpiride,D(2) dopamine receptor,Drd2,8.16,Ki,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
oxybutynin,Muscarinic acetylcholine receptor M2,Chrm2,8.16,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
tolterodine,Muscarinic acetylcholine receptor M2,Chrm2,8.16,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
tropisetron,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,8.16,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
tropisetron,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,8.16,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
pentazocine,Mu-type opioid receptor,Oprm1,8.16,Ki,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
tucatinib,ERBB2/ERBB3,ERBB2|ERBB3,8.16,IC50,CC1=CC(NC2=NC=NC3=C2C=C(NC2=NC(C)(C)CO2)C=C3)=CC=C1OC1=CC2=NC=NN2C=C1
azelastine,Histamine H1 receptor,HRH1,8.168,Ki,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
pitavastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,8.168,IC50,O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=C(C=CC=C2)N=C1C1CC1)CC(O)=O
benzthiazide,Solute carrier family 12 member 3,SLC12A3,8.17,A2,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O
finasteride,3-oxo-5-alpha-steroid 4-dehydrogenase 1,Srd5a1,8.17,Ki,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
mianserin,5-hydroxytryptamine receptor 2A,HTR2A,8.17,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
pentagastrin,Gastrin/cholecystokinin type B receptor,Cckbr,8.17,IC50,CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
phentolamine,Alpha-1A adrenergic receptor,ADRA1A,8.17,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
tamsulosin,Alpha-2B adrenergic receptor,Adra2b,8.17,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
trihexyphenidyl,Muscarinic acetylcholine receptor M4,CHRM4,8.17,IC50,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
lurasidone,5-hydroxytryptamine receptor 1A,Htr1a,8.17,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
ponatinib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,8.17,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
ponatinib,Cyclin-dependent kinase 8,CDK8,8.17,Kd,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
tirabrutinib hydrochloride,Tyrosine-protein kinase BTK,BTK,8.17,IC50,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
brodimoprim,Dihydrofolate reductase,folA,8.18,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br
brodimoprim,Dihydrofolate reductase,folA,8.18,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br
dopamine,Sodium-dependent noradrenaline transporter,SLC6A2,8.18,IC50,NCCC1=CC(O)=C(O)C=C1
haloperidol,Zinc finger protein 664,ZNF664,8.18,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
sorafenib,Discoidin domain-containing receptor 2,DDR2,8.18,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
topiramate,Carbonate dehydratase,,8.18,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
trimetrexate,Bifunctional dihydrofolate reductase-thymidylate synthase,,8.18,Ki,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
estrone,Sex hormone-binding globulin,SHBG,8.18,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
fedratinib,Serine/threonine-protein kinase 16,STK16,8.18,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
clozapine,Muscarinic acetylcholine receptor M1,CHRM1,8.181,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
amoxapine,5-hydroxytryptamine receptor 2B,HTR2B,8.182,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
cyproheptadine,Histamine H4 receptor,HRH4,8.185,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
asenapine,Alpha-2A adrenergic receptor,ADRA2A,8.187,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
larotrectinib,High affinity nerve growth factor receptor,NTRK1,8.187,IC50,O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=CC(F)=CC=C1F
promethazine,5-hydroxytryptamine receptor 2C,HTR2C,8.188,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
pipamazine,Alpha-2C adrenergic receptor,ADRA2C,8.189,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
bosentan,Endothelin-1 receptor,EDNRA,8.19,Ki,COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1
bosentan,Endothelin-1 receptor,Ednra,8.19,Ki,COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1
cinalukast,Cysteinyl leukotriene receptor 1,CYSLTR1,8.19,Ki,CCC(CC)(CC(=O)NC1=CC=CC(\C=C\C2=NC(=CS2)C2CCC2)=C1)C(O)=O
cisapride,Potassium voltage-gated channel subfamily H member 2,KCNH2,8.19,IC50,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
dasatinib,Serine/threonine-protein kinase SIK2,SIK2,8.19,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dofetilide,Potassium voltage-gated channel subfamily H member 2,KCNH2,8.19,Ki,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
fluphenazine enanthate,Alpha-1A adrenergic receptor,ADRA1A,8.19,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
fluvoxamine,Sodium-dependent serotonin transporter,Slc6a4,8.19,Ki,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F
indomethacin,Prostaglandin G/H synthase 2,Ptgs2,8.19,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
oxymetazoline,Alpha-1A adrenergic receptor,Adra1a,8.19,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
sumatriptan,5-hydroxytryptamine receptor 1B,HTR1B,8.19,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
zotepine,D(3) dopamine receptor,DRD3,8.19,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
neratinib,Serine/threonine-protein kinase 24,STK24,8.19,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
fluphenazine,Alpha-1A adrenergic receptor,ADRA1A,8.191,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
pridinol,Muscarinic acetylcholine receptor M3,CHRM3,8.194,Ki,OC(CCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
ibrutinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,8.194,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
copanlisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,8.194,IC50,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
paliperidone,Alpha-2C adrenergic receptor,ADRA2C,8.195,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
lurasidone,5-hydroxytryptamine receptor 1A,HTR1A,8.195,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
amoxapine,5-hydroxytryptamine receptor 6,Htr6,8.2,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
biperiden,Muscarinic acetylcholine receptor M2,CHRM2,8.2,Kd,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
bufuralol,Beta-1 adrenergic receptor,ADRB1,8.2,Ki,CCC1=CC=CC2=C1OC(=C2)C(O)CNC(C)(C)C
cabergoline,5-hydroxytryptamine receptor 2A,HTR2A,8.2,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
chlorpromazine,Histamine H1 receptor,HRH1,8.2,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clozapine,5-hydroxytryptamine receptor 1A,HTR1A,8.2,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,5-hydroxytryptamine receptor 7,Htr7,8.2,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
danazol,Sex hormone-binding globulin,SHBG,8.2,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
dexniguldipine,Alpha-1A adrenergic receptor,Adra1a,8.2,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
ergotamine,5-hydroxytryptamine receptor 5A,Htr5a,8.2,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
fadrozole,"Cytochrome P450 11B1, mitochondrial",CYP11B1,8.2,IC50,N#CC1=CC=C(C=C1)C1CCCC2=CN=CN12
fludrocortisone acetate,Glucocorticoid receptor,NR3C1,8.2,EC50,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
fluoxetine,Alpha-2A adrenergic receptor,ADRA2A,8.2,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
histamine,Histamine H3 receptor,Hrh3,8.2,Ki,NCCC1=CN=CN1
ketanserin,Alpha-1A adrenergic receptor,ADRA1A,8.2,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketanserin,Alpha-1B adrenergic receptor,ADRA1B,8.2,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
lanreotide,Somatostatin receptor type 3,Sstr3,8.2,IC50,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
loxapine,Histamine H1 receptor,HRH1,8.2,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
medroxyprogesterone,Androgen receptor,AR,8.2,EC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
metergoline,5-hydroxytryptamine receptor 7,HTR7,8.2,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
metergoline,5-hydroxytryptamine receptor 7,Htr7,8.2,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
methysergide,5-hydroxytryptamine receptor 1F,HTR1F,8.2,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nabilone,Cannabinoid receptor 2,CNR2,8.2,Ki,CCCCCCC(C)(C)C1=CC(O)=C2C3CC(=O)CCC3C(C)(C)OC2=C1
naratriptan,5-hydroxytryptamine receptor 1F,HTR1F,8.2,Ki,CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1
olanzapine,Histamine H1 receptor,HRH1,8.2,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
oxymetazoline,Alpha-1A adrenergic receptor,ADRA1A,8.2,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
pergolide,5-hydroxytryptamine receptor 2B,HTR2B,8.2,EC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
raltitrexed,Folate transporter 1,SLC19A1,8.2,IC50,CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
sorafenib,Mitogen-activated protein kinase kinase kinase MLT,ZAK,8.2,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
terguride,5-hydroxytryptamine receptor 2B,HTR2B,8.2,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
thioridazine,5-hydroxytryptamine receptor 6,Htr6,8.2,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
xanomeline,5-hydroxytryptamine receptor 1D,HTR1D,8.2,Ki,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
afatinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,8.2,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
bosutinib,Tyrosine-protein kinase Fgr,FGR,8.2,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ipragliflozin,Sodium/glucose cotransporter 2,Slc5a2,8.2,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC3=C(S2)C=CC=C3)=C(F)C=C1
revefenacin,Muscarinic acetylcholine receptor M5,CHRM5,8.2,Ki,CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1
tenapanor,Sodium/hydrogen exchanger 3,Slc9a3,8.2,IC50,CN1C[C@@H](C2=CC=CC(=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C(Cl)C=C(Cl)C=C23)C2=CC(Cl)=CC(Cl)=C2C1
biperiden,Muscarinic acetylcholine receptor M5,CHRM5,8.201,Ki,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
pancuronium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,8.201,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1
ibrutinib,Tyrosine-protein kinase Lck,LCK,8.201,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
brexpiprazole,D(4) dopamine receptor,DRD4,8.201,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
racecadotril,Neprilysin,MME,8.21,IC50,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1
cisapride,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.21,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
glibenclamide,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,8.21,Ki,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
maxacalcitol,Vitamin D3 receptor,Vdr,8.21,EC50,C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
medroxyprogesterone,Androgen receptor,Ar,8.21,EC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
oxymetazoline,Nischarin,NISCH,8.21,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
asenapine,Histamine H2 receptor,HRH2,8.21,IC50,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
regorafenib,Mast/stem cell growth factor receptor Kit,KIT,8.21,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
nintedanib,Tyrosine-protein kinase Lck,LCK,8.21,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
umbralisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,8.21,Kd,C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
brompheniramine,Histamine H1 receptor,HRH1,8.218,Ki,CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1
alprostadil,Prostaglandin E2 receptor EP1 subtype,Ptger1,8.22,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
aztreonam,Efflux transporter; SugE,sugE,8.22,IC50,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
aztreonam,Beta-lactamase,bla LAT-2,8.22,IC50,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
bendamustine,Histone deacetylase 6,HDAC6,8.22,IC50,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
clemastine,Muscarinic acetylcholine receptor M5,CHRM5,8.22,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
clozapine,5-hydroxytryptamine receptor 2A,Htr2a,8.22,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
ciclosporin,Peptidyl-prolyl cis-trans isomerase FKBP1B,FKBP1B,8.22,Ki,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
dinoprostone,Prostaglandin E2 receptor EP1 subtype,Ptger1,8.22,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
duloxetine,Sodium-dependent noradrenaline transporter,SLC6A2,8.22,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
glycyrrhizic acid,Corticosteroid 11-beta-dehydrogenase isozyme 1,HSD11B1,8.22,IC50,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O
histamine,Histamine H4 receptor,HRH4,8.22,Ki,NCCC1=CN=CN1
imatinib,Abelson tyrosine-protein kinase 2,ABL2,8.22,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
indomethacin,Prostaglandin G/H synthase 1,Ptgs1,8.22,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
letrozole,Aromatase,CYP19A1,8.22,IC50,N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
loxapine,5-hydroxytryptamine receptor 2A,Htr2a,8.22,IC50,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
metergoline,5-hydroxytryptamine receptor 1A,Htr1a,8.22,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
mianserin,Cerebral cortex alpha adrenergic receptor,ADRA1A|ADRA2A,8.22,IC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
morphine,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,8.22,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
mycophenolic acid,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,8.22,Ki,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
nilotinib,Discoidin domain-containing receptor 2,DDR2,8.22,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
omapatrilat,Angiotensin-converting enzyme,ACE,8.22,Ki,OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12
orlistat,Endothelial lipase,LIPG,8.22,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
pimecrolimus,Peptidyl-prolyl cis-trans isomerase FKBP1A,Fkbp1a,8.22,IC50,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC
sildenafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,8.22,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sorafenib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,8.22,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
zidovudine,Pol polyprotein,pol,8.22,IC50,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
somatostatin,Mu-type opioid receptor,Oprm1,8.22,IC50,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
capsaicin,Transient receptor potential cation channel subfamily V member 1,TRPV1,8.22,Ki,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
crizotinib,Ephrin type-B receptor 6,EPHB6,8.22,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
cabozantinib,Vascular endothelial growth factor receptor 3,FLT4,8.22,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
cabozantinib,Vascular endothelial growth factor receptor 3,FLT4,8.22,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
lemborexant,Orexin receptor type 1,HCRTR1,8.22,Ki,CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=CC=C(F)C=N2)C2=CC=CC(F)=C2)C(C)=N1
oliceridine,Mu-type opioid receptor,OPRM1,8.22,Ki,COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
tirabrutinib hydrochloride,Cytoplasmic tyrosine-protein kinase BMX,BMX,8.22,IC50,CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
cyclobenzaprine,Muscarinic acetylcholine receptor M3,CHRM3,8.222,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
primaquine,Heat shock protein HSP 90-alpha,HSP90AA1,8.222,IC50,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
carfilzomib,Proteasome subunit beta type-5,PSMB5,8.222,IC50,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
sonidegib,Smoothened homolog,SMO,8.222,Ki,C[C@H]1CN(C[C@@H](C)O1)C1=NC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=C1
dacomitinib,Epidermal growth factor receptor,EGFR,8.222,IC50,COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1
lorlatinib,Tyrosine-protein kinase Fes/Fps,FES,8.222,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
cetilistat,Pancreatic triacylglycerol lipase,PNLIP,8.225,IC50,CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1
promazine,Alpha-1A adrenergic receptor,ADRA1A,8.226,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
isotretinoin,Retinoic acid receptor alpha,RARA,8.229,ED50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
baricitinib,Tyrosine-protein kinase JAK1,JAK1,8.229,IC50,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
bexarotene,Retinoic acid receptor RXR-beta,RXRB,8.23,Ki,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O
clozapine,Histamine H4 receptor,HRH4,8.23,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
etonogestrel,Sex hormone-binding globulin,SHBG,8.23,Kd,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
fentanyl,Mu-type opioid receptor,Oprm1,8.23,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
fludarabine phosphate,Adenosine receptor A1,Adora1,8.23,Ki,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
fulvestrant,Estrogen receptor,Esr1,8.23,IC50,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
oxybutynin,Muscarinic acetylcholine receptor M1,Chrm1,8.23,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
sunitinib,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",PHKG2,8.23,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
glucagon,Adenylate cyclase,Adcy1|Adcy3|Adcy2|Adcy4|Adcy8|Adcy6|Adcy5,8.23,EC50,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
eribulin,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,8.23,IC50,CO[C@H]1[C@@H](C[C@H](O)CN)O[C@H]2C[C@H]3O[C@H](C[C@@H](C)C3=C)CC[C@@H]3O[C@H](CC3=C)CC[C@@]34C[C@H]5O[C@@H]6[C@@H](O[C@H]7CC[C@H](CC(=O)C[C@H]12)O[C@@H]7[C@@H]6O3)[C@H]5O4
axitinib,Vascular endothelial growth factor receptor 2,KDR,8.23,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
labetalol,Beta-1 adrenergic receptor,ADRB1,8.234,Ki,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
cyamemazine,D(2) dopamine receptor,DRD2,8.237,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
mequitazine,Histamine H1 receptor,HRH1,8.237,Ki,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
acetazolamide,Carbonic anhydrase 13,CA13,8.24,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Carbonic anhydrase-related protein 11,CA11,8.24,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
donepezil,Acetylcholinesterase,ache,8.24,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
donepezil,Acetylcholinesterase,Ache,8.24,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
flumazenil,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,8.24,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
fluoxymesterone,Androgen receptor,AR,8.24,Ki,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
mepyramine,Histamine H1 receptor,Hrh1,8.24,IC50,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
talipexole,D(2) dopamine receptor,Drd2,8.24,Ki,NC1=NC2=C(CCN(CC=C)CC2)S1
naphazoline,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.24,Ki,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
naphazoline,Adrenergic receptor alpha,Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a,8.24,Ki,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
sabcomeline,Muscarinic acetylcholine receptor M4,CHRM4,8.24,EC50,CO\N=C(/C#N)[C@H]1CN2CCC1CC2
axitinib,Vascular endothelial growth factor receptor 1,FLT1,8.24,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Ephrin type-A receptor 3,EPHA3,8.24,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
haloperidol decanoate,D(4) dopamine receptor,DRD4,8.24,Ki,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
angiotensin II,Type-1 angiotensin II receptor,AGTR1,8.24,Kd,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
baricitinib,Tyrosine-protein kinase JAK2,JAK2,8.244,IC50,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
erdafitinib,Fibroblast growth factor receptor 4,FGFR4,8.244,IC50,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1
atracurium,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,8.25,IC50,COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1
bromocriptine,5-hydroxytryptamine receptor 1A,Htr1a,8.25,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
chlorprothixene,5-hydroxytryptamine receptor 7,Htr7,8.25,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dasatinib,Activated CDC42 kinase 1,TNK2,8.25,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
lofexidine,Nischarin,Nisch,8.25,Ki,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
oxymetazoline,5-hydroxytryptamine receptor 1A,Htr1a,8.25,IC50,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
propranolol,Beta-2 adrenergic receptor,ADRB2,8.25,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
valethamate,Muscarinic acetylcholine receptor M3,CHRM3,8.25,Ki,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1
ibrutinib,Epidermal growth factor receptor,EGFR,8.25,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
ipragliflozin,Sodium/glucose cotransporter 2,Slc5a2,8.25,IC50,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC3=C(S2)C=CC=C3)=C(F)C=C1
paliperidone,Histamine H1 receptor,HRH1,8.251,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
amitriptyline,Alpha-1D adrenergic receptor,ADRA1D,8.252,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
mequitazine,Muscarinic acetylcholine receptor M1,CHRM1,8.252,Ki,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
perphenazine,5-hydroxytryptamine receptor 2A,HTR2A,8.252,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
astemizole,5-hydroxytryptamine receptor 2A,HTR2A,8.253,Ki,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
tolperisone,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.253,Ki,CC(CN1CCCCC1)C(=O)C1=CC=C(C)C=C1
mifepristone,Androgen receptor,Ar,8.255,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
lisuride,5-hydroxytryptamine receptor 6,HTR6,8.259,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
calcitriol,Vitamin D3 receptor A,vdra,8.26,EC50,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
clozapine,5-hydroxytryptamine receptor 2B,HTR2B,8.26,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dexamethasone palmitate,Glucocorticoid receptor,NR3C1,8.26,Ki,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
dexamethasone valerate,Glucocorticoid receptor,NR3C1,8.26,Ki,CCCCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
everolimus,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,8.26,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO
finasteride,3-oxo-5-alpha-steroid 4-dehydrogenase 2,SRD5A2,8.26,IC50,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
flunitrazepam,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,8.26,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
midazolam,GABA A receptor alpha-5/beta-3/gamma-3,GABRB3|GABRA5|GABRG3,8.26,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
midazolam,GABA A receptor alpha-5/beta-2/gamma-3,GABRA5|GABRB2|GABRG3,8.26,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
mirtazapine,5-hydroxytryptamine receptor 2C,Htr2c,8.26,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
nicotine,Neuronal acetylcholine receptor; alpha2/beta2,Chrna2|Chrnb2,8.26,Ki,CN1CCC[C@H]1C1=CC=CN=C1
nicotine,Neuronal acetylcholine receptor; alpha4/beta4,Chrna4|Chrnb4,8.26,Ki,CN1CCC[C@H]1C1=CC=CN=C1
nicotine,Neuronal acetylcholine receptor; alpha2/beta2,CHRNB2|CHRNA2,8.26,Ki,CN1CCC[C@H]1C1=CC=CN=C1
pancuronium,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,8.26,IC50,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1
sumatriptan,5-hydroxytryptamine receptor 1B,HTR1B,8.26,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
sunitinib,"Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform",PHKG1,8.26,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sunitinib,BMP-2-inducible protein kinase,BMP2K,8.26,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
sonidegib,Sonic hedgehog protein,Shh,8.26,IC50,C[C@H]1CN(C[C@@H](C)O1)C1=NC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=C1
daprodustat,Egl nine homolog 3,EGLN3,8.26,IC50,C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O
alpha-Ergocryptine,Alpha-2C adrenergic receptor,ADRA2C,8.261,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
lofepramine,Sodium-dependent noradrenaline transporter,SLC6A2,8.268,Ki,CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1
tetracosactide,Adrenocorticotropic hormone receptor,MC2R,8.268,Ki,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O
ponatinib,Tyrosine-protein kinase CSK,CSK,8.268,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
maprotiline,Sodium-dependent noradrenaline transporter,SLC6A2,8.27,Kd,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
morphine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,8.27,IC50,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
tretoquinol,Beta-1 adrenergic receptor,ADRB1,8.27,Ki,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC
pentazocine,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.27,Ki,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
ripretinib,Angiopoietin-1 receptor,TEK,8.27,IC50,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
zotepine,Alpha-2B adrenergic receptor,ADRA2B,8.273,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
mequitazine,Muscarinic acetylcholine receptor M3,CHRM3,8.276,Ki,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
topiroxostat,Xanthine dehydrogenase/oxidase,XDH,8.276,IC50,N#CC1=NC=CC(=C1)C1=NNC(=N1)C1=CC=NC=C1
betamethasone dipropionate,Glucocorticoid receptor,Nr3c1,8.28,IC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
bisoprolol,Beta-1 adrenergic receptor,Adrb1,8.28,Ki,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
bisoprolol,Beta-1 adrenergic receptor,Adrb1,8.28,Ki,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
dinoprostone,Prostaglandin E2 receptor EP2 subtype,Ptger2,8.28,IC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
donepezil,Choline O-acetyltransferase,Chat,8.28,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
flunitrazepam,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,8.28,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
flunitrazepam,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,8.28,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
gabapentin,Potassium voltage-gated channel subfamily KQT member 3,KCNQ3,8.28,EC50,NCC1(CC(O)=O)CCCCC1
histamine,Histamine H3 receptor,HRH3,8.28,Ki,NCCC1=CN=CN1
maraviroc,C-C chemokine receptor type 5,Ccr5,8.28,IC50,CC(C)C1=NN=C(C)N1[C@@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
methysergide,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.28,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
pirenzepine,Muscarinic acetylcholine receptor M1,Chrm1,8.28,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
tropisetron,5-hydroxytryptamine receptor 1A,HTR1A,8.28,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
valdecoxib,Carbonate dehydratase,,8.28,Ki,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
avanafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,8.28,IC50,COC1=C(Cl)C=C(CNC2=NC(=NC=C2C(=O)NCC2=NC=CC=N2)N2CCC[C@H]2CO)C=C1
vortioxetine,Sodium-dependent serotonin transporter,Slc6a4,8.28,IC50,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
nintedanib,Mitogen-activated protein kinase kinase kinase 19,MAP3K19,8.28,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
olaparib,Tankyrase-2,TNKS2,8.28,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
lonafarnib,GTPase KRas,KRAS,8.28,IC50,C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
lonafarnib,GTPase KRas,KRAS,8.28,IC50,C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
mestranol,Estrogen receptor,ESR1,8.282,Ki,COC1=CC2=C(C=C1)[C@H]1CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@@H]1CC2
olopatadine,Histamine H1 receptor,HRH1,8.284,Ki,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
avanafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,8.284,IC50,COC1=C(Cl)C=C(CNC2=NC(=NC=C2C(=O)NCC2=NC=CC=N2)N2CCC[C@H]2CO)C=C1
cabozantinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.284,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
lenvatinib,Vascular endothelial growth factor receptor 3,FLT4,8.284,IC50,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
adenosine,Adenosine receptor A1,Adora1,8.29,Ki,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
bromfenac,Prostaglandin G/H synthase 1,PTGS1,8.29,IC50,NC1=C(C=CC=C1CC(O)=O)C(=O)C1=CC=C(Br)C=C1
buprenorphine,Mu-type opioid receptor,OPRM1,8.29,Ki,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
pipamazine,Alpha-1A adrenergic receptor,Adra1a,8.29,IC50,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
thioridazine,Alpha-1A adrenergic receptor,Adra1a,8.29,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
trimetrexate,Bifunctional dihydrofolate reductase-thymidylate synthase,,8.29,IC50,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
bosutinib,Mitogen-activated protein kinase kinase kinase kinase 3,MAP4K3,8.29,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
acalabrutinib,Tyrosine-protein kinase BTK,BTK,8.292,IC50,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
alpha-Ergocryptine,5-hydroxytryptamine receptor 1B,Htr1b,8.299,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
aminopterin,Dihydrofolate reductase,folA,8.3,IC50,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
adenosine,Adenosine A2 receptor,Adora2b|Adora2a,8.3,Ki,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
alprostadil,Prostaglandin E2 receptor EP3 subtype,Ptger3,8.3,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
alvimopan,Kappa-type opioid receptor,OPRK1,8.3,Ki,C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1
bendroflumethiazide,Solute carrier family 12 member 3,SLC12A3,8.3,A2,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F
clofarabine,Ribonucleoside-diphosphate reductase large subunit,RRM1,8.3,IC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1
clofarabine,Ribonucleoside-diphosphate reductase subunit M2,RRM2,8.3,IC50,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1
clomipramine,Serotonin (5-HT) receptor,Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b,8.3,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clozapine,5-hydroxytryptamine receptor 2A,HTR2A,8.3,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproterone acetate,Adenosine receptor A1,Adora1,8.3,IC50,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
darifenacin,Muscarinic acetylcholine receptor M1,CHRM1,8.3,Ki,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
desmopressin,Vasopressin V2 receptor,AVPR2,8.3,Ki,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
dexmedetomidine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,8.3,Ki,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
dihydroergotamine,Alpha-1A adrenergic receptor,Adra1a,8.3,IC50,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergotamine,5-hydroxytryptamine receptor 6,Htr6,8.3,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dinoprostone,Prostaglandin E2 receptor EP3 subtype,Ptger3,8.3,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
efavirenz,Gag-Pol polyprotein,gag-pol,8.3,IC50,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
hexocyclium,Muscarinic acetylcholine receptor M4,CHRM4,8.3,Ki,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
imipramine,Sodium-dependent serotonin transporter,Slc6a4,8.3,Ki,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
ketanserin,5-hydroxytryptamine receptor 1B,Htr1b,8.3,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
lisuride,5-hydroxytryptamine receptor 2C,HTR2C,8.3,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
lisuride,Alpha-1A adrenergic receptor,ADRA1A,8.3,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
lisuride,D(4) dopamine receptor,DRD4,8.3,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
lisuride,5-hydroxytryptamine receptor 6,Htr6,8.3,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
lysergide,5-hydroxytryptamine receptor 2C,HTR2C,8.3,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
lysergide,5-hydroxytryptamine receptor 1A,Htr1a,8.3,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
methylergometrine,5-hydroxytryptamine receptor 2C,HTR2C,8.3,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
mianserin,5-hydroxytryptamine receptor 1B,Htr1b,8.3,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
moclobemide,Amine oxidase [flavin-containing] A,MAOA,8.3,Ki,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
moclobemide,Amine oxidase [flavin-containing] A,Maoa,8.3,Ki,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
naloxone,Kappa-type opioid receptor,Oprk1,8.3,IC50,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
naloxone,Mu-type opioid receptor,OPRM1,8.3,IC50,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
nicotine,Neuronal acetylcholine receptor subunit alpha-9,Chrna9,8.3,Kd,CN1CCC[C@H]1C1=CC=CN=C1
octreotide,Somatostatin receptor type 3,SSTR3,8.3,Ki,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
omapatrilat,Angiotensin-converting enzyme,ACE,8.3,IC50,OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12
ondansetron,5-hydroxytryptamine receptor 3B,HTR3B,8.3,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
oxymorphone,Mu-type opioid receptor,Oprm1,8.3,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
pergolide,D(2) dopamine receptor,DRD2,8.3,EC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
phenazocine,Delta-type opioid receptor,OPRD1,8.3,Ki,CC1C2CC3=C(C=C(O)C=C3)C1(C)CCN2CCC1=CC=CC=C1
pipamperone,5-hydroxytryptamine receptor 2A,HTR2A,8.3,Ki,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1
piretanide,Solute carrier family 12 member 1,SLC12A1,8.3,Kd,NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O
raltegravir,C-C chemokine receptor type 1,CCR1,8.3,Ki,CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
sertindole,5-hydroxytryptamine receptor 6,HTR6,8.3,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
spiperone,5-hydroxytryptamine receptor 1B,Htr1b,8.3,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
tadalafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",Pde5a,8.3,Ki,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
terguride,5-hydroxytryptamine receptor 2A,HTR2A,8.3,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
tolfenamic acid,Prostaglandin G/H synthase 2,PTGS2,8.3,IC50,CC1=C(NC2=C(C=CC=C2)C(O)=O)C=CC=C1Cl
topiramate,Carbonic anhydrase 2,CA2,8.3,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
valdecoxib,Prostaglandin G/H synthase 2,PTGS2,8.3,IC50,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
riboflavin,Riboflavin-binding protein,,8.3,Kd,CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO)C1=NC(=O)NC(=O)C1=N2
ziprasidone,5-hydroxytryptamine receptor 7,HTR7,8.3,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
ziprasidone,5-hydroxytryptamine receptor 1B,HTR1B,8.3,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
zotepine,5-hydroxytryptamine receptor 6,HTR6,8.3,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
yohimbine,5-hydroxytryptamine receptor 1B,Htr1b,8.3,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
vorinostat,Histone deacetylase 3,HDAC3,8.3,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
vismodegib,Smoothened homolog,Smo,8.3,IC50,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1
afatinib,Receptor tyrosine-protein kinase erbB-2,ERBB2,8.3,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
fluticasone furoate,Glucocorticoid receptor,Nr3c1,8.3,IC50,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)SCF
panobinostat,Bromodomain-containing protein 4,BRD4,8.3,IC50,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
peramivir,Neuraminidase,,8.3,IC50,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
cangrelor,P2Y purinoceptor 13,P2RY13,8.3,IC50,CSCCNC1=NC(SCCC(F)(F)F)=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O
fostamatinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.3,IC50,COC1=CC(NC2=NC(NC3=CC=C4OC(C)(C)C(=O)N(COP(O)(O)=O)C4=N3)=C(F)C=N2)=CC(OC)=C1OC
fostamatinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.3,IC50,COC1=CC(NC2=NC(NC3=CC=C4OC(C)(C)C(=O)N(COP(O)(O)=O)C4=N3)=C(F)C=N2)=CC(OC)=C1OC
glasdegib,Smoothened homolog,Smo,8.3,IC50,CN1CC[C@H](C[C@@H]1C1=NC2=C(N1)C=CC=C2)NC(=O)NC1=CC=C(C=C1)C#N
entrectinib,NT-3 growth factor receptor,NTRK3,8.3,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
dichlorphenamide,Carbonic anhydrase 1,CA1,8.301,IC50,NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
parecoxib,Prostaglandin G/H synthase 2,PTGS2,8.301,IC50,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1
tamoxifen,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,8.301,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
zonisamide,Carbonic anhydrase 9,CA9,8.301,Ki,NS(=O)(=O)CC1=NOC2=CC=CC=C12
zotepine,Alpha-1B adrenergic receptor,ADRA1B,8.301,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
nintedanib,Vascular endothelial growth factor receptor 2,KDR,8.301,IC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
nintedanib,Vascular endothelial growth factor receptor 3,FLT4,8.301,IC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
olaparib,Poly [ADP-ribose] polymerase 1,PARP1,8.301,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
glasdegib,Smoothened homolog,SMO,8.301,IC50,CN1CC[C@H](C[C@@H]1C1=NC2=C(N1)C=CC=C2)NC(=O)NC1=CC=C(C=C1)C#N
gilteritinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,8.301,IC50,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1
chlorpromazine,Alpha-1B adrenergic receptor,Adra1b,8.305,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
haloperidol,Alpha-1B adrenergic receptor,Adra1b,8.305,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
isoprenaline,Taste receptor type 2 member 14,TAS2R14,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 46,TAS2R46,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 38,TAS2R38,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 39,TAS2R39,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 40,TAS2R40,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 41,TAS2R41,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 43,TAS2R43,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 31,TAS2R31,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 45,TAS2R45,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 46,TAS2R46,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 30,TAS2R30,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 19,TAS2R19,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 20,TAS2R20,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 50,TAS2R50,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 60,TAS2R60,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 42,TAS2R42,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 16,TAS2R16,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 14,TAS2R14,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 13,TAS2R13,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 10,TAS2R10,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 9,TAS2R9,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 8,TAS2R8,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 7,TAS2R7,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 5,TAS2R5,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 4,TAS2R4,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 3,TAS2R3,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
isoprenaline,Taste receptor type 2 member 1,TAS2R1,8.31,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
lindane,GABA-A receptor alpha-6/beta-3/gamma-2,GABRG2|GABRB3|GABRA6,8.31,IC50,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
loxapine,D(4) dopamine receptor,DRD4,8.31,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
oseltamivir,Neuraminidase,,8.31,Ki,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
zidovudine,Gag-Pro-Pol polyprotein,gag-pro-pol,8.31,EC50,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
pazopanib,Platelet-derived growth factor receptor alpha,PDGFRA,8.31,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
ibrutinib,Tyrosine-protein kinase ITK/TSK,ITK,8.31,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
nintedanib,Maternal embryonic leucine zipper kinase,MELK,8.31,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
estetrol,Estrogen receptor,ESR1,8.31,Ki,C[C@]12CC[C@H]3[C@H]([C@@H]1[C@H]([C@H]([C@@H]2O)O)O)CCC4=C3C=CC(=C4)O
cyproterone acetate,Progesterone receptor,PGR,8.315,Ki,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
mianserin,Alpha-2A adrenergic receptor,ADRA2A,8.319,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
olanzapine,5-hydroxytryptamine receptor 2A,HTR2A,8.319,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
alectinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.319,IC50,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O
racecadotril,Neprilysin,Mme,8.32,IC50,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1
apraclonidine,Alpha-2B adrenergic receptor,Adra2b,8.32,Ki,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1
beclometasone dipropionate,Mineralocorticoid receptor,NR3C2,8.32,EC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
benzquinamide,Prostaglandin G/H synthase 2,PTGS2,8.32,IC50,CCN(CC)C(=O)C1CN2CCC3=C(C=C(OC)C(OC)=C3)C2CC1OC(C)=O
haloperidol,D(2) dopamine receptor,DRD2,8.32,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
naltrexone,Delta-type opioid receptor,Oprd1,8.32,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
norepinephrine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.32,Ki,NC[C@H](O)C1=CC(O)=C(O)C=C1
ziprasidone,D(2) dopamine receptor,DRD2,8.32,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
ziprasidone,D(2) dopamine receptor,Drd2,8.32,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
linoleic acid,Peroxisome proliferator-activated receptor alpha,PPARA,8.32,Kd,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
xylometazoline,Adrenergic receptor alpha,Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a,8.32,Ki,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
vandetanib,Epidermal growth factor receptor,EGFR,8.32,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
bosutinib,Tyrosine-protein kinase BTK,BTK,8.32,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
topiroxostat,Xanthine dehydrogenase/oxidase,XDH,8.32,IC50,N#CC1=NC=CC(=C1)C1=NNC(=N1)C1=CC=NC=C1
nintedanib,Tyrosine-protein kinase JAK1,JAK1,8.32,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
prochlorperazine,Alpha-2B adrenergic receptor,ADRA2B,8.324,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
ingenol mebutate,Protein kinase C delta type,PRKCD,8.328,EC50,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C
dexamethasone,Interleukin-4,IL4,8.33,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
mifepristone,Androgen receptor,AR,8.33,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
nifedipine,Voltage-gated L-type calcium channel,Cacna1c|Cacna1d|Cacna1s,8.33,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
oxymorphone,Opioid receptors; mu and delta,Oprd1|Oprm1,8.33,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
phentolamine,Alpha-2A adrenergic receptor,Adra2a,8.33,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
kainic acid,"Glutamate receptor ionotropic, kainate 4",Grik4,8.33,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
ruboxistaurin,Protein kinase C beta type,PRKCB,8.33,IC50,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
bosutinib,STE20-like serine/threonine-protein kinase,SLK,8.33,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ergometrine,5-hydroxytryptamine receptor 1A,HTR1A,8.333,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
procyclidine,Muscarinic acetylcholine receptor M1,CHRM1,8.337,Ki,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
cabozantinib,Mast/stem cell growth factor receptor Kit,KIT,8.337,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
alpelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,8.337,IC50,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F
lisuride,5-hydroxytryptamine receptor 1B,Htr1b,8.338,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
apomorphine,D(1A) dopamine receptor,DRD1,8.34,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
chlorprothixene,D(3) dopamine receptor,DRD3,8.34,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
losartan,Angiotensin II receptor,Agtr1|Agtr1b|Agtr2,8.34,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
methysergide,5-hydroxytryptamine receptor 2C,HTR2C,8.34,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
neostigmine,Acetylcholinesterase,ache,8.34,IC50,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
vandetanib,Receptor-interacting serine/threonine-protein kinase 2,RIPK2,8.34,Kd,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
ergotamine,Alpha-1B adrenergic receptor,Adra1b,8.342,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ramipril,Angiotensin-converting enzyme,ACE,8.342,Ki,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O
promazine,Alpha-1B adrenergic receptor,Adra1b,8.344,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
flunitrazepam,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,8.347,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
fluorometholone acetate,Glucocorticoid receptor,NR3C1,8.347,Ki,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12
dihydroergotamine,Alpha-1B adrenergic receptor,Adra1b,8.349,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
acetazolamide,Carbonate dehydratase,,8.35,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
aliskiren,Renin-1,Ren1,8.35,IC50,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
chlortalidone,Carbonic anhydrase 12,CA12,8.35,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
dabigatran etexilate,Prothrombin,F2,8.35,Ki,CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1
dopamine,D(2) dopamine receptor,Drd2,8.35,Ki,NCCC1=CC(O)=C(O)C=C1
quetiapine,Histamine H1 receptor,HRH1,8.35,IC50,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
sorafenib,Receptor-type tyrosine-protein kinase FLT3,FLT3,8.35,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
tetroxoprim,Dihydrofolate reductase,folA,8.35,Ki,COCCOC1=C(OC)C=C(CC2=CN=C(N)N=C2N)C=C1OC
tetroxoprim,Dihydrofolate reductase,folA,8.35,Ki,COCCOC1=C(OC)C=C(CC2=CN=C(N)N=C2N)C=C1OC
tofacitinib,Serine/threonine-protein kinase DCLK3,DCLK3,8.35,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
nintedanib,High affinity nerve growth factor receptor,NTRK1,8.35,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
ibrexafungerp,"Beta-1,3-glucan synthase catalytic subunit 1",GSC1,8.35,IC50,C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
cyclizine,Histamine H1 receptor,HRH1,8.353,Ki,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
clotiapine,D(2) dopamine receptor,Drd2,8.36,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
edatrexate,Dihydrofolate reductase,DHFR,8.36,IC50,CCC(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
frovatriptan,5-hydroxytryptamine receptor 1D,HTR1D,8.36,Ki,CN[C@@H]1CCC2=C(C1)C1=CC(=CC=C1N2)C(N)=O
imipramine,Adenosine receptor A3,ADORA3,8.36,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
lofexidine,Alpha-2A adrenergic receptor,ADRA2A,8.36,Ki,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
nortriptyline,Sodium-dependent noradrenaline transporter,SLC6A2,8.36,Kd,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
rasagiline,Amine oxidase [flavin-containing] B,Maob,8.36,IC50,C#CCN[C@@H]1CCC2=C1C=CC=C2
yohimbine,Alpha-2A adrenergic receptor,ADRA2A,8.36,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
tofacitinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,8.36,Ki,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
dihydroergotamine,5-hydroxytryptamine receptor 2B,HTR2B,8.364,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
amitriptyline,Sodium-dependent serotonin transporter,SLC6A4,8.367,Kd,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
alpha-Ergocryptine,Alpha-1D adrenergic receptor,ADRA1D,8.369,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
acetazolamide,"Carbonic anhydrase, alpha family",,8.37,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
beraprost,Prostacyclin receptor,PTGIR,8.37,IC50,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12
levonorgestrel,Androgen receptor,Ar,8.37,Ki,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
ramatroban,Prostaglandin D2 receptor 2,PTGDR2,8.37,Ki,OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C2=CC=C(F)C=C2)C2=CC=CC=C12
simvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,8.37,IC50,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
kainic acid,"Glutamate receptor ionotropic, kainate",Grik1|Grik2|Grik3|Grik4|Grik5,8.37,IC50,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
dihydroergocristine,5-hydroxytryptamine receptor 2A,HTR2A,8.373,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergocristine,5-hydroxytryptamine receptor 2B,HTR2B,8.377,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
netarsudil,Rho-associated protein kinase 2,ROCK2,8.377,Ki,CC1=CC=C(C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC2=CC3=C(C=C2)C=NC=C3)C(C)=C1
brinzolamide,"Carbonic anhydrase, alpha family",,8.38,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
bromocriptine,Alpha-1A adrenergic receptor,ADRA1A,8.38,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
dinoprost,Prostaglandin E2 receptor EP3 subtype,Ptger3,8.38,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
haloperidol,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.38,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
levorphanol,Delta-type opioid receptor,OPRD1,8.38,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
moxonidine,Nischarin,NISCH,8.38,Ki,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1
pravastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,8.38,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12
prednisolone,Interleukin-6,IL6,8.38,IC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,Interleukin-6,IL6,8.38,IC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
tramazoline,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.38,Ki,C1CN=C(NC2=C3CCCCC3=CC=C2)N1
axitinib,Serine/threonine-protein kinase PLK4,PLK4,8.38,Ki,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Tyrosine-protein kinase Lyn,LYN,8.38,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
linaclotide,Heat-stable enterotoxin receptor,Gucy2c,8.38,Ki,C[C@@H](O)[C@@H]1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2
promethazine,Muscarinic acetylcholine receptor M3,CHRM3,8.382,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
imidafenacin,Muscarinic acetylcholine receptor M1,CHRM1,8.384,Kb,CC1=NC=CN1CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1
brimonidine,Alpha-2A adrenergic receptor,ADRA2A,8.387,EC50,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
ibrutinib,Tyrosine-protein kinase Yes,YES1,8.387,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
dapiprazole,Alpha-1D adrenergic receptor,ADRA1D,8.388,Ki,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
dasatinib,Ephrin type-A receptor 1,EPHA1,8.39,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
ethoxzolamide,"Carbonic anhydrase, alpha family",,8.39,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
flurbiprofen,Prostaglandin G/H synthase 2,PTGS2,8.39,IC50,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
indomethacin,Prostaglandin G/H synthase 1,PTGS1,8.39,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
methylergometrine,5-hydroxytryptamine receptor 1A,Htr1a,8.39,IC50,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
nilotinib,Carbonic anhydrase 2,CA2,8.39,Ki,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
phentolamine,Alpha-1A adrenergic receptor,ADRA1A,8.39,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
protriptyline,Sodium-dependent noradrenaline transporter,SLC6A2,8.39,Ki,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
crizotinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,8.39,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
nintedanib,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,8.39,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
triflupromazine,5-hydroxytryptamine receptor 2A,HTR2A,8.398,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
lenvatinib,Vascular endothelial growth factor receptor 2,KDR,8.398,IC50,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
trelagliptin,Dipeptidyl peptidase 4,DPP4,8.398,IC50,CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=CC(F)=CC=C2C#N)C1=O
flibanserin,D(4) dopamine receptor,DRD4,8.398,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
levobunolol,Beta-1 adrenergic receptor,ADRB1,8.399,Ki,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
(S)-nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,8.4,IC50,CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
racecadotril,Neprilysin,MME,8.4,IC50,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1
amitriptyline,5-hydroxytryptamine receptor 2A,Htr2a,8.4,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
atazanavir,Protease,protease,8.4,IC50,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
atomoxetine,Transporter,NET,8.4,Ki,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
bromfenac,Prostaglandin G/H synthase 2,PTGS2,8.4,IC50,NC1=C(C=CC=C1CC(O)=O)C(=O)C1=CC=C(Br)C=C1
bromocriptine,D(2) dopamine receptor,Drd2,8.4,Kd,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
calcitriol,Vitamin D3 receptor,VDR,8.4,EC50,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
carbachol,Muscarinic acetylcholine receptor M2,Chrm2,8.4,Ki,C[N+](C)(C)CCOC(N)=O
chlorpromazine,5-hydroxytryptamine receptor 6,Htr6,8.4,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
cloxacillin,Efflux transporter; SugE,sugE,8.4,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1
cloxacillin,Beta-lactamase,bla LAT-2,8.4,IC50,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1
clozapine,5-hydroxytryptamine receptor 6,Htr6,8.4,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
ciclosporin,Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform,PPP3CA,8.4,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
cyproheptadine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,8.4,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dinoprost,Prostaglandin F2-alpha receptor,PTGFR,8.4,Kd,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
domperidone,D(2) dopamine receptor,DRD2,8.4,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
ergotamine,5-hydroxytryptamine receptor 5A,Htr5a,8.4,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
febuxostat,Xanthine dehydrogenase/oxidase,Xdh,8.4,IC50,CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
felodipine,Cystic fibrosis transmembrane conductance regulator,CFTR,8.4,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
flupentixol,D(1A) dopamine receptor,DRD1,8.4,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
hexocyclium,Muscarinic acetylcholine receptor M5,CHRM5,8.4,Ki,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
lysergide,5-hydroxytryptamine receptor 6,HTR6,8.4,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
nabilone,Cannabinoid receptor 1,CNR1,8.4,Ki,CCCCCCC(C)(C)C1=CC(O)=C2C3CC(=O)CCC3C(C)(C)OC2=C1
nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,8.4,IC50,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
nomifensine,Transporter,NET,8.4,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
olanzapine,5-hydroxytryptamine receptor 2A,Htr2a,8.4,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
palmidrol,G-protein coupled receptor 55,GPR55,8.4,EC50,CCCCCCCCCCCCCCCC(=O)NCCO
pergolide,D(2) dopamine receptor,Drd2,8.4,Kd,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
rotigotine,D(3) dopamine receptor,DRD3,8.4,Ki,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
ademetionine,Met repressor,metJ,8.4,Kd,C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N
spiperone,5-hydroxytryptamine receptor 1F,HTR1F,8.4,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
tazobactam,Beta-lactamase,bcl1,8.4,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tegaserod,5-hydroxytryptamine receptor 2B,HTR2B,8.4,Ki,CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2
tegaserod,5-hydroxytryptamine receptor 4,HTR4,8.4,Ki,CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2
terguride,D(2) dopamine receptor,Drd2,8.4,IC50,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
tetrabenazine,Synaptic vesicular amine transporter,SLC18A2,8.4,Ki,COC1=CC2=C(C=C1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
thiothixene,Histamine H1 receptor,HRH1,8.4,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
treprostinil,Prostaglandin E2 receptor EP2 subtype,PTGER2,8.4,Ki,CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2CC3=C(OCC(O)=O)C=CC=C3C[C@H]12
treprostinil,Prostaglandin D2 receptor,PTGDR,8.4,Ki,CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2CC3=C(OCC(O)=O)C=CC=C3C[C@H]12
zanamivir,Neuraminidase,,8.4,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
zotepine,5-hydroxytryptamine receptor 7,HTR7,8.4,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
estriol,Estrogen receptor beta,ESR2,8.4,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
alitretinoin,Retinoic acid receptor RXR-gamma,Rxrg,8.4,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
asenapine,5-hydroxytryptamine receptor 1B,HTR1B,8.4,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
asenapine,5-hydroxytryptamine receptor 1D,HTR1D,8.4,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
bosutinib,Tyrosine-protein kinase Yes,YES1,8.4,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
pleconaril,Genome polyprotein,,8.4,EC50,CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C2=NOC(=N2)C(F)(F)F)=C1
trilaciclib,Cyclin-dependent kinase 6,CDK6,8.4,IC50,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
fluspirilene,D(3) dopamine receptor,DRD3,8.409,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
pentazocine,Mu-type opioid receptor,OPRM1,8.409,Ki,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
asenapine,Alpha-1B adrenergic receptor,ADRA1B,8.409,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
azatadine,Histamine H1 receptor,Hrh1,8.41,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2
biperiden,Muscarinic acetylcholine receptor M3,CHRM3,8.41,Kd,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
dasatinib,Serine/threonine-protein kinase SIK1,SIK1,8.41,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
ifenprodil,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.41,IC50,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
lysergide,5-hydroxytryptamine receptor 1D,HTR1D,8.41,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
progesterone,Estrogen receptor,Esr1|Esr2,8.41,Kd,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
rupatadine,Histamine H1 receptor,HRH1,8.41,IC50,CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1
sulpiride,Carbonic anhydrase 12,CA12,8.41,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
terguride,Alpha-1D adrenergic receptor,ADRA1D,8.41,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
trifluoperazine,Emopamil-binding protein-like,EBPL,8.41,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
telaprevir,NS3 protease,,8.41,Ki,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
setmelanotide,Melanocyte-stimulating hormone receptor,MC1R,8.41,Ki,C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
setmelanotide,Melanocyte-stimulating hormone receptor,MC1R,8.41,Ki,C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
cyproheptadine,5-hydroxytryptamine receptor 2A,HTR2A,8.419,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
aldosterone,Mineralocorticoid receptor,NR3C2,8.42,EC50,C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3CC[C@H](C(=O)CO)[C@]3(C[C@H](O)[C@H]21)C=O
atorvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,8.42,IC50,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
buspirone,5-hydroxytryptamine receptor 1A,Htr1a,8.42,Ki,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
clonidine,Alpha-2A adrenergic receptor,ADRA2A,8.42,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
clozapine,Histamine H1 receptor,HRH1,8.42,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyamemazine,D(1A) dopamine receptor,DRD1,8.42,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
desmopressin,Vasopressin V1a receptor,AVPR1A,8.42,Ki,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
edatrexate,Dihydrofolate reductase,folA,8.42,IC50,CCC(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
flunitrazepam,GABA A receptor alpha-5/beta-3/gamma-3,GABRB3|GABRA5|GABRG3,8.42,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
flunitrazepam,GABA A receptor alpha-5/beta-2/gamma-3,GABRA5|GABRB2|GABRG3,8.42,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
lysergide,5-hydroxytryptamine receptor 2C,Htr2c,8.42,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
mianserin,Alpha-2C adrenergic receptor,ADRA2C,8.42,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nomifensine,Transporter,Slc6a2,8.42,Ki,CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1
sultopride,D(3) dopamine receptor,DRD3,8.42,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(=O)(=O)CC
topiramate,Carbonic anhydrase 12,CA12,8.42,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
tropisetron,Serotonin 3 receptor (5HT3),Htr3a|Htr3b,8.42,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
kainic acid,"Glutamate receptor ionotropic, kainate 3",Grik3,8.42,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
bazedoxifene,Estrogen receptor beta,ESR2,8.42,IC50,CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1
anagliptin,Dipeptidyl peptidase 4,DPP4,8.42,IC50,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N
palbociclib,CDK6/cyclin D1,CCND1|CDK6,8.42,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
brexpiprazole,Alpha-1A adrenergic receptor,ADRA1A,8.42,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
plecanatide,Tumor necrosis factor,TNF,8.42,Kd,CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(O)=O
niraparib,Poly [ADP-ribose] polymerase 1,PARP1,8.42,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
beclometasone dipropionate,Glucocorticoid receptor,NR3C1,8.427,Ki,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
promazine,Alpha-1D adrenergic receptor,ADRA1D,8.427,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
betamethasone phosphate,Glucocorticoid receptor,NR3C1,8.428,Ki,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
bromperidol,D(2) dopamine receptor,DRD2,8.43,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
celecoxib,Prostaglandin G/H synthase 1,PTGS1,8.43,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorprothixene,Histamine H1 receptor,HRH1,8.43,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dihydroergotamine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.43,IC50,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dopamine,Dopamine receptor,DRD2|DRD1,8.43,IC50,NCCC1=CC(O)=C(O)C=C1
indoramin,Alpha-1A adrenergic receptor,ADRA1A,8.43,Ki,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
losartan,Angiotensin II receptor,AGTR1|AGTR2,8.43,Kd,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
procaterol,Beta-2 adrenergic receptor,ADRB2,8.43,EC50,CC[C@@H](NC(C)C)[C@@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
verapamil,Voltage-gated L-type calcium channel,Cacna1c|Cacna1d|Cacna1s,8.43,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
kainic acid,"Glutamate receptor ionotropic, kainate 2",Grik2,8.43,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
methyltestosterone,Sex hormone-binding globulin,SHBG,8.43,Kd,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
naftopidil,Alpha-1A adrenergic receptor,ADRA1A,8.432,Ki,COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1
vortioxetine,5-hydroxytryptamine receptor 3A,HTR3A,8.432,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
brexpiprazole,5-hydroxytryptamine receptor 7,HTR7,8.432,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
copanlisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",PIK3CB,8.432,IC50,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
alfuzosin,Alpha-1D adrenergic receptor,ADRA1D,8.44,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
estradiol,Steroid hormone receptor ERR1,ESRRA,8.44,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
ibandronic acid,Farnesyl pyrophosphate synthase,FDPS,8.44,Ki,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
losartan,Type-1B angiotensin II receptor,Agtr1b,8.44,Ki,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
nilotinib,Tyrosine-protein kinase ABL1,ABL1,8.44,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
oxybutynin,Muscarinic acetylcholine receptor M4,CHRM4,8.44,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
pirenzepine,Muscarinic receptor M1,,8.44,Ki,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
sulpiride,Carbonic anhydrase 7,CA7,8.44,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
valethamate,Muscarinic acetylcholine receptor M4,CHRM4,8.44,Ki,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1
ruboxistaurin,Protein kinase C delta type,PRKCD,8.44,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
yohimbine,Alpha-1A adrenergic receptor,ADRA1A,8.44,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
crizotinib,Tyrosine-protein kinase Mer,MERTK,8.44,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
nintedanib,Serine/threonine-protein kinase PknB,pknB,8.44,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
ripretinib,Platelet-derived growth factor receptor alpha,PDGFRA,8.44,IC50,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
norethindrone acetate,Progesterone receptor,PGR,8.441,Ki,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
progesterone,Progesterone receptor,PGR,8.441,Ki,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
dihydroergocristine,Alpha-2B adrenergic receptor,ADRA2B,8.442,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
midazolam,GABA A receptor alpha-3/beta-2/gamma-2,GABRG2|GABRA3|GABRB2,8.444,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
temocapril,Angiotensin-converting enzyme,ACE,8.444,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)C1=CC=CS1
clozapine,Alpha-1B adrenergic receptor,Adra1b,8.445,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
metolazone,Solute carrier family 12 member 1,SLC12A1,8.45,Kd,CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=C(C)C=CC=C1)S(N)(=O)=O
dexamethasone,Interleukin-5,IL5,8.456,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
lorazepam,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,8.456,IC50,OC1N=C(C2=CC(Cl)=CC=C2NC1=O)C1=C(Cl)C=CC=C1
phenoxybenzamine,Alpha-2B adrenergic receptor,ADRA2B,8.456,Ki,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
trifluperidol,D(3) dopamine receptor,DRD3,8.456,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC(=CC=C1)C(F)(F)F
alfuzosin,Alpha-1D adrenergic receptor,Adra1d,8.46,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
domperidone,D(3) dopamine receptor,DRD3,8.46,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
dorzolamide,Carbonic anhydrase 12,CA12,8.46,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
dorzolamide,Carbonic anhydrase 7,CA7,8.46,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
ketanserin,D(4) dopamine receptor,DRD4,8.46,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
lysergide,5-hydroxytryptamine receptor 2A,Htr2a,8.46,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
mifepristone,Progesterone receptor,Pgr,8.46,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
nifedipine,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,8.46,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
tropicamide,Muscarinic acetylcholine receptor M4,CHRM4,8.46,Ki,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1
haloperidol decanoate,D(3) dopamine receptor,DRD3,8.46,Ki,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
panobinostat,Histone deacetylase 11,HDAC11,8.46,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
daprodustat,Egl nine homolog 1,EGLN1,8.46,IC50,C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O
brimonidine,Alpha-2C adrenergic receptor,ADRA2C,8.469,EC50,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
ibrutinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,8.469,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
aripiprazole lauroxil,5-hydroxytryptamine receptor 2A,HTR2A,8.469,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
ixazomib,Proteasome subunit beta type-5,PSMB5,8.469,IC50,CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O
benperidol,Potassium voltage-gated channel subfamily H member 2,KCNH2,8.47,IC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2
flunitrazepam,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,8.47,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
methazolamide,Carbonic anhydrase 12,CA12,8.47,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
nalmefene,Delta-type opioid receptor,Oprd1,8.47,Ki,OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
prednisolone,Glucocorticoid receptor,Nr3c1,8.47,EC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,Glucocorticoid receptor,Nr3c1,8.47,EC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
risperidone,5-hydroxytryptamine receptor 7,HTR7,8.47,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sertindole,Alpha-1A adrenergic receptor,Adra1a,8.47,IC50,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
valsartan,Type-1A angiotensin II receptor,Agtr1,8.47,IC50,CCCCC(=O)N(CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)[C@@H](C(C)C)C(O)=O
zanamivir,Neuraminidase,,8.47,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
ziprasidone,5-hydroxytryptamine receptor 1A,HTR1A,8.47,EC50,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
gabexate,Tryptase alpha/beta-1,TPSAB1,8.47,IC50,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
paliperidone,D(2) dopamine receptor,DRD2,8.47,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
bosutinib,Tyrosine-protein kinase HCK,HCK,8.47,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
cabozantinib,Tyrosine-protein kinase receptor UFO,AXL,8.47,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
gilteritinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.47,IC50,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1
ripretinib,Vascular endothelial growth factor receptor 2,KDR,8.47,IC50,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
fluocinolone acetonide,Progesterone receptor,PGR,8.475,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
carvedilol,5-hydroxytryptamine receptor 1A,HTR1A,8.476,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
promethazine,Muscarinic acetylcholine receptor M1,CHRM1,8.479,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
acetazolamide,Carbonic anhydrase 2,CA2,8.48,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
dasatinib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,8.48,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexetimide,Muscarinic acetylcholine receptor,Chrm1|Chrm4|Chrm5|Chrm3|Chrm2,8.48,IC50,O=C1CC[C@@](C2CCN(CC3=CC=CC=C3)CC2)(C(=O)N1)C1=CC=CC=C1
hesperetin,Carbonic anhydrase 7,CA7,8.48,Ki,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1
indinavir,Protease,protease,8.48,Ki,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
naratriptan,5-hydroxytryptamine receptor 1B,HTR1B,8.48,Ki,CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1
promethazine,Muscarinic acetylcholine receptor M5,CHRM5,8.48,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
risperidone,Alpha-1B adrenergic receptor,ADRA1B,8.48,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
tadalafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,8.48,IC50,CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C2=CC=C3OCOC3=C2)C1=O
vasopressin,Vasopressin V2 receptor,AVPR2,8.48,IC50,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
zotarolimus,Serine/threonine-protein kinase mTOR,MTOR,8.48,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1N1C=NN=N1
dronabinol,Cannabinoid receptor 2,CNR2,8.48,Ki,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
bosutinib,Tyrosine-protein kinase Blk,BLK,8.48,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
ibrutinib,Protein-tyrosine kinase 6,PTK6,8.48,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
elagolix,Gonadotropin-releasing hormone receptor,GNRHR,8.48,Ki,COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(F)C=CC=C2C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O
tofacitinib,Tyrosine-protein kinase JAK3,JAK3,8.481,IC50,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
ibrutinib,Tyrosine-protein kinase Fgr,FGR,8.481,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
corticorelin,Corticotropin-releasing factor receptor 1,CRHR1,8.481,Kd,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)CC)C(N)=O
avatrombopag,Thrombopoietin receptor,MPL,8.481,EC50,OC(=O)C1CCN(CC1)C1=NC=C(C=C1Cl)C(=O)NC1=NC(C2=CC(Cl)=CS2)=C(S1)N1CCN(CC1)C1CCCCC1
lorlatinib,Tyrosine-protein kinase Fer,FER,8.481,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
ergotamine,Alpha-1D adrenergic receptor,ADRA1D,8.487,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
lisuride,5-hydroxytryptamine receptor 2B,HTR2B,8.489,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
clebopride,D(4) dopamine receptor,DRD4,8.49,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
dutasteride,3-oxo-5-alpha-steroid 4-dehydrogenase 1,SRD5A1,8.49,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=C(C=CC(=C1)C(F)(F)F)C(F)(F)F
estradiol,Steroid hormone receptor ERR2,ESRRB,8.49,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
nelfinavir,Protease,HIV-1 protease,8.49,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
risperidone,D(2) dopamine receptor,DRD2,8.49,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
tolterodine,Muscarinic acetylcholine receptor M3,CHRM3,8.49,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
dapagliflozin,Sodium/glucose cotransporter 1,SLC5A1,8.49,IC50,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
bosutinib,Misshapen-like kinase 1,MINK1,8.49,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
mefuparib,Poly [ADP-ribose] polymerase 1,PARP1,8.49,IC50,CNCC1=CC=C(C=C1)C1=CC2=C(O1)C(=CC(F)=C2)C(N)=O
oxymetazoline,5-hydroxytryptamine receptor 1A,HTR1A,8.493,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
amisulpride,D(3) dopamine receptor,DRD3,8.495,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
clomipramine,Alpha-1A adrenergic receptor,ADRA1A,8.495,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
risperidone,Alpha-2C adrenergic receptor,ADRA2C,8.495,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
alfentanil,Mu-type opioid receptor,OPRM1,8.5,EC50,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O
bambuterol,Cholinesterase,BCHE,8.5,IC50,CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C
beclometasone dipropionate,Probable G-protein coupled receptor 97,ADGRG3,8.5,EC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
carvedilol,5-hydroxytryptamine receptor 1A,Htr1a,8.5,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
dipyridamole,Equilibrative nucleoside transporter 1,SLC29A1,8.5,Ki,OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO
drospirenone,Androgen receptor,AR,8.5,IC50,C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1
ergometrine,5-hydroxytryptamine receptor 2A,HTR2A,8.5,EC50,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
ergometrine,5-hydroxytryptamine receptor 2A,Htr2a,8.5,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
hydrocortisone,Glucocorticoid receptor,NR3C1,8.5,EC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
isoprenaline,Beta-3 adrenergic receptor,ADRB3,8.5,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
lisuride,D(1B) dopamine receptor,DRD5,8.5,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
methylprednisolone,Glucocorticoid receptor,NR3C1,8.5,EC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
naloxone,Kappa-type opioid receptor,OPRK1,8.5,Ki,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
naloxone,Kappa-type opioid receptor,OPRK1,8.5,Ki,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
nebivolol,Beta-1 adrenergic receptor,ADRB1,8.5,Ki,OC(CNCC(O)C1CCC2=CC(F)=CC=C2O1)C1CCC2=CC(F)=CC=C2O1
pergolide,5-hydroxytryptamine receptor 1A,HTR1A,8.5,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
sarpogrelate,5-hydroxytryptamine receptor 2A,HTR2A,8.5,Ki,COC1=CC=CC(CCC2=C(OCC(CN(C)C)OC(=O)CCC(O)=O)C=CC=C2)=C1
terguride,5-hydroxytryptamine receptor 1A,HTR1A,8.5,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
terguride,Alpha-1A adrenergic receptor,ADRA1A,8.5,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
clobetasol propionate,Glucocorticoid receptor,Nr3c1,8.5,IC50,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
tacalcitol,Vitamin D3 receptor,VDR,8.5,Kd,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
rucaparib,Poly [ADP-ribose] polymerase 1,PARP1,8.5,IC50,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23
pecazine,Histamine H1 receptor,HRH1,8.504,Ki,CN1CCCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
tolrestat,Aldose reductase,AKR1B1,8.509,IC50,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
acetazolamide,Carbonic anhydrase 3,CA3,8.51,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
alprostadil,Prostaglandin E2 receptor EP4 subtype,Ptger4,8.51,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
cyproheptadine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.51,IC50,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dinoprostone,Prostaglandin E2 receptor EP4 subtype,Ptger4,8.51,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
erlotinib,Cyclin-G-associated kinase,GAK,8.51,Kd,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
profenamine,Muscarinic acetylcholine receptor M1,Chrm1,8.51,Ki,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
fluvoxamine,Sodium-dependent serotonin transporter,SLC6A4,8.51,Ki,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F
pergolide,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,8.51,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pramipexole,D(2) dopamine receptor,Drd2,8.51,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
tolterodine,Muscarinic acetylcholine receptor M4,CHRM4,8.51,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
tolterodine,Muscarinic acetylcholine receptor M4,Chrm4,8.51,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
bosutinib,Mitogen-activated protein kinase kinase kinase kinase 2,MAP4K2,8.51,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
bortezomib,Proteasome subunit beta type-9,PSMB9,8.52,IC50,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
brinzolamide,Carbonic anhydrase 1,CA1,8.52,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
brinzolamide,Carbonic anhydrase 12,CA12,8.52,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
brinzolamide,Carbonic anhydrase,NCE103,8.52,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
chlorprothixene,5-hydroxytryptamine receptor 6,HTR6,8.52,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clodronic acid,Type IV secretion-like conjugative transfer relaxase protein TraI,traI,8.52,Ki,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O
clozapine,5-hydroxytryptamine receptor 2A,HTR2A,8.52,IC50,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
conivaptan,Vasopressin V2 receptor,Avpr2,8.52,Ki,CC1=NC2=C(N1)C1=C(C=CC=C1)N(CC2)C(=O)C1=CC=C(NC(=O)C2=C(C=CC=C2)C2=CC=CC=C2)C=C1
dasatinib,Discoidin domain-containing receptor 2,DDR2,8.52,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diclofenac,Prostaglandin G/H synthase 1,PTGS1,8.52,IC50,OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
duloxetine,Transporter,NET,8.52,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
efavirenz,Reverse transcriptase/RNaseH,pol,8.52,Ki,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
eletriptan,5-hydroxytryptamine receptor 1B,HTR1B,8.52,Kd,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
etidronic acid,Type IV secretion-like conjugative transfer relaxase protein TraI,traI,8.52,Ki,CC(O)(P(O)(O)=O)P(O)(O)=O
famotidine,Carbonic anhydrase 7,CA7,8.52,Ki,NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
febuxostat,Xanthine dehydrogenase/oxidase,XDH,8.52,IC50,CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
fenoldopam,D(1A) dopamine receptor,Drd1,8.52,Ki,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
flupentixol,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,8.52,IC50,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
glycyrrhizic acid,Corticosteroid 11-beta-dehydrogenase isozyme 1,Hsd11b1,8.52,IC50,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O
haloperidol,D(3) dopamine receptor,DRD3,8.52,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,D(3) dopamine receptor,Drd3,8.52,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
haloperidol,D(3) dopamine receptor,DRD3,8.52,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
lovastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,8.52,IC50,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
lysergide,5-hydroxytryptamine receptor 7,HTR7,8.52,Kd,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
medetomidine,Adrenergic receptor alpha-2,ADRA2A|ADRA2B|ADRA2C,8.52,EC50,CC(C1=CNC=N1)C1=C(C)C(C)=CC=C1
mianserin,5-hydroxytryptamine receptor 2C,HTR2C,8.52,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
octreotide,Somatostatin receptor type 3,Sstr3,8.52,IC50,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
orlistat,Hepatic triacylglycerol lipase,LIPC,8.52,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
propranolol,Beta-1 adrenergic receptor,Adrb1,8.52,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
scopolamine,Muscarinic acetylcholine receptor M2,Chrm2,8.52,Kd,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
sirolimus,Peptidyl-prolyl cis-trans isomerase FKBP5,FKBP5,8.52,Ki,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
telmisartan,Type-1B angiotensin II receptor,Agtr1b,8.52,IC50,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O
levothyroxine,Thyroid hormone receptor beta,THRB,8.52,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
trimetrexate,Dihydrofolate reductase,Dhfr,8.52,IC50,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
zidovudine,Reverse transcriptase/RNaseH,pol,8.52,IC50,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
estrone,Estradiol 17-beta-dehydrogenase 1,HSD17B1,8.52,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
vildagliptin,Dipeptidyl peptidase 4,DPP4,8.52,Ki,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
clorotepine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,8.52,IC50,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
minodronic acid,Farnesyl pyrophosphate synthase,FDPS,8.52,IC50,OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O
fingolimod,Sphingosine 1-phosphate receptor 3,S1PR3,8.52,EC50,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
vismodegib,Sonic hedgehog protein,Shh,8.52,IC50,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1
ivacaftor,Cystic fibrosis transmembrane conductance regulator,CFTR,8.52,EC50,CC(C)(C)C1=CC(=C(NC(=O)C2=CNC3=CC=CC=C3C2=O)C=C1O)C(C)(C)C
dapagliflozin,Sodium/glucose cotransporter 2,Slc5a2,8.52,EC50,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
trabectedin,Nuclear receptor subfamily 1 group I member 2,Nr1i2,8.52,IC50,COC1=CC2=C(CCN[C@]22CS[C@H]3[C@H]4[C@@H]5N(C)[C@@H](CC6=C5C(O)=C(OC)C(C)=C6)[C@H](O)N4[C@@H](COC2=O)C2=C3C(OC(C)=O)=C(C)C3=C2OCO3)C=C1O
ponatinib,Proto-oncogene tyrosine-protein kinase Src,SRC,8.52,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
migalastat,Alpha-galactosidase,,8.52,IC50,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
polmacoxib,Prostaglandin G/H synthase 1,Ptgs1,8.52,IC50,CC1(C)OC(=C(C1=O)C1=CC=CC(F)=C1)C1=CC=C(C=C1)S(N)(=O)=O
polmacoxib,Prostaglandin G/H synthase 1,Ptgs1,8.52,IC50,CC1(C)OC(=C(C1=O)C1=CC=CC(F)=C1)C1=CC=C(C=C1)S(N)(=O)=O
gilteritinib,Tyrosine-protein kinase Mer,MERTK,8.52,IC50,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1
entrectinib,BDNF/NT-3 growth factors receptor,NTRK2,8.52,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
fedratinib,Tyrosine-protein kinase JAK2,JAK2,8.52,IC50,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
lemborexant,Orexin receptor type 2,HCRTR2,8.52,Ki,CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=CC=C(F)C=N2)C2=CC=CC(F)=C2)C(C)=N1
remdesivir,Replicase polyprotein 1ab,REP,8.52,EC50,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1
ripretinib,Mast/stem cell growth factor receptor Kit,KIT,8.52,IC50,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
cabotegravir,Integrase,,8.52,IC50,C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
cabotegravir,Integrase,,8.52,IC50,C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
cabotegravir,Integrase,pol,8.52,IC50,C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
carbachol,Muscarinic acetylcholine receptor M1,CHRM1,8.523,EC50,C[N+](C)(C)CCOC(N)=O
formoterol,Heat shock protein HSP 90-alpha,HSP90AA1,8.523,IC50,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
octreotide,Somatostatin receptor type 5,SSTR5,8.523,IC50,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
olanzapine,D(2) dopamine receptor,DRD2,8.523,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
saroglitazar,Peroxisome proliferator-activated receptor gamma,PPARG,8.523,EC50,CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C2=CC=C(SC)C=C2)C=C1)C(O)=O
valbenazine,Synaptic vesicular amine transporter,SLC18A2,8.523,Ki,COC1=CC2=C(C=C1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2
erdafitinib,Fibroblast growth factor receptor 3,FGFR3,8.523,IC50,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1
alpha-Ergocryptine,Alpha-2A adrenergic receptor,ADRA2A,8.526,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
dihydroergotamine,D(2) dopamine receptor,DRD2,8.529,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
alprenolol,Beta-2 adrenergic receptor,ADRB2,8.53,IC50,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
aripiprazole,D(3) dopamine receptor,DRD3,8.53,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
betaxolol,Beta-1 adrenergic receptor,Adrb1,8.53,Kd,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
brodimoprim,Dihydrofolate reductase,dfrA17,8.53,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br
chlorprothixene,D(2) dopamine receptor,DRD2,8.53,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
sorafenib,Epidermal growth factor receptor,EGFR,8.53,IC50,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
laropiprant,Thromboxane A2 receptor,TBXA2R,8.53,Ki,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
lifitegrast,Intercellular adhesion molecule 1,ICAM1,8.53,IC50,CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C2=C(Cl)C=C3CN(CCC3=C2Cl)C(=O)C2=CC=C3C=COC3=C2)C(O)=O)=C1
diflorasone diacetate,Glucocorticoid receptor,NR3C1,8.536,Ki,C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O
fluocinonide,Progesterone receptor,PGR,8.538,Ki,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C
raloxifene,Aldehyde oxidase,AOX1,8.538,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
tofogliflozin,Sodium/glucose cotransporter 2,SLC5A2,8.538,IC50,CCC1=CC=C(CC2=CC3=C(CO[C@]33O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C2)C=C1
arformoterol,Beta-2 adrenergic receptor,ADRB2,8.538,Kd,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1
apraclonidine,Alpha-2A adrenergic receptor,ADRA2A,8.54,Ki,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1
beclometasone dipropionate,Glucocorticoid receptor,Nr3c1,8.54,IC50,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
budesonide,Glucocorticoid receptor,Nr3c1,8.54,IC50,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
chlorpromazine,D(3) dopamine receptor,DRD3,8.54,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
citalopram,Sodium-dependent dopamine transporter,Slc6a3,8.54,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
clozapine,Alpha-2C adrenergic receptor,ADRA2C,8.54,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
clozapine,Histamine H1 receptor,Hrh1,8.54,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
diazepam,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,8.54,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
donepezil,Acetylcholinesterase,ACHE,8.54,Ki,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
oseltamivir,Neuraminidase,,8.54,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
saquinavir,Protease,HIV-1 protease,8.54,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
zanamivir,Neuraminidase,,8.54,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
zotepine,5-hydroxytryptamine receptor 2C,HTR2C,8.54,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
dronabinol,Cannabinoid receptor 1,CNR1,8.54,Ki,CCCCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1
abiraterone acetate,"Steroid 17-alpha-hydroxylase/17,20 lyase",CYP17A1,8.54,IC50,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C4=CC=CN=C4)[C@@H]3CC=C2C1
Florbetapir F-18,Amyloid beta A4 protein,APP,8.54,Ki,CNC1=CC=C(\C=C\C2=CN=C(OCCOCCOCC[18F])C=C2)C=C1
alfuzosin,Alpha-1B adrenergic receptor,ADRA1B,8.55,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
brinzolamide,Carbonic anhydrase 7,CA7,8.55,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
bromocriptine,Alpha-1D adrenergic receptor,ADRA1D,8.55,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
cerivastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,8.55,IC50,COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(N=C1C(C)C)C(C)C
chlortalidone,Carbonic anhydrase 7,CA7,8.55,Ki,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
delorazepam,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,8.55,IC50,ClC1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1
hydromorphone,Kappa-type opioid receptor,OPRK1,8.55,Ki,CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CCC4=O)=CC=C5O
tamoxifen,Emopamil-binding protein-like,EBPL,8.55,Ki,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
thioridazine,D(2) dopamine receptor,Drd2,8.55,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
zotarolimus,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,8.55,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1N1C=NN=N1
lonafarnib,GTPase NRas,NRAS,8.55,IC50,C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
delgocitinib,Tyrosine-protein kinase JAK1,JAK1,8.55,IC50,C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N
amisulpride,D(2) dopamine receptor,DRD2,8.553,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC
benzatropine,Muscarinic acetylcholine receptor M5,CHRM5,8.553,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
risperidone,Alpha-1A adrenergic receptor,ADRA1A,8.553,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
triflupromazine,D(2) dopamine receptor,DRD2,8.553,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
paliperidone,Alpha-1A adrenergic receptor,ADRA1A,8.553,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
clemastine,Muscarinic acetylcholine receptor M4,CHRM4,8.558,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
cyproheptadine,Muscarinic acetylcholine receptor M5,CHRM5,8.559,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
nicotine,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,8.56,Ki,CN1CCC[C@H]1C1=CC=CN=C1
raloxifene,Estrogen receptor beta,Esr2,8.56,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
valethamate,Muscarinic acetylcholine receptor M1,CHRM1,8.56,Ki,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1
linolenic acid,"Fatty acid-binding protein, heart",FABP3,8.56,Kd,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
buserelin,Lutropin-choriogonadotropic hormone receptor,LHCGR,8.569,Kd,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
thioridazine,Muscarinic acetylcholine receptor M1,CHRM1,8.569,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
paliperidone,5-hydroxytryptamine receptor 7,HTR7,8.569,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
lorlatinib,Leukocyte tyrosine kinase receptor,LTK,8.569,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
ifenprodil,"3-beta-hydroxysteroid-delta(8),delta(7)-isomerase",EBP,8.57,Ki,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
ketanserin,Adenosine receptor A3,ADORA3,8.57,IC50,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
sertindole,Potassium voltage-gated channel subfamily H member 2,KCNH2,8.57,IC50,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sorafenib,Homeodomain-interacting protein kinase 4,HIPK4,8.57,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
tolterodine,Muscarinic acetylcholine receptor M2,CHRM2,8.57,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
valsartan,Angiotensin II receptor (AT-1) type-1,Agtr1|Agtr1b,8.57,IC50,CCCCC(=O)N(CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)[C@@H](C(C)C)C(O)=O
methylatropine,Muscarinic acetylcholine receptor M2,Chrm2,8.57,Kd,C[N+]1(C)[C@H]2CC[C@@H]1C[C@H](C2)OC(=O)[C@@H](CO)C1=CC=CC=C1
dolutegravir,Integrase,,8.57,IC50,C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12
nintedanib,Mast/stem cell growth factor receptor Kit,KIT,8.57,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
sultopride,D(2) dopamine receptor,DRD2,8.571,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(=O)(=O)CC
atazanavir,Gag-Pol polyprotein,gag-pol,8.575,Ki,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
astemizole,Histamine H1 receptor,HRH1,8.58,A2,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
alpha-Ergocryptine,5-hydroxytryptamine receptor 1A,Htr1a,8.58,IC50,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
ergometrine,5-hydroxytryptamine receptor 2B,HTR2B,8.58,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
zanamivir,Neuraminidase,,8.58,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
trenbolone hexahydrobenzylcarbonate,Androgen receptor,Ar,8.58,IC50,C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)OCC1CCCCC1
delgocitinib,Tyrosine-protein kinase JAK2,JAK2,8.58,IC50,C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N
metergoline,D(3) dopamine receptor,DRD3,8.583,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
clemastine,Histamine H1 receptor,HRH1,8.585,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
mesoridazine,D(3) dopamine receptor,DRD3,8.585,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
pridinol,Muscarinic acetylcholine receptor M4,CHRM4,8.585,Ki,OC(CCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
thioridazine,Alpha-1B adrenergic receptor,Adra1b,8.585,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
brexpiprazole,Alpha-1D adrenergic receptor,ADRA1D,8.585,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
apomorphine,D(3) dopamine receptor,DRD3,8.59,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
benzatropine,Muscarinic acetylcholine receptor M2,Chrm2,8.59,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Cyclin-G-associated kinase,GAK,8.59,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
mepenzolate,Muscarinic acetylcholine receptor M3,CHRM3,8.59,Ki,C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
moexipril,Angiotensin-converting enzyme,ACE,8.59,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O
nifedipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,8.59,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
sertindole,D(3) dopamine receptor,DRD3,8.59,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
methylatropine,Muscarinic acetylcholine receptor M3,Chrm3,8.59,Kd,C[N+]1(C)[C@H]2CC[C@@H]1C[C@H](C2)OC(=O)[C@@H](CO)C1=CC=CC=C1
nintedanib,Potassium voltage-gated channel subfamily H member 2,KCNH2,8.59,IC50,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
cariprazine,5-hydroxytryptamine receptor 1A,HTR1A,8.59,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
samidorphan,Delta-type opioid receptor,OPRD1,8.59,Ki,C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O
acetazolamide,Carbonic anhydrase 12,CA12,8.6,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetazolamide,Carbonic anhydrase 7,CA7,8.6,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
bivalirudin,Prothrombin,F2,8.6,Ki,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O
darifenacin,Muscarinic acetylcholine receptor M3,Chrm3,8.6,Ki,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
ergotamine,5-hydroxytryptamine receptor 6,HTR6,8.6,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ergotamine,5-hydroxytryptamine receptor 6,Htr6,8.6,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ethoxzolamide,Carbonic anhydrase 14,CA14,8.6,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
fluvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,8.6,IC50,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C1=CC=C(F)C=C1
formoterol,Beta-2 adrenergic receptor,ADRB2,8.6,Kd,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
hexocyclium,Muscarinic acetylcholine receptor M1,Chrm1,8.6,Ki,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
lansoprazole,Microtubule-associated protein tau,MAPT,8.6,Ki,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
lofexidine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.6,IC50,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
lysergide,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.6,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
metergoline,5-hydroxytryptamine receptor 2A,HTR2A,8.6,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
methazolamide,Carbonic anhydrase V,CA5A|CA5B,8.6,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
mupirocin,Isoleucine--tRNA ligase,ileS,8.6,Ki,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O
nadolol,Beta-2 adrenergic receptor,ADRB2,8.6,Ki,CC(C)(C)NCC(O)COC1=CC=CC2=C1CC(O)C(O)C2
olanzapine,5-hydroxytryptamine receptor 6,Htr6,8.6,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
pimethixene,5-hydroxytryptamine receptor 2A,Htr2a,8.6,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2SC2=C1C=CC=C2
tertatolol,Beta-3 adrenergic receptor,ADRB3,8.6,Ki,CC(C)(C)NCC(O)COC1=C2SCCCC2=CC=C1
eledoisin,Substance-P receptor,TACR1,8.6,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCC(=O)N1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O
moxestrol,Estrogen receptor,ESR1|ESR2,8.6,IC50,CO[C@H]1C[C@@]2(C)[C@@H](CC[C@@]2(O)C#C)[C@@H]2CCC3=C(C=CC(O)=C3)[C@@H]12
prucalopride,5-hydroxytryptamine receptor 4,HTR4,8.6,Ki,COCCCN1CCC(CC1)NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2
ruboxistaurin,Protein kinase C theta type,PRKCQ,8.6,Kd,CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=CC=CC=C21
asenapine,5-hydroxytryptamine receptor 5A,HTR5A,8.6,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
methylatropine,Muscarinic acetylcholine receptor M1,Chrm1,8.6,Kd,C[N+]1(C)[C@H]2CC[C@@H]1C[C@H](C2)OC(=O)[C@@H](CO)C1=CC=CC=C1
bedaquiline,ATP synthase subunit c,atpE,8.6,IC50,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2
corticotropin,Melanocyte-stimulating hormone receptor,MC1R,8.6,Ki,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
latanoprostene bunod,Prostaglandin F2-alpha receptor,PTGFR,8.6,Ki,O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1
osilodrostat,"Cytochrome P450 11B1, mitochondrial",CYP11B1,8.6,IC50,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12
cyamemazine,D(3) dopamine receptor,DRD3,8.602,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
idelalisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,8.602,IC50,CC[C@H](NC1=NC=NC2=C1NC=N2)C1=NC2=C(C(F)=CC=C2)C(=O)N1C1=CC=CC=C1
erdafitinib,Fibroblast growth factor receptor 2,FGFR2,8.602,IC50,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1
clemastine,D(3) dopamine receptor,DRD3,8.604,Ki,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
dicycloverine,Muscarinic acetylcholine receptor M1,Chrm1,8.61,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
tacrine,Cholinesterase,BCHE,8.61,IC50,NC1=C2CCCCC2=NC2=CC=CC=C12
prochlorperazine,D(3) dopamine receptor,DRD3,8.611,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
biperiden,Muscarinic acetylcholine receptor M4,CHRM4,8.62,Kd,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
dopamine,D(4) dopamine receptor,Drd4,8.62,EC50,NCCC1=CC(O)=C(O)C=C1
loxapine,5-hydroxytryptamine receptor 2A,HTR2A,8.62,Ki,CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2
penbutolol,5-hydroxytryptamine receptor 1A,Htr1a,8.62,Ki,CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C1CCCC1
pergolide,D(3) dopamine receptor,Drd3,8.62,IC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pizotifen,D(2) dopamine receptor,DRD2,8.62,Ki,CN1CCC(CC1)=C1C2=C(CCC3=C1C=CC=C3)SC=C2
propranolol,Adrenergic receptor beta,Adrb2|Adrb1|Adrb3,8.62,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
propranolol,Beta-1 adrenergic receptor,Adrb1,8.62,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
propranolol,Beta-1 adrenergic receptor,Adrb1,8.62,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
thioridazine,Alpha-1B adrenergic receptor,ADRA1B,8.62,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
zanamivir,Neuraminidase,,8.62,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
saralasin,Type-1B angiotensin II receptor,Agtr1b,8.62,IC50,CNCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O
clorotepine,D(3) dopamine receptor,Drd3,8.62,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
methylatropine,Muscarinic acetylcholine receptor DM1,mAChR-A,8.62,Ki,C[N+]1(C)[C@H]2CC[C@@H]1C[C@H](C2)OC(=O)[C@@H](CO)C1=CC=CC=C1
neratinib,Receptor tyrosine-protein kinase erbB-4,ERBB4,8.62,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
abemaciclib,Cyclin-dependent kinase 6,CDK6,8.62,Ki,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
bremelanotide,Melanocortin receptor 3,MC3R,8.62,EC50,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O
fluocinonide,Glucocorticoid receptor,NR3C1,8.622,Ki,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C
cangrelor,P2Y purinoceptor 12,P2RY12,8.627,IC50,CSCCNC1=NC(SCCC(F)(F)F)=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O
methylergometrine,5-hydroxytryptamine receptor 1A,HTR1A,8.633,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
triazolam,GABA-A receptor alpha-1/beta-2/gamma-3,GABRA1|GABRB2|GABRG3,8.638,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
darifenacin,Muscarinic acetylcholine receptor M5,CHRM5,8.64,Ki,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
estradiol,Estrogen receptor beta,Esr2,8.64,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
levorphanol,Kappa-type opioid receptor,OPRK1,8.64,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
levorphanol,Kappa-type opioid receptor,OPRK1,8.64,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
metergoline,5-hydroxytryptamine receptor 1A,HTR1A,8.64,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
pramlintide,Amylin receptor AMY2,CALCR|RAMP2,8.64,EC50,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O
kainic acid,"Glutamate receptor ionotropic, kainate 4",GRIK4,8.64,Ki,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
clorotepine,D(1A) dopamine receptor,Drd1,8.64,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
panobinostat,Histone deacetylase 7,HDAC7,8.64,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
brexpiprazole,5-hydroxytryptamine receptor 2A,Htr2a,8.64,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
dihydroergotamine,5-hydroxytryptamine receptor 2A,HTR2A,8.644,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
luseogliflozin,Sodium/glucose cotransporter 2,SLC5A2,8.646,IC50,CCOC1=CC=C(CC2=C(C)C=C(OC)C(=C2)[C@@H]2S[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
flupentixol,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.65,IC50,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
spiperone,5-hydroxytryptamine receptor 2A,HTR2A,8.65,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
florbetaben F18,Amyloid beta A4 protein,APP,8.65,Ki,CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1
tivozanib,Platelet-derived growth factor receptor alpha,PDGFRA,8.65,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
lasmiditan,5-hydroxytryptamine receptor 1F,HTR1F,8.65,Ki,CN1CCC(CC1)C(=O)C1=NC(NC(=O)C2=C(F)C=C(F)C=C2F)=CC=C1
cyproheptadine,5-hydroxytryptamine receptor 2C,HTR2C,8.652,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
pentazocine,Kappa-type opioid receptor,OPRK1,8.658,Ki,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
ponatinib,Fibroblast growth factor receptor 1,FGFR1,8.658,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
canagliflozin,Sodium/glucose cotransporter 2,SLC5A2,8.658,IC50,CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
carvedilol,Alpha-1A adrenergic receptor,ADRA1A,8.66,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
cyproheptadine,Muscarinic acetylcholine receptor M4,CHRM4,8.66,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
estradiol,Estrogen receptor,Esr1,8.66,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
nabilone,Cannabinoid receptor 1,Cnr1,8.66,Ki,CCCCCCC(C)(C)C1=CC(O)=C2C3CC(=O)CCC3C(C)(C)OC2=C1
tazobactam,Beta-lactamase,blaCTX-M-53,8.66,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
tolcapone,Catechol O-methyltransferase,Comt,8.66,IC50,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
tolterodine,Muscarinic acetylcholine receptor M5,CHRM5,8.66,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
tolterodine,Muscarinic acetylcholine receptor M5,Chrm5,8.66,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
trimethoprim,Dihydrofolate reductase,DFR1,8.66,IC50,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
benzylsulfamide,Carbonic anhydrase 9,CA9,8.66,Ki,NS(=O)(=O)C1=CC=C(NCC2=CC=CC=C2)C=C1
ibrutinib,Tyrosine-protein kinase CSK,CSK,8.66,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
istradefylline,Adenosine receptor A2a,ADORA2A,8.66,Ki,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
nintedanib,BMP-2-inducible protein kinase,BMP2K,8.66,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
pralsetinib,Tyrosine-protein kinase JAK1,JAK1,8.66,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
clorotepine,5-hydroxytryptamine receptor 6,HTR6,8.665,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
pramipexole,D(3) dopamine receptor,DRD3,8.668,EC50,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
fentanyl,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,8.67,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
estriol,Estrogen receptor,ESR1,8.67,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O
oxitriptan,5-hydroxytryptamine receptor 7,HTR7,8.67,Ki,N[C@@H](CC1=CNC2=CC=C(O)C=C12)C(O)=O
nandrolone,Androgen receptor,Ar,8.678,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O
brigatinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,8.678,IC50,COC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3P(C)(C)=O)=N2)C=CC(=C1)N1CCC(CC1)N1CCN(C)CC1
letermovir,DNA terminase complex,TRM1|TRM2|TRM3,8.678,EC50,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=C(OC)C=CC(=C1)C(F)(F)F
clozapine,Muscarinic acetylcholine receptor M1,Chrm1,8.68,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Tyrosine-protein kinase TXK,TXK,8.68,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diazepam,GABA A receptor alpha-6/beta-2/gamma-2,Gabrg2|Gabra6|Gabrb2,8.68,Ki,CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
dinoprostone,Prostaglandin E2 receptor EP4 subtype,Ptger4,8.68,IC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
ergotamine,5-hydroxytryptamine receptor 1B,HTR1B,8.68,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
methazolamide,Carbonic anhydrase 7,CA7,8.68,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
metolazone,Carbonic anhydrase 7,CA7,8.68,Ki,CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=C(C)C=CC=C1)S(N)(=O)=O
nandrolone decanoate,Androgen receptor,Ar,8.68,Ki,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
nelfinavir,Protease,HIV-1 protease,8.68,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
niflumic acid,Potassium channel subfamily T member 2,KCNT2,8.68,EC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)N=CC=C1
rosuvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,Hmgcr,8.68,IC50,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
estrone,Estrogen receptor beta,ESR2,8.68,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
osimertinib,Receptor tyrosine-protein kinase erbB-3,ERBB3,8.68,IC50,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
niraparib,Poly [ADP-ribose] polymerase 2,PARP2,8.68,IC50,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
setmelanotide,Melanocortin receptor 4,MC4R,8.68,Kd,C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
dicycloverine,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.686,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
thioridazine,Alpha-1D adrenergic receptor,ADRA1D,8.686,Ki,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
atomoxetine,Sodium-dependent noradrenaline transporter,SLC6A2,8.69,Kd,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
dihydroergotamine,Alpha-1D adrenergic receptor,ADRA1D,8.69,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
lurasidone,5-hydroxytryptamine receptor 2A,Htr2a,8.69,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
fludroxycortide,Glucocorticoid receptor,NR3C1,8.695,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
carbachol,Muscarinic acetylcholine receptor M3,CHRM3,8.699,EC50,C[N+](C)(C)CCOC(N)=O
desalkylflurazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,8.699,IC50,FC1=C(C=CC=C1)C1=NCC(=O)NC2=CC=C(Cl)C=C12
desoxycortone,5-hydroxytryptamine receptor 2C,HTR2C,8.699,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO
dosulepin,Histamine H1 receptor,HRH1,8.699,Ki,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
flunitrazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,8.699,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
flunitrazepam,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,8.699,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
hydroxyzine,Histamine H1 receptor,HRH1,8.699,Ki,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
promazine,Histamine H1 receptor,HRH1,8.699,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2
terfenadine,Histamine H1 receptor,HRH1,8.699,Ki,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
thiethylperazine,D(2) dopamine receptor,DRD2,8.699,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thiethylperazine,Alpha-1A adrenergic receptor,ADRA1A,8.699,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thiethylperazine,D(3) dopamine receptor,DRD3,8.699,Ki,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
triazolam,GABA A receptor alpha-5/beta-3/gamma-3,GABRB3|GABRA5|GABRG3,8.699,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
triazolam,GABA A receptor alpha-5/beta-2/gamma-3,GABRA5|GABRB2|GABRG3,8.699,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
ibrutinib,Tyrosine-protein kinase TXK,TXK,8.699,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
avibactam,Beta-lactamase,blaUOE-1,8.699,Kd,NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O
icotinib,Epidermal growth factor receptor,EGFR,8.699,IC50,C#CC1=CC=CC(NC2=NC=NC3=C2C=C2OCCOCCOCCOC2=C3)=C1
aminopterin,Dihydrofolate reductase,Dhfr,8.7,IC50,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
alcuronium,Muscarinic acetylcholine receptor M2,CHRM2,8.7,EC50,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
aliskiren,Renin,REN,8.7,IC50,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
amlodipine,Voltage-dependent L-type calcium channel subunit alpha-1C,Cacna1c,8.7,Ki,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
amoxapine,5-hydroxytryptamine receptor 2C,HTR2C,8.7,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
amoxapine,5-hydroxytryptamine receptor 2C,Htr2c,8.7,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
astemizole,Protein farnesyltransferase,FNTA|FNTB,8.7,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
benazepril,Angiotensin-converting enzyme,ACE,8.7,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
benperidol,D(4) dopamine receptor,DRD4,8.7,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2
captopril,Angiotensin-converting enzyme,ACE,8.7,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
captopril,Angiotensin-converting enzyme,Ace,8.7,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
carazolol,Beta-3 adrenergic receptor,ADRB3,8.7,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
chlorphenamine,Histamine H1 receptor,Hrh1,8.7,Ki,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
cilazapril,Angiotensin-converting enzyme,ACE,8.7,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O
clonidine,Alpha-2A adrenergic receptor,ADRA2A,8.7,IC50,ClC1=CC=CC(Cl)=C1NC1=NCCN1
dexamfetamine,Trace amine-associated receptor 1,Taar1,8.7,EC50,C[C@H](N)CC1=CC=CC=C1
eprosartan,Type-1 angiotensin II receptor,AGTR1,8.7,IC50,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O
ergotamine,5-hydroxytryptamine receptor 2C,HTR2C,8.7,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ethoxzolamide,Carbonic anhydrase V,CA5A|CA5B,8.7,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
everolimus,Serine/threonine-protein kinase mTOR,MTOR,8.7,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO
flumazenil,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,8.7,Kd,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
flumazenil,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,8.7,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
fluoxetine,Sodium-dependent serotonin transporter,Slc6a4,8.7,Ki,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
fulvestrant,Steroid hormone receptor ERR1,ESRRA,8.7,IC50,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
granisetron,5-hydroxytryptamine receptor 3A,HTR3A,8.7,Ki,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
haloperidol,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,8.7,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ifenprodil,Sigma non-opioid intracellular receptor 1,Sigmar1,8.7,Ki,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
indalpine,Sodium-dependent serotonin transporter,Slc6a4,8.7,Ki,C(CC1=CNC2=CC=CC=C12)C1CCNCC1
indomethacin,Prostaglandin G/H synthase 1,Ptgs1,8.7,IC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
ketobemidone,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,8.7,EC50,CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1
levocabastine,Neurotensin receptor type 2,Ntsr2,8.7,IC50,C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1
lysergide,5-hydroxytryptamine receptor 7,Htr7,8.7,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
lysergide,5-hydroxytryptamine receptor 6,Htr6,8.7,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
midazolam,Translocator protein,Tspo,8.7,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
midazolam,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,8.7,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
mirtazapine,5-hydroxytryptamine receptor 2A,Htr2a,8.7,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
nalmefene,Kappa-type opioid receptor,OPRK1,8.7,Ki,OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
nalorphine,Mu-type opioid receptor,Oprm1,8.7,Ki,O[C@H]1C=C[C@H]2[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
octreotide,Somatostatin receptor type 2,Sstr2,8.7,Ki,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
olanzapine,Histone H1.0,H1F0,8.7,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
paricalcitol,Vitamin D3 receptor,VDR,8.7,EC50,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1
phenazocine,Kappa-type opioid receptor,OPRK1,8.7,Ki,CC1C2CC3=C(C=C(O)C=C3)C1(C)CCN2CCC1=CC=CC=C1
pizotifen,5-hydroxytryptamine receptor 2B,HTR2B,8.7,Ki,CN1CCC(CC1)=C1C2=C(CCC3=C1C=CC=C3)SC=C2
pizotifen,Muscarinic acetylcholine receptor M1,CHRM1,8.7,Ki,CN1CCC(CC1)=C1C2=C(CCC3=C1C=CC=C3)SC=C2
spiperone,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,8.7,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,8.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tazobactam,Beta-lactamase,blaUOE-1,8.7,IC50,C[C@]1(CN2C=CN=N2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
thioridazine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,8.7,IC50,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
tiquizium,Muscarinic acetylcholine receptor,CHRM1,8.7,Ki,C[N@+]12CCCC[C@@H]1CCC(C2)=C(C1=CC=CS1)C1=CC=CS1
tolrestat,Aldose reductase,Akr1b1,8.7,IC50,COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O
tretinoin,Cellular retinoic acid-binding protein 2,Crabp2,8.7,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
triparanol,C-8 sterol isomerase,ERG2,8.7,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(O)(CC1=CC=C(Cl)C=C1)C1=CC=C(C)C=C1
ziprasidone,5-hydroxytryptamine receptor 1D,HTR1D,8.7,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
gonadorelin,Gonadotropin-releasing hormone receptor,Gnrhr,8.7,IC50,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
enoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 1,Hsd11b1,8.7,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
fenoxazoline,Nischarin,NISCH,8.7,Ki,CC(C)C1=C(OCC2=NCCN2)C=CC=C1
xanomeline,Muscarinic acetylcholine receptor M1,Chrm1,8.7,IC50,CCCCCCOC1=NSN=C1C1=CCCN(C)C1
yohimbine,Alpha-2B adrenergic receptor,ADRA2B,8.7,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
yohimbine,Alpha-2B adrenergic receptor,Adra2b,8.7,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
asenapine,D(1A) dopamine receptor,DRD1,8.7,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
pazopanib,Platelet-derived growth factor receptor beta,PDGFRB,8.7,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
vorinostat,Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2),HDAC3|NCOR2,8.7,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
silodosin,Alpha-1D adrenergic receptor,ADRA1D,8.7,Ki,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
ruxolitinib,Tyrosine-protein kinase JAK3,JAK3,8.7,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
bosutinib,Serine/threonine-protein kinase 35,STK35,8.7,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
teriparatide,Parathyroid hormone/parathyroid hormone-related peptide receptor,Pth1r,8.7,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
levomethadone,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,8.7,Ki,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
dabrafenib,Receptor-interacting serine/threonine-protein kinase 3,RIPK3,8.7,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
dabrafenib,Receptor-interacting serine/threonine-protein kinase 3,RIPK3,8.7,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
peramivir,Neuraminidase,,8.7,IC50,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
istradefylline,Adenosine receptor A2a,Adora2a,8.7,Ki,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
palbociclib,Cyclin-dependent kinase 4/cyclin D1,CDK4|CCND1,8.7,IC50,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O
tazemetostat,Polycomb protein EED,EED,8.7,IC50,CCN(C1CCOCC1)C1=CC(=CC(C(=O)NCC2=C(C)C=C(C)NC2=O)=C1C)C1=CC=C(CN2CCOCC2)C=C1
pralsetinib,Epithelial discoidin domain-containing receptor 1,DDR1,8.7,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
infigratinib,Fibroblast growth factor receptor 3,FGFR3,8.7,,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
carvedilol,Alpha-1B adrenergic receptor,Adra1b,8.706,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
bromocriptine,Alpha-1B adrenergic receptor,Adra1b,8.708,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
chlorpromazine,Alpha-1D adrenergic receptor,ADRA1D,8.708,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
aripiprazole,D(2) dopamine receptor,DRD2,8.71,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
propranolol,Beta-1 adrenergic receptor,ADRB1,8.71,Ki,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
asenapine,D(4) dopamine receptor,DRD4,8.71,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
clavulanic acid,Beta-lactamase,blaZ,8.719,MPC,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
dexketoprofen,Prostaglandin G/H synthase 1,PTGS1,8.72,IC50,C[C@H](C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
estradiol,Estrogen receptor,Esr1,8.72,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
gabapentin,Potassium voltage-gated channel subfamily KQT member 5,KCNQ5,8.72,EC50,NCC1(CC(O)=O)CCCCC1
levorphanol,Sigma non-opioid intracellular receptor 1,Sigmar1,8.72,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
losartan,Angiotensin II receptor (AT-1) type-1,Agtr1|Agtr1b,8.72,Ki,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
nicotine,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,8.72,Ki,CN1CCC[C@H]1C1=CC=CN=C1
oxymetazoline,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.72,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
treprostinil,Prostacyclin receptor,PTGIR,8.72,EC50,CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2CC3=C(OCC(O)=O)C=CC=C3C[C@H]12
trimetrexate,Dihydrofolate reductase,DFR1,8.72,Ki,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
valsartan,Type-1B angiotensin II receptor,Agtr1b,8.72,IC50,CCCCC(=O)N(CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)[C@@H](C(C)C)C(O)=O
varenicline,Neuronal acetylcholine receptor; alpha3/beta2,Chrna3|Chrnb2,8.72,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
terazosin,Alpha-1B adrenergic receptor,Adra1b,8.72,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
benzoic acid,Nicotinate phosphoribosyltransferase,NAPRT,8.72,Ki,OC(=O)C1=CC=CC=C1
gilteritinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,8.72,IC50,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1
mefuparib,Poly [ADP-ribose] polymerase 2,PARP2,8.72,IC50,CNCC1=CC=C(C=C1)C1=CC2=C(O1)C(=CC(F)=C2)C(N)=O
lonafarnib,GTPase HRas,HRAS,8.72,IC50,C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
lonafarnib,GTPase HRas,HRAS,8.72,IC50,C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
lonafarnib,Protein farnesyltransferase,FNTA|FNTB,8.72,IC50,C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
pyrimethamine,Muscarinic acetylcholine receptor M1,CHRM1,8.721,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
alectinib,ALK tyrosine kinase receptor,ALK,8.721,IC50,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O
brexpiprazole,5-hydroxytryptamine receptor 2B,HTR2B,8.721,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
brigatinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,8.721,IC50,COC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3P(C)(C)=O)=N2)C=CC(=C1)N1CCC(CC1)N1CCN(C)CC1
raloxifene,Estrogen receptor,Esr1|Esr2,8.73,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
voriconazole,Lanosterol 14-alpha demethylase,ERG11,8.73,MIC,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
asenapine,Alpha-2B adrenergic receptor,ADRA2B,8.73,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
acetazolamide,Carbonic anhydrase V,CA5A|CA5B,8.74,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
apomorphine,D(2) dopamine receptor,Drd2,8.74,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
clotrimazole,Aromatase,CYP19A1,8.74,IC50,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clozapine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.74,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dopamine,D(2) dopamine receptor,DRD2,8.74,Ki,NCCC1=CC(O)=C(O)C=C1
flurbiprofen,Prostaglandin G/H synthase 1,PTGS1,8.74,IC50,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
fulvestrant,Estrogen receptor beta,ESR2,8.74,Ki,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
haloperidol,Dopamine receptor,DRD2|DRD1,8.74,IC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
indisetron,5-hydroxytryptamine receptor 3A,HTR3A,8.74,Ki,CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C1=NNC2=C1C=CC=C2
liothyronine,Thyroid hormone receptor beta,Thrb,8.74,IC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
mifepristone,Progesterone receptor,PGR,8.74,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
morphine,Delta-type opioid receptor,Oprd1,8.74,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
nabilone,Cannabinoid receptor 2,Cnr2,8.74,Ki,CCCCCCC(C)(C)C1=CC(O)=C2C3CC(=O)CCC3C(C)(C)OC2=C1
phenoxybenzamine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,8.74,Ki,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
risperidone,D(2) dopamine receptor,Drd2,8.74,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sildenafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",Pde5a,8.74,Ki,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
pazopanib,Mast/stem cell growth factor receptor Kit,KIT,8.74,Kd,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
lasofoxifene,Estrogen receptor beta,ESR2,8.74,IC50,OC1=CC=C2C(C(CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
panobinostat,Histone deacetylase,HDAC1,8.74,IC50,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
nintedanib,Dual specificity mitogen-activated protein kinase kinase 5,MAP2K5,8.74,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
dasabuvir,NS5B protein,NS5B,8.74,EC50,COC1=C(C=C(C=C1C(C)(C)C)N1C=CC(=O)NC1=O)C1=CC=C2C=C(NS(C)(=O)=O)C=CC2=C1
dasabuvir,NS5B protein,NS5B,8.74,EC50,COC1=C(C=C(C=C1C(C)(C)C)N1C=CC(=O)NC1=O)C1=CC=C2C=C(NS(C)(=O)=O)C=CC2=C1
cobimetinib,Serine/threonine-protein kinase B-raf,BRAF,8.74,IC50,OC1(CN(C1)C(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1)[C@@H]1CCCCN1
dihydroergotamine,D(3) dopamine receptor,DRD3,8.742,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ergotamine,Alpha-2C adrenergic receptor,ADRA2C,8.742,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
mesoridazine,Histamine H1 receptor,HRH1,8.744,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
delorazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,8.745,IC50,ClC1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1
methapyrilene,Histamine H1 receptor,HRH1,8.745,Ki,CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
midazolam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,8.745,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
pimozide,D(4) dopamine receptor,DRD4,8.745,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
sertindole,Alpha-1A adrenergic receptor,ADRA1A,8.745,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
trametinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,8.745,IC50,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=C(F)C=C(I)C=C1)C1=CC(NC(C)=O)=CC=C1
sotagliflozin,Sodium/glucose cotransporter 2,SLC5A2,8.745,IC50,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1
ketanserin,Histamine H1 receptor,HRH1,8.747,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
amoxapine,5-hydroxytryptamine receptor 2A,HTR2A,8.75,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
atenolol,Adenosine receptor A3,ADORA3,8.75,IC50,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
reserpine,Synaptic vesicular amine transporter,Slc18a2,8.75,IC50,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
toliprolol,Beta-1 adrenergic receptor,ADRB1,8.75,Kd,CC(C)NCC(O)COC1=CC(C)=CC=C1
asenapine,D(2) dopamine receptor,DRD2,8.75,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
elvitegravir,Integrase,,8.75,IC50,COC1=C(CC2=C(F)C(Cl)=CC=C2)C=C2C(=O)C(=CN([C@H](CO)C(C)C)C2=C1)C(O)=O
esatenolol,Adenosine receptor A3,ADORA3,8.75,IC50,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
dihydroergotamine,Alpha-2B adrenergic receptor,ADRA2B,8.752,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ergotamine,Alpha-2B adrenergic receptor,ADRA2B,8.754,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
betaxolol,Beta-1 adrenergic receptor,ADRB1,8.76,Kd,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
propranolol,Beta-1 adrenergic receptor,ADRB1,8.76,Kd,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
zanamivir,Neuraminidase,,8.76,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
pentazocine,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.76,EC50,CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC=C(C)C
prochlorperazine,D(2) dopamine receptor,DRD2,8.764,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
tivozanib,Platelet-derived growth factor receptor beta,PDGFRB,8.764,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
dicycloverine,Muscarinic acetylcholine receptor M5,CHRM5,8.767,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
benazepril,Angiotensin-converting enzyme,Ace,8.77,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
captopril,Renin,REN,8.77,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
captopril,Angiotensin-converting enzyme,ACE,8.77,Ki,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
clonazepam,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,8.77,IC50,[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1
dinoprostone,Prostaglandin E2 receptor EP2 subtype,PTGER2,8.77,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
donepezil,Acetylcholinesterase,Ache,8.77,IC50,COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2
eperisone,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.77,Ki,CCC1=CC=C(C=C1)C(=O)C(C)CN1CCCCC1
estradiol,Estrogen receptor beta,Esr2,8.77,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
imipramine,Alpha-1A adrenergic receptor,Adra1a,8.77,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
ipratropium,Muscarinic acetylcholine receptor M5,CHRM5,8.77,Ki,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
lisuride,D(3) dopamine receptor,DRD3,8.77,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
methotrexate,Dihydrofolate reductase,DHFR,8.77,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
phentolamine,Alpha-2A adrenergic receptor,ADRA2A,8.77,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
saralasin,Angiotensin II receptor (AT-1) type-1,Agtr1|Agtr1b,8.77,IC50,CNCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O
guanabenz,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.77,IC50,NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl
lurasidone,D(2) dopamine receptor,Drd2,8.77,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
degarelix,Gonadotropin-releasing hormone receptor,GNRHR,8.77,Ki,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
suvorexant,Orexin receptor type 1,Hcrtr1,8.77,Ki,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2
eluxadoline,Mu-type opioid receptor,OPRM1,8.77,Ki,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O
aripiprazole lauroxil,5-hydroxytryptamine receptor 1A,HTR1A,8.77,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
tepotinib,Hepatocyte growth factor receptor,MET,8.77,IC50,CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N
maprotiline,Histamine H1 receptor,HRH1,8.777,Ki,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
chlorambucil,Cathepsin E,CTSE,8.78,IC50,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
droperidol,Alpha-1A adrenergic receptor,Adra1a,8.78,IC50,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
ethisterone,Sex hormone-binding globulin,SHBG,8.78,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C
methadone,Mu-type opioid receptor,OPRM1,8.78,Ki,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
vasopressin,Oxytocin receptor,OXTR,8.78,Ki,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
tivozanib,Mast/stem cell growth factor receptor Kit,KIT,8.788,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
dihydroergocristine,Alpha-1A adrenergic receptor,Adra1a,8.79,IC50,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
edrophonium,Acetylcholinesterase,ACHE,8.79,Ki,CC[N+](C)(C)C1=CC=CC(O)=C1
lodoxamide,G-protein coupled receptor 35,GPR35,8.793,EC50,OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N
flupentixol,D(4) dopamine receptor,DRD4,8.796,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
mirtazapine,Histamine H1 receptor,HRH1,8.796,Ki,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
naratriptan,5-hydroxytryptamine receptor 1D,HTR1D,8.796,EC50,CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1
olanzapine,D(4) dopamine receptor,DRD4,8.796,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
pridinol,Muscarinic acetylcholine receptor M1,CHRM1,8.796,Ki,OC(CCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
vortioxetine,Sodium-dependent serotonin transporter,SLC6A4,8.796,Ki,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1
quizartinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,8.796,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
pipamazine,D(3) dopamine receptor,DRD3,8.799,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
alprostadil,Prostaglandin E2 receptor EP4 subtype,PTGER4,8.8,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
betaxolol,Beta-1 adrenergic receptor,ADRB1,8.8,Kd,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
bufuralol,Beta-2 adrenergic receptor,ADRB2,8.8,Ki,CCC1=CC=CC2=C1OC(=C2)C(O)CNC(C)(C)C
cetrorelix,Gonadotropin-releasing hormone receptor,GNRHR,8.8,Ki,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
cyamemazine,5-hydroxytryptamine receptor 2A,HTR2A,8.8,Ki,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
cyproheptadine,5-hydroxytryptamine receptor 2A,Htr2a,8.8,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dexetimide,Muscarinic acetylcholine receptor M2,Chrm2,8.8,Ki,O=C1CC[C@@](C2CCN(CC3=CC=CC=C3)CC2)(C(=O)N1)C1=CC=CC=C1
doxazosin,Alpha-1A adrenergic receptor,ADRA1A,8.8,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
epinastine,Histamine H1 receptor,HRH1,8.8,IC50,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
formoterol,Beta-2 adrenergic receptor,Adrb2,8.8,EC50,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
granisetron,5-hydroxytryptamine receptor 3B,HTR3B,8.8,Ki,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
isradipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,8.8,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
lanreotide,Somatostatin receptor type 2,Sstr2,8.8,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
losartan,Type-1 angiotensin II receptor,AGTR1,8.8,Kd,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
metergoline,5-hydroxytryptamine receptor 2B,HTR2B,8.8,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
methysergide,5-hydroxytryptamine receptor 2A,Htr2a,8.8,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
nalbuphine,Mu-type opioid receptor,OPRM1,8.8,Ki,O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5
naloxone,Adenosine receptor A3,ADORA3,8.8,IC50,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
penbutolol,Beta-1 adrenergic receptor,ADRB1,8.8,Ki,CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C1CCCC1
phenindamine,Histamine H1 receptor,HRH1,8.8,Kd,CN1CCC2=C(C1)C(C1=C2C=CC=C1)C1=CC=CC=C1
pramipexole,D(2) dopamine receptor,DRD2,8.8,Kd,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
sunitinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.8,IC50,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tropisetron,5-hydroxytryptamine receptor 3A,HTR3A,8.8,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
tropisetron,5-hydroxytryptamine receptor 3B,HTR3B,8.8,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
ubenimex,Bacterial leucyl aminopeptidase,,8.8,Ki,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
zotepine,5-hydroxytryptamine receptor 7,Htr7,8.8,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
triptorelin,Gonadotropin-releasing hormone receptor,Gnrhr,8.8,Ki,CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
yohimbine,Alpha-1D adrenergic receptor,ADRA1D,8.8,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
vorinostat,Histone deacetylase 2,HDAC2,8.8,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
pasireotide,Somatostatin receptor type 3,SSTR3,8.8,IC50,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
ponatinib,Receptor-interacting serine/threonine-protein kinase 3,RIPK3,8.8,Ki,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
afamelanotide,Melanocortin receptor 4,MC4R,8.8,Ki,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
belinostat,Histone deacetylase 6,HDAC6,8.8,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
cariprazine,D(3) dopamine receptor,Drd3,8.8,IC50,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
pimavanserin,5-hydroxytryptamine receptor 2C,HTR2C,8.8,Ki,CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1
quizartinib,Platelet-derived growth factor receptor beta,PDGFRB,8.8,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
quizartinib,Mast/stem cell growth factor receptor Kit,KIT,8.8,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
quizartinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.8,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
quizartinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,8.8,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
quizartinib,Platelet-derived growth factor receptor alpha,PDGFRA,8.8,Kd,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
fluorometholone,Glucocorticoid receptor,NR3C1,8.801,Ki,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12
doxazosin,Alpha-1A adrenergic receptor,Adra1a,8.81,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
naloxone,Mu-type opioid receptor,OPRM1,8.81,Ki,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
oseltamivir,Neuraminidase,,8.81,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
repaglinide,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,8.81,Ki,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N2CCCCC2)=C1)C(O)=O
spiperone,Beta-casein,Csn2,8.81,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
mestanolone,Sex hormone-binding globulin,SHBG,8.81,Kd,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
hydroxyprogesterone caproate,Progesterone receptor,PGR,8.81,Ki,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
cyproheptadine,5-hydroxytryptamine receptor 2B,HTR2B,8.812,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
clobetasol propionate,Progesterone receptor,PGR,8.818,Ki,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
apomorphine,D(4) dopamine receptor,Drd4,8.82,EC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
citalopram,Sodium-dependent serotonin transporter,Slc6a4,8.82,Ki,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
clonidine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.82,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
dexmedetomidine,Alpha-2A adrenergic receptor,ADRA2A,8.82,EC50,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
eritoran,Toll-like receptor 4,TLR4,8.82,IC50,CCCCCCCCCCCC(=O)CC(=O)N[C@H]1[C@H](OP(O)(O)=O)O[C@H](CO[C@@H]2O[C@H](COC)[C@@H](OP(O)(O)=O)[C@H](OCC[C@@H](CCCCCCC)OC)[C@H]2NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](O)[C@@H]1OCCCCCCCCCC
fentanyl,Mu-type opioid receptor,Oprm1,8.82,Ki,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
flunitrazepam,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,8.82,IC50,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
flupentixol,D(2) dopamine receptor,DRD2,8.82,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fosinopril,Angiotensin-converting enzyme,ACE,8.82,Ki,CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C
mianserin,5-hydroxytryptamine receptor 2A,Htr2a,8.82,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nalorphine,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,8.82,EC50,O[C@H]1C=C[C@H]2[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
oxymetazoline,Alpha-2A adrenergic receptor,ADRA2A,8.82,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
perindopril,Angiotensin-converting enzyme,ACE,8.82,IC50,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC
risperidone,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.82,IC50,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sorafenib,Epithelial discoidin domain-containing receptor 1,DDR1,8.82,Kd,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
sulpiride,D(2) dopamine receptor,Drd2,8.82,Kd,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
trimetrexate,Dihydrofolate reductase,folA,8.82,IC50,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
vasopressin,Vasopressin V2 receptor,AVPR2,8.82,Kd,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
glucagon,Glucagon receptor,Gcgr,8.82,IC50,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
rimonabant,Cannabinoid receptor 1,Cnr1,8.82,Ki,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
axitinib,Tyrosine-protein kinase ABL1,ABL1,8.82,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
bosutinib,Abelson tyrosine-protein kinase 2,ABL2,8.82,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
regorafenib,Platelet-derived growth factor receptor beta,PDGFRB,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Vascular endothelial growth factor receptor 1,FLT1,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Angiopoietin-1 receptor,TEK,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Fibroblast growth factor receptor 1,FGFR1,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Vascular endothelial growth factor receptor 2,Kdr,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Vascular endothelial growth factor receptor 3,Flt4,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Platelet-derived growth factor receptor beta,PDGFRB,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Fibroblast growth factor receptor 1,FGFR1,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Vascular endothelial growth factor receptor 1,FLT1,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Vascular endothelial growth factor receptor 3,Flt4,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Vascular endothelial growth factor receptor 2,Kdr,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
regorafenib,Angiopoietin-1 receptor,TEK,8.82,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
belinostat,Histone deacetylase 3,HDAC3,8.82,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
lenvatinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,8.82,Ki,COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2
opicapone,Catechol O-methyltransferase,Comt,8.82,Ki,CC1=C(C2=NOC(=N2)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl
opicapone,Catechol O-methyltransferase,Comt,8.82,Ki,CC1=C(C2=NOC(=N2)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl
gilteritinib,ALK tyrosine kinase receptor,ALK,8.82,IC50,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1
dihydroergotamine,Alpha-2C adrenergic receptor,ADRA2C,8.821,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
alpha-Ergocryptine,5-hydroxytryptamine receptor 1A,HTR1A,8.824,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
ergometrine,5-hydroxytryptamine receptor 6,HTR6,8.824,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
flunitrazepam,GABA A receptor alpha-3/beta-2/gamma-2,GABRG2|GABRA3|GABRB2,8.824,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
ipratropium,Muscarinic acetylcholine receptor M2,CHRM2,8.824,Ki,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
loperamide,Mu-type opioid receptor,OPRM1,8.824,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
ponatinib,Vascular endothelial growth factor receptor 2,KDR,8.824,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
betrixaban,Coagulation factor X,F10,8.824,IC50,COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1
elagolix,Gonadotropin-releasing hormone receptor,GNRHR,8.824,IC50,COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(F)C=CC=C2C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O
cyclobenzaprine,Histamine H1 receptor,HRH1,8.829,Ki,CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dihydroergotamine,5-hydroxytryptamine receptor 6,HTR6,8.83,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
estradiol,Sex hormone-binding globulin,SHBG,8.83,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
ergotamine,D(3) dopamine receptor,DRD3,8.836,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
flunitrazepam,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,8.84,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
fluvoxamine,Sodium-dependent dopamine transporter,SLC6A3,8.84,Ki,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F
naltrexone,Kappa-type opioid receptor,Oprk1,8.84,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
mizolastine,Histamine H1 receptor,HRH1,8.84,Ki,CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1
trifluoperazine,D(2) dopamine receptor,DRD2,8.841,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
dextromethorphan,Sodium-dependent serotonin transporter,SLC6A4,8.842,Ki,COC1=CC2=C(C[C@H]3[C@H]4CCCC[C@@]24CCN3C)C=C1
megestrol acetate,Progesterone receptor,PGR,8.842,Ki,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
ergotamine,D(2) dopamine receptor,DRD2,8.845,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
triazolam,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,8.845,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
lixisenatide,Glucagon-like peptide 1 receptor,GLP1R,8.845,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O
fluocinolone acetonide,Glucocorticoid receptor,NR3C1,8.848,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
pipamazine,Alpha-1B adrenergic receptor,Adra1b,8.848,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
cabergoline,5-hydroxytryptamine receptor 2B,HTR2B,8.85,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
dasatinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,8.85,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Tyrosine-protein kinase BTK,BTK,8.85,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
doxazosin,Alpha-1D adrenergic receptor,ADRA1D,8.85,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
enalaprilat,Angiotensin-converting enzyme,ACE,8.85,Ki,C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
flufenamic acid,Potassium channel subfamily T member 2,KCNT2,8.85,EC50,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
methotrexate,Bifunctional dihydrofolate reductase-thymidylate synthase,,8.85,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methotrexate,Dihydrofolate reductase,folA,8.85,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mianserin,5-hydroxytryptamine receptor 2C,Htr2c,8.85,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
mifepristone,Glucocorticoid receptor,Nr3c1,8.85,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
mofezolac,Prostaglandin G/H synthase 1,PTGS1,8.85,IC50,COC1=CC=C(C=C1)C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1
mofezolac,Prostaglandin G/H synthase 1,PTGS1,8.85,IC50,COC1=CC=C(C=C1)C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1
phentolamine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,8.85,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
pizotifen,5-hydroxytryptamine receptor 2C,HTR2C,8.85,Ki,CN1CCC(CC1)=C1C2=C(CCC3=C1C=CC=C3)SC=C2
risperidone,5-hydroxytryptamine receptor 7,Htr7,8.85,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
sertindole,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,8.85,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
testosterone,Androgen receptor,Ar,8.85,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
tolterodine,Muscarinic acetylcholine receptor M1,CHRM1,8.85,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
tolterodine,Muscarinic acetylcholine receptor M1,Chrm1,8.85,Ki,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
tretinoin,Retinoic acid receptor RXR-gamma,RXRG,8.85,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
trimetrexate,Dihydrofolate reductase,DHFR,8.85,Ki,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
urapidil,Alpha-1A adrenergic receptor,ADRA1A,8.85,Ki,COC1=C(C=CC=C1)N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1
verapamil,Translocator protein,Tspo,8.85,IC50,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
bosutinib,Tyrosine-protein kinase FRK,FRK,8.85,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
peramivir,Neuraminidase,,8.85,IC50,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
benzatropine,Muscarinic acetylcholine receptor M2,CHRM2,8.854,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
desoxycortone,5-hydroxytryptamine receptor 2A,HTR2A,8.854,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO
imipramine,Sodium-dependent serotonin transporter,SLC6A4,8.854,Kd,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
trimipramine,Histamine H1 receptor,HRH1,8.854,Ki,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=C1C=CC=C2
baloxavir marboxil,Polymerase acidic protein,PA,8.854,IC50,COC(=O)OCOC1=C2N(C=CC1=O)N([C@@H]1COCCN1C2=O)[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12
lysergide,5-hydroxytryptamine receptor 1A,HTR1A,8.856,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
bromocriptine,Alpha-1B adrenergic receptor,ADRA1B,8.86,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
oseltamivir,Neuraminidase,,8.86,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
scopolamine,Muscarinic acetylcholine receptor M2,CHRM2,8.86,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
vorozole,Aromatase,CYP19A1,8.86,IC50,CN1N=NC2=C1C=C(C=C2)[C@@H](N1C=NC=N1)C1=CC=C(Cl)C=C1
pimozide,D(2) dopamine receptor,DRD2,8.862,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pipamazine,D(2) dopamine receptor,DRD2,8.87,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
dapagliflozin,Low affinity sodium-glucose cotransporter,SLC5A4,8.87,IC50,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
triazolam,GABA A receptor alpha-3/beta-2/gamma-2,GABRG2|GABRA3|GABRB2,8.876,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
dexamethasone,Glucocorticoid receptor,NR3C1,8.88,EC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
bromazine,Histamine H1 receptor,HRH1,8.886,Ki,CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1
clomifene,Estrogen receptor,ESR1,8.886,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
emedastine,Histamine H1 receptor,HRH1,8.886,Ki,CCOCCN1C(=NC2=C1C=CC=C2)N1CCCN(C)CC1
cabozantinib,Hepatocyte growth factor receptor,MET,8.886,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
eluxadoline,Delta-type opioid receptor,OPRD1,8.886,Ki,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O
ergometrine,5-hydroxytryptamine receptor 1B,Htr1b,8.889,Ki,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
carbachol,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,8.89,Ki,C[N+](C)(C)CCOC(N)=O
efavirenz,Reverse transcriptase,reverse transcriptas,8.89,IC50,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
etravirine,Reverse transcriptase protein,reverse transcriptase,8.89,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
irbesartan,Angiotensin II receptor (AT-1) type-1,Agtr1|Agtr1b,8.89,IC50,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
irbesartan,Angiotensin II receptor,Agtr1|Agtr1b|Agtr2,8.89,IC50,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
methotrexate,Dihydrofolate reductase,folA,8.89,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mepyramine,Adenosine receptor A3,ADORA3,8.89,IC50,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
spiperone,Alpha-1B adrenergic receptor,Adra1b,8.89,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
trihexyphenidyl,Muscarinic acetylcholine receptor M1,CHRM1,8.89,IC50,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
trimethoprim,Dihydrofolate reductase,dfrA17,8.89,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
tropisetron,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,8.89,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2
ziprasidone,5-hydroxytryptamine receptor 2C,HTR2C,8.89,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
caspofungin,"Beta-1,3-glucan synthase catalytic subunit 1",GSC1,8.89,IC50,CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN
vorinostat,Histone deacetylase 1,HDAC1,8.89,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
axitinib,Aurora kinase C,AURKC,8.89,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
lasofoxifene,Estrogen receptor,ESR1,8.89,IC50,OC1=CC=C2C(C(CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
bosutinib,Cyclin-G-associated kinase,GAK,8.89,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
metizoline,Nischarin,Nisch,8.89,Ki,CC1=C(CC2=NCCN2)C2=CC=CC=C2S1
ponatinib,Fibroblast growth factor receptor 2,FGFR2,8.89,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
laninamivir octanoate hydrate,Neuraminidase,,8.89,IC50,CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O
eluxadoline,Delta-type opioid receptor,Oprd1,8.89,Ki,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O
dihydroergocristine,Alpha-1B adrenergic receptor,Adra1b,8.896,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dexetimide,Muscarinic acetylcholine receptor M2,CHRM2,8.9,Ki,O=C1CC[C@@](C2CCN(CC3=CC=CC=C3)CC2)(C(=O)N1)C1=CC=CC=C1
dihydroergocristine,Alpha-2C adrenergic receptor,ADRA2C,8.9,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
epinastine,Histamine H1 receptor,HRH1,8.9,Ki,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
ergotamine,5-hydroxytryptamine receptor 2B,HTR2B,8.9,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
hexocyclium,Muscarinic acetylcholine receptor M3,CHRM3,8.9,Ki,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
methysergide,5-hydroxytryptamine receptor 1D,HTR1D,8.9,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
orlistat,Pancreatic triacylglycerol lipase,PNLIP,8.9,IC50,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
zolmitriptan,5-hydroxytryptamine receptor 1D,HTR1D,8.9,Ki,CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2
zotepine,5-hydroxytryptamine receptor 6,Htr6,8.9,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
gonadorelin,Lutropin-choriogonadotropic hormone receptor,Lhcgr,8.9,Ki,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
tolvaptan,Vasopressin V2 receptor,Avpr2,8.9,Ki,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=CC(Cl)=CC=C12
afamelanotide,Melanocortin receptor 3,MC3R,8.9,Ki,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
ketanserin,5-hydroxytryptamine receptor 1F,HTR1F,8.903,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
linaclotide,Heat-stable enterotoxin receptor,GUCY2C,8.907,Ki,C[C@@H](O)[C@@H]1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2
levonorgestrel,Sex hormone-binding globulin,SHBG,8.91,Kd,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
enoxolone,Corticosteroid 11-beta-dehydrogenase isozyme 2,HSD11B2,8.91,IC50,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O
hydroquinone,Acetylcholinesterase,ache,8.91,Ki,OC1=CC=C(O)C=C1
glycopyrronium bromide,Muscarinic acetylcholine receptor M5,CHRM5,8.91,Ki,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
norethisterone,Progesterone receptor,PGR,8.914,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
aliskiren,Renin,REN,8.92,IC50,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
caramiphen,Muscarinic acetylcholine receptor M1,Chrm1,8.92,Ki,CCN(CC)CCOC(=O)C1(CCCC1)C1=CC=CC=C1
chlorpromazine,D(2) dopamine receptor,Drd2,8.92,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dasatinib,Ephrin type-A receptor 4,EPHA4,8.92,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
haloperidol,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.92,EC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
lisinopril,Angiotensin-converting enzyme,ACE,8.92,IC50,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
methotrexate,Dihydrofolate reductase,DHFR,8.92,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
morphine,Mu-type opioid receptor,Oprm1,8.92,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
nifedipine,Voltage-dependent L-type calcium channel subunit alpha-1D,Cacna1d,8.92,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
pyrimethamine,Dihydrofolate reductase,dfrA17,8.92,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
sumatriptan,5-hydroxytryptamine receptor 1D,HTR1D,8.92,Ki,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1
trimethoprim,Dihydrofolate reductase,folA,8.92,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
vasopressin,Vasopressin V2 receptor,AVPR2,8.92,Ki,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
toliprolol,Beta-2 adrenergic receptor,ADRB2,8.92,Kd,CC(C)NCC(O)COC1=CC(C)=CC=C1
tasosartan,Angiotensin II receptor (AT-1) type-1,Agtr1|Agtr1b,8.92,IC50,CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=C(C=CC=C3)C3=NN=NN3)C2=N1
asenapine,Alpha-1A adrenergic receptor,ADRA1A,8.92,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
fosaprepitant,Substance-P receptor,TACR1,8.92,IC50,C[C@@H](O[C@H]1OCCN(CC2=NN(C(=O)N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
panobinostat,Histone deacetylase 9,HDAC9,8.92,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
ponatinib,Platelet-derived growth factor receptor beta,PDGFRB,8.92,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
asunaprevir,NS3,NS3,8.92,EC50,COC1=C2C=CC(Cl)=CC2=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)N=C1
cangrelor,Uracil nucleotide/cysteinyl leukotriene receptor,Gpr17,8.92,IC50,CSCCNC1=NC(SCCC(F)(F)F)=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O
fedratinib,Death-associated protein kinase 3,DAPK3,8.92,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
naftopidil,Alpha-1D adrenergic receptor,ADRA1D,8.921,Ki,COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1
thioproperazine,D(3) dopamine receptor,DRD3,8.921,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1
talazoparib tosylate,Poly [ADP-ribose] polymerase 1,PARP1,8.921,Ki,CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1
erdafitinib,Fibroblast growth factor receptor 1,FGFR1,8.921,IC50,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1
methylergometrine,5-hydroxytryptamine receptor 6,HTR6,8.928,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
chlorambucil,Cathepsin D,CTSD,8.93,IC50,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
naltrexone,Kappa-type opioid receptor,OPRK1,8.93,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
vasopressin,Oxytocin receptor,Oxtr,8.93,Ki,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
desoximetasone,Glucocorticoid receptor,NR3C1,8.932,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
citalopram,Sodium-dependent serotonin transporter,SLC6A4,8.935,Kd,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
pipamazine,Histamine H1 receptor,HRH1,8.939,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
tiquizium,Muscarinic acetylcholine receptor,CHRM2,8.94,Ki,C[N@+]12CCCC[C@@H]1CCC(C2)=C(C1=CC=CS1)C1=CC=CS1
ertugliflozin,Sodium/glucose cotransporter 2,Slc5a2,8.94,IC50,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1
clebopride,D(2) dopamine receptor,Drd2,8.95,Ki,COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CCN(CC2=CC=CC=C2)CC1
terazosin,Alpha-1A adrenergic receptor,ADRA1A,8.95,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
dapoxetine,Sodium-dependent serotonin transporter,SLC6A4,8.95,IC50,CN(C)[C@@H](CCOC1=CC=CC2=C1C=CC=C2)C1=CC=CC=C1
naldemedine,Mu-type opioid receptor,OPRM1,8.95,Ki,CC(C)(NC(=O)C1=C(O)[C@@H]2OC3=C(O)C=CC4=C3[C@@]22CCN(CC3CC3)[C@H](C4)[C@]2(O)C1)C1=NC(=NO1)C1=CC=CC=C1
benzatropine,Histamine H1 receptor,HRH1,8.959,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
benzatropine,Muscarinic acetylcholine receptor M3,CHRM3,8.959,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
benzatropine,Muscarinic acetylcholine receptor M4,CHRM4,8.959,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
escitalopram,Sodium-dependent serotonin transporter,SLC6A4,8.959,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
paliperidone,5-hydroxytryptamine receptor 2A,HTR2A,8.959,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
boceprevir,"Hepatitis C virus serine protease, NS3/NS4A",NS3|NS4A,8.959,Ki,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
ingenol mebutate,Protein kinase C epsilon type,PRKCE,8.959,EC50,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C
ponatinib,Platelet-derived growth factor receptor alpha,PDGFRA,8.959,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
brexpiprazole,D(3) dopamine receptor,DRD3,8.959,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
vibegron,Beta-3 adrenergic receptor,ADRB3,8.959,EC50,O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C1=CC=CC=C1
cisapride,5-hydroxytryptamine receptor 2A,HTR2A,8.96,Ki,COC1CN(CCCOC2=CC=C(F)C=C2)CCC1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
cycloguanil,Bifunctional dihydrofolate reductase-thymidylate synthase,,8.96,Ki,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1
flupentixol,D(3) dopamine receptor,DRD3,8.96,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
imatinib,Tyrosine-protein kinase ABL1,ABL1,8.96,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
methazolamide,Carbonic anhydrase 3,CA3,8.96,Ki,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
mianserin,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.96,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nilotinib,Epithelial discoidin domain-containing receptor 1,DDR1,8.96,Kd,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
oseltamivir,Neuraminidase,,8.96,Ki,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
oseltamivir,Neuraminidase,,8.96,Ki,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
protriptyline,Adenosine receptor A3,ADORA3,8.96,IC50,CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2
reboxetine,Sodium-dependent noradrenaline transporter,SLC6A2,8.96,Ki,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
sirolimus,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,8.96,Kd,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
yohimbine,Alpha-1B adrenergic receptor,ADRA1B,8.96,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
rimonabant,Cannabinoid receptor 2,CNR2,8.96,Ki,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
bosutinib,Tyrosine-protein kinase ABL,ABL1|ABL2,8.96,IC50,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
panobinostat,Histone deacetylase 3,HDAC3,8.96,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
gilteritinib,High affinity nerve growth factor receptor,NTRK1,8.96,IC50,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1
fedratinib,Cyclin-G-associated kinase,GAK,8.96,Kd,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
risperidone,Alpha-1B adrenergic receptor,Adra1b,8.967,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
iloperidone,D(2) dopamine receptor,DRD2,8.969,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
atropine,Muscarinic acetylcholine receptor M2,CHRM2,8.97,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
chlorprothixene,Histamine H1 receptor,Hrh1,8.97,IC50,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
naltrexone,Kappa-type opioid receptor,Oprk1,8.97,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
ibrexafungerp,"1,3-Beta-D-glucan-UDP glucosyltransferase",FKS,8.97,IC50,C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
promethazine,Muscarinic acetylcholine receptor M4,CHRM4,8.975,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
flumazenil,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,8.979,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
octreotide,Somatostatin receptor type 5,Sstr5,8.98,IC50,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
trifluoperazine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,8.98,Kd,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
atropine,Muscarinic acetylcholine receptor,GPM3,8.99,Kd,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
atropine,Muscarinic acetylcholine receptor,GPM3,8.99,Kd,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
ifenprodil,Sigma non-opioid intracellular receptor 1,SIGMAR1,8.99,Ki,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
infigratinib,Fibroblast growth factor receptor 1,FGFR1,8.99,,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
acetanilide,Nicotinate phosphoribosyltransferase,NAPRT,9,Ki,CC(=O)NC1=CC=CC=C1
racecadotril,Neprilysin,MME,9,IC50,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1
alprostadil,Prostaglandin E2 receptor EP3 subtype,PTGER3,9,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
aminophenazone,Nicotinate phosphoribosyltransferase,NAPRT,9,Ki,CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1
amoxapine,5-hydroxytryptamine receptor 2A,Htr2a,9,Ki,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
apomorphine,Dopamine receptor,DRD2|DRD1,9,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
apomorphine,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,9,IC50,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
benperidol,5-hydroxytryptamine receptor 2A,HTR2A,9,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2
bupranolol,Beta-1 adrenergic receptor,ADRB1,9,Ki,CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1
carperitide,Atrial natriuretic peptide receptor 1,Npr1,9,EC50,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO
clomifene,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,9,Ki,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
clozapine,Histone H1.0,H1F0,9,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
cyproheptadine,Histamine H1 receptor,HRH1,9,Kd,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
dasatinib,Tyrosine-protein kinase CSK,CSK,9,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexamethasone,Mineralocorticoid receptor,NR3C2,9,EC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
phenazone,Nicotinate phosphoribosyltransferase,NAPRT,9,Ki,CN1N(C(=O)C=C1C)C1=CC=CC=C1
dicoumarol,NULLD(P)H dehydrogenase [quinone] 1,Nqo1,9,Ki,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12
dilazep,Equilibrative nucleoside transporter 1,SLC29A1,9,Ki,COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN1CCCN(CCCOC(=O)C2=CC(OC)=C(OC)C(OC)=C2)CC1
diphenhydramine,Histamine H1 receptor,HRH1,9,IC50,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
dopamine,D(1A) dopamine receptor,DRD1,9,Ki,NCCC1=CC(O)=C(O)C=C1
dopamine,D(2) dopamine receptor,DRD2,9,Ki,NCCC1=CC(O)=C(O)C=C1
dopamine,D(3) dopamine receptor,DRD3,9,Ki,NCCC1=CC(O)=C(O)C=C1
dopamine,D(1B) dopamine receptor,DRD5,9,Ki,NCCC1=CC(O)=C(O)C=C1
dopamine,D(4) dopamine receptor,DRD4,9,Ki,NCCC1=CC(O)=C(O)C=C1
eprosartan,Type-1B angiotensin II receptor,Agtr1b,9,IC50,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O
eprosartan,Type-2 angiotensin II receptor,Agtr2,9,IC50,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O
eprosartan,Angiotensin II receptor (AT-1) type-1,Agtr1|Agtr1b,9,IC50,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O
eprosartan,Angiotensin II receptor,Agtr1|Agtr1b|Agtr2,9,IC50,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O
ergometrine,5-hydroxytryptamine receptor 1D,HTR1D,9,EC50,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
ergotamine,5-hydroxytryptamine receptor 2A,HTR2A,9,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
etravirine,Gag-Pol polyprotein,gag-pol,9,IC50,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
flunitrazepam,GABA A receptor alpha-5/beta-2/gamma-2,GABRG2|GABRA5|GABRB2,9,Ki,CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O
fosinopril,Angiotensin-converting enzyme,ACE,9,IC50,CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C
gliquidone,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,9,Kd,COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C
hydromorphone,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,9,EC50,CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CCC4=O)=CC=C5O
hyoscyamine,Muscarinic acetylcholine receptor M1,CHRM1,9,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
isoniazid,Dihydrofolate reductase,folA,9,Ki,NNC(=O)C1=CC=NC=C1
isoprenaline,Beta-1 adrenergic receptor,ADRB1,9,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
ketanserin,Sigma non-opioid intracellular receptor 1,SIGMAR1,9,IC50,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketobemidone,Mu-type opioid receptor,OPRM1,9,EC50,CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1
aspartic acid,Glutamate transporter homolog,,9,Kd,N[C@@H](CC(O)=O)C(O)=O
liothyronine,THAP domain-containing protein 1,THAP1,9,EC50,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
lisuride,5-hydroxytryptamine receptor 1D,HTR1D,9,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
melatonin,Nuclear receptor ROR-alpha,RORA,9,EC50,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
methotrexate,Dihydrofolate reductase,,9,IC50,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methotrexate,Dihydrofolate reductase,folA,9,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
mifepristone,Glucocorticoid receptor,NR3C1,9,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
moperone,D(2) dopamine receptor,DRD2,9,Ki,CC1=CC=C(C=C1)C1(O)CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
naloxone,Mu-type opioid receptor,Oprm1,9,Ki,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
naloxone,Kappa-type opioid receptor,Oprk1,9,Kd,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
naloxone,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,9,Kd,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
nicotine,Acetylcholine receptor subunit delta,chrnd,9,Ki,CN1CCC[C@H]1C1=CC=CN=C1
nicotine,Neuronal acetylcholine receptor; alpha3/beta2,Chrna3|Chrnb2,9,Ki,CN1CCC[C@H]1C1=CC=CN=C1
nifedipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,9,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
oseltamivir,Sialidase,nanH,9,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
oxybutynin,Muscarinic acetylcholine receptor M1,CHRM1,9,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
oxymetazoline,Alpha-2C adrenergic receptor,ADRA2C,9,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
penbutolol,Beta-2 adrenergic receptor,ADRB2,9,Ki,CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C1CCCC1
pergolide,D(3) dopamine receptor,DRD3,9,EC50,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pergolide,5-hydroxytryptamine receptor 7,Htr7,9,Ki,CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1=CNC3=C1C2=CC=C3
pimecrolimus,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,9,Kd,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC
pindolol,Beta-2 adrenergic receptor,ADRB2,9,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
raloxifene,"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase",EBP,9,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
reserpine,Synaptic vesicular amine transporter,SLC18A2,9,Ki,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
scopolamine,Muscarinic acetylcholine receptor M1,CHRM1,9,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
sildenafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,9,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sildenafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,9,IC50,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
sirolimus,Peptidyl-prolyl cis-trans isomerase FKBP1A,Fkbp1a,9,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
spiperone,5-hydroxytryptamine receptor 2A,Htr2a,9,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Serine/threonine-protein kinase 17A,STK17A,9,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
tamoxifen,Anti-estrogen binding site (AEBS),EBP|DHCR7,9,Kd,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
terguride,D(3) dopamine receptor,DRD3,9,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
vinblastine,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,9,IC50,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
zanamivir,Neuraminidase,,9,Ki,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
glucagon,Glucagon receptor,GCGR,9,EC50,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
saralasin,Type-2 angiotensin II receptor,Agtr2,9,IC50,CNCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O
terazosin,Alpha-1D adrenergic receptor,Adra1d,9,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
androstanolone,Androgen receptor,Ar,9,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
oxitriptan,5-hydroxytryptamine receptor 2B,HTR2B,9,EC50,N[C@@H](CC1=CNC2=CC=C(O)C=C12)C(O)=O
timolol,Beta-1 adrenergic receptor,ADRB1,9,Ki,CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1
tolvaptan,Vasopressin V2 receptor,AVPR2,9,Ki,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=CC(Cl)=CC=C12
asenapine,Histamine H1 receptor,HRH1,9,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
vorinostat,Histone deacetylase 6,HDAC6,9,Ki,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
pasireotide,Somatostatin receptor type 2,SSTR2,9,IC50,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
alogliptin,Dipeptidyl peptidase 4,DPP4,9,IC50,CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
bosutinib,Proto-oncogene tyrosine-protein kinase Src,SRC,9,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
panobinostat,Histone deacetylase 1,HDAC1,9,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
thioctic acid,Acetylcholinesterase,ACHE,9,IC50,OC(=O)CCCCC1CCSS1
afamelanotide,Melanocortin receptor 5,MC5R,9,IC50,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
olaparib,Poly [ADP-ribose] polymerase 2,PARP2,9,IC50,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
flibanserin,5-hydroxytryptamine receptor 1A,HTR1A,9,Ki,FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
opicapone,Catechol O-methyltransferase,COMT,9,Ki,CC1=C(C2=NOC(=N2)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl
olmutinib,Tyrosine-protein kinase BTK,BTK,9,IC50,CN1CCN(CC1)C1=CC=C(NC2=NC3=C(SC=C3)C(OC3=CC=CC(NC(=O)C=C)=C3)=N2)C=C1
apatinib,Vascular endothelial growth factor receptor 2,KDR,9,IC50,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1
pemafibrate,Peroxisome proliferator-activated receptor alpha,PPARA,9,EC50,CC[C@@H](OC1=CC=CC(CN(CCCOC2=CC=C(OC)C=C2)C2=NC3=C(O2)C=CC=C3)=C1)C(O)=O
entrectinib,High affinity nerve growth factor receptor,NTRK1,9,IC50,CN1CCN(CC1)C1=CC(NC2CCOCC2)=C(C=C1)C(=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12
pemigatinib,Fibroblast growth factor receptor 3,FGFR3,9,IC50,CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F
trilaciclib,Cyclin-dependent kinase 4,CDK4,9,IC50,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
infigratinib,Fibroblast growth factor receptor 2,FGFR2,9,,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
fentanyl,Mu-type opioid receptor,OPRM1,9.001,EC50,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
lurasidone,D(2) dopamine receptor,DRD2,9.003,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
siponimod,Sphingosine 1-phosphate receptor 5,S1PR5,9.009,EC50,CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F
buprenorphine,Kappa-type opioid receptor,OPRK1,9.01,Ki,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
desmopressin,Oxytocin receptor,Oxtr,9.01,Ki,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
oxymorphone,Mu-type opioid receptor,Oprm1,9.01,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
propranolol,Beta-2 adrenergic receptor,Adrb2,9.01,Kd,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
bromperidol,Sigma non-opioid intracellular receptor 1,SIGMAR1,9.02,EC50,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
enalaprilat,Angiotensin-converting enzyme,Ace,9.02,IC50,C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
memantine,Glutamate NMDA receptor; GRIN1/GRIN2A,GRIN1|GRIN2A,9.02,IC50,CC12CC3CC(C)(C1)CC(N)(C3)C2
oxybutynin,Muscarinic acetylcholine receptor M3,Chrm3,9.02,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
pipamazine,Alpha-1D adrenergic receptor,ADRA1D,9.02,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
tacrolimus,Serine/threonine-protein kinase mTOR,MTOR,9.02,IC50,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
tacrolimus,Peptidyl-prolyl cis-trans isomerase FKBP10,FKBP10,9.02,IC50,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
triazolam,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,9.02,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
netupitant,Substance-P receptor,TACR1,9.022,Ki,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=C(C)C=CC=C1)N1CCN(C)CC1
fosnetupitant,Substance-P receptor,TACR1,9.022,Ki,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=C(C)C=CC=C1)N1CC[N+](C)(COP(O)(O)=O)CC1
triptorelin,Gonadotropin-releasing hormone receptor,GNRHR,9.025,EC50,CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
droperidol,D(3) dopamine receptor,DRD3,9.027,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
nicotine,Neuronal acetylcholine receptor subunit alpha-4,Chrna4,9.03,Ki,CN1CCC[C@H]1C1=CC=CN=C1
phentolamine,Alpha-2A adrenergic receptor,ADRA2A,9.03,Ki,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
dicycloverine,Muscarinic acetylcholine receptor M3,CHRM3,9.033,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
trametinib,Dual specificity mitogen-activated protein kinase kinase 2,MAP2K2,9.036,IC50,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=C(F)C=C(I)C=C1)C1=CC(NC(C)=O)=CC=C1
lapatinib,Epidermal growth factor receptor,EGFR,9.04,Kd,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
nalmefene,Delta-type opioid receptor,OPRD1,9.04,Kd,OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
zotepine,5-hydroxytryptamine receptor 2A,HTR2A,9.04,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
oxitriptan,5-hydroxytryptamine receptor 1A,HTR1A,9.04,Ki,N[C@@H](CC1=CNC2=CC=C(O)C=C12)C(O)=O
naldemedine,Delta-type opioid receptor,OPRD1,9.04,Ki,CC(C)(NC(=O)C1=C(O)[C@@H]2OC3=C(O)C=CC4=C3[C@@]22CCN(CC3CC3)[C@H](C4)[C@]2(O)C1)C1=NC(=NO1)C1=CC=CC=C1
oxymetazoline,5-hydroxytryptamine receptor 1B,Htr1b,9.041,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
astemizole,Potassium voltage-gated channel subfamily H member 2,KCNH2,9.046,IC50,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
flumazenil,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,9.046,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
pimozide,D(3) dopamine receptor,DRD3,9.046,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
paliperidone,D(3) dopamine receptor,DRD3,9.046,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
vaniprevir,Genome polyprotein,,9.046,Ki,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1[C@H]2CCN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
cobimetinib,Dual specificity mitogen-activated protein kinase kinase 1,MAP2K1,9.046,IC50,OC1(CN(C1)C(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1)[C@@H]1CCCCN1
evogliptin,Dipeptidyl peptidase 4,DPP4,9.046,IC50,CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F
atracurium,Neuronal acetylcholine receptor subunit alpha-3,CHRNA3,9.05,IC50,COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1
brinzolamide,Carbonic anhydrase 6,CA6,9.05,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
eletriptan,5-hydroxytryptamine receptor 1D,HTR1D,9.05,Kd,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
escitalopram,Sodium-dependent serotonin transporter,Slc6a4,9.05,Ki,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
flumazenil,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,9.05,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
haloperidol,Sigma non-opioid intracellular receptor 1,Sigmar1,9.05,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
lindane,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,9.05,IC50,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
oxytocin,Oxytocin receptor,Oxtr,9.05,Ki,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
pramlintide,Amylin receptor AMY3,CALCR|RAMP3,9.05,EC50,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O
propranolol,Beta-2 adrenergic receptor,ADRB2,9.05,Kd,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
rosuvastatin,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,9.05,Ki,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
demoxytocin,Oxytocin receptor,Oxtr,9.05,Ki,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
ponatinib,Proto-oncogene tyrosine-protein kinase Src,SRC,9.05,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
eluxadoline,Mu-type opioid receptor,Oprm1,9.05,Ki,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O
cytisine,Neuronal acetylcholine receptor subunit alpha-7,Chrna7,9.05,Ki,O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12
carvedilol,Alpha-1D adrenergic receptor,ADRA1D,9.054,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
ertugliflozin,Sodium/glucose cotransporter 2,SLC5A2,9.057,IC50,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1
indinavir,Protease,HIV-1 protease,9.06,Ki,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
naltrexone,Opioid receptors; mu and delta,Oprd1|Oprm1,9.06,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
morphine,Mu-type opioid receptor,OPRM1,9.06,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
topiramate,Carbonic anhydrase 7,CA7,9.06,Ki,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
asenapine,D(3) dopamine receptor,DRD3,9.06,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
glycopyrronium bromide,Muscarinic acetylcholine receptor M4,CHRM4,9.06,Ki,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
ertugliflozin,Low affinity sodium-glucose cotransporter,SLC5A4,9.06,IC50,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1
talazoparib tosylate,Poly [ADP-ribose] polymerase 2,PARP2,9.06,Ki,CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1
tenapanor,Sodium/hydrogen exchanger 3,SLC9A3,9.06,IC50,CN1C[C@@H](C2=CC=CC(=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C(Cl)C=C(Cl)C=C23)C2=CC(Cl)=CC(Cl)=C2C1
lisuride,5-hydroxytryptamine receptor 2A,HTR2A,9.061,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
flupentixol,Histamine H1 receptor,HRH1,9.066,Ki,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
atropine,Muscarinic acetylcholine receptor M5,Chrm5,9.07,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
clonazepam,GABA-A receptor; anion channel,GABRA1|GABRB1|GABRA2|GABRA3|GABRA4|GABRG2,9.07,Ki,[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1
clonazepam,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,9.07,Ki,[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1
dasatinib,Ephrin type-A receptor 2,EPHA2,9.07,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
maxacalcitol,Vitamin D3 receptor,VDR,9.07,EC50,C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
mianserin,Histamine H1 receptor,HRH1,9.07,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
pyrimethamine,Bifunctional dihydrofolate reductase-thymidylate synthase,,9.07,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
sertraline,Sodium-dependent serotonin transporter,Slc6a4,9.07,Ki,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
somatostatin,Somatostatin receptor type 5,Sstr5,9.07,IC50,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
prazosin,Adenosine receptor A3,ADORA3,9.07,IC50,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
pasireotide,Somatostatin receptor type 2,Sstr2,9.07,EC50,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
belinostat,Histone deacetylase 2,HDAC2,9.07,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
belinostat,Histone deacetylase 1,HDAC1,9.07,Ki,ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1
forodesine,Purine nucleoside phosphorylase,PNP,9.07,Ki,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1NC=NC2=O
droperidol,D(4) dopamine receptor,DRD4,9.076,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
dicycloverine,Muscarinic acetylcholine receptor M1,CHRM1,9.079,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
haloperidol,Sigma non-opioid intracellular receptor 1,SIGMAR1,9.08,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
nicardipine,Voltage-gated L-type calcium channel,Cacna1c|Cacna1d|Cacna1s,9.08,Ki,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
trifluperidol,Sigma non-opioid intracellular receptor 1,SIGMAR1,9.08,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC(=CC=C1)C(F)(F)F
terazosin,Alpha-1B adrenergic receptor,ADRA1B,9.08,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
prazosin,Alpha-1B adrenergic receptor,ADRA1B,9.08,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
peramivir,Neuraminidase,,9.08,Ki,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
fostemsavir,Envelope glycoprotein gp160,env,9.08,Kd,CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC
desipramine,Sodium-dependent noradrenaline transporter,SLC6A2,9.081,Kd,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
docetaxel,Epidermal growth factor receptor,EGFR,9.086,Kd,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
carvedilol,Beta-1 adrenergic receptor,Adrb1,9.09,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
polythiazide,Solute carrier family 12 member 3,SLC12A3,9.09,A2,CN1C(CSCC(F)(F)F)NC2=C(C=C(C(Cl)=C2)S(N)(=O)=O)S1(=O)=O
terazosin,Alpha-1A adrenergic receptor,Adra1a,9.09,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
fluoxetine,Sodium-dependent serotonin transporter,SLC6A4,9.091,Kd,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
blonanserin,5-hydroxytryptamine receptor 2A,HTR2A,9.092,Ki,CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1
chlorpromazine,Alpha-1B adrenergic receptor,ADRA1B,9.092,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
flumazenil,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,9.097,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
glipizide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,9.097,Kd,CC1=CN=C(C=N1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
triazolam,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,9.097,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
aripiprazole lauroxil,D(3) dopamine receptor,DRD3,9.097,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
omarigliptin,Dipeptidyl peptidase 4,DPP4,9.097,Ki,CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=C(F)C=CC(F)=C1
ergotamine,Alpha-2A adrenergic receptor,ADRA2A,9.099,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
acetazolamide,Carbonic anhydrase,CA12|CA1|CA2|CA3|CA4|CA6|CA5A|CA7|CA9|CA13|CA14|CA5B,9.1,Ki,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
aripiprazole,D(2) dopamine receptor,Drd2,9.1,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
aripiprazole,D(1A) dopamine receptor,Drd1,9.1,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
bupranolol,Beta-2 adrenergic receptor,ADRB2,9.1,Ki,CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1
cabergoline,D(3) dopamine receptor,DRD3,9.1,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
dasatinib,Tyrosine-protein kinase Fyn,FYN,9.1,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Bcr/Abl fusion protein,ABL1|BCR,9.1,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desipramine,Histamine H1 receptor,Hrh1,9.1,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
desmopressin,Vasopressin V2 receptor,Avpr2,9.1,Ki,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
doxazosin,Alpha-1B adrenergic receptor,ADRA1B,9.1,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
ergotamine,5-hydroxytryptamine receptor 1D,HTR1D,9.1,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
fadrozole,"Cytochrome P450 11B2, mitochondrial",CYP11B2,9.1,IC50,N#CC1=CC=C(C=C1)C1CCCC2=CN=CN12
flumazenil,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,9.1,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
flunisolide,Glucocorticoid receptor,NR3C1,9.1,EC50,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
irbesartan,Type-1 angiotensin II receptor,AGTR1,9.1,Ki,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
irbesartan,Type-1B angiotensin II receptor,Agtr1b,9.1,Ki,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
lanreotide,Somatostatin receptor type 2,Sstr2,9.1,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
mazindol,Transporter,Slc6a2,9.1,Ki,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
methylergometrine,5-hydroxytryptamine receptor 2B,HTR2B,9.1,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
mupirocin,"Isoleucine--tRNA ligase, cytoplasmic",IARS,9.1,IC50,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O
oxytocin,Oxytocin receptor,OXTR,9.1,Ki,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
pentagastrin,Gastrin/cholecystokinin type B receptor,Cckbr,9.1,IC50,CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
pranlukast,Cysteinyl leukotriene receptor 1,CYSLTR1,9.1,Ki,O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
mepyramine,Histamine H1 receptor,HRH1,9.1,Ki,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
spirapril,Angiotensin-converting enzyme,ACE,9.1,IC50,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2
sulpiride,Carbonic anhydrase 6,CA6,9.1,Ki,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
tamsulosin,5-hydroxytryptamine receptor 1A,HTR1A,9.1,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
tazarotene,Retinoic acid receptor beta,RARB,9.1,EC50,CCOC(=O)C1=CN=C(C=C1)C#CC1=CC=C2SCCC(C)(C)C2=C1
terguride,D(2) dopamine receptor,DRD2,9.1,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
terguride,Alpha-2C adrenergic receptor,ADRA2C,9.1,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
triazolam,GABA-A receptor; anion channel,Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre,9.1,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
triazolam,GABA-A receptor,GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRA6|GABRG1|GABRG3,9.1,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
trifluperidol,Sigma non-opioid intracellular receptor 1,Sigmar1,9.1,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC(=CC=C1)C(F)(F)F
roflumilast,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,9.1,IC50,FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl
silodosin,Alpha-1A adrenergic receptor,Adra1a,9.1,IC50,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
rilpivirine,Reverse transcriptase protein,reverse transcriptase,9.1,EC50,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=NC(NC2=CC=C(C=C2)C#N)=NC=C1
levobetaxolol,Beta-1 adrenergic receptor,ADRB1,9.1,Ki,CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1
ibrutinib,Cytoplasmic tyrosine-protein kinase BMX,BMX,9.1,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
gilteritinib,Tyrosine-protein kinase receptor UFO,AXL,9.1,IC50,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1
pipamazine,Alpha-2B adrenergic receptor,ADRA2B,9.105,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
desipramine,Transporter,NET,9.11,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
dihydroergocristine,D(3) dopamine receptor,DRD3,9.11,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ergotamine,5-hydroxytryptamine receptor 1A,Htr1a,9.11,IC50,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ipratropium,Muscarinic acetylcholine receptor M2,Chrm2,9.11,Ki,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
morphine,Mu-type opioid receptor,Oprm1,9.11,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
ondansetron,5-hydroxytryptamine receptor 3A,Htr3a,9.11,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
ondansetron,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,9.11,Ki,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
oxybutynin,Muscarinic acetylcholine receptor M3,CHRM3,9.11,Ki,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
tiquizium,Muscarinic acetylcholine receptor,CHRM3,9.11,Ki,C[N@+]12CCCC[C@@H]1CCC(C2)=C(C1=CC=CS1)C1=CC=CS1
clorotepine,Alpha-1D adrenergic receptor,Adra1d,9.11,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
bosutinib,Receptor tyrosine-protein kinase erbB-3,ERBB3,9.11,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
fluticasone propionate,Glucocorticoid receptor,Nr3c1,9.12,EC50,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF
lysergide,5-hydroxytryptamine receptor 2A,HTR2A,9.12,Ki,CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
midazolam,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,9.125,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
midazolam,GABA A receptor alpha-5/beta-2/gamma-2,GABRG2|GABRA5|GABRB2,9.125,Ki,CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1
dihydroergocristine,Alpha-2A adrenergic receptor,ADRA2A,9.127,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
crizotinib,ALK tyrosine kinase receptor,ALK,9.13,Ki,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
droperidol,5-hydroxytryptamine receptor 2A,HTR2A,9.132,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
halcinonide,Glucocorticoid receptor,NR3C1,9.135,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl
dihydroergocristine,5-hydroxytryptamine receptor 1A,Htr1a,9.14,IC50,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
repaglinide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,9.14,Ki,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N2CCCCC2)=C1)C(O)=O
dexchlorpheniramine,Histamine H1 receptor,HRH1,9.14,Ki,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
nalfurafine,Mu-type opioid receptor,OPRM1,9.14,EC50,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
olodaterol,Beta-2 adrenergic receptor,ADRB2,9.14,Ki,COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1
ibrutinib,Tyrosine-protein kinase BTK,BTK,9.143,Ki,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
atomoxetine,Transporter,Slc6a2,9.15,Ki,CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1
atropine,Muscarinic acetylcholine receptor M2,Chrm2,9.15,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
celecoxib,Prostaglandin G/H synthase 1,Ptgs1,9.15,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
chlorpromazine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,9.15,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
ethoxzolamide,Carbonic anhydrase 7,CA7,9.15,Kd,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
haloperidol,D(2) dopamine receptor,DRD2,9.15,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
imatinib,Epithelial discoidin domain-containing receptor 1,DDR1,9.15,Kd,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
levorphanol,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,9.15,EC50,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
melatonin,Melatonin receptor type 1B,,9.15,Ki,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
mometasone furoate,Glucocorticoid receptor,NR3C1,9.15,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)CCl
scopolamine,Muscarinic acetylcholine receptor DM1,mAChR-A,9.15,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
trimetrexate,Dihydrofolate reductase,,9.15,Ki,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
estrone,Estrogen receptor,ESR1,9.15,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
xylometazoline,5-hydroxytryptamine receptor 1D,HTR1D,9.15,Ki,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
Flutemetamol (18F),Amyloid beta A4 protein,APP,9.15,Ki,CNC1=C([18F])C=C(C=C1)C1=NC2=CC=C(O)C=C2S1
panobinostat,Histone deacetylase 5,HDAC5,9.15,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
panobinostat,Histone deacetylase 6,HDAC6,9.15,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
osilodrostat,"Cytochrome P450 11B2, mitochondrial",CYP11B2,9.15,IC50,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12
trilaciclib,Receptor-type tyrosine-protein kinase FLT3,FLT3,9.15,Kd,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
trilaciclib,NUAK family SNF1-like kinase 2,NUAK2,9.15,Kd,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
sulforidazine,D(3) dopamine receptor,DRD3,9.155,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)(=O)=O
triazolam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,9.155,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
vardenafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,9.155,IC50,CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
paliperidone,Alpha-1B adrenergic receptor,ADRA1B,9.155,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
remikiren,Renin,REN,9.155,IC50,CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)C1CC1
dabrafenib,Serine/threonine-protein kinase B-raf,BRAF,9.155,IC50,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
copanlisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,9.155,IC50,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
candesartan cilexetil,Type-1 angiotensin II receptor,AGTR1,9.16,IC50,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
dasatinib,Epithelial discoidin domain-containing receptor 1,DDR1,9.16,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dimetindene,Histamine H1 receptor,HRH1,9.16,Ki,CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C1=CC=CC=N1
iloprost,Prostacyclin receptor,Ptgir,9.16,EC50,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
reboxetine,Transporter,NET,9.16,Ki,CCOC1=C(O[C@@H]([C@H]2CNCCO2)C2=CC=CC=C2)C=CC=C1
terazosin,Alpha-1B adrenergic receptor,ADRA1B,9.16,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
pralatrexate,Folate transporter 1,SLC19A1,9.16,IC50,NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
chlormadinone,Progesterone receptor,PGR,9.163,Ki,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
androstenediol,Sex hormone-binding globulin,SHBG,9.17,Kd,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O
mepenzolate,Muscarinic acetylcholine receptor M2,CHRM2,9.17,Ki,C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
naloxone,Mu-type opioid receptor,OPRM1,9.17,Ki,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
physostigmine,Acetylcholinesterase,Ache,9.17,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
physostigmine,Acetylcholinesterase,Ache,9.17,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
clorotepine,D(2) dopamine receptor,DRD2,9.17,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
tofacitinib,Tyrosine-protein kinase JAK1,JAK1,9.17,Ki,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
droperidol,Alpha-1D adrenergic receptor,ADRA1D,9.175,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
clobetasol propionate,Glucocorticoid receptor,NR3C1,9.179,Ki,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
ciprofloxacin,Histamine H3 receptor,Hrh3,9.18,Ki,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
dihydroergotamine,5-hydroxytryptamine receptor 1A,Htr1a,9.18,IC50,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
exenatide,Glucagon-like peptide 1 receptor,GLP1R,9.18,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
sertindole,Alpha-1D adrenergic receptor,Adra1d,9.18,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
clorotepine,Alpha-1A adrenergic receptor,ADRA1A,9.18,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
rolapitant,Substance-P receptor,TACR1,9.18,Ki,C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
ipratropium,Muscarinic acetylcholine receptor M4,CHRM4,9.181,Ki,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
dihydroergocristine,Alpha-1D adrenergic receptor,ADRA1D,9.183,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
alpha-Ergocryptine,D(2) dopamine receptor,DRD2,9.187,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
saroglitazar,Peroxisome proliferator-activated receptor alpha,PPARA,9.187,EC50,CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C2=CC=C(SC)C=C2)C=C1)C(O)=O
candesartan cilexetil,Type-1 angiotensin II receptor,AGTR1,9.19,Ki,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
desipramine,Transporter,Slc6a2,9.19,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
scopolamine,Muscarinic acetylcholine receptor M3,Chrm3,9.19,Kd,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
vasopressin,Vasopressin V1a receptor,Avpr1a,9.19,Kd,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
vasopressin,Vasopressin V1 receptor,Avpr1a|Avpr1b,9.19,Kd,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
tetracosactide,Melanocortin receptor 4,MC4R,9.19,EC50,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O
panobinostat,Histone deacetylase 2,HDAC2,9.19,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
neratinib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,9.19,Kd,CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C
chlorprothixene,D(4) dopamine receptor,DRD4,9.194,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
alprostadil,Prostaglandin E2 receptor EP4 subtype,Ptger4,9.2,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
cabergoline,D(2) dopamine receptor,DRD2,9.2,Ki,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1
carteolol,Beta-2 adrenergic receptor,ADRB2,9.2,Ki,CC(C)(C)NCC(O)COC1=C2CCC(=O)NC2=CC=C1
clozapine,Histamine H1 receptor,HRH1,9.2,Ki,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2
dasatinib,Platelet-derived growth factor receptor beta,PDGFRB,9.2,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
diethylstilbestrol,Estrogen receptor beta,ESR2,9.2,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
dihydroergotamine,5-hydroxytryptamine receptor 1B,HTR1B,9.2,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dutasteride,3-oxo-5-alpha-steroid 4-dehydrogenase 2,SRD5A2,9.2,IC50,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=C(C=CC(=C1)C(F)(F)F)C(F)(F)F
hyoscyamine,Muscarinic acetylcholine receptor M5,CHRM5,9.2,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
iloprost,Prostaglandin E2 receptor EP3 subtype,Ptger3,9.2,EC50,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
levallorphan,Mu-type opioid receptor,Oprm1,9.2,IC50,OC1=CC2=C(C[C@@H]3[C@@H]4CCCC[C@]24CCN3CC=C)C=C1
metergoline,5-hydroxytryptamine receptor 1D,HTR1D,9.2,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
norethisterone,Estrogen receptor,Esr1|Esr2,9.2,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
spiperone,Alpha-1B adrenergic receptor,ADRA1B,9.2,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sulprostone,Prostaglandin E2 receptor EP3 subtype,Ptger3,9.2,Ki,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
testosterone,Androgen receptor,AR,9.2,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
testosterone,Sex hormone-binding globulin,SHBG,9.2,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
domitroban,Thromboxane A2 receptor,Tbxa2r,9.2,Ki,OC(=O)CCC\C=C/C[C@H]1[C@@H]2CC[C@@H](C2)[C@@H]1NS(=O)(=O)C1=CC=CC=C1
fumagillin,Methionine aminopeptidase 2,METAP2,9.2,IC50,CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O
terazosin,Alpha-1D adrenergic receptor,ADRA1D,9.2,Ki,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
metizoline,Nischarin,NISCH,9.2,Ki,CC1=C(CC2=NCCN2)C2=CC=CC=C2S1
lisuride,Alpha-2C adrenergic receptor,ADRA2C,9.203,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
bortezomib,Proteasome subunit alpha type-1,PSMA1,9.208,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
apomorphine,D(2) dopamine receptor,DRD2,9.21,Ki,CN1CCC2=C3[C@H]1CC1=CC=C(O)C(O)=C1C3=CC=C2
metopimazine,D(3) dopamine receptor,DRD3,9.21,Ki,CS(=O)(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCC(CC3)C(N)=O)C2=C1
tamsulosin,Alpha-1B adrenergic receptor,ADRA1B,9.21,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
zotepine,Histamine H1 receptor,HRH1,9.21,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
aliskiren,Renin,REN,9.22,IC50,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
erlotinib,Epidermal growth factor receptor,EGFR,9.22,IC50,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2
febuxostat,Xanthine dehydrogenase/oxidase,XDH,9.22,Ki,CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
flumazenil,GABA A receptor alpha-3/beta-2/gamma-2,Gabrg2|Gabra3|Gabrb2,9.22,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
perospirone,D(2) dopamine receptor,DRD2,9.22,Ki,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)C1=NSC2=CC=CC=C12
pimozide,D(2) dopamine receptor,DRD2,9.22,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
remifentanil,Mu-type opioid receptor,Oprm1,9.22,IC50,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC
remifentanil,Mu-type opioid receptor,Oprm1,9.22,IC50,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC
sertindole,5-hydroxytryptamine receptor 2A,HTR2A,9.22,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
theophylline,Adenosine receptor A2a,ADORA2A,9.22,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
theophylline,Adenosine receptor A1,ADORA1,9.22,Ki,CN1C2=C(N=CN2)C(=O)N(C)C1=O
ubenimex,Cytosol aminopeptidase,LAP3,9.22,Ki,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
desomorphine,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,9.22,EC50,CN1CC[C@]23[C@@H]4CCC[C@H]2[C@H]1CC1=CC=C(O)C(O4)=C31
yohimbine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,9.22,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
yohimbine,Alpha-2 adrenergic receptor,Adra2b|Adra2c|Adra2a,9.22,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
saxagliptin,Dipeptidyl peptidase 4,DPP4,9.22,Ki,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2
asenapine,5-hydroxytryptamine receptor 6,HTR6,9.22,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
bazedoxifene,Estrogen receptor,ESR1,9.22,IC50,CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1
panobinostat,Histone deacetylase 4,HDAC4,9.22,Ki,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
flumazenil,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,9.222,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
indinavir,Gag-Pol polyprotein,gag-pol,9.222,IC50,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
triazolam,GABA A receptor alpha-5/beta-2/gamma-2,GABRG2|GABRA5|GABRB2,9.222,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
brigatinib,ALK tyrosine kinase receptor,ALK,9.222,IC50,COC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3P(C)(C)=O)=N2)C=CC(=C1)N1CCC(CC1)N1CCN(C)CC1
abemaciclib,Cyclin-dependent kinase 4,CDK4,9.222,Ki,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
triazolam,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,9.229,Ki,CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1
brexpiprazole,Alpha-2C adrenergic receptor,ADRA2C,9.229,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
benzatropine,Muscarinic acetylcholine receptor M1,Chrm1,9.23,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
clotiapine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,9.23,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
ritonavir,Gag-Pol polyprotein,gag-pol,9.23,Ki,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
somatostatin,Somatostatin receptor type 4,SSTR4,9.23,Ki,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
bosutinib,Tyrosine-protein kinase Lck,LCK,9.23,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
levomepromazine,Histamine H1 receptor,HRH1,9.237,Ki,COC1=CC2=C(SC3=CC=CC=C3N2C[C@H](C)CN(C)C)C=C1
dasatinib,Mast/stem cell growth factor receptor Kit,KIT,9.24,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Macrophage colony-stimulating factor 1 receptor,CSF1R,9.24,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Tyrosine-protein kinase Lyn,LYN,9.24,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
glimepiride,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,9.24,Ki,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O
ramatroban,Thromboxane A2 receptor,TBXA2R,9.24,Ki,OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C2=CC=C(F)C=C2)C2=CC=CC=C12
clorotepine,5-hydroxytryptamine receptor 2C,HTR2C,9.24,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
clorotepine,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,9.24,IC50,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
axitinib,Platelet-derived growth factor receptor beta,PDGFRB,9.24,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
nalfurafine,Mu-type opioid receptor,OPRM1,9.24,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
tofacitinib,Tyrosine-protein kinase JAK2,JAK2,9.24,Kd,C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N
cariprazine,5-hydroxytryptamine receptor 2B,HTR2B,9.24,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
vibegron,Beta-3 adrenergic receptor,ADRB3,9.24,EC50,O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C1=CC=CC=C1
flortaucipir F 18,Microtubule-associated protein tau,MAPT,9.24,Kd,C1=CC2=C(C=C1C3=CN=C(C=C3)[18F])NC4=C2C=NC=C4
mianserin,Histamine H1 receptor,HRH1,9.245,Ki,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
itraconazole,Lanosterol 14-alpha demethylase,ERG11,9.246,MIC,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
clorotepine,Alpha-1B adrenergic receptor,ADRA1B,9.25,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
glycopyrronium bromide,Muscarinic acetylcholine receptor M2,CHRM2,9.25,Ki,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
trifluoperazine,D(3) dopamine receptor,DRD3,9.251,Ki,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
edoxaban,Coagulation factor X,F10,9.252,Ki,CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=CC=C(Cl)C=N2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1
pipamazine,5-hydroxytryptamine receptor 2A,HTR2A,9.256,Ki,NC(=O)C1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
bortezomib,Proteasome subunit beta type-5,PSMB5,9.26,Ki,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
naltrexone,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,9.26,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
crizotinib,Hepatocyte growth factor receptor,MET,9.26,Kd,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
nalfurafine,Mitogen-activated protein kinase 3,MAPK3,9.26,EC50,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
nalfurafine,Mitogen-activated protein kinase 1,MAPK1,9.26,EC50,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
nalfurafine,Mitogen-activated protein kinase 3,MAPK3,9.26,EC50,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
nalfurafine,Mitogen-activated protein kinase 1,MAPK1,9.26,EC50,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
suvorexant,Orexin receptor type 1,HCRTR1,9.26,Ki,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2
revefenacin,Muscarinic acetylcholine receptor M4,CHRM4,9.26,Ki,CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1
lumateperone,5-hydroxytryptamine receptor 2A,HTR2A,9.26,Ki,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C3=C2C1=CC=C3
levobunolol,Beta-2 adrenergic receptor,ADRB2,9.263,Ki,CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
azasetron,5-hydroxytryptamine receptor 3A,HTR3A,9.268,Ki,CN1C(=O)COC2=C(C=C(Cl)C=C12)C(=O)NC1CN2CCC1CC2
fluphenazine enanthate,D(2) dopamine receptor,DRD2,9.268,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
fluphenazine,D(2) dopamine receptor,DRD2,9.269,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
indinavir,Protease,protease,9.27,Ki,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
levallorphan,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,9.27,IC50,OC1=CC2=C(C[C@@H]3[C@@H]4CCCC[C@]24CCN3CC=C)C=C1
oxymorphone,Mu-type opioid receptor,OPRM1,9.27,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
trifluoperazine,D(2) dopamine receptor,Drd2,9.27,Kd,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
elobixibat,Ileal sodium/bile acid cotransporter,SLC10A2,9.276,IC50,CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C3=CC=CC=C3)C(SC)=C2)S(=O)(=O)C1
agomelatine,Melatonin receptor,,9.28,Ki,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
atropine,Muscarinic acetylcholine receptor M4,Chrm4,9.28,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
domperidone,D(2) dopamine receptor,Drd2,9.28,Ki,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
nafamostat,Serine protease hepsin,HPN,9.28,Ki,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
prednisolone tebutate,Glucocorticoid receptor,NR3C1,9.28,IC50,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
scopolamine,Muscarinic acetylcholine receptor M1,Chrm1,9.28,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
atropine,Muscarinic acetylcholine receptor M5,CHRM5,9.29,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
celecoxib,Prostaglandin G/H synthase 2,Ptgs2,9.29,IC50,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
sertindole,Histamine H1 receptor,HRH1,9.29,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sertindole,5-hydroxytryptamine receptor 2C,Htr2c,9.29,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
axitinib,Platelet-derived growth factor receptor alpha,PDGFRA,9.29,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
ipratropium,Muscarinic acetylcholine receptor M3,CHRM3,9.292,Ki,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
acetylsalicylic acid,Nicotinate phosphoribosyltransferase,NAPRT,9.3,Ki,CC(=O)OC1=CC=CC=C1C(O)=O
alosetron,5-hydroxytryptamine receptor 3A,HTR3A,9.3,Ki,CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC1=C(C)N=CN1)CC2
alpidem,Translocator protein,TSPO,9.3,Ki,CCCN(CCC)C(=O)CC1=C(N=C2C=CC(Cl)=CN12)C1=CC=C(Cl)C=C1
alpidem,Translocator protein,Tspo,9.3,Ki,CCCN(CCC)C(=O)CC1=C(N=C2C=CC(Cl)=CN12)C1=CC=C(Cl)C=C1
alpidem,Translocator protein,TSPO,9.3,Ki,CCCN(CCC)C(=O)CC1=C(N=C2C=CC(Cl)=CN12)C1=CC=C(Cl)C=C1
amitriptyline,Histamine H1 receptor,HRH1,9.3,Ki,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
buprenorphine,Kappa-type opioid receptor,OPRK1,9.3,Ki,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
carteolol,Beta-1 adrenergic receptor,ADRB1,9.3,Ki,CC(C)(C)NCC(O)COC1=C2CCC(=O)NC2=CC=C1
dasatinib,Tyrosine-protein kinase Fgr,FGR,9.3,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dexmedetomidine,Alpha-2C adrenergic receptor,ADRA2C,9.3,Ki,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
enalaprilat,Angiotensin-converting enzyme 2,Ace2,9.3,Ki,C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
etomidate,"Cytochrome P450 11B1, mitochondrial",CYP11B1,9.3,IC50,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
flumazenil,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,9.3,Kd,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
flumazenil,GABA-A receptor; alpha-1/beta-2/gamma-2,Gabrg2|Gabra1|Gabrb2,9.3,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
haloperidol,C-8 sterol isomerase,ERG2,9.3,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
hyoscyamine,Muscarinic acetylcholine receptor M2,CHRM2,9.3,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
isradipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,9.3,IC50,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
lanreotide,Somatostatin receptor type 5,SSTR5,9.3,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
leuprorelin,Gonadotropin-releasing hormone receptor,Gnrhr,9.3,IC50,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
lisuride,D(2) dopamine receptor,DRD2,9.3,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
lisuride,5-hydroxytryptamine receptor 7,Htr7,9.3,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
mazindol,Sodium-dependent noradrenaline transporter,SLC6A2,9.3,Kd,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
melatonin,Histamine H3 receptor,HRH3,9.3,Ki,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
melatonin,Histamine H3 receptor,HRH3,9.3,Ki,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
metergoline,5-hydroxytryptamine receptor 2C,HTR2C,9.3,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
montelukast,Cysteinyl leukotriene receptor 1,CYSLTR1,9.3,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
montelukast,Cysteinyl leukotriene receptor 1,CYSLTR1,9.3,Ki,CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1
morphine,Mu-type opioid receptor,OPRM1,9.3,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@@H]2C=C[C@@H]4O)=C35
nemonapride,D(3) dopamine receptor,DRD3,9.3,Ki,CNC1=CC(OC)=C(C=C1Cl)C(=O)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C
pimozide,5-hydroxytryptamine receptor 7,Htr7,9.3,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pralmorelin,Growth hormone secretagogue receptor type 1,Ghsr,9.3,Ki,C[C@@H](N)C(=O)N[C@H](CC1=CC=C2C=CC=CC2=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(N)=O
saquinavir,Protease,protease,9.3,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
sirolimus,Eukaryotic translation initiation factor 4E,EIF4E,9.3,Kd,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
sulfinpyrazone,Nicotinate phosphoribosyltransferase,NAPRT,9.3,Ki,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1
tretinoin,Retinoic acid receptor RXR-beta,RXRB,9.3,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
triamcinolone acetonide,Glucocorticoid receptor,NR3C1,9.3,EC50,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
ubenimex,Aminopeptidase N,ANPEP,9.3,Ki,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
zanamivir,Neuraminidase,,9.3,IC50,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
zanamivir,Neuraminidase,,9.3,Ki,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
zanamivir,Neuraminidase,,9.3,Ki,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
ziprasidone,Alpha-1A adrenergic receptor,Adra1a,9.3,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
zotepine,5-hydroxytryptamine receptor 1D,HTR1D,9.3,Ki,CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2
yohimbine,Alpha-2C adrenergic receptor,ADRA2C,9.3,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
clorotepine,D(2) dopamine receptor,Drd2,9.3,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
dexamethasone phosphate,Glucocorticoid receptor,NR3C1,9.3,IC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
ruxolitinib,Non-receptor tyrosine-protein kinase TYK2,TYK2,9.3,Ki,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
vilazodone,Sodium-dependent serotonin transporter,SLC6A4,9.3,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
vilazodone,Sodium-dependent serotonin transporter,Slc6a4,9.3,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
dapagliflozin,Sodium/glucose cotransporter 2,SLC5A2,9.3,IC50,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
bosutinib,Mitogen-activated protein kinase kinase kinase kinase 5,MAP4K5,9.3,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
regorafenib,Bifunctional epoxide hydrolase 2,EPHX2,9.3,IC50,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1
nalfurafine,Kappa-type opioid receptor,Oprk1,9.3,EC50,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
nalfurafine,Kappa-type opioid receptor,Oprk1,9.3,EC50,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
ponatinib,Bcr/Abl fusion protein,ABL1|BCR,9.3,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
simeprevir,"Hepatitis C virus serine protease, NS3/NS4A",NS3|NS4A,9.3,Ki,COC1=C(C)C2=C(C=C1)C(O[C@@H]1C[C@@H]3[C@@H](C1)C(=O)N(C)CCCC\C=C/[C@@H]1C[C@]1(NC3=O)C(=O)NS(=O)(=O)C1CC1)=CC(=N2)C1=NC(=CS1)C(C)C
pimavanserin,5-hydroxytryptamine receptor 2A,HTR2A,9.3,Ki,CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1
angiotensin II,Type-1 angiotensin II receptor,AGTR1,9.3,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
pemigatinib,Fibroblast growth factor receptor 2,FGFR2,9.3,IC50,CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F
pimozide,5-hydroxytryptamine receptor 7,HTR7,9.301,Ki,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
macitentan,Endothelin-1 receptor,EDNRA,9.301,IC50,CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1
copanlisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",PIK3CA,9.301,IC50,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
lorlatinib,Proto-oncogene tyrosine-protein kinase ROS,ROS1,9.301,IC50,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
lurasidone,5-hydroxytryptamine receptor 7,HTR7,9.305,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
dihydroergocristine,D(2) dopamine receptor,DRD2,9.309,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
atropine,Muscarinic acetylcholine receptor M1,CHRM1,9.31,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
clotiapine,D(2) dopamine receptor,DRD2,9.31,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
desipramine,Sodium-dependent dopamine transporter,SLC6A3,9.31,Ki,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
ethoxzolamide,Carbonic anhydrase 2,CA2,9.31,Ki,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O
ipratropium,Muscarinic acetylcholine receptor M1,CHRM1,9.31,Ki,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
pramipexole,D(4) dopamine receptor,DRD4,9.31,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
telmisartan,Type-1 angiotensin II receptor,AGTR1,9.31,IC50,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O
vasopressin,Vasopressin V1b receptor,AVPR1B,9.31,Ki,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
axitinib,Mast/stem cell growth factor receptor Kit,KIT,9.31,Kd,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
cariprazine,D(2) dopamine receptor,DRD2,9.31,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
biperiden,Muscarinic acetylcholine receptor M1,CHRM1,9.32,Kd,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
buprenorphine,Delta-type opioid receptor,Oprd1,9.32,Ki,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
conivaptan,Vasopressin V1a receptor,Avpr1a,9.32,Ki,CC1=NC2=C(N1)C1=C(C=CC=C1)N(CC2)C(=O)C1=CC=C(NC(=O)C2=C(C=CC=C2)C2=CC=CC=C2)C=C1
estriol succinate,Estrogen receptor,ESR1,9.32,Ki,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
levallorphan,Mu-type opioid receptor,OPRM1,9.32,Ki,OC1=CC2=C(C[C@@H]3[C@@H]4CCCC[C@]24CCN3CC=C)C=C1
perphenazine,D(2) dopamine receptor,DRD2,9.32,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
lurasidone,5-hydroxytryptamine receptor 2A,HTR2A,9.328,Ki,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=C1C=CC=C2
brexpiprazole,5-hydroxytryptamine receptor 2A,HTR2A,9.328,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
encorafenib,Serine/threonine-protein kinase B-raf,BRAF,9.328,IC50,COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C
dasatinib,Platelet-derived growth factor receptor alpha,PDGFRA,9.33,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
ketanserin,5-hydroxytryptamine receptor 2A,Htr2a,9.33,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
lisuride,5-hydroxytryptamine receptor 1A,Htr1a,9.33,IC50,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
levonorgestrel,Progesterone receptor,PGR,9.339,Ki,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
naltrexone,Mu-type opioid receptor,Oprm1,9.34,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
methysergide,5-hydroxytryptamine receptor 2B,HTR2B,9.34,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
haloperidol decanoate,D(2) dopamine receptor,DRD2,9.34,Ki,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
thioproperazine,D(2) dopamine receptor,DRD2,9.347,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1
thiothixene,D(2) dopamine receptor,DRD2,9.347,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
alprostadil,Prostaglandin E2 receptor EP3 subtype,Ptger3,9.35,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
dasatinib,Ephrin type-B receptor 1,EPHB1,9.35,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
pramipexole,D(3) dopamine receptor,Drd3,9.35,Ki,CCCN[C@H]1CCC2=C(C1)SC(N)=N2
sertindole,D(2) dopamine receptor,Drd2,9.35,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sertindole,D(2) dopamine receptor,DRD2,9.35,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
spiperone,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,9.35,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
vasopressin,Vasopressin V2 receptor,Avpr2,9.35,Ki,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
ergotamine,5-hydroxytryptamine receptor 1A,HTR1A,9.354,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
paroxetine,Sodium-dependent dopamine transporter,Slc6a3,9.36,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
risperidone,5-hydroxytryptamine receptor 2A,HTR2A,9.364,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
chlorprothixene,5-hydroxytryptamine receptor 2A,HTR2A,9.367,Ki,CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
conivaptan,Vasopressin V1a receptor,AVPR1A,9.37,Ki,CC1=NC2=C(N1)C1=C(C=CC=C1)N(CC2)C(=O)C1=CC=C(NC(=O)C2=C(C=CC=C2)C2=CC=CC=C2)C=C1
fluphenazine,D(3) dopamine receptor,DRD3,9.37,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
physostigmine,Acetylcholinesterase,ACHE,9.37,IC50,CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1
scopolamine,Muscarinic acetylcholine receptor M4,CHRM4,9.37,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
sitaxentan,Endothelin-1 receptor,EDNRA,9.37,Ki,CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl
sitaxentan,Endothelin-1 receptor,Ednra,9.37,Ki,CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl
nalfurafine,Mu-type opioid receptor,Oprm1,9.37,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
clorotepine,D(3) dopamine receptor,DRD3,9.372,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
mifepristone,Progesterone receptor,PGR,9.374,Ki,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C(C=C1)N(C)C
fimasartan,Type-1 angiotensin II receptor,AGTR1,9.377,IC50,CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
naltrexone,Mu-type opioid receptor,OPRM1,9.38,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
sulprostone,Prostaglandin E2 receptor EP3 subtype,Ptger3,9.38,EC50,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
ziprasidone,5-hydroxytryptamine receptor 2A,Htr2a,9.38,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
yohimbine,Alpha-2A adrenergic receptor,ADRA2A,9.38,Ki,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12
nintedanib,Receptor-type tyrosine-protein kinase FLT3,FLT3,9.38,Kd,COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2
revefenacin,Muscarinic acetylcholine receptor M1,CHRM1,9.38,Ki,CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1
doxazosin,Alpha-1B adrenergic receptor,Adra1b,9.381,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=C(O1)C=CC=C2
dihydroergocristine,5-hydroxytryptamine receptor 1A,HTR1A,9.385,Ki,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dicycloverine,Muscarinic acetylcholine receptor M4,CHRM4,9.386,Ki,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
atropine,Muscarinic acetylcholine receptor M4,CHRM4,9.39,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
dinoprostone,Prostaglandin E2 receptor EP3 subtype,Ptger3,9.39,EC50,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
scopolamine,Muscarinic receptor M1,,9.39,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
sincalide,Gastrin/cholecystokinin type B receptor,Cckbr,9.39,Ki,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
ozanimod,Sphingosine 1-phosphate receptor 1,S1PR1,9.39,EC50,CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1
pralsetinib,Proto-oncogene tyrosine-protein kinase receptor Ret,RET,9.39,IC50,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
alvimopan,Mu-type opioid receptor,OPRM1,9.398,Ki,C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1
tacrolimus,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,9.398,Kd,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
varenicline,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,9.398,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
posaconazole,Lanosterol 14-alpha demethylase,ERG11,9.398,MIC,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=CC=C(F)C=C2F)C=C1
clorotepine,D(4) dopamine receptor,DRD4,9.398,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
asunaprevir,Genome polyprotein,,9.398,Ki,COC1=C2C=CC(Cl)=CC2=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)N=C1
aripiprazole,5-hydroxytryptamine receptor 1A,Htr1a,9.4,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
buprenorphine,Mu-type opioid receptor,OPRM1,9.4,Ki,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
carvedilol,Beta-3 adrenergic receptor,ADRB3,9.4,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
desloratadine,Histamine H1 receptor,HRH1,9.4,Ki,ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1
floxuridine,Thymidylate synthase,Tyms,9.4,IC50,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O
gefitinib,Epidermal growth factor receptor,EGFR,9.4,Ki,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
glycyrrhizic acid,Corticosteroid 11-beta-dehydrogenase isozyme 2,HSD11B2,9.4,IC50,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O
ketanserin,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,9.4,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
lisuride,5-hydroxytryptamine receptor 1A,HTR1A,9.4,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
melatonin,Melatonin receptor type 1A,MTNR1A,9.4,EC50,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
methylergometrine,5-hydroxytryptamine receptor 2A,HTR2A,9.4,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
naloxone,Mu-type opioid receptor,Oprm1,9.4,Kd,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
nicotine,Neuronal acetylcholine receptor; alpha4/beta2,Chrna4|Chrnb2,9.4,Kd,CN1CCC[C@H]1C1=CC=CN=C1
nifedipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,9.4,Kd,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC
oxymetazoline,5-hydroxytryptamine receptor 1D,HTR1D,9.4,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
pimozide,Dopamine receptor,Drd1|Drd3|Drd5|Drd4|Drd2,9.4,IC50,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1
pindolol,Beta-1 adrenergic receptor,ADRB1,9.4,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
promegestone,Progesterone receptor,PGR,9.4,Kd,CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C
raloxifene,Estrogen receptor,ESR1,9.4,IC50,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
scopolamine,Muscarinic acetylcholine receptor M3,CHRM3,9.4,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
tacrolimus,Peptidyl-prolyl cis-trans isomerase FKBP1B,FKBP1B,9.4,Kd,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
terguride,Alpha-2B adrenergic receptor,ADRA2B,9.4,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
tretinoin,Retinoic acid receptor RXR-alpha,RXRA,9.4,Ki,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
tretinoin,Cellular retinoic acid-binding protein 1,Crabp1,9.4,Kd,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
zanamivir,Neuraminidase,,9.4,Ki,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
ziprasidone,5-hydroxytryptamine receptor 2A,HTR2A,9.4,Ki,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
zofenopril,Angiotensin-converting enzyme,ACE,9.4,Ki,C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1
zofenopril,Angiotensin-converting enzyme,ACE,9.4,IC50,C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1
iloperidone,Alpha-2A adrenergic receptor,Adra2a,9.4,IC50,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
roflumilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,9.4,IC50,FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl
rivaroxaban,Coagulation factor X,F10,9.4,Ki,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
prazosin,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,9.4,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
vilanterol,Beta-2 adrenergic receptor,ADRB2,9.4,EC50,OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl
peramivir,Neuraminidase,,9.4,IC50,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
angiotensin II,Type-1A angiotensin II receptor,Agtr1,9.4,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
pemigatinib,Fibroblast growth factor receptor 1,FGFR1,9.4,IC50,CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F
siponimod,Sphingosine 1-phosphate receptor 1,S1PR1,9.409,EC50,CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F
clonidine,Alpha-2A adrenergic receptor,Adra2a,9.41,Ki,ClC1=CC=CC(Cl)=C1NC1=NCCN1
dasatinib,Ephrin type-B receptor 2,EPHB2,9.41,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
salmeterol,Beta-2 adrenergic receptor,ADRB2,9.41,Ki,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
sertindole,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,9.41,IC50,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
dihydroergotamine,Alpha-2A adrenergic receptor,ADRA2A,9.412,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
thiothixene,D(3) dopamine receptor,DRD3,9.412,Ki,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
dihydroergotamine,5-hydroxytryptamine receptor 1B,Htr1b,9.416,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dexniguldipine,Alpha-1A adrenergic receptor,ADRA1A,9.42,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
haloperidol,D(4) dopamine receptor,DRD4,9.42,Kd,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
indinavir,Protease,HIV-1 protease,9.42,Ki,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
nalorphine,Kappa-type opioid receptor,OPRK1,9.42,Ki,O[C@H]1C=C[C@H]2[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
toliprolol,Beta-1 adrenergic receptor,ADRB1,9.42,Kd,CC(C)NCC(O)COC1=CC(C)=CC=C1
semaglutide,Glucagon-like peptide 1 receptor,GLP1R,9.42,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)[C@H](CCC(O)=O)NC(=O)CCCCCCCCCCCCCCCCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O
dihydroergotamine,5-hydroxytryptamine receptor 1A,HTR1A,9.424,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
desmopressin,Vasopressin V1b receptor,AVPR1B,9.43,Ki,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
raloxifene,Estrogen receptor,Esr1,9.43,Ki,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
sertindole,Alpha-1A adrenergic receptor,ADRA1A,9.43,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
nalfurafine,Delta-type opioid receptor,Oprd1,9.43,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
ponatinib,Tyrosine-protein kinase ABL1,ABL1,9.432,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
teneligliptin,Dipeptidyl peptidase 4,DPP4,9.432,IC50,CC1=NN(C(=C1)N1CCN(CC1)[C@@H]1CN[C@@H](C1)C(=O)N1CCSC1)C1=CC=CC=C1
fluspirilene,D(2) dopamine receptor,DRD2,9.436,Ki,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
conivaptan,Vasopressin V2 receptor,AVPR2,9.44,Ki,CC1=NC2=C(N1)C1=C(C=CC=C1)N(CC2)C(=O)C1=CC=C(NC(=O)C2=C(C=CC=C2)C2=CC=CC=C2)C=C1
risedronic acid,Farnesyl pyrophosphate synthase,FDPS,9.44,Ki,OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
dexamethasone phosphate,Mineralocorticoid receptor,NR3C2,9.44,Ki,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
timolol,Beta-1 adrenergic receptor,ADRB1,9.44,Kd,CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1
prazosin,Beta-casein,Csn2,9.44,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
simeprevir,Nonstructural protein NS3-4A,,9.44,Ki,COC1=C(C)C2=C(C=C1)C(O[C@@H]1C[C@@H]3[C@@H](C1)C(=O)N(C)CCCC\C=C/[C@@H]1C[C@]1(NC3=O)C(=O)NS(=O)(=O)C1CC1)=CC(=N2)C1=NC(=CS1)C(C)C
simeprevir,Polyprotein,,9.44,Ki,COC1=C(C)C2=C(C=C1)C(O[C@@H]1C[C@@H]3[C@@H](C1)C(=O)N(C)CCCC\C=C/[C@@H]1C[C@]1(NC3=O)C(=O)NS(=O)(=O)C1CC1)=CC(=N2)C1=NC(=CS1)C(C)C
aripiprazole,5-hydroxytryptamine receptor 2B,HTR2B,9.444,Ki,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
oxymorphone,Mu-type opioid receptor,OPRM1,9.444,Ki,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
simeprevir,Genome polyprotein,,9.444,Ki,COC1=C(C)C2=C(C=C1)C(O[C@@H]1C[C@@H]3[C@@H](C1)C(=O)N(C)CCCC\C=C/[C@@H]1C[C@]1(NC3=O)C(=O)NS(=O)(=O)C1CC1)=CC(=N2)C1=NC(=CS1)C(C)C
estradiol,Estrogen receptor,Esr1|Esr2,9.45,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
methysergide,5-hydroxytryptamine receptor 2A,HTR2A,9.45,Ki,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=CC=CC(=C34)C2=C1
pramlintide,Amylin receptor AMY1,CALCR|RAMP1,9.45,EC50,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O
tasimelteon,Melatonin receptor type 1A,MTNR1A,9.45,Ki,CCC(=O)NC[C@@H]1C[C@H]1C1=C2CCOC2=CC=C1
trifluperidol,D(4) dopamine receptor,DRD4,9.456,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC(=CC=C1)C(F)(F)F
urapidil,5-hydroxytryptamine receptor 1A,HTR1A,9.456,Ki,COC1=C(C=CC=C1)N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1
suvorexant,Orexin receptor type 2,HCRTR2,9.456,Ki,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2
atropine,Acetylcholinesterase,Ache,9.46,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
atropine,Muscarinic acetylcholine receptor M2,Chrm2,9.46,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
dasatinib,Tyrosine-protein kinase HCK,HCK,9.46,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
granisetron,Serotonin 3 (5-HT3) receptor,Htr3a|Htr3b,9.46,Ki,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
sulprostone,Prostaglandin E2 receptor EP3 subtype,PTGER3,9.46,Ki,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
roflumilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",PDE4A,9.46,IC50,FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl
mirodenafil,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,9.469,IC50,CCCOC1=CC=C(C=C1C1=NC2C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1
aripiprazole lauroxil,D(2) dopamine receptor,DRD2,9.469,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
dasatinib,Ephrin type-B receptor 4,EPHB4,9.47,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
asenapine,5-hydroxytryptamine receptor 7,HTR7,9.47,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
cytisine,Neuronal acetylcholine receptor subunit alpha-4,Chrna4,9.47,Ki,O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12
dinoprostone,Prostaglandin E2 receptor EP3 subtype,PTGER3,9.48,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
losartan,Type-1 angiotensin II receptor,AGTR1,9.48,IC50,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
nilotinib,Bcr/Abl fusion protein,ABL1|BCR,9.48,IC50,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
sertindole,Alpha-1B adrenergic receptor,ADRA1B,9.48,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
telmisartan,Type-2 angiotensin II receptor,AGTR2,9.48,IC50,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O
prazosin,5-hydroxytryptamine receptor 1D,HTR1D,9.48,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
relugolix,Gonadotropin-releasing hormone receptor,Gnrhr,9.48,IC50,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
relugolix,Gonadotropin-releasing hormone receptor,Gnrhr,9.48,IC50,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
abarelix,Gonadotropin-releasing hormone receptor,GNRHR,9.49,Ki,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
calcitonin (salmon synthetic),Amylin receptor AMY3,CALCR|RAMP3,9.499,IC50,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O
imidafenacin,Muscarinic acetylcholine receptor M3,CHRM3,9.499,Kb,CC1=NC=CN1CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1
atropine,Muscarinic acetylcholine receptor M3,CHRM3,9.5,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
budesonide,Interferon gamma,IFNG,9.5,IC50,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
carvedilol,Beta-1 adrenergic receptor,ADRB1,9.5,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
moperone,D(3) dopamine receptor,DRD3,9.5,Ki,CC1=CC=C(C=C1)C1(O)CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
nandrolone phenpropionate,Androgen receptor,AR,9.5,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2OC(=O)CCC1=CC=CC=C1
propantheline,Muscarinic acetylcholine receptor M2,CHRM2,9.5,Ki,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2)C(C)C
mepyramine,Histamine H1 receptor,HRH1,9.5,Kd,COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1
terguride,Alpha-2A adrenergic receptor,ADRA2A,9.5,Ki,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1
zafirlukast,Cysteinyl leukotriene receptor 1,CYSLTR1,9.5,Ki,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
ketotifen,Histamine H1 receptor,HRH1,9.509,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
bopindolol,Beta-1 adrenergic receptor,ADRB1,9.51,Ki,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
calcipotriene,Vitamin D3 receptor,VDR,9.51,Kd,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
dasatinib,Tyrosine-protein kinase FRK,FRK,9.51,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
ketotifen,Histamine H1 receptor,HRH1,9.51,Ki,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
naltrexone,Kappa-type opioid receptor,OPRK1,9.51,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
rimonabant,Cannabinoid receptor 1,Cnr1,9.51,Ki,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
angiotensin II,Type-1B angiotensin II receptor,Agtr1b,9.51,Ki,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
atropine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,9.52,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
darifenacin,Muscarinic acetylcholine receptor M3,CHRM3,9.52,Kd,NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Tyrosine-protein kinase Yes,YES1,9.52,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
estradiol,G-protein coupled estrogen receptor 1,GPER1,9.52,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
flupentixol,D(1A) dopamine receptor,Drd1,9.52,IC50,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
haloperidol,D(2) dopamine receptor,DRD2,9.52,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
levorphanol,Mu-type opioid receptor,Oprm1,9.52,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
lisuride,D(2) dopamine receptor,Drd2,9.52,Kd,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
mafenide,Carbonic anhydrase 12,CA12,9.52,Ki,NCC1=CC=C(C=C1)S(N)(=O)=O
metergoline,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,9.52,Ki,CN1C=C2C[C@@H]3[C@H](C[C@@H](CNC(=O)OCC4=CC=CC=C4)CN3C)C3=CC=CC1=C23
olanzapine,Histamine H1 receptor,Hrh1,9.52,Ki,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
oxymetazoline,5-hydroxytryptamine receptor 1B,HTR1B,9.52,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
oxyphenbutazone,Nicotinate phosphoribosyltransferase,NAPRT,9.52,Ki,CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
tiotropium bromide,Muscarinic acetylcholine receptor M3,Chrm3,9.52,Ki,C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
zafirlukast,Cysteinyl leukotriene receptor 1,CYSLTR1,9.52,Ki,COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1
zolmitriptan,D(1A) dopamine receptor,Drd1,9.52,Kd,CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2
fingolimod,Sphingosine 1-phosphate receptor 1,S1PR1,9.52,EC50,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
fingolimod,Sphingosine 1-phosphate receptor 5,S1PR5,9.52,EC50,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
fingolimod,Sphingosine 1-phosphate receptor 4,S1PR4,9.52,EC50,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
vilazodone,5-hydroxytryptamine receptor 1A,Htr1a,9.52,IC50,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
sincalide,Gastrin/cholecystokinin type B receptor,Cckbr,9.52,IC50,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
sincalide,Cholecystokinin receptor,Cckar|Cckbr,9.52,Ki,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
ponatinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,9.52,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
peramivir,Neuraminidase,,9.52,IC50,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
revefenacin,Muscarinic acetylcholine receptor M2,CHRM2,9.52,Ki,CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1
zanubrutinib,Tyrosine-protein kinase BTK,BTK,9.52,IC50,NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1
perphenazine,D(3) dopamine receptor,DRD3,9.521,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
betahistine,Histamine H3 receptor,HRH3,9.523,EC50,CNCCC1=CC=CC=N1
entacapone,Catechol O-methyltransferase,COMT,9.523,Ki,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N
glibenclamide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,9.523,Kd,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
leuprorelin,Gonadotropin-releasing hormone receptor,GNRHR,9.523,IC50,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
brexpiprazole,D(2) dopamine receptor,DRD2,9.523,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
encorafenib,RAF proto-oncogene serine/threonine-protein kinase,RAF1,9.523,IC50,COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C
nalmefene,Mu-type opioid receptor,OPRM1,9.53,Kd,OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
malathion,Melatonin receptor type 1A,MTNR1A,9.538,Ki,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC
ipratropium,Muscarinic acetylcholine receptor M1,Chrm1,9.54,Ki,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
nalmefene,Mu-type opioid receptor,Oprm1,9.54,Ki,OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
oxymetazoline,Alpha-2A adrenergic receptor,ADRA2A,9.54,Ki,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
prednisolone,Mineralocorticoid receptor,NR3C2,9.54,Ki,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone tebutate,Mineralocorticoid receptor,NR3C2,9.54,Ki,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
sertraline,Sodium-dependent serotonin transporter,SLC6A4,9.54,Kd,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
vasopressin,Vasopressin V1b receptor,Avpr1b,9.54,Ki,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
somatostatin,Somatostatin receptor type 1,SSTR1,9.54,Ki,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
teneligliptin,Dipeptidyl peptidase 4,Dpp4,9.54,IC50,CC1=NN(C(=C1)N1CCN(CC1)[C@@H]1CN[C@@H](C1)C(=O)N1CCSC1)C1=CC=CC=C1
finasteride,3-oxo-5-alpha-steroid 4-dehydrogenase 2,Srd5a2,9.55,IC50,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
hydromorphone,Mu-type opioid receptor,OPRM1,9.55,Ki,CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CCC4=O)=CC=C5O
octreotide,Somatostatin receptor type 2,Sstr2,9.55,IC50,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
perospirone,D(3) dopamine receptor,DRD3,9.55,Ki,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)C1=NSC2=CC=CC=C12
tamsulosin,D(3) dopamine receptor,DRD3,9.55,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
somatostatin,Somatostatin receptor type 2,Sstr2,9.55,IC50,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
sincalide,Cholecystokinin receptor type A,CCKAR,9.55,Ki,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
sincalide,Gastrin/cholecystokinin type B receptor,CCKBR,9.55,Ki,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
sincalide,Cholecystokinin receptor type A,CCKAR,9.55,Ki,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
trazodone,Alpha-1A adrenergic receptor,ADRA1A,9.551,IC50,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
chlorpromazine,Alpha-1A adrenergic receptor,ADRA1A,9.553,Ki,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
pipotiazine palmitate,D(3) dopamine receptor,DRD3,9.553,Ki,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)S(=O)(=O)N(C)C)CC1
tolcapone,Catechol O-methyltransferase,COMT,9.569,Ki,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
roflumilast,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",PDE4D,9.57,IC50,FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl
androstanolone,Androgen receptor,Ar,9.57,Ki,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
avapritinib,Mast/stem cell growth factor receptor Kit,KIT,9.57,IC50,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1
trilaciclib,Serine/threonine-protein kinase Nek10,NEK10,9.57,Kd,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
naltrexone,Mu-type opioid receptor,Oprm1,9.58,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
atropine,Muscarinic acetylcholine receptor M1,Chrm1,9.59,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
medroxyprogesterone,Progesterone receptor,PGR,9.59,EC50,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12
vasopressin,Vasopressin V1a receptor,AVPR1A,9.59,Ki,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O
clidinium,Muscarinic acetylcholine receptor M3,CHRM3,9.6,Ki,C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
dasatinib,Tyrosine-protein kinase ABL1,ABL1,9.6,IC50,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desipramine,Alpha-1A adrenergic receptor,Adra1a,9.6,IC50,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
lanreotide,Somatostatin receptor type 2,SSTR2,9.6,Ki,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1
nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,9.6,Ki,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
domitroban,Thromboxane A2 receptor,TBXA2R,9.6,Ki,OC(=O)CCC\C=C/C[C@H]1[C@@H]2CC[C@@H](C2)[C@@H]1NS(=O)(=O)C1=CC=CC=C1
mesterolone,Sex hormone-binding globulin,SHBG,9.6,Kd,C[C@H]1CC(=O)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]12C
testosterone propionate,Androgen receptor,AR,9.6,Ki,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
icatibant,B2 bradykinin receptor,Bdkrb2,9.6,Ki,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CS1)C(=O)N[C@@H](CO)C(=O)N1CC2=C(C[C@@H]1C(=O)N1[C@H]3CCCC[C@H]3C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C2
droperidol,D(2) dopamine receptor,DRD2,9.602,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2
asenapine,5-hydroxytryptamine receptor 2A,HTR2A,9.61,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
fluphenazine enanthate,D(3) dopamine receptor,DRD3,9.611,Ki,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
sulforidazine,D(2) dopamine receptor,DRD2,9.611,Ki,CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)(=O)=O
atazanavir,Pol polyprotein,pol,9.62,Ki,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
dasatinib,Ephrin type-A receptor 8,EPHA8,9.62,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Ephrin type-A receptor 5,EPHA5,9.62,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
duloxetine,Sodium-dependent serotonin transporter,SLC6A4,9.62,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
entecavir,Capsid protein,HBcAg,9.62,EC50,NC1=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](CO)C2=C)C(=O)N1
fulvestrant,Estrogen receptor,ESR1,9.62,Ki,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
maraviroc,C-C chemokine receptor type 5,CCR5,9.62,Ki,CC(C)C1=NN=C(C)N1[C@@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
promethazine,Histamine H1 receptor,HRH1,9.62,Ki,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
caspofungin,"1,3-beta-D-glucan synthase catalytic subunit",CaFKS1,9.62,IC50,CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN
ponatinib,Tyrosine-protein kinase Lyn,LYN,9.62,IC50,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
tivozanib,Vascular endothelial growth factor receptor 3,FLT4,9.62,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
duvelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",PIK3CG,9.62,Kd,C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=C(C(Cl)=CC=C2)C(=O)N1C1=CC=CC=C1
avapritinib,Platelet-derived growth factor receptor alpha,PDGFRA,9.62,IC50,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1
lisuride,Alpha-2B adrenergic receptor,ADRA2B,9.625,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
benzatropine,Muscarinic acetylcholine receptor M1,CHRM1,9.636,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1
adenosine phosphate,Pol polyprotein,pol,9.64,Ki,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
indapamide,Carbonic anhydrase 7,CA7,9.64,Ki,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
rosiglitazone,Type-1A angiotensin II receptor,Agtr1,9.64,Ki,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
telmisartan,Type-1A angiotensin II receptor,Agtr1,9.64,Ki,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O
clorotepine,5-hydroxytryptamine receptor 2A,Htr2a,9.64,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
glycopyrronium bromide,Muscarinic acetylcholine receptor M3,CHRM3,9.64,Ki,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
nalfurafine,Kappa-type opioid receptor,OPRK1,9.64,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
samidorphan,Kappa-type opioid receptor,OPRK1,9.64,Ki,C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O
bopindolol,Beta-2 adrenergic receptor,ADRB2,9.65,Ki,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
calcitonin (salmon synthetic),Amylin receptor AMY1,CALCR|RAMP1,9.65,IC50,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O
ambrisentan,Endothelin-1 receptor,EDNRA,9.65,Ki,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
alprenolol,Beta-2 adrenergic receptor,ADRB2,9.658,Kd,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
darunavir,Gag-Pol polyprotein,gag-pol,9.658,Ki,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1
diethylstilbestrol,Estrogen receptor,ESR1,9.66,Ki,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
ketoconazole,Gonadotropin-releasing hormone receptor,Gnrhr,9.66,Kd,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
saquinavir,Protease,HIV-1 protease,9.66,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
sufentanil,Mu-type opioid receptor,Oprm1,9.66,Ki,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
sunitinib,Receptor-type tyrosine-protein kinase FLT3,FLT3,9.66,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
varenicline,Neuronal acetylcholine receptor; alpha2/beta2,Chrna2|Chrnb2,9.66,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
eledoisin,Neuromedin-K receptor,TACR3,9.66,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCC(=O)N1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O
methyltestosterone,Androgen receptor,AR,9.66,EC50,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
alprenolol,Beta-1 adrenergic receptor,ADRB1,9.678,Kd,CC(C)NCC(O)COC1=C(CC=C)C=CC=C1
cyproterone acetate,Progesterone receptor,PGR,9.678,IC50,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
tivozanib,Vascular endothelial growth factor receptor 1,FLT1,9.678,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
dasatinib,Proto-oncogene tyrosine-protein kinase Src,SRC,9.68,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dasatinib,Tyrosine-protein kinase Blk,BLK,9.68,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
fulvestrant,Progesterone receptor,PGR,9.68,IC50,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=CC(O)=CC=C31
levorphanol,Mu-type opioid receptor,OPRM1,9.68,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
levorphanol,Mu-type opioid receptor,OPRM1,9.68,Ki,CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
methscopolamine,Muscarinic acetylcholine receptor M5,CHRM5,9.68,Ki,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
nemonapride,D(4) dopamine receptor,DRD4,9.68,Kd,CNC1=CC(OC)=C(C=C1Cl)C(=O)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C
sunitinib,Mast/stem cell growth factor receptor Kit,KIT,9.68,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
colecalciferol,Vitamin D3 receptor,VDR,9.68,EC50,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
prazosin,Alpha-1B adrenergic receptor,ADRA1B,9.68,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
glycopyrronium bromide,Muscarinic acetylcholine receptor M1,CHRM1,9.69,Ki,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
alpha-Ergocryptine,D(3) dopamine receptor,DRD3,9.699,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=CNC6=CC=CC(=C56)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
nafarelin,Gonadotropin-releasing hormone receptor,GNRHR,9.699,Kd,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
pipotiazine palmitate,D(2) dopamine receptor,DRD2,9.699,Ki,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)S(=O)(=O)N(C)C)CC1
trifluperidol,D(2) dopamine receptor,DRD2,9.699,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC(=CC=C1)C(F)(F)F
ridaforolimus,Serine/threonine-protein kinase mTOR,MTOR,9.699,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O
ceritinib,ALK tyrosine kinase receptor,ALK,9.699,IC50,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
albiglutide,Glucagon-like peptide 1 receptor,GLP1R,9.699,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O
atropine,Muscarinic receptor M1,,9.7,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
bromocriptine,D(2) dopamine receptor,DRD2,9.7,Ki,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C
clomipramine,Histamine H1 receptor,Hrh1,9.7,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
dasatinib,Tyrosine-protein kinase Lck,LCK,9.7,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
desmopressin,Vasopressin V1b receptor,Avpr1b,9.7,Ki,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
dexmedetomidine,Alpha-2B adrenergic receptor,ADRA2B,9.7,Ki,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
dorzolamide,Carbonic anhydrase 2,CA2,9.7,Ki,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
estradiol,Estrogen receptor beta,ESR2,9.7,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
haloperidol,D(2) dopamine receptor,Drd2,9.7,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
ketanserin,5-hydroxytryptamine receptor 2A,HTR2A,9.7,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
melatonin,Melatonin receptor type 1B,MTNR1B,9.7,EC50,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
opipramol,Sigma non-opioid intracellular receptor 1,SIGMAR1,9.7,Ki,OCCN1CCN(CCCN2C3=CC=CC=C3C=CC3=C2C=CC=C3)CC1
phenazocine,Mu-type opioid receptor,OPRM1,9.7,Ki,CC1C2CC3=C(C=C(O)C=C3)C1(C)CCN2CCC1=CC=CC=C1
propantheline,Muscarinic acetylcholine receptor M1,CHRM1,9.7,Ki,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2)C(C)C
sertindole,5-hydroxytryptamine receptor 2A,Htr2a,9.7,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sertindole,5-hydroxytryptamine receptor 2C,HTR2C,9.7,Ki,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
sirolimus,Peptidyl-prolyl cis-trans isomerase FKBP3,FKBP3,9.7,Kd,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
sirolimus,Peptidyl-prolyl cis-trans isomerase FKBP1B,FKBP1B,9.7,Kd,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
spiperone,D(4) dopamine receptor,DRD4,9.7,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
sunitinib,Vascular endothelial growth factor receptor 2,KDR,9.7,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
secretin human,Secretin receptor,SCTR,9.7,EC50,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(N)=O
tamsulosin,Alpha-1B adrenergic receptor,ADRA1B,9.7,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
somatostatin,Somatostatin receptor,Sstr1|Sstr2|Sstr3|Sstr4|Sstr5,9.7,IC50,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
linoleic acid,"Fatty acid-binding protein, heart",FABP3,9.7,Kd,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
androstanolone,Androgen receptor,AR,9.7,Ki,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
timolol,Beta-2 adrenergic receptor,ADRB2,9.7,Ki,CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1
ulipristal,Progesterone receptor,PGR,9.7,IC50,CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12
prazosin,Alpha-1D adrenergic receptor,ADRA1D,9.7,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
prazosin,Alpha-1D adrenergic receptor,Adra1d,9.7,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
prazosin,Mu-type opioid receptor,Oprm1,9.7,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
vilazodone,5-hydroxytryptamine receptor 1A,HTR1A,9.7,Ki,NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
aclidinium bromide,Muscarinic acetylcholine receptor M4,CHRM4,9.7,IC50,OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
brexpiprazole,D(2) dopamine receptor,Drd2,9.7,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
aripiprazole lauroxil,D(2) dopamine receptor,Drd2,9.7,Ki,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
abaloparatide,Parathyroid hormone/parathyroid hormone-related peptide receptor,PTH1R,9.7,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(N)=O
pibrentasvir,Genome polyprotein [Cleaved into: Core protein p21,,9.7,EC50,CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=CC([C@H]3CC[C@@H](N3C3=CC(F)=C(N4CCC(CC4)C4=CC=C(F)C=C4)C(F)=C3)C3=C(F)C=C4NC(=NC4=C3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)=C(F)C=C2N1
gilteritinib,Leukocyte tyrosine kinase receptor,LTK,9.7,IC50,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1
clomipramine,Sodium-dependent serotonin transporter,SLC6A4,9.703,Ki,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
ketorolac,Prostaglandin G/H synthase 1,PTGS1,9.72,IC50,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1
nalorphine,Mu-type opioid receptor,OPRM1,9.72,Ki,O[C@H]1C=C[C@H]2[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
pyrimethamine,Bifunctional dihydrofolate reductase-thymidylate synthase,,9.72,Ki,CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1
tacrolimus,Interleukin-2,IL2,9.72,IC50,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
clorotepine,Histamine H1 receptor,HRH1,9.72,Ki,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
rimonabant,Cannabinoid receptor 1,CNR1,9.72,Ki,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1
ipratropium,Muscarinic acetylcholine receptor M3,Chrm3,9.74,Ki,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
palonosetron,Serotonin 3 receptor (5HT3),HTR3B|HTR3A,9.74,Kd,O=C1N(C[C@H]2CCCC3=CC=CC1=C23)[C@@H]1CN2CCC1CC2
clorotepine,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,9.74,IC50,CN1CCN(CC1)C1CC2=CC=CC=C2SC2=C1C=C(Cl)C=C2
androstanolone,Sex hormone-binding globulin,SHBG,9.74,Kd,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
oxitriptan,5-hydroxytryptamine receptor 2C,HTR2C,9.74,EC50,N[C@@H](CC1=CNC2=CC=C(O)C=C12)C(O)=O
doxepin,Histamine H1 receptor,HRH1,9.75,Ki,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
melatonin,Melatonin receptor,,9.75,Ki,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1
nalfurafine,Kappa-type opioid receptor,OPRK1,9.75,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
nalfurafine,Kappa-type opioid receptor,Oprk1,9.75,Ki,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC1CC1)=C(O)C=C4)C(=O)\C=C\C1=COC=C1
revefenacin,Muscarinic acetylcholine receptor M3,CHRM3,9.75,Ki,CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1
dasatinib,Abelson tyrosine-protein kinase 2,ABL2,9.77,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
dinoprostone,Prostaglandin E2 receptor EP4 subtype,PTGER4,9.77,Ki,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
fluticasone propionate,Progesterone receptor,PGR,9.77,EC50,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF
naltrexone,Mu-type opioid receptor,OPRM1,9.77,Ki,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
saralasin,Type-1 angiotensin II receptor,AGTR1,9.77,Ki,CNCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O
prazosin,Alpha-1A adrenergic receptor,ADRA1A,9.77,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
apixaban,Coagulation factor X,F10,9.77,Ki,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
brexpiprazole,Alpha-1B adrenergic receptor,ADRA1B,9.77,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
timolol,Beta-2 adrenergic receptor,Adrb2,9.78,Kd,CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1
ingenol mebutate,Protein kinase C gamma type,PRKCG,9.79,Ki,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C
umeclidinium,Muscarinic acetylcholine receptor M1,CHRM1,9.796,Ki,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
pitolisant,Histamine H3 receptor,HRH3,9.796,Ki,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
tivozanib,Vascular endothelial growth factor receptor 2,KDR,9.796,IC50,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1
hyoscyamine,Muscarinic acetylcholine receptor M3,CHRM3,9.8,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
isoprenaline,Beta-2 adrenergic receptor,ADRB2,9.8,EC50,CC(C)NCC(O)C1=CC=C(O)C(O)=C1
loperamide,Mu-type opioid receptor,Oprm1,9.8,Ki,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
nemonapride,D(2) dopamine receptor,Drd2,9.8,Ki,CNC1=CC(OC)=C(C=C1Cl)C(=O)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C
nemonapride,D(3) dopamine receptor,Drd3,9.8,Ki,CNC1=CC(OC)=C(C=C1Cl)C(=O)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C
salicylic acid,Nicotinate phosphoribosyltransferase,NAPRT,9.8,Ki,OC(=O)C1=CC=CC=C1O
tiotropium bromide,Muscarinic acetylcholine receptor M1,Chrm1,9.8,Ki,C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
asenapine,5-hydroxytryptamine receptor 2B,HTR2B,9.8,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
pasireotide,Somatostatin receptor type 5,SSTR5,9.8,IC50,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
aclidinium bromide,Muscarinic acetylcholine receptor M5,CHRM5,9.8,IC50,OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
tasimelteon,Melatonin receptor type 1B,MTNR1B,9.8,Ki,CCC(=O)NC[C@@H]1C[C@H]1C1=C2CCOC2=CC=C1
corticotropin,Adrenocorticotropic hormone receptor,Mc2r,9.8,Kd,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
pitolisant,Histamine H3 receptor,HRH3,9.8,Ki,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
pitolisant,Histamine H3 receptor,HRH3,9.8,Ki,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
amprenavir,Protease,HIV-1 protease,9.82,Ki,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
indomethacin,Nicotinate phosphoribosyltransferase,NAPRT,9.82,Ki,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
methscopolamine,Muscarinic acetylcholine receptor M2,CHRM2,9.82,Ki,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
risperidone,5-hydroxytryptamine receptor 2A,Htr2a,9.82,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
tacrine,Choline O-acetyltransferase,Chat,9.82,Ki,NC1=C2CCCCC2=NC2=CC=CC=C12
tiotropium bromide,Muscarinic acetylcholine receptor M2,Chrm2,9.82,Ki,C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
tretinoin,Nuclear receptor ROR-beta,RORB,9.82,IC50,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
trifluperidol,C-8 sterol isomerase,ERG2,9.82,Ki,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC(=CC=C1)C(F)(F)F
atosiban,Vasopressin V1a receptor,AVPR1A,9.82,Ki,CCOC1=CC=C(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)C=C1
saralasin,Type-2 angiotensin II receptor,AGTR2,9.82,Ki,CNCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O
tiratricol,Thyroid hormone receptor beta,Thrb,9.82,IC50,OC(=O)CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
romidepsin,Histone deacetylase 8,HDAC8,9.82,Ki,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
romidepsin,Histone deacetylase 3/NCoR1,HDAC3|NCOR1,9.82,Ki,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
umeclidinium,Muscarinic acetylcholine receptor M2,CHRM2,9.824,Ki,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
ethinylestradiol,Estrogen receptor,ESR1,9.83,Kd,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
oseltamivir,Neuraminidase,,9.83,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
histamine,Histamine H3 receptor,HRH3,9.84,Ki,NCCC1=CN=CN1
oxyphenonium,Muscarinic acetylcholine receptor M4,CHRM4,9.84,Ki,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
docetaxel,Growth hormone-releasing hormone receptor,GHRHR,9.85,IC50,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
exenatide,Glucagon-like peptide 1 receptor,Glp1r,9.85,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
indomethacin,Androgen receptor,AR,9.85,EC50,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
risperidone,Serotonin 2 (5-HT2) receptor,Htr2c|Htr2a|Htr2b,9.85,Ki,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
somatostatin,Somatostatin receptor type 5,SSTR5,9.85,Ki,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
tiratricol,Thyroid hormone receptor alpha,THRA,9.85,IC50,OC(=O)CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
grazoprevir,Genome polyprotein,,9.85,Ki,COC1=CC2=C(C=C1)N=C1CCCCC[C@@H]3C[C@H]3OC(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)OC1=N2)C(C)(C)C
blonanserin,D(2) dopamine receptor,DRD2,9.854,Ki,CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1
maprotiline,Alpha-1A adrenergic receptor,ADRA1A,9.854,IC50,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
iloperidone,5-hydroxytryptamine receptor 2A,HTR2A,9.859,Ki,COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O
calcitonin (salmon synthetic),Amylin receptor AMY2,CALCR|RAMP2,9.873,IC50,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O
progesterone,Progesterone receptor,PGR,9.876,ED50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
capmatinib,Hepatocyte growth factor receptor,MET,9.88,IC50,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
spironolactone,Mineralocorticoid receptor,NR3C2,9.884,IC50,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
buprenorphine,Mu-type opioid receptor,Oprm1,9.89,Ki,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5
methotrexate,Bifunctional dihydrofolate reductase-thymidylate synthase,,9.89,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
brinzolamide,Carbonic anhydrase 2,CA2,9.9,Ki,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
carvedilol,Beta-2 adrenergic receptor,ADRB2,9.9,Ki,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1
dihydroergotamine,5-hydroxytryptamine receptor 1D,HTR1D,9.9,Ki,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
estriol succinate,Estrogen receptor beta,ESR2,9.9,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](OC(=O)CCC(O)=O)[C@@H]2OC(=O)CCC(O)=O
hyoscyamine,Muscarinic acetylcholine receptor M4,CHRM4,9.9,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
methscopolamine,Muscarinic acetylcholine receptor M1,CHRM1,9.9,Ki,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
mometasone furoate,Progesterone receptor,PGR,9.9,EC50,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)CCl
octreotide,Somatostatin receptor type 5,Sstr5,9.9,Ki,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
tamsulosin,Alpha-1A adrenergic receptor,ADRA1A,9.9,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
triprolidine,Histamine H1 receptor,HRH1,9.9,Ki,CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1
triprolidine,Histamine H1 receptor,HRH1,9.9,Kd,CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1
casopitant,Substance-P receptor,TACR1,9.9,Ki,C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=C(C)C=C(F)C=C1)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
umeclidinium,Muscarinic acetylcholine receptor M5,CHRM5,9.9,Ki,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
arformoterol,Beta-2 adrenergic receptor,Adrb2,9.9,EC50,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1
thiamine,Thiamine transporter ThiT,thiT,9.91,Kd,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
halcinonide,Progesterone receptor,PGR,9.917,Ki,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl
ambenonium,Acetylcholinesterase,ACHE,9.92,IC50,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC1=C(Cl)C=CC=C1
atropine,Muscarinic acetylcholine receptor M3,Chrm3,9.92,Ki,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
budesonide,Interleukin-5,IL5,9.92,IC50,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
butorphanol,Mu-type opioid receptor,OPRM1,9.92,Ki,OC1=CC2=C(C[C@H]3N(CC4CCC4)CC[C@@]22CCCC[C@@]32O)C=C1
butorphanol,Kappa-type opioid receptor,OPRK1,9.92,Ki,OC1=CC2=C(C[C@H]3N(CC4CCC4)CC[C@@]22CCCC[C@@]32O)C=C1
fludrocortisone acetate,Mineralocorticoid receptor,NR3C2,9.92,IC50,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
nalmefene,Kappa-type opioid receptor,OPRK1,9.92,Ki,OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1
spiperone,D(3) dopamine receptor,DRD3,9.92,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
afamelanotide,Melanocortin receptor 4,Mc4r,9.92,EC50,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
relugolix,Gonadotropin-releasing hormone receptor,GNRHR,9.92,IC50,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
brexpiprazole,5-hydroxytryptamine receptor 1A,HTR1A,9.921,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
asenapine,5-hydroxytryptamine receptor 2C,HTR2C,9.93,Ki,CN1CC2C(C1)C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1
lisuride,Alpha-2A adrenergic receptor,ADRA2A,9.936,Ki,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1
carazolol,Beta-2 adrenergic receptor,ADRB2,9.94,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
hydrocortisone,Mineralocorticoid receptor,NR3C2,9.95,IC50,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
lorlatinib,ALK tyrosine kinase receptor,ALK,9.959,Ki,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12
oseltamivir,Neuraminidase,,9.96,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
icatibant,B2 bradykinin receptor,BDKRB2,9.96,Ki,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CS1)C(=O)N[C@@H](CO)C(=O)N1CC2=C(C[C@@H]1C(=O)N1[C@H]3CCCC[C@H]3C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C2
delapril,Angiotensin-converting enzyme,ACE,9.97,Ki,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=C(C1)C=CC=C2
agomelatine,Melatonin receptor,MTNR1A|MTNR1B,10,Ki,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
agomelatine,Melatonin receptor type 1B,MTNR1B,10,Ki,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
carperitide,Atrial natriuretic peptide receptor 1,NPR1,10,EC50,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO
dexniguldipine,Alpha-1A adrenergic receptor,ADRA1A,10,Ki,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
etomidate,"Cytochrome P450 11B2, mitochondrial",CYP11B2,10,IC50,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
nafamostat,Tryptase alpha/beta-1,TPSAB1,10,IC50,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
oseltamivir,Neuraminidase,,10,Ki,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
phenylbutazone,Nicotinate phosphoribosyltransferase,NAPRT,10,Ki,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
pranlukast,Cysteinyl leukotriene receptor 1,CYSLTR1,10,IC50,O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
propantheline,Muscarinic acetylcholine receptor M3,CHRM3,10,Ki,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2)C(C)C
sirolimus,Serine/threonine-protein kinase mTOR,MTOR,10,IC50,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
zanamivir,Neuraminidase,,10,Ki,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
somatostatin,Somatostatin receptor type 3,SSTR3,10,Ki,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
linagliptin,Dipeptidyl peptidase 4,DPP4,10,IC50,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1
prazosin,Alpha-1B adrenergic receptor,Adra1b,10,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
afatinib,Epidermal growth factor receptor,EGFR,10,Kd,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1
ibrutinib,Tyrosine-protein kinase Blk,BLK,10,IC50,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C
afamelanotide,Melanocyte-stimulating hormone receptor,MC1R,10,IC50,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
erdafitinib,Vascular endothelial growth factor receptor 2,Kdr,10,IC50,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1
erdafitinib,Vascular endothelial growth factor receptor 2,Kdr,10,IC50,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1
methscopolamine,Muscarinic acetylcholine receptor M4,CHRM4,10.01,Ki,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
bremelanotide,Melanocyte-stimulating hormone receptor,MC1R,10.02,EC50,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O
dasatinib,Ephrin type-A receptor 3,EPHA3,10.03,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
ergotamine,5-hydroxytryptamine receptor 1B,Htr1b,10.041,Ki,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
aprepitant,Substance-P receptor,TACR1,10.05,IC50,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
buserelin,Gonadotropin-releasing hormone receptor,Gnrhr,10.05,EC50,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
carazolol,Beta-1 adrenergic receptor,Adrb1,10.05,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
carazolol,Beta-1 adrenergic receptor,Adrb1,10.05,Ki,CC(C)NCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
flumazenil,GABA-A receptor; anion channel,GABRA1|GABRB1|GABRA2|GABRA3|GABRA4|GABRG2,10.05,Ki,CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1
perospirone,D(4) dopamine receptor,DRD4,10.05,Ki,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)C1=NSC2=CC=CC=C12
ruxolitinib,Tyrosine-protein kinase JAK1,JAK1,10.05,Ki,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
sincalide,Cholecystokinin receptor type A,Cckar,10.05,Ki,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
teduglutide,Glucagon-like peptide 2 receptor,GLP2R,10.05,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O
brexpiprazole,5-hydroxytryptamine receptor 1A,Htr1a,10.05,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
brexpiprazole,5-hydroxytryptamine receptor 1A,Htr1a,10.05,Ki,O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2
cariprazine,D(3) dopamine receptor,DRD3,10.07,Ki,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
fluoroestradiol F 18,Estrogen receptor,ESR1,10.07,IC50,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)[18F])CCC4=C3C=CC(=C4)O
duloxetine,Sodium-dependent serotonin transporter,Slc6a4,10.09,Ki,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1
liothyronine,Thyroid hormone receptor beta,THRB,10.1,Ki,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
scopolamine,Muscarinic acetylcholine receptor,Chrm1|Chrm3|Chrm4|Chrm5|Chrm2,10.1,Ki,CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
somatostatin,Somatostatin receptor type 3,Sstr3,10.1,IC50,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
apixaban,Coagulation factor X,F10,10.1,Ki,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
aclidinium bromide,Muscarinic acetylcholine receptor M1,CHRM1,10.1,Ki,OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
aclidinium bromide,Muscarinic acetylcholine receptor M2,CHRM2,10.1,Ki,OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
iclaprim,Dihydrofolate reductase,folA,10.1,Ki,COC1=CC(CC2=CN=C(N)N=C2N)=C2C=CC(OC2=C1OC)C1CC1
teduglutide,Glucagon-like peptide 2 receptor,Glp2r,10.1,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O
icatibant,B2 bradykinin receptor,Bdkrb2,10.11,Ki,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CS1)C(=O)N[C@@H](CO)C(=O)N1CC2=C(C[C@@H]1C(=O)N1[C@H]3CCCC[C@H]3C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C2
atazanavir,Protease,HIV-1 protease,10.12,Ki,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
sunitinib,Platelet-derived growth factor receptor beta,PDGFRB,10.12,Kd,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
fluticasone furoate,Glucocorticoid receptor,NR3C1,10.12,IC50,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)SCF
methotrexate,Dihydrofolate reductase,Dhfr,10.14,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
forodesine,Purine nucleoside phosphorylase,PNP,10.143,Ki,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1NC=NC2=O
calcitriol,Vitamin D3 receptor,VDR,10.15,Kd,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
indinavir,Pol polyprotein,pol,10.15,Ki,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=C1C=CC=C2
metopimazine,D(2) dopamine receptor,DRD2,10.15,Ki,CS(=O)(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCC(CC3)C(N)=O)C2=C1
mianserin,Alpha-1A adrenergic receptor,Adra1a,10.15,IC50,CN1CCN2C(C1)C1=C(CC3=C2C=CC=C3)C=CC=C1
nelfinavir,Protease,protease,10.15,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
tamsulosin,Alpha-1D adrenergic receptor,Adra1d,10.15,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
zoledronic acid,Farnesyl pyrophosphate synthase,FDPS,10.15,Ki,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
prazosin,Alpha-1A adrenergic receptor,Adra1a,10.15,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
aclidinium bromide,Muscarinic acetylcholine receptor M3,CHRM3,10.15,Ki,OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
peramivir,Neuraminidase,,10.15,IC50,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
afamelanotide,Melanocortin receptor 3,Mc3r,10.15,EC50,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
afamelanotide,Melanocortin receptor 5,Mc5r,10.15,EC50,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
grazoprevir,NS3 protease,NS3,10.15,IC50,COC1=CC2=C(C=C1)N=C1CCCCC[C@@H]3C[C@H]3OC(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)OC1=N2)C(C)(C)C
benperidol,D(3) dopamine receptor,DRD3,10.18,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2
voxilaprevir,Genome polyprotein,,10.18,Ki,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=NC3=CC=C(OC)C=C3N=C1O2)C(C)(C)C
clavulanic acid,Beta-lactamase TEM,bla; blaT-3; blaT-4;,10.187,IC50,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O
saquinavir,Gag-Pol polyprotein,gag-pol,10.187,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
dasatinib,Proto-oncogene tyrosine-protein kinase LCK,Lck,10.19,Ki,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
pibrentasvir,Nonstructural protein 5A,NS5A,10.19,EC50,CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=CC([C@H]3CC[C@@H](N3C3=CC(F)=C(N4CCC(CC4)C4=CC=C(F)C=C4)C(F)=C3)C3=C(F)C=C4NC(=NC4=C3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)=C(F)C=C2N1
propantheline,Muscarinic acetylcholine receptor M4,CHRM4,10.2,Ki,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2)C(C)C
liraglutide,Glucagon-like peptide 1 receptor,GLP1R,10.2,EC50,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
angiotensin II,Type-2 angiotensin II receptor,AGTR2,10.2,Kd,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
ubrogepant,Calcitonin gene-related peptide type 1 receptor,CALCRL,10.2,Ki,C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=NC=CC=C42)C(=O)N1CC(F)(F)F)C1=CC=CC=C1
darunavir,Protease,protease,10.21,IC50,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1
agomelatine,Melatonin receptor type 1A,MTNR1A,10.22,Ki,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
imipramine,Histamine H1 receptor,Hrh1,10.22,IC50,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
oseltamivir,Neuraminidase,,10.22,IC50,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
ramosetron,5-hydroxytryptamine receptor 3A,HTR3A,10.22,Ki,CN1C=C(C(=O)[C@@H]2CCC3=C(C2)NC=N3)C2=CC=CC=C12
rotigotine,D(2) dopamine receptor,DRD2,10.22,Ki,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
spiperone,D(2) dopamine receptor,DRD2,10.22,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
tacrolimus,Interleukin-5,IL5,10.22,IC50,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
tacrolimus,Interferon gamma,IFNG,10.22,IC50,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@@H]1C)OC
trimetrexate,Dihydrofolate reductase,Dhfr,10.22,Ki,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
icatibant,B2 bradykinin receptor,BDKRB2,10.22,Ki,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CS1)C(=O)N[C@@H](CO)C(=O)N1CC2=C(C[C@@H]1C(=O)N1[C@H]3CCCC[C@H]3C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C2
cyproheptadine,Histamine H1 receptor,HRH1,10.222,Ki,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
umeclidinium,Muscarinic acetylcholine receptor M3,CHRM3,10.222,Ki,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
liothyronine,Thyroid hormone receptor alpha,THRA,10.24,Kd,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
tamsulosin,Alpha-1D adrenergic receptor,ADRA1D,10.24,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
atazanavir,Protease,HIV-1 protease,10.27,Ki,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
triclosan,Enoyl-acyl-carrier protein reductase,fabI,10.28,Ki,OC1=C(OC2=CC=C(Cl)C=C2Cl)C=CC(Cl)=C1
samidorphan,Mu-type opioid receptor,OPRM1,10.28,Ki,C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O
budesonide,Glucocorticoid receptor,NR3C1,10.3,EC50,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
calcitriol,Vitamin D3 receptor,Vdr,10.3,Ki,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
calcitriol,Vitamin D3 receptor,VDR,10.3,EC50,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
estradiol,Estrogen receptor,ESR1,10.3,EC50,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O
fadrozole,Aromatase,CYP19A1,10.3,Ki,N#CC1=CC=C(C=C1)C1CCCC2=CN=CN12
hexestrol,Estrogen receptor,ESR1,10.3,Ki,CC[C@@H]([C@@H](CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
mefenamic acid,Nicotinate phosphoribosyltransferase,NAPRT,10.3,Ki,CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C
methscopolamine,Muscarinic acetylcholine receptor M3,Chrm3,10.3,EC50,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
nortriptyline,Histamine H1 receptor,Hrh1,10.3,IC50,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
paroxetine,Sodium-dependent serotonin transporter,Slc6a4,10.3,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
levisoprenaline,Beta-2 adrenergic receptor,ADRB2,10.3,IC50,CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1
varenicline,Neuronal acetylcholine receptor; alpha4/beta2,Chrna4|Chrnb2,10.3,Ki,C1[C@H]2CNC[C@@H]1C1=C2C=C2N=CC=NC2=C1
ziconotide,Voltage-dependent N-type calcium channel subunit alpha-1B,Cacna1b,10.3,IC50,CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)[C@@H](C)O
umeclidinium,Muscarinic acetylcholine receptor M4,CHRM4,10.3,Ki,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
vaniprevir,Nonstructural protein NS3-4A,,10.3,Ki,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1[C@H]2CCN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
daclatasvir,Genome polyprotein,,10.301,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C
vaniprevir,Genome polyprotein,,10.301,Ki,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1[C@H]2CCN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
glucagon,Glucagon-like peptide 1 receptor,Glp1r,10.36,EC50,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
ramelteon,Melatonin receptor type 1B,MTNR1B,10.39,Ki,CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2
thyropropic acid,Thyroid hormone receptor alpha,THRA,10.39,IC50,OC(=O)CCC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
tiratricol,Thyroid hormone receptor beta,THRB,10.39,IC50,OC(=O)CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
amprenavir,Pol polyprotein,pol,10.4,Ki,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
clomipramine,Alpha-1A adrenergic receptor,Adra1a,10.4,IC50,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
lopinavir,Pol polyprotein,pol,10.4,Ki,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
methscopolamine,Muscarinic acetylcholine receptor M3,CHRM3,10.4,Ki,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
nortriptyline,Alpha-1A adrenergic receptor,Adra1a,10.4,IC50,CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
paroxetine,Sodium-dependent serotonin transporter,SLC6A4,10.4,Ki,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
saquinavir,Pol polyprotein,pol,10.4,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
saquinavir,Protease,protease,10.4,Ki,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
zolmitriptan,D(2) dopamine receptor,Drd2,10.4,Kd,CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2
prazosin,Alpha-1A adrenergic receptor,ADRA1A,10.4,Ki,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
plerixafor,C-C chemokine receptor type 2,CCR2,10.4,IC50,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
grazoprevir,NS3,NS3,10.4,Ki,COC1=CC2=C(C=C1)N=C1CCCCC[C@@H]3C[C@H]3OC(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)OC1=N2)C(C)(C)C
dasatinib,Ephrin type-B receptor 6,EPHB6,10.41,Kd,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
voxilaprevir,Genome polyprotein,,10.42,Ki,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=NC3=CC=C(OC)C=C3N=C1O2)C(C)(C)C
velpatasvir,Genome polyprotein,,10.426,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
amprenavir,Protease,protease,10.44,Ki,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
silodosin,Alpha-1A adrenergic receptor,ADRA1A,10.44,Ki,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
ruxolitinib,Tyrosine-protein kinase JAK2,JAK2,10.44,Kd,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
cabozantinib,Vascular endothelial growth factor receptor 2,KDR,10.456,IC50,COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC
somatostatin,Somatostatin receptor type 2,SSTR2,10.46,Ki,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
ritonavir,Protease,protease,10.47,Ki,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
drospirenone,Mineralocorticoid receptor,NR3C2,10.5,IC50,C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1
drospirenone,Progesterone receptor,PGR,10.5,EC50,C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1
palonosetron,5-hydroxytryptamine receptor 3A,HTR3A,10.5,Ki,O=C1N(C[C@H]2CCCC3=CC=CC1=C23)[C@@H]1CN2CCC1CC2
ledipasvir,Genome polyprotein,,10.509,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC2=C(NC(=N2)[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
glucagon,Glucagon-like peptide 1 receptor,GLP1R,10.51,EC50,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
ledipasvir,Nonstructural protein 5A,NS5A,10.51,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC2=C(NC(=N2)[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
ledipasvir,Nonstructural protein 5A,NS5A,10.51,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC2=C(NC(=N2)[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
amprenavir,Protease,HIV-1 protease,10.52,Ki,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
buserelin,Gonadotropin-releasing hormone receptor,GNRHR,10.52,EC50,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
mosapramine,D(4) dopamine receptor,DRD4,10.52,Ki,ClC1=CC=C2CCC3=C(C=CC=C3)N(CCCN3CCC4(CC3)N3CCCCC3NC4=O)C2=C1
mosapramine,D(4) dopamine receptor,DRD4,10.52,Ki,ClC1=CC=C2CCC3=C(C=CC=C3)N(CCCN3CCC4(CC3)N3CCCCC3NC4=O)C2=C1
tamsulosin,Alpha-1A adrenergic receptor,Adra1a,10.52,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
laropiprant,Prostaglandin D2 receptor,PTGDR,10.52,Kd,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
lopinavir,Protease,HIV-1 protease,10.54,Ki,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
tamsulosin,Alpha-1A adrenergic receptor,ADRA1A,10.54,Ki,CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1
bosutinib,Tyrosine-protein kinase ABL1,ABL1,10.54,Kd,COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl
rimegepant,Calcitonin gene-related peptide type 1 receptor,CALCRL,10.56,Ki,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N2C(=O)NC3=NC=CC=C23)C2=NC=CC=C12)C1=C(F)C(F)=CC=C1
benperidol,D(2) dopamine receptor,DRD2,10.57,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2
lopinavir,Protease,HIV-1 protease,10.59,Ki,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
calcitriol,Vitamin D3 receptor,VDR,10.6,Ki,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
duvelisib,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",PIK3CD,10.638,Kd,C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=C(C(Cl)=CC=C2)C(=O)N1C1=CC=CC=C1
daclatasvir,Nonstructural protein 5A,NS5A,10.64,IC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C
daclatasvir,Nonstructural protein 5A,NS5A,10.64,IC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C
forodesine,Purine nucleoside phosphorylase,PNP,10.64,Ki,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1NC=NC2=O
methotrexate,Dihydrofolate reductase,dfrA17,10.68,Ki,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
sorafenib,Vascular endothelial growth factor receptor 2,KDR,10.68,Ki,CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
octreotide,Somatostatin receptor type 2,SSTR2,10.699,EC50,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
amitriptyline,Alpha-1A adrenergic receptor,Adra1a,10.7,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
amitriptyline,Histamine H1 receptor,Hrh1,10.7,IC50,CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2
aprepitant,Substance-P receptor,TACR1,10.7,Ki,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
nafamostat,Suppressor of tumorigenicity 14 protein,ST14,10.7,Ki,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
sufentanil,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,10.7,Ki,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
elbasvir,Nonstructural protein 5A,NS5A,10.7,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=CC(=CC=C3C1=C2)C1=CNC(=N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=CC=CC=C1
elbasvir,Nonstructural protein 5A,NS5A,10.7,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=CC(=CC=C3C1=C2)C1=CNC(=N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=CC=CC=C1
thyropropic acid,Thyroid hormone receptor beta,THRB,10.72,IC50,OC(=O)CCC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1
fluticasone propionate,Glucocorticoid receptor,NR3C1,10.74,EC50,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF
velpatasvir,Genome polyprotein,,10.796,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
pentostatin,Adenosine deaminase,ADA,10.8,IC50,OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1NC=NC[C@H]2O
dexmedetomidine,Alpha-1D adrenergic receptor,ADRA1D,10.82,Ki,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
dexmedetomidine,Alpha-2A adrenergic receptor,Adra2a,10.82,Ki,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
dexmedetomidine,Adrenergic receptor alpha-2,Adra2b|Adra2c|Adra2a,10.82,Ki,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
ritonavir,Pol polyprotein,pol,10.82,Ki,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
spiperone,D(2) dopamine receptor,Drd2,10.82,Ki,FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1
darunavir,Protease,HIV-1 protease,10.82,Ki,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1
darunavir,Pol polyprotein,pol,10.85,Ki,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1
ombitasvir,Nonstructural protein 5A,NS5A,10.85,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
ombitasvir,Genome polyprotein,,10.854,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
velpatasvir,Genome polyprotein,,10.854,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
oxymorphone,Opioid receptor,Oprd1|Oprm1|Oprk1|Sigmar1,10.89,IC50,CN1CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
ramelteon,Melatonin receptor type 1A,MTNR1A,10.9,Ki,CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2
ombitasvir,Genome polyprotein [Cleaved into: Core protein p21,,10.92,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
darunavir,Protease,HIV-1 protease,10.96,Ki,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1
velpatasvir,Genome polyprotein,,10.979,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
prazosin,Adrenergic receptor alpha-1,Adra1b|Adra1d|Adra1a,10.99,Kd,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
desoxycortone,Mineralocorticoid receptor,NR3C2,11,IC50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO
desoxycorticosterone pivalate,Mineralocorticoid receptor,NR3C2,11,EC50,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
doxepin,Alpha-1A adrenergic receptor,Adra1a,11,IC50,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
flufenamic acid,Nicotinate phosphoribosyltransferase,NAPRT,11,Ki,OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1
nelfinavir,Pol polyprotein,pol,11,Ki,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
nicotine,Neuronal acetylcholine receptor,Chrna3|Chrna4|Chrna2|Chrnb2|Chrnb3|Chrnb4|Chrna5|Chrna1|Chrnb1|Chrna6|Chrna9|Chrna7|Chrna10,11,Kd,CN1CCC[C@H]1C1=CC=CN=C1
pentostatin,Adenosine deaminase,ADA,11,Ki,OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1NC=NC[C@H]2O
progesterone,Mineralocorticoid receptor,NR3C2,11,EC50,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
tiotropium bromide,Muscarinic acetylcholine receptor M1,CHRM1,11,Ki,C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
tiotropium bromide,Muscarinic acetylcholine receptor M2,CHRM2,11,Ki,C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
tiotropium bromide,Muscarinic acetylcholine receptor M4,CHRM4,11,Ki,C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
tiotropium bromide,Muscarinic acetylcholine receptor M5,CHRM5,11,Ki,C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
afamelanotide,Melanocyte-stimulating hormone receptor,Mc1r,11,EC50,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
venetoclax,Apoptosis regulator Bcl-2,BCL2,11,Ki,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CC4=C(NC=C4)N=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC(=C(NCC3CCOCC3)C=C2)[N+]([O-])=O)=C(C1)C1=CC=C(Cl)C=C1
velpatasvir,Nonstructural protein 5A,NS5A,11,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
velpatasvir,Nonstructural protein 5A,NS5A,11,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
dasiglucagon,Glucagon receptor,GCGR,11,EC50,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O
daclatasvir,Genome polyprotein,,11.046,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C
velpatasvir,Genome polyprotein,,11.046,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
calcitonin (salmon synthetic),Calcitonin receptor,CALCR,11.086,EC50,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O
velpatasvir,Genome polyprotein,,11.097,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
tiotropium bromide,Muscarinic acetylcholine receptor M3,CHRM3,11.1,Ki,C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
norethisterone,Progesterone receptor,PGR,11.26,ED50,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
norethindrone acetate,Progesterone receptor,PGR,11.26,ED50,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
ombitasvir,Genome polyprotein,,11.301,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
ledipasvir,Genome polyprotein,,11.398,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC2=C(NC(=N2)[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
elbasvir,Genome polyprotein,,11.398,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=CC(=CC=C3C1=C2)C1=CNC(=N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=CC=CC=C1
velpatasvir,Genome polyprotein,,11.398,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
velpatasvir,Genome polyprotein,,11.398,EC50,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC(=CN1)C1=CC2=C(C=C1)C1=C(OC2)C=C2C3=C(C=CC2=C1)N=C(N3)[C@@H]1CC[C@H](C)N1C(=O)[C@@H](NC(=O)OC)C(C)C
elbasvir,Genome polyprotein,,11.523,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=CC(=CC=C3C1=C2)C1=CNC(=N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=CC=CC=C1
grazoprevir,Genome polyprotein,,12.301,EC50,COC1=CC2=C(C=C1)N=C1CCCCC[C@@H]3C[C@H]3OC(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)OC1=N2)C(C)(C)C
grazoprevir,Genome polyprotein,,12.398,EC50,COC1=CC2=C(C=C1)N=C1CCCCC[C@@H]3C[C@H]3OC(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)OC1=N2)C(C)(C)C
elbasvir,Genome polyprotein,,12.523,EC50,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=CC(=CC=C3C1=C2)C1=CNC(=N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=CC=CC=C1
grazoprevir,Genome polyprotein,,12.523,EC50,COC1=CC2=C(C=C1)N=C1CCCCC[C@@H]3C[C@H]3OC(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)OC1=N2)C(C)(C)C
levonorgestrel,Progesterone receptor,PGR,12.796,ED50,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
levobupivacaine,Sodium channel protein type 4 subunit alpha,SCN4A,,,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
levobupivacaine,Prostaglandin E2 receptor EP1 subtype,PTGER1,,,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
levobupivacaine,5-hydroxytryptamine receptor 3A,HTR3A,,,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
levobupivacaine,Potassium voltage-gated channel subfamily A member 5,KCNA5,,,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
(S)-nicardipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
(S)-nitrendipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
levdobutamine,Beta-1 adrenergic receptor,ADRB1,,,C[C@@H](CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1
azacitidine,DNA (cytosine-5)-methyltransferase 3A,DNMT3A,,,NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
fluorouracil,Thymidylate synthase,TYMS,,,FC1=CNC(=O)NC1=O
fluorouracil,Multidrug resistance-associated protein 5,ABCC5,,,FC1=CNC(=O)NC1=O
fluorouracil,ATP-binding cassette sub-family C member 11,ABCC11,,,FC1=CNC(=O)NC1=O
acamprosate,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CC(=O)NCCCS(O)(=O)=O
acamprosate,Glutamate [NMDA] receptor,GRIN2D|GRIN3B|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN3A,,,CC(=O)NCCCS(O)(=O)=O
acarbose,Pancreatic alpha-amylase,AMY2A,,,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
aceclofenac,Prostaglandin G/H synthase 2,PTGS2,,,OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
acemetacin,Prostaglandin G/H synthase 2,PTGS2,,,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O
acemetacin,Prostaglandin G/H synthase 1,PTGS1,,,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O
aceprometazine,Histamine H1 receptor,HRH1,,,CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O)N(C)C
paracetamol,Transient receptor potential cation channel subfamily V member 1,TRPV1,,,CC(=O)NC1=CC=C(O)C=C1
paracetamol,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,CC(=O)NC1=CC=C(O)C=C1
paracetamol,Cannabinoid receptor 1,CNR1,,,CC(=O)NC1=CC=C(O)C=C1
acetazolamide,Aquaporin-1,AQP1,,,CC(=O)NC1=NN=C(S1)S(N)(=O)=O
acetohydroxamic acid,Bacterial urease,ureA|ureB|ureC,,,CC(=O)NO
acetophenazine,D(2) dopamine receptor,DRD2,,,CC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(CCO)CC3)C2=C1
acetylcysteine,Cytochrome c,CYCS,,,CC(=O)N[C@@H](CS)C(O)=O
acetylcysteine,Vascular endothelial growth factor A,VEGFA,,,CC(=O)N[C@@H](CS)C(O)=O
acetylcysteine,"Superoxide dismutase [Mn], mitochondrial",SOD2,,,CC(=O)N[C@@H](CS)C(O)=O
acetylcysteine,Glutathione synthetase,GSS,,,CC(=O)N[C@@H](CS)C(O)=O
acetylcysteine,Cystine/glutamate transporter,SLC7A11,,,CC(=O)N[C@@H](CS)C(O)=O
acetyldigitoxin,Sodium/potassium-transporting ATPase,ATP1A1|ATP1B1|ATP1A3|ATP1B2|ATP1A2|ATP1B3|FXYD2|ATP1A4,,,C[C@H]1O[C@H](C[C@H](OC(C)=O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
acepromazine,D(1A) dopamine receptor,DRD1,,,CN(C)CCCN1C2=CC=CC=C2SC2=CC=C(C=C12)C(C)=O
acepromazine,D(2) dopamine receptor,DRD2,,,CN(C)CCCN1C2=CC=CC=C2SC2=CC=C(C=C12)C(C)=O
acitretin,Retinoic acid receptor alpha,RARA,,,COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
acitretin,Retinoic acid receptor gamma,RARG,,,COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
aclarubicin,DNA topoisomerase 1,TOP1,,,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C2=C(O)C3=C(C=C2[C@H]1C(=O)OC)C(=O)C1=CC=CC(O)=C1C3=O
aclarubicin,DNA topoisomerase II,TOP2A|TOP2B,,,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C2=C(O)C3=C(C=C2[C@H]1C(=O)OC)C(=O)C1=CC=CC(O)=C1C3=O
aclatonium,Muscarinic acetylcholine receptor,CHRM2|CHRM4|CHRM5|CHRM1|CHRM3,,,CC(OC(C)=O)C(=O)OCC[N+](C)(C)C
acrivastine,Multidrug resistance protein 1,ABCB1,,,CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC(\C=C\C(O)=O)=N1
acyclovir,Thymidine kinase,,,,NC1=NC2=C(N=CN2COCCO)C(=O)N1
acyclovir,DNA polymerase catalytic subunit,,,,NC1=NC2=C(N=CN2COCCO)C(=O)N1
acyclovir,DNA polymerase catalytic subunit,,,,NC1=NC2=C(N=CN2COCCO)C(=O)N1
acyclovir,Thymidine kinase,TK,,,NC1=NC2=C(N=CN2COCCO)C(=O)N1
acyclovir,Thymidine kinase,TK,,,NC1=NC2=C(N=CN2COCCO)C(=O)N1
adefovir dipivoxil,Protein P,P,,,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
adefovir dipivoxil,DNA polymerase subunit gamma-1,POLG,,,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
adinazolam,GABA-A receptor,GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRA6|GABRG1|GABRG3,,,CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12
ajmaline,Sodium channel protein type 5 subunit alpha,SCN5A,,,CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H]([C@H]2[C@H]4O)N3[C@@H]1O
alacepril,Angiotensin-converting enzyme,ACE,,,C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
alatrofloxacin,Topoisomerase IV,parC|parE,,,C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]1[C@H]2CN(C[C@@H]12)C1=C(F)C=C2C(=O)C(=CN(C3=C(F)C=C(F)C=C3)C2=N1)C(O)=O
alatrofloxacin,DNA gyrase,gyrA|gyrB,,,C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]1[C@H]2CN(C[C@@H]12)C1=C(F)C=C2C(=O)C(=CN(C3=C(F)C=C(F)C=C3)C2=N1)C(O)=O
albendazole,Tubulin alpha chain,,,,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
albendazole,Tubulin,,,,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
albendazole,Tubulin,,,,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
albendazole sulfoxide,Tubulin alpha chain,,,,CCCS(=O)C1=CC=C2N=C(NC(=O)OC)NC2=C1
alclofenac,Prostaglandin G/H synthase 2,PTGS2,,,OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1
alclofenac,Prostaglandin G/H synthase 1,PTGS1,,,OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1
alcuronium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,,,OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C1=CN2[C@H]5C(=CN([C@H]31)C1=CC=CC=C41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C\CO)C1=CC=CC=C21
allopurinol,Hypoxanthine-guanine phosphoribosyltransferase,HPRT1,,,OC1=NC=NC2=C1C=NN2
alfacalcidol,Vitamin D3 receptor,VDR,,,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
alfaxalone,Sodium- and chloride-dependent GABA transporter 1,SLC6A1,,,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
alpidem,Gamma-aminobutyric acid receptor subunit alpha-1,GABRA1,,,CCCN(CCC)C(=O)CC1=C(N=C2C=CC(Cl)=CN12)C1=CC=C(Cl)C=C1
ambenonium,Acetylcholinesterase,ACHE,,,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC1=C(Cl)C=CC=C1
ambroxol,Sodium channel protein type 10 subunit alpha,SCN10A,,,NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br
amcinonide,Glucocorticoid receptor,NR3C1,,,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C
amifostine,"Alkaline phosphatase, tissue-nonspecific isozyme",ALPL,,,NCCCNCCSP(O)(O)=O
aminocaproic acid,Tissue-type plasminogen activator,PLAT,,,NCCCCCC(O)=O
aminoglutethimide,"Cholesterol side-chain cleavage enzyme, mitochondrial",CYP11A1,,,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1
aminophenazone,Prostaglandin G/H synthase 2,PTGS2,,,CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1
aminophenazone,Prostaglandin G/H synthase 1,PTGS1,,,CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1
amlexanox,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,,,CC(C)C1=CC=C2OC3=C(C=C(C(O)=O)C(N)=N3)C(=O)C2=C1
amlodipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
amlodipine,Carbonic anhydrase 1,CA1,,,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=C(Cl)C=CC=C1)C(=O)OC
amoxapine,Multidrug resistance protein 1,ABCB1,,,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
amoxapine,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1
amoxicillin,Penicillin-binding protein 1A,pbpA,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O
amoxicillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O
amfetamine,Alpha-2A adrenergic receptor,ADRA2A,,,CC(N)CC1=CC=CC=C1
amfetamine,Sodium-dependent noradrenaline transporter,SLC6A2,,,CC(N)CC1=CC=CC=C1
amfetamine,Alpha-1A adrenergic receptor,ADRA1A,,,CC(N)CC1=CC=CC=C1
amfetamine,Cocaine- and amphetamine-regulated transcript protein,CARTPT,,,CC(N)CC1=CC=CC=C1
ampicillin,Penicillin-binding protein 1A,pbpA,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
ampicillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
amprenavir,Gag-Pol polyprotein,gag-pol,,,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
androisoxazole,Androgen receptor,AR,,,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=NOC=C5C[C@]4(C)[C@H]3CC[C@]12C
anecortave,Plasminogen activator inhibitor 1,SERPINE1,,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C
anhydrovinblastine,Multidrug resistance protein 1,ABCB1,,,CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
anhydrovinblastine,Canalicular multispecific organic anion transporter 1,ABCC2,,,CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
anhydrovinblastine,Multidrug resistance-associated protein 1,ABCC1,,,CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
anhydrovinblastine,Multidrug resistance-associated protein 7,ABCC10,,,CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
anhydrovinblastine,Tubulin beta-4B chain,TUBB4B,,,CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
anileridine,Mu-type opioid receptor,OPRM1,,,CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1
anisindione,Vitamin K-dependent gamma-carboxylase,GGCX,,,COC1=CC=C(C=C1)C1C(=O)C2=C(C=CC=C2)C1=O
octatropine methylbromide,Muscarinic acetylcholine receptor M1,CHRM1,,,CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C
octatropine methylbromide,Muscarinic acetylcholine receptor M3,CHRM3,,,CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C
antazoline,Histamine H1 receptor,HRH1,,,C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1
dithranol,"Arachidonate 12-lipoxygenase, 12R-type",ALOX12B,,,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2
aprepitant,Cytochrome P450 3A4,CYP3A4,,,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
aprindine,Sodium channel protein type 5 subunit alpha,SCN5A,,,CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1
aprindine,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1
aranidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)=O
arbutamine,Beta-1 adrenergic receptor,ADRB1,,,O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1
arsenic trioxide,"Thioredoxin reductase 1, cytoplasmic",TXNRD1,,,O=[As]O[As]=O
astemizole,ATP-binding cassette sub-family G member 2,ABCG2,,,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1
asulacrine,DNA topoisomerase 2-alpha,TOP2A,,,CNC(=O)C1=CC=CC2=C(NC3=C(OC)C=C(NS(C)(=O)=O)C=C3)C3=CC=CC(C)=C3N=C12
atorvastatin,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
atovaquone,"Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial",,,,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O
atovaquone,Cytochrome b,MT-CYB,,,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O
atracurium,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,,,COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1
azapropazone,Prostaglandin G/H synthase 1,PTGS1,,,CCCC1C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C
azapropazone,Xanthine dehydrogenase/oxidase,XDH,,,CCCC1C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C
azatadine,Histamine H1 receptor,HRH1,,,CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2
azathioprine,ATP-binding cassette sub-family G member 2,ABCG2,,,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O
azathioprine,Multidrug resistance-associated protein 5,ABCC5,,,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O
azathioprine,Multidrug resistance-associated protein 4,ABCC4,,,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O
azathioprine,Ras-related C3 botulinum toxin substrate 1,RAC1,,,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O
azathioprine,Thiopurine S-methyltransferase,TPMT,,,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O
azelaic acid,3-oxo-5-alpha-steroid 4-dehydrogenase 2,SRD5A2,,,OC(=O)CCCCCCCC(O)=O
azelastine,Multidrug resistance protein 1,ABCB1,,,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O
azelnidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,CC(C)OC(=O)C1=C(C)NC(N)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC1CN(C1)C(C1=CC=CC=C1)C1=CC=CC=C1
azlocillin,Penicillin-binding protein,mrcA|pbpB|pbpC|pbpA|dacA|ponB,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
bacampicillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)C1=CC=CC=C1)C2=O
balsalazide,Prostaglandin G/H synthase 2,PTGS2,,,OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O
balsalazide,Prostaglandin G/H synthase 1,PTGS1,,,OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O
balsalazide,Arachidonate 5-lipoxygenase,ALOX5,,,OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O
balsalazide,Peroxisome proliferator-activated receptor gamma,PPARG,,,OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O
bambuterol,Beta-2 adrenergic receptor,ADRB2,,,CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C
bamipine,Histamine H1 receptor,HRH1,,,CN1CCC(CC1)N(CC1=CC=CC=C1)C1=CC=CC=C1
barnidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@H]1CCN(CC2=CC=CC=C2)C1
bendroflumethiazide,Carbonic anhydrase 2,CA2,,,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F
bendroflumethiazide,Carbonic anhydrase 1,CA1,,,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F
bendroflumethiazide,Carbonic anhydrase 4,CA4,,,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F
bendroflumethiazide,Calcium-activated potassium channel subunit alpha-1,KCNMA1,,,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F
benoxaprofen,Arachidonate 5-lipoxygenase,ALOX5,,,CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1
benserazide,Aromatic-L-amino-acid decarboxylase,DDC,,,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
benzocaine,Sodium channel protein type 1 subunit alpha,SCN1A,,,CCOC(=O)C1=CC=C(N)C=C1
benzocaine,Sodium channel protein type 2 subunit alpha,SCN2A,,,CCOC(=O)C1=CC=C(N)C=C1
benzocaine,Sodium channel protein type 3 subunit alpha,SCN3A,,,CCOC(=O)C1=CC=C(N)C=C1
benzocaine,Sodium channel protein type 4 subunit alpha,SCN4A,,,CCOC(=O)C1=CC=C(N)C=C1
benzocaine,Sodium channel protein type 8 subunit alpha,SCN8A,,,CCOC(=O)C1=CC=C(N)C=C1
benzocaine,Sodium channel protein type 9 subunit alpha,SCN9A,,,CCOC(=O)C1=CC=C(N)C=C1
benzocaine,Sodium channel protein type 11 subunit alpha,SCN11A,,,CCOC(=O)C1=CC=C(N)C=C1
benzocaine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCOC(=O)C1=CC=C(N)C=C1
benzocaine,Sodium channel protein type 7 subunit alpha,SCN7A,,,CCOC(=O)C1=CC=C(N)C=C1
benzphetamine,Alpha-2A adrenergic receptor,ADRA2A,,,C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1
benzphetamine,Sodium-dependent noradrenaline transporter,SLC6A2,,,C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1
benzphetamine,Alpha-1A adrenergic receptor,ADRA1A,,,C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1
benzphetamine,Synaptic vesicular amine transporter,SLC18A2,,,C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1
benzthiazide,Carbonic anhydrase 2,CA2,,,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O
benzthiazide,Carbonic anhydrase 1,CA1,,,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O
benzthiazide,Carbonic anhydrase 4,CA4,,,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O
benzthiazide,Calcium-activated potassium channel subunit alpha-1,KCNMA1,,,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O
bepotastine,Histamine H1 receptor,HRH1,,,OC(=O)CCCN1CCC(CC1)O[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
bepridil,Sodium channel protein type 5 subunit alpha,SCN5A,,,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
bepridil,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
bepridil,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
betamethasone,Annexin A1,ANXA1,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
betamethasone acetate,Glucocorticoid receptor,NR3C1,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O
betamethasone benzoate,Glucocorticoid receptor,NR3C1,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CC=C1)C(=O)CO
betamethasone dipropionate,Glucocorticoid receptor,NR3C1,,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
betamethasone valerate,Glucocorticoid receptor,NR3C1,,,CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
betazole,Histamine H2 receptor,HRH2,,,NCCC1=NNC=C1
betanidine,Sodium-dependent noradrenaline transporter,SLC6A2,,,CNC(NC)=NCC1=CC=CC=C1
bevantolol,Beta-1 adrenergic receptor,ADRB1,,,COC1=C(OC)C=C(CCNCC(O)COC2=CC(C)=CC=C2)C=C1
bezafibrate,Lipoprotein lipase,LPL,,,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
bezafibrate,3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,,,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
biapenem,Penicillin-binding protein 2,pbpA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N+]4C3)=C(N2C1=O)C([O-])=O
biapenem,Penicillin-binding protein 4,,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N+]4C3)=C(N2C1=O)C([O-])=O
biapenem,D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5,dacA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N+]4C3)=C(N2C1=O)C([O-])=O
biapenem,Penicillin-binding protein 1,ponA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N+]4C3)=C(N2C1=O)C([O-])=O
biapenem,D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6,dacC,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N+]4C3)=C(N2C1=O)C([O-])=O
biperiden,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,,,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
bisulepine,Histamine H1 receptor,HRH1,,,CN(C)CC\C=C1/C2=C(SC=C2)SCC2=C1C=CC=C2
bitolterol,Beta-2 adrenergic receptor,ADRB2,,,CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C
bosentan,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1
bretylium,Beta-1 adrenergic receptor,ADRB1,,,CC[N+](C)(C)CC1=C(Br)C=CC=C1
bretylium,Beta-2 adrenergic receptor,ADRB2,,,CC[N+](C)(C)CC1=C(Br)C=CC=C1
bretylium,Sodium-dependent noradrenaline transporter,SLC6A2,,,CC[N+](C)(C)CC1=C(Br)C=CC=C1
bromazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,BrC1=CC=C2NC(=O)CN=C(C3=CC=CC=N3)C2=C1
buclizine,Histamine H1 receptor,HRH1,,,CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1
budesonide,Multidrug resistance protein 1,ABCB1,,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
buflomedil,Alpha-2A adrenergic receptor,ADRA2A,,,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
buflomedil,Alpha-1A adrenergic receptor,ADRA1A,,,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
buflomedil,Alpha-2C adrenergic receptor,ADRA2C,,,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
buflomedil,Alpha-1D adrenergic receptor,ADRA1D,,,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
buflomedil,Alpha-1B adrenergic receptor,ADRA1B,,,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
buflomedil,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,,,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
bufuralol,Multidrug resistance protein 1,ABCB1,,,CCC1=CC=CC2=C1OC(=C2)C(O)CNC(C)(C)C
bunazosin,Alpha-1A adrenergic receptor,ADRA1A,,,CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1
bunazosin,Alpha-2B adrenergic receptor,ADRA2B,,,CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1
bunazosin,Alpha-1B adrenergic receptor,ADRA1B,,,CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1
bunazosin,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,,CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1
bupropion,Cytochrome P450 2D6,CYP2D6,,,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
secbutabarbital,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CCC(C)C1(CC)C(=O)NC(=O)NC1=O
butalbital,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O
butenafine,Squalene epoxidase,,,,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
butoconazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=CC=C(CCC(CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1
scopolamine butylbromide,Muscarinic acetylcholine receptor M1,CHRM1,,,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
scopolamine butylbromide,Muscarinic acetylcholine receptor M2,CHRM2,,,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
scopolamine butylbromide,Muscarinic acetylcholine receptor M3,CHRM3,,,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
scopolamine butylbromide,Muscarinic acetylcholine receptor M4,CHRM4,,,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
cadralazine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,CCOC(=O)NNC1=CC=C(N=N1)N(CC)CC(C)O
calcifediol,Vitamin D3 receptor,VDR,,,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
calcitriol,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial",CYP27B1,,,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
calcitriol,Vitamin D 25-hydroxylase,CYP2R1,,,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
capecitabine,Thymidylate synthase,TYMS,,,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
carbamazepine,Sodium channel protein type 5 subunit alpha,SCN5A,,,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
carbamazepine,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
carbamazepine,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2
carbenicillin,Penicillin-binding protein 1A,pbpA,,,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
carbenicillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
carbidopa,Aromatic-L-amino-acid decarboxylase,DDC,,,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
carbimazole,Thyroid peroxidase,TPO,,,CCOC(=O)N1C=CN(C)C1=S
carbinoxamine,Histamine H1 receptor,HRH1,,,CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
carboprost,Prostaglandin F2-alpha receptor,PTGFR,,,CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
carindacillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)OC3=CC4=C(CCC4)C=C3)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
carubicin,DNA topoisomerase 2-alpha,TOP2A,,,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=C(O)C=CC=C3C(=O)C1=C2O)C(C)=O
levocarnitine,"Carnitine O-palmitoyltransferase 1, liver isoform",CPT1A,,,C[N+](C)(C)C[C@H](O)CC([O-])=O
carfenazine,D(2) dopamine receptor,DRD2,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(CCO)CC3)C2=C1
carfenazine,5-hydroxytryptamine receptor 2A,HTR2A,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(CCO)CC3)C2=C1
carumonam,Peptidoglycan synthase FtsI,ftsI,,,NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
cefacetrile,Penicillin-binding protein 1A,pbpA,,,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC#N)C2=O)C(O)=O
cefaclor,Penicillin-binding protein 1A,pbpA,,,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
cefaclor,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
cefadroxil,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=C(O)C=C1)C2=O)C(O)=O
cefamandole nafate,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)C1=CC=CC=C1)C2=O)C(O)=O
cefazolin,Penicillin-binding protein 1A,pbpA,,,CC1=NN=C(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CN2C=NN=N2)C3=O)C(O)=O)S1
cefazolin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1=NN=C(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CN2C=NN=N2)C3=O)C(O)=O)S1
cefdinir,"Pencillin binding protein 2a; Penicillin binding protein 2'; Penicillin binding protein, PBP2; Penicillin-binding protein 2; Penicillin-binding protein 2'; Peptidase",mecA,,,NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
cefdinir,Penicillin-binding protein 3,pbp3,,,NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
cefdinir,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
cefditoren pivoxil,Penicillin-binding protein 3,pbp3,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/C3=C(C)N=CS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1=CSC(N)=N1
cefditoren pivoxil,Penicillin-binding protein,dacA,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/C3=C(C)N=CS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1=CSC(N)=N1
cefditoren pivoxil,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/C3=C(C)N=CS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1=CSC(N)=N1
cefepime,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1
cefetamet pivoxil,Penicillin-binding protein 3,pbpC,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1=CSC(N)=N1
cefetamet pivoxil,Penicillin-binding protein 1,ponA,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1=CSC(N)=N1
cefixime,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,NC1=NC(=CS1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
cefmenoxime,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
cefmetazole,Penicillin-binding protein 1A,pbpA,,,CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
cefmetazole,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
cefonicid,Penicillin-binding protein 1A,pbpA,,,O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
cefonicid,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
cefoperazone,Penicillin-binding protein 1A,pbpA,,,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C2=CC=C(O)C=C2)C(=O)C1=O
cefoperazone,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C2=CC=C(O)C=C2)C(=O)C1=O
ceforanide,Penicillin-binding protein 1A,pbpA,,,NCC1=C(CC(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4CC(O)=O)=C(N3C2=O)C(O)=O)C=CC=C1
ceforanide,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,NCC1=C(CC(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4CC(O)=O)=C(N3C2=O)C(O)=O)C=CC=C1
cefotetan,Penicillin-binding protein 1A,pbpA,,,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
cefotetan,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O
cefotiam,Penicillin-binding protein 1A,pbpA,,,CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
cefotiam,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
cefoxitin,Penicillin-binding protein 1A,pbpA,,,CO[C@]1(NC(=O)CC2=CC=CS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O
cefoxitin,Beta-lactamase,penP,,,CO[C@]1(NC(=O)CC2=CC=CS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O
cefoxitin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO[C@]1(NC(=O)CC2=CC=CS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O
cefpiramide,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](NC(=O)C1=CN=C(C)C=C1O)C1=CC=C(O)C=C1)C2=O)C(O)=O
cefprozil,Penicillin-binding protein 1A,pbpA,,,C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=C(O)C=C1)C2=O)C(O)=O
ceftibuten,Penicillin-binding protein,,,,NC1=NC(=CS1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O
ceftibuten,Penicillin-binding protein 3,pbp3,,,NC1=NC(=CS1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O
ceftibuten,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,NC1=NC(=CS1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O
ceftizoxime,Penicillin-binding protein 1A,pbpA,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
ceftizoxime,Beta-lactamase,penP,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
ceftizoxime,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)C1=CSC(N)=N1
cefuroxime,Penicillin-binding protein 1A,pbpA,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C1=CC=CO1
cefuroxime,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C1=CC=CO1
cefuroxime axetil,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)C1=CC=CO1
cefalexin,Penicillin-binding protein 3,pbpC,,,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=CC=C1)C2=O)C(O)=O
cefalexin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=CC=C1)C2=O)C(O)=O
cefaloglycin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=CC=C1)C2=O)C(O)=O
cefalotin,Penicillin-binding protein 1A,pbpA,,,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O
cefalotin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O
cefapirin,Penicillin-binding protein 1A,pbpA,,,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
cefapirin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O
cefradine,Penicillin-binding protein 1A,pbpA,,,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O
cefradine,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O
cerivastatin,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(N=C1C(C)C)C(C)C
ceruletide,Cholecystokinin receptor type A,CCKAR,,,CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
cetrorelix,Lutropin-choriogonadotropic hormone receptor,LHCGR,,,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
clomethiazole,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CC1=C(CCCl)SC=N1
chloroprocaine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1
chlorothiazide,Carbonic anhydrase 2,CA2,,,NS(=O)(=O)C1=C(Cl)C=C2N=CNS(=O)(=O)C2=C1
chlorotrianisene,Estrogen receptor,ESR1,,,COC1=CC=C(C=C1)C(Cl)=C(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1
chlorotrianisene,Estrogen receptor beta,ESR2,,,COC1=CC=C(C=C1)C(Cl)=C(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1
chlortetracycline,Major prion protein,PRNP,,,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)C1=C(C(Cl)=CC=C1O)[C@@]3(C)O
chlortalidone,Solute carrier family 12 member 3,SLC12A3,,,NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12
cibenzoline,ATP-sensitive inward rectifier potassium channel 11,KCNJ11,,,C1C(C2=NCCN2)C1(C1=CC=CC=C1)C1=CC=CC=C1
cyclacillin,Penicillin-binding protein 1A,pbpA,,,CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(O)=O
cyclacillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(O)=O
cidofovir,DNA polymerase catalytic subunit,,,,NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1
cilnidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1
cinalukast,Cysteinyl leukotriene receptor 1,CYSLTR1,,,CCC(CC)(CC(=O)NC1=CC=CC(\C=C\C2=NC(=CS2)C2CCC2)=C1)C(O)=O
cinoxacin,DNA gyrase,gyrA|gyrB,,,CCN1N=C(C(O)=O)C(=O)C2=C1C=C1OCOC1=C2
cladribine,Deoxycytidine kinase,DCK,,,NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1
clevidipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
clevidipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
clidinium,Muscarinic acetylcholine receptor M1,CHRM1,,,C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
clindamycin,50S ribosomal protein L10,rpl10,,,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
clobazam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CN1C2=CC=C(Cl)C=C2N(C2=CC=CC=C2)C(=O)CC1=O
clodronic acid,ADP/ATP translocase 2,SLC25A5,,,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O
clodronic acid,ADP/ATP translocase 1,SLC25A4,,,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O
clodronic acid,ADP/ATP translocase 3,SLC25A6,,,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O
clodronic acid,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O
clofarabine,DNA polymerase alpha catalytic subunit,POLA1,,,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1
clofarabine,Ribose-phosphate pyrophosphokinase 1,PRPS1,,,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1
clofarabine,Uridine-cytidine kinase 1,UCK1,,,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1
clofarabine,Uridine-cytidine kinase 2,UCK2,,,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1
clofazimine,Uncharacterized oxidoreductase CzcO-like,,,,CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C3=CC=CC=C3N=C2C=C1NC1=CC=C(Cl)C=C1
clofibric acid,Lipoprotein lipase,LPL,,,CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O
clomipramine,Glutathione S-transferase P,GSTP1,,,CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2
clorazepate,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,,,OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O
clorazepate,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,,,OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O
clorazepate,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,,,OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O
clotrimazole,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
clotrimazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
cloxacillin,Penicillin-binding protein 1A,pbpA,,,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1
cloxacillin,Penicillin-binding protein,pbp4|mecA|pbpA|PBP2|pbpF,,,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1
cocaine,Sodium channel protein type 5 subunit alpha,SCN5A,,,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
cocaine,Sodium channel protein type 11 subunit alpha,SCN11A,,,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
cocaine,Cocaine- and amphetamine-regulated transcript protein,CARTPT,,,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C1=CC=CC=C1)N2C
colchicine,Multidrug resistance-associated protein 1,ABCC1,,,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=CC(=O)C(OC)=CC=C23)=C1
cortisone acetate,Annexin A1,ANXA1,,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
cortivazol,Glucocorticoid receptor,NR3C1,,,C[C@@H]1C[C@H]2[C@@H]3C=C(C)C4=CC5=C(C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O)C=NN5C1=CC=CC=C1
cotinine,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,,,CN1[C@@H](CCC1=O)C1=CN=CC=C1
cromoglicic acid,Protein S100-P,S100P,,,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O
cyclizine,Amine oxidase [flavin-containing] B,MAOB,,,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
cyclopentolate,Muscarinic acetylcholine receptor M3,CHRM3,,,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
cycloserine,Alanine racemase,alr,,,N[C@@H]1CONC1=O
cycloserine,D-alanine--D-alanine ligase,ddl,,,N[C@@H]1CONC1=O
cycloserine,Alanine racemase,alr,,,N[C@@H]1CONC1=O
cyclothiazide,Solute carrier family 12 member 3,SLC12A3,,,NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C2CC3CC2C=C3)C=C1Cl
cycrimine,Muscarinic acetylcholine receptor M1,CHRM1,,,OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1
cyproheptadine,Multidrug resistance protein 1,ABCB1,,,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cyproheptadine,Calmodulin,CALM1|CALM2|CALM3,,,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2
cytarabine,DNA polymerase beta,POLB,,,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
cytarabine,DNA polymerase (alpha/delta/epsilon),POLA1|POLD1|POLE,,,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
dacarbazine,DNA polymerase alpha subunit B,POLA2,,,CN(C)\N=N\C1=C(NC=N1)C(N)=O
danazol,Androgen receptor,AR,,,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
danazol,Progesterone receptor,PGR,,,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
danazol,Steryl-sulfatase,STS,,,C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C
dantrolene,Ryanodine receptor 3,RYR3,,,[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
dapiprazole,Alpha-1A adrenergic receptor,ADRA1A,,,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
dapiprazole,Alpha-1B adrenergic receptor,ADRA1B,,,CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1
dapsone,Glucose-6-phosphate 1-dehydrogenase,G6PD,,,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
daptomycin,Outer membrane porin protein OmpD,ompD,,,CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
dasatinib,Breakpoint cluster region protein,BCR,,,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
daunorubicin,Multidrug resistance protein 1,ABCB1,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1
daunorubicin,DNA topoisomerase 2-alpha,TOP2A,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1
daunorubicin,Multidrug resistance-associated protein 1,ABCC1,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1
daunorubicin,ATP-binding cassette sub-family G member 2,ABCG2,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1
daunorubicin,Multidrug resistance-associated protein 6,ABCC6,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1
debrisoquine,Amine oxidase [flavin-containing] B,MAOB,,,NC(=N)N1CCC2=CC=CC=C2C1
debrisoquine,Amine oxidase [flavin-containing] A,MAOA,,,NC(=N)N1CCC2=CC=CC=C2C1
decamethonium,Muscle-type nicotinic acetylcholine receptor,CHRNA1|CHRNG|CHRNB1|CHRNE|CHRND,,,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
decitabine,DNA (cytosine-5)-methyltransferase 3A,DNMT3A,,,NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
demecarium,Acetylcholinesterase,ACHE,,,CN(CCCCCCCCCCN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
demeclocycline,30S ribosomal protein S4,rpsD,,,CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(Cl)C=CC(O)=C4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
demeclocycline,30S ribosomal protein S9,rpsI,,,CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(Cl)C=CC(O)=C4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
deserpidine,Synaptic vesicular amine transporter,SLC18A2,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=CC=CC=C45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1
desflurane,Potassium channel subfamily K member 2,KCNK2,,,FC(F)OC(F)C(F)(F)F
desflurane,Potassium channel subfamily K member 3,KCNK3,,,FC(F)OC(F)C(F)(F)F
desflurane,Potassium channel subfamily K member 9,KCNK9,,,FC(F)OC(F)C(F)(F)F
desflurane,Potassium channel subfamily K member 10,KCNK10,,,FC(F)OC(F)C(F)(F)F
desflurane,Potassium channel subfamily K member 18,KCNK18,,,FC(F)OC(F)C(F)(F)F
desflurane,Glycine receptor (alpha-1/beta),GLRA1|GLRB,,,FC(F)OC(F)C(F)(F)F
desflurane,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,FC(F)OC(F)C(F)(F)F
desipramine,Alpha-2B adrenergic receptor,ADRA2B,,,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
desipramine,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,,,CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2
deslanoside,Sodium/potassium-transporting ATPase,ATP1A1|ATP1B1|ATP1A3|ATP1B2|ATP1A2|ATP1B3|FXYD2|ATP1A4,,,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1
nordazepam,Gamma-aminobutyric acid receptor subunit rho-2,GABRR2,,,ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1
desogestrel,Progesterone receptor,PGR,,,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
desoximetasone,Annexin A1,ANXA1,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
desoxycorticosterone acetate,Mineralocorticoid receptor,NR3C2,,,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
dexamethasone,Annexin A1,ANXA1,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
dexamethasone acetate,Glucocorticoid receptor,NR3C1,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O
dexbrompheniramine,Histamine H1 receptor,HRH1,,,CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1
dexmethylphenidate,Sodium-dependent noradrenaline transporter,SLC6A2,,,COC(=O)[C@@H]([C@H]1CCCCN1)C1=CC=CC=C1
dexniguldipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
dexamfetamine,Alpha-2A adrenergic receptor,ADRA2A,,,C[C@H](N)CC1=CC=CC=C1
dexamfetamine,Alpha-1A adrenergic receptor,ADRA1A,,,C[C@H](N)CC1=CC=CC=C1
dexamfetamine,Cocaine- and amphetamine-regulated transcript protein,CARTPT,,,C[C@H](N)CC1=CC=CC=C1
dexamfetamine,Synaptic vesicular amine transporter,SLC18A2,,,C[C@H](N)CC1=CC=CC=C1
dextropropoxyphene,Sodium channel protein type 5 subunit alpha,SCN5A,,,CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1
dextropropoxyphene,Mu-type opioid receptor,OPRM1,,,CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1
dextrothyroxine,Thyroid hormone receptor,THRA|THRB,,,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
dezocine,Kappa-type opioid receptor,OPRK1,,,C[C@@]12CCCCC[C@@H](CC3=CC=C(O)C=C13)[C@@H]2N
cinchocaine,Sodium channel protein type 5 subunit alpha,SCN5A,,,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
cinchocaine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
dicloxacillin,Penicillin-binding protein 1A,pbpA,,,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
dicloxacillin,Penicillin-binding protein,pbp4|mecA|pbpA|PBP2|pbpF,,,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl
dienogest,Progesterone receptor,PGR,,,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N
diethylcarbamazine,Prostaglandin G/H synthase 1,PTGS1,,,CCN(CC)C(=O)N1CCN(C)CC1
diethylcarbamazine,Arachidonate 5-lipoxygenase,ALOX5,,,CCN(CC)C(=O)N1CCN(C)CC1
diethylcarbamazine,Nematode GABA-A receptor,,,,CCN(CC)C(=O)N1CCN(C)CC1
diethylpropion,Sodium-dependent noradrenaline transporter,SLC6A2,,,CCN(CC)C(C)C(=O)C1=CC=CC=C1
diethylpropion,Sodium-dependent dopamine transporter,SLC6A3,,,CCN(CC)C(C)C(=O)C1=CC=CC=C1
difenoxin,Mu-type opioid receptor,OPRM1,,,OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1
digitoxin,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
dihydrocodeine,Mu-type opioid receptor,OPRM1,,,COC1=CC=C2C[C@@H]3[C@@H]4CC[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C
dihydroergocristine,Alpha-1A adrenergic receptor,ADRA1A,,,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergocristine,5-hydroxytryptamine receptor 1D,HTR1D,,,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergocristine,Alpha-1B adrenergic receptor,ADRA1B,,,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4=CNC5=CC=CC3=C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergotamine,Alpha-1A adrenergic receptor,ADRA1A,,,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergotamine,Alpha-1B adrenergic receptor,ADRA1B,,,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
dihydroergotamine,5-hydroxytryptamine receptor 5A,HTR5A,,,CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
hydroquinidine,Sodium channel protein type 5 subunit alpha,SCN5A,,,CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12
hydroquinidine,Sodium channel subunit beta-1,SCN1B,,,CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12
hydroquinidine,Sodium channel subunit beta-2,SCN2B,,,CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12
hydroquinidine,Sodium channel subunit beta-3,SCN3B,,,CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12
hydroquinidine,Sodium channel subunit beta-4,SCN4B,,,CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12
hydroquinidine,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12
dilevalol,Beta-1 adrenergic receptor,ADRB1,,,C[C@H](CCC1=CC=CC=C1)NC[C@H](O)C1=CC(C(N)=O)=C(O)C=C1
dilevalol,Beta-2 adrenergic receptor,ADRB2,,,C[C@H](CCC1=CC=CC=C1)NC[C@H](O)C1=CC(C(N)=O)=C(O)C=C1
dilevalol,Alpha-1A adrenergic receptor,ADRA1A,,,C[C@H](CCC1=CC=CC=C1)NC[C@H](O)C1=CC(C(N)=O)=C(O)C=C1
dilevalol,Alpha-1B adrenergic receptor,ADRA1B,,,C[C@H](CCC1=CC=CC=C1)NC[C@H](O)C1=CC(C(N)=O)=C(O)C=C1
dimethyltubocurarinium,Neuronal acetylcholine receptor; alpha2/beta2,CHRNB2|CHRNA2,,,COC1=CC=C2C[C@@H]3C4=C(OC5=CC=C(C[C@H]6C7=C(CC[N+]6(C)C)C=C(OC)C(OC1=C2)=C7)C=C5)C(OC)=C(OC)C=C4CC[N+]3(C)C
diphemanil,Muscarinic acetylcholine receptor M1,CHRM1,,,C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1
diphemanil,Muscarinic acetylcholine receptor M3,CHRM3,,,C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1
diphenylpyraline,Cytochrome P450 2D6,CYP2D6,,,CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
dipivefrine,Alpha-2A adrenergic receptor,ADRA2A,,,CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1
dipivefrine,Alpha-2B adrenergic receptor,ADRA2B,,,CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1
dipivefrine,Alpha-2C adrenergic receptor,ADRA2C,,,CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1
diprafenone,Beta-1 adrenergic receptor,ADRB1,,,CCC(C)(C)NCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
diprafenone,Sodium channel protein type 5 subunit alpha,SCN5A,,,CCC(C)(C)NCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
diprafenone,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,CCC(C)(C)NCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
disopyramide,Sodium channel protein type 5 subunit alpha,SCN5A,,,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
disopyramide,Muscarinic acetylcholine receptor M1,CHRM1,,,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
disopyramide,Muscarinic acetylcholine receptor M2,CHRM2,,,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
disopyramide,Muscarinic acetylcholine receptor M3,CHRM3,,,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C
distigmine,Acetylcholinesterase,ACHE,,,CN(CCCCCCN(C)C(=O)OC1=C[N+](C)=CC=C1)C(=O)OC1=C[N+](C)=CC=C1
disulfiram,Translocator protein,TSPO,,,CCN(CC)C(=S)SSC(=S)N(CC)CC
disulfiram,"Aldehyde dehydrogenase, mitochondrial",ALDH2,,,CCN(CC)C(=S)SSC(=S)N(CC)CC
docetaxel,Multidrug resistance protein 1,ABCB1,,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
docetaxel,Multidrug resistance-associated protein 7,ABCC10,,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
docosanol,Envelope glycoprotein,gN|gM|gE|gH|gJ|gG|gI|gL|gB|gC|gK|gD,,,CCCCCCCCCCCCCCCCCCCCCCO
dofetilide,Potassium channel subfamily K member 2,KCNK2,,,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
domperidone,Multidrug resistance protein 1,ABCB1,,,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
domperidone,Calmodulin,CALM1|CALM2|CALM3,,,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2
dopexamine,Beta-2 adrenergic receptor,ADRB2,,,OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1
dopexamine,D(1A) dopamine receptor,DRD1,,,OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1
doxapram,Potassium channel subfamily K member 3,KCNK3,,,CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
doxapram,Potassium channel subfamily K member 9,KCNK9,,,CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
doxepin,5-hydroxytryptamine receptor 7,HTR7,,,CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2
doxercalciferol,Vitamin D3 receptor,VDR,,,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
doxifluridine,Thymidylate synthase,TYMS,,,C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=C(F)C(=O)NC1=O
doxorubicin,Canalicular multispecific organic anion transporter 1,ABCC2,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
doxorubicin,Multidrug resistance-associated protein 1,ABCC1,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
doxorubicin,ATP-binding cassette sub-family G member 2,ABCG2,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
doxorubicin,Multidrug resistance-associated protein 6,ABCC6,,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1
doxycycline,50S ribosomal protein L10,rpl10,,,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C2=C(O)C=CC=C12
doxylamine,Histamine H1 receptor,HRH1,,,CN(C)CCOC(C)(C1=CC=CC=C1)C1=NC=CC=C1
drostanolone propionate,Androgen receptor,AR,,,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)[C@H](C)C[C@]4(C)[C@H]3CC[C@]12C
drotaverine,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,,CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1
drotaverine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1
droxidopa,Adrenergic receptor,ADRB2|ADRB1|ADRA2A|ADRB3|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B,,,N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O
dyclonine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1
diprophylline,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,,,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O
diprophylline,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O
ebrotidine,Histamine H2 receptor,HRH2,,,NC(=N)NC1=NC(CSCCN\C=N\S(=O)(=O)C2=CC=C(Br)C=C2)=CS1
echothiophate,Acetylcholinesterase,ACHE,,,CCOP(=O)(OCC)SCC[N+](C)(C)C
econazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
edatrexate,"Folylpolyglutamate synthase, mitochondrial",FPGS,,,CCC(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
edetic acid,Ceramide glucosyltransferase,UGCG,,,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
efavirenz,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
eflornithine,Ornithine decarboxylase,,,,NCCCC(N)(C(F)F)C(O)=O
efonidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,CC1=C(C(C2=CC(=CC=C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1=CC=CC=C1)C1=CC=CC=C1
emtricitabine,Reverse transcriptase/RNaseH,pol,,,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1
encainide,Sodium channel protein type 5 subunit alpha,SCN5A,,,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
encainide,Sodium channel subunit beta-1,SCN1B,,,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
encainide,Sodium channel subunit beta-2,SCN2B,,,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
encainide,Sodium channel subunit beta-3,SCN3B,,,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
encainide,Sodium channel subunit beta-4,SCN4B,,,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
endralazine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,NNC1=CC2=C(CCN(C2)C(=O)C2=CC=CC=C2)N=N1
enflurane,Glycine receptor subunit alpha-1,GLRA1,,,FC(F)OC(F)(F)C(F)Cl
enflurane,Potassium channel subfamily K member 2,KCNK2,,,FC(F)OC(F)(F)C(F)Cl
enflurane,Potassium channel subfamily K member 3,KCNK3,,,FC(F)OC(F)(F)C(F)Cl
enflurane,Potassium channel subfamily K member 9,KCNK9,,,FC(F)OC(F)(F)C(F)Cl
enflurane,Potassium channel subfamily K member 10,KCNK10,,,FC(F)OC(F)(F)C(F)Cl
enflurane,Potassium channel subfamily K member 18,KCNK18,,,FC(F)OC(F)(F)C(F)Cl
enfuvirtide,Envelope glycoprotein,gp41,,,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
enfuvirtide,Transmembrane glycoprotein gp41,env,,,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
enoxacin,DNA gyrase subunit A,gyrA,,,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
enoxacin,Topoisomerase IV,parC|topB,,,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
enoxacin,DNA gyrase,gyrB|gyrA,,,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
enprofylline,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,,CCCN1C2=C(N=CN2)C(=O)NC1=O
enprostil,Prostacyclin receptor,PTGIR,,,COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O
entecavir,Protein P,P,,,NC1=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](CO)C2=C)C(=O)N1
entecavir,Protein P,P,,,NC1=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](CO)C2=C)C(=O)N1
epinastine,Alpha-2A adrenergic receptor,ADRA2A,,,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
epinastine,Multidrug resistance protein 1,ABCB1,,,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
epinastine,5-hydroxytryptamine receptor 2A,HTR2A,,,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
epinastine,Alpha-1A adrenergic receptor,ADRA1A,,,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
epinastine,Histamine H2 receptor,HRH2,,,NC1=NCC2N1C1=C(CC3=C2C=CC=C3)C=CC=C1
epoprostenol,P2Y purinoceptor 12,P2RY12,,,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O
ergotamine,Alpha-1A adrenergic receptor,ADRA1A,,,CN1C[C@@H](C=C2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O
ertapenem,Penicillin-binding protein 2,pbpA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O
ertapenem,Penicillin-binding protein 4,,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O
ertapenem,D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5,dacA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O
ertapenem,Penicillin-binding protein 1,ponA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O
ertapenem,D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6,dacC,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O
ertapenem,D-alanyl-D-alanine carboxypeptidase DacB,dacB,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O
ertapenem,Penicillin-binding protein 1A,mrcA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O
ertapenem,Penicillin-binding protein 1B,mrcB,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O
esomeprazole,Potassium-transporting ATPase,ATP4A|ATP4B,,,COC1=CC=C2N=C(NC2=C1)[S@@](=O)CC1=C(C)C(OC)=C(C)C=N1
estazolam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1
estazolam,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,,,ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1
estazolam,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,,,ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1
estazolam,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,,,ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1
estradiol cypionate,Estrogen receptor,ESR1,,,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1
estradiol valerate,Estrogen receptor,ESR1,,,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=C(C=CC(O)=C4)[C@H]3CC[C@]12C
estramustine phosphate,Estrogen receptor beta,ESR2,,,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2OP(O)(O)=O
eszopiclone,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
eszopiclone,GABA-A receptor alpha-1/beta-2/gamma-3,GABRA1|GABRB2|GABRG3,,,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
eszopiclone,GABA A receptor alpha-3/beta-2/gamma-2,GABRG2|GABRA3|GABRB2,,,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
eszopiclone,GABA A receptor alpha-3/beta-2/gamma-3,GABRA3|GABRB2|GABRG3,,,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
eszopiclone,GABA A receptor alpha-5/beta-2/gamma-2,GABRG2|GABRA5|GABRB2,,,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
eszopiclone,GABA A receptor alpha-5/beta-2/gamma-3,GABRA5|GABRB2|GABRG3,,,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1
ethacrynic acid,Solute carrier family 12 member 1,SLC12A1,,,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
ethambutol,Probable arabinosyltransferase A,embA,,,CC[C@@H](CO)NCCN[C@@H](CC)CO
ethambutol,Probable arabinosyltransferase B,embB,,,CC[C@@H](CO)NCCN[C@@H](CC)CO
ethambutol,Probable arabinosyltransferase C,embC,,,CC[C@@H](CO)NCCN[C@@H](CC)CO
ethambutol,Probable arabinosyltransferase A,embA,,,CC[C@@H](CO)NCCN[C@@H](CC)CO
ethanol,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,,CCO
ethanol,Glycine receptor subunit alpha-1,GLRA1,,,CCO
ethanol,Glycine receptor subunit alpha-2,GLRA2,,,CCO
ethanol,GABA A receptor alpha-4/beta-2/delta,GABRD|GABRB2|GABRA4,,,CCO
ethchlorvynol,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CCC(O)(C=CCl)C#C
ethionamide,Catalase-peroxidase,katG,,,CCC1=CC(=CC=N1)C(N)=S
ethionamide,Enoyl-[acyl-carrier-protein] reductase [NADH],inhA,,,CCC1=CC(=CC=N1)C(N)=S
profenamine,Muscarinic acetylcholine receptor M1,CHRM1,,,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
profenamine,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
ethosuximide,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,,,CCC1(C)CC(=O)NC1=O
ethotoin,Sodium channel alpha subunit,SCN1A|SCN4A|SCN7A|SCN5A|SCN9A|SCN2A|SCN3A|SCN11A|SCN8A|SCN10A,,,CCN1C(=O)NC(C1=O)C1=CC=CC=C1
ethyl biscoumacetate,Vitamin K epoxide reductase complex subunit 1,VKORC1,,,CCOC(=O)C(C1=C(O)C2=CC=CC=C2OC1=O)C1=C(O)C2=CC=CC=C2OC1=O
ethylestrenol,Androgen receptor,AR,,,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C
etynodiol,Estrogen receptor,ESR1,,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1
etynodiol,Progesterone receptor,PGR,,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1
etidocaine,Sodium channel protein type 5 subunit alpha,SCN5A,,,CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
etidocaine,Sodium channel protein type 2 subunit alpha,SCN2A,,,CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
etidocaine,Sodium channel protein type 4 subunit alpha,SCN4A,,,CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
etilefrine,Beta-1 adrenergic receptor,ADRB1,,,CCNCC(O)C1=CC(O)=CC=C1
etizolam,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,,,CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=C(Cl)C=CC=C1
etizolam,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,,,CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=C(Cl)C=CC=C1
etizolam,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,,,CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=C(Cl)C=CC=C1
etonogestrel,Estrogen receptor,ESR1,,,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
etonogestrel,Progesterone receptor,PGR,,,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
etoposide,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
etoposide,Multidrug resistance-associated protein 1,ABCC1,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
etoposide,ATP-binding cassette sub-family G member 2,ABCG2,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
etoposide,Multidrug resistance-associated protein 6,ABCC6,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
etoposide,Canalicular multispecific organic anion transporter 2,ABCC3,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
etravirine,Reverse transcriptase/RNaseH,pol,,,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
etretinate,Retinoic acid receptor alpha,RARA,,,CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(C)=C(OC)C=C1C
etretinate,Retinoic acid receptor RXR-gamma,RXRG,,,CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(C)=C(OC)C=C1C
everolimus,Multidrug resistance protein 1,ABCB1,,,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO
exemestane,Androgen receptor,AR,,,C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O
famciclovir,DNA polymerase catalytic subunit,,,,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O
famciclovir,DNA polymerase catalytic subunit,,,,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O
felbamate,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,,,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
felbinac,Prostaglandin G/H synthase 2,PTGS2,,,OC(=O)CC1=CC=C(C=C1)C1=CC=CC=C1
felodipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
felodipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
fenbufen,Prostaglandin G/H synthase 2,PTGS2,,,OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
fenbufen,Prostaglandin G/H synthase 1,PTGS1,,,OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
flavoxate,Phosphodiesterase 4,PDE4A|PDE4B|PDE4C|PDE4D,,,CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1
flavoxate,Phosphodiesterase 7,PDE7A|PDE7B,,,CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1
flavoxate,Phosphodiesterase 8,PDE8A|PDE8B,,,CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1
flopropione,Catechol O-methyltransferase,COMT,,,CCC(=O)C1=C(O)C=C(O)C=C1O
floxacillin,Penicillin-binding protein 1A,pbpA,,,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1F
floxuridine,Thymidylate synthase,TYMS,,,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O
flucytosine,Thymidylate synthase,TMP1,,,NC1=NC(=O)NC=C1F
flucytosine,Thymidylate synthase,TMP1,,,NC1=NC(=O)NC=C1F
fludarabine phosphate,DNA polymerase alpha catalytic subunit,POLA1,,,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
fludrocortisone acetate,Annexin A1,ANXA1,,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
flumetasone pivalate,Glucocorticoid receptor,NR3C1,,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C
flupentixol,Alpha-1A adrenergic receptor,ADRA1A,,,OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1
fluphenazine decanoate,D(2) dopamine receptor,DRD2,,,CCCCCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
flupirtine,Potassium voltage-gated channel subfamily KQT member 3,KCNQ3,,,CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1
fluprednisolone,Glucocorticoid receptor,NR3C1,,,C[C@]12C[C@H](O)[C@H]3[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
fluticasone propionate,Cytosolic phospholipase A2,PLA2G4A,,,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF
fluvastatin,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C1=CC=C(F)C=C1
fomepizole,Alcohol dehydrogenase,ADH1B|ADH1C|ADH1A,,,CC1=CNN=C1
fosamprenavir,Gag-Pol polyprotein,gag-pol,,,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
fosamprenavir,Pol polyprotein,pol,,,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
fosfluconazole,Lanosterol 14-alpha demethylase,ERG11,,,OP(O)(=O)OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
fosfomycin,UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1,murA1,,,C[C@@H]1O[C@@H]1P(O)(O)=O
fosfomycin,UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2,murA2,,,C[C@@H]1O[C@@H]1P(O)(O)=O
fosphenytoin,Sodium channel protein type 5 subunit alpha,SCN5A,,,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
furosemide,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,,NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl
gabapentin,Sodium channel protein type 5 subunit alpha,SCN5A,,,NCC1(CC(O)=O)CCCCC1
gabapentin,Alpha-2A adrenergic receptor,ADRA2A,,,NCC1(CC(O)=O)CCCCC1
gabapentin,Adenosine receptor A1,ADORA1,,,NCC1(CC(O)=O)CCCCC1
gabapentin,Gamma-aminobutyric acid type B receptor subunit 2,GABBR2,,,NCC1(CC(O)=O)CCCCC1
gabapentin,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,,NCC1(CC(O)=O)CCCCC1
ganciclovir,DNA polymerase catalytic subunit,,,,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
ganciclovir,Thymidine kinase,TK,,,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
ganirelix,Gonadotropin-releasing hormone receptor,GNRHR,,,CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
gatifloxacin,DNA topoisomerase 4,parC|parE,,,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1
gatifloxacin,DNA gyrase,gyrB|gyrA,,,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1
gemcitabine,Thymidylate synthase,TYMS,,,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
gemcitabine,Deoxycytidine kinase,DCK,,,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
gemcitabine,Ribonucleoside-diphosphate reductase large subunit,RRM1,,,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
gemcitabine,Ribonucleoside-diphosphate reductase subunit M2,RRM2,,,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
gemcitabine,UMP-CMP kinase,CMPK1,,,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
gemcitabine,DNA polymerase (alpha/delta/epsilon),POLA1|POLD1|POLE,,,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
gemfibrozil,Lipoprotein lipase,LPL,,,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1
gemifloxacin,DNA gyrase subunit B,gyrB,,,CO\N=C1/CN(CC1CN)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=N1)C(O)=O
gemifloxacin,DNA topoisomerase 4 subunit A,parC,,,CO\N=C1/CN(CC1CN)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=N1)C(O)=O
gestodene,Progesterone receptor,PGR,,,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
gestodene,Cytochrome P450 3A5,CYP3A5,,,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
glutamic acid,"Glutamate dehydrogenase 1, mitochondrial",GLUD1,,,N[C@@H](CCC(O)=O)C(O)=O
glutamic acid,"Glutamate dehydrogenase 2, mitochondrial",GLUD2,,,N[C@@H](CCC(O)=O)C(O)=O
glutethimide,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
goserelin,Lutropin-choriogonadotropic hormone receptor,LHCGR,,,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
goserelin,Gonadotropin-releasing hormone receptor,GNRHR,,,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
grepafloxacin,DNA topoisomerase 4,parC|parE,,,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O
grepafloxacin,DNA gyrase,gyrB|gyrA,,,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O
griseofulvin,Tubulin beta chain,TUB2,,,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC
griseofulvin,Tubulin,,,,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC
guanadrel,Sodium-dependent noradrenaline transporter,SLC6A2,,,NC(=N)NCC1COC2(CCCCC2)O1
guanadrel,Alpha-1A adrenergic receptor,ADRA1A,,,NC(=N)NCC1COC2(CCCCC2)O1
guanethidine,Alpha-2A adrenergic receptor,ADRA2A,,,NC(=N)NCCN1CCCCCCC1
guanethidine,Sodium-dependent noradrenaline transporter,SLC6A2,,,NC(=N)NCCN1CCCCCCC1
guanethidine,Alpha-1A adrenergic receptor,ADRA1A,,,NC(=N)NCCN1CCCCCCC1
guanethidine,Alpha-2B adrenergic receptor,ADRA2B,,,NC(=N)NCCN1CCCCCCC1
guanethidine,Alpha-2C adrenergic receptor,ADRA2C,,,NC(=N)NCCN1CCCCCCC1
guanethidine,Alpha-1D adrenergic receptor,ADRA1D,,,NC(=N)NCCN1CCCCCCC1
guanethidine,Alpha-1B adrenergic receptor,ADRA1B,,,NC(=N)NCCN1CCCCCCC1
guanidine,Voltage-gated potassium channel,KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4,,,NC(N)=N
halazepam,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1
ulobetasol propionate,Glucocorticoid receptor,NR3C1,,,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
halopredone acetate,Glucocorticoid receptor,NR3C1,,,CC(=O)OCC(=O)[C@]1(CC[C@H]2[C@@H]3C[C@@H](F)C4=CC(=O)C(Br)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)OC(C)=O
halothane,Potassium channel subfamily K member 2,KCNK2,,,FC(F)(F)C(Cl)Br
halothane,Potassium channel subfamily K member 3,KCNK3,,,FC(F)(F)C(Cl)Br
halothane,Potassium channel subfamily K member 9,KCNK9,,,FC(F)(F)C(Cl)Br
halothane,Potassium channel subfamily K member 10,KCNK10,,,FC(F)(F)C(Cl)Br
halothane,Potassium channel subfamily K member 18,KCNK18,,,FC(F)(F)C(Cl)Br
halothane,Glycine receptor (alpha-1/beta),GLRA1|GLRB,,,FC(F)(F)C(Cl)Br
halothane,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,FC(F)(F)C(Cl)Br
hetacillin,Penicillin-binding protein,pbp2b|pbp3|PBP2X|pbp2a|pbp1b|pbp1a,,,CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
hexachlorophene,D-lactate dehydrogenase,dld,,,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
hexachlorophene,Enoyl-[acyl-carrier-protein] reductase [NADH] FabI,fabI,,,OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(Cl)C(Cl)=CC(Cl)=C1O
hexafluronium,Acetylcholinesterase,ACHE,,,C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C2=C1C=CC=C2)C1C2=CC=CC=C2C2=C1C=CC=C2
hexobarbital,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,,,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1
hexobarbital,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,,,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1
hexobarbital,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,,,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1
hexobarbital,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1
hexocyclium,Muscarinic acetylcholine receptor M1,CHRM1,,,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
hydralazine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,NNC1=NN=CC2=CC=CC=C12
hydralazine,DNA (cytosine-5)-methyltransferase 1,DNMT1,,,NNC1=NN=CC2=CC=CC=C12
hydralazine,DNA (cytosine-5)-methyltransferase 3A,DNMT3A,,,NNC1=NN=CC2=CC=CC=C12
hydralazine,DNA (cytosine-5)-methyltransferase 3B,DNMT3B,,,NNC1=NN=CC2=CC=CC=C12
hydralazine,Ryanodine receptor 2,RYR2,,,NNC1=NN=CC2=CC=CC=C12
hydrochlorothiazide,Carbonic anhydrase 4,CA4,,,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
hydrochlorothiazide,Calcium-activated potassium channel subunit alpha-1,KCNMA1,,,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
hydrocortamate,Glucocorticoid receptor,NR3C1,,,CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
hydrocortisone,Annexin A1,ANXA1,,,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
hydrocortisone cypionate,Glucocorticoid receptor,NR3C1,,,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
hydroxychloroquine,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
hydroxychloroquine,Hemoglobin subunit alpha,HBA1,,,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
hydroxycarbamide,Ribonucleoside-diphosphate reductase large subunit,RRM1,,,NC(=O)NO
hydroxycarbamide,Ribonucleoside-diphosphate reductase subunit M2,RRM2,,,NC(=O)NO
ibuprofen,Arachidonate 5-lipoxygenase,ALOX5,,,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
icosapent ethyl,Diacylglycerol O-acyltransferase 1,DGAT1,,,CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC
idarubicin,Multidrug resistance protein 1,ABCB1,,,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=CC=CC=C1C3=O)C(C)=O
idarubicin,DNA topoisomerase 2-alpha,TOP2A,,,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=CC=CC=C1C3=O)C(C)=O
idarubicin,Multidrug resistance-associated protein 1,ABCC1,,,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=CC=CC=C1C3=O)C(C)=O
imatinib,Multidrug resistance-associated protein 1,ABCC1,,,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1
imipenem,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O
indapamide,Potassium voltage-gated channel subfamily KQT member 1,KCNQ1,,,CC1CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
indecainide,Sodium channel protein type 5 subunit alpha,SCN5A,,,CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C2=C1C=CC=C2
indobufen,Prostaglandin G/H synthase 2,PTGS2,,,CCC(C(O)=O)C1=CC=C(C=C1)N1CC2=C(C=CC=C2)C1=O
indobufen,Prostaglandin G/H synthase 1,PTGS1,,,CCC(C(O)=O)C1=CC=C(C=C1)N1CC2=C(C=CC=C2)C1=O
irinotecan,Multidrug resistance protein 1,ABCB1,,,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
irinotecan,Canalicular multispecific organic anion transporter 1,ABCC2,,,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
irinotecan,Multidrug resistance-associated protein 1,ABCC1,,,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
irinotecan,ATP-binding cassette sub-family G member 2,ABCG2,,,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
irinotecan,Multidrug resistance-associated protein 4,ABCC4,,,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
irinotecan,DNA topoisomerase 1,TOP1,,,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
irofulven,Serine/threonine-protein kinase Chk2,CHEK2,,,CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1
isocarboxazid,Amine oxidase [flavin-containing] B,MAOB,,,CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1
isocarboxazid,Amine oxidase [flavin-containing] A,MAOA,,,CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1
isoflurane,Potassium channel subfamily K member 2,KCNK2,,,FC(F)OC(Cl)C(F)(F)F
isoflurane,Potassium channel subfamily K member 3,KCNK3,,,FC(F)OC(Cl)C(F)(F)F
isoflurane,Potassium channel subfamily K member 9,KCNK9,,,FC(F)OC(Cl)C(F)(F)F
isoflurane,Potassium channel subfamily K member 10,KCNK10,,,FC(F)OC(Cl)C(F)(F)F
isoflurane,Potassium channel subfamily K member 18,KCNK18,,,FC(F)OC(Cl)C(F)(F)F
isoflurane,Glycine receptor (alpha-1/beta),GLRA1|GLRB,,,FC(F)OC(Cl)C(F)(F)F
isoflurane,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,FC(F)OC(Cl)C(F)(F)F
isoniazid,Catalase-peroxidase,katG,,,NNC(=O)C1=CC=NC=C1
isopropamide,Muscarinic acetylcholine receptor M1,CHRM1,,,CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C
isopropamide,Muscarinic acetylcholine receptor M3,CHRM3,,,CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C
isosorbide dinitrate,Atrial natriuretic peptide receptor 1,NPR1,,,[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O
isosorbide dinitrate,Soluble guanylate cyclase,GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3,,,[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O
isosorbide mononitrate,Atrial natriuretic peptide receptor 1,NPR1,,,O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O
isosorbide mononitrate,Soluble guanylate cyclase,GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3,,,O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O
isotretinoin,Retinoic acid receptor beta,RARB,,,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
isradipine,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
isradipine,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
ixabepilone,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,,,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=CSC(C)=N1
ketamine,Glutamate receptor ionotropic AMPA,GRIA1|GRIA2|GRIA3|GRIA4,,,CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1
ketanserin,Alpha-2A adrenergic receptor,ADRA2A,,Ki,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1
ketoconazole,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
ketotifen,Multidrug resistance protein 1,ABCB1,,,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2
lacidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC
lamivudine,Deoxycytidine kinase,DCK,,,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
lamivudine,Protein P,P,,,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
lamotrigine,Sodium channel protein type 1 subunit alpha,SCN1A,,,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
lamotrigine,Sodium channel protein type 8 subunit alpha,SCN8A,,,NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1
landiolol,Beta-1 adrenergic receptor,ADRB1,,,CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1
lansoprazole,Potassium-transporting ATPase,ATP4A|ATP4B,,,CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F
lapatinib,Multidrug resistance protein 1,ABCB1,,,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
lapatinib,ATP-binding cassette sub-family G member 2,ABCG2,,,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
lapatinib,Solute carrier organic anion transporter family member 1B1,SLCO1B1,,,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1
aspartic acid,Calcium-binding mitochondrial carrier protein Aralar1,SLC25A12,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,"Aspartate aminotransferase, cytoplasmic",GOT1,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,Aspartoacylase,ASPA,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,Asparagine synthetase [glutamine-hydrolyzing],ASNS,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,Argininosuccinate synthase,ASS1,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,Aminoacylase-1,ACY1,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,"Aspartate aminotransferase, mitochondrial",GOT2,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,"Aspartate--tRNA ligase, cytoplasmic",DARS,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,Aspartyl/asparaginyl beta-hydroxylase,ASPH,,,N[C@@H](CC(O)=O)C(O)=O
aspartic acid,Calcium-binding mitochondrial carrier protein Aralar2,SLC25A13,,,N[C@@H](CC(O)=O)C(O)=O
levamisole,Acetylcholine receptor subunit alpha-type unc-63,unc-63,,,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1
levamisole,Nicotinic acetylcholine receptor alpha subunit,,,,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1
levetiracetam,Sodium channel protein type 1 subunit alpha,SCN1A,,,CC[C@H](N1CCCC1=O)C(N)=O
levetiracetam,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,,,CC[C@H](N1CCCC1=O)C(N)=O
levetiracetam,Carbonic anhydrase 1,CA1,,,CC[C@H](N1CCCC1=O)C(N)=O
levocabastine,Multidrug resistance protein 1,ABCB1,,,C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1
levodopa,D(1A) dopamine receptor,DRD1,,,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
levodopa,D(2) dopamine receptor,DRD2,,,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
levofloxacin,DNA topoisomerase 4,parC|parE,,,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
levofloxacin,DNA gyrase,gyrB|gyrA,,,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
levomethadyl acetate,Mu-type opioid receptor,OPRM1,,,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
levonorgestrel,Estrogen receptor,ESR1,,,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
levosimendan,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A",PDE3A,,,C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1
levosimendan,ATP-sensitive inward rectifier potassium channel 11,KCNJ11,,,C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1
levosimendan,ATP-sensitive inward rectifier potassium channel 8,KCNJ8,,,C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1
lidocaine,Sodium channel protein type 2 subunit alpha,SCN2A,,,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
lidocaine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
limaprost,Prostaglandin E2 receptor EP1 subtype,PTGER1,,,CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O
lincomycin,50S ribosomal protein L10,rpl10,,,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
lindane,GABA-A receptor,Rdl1|Rdl2|Rdl3,,,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
lindane,GABA-A receptor,,,,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
lomefloxacin,DNA gyrase,gyrA|gyrB,,,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12
loperamide,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,,,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
loperamide,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CACNA1A,,,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
loperamide,Calmodulin,CALM1|CALM2|CALM3,,,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
loperamide,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,,,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
loperamide,"Glutamate receptor ionotropic, NMDA 2C",GRIN2C,,,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
loperamide,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,,,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
lopinavir,Gag-Pol polyprotein,gag-pol,,,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
loprazolam,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,,,CN1CCN(CC1)\C=C1/N=C2CN=C(C3=CC(=CC=C3N2C1=O)[N+]([O-])=O)C1=C(Cl)C=CC=C1
loprazolam,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,,,CN1CCN(CC1)\C=C1/N=C2CN=C(C3=CC(=CC=C3N2C1=O)[N+]([O-])=O)C1=C(Cl)C=CC=C1
loprazolam,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,,,CN1CCN(CC1)\C=C1/N=C2CN=C(C3=CC(=CC=C3N2C1=O)[N+]([O-])=O)C1=C(Cl)C=CC=C1
loprazolam,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CN1CCN(CC1)\C=C1/N=C2CN=C(C3=CC(=CC=C3N2C1=O)[N+]([O-])=O)C1=C(Cl)C=CC=C1
loracarbef,Penicillin-binding protein 1A,pbpA,,,N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
loracarbef,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
lorcainide,Sodium channel protein type 5 subunit alpha,SCN5A,,,CC(C)N1CCC(CC1)N(C(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C=C1
lorcainide,Sodium channel subunit beta-1,SCN1B,,,CC(C)N1CCC(CC1)N(C(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C=C1
lorcainide,Sodium channel subunit beta-2,SCN2B,,,CC(C)N1CCC(CC1)N(C(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C=C1
lorcainide,Sodium channel subunit beta-3,SCN3B,,,CC(C)N1CCC(CC1)N(C(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C=C1
lorcainide,Sodium channel subunit beta-4,SCN4B,,,CC(C)N1CCC(CC1)N(C(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C=C1
loteprednol etabonate,Glucocorticoid receptor,NR3C1,,,CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl
mafenide,Dihydropteroate synthase,folP,,,NCC1=CC=C(C=C1)S(N)(=O)=O
malathion,Acetylcholinesterase,Ace1,,,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC
manidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
maprotiline,ATP-binding cassette sub-family G member 2,ABCG2,,,CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1
mebendazole,Tubulin,,,,COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1=CC=CC=C1
mebendazole,Tubulin,,,,COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1=CC=CC=C1
mebhydrolin,Histamine H4 receptor,HRH4,,,CN1CCC2=C(C1)C1=C(C=CC=C1)N2CC1=CC=CC=C1
meclozine,Histamine H1 receptor,HRH1,,,CC1=CC=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=C1
medrysone,Glucocorticoid receptor,NR3C1,,,C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12
mefloquine,Multidrug resistance protein 1,ABCB1,,,O[C@H]([C@H]1CCCCN1)C1=CC(=NC2=C(C=CC=C12)C(F)(F)F)C(F)(F)F
mefloquine,Hemoglobin subunit alpha,HBA1,,,O[C@H]([C@H]1CCCCN1)C1=CC(=NC2=C(C=CC=C12)C(F)(F)F)C(F)(F)F
megestrol acetate,Multidrug resistance protein 1,ABCB1,,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
megestrol acetate,Progesterone receptor,PGR,,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
melperone,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
melperone,Cytochrome P450 2D6,CYP2D6,,,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
memantine,5-hydroxytryptamine receptor 3A,HTR3A,,,CC12CC3CC(C)(C1)CC(N)(C3)C2
memantine,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,,CC12CC3CC(C)(C1)CC(N)(C3)C2
mepenzolate,Muscarinic acetylcholine receptor M1,CHRM1,,,C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
pethidine,Sodium-dependent dopamine transporter,SLC6A3,,,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
pethidine,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
mephentermine,Alpha-1A adrenergic receptor,ADRA1A,,,CNC(C)(C)CC1=CC=CC=C1
mephenytoin,Sodium channel alpha subunit,SCN1A|SCN4A|SCN7A|SCN5A|SCN9A|SCN2A|SCN3A|SCN11A|SCN8A|SCN10A,,,CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
methylphenobarbital,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1
mepivacaine,Sodium channel protein type 5 subunit alpha,SCN5A,,,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
mepivacaine,Sodium channel protein type 1 subunit alpha,SCN1A,,,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
mepivacaine,Sodium channel protein type 2 subunit alpha,SCN2A,,,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
mepivacaine,Sodium channel protein type 3 subunit alpha,SCN3A,,,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
mepivacaine,Sodium channel protein type 4 subunit alpha,SCN4A,,,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
mepivacaine,Sodium channel protein type 8 subunit alpha,SCN8A,,,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
mepivacaine,Sodium channel protein type 9 subunit alpha,SCN9A,,,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
meprednisone,Glucocorticoid receptor,NR3C1,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
meprobamate,GABA-A receptor alpha-2/beta-3/gamma-2,GABRG2|GABRB3|GABRA2,,,CCCC(C)(COC(N)=O)COC(N)=O
meprobamate,GABA-A receptor alpha-3/beta-3/gamma-2,GABRG2|GABRB3|GABRA3,,,CCCC(C)(COC(N)=O)COC(N)=O
meprobamate,GABA-A receptor alpha-5/beta-3/gamma-2,GABRG2|GABRB3|GABRA5,,,CCCC(C)(COC(N)=O)COC(N)=O
meprobamate,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CCCC(C)(COC(N)=O)COC(N)=O
meproscillarin,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,,CO[C@H]1[C@H](C)O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)C2=COC(=O)C=C2)[C@H](O)[C@@H]1O
mercaptopurine,Multidrug resistance-associated protein 5,ABCC5,,,S=C1N=CNC2=C1NC=N2
mercaptopurine,Multidrug resistance-associated protein 4,ABCC4,,,S=C1N=CNC2=C1NC=N2
mercaptopurine,Purine nucleoside phosphorylase,PNP,,,S=C1N=CNC2=C1NC=N2
mercaptopurine,Amidophosphoribosyltransferase,PPAT,,,S=C1N=CNC2=C1NC=N2
mercaptopurine,Thiopurine S-methyltransferase,TPMT,,,S=C1N=CNC2=C1NC=N2
meropenem,Penicillin-binding protein 2,pbpA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
meropenem,Penicillin-binding protein 4,,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
meropenem,D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5,dacA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
meropenem,Penicillin-binding protein 1,ponA,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
meropenem,D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6,dacC,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
meropenem,D-alanyl-D-alanine carboxypeptidase DacB,dacB,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O
mesalazine,Prostaglandin G/H synthase 1,PTGS1,,,NC1=CC(C(O)=O)=C(O)C=C1
mesalazine,Arachidonate 5-lipoxygenase,ALOX5,,,NC1=CC(C(O)=O)=C(O)C=C1
mesalazine,Peroxisome proliferator-activated receptor gamma,PPARG,,,NC1=CC(C(O)=O)=C(O)C=C1
metaraminol,Alpha-1A adrenergic receptor,ADRA1A,,,C[C@H](N)[C@H](O)C1=CC(O)=CC=C1
metformin,5'-AMP-activated protein kinase subunit beta-1,PRKAB1,,,CN(C)C(=N)NC(N)=N
metformin,Mitochondrial complex I (NADH dehydrogenase),NDUFS8|NDUFA4|NDUFAB1|NDUFA1|NDUFS4|NDUFB5|NDUFB3|NDUFC1|NDUFA2|NDUFS5|NDUFS7|NDUFS2|NDUFS6|NDUFB1|NDUFS3|NDUFB6|NDUFA3|NDUFB4|NDUFB8|NDUFB2|NDUFA7|NDUFC2|NDUFA10|NDUFB10|MT-ND1|MT-ND2|MT-ND3|MT-ND4L|MT-ND4|MT-ND5|MT-ND6|NDUFB7|NDUFV2|NDUFS1|NDUFV1|NDUFA8|NDUFV3|NDUFA6|NDUFA5|NDUFA9|NDUFA11|NDUFAF2|NDUFAF3|NDUFA4L2|NDUFB11|NDUFAF4|NDUFA13|NDUFA12|NDUFAF1|NDUFB9,,,CN(C)C(=N)NC(N)=N
methacholine,Muscarinic acetylcholine receptor M3,CHRM3,,,CC(C[N+](C)(C)C)OC(C)=O
methadone,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
methadone,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,,,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
acetylmethadol,Mu-type opioid receptor,OPRM1,,,CCC(OC(C)=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
methanthelinium,Muscarinic acetylcholine receptor,CHRM2|CHRM4|CHRM5|CHRM1|CHRM3,,,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2
metharbital,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,CCC1(CC)C(=O)NC(=O)N(C)C1=O
methdilazine,Histamine H1 receptor,HRH1,,,CN1CCC(CN2C3=CC=CC=C3SC3=C2C=CC=C3)C1
meticillin,Beta-lactam-inducible penicillin-binding protein,pbp,,,COC1=CC=CC(OC)=C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O
meticillin,Penicillin-binding protein,pbp4|mecA|pbpA|PBP2|pbpF,,,COC1=CC=CC(OC)=C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O
methohexital,Glycine receptor subunit alpha-1,GLRA1,,,CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O
methohexital,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O
methohexital,Neuronal acetylcholine receptor; alpha2/beta2,CHRNB2|CHRNA2,,,CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O
methotrexate,Multidrug resistance protein 1,ABCB1,,,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methotrexate,Canalicular multispecific organic anion transporter 1,ABCC2,,,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methotrexate,Multidrug resistance-associated protein 1,ABCC1,,,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methotrexate,ATP-binding cassette sub-family G member 2,ABCG2,,,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methotrexate,Multidrug resistance-associated protein 5,ABCC5,,,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methotrexate,Multidrug resistance-associated protein 4,ABCC4,,,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
methoxyflurane,Glycine receptor subunit alpha-1,GLRA1,,,COC(F)(F)C(Cl)Cl
methoxyflurane,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,COC(F)(F)C(Cl)Cl
methsuximide,Voltage-gated T-type calcium channel,CACNA1G|CACNA1H|CACNA1I,,,CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
methylclothiazide,Solute carrier family 12 member 3,SLC12A3,,,CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O
metildigoxin,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,,CO[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@H](CC[C@]65O)C5=CC(=O)OC5)C4)O[C@@H]3C)O[C@@H]2C)O[C@@H]1C
methyldopa,Alpha-2A adrenergic receptor,ADRA2A,,,C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O
methyldopa,Aromatic-L-amino-acid decarboxylase,DDC,,,C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O
methylprednisolone,Annexin A1,ANXA1,,,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
methylprednisolone acetate,Glucocorticoid receptor,NR3C1,,,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
methylprednisolone succinate,Glucocorticoid receptor,NR3C1,,,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
methyprylon,GABA-A receptor alpha-1/beta-3/gamma-2,GABRA1|GABRG2|GABRB3,,,CCC1(CC)C(=O)NCC(C)C1=O
metipranolol,Beta-1 adrenergic receptor,ADRB1,,,CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1
metipranolol,Beta-2 adrenergic receptor,ADRB2,,,CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1
metixene,5-hydroxytryptamine receptor 2C,HTR2C,,,CN1CCCC(CC2C3=CC=CC=C3SC3=C2C=CC=C3)C1
metixene,Muscarinic acetylcholine receptor M1,CHRM1,,,CN1CCCC(CC2C3=CC=CC=C3SC3=C2C=CC=C3)C1
metoclopramide,Muscarinic acetylcholine receptor M1,CHRM1,,,CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1
metolazone,Solute carrier family 12 member 3,SLC12A3,,,CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=C(C)C=CC=C1)S(N)(=O)=O
metirosine,Tyrosine 3-monooxygenase,TH,,,C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O
mexiletine,Sodium channel subunit beta-1,SCN1B,,,CC(N)COC1=C(C)C=CC=C1C
mexiletine,Sodium channel subunit beta-2,SCN2B,,,CC(N)COC1=C(C)C=CC=C1C
mexiletine,Sodium channel subunit beta-3,SCN3B,,,CC(N)COC1=C(C)C=CC=C1C
mexiletine,Sodium channel subunit beta-4,SCN4B,,,CC(N)COC1=C(C)C=CC=C1C
mezlocillin,Penicillin-binding protein 1A,pbpA,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
mezlocillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
micafungin,"Beta-1,3-glucan synthase",GSC1,,,CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O
micafungin,"Beta-1,3-glucan synthase catalytic subunit 1",GSC1,,,CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O
miconazole,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
miconazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
midodrine,Alpha-1A adrenergic receptor,ADRA1A,,,COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1
miglitol,Pancreatic alpha-amylase,AMY2A,,,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
mimosine,"Serine hydroxymethyltransferase, cytosolic",SHMT1,,,N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O
minoxidil,"Sulfonylurea receptor 2, Kir6.2",ABCC9|KCNJ11,,,NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1
mirtazapine,Muscarinic acetylcholine receptor M1,CHRM1,,,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
mirtazapine,Muscarinic acetylcholine receptor M2,CHRM2,,,CN1CCN2C(C1)C1=C(CC3=C2N=CC=C3)C=CC=C1
mitotane,"Cytochrome P450 11B1, mitochondrial",CYP11B1,,,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
mitotane,"Adrenodoxin, mitochondrial",FDX1,,,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
mitotane,"Cholesterol side-chain cleavage enzyme, mitochondrial",CYP11A1,,,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
mitoxantrone,Canalicular multispecific organic anion transporter 1,ABCC2,,,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O
mivacurium,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,,,COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
mivacurium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,,,COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
mizolastine,Arachidonate 5-lipoxygenase,ALOX5,,,CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1
modafinil,Alpha-1B adrenergic receptor,ADRA1B,,,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
modafinil,Cytochrome P450 2C19,CYP2C19,,,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
monobenzone,Tyrosinase,TYR,,,OC1=CC=C(OCC2=CC=CC=C2)C=C1
moracizine,Sodium channel protein type 5 subunit alpha,SCN5A,,,CCOC(=O)NC1=CC=C2SC3=CC=CC=C3N(C(=O)CCN3CCOCC3)C2=C1
moxastine,Histamine H1 receptor,HRH1,,,CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=C1
moxifloxacin,Topoisomerase IV,parC|parE,,,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1C[C@@H]2CCCN[C@@H]2C1)C1CC1
mupirocin,Isoleucine--tRNA ligase,ileS,,,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O
mupirocin,Isoleucine--tRNA ligase,ileS,,,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O
nabumetone,Prostaglandin G/H synthase 2,PTGS2,,,COC1=CC=C2C=C(CCC(C)=O)C=CC2=C1
nafcillin,Penicillin-binding protein 1A,pbpA,,,CCOC1=CC=C2C=CC=CC2=C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O
nafcillin,Penicillin-binding protein,pbp4|mecA|pbpA|PBP2|pbpF,,,CCOC1=CC=C2C=CC=CC2=C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O
naftifine,Squalene monooxygenase,SQLE,,,CN(C\C=C\C1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12
naftifine,Squalene epoxidase,,,,CN(C\C=C\C1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12
nalidixic acid,DNA gyrase,gyrA|gyrB,,,CCN1C=C(C(O)=O)C(=O)C2=CC=C(C)N=C12
nandrolone,Androgen receptor,AR,,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O
nandrolone decanoate,Androgen receptor,AR,,,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
nedocromil,Cysteinyl leukotriene receptor 1,CYSLTR1,,,CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O
nefopam,Sodium channel protein type 5 subunit alpha,SCN5A,,,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1
nelfinavir,Gag-Pol polyprotein,gag-pol,,,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
framycetin,30S ribosomal protein S12,rpsL,,,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
framycetin,Phenylalanine--tRNA ligase alpha subunit,pheS,,,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
framycetin,Phenylalanine--tRNA ligase beta subunit,pheT,,,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
nesiritide,Atrial natriuretic peptide receptor 1,NPR1,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(C)C
nicotinamide,Hydroxycarboxylic acid receptor 2,HCAR2,,,NC(=O)C1=CN=CC=C1
nicotinamide,Hydroxycarboxylic acid receptor 3,HCAR3,,,NC(=O)C1=CN=CC=C1
nicotinamide,Nicotinamide N-methyltransferase,NNMT,,,NC(=O)C1=CN=CC=C1
nicotinamide,Nicotinate-nucleotide pyrophosphorylase [carboxylating],QPRT,,,NC(=O)C1=CN=CC=C1
nicardipine,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
nicardipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
nilvadipine,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,,,COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
nilvadipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
nilvadipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,,COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
nilvadipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
nimodipine,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,,,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nimodipine,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,,,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nimodipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
nisoldipine,Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CACNA1A,,,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
nisoldipine,Voltage-dependent L-type calcium channel subunit alpha-1D,CACNA1D,,,COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C
nitazoxanide,Pyruvate dehydrogenase [NADP(+)],PFOR,,,CC(=O)OC1=C(C=CC=C1)C(=O)NC1=NC=C(S1)[N+]([O-])=O
nitazoxanide,Pyruvate:ferredoxin oxidoreductase,,,,CC(=O)OC1=C(C=CC=C1)C(=O)NC1=NC=C(S1)[N+]([O-])=O
nitrendipine,Voltage-dependent calcium channel gamma-1 subunit,CACNG1,,,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
nitric oxide,Soluble guanylate cyclase,GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3,,,[N]=O
nitrofurantoin,Glucose-6-phosphate 1-dehydrogenase,G6PD,,,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
nitrofurazone,Glucose-6-phosphate 1-dehydrogenase,G6PD,,,NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O
glyceryl trinitrate,Atrial natriuretic peptide receptor 1,NPR1,,,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O
glyceryl trinitrate,Soluble guanylate cyclase,GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3,,,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O
norelgestromin,Progesterone receptor,PGR,,,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(CC[C@H]34)=NO)[C@@H]1CC[C@@]2(O)C#C
norethynodrel,Progesterone receptor,PGR,,,C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C
norgestimate,Progesterone receptor,PGR,,,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C
novobiocin,DNA gyrase,gyrB|gyrA,,,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C
ofloxacin,DNA gyrase subunit B,gyrB,,,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
olprinone,Phosphodiesterase 3,PDE3B|PDE3A,,,CC1=C(C=C(C#N)C(=O)N1)C1=CN2C=CN=C2C=C1
olsalazine,Arachidonate 5-lipoxygenase,ALOX5,,,OC(=O)C1=CC(=CC=C1O)N=NC1=CC(C(O)=O)=C(O)C=C1
olsalazine,Peroxisome proliferator-activated receptor gamma,PPARG,,,OC(=O)C1=CC(=CC=C1O)N=NC1=CC(C(O)=O)=C(O)C=C1
olsalazine,Cyclooxygenase,PTGS1|PTGS2,,,OC(=O)C1=CC(=CC=C1O)N=NC1=CC(C(O)=O)=C(O)C=C1
orlistat,Gastric triacylglycerol lipase,LIPF,,,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
oteracil,Uridine 5'-monophosphate synthase,UMPS,,,OC(=O)C1=NC(=O)NC(=O)N1
ouabain,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O
oxacillin,Penicillin-binding protein 1A,pbpA,,,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=CC=CC=C1
oxacillin,Penicillin-binding protein,pbp4|mecA|pbpA|PBP2|pbpF,,,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C1=CC=CC=C1
oxandrolone,Androgen receptor,AR,,,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C
oxaprozin,fMet-Leu-Phe receptor,FPR1,,,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
oxcarbazepine,Sodium channel protein type 5 subunit alpha,SCN5A,,,NC(=O)N1C2=CC=CC=C2C(=O)CC2=C1C=CC=C2
oxyphencyclimine,Muscarinic acetylcholine receptor M1,CHRM1,,,CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
oxyphencyclimine,Muscarinic acetylcholine receptor M3,CHRM3,,,CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
oxymetholone,Estrogen receptor,ESR1,,,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)\C(C[C@]4(C)[C@H]3CC[C@]12C)=C/O
oxymetholone,Androgen receptor,AR,,,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)\C(C[C@]4(C)[C@H]3CC[C@]12C)=C/O
oxyphenbutazone,fMet-Leu-Phe receptor,FPR1,,,CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
oxyphenbutazone,Prostacyclin synthase,PTGIS,,,CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
oxyphenbutazone,Cyclooxygenase,PTGS1|PTGS2,,,CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
oxyphenonium,Muscarinic acetylcholine receptor M1,CHRM1,,,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
oxyphenonium,Muscarinic acetylcholine receptor M3,CHRM3,,,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
oxytetracycline,30S ribosomal protein S4,rpsD,,,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
oxytetracycline,30S ribosomal protein S9,rpsI,,,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
oxytocin,Oxytocin-neurophysin 1,OXT,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
paclitaxel,Bile salt export pump,ABCB11,,,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
paclitaxel,Multidrug resistance-associated protein 7,ABCC10,,,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1
aminosalicylic acid,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,folK,,,NC1=CC(O)=C(C=C1)C(O)=O
aminosalicylic acid,Cyclooxygenase,PTGS1|PTGS2,,,NC1=CC(O)=C(C=C1)C(O)=O
pantoprazole,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
pantoprazole,Potassium-transporting ATPase,ATP4A|ATP4B,,,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC
papaverine,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
paramethadione,Voltage-gated T-type calcium channel,CACNA1G|CACNA1H|CACNA1I,,,CCC1(C)OC(=O)N(C)C1=O
pemetrexed,"Folylpolyglutamate synthase, mitochondrial",FPGS,,,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
penbutolol,Alpha-1-acid glycoprotein 1,ORM1,,,CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C1CCCC1
penciclovir,DNA polymerase catalytic subunit,,,,NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2
benzylpenicillin,Penicillin-binding protein 1A,pbpA,,,CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
benzylpenicillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
phenoxymethylpenicillin,Penicillin-binding protein 1A,pbpA,,,CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
phenoxymethylpenicillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
pentolonium,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,,,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1
pentolonium,Neuronal acetylcholine receptor; alpha3/beta4,CHRNB4|CHRNA3,,,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1
pentoxifylline,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",PDE4B,,,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
pentoxifylline,"cGMP-specific 3',5'-cyclic phosphodiesterase",PDE5A,,,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
perhexiline,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,,,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
perhexiline,Voltage-dependent T-type calcium channel subunit alpha-1I,CACNA1I,,,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
perhexiline,"Carnitine O-palmitoyltransferase 1, liver isoform",CPT1A,,,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
phenacemide,Sodium channel protein type 1 subunit alpha,SCN1A,,,NC(=O)NC(=O)CC1=CC=CC=C1
phenacetin,Prostaglandin G/H synthase 1,PTGS1,,,CCOC1=CC=C(NC(C)=O)C=C1
phenazopyridine,Sodium channel alpha subunit,SCN1A|SCN4A|SCN7A|SCN5A|SCN9A|SCN2A|SCN3A|SCN11A|SCN8A|SCN10A,,,NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
phendimetrazine,Sodium-dependent noradrenaline transporter,SLC6A2,,,C[C@H]1[C@@H](OCCN1C)C1=CC=CC=C1
phendimetrazine,Sodium-dependent dopamine transporter,SLC6A3,,,C[C@H]1[C@@H](OCCN1C)C1=CC=CC=C1
phenformin,5'-AMP-activated protein kinase subunit beta-1,PRKAB1,,,NC(=N)NC(=N)NCCC1=CC=CC=C1
phenindione,Vitamin K epoxide reductase complex subunit 1,VKORC1,,,O=C1C(C(=O)C2=C1C=CC=C2)C1=CC=CC=C1
phenindione,Prothrombin,F2,,,O=C1C(C(=O)C2=C1C=CC=C2)C1=CC=CC=C1
pheniprazine,Amine oxidase [flavin-containing] B,MAOB,,,CC(CC1=CC=CC=C1)NN
pheniprazine,Amine oxidase [flavin-containing] A,MAOA,,,CC(CC1=CC=CC=C1)NN
pheniramine,Histamine H1 receptor,HRH1,,,CN(C)CCC(C1=CC=CC=C1)C1=NC=CC=C1
phenmetrazine,Amine oxidase [flavin-containing] A,MAOA,,,CC1NCCOC1C1=CC=CC=C1
phenobarbital,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1
phenobarbital,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1
phenobarbital,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1
phensuximide,Voltage-gated T-type calcium channel,CACNA1G|CACNA1H|CACNA1I,,,CN1C(=O)CC(C1=O)C1=CC=CC=C1
phentermine,Sodium-dependent noradrenaline transporter,SLC6A2,,,CC(C)(N)CC1=CC=CC=C1
phenylbutazone,Prostacyclin synthase,PTGIS,,,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
phenylpropanolamine,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,CC(N)C(O)C1=CC=CC=C1
phenylpropanolamine,Alpha-1A adrenergic receptor,ADRA1A,,,CC(N)C(O)C1=CC=CC=C1
phenyltoloxamine,Histamine H1 receptor,HRH1,,,CN(C)CCOC1=C(CC2=CC=CC=C2)C=CC=C1
phenytoin,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
phenytoin,Sodium channel protein type 5 subunit alpha,SCN5A,,,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
phenytoin,Sodium channel protein type 1 subunit alpha,SCN1A,,,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
phenytoin,Sodium channel protein type 3 subunit alpha,SCN3A,,,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
phenytoin,Sodium channel protein type 8 subunit alpha,SCN8A,,,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
phenytoin,Sodium channel protein type 9 subunit alpha,SCN9A,,,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
piketoprofen,Prostaglandin G/H synthase 2,PTGS2,,,CC(C(=O)NC1=CC(C)=CC=N1)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
piketoprofen,Prostaglandin G/H synthase 1,PTGS1,,,CC(C(=O)NC1=CC(C)=CC=N1)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
pimecrolimus,Interleukin-5,IL5,,,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC
pimecrolimus,Interferon gamma,IFNG,,,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC
pimecrolimus,Interleukin-2,IL2,,,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC
pimecrolimus,Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform,PPP3CC,,,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC
pinacidil,Calcium-activated potassium channel subunit alpha-1,KCNMA1,,,CC(NC(NC1=CC=NC=C1)=NC#N)C(C)(C)C
pipecuronium,Neuronal acetylcholine receptor; alpha2/beta4,CHRNB4|CHRNA2,,,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1
pipecuronium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,,,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1
pipecuronium,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,,,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1
pipecuronium,Neuronal acetylcholine receptor; alpha4/beta4,CHRNB4|CHRNA4,,,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1
piperacillin,Penicillin-binding protein 1A,pbpA,,,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C2=CC=CC=C2)C(=O)C1=O
piperacillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C2=CC=CC=C2)C(=O)C1=O
piperazine,Gamma-aminobutyric acid receptor subunit beta,gab-1,,,C1CNCCN1
pirbuterol,Beta-2 adrenergic receptor,ADRB2,,,CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1
pirmenol,Sodium channel protein type 5 subunit alpha,SCN5A,,,C[C@H]1CCC[C@@H](C)N1CCCC(O)(C1=CC=CC=C1)C1=CC=CC=N1
pirprofen,Prostaglandin G/H synthase 2,PTGS2,,,CC(C(O)=O)C1=CC(Cl)=C(C=C1)N1CC=CC1
pirprofen,Prostaglandin G/H synthase 1,PTGS1,,,CC(C(O)=O)C1=CC(Cl)=C(C=C1)N1CC=CC1
pralmorelin,Growth hormone secretagogue receptor type 1,GHSR,,,C[C@@H](N)C(=O)N[C@H](CC1=CC=C2C=CC=CC2=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(N)=O
prazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,ClC1=CC=C2N(CC3CC3)C(=O)CN=C(C3=CC=CC=C3)C2=C1
praziquantel,Glutathione S-transferase class-mu 26 kDa isozyme,,,,O=C(C1CCCCC1)N1CC2N(CCC3=C2C=CC=C3)C(=O)C1
praziquantel,High voltage-activated calcium channel beta subunit CavB1,,,,O=C(C1CCCCC1)N1CC2N(CCC3=C2C=CC=C3)C(=O)C1
praziquantel,High voltage-activated calcium channel beta subunit CavB2,,,,O=C(C1CCCCC1)N1CC2N(CCC3=C2C=CC=C3)C(=O)C1
prednicarbate,Glucocorticoid receptor,NR3C1,,,CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC
prednisolone,Annexin A1,ANXA1,,,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
prednisolone acetate,Glucocorticoid receptor,NR3C1,,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
prednisone,Annexin A1,ANXA1,,,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
primaquine,Hemoglobin subunit alpha,HBA1,,,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
primaquine,Glucose-6-phosphate 1-dehydrogenase,G6PD,,,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
primidone,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CCC1(C(=O)NCNC1=O)C1=CC=CC=C1
probenecid,Solute carrier family 22 member 8,SLC22A8,,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
probenecid,Solute carrier family 22 member 11,SLC22A11,,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
probucol,ATP-binding cassette sub-family A member 1,ABCA1,,,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
procainamide,DNA (cytosine-5)-methyltransferase 1,DNMT1,,,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
procainamide,DNA (cytosine-5)-methyltransferase 3A,DNMT3A,,,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
procainamide,DNA (cytosine-5)-methyltransferase 3B,DNMT3B,,,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
procainamide,Sodium channel alpha subunit,SCN1A|SCN4A|SCN7A|SCN5A|SCN9A|SCN2A|SCN3A|SCN11A|SCN8A|SCN10A,,,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
procaine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
progesterone,Estrogen receptor,ESR1,,,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
proglumide,Gastrin/cholecystokinin type B receptor,CCKBR,,,CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1
proguanil,Bifunctional dihydrofolate reductase-thymidylate synthase,,,,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1
proguanil,Bifunctional dihydrofolate reductase-thymidylate synthase,,,,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1
proguanil,Bifunctional dihydrofolate reductase-thymidylate synthase,,,,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1
promethazine,Alpha-1A adrenergic receptor,ADRA1A,,,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C
propafenone,Sodium channel subunit beta-1,SCN1B,,,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
propafenone,Sodium channel subunit beta-2,SCN2B,,,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
propafenone,Sodium channel subunit beta-3,SCN3B,,,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
propafenone,Sodium channel subunit beta-4,SCN4B,,,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
proparacaine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC
propiomazine,D(1A) dopamine receptor,DRD1,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,D(2) dopamine receptor,DRD2,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,5-hydroxytryptamine receptor 2A,HTR2A,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,5-hydroxytryptamine receptor 2C,HTR2C,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,Histamine H1 receptor,HRH1,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,Muscarinic acetylcholine receptor M1,CHRM1,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,Muscarinic acetylcholine receptor M2,CHRM2,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,Muscarinic acetylcholine receptor M3,CHRM3,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,Muscarinic acetylcholine receptor M4,CHRM4,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,Muscarinic acetylcholine receptor M5,CHRM5,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,D(4) dopamine receptor,DRD4,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiomazine,Alpha-1B adrenergic receptor,ADRA1B,,,CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1
propiram,Mu-type opioid receptor,OPRM1,,,CCC(=O)N(C(C)CN1CCCCC1)C1=CC=CC=N1
propylthiouracil,Type I iodothyronine deiodinase,DIO1,,,CCCC1=CC(=O)NC(=S)N1
proquazone,Prostaglandin G/H synthase 2,PTGS2,,,CC(C)N1C(=O)N=C(C2=CC=CC=C2)C2=CC=C(C)C=C12
proquazone,Prostaglandin G/H synthase 1,PTGS1,,,CC(C)N1C(=O)N=C(C2=CC=CC=C2)C2=CC=C(C)C=C12
proscillaridin,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,,C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)C2=COC(=O)C=C2)[C@H](O)[C@H](O)[C@H]1O
protokylol,Beta-2 adrenergic receptor,ADRB2,,,CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1
pseudoephedrine,Beta-2 adrenergic receptor,ADRB2,,,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
pseudoephedrine,Alpha-2A adrenergic receptor,ADRA2A,,,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
pseudoephedrine,Sodium-dependent noradrenaline transporter,SLC6A2,,,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
pseudoephedrine,Alpha-1A adrenergic receptor,ADRA1A,,,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
pyrazinamide,Cyclopropane mycolic acid synthase 1,cmaA1,,,NC(=O)C1=NC=CN=C1
pyrazinamide,Amidase; Nicotinamidase; Nicotinamidase/pyrazinamidase; Pyrazinamidase; Pyrazinamidase/nicotinamidase; Pyrazinamidase/nicotinamidase PncA,pncA,,,NC(=O)C1=NC=CN=C1
pyrazinamide,3-oxoacyl-ACP synthase; Fatty acid synthase Fas; Probable fatty acid synthase Fas (Fatty acid synthetase),fas,,,NC(=O)C1=NC=CN=C1
quinestrol,Estrogen receptor,ESR1,,,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC3CCCC3)=C4)[C@@H]1CC[C@@]2(O)C#C
quinethazone,Solute carrier family 12 member 3,SLC12A3,,,CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O
quingestanol acetate,Progesterone receptor,PGR,,,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CC=C4C=C(CC[C@@H]4[C@H]3CC[C@]12C)OC1CCCC1)C#C
quinidine,Sodium channel subunit beta-1,SCN1B,,,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
quinidine,Sodium channel subunit beta-2,SCN2B,,,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
quinidine,Sodium channel subunit beta-3,SCN3B,,,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
quinidine,Sodium channel subunit beta-4,SCN4B,,,COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
rabeprazole,Sodium/potassium-transporting ATPase subunit alpha-1,ATP1A1,,,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
rabeprazole,Potassium-transporting ATPase,ATP4A|ATP4B,,,COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C
ranolazine,Multidrug resistance protein 1,ABCB1,,,COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1
remifentanil,Mu-type opioid receptor,OPRM1,,,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC
repaglinide,Solute carrier organic anion transporter family member 1B1,SLCO1B1,,,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N2CCCCC2)=C1)C(O)=O
reproterol,Beta-2 adrenergic receptor,ADRB2,,,CN1C2=C(N(CCCNCC(O)C3=CC(O)=CC(O)=C3)C=N2)C(=O)N(C)C1=O
rescinnamine,Synaptic vesicular amine transporter,SLC18A2,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)\C=C\C1=CC(OC)=C(OC)C(OC)=C1
ribavirin,Adenosine kinase,ADK,,,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
ribavirin,Ectonucleotide pyrophosphatase/phosphodiesterase family member 1,ENPP1,,,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
ribavirin,Cytosolic purine 5'-nucleotidase,NT5C2,,,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
ribavirin,NS5B protein,NS5B,,,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
rifabutin,Bacterial DNA-directed RNA polymerase,rpoA|rpoZ|rpoC|rpoB,,,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC(C)C)CC3)N=C21
rifampicin,DNA-directed RNA polymerase subunit beta,rpoB,,,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(C)CC1)=C(O)C4=C3C2=O
rifapentine,Bacterial DNA-directed RNA polymerase,rpoA|rpoZ|rpoC|rpoB,,,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(CC1)C1CCCC1)=C(O)C4=C3C2=O
rifaximin,Bacterial DNA-directed RNA polymerase,rpoA|rpoZ|rpoC|rpoB,,,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C2N=C2C=C(C)C=CN12
riluzole,Sodium channel protein type 5 subunit alpha,SCN5A,,,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
riluzole,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,,,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
rimantadine,Matrix protein 2,M,,,CC(N)C12CC3CC(CC(C3)C1)C2
rimantadine,Matrix protein 2,M,,,CC(N)C12CC3CC(CC(C3)C1)C2
rimexolone,Glucocorticoid receptor,NR3C1,,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
ritonavir,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
ropivacaine,Sodium channel protein type 1 subunit alpha,SCN1A,,,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
ropivacaine,Sodium channel protein type 2 subunit alpha,SCN2A,,,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
ropivacaine,Sodium channel protein type 3 subunit alpha,SCN3A,,,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
ropivacaine,Sodium channel protein type 4 subunit alpha,SCN4A,,,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
ropivacaine,Sodium channel protein type 8 subunit alpha,SCN8A,,,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
ropivacaine,Sodium channel protein type 9 subunit alpha,SCN9A,,,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
ropivacaine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
roxithromycin,50S ribosomal protein L10,rpl10,,,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
salicylic acid,Salicylic acid-binding protein 2,SABP2,,,OC(=O)C1=CC=CC=C1O
saquinavir,Multidrug resistance-associated protein 1,ABCC1,,,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
secobarbital,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
sermorelin,Growth hormone-releasing hormone receptor,GHRHR,,,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
sertaconazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl
setastine,Histamine H1 receptor,HRH1,,,CC(OCCN1CCCCCC1)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
sevoflurane,Glycine receptor subunit alpha-1,GLRA1,,,FCOC(C(F)(F)F)C(F)(F)F
sevoflurane,Potassium channel subfamily K member 2,KCNK2,,,FCOC(C(F)(F)F)C(F)(F)F
sevoflurane,Potassium channel subfamily K member 3,KCNK3,,,FCOC(C(F)(F)F)C(F)(F)F
sevoflurane,Potassium channel subfamily K member 9,KCNK9,,,FCOC(C(F)(F)F)C(F)(F)F
sevoflurane,Potassium channel subfamily K member 10,KCNK10,,,FCOC(C(F)(F)F)C(F)(F)F
sevoflurane,Potassium channel subfamily K member 18,KCNK18,,,FCOC(C(F)(F)F)C(F)(F)F
sevoflurane,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,FCOC(C(F)(F)F)C(F)(F)F
sibutramine,Alpha-2C adrenergic receptor,ADRA2C,,,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
sildenafil,"Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha",PDE6A,,,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
simvastatin,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
sisomicin,30S ribosomal protein S12,rpsL,,,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O
sitafloxacin,DNA gyrase subunit B,gyrB,,,N[C@@H]1CN(CC11CC1)C1=C(F)C=C2C(=O)C(=CN([C@@H]3C[C@@H]3F)C2=C1Cl)C(O)=O
sitafloxacin,DNA topoisomerase 4 subunit A,parC,,,N[C@@H]1CN(CC11CC1)C1=C(F)C=C2C(=O)C(=CN([C@@H]3C[C@@H]3F)C2=C1Cl)C(O)=O
sparfloxacin,Topoisomerase IV,parC|parE,,,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O
sparfloxacin,DNA gyrase,gyrA|gyrB,,,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O
spectinomycin,30S ribosomal protein S12,rpsL,,,CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O
spironolactone,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12
stanozolol,Androgen receptor,AR,,,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=NN5
stavudine,Gag-Pol polyprotein,gag-pol,,,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
stiripentol,Cytochrome P450 3A4,CYP3A4,,,CC(C)(C)C(O)C=CC1=CC=C2OCOC2=C1
stiripentol,Cytochrome P450 1A2,CYP1A2,,,CC(C)(C)C(O)C=CC1=CC=C2OCOC2=C1
stiripentol,Cytochrome P450 2C19,CYP2C19,,,CC(C)(C)C(O)C=CC1=CC=C2OCOC2=C1
streptomycin,30S ribosomal protein S12,rpsL,,,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O
suxamethonium,Muscle-type nicotinic acetylcholine receptor,CHRNA1|CHRNG|CHRNB1|CHRNE|CHRND,,,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
sulconazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
sulfacetamide,Dihydropteroate synthase,folP,,,CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1
sulfacytine,"7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase-dihydropteroate synthase; Dihydropteroate synthetase",PPPK-DHPS,,,CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O
sulfadiazine,"Dihydroorotate dehydrogenase (quinone), mitochondrial",,,,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
sulfadiazine,Dihydropteroate synthase,folP,,,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
sulfadimidine,Dihydropteroate synthase,folP,,,CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1
sulfadimidine,Lactoylglutathione lyase,GLO1,,,CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1
sulfadoxine,"7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase-dihydropteroate synthase; Dihydropteroate synthetase",PPPK-DHPS,,,COC1=C(OC)C(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=N1
sulfamerazine,Dihydropteroate synthase,folP,,,CC1=CC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1
sulfameter,Dihydropteroate synthase,folP,,,COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1
sulfamethizole,Dihydropteroate synthase,folP,,,CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1
sulfamethoxazole,Bifunctional protein FolC,folC,,,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
sulfalene,Dihydropteroate synthase,folP,,,COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1
sulfanilamide,Dihydropteroate synthase,folP,,,NC1=CC=C(C=C1)S(N)(=O)=O
sulfaphenazole,Dihydropteroate synthase,folP,,,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1
sulfapyridine,Dihydropteroate synthase,folP,,,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
sulfapyridine,Dihydropteroate synthase type-1,sulI,,,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
sulfasalazine,"Acetyl-CoA acetyltransferase, mitochondrial",ACAT1,,,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
sulfasalazine,Arachidonate 5-lipoxygenase,ALOX5,,,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
sulfasalazine,Cyclooxygenase,PTGS1|PTGS2,,,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
sulfinpyrazone,Multidrug resistance-associated protein 1,ABCC1,,,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1
sulfafurazole,"Dihydroorotate dehydrogenase (quinone), mitochondrial",,,,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
sulfafurazole,Dihydropteroate synthase,folP,,,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
aldesulfone,Dihydropteroate synthase 1,folP1,,,OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1
aldesulfone,Glucose-6-phosphate 1-dehydrogenase,G6PD,,,OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1
sulindac,72 kDa type IV collagenase,MMP2,,,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O
talbutal,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
talinolol,Multidrug resistance protein 1,ABCB1,,,CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1
tegaserod,5-hydroxytryptamine receptor 1A,HTR1A,,,CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2
tegaserod,5-hydroxytryptamine receptor 1D,HTR1D,,,CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2
temazepam,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,CN1C2=CC=C(Cl)C=C2C(=NC(O)C1=O)C1=CC=CC=C1
temazepam,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CN1C2=CC=C(Cl)C=C2C(=NC(O)C1=O)C1=CC=CC=C1
temocapril,Angiotensin-converting enzyme,ACE,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)C1=CC=CS1
teniposide,Multidrug resistance protein 1,ABCB1,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)C2=CC=CS2)C2=CC3=C(OCO3)C=C12
teniposide,DNA topoisomerase 2-alpha,TOP2A,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)C2=CC=CS2)C2=CC3=C(OCO3)C=C12
teniposide,ATP-binding cassette sub-family G member 2,ABCG2,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)C2=CC=CS2)C2=CC3=C(OCO3)C=C12
teniposide,Multidrug resistance-associated protein 6,ABCC6,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)C2=CC=CS2)C2=CC3=C(OCO3)C=C12
teniposide,Canalicular multispecific organic anion transporter 2,ABCC3,,,COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)C2=CC=CS2)C2=CC3=C(OCO3)C=C12
tenofovir disoproxil,Gag-Pol polyprotein,gag-pol,,,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C
tenofovir disoproxil,Reverse transcriptase/RNaseH,pol,,,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C
tenoxicam,Prostaglandin G/H synthase 2,PTGS2,,,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
terbinafine,Squalene epoxidase,,,,CN(C\C=C\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1
terconazole,Lanosterol 14-alpha demethylase,ERG11,,,CC(C)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
testosterone undecanoate,Androgen receptor,AR,,,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
tetracycline,30S ribosomal protein S4,rpsD,,,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)C1=C(C=CC=C1O)[C@@]3(C)O
tetracycline,30S ribosomal protein S9,rpsI,,,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)C1=C(C=CC=C1O)[C@@]3(C)O
thiabendazole,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",sdha-1,,,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
thiabendazole,Tubulin,,,,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
thiabendazole,Tubulin,,,,N1C2=C(C=CC=C2)N=C1C1=CSC=N1
thiamphenicol,50S ribosomal protein L10,rpl10,,,CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl
thiamylal,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O
thiethylperazine,Muscarinic acetylcholine receptor M1,CHRM1,,,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thiethylperazine,Muscarinic acetylcholine receptor M2,CHRM2,,,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thiethylperazine,Muscarinic acetylcholine receptor M3,CHRM3,,,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thiethylperazine,Muscarinic acetylcholine receptor M4,CHRM4,,,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thiethylperazine,Muscarinic acetylcholine receptor M5,CHRM5,,,CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1
thioguanine,Multidrug resistance-associated protein 5,ABCC5,,,NC1=NC2=C(NC=N2)C(=S)N1
thioguanine,Multidrug resistance-associated protein 4,ABCC4,,,NC1=NC2=C(NC=N2)C(=S)N1
thioguanine,Inosine-5'-monophosphate dehydrogenase 1,IMPDH1,,,NC1=NC2=C(NC=N2)C(=S)N1
thioguanine,Inosine-5'-monophosphate dehydrogenase 2,IMPDH2,,,NC1=NC2=C(NC=N2)C(=S)N1
thioguanine,Hypoxanthine-guanine phosphoribosyltransferase,HPRT1,,,NC1=NC2=C(NC=N2)C(=S)N1
thiopental,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O
thioridazine,Nuclear receptor subfamily 1 group I member 3,NR1I3,,,CSC1=CC=C2SC3=CC=CC=C3N(CCC3CCCCN3C)C2=C1
levothyroxine,Thyroid hormone receptor alpha,THRA,,,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
levothyroxine,THAP domain-containing protein 1,THAP1,,,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
tibolone,Androgen receptor,AR,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
tibolone,Progesterone receptor,PGR,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
tibolone,Steryl-sulfatase,STS,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
ticarcillin,Penicillin-binding protein 1A,pbpA,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O
ticarcillin,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O
ticlopidine,P2Y purinoceptor 12,P2RY12,,,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
tiludronic acid,Tyrosine-protein phosphatase non-receptor type 1,PTPN1,,,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O
tiludronic acid,V-type proton ATPase 116 kDa subunit a isoform 3,TCIRG1,,,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O
tioconazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1
tizanidine,Alpha-2B adrenergic receptor,ADRA2B,,,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
tocainide,Sodium channel alpha subunit,SCN1A|SCN4A|SCN7A|SCN5A|SCN9A|SCN2A|SCN3A|SCN11A|SCN8A|SCN10A,,,CC(N)C(=O)NC1=C(C)C=CC=C1C
tolazamide,"Sulfonylurea receptor 1, Kir6.2",ABCC8|KCNJ11,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1
topiramate,Sodium channel protein type 5 subunit alpha,SCN5A,,,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topiramate,Sodium channel protein type 1 subunit alpha,SCN1A,,,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topiramate,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topiramate,GABA-A receptor alpha-1/beta-2/gamma-2,GABRA1|GABRG2|GABRB2,,,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topiramate,Glutamate receptor ionotropic kainate,GRIK1|GRIK2|GRIK3|GRIK4|GRIK5,,,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topiramate,Glutamate receptor ionotropic AMPA,GRIA1|GRIA2|GRIA3|GRIA4,,,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
topotecan,Multidrug resistance protein 1,ABCB1,,,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
topotecan,Canalicular multispecific organic anion transporter 1,ABCC2,,,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
topotecan,Nuclear receptor subfamily 1 group I member 2,NR1I2,,,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
topotecan,ATP-binding cassette sub-family G member 2,ABCG2,,,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
topotecan,Multidrug resistance-associated protein 4,ABCC4,,,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
topotecan,"DNA topoisomerase I, mitochondrial",TOP1MT,,,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O
toremifene,Estrogen receptor,ESR1,,,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
toremifene,Estrogen-related receptor gamma,ESRRG,,,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
triamcinolone,Annexin A1,ANXA1,,,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
triamcinolone,Progesterone receptor,PGR,,,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
triamcinolone acetonide,Annexin A1,ANXA1,,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
triamcinolone diacetate,Glucocorticoid receptor,NR3C1,,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)OC(C)=O
triamterene,Solute carrier family 12 member 1,SLC12A1,,,NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1
triclofos,GABA-A receptor; anion channel,GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ,,,OP(O)(=O)OCC(Cl)(Cl)Cl
tridihexethyl,Muscarinic acetylcholine receptor M1,CHRM1,,,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1
tridihexethyl,Muscarinic acetylcholine receptor M3,CHRM3,,,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1
trilostane,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2,HSD3B2,,,C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O
alimemazine,Histamine H1 receptor,HRH1,,,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=CC=C2
trimethadione,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,,,CN1C(=O)OC(C)(C)C1=O
trimetaphan,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,,,O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
trimetaphan,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,,,O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
trimetaphan,Neuronal acetylcholine receptor; alpha3/beta4,CHRNB4|CHRNA3,,,O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
trimetrexate,"Folylpolyglutamate synthase, mitochondrial",FPGS,,,COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC
troglitazone,Aldose reductase,AKR1B1,,,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
troglitazone,"Glycogen [starch] synthase, liver",GYS2,,,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C
trospium,Muscarinic acetylcholine receptor M1,CHRM1,,,OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
trospium,Muscarinic acetylcholine receptor M2,CHRM2,,,OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
trospium,Muscarinic acetylcholine receptor M3,CHRM3,,,OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
trospium,Muscarinic acetylcholine receptor M5,CHRM5,,,OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
trovafloxacin,Topoisomerase IV,parC|parE,,,N[C@H]1[C@@H]2CN(C[C@H]12)C1=C(F)C=C2C(=O)C(=CN(C3=C(F)C=C(F)C=C3)C2=N1)C(O)=O
trovafloxacin,DNA gyrase,gyrA|gyrB,,,N[C@H]1[C@@H]2CN(C[C@H]12)C1=C(F)C=C2C(=O)C(=CN(C3=C(F)C=C(F)C=C3)C2=N1)C(O)=O
tulobuterol,Beta-2 adrenergic receptor,ADRB2,,,CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1
ursodiol,Aldo-keto reductase family 1 member C2,AKR1C2,,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
ursodiol,Bile acid receptor,NR1H4,,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
valaciclovir,DNA polymerase catalytic subunit,,,,CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1N=C(N)NC2=O
valganciclovir,DNA polymerase catalytic subunit,,,,CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1N=C(N)NC2=O
valproic acid,"Succinate-semialdehyde dehydrogenase, mitochondrial",ALDH5A1,,,CCCC(CCC)C(O)=O
valproic acid,UDP-glucuronosyltransferase 1-5,UGT1A5,,,CCCC(CCC)C(O)=O
valrubicin,DNA topoisomerase 2-alpha,TOP2A,,,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C2=C(C1)C(O)=C1C(=O)C3=CC=CC(OC)=C3C(=O)C1=C2O
vecuronium,Neuronal acetylcholine receptor; alpha2/beta4,CHRNB4|CHRNA2,,,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
vecuronium,Neuronal acetylcholine receptor; alpha4/beta2,CHRNB2|CHRNA4,,,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
vecuronium,Neuronal acetylcholine receptor; alpha4/beta4,CHRNB4|CHRNA4,,,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
verapamil,Sodium channel protein type 5 subunit alpha,SCN5A,,,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
verapamil,Carbonic anhydrase 1,CA1,,,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
verapamil,G protein-activated inward rectifier potassium channel 2,KCNJ6,,,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
verapamil,Voltage-dependent L-type calcium channel subunit alpha-1S,CACNA1S,,,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
vesnarinone,Transitional endoplasmic reticulum ATPase,VCP,,,COC1=C(OC)C=C(C=C1)C(=O)N1CCN(CC1)C1=CC=C2NC(=O)CCC2=C1
vidarabine,DNA polymerase catalytic subunit,,,,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
vidarabine,Deoxycytidine kinase,DCK,,,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
vidarabine,DNA polymerase alpha catalytic subunit,POLA1,,,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
vidarabine,Ribonucleoside-diphosphate reductase large subunit,RRM1,,,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
vidarabine,Ribonucleoside-diphosphate reductase subunit M2,RRM2,,,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
vidarabine,"Deoxyguanosine kinase, mitochondrial",DGUOK,,,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
vidarabine,Ribose-phosphate pyrophosphokinase 1,PRPS1,,,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
vigabatrin,"4-aminobutyrate aminotransferase, mitochondrial",ABAT,,,NC(CCC(O)=O)C=C
vinblastine,Canalicular multispecific organic anion transporter 1,ABCC2,,,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
vinblastine,Multidrug resistance-associated protein 1,ABCC1,,,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
vinblastine,Multidrug resistance-associated protein 7,ABCC10,,,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
vincristine,Multidrug resistance protein 1,ABCB1,,,CC[C@]1(O)C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
vincristine,Canalicular multispecific organic anion transporter 1,ABCC2,,,CC[C@]1(O)C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
vincristine,Multidrug resistance-associated protein 1,ABCC1,,,CC[C@]1(O)C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
vincristine,Multidrug resistance-associated protein 7,ABCC10,,,CC[C@]1(O)C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
vincristine,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,,,CC[C@]1(O)C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
vinorelbine,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,,,CCC1=C[C@@H]2C[N@](C1)CC1=C(NC3=C1C=CC=C3)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC
retinol,11-cis retinol dehydrogenase,RDH5,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinol dehydrogenase 12,RDH12,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinol dehydrogenase 13,RDH13,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinol-binding protein 3,RBP3,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinol-binding protein 5,RBP5,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinoid-binding protein 7,RBP7,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinol-binding protein 2,RBP2,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinal dehydrogenase 2,ALDH1A2,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinal dehydrogenase 1,ALDH1A1,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinaldehyde-binding protein 1,RLBP1,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
retinol,Retinol-binding protein 1,RBP1,,,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
thiamine,Thiamine transporter 1,SLC19A2,,,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
thiamine,Transketolase,TKT,,,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
thiamine,Thiamin pyrophosphokinase 1,TPK1,,,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
thiamine,Thiamine-triphosphatase,THTPA,,,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
thiamine,Transketolase-like protein 1,TKTL1,,,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
riboflavin,Flavin reductase (NADPH),BLVRB,,,CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO)C1=NC(=O)NC(=O)C1=N2
riboflavin,Riboflavin kinase,RFK,,,CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO)C1=NC(=O)NC(=O)C1=N2
nicotinic acid,Nicotinamide N-methyltransferase,NNMT,,,OC(=O)C1=CN=CC=C1
nicotinic acid,Nicotinate-nucleotide pyrophosphorylase [carboxylating],QPRT,,,OC(=O)C1=CN=CC=C1
nicotinic acid,Nicotinamide phosphoribosyltransferase,NAMPT,,,OC(=O)C1=CN=CC=C1
pyridoxine,"Serine hydroxymethyltransferase, cytosolic",SHMT1,,,CC1=C(O)C(CO)=C(CO)C=N1
pyridoxine,Pyridoxine-5'-phosphate oxidase,PNPO,,,CC1=C(O)C(CO)=C(CO)C=N1
pyridoxine,Pyridoxal phosphate phosphatase,PDXP,,,CC1=C(O)C(CO)=C(CO)C=N1
pyridoxine,Pyridoxal kinase,PDXK,,,CC1=C(O)C(CO)=C(CO)C=N1
pyridoxine,Cystathionine beta-synthase,CBS,,,CC1=C(O)C(CO)=C(CO)C=N1
pyridoxine,Phosphoserine aminotransferase,PSAT1,,,CC1=C(O)C(CO)=C(CO)C=N1
ergocalciferol,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial",CYP27B1,,,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
ergocalciferol,Vitamin D3 receptor,VDR,,,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
ergocalciferol,Vitamin D 25-hydroxylase,CYP2R1,,,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
colecalciferol,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial",CYP27B1,,,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
colecalciferol,Vitamin D 25-hydroxylase,CYP2R1,,,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
colecalciferol,"Sterol 26-hydroxylase, mitochondrial",CYP27A1,,,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
dihydrotachysterol,Vitamin D3 receptor,VDR,,,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C
zalcitabine,Deoxycytidine kinase,DCK,,,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1
ziprasidone,Sodium-dependent dopamine transporter,SLC6A3,,,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2
zonisamide,Sodium channel protein type 1 subunit alpha,SCN1A,,,NS(=O)(=O)CC1=NOC2=CC=CC=C12
zonisamide,Voltage-dependent T-type calcium channel subunit alpha-1G,CACNA1G,,,NS(=O)(=O)CC1=NOC2=CC=CC=C12
zuclopenthixol,5-hydroxytryptamine receptor 2A,HTR2A,,,OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
zuclopenthixol,Alpha-1A adrenergic receptor,ADRA1A,,,OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
zuclopenthixol,D(1A) dopamine receptor,DRD1,,,OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
zuclopenthixol,D(2) dopamine receptor,DRD2,,,OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1
ziconotide,Voltage-dependent N-type calcium channel subunit alpha-1B,CACNA1B,,,CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)[C@@H](C)O
lypressin,Vasopressin receptor,AVPR2|AVPR1A|AVPR1B,,,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
mifamurtide,Nucleotide-binding oligomerization domain-containing protein 2,NOD2,,,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC
doxacurium,Muscarinic acetylcholine receptor M2,CHRM2,,,COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
doxacurium,Neuronal acetylcholine receptor subunit alpha-2,CHRNA2,,,COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
doxacurium,Acetylcholine receptor,CHRNA1|CHRNB1|CHRND,,,COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
histrelin,Gonadotropin-releasing hormone receptor,GNRHR,,,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
caspofungin,"1,3-beta-glucan synthase catalytic subunit FksP",,,,CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN
pyrantel,Acetylcholinesterase,ACHE,,,CN1CCCN=C1\C=C\C1=CC=CS1
oxybuprocaine,Sodium channel protein type 10 subunit alpha,SCN10A,,,CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC
carglumic acid,"Carbamoyl-phosphate synthase [ammonia], mitochondrial",CPS1,,,NC(=O)N[C@@H](CCC(O)=O)C(O)=O
desonide,Glucocorticoid receptor,NR3C1,,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
difluprednate,Glucocorticoid receptor,NR3C1,,,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O
fosfestrol,Estrogen receptor,ESR1|ESR2,,,CC\C(=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1)C1=CC=C(OP(O)(O)=O)C=C1
fospropofol,GABA-A receptor,GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRA6|GABRG1|GABRG3,,,CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O
ivabradine,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2,HCN2,,,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
mestanolone,Androgen receptor,AR,,,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
oxiconazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
posaconazole,Cytochrome P450 3A4,CYP3A4,,,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=CC=C(F)C=C2F)C=C1
rapacuronium,Muscle-type nicotinic acetylcholine receptor,CHRNA1|CHRNG|CHRNB1|CHRNE|CHRND,,,CCC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1
revaprazan,Potassium-transporting ATPase,ATP4A|ATP4B,,,CC1N(CCC2=CC=CC=C12)C1=C(C)C(C)=NC(NC2=CC=C(F)C=C2)=N1
rioprostil,Prostaglandin E2 receptor EP2 subtype,PTGER2,,,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCCO
rufinamide,Sodium channel alpha subunit,SCN1A|SCN4A|SCN7A|SCN5A|SCN9A|SCN2A|SCN3A|SCN11A|SCN8A|SCN10A,,,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1
talastine,Histamine H1 receptor,HRH1,,,CN(C)CCN1N=C(CC2=CC=CC=C2)C2=C(C=CC=C2)C1=O
terazosin,Ribosyldihydronicotinamide dehydrogenase [quinone],NQO2,,,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1
tetryzoline,Adrenergic receptor alpha,ADRA2A|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B,,,C1CN=C(N1)C1CCCC2=CC=CC=C12
tipranavir,Multidrug resistance protein 1,ABCB1,,,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC(NS(=O)(=O)C3=CC=C(C=N3)C(F)(F)F)=CC=C2)C(=O)O1
vinflunine,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,,,CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=C4C=C(C(OC)=C1)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=C3C=CC=C1)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC
ciramadol,Mu-type opioid receptor,OPRM1,,,CN(C)[C@H]([C@H]1CCCC[C@H]1O)C1=CC(O)=CC=C1
clobetasone butyrate,Glucocorticoid receptor,NR3C1,,,CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl
etoposide phosphate,DNA topoisomerase 2-alpha,TOP2A,,,COC1=CC(=CC(OC)=C1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=C1C=C1OCOC1=C2
hydrocortisone butyrate,Glucocorticoid receptor,NR3C1,,,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO
ilaprazole,Potassium-transporting ATPase,ATP4A|ATP4B,,,COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC(=C3)N2C=CC=C2)=C1C
niperotidine,Histamine H2 receptor,HRH2,,,CN(C)CC1=CC=C(CSCCNC(NCC2=CC3=C(OCO3)C=C2)=C[N+]([O-])=O)O1
ascorbic acid,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,,,OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
ascorbic acid,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,,,OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
ascorbic acid,Solute carrier family 23 member 2,SLC23A2,,,OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
ascorbic acid,Solute carrier family 23 member 1,SLC23A1,,,OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
levamlodipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=C(Cl)C=CC=C1)C(=O)OC
besifloxacin,Topoisomerase IV,parC|parE,,,N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O
besifloxacin,DNA gyrase,gyrA|gyrB,,,N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O
dronedarone,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1,HCN1,,,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
dronedarone,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2,HCN2,,,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
dronedarone,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3,HCN3,,,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
dronedarone,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,HCN4,,,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
prasugrel,P2Y purinoceptor 12,P2RY12,,,CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=C(F)C=CC=C2)S1
saxagliptin,Cytochrome P450 3A4,CYP3A4,,,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2
saxagliptin,Multidrug resistance protein 1,ABCB1,,,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2
pazopanib,Tyrosine-protein kinase ITK/TSK,ITK,,,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1
lubiprostone,Chloride channel protein 2,CLCN2,,,CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(O)=O)O1
lisdexamfetamine,Sodium-dependent noradrenaline transporter,SLC6A2,,,C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
lisdexamfetamine,Sodium-dependent dopamine transporter,SLC6A3,,,C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
lisdexamfetamine,Synaptic vesicular amine transporter,SLC18A2,,,C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
udenafil,Multidrug resistance protein 1,ABCB1,,,CCCOC1=CC=C(C=C1C1=NC(=O)C2=C(N1)C(CCC)=NN2C)S(=O)(=O)NCCC1CCCN1C
doripenem,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O
silodosin,Multidrug resistance protein 1,ABCB1,,,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
permethrin,Sodium channel protein,vssc,,,CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC2=CC=CC=C2)=C1
cabazitaxel,Tubulin beta,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,,,CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C
lercanidipine,Voltage-gated L-type calcium channel,CACNA1D|CACNA1C,,,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
temsirolimus,Multidrug resistance protein 1,ABCB1,,,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO
temsirolimus,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP1A,,,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO
temsirolimus,Peptidyl-prolyl cis-trans isomerase FKBP3,FKBP3,,,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO
dexlansoprazole,Potassium-transporting ATPase,ATP4A|ATP4B,,,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=C(N1)C=CC=C2
alcaftadine,Histamine H1 receptor,HRH1,,,CN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=C1C=CC=C2
ceftaroline fosamil,Bacterial penicillin-binding protein,mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB,,,CCO\N=C(/C(=O)N[C@H]1[C@H]2SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N2C1=O)C([O-])=O)C1=NSC(NP(O)(O)=O)=N1
telaprevir,"Hepatitis C virus serine protease, NS3/NS4A",NS3|NS4A,,,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
rilpivirine,Reverse transcriptase/RNaseH,pol,,,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=NC(NC2=CC=C(C=C2)C#N)=NC=C1
gabapentin enacarbil,Voltage-dependent calcium channel subunit alpha-2/delta-1,CACNA2D1,,,CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
gabapentin enacarbil,Voltage-dependent calcium channel subunit alpha-2/delta-2,CACNA2D2,,,CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
fidaxomicin,DNA-directed RNA polymerase,rpoZ|rpoB|rpoC|rpoA,,,CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O
hydrocortisone acetate,Glucocorticoid receptor,NR3C1,,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
methyldopate,Adrenergic receptor alpha-2,ADRA2A|ADRA2B|ADRA2C,,,CCOC(=O)[C@@](C)(N)CC1=CC(O)=C(O)C=C1
mequinol,Tyrosinase,TYR,,,COC1=CC=C(O)C=C1
tafluprost,Prostaglandin F2-alpha receptor,PTGFR,,,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1
avobenzone,Tyrosinase,TYR,,,COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
bismuth subsalicylate,Cyclooxygenase,PTGS1|PTGS2,,,O[Bi]1OC(=O)C2=CC=CC=C2O1
piperonyl butoxide,Cytochrome P450,,,,CCCCOCCOCCOCC1=CC2=C(OCO2)C=C1CCC
eslicarbazepine acetate,Sodium channel alpha subunit,SCN1A|SCN4A|SCN7A|SCN5A|SCN9A|SCN2A|SCN3A|SCN11A|SCN8A|SCN10A,,,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12
lacosamide,Dihydropyrimidinase-related protein 2,DPYSL2,,,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
amifampridine,Voltage-gated potassium channel,KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4,,,NC1=CC=NC=C1N
plerixafor,Stromal cell-derived factor 1,CXCL12,,,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
prednisolone sodium phosphate,Glucocorticoid receptor,NR3C1,,,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COP(O)(O)=O
clobetasol propionate,Annexin A1,ANXA1,,,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
testosterone cypionate,Androgen receptor,AR,,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1
hydrocortisone succinate,Glucocorticoid receptor,NR3C1,,,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O
sulfisoxazole acetyl,Dihydropteroate synthase,folP,,,CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1
corbadrine,Adrenergic receptor alpha-2,ADRA2A|ADRA2B|ADRA2C,,,C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1
alclometasone dipropionate,Glucocorticoid receptor,NR3C1,,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
estradiol acetate,Estrogen receptor,ESR1,,,CC(=O)OC1=CC2=C(C=C1)[C@H]1CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CC2
paliperidone palmitate,D(2) dopamine receptor,DRD2,,,CCCCCCCCCCCCCCCC(=O)OC1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=C3C=CC(F)=C4)=C(C)N=C12
paliperidone palmitate,5-hydroxytryptamine receptor 2A,HTR2A,,,CCCCCCCCCCCCCCCC(=O)OC1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=C3C=CC(F)=C4)=C(C)N=C12
armodafinil,Alpha-1B adrenergic receptor,ADRA1B,,,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
armodafinil,Cytochrome P450 1A2,CYP1A2,,,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
armodafinil,Cytochrome P450 2C19,CYP2C19,,,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
hydrocortisone valerate,Glucocorticoid receptor,NR3C1,,,CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO
quinine,Potassium voltage-gated channel subfamily H member 2,KCNH2,,,COC1=CC=C2N=CC=C([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
quinine,Hemoglobin subunit alpha,HBA1,,,COC1=CC=C2N=CC=C([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1
hydrocortisone probutate,Glucocorticoid receptor,NR3C1,,,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC
clocortolone pivalate,Glucocorticoid receptor,NR3C1,,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C
testosterone enantate,Androgen receptor,AR,,,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
levomefolic acid,Thymidylate synthase,TYMS,,,CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2
ponatinib,Breakpoint cluster region protein,BCR,,,CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1
daunorubicinol,Multidrug resistance protein 1,ABCB1,,,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)[C@H](C)O)C(O)=C3C(=O)C2=CC=C1
daunorubicinol,DNA topoisomerase 2-alpha,TOP2A,,,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)[C@H](C)O)C(O)=C3C(=O)C2=CC=C1
daunorubicinol,Multidrug resistance-associated protein 1,ABCC1,,,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)[C@H](C)O)C(O)=C3C(=O)C2=CC=C1
daunorubicinol,ATP-binding cassette sub-family G member 2,ABCG2,,,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)[C@H](C)O)C(O)=C3C(=O)C2=CC=C1
daunorubicinol,Multidrug resistance-associated protein 6,ABCC6,,,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)[C@H](C)O)C(O)=C3C(=O)C2=CC=C1
bedaquiline,ATP synthase,atpE|atpD|atpA|atpG|atpC|atpFH|atpF|atpB,,,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2
dimethyl fumarate,Kelch-like ECH-associated protein 1,KEAP1,,,COC(=O)\C=C\C(=O)OC
luliconazole,Lanosterol 14-alpha demethylase,ERG11,,,ClC1=CC(Cl)=C(C=C1)[C@@H]1CS\C(S1)=C(\C#N)N1C=CN=C1
rifamycin,DNA-directed RNA polymerase subunit beta,rpoB,,,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O
etilefrine pivalate,Beta-1 adrenergic receptor,ADRB1,,,CCNCC(O)C1=CC(OC(=O)C(C)(C)C)=CC=C1
naloxegol,Mu-type opioid receptor,OPRM1,,,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC=C)=C(O)C=C4
estrone sulphate,Estrogen receptor,ESR1,,,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
estrone sulphate,Estrogen receptor beta,ESR2,,,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
phenibut,GABA-B receptor,GABBR2|GABBR1,,,NCC(CC(O)=O)C1=CC=CC=C1
mebanazine,Amine oxidase [flavin-containing] B,MAOB,,,CC(NN)C1=CC=CC=C1
mebanazine,Amine oxidase [flavin-containing] A,MAOA,,,CC(NN)C1=CC=CC=C1
dexrabeprazole,Potassium-transporting ATPase,ATP4A|ATP4B,,,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C
efinaconazole,Lanosterol 14-alpha demethylase,,,,C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
tavaborole,Leucine-tRNA ligase,,,,OB1OCC2=C1C=CC(F)=C2
felypressin,Vasopressin V1a receptor,AVPR1A,,,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
corticotropin,Adrenocorticotropic hormone receptor,MC2R,,,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
triamcinolone hexacetonide,Glucocorticoid receptor,NR3C1,,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C
sacubitril,Neprilysin,MME,,,CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O
eldecalcitol,Vitamin D3 receptor,VDR,,,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C
deutetrabenazine,Synaptic vesicular amine transporter,SLC18A2,,,[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2
moxidectin,Glutamate-gated chloride channel,GluClX,,,CO\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C
cannabidiol,Transient receptor potential cation channel subfamily V member 1,TRPV1,,,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
bremelanotide,Adrenocorticotropic hormone receptor,MC2R,,,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O
darolutamide,Progesterone receptor,PGR,,,C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)[C@@H](C)O
cepharanthine,5'-AMP-activated protein kinase catalytic subunit alpha-1,PRKAA1,,,COC1=C2OC3=CC=C(C[C@@H]4N(C)CCC5=CC6=C(OCO6)C(OC6=C(OC)C=C7CCN(C)[C@H](CC(C=C1)=C2)C7=C6)=C45)C=C3
cepharanthine,Nuclear factor NF-kappa-B p105 subunit,NFKB1,,,COC1=C2OC3=CC=C(C[C@@H]4N(C)CCC5=CC6=C(OCO6)C(OC6=C(OC)C=C7CCN(C)[C@H](CC(C=C1)=C2)C7=C6)=C45)C=C3
borofalan (10B),L-type amino acid transporter 1,Slc7a5,,,B(C1=CC=C(C=C1)CC(C(=O)O)N)(O)O
sofpironium bromide,Muscarinic acetylcholine receptor M3,CHRM3,,,CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C
vericiguat,Guanylate cyclase soluble subunit beta-1,GUCY1B3,,,COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
fosdenopterin,Molybdenum cofactor biosynthesis protein 1,MOCS1,,,C1[C@@H]2[C@@H](C([C@H]3[C@@H](O2)NC4=C(N3)C(=O)NC(=N4)N)(O)O)OP(=O)(O1)O
piflufolastat F-18,Glutamate carboxypeptidase 2,FOLH1,,,    OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O
